PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Tasaki, O; Shiozaki, T; Hamasaki, T; Kajino, K; Nakae, H; Tanaka, H; Shimazu, T; Sugimoto, H				Tasaki, Osamu; Shiozaki, Tadahiko; Hamasaki, Toshimitsu; Kajino, Kentaro; Nakae, Haruhiko; Tanaka, Hiroshi; Shimazu, Takeshi; Sugimoto, Hisashi			Prognostic Indicators and Outcome Prediction Model for Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	23rd Annual National-Neurotrauma-Society Symposium	NOV 10-11, 2005	Washington, DC	Natl Neurotrauma Soc		Severe traumatic brain injury; Outcome prediction; Multivariate logistic regression; Akaike Information Criterion	VARIABLES; SURVIVAL	Background: Although sonic predictive models for patient outcomes after severe traumatic brain injury have been proposed, a mathematical model with high predictive value has not been established. The purpose of the present study was to analyze the most important indicators of prognosis and to develop the best outcome prediction model. Methods: One hundred eleven consecutive patients with a Glasgow Coma Scale score of <9 were examined and 14 factors were evaluated. Intracranial pressure and cerebral perfusion pressure were recorded at admission to the intensive care unit. The absence of the basal cisterns, presence of extensive subarachnoid hemorrhage, and degree of midline shift were evaluated by means of computed tomography within 24 hours after injury. Multivariate logistic regression analysis was used to identify independent risk factors for a poor prognosis and to develop the best prediction model. Results: The best model included the following variables: age (p < 0.01), light reflex (p = 0.01), extensive subarachnoid hemorrhage (p = 0.01), intracranial pressure (p = 0.04), and midline shift (p = 0.12). Positive predictive value of the model was 97.3%, negative predictive value was 87.1%, and overall predictive value was 94.2%. The area under the receiver operating characteristic curve was 0.977, and the p value for the Hosmer-Lemeshow goodness-of-fit was 0.866. Conclusions: Our predictive model based on age, absence of light reflex, presence of extensive subarachnoid hemorrhage, intracranial pressure, and midline shift was shown to have high predictive value and will be useful for decision making, review of treatment, and family counseling in case of traumatic brain injury.	[Tasaki, Osamu; Shiozaki, Tadahiko; Kajino, Kentaro; Nakae, Haruhiko; Tanaka, Hiroshi; Shimazu, Takeshi; Sugimoto, Hisashi] Osaka Univ, Grad Sch Med, Dept Traumatol & Acute Crit Med, Osaka, Japan; [Hamasaki, Toshimitsu] Osaka Univ, Grad Sch Med, Dept Biomed Stat, Osaka, Japan	Tasaki, O (corresponding author), 2-15 Yamadaoka Suita, Osaka 5650871, Japan.	tasaki@hp-emerg.med.osaka-u.ac.jp	Hamasaki, Toshimitsu/N-3851-2015	Hamasaki, Toshimitsu/0000-0002-4928-1160	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [19390459] Funding Source: KAKEN		AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; *AM COLL SURG COMM, 1999, ADV TRAUM LIF SUPP P; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1975, LANCET, V1, P480; Lu J, 2005, ACT NEUR S, V95, P281; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; ROVIAS A, 2004, J NEUROTRAUM, V21, P886; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Tibshirani, 1994, INTRO BOOTSTRAP, DOI 10.1201/9780429246593	16	29	30	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2009	66	2					304	308		10.1097/TA.0b013e31815d9d3f			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	408NX	WOS:000263442800003	19204501				2021-06-18	
J	Biber, N; Toklu, HZ; Solakoglu, S; Gultomruk, M; Hakan, T; Berkman, Z; Dulger, FG				Biber, Necat; Toklu, Hale Z.; Solakoglu, Seyhun; Gultomruk, Mine; Hakan, Tayfun; Berkman, Zafer; Dulger, F. Gul			Cysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury	BRAIN INJURY			English	Article						Montelukast; cysteinyl-leukotriene; brain injury; closed head; trauma; blood-brain barrier; oedema; antioxidant; neutrophil	INFLAMMATION; ACTIVATION; PROTECTS	Introduction: Traumatic brain injury is highly associated with the over-production of reactive oxygen species. The aim of this study was to investigate the putative neuroprotective effect of montelukast, a cysteinyl-leukotriene receptor antagonist, in a rat model of traumatic brain injury (TBI). Methods: Sprague Dawley rats were subjected to TBI with a weight-drop device using 300 g-1 m weight-height impact. The groups were: control (saline), montelukast (10 mg kg -1 per day, ip), trauma and trauma + montelukast. Two days post-trauma, neurological examination scores were measured and animals were decapitated and the brain tissues were taken for the histologic and biochemical [malondialdehyde (MDA)an index for lipid peroxidation, reduced glutathione (GSH), myeloperoxidase (MPO)an index for neutrophil infiltration and Na +/K +-ATPase activity] evaluations. Brain oedema and blood-brain barrier (BBB) permeability were also evaluated. Results: The neurological examination scores mildly increased in trauma groups at 48 hours. Although the scores were decreased in the montelukast treated group, they were still significantly higher than the control. The trauma caused a significant increase in brain water content and Evans blue (EB) extravasation. Montelukast treatment reduced BBB permeability. It also decreased lipid peroxidation and MPO activity. Conclusion: The present study suggests that montelukast may have beneficial effects against TBI-induced oxidative stress of the brain.	[Toklu, Hale Z.; Dulger, F. Gul] Marmara Univ, Sch Pharm, Dept Pharmacol, TR-34668 Istanbul, Turkey; [Biber, Necat; Hakan, Tayfun; Berkman, Zafer] Haydarpasa Numune Teaching & Res Hosp, Dept Neurosurg, Istanbul, Turkey; [Solakoglu, Seyhun; Gultomruk, Mine] Istanbul Univ, Istanbul Sch Med, Istanbul, Turkey	Dulger, FG (corresponding author), Marmara Univ, Sch Pharm, Dept Pharmacol, Tibbiye Cad 49, TR-34668 Istanbul, Turkey.	gdulger@marmara.edu.tr	Toklu, Hale/AAR-2330-2020; Hakan, Tayfun/P-8626-2015; solakoglu, seyhun/AAA-4412-2021; Hakan, Tayfun/O-9979-2019; solakoglu, seyhun/AAE-5691-2020	Toklu, Hale/0000-0002-9797-3591; Hakan, Tayfun/0000-0003-1444-7076; solakoglu, seyhun/0000-0002-1389-9639; Hakan, Tayfun/0000-0003-1444-7076; 			Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ayata C, 2002, J CLIN NEUROSCI, V9, P113, DOI 10.1054/jocn.2001.1031; Back M, 2007, THESCIENTIFICWORLDJO, V7, P1422, DOI 10.1100/tsw.2007.187; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Buege J A, 1978, Methods Enzymol, V52, P302; Capra V, 2006, CURR MED CHEM, V13, P3213, DOI 10.2174/092986706778742963; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Di Gennaro A, 2004, FASEB J, V18, P842, DOI 10.1096/fj.03-0599fje; Fiske CH, 1925, J BIOL CHEM, V66, P375; Genovese T, 2008, BRIT J PHARMACOL, V153, P568, DOI 10.1038/sj.bjp.0707577; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; Huang XJ, 2008, GLIA, V56, P27, DOI 10.1002/glia.20588; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Moos MPW, 2008, FASEB J, V22, P4352, DOI 10.1096/fj.08-113274; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; READING HW, 1980, Q J EXP PHYSIOL CMS, V65, P105, DOI 10.1113/expphysiol.1980.sp002495; Rovati GE, 2007, THESCIENTIFICWORLDJO, V7, P1375, DOI 10.1100/tsw.2007.185; Sala A, 2001, BIOCHEM BIOPH RES CO, V283, P1003, DOI 10.1006/bbrc.2001.4865; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Sener G, 2007, J PHARM PHARMACOL, V59, P837, DOI 10.1211/jpp.59.6.0009; Sener G, 2006, PHARMACOL RES, V54, P65, DOI 10.1016/j.phrs.2006.02.007; Sheng WW, 2006, BIOCHEM BIOPH RES CO, V346, P19, DOI 10.1016/j.bbrc.2006.05.023; Toklu HZ, 2009, J SURG RES, V152, P238, DOI 10.1016/j.jss.2008.03.013; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang ML, 2006, BIOCHEM BIOPH RES CO, V350, P399, DOI 10.1016/j.bbrc.2006.09.057; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yu GL, 2005, PHARMACOLOGY, V73, P31, DOI 10.1159/000081072; Zhang CM, 2008, RARE METAL MAT ENG, V37, P320, DOI 10.1016/S1875-5372(09)60008-4; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088	38	29	29	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	6					577	584	PII 911809930	10.1080/02699050902926317			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	451SF	WOS:000266489800011	19484631				2021-06-18	
J	Boone, KB				Boone, Kyle Brauer			[image omitted] Fixed Belief in Cognitive Dysfunction Despite Normal Neuropsychological Scores: Neurocognitive Hypochondriasis?	CLINICAL NEUROPSYCHOLOGIST			English	Article						Neurocognitive hypochondriasis; Fixed belief in cognitive dysfunction; Mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; TEST-PERFORMANCE; BASE-RATES; CHILDHOOD TRAUMA; SOMATIZATION; PERSONALITY; DEPRESSION; SYMPTOMS; AMPLIFICATION	A subset of patients who present for neuropsychological testing report dysfunction in daily life activities secondary to cognitive deficits, but are found on formal testing to have no objective abnormalities, raising the possibility of oneurocognitive hypochondriasis.o Such a case is presented, and the factors that appear to give rise to this presentation are explored. Cases of hypochondriacal overconcern regarding cognitive function are likely not rare, particularly given research showing there is little correlation between objective report of cognitive dysfunction and actual test scores in such conditions as mild traumatic brain injury, chronic fatigue syndrome, fibromyalgia, toxic mold exposure, and post-polio syndrome.	[Boone, Kyle Brauer] Alliant Univ, Ctr Forens Studies, Los Angeles, CA USA; [Boone, Kyle Brauer] Los Angeles Biomed Inst, Los Angeles, CA USA	Boone, KB (corresponding author), Alliant Int Univ LA, Ctr Forens Studies, 1000 S Fremont Ave, Alhambra, CA 91803 USA.	kboone@labiomed.org					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Applegate KL, 2005, J PAIN, V6, P92, DOI 10.1016/j.jpain.2004.11.001; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; BARSKY AJ, 1994, AM J PSYCHIAT, V151, P397; Barsky AJ, 2002, JAMA-J AM MED ASSOC, V287, P622, DOI 10.1001/jama.287.5.622; BARSKY AJ, 1993, AM J PSYCHIAT, V150, P1085; BARSKY AJ, 1992, PSYCHOSOMATICS, V33, P28, DOI 10.1016/S0033-3182(92)72018-0; BARSKY AJ, 1995, J PSYCHOSOM RES, V39, P489, DOI 10.1016/0022-3999(94)00166-3; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Boone, 2007, ASSESSMENT FEIGNED C; Boone K. B., 2002, B TEST; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; BOONE KB, 1995, NEUROPSYCHOLOGY, V9, P390, DOI 10.1037/0894-4105.9.3.390; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; CARROLL LJ, 2004, J REHABILITATION MED, V37, P61; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; DEMICK J, 1997, HDB NORMATIVE DATA N; Demopulos C, 1996, PSYCHOSOM MED, V58, P314, DOI 10.1097/00006842-199607000-00003; Diaz-Asper CM, 2004, J INT NEUROPSYCH SOC, V10, P82; Ferguson E, 1998, BRIT J MED PSYCHOL, V71, P281, DOI 10.1111/j.2044-8341.1998.tb00992.x; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Fink P, 2004, AM J PSYCHIAT, V161, P1680, DOI 10.1176/appi.ajp.161.9.1680; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Geisser ME, 2003, PAIN, V102, P243, DOI 10.1016/S0304-3959(02)00417-7; GRAHAM JR, 2000, MMP 2 ASSESSING PERS; GREENE RL, 1991, MMPI 2 MMPI INTERPRE; Greiffenstein M. F., 2000, BRAIN INJ SOURCE, V4, P26; Guze S B, 1993, Ann Clin Psychiatry, V5, P225, DOI 10.3109/10401239309148821; Hadjistavropoulos HD, 2000, BEHAV RES THER, V38, P425, DOI 10.1016/S0005-7967(99)00044-3; Hakala M, 2002, PSYCHOL MED, V32, P1379, DOI 10.1017/S0033291702006578; Hawkins KA, 2001, J INT NEUROPSYCH SOC, V7, P875, DOI 10.1017/S1355617701777119; Hazendonk KM, 2000, NEUROPSY NEUROPSY BE, V13, P112; Hollifield M, 1999, PSYCHOSOMATICS, V40, P387, DOI 10.1016/S0033-3182(99)71203-X; JOHNSON SK, 2007, MED UNEXPLAINED ILLN; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Keeley R, 2000, ARCH FAM MED, V9, P46, DOI 10.1001/archfami.9.1.46; KELLNER R, 1987, J NERV MENT DIS, V175, P20, DOI 10.1097/00005053-198701000-00004; LAMBERTY GJ, 2007, UNDERSTANDING SOMATI; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Lindberg MA, 2002, J PSYCHOL, V136, P125, DOI 10.1080/00223980209604144; Liu G, 1997, PSYCHOL MED, V27, P617, DOI 10.1017/S0033291797004844; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; MACE CJ, 1994, J NERV MENT DIS, V182, P186, DOI 10.1097/00005053-199403000-00012; Mayou R, 2005, AM J PSYCHIAT, V162, P847, DOI 10.1176/appi.ajp.162.5.847; MEALEY L, 1995, BEHAV BRAIN SCI, V18, P523, DOI 10.1017/S0140525X00039595; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nakao M, 2007, NEUROSCI LETT, V415, P185, DOI 10.1016/j.neulet.2007.01.021; Nitch S, 2006, CLIN NEUROPSYCHOL, V20, P873, DOI 10.1080/13854040590967603; Noyes R, 2005, J NERV MENT DIS, V193, P110, DOI 10.1097/01.nmd.0000152794.87100.92; Noyes R, 2004, J PSYCHOSOM RES, V57, P529, DOI 10.1016/j.jpsychores.2004.05.006; Noyes R, 2002, J NERV MENT DIS, V190, P503, DOI 10.1097/00005053-200208000-00002; Noyes R, 1999, PSYCHOSOMATICS, V40, P461, DOI 10.1016/S0033-3182(99)71183-7; Palmer BW, 1998, ARCH CLIN NEUROPSYCH, V13, P503, DOI 10.1016/S0887-6177(97)00037-1; PENNEBAKER JW, 1994, TOXICOL IND HEALTH, V10, P497; Persing JS, 2000, INT J PSYCHIAT MED, V30, P329, DOI 10.2190/KMXW-T53N-BTDW-GTGH; Rief W, 1998, J ABNORM PSYCHOL, V107, P587, DOI 10.1037/0021-843X.107.4.587; Rodriguez AM, 2005, J PSYCHOSOM RES, V58, P447, DOI 10.1016/j.jpsychores.2004.11.011; Russell EW, 2001, CLIN NEUROPSYCHOL, V15, P423, DOI 10.1076/clin.15.3.423.10267; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; SELNES OA, 1991, PERCEPT MOTOR SKILL, V73, P539, DOI 10.2466/PMS.73.5.539-550; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Speckens AEM, 2000, PSYCHOL MED, V30, P841, DOI 10.1017/S0033291799002378; Stone DC, 2006, CLIN NEUROPSYCHOL, V20, P766, DOI 10.1080/13854040500428459; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Suhr JA, 2003, J PSYCHOSOM RES, V55, P321, DOI 10.1016/S0022-3999(02)00628-1; Taylor S., 2004, TREATING HLTH ANXIET; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; TRAHAN D, 1987, HDB NORMATIVE DATA N; Waldinger RJ, 2006, PSYCHOSOM MED, V68, P129, DOI 10.1097/01.psy.0000195834.37094.a4; Wearden A, 2003, J PSYCHOSOM RES, V55, P341, DOI 10.1016/S0022-3999(02)00635-9; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; WILLIAMSON DJ, 2007, ASSESSMENT FEIGNED C	77	29	30	1	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	6					1016	1036	PII 904178676	10.1080/13854040802441135			21	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	473BG	WOS:000268178000007	18923966				2021-06-18	
J	Linnman, C; Appel, L; Soderlund, A; Frans, O; Engler, H; Furmark, T; Gordh, T; Langstrom, B; Fredrikson, M				Linnman, Clas; Appel, Lieuwe; Soderlund, Anne; Frans, Orjan; Engler, Henry; Furmark, Tomas; Gordh, Torsten; Langstrom, Bengt; Fredrikson, Mats			Chronic whiplash symptoms are related to altered regional cerebral blood flow in the resting state	EUROPEAN JOURNAL OF PAIN			English	Article						Whiplash; Positron emission tomography; Neuroimaging; Chronic pain; Post traumatic stress	POSTTRAUMATIC-STRESS-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; NECK DISABILITY INDEX; MUSCLE PAIN; HUMAN BRAIN; CENTRAL REPRESENTATION; FUNCTIONAL MRI; STIMULATION; ACTIVATION; INJURY	The neural pathogenic mechanisms involved in mediating chronic pain and whiplash associated disorders (WAD) after rear impact car collisions are largely unknown. This study's first objective was to compare resting state regional cerebral blood flow (rCBF) by means of positron emission tomography with (15)O labelled water in 21 WAD patients with 18 healthy, pain-free controls. A second objective was to investigate the relations between brain areas with altered rCBF to pain experience, somatic symptoms, posttraumatic stress symptoms and personality traits in the patient group. Patients had heightened resting rCBF bilaterally in the posterior parahippocampal and the posterior cingulate gyri, in the right thalamus and the right medial prefrontal gyrus as well as lowered tempero-occipital blood flow compared with healthy controls. The altered rCBF in the patient group was correlated to neck disability ratings. We thus suggest an involvement of the posterior cingulate, parahippocampal and medial prefrontal gyri in WAD and speculate that alterations in the resting state are linked to an increased self-relevant evaluation of pain and stress. (C) 2008 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All rights reserved.	[Linnman, Clas; Frans, Orjan; Furmark, Tomas; Fredrikson, Mats] Uppsala Univ, Dept Psychol, SE-75142 Uppsala, Sweden; [Appel, Lieuwe; Engler, Henry; Langstrom, Bengt] GE Healthcare, Uppsala Imanet AB, Uppsala, Sweden; [Soderlund, Anne] Uppsala Univ, Dept Publ Hlth & Caring Sci, Sect Caring Sci, SE-75142 Uppsala, Sweden; [Gordh, Torsten] Univ Uppsala Hosp, Div Anaesthesiol & Intens Care Med, Dept Surg Sci, Lab Pain Res, Uppsala, Sweden	Linnman, C (corresponding author), Uppsala Univ, Dept Psychol, Box 1225, SE-75142 Uppsala, Sweden.	clas.linnman@psyk.uu.se	Engler, Henry/ABD-8950-2020	Engler, Henry/0000-0002-8966-3788; Linnman, Clas/0000-0001-8449-894X; Furmark, Tomas/0000-0001-6821-9058; Soderlund, Anne/0000-0002-4537-030X; Gordh, Torsten/0000-0003-1454-3148	LF insurance research foundation; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Uppsala University Amersham Fund; Uppsala Imanet AB	The authors would like to thank two anonymous rewievers and Dr Stephen Butler for valuable comments, Anna Hillered Hultman for assistance in recruiting patients, Anna Pissiota, Fredrik Ahs and Asa Michelgard for assistance during data collection and the staff at Uppsala Imanet AB for providing an excellent research environment.; This work was supported by LF insurance research foundation, the Swedish Research Council, the Uppsala University Amersham Fund and Uppsala Imanet AB.	Ackelman BH, 2002, J REHABIL MED, V34, P284, DOI 10.1080/165019702760390383; Alexander Michael P, 2003, Pain Res Manag, V8, P19; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Baciu MV, 1999, AM J NEURORADIOL, V20, P1920; Bantick SJ, 2002, BRAIN, V125, P310, DOI 10.1093/brain/awf022; BERGMAN H, 2003, NEO PI R SVENSK VERS; Bicik I, 1998, NEUROLOGY, V51, P345, DOI 10.1212/WNL.51.2.345; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; Brett M., 2002, NEUROIMAGE, V16; Buitenhuis J, 2006, J PSYCHOSOM RES, V61, P681, DOI 10.1016/j.jpsychores.2006.07.008; Costa P., 1992, REVISED NEO PERSONAL; Creac'h C, 2000, AM J NEURORADIOL, V21, P1402; Curatolo M, 2001, CLIN J PAIN, V17, P306, DOI 10.1097/00002508-200112000-00004; Derbyshire SWG, 1997, PAIN, V73, P431, DOI 10.1016/S0304-3959(97)00138-3; Dickerson BC, 2004, ANN NEUROL, V56, P27, DOI 10.1002/ana.20163; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Frans O, 2005, ACTA PSYCHIAT SCAND, V111, P291, DOI 10.1111/j.1600-0447.2004.00463.x; Freitag P, 2001, NEUROREHAB NEURAL RE, V15, P31, DOI 10.1177/154596830101500105; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Gelnar PA, 1999, NEUROIMAGE, V10, P460, DOI 10.1006/nimg.1999.0482; Hsieh JC, 1996, PAIN, V67, P59, DOI 10.1016/0304-3959(96)03066-7; HSIEH JC, 1995, PAIN, V63, P225, DOI 10.1016/0304-3959(95)00048-W; Iadarola MJ, 1998, BRAIN, V121, P931, DOI 10.1093/brain/121.5.931; Johansen MK, 1999, PAIN, V83, P229, DOI 10.1016/S0304-3959(99)00106-2; Kuchinad A, 2007, J NEUROSCI, V27, P4004, DOI 10.1523/JNEUROSCI.0098-07.2007; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Liberzon I, 1999, BIOL PSYCHIAT, V45, P817, DOI 10.1016/S0006-3223(98)00246-7; Lorberboym M, 2002, J TRAUMA, V52, P521, DOI 10.1097/00005373-200203000-00017; Maddock RJ, 1999, TRENDS NEUROSCI, V22, P310, DOI 10.1016/S0166-2236(98)01374-5; Mai J. K., 1997, ATLAS HUMAN BRAIN; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Naliboff BD, 2001, PSYCHOSOM MED, V63, P365, DOI 10.1097/00006842-200105000-00006; Niddam DM, 2002, NEUROIMAGE, V17, P1437, DOI 10.1006/nimg.2002.1270; Nygren A., 2000, NACKSKADOR EFTER BIL; Otte A, 1998, EUR J NUCL MED, V25, P306; Otte A, 1996, EUR J NUCL MED, V23, P72, DOI 10.1007/BF01736993; OTTE A, 1995, LANCET, V345, P1513, DOI 10.1016/S0140-6736(95)91075-1; Otte A, 1997, J NEUROL NEUROSUR PS, V63, P368, DOI 10.1136/jnnp.63.3.368; Otte A, 1997, J NUCL MED, V38, P1002; Otte A, 1995, J VASC INVEST, V1, P157; Peyron R, 1999, BRAIN, V122, P1765, DOI 10.1093/brain/122.9.1765; Pissiota A, 2002, EUR ARCH PSY CLIN N, V252, P68, DOI 10.1007/s004060200014; Ploghaus A, 2001, J NEUROSCI, V21, P9896, DOI 10.1523/JNEUROSCI.21-24-09896.2001; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rodriquez AA, 2004, MUSCLE NERVE, V29, P768, DOI 10.1002/mus.20060; SCHALLING D, 1987, ACTA PSYCHIAT SCAND, V76, P172, DOI 10.1111/j.1600-0447.1987.tb02881.x; Seminowicz DA, 2006, PAIN, V120, P297, DOI 10.1016/j.pain.2005.11.008; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Soderlund A, 2006, EUR J PAIN, V10, P113, DOI 10.1016/j.ejpain.2005.01.015; Spielberger C.D., 1970, STATE TRAIT ANXIETY; SPITZER WO, 1995, SPINE, V20, pS1; Sterling M, 2006, PAIN, V122, P102, DOI 10.1016/j.pain.2006.01.014; Sturzenegger M, 2008, ACTA NEUROL SCAND, V117, P49, DOI 10.1111/j.1600-0404.2007.00939.x; Sundstrom T, 2006, EUR SPINE J, V15, P1189, DOI 10.1007/s00586-005-0040-5; Svensson P, 1997, J NEUROPHYSIOL, V78, P450; Talairach J., 1988, COPLANAR STEREOTAXIC; Thunberg J, 2005, EUR J PAIN, V9, P185, DOI 10.1016/j.ejpain.2004.05.003; Tolle TR, 1999, ANN NEUROL, V45, P40, DOI 10.1002/1531-8249(199901)45:1<40::AID-ART8>3.0.CO;2-L; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704; Wik G, 2006, INT J NEUROSCI, V116, P1, DOI 10.1080/00207450690962208; Wik G, 2003, NEUROREPORT, V14, P619, DOI 10.1097/00001756-200303240-00019	64	29	29	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3801			EUR J PAIN	Eur. J. Pain	JAN	2009	13	1					65	70		10.1016/j.ejpain.2008.03.001			6	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	402KL	WOS:000263012500011	18486506				2021-06-18	
J	Pare, N; Rabin, L; Fogel, J; Pepin, M				Pare, Nadia; Rabin, Laura A.; Fogel, Joshua; Pepin, Michel			Mild traumatic brain injury and its sequelae: Characterisation of divided attention deficits	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Attention; Brain injuries; Neuropsychological tests	MINOR HEAD-INJURY; POST-CONCUSSION SYMPTOMS; REACTION-TIME; POSTCONCUSSION SYNDROME; MODERATE; PERFORMANCE; MEMORY; PREDICTION; LONG; PATHOPHYSIOLOGY	Deficits in divided attention occur after a mild traumatic brain injury (MTBI) but many extant tasks lack sensitivity for detecting subtle cognitive difficulties. We use the Test d'Attention Partagee Informatise (TAPI), a novel dual-task paradigm, to investigate the impact of MTBI on the ability to divide attention between two stimuli sources. Individuals with MTBI (n = 37) were evaluated within the first week following head trauma and at three months post-injury. A healthy control (HC) group (n = 79) was also assessed. The primary outcome was reaction time and there were three different conditions that included visual target detection and auditory digit span tasks. Analyses utilised repeated measures ANOVA and ANCOVA models that adjusted for relevant variables including post-concussive and affective symptoms. Results indicated that at both baseline and follow-up, the MTBI group had significantly slower reaction time than the HC group. Also, both the MTBI and HC groups had slower reaction times as participants progressed through each of the more challenging TAPI conditions. This study supports the usefulness of this novel instrument and allows clinicians and researchers to assess for subtle divided attention deficits that may persist in those with MTBI even three months post-injury.	[Pare, Nadia] Kaiser Fdn Rehabil Ctr, Vallejo, CA USA; [Rabin, Laura A.; Fogel, Joshua] Brooklyn Coll, City Univ New York, Brooklyn, NY USA; [Pare, Nadia] Kaiser Fdn Rehabil Ctr, Vallejo, CA 94589 USA; [Pare, Nadia; Pepin, Michel] Univ Laval, Quebec City, PQ, Canada; [Rabin, Laura A.; Fogel, Joshua] CUNY Brooklyn Coll, Brooklyn, NY 11210 USA	Pare, N (corresponding author), Kaiser Fdn Rehabil Ctr, 975 Sereno Dr, Vallejo, CA 94589 USA.	nad.pare@gmail.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alfano MS, 2000, J CLIN PSYCHOL, V56, P975, DOI 10.1002/1097-4679(200007)56:7<975::AID-JCLP13>3.0.CO;2-Z; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Andres P, 2000, J GERONTOL B-PSYCHOL, V55, pP373, DOI 10.1093/geronb/55.6.P373; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Beck A.T., 1996, MANUAL BECK DEPRESSI; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2000, BRAIN COGNITION, V44, P50, DOI 10.1006/brcg.1999.1209; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1989, MILD HEAD INJURY, P229; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; EVANS RW, 1992, NEUROL CLIN, V10, P815; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GENTILINI M, 1989, MILD HEAD INJURY, P163; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; GRONWALL D, 1974, LANCET, V2, P605; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jagoda A, 2000, EMERG MED CLIN N AM, V18, P355, DOI 10.1016/S0733-8627(05)70130-9; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Keller M, 2000, J NEUROL NEUROSUR PS, V68, P761, DOI 10.1136/jnnp.68.6.761; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; PARE N, 2003, DISS ABSTR INT, V65, P478; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P315; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; SPIELBERGER CD, 1970, MANUAL STAI; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; *SPSS, 2006, VERS 15 01; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; VANZOMEREN AH, 2002, 30 ANN CONV INT NEUR; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924	71	29	30	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	1					110	137	PII 794347145	10.1080/09602010802106486			28	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	386HX	WOS:000261874300007	18609010				2021-06-18	
J	Ren, YJ; Zhou, ZY; Cui, FZ				Ren, Yong-Juan; Zhou, Zi-You; Cui, Fu-Zhai			Hyaluronic Acid/Polylysine Hydrogel as a Transfer System for Transplantation of Neural Stem Cells	JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS			English	Article						neural stem cell; tissue engineering; tissue scaffolds; stem cell transplantation; hydrogels; hyaluronic acid hydrogels; polylysine hydrogels; hyaluronic acid/polylysine hydrogels	TRAUMATIC BRAIN-INJURY; REPAIR; REGENERATION; TISSUE	Graft integration and survival are major factors that limit cell therapy for diseases and injury in the central nervous system. Efforts to improve graft survival and integration have focused on the development of biocompatible scaffolds to support neural cells. In this study, rat neural stem cells (NSC), including neurospheres and single cells, were seeded into hyaluronic acid/polylysine hydrogels. Confocal microscopy was used to noninvasively investigate the key cell phonotypes. After culture for 5 days, single NSC had survived and differentiated into neurons and astrocytes, while neurosphere-forming cells had migrated from their original aggregate and maintained the NSC phonotype. These studies, carried out in the absence of serum, identified HA/polylysine hydrogels as potential synthetic cell carriers for transplantation of NSC.	[Ren, Yong-Juan; Zhou, Zi-You; Cui, Fu-Zhai] Tsinghua Univ, Biomat Lab, Dept Mat Sci & Engn, Beijing 100084, Peoples R China	Cui, FZ (corresponding author), Tsinghua Univ, Biomat Lab, Dept Mat Sci & Engn, Beijing 100084, Peoples R China.	Cuifz@mail.tsinghua.edu.cn			National Basic Research Program of ChinaNational Basic Research Program of China [2005CB623905]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [50573044, 30670656]; Laboratory Fund of Tsinghua University	This work was supported by National Basic Research Program of China (No. 2005CB623905), National Natural Science Foundation of China (No. 50573044 and 30670656) and Laboratory Fund of Tsinghua University.	CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; Cui FZ, 2003, J BIOACT COMPAT POL, V18, P413, DOI 10.1177/0883911503040470; Geller HM, 2002, EXP NEUROL, V174, P125, DOI 10.1006/exnr.2002.7865; Hung CH, 2006, BIOMATERIALS, V27, P5901, DOI 10.1016/j.biomaterials.2006.08.009; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Schmidt CE, 2003, ANNU REV BIOMED ENG, V5, P293, DOI 10.1146/annurev.bioeng.5.011303.120731; Tatard VM, 2005, BIOMATERIALS, V26, P3727, DOI 10.1016/j.biomaterials.2004.09.042; Tsai RYL, 2000, J NEUROSCI, V20, P3725; Yin DZ, 2007, J BIOACT COMPAT POL, V22, P143, DOI 10.1177/0883911506076063; Zhang T, 2007, J BIOACT COMPAT POL, V22, P19, DOI 10.1177/0883911506074025	10	29	29	1	42	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0883-9115	1530-8030		J BIOACT COMPAT POL	J. Bioact. Compat. Polym.	JAN	2009	24	1					56	62		10.1177/0883911508099472			7	Biotechnology & Applied Microbiology; Materials Science, Biomaterials; Polymer Science	Biotechnology & Applied Microbiology; Materials Science; Polymer Science	397AV	WOS:000262635100004					2021-06-18	
J	Rubiano, AM; Villarreal, W; Hakim, EJ; Aristizabal, J; Hakim, F; Diez, JC; Pena, G; Puyana, JC				Rubiano, Andres Mariano; Villarreal, Wilson; Hakim, Enrique Jimenez; Aristizabal, Jorge; Hakim, Fernando; Diez, Juan Carlos; Pena, German; Puyana, Juan Carlos			Early decompressive craniectomy for neurotrauma: an institutional experience	ULUSAL TRAVMA VE ACIL CERRAHI DERGISI-TURKISH JOURNAL OF TRAUMA & EMERGENCY SURGERY			English	Article						Decompressive craniectomy; neurotrauma severe head trauma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; REFRACTORY INTRACRANIAL HYPERTENSION; CEREBRAL BLOOD-FLOW; SUBTEMPORAL DECOMPRESSION; SECONDARY INSULTS; SINGLE-CENTER; MANAGEMENT; CHILDREN; EDEMA	BACKGROUND Neurotrauma centers have developed management protocols on the basis of evidence obtained from literature analysis and institutional experience. This article reviews our institutional experience in the management of severe traumatic brain injury (TBI) at Simon Bolivar Hospital, the district trauma center for Bogota's north zone. METHODS This is a case control study comparing a group of patients (n: 16) operated for severe TBI between January 2002 and July 2004 according to an institutional management protocol characterized by an early decompressive craniectomy (DC) approach versus a historical control group (n: 20) managed before the implementation of such protocol. Mortality and Glasgow Outcome Score (GOS) at 6 months were used as the main outcome variables. RESULTS An early DC protocol implemented within 12 hours from injury in 16 patients with severe isolated TBI and a Marshall score between III or IV was associated with a lesser mortality than the conventional approach with ventriculostomy and Intensive Care Unit (ICU) management alone. The GOS was significantly better in the DC group (p=0.0002) than in the control group. CONCLUSION The use of an early DC protocol for severe TBI patients (Glasgow Coma Scale <9) had a significantly improved outcome compared with the conventional approach with ventriculostomy and ICU management in Simon Bolivar Hospital in Bogotd, Colombia.	[Rubiano, Andres Mariano; Villarreal, Wilson] Univ Simon Bolivar, Neurol Surg Serv, Bogota, Colombia; [Hakim, Enrique Jimenez; Hakim, Fernando; Pena, German] Fdn Santa Fe Bogota, Bogota, Colombia; [Aristizabal, Jorge; Diez, Juan Carlos] Clin El Bosque, Bogota, Colombia; [Puyana, Juan Carlos] Univ Pittsburgh, Trauma & Crit Care Dept, Pittsburgh, PA 15260 USA	Rubiano, AM (corresponding author), Cra 5A, 16-29 Ap 301 El Triunfo, Neiva, Huila, Colombia.	andresrubiano@hispavista.com	RUBIANO, ANDRES M/K-6704-2012	RUBIANO, ANDRES M/0000-0001-8931-3254	FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43 TW007560-05] Funding Source: Medline; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW007560] Funding Source: NIH RePORTER		Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Alexander E, 1987, Br J Neurosurg, V1, P427, DOI 10.3109/02688698708999632; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; Berger S, 2002, J TRAUMA, V53, P558, DOI 10.1097/00005373-200209000-00027; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; *BRAIN TRAUM FDN, 2006, NEUROSURGERY, V58, pS2; *BRAIN TRAUM FDN S, 2003, PEDIATR CRIT CARE ME, V4, P1; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Bullock MR, 2000, NEUROSURGERY, V47, P322; Burkert W, 1989, Zentralbl Neurochir, V50, P106; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chestnut RM, 2000, J NEUROTRAUM, V17, P614; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Compagnone C, 2005, NEUROSURGERY, V57, P1183; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; CRONE KR, 1985, NEUROSURGERY, V16, P726; *EUR BRAIN INJ CON, 1997, ACTA NEUROCHIR WIEN, V139, P286; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; GAAB MR, 1990, ACT NEUR S, V51, P326; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; HATASHITA S, 1987, J NEUROSURG, V67, P573, DOI 10.3171/jns.1987.67.4.0573; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Hlatky Roman, 2003, Neurosurg Focus, V14, pe2; Hutchinson P J, 2004, Curr Opin Crit Care, V10, P101, DOI 10.1097/00075198-200404000-00004; IBANEZ J, 2000, EST MULT CENTR MULT, V1, P179; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; JENNETT B, 1975, LANCET, V1, P480; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; KARLEN J, 1987, NEUROCHIRURGIA, V30, P35; KERR FWL, 1968, MAYO CLIN PROC, V43, P852; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Meier U, 2005, ACT NEUR S, V95, P55; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; Munch E, 2000, NEUROSURGERY, V47, P315; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reithmeier T, 2005, CHILD NERV SYST, V21, P249, DOI 10.1007/s00381-004-1044-x; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; RUBIANO A, 2004, SURG MANAGEMENT HEAD, P1; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Spagnuolo E, 2004, NEUROCIRUGIA, V15, P36; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Xi GH, 2002, NEUROSURG CLIN N AM, V13, P371, DOI 10.1016/S1042-3680(02)00007-4; ZAPATA GDP, 2003, PREHOSPITAL DISAST M, V18, P80; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083; 2000, J NEUROTRAUMA, V17, P457	68	29	29	0	0	TURKISH ASSOC TRAUMA EMERGENCY SURGERY	ISTANBUL	KOPRULU MEHMET PASA SOC, DENIZ ABDAL MAH, DADASOGLU AP, 25-1 SEHREMINI, ISTANBUL, 00000, TURKEY	1306-696X			ULUS TRAVMA ACIL CER	Ulus. Travma Acil Cerrahi Derg.	JAN	2009	15	1					28	38					11	Emergency Medicine	Emergency Medicine	388QM	WOS:000262034300007	19130336				2021-06-18	
J	Tenovuo, O; Alin, J; Helenius, H				Tenovuo, Olli; Alin, Jouni; Helenius, Hans			A randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injuryWhat it showed and taught?	BRAIN INJURY			English	Article						Traumatic brain injury; rivastigmine; randomized controlled trial; placebo-controlled trial; crossover study	SEVERE HEAD-INJURY; COGNITIVE IMPAIRMENT; CHOLINERGIC SYSTEM; BASAL FOREBRAIN; DONEPEZIL; MEMORY; ATTENTION; POLYMORPHISM; DYSFUNCTION; RECOVERY	Primary objective: To evaluate the effectiveness of rivastigmine for chronic sequels of traumatic brain injury (TBI). Research design: Randomized, placebo-controlled, double-blind crossover trial. Methods and procedures: Of 772 outpatients with TBI treated during 1993-2002, all eligible patients were contacted and 102 patients volunteered. They were randomized to receive either rivastigmine (Exelon) or placebo. The study included two periods with titration to the highest tolerated or maximum dose (12 mg rivastigmine daily) and a maintenance period of 8 weeks, separated by a 4-week washout. Computerized neuropsychological testing and standardized clinical interviews were used to assess the outcome. Main outcomes and results: Sixty-nine patients completed the study and 17 withdrew because of adverse effects. In two measures of computerized testing (subtraction test, p = 0.034 and correct answers in the 10-15 minute vigilance test, p = 0.048) rivastigmine was better than placebo. The clinical interviews did not yield significant results. After the study, 45% of patients considered rivastigmine beneficial compared to 20% with placebo. Conclusions: A weak trend favouring rivastigmine for chronic symptoms of TBI was observed. The clinical significance of the results and the problems in conducting drug trials for chronic TBI symptoms are discussed.	[Tenovuo, Olli] Univ Turku, Dept Neurol, FIN-20520 Turku, Finland; [Alin, Jouni; Helenius, Hans] Univ Turku, Dept Biostat, FIN-20520 Turku, Finland	Tenovuo, O (corresponding author), Univ Turku, Dept Neurol, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland.	olli.tenovuo@tyks.fi			Novartis FinlandNovartis	This study was supported by Novartis Finland (drugs and funding). The technical assistance of Tuula Tenovuo, Mari Toivola and the Clinical Research Service Turku are warmly acknowledged.	[Anonymous], 2003, J NEUROPSYCH CLIN N, V15, P383, DOI 10.1176/appi.neuropsych.15.3.383; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Bentley P, 2003, NEUROIMAGE, V20, P58, DOI 10.1016/S1053-8119(03)00302-1; Bourgeois JA, 2002, J NEUROPSYCH CLIN N, V14, P463, DOI 10.1176/appi.neuropsych.14.4.463; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; DEKKER AJAM, 1991, NEUROSCI BIOBEHAV R, V15, P299, DOI 10.1016/S0149-7634(05)80008-9; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Donohoe GG, 1999, CLIN CHEM, V45, P143; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Griffin SL, 2003, J NEUROPSYCH CLIN N, V15, P17, DOI 10.1176/appi.neuropsych.15.1.17; Grizzle J. E., 1974, BIOMETRICS, V30, P727; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jones B, 2003, DESIGN ANAL CROSS OV; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; Poole NA, 2008, BRAIN INJURY, V22, P519, DOI 10.1080/02699050802132495; REVONSUO A, 1995, COGNISPEED COMPUTER; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Semba K, 2000, BEHAV BRAIN RES, V115, P117, DOI 10.1016/S0166-4328(00)00254-0; Silver JM, 2006, NEUROLOGY, V67, P748, DOI 10.1212/01.wnl.0000234062.98062.e9; Silver JM., 1994, NEUROPSYCHIATRY TRAU; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Tenovuo OS, 2006, CURR DRUG THER, V1, P187, DOI 10.2174/157488506776930932; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Whitlock JA, 1999, J HEAD TRAUMA REHAB, V14, P424, DOI 10.1097/00001199-199908000-00010; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	41	29	29	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	6					548	558	PII 911808147	10.1080/02699050902926275			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	451SF	WOS:000266489800008	19484628				2021-06-18	
J	Unden, J; Romner, B				Unden, Johan; Romner, Bertil			A new objective method for CT triage after minor head injury - serum S100B	SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION			English	Article; Proceedings Paper	Symposium on Diagnosis of Neurological Disorders	NOV, 2007	Karolinska Univ Hosp, Stockholm, SWEDEN		Karolinska Univ Hosp	Biomarker; CT; guidelines; head injury; management; minor; S100B; S100; S-100; serum; TBI	NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; S-100 PROTEIN MEASUREMENTS; FIBRILLARY ACIDIC PROTEIN; NEW-ORLEANS CRITERIA; COMPUTED-TOMOGRAPHY; MILD; MANAGEMENT; DAMAGE; RULE	The risk of acute intracranial complication after minor head injury (MHI) is low. Despite this, a computed tomography (CT) scan is generally recommended for all patients following MHI. Admission for clinical observation is a secondary management option when a CT scan is unavailable or is judged inappropriate. Both alternatives are associated with disadvantages and several attempts at refining existing guidelines for MHI management have been proposed as a means of reducing CT and/or admission. However, they are based on potentially unreliable patient history and clinical examination and, furthermore, may be compromised by patient factors such as intoxication. Clinical studies from several research groups have shown the potential of brain biomarker S100B in this patient category. The specificity of S100B is poor, but a high sensitivity for brain damage effectively rules out relevant complications after MHI. Used in conjunction with existing guidelines, serum levels of S100B can accurately identify patients who do not need a CT scan after MHI. Based on 6 prospective studies comprising almost 2,000 patients with MHI, the sensitivity and negative predictive value of S100B for CT findings were 98.2 % and 99.5 %, respectively, and for clinically relevant intracranial complications 100 % and 100 %, respectively. Integration of S100B within existing management routines can reduce the need for CT scans by 30 %, resulting in improved and more efficient patient care.	[Romner, Bertil] Rigshosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark; [Unden, Johan] Halmstad Cty Hosp, Dept Anesthesia & Intens Care, Halmstad, Sweden	Romner, B (corresponding author), Rigshosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark.	Bertil.Romner@med.lu.se					af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; af Geijerstam JL, 2000, EUR J SURG, V166, P526; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Astrand R, 2006, ACTA NEUROL SCAND, V113, P262, DOI 10.1111/j.1600-0404.2005.00573.x; Bellner J, 1999, ACTA NEUROL SCAND, V100, P355; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Bottiger BW, 2001, CIRCULATION, V103, P2694; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Enochsson L, 2005, EUR J NEUROL, V12, P445, DOI 10.1111/j.1468-1331.2005.00996.x; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P177; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Nylen K, 2007, STROKE, V38, P1489, DOI 10.1161/STROKEAHA.106.478362; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2004, SCAND J INFECT DIS, V36, P10, DOI 10.1080/00365540310017294; Unden Johan, 2008, Lakartidningen, V105, P1846; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Yates DW, 2003, EMERG MED J, V20, P117, DOI 10.1136/emj.20.2.117	45	29	29	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0036-5513	1502-7686		SCAND J CLIN LAB INV	Scand. J. Clin. Lab. Invest.		2009	69	1					13	17	PII 908528277	10.1080/00365510802651833			5	Medicine, Research & Experimental	Research & Experimental Medicine	404IR	WOS:000263145500004	19199125				2021-06-18	
J	Ahmad, M; Rose, ME; Vagni, V; Griffith, RP; Dixon, CE; Kochanek, PM; Hickey, RW; Graham, SH				Ahmad, Muzamil; Rose, Marie E.; Vagni, Vincent; Griffith, Raymond P.; Dixon, C. Edward; Kochanek, Patrick M.; Hickey, Robert W.; Graham, Steven H.			Genetic Disruption of Cyclooxygenase-2 Does Not Improve Histological or Behavioral Outcome After Traumatic Brain Injury in Mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						cyclooxygenase; prostaglandin E-2; TUNEL staining; behavior; Morris water maze	CELL-DEATH; INHIBITOR ROFECOXIB; COX-2 INHIBITORS; IN-SITU; RATS; EXPRESSION; CELECOXIB; INFLAMMATION; NEURONS; EDEMA	Increasing evidence suggests a role for cyclooxygenase-2 (COX-2) in traumatic brain injury (TBI). In the present study, the role of COX-2 in TBI was investigated using COX-2 gene-disrupted (COX-2 null) mice and wild-type (WT) controls that were subjected to the controlled cortical impact (CCI) model of TBI. There was increased expression of COX-2 in ipsilateral hippocampus in WT mice subjected to CCI. CCI resulted in a significant increase in prostaglandin E-2 concentrations in WT compared with COX-2 null hippocampi. There was a significant increase in TUNEL staining of CA1 neurons 24 hr after CCI in WT, but not in COX-2 null mice, compared with sham-operated controls, which is consistent with a protective role for COX-2 in the early phase of injury after TBI. However, there was no difference in lesion volume 21 days after CCI in COX-2 null and WT mice. COX-2 gene disruption did not alter Morris water maze performance. Taken together, these results suggest only a minor role for COX-2 activity in determining outcome after TBI in mouse. (c) 2008 Wiley-Liss, Inc.	[Ahmad, Muzamil; Rose, Marie E.; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15206 USA; [Ahmad, Muzamil; Rose, Marie E.; Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Vagni, Vincent; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Griffith, Raymond P.; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Kochanek, Patrick M.; Hickey, Robert W.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA	Graham, SH (corresponding author), VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, 151-UH,7108 Highland Dr, Pittsburgh, PA 15206 USA.	sgra@pitt.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	Department of Veterans Affairs/Department of DefenseUS Department of Veterans AffairsUnited States Department of Defense; Traumatic Brain Injury Initiative Merit Review Program; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS37459]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS037459] Funding Source: NIH RePORTER	Contract grant sponsor: Department of Veterans Affairs/Department of Defense, Traumatic Brain Injury Initiative Merit Review Program (to S.H.G.); Contract grant sponsor: NIH; Contract grant number: R01 NS37459 (to S.H.G.).	Alkayed NJ, 1996, AM J PHYSIOL-HEART C, V271, pH1541; Alloza I, 2006, MOL PHARMACOL, V69, P1579, DOI 10.1124/mol.105.020669; Belton Orina, 2003, Expert Reviews in Molecular Medicine, V5, P1, DOI 10.1017/S1462399403005842; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chang JW, 1996, NEUROBIOL AGING, V17, P801; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Drachman DB, 2000, ANN NEUROL, V48, P792, DOI 10.1002/1531-8249(200011)48:5<792::AID-ANA14>3.0.CO;2-5; ELLIS EF, 1990, AM J PHYSIOL, V259, pH1171, DOI 10.1152/ajpheart.1990.259.4.H1171; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Han SW, 2006, LUNG CANCER, V51, P283, DOI 10.1016/j.lungcan.2005.10.015; Hatton J, 2001, CNS DRUGS, V15, P553, DOI 10.2165/00023210-200115070-00005; Hickey RW, 2007, PEDIATR RES, V62, P271, DOI 10.1203/PDR.0b013e3180db2902; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Kaloustian S, 2007, APOPTOSIS, V12, P1945, DOI 10.1007/s10495-007-0122-4; Kardosh A, 2004, CANCER BIOL THER, V3, P55, DOI 10.4161/cbt.3.1.571; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Kunz T, 2001, EUR J NEUROSCI, V13, P569, DOI 10.1046/j.1460-9568.2001.01420.x; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Kunz T, 2006, RESTOR NEUROL NEUROS, V24, P55; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Larsen BT, 2006, EUR J CLIN INVEST, V36, P293, DOI 10.1111/j.1365-2362.2006.01634.x; Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355; Marklund N, 2002, J NEUROTRAUM, V19, P1139, DOI 10.1089/08977150260337958; Miyamoto K, 2006, BRAIN, V129, P1984, DOI 10.1093/brain/awl170; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; SASAKI T, 1988, STROKE, V19, P1399, DOI 10.1161/01.STR.19.11.1399; Schwab JM, 2006, CURR OPIN PHARMACOL, V6, P414, DOI 10.1016/j.coph.2006.02.006; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Toscano CD, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r14; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yoon JB, 2003, J BIOL CHEM, V278, P15319, DOI 10.1074/jbc.M212520200; Zhang WR, 2007, J CEREBR BLOOD F MET, V27, P1931, DOI 10.1038/sj.jcbfm.9600494; Zhong H, 2004, INT J CANCER, V112, P585, DOI 10.1002/ijc.20438	48	29	29	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC	2008	86	16					3605	3612		10.1002/jnr.21809			8	Neurosciences	Neurosciences & Neurology	383CO	WOS:000261651900012	18711748	Green Accepted			2021-06-18	
J	Folkersma, H; Breve, JJP; Tilders, FJH; Cherian, L; Robertson, CS; Vandertop, WP				Folkersma, Hedy; Breve, John J. P.; Tilders, Fred J. H.; Cherian, Leela; Robertson, Claudia S.; Vandertop, W. Peter			Cerebral microdialysis of interleukin (IL)-1ss and IL-6: extraction efficiency and production in the acute phase after severe traumatic brain injury in rats	ACTA NEUROCHIRURGICA			English	Article						Brain injury; Cytokines; ELISA; Interleukins; IL-1 beta; IL-6; Microdialysis	TUMOR-NECROSIS-FACTOR; NERVE GROWTH-FACTOR; CEREBROSPINAL-FLUID; IN-VIVO; HIPPOCAMPAL-NEURONS; TEMPORAL PROFILE; MESSENGER-RNA; HEAD-INJURY; TNF-ALPHA; EXPRESSION	Background As a research tool, cerebral microdialysis might be a useful technique in monitoring the release of cytokines into the extracellular fluid (ECF) following traumatic brain injury (TBI). We established extraction efficiency of Interleukin(IL)-1ss and Interleukin(IL)-6 by an in vitro microdialysis-perfusion system, followed by in vivo determination of the temporal profile of extracellular fluid cytokines after severe TBI in rats. Materials and methods In vitro experiments using a polyether sulfon (PES) microdialysis probe especially developed for recovery of macromolecules such as cytokines, were carried out to establish the extraction efficiency of IL-1ss and IL-6 from artificial cerebrospinal fluid (CSF) with defined IL-1ss and IL-6 concentrations. In vivo experiments in which rats were subjected to TBI or sham and microdialysis samples were collected from the parietal lobe for measurement of cytokines. Findings The extraction efficiency was maximal 6.05% (range, 5.97-6.13%) at 0.5 mu l/min(-1) and decreased at higher flow rates. Both cytokines were detectable in the dialysates. Highest IL-1ss levels were found within 200 min, highest IL-6 concentrations were detected at later intervals (200-400 min). No differences were found between the TBI and control groups. Conclusions Cerebral microdialysis allows measurement of cytokine secretion in the ECF of brain tissue in rats.	[Folkersma, Hedy; Vandertop, W. Peter] Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, NL-1008 MB Amsterdam, Netherlands; [Folkersma, Hedy; Vandertop, W. Peter] Vrije Univ Amsterdam, Med Ctr, Neurosurg Ctr Amsterdam, NL-1008 MB Amsterdam, Netherlands; [Breve, John J. P.; Tilders, Fred J. H.] Vrije Univ Amsterdam, Med Ctr, Dept Med Pharmacol, NL-1008 MB Amsterdam, Netherlands; [Cherian, Leela; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Vandertop, WP (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, POB 7057, NL-1008 MB Amsterdam, Netherlands.	hedy.folkersma@vumc.nl; jjp.breve@vumc.nl; fjh.tilders@vumc.nl; claudiar@bcm.tmc.edu; wp.vandertop@vumc.nl	Vandertop, William P./K-9288-2018		Neurosurgery Foundation AZVU	The Neurosurgery Foundation AZVU supported this study. Recombinant rat IL-1ss and IL-6 and reagents for measurements of rat IL-1ss and IL-6 were kindly provided by Dr. Stephan Poole (National Institute for Biological Standards and Control, Potters Bar, UK).	Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; BENVENISTE H, 1987, ACTA NEUROPATHOL, V74, P234, DOI 10.1007/BF00688186; Berger C, 2005, STROKE, V36, pE4, DOI 10.1161/01.STR.0000151328.70519.e9; Cano-Cebrian MJ, 2005, CURR DRUG METAB, V6, P83, DOI 10.2174/1389200053586109; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Friedman WJ, 2001, EXP NEUROL, V168, P23, DOI 10.1006/exnr.2000.7595; Godbout JP, 2004, J NEUROIMMUNOL, V147, P141, DOI 10.1016/j.jneuroim.2003.10.031; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; HAZUDA DJ, 1991, J BIOL CHEM, V266, P7081; Jensen SM, 2007, J PHARMACEUT BIOMED, V43, P1751, DOI 10.1016/j.jpba.2006.12.014; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Lenczowski MJP, 1997, AM J PHYSIOL-REG I, V273, pR1870; LONNROTH P, 1987, AM J PHYSIOL, V253, pE228; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Meixensberger J, 2001, NEUROL RES, V23, P801, DOI 10.1179/016164101101199379; Miyachi T, 2001, NEUROSCI RES, V40, P53, DOI 10.1016/S0168-0102(01)00208-5; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Oprica M, 2003, J CELL MOL MED, V7, P127, DOI 10.1111/j.1582-4934.2003.tb00211.x; Peerdeman SM, 2000, INTENS CARE MED, V26, P662, DOI 10.1007/s001340051230; Peerdeman SM, 2003, INTENS CARE MED, V29, P1825, DOI 10.1007/s00134-003-1850-8; Peerdeman SM, 2002, J NEUROL, V249, P676, DOI 10.1007/s00415-002-0689-1; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Rees GS, 1999, CYTOKINE, V11, P95, DOI 10.1006/cyto.1998.0408; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; SANTHANAM U, 1989, ARCH BIOCHEM BIOPHYS, V274, P161, DOI 10.1016/0003-9861(89)90427-X; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	52	29	35	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	DEC	2008	150	12					1277	1284		10.1007/s00701-008-0151-y			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	382FF	WOS:000261590000009	19031041	Other Gold			2021-06-18	
J	Wei, YZ; Wang, L; Clark, JCM; Dass, CR; Choong, PFM				Wei, Yongzhong; Wang, Lei; Clark, Jonathan C. M.; Dass, Crispin R.; Choong, Peter F. M.			Elevated leptin expression in a rat model of fracture and traumatic brain injury	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Article							SYMPATHETIC NERVOUS-SYSTEM; BONE METABOLISM; SERUM LEPTIN; HEAD-INJURY; LOCALIZATION; RECEPTORS; INCREASES; MINERALIZATION; INFLAMMATION; RELEASE	A few studies have reported a relationship between leptin induced by brain injury and healing of bone tissue. Our objective was to measure serum and callus leptin expression within the setting of fracture and traumatic brain injury (TBI). Sixty-four male Sprague-Dawley rats were randomised equally into four groups: control, TBI group, fracture group and fracture/TBI group. Rats were sacrificed at 2, 4, 8 and 12 weeks after fracture/TBI. Serum leptin was detected using radioimmunoassay, and callus formation was measured radiologically. Callus leptin was analysed with immunohistochemistry. Serum leptin was significantly increased in the fracture, TBI and combined fracture/TBI groups compared with the control group at 2 weeks (P < 0.05). Serum leptin was significantly higher in the combined fracture/TBI group than in the fracture and TBI groups at 4 and 8 weeks (P < 0.05). The percentage of leptin-positive cells in the callus and callus volume were significantly higher in the fracture/TBI group than in the fracture-only group (P < 0.001). Thus, we demonstrated elevated leptin expression within healing bone, particularly in the first 8 weeks of a rat model combining fracture and TBI. A close association exists between leptin levels and the degree of callus formation in fractures.	[Wei, Yongzhong; Wang, Lei] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing, Peoples R China; [Clark, Jonathan C. M.; Dass, Crispin R.; Choong, Peter F. M.] Univ Melbourne, Melbourne, Vic 3010, Australia	Wei, YZ (corresponding author), Guangzhou Rd 300, Jiangsu 210029, Peoples R China.	wyz202@hotmail.com	Choong, Peter/F-1109-2014	Choong, Peter/0000-0002-3522-7374	Medical Science and Technology Development of Jiangsu Health Bureau [H200512]	This work was supported by funds from the Medical Science and Technology Development of Jiangsu Health Bureau (H200512), China.	Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Barr VA, 1999, J BIOL CHEM, V274, P21416, DOI 10.1074/jbc.274.30.21416; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; Bonnet N, 2007, BONE, V40, P1209, DOI 10.1016/j.bone.2007.01.006; Ealey KN, 2006, REGUL PEPTIDES, V136, P9, DOI 10.1016/j.regpep.2006.04.013; Faggioni R, 2000, AM J PATHOL, V156, P1781, DOI 10.1016/S0002-9440(10)65049-3; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156; Janik JE, 1997, J CLIN ENDOCR METAB, V82, P3084, DOI 10.1210/jc.82.9.3084; Jeevanandam M, 1998, JPEN-PARENTER ENTER, V22, P340, DOI 10.1177/0148607198022006340; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; KOLACZYNSKI JW, 1996, DIABETES, V45, P701; Li JL, 2000, J BONE MINER RES, V15, P2042, DOI 10.1359/jbmr.2000.15.10.2042; Li S, 2001, Hua Xi Yi Ke Da Xue Xue Bao, V32, P240; Lin Ji, 2006, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V18, P19; Lolmede K, 2003, INT J OBESITY, V27, P1187, DOI 10.1038/sj.ijo.0802407; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P3408, DOI 10.1210/jc.82.10.3408; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; Miell JP, 1996, HORM METAB RES, V28, P704, DOI 10.1055/s-2007-979882; PASINETTI GM, 1993, NEUROSCIENCE, V54, P893, DOI 10.1016/0306-4522(93)90583-2; Patel L, 2002, J PEDIATR ENDOCR MET, V15, P963; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; Rayner DV, 2001, J MOL MED-JMM, V79, P8, DOI 10.1007/s001090100198; Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426; Rigaux P, 2005, JOINT BONE SPINE, V72, P146, DOI 10.1016/j.jbspin.2004.05.012; Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018; Shahbazian LM, 1999, METABOLISM, V48, P1397, DOI 10.1016/S0026-0495(99)90149-X; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; Thomas T, 2004, CURR OPIN PHARMACOL, V4, P295, DOI 10.1016/j.coph.2004.01.009; Thomas T, 2002, J BONE MINER RES, V17, P1563, DOI 10.1359/jbmr.2002.17.9.1563; Trentz OA, 2005, CRIT CARE MED, V33, P399, DOI 10.1097/01.CCM.0000152221.87477.21; Utriainen T, 1996, DIABETES, V45, P1364, DOI 10.2337/diabetes.45.10.1364; Wang YH, 2005, ARCH PHYS MED REHAB, V86, P1964, DOI 10.1016/j.apmr.2005.04.017; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009	43	29	35	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3573	2042-7158		J PHARM PHARMACOL	J. Pharm. Pharmacol.	DEC	2008	60	12					1667	1672		10.1211/jpp/60.12.0013			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	380ON	WOS:000261475100013	19000372				2021-06-18	
J	Lu, HX; Li, MJ; Song, TS; Qian, YH; Xiao, XL; Chen, XL; Zhang, PB; Feng, XS; Terence, P; Liu, Y				Lu Haixia; Li Minjie; Song Tusheng; Qian Yihua; Xiao Xinli; Chen Xinlin; Zhang Pengbo; Feng Xinshun; Terence, Parker; Liu Yong			Retrovirus delivered neurotrophin-3 promotes survival, proliferation and neuronal differentiation of human fetal neural stem cells in vitro	BRAIN RESEARCH BULLETIN			English	Article						Neural stem cells; Neurotrophin-3; Retrovirus; Survival; Proliferation; Differentiation	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; PROGENITOR CELLS; FUNCTIONAL RECOVERY; PARKINSONS-DISEASE; PRECURSOR CELLS; RETINOIC ACID; AXONAL GROWTH; SCHWANN-CELLS	Poor survival and insufficient neuronal differentiation are the main obstacles to neural stem cell (NSC) transplantation therapy. Genetic modification of NSCs with neurotrophins is considered a promising approach to overcome these difficulties. In this study, the effects on survival, proliferation and neuronal differentiation of human fetal NSCs (hfNSCs) were observed after infection by a neurotrophin-3 (NT-3) recombinant retrovirus. The hfNSCs, from 12-week human fetal brains formed neurospheres, expressed the stem cell marker nestin and differentiated into the three main cell types of the nervous system. NT-3 recombinant retrovirus (Retro-NT-3) infected hfNSCs efficiently expressed NT-3 gene for at least 8 weeks, presented an accelerated proliferation, and therefore produced an increased number of neurospheres and after differentiation in vitro, contained a higher percentage of neuronal cells. Eight weeks after infection, 37.9 +/- 4.2% of hfNSCs in the Retro-NT-3 infection group expressed the neuronal marker, this was significantly higher than the control and mock infection groups. NT-3 transduced hfNSCs also displayed longer protruding neurites compared with other groups. Combined these results demonstrate that NT-3 modification promote the survival/proliferation, neuronal differentiation and growth of neurites of hfNSCs in vitro. This study proposes recombinant retrovirus mediated NT-3 modification may provide a promising means to resolve the poor survival and insufficient neuronal differentiation of NSCs. (c) 2008 Published by Elsevier Inc.	[Lu Haixia; Li Minjie; Xiao Xinli; Chen Xinlin; Zhang Pengbo; Liu Yong] Xian Jiaotong Univ, Sch Med, Inst Neurobiol, Xian 710061, Peoples R China; [Lu Haixia] Xian Jiaotong Univ, Sch Med, Affiliated Hosp 2, Dept Obstet & Gynecol, Xian 710004, Peoples R China; [Song Tusheng] Xian Jiaotong Univ, Sch Med, Dept Genet & Mol Biol, Xian 710061, Peoples R China; [Qian Yihua] Xian Jiaotong Univ, Sch Med, Dept Anat & Histoembryol, Xian 710061, Peoples R China; [Feng Xinshun] Xian Jiaotong Univ, Sch Med, Affiliated Hosp 1, Kidney Transplantat Ctr, Xian 710061, Peoples R China; [Terence, Parker] Univ Nottingham, Sch Biomed Sci, QMC, Dept Human Anat & Cell Biol,Inst Neurosci, Nottingham NG7 2UH, England	Liu, Y (corresponding author), Xian Jiaotong Univ, Sch Med, Inst Neurobiol, Xian 710061, Peoples R China.	lhaixia71@hotmail.com; limin_71@163.com; tusheng@mail.xjtu.edu.cn; qianyh38@mail.xjtu.edu.cn; xxli-2001@163.com; chenxl@mail.xjtu.edu.cn; zhpbo@163.com; xinshunf@163.com; terry.parker@nottingham.ac.uk; liuy5599@mail.xjtu.edu.cn			Natural Science Foundation of Shaanxi ProvinceNatural Science Foundation of Shaanxi Province [2001SM63]; Xi'an Jiaotong University for Stem Cell ResearchXi'an Jiaotong University	This work was supported partly by grants from Natural Science Foundation of Shaanxi Province (2001SM63) and Xi'an Jiaotong University for Stem Cell Research. The authors would like to thank Prof. Guangxiao Yang and Prof. Quanying Wang at Huaguang Biothechnol Co. Ltd., Xi'an for their excellent technical assistance. The authors are also grateful to Dr H. Levis and Dr J. Rimmer from University of Nottingham for their expert help in the English editing.	Bithell A, 2005, CLIN SCI, V108, P13, DOI 10.1042/CS20040276; Bjorklund A, 2003, LANCET NEUROL, V2, P437, DOI 10.1016/S1474-4422(03)00442-3; Bodmer D, 2002, LARYNGOSCOPE, V112, P2057, DOI 10.1097/00005537-200211000-00028; Caldwell MA, 2001, NAT BIOTECHNOL, V19, P475, DOI 10.1038/88158; Calza L, 2003, P NATL ACAD SCI USA, V100, P7325, DOI 10.1073/pnas.1132092100; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Cao QL, 2002, EXP NEUROL, V177, P349, DOI 10.1006/exnr.2002.7981; Capone C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000373; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chow SY, 2000, BRAIN RES, V874, P87, DOI 10.1016/S0006-8993(00)02443-4; Dutton R, 1999, J NEUROSCI, V19, P2601; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Grider MH, 2005, J NEUROSCI RES, V82, P404, DOI 10.1002/jnr.20635; Grill R, 1997, J NEUROSCI, V17, P5560; Grondin R, 2002, BRAIN, V125, P2191, DOI 10.1093/brain/awf234; Guo JS, 2007, SPINAL CORD, V45, P15, DOI 10.1038/sj.sc.3101943; Hapner SJ, 2006, DEV BIOL, V297, P182, DOI 10.1016/j.ydbio.2006.05.007; Himes BT, 2001, J NEUROSCI RES, V65, P549, DOI 10.1002/jnr.1185; Ito H, 2003, J NEUROSCI RES, V71, P648, DOI 10.1002/jnr.10532; Kamei N, 2007, SPINE, V32, P1272, DOI 10.1097/BRS.0b013e318059afab; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kim S, 2004, CELL MOL NEUROBIOL, V24, P343, DOI 10.1023/B:CEMN.0000022767.74774.38; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lepore AC, 2006, NEUROSCIENCE, V139, P513, DOI 10.1016/j.neuroscience.2005.12.043; Lepore AC, 2004, NEURON GLIA BIOL, V1, P113, DOI 10.1017/S1740925X04000213; Lim MS, 2007, BIOCHEM BIOPH RES CO, V357, P903, DOI 10.1016/j.bbrc.2007.04.045; Liu Y, 1999, EXP NEUROL, V158, P9, DOI 10.1006/exnr.1999.7079; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Lundberg C, 1997, EXP NEUROL, V145, P342, DOI 10.1006/exnr.1997.6503; Park KI, 2006, EXP NEUROL, V199, P179, DOI 10.1016/j.expneurol.2006.03.016; Pyle AD, 2006, NAT BIOTECHNOL, V24, P344, DOI 10.1038/nbt1189; Rothstein JD, 2004, NAT BIOTECHNOL, V22, P283, DOI 10.1038/nbt0304-283; Roy NS, 2004, NAT BIOTECHNOL, V22, P297, DOI 10.1038/nbt944; Sgubin D, 2007, J NEUROSCI RES, V85, P1647, DOI 10.1002/jnr.21303; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007; Ubiali F, 2007, INT IMMUNOL, V19, P1063, DOI 10.1093/intimm/dxm079; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Wada K, 2003, STROKE, V34, P2722, DOI 10.1161/01.STR.0000094421.61917.71; Wang JM, 2007, EXP NEUROL, V203, P123, DOI 10.1016/j.expneurol.2006.07.028; Wang Y, 2007, J NEUROIMMUNE PHARM, V2, P243, DOI 10.1007/s11481-007-9074-2; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Winkler C, 1998, MOL CELL NEUROSCI, V11, P99, DOI 10.1006/mcne.1998.0674; Yan J, 2004, J COMP NEUROL, V480, P101, DOI 10.1002/cne.20344; Zhang LY, 2007, CELL TRANSPLANT, V16, P475, DOI 10.3727/000000007783464902; Zhang XB, 2007, J NEUROTRAUM, V24, P1863, DOI 10.1089/neu.2007.0334; Zhao LX, 2004, EXP NEUROL, V190, P396, DOI 10.1016/j.expneurol.2004.06.025; Zhou LJ, 2003, J NEUROSCI RES, V74, P221, DOI 10.1002/jnr.10718	53	29	34	1	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	OCT 22	2008	77	4					158	164		10.1016/j.brainresbull.2008.02.037			7	Neurosciences	Neurosciences & Neurology	368LW	WOS:000260623600002	19875351				2021-06-18	
J	Vincent, AS; Bleiberg, J; Yan, S; Ivins, B; Reeves, DL; Schwab, K; Gilliland, K; Schlegel, R; Warden, D				Vincent, Andrea S.; Bleiberg, Joseph; Yan, Sam; Ivins, Brian; Reeves, Dennis L.; Schwab, Karen; Gilliland, Kirby; Schlegel, Robert; Warden, Deborah			Reference data from the Automated Neuropsychological Assessment Metrics for use in traumatic brain injury in an active duty military sample	MILITARY MEDICINE			English	Article							PERFORMANCE; TESTS	The current study examined the performance of active duty soldiers on the Automated Neuropsychological Assessment Metrics (ANAM) traumatic brain injury test battery, to expand the reference data for use in military settings. The effects of age and gender on cognitive performance also were explored. The ANAM traumatic brain injury battery, consisting of six performance tests and two subjective scales, was administered to a sample of healthy active duty soldiers (N = 5,247) as part of a concussion surveillance program. Performance means and SDs, stratified according to age and gender, are reported as reference data. In addition, the impact of age and gender on performance measures was analyzed. Because ANAM is rapidly being adopted for use in many military medical and research applications, the establishment of these reference values is invaluable, particularly for assisting with rapid accurate evaluation and treatment in clinical settings.	[Vincent, Andrea S.; Gilliland, Kirby; Schlegel, Robert] Univ Oklahoma, Ctr Study Human Operator Performance, Norman, OK 73072 USA; [Bleiberg, Joseph; Yan, Sam] Natl Rehabil Hosp, Ctr Cognit Neurosci, Washington, DC 20010 USA; [Ivins, Brian; Schwab, Karen; Warden, Deborah] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Reeves, Dennis L.] Clinvest, Springfield, MO 65807 USA	Vincent, AS (corresponding author), Univ Oklahoma, Ctr Study Human Operator Performance, Norman, OK 73072 USA.			Bleiberg, Joseph/0000-0003-0867-5494	DVBICUS Department of Veterans Affairs [DAMD17-00-1-0056]	This study was funded primarily by the DVBIC, with additional support from Cooperative Agreement DAMD17-00-1-0056 between the U.S. Army Medical Research and Materiel Command and the National Rehabilitation Hospital.	Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; D'Agostino RB., 1986, GOODNESS OF FIT TECH; ENGLUND CE, 1987, 8710 JOINT WORK GROU; HANNAY HJ, 2004, NEUROPSYCHOLOGICAL A, P133; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; Langlois JA., 2004, TRAUMATIC BRAIN INJU; National Institute of Neurological Disorders and Stroke, TRAUM BRAIN INJ HOP; Perez W.A., 1987, AAMRLTR87007; REEVES D, 1993, NEUROPSYCHOLOGICAL A; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Roebuck-Spencer TM, 2008, MIL PSYCHOL, V20, P187, DOI 10.1080/08995600802118825; Salthouse TA, 2002, J CLIN EXP NEUROPSYC, V24, P858, DOI 10.1076/jcen.24.7.858.8392; SANTUCCI G, 1989, 308 AGARDOGRAPH NATO; Schatz P, 2002, J HEAD TRAUMA REHAB, V17, P395, DOI 10.1097/00001199-200210000-00003; Short P, 2007, ARCH CLIN NEUROPSYCH, V22, pS63, DOI 10.1016/j.acn.2006.10.012; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]	22	29	29	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	SEP	2008	173	9					836	852		10.7205/MILMED.173.9.836			17	Medicine, General & Internal	General & Internal Medicine	352YW	WOS:000259534300004	18816922	Bronze			2021-06-18	
J	Stein, SC; Fabbri, A; Servadei, F				Stein, Sherman C.; Fabbri, Andrea; Servadei, Franco			Routine serial computed tomographic scans in mild traumatic brain injury: When are they cost-effective?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						mild traumatic brain injury, cranial computed tomography scan; serial computed tomography studies	MINOR HEAD-INJURY; BLUNT INTRACRANIAL INJURY; NEW-ORLEANS CRITERIA; EXTRADURAL HEMATOMAS; BENEFIT PATIENTS; PRACTICAL SCALE; CT; UTILITY; CHILDREN; RULE	Background: Most case series involving routine serial computed tomography (CT) scans of the head in patients with mild traumatic brain injury (TBI) have suggested that they only occasionally provide useful information and imply that the practice is unnecessary and wasteful. No study has looked at the special case in which the initial scan revealed an intracranial abnormality which did not require surgery. Methods: We performed a structured review of the literature for the probabilities and costs of various outcomes in patients with mild TBI who demonstrate at least one intracranial abnormality on their admission CT scans. We supplemented this data with additional information from a large database of mild TBI patients. We then constructed a decision-analytic model to calculate costs and outcomes, comparing the strategy of routine serial scanning with that of awaiting clinical deterioration before repeating the study (expectant strategy). Results: For the 20-year-old patient, the routine CT strategy is slightly more effective than the expectant strategy and is also only slightly more expensive. With advancing age, the relative cost-effectiveness of routine CT declines. Conclusions: Awaiting clinical deterioration in patients with mild TBI whose first CT scan reveals intracranial injury is not cost-effective compared with routine follow-up CT scans. Although the difference is not statistically significant, routine follow-up scanning is slightly more cost-effective, especially in younger patients.	[Stein, Sherman C.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19106 USA; [Fabbri, Andrea] Osped Morgagni Pierantoni, Dept Emergency Med, Forli, Italy; [Servadei, Franco] Osped Bufalini, Dept Neurosurg, Cesena, Italy	Stein, SC (corresponding author), Hosp Univ Penn, Dept Neurosurg, 310 Spruce St, Philadelphia, PA 19106 USA.	sherman.stein@uphs.upenn.edu	Fabbri, Andrea/K-9994-2016	Servadei, Franco/0000-0002-3595-3464; Fabbri, Andrea/0000-0002-9837-4638			Aoki N, 1998, MED DECIS MAKING, V18, P357, DOI 10.1177/0272989X9801800401; Arias Elizabeth, 2004, Natl Vital Stat Rep, V53, P1; *BDO, 2003, REP SHORTF MED FUND; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Chapman RH, 2004, HEALTH ECON, V13, P429, DOI 10.1002/hec.853; Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation National Research Council, 2005, HLTH RISKS EXP LOW L; Concato J, 1997, J INVEST MED, V45, P394; Dharap SB, 2005, INJURY, V36, P412, DOI 10.1016/j.injury.2004.06.020; DRUMMOND MF, 1997, PRESENTATION USE EC, P265; Durham SR, 2006, J NEUROSURG, V105, P365, DOI 10.3171/ped.2006.105.5.365; Einarson TR, 1997, CLIN THER, V19, P559, DOI 10.1016/S0149-2918(97)80140-3; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; FELDMAN KW, 1995, CHILD ABUSE NEGLECT, V19, P307, DOI 10.1016/S0145-2134(94)00130-8; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Gold M., 1996, Cost-Effectiveness in Health and Medicine.; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; JENNETT B, 1975, LANCET, V1, P480; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; KING JT, 1994, J NEUROSURG, V81, P837, DOI 10.3171/jns.1994.81.6.0837; KUDAY C, 1994, ACTA NEUROCHIR, V131, P203, DOI 10.1007/BF01808613; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MOHANTY A, 1995, PEDIATR NEUROSURG, V23, P57, DOI 10.1159/000120936; RIVAS JJ, 1988, NEUROSURGERY, V23, P44, DOI 10.1227/00006123-198807000-00010; Schackman BR, 2004, PHARMACOECONOMICS, V22, P293, DOI 10.2165/00019053-200422050-00003; *SERV CFMAM, 2005, AC INP PROSP PAYM SY; SERVADEI F, 1995, ACTA NEUROCHIR, V133, P50, DOI 10.1007/BF01404947; Shackford SR, 2004, J TRAUMA, V56, P480; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Sinson G, 2001, J TRAUMA, V51, P875; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Sox H.C., 1988, MED DECISION MAKING; STAMMLER U, 1989, Neurosurgical Review, V12, P159, DOI 10.1007/BF01790640; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; STEIN SC, 1995, PEDIAT SURG INT, V10, P271; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; TEASDALE G, 1974, LANCET, V2, P81; Ubel PA, 2003, ARCH INTERN MED, V163, P1637, DOI 10.1001/archinte.163.14.1637; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89	55	29	31	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2008	65	1					66	72		10.1097/TA.0b013e318068d75f			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	327ZP	WOS:000257767300012	18580532				2021-06-18	
J	Tian, HL; Chen, SW; Xu, T; Hu, J; Rong, BY; Wang, G; Gao, WW; Chen, H				Tian Heng-Li; Chen Shi-Wen; Xu Tao; Hu Jin; Rong Bo-Ying; Wang Gan; Gao Wen-Wei; Chen Hao			Risk factors related to hospital mortality in patients with isolated traumatic acute subdural haematoma: analysis of 308 patients undergone surgery	CHINESE MEDICAL JOURNAL			English	Article						acute subdural haematoma; hospital mortality; risk factors	SEVERE HEAD-INJURY; OUTCOME PREDICTION; PROGNOSTIC-FACTORS; BRAIN-INJURY; MANAGEMENT; AGE	Background Acute subdural haematoma (ASDH) is a common traumatic brain injury with a relatively high mortality rate. However, few studies have examined the factors predicting the outcome of isolated traumatic ASDH. This clinical study examined the hospital mortality and analyzed the risk factors for mortality in patients treated surgically for isolated traumatic ASDH. Methods We collected 308 consecutive patients who underwent neurosurgery for isolated traumatic ASDH between January 1999 and December 2007 and used multivariate Logistic regression analysis to evaluate the influence of 11 clinical variables on hospital mortality. Results The overall hospital mortality was 21.75% (67/308). Age (OR=1.807), preoperative Glasgow Coma Score (OR=0.316), brain herniation (OR=2.181) and the time from trauma to decompression (OR=1.815) were independent predictors of death, while no independent association was observed between hospital mortality and haematoma volume, midline shift, acute brain swelling or brain herniation duration, although these variables were correlated with hospital mortality in univariate analyses. Conclusions This study identified the risk factors for hospital mortality inpatients who underwent surgical treatment for isolated traumatic ASDH. An increased risk of death occurs in patients who are over 50 years of age and have lower preoperative Glasgow Coma Scores, the presence of brain herniation and a long interval between trauma and decompression. The findings should help clinicians determine management criteria and improve survival.	[Tian Heng-Li; Chen Shi-Wen; Xu Tao; Hu Jin; Rong Bo-Ying; Wang Gan; Gao Wen-Wei; Chen Hao] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Neurosurg, Shanghai 200233, Peoples R China	Chen, H (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Neurosurg, Shanghai 200233, Peoples R China.	chenhao_316@yahoo.com.cn		Chen, Hao/0000-0002-9943-9237			Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; D'Amato L, 2007, J Neurosurg Sci, V51, P107; Jiang JY, 1998, CHINESE MED J-PEKING, V111, P180; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Leach P, 2007, BRIT J NEUROSURG, V21, P11, DOI 10.1080/02688690701210562; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Marion DW, 2006, NEUROSURGERY, V58, P655; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; PIOTROWSKI WP, 1995, UNFALLCHIRURG, V98, P432; Saito T, 2003, ACTA NEUROCHIR SUPPL, V86, P351; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; VILALTA J, 1989, NEUROLOGIA, V6, P247; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212	20	29	29	0	3	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0366-6999			CHINESE MED J-PEKING	Chin. Med. J.	JUN 20	2008	121	12					1080	1084		10.1097/00029330-200806020-00007			5	Medicine, General & Internal	General & Internal Medicine	316IV	WOS:000256943800007	18706221	DOAJ Gold			2021-06-18	
J	Kaminski, TW; Cousino, ES; Glutting, JJ				Kaminski, Thomas W.; Cousino, Eric S.; Glutting, Joseph J.			Examining the relationship between puposeful heading in soccer and computerized neuropsychological test performance	RESEARCH QUARTERLY FOR EXERCISE AND SPORT			English	Article						concussion; memory; neurocognition; reaction time	SPORT-RELATED CONCUSSION; BRAIN-INJURY; FOOTBALL PLAYERS; NEUROCOGNITIVE PERFORMANCE; COGNITIVE IMPAIRMENT; POSTURAL CONTROL; ALTERNATE FORMS; COLLEGIATE; MANAGEMENT; TRAUMA	The Purpose of this study was to determine if a relationship exists between Purposeful heading in soccer and neuropychological test performance. Automated Neuropsychological Assessment Metrics throughput scores were derived on seven subset variables that measure a variety of neurocognitive abilities. Simple Spearman's rank correlations were calculated between headers per game (HPG) and the criterion variables. Interestingly, math processing speed. (Spearman's rho = .160) and continuous performance test #2 (rho = .124) had small but significant correlations; both showed improvement in Performance Pre- to postseason. There were no significant correlations between HPG and the other five variables. This study found no detrimental relationship between the number of purposeful headers and the neurocognitive measures in this population.	[Kaminski, Thomas W.] Univ Delaware, Dept Hlth Nutr & Exercise Sci, Human Performance Lab, Newark, DE 19716 USA; [Glutting, Joseph J.] Univ Delaware, Sch Educ, Newark, DE 19716 USA	Kaminski, TW (corresponding author), Univ Delaware, Dept Hlth Nutr & Exercise Sci, Human Performance Lab, 159 Fred Rust Ice Arena,541 S Coll Ave, Newark, DE 19716 USA.	kaminski@udel.edu					Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Asken MJ, 1998, PHYSICIAN SPORTSMED, V26, P37, DOI 10.3810/psm.1998.11.1190; ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; Babbs CF, 2000, JAMA-J AM MED ASSOC, V283, P882, DOI 10.1001/jama.283.7.882; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Beglinger LJ, 2005, ARCH CLIN NEUROPSYCH, V20, P517, DOI 10.1016/j.acn.2004.12.003; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Broglio SP, 2001, ATHLET THER TODAY, V6, P28, DOI 10.1123/att.6.1.28; BROWN CN, 2004, J ATHL TRAINING, V39, pS17; Bruggemans EF, 1997, J CLIN EXP NEUROPSYC, V19, P543, DOI 10.1080/01688639708403743; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COUGHLIN SS, 1990, J CLIN EPIDEMIOL, V43, P87, DOI 10.1016/0895-4356(90)90060-3; Cousino E, 2006, J ATHL TRAINING, V41, pS; COUSINO ES, 2005, J ATHL TRAINING, V40, pS97; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Faude O, 2005, AM J SPORT MED, V33, P1694, DOI 10.1177/0363546505275011; FELD A, 2005, DISCOVERING STAT USI; Giza CC, 2001, J ATHL TRAINING, V36, P228; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; GREGORY RJ, 1996, PSYCHOL TESTING HIST; Grote C, 2000, JAMA-J AM MED ASSOC, V283, P882; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Guskiewicz KM, 2001, ATHLET THER TODAY, V6, P18, DOI 10.1123/att.6.1.18; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Holbourn AHS, 1943, LANCET, V2, P438; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski T. W., 2002, Medicine & Science in Sports & Exercise, V34, pS2, DOI 10.1097/00005768-200205001-00009; KAMINSKI TW, 2006, J ATHL TRAINING, V41, pS39; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lynch JM, 1996, US SOCCER SPORTS MED, P81; Mangus Brent C, 2004, Sports Biomech, V3, P209, DOI 10.1080/14763140408522841; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Maxwell S. E., 2004, DESIGNING EXPT ANAL; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Overall JE, 1996, J CLIN PSYCHOL, V52, P243, DOI 10.1002/(SICI)1097-4679(199605)52:3<243::AID-JCLP1>3.0.CO;2-T; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Randolph C, 2005, J ATHL TRAINING, V40, P139; RASMUSSEN AM, 2002, J ATHL TRAINING, V3, pS64; Ravdin LD, 2003, CLIN J SPORT MED, V13, P21, DOI 10.1097/00042752-200301000-00005; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Salvia J., 2007, ASSESSMENT SPECIAL I, V11th; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; Smodlaka VN, 1984, PHYSICIAN SPORTSMED, V12, P127, DOI DOI 10.1080/00913847.1984.11701777; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Stevens J.P., 2002, APPL MULTIVARIATE ST, V4th ed; SULLIVAN JA, 1980, AM J SPORT MED, V8, P325, DOI 10.1177/036354658000800505; Tabachnick BG, 2007, USING MULTIVARIATE S; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; Thorndike R. M., 1997, MEASUREMENT EVALUATI; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Westerman R, 2001, ADF HLTH, V2, P29	71	29	29	0	8	AMER ALLIANCE HEALTH PHYS EDUC REC & DANCE	RESTON	1900 ASSOCIATION DRIVE, RESTON, VA 22091 USA	0270-1367			RES Q EXERCISE SPORT	Res. Q. Exerc. Sport	JUN	2008	79	2					235	244					10	Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences	Social Sciences - Other Topics; Psychology; Sport Sciences	316EJ	WOS:000256931400012	18664047				2021-06-18	
J	Schoenberg, MR; Ruwe, WD; Dawson, K; McDonald, NB; Houston, B; Forducey, PG				Schoenberg, Mike R.; Ruwe, William D.; Dawson, Kyra; McDonald, Nicholas B.; Houston, Beki; Forducey, Pamela G.			Comparison of functional outcomes and treatment cost between a computer-based cognitive rehabilitation teletherapy program and a face-to-face rehabilitation program	PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE			English	Article						cognitive rehabilitation; telemedicine; teletherapy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DISABILITY RATING-SCALE; HEAD-INJURY; TELEMEDICINE; TELEREHABILITATION; RECOVERY; RECOMMENDATIONS; OPPORTUNITIES; TECHNOLOGY; SYSTEM	The authors compared outcomes of 19 participants who received computer-based cognitive teletherapy rehabilitation with 20 participants who received face-to-face speech-language rehabilitation. The study compared outcomes from 2 "real-word" treatment programs provided by an outpatient rehabilitation center. A total of 39 participants with moderate to severe closed head traumatic brain injuries and a minimum of I year following injury were analyzed. Outcome measures included clinical indicators of independent living status, return to work or school, and independent driving. Cost measures included the total cost of the treatment and a measure of service costs per hour. Time since injury was a covariate, and an analysis of covariance revealed no differences between groups in independent living, driving status, return to work or school, or total treatment costs. The computer-based teletherapy cognitive rehabilitation program provided similar functional outcomes as face-to-face speech-language therapy at a similar total cost.	[Schoenberg, Mike R.] Univ Hosp, Case Med Ctr, Dept Neurol, Cleveland, OH 44106 USA; [Ruwe, William D.] Univ Oklahoma, Hlth Sci Ctr, Norman, OK 73019 USA; [Houston, Beki] INTEGRIS Hosp, Oklahoma City, OK USA; [Forducey, Pamela G.] INTEGRIS Southwest Med Ctr, INTEGRIS Telehlth & Neurosci Inst, Oklahoma City, OK USA; [Dawson, Kyra] Cleveland State Univ, Cleveland, OH 44115 USA	Schoenberg, MR (corresponding author), Univ Hosp, Case Med Ctr, Dept Neurol, HH 5,11100 Euclid Ave, Cleveland, OH 44106 USA.	michael.schoenberg@uhhospitals.org	Schoenberg, Mike R/J-9018-2012	Schoenberg, Mike/0000-0003-1355-3651			Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Brunicardi BO, 1998, TELEMED J, V4, P49, DOI 10.1089/tmj.1.1998.4.49; Burns RB, 1998, ASSIST TECHNOL, V10, P126, DOI 10.1080/10400435.1998.10131970; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cicerone KD, 1999, J HEAD TRAUMA REHAB, V14, P316, DOI 10.1097/00001199-199906000-00011; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CLARK P, 2002, NEUROLOGY REPORT, V26, P87, DOI DOI 10.1097/01253086-200226020-00006]; Conrad K. C., 1998, PROFESSIONAL PSYCHOL, V29, P525; Day SX, 2002, J COUNS PSYCHOL, V49, P499, DOI 10.1037/0022-0167.49.4.499; Fitzgerald Maureen H., 1992, World Health Forum, V13, P303; Hailey D, 2002, J TELEMED TELECARE, V8, P1; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; HARLEY JP, 1992, NEUROREHABILITATION, V2, P62; Lacroix A, 2002, TELEMED J E-HEALTH, V8, P149, DOI 10.1089/15305620260008084; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; Mair FS, 2000, J TELEMED TELECARE, V6, P38, DOI 10.1258/1357633001934096; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; *NAT AC NEUR, 2002, POS PAP COGN REH; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Phipps EJ, 1999, J HEAD TRAUMA REHAB, V14, P329, DOI 10.1097/00001199-199906000-00014; Popescu VG, 2000, IEEE T INF TECHNOL B, V4, P45, DOI 10.1109/4233.826858; Prigatano GP, 1999, J HEAD TRAUMA REHAB, V14, P308, DOI 10.1097/00001199-199906000-00009; *PSCYH CORP, 1999, MAN WECHSL ABBR SCAL; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Ricker J H, 1998, Appl Neuropsychol, V5, P184, DOI 10.1207/s15324826an0504_3; Riva G, 2000, Technol Health Care, V8, P113; Roine R, 2001, CAN MED ASSOC J, V165, P765; Salvatore Tony, 2002, Home Healthc Nurse, V20, P127; Sandberg L, 1998, Health Manag Technol, V19, P29; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schopp L, 2000, PROF PSYCHOL-RES PR, V31, P179, DOI 10.1037/0735-7028.31.2.179; Sjogren LH, 2001, J TELEMED TELECARE, V7, pS12; Sosin DM, 1996, BRAIN INJURY, V10, P47; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Whitten P, 2000, J TELEMED TELECARE, V6, P4, DOI 10.1258/1357633001934177; Whitten PS, 2002, BRIT MED J, V324, P1434, DOI 10.1136/bmj.324.7351.1434; Winters JM, 2002, ANNU REV BIOMED ENG, V4, P287, DOI 10.1146/annurev.bioeng.4.112801.121923; Woods K, 1998, TELEMED J, V4, P353, DOI 10.1089/tmj.1.1998.4.353; Wootton R, 2001, BRIT MED J, V323, P557, DOI 10.1136/bmj.323.7312.557; Ziegler J, 1995, Bus Health, V13, P47	44	29	30	0	17	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0735-7028	1939-1323		PROF PSYCHOL-RES PR	Prof. Psychol.-Res. Pract.	APR	2008	39	2					169	175		10.1037/0735-7028.39.2.169			7	Psychology, Multidisciplinary	Psychology	282WW	WOS:000254599000008					2021-06-18	
J	Walz, NC; Cecil, KM; Wade, SL; Michaud, LJ				Walz, Nicolay Chertkoff; Cecil, Kim M.; Wade, Shari L.; Michaud, Linda J.			Late proton magnetic resonance spectroscopy following traumatic brain injury during early childhood: Relationship with neurobehavioral outcomes	JOURNAL OF NEUROTRAUMA			English	Article						early childhood; neurobehavioral outcomes; proton MR spectroscopy; traumatic brain injury	MR SPECTROSCOPY; N-ACETYLASPARTATE; LOCALIZED PROTON; CHILDREN	We sought to extend previous research that demonstrates reduced neurometabolite concentrations during the chronic phase of pediatric traumatic brain injury (TBI) in children injured during early childhood. We hypothesized that young children with TBI in the chronic phase post-injury would have lower N-acetyl aspartate (NAA) metabolite concentrations in gray and white matter in comparison to controls. We also hypothesized that metabolite levels would be correlated with acute TBI severity and neurobehavioral skills. Ten children with a history of TBI between the ages of 3 and 6 years were compared to an age, gender, and race-matched group of 10 children with a history of an orthopedic injury (OI). Children completed neurobehavioral testing at 12 months post-injury. Proton magnetic resonance (MR) spectroscopy was completed at least 12 months post-injury when the children were 6-9 years old. Groups were compared on metabolite concentrations in the medial frontal gray matter and left frontal white matter. Metabolite levels were correlated with Glasgow Coma Scale (GCS) scores and neurobehavioral functioning. There was a trend for lower NAA concentrations in the medial frontal gray matter for the TBI group. Late NAA and Cr levels in the medial frontal gray matter and NAA levels in the left frontal white matter were strongly positively correlated with initial GCS score. Metabolite levels were correlated with some neurobehavioral measures differentially for children with TBI or OI. Some neurometabolite levels differed between the TBI and OI groups more than 1 year post-injury and were related to injury severity, as well as some neurobehavioral outcomes following TBI during early childhood.	[Walz, Nicolay Chertkoff; Cecil, Kim M.; Wade, Shari L.; Michaud, Linda J.] Childrens Hosp, Med Ctr, Div Behav Med & Clin Psychol, Dept Pediat, Cincinnati, OH 45229 USA; [Michaud, Linda J.] Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Cecil, Kim M.] Childrens Hosp, Med Ctr, Dept Radiol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA	Walz, NC (corresponding author), Childrens Hosp, Med Ctr, Div Behav Med & Clin Psychol, Dept Pediat, MLC 3015,3333 Burnet Ave, Cincinnati, OH 45229 USA.	nicolay.walz@cchmc.org		Cecil, Kim/0000-0001-8233-5485	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R43HD044279, K23HD046690] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA112181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P01ES011261] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01 CA112181, CA112181] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD044279, R43 HD044279, R01 HD042729, K23 HD046690] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R21 ES012524, P01 ES011261] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Bracken BA, 1998, BRACKEN BASIC CONCEP; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Caldarella, 2002, HOME COMMUNITY SOCIA; CARROWWOODFOLK E, 2000, COMPREHENSIVE ASSESS; *CDC, 2003, TRAU BRAIN INJ US AS; Cecil K M, 2001, Top Magn Reson Imaging, V12, P435, DOI 10.1097/00002142-200112000-00005; Elliott C.D., 1990, DIFFERENTIAL ABILITY; Gioia G.A., 2000, BEHAV RATING INVENTO; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; Jung RE, 2005, NEUROIMAGE, V26, P965, DOI 10.1016/j.neuroimage.2005.02.039; MOFFET JR, 2006, N ACETYLASPARTATE UN; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Parry L, 2004, CHILD NEUROPSYCHOL, V10, P248, DOI 10.1080/09297040490909279; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Traber F, 2004, J MAGN RESON IMAGING, V19, P537, DOI 10.1002/jmri.20053; TZIKA AA, 1993, JMRI-J MAGN RESON IM, V3, P719, DOI 10.1002/jmri.1880030506; VANDERKNAAP MS, 1990, RADIOLOGY, V176, P509, DOI 10.1148/radiology.176.2.2164237; Woodcock R.W., 2001, WOODCOCK JOHNSON 3 T; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427	30	29	30	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2008	25	2					94	103		10.1089/neu.2007.0362			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266RZ	WOS:000253456000002	18260792	Green Accepted			2021-06-18	
J	Geurtsen, GJ; Martina, JD; Van Heugten, CM; Geurts, ACH				Geurtsen, G. J.; Martina, J. D.; Van Heugten, C. M.; Geurts, A. C. H.			A prospective study to evaluate a new residential community reintegration programme for severe chronic brain injury: The Brain Integration Programme	BRAIN INJURY			English	Article						community integration; employment; living skills; residential community reintegration programme; neurobehavioural; outcome	COGNITIVE REHABILITATION; SELF-AWARENESS; ADJUSTMENT; PEOPLE	Purpose: To assess the effectiveness of a residential community reintegration programme for participants with chronic sequelae of severe acquired brain injury that hamper community functioning. Design: Prospective cohort study. Subjects: Twenty-four participants with acquired brain injury (traumatic n = 18; stroke n = 3, tumour n = 2, encephalitis n = 1). Participants had impaired illness awareness, alcohol and drug problems and/or behavioural problems. Intervention: A skills-oriented programme with modules related to independent living, work, social and emotional well-being. Methods: The Community Integration Questionnaire, CES-Depression, EuroQOL, Employability Rating Scale, living situation and work status were scored at the start (T0), end of treatment (T1) and 1-year follow-up (T2). Results: Significant effects on the majority of outcome measures were present at T1. Employability significantly improved at T2 and living independently rose from 42% to over 70%. Participants working increased from 38% to 58% and the hours of work per week increased from 8 to 15. Conclusion: The Brain Integration Programme led to a sustained reduction in experienced problems and improved community integration. It is concluded that even participants with complex problems due to severe brain injury who got stuck in life could improve their social participation and emotional well-being through a residential community reintegration programme.	[Geurtsen, G. J.] Rehabil Ctr Groot Klimmendaal, Dept Acquired Brain Injury, NL-6800 GG Arnhem, Netherlands; [Van Heugten, C. M.] Univ Maastricht, Utrecht, Netherlands; [Van Heugten, C. M.] Univ Utrecht, Rudolf Magnus Inst, Rehabil Ctr Hoogstr, Utrecht, Netherlands; [Geurts, A. C. H.] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Rehabil, Nijmegen, Netherlands	Geurtsen, GJ (corresponding author), Rehabil Ctr Groot Klimmendaal, Dept Acquired Brain Injury, POB 9044, NL-6800 GG Arnhem, Netherlands.	g.geurtsen@grootklimmendaal.nl	Geurts, Alexander/H-8032-2014	Geurts, Alexander/0000-0001-7478-1119; Geurtsen, G.J./0000-0002-2508-340X			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ARCINIEGAS DB, 2000, CURRENT TREATMENT OP, V2, P169; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Bouma J, 1995, MEASUREMENT DEPRESSI; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cope DN, 2005, J HEAD TRAUMA REHAB, V20, P128, DOI 10.1097/00001199-200503000-00002; CORRIGAN JD, 2005, REHABILITATION TRAUM, P133; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Evans R W, 1991, J Insur Med, V23, P192; GAINOTTI G, 1999, HDB CLIN EXPT NEUROP, P613; Geurtsen GJ, 2004, INT J REHABIL RES, V27, P52; GEURTSEN GJ, 2004, NEUROPRAXIS, V8, P82; HEATON RK, 1993, WISCONSIM CARD SORTI; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Kirk RE, 1968, EXPT DESIGN PROCEDUR; KOVACS F, 2001, TOWER LONDON TEST MA; KOVACS F, 2001, TEST SUSTAINED SELEC; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; McCluskey AE, 2000, BRAIN INJURY, V14, P943, DOI 10.1080/02699050050191896; Oddy M, 2003, NEUROPSYCHOL REHABIL, V13, P259, DOI 10.1080/09602010244000345; PETERS M D, 1992, Brain Injury, V6, P299, DOI 10.3109/02699059209034944; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Reitan R. M., 1992, TRAIL MAKING TEST MA; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1964, CLIN PSYCHOL EXAMINA; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Rothwell NA, 1999, BRAIN INJURY, V13, P521; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; TEASDALE G, 1974, LANCET, V2, P81; VANBALEN HGG, 2002, COGNITIVE REHABILITA, P71; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746; Yates PJ, 2003, NEUROPSYCHOL REHABIL, V13, P291, DOI 10.1080/09602010244000408; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	47	29	29	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	7-8					545	554		10.1080/02699050802132479			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	318MG	WOS:000257095300005	18568707				2021-06-18	
J	Petersen, C; Scherwath, A; Fink, J; Koch, U				Petersen, Corinna; Scherwath, Angela; Fink, Juliane; Koch, Uwe			Health-related quality of life and psychosocial consequences after mild traumatic brain injury in children and adolescents	BRAIN INJURY			English	Article						quality of life; cognitive screening; mild traumatic brain injury; children; adolescents; follow-up	HEAD-INJURY; QUESTIONNAIRE; STRENGTHS; BEHAVIOR	Background: Little is known about the course of health-related quality of life (HRQOL) and functional outcome parameters in children and adolescents with TBI. In addition, a neuropsychological screening instrument would be useful for routine clinical care. Objective: To describe health-related quality of life and psychosocial consequences following mild traumatic brain injury (TBI). Methods: One chose a prospective, longitudinal design (two measurement time points). Methods included a telephone interview and a questionnaire, which was mailed to the parents whose children (older than 4 years of age) were admitted (with TBI) to a collaborating hospital. In addition, a feasibility study for screening children for cognitive side effects, attention and memory tasks was conducted. A group of 59 parents filled out questionnaires assessing health-related quality of life (KINDL), behavioural problems (SDQ) and health status (FS-II-R). Ten families participated in the feasibility study. Results: Results indicated that HRQOL, behavioural problems and health status remained stable over time. Compared to the reference groups, no significant differences in HRQOL were noted. Thirty per cent of the children screened were classified as being cognitively impaired. Conclusion: Mild TBI resulted in no decline in the children's health outcome after injury. The cognitive screening approach proved itself to be a useful instrument for routine clinical care.	[Petersen, Corinna; Scherwath, Angela; Fink, Juliane; Koch, Uwe] Univ Hamburg, Med Ctr, Inst & Policlin Med Psychol, Ctr Psychosocial Med, D-20246 Hamburg, Germany	Petersen, C (corresponding author), Univ Hamburg, Med Ctr, Inst & Policlin Med Psychol, Ctr Psychosocial Med, Martinistr 52, D-20246 Hamburg, Germany.	copeters@uke.unihamburg.de	Scherwath, Angela/Q-4197-2016; Koch, Uwe/A-5825-2009				Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; DROTAR D, 1998, MEASURING HLTH RELAT; Eiser C, 2001, J DEV BEHAV PEDIATR, V22, P248, DOI 10.1097/00004703-200108000-00007; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Helmstaedter C., 2001, VERBALER LERNUND MER; KENNARD M, 1942, ARCH NEUROL PSYCHIAT, V48, P377; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LAZAR MF, 1995, J HEAD TRAUMA REHAB, V10, P55, DOI 10.1097/00001199-199510000-00007; Lenneberg Eric H., 1967, BIOL FDN LANGUAGE; Parmelee D X, 1989, Psychiatr Med, V7, P11; Petersen C, 2006, BRAIN INJURY, V20, P321, DOI 10.1080/02699050500488108; Ravens-Sieberer U, 2000, GESUNDHEITSWESEN, V62, P148, DOI 10.1055/s-2000-10487; Ravens-Sieberer U, 1998, QUAL LIFE RES, V7, P399, DOI 10.1023/A:1008853819715; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; STEIN REK, 1990, MED CARE, V28, P1041, DOI 10.1097/00005650-199011000-00006; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEWES U, 2001, HAWIE R HAMBURG WECH; TEWES U, 2001, HAWIK 3 HAMBURG WECH; WILLER B, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P18; Woerner W, 2004, EUR CHILD ADOLES PSY, V13, P47, DOI 10.1007/s00787-004-2008-0; World Health Organization, 1992, ICD 10 CLASS MENT BE	26	29	29	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	3					215	221		10.1080/02699050801935245			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	267LW	WOS:000253511500002	18297593				2021-06-18	
J	Yorkston, KM; Kuehn, CM; Johnson, KL; Ehde, DM; Jensen, MP; Amtmann, D				Yorkston, Kathryn M.; Kuehn, Carrie M.; Johnson, Kurt L.; Ehde, Dawn M.; Jensen, Mark P.; Amtmann, Dagmar			Measuring participation in people living with multiple sclerosis: A comparison of self-reported frequency, importance and self-efficacy	DISABILITY AND REHABILITATION			English	Article						multiple sclerosis; participation; treatment outcomes; healthcare survey	TRAUMATIC BRAIN-INJURY; COMMUNITY INTEGRATION QUESTIONNAIRE; SPINAL-CORD-INJURY; QUALITY-OF-LIFE; REHABILITATION; SATISFACTION; HANDICAP; INDIVIDUALS; DISABILITY; HEALTH	Purpose.To compare three dimensions related to participation in everyday situations in community-dwelling adults with multiple sclerosis (MS). Methods.Mail survey was obtained from 112 respondents. Data were analyzed using Kendall's tau-b correlation coefficients between responses to participation items relative to three question dimensions (importance, frequency, and self-efficacy) and criterion variables (mobility, depression, general health, fatigue and pain). Results.No significant associations were found between item responses in the importance dimension and the criterion variables. Weak associations were found for items in the frequency dimension, and stronger associations were found for items in the self-efficacy dimension. Conclusions.Different dimensions of participation in specific life situations yielded different responses and associations of those responses with key criterion measures. Subjective importance of participating in everyday situations is relatively independent of measures of mobility, general health, depression, fatigue and pain. Subjective judgments of self-efficacy for participation are more closely linked to these criterion measures. Caution is warranted when interpreting scales of participation because participation is a complex construct, potentially composed of several dimensions.	[Yorkston, Kathryn M.; Kuehn, Carrie M.; Johnson, Kurt L.; Ehde, Dawn M.; Jensen, Mark P.; Amtmann, Dagmar] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA	Yorkston, KM (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	yorkston@u.washington.edu	Ehde, Dawn/K-1883-2016	Ehde, Dawn/0000-0002-9555-2347	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD033988, P01 HD033988-09, P01 HD33988] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD033988] Funding Source: NIH RePORTER		BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bowen J, 2001, MULT SCLER, V7, P201, DOI 10.1191/135245801678438447; BOWEN J, 2005, PHYS MED REHABIL CLI, V19, P359; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Brown M, 2002, TOPICS SPINAL CORD I, V7, P83, DOI DOI 10.1310/7U35-GDQ4-FDV3-GVYV; Cardol M, 1999, DISABIL REHABIL, V21, P97, DOI 10.1080/096382899297819; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; Chwastiak L, 2002, AM J PSYCHIAT, V159, P1862, DOI 10.1176/appi.ajp.159.11.1862; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Desrosiers J, 2002, DISABIL REHABIL, V24, P774, DOI 10.1080/09638280210125814; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Ehde DM, 2003, MULT SCLER J, V9, P605, DOI 10.1191/1352458503ms939oa; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; HATCHER L, 2004, STEP STEP APPROACH U; Jensen M.P., 2001, HDB PAIN ASSESSMENT, P15; JENSEN MP, IN PRESS EVIDENCE OU; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; Kendall M., 1990, RANK CORRELATION MET, V5th; King G., 2004, CHILDRENS ASSESSMENT; Kroencke DC, 2001, MULT SCLER, V7, P237, DOI 10.1177/135245850100700405; Lowe B, 2004, J AFFECT DISORDERS, V81, P61, DOI 10.1016/S0165-0327(03)00198-8; Noreau L, 2004, DISABIL REHABIL, V26, P346, DOI 10.1080/09638280410001658649; Ostir GV, 2006, ARCH PHYS MED REHAB, V87, P1043, DOI 10.1016/j.apmr.2006.04.024; Perenboom RJM, 2003, DISABIL REHABIL, V25, P577, DOI 10.1080/0963828031000137081; Salter K, 2005, DISABIL REHABIL, V27, P507, DOI 10.1080/0963828040008552; *SAS I INC, 2003, SAS 9 1 COMP PROGR V; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; *STATA, 2005, STATA 9 1 COMP PROGR; Van Brakel WH, 2006, DISABIL REHABIL, V28, P193, DOI 10.1080/09638280500192785; Ware JE., 1993, SF 36 HLTH SURVEY MA; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, P1793, DOI 10.1016/j.apmr.2004.04.024; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 2001, INT CLASS FUNCT DIS; Yorkston KM, 2003, J MED SPEECH-LANG PA, V11, P73	39	29	29	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.		2008	30	2					88	97		10.1080/09638280701191891			10	Rehabilitation	Rehabilitation	251EB	WOS:000252353000002	17852211	Green Accepted			2021-06-18	
J	Burgos, M; Neary, JT; Gonzalez, FA				Burgos, Michelle; Neary, Joseph T.; Gonzalez, Fernando A.			P2Y(2) nucleotide receptors inhibit trauma-induced death of astrocytic cells	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; cell survival; neuroprotection; purinergic receptors	SIGNAL-REGULATED KINASE; ACTIVATED PROTEIN-KINASES; P2 PURINERGIC RECEPTORS; STRETCH-INDUCED INJURY; SPINAL-CORD-INJURY; FIBRILLARY ACIDIC PROTEIN; BRAIN-INJURY; EXTRACELLULAR ATP; IN-VIVO; INDUCED APOPTOSIS	Nucleotides as well as other neurotransmitters are known to be released to the extracellular space upon injury. To determine whether nucleotides acting on P2Y(2) nucleotide receptors promote protective or degenerative events after trauma in astrocytic cells, a well-established model of in vitro brain trauma was applied to 1321N1 cells expressing recombinant P2Y(2) nucleotide receptors (P2Y(2)R-1321N1). Cellular death was examined by measuring DNA fragmentation and caspase activation. Fragmented DNA was observed 48 h post-injury in 1321N1 cells, while P2Y(2) nucleotide receptor expressing cells did not show DNA fragmentation. A laddering pattern of fragmented DNA following injury was observed upon inhibition of P2Y(2) nucleotide receptors with suramin. Time-dependent increases of cleaved caspase-9, a mitochondrial-associated caspase, correlated with injury-induced cellular death. A decreased bax/bcl-2 gene expression ratio was observed in P2Y(2)R-1321N1 cells after traumatic injury, while untransfected 1321N1 cells showed a significant time-dependent increase of the bax/bcl-2 gene expression ratio. Activation of protein kinases was assessed to determine the signaling pathways involved in cell death and survival responses following traumatic injury. In P2Y(2)R-1321N1 and 1321N1 cells p38 phosphorylation was stimulated in a time-dependent manner but the phosphatidylinositol 3-kinase-dependent activation of extracellular signal-regulated kinase 1/2 and protein kinase B (PKB)/Akt was only observed in P2Y(2)R-1321N1 cells after injury. The stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) signaling pathway was not activated by traumatic injury in either astrocytic cell line. Inhibition of p38 kinase signaling pathway by treatment with PD1693, a MKK3/6 inhibitor, abolished the expression of cleaved caspase-9, the increase in the bax/bcl-2 gene expression ratio, as well as the fragmentation of DNA that followed injury of 1321N1 cells. Taken together, our results demonstrate a novel role for P2Y(2) nucleotide receptors and extracellular nucleotides in mediating survival responses to glial cells undergoing cellular death induced by trauma.	Univ Puerto Rico, Dept Chem, San Juan, PR 00931 USA; Univ Puerto Rico, Dept Biochem, San Juan, PR 00936 USA; Univ Miami Miller Sch Med, Vet Adm Med Ctr, Dept Pathol, Res Serv, Miami, FL USA; Univ Miami Miller Sch Med, Vet Adm Med Ctr, Dept Biochem & Mol Biol, Res Serv, Miami, FL USA; Univ Miami Miller Sch Med, Vet Adm Med Ctr, Dept Neurosci Program, Res Serv, Miami, FL USA	Gonzalez, FA (corresponding author), Univ Puerto Rico, Dept Chem, San Juan, PR 00931 USA.	fgonzal@hpcf.upr.edu					ABBRACCHIO MP, 1994, NEUROSCIENCE, V59, P67, DOI 10.1016/0306-4522(94)90099-X; ADMAS JM, 2001, TRENDS BIOCHEM SCI, V26, P61; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Arthur DB, 2005, P NATL ACAD SCI USA, V102, P19138, DOI 10.1073/pnas.0505913102; Arthur DB, 2006, J NEUROSCI, V26, P3798, DOI 10.1523/JNEUROSCI.5338-05.2006; Bambrick L, 2004, NEUROCHEM RES, V29, P601, DOI 10.1023/B:NERE.0000014830.06376.e6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan PH, 2004, NEUROCHEM RES, V29, P1943, DOI 10.1007/s11064-004-6869-x; Cho SG, 2002, J BIOCHEM MOL BIOL, V35, P24, DOI 10.5483/BMBRep.2002.35.1.024; Chorna NE, 2004, J NEUROCHEM, V91, P119, DOI 10.1111/j.1471-4159.2004.02699.x; Copland IB, 2007, J CELL PHYSIOL, V210, P133, DOI 10.1002/jcp.20840; Dai Y, 2004, PAIN, V108, P258, DOI 10.1016/j.pain.2003.12.034; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; De Chiara G, 2006, J BIOL CHEM, V281, P21353, DOI 10.1074/jbc.M511052200; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Franke H, 2004, NEUROSCIENCE, V127, P431, DOI 10.1016/j.neuroscience.2004.05.003; Franke H, 2001, BRIT J PHARMACOL, V134, P1180, DOI 10.1038/sj.bjp.0704353; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hagberg H, 2004, J BIOENERG BIOMEMBR, V36, P369, DOI 10.1023/B:JOBB.0000041770.00567.4f; Harada C, 2006, AM J PATHOL, V168, P261, DOI 10.2353/ajpath.2006.050765; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; Houslay MD, 2000, MOL PHARMACOL, V58, P659; Hsieh MH, 2005, INT REV CYTOL, V245, P45, DOI 10.1016/S0074-7696(05)45003-2; James G, 2002, EUR J PHARMACOL, V447, P247, DOI 10.1016/S0014-2999(02)01756-9; Kassa RM, 2007, NEUROBIOL DIS, V25, P121, DOI 10.1016/j.nbd.2006.08.020; Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335; Kikuchi M, 2000, J NEUROSCI, V20, P5037; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim D, 2002, J BIOCHEM MOL BIOL, V35, P106; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Le Feuvre R, 2002, EUR J PHARMACOL, V447, P261, DOI 10.1016/S0014-2999(02)01848-4; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Moon DO, 2006, INT IMMUNOPHARMACOL, V6, P1796, DOI 10.1016/j.intimp.2006.07.027; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Muscella A, 2003, J CELL PHYSIOL, V195, P234, DOI 10.1002/jcp.10242; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Neary J. T., 2001, V151, P305; Neary JT, 2006, J NEUROSCI RES, V84, P515, DOI 10.1002/jnr.20969; Neary JT, 2005, MOL NEUROBIOL, V31, P95, DOI 10.1385/MN:31:1-3:095; Neary JT, 2005, IUBMB LIFE, V57, P711, DOI 10.1080/15216540500319143; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; NEARY JT, 1994, J NEUROCHEM, V63, P490; NEARY JT, 1994, ACTA NEUROPATHOL, V87, P8; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nguyen HT, 2006, NEPHRON EXP NEPHROL, V102, P49, DOI 10.1159/000088401; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Petrin D, 2006, CELL SIGNAL, V18, P479, DOI 10.1016/j.cellsig.2005.05.021; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Rios-Munoz W, 2005, J NEUROCHEM, V93, P1422, DOI 10.1111/j.1471-4159.2005.03129.x; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Santiago-Perez LI, 2001, J CELL PHYSIOL, V187, P196, DOI 10.1002/jcp.1063; Santos-Beneit AM, 2000, J LEUKOCYTE BIOL, V67, P712; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Sedding DG, 2005, CIRC RES, V96, P635, DOI 10.1161/01.RES.0000160610.61306.0f; Shaw Anthony, 2003, Current Vascular Pharmacology, V1, P41, DOI 10.2174/1570161033386745; Torres JES, 2006, NEUROSCI LETT, V403, P233, DOI 10.1016/j.neulet.2006.04.063; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wang XD, 2001, GENE DEV, V15, P2922; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Yang LL, 2004, J CELL BIOCHEM, V91, P938, DOI 10.1002/jcb.10774; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhou YN, 2006, BIOCHEM BIOPH RES CO, V350, P860, DOI 10.1016/j.bbrc.2006.09.103; Zimmermann H, 2006, PFLUG ARCH EUR J PHY, V452, P573, DOI 10.1007/s00424-006-0067-4	84	29	30	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	DEC	2007	103	5					1785	1800		10.1111/j.1471-4159.2007.04872.x			16	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	231YN	WOS:000250985200009	17868308	Bronze			2021-06-18	
J	Colantonio, A; Stamenova, V; Abramowitz, C; Clarke, D; Christensen, B				Colantonio, A.; Stamenova, V.; Abramowitz, C.; Clarke, D.; Christensen, B.			Brain injury in a forensic psychiatry population	BRAIN INJURY			English	Article						traumatic brain injury; forensic psychiatry	VIOLENT CRIMINAL BEHAVIOR; HEAD-INJURY; PRISON POPULATION; UNITED-STATES; PREVALENCE; OUTCOMES; INMATES; NEUROPSYCHOLOGY; PERSONALITY; DISORDERS	Objectives: The prevalence and profile of adults with a history of traumatic brain injury (TBI) has not been studied in large North American forensic mental health populations. This study investigated how adults with a documented history of TBI differed with the non-TBI forensic population with respect to demographics, psychiatric diagnoses and history of offences. Method: A retrospective chart review of all consecutive admissions to a forensic psychiatry programme in Toronto, Canada was conducted. Information on history of TBI, psychiatric diagnoses, living environments and types of criminal offences were obtained from medical records. Results: History of TBI was ascertained in 23% of 394 eligible patient records. Compared to those without a documented history of TBI, persons with this history were less likely to be diagnosed with schizophrenia but more likely to have alcohol/substance abuse disorder. There were also differences observed with respect to offence profiles. Conclusions: This study provides evidence to support routine screening for a history of TBI in forensic psychiatry.	[Colantonio, A.] Toronto Rehabil Inst, Saunderson Family Chair Acquired Brain Injury Res, Toronto, ON M5G 1V7, Canada; [Colantonio, A.; Stamenova, V.; Clarke, D.] Univ Toronto, Toronto, ON, Canada; [Abramowitz, C.; Christensen, B.] Ctr Addict & Mental Hlth, Toronto, ON, Canada	Colantonio, A (corresponding author), Toronto Rehabil Inst, Saunderson Family Chair Acquired Brain Injury Res, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca	Stamenova, Vessela/H-1712-2013	Stamenova, Vessela/0000-0003-3252-7766; Colantonio, Angela/0000-0003-2094-4765			BACHYRITA G, 1974, AM J PSYCHIAT, V131, P1015; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Blanchard R, 2002, ARCH SEX BEHAV, V31, P511, DOI 10.1023/A:1020659331965; Brewer-Smyth K, 2004, BIOL PSYCHIAT, V55, P21, DOI 10.1016/S0006-3223(03)00705-4; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Souza Carlos Alberto Crespo de, 2003, Rev. Bras. Psiquiatr., V25, P206, DOI 10.1590/S1516-44462003000400005; Diaz F G, 1995, Med Law, V14, P131; Hawley CA, 2003, BRAIN INJURY, V17, P743, DOI 10.1080/0269905031000089341; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; HWANG S, 2007, AM PUBL HLTH ASS ANN; Jensen J, 1999, J INT NEUROPSYCH SOC, V5, P452, DOI 10.1017/S1355617799555070; KIM H, 2008, INT TRAUMATIC BRAIN; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; LEWIS DO, 1988, AM J PSYCHIAT, V145, P584; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; Merbitz C., 1995, J OFFENDER REHABILIT, V22, P11, DOI DOI 10.1300/J076V22N03_02; Miller E, 1999, J FORENSIC PSYCHIATR, V10, P157, DOI 10.1080/09585189908402146; Miller E, 1999, PSYCHOL CRIME LAW, V5, P297, DOI 10.1080/10683169908401774; Morrell RF, 1998, J OFFENDER REHABIL, V27, P1, DOI DOI 10.1300/J076V27N03_01; NESTOR PG, 1992, J NERV MENT DIS, V180, P418, DOI 10.1097/00005053-199207000-00003; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Pickett William, 2004, Chronic Dis Can, V25, P32; Rasmussen K, 2001, J AM ACAD PSYCHIATRY, V29, P186; Rucklidge JJ, 2006, BIOL PSYCHIAT, V60, P921, DOI 10.1016/j.biopsych.2006.03.067; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Seto Michael, 2001, DEMANDS FORENSIC SER; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Waldmann CA, 2004, HLTH HOMELESS PERSON, P237	30	29	29	1	19	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2007	21	13-14					1353	1360		10.1080/02699050701785054			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	253AA	WOS:000252488200003	18066937				2021-06-18	
J	Gilliland, MGF; Levin, AV; Enzenauer, RW; Smith, C; Parsons, A; Rorke-Adams, LB; Lauridson, JR; La Roche, GR; Christmann, LM; Mian, M; Jentzen, J; Simons, KB; Morad, Y; Alexander, R; Jenny, C; Wygnanski-Jaffe, T				Gilliland, M. G. F.; Levin, Alex V.; Enzenauer, Robert W.; Smith, Charles; Parsons, Andrew; Rorke-Adams, Lucy B.; Lauridson, James R.; La Roche, G. Robert; Christmann, Linda M.; Mian, Marcellina; Jentzen, Jeffrey; Simons, Kenneth B.; Morad, Yair; Alexander, Randell; Jenny, Carole; Wygnanski-Jaffe, Tamara			Guidelines for postmortem protocol for ocular investigation of sudden unexplained infant death and suspected physical child abuse	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						postmortem; autopsy; child abuse; shaken baby syndrome; retinal hemorrhage; orbit	PERIMACULAR RETINAL FOLDS; PERMANENT BRAIN-DAMAGE; HEMORRHAGES; AUTOPSY; INJURY; EYES; MANIFESTATIONS; VICTIMS; SHAKING	Postmortem examination is a cornerstone in identifying the cause of unexplained sudden death in children. Even in cases of suspected or known abuse, an autopsy may help characterize the nature of the abuse, which is particularly important in the forensic autopsy of children in the first 3 to 4 years of life when inflicted neurotrauma is most common. Forensic examinations are vital in cases that might otherwise be diagnosed as sudden infant death syndrome. The ocular autopsy in particular may demonstrate findings that were not appreciated on antemortem clinical examination. This protocol for postmortem examination of the eyes and orbits was developed to promote more consistent documentation of findings, improved clinical and forensic decision making, and more replicable and coherent research outcomes.	E Carolina Univ, Brody Sch Med, Dept Pathol & Lab Med, Greenville, NC USA; Univ Toronto, Hosp Sick Children, Dept Pathol & Vis Sci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Paediat, Suspected Child Abuse & Neglect Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Tennessee, Ctr Hlth Sci, Dept Ophthalmol, Memphis, TN 38163 USA; Univ Sheffield, Ophthalm Sci Unit, Sheffield, S Yorkshire, England; Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA; Graphics, Montgomery, AL USA; Dalhousie Univ, Dept Ophthalmol, Halifax, NS B3H 3J5, Canada; IWK Hlth Ctr, Halifax, NS, Canada; Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada; McGill Univ, Ctr Hlth, Montreal, PQ, Canada; Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; Tel Aviv Univ, Assaf Harofeh Med Ctr, Zerifin, Israel; Univ Florida, Gainesville, FL USA; Morehouse Sch Med, Atlanta, GA 30310 USA; Brown Med Sch, Providence, RI USA; Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer, Israel	Levin, AV (corresponding author), Hosp Sick Children, Dept Ophthalmol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	alex.levin@sickids.ca					Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; BUDENZ DL, 1994, OPHTHALMOLOGY, V101, P559; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; ELNER SG, 1990, ARCH OPHTHALMOL-CHIC, V108, P1094, DOI 10.1001/archopht.1990.01070100050033; GAYNON MW, 1988, AM J OPHTHALMOL, V106, P423, DOI 10.1016/0002-9394(88)90877-X; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; GIANGIACOMO J, 1985, Journal of Pediatric Ophthalmology and Strabismus, V22, P234; GILKES MJ, 1967, LANCET, V2, P468; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GILLILAND MGF, 1992, FORENSIC SCI INT, V56, P77, DOI 10.1016/0379-0738(92)90149-Q; Gleckman AM, 2000, ARCH PATHOL LAB MED, V124, P251; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HARCOURT B, 1971, BMJ-BRIT MED J, V3, P398, DOI 10.1136/bmj.3.5771.398; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; KIFFNEY GT, 1964, ARCH OPHTHALMOL-CHIC, V72, P231; Kivlin JD, 2001, CURR OPIN OPHTHALMOL, V12, P158, DOI 10.1097/00055735-200106000-00002; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; LAMBERT SR, 1986, ARCH OPHTHALMOL-CHIC, V104, P1509; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; LEVIN A, 1998, AM ACAD OPHTHALMOL F, V16, P13; Levin AV, 2000, RECENT ADV PAEDIAT, P151; Levitt CJ, 1994, CHILD ABUSE MED DIAG, P1; Lin KC, 1999, AM J OPHTHALMOL, V127, P473, DOI 10.1016/S0002-9394(98)00392-4; Marshall DH, 2001, CAN J OPHTHALMOL, V36, P377, DOI 10.1016/S0008-4182(01)80081-8; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; MUSHIN AS, 1971, BRIT MED J, V3, P402, DOI 10.1136/bmj.3.5771.402; Parsons MA, 2001, J CLIN PATHOL, V54, P417, DOI 10.1136/jcp.54.6.417; RAO N, 1988, FORENSIC SCI INT, V39, P293, DOI 10.1016/0379-0738(88)90133-8; REECE RM, 2003, INFLICTED CHILDHOOD; RIFFENBURGH RS, 1991, J FORENSIC SCI, V36, P741; RIFFENBURGH RS, 1991, OPHTHALMOLOGY, V98, P1519; Royal College of Pathologists, 2002, GUID AUT PRACT REP W; Taylor D, 1999, EYE, V13, P3; TOMASI L, 1986, AM J DIS CHILD, V93, P1335; TSENG SS, 1976, ARCH OPHTHALMOL-CHIC, V94, P839; WEIDENTHAL DT, 1976, AM J OPHTHALMOL, V81, P725, DOI 10.1016/0002-9394(76)90353-6; WILLSHAW HE, 2004, EYE, V18, P795; Wygnanski-Jaffe T, 2006, AM J OPHTHALMOL, V142, P233, DOI 10.1016/j.ajo.2006.03.038	44	29	31	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-7910	1533-404X		AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	DEC	2007	28	4					323	329		10.1097/PAF.0b013e31815b4c00			7	Medicine, Legal; Pathology	Legal Medicine; Pathology	237EH	WOS:000251355900010	18043020				2021-06-18	
J	Peterson, RS; Fernando, G; Day, L; Allen, TA; Chapleau, JD; Menjivar, J; Schlinger, BA; Lee, DW				Peterson, R. Scott; Fernando, Gowry; Day, Lainy; Allen, Timothy A.; Chapleau, Jeanette D.; Menjivar, Jenny; Schlinger, Barney A.; Lee, Diane W.			Aromatase expression and cell proliferation following injury of the adult zebra finch hippocampus	DEVELOPMENTAL NEUROBIOLOGY			English	Article						estrogen; aromatase; astrocytes; proliferation; repair	TRAUMATIC BRAIN-INJURY; NEURAL STEM-CELLS; EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; FEMALE CANARY BRAIN; SUBVENTRICULAR ZONE; TAENIOPYGIA-GUTTATA; CEREBRAL-ISCHEMIA; AVIAN BRAIN; HEME OXYGENASE-1	Estrogens can be neuroprotective following traumatic brain injury. Immediately after trauma to the zebra finch hippocampus, the estrogen-synthetic enzyme aromatase is rapidly upregulated in astrocytes and radial glia around the lesion site. Brain injury also induces high levels of cell proliferation. Estrogens promote neuronal differentiation, migration, and survival naturally in the avian brain. We suspect that glia are a source of estrogens promoting cell proliferation after neural injury. To explore this hypothesis, we examined the spatial and temporal relationship between glial aromatase expression and cell proliferation after neural injury in adult female zebra finches. Birds were ovariectomized and given a blank implant or one filled with estradiol; some birds were also administered an aromatase inhibitor or vehicle. All birds received penetrating injuries to the right hippocampus. Twenty-four hours after lesioning, birds were injected once with BrdU to label mitotically active cells and euthanized 2 h, 24 h, or 7 days later. The brains were processed for double-label BrdU and aromatase immunocytochemistry. Injury-induced glial aromatase expression was unaffected by survival time and aromatase inhibition. BrdU labeling was significantly reduced at 24 h by ovariectomy and by aromatase inhibition; effects were partially reversed by E2 replacement. Irrespective of ovariectomy, the densities of aromatase immunoreactive astrocytes and BrdU-Iabeled cells at known distances from the lesion site were highly correlated. These data suggest that injury-induced glial aromatization may influence the reorganization of injured tissue by providing a rich estrogenic environment available to influence cellular incorporation. (c) 2007 Wiley Periodicals, Inc.	Calif State Univ Long Beach, Dept Psychol, Long Beach, CA 90840 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Neuroendocrinol Lab, Los Angeles, CA 90095 USA	Lee, DW (corresponding author), Calif State Univ Long Beach, Dept Psychol, Long Beach, CA 90840 USA.	dlee6@csulb.edu	Allen, Timothy/AAD-6903-2020	Allen, Timothy/0000-0002-3512-9475; Day, Lainy/0000-0002-9122-3044	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07228-18] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [S06 GM063119] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH59730-03, MH61994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [S06GM063119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R03MH059730, R01MH061994] Funding Source: NIH RePORTER		ADKINSREGAN E, 1990, GEN COMP ENDOCR, V78, P93, DOI 10.1016/0016-6480(90)90051-M; ADKINSREGAN E, 1990, HORM BEHAV, V24, P114, DOI 10.1016/0018-506X(90)90031-R; Alvarez-Buylla A, 1998, J NEUROSCI, V18, P1020; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; AlvarezBuylla A, 1997, J NEUROBIOL, V33, P585, DOI 10.1002/(SICI)1097-4695(19971105)33:5<585::AID-NEU7>3.0.CO;2-0; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; BARNEA A, 1994, P NATL ACAD SCI USA, V91, P11217, DOI 10.1073/pnas.91.23.11217; Barnett V., 1994, OUTLIERS STAT DATA; BROWN SD, 1993, J NEUROSCI, V13, P2024; Cao J, 2002, BRAIN RES, V943, P80, DOI 10.1016/S0006-8993(02)02537-4; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; CHOI DW, 1989, ANN NY ACAD SCI, V568, P219; Cooper-Kuhn CM, 2002, DEV BRAIN RES, V134, P13, DOI 10.1016/S0165-3806(01)00243-7; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DeWulf V, 2002, J NEUROSCI, V22, P4080, DOI 10.1523/JNEUROSCI.22-10-04080.2002; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; FOIDART A, 1994, BRAIN RES, V657, P105, DOI 10.1016/0006-8993(94)90958-X; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6; Garcia-Segura LM, 2003, PROG NEUROBIOL, V71, P31, DOI 10.1016/j.pneurobio.2003.09.005; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HIDALGO A, 1995, J NEUROBIOL, V27, P470, DOI 10.1002/neu.480270404; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; LEE DW, 2007, J NEUROBIOL, V67, P1107; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lim DA, 1999, P NATL ACAD SCI USA, V96, P7526, DOI 10.1073/pnas.96.13.7526; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; London SE, 2006, ENDOCRINOLOGY, V147, P5975, DOI 10.1210/en.2006-0154; London SE, 2003, J COMP NEUROL, V467, P496, DOI 10.1002/cne.10936; McIntosh TK, 1996, LAB INVEST, V74, P315; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Peterson RS, 2004, J COMP NEUROL, V475, P261, DOI 10.1002/cne.20157; Peterson RS, 2001, J NEUROENDOCRINOL, V13, P317, DOI 10.1046/j.1365-2826.2001.00647.x; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Reiner A, 2004, J COMP NEUROL, V473, P377, DOI 10.1002/cne.20118; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Saldanha CJ, 1998, HORM BEHAV, V34, P85, DOI 10.1006/hbeh.1998.1447; Saldanha CJ, 2000, J COMP NEUROL, V423, P619, DOI 10.1002/1096-9861(20000807)423:4<619::AID-CNE7>3.0.CO;2-U; Saldanha CJ, 2005, J NEUROBIOL, V64, P192, DOI 10.1002/neu.20147; SALDANHA CJ, 2004, HORM BEHAV, V45, P250; Scharff C, 2000, NEURON, V25, P481, DOI 10.1016/S0896-6273(00)80910-1; Soma KK, 2004, ENDOCRINOLOGY, V145, P1668, DOI 10.1210/en.2003-0883; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; STOKES TM, 1974, J COMP NEUROL, V156, P337, DOI 10.1002/cne.901560305; Takeda A, 1996, NEUROSCI LETT, V205, P169, DOI 10.1016/0304-3940(96)12405-8; Tzeng SF, 1999, NEUROREPORT, V10, P2287, DOI 10.1097/00001756-199908020-00012; Williams S, 1999, MOL CELL NEUROSCI, V13, P41, DOI 10.1006/mcne.1998.0729; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Wynne RD, 2004, J NEUROENDOCRINOL, V16, P676, DOI 10.1111/j.1365-2826.2004.01217.x; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	63	29	29	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-8451	1932-846X		DEV NEUROBIOL	Dev. Neurobiol.	DEC	2007	67	14					1867	1878		10.1002/dneu.20548			12	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	239TG	WOS:000251540000004	17823932				2021-06-18	
J	Farias, SE; Zarini, S; Precht, T; Murphy, RC; Heidenreich, KA				Farias, Santiago E.; Zarini, Simona; Precht, Thomas; Murphy, Robert C.; Heidenreich, Kim A.			Transcellular biosynthesis of cysteinyl leukotrienes in rat neuronal and glial cells	JOURNAL OF NEUROCHEMISTRY			English	Article						glia; leukotrienes; mass spectrometry; neurons; neutrophils; transcellular biosynthesis	POLYMORPHONUCLEAR LEUKOCYTE; ARACHIDONIC-ACID; CEREBRAL-ISCHEMIA; BRAIN-INJURY; METABOLISM; EDEMA; C-4; 5-LIPOXYGENASE; RECEPTOR; RELEASE	Leukotrienes are mediators of inflammation that belong to a family of lipids derived from arachidonic acid by the action of 5-lipoxygenase. Leukotrienes have been detected in the central nervous system in association with different pathological events, but little is known about their biosynthesis or function in the brain. When rat neurons and glial cells in primary culture were stimulated with the calcium ionophore, no significant biosynthesis of leukotrienes was detected using liquid chromatography/mass spectrometry (LC/MS) techniques. However, when exogenous LTA(4) was added to these cultured cells, both neurons and glia were able to synthesize LTC4. Activated neutrophils are known to supply LTA(4) to other cells for transcellular biosynthesis of cysteinyl-leukotrienes. Since neutrophils can infiltrate brain tissue after stroke or traumatic brain injury, we examined whether neutrophils play a similar role in the central nervous system. When peripheral blood neutrophils were co-cultured with rat neurons, glia cells, and then stimulated with calcium ionophore, a robust production of LTC4, LTD4, and LTE4 was observed, revealing that neurons and glia can participate in the transcellular mechanism of leukotriene biosynthesis. The formation of LTC4 through this mechanism may be relevant in the genesis and progression of the inflammatory response as a result of brain injury.	Univ Colorado, Denver & Hlth Sci Ctr, Dept Pharmacol, Aurora, CO USA; VA Med Ctr, Denver, CO USA	Heidenreich, KA (corresponding author), Univ Colorado, Denver & Hlth Sci Ctr, Vet Affairs Res Ctr, Dept Pharmacol, POB 6511,Mail Stop 8303, Aurora, CO 80045 USA.	Kim.Heidenreich@UCHSC.edu	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL025785, R01HL025785] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL025785] Funding Source: Medline		Akopov SE, 1996, STROKE, V27, P1739, DOI 10.1161/01.STR.27.10.1739; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BORGEAT P, 1979, J BIOL CHEM, V254, P7865; Boyce JA, 2005, CHEM IMMUNOL ALLERGY, V87, P59, DOI 10.1159/000087571; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; Ciccarelli R, 2004, EUR J NEUROSCI, V20, P1514, DOI 10.1111/j.1460-9568.2004.03613.x; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; Di Gennaro A, 2004, FASEB J, V18, P842, DOI 10.1096/fj.03-0599fje; Fetissov SO, 2002, NEUROSCIENCE, V115, P891, DOI 10.1016/S0306-4522(02)00411-6; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; Ge QF, 2006, J NEUROCHEM, V97, P992, DOI 10.1111/j.1471-4159.2006.03828.x; Habib GM, 2003, FASEB J, V17, P1313, DOI 10.1096/fj.02-0899fje; Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200; Hall LM, 1998, J AM SOC MASS SPECTR, V9, P527, DOI 10.1016/S1044-0305(98)00013-0; HASLETT C, 1985, AM J PATHOL, V119, P101; HULTING AL, 1985, P NATL ACAD SCI USA, V82, P3834, DOI 10.1073/pnas.82.11.3834; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; Lam BK, 2003, PROSTAG LEUKOTR ESS, V69, P111, DOI 10.1016/S0952-3278(03)00071-1; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Lieberman MW, 1999, ADV EXP MED BIOL, V469, P301; LINDGREN JA, 1984, P NATL ACAD SCI-BIOL, V81, P6212, DOI 10.1073/pnas.81.19.6212; Linseman DA, 2002, J NEUROSCI, V22, P9287; Luo M, 2003, P NATL ACAD SCI USA, V100, P12165, DOI 10.1073/pnas.2133253100; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; Mayatepek E, 2000, J INHERIT METAB DIS, V23, P404, DOI 10.1023/A:1005664204956; McMillan R M, 2001, Paediatr Respir Rev, V2, P238, DOI 10.1053/prrv.2001.0146; MEDINA JF, 1988, BIOCHIM BIOPHYS ACTA, V961, P203, DOI 10.1016/0005-2760(88)90115-4; ORNING L, 1980, J BIOL CHEM, V255, P8023; PALMER MR, 1980, NEUROSCI LETT, V18, P173, DOI 10.1016/0304-3940(80)90322-5; PRZYLIPIAK A, 1990, EXPERIENTIA, V46, P298, DOI 10.1007/BF01951771; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Rouzer C A, 1986, Adv Prostaglandin Thromboxane Leukot Res, V16, P3; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; SAADI M, 1990, LIFE SCI, V46, P1857, DOI 10.1016/0024-3205(90)90238-M; Sala A, 1997, J PHYSIOL PHARMACOL, V48, P665; Sala A, 2000, CIRCULATION, V101, P1436, DOI 10.1161/01.CIR.101.12.1436; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Shimada A, 2005, NEUROSCIENCE, V131, P683, DOI 10.1016/j.neuroscience.2004.11.016; Wang ML, 2006, BIOCHEM BIOPH RES CO, V350, P399, DOI 10.1016/j.bbrc.2006.09.057; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; Winking M, 1998, CEREBROVASC DIS, V8, P318, DOI 10.1159/000015874	44	29	29	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	NOV	2007	103	4					1310	1318		10.1111/j.1471-4159.2007.04830.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	223WH	WOS:000250403500005	17711426	Bronze			2021-06-18	
J	Titsworth, WL; Onifer, SM; Liu, NK; Xu, XM				Titsworth, W. Lee; Onifer, Stephen M.; Liu, Nal-Kui; Xu, Xiao-Ming			Focal phospholipases A2 group III injections induce cervical white matter injury and functional deficits with delayed recovery concomitant with Schwann cell remyelination	EXPERIMENTAL NEUROLOGY			English	Article						demyelination; schwarm cell; pellet retrieval; dorsolateral funiculus; cervical; spinal cord; phospholipases A(2); secretory phospholipases A(2)	SPINAL-CORD-INJURY; ADULT-RAT; AXONAL REGENERATION; ETHIDIUM-BROMIDE; DORSAL COLUMN; A(2); FORELIMB; DEMYELINATION; DIFFERENTIATION; PERFORMANCE	Phospholipases A(2) (PLA(2)) are group of enzymes that hydrolyze membrane phospholipids at the sn-2 position. PLA2 are present in the brain and spinal cord and are implicated in several neurological disorders. Previously, we showed that PLA2 activity increases following traumatic spinal cord injury and injection of group III secretory PLA(2) (sPLA(2)-III) demyelinates spinal cord axons. Here, we demonstrate that injections of sPLA(2)-III into the cervical dorsolateral funiculus (DLF) resulted in dose-dependent demyelination, loss of oligodendrocytes and astrocytes, as well as axonopathy. Additionally, spared axons within the lesion were remyelinated by Schwann cells between weeks 2 and 3. To assess functional loss and recovery, we employed a modified "Staircase Test" pellet retrieval device and footprint analysis of forelimb function during locomotion. Pellet retrieval assessment sensitively detected the dose dependent lesion and its recovery after sPLA(2)-III injections with greater sensitivity than footprint analysis. We believe that this is the first report of a reaching task being able to discriminate between various grades of cervical white matter damage and varying extents of recovery. Thus, our results indicate that sPLA(2)-III can create white matter pathologies that are remyelinated by Schwann cells 2 to 3 weeks after injury. Additionally, the pellet retrieval test is a sensitive and quantifiable method for assessing the dysfunction and later recovery mediated by sPLA(2)-III injections. (c) 2007 Elsevier Inc. All rights reserved.	Univ Louisville, Sch Med, Kentucky Spinal Cord Injury Res Ctr, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Xu, XM (corresponding author), Univ Louisville, Sch Med, Kentucky Spinal Cord Injury Res Ctr, Dept Neurol Surg, 511 S Floyd St,MDR 616, Louisville, KY 40292 USA.	xmxu001@gwise.louisville.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Xu, Xiao-ming/0000-0002-7229-0081	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR15576] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36350, F31 NS5657401, NS40411, NS52290] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS056574, R01NS040411, R01NS036350, R01NS052290] Funding Source: NIH RePORTER		BLAKEMORE WF, 1977, J NEUROL SCI, V33, P31, DOI 10.1016/0022-510X(77)90179-4; BLAKEMORE WF, 1978, NEUROPATH APPL NEURO, V4, P47, DOI 10.1111/j.1365-2990.1978.tb00528.x; BLAKEMORE WF, 1982, NEUROPATH APPL NEURO, V8, P365, DOI 10.1111/j.1365-2990.1982.tb00305.x; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; BUNGE RP, 1994, CLIN IMPLICATIONS RE; Cao QL, 2005, EXP NEUROL, V191, pS3, DOI 10.1016/j.expneurol.2004.08.026; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; DEMEDIUK P, 1989, J NEUROSCI RES, V23, P95, DOI 10.1002/jnr.490230113; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; DUTTA J, 1979, J CHROMATOGR, V173, P379, DOI 10.1016/S0021-9673(00)92307-0; Guest JD, 2005, EXP NEUROL, V192, P384, DOI 10.1016/j.expneurol.2004.11.033; Huterer SJ, 1995, NEUROCHEM RES, V20, P1335, DOI 10.1007/BF00992509; Jasmin L, 2000, J NEUROSCI, V20, P9215; JEFFERY ND, 1995, J NEUROCYTOL, V24, P775, DOI 10.1007/BF01191213; Kolko M, 2006, J NEUROSCI RES, V83, P874, DOI 10.1002/jnr.20773; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Liu NK, 2006, ANN NEUROL, V59, P606, DOI 10.1002/ana.20798; Lucas KK, 2005, BRIT J PHARMACOL, V144, P940, DOI 10.1038/sj.bjp.0706116; McKenna JE, 1999, J NEUROSCI, V19, P1885; McKenna JE, 2000, J COMP NEUROL, V419, P286, DOI 10.1002/(SICI)1096-9861(20000410)419:3<286::AID-CNE2>3.0.CO;2-3; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Molloy GY, 1998, NEUROSCI LETT, V258, P139, DOI 10.1016/S0304-3940(98)00838-6; MONTOYA CP, 1990, PROG BRAIN RES, V82, P459; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; MORELL P, 1984, MYELN; Moses GSD, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-28; MUHL H, 1991, FEBS LETT, V291, P249, DOI 10.1016/0014-5793(91)81295-J; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Onifer SM, 1997, RESTOR NEUROL NEUROS, V11, P211, DOI 10.3233/RNN-1997-11405; OORSCHOT DE, 1994, PROG NEUROBIOL, V44, P233, DOI 10.1016/0301-0082(94)90040-X; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Peilot H, 2000, J BIOL CHEM, V275, P22895, DOI 10.1074/jbc.M002783200; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; SCHRIMSHER GW, 1993, EXP NEUROL, V120, P264, DOI 10.1006/exnr.1993.1060; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200; Takami T, 2002, J NEUROSCI, V22, P6670; Talbott JF, 2006, GLIA, V54, P147, DOI 10.1002/glia.20369; Talbott JF, 2005, EXP NEUROL, V192, P11, DOI 10.1016/j.expneurol.2004.05.038; Touqui Lhousseine, 2001, Current Molecular Medicine (Hilversum), V1, P739, DOI 10.2174/1566524013363258; Woodruff RH, 1999, GLIA, V25, P216, DOI 10.1002/(SICI)1098-1136(19990201)25:3<216::AID-GLIA2>3.0.CO;2-L; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu XM, 1999, EUR J NEUROSCI, V11, P1723, DOI 10.1046/j.1460-9568.1999.00591.x; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113; Yagami T, 2002, MOL PHARMACOL, V61, P114, DOI 10.1124/mol.61.1.114	49	29	32	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2007	207	1					150	162		10.1016/j.expneurol.2007.06.010			13	Neurosciences	Neurosciences & Neurology	210TB	WOS:000249477400016	17678647				2021-06-18	
J	Yan, B; Bi, XY; He, J; Zhang, YB; Thakur, S; Xu, HY; Gendron, A; Kong, JM; Li, XM				Yan, Bin; Bi, Xiaoying; He, Jue; Zhang, Yanbo; Thakur, Sonia; Xu, Haiyun; Gendron, Alain; Kong, Jiming; Li, Xin-Min			Quetiapine attenuates spatial memory impairment and hippocampal neurodegeneration induced by bilateral common carotid artery occlusion in mice	LIFE SCIENCES			English	Article						quetiapine; common carotid artery occlusion (CCAO); memory; neurodegeneration; hippocampus	TRAUMATIC BRAIN-INJURY; ATYPICAL ANTIPSYCHOTIC-DRUGS; NEUROTROPHIC FACTOR EXPRESSION; TRANSIENT GLOBAL-ISCHEMIA; CEREBRAL-ISCHEMIA; NEURONAL DEGENERATION; SEROQUEL QUETIAPINE; FLUORO-JADE; PC12 CELLS; WATER MAZE	Quetiapine, a new atypical antipsychotic drug, has beneficial effects on cognitive impairment and neuropathological changes in treating chronic neurodegenerative diseases. Our previous studies have demonstrated that quetiapine may have neuroprotective properties. In the present study, we investigated the effects of a 2-week pre-administration of quetiapine (10 mg/kg/day, i.p.) on spatial memory impairment and hippocampal neurodegeneration induced by 60-minute bilateral common carotid artery occlusion (CCAO). Following a 7-day recovery phase from CCAO, the spatial memory of the mice was tested using a modified water maze test. After the behavioural test, the mice were sacrificed and brain sections were stained with NeuN (a neuron-specific soluble nuclear antigen), cresyl violet (Nissl), and Fluoro-Jade B. CCAO significantly induced spatial memory impairment and caused neurodegeneration in the hilus of hippocampus, while quetiapine significantly attenuated these changes. This is the first study showing that quetiapine significantly attenuates CCAO-induced spatial memory impairment and this improvement parallels the alleviative effects of quetiapine on CCAO-induced neurodegeneration in the hilus of hippocampus. The results suggest that quetiapine may have defending effects on the impairments induced by cerebral ischemia, which enhances our understanding about the mechanisms of quetiapine. (c) 2007 Elsevier Inc. All rights reserved.	Univ Saskatchewan, Dept Psychiat, Coll Med, Neuropsychiat Res Unit, Saskatoon, SK S7N 5E4, Canada; So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA; AstraZeneca, Mississauga, ON L4Y 1M4, Canada; Univ Manitoba, Fac Med, Dept Human Anat & Cell Sci, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Psychiat, Winnipeg, MB R3E 3N4, Canada	Li, XM (corresponding author), Univ Saskatchewan, Dept Psychiat, Coll Med, Neuropsychiat Res Unit, A114 Med Res Bldg,103 Wiggins Rd, Saskatoon, SK S7N 5E4, Canada.	xin-min.li@usask.ca		Zhang, Yanbo/0000-0002-2421-157X; Kong, Jiming/0000-0002-2859-9831			Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Arvanitis LA, 1997, BIOL PSYCHIAT, V42, P233, DOI 10.1016/S0006-3223(97)00190-X; Bai O, 2002, J NEUROSCI RES, V69, P278, DOI 10.1002/jnr.10290; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; Belcher AM, 2005, NEUROPSYCHOPHARMACOL, V30, P2026, DOI 10.1038/sj.npp.1300771; Bendel O, 2005, BRAIN RES, V1033, P135, DOI 10.1016/j.brainres.2004.11.033; Bokura H, 1997, STROKE, V28, P970, DOI 10.1161/01.STR.28.5.970; BRADVIK B, 1989, ACTA NEUROL SCAND, V80, P411, DOI 10.1111/j.1600-0404.1989.tb03902.x; Caccamo D, 2004, AMINO ACIDS, V27, P373, DOI 10.1007/s00726-004-0117-1; Chan PH, 2004, NEUROCHEM RES, V29, P1943, DOI 10.1007/s11064-004-6869-x; Cizkova D, 2000, CELL MOL NEUROBIOL, V20, P367, DOI 10.1023/A:1007018327133; DU L, 2000, CHINESE PHARMACOL B, V35, P93; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fumagalli F, 2004, NEUROREPORT, V15, P2109, DOI 10.1097/00001756-200409150-00022; GONGMING Y, 1997, BRAIN RES, V752, P209; Green AR, 2000, NEUROPHARMACOLOGY, V39, P1483, DOI 10.1016/S0028-3908(99)00233-6; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hartman RE, 2005, BRAIN RES, V1043, P48, DOI 10.1016/j.brainres.2005.02.030; He J, 2006, BEHAV BRAIN RES, V168, P236, DOI 10.1016/j.bbr.2005.11.014; He J, 2005, BEHAV BRAIN RES, V160, P178, DOI 10.1016/j.bbr.2004.11.028; Horacek J, 2006, CNS DRUGS, V20, P389, DOI 10.2165/00023210-200620050-00004; JASPERS RMA, 1990, NEUROSCI LETT, V117, P149, DOI 10.1016/0304-3940(90)90135-V; JOHANSEN FF, 1987, ACTA NEUROPATHOL, V73, P110, DOI 10.1007/BF00693775; Kasper S, 2003, PSYCHONEUROENDOCRINO, V28, P27, DOI 10.1016/S0306-4530(02)00115-4; Kim DH, 2006, PHARMACOL BIOCHEM BE, V85, P658, DOI 10.1016/j.pbb.2006.10.025; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kurz AF, 2005, INT PSYCHOGERIATR, V17, pS35, DOI 10.1017/S1041610205001936; Martin LJ, 2001, INT J MOL MED, V7, P455; Nasrallah HA, 2002, J CLIN PSYCHIAT, V63, P12; NUNN JA, 1994, BEHAV BRAIN RES, V62, P41, DOI 10.1016/0166-4328(94)90036-1; Ogren SO, 1996, NEUROSCIENCE, V75, P1127, DOI 10.1016/0306-4522(96)00215-1; Park SW, 2006, NEUROSCI LETT, V402, P25, DOI 10.1016/j.neulet.2006.03.028; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Perez-Neri I, 2006, NEUROCHEM RES, V31, P1279, DOI 10.1007/s11064-006-9162-3; Purdon SE, 2001, J PSYCHIATR NEUROSCI, V26, P137; Qing H, 2003, EUR J NEUROSCI, V17, P1563, DOI 10.1046/j.1460-9568.2003.02590.x; Raggi MA, 2004, CURR MED CHEM, V11, P279, DOI 10.2174/0929867043456089; Riva MA, 1997, MOL BRAIN RES, V50, P136, DOI 10.1016/S0169-328X(97)00175-7; Rodrigo J, 2005, FREE RADICAL BIO MED, V39, P26, DOI 10.1016/j.freeradbiomed.2005.02.010; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Tanaka R, 2004, STROKE, V35, P1454, DOI 10.1161/01.STR.0000126480.40967.b3; Tarazi FI, 2003, J PHARMACOL EXP THER, V306, P1145, DOI 10.1124/jpet.103.052597; Tascedda F, 1999, NEUROPSYCHOPHARMACOL, V21, P211, DOI 10.1016/S0893-133X(99)00034-2; Velligan DI, 2002, SCHIZOPHR RES, V53, P239, DOI 10.1016/S0920-9964(01)00268-7; Wei ZL, 2003, J NEUROSCI RES, V74, P942, DOI 10.1002/jnr.10832; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P; Xu HY, 2002, NEUROSCI LETT, V321, P65, DOI 10.1016/S0304-3940(02)00034-4; Yu L, 1997, CHINESE PHARMACOL B, V13, P223	50	29	31	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205			LIFE SCI	Life Sci.	JUL 12	2007	81	5					353	361		10.1016/j.lfs.2007.05.020			9	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	201NN	WOS:000248839000002	17631910				2021-06-18	
J	Cui, Q; Hodgetts, SI; Hu, Y; Luo, JM; Harvey, AR				Cui, Q.; Hodgetts, S. I.; Hu, Y.; Luo, J.-M.; Harvey, A. R.			Strain-specific differences in the effects of cyclosporin A and FK506 on the survival and regeneration of axotomized retinal ganglion cells in adult rats	NEUROSCIENCE			English	Article						retina; axonal regeneration; neuronal survival; autoimmune disease; peripheral nerve grafts; visual system	SPINAL-CORD-INJURY; PERIPHERAL-NERVE REGENERATION; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; MITOCHONDRIAL PERMEABILITY TRANSITION; IMPROVES FUNCTIONAL RECOVERY; IMMUNOPHILIN-LIGANDS FK506; OPTIC-NERVE; T-CELLS; PROTECTIVE AUTOIMMUNITY	The immune response can influence neuronal viability and plasticity after injury, effects differing in strains of rats with different susceptibility to autoimmune disease. We assessed the effects of i.p. injections of cyclosporin A (CsA) or FK506 on adult retinal ganglion cell (RGC) survival and axonal regeneration into peripheral nerve (PN) autografted onto the cut optic nerve of rats resistant (Fischer F344) or vulnerable (Lewis) to autoimmune disease. Circulating and tissue CsA and FK506 levels were similar in both strains. Three weeks after autologous PN transplantation the number of viable beta-III tubulin-positive RGCs was significantly greater in CsA- and FK506-treated F344 rats compared with saline-injected controls. RGC survival in Lewis rats was not significantly altered. In F344 rats, retrograde labeling of RGCs revealed that CsA or FK506 treatment significantly increased the number of RGCs that regenerated an axon into a PN autograft; however these agents had no beneficial effect on axonal regeneration in Lewis rats. PN grafts in F344 rats also contained comparatively more pan-neurofilament immunoreactive axons. In both strains, 3 weeks after transplantation CsA or FK506 treatment resulted in increased retinal macrophage numbers, but only in F344 rats was this increase significant. At this time-point PN grafts in both strains contained many macrophages and some T cells. T cell numbers in Lewis rats were significantly greater than in F344 animals. The increased RGC axonal regeneration seen in CsA- or FK506-treated F344 but not Lewis rats shows that modulation of immune responses after neurotrauma has complex and not always predictable outcomes. (c) 2007 IBRO. Published by Elsevier Ltd. All rights reserved.	Chinese Univ Hong Kong, Fac Med, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China; Univ Western Australia, Sect Anat & Human Biol, Perth, WA 6009, Australia; Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China; Shantou Univ, Coll Med, Chinese Univ Hong Kong, Shantou, Peoples R China	Cui, Q (corresponding author), Chinese Univ Hong Kong, Fac Med, Dept Ophthalmol & Visual Sci, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.	qcui@cuhk.edu.hk; arharvey@anhb.uwa.edu.au	Ying, Hu/F-3581-2010; Harvey, Alan/A-4911-2008	, Alan/0000-0002-2590-831X; Hodgetts, Stuart/0000-0002-3318-0410			Arumugam TV, 2005, NEUROMOL MED, V7, P229, DOI 10.1385/NMM:7:3:229; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Bahr M, 2000, TRENDS NEUROSCI, V23, P483, DOI 10.1016/S0166-2236(00)01637-4; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BRAY GM, 1987, J EXP BIOL, V132, P5; Brodie C, 1996, FEBS LETT, V394, P117, DOI 10.1016/0014-5793(96)00911-8; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Byram SC, 2004, J NEUROSCI, V24, P4333, DOI 10.1523/JNEUROSCI.5276-03.2004; Carrigan KA, 2004, INT IMMUNOPHARMACOL, V4, P419, DOI 10.1016/j.intimp.2004.01.011; Chierzi S, 2001, RESTOR NEUROL NEUROS, V19, P109; Cizza G, 1994, Immunomethods, V5, P73, DOI 10.1006/immu.1994.1039; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Dhabhar FS, 1998, ANN NY ACAD SCI, V840, P359, DOI 10.1111/j.1749-6632.1998.tb09575.x; DHABHAR FS, 1995, J NEUROIMMUNOL, V56, P77, DOI 10.1016/0165-5728(94)00135-B; Diaz-Ruiz A, 2005, NEUROCHEM RES, V30, P245, DOI 10.1007/s11064-005-2447-0; Dimou L, 2006, J NEUROSCI, V26, P5591, DOI 10.1523/JNEUROSCI.1103-06.2006; Elena G, 1997, INT J IMMUNOPHARMACO, V19, P699; Elenkov IJ, 2004, ANN NY ACAD SCI, V1024, P138, DOI 10.1196/annals.1321.010; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Freeman EE, 2000, INVEST OPHTH VIS SCI, V41, P1111; Friberg H, 1998, J NEUROSCI, V18, P5151; Frost P, 2001, J NEUROIMMUNOL, V121, P32, DOI 10.1016/S0165-5728(01)00440-4; Gillon RS, 2003, J NEUROSCI RES, V74, P524, DOI 10.1002/jnr.10788; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; Gold BG, 1998, NEUROSCI LETT, V241, P25, DOI 10.1016/S0304-3940(97)00960-9; Gong D, 1998, ANESTH ANALG, V87, P963, DOI 10.1097/00000539-199810000-00040; Gonzalez R, 2003, EXP NEUROL, V184, P456, DOI 10.1016/S0014-4886(03)00257-7; Gonzalez-Rey E, 2007, NAT REV IMMUNOL, V7, P52, DOI 10.1038/nri1984; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x; Hayashi Y, 2005, J NEUROTRAUM, V22, P1267, DOI 10.1089/neu.2005.22.1267; Heiduschka P, 2000, PROG RETIN EYE RES, V19, P577, DOI 10.1016/S1350-9462(00)00011-2; HO S, 1996, CLIN IMMUNOL IMMUNOP, V80, P40; Hodgetts SI, 2003, TRANSPLANTATION, V75, P863, DOI 10.1097/01.TP.0000053754.33317.4B; HOLLANDER GA, 1994, TRANSFUS SCI, V15, P207, DOI 10.1016/0955-3886(94)90133-3; Hortelano S, 1999, BRIT J PHARMACOL, V126, P1139, DOI 10.1038/sj.bjp.0702422; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; Ibarra A, 1996, J NEUROTRAUM, V13, P267, DOI 10.1089/neu.1996.13.267; Isenmann S, 2003, PROG RETIN EYE RES, V22, P483, DOI 10.1016/S1350-9462(03)00027-2; Jensen JN, 2005, ANN PLAS SURG, V54, P420, DOI 10.1097/01.sap.0000151461.60911.c0; Jiang HS, 2002, TRANSPLANTATION, V73, P1808, DOI 10.1097/00007890-200206150-00019; Jones TB, 2005, CURR PHARM DESIGN, V11, P1223, DOI 10.2174/1381612053507468; Jones TB, 2004, J NEUROSCI, V24, P3752, DOI 10.1523/JNEUROSCI.0406-04.2004; Jones TB, 2002, J NEUROSCI, V22, P2690, DOI 10.1523/JNEUROSCI.22-07-02690.2002; Jost SC, 2000, RESTOR NEUROL NEUROS, V17, P39; Kawai R, 1998, J PHARMACOL EXP THER, V287, P457; KAY JE, 1989, IMMUNOLOGY, V67, P473; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kipnis J, 2002, P NATL ACAD SCI USA, V99, P15620, DOI 10.1073/pnas.232565399; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152; Klettner A, 2003, BRIT J PHARMACOL, V138, P1004, DOI 10.1038/sj.bjp.0705132; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Koeberle PD, 2004, NEUROSCIENCE, V125, P903, DOI 10.1016/S0306-4522(03)00398-1; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Ling CY, 2006, J NEUROSCI, V26, P731, DOI 10.1523/JNEUROSCI.3502-05.2006; LYONS WE, 1995, J NEUROSCI, V15, P2985; Madsen JR, 1998, EXP NEUROL, V154, P673, DOI 10.1006/exnr.1998.6974; Marks AR, 1996, PHYSIOL REV, V76, P631; Marsen TA, 2000, FUNDAM CLIN PHARM, V14, P401, DOI 10.1111/j.1472-8206.2000.tb00422.x; Martucci C, 2004, PAIN, V110, P385, DOI 10.1016/j.pain.2004.04.020; McGuirk P, 2002, TRENDS IMMUNOL, V23, P450, DOI 10.1016/S1471-4906(02)02288-3; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nevo U, 2003, TRENDS MOL MED, V9, P88, DOI 10.1016/S1471-4914(03)00024-8; NG TF, 1995, J NEUROCYTOL, V24, P487, DOI 10.1007/BF01179974; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Pan YA, 2003, J NEUROSCI, V23, P11479; Pompeo A, 1999, LIFE SCI, V64, P837, DOI 10.1016/S0024-3205(99)00005-3; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 2003, TRENDS PHARMACOL SCI, V24, P13, DOI 10.1016/S0165-6147(02)00006-8; Rosenstiel P, 2003, J NEUROTRAUM, V20, P297, DOI 10.1089/089771503321532888; ROTT O, 1994, EUR J IMMUNOL, V24, P1434, DOI 10.1002/eji.1830240629; Sauve Y, 2001, J NEUROSCI, V21, P951; Schwartz M, 2005, J NEUROL SCI, V233, P163, DOI 10.1016/j.jns.2005.03.014; Schwartz M, 2002, TRENDS IMMUNOL, V23, P530, DOI 10.1016/S1471-4906(02)02322-0; Sheehan Jason, 2006, Neurosurg Focus, V20, pE9; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Steiniger B, 2001, IMMUNOL REV, V184, P38, DOI 10.1034/j.1600-065x.2001.1840104.x; Sternberg EM, 2001, J ENDOCRINOL, V169, P429, DOI 10.1677/joe.0.1690429; Sternberg EM, 2006, NAT REV IMMUNOL, V6, P318, DOI 10.1038/nri1810; Stevens DB, 2002, J NEUROIMMUNOL, V126, P25, DOI 10.1016/S0165-5728(02)00045-0; Strestikova P, 2001, IMMUNOPHARM IMMUNOT, V23, P67, DOI 10.1081/IPH-100102568; SUZUKI N, 1990, CLIN EXP IMMUNOL, V79, P240; Tanaka C, 2000, DRUG METAB DISPOS, V28, P582; Taskinen HS, 2000, J NEUROTRAUM, V17, P431, DOI 10.1089/neu.2000.17.431; THANOS S, 1993, J NEUROSCI, V13, P455; TOCCI MJ, 1989, J IMMUNOL, V143, P718; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Vidal-Sanz M, 2002, PROG BRAIN RES, V137, P443; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang M S, 1999, J Spinal Cord Med, V22, P287; Warrington AE, 2001, J ALLERGY CLIN IMMUN, V108, pS121, DOI 10.1067/mai.2001.118301; WICKER LS, 1990, EUR J IMMUNOL, V20, P2277, DOI 10.1002/eji.1830201017; WIRT DP, 1993, CLIN IMMUNOL IMMUNOP, V67, P224; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001	99	29	29	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	MAY 25	2007	146	3					986	999		10.1016/j.neuroscience.2007.02.034			14	Neurosciences	Neurosciences & Neurology	169HY	WOS:000246584500010	17408862				2021-06-18	
J	Thombs, BD; Bresnick, MG; Magyar-Russell, G; Lawrence, JW; McCann, UD; Fauerbach, JA				Thombs, Brett D.; Bresnick, Melissa G.; Magyar-Russell, Gina; Lawrence, John W.; McCann, Una D.; Fauerbach, James A.			Symptoms of depression predict change in physical health after burn injury	BURNS			English	Article						depression; burn; physical function	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; MAJOR DEPRESSION; MYOCARDIAL-INFARCTION; CLINICAL-SIGNIFICANCE; CONTROLLED-TRIAL; MEDICALLY ILL; PREVALENCE	This study investigated the prevalence of symptoms of depression in patients hospitalized with severe burns and the association of symptoms of depression in the hospital with physical health 2 months after discharge, controlling for pre-burn physical health as measured by the SF-36 physical composite score. Survivors of acute burns were evaluated during the hospitalization (N = 262) and at 1 week (N = 165) and 2 months (N = 100) after discharge. The prevalence of at least mild to moderate symptoms of depression (Beck Depression Inventory >= 10) ranged from 23% to 26%. In-hospital symptoms of depression predicted change in physical health from pre-burn to 2 months post-discharge (p =.02), controlling for patient demographics, burn severity, and symptoms of PTSD. These results suggest that patients should be screened for depression, both in-hospital and during rehabilitation after discharge. (c) 2006 Elsevier Ltd and ISBI. All rights reserved.	Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; CUNY Coll Staten Isl, New York, NY 10021 USA	Thombs, BD (corresponding author), Sir Mortimer B Davis Jewish Hosp, Inst Community & Family Psychiat, 4333 Cote Ste Catherine Rd, Montreal, PQ H3T 1E4, Canada.	brett.thombs@mcgill.ca		Thombs, Brett/0000-0002-5644-8432			*AM BURN ASS, 1984, B AM COLL SURG, V69, P24; Beck A.T., 1987, MANUAL REVISED BECK; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348; Breslau N, 2000, BIOL PSYCHIAT, V48, P902, DOI 10.1016/S0006-3223(00)00933-1; Brown KW, 2003, PSYCHOSOM MED, V65, P636, DOI 10.1097/01.PSY.0000077503.96903.A6; Carrougher GF, 2003, J BURN CARE REHABIL, V24, P1, DOI 10.1097/00004630-200301000-00003; CHOINIERE M, 1989, J TRAUMA, V29, P1531, DOI 10.1097/00005373-198911000-00013; Darnall BD, 2005, ARCH PHYS MED REHAB, V86, P650, DOI 10.1016/j.apmr.2004.10.028; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; de Groot M, 2001, PSYCHOSOM MED, V63, P619, DOI 10.1097/00006842-200107000-00015; Dowson CA, 2004, J PSYCHOSOM RES, V56, P333, DOI 10.1016/S0022-3999(03)00040-0; Dryden DM, 2005, NEUROEPIDEMIOLOGY, V25, P55, DOI 10.1159/000086284; Esselman PC, 2006, AM J PHYS MED REHAB, V85, P383, DOI 10.1097/01.phm.0000202095.51037.a3; Evans DL, 2005, BIOL PSYCHIAT, V58, P175, DOI 10.1016/j.biopsych.2005.05.001; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Fauerbach JA, 1997, PSYCHOSOMATICS, V38, P374, DOI 10.1016/S0033-3182(97)71445-2; Garratt AN, 2002, BMJ-BRIT MED J, V324, P1417, DOI 10.1136/bmj.324.7351.1417; Glassman AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/jama.288.6.701; Holland JC, 1998, PSYCHO-ONCOL, V7, P291, DOI 10.1002/(SICI)1099-1611(199807/08)7:4<291::AID-PON361>3.3.CO;2-L; House A, 2001, STROKE, V32, P696, DOI 10.1161/01.STR.32.3.696; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; Kauhanen ML, 2000, ARCH PHYS MED REHAB, V81, P1541, DOI 10.1053/apmr.2000.9391; Kemp BJ, 2004, J SPINAL CORD MED, V27, P22, DOI 10.1080/10790268.2004.11753726; Kilbourne AM, 2005, AM J GERIAT PSYCHIAT, V13, P202; Koenig HG, 1997, AM J PSYCHIAT, V154, P1376; Krause JS, 2004, ARCH PHYS MED REHAB, V85, P1503, DOI 10.1016/j.apmr.2004.01.017; Lenze EJ, 2004, INT J GERIATR PSYCH, V19, P472, DOI 10.1002/gps.1116; Lustman PJ, 2000, DIABETES CARE, V23, P618, DOI 10.2337/diacare.23.5.618; Lyketsos CG, 1997, J NEUROPSYCH CLIN N, V9, P556; Madianos MG, 2001, PSYCHOTHER PSYCHOSOM, V70, P30, DOI 10.1159/000056222; MAGYARRUSSELL GM, 2006, J BURN CARE RES, V27, pS103; McQuaid D, 2003, J BURN CARE REHABIL, V24, P203, DOI 10.1097/01.BCR.0000075849.08794.36; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; MORENO JK, 1993, J PERS ASSESS, V61, P511, DOI 10.1207/s15327752jpa6103_7; Pallua N, 2003, BURNS, V29, P143, DOI 10.1016/S0305-4179(02)00238-3; Phillips P, 1999, JAMA-J AM MED ASSOC, V282, P1118, DOI 10.1001/jama.282.12.1118; Raison CL, 2003, BIOL PSYCHIAT, V54, P283, DOI 10.1016/S0006-3223(03)00413-X; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Robinson RG, 2003, BIOL PSYCHIAT, V54, P376, DOI 10.1016/S0006-3223(03)00423-2; Robinson RG, 2000, AM J PSYCHIAT, V157, P351, DOI 10.1176/appi.ajp.157.3.351; Rudisch B, 2003, BIOL PSYCHIAT, V54, P227, DOI 10.1016/S0006-3223(03)00587-0; Simon G E, 1995, Arch Fam Med, V4, P99, DOI 10.1001/archfami.4.2.99; Thombs BD, 2006, J GEN INTERN MED, V21, P30, DOI 10.1111/j.1525-1497.2005.00269.x; Thombs BD, 2006, GEN HOSP PSYCHIAT, V28, P494, DOI 10.1016/j.genhosppsych.2006.08.010; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; van Melle JP, 2004, PSYCHOSOM MED, V66, P814, DOI 10.1097/01.psy.0000146294.82810.9c; Ward H W, 1987, J Burn Care Rehabil, V8, P294, DOI 10.1097/00004630-198707000-00011; Ware JE., 1993, SF 36 HLTH SURVEY MA; Wiechman SA, 2001, J BURN CARE REHABIL, V22, P417, DOI 10.1097/00004630-200111000-00012; Ziegelstein RC, 2000, ARCH INTERN MED, V160, P1818, DOI 10.1001/archinte.160.12.1818; 2005, NIDRR MODEL SYSTEMS	54	29	29	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0305-4179	1879-1409		BURNS	Burns	MAY	2007	33	3					292	298		10.1016/j.burns.2006.10.399			7	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	160WJ	WOS:000245972800002	17382189				2021-06-18	
J	Hart, T; O'Neil-Pirozzi, TM; Williams, KD; Rapport, LJ; Hammond, F; Kreutzer, J				Hart, Tessa; O'Neil-Pirozzi, Therese M.; Williams, Kelli D.; Rapport, Lisa J.; Hammond, Flora; Kreutzer, Jefftey			Racial differences in caregiving patterns, caregiver emotional function, and sources of emotional support following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; caregiver function; race differences	QUALITY-OF-LIFE; AFRICAN-AMERICAN; PSYCHOLOGICAL DISTRESS; DEMENTIA CAREGIVERS; SOCIAL SUPPORT; RACE; OUTCOMES; SCALE; REHABILITATION; SATISFACTION	Objective: Compare white and African American caregivers of people with moderate to severe traumatic brain injury (TBI) regarding caregiving patterns, emotional function and life satisfaction, and preferred supports. Design: Prospective, observational study; 1, 2, or 5 years post-TBI. Setting: Six TBI model systems. Participants: Two hundred fifty-six caregivers (195 white and 61 African American). Measures: Brief Symptom Inventory-18, Satisfaction With Life Scale. Results: Races differed as to kinship patterns, with more white caregivers including spouses and more African Americans including "other relatives." African Americans spent significantly more time in direct caregiving, and reported more depression. African American TBI survivors were significantly more disabled than whites, which appeared to account for emotional function differences. Whites were more likely to use professional services for emotional support. Conclusion: Across races, TBI caregiver emotional health is affected by the functional level of the survivor. African American caregivers may be at risk for worse emotional consequences due to worse survivor outcomes, yet may underutilize professional services.	Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA; Spaulding Rehabil Hosp, Boston, MA USA; Northeastern Univ, Boston, MA 02115 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Carolinas Rehabil, Charlotte, NC USA	Hart, T (corresponding author), Jefferson Med Coll, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu					Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Corrigan J, 2003, TECHNICAL REPORT PRO; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cox C, 1999, J GERONTOL SOC WORK, V32, P5, DOI 10.1300/J083v32n02_02; Cox C, 1993, AM J ALZHEIMERS CARE, V8, P33; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DEROGATIS LR, 2000, BRIEF SYMTPOM INVENT, V18; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dilworth-Anderson P, 2005, J GERONTOL B-PSYCHOL, V60, pS257, DOI 10.1093/geronb/60.5.S257; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Farran CJ, 1997, J AGING HEALTH, V9, P316, DOI 10.1177/089826439700900303; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Haley WE, 2004, AGING MENT HEALTH, V8, P316, DOI 10.1080/13607860410001728998; Haley WE, 1996, J CONSULT CLIN PSYCH, V64, P121, DOI 10.1037/0022-006X.64.1.121; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hart T, 2003, REHABIL PSYCHOL, V48, P86, DOI 10.1037/0090-5550.48.2.86; HORWITZ AV, 1995, J HEALTH SOC BEHAV, V36, P138, DOI 10.2307/2137221; Knight BG, 1998, AGING MENT HEALTH, V2, P212, DOI 10.1080/13607869856696; Knight BG, 2000, J GERONTOL B-PSYCHOL, V55, pP142, DOI 10.1093/geronb/55.3.P142; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LAWTON MP, 1992, J GERONTOL, V47, pS156, DOI 10.1093/geronj/47.4.S156; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; MILLER B, 1995, J GERONTOL B-PSYCHOL, V50, pS374, DOI 10.1093/geronb/50B.6.S374; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roff LL, 2004, J GERONTOL B-PSYCHOL, V59, pP185, DOI 10.1093/geronb/59.4.P185; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P69; Sander AM, 2007, NEUROREHABILITATION, V22, P1; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sleath B, 2005, J AM GERIATR SOC, V53, P397, DOI 10.1111/j.1532-5415.2005.53155.x; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; *UDS, 1997, GUID UN DAT SET MED; Valentine DP, 1998, FAM SOC-J CONTEMP H, V79, P577, DOI 10.1606/1044-3894.861; Warschausky S, 2001, ARCH PHYS MED REHAB, V82, P329, DOI 10.1053/apmr.2001.21510; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; White TM, 2000, GERONTOLOGIST, V40, P718, DOI 10.1093/geront/40.6.718; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393	47	29	29	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2007	22	2					122	131		10.1097/01.HTR.0000265100.37059.44			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	152NU	WOS:000245369500007	17414314				2021-06-18	
J	Vilar-Lopez, R; Santiago-Ramajo, S; Gomez-Rio, M; Verdejo-Garcia, A; Llamas, JM; Perez-Garcia, M				Vilar-Lopez, Raquel; Santiago-Ramajo, S.; Gomez-Rio, Manuel; Verdejo-Garcia, Antonio; Llamas, Jose M.; Perez-Garcia, Miguel			Detection of malingering in a Spanish population using three specific malingering tests	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; post-concussion syndrome; Spanish speakers; VSVT; TOMM; b test	SYMPTOM VALIDITY TEST; MEMORY IMPAIRMENT; PERFORMANCE; NEUROPSYCHOLOGY; VALIDATION; HISCOCK; RATES	\The detection of feigned cognitive impairment remains difficult and may be even more challenging in certain population groups. Studies on the use of neuropsychological tests in ethnic groups for which they were not designed have shown variations in performance associated with cultural differences. With this background, our group studied a Spanish population by applying commonly used procedures [Victoria Symptom Validity Test (VSVT), Test of Memory Malingering (TOMM), and the b test] in a group with post-concussion syndrome (PCs) (whether litigants or not) and in a group of analog malingerers (AN). These tests appeared to function adequately in this Spanish population, who showed similar performances to results published for North Americans. (C) 2007 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ Granada, Fac Psicol, Dept Personalidad Evaluac & Tratamiento Psicol, E-18071 Granada, Spain; Univ Granada, Hosp Virgen de las Nieves, Med Serv, E-18071 Granada, Spain; Univ Granada, Inst Neurosci, E-18071 Granada, Spain	Vilar-Lopez, R (corresponding author), Univ Granada, Fac Psicol, Dept Personalidad Evaluac & Tratamiento Psicol, Campus Cartuja S-N, E-18071 Granada, Spain.	raquelvilarlopez@hotmail.com	Garcia, Miguel Perez/F-9630-2010; Vilar-Lopez, Raquel/I-7847-2016; Santiago-Ramajo, Sandra/H-6801-2015	Garcia, Miguel Perez/0000-0003-4775-7556; Vilar-Lopez, Raquel/0000-0001-9639-0143; Santiago-Ramajo, Sandra/0000-0002-6358-6155; Verdejo-Garcia, Antonio/0000-0001-8874-9339; Llamas-Elvira, Jose Manuel/0000-0002-4661-5030			Bender SD, 2004, ARCH CLIN NEUROPSYCH, V19, P49, DOI 10.1016/S0887-6177(02)00165-8; Bezeau S, 2001, J CLIN EXP NEUROPSYC, V23, P399, DOI 10.1076/jcen.23.3.399.1181; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boone K., 2002, B TEST MANUAL; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gouvier WD, 2003, NEURO S B C, P405; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Haines ME, 1995, NEUROPSYCHOL REV, V5, P125, DOI 10.1007/BF02208438; Holmquist LA, 2002, ARCH CLIN NEUROPSYCH, V17, P143, DOI 10.1016/S0887-6177(00)00106-2; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Prigatano GP, 1997, ARCH CLIN NEUROPSYCH, V12, P609, DOI 10.1016/S0887-6177(97)00020-6; PUENTE AE, 2000, HDB MULTICULTURAL ME, P419; PUENTE AE, 2000, HDB PSYCHOL ASSESSME, P527; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Tombaugh TN, 1996, TEST MEMORY MALINGER; Verdejo A, 2004, REV NEUROLOGIA, V39, P60, DOI 10.33588/rn.3901.2004229; World Health Organization, 1992, ICD 10 INT STAT CLAS; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	34	29	30	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2007	22	3					379	388		10.1016/j.acn.2007.01.012			10	Psychology, Clinical; Psychology	Psychology	196IO	WOS:000248475100012	17303375	Bronze			2021-06-18	
J	Abadal-Centellas, JM; Llompart-Pou, JA; Homar-Ramirez, J; Perez-Barcena, J; Rossello-Ferrer, A; Ibanez-Juve, J				Abadal-Centellas, Josep M.; Llompart-Pou, Juan A.; Homar-Ramirez, Javier; Perez-Barcena, Jon; Rossello-Ferrer, Ainhoa; Ibanez-Juve, Jordi			Neurologic outcome of posttraumatic refractory intracranial hypertension treated with external lumbar drainage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; intracranial hypertension; external lumbar drainage	SEVERE HEAD-INJURY; TRAUMATIC BRAIN-INJURY; PRESSURE MONITORS; PLACEMENT	Background: Refractory intracranial hypertension (ICH) to second level measures after severe traumatic brain injury (TBI) is associated with mortality up to 84% to 100%. The use of external lumbar drainage (ELD) has been described in these patients. We report our experience with the use of ELD in 17 cases of refractory ICH after severe TBI. Methods: In our Level 3 Intensive Care Unit (ICU) at a university hospital, ICH is treated according to a progressive approach following the Brain Trauma Foundation guidelines. When second level measures fail to control ICH, we use an ELD as a rescue therapy if basal cisterns are discernible. Outcome at ICU discharge and 6 months after injury were analyzed using Glasgow Outcome Scale (GOS). Results: Mean age was 32.5 +/- 13.3 years. ICH was reduced in all patients. ICP before ELD was 30.9 +/- 7.9 mm Hg and after ELD 14.1 +/- 5.9 mm Hg. Four patients (24%) had an ICH rebound after 5 days of ELD placement and died in the ICU. At 6 months after TBI, 13 patients (76%) presented a good outcome (GOS score of 4 and 5). No patient presented pupillary changes or cerebrospinal fluid infection during ELD use. Conclusion: External lumbar drainage is an effective and safe procedure to treat refractory ICH when basal cisterns are discernible. Control of refractory ICH with ELD is associated with an important reduction of mortality and a good functional recovery at 6 months.	Hosp Univ Son Dureta, Serv Med Intens, Palma de Mallorca 07014, Baleares, Spain	Llompart-Pou, JA (corresponding author), Hosp Univ Son Dureta, Serv Med Intens, C Andrea Doria N 55, Palma de Mallorca 07014, Baleares, Spain.	ja_llompart@hotmail.com					Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; Davis JW, 2004, J TRAUMA, V57, P1173, DOI 10.1097/01.TA.0000151257.79108.FB; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Guyot LL, 1998, ACT NEUR S, V71, P47; Harris CH, 2002, AM SURGEON, V68, P787; JENNETT B, 1975, LANCET, V2, P480; Khan SH, 1998, ACT NEUR S, V71, P50; KOREIN J, 1959, NEUROLOGY, V9, P290, DOI 10.1212/WNL.9.4.290; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARTINEZ E, 1994, LANCET, V344, P1015, DOI 10.1016/S0140-6736(94)91671-3; Munch EC, 2001, CRIT CARE MED, V29, P976; Perez-Barcena J, 2005, NEUROCIRUGIA, V16, P5; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; SENCER W, 1956, J Mt Sinai Hosp N Y, V23, P808; SHAPIRO K, 1980, ANN NEUROL, V7, P508, DOI 10.1002/ana.410070603; Stocchetti N, 2003, ACTA NEUROCHIR, V145, P761, DOI 10.1007/s00701-003-0092-4; Tomosvari Adrienn, 2005, Orvosi Hetilap, V146, P159; Willemse RB, 1998, ACT NEUR S, V71, P37	22	29	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2007	62	2					282	286		10.1097/01.ta.0000199422.01949.78			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	137ZY	WOS:000244333300002	17297313				2021-06-18	
J	Bartnik, BL; Hovda, DA; Lee, PWN				Bartnik, Brenda L.; Hovda, David A.; Lee, Paul W. N.			Glucose metabolism after traumatic brain injury: Estimation of pyruvate carboxylase and pyruvate dehydrogenase flux by mass isotopomer analysis	JOURNAL OF NEUROTRAUMA			English	Article						gas chromatography-mass spectrometry; [1, 2 C-13(2)] glucose; glutamate; pyruvate carboxylase; pyruvate dehydrogenase; rat	CORTICAL CONTUSION INJURY; C-13 NMR; IN-VIVO; RAT-BRAIN; AMINO-ACIDS; NEUROTRANSMITTER GLUTAMATE; CEREBRAL METABOLISM; KREBS CYCLE; TCA CYCLE; COMPARTMENTATION	The metabolism of [1, 2 C-13(2)] glucose via the tricarboxylic acid (TCA) cycle yields a number of key glutamate mass isotoporners whose formation is a function of pyruvate carboxylase (PC) and pyruvate dehydrogenase (PDH). Analysis of the isotopomer distribution patterns was used to determine the relative flux of glucose entry into the TCA cycle through anaplerotic and oxidative pathways in the cerebral cortex of both uninjured and traumatically injured adult male rats. In the cerebral cortex of uninjured animals the PC/PDH ratio showed greater metabolism of glucose via pyruvate carboxylase, which is consistent with the notion that the majority of glucose taken up at rest is used as a substrate for anaplerotic processes and not as an energy source. While traumatic brain injury did not change the overall C-13 enrichment of glutamate indicating a continued oxidation of glucose, the PC/PDH ratio was reduced in the injured cortex at 3.5 h after injury. This suggests that glucose metabolism is primarily directed through pathways associated with energy production in the early post-injury period. By 24 h, the anaplerotic flux decreased and the PC/PDH ratio increased in both the injured and non-injured cortex indicating a switch away from energy production to pathways associated with anabolic and/or regenerative processes.	Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Surg, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Los Angeles Biomed Res Inst, Dept Pediat, Torrance, CA 90509 USA	Bartnik, BL (corresponding author), Loma Linda Univ, Dept Radiol, 11234 Anderson St,Room B623, Loma Linda, CA 92354 USA.	bbartnik@llu.edu		Bartnik-Olson, Brenda/0000-0002-1137-9437	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01 CA 42710] Funding Source: Medline; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 00425] Funding Source: Medline; ONDIEH CDC HHS [ND 36373, ND 27544] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA042710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000425] Funding Source: NIH RePORTER		Aureli T, 1997, BRAIN RES, V765, P218, DOI 10.1016/S0006-8993(97)00514-3; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Behar KL, 2001, J NUTR, V131, p2498S, DOI 10.1093/jn/131.9.2498S; BRAND A, 1992, BIOCHIMIE, V74, P941, DOI 10.1016/0300-9084(92)90078-S; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Cruz F, 1998, J NEUROCHEM, V70, P2613; Cruz F, 1999, NMR BIOMED, V12, P451, DOI 10.1002/(SICI)1099-1492(199911)12:7<451::AID-NBM571>3.3.CO;2-5; Daikhin Y, 2000, J NUTR, V130, p1026S, DOI 10.1093/jn/130.4.1026S; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; GARFINKEL D, 1966, J BIOL CHEM, V241, P3918; Gruetter R, 2002, NEUROCHEM INT, V41, P143, DOI 10.1016/S0197-0186(02)00034-7; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HASSEL B, 1995, J NEUROCHEM, V64, P2773; Hassel B, 2000, MOL NEUROBIOL, V22, P21, DOI 10.1385/MN:22:1-3:021; Hertz L, 1999, J NEUROSCI RES, V57, P417, DOI 10.1002/(SICI)1097-4547(19990815)57:4<417::AID-JNR1>3.3.CO;2-E; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Kanamatsu T, 1999, BRAIN RES, V841, P11, DOI 10.1016/S0006-8993(99)01772-2; Kanamori K, 2002, J NEUROCHEM, V83, P682, DOI 10.1046/j.1471-4159.2002.01161.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATZ J, 1993, J BIOL CHEM, V268, P25509; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kondrat RW, 2002, J NEUROSCI METH, V120, P179, DOI 10.1016/S0165-0270(02)00201-7; KUNNECKE B, 1993, NMR BIOMED, V6, P264, DOI 10.1002/nbm.1940060406; LAPIDOT A, 1994, J BIOL CHEM, V269, P27198; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; Lee WNP, 1996, DEV NEUROSCI-BASEL, V18, P469, DOI 10.1159/000111442; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843; LEE WNP, 1993, J BIOL CHEM, V268, P25522; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; LIFSHITZ J, 1993, J CEREB BLOOD FLOW M, V23, P219; McKenna MC, 1996, J NEUROCHEM, V66, P386; Merle M, 2002, J NEUROCHEM, V82, P47, DOI 10.1046/j.1471-4159.2002.00924.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OPIL WO, 2004, 68616 SOC NEUR; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Patel AB, 2005, J NEUROSCI RES, V79, P128, DOI 10.1002/jnr.20311; Patel AB, 2004, J CEREBR BLOOD F MET, V24, P972, DOI 10.1097/01.WCB.0000126234.16188.71; Preece NE, 1996, J NEUROCHEM, V67, P1718; Qu H, 2001, J NEUROSCI RES, V66, P1127, DOI 10.1002/jnr.10032.abs; Ramonet D, 2004, HIPPOCAMPUS, V14, P586, DOI 10.1002/hipo.10188; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; SHANK RP, 1985, BRAIN RES, V329, P364, DOI 10.1016/0006-8993(85)90552-9; SHANK RP, 1993, J NEUROCHEM, V61, P315, DOI 10.1111/j.1471-4159.1993.tb03570.x; Sibson NR, 2001, J NEUROCHEM, V76, P975, DOI 10.1046/j.1471-4159.2001.00074.x; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tyson RL, 2003, BRAIN RES, V992, P43, DOI 10.1016/j.brainres.2003.08.027; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xu Y, 2004, J NEUROCHEM, V90, P1104, DOI 10.1111/j.1471-4159.2004.02576.x; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU ACH, 1983, J NEUROCHEM, V41, P1484, DOI 10.1111/j.1471-4159.1983.tb00849.x	61	29	29	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					181	194		10.1089/neu.2006.0038			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100018	17263682				2021-06-18	
J	Cantin, JF; Mcfadyen, BJ; Doyon, J; Swaine, B; Dumas, D; Vallee, M				Cantin, Jean-Francois; Mcfadyen, Bradford J.; Doyon, Julien; Swaine, Bonnie; Dumas, Denyse; Vallee, Marie			Can measures of cognitive function predict locomotor behaviour in complex environments following a traumatic brain injury?	BRAIN INJURY			English	Article						cognition; attention; executive functioning; gait; locomotion	EXECUTIVE FUNCTION; INATTENTIVE BEHAVIOR; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; DIVIDED ATTENTION; GAIT VARIABILITY; HEAD-INJURY; WALKING; TASK; PERFORMANCE	Primary objective: To determine the relationships between clinical measures of executive function and attention, and laboratory measures of anticipatory locomotor adaptations with dual tasks following a TBI. Methods and procedures: Ten people with moderate or severe TBI were compared to 10 healthy subjects for neuropsychological measures in the clinic, as well as locomotor patterns and reading time in the laboratory for adapted Stroop tasks ( Bar and Word) during unobstructed and obstructed walking. Main outcomes and results: As previously found [ 1] ( Vallee M, McFadyen BJ, Swaine B, Doyon J, Cantin JF, Dumas D. Effects of environmental demands on locomotion after traumatic brain injury. Archives of Physical Medicine Rehabilitation 2006; 87: 806 - 813) during the locomotor activities, subjects with TBI walked slower, had higher clearance margins and took longer to read during the Stroop tasks than healthy subjects. In general, subjects with TBI also showed deficits in executive functions and attention. Significant relationships were specifically observed between scores on Trail Making B and clearance margins for subjects with TBI, but not for healthy subjects. Alternatively, significant relationships between clinical scores on Stroop and dual task Stroop reading times were obtained for healthy subjects but not for subjects with TBI. Conclusions: These results suggest that measures of executive functioning and attention may be associated to locomotor behaviour in complex environments following a moderate to severe TBI.	Ctr Interdisciplinary Res Rehabil & Social Integr, Quebec City, PQ G1M 2S8, Canada; Univ Laval, Sch Psychol, Quebec City, PQ, Canada; Quebec Rehabil Inst, Quebec City, PQ, Canada; Univ Laval, Dept Rehabil, Quebec City, PQ, Canada; Univ Montreal, Dept Psychol, Montreal, PQ, Canada; Univ Montreal, Sch Rehabil, Fac Med, Montreal, PQ, Canada; CHUQ, St Francois Assise Hosp, Quebec City, PQ, Canada	Mcfadyen, BJ (corresponding author), Ctr Interdisciplinary Res Rehabil & Social Integr, 525 Harnel, Quebec City, PQ G1M 2S8, Canada.	brad.mcfadyen@rea.ulaval.ca		McFadyen, Bradford/0000-0003-1992-4927			ALEXANDER NB, 1995, NEUROLOGY, V45, P908, DOI 10.1212/WNL.45.5.908; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Ble A, 2005, J AM GERIATR SOC, V53, P410, DOI 10.1111/j.1532-5415.2005.53157.x; Bowen A, 2001, AGE AGEING, V30, P319, DOI 10.1093/ageing/30.4.319; BRICKENKAMP R, 1981, D2 TEST ATTENTION; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Golden C., 1978, STROOP COLOUR WORD T; Halstead WC, 1985, HALSTEAD REITAN NEUR; Hausdorff JM, 2005, EXP BRAIN RES, V164, P541, DOI 10.1007/s00221-005-2280-3; Hausdorff JM, 2003, J GERIATR PSYCH NEUR, V16, P53, DOI 10.1177/0891988702250580; Kantor B, 2004, J AM GERIATR SOC, V52, P1326, DOI 10.1111/j.1532-5415.2004.52363.x; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; Kim J, 2005, J INT NEUROPSYCH SOC, V11, P434, DOI 10.1017/S1355617705050563; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Meher I, 2004, J AM GERIATR SOC, V52, P1255, DOI 10.1111/j.1532-5415.2004.52353.x; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Regnaux JP, 2005, NEUROREHAB NEURAL RE, V19, P125, DOI 10.1177/1545968305275612; Schrodt LA, 2004, GAIT POSTURE, V19, P279, DOI 10.1016/S0966-6362(03)00067-5; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Sheridan PL, 2003, J AM GERIATR SOC, V51, P1633, DOI 10.1046/j.1532-5415.2003.51516.x; Smith A., 1982, SYMBOL DIGIT MODALIT; Stierwalt Julie A. G., 2002, Seminars in Speech and Language, V23, P129, DOI 10.1055/s-2002-24989; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Weschler D., 1997, WESCHLER MEMORY SCAL; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; Yogev G, 2005, EUR J NEUROSCI, V22, P1248, DOI 10.1111/j.1460-9568.2005.04298.x	36	29	29	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	3					327	334		10.1080/02699050701209972			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	168IW	WOS:000246518400008	17453761				2021-06-18	
J	Hang, CH; Shi, JX; Sun, BW; Li, JS				Hang, Chun-Hua; Shi, Ji-Xin; Sun, Bing-Wei; Li, Jie-Shou			Apoptosis and functional changes of dipeptide transporter (PepT1) in the rat small intestine after traumatic brain injury	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; intestine; mucosal damage; apoptosis; dipeptide transporter	NF-KAPPA-B; EPITHELIAL TRANSPORT; HORMONAL-REGULATION; EXPRESSION CLONING; HPEPT1 EXPRESSION; MOLECULAR-CLONING; CELL-DEATH; PEPTIDES; ISCHEMIA; MUCOSA	Background. Traumatic brain injury (TBI) can induce significant alterations of intestinal mucosal structure c and barrier function. However, it has not been investigated whether, and to what degree, apoptosis and alterations of absorptive function in the intestinal mucosal epithelium occur after TBI. Material and methods. Male Wistar rats were randomly divided into seven groups (five rats each group) including normal group, control group with sham operation, and TBI groups at hours 3, 12, 24, and 72, and on day 7. Parietal brain contusion was adopted using weight-dropping method. Intestinal mucosal structure was examined using histomorphmetric study and electron microscopy, and apoptosis was detected by TUNEL method. An everted sleeve of intestine was securely incubated in Kreb's solution with radioactive dipeptide (H-3-Gly-Sar, 10 mu Ci/mL) to measure the uptake and transport of PepT1 of small intestinal epithelial cells. Results. The villous height, crypt depth and surface area were significantly decreased at 24 h after TBI, and further declined to the degree of mucosal atrophy on day 7 after TBI. Apoptotic changes of condensed nuclei in epithelial cells and fractured, distorted, and sparse microvilli were found by electron microscopy. The number of apoptotic cells in the mucosal epithelium was significantly increased since 3 h after TBI, peaked at 72 h post-injury, then declined at 7 days, but was still higher than that of control. There was a highly negative relation between the apoptotic index and the villous height, the crypt depth, and villous surface area. Compared with that of normal and control rats, the transport and uptake of dipeptide was significantly increased at 3 h post-injury (P < 0.01), peaked at 12 h and declined a bit at 24 h post-injury, and returned to the level of normal and control rats at 72 h and 7 days. Conclusions. It is highly suggested that intestinal mucosa apoptosis plays an important role in the pathogenesis of acute gut damage after TBI. Intestinal PepT1 expression could be up-regulated after traumatic brain injury, and maintained the normal level under the condition of serious intestinal damage. Upregulation of PepT1 may adaptively improve absorption of di- and tripeptides, independent of changes in the mucosal surface area. (c) 2007 Elsevier Inc. All rights reserved.	Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Clin Med, Nanjing 210002, Peoples R China; Nanjing Univ, Jinling Hosp, Res Inst Gen Surg, Sch Clin Med, Nanjing 210002, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Clin Med, 305 Zhongshan Rd, Nanjing 210002, Peoples R China.	hang1965@public1.ptt.js.cn					Adibi SA, 1997, GASTROENTEROLOGY, V113, P332, DOI 10.1016/S0016-5085(97)70112-4; ADIBI SA, 1971, J CLIN INVEST, V50, P2266, DOI 10.1172/JCI106724; Barbot L, 2003, PARASITOL RES, V89, P364, DOI 10.1007/s00436-002-0776-3; Bolger MB, 1998, J PHARM SCI-US, V87, P1286, DOI 10.1021/js980090u; BOLL M, 1994, PFLUG ARCH EUR J PHY, V429, P146, DOI 10.1007/BF02584043; Brodin B, 2002, PHARMACOL TOXICOL, V90, P285, DOI 10.1034/j.1600-0773.2002.900601.x; Buyse M, 2001, J CLIN INVEST, V108, P1483, DOI 10.1172/JCI200113219; CALBAN C, 2000, CRIT CARE MED, V28, P643; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hotchkiss RS, 2000, CRIT CARE MED, V28, P3207, DOI 10.1097/00003246-200009000-00016; Hsu CP, 1999, AAPS PHARMSCI, V1; Ihara T, 2000, DIGESTION, V61, P59, DOI 10.1159/000007736; Ikeda H, 1998, GUT, V42, P530, DOI 10.1136/gut.42.4.530; LANGKAMPHENKEN B, 1995, CRIT CARE MED, V23, P660, DOI 10.1097/00003246-199504000-00013; LIU W, 1995, BBA-BIOMEMBRANES, V1235, P461, DOI 10.1016/0005-2736(95)80036-F; Merlin D, 1998, J CLIN INVEST, V102, P2011, DOI 10.1172/JCI4179; Merlin D, 2001, GASTROENTEROLOGY, V120, P1666, DOI 10.1053/gast.2001.24845; Nielsen CU, 2001, AM J PHYSIOL-GASTR L, V281, pG191; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; POTTEN CS, 1994, INT J RADIAT BIOL, V18, P77; Saito H, 1996, BBA-BIOMEMBRANES, V1280, P173, DOI 10.1016/0005-2736(96)00024-7; Shiraga T, 1999, GASTROENTEROLOGY, V116, P354, DOI 10.1016/S0016-5085(99)70132-0; Sun BW, 2003, WORLD J GASTROENTERO, V9, P2782; Tanaka H, 1998, GASTROENTEROLOGY, V114, P714, DOI 10.1016/S0016-5085(98)70585-2; Thamotharan M, 1999, METABOLISM, V48, P681, DOI 10.1016/S0026-0495(99)90164-6; Thamotharan M, 1999, AM J PHYSIOL-CELL PH, V276, pC821; Zhang C, 2002, BURNS, V28, P731, DOI 10.1016/S0305-4179(02)00210-3; Ziegler TR, 2002, AM J CLIN NUTR, V75, P922	34	29	34	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JAN	2007	137	1					53	60		10.1016/j.jss.2006.06.026			8	Surgery	Surgery	125NS	WOS:000243449400008	17081567				2021-06-18	
J	Lark, SD; McCarthy, PW				Lark, Sally D.; McCarthy, Peter W.			Cervical range of motion and proprioception in rugby players versus non-rugby players	JOURNAL OF SPORTS SCIENCES			English	Article						cervical; range of motion; whiplash; neck; rugby; spine	HUMAN PERCEPTION; INJURIES; SPINE; HEAD; EPIDEMIOLOGY; STIMULATION; ORIENTATION; RELIABILITY; FOOTBALL; ROTATION	In this study, we examined the effects of number of years of playing rugby on neck function. Active cervical spine range of motion and proprioception were assessed in 14 non-rugby-playing but trained sportsmen ( mean age 28 years, s 7) and 46 rugby players ( 26 rugby forwards: mean age 26 years, s 5; mean years played 14 years; 20 backs: mean age 24 years, s 5; mean years played 14 years). Active cervical range of motion in flexion, extension, left and right lateral flexion, plus left and right rotation were measured using a cervical range of motion device. The ability to reposition the head in a central position with eyes closed was taken as a measure of proprioception. Results show that rugby forwards generally had the least active cervical range of motion, particularly neck extension ( forwards, 438; backs, 558; controls, 588), with the decrement correlating with the number of years played. In addition, repositioning was significantly worse in rugby players after neck extension than non- rugby players ( 68 vs. 38). The active cervical range of motion of rugby forwards is similar to that of whiplash patients, suggesting that participation in rugby can have an effect on neck range of motion that is equivalent to chronic disability. Reduced active cervical range of motion could also increase the likelihood of injury and exacerbate agerelated neck problems.	Univ Glamorgan, Sch Appl Sci, Pontypridd CF37 1DL, Wales	Lark, SD (corresponding author), Univ Glamorgan, Sch Appl Sci, Pontypridd CF37 1DL, Wales.	slark@glam.ac.uk					BARIN K, 1992, OTOLARYNG HEAD NECK, V106, P355, DOI 10.1177/019459989210600407; Berge J, 1999, AM J SPORT MED, V27, P422, DOI 10.1177/03635465990270040401; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Bottini E, 2000, BRIT J SPORT MED, V34, P94, DOI 10.1136/bjsm.34.2.94; CAPUANOPUCCI D, 1991, ARCH PHYS MED REHAB, V72, P338; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dall'Alba PT, 2001, SPINE, V26, P2090, DOI 10.1097/00007632-200110010-00009; Feipel V, 1999, CLIN BIOMECH, V14, P462, DOI 10.1016/S0268-0033(98)90098-5; Gabbett TJ, 2000, BRIT J SPORT MED, V34, P98, DOI 10.1136/bjsm.34.2.98; GARFIN SR, 1995, SPINE, V20, P1810, DOI 10.1097/00007632-199508150-00012; GARRAWAY M, 1995, LANCET, V345, P1485; Karnath HO, 2002, EXP BRAIN RES, V143, P350, DOI 10.1007/s00221-001-0996-2; Kogler A, 2000, ACTA OTO-LARYNGOL, V120, P151; Loudon JK, 1997, SPINE, V22, P865, DOI 10.1097/00007632-199704150-00008; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; Mergner T, 1997, J VESTIBUL RES-EQUIL, V7, P347; MERGNER T, 1991, EXP BRAIN RES, V85, P389; Mergner T, 1993, J Vestib Res, V3, P41; Pearl A J, 1979, Am J Sports Med, V7, P231, DOI 10.1177/036354657900700404; Quarrie KL, 2002, SPORTS MED, V32, P633, DOI 10.2165/00007256-200232100-00003; REVEL M, 1991, ARCH PHYS MED REHAB, V72, P288; Scher A T, 1991, Br J Sports Med, V25, P57; SCHER AT, 1990, S AFR MED J, V77, P557; SILVER JR, 1994, PARAPLEGIA, V32, P442, DOI 10.1038/sc.1994.71; Stephensen S, 1996, BRIT J SPORT MED, V30, P331, DOI 10.1136/bjsm.30.4.331; Targett SGR, 1998, CLIN J SPORT MED, V8, P280, DOI 10.1097/00042752-199810000-00005; Tousignant M, 2002, SPINE, V27, P812, DOI 10.1097/00007632-200204150-00007; Trott PH, 1996, CLIN BIOMECH, V11, P201, DOI 10.1016/0268-0033(95)00072-0; VELAY JL, 1994, VISION RES, V34, P2169, DOI 10.1016/0042-6989(94)90325-5; Wetzler MJ, 1998, AM J SPORT MED, V26, P177, DOI 10.1177/03635465980260020501; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9; YOO JU, 1992, SPINE, V17, P1131, DOI 10.1097/00007632-199210000-00001; YOUDAS JW, 1991, PHYS THER, V71, P98, DOI 10.1093/ptj/71.2.98; ZACHARIAS GL, 1981, EXP BRAIN RES, V41, P159	34	29	30	0	13	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0264-0414			J SPORT SCI	J. Sports Sci.		2007	25	8					887	894		10.1080/02640410600944543			8	Sport Sciences	Sport Sciences	168JB	WOS:000246519100006	17474042				2021-06-18	
J	Lippert-Gruner, M; Maegele, M; Pokorny, J; Angelov, DN; Svestkova, O; Wittner, M; Trojan, S				Lippert-Gruener, M.; Maegele, M.; Pokorny, J.; Angelov, D. N.; Svestkova, O.; Wittner, M.; Trojan, S.			Early rehabilitation model shows positive effects on neural degeneration and recovery from neuromotor deficits following traumatic brain injury	PHYSIOLOGICAL RESEARCH			English	Article						traumatic brain injury; rehabilitation; motor dysfunction; neural loss	USE-DEPENDENT EXAGGERATION; NERVE GROWTH-FACTOR; ENVIRONMENTAL ENRICHMENT; NEUROTROPHIC FACTOR; CEREBRAL INFARCTION; PHYSICAL-ACTIVITY; AFFECTED FORELIMB; AEROBIC EXERCISE; FOCAL ISCHEMIA; ADULT-RATS	This study used an experimental early rehabilitation model combining an enriched environment, multisensory (visual, acoustic and olfactory) stimulation and motor training after traumatic brain injury (via fluid-percussion model) to simulate early multisensory rehabilitation. This therapy will be used by brain injured patients to improve neural plasticity and to restore brain integration functions. Motor dysfunction was evaluated using a composite neuroscore test. Direct structural effects of traumatic brain injury were examined using Fluoro-Jade staining, which allows identification of degenerating neural cell bodies and processes. Animals in the rehabilitation model group performed significantly better when tested for neuromotor function than the animals in standard housing in the 7-day and 15-day interval after injury (7d: p=0.005; 15d: p < 0.05). Statistical analysis revealed significantly lower numbers of Fluoro-Jade positive cells (degenerating neurons) in the rehabilitation model group (n=5: mean 13.4) compared to the standard housing group (n=6: mean 123.8) (p < 0.005). It appears that the housing of animals in the rehabilitation model led to a clear functional increase in neuromotor functions and to reduced neural loss compared with the animal group in standard housing.	Cologne Univ Hosp, Dept Neurosurg, Cologne, Germany; Charles Univ Prague, Inst Physiol, Prague, Czech Republic; Univ Cologne, Inst Anat, D-5000 Cologne 41, Germany; Univ Hosp, Dept Rehabil, Prague, Czech Republic	Lippert-Gruner, M (corresponding author), Univ Cologne, Klin Allgemeine Neurochirurg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	physres@biomed.cas.cz	Jaroslav, Pokorny/I-3838-2017; Svetkova, Olga/O-1062-2017; Wittner, Michal/A-5892-2008	Jaroslav, Pokorny/0000-0002-9716-3409; Svetkova, Olga/0000-0002-4271-4795; 			Artola A, 2006, EUR J NEUROSCI, V23, P261, DOI 10.1111/j.1460-9568.2005.04552.x; Benefiel AC, 2005, ILAR J, V46, P95, DOI 10.1093/ilar.46.2.95; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Bland ST, 2001, BEHAV BRAIN RES, V126, P33, DOI 10.1016/S0166-4328(01)00243-1; Bland ST, 2000, STROKE, V31, P1144, DOI 10.1161/01.STR.31.5.1144; DUA J, 1992, PERCEPT MOTOR SKILL, V75, P355, DOI 10.2466/pms.1992.75.2.355; DUSTMAN RE, 1984, NEUROBIOL AGING, V5, P35, DOI 10.1016/0197-4580(84)90083-6; GENTILE AM, 1987, BEHAV NEURAL BIOL, V47, P321, DOI 10.1016/S0163-1047(87)90435-3; GRABOWSKI M, 1995, EXP NEUROL, V133, P96, DOI 10.1006/exnr.1995.1011; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; GREENOUGH WT, 1988, DEV BRAIN RES, V43, P148, DOI 10.1016/0165-3806(88)90160-5; Gruner ML, 2000, BRAIN INJURY, V14, P585; Humm JL, 1999, EXP NEUROL, V157, P349, DOI 10.1006/exnr.1999.7061; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; INGLIS FM, 1995, NEUROSCIENCE, V66, P81, DOI 10.1016/0306-4522(94)00578-S; Irvine GI, 2006, HIPPOCAMPUS, V16, P149, DOI 10.1002/hipo.20142; Johansson BB, 2004, RESTOR NEUROL NEUROS, V22, P163; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Johansson BB, 2002, J CEREBR BLOOD F MET, V22, P89, DOI 10.1097/00004647-200201000-00011; KELLER A, 1992, J NEUROPHYSIOL, V68, P295; Kolb B., 1995, BRAIN PLASTICITY BEH; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Lippert-Gruner M, 2002, ACT NEUR S, V79, P21; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; Nygren J, 2005, J CEREBR BLOOD F MET, V25, P1625, DOI 10.1038/sj.jcbfm.9600157; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Oliff HS, 1998, MOL BRAIN RES, V61, P147, DOI 10.1016/S0169-328X(98)00222-8; OSTENDORF CG, 1981, J AM PHYS THER ASSOC, V61, P1022; REJESKI WJ, 1992, HEALTH PSYCHOL, V11, P355, DOI 10.1037/0278-6133.11.6.355; Risedal A, 1999, J CEREBR BLOOD F MET, V19, P997, DOI 10.1097/00004647-199909000-00007; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; Saenz JCB, 2006, BEHAV BRAIN RES, V169, P57, DOI 10.1016/j.bbr.2005.12.001; SINSON G, 1995, J NEUROCHEM, V65, P2209; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Young D, 1999, NAT MED, V5, P448; Zeng JS, 2000, EXP NEUROL, V164, P176, DOI 10.1006/exnr.2000.7423; Zhao LR, 2001, NEUROSCI LETT, V305, P169, DOI 10.1016/S0304-3940(01)01837-7; Zhu SW, 2006, BEHAV BRAIN RES, V169, P10, DOI 10.1016/j.bbr.2005.11.024	45	29	34	1	10	ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY	PRAGUE 4	VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC	0862-8408	1802-9973		PHYSIOL RES	Physiol. Res.		2007	56	3					359	368					10	Physiology	Physiology	183VP	WOS:000247600800013	16792466	DOAJ Gold			2021-06-18	
J	Zanier, ER; Ortolano, F; Ghisoni, L; Colombo, A; Losappio, S; Stocchetti, N				Zanier, Elisa Roncati; Ortolano, Fabrizio; Ghisoni, Laura; Colombo, Angelo; Losappio, Sabina; Stocchetti, Nino			Intracranial pressure monitoring in intensive care: clinical advantages of a computerized system over manual recording	CRITICAL CARE			English	Article							CEREBRAL PERFUSION-PRESSURE; ASSESSING AGREEMENT; HEAD-INJURY; DEXANABINOL; TRIAL	Introduction The presence of intracranial hypertension ( HICP) after traumatic brain injury ( TBI) affects patient outcome. Intracranial pressure ( ICP) data from electronic monitoring equipment are usually calculated and recorded hourly in the clinical chart by trained nurses. Little is known, however, about how precisely this method reflects the real patterns of ICP after severe TBI. In this study, we compared hourly manual recording with a validated and continuous computerized reference standard. Methods Thirty randomly selected patients with severe TBI and HICP admitted to the neuroscience intensive care unit ( Policlinico University Hospital, Milan, Italy) were retrospectively studied. A 24-hour interval with ICP monitoring was randomly selected for each patient. The manually recorded data available for analysis covered 672 hours corresponding to 36,492 digital data points. The two methods were evaluated using the correlation coefficient and the Bland and Altman method. We used the proportion test to analyze differences in the number of episodes of HICP ( ICP > 20 mm Hg) detected with the two methods and the paired t test to analyze differences in the percentage of time of HICP. Results There was good agreement between the digitally collected ICP and the manual recordings of the end-hour values. Bland and Altman analysis confirmed a mean difference between the two methods of 0.05 mm Hg ( standard deviation 3.66); 96% of data were within the limits of agreement (+7.37 and -7.28). The average percentages of time of ICP greater than 20 mm Hg were 39% calculated from the digital measurements and 34% from the manual observations. From the continuous digital recording, we identified 351 episodes of ICP greater than 20 mm Hg lasting at least five minutes and 287 similar episodes lasting at least ten minutes. Conversely, end-hour ICP of greater than 20 mm Hg was observed in only 204 cases using manual recording methods. Conclusion Although manually recorded end-hour ICP accurately reflected the computerized end-hour and mean hour values, the important omission of a number of episodes of high ICP, some of long duration, results in a clinical picture that is not accurate or informative of the true pattern of unstable ICP in patients with TBI.	Univ Milan, Osped Maggiore & Policlin Mangiagalli & Regina El, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit,Fdn IRCCS, I-20122 Milan, Italy	Zanier, ER (corresponding author), Univ Milan, Osped Maggiore & Policlin Mangiagalli & Regina El, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit,Fdn IRCCS, Via Sforza 35, I-20122 Milan, Italy.	ezanier@policlinico.mi.it	Zanier, Elisa/AAA-8095-2020; Stocchetti, Nino/O-7444-2017	Stocchetti, Nino/0000-0003-3250-6834; Ortolano, Fabrizio/0000-0003-1996-948X; Zanier, Elisa/0000-0002-3011-8718			BLAND JM, 1995, LANCET, V346, P1085, DOI 10.1016/S0140-6736(95)91748-9; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Cunningham S, 1996, INT J CLIN MONIT COM, V13, P235, DOI 10.1023/A:1016967407632; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McGraw C P, 1976, Surg Neurol, P149; SZEWCZYKOWSKI J, 1975, EUR J INTEN CARE MED, V1, P189, DOI 10.1007/BF00624437; Tindall G T, 1975, Clin Neurosurg, V22, P332; Turner H B, 1988, J Neurosci Nurs, V20, P236; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; 2000, J NEUROTRAUMA, V17, P479	15	29	30	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2007	11	1							R7	10.1186/cc5155			6	Critical Care Medicine	General & Internal Medicine	185OT	WOS:000247721000007	17233895	DOAJ Gold, Green Published			2021-06-18	
J	Bowden, SC; Shores, EA; Mathias, JL				Bowden, Stephen C.; Shores, E. Arthur; Mathias, Jane L.			Does effort suppress cognition after traumatic brain injury? A re-examination of the evidence for the Word Memory Test	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	Conference of the Association-of-Forensic-Neuropsychology	FEB, 2004	London, ENGLAND				MALINGERED NEUROCOGNITIVE DYSFUNCTION; CLINICAL-PRACTICE; VALIDITY; DAUBERT; SCORES; MUNNS	Green, Rohling, Lees-Haley, and Allen (2001) suggested that scores on a test of "effort,'' the Word Memory Test (WMT), explains more variance in outcome after brain injury than does injury severity. As a consequence, Green and colleagues recommend using the WMT to control for sub-optimal effort in neuropsychological evaluations and group research. We re-examine the evidence for their conclusions and argue that identifying a larger proportion of explained variance is not in itself evidence of validity unless the premise to be proven is already assumed, namely, that the test is a valid measure of effort. Instead, the crux of Green and colleagues claim for the validity of the WMT implies an interaction between effort and injury severity on outcome scores, although the specific interaction has not been tested in their previous research. We failed to find any evidence for this interaction in a sample of 100 Australian litigants. We conclude that our data do not support the view that effort, as measured by the WMT, interacts with injury severity to suppress cognition after brain injury.	Univ Melbourne, Dept Psychol, Parkville, Vic 3010, Australia; Macquarie Univ, Sydney, NSW 2109, Australia; Univ Adelaide, Adelaide, SA, Australia	Bowden, SC (corresponding author), Univ Melbourne, Dept Psychol, Parkville, Vic 3010, Australia.	sbowden@unimelb.edu.au	Mathias, J L/L-6295-2013	Mathias, Jane/0000-0001-8957-8594; Shores, Edwin A/0000-0003-1553-5131			Bianchini KJ, 2003, CLIN NEUROPSYCHOL, V17, P574, DOI 10.1076/clin.17.4.574.27946; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bowden SC, 1999, PSYCHOL ASSESSMENT, V11, P339, DOI 10.1037/1040-3590.11.3.339; Bowden SC, 1998, NEUROPSYCHOL REHABIL, V8, P243, DOI 10.1080/713755573; BOWDEN SC, 1996, ANN C AUSTR PSYCH SO; Carstairs JR, 2000, AUST PSYCHOL, V35, P36, DOI 10.1080/00050060008257466; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cohen M.J., 1997, CHILDRENS MEMORY SCA; CONNOR C, 2004, ANN M AUSTR PSYCH SO; Draper NR, 1981, APPL REGRESSION ANAL; EMBRETSON SE, 1983, PSYCHOL BULL, V93, P179, DOI DOI 10.1037/0033-2909.93.1.179; FAUST D, 2003, MALINGERING ILLNESS, P107; FLANAGAN DP, 1997, CONT INTELLECTUAL AS; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97, DOI DOI 10.1300/J151V02N03_05; Green P., 1996, WORD MEMORY TEST USE; HALLIGAN P, 2003, MALINGERING ILLNESS; HARRIS RJ, 1994, ANOVA ANAL VARIANCE; Hartman DE, 2002, ARCH CLIN NEUROPSYCH, V17, P709, DOI 10.1016/S0887-6177(01)00172-X; Holdnack JA, 2004, AUST PSYCHOL, V39, P220, DOI 10.1080/00050060412331295072; Hom J, 2003, ARCH CLIN NEUROPSYCH, V18, P827, DOI 10.1016/S0887-6177(03)00076-3; HOSMER DW, 1995, STAT MED, V14, P2161, DOI 10.1002/sim.4780141909; Howell D. C., 1997, STAT METHODS PSYCHOL; MEEHL PE, 1955, PSYCHOL BULL, V52, P194, DOI 10.1037/h0048070; Mossman D, 2003, LAW HUMAN BEHAV, V27, P229, DOI 10.1023/A:1023437122752; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; Petty RE, 1996, PSYCHOL SCI, V7, P247, DOI 10.1111/j.1467-9280.1996.tb00368.x; ROGERS R, 1997, CLINICAL ASSESSMENT; Rohling Martin L, 2002, CNS Spectr, V7, P387; ROSNOW RL, 1989, PSYCHOL BULL, V105, P143, DOI 10.1037/0033-2909.105.1.143; SACKETT DL, 2000, EVIDENCE BASED MED H; Schmidt FL, 1996, PSYCHOL METHODS, V1, P199, DOI 10.1037/1082-989X.1.2.199; Shores EA, 2000, AUST PSYCHOL, V35, P41, DOI 10.1080/00050060008257467; SHORES EA, 2004, ASS FOR NEUR C I CHI; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; SNODGRASS JG, 1988, J EXP PSYCHOL GEN, V117, P34, DOI 10.1037/0096-3445.117.1.34; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; The Psychological Corporation, 1997, WAIS III WMS III TEC; Vallabhajosula B, 2001, J AM ACAD PSYCHIATRY, V29, P207; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]; Winer BJ., 1971, STAT PRINCIPLES EXPT; Wynkoop T.F., 2001, J FORENSIC NEUROPSYC, V2, P71	44	29	29	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	DEC	2006	20	4					858	872		10.1080/13854040500246935			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	085IE	WOS:000240597000019	16980267				2021-06-18	
J	Geddes, JF; Talbert, DG				Geddes, J. F.; Talbert, D. G.			Paroxysmal coughing, subdural and retinal bleeding: a computer modelling approach	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						paroxysmal coughing; retinal haemorrhage; subdural haemorrhage	SHAKEN BABY SYNDROME; BLOOD-BRAIN-BARRIER; VELOCITY WAVE-FORM; FLOW VELOCITY; TRANSFUSION SYNDROME; HYPOTHETICAL MODEL; DYNAMIC PLACENTA; INJURY; INFANTS; HEMORRHAGE	Unexplained subdural and retinal haemorrhages in an infant are commonly attributed to 'shaking', the mechanism of which is believed to be traumatic venous rupture. However, the haemorrhagic retinopathy reported as a result of Valsalva manoeuvres and the subdural bleeding that is a rare complication of pertussis together demonstrate that if a sustained rise in intrathoracic pressure is transmitted to cerebral and retinal vessels, it may result in bleeding, similar to that reported in inflicted injury. Such haemorrhages would be expected to occur whenever severe paroxysmal coughing were induced, whatever the cause. This study used a computer modelling approach to investigate feeding accidents as the trigger for bleeding. A dynamic circulatory model of a 3-month-old infant was induced to 'cough', and the response to changes in physiological variables monitored. It showed that coughing causes intracranial pressures to build up exponentially to approach a maximum, proportional to the amount of pressure the musculature of the thorax can produce, as venous return is impeded. They do not have time to become dangerous during individual coughs, as blood quickly returns after the cough is over, reestablishing normal pressures. Paroxysmal coughing, however, does not allow blood to return between coughs, with the result that very high luminal pressures may be generated, sufficient to damage veins. A history of coughing, vomiting or choking is not uncommon in otherwise normal infants with retinal and subdural bleeding. Our findings suggest that paroxysmal coughing could account for such bleeding in some cases.	Univ London Imperial Coll Sci & Technol, Sch Med, Inst Reprod & Dev Biol, London, England		jfgeddes@doctors.org.uk					Alaraj AM, 2005, ACTA NEUROCHIR, V147, P85, DOI 10.1007/s00701-004-0415-0; ALSAYED LE, 1994, J APPL PHYSIOL, V77, P78; Anteby II, 2001, J AAPOS, V5, P90, DOI 10.1067/mpa.2001.113841; ARDRAN GM, 1958, BRIT J RADIOL, V31, P11, DOI 10.1259/0007-1285-31-361-11; ASHBY H, 1905, DIS CHILDREN, P337; Bandak FA, 2005, FORENSIC SCI INT, V151, P71, DOI 10.1016/j.forsciint.2005.02.033; BISGARD K, 2000, GUIDELINES CONTROL P, pCH1; Deane JS, 1997, EYE, V11, P137, DOI 10.1038/eye.1997.33; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Georgiou T, 1999, EYE, V13, P686, DOI 10.1038/eye.1999.193; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; HAINES DE, 1991, ANAT RECORD, V230, P3, DOI 10.1002/ar.1092300103; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; HOLT LE, 1926, DIS INFANCY CHILDHOO, P840; Jones W L, 1995, J Am Optom Assoc, V66, P301; Kemp AM, 2002, ARCH DIS CHILD, V86, P98, DOI 10.1136/adc.86.2.98; KONTOS HA, 1981, AM J PHYSIOL, V240, pH511; Leestma JE, 2005, AM J FOREN MED PATH, V26, P199, DOI 10.1097/01.paf.0000164228.79784.5a; Lumb AB, 2000, NUNNS APPL RESP PHYS, P82; MACKENZIE ET, 1976, CIRC RES, V39, P33, DOI 10.1161/01.RES.39.1.33; Man WDC, 2003, AM J RESP CRIT CARE, V168, P714, DOI 10.1164/rccm.200303-334BC; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Marshall J N, 1885, Glasgow Med J, V23, P24; MAYHAN WG, 1985, AM J PHYSIOL, V248, pH712; MAYHAN WG, 1986, CIRC RES, V59, P216, DOI 10.1161/01.RES.59.2.216; NOBECOURT P, 1934, TRAITE MED INFANTS, V2, P288; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; PERLMAN JM, 1985, NEW ENGL J MED, V312, P1353, DOI 10.1056/NEJM198505233122104; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; Prange M. T., 2003, INFLICTED CHILDHOOD, P237; ROTCH TM, 1901, PEDIAT HYGIENIC MED, P508; Sebire NJ, 2004, MED HYPOTHESES, V62, P520, DOI 10.1016/j.mehy.2003.10.019; Sebire NJ, 2001, PLACENTA, V22, P383, DOI 10.1053/plac.2001.0631; SOUTHALL DP, 1987, CURRENT TOPICS PULMO, V8, P210; Talbert D, 2004, MED HYPOTHESES, V62, P511, DOI 10.1016/j.mehy.2003.10.025; Talbert DG, 2005, MED HYPOTHESES, V64, P8, DOI 10.1016/j.mehy.2004.07.017; Talbert DG, 1996, AM J OBSTET GYNECOL, V174, P598, DOI 10.1016/S0002-9378(96)70434-9; Talbert DG, 2000, ULTRASOUND OBST GYN, V16, P457, DOI 10.1046/j.1469-0705.2000.00224.x; TALBERT DG, 1995, ULTRASOUND OBST GYN, V6, P261, DOI 10.1046/j.1469-0705.1995.06040261.x; VINALL PE, 1981, STROKE, V12, P640, DOI 10.1161/01.STR.12.5.640; Weller R. O., 2005, Morphologie, V89, P22, DOI 10.1016/S1286-0115(05)83235-7; Whitby EH, 2004, LANCET, V363, P846, DOI 10.1016/S0140-6736(04)15730-9; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121; Yoshimoto Y, 1997, J NEUROSURG, V86, P694, DOI 10.3171/jns.1997.86.4.0694; 2005, GEN PERTUSSIS INFORM, P3; 2003, AM ACAD PEDIAT RED B, P472	49	29	30	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	DEC	2006	32	6					625	634		10.1111/j.1365-2990.2006.00771.x			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	101XM	WOS:000241774600007	17083477				2021-06-18	
J	Greenspan, AI; Coronado, VG; MacKenzie, EJ; Schulman, J; Pierce, B; Provenzano, G				Greenspan, Arlene I.; Coronado, Victor G.; MacKenzie, Ellen J.; Schulman, Jane; Pierce, Ben; Provenzano, George			Injury hospitalizations: Using the nationwide inpatient sample	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						hospital discharge; injury; falls; motor vehicle crashes	TRAUMATIC BRAIN-INJURY; TRENDS; SURVEILLANCE; FRACTURE	Background. The aims of this study are to develop estimates of discharge rates and frequencies for all injury-related hospitalizations in the United States for the year 2000 and to characterize patterns of hospitalized injury and anatomic region using a modified Barell Matrix. The utility of the Nationwide Inpatient Sample (NIS) for providing national estimates of hospitalized injuries will be discussed. Methods: This study is a retrospective analysis of hospital discharge data using the Nationwide Inpatient Sample. All hospital discharges with a primary diagnosis of injury were selected. Total number of hospitalizations, annual discharge rates, and 95% confidence intervals were calculated by body region, nature of injury, and injury mechanism. Number of injuries by age, sex, body region, and nature of injury were also calculated for falls and motor vehicle crashes. Results. In 2000, there were an estimated 1,690,780 hospital discharges with a primary injury diagnosis. Discharge rates were highest for the oldest age groups. Falls and motor vehicle crashes were the leading causes of hospitalization. Fracture was the most common diagnosis and lower extremity injury was the most common anatomic region. Conclusions. Hospital discharge data adds another dimension to our understanding of the total injury burden. The Nationwide Inpatient Sample may be useful in providing national estimates of hospital discharges.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Battelle Mem Inst, Atlanta, GA USA; Ctr Publ Hlth Res & Evaluat, Atlanta, GA USA	Greenspan, AI (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop K-63, Atlanta, GA USA.	aig0@cdc.gov					*AG HEALTHC RES QU, 2004, HCUP DAT HEALTHC COS; *AG HEALTHC RES QU, 2004, HCUP NIS DAT DOC HEA; *AM MED ASS, 1999, INT CLASS DIS, V1; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bosse MJ, 2002, NEW ENGL J MED, V347, P1924, DOI 10.1056/NEJMoa012604; *CDCP, 10 LEAD CAUS DEATH 2; *CTR DIS CONTR PRE, 2004, WEB BAS INJ STAT QUE; DAVIES M, 2001, STATE INJURY INDICAT; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HALL MJ, 2003, ADV DATA VITAL HLTH, V332; Horan JM, 2003, EPIDEMIOL REV, V25, P24, DOI 10.1093/epirev/mxg010; Injury Surveillance Workgroup, 2003, CONS REC US HOSP DIS; Irwin ZN, 2004, SPINE, V29, P796, DOI 10.1097/01.BRS.0000119400.92204.B5; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; Langlois JA., 2004, TRAUMATIC BRAIN INJU; MACKENZIE EJ, 1993, J ORTHOP TRAUMA, V7, P393, DOI 10.1097/00005131-199310000-00001; MacKenzie EJ, 2000, EPIDEMIOL REV, V22, P112, DOI 10.1093/oxfordjournals.epirev.a018006; Mukamel DB, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-10; Quinlan KP, 1999, ANN EMERG MED, V34, P637, DOI 10.1016/S0196-0644(99)70166-6; Shinoda-Tagawa T, 2003, INJURY PREV, V9, P214, DOI 10.1136/ip.9.3.214; SMITH GS, 1991, AM J EPIDEMIOL, V134, P1146, DOI 10.1093/oxfordjournals.aje.a116018; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; *US DEP HHS, 2005, DHHS PUBL; Wadman MC, 2003, ANN EMERG MED, V42, P468, DOI 10.1067/S0196-0644(03)00489-X; 2001, MMWR MORB MORTAL WKL, V50, P340	25	29	30	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2006	61	5					1234	1243		10.1097/01.ta.0000231558.71696.1a			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	105TB	WOS:000242054100036	17099535				2021-06-18	
J	Lin, L; Chen, LX; Wei, XL; Fu, X; Zhang, JY; Ma, KT; Zhou, CY; Yu, CL				Lin, Lin; Chen, Lianxu; Wei, Xuelei; Fu, Xin; Zhang, Jiying; Ma, Kangtao; Zhou, Chunyan; Yu, Changlong			Adenovirus-mediated transfer of siRNA against Runx2/Cbfa1 inhibits the formation of heterotopic ossification in animal model	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						siRNA; Runx2/Cbfa1; osteoblast; gene therapy; heterotopic ossification; adenovirus	TOTAL HIP-ARTHROPLASTY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; ECTOPIC BONE-FORMATION; OSTEOBLAST DIFFERENTIATION; RNA INTERFERENCE; IN-VITRO; CLEIDOCRANIAL DYSPLASIA; ENHANCED OSTEOGENESIS	The heterotopic ossification of muscles, tendons, and ligaments is a common problem faced by orthopaedic surgeons. Runx2/Cbfa1 plays an essential role during the osteoblast differentiation and is considered as a molecular switch in osteoblast biology. RNA interference technology is a powerful tool for silencing endogenous or exogenous genes in mammalian cells. In this study, we investigated the effect of Runx2/Cbfa1-specific siRNA on osteoblast differentiation and mineralization in osteoblastic cells, and then constructed adenovirus containing siRNA against Runx2/Cbfa1 (Ad-Runx2-siRNA) to inhibit the formation of heterotopic ossification induced by BMP4, dernineralized bone matrix, and trauma in animal model. Our results showed that the Runx2/Cbfa1-specific siRNA could inhibit the expression of Runx2/Cbfa1 at the level of mRNA and protein. Analysis of the expression of osteoblast maturation genes including type I collagen, osteopontin, bone sialoprotein, and osteocalcin, alkaline phosphatase activity, and matrix mineralization (von kossa) revealed that osteoblast differentiation was inhibited in cultured primary mouse osteoblasts transduced with Ad-Runx2-siRNA. Furthermore, adenovirus-mediated transfer of siRNA against Runx2/Cbfa1 could inhibit the formation of heterotopic ossification induced by BMP4, dernineralized bone matrix, and trauma in animal model. It is likely that the inhibition of Runx2/Cbfa1 by RNAi could be developed as a powerful approach to prevent or treat heterotopic ossification. (c) 2006 Elsevier Inc. All rights reserved.	Peking Univ Third Hosp, Inst Sports Med, Beijing 100083, Peoples R China; Peking Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China	Zhou, CY (corresponding author), Peking Univ Third Hosp, Inst Sports Med, 49 N Garden Rd, Beijing 100083, Peoples R China.	chunyanzhou@bjmu.edu.cn; YCL123@vip.sina.com					AHRENGART L, 1991, CLIN ORTHOP RELAT R, V263, P49; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; ALTMAN RD, 1995, J ORTHOP TRAUMA, V9, P392, DOI 10.1097/00005131-199505000-00006; BANERJEE U, 1997, LOOP TR RESTRUCT COM, V3, P1; BONARIGO BC, 1967, RADIOLOGY, V88, P889, DOI 10.1148/88.5.889; BRADY LW, 1979, SKELETAL RADIOL, V4, P72, DOI 10.1007/BF00349330; BRUMBACK RJ, 1990, J BONE JOINT SURG AM, V72A, P1067, DOI 10.2106/00004623-199072070-00017; BUCK RC, 1953, J PATHOL BACTERIOL, V66, P1, DOI 10.1002/path.1700660103; CHALMERS J, 1975, J BONE JOINT SURG BR, VB 57, P36; CONNOR JM, 1982, J BONE JOINT SURG BR, V64, P76; Crawford C M, 1986, J Burn Care Rehabil, V7, P323, DOI 10.1097/00004630-198607000-00005; DELEE J, 1976, CLIN ORTHOP RELAT R, V121, P53; Dimar JR, 1996, SPINE, V21, P1870, DOI 10.1097/00007632-199608150-00006; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Enomoto H, 2004, J CELL SCI, V117, P417, DOI 10.1242/jcs.00866; FAHRER H, 1988, BRIT J RHEUMATOL, V27, P187; GREEN DP, 1979, J BONE JOINT SURG AM, V61, P1092, DOI 10.2106/00004623-197961070-00021; Hannallah D, 2004, J BONE JOINT SURG AM, V86A, P80, DOI 10.2106/00004623-200401000-00013; Haque S, 1996, ARCH PATHOL LAB MED, V120, P666; HU HP, 1991, CLIN ORTHOP RELAT R, P259; Igarashi M, 2004, J MOL HISTOL, V35, P3, DOI 10.1023/B:HIJO.0000020883.33256.fe; Johns JS, 1999, J HEAD TRAUMA REHAB, V14, P269, DOI 10.1097/00001199-199906000-00007; Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LAL S, 1989, ARCH PHYS MED REHAB, V70, P387; LEE J, 1997, CARBOHYDR LETT, V2, P307; Lianxu C, 2006, OSTEOARTHR CARTILAGE, V14, P367, DOI 10.1016/j.joca.2005.10.009; LIN L, IN PRESS ACTA PHARM; LOVELOCK JE, 1990, SKELETAL RADIOL, V19, P31; MAHY PR, 1988, CLIN ORTHOP RELAT R, P236; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; MCCLURE J, 1983, J PATHOL, V139, P419, DOI 10.1002/path.1711390403; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Musgrave DS, 2000, CLIN ORTHOP RELAT R, P290; Naraghi FF, 1996, ORTHOPEDICS, V19, P145; O'Connor JP, 1998, CLIN ORTHOP RELAT R, P71; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PETERSON SL, 1989, J TRAUMA, V29, P365, DOI 10.1097/00005373-198903000-00015; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PUZAS JE, 1989, CLIN ORTHOP RELAT R, V245, P269; QUINLAN JG, 1995, MUSCLE NERVE, V18, P201, DOI 10.1002/mus.880180209; REDDI AH, 1995, CLIN ORTHOP RELAT R, P115; Richards AM, 1997, BURNS, V23, P64, DOI 10.1016/S0305-4179(96)00074-5; Shafritz AB, 1996, NEW ENGL J MED, V335, P555, DOI 10.1056/NEJM199608223350804; SHAFRITZ AB, 1998, CLIN ORTHOP RELAT R, V346, P46; SHAMBERGER R, 1985, RECENT RESULTS CANC, V98, P17; SOBALLE K, 1988, CLIN ORTHOP RELAT R, V228, P57; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VIOLA RW, 2000, CLIN ORTHOP RELAT R, V370, P65; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Williams JT, 1999, AM SURGEON, V65, P22; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	55	29	43	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	OCT 20	2006	349	2					564	572		10.1016/j.bbrc.2006.08.089			9	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	088DN	WOS:000240791800016	16949041				2021-06-18	
J	Schneider, HJ; Rovere, S; Corneli, G; Croce, CG; Gasco, V; Ruda, R; Grottoli, S; Stalla, GK; Soffietti, R; Ghigo, E; Aimaretti, G				Schneider, H. J.; Rovere, S.; Corneli, G.; Croce, C. G.; Gasco, V.; Ruda, R.; Grottoli, S.; Stalla, G. K.; Soffietti, R.; Ghigo, E.; Aimaretti, G.			Endocrine dysfunction in patients operated on for non-pituitary intracranial tumors	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; HORMONE (GH)-RELEASING HORMONE; BODY-MASS INDEX; GH DEFICIENCY; PITUITARY-FUNCTION; SUBARACHNOID HEMORRHAGE; DIAGNOSIS; ADULTS; HYPOPITUITARISM; ARGININE	Objective: Hypopituitarism frequently follows pituitary neurosurgery (NS) and/or irradiation. However, the frequency of hypothalamic-pituitary dysfunction after NS of non-pituitary intracranial tumors is unclear. The aim of this study was to assess the presence of endocrine alterations in patients operated on for intracranial tumors. Design: This is a retrospective study. Methods: We studied 68 consecutive adult patients (28 female, 40 male, age 4 5.0 +/- 1.8 years; body mass index (BMI): 26.5 +/- 0.6) with intracranial tumors who underwent NS only (n=17) or in combination with radiotherapy IRT) and/or chemotherapy (CT) (n=51). In all subjects, basal endocrine parameters and the GH response to GHRH+arginine test (using BMI-dcpendent cut offs) were evaluated. Results: In 20.6% of the patients, peripheral endocrinopathy related to CT and/or RT was present. Hypopituitarism was found in 38.2% of the patients. Total pituitary hormone. multiple pituitary hormone, and isolated pituitary hormone deficits were present in 16.2, 5.8, and 16.2%, respectively. The most common pituitary deficits were, in decreasing order: LH/FSH 29.49%, GH 27.9%, ACTH 19.1%, TSH 17.7%, and diabetes insipidus 4.4%. Hyperprolactinemia was present in 13.2%. The prevalence of hypopituitarism was higher in patients who underwent NS only and with tumors located closely to the sella turcica, but a substantial proportion of patients with tumors not directly neighboring the sella also showed hypopituitarism. Conclusions: Hypopituitarism frequently occurs after NS for intracranial tumors. Also, exposure of these patients to CT and/or RT is frequently associated with peripheral endocrinopathies. Thus, endocrine evaluation and follow-up of patients treated for intracranial tumors should be performed on a regular basis.	Univ Turin, Dept Internal Med, Div Endocrinol & Metab, I-10126 Turin, Italy; Univ Turin, Div Neurol, I-10126 Turin, Italy; Max Planck Inst Psychiat, D-80804 Munich, Germany	Aimaretti, G (corresponding author), Univ Turin, Dept Internal Med, Div Endocrinol & Metab, Cso Dogliotti 14, I-10126 Turin, Italy.	gianluca.aimaretti@unito.it		RUDA', Roberta/0000-0001-9134-1537; SOFFIETTI, Riccardo/0000-0002-9204-7038			Agha A, 2005, J CLIN ENDOCR METAB, V90, P6355, DOI 10.1210/jc.2005-1525; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Bonert VS, 2004, J CLIN ENDOCR METAB, V89, P3397, DOI 10.1210/jc.2003-032213; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Cornelia G, 2003, GROWTH HORM IGF RES, V13, P104, DOI 10.1016/S1096-6374(03)00010-8; Darzy K H, 2005, J Endocrinol Invest, V28, P78; Darzy KH, 2003, J CLIN ENDOCR METAB, V88, P95, DOI 10.1210/jc.2002-021094; Dorin RI, 2003, ANN INTERN MED, V139, P194, DOI 10.7326/0003-4819-139-3-200308050-00009; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Ghigo E, 1996, EUR J ENDOCRINOL, V134, P352, DOI 10.1530/eje.0.1340352; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; Honegger J, 1999, J NEUROSURG, V90, P251, DOI 10.3171/jns.1999.90.2.0251; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; LAM KSL, 1991, Q J MED, V78, P165; LITTLEY MD, 1989, Q J MED, V70, P145; LIVESEY EA, 1990, BRIT J CANCER, V61, P622, DOI 10.1038/bjc.1990.138; Nieschlag E, 2004, HUM REPROD UPDATE, V10, P409, DOI 10.1093/humupd/dmh035; Nomikos P, 2004, ACTA NEUROCHIR, V146, P27, DOI 10.1007/s00701-003-0174-3; Schneider HJ, 2006, ACTA NEUROCHIR, V148, P449, DOI 10.1007/s00701-005-0724-y; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937	23	29	33	1	3	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643			EUR J ENDOCRINOL	Eur. J. Endocrinol.	OCT	2006	155	4					559	566		10.1530/eje.1.02272			8	Endocrinology & Metabolism	Endocrinology & Metabolism	098CG	WOS:000241498000007	16990655	Bronze			2021-06-18	
J	Hart, T; Whyte, J; Millis, S; Bode, R; Malec, J; Richardson, RN; Hammond, F				Hart, T; Whyte, J; Millis, S; Bode, R; Malec, J; Richardson, RN; Hammond, F			Dimensions of disordered attention in traumatic brain injury: Further validation of the Moss Attention Rating Scale	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						attention; brain injuries; cognition disorders; rehabilitation	HEAD-INJURY; DEFICITS; TASK	Objectives: To investigate the factor structure of disordered attention in moderate to severe, acute traumatic brain injury (TBI) and to use factor analysis and item response theory to further validate and refine an observational rating scale of attention for clinical and research purposes. Design: Multicenter inception cohort. Setting: Inpatient rehabilitation units. Participants: Patients with TBI (N=372) consecutively admitted to 8 Traumatic Brain Injury Model System centers within 2 weeks prior to observation, who consistently followed commands and who were on stable doses of all psychotropic medications for a 3-day rating period. Interventions: Not applicable. Main Outcome Measure: Participants were rated independently by treating occupational and physical therapists at an average of 1 month postinjury on the Moss Attention Rating Scale (MARS), a 45-item. Likert-type scale of attention-related behavior. Results: Exploratory and confirmatory factor analyses revealed 3 correlated factors of disordered attention, interpreted as restlessness/distractibility, initiation, and sustained/consistent attention. Item response (Rasch) analysis was used to eliminate redundant items and to fill gaps in item difficulty. The resulting MARS consists of 22 items that can produce 3 factor scores and a total score that covers the broad construct of disordered attention. Conclusions: The factor-scored MARS has potential utility as a quantitative observational method with which to assess and study different dimensions of disordered attention in acute TBI, and to monitor change over time and treatment response within these dimensions.	Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19141 USA; Wayne State Univ, Sch Med, Detroit, MI USA; Rehabil Inst Chicago, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Mayo Clin, Rochester, MN USA; Mississippi Methodist Rehabil Ctr, Jackson, MS USA; Charlotte Inst Rehabil, Charlotte, NC USA	Hart, T (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu		Whyte, John/0000-0002-4381-1474			Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bond T.G., 2001, APPL RASCH MODEL FUN; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; DELIS D, 2003, J INT NEUROPSYCH SOC, V9, P947; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hinshaw SP, 1999, DIAGNOSTIC ASSESSMENT IN CHILD AND ADOLESCENT PSYCHOPATHOLOGY, P91; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Joreskog K.G., 2000, LISREL 8 NEW STAT FE; Kennedy MA, 2003, CURR ANTHROPOL, V44, P4; Long JS., 1993, TESTING STRUCTURAL E, P163; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky A.F., 1996, ATTENTION MEMORY EXE, P71; POGGE DL, 1994, J CLIN EXP NEUROPSYC, V16, P344, DOI 10.1080/01688639408402645; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Raz Amir, 2004, Anatomical Record Part B:The New Anatomist, V281, P21, DOI 10.1002/ar.b.20035; Riccio CA, 2004, CLIN NEUROPSYCHOL, V18, P528, DOI 10.1080/138540490516662; Smith E V Jr, 2001, J Appl Meas, V2, P281; Spikman JM, 2001, BRAIN COGNITION, V47, P446, DOI 10.1006/brcg.2001.1320; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; TEASDALE G, 1974, LANCET, V2, P81; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 2003, ARCH PHYS MED REHAB, V84, P268, DOI 10.1053/apmr.2003.50108; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; WHYTE J, 1998, INT PERSPECTIVES TRA, P154; Wright B. D., 1982, RATING SCALE ANAL RA	32	29	30	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2006	87	5					647	655		10.1016/j.apmr.2006.01.016			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	039UW	WOS:000237333900007	16635627				2021-06-18	
J	Wang, H; Olivero, W; Wang, D; Lanzino, G				Wang, H; Olivero, W; Wang, D; Lanzino, G			Cold as a therapeutic agent	ACTA NEUROCHIRURGICA			English	Article						hypothermia; cold; history of medicine	EXTRACORPOREAL CIRCULATION; INDUCED HYPOTHERMIA; CEREBRAL-ISCHEMIA; CARDIAC-ARREST; BRAIN; RESUSCITATION; POTENTIALS; INDUCTION; ANEURYSMS; ARTERY	The use of cold as a therapeutic agent has a long and colorful history. The Edwin Smith Papyrus, the most ancient medical text known, dated 3500 B.C., made numerous references to the use of cold as therapy. Baron de Larrey, a French army surgeon during Napoleon's Russian campaign, packed the limbs in ice prior to amputations to render the procedures painless. In the early twentieth century, a neurosurgeon, Temple Fay, pioneered "human refrigeration" as a treatment for malignancies and head injuries. In 1961, Irving Cooper developed the first closed cryoprobe system and ushered in the modern era of cryogenic surgery with his imperturbable convictions. Fay's early work fell victim to the disruptive sequel of the World War II. The Nazis confiscated his data (presented before the Third International Cancer Congress in 1939) forwarded to Belgium for publication and brutally applied his refrigeration techniques experimentally without any benefit of anesthesia in the concentration camps, especially Dachau. Hypothermia became associated in the public mind with the atrocities exposed at the war trials in Nurnberg. After lying dormant for decades, the interest was rekindled in the late 80s when mild hypothermia was shown to confer dramatic neuroprotection in a number of experimental models of brain injury. With several large multi-center clinical studies currently under way, hypothermia is receiving unprecedented attention from the medical and scientific communities.	Univ Illinois, Coll Med, Dept Neurosurg, Illinois Neurol Inst, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Illinois Neurol Inst, Dept Neurol, Peoria, IL USA	Lanzino, G (corresponding author), UNICOMP, POB 1649, Peoria, IL 61656 USA.	lanzino@uic.edu					ADAMS F, 1929, GENUINE WORKS HIPPOC, P741; Baiping Lei, 1994, Stroke, V25, P147; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BIGLOW EG, 1950, ANN SURG, V132, P849; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; COOPER IS, 1961, J NERV MENT DIS, V133, P259, DOI 10.1097/00005053-196109000-00013; DRAKE CG, 1964, J NEUROSURG, V21, P575, DOI 10.3171/jns.1964.21.7.0575; FAY T, 1959, J NEUROSURG, V16, P239, DOI 10.3171/jns.1959.16.3.0239; FLOYER J, 1715, HIST COLD BATHING BO, P92; Gage AA, 1998, SEMIN SURG ONCOL, V14, P99, DOI 10.1002/(SICI)1098-2388(199803)14:2<99::AID-SSU2>3.0.CO;2-1; HENDERSON A R, 1971, Medical Annals of the District of Columbia, V40, P583; Holzer M, 2002, NEW ENGL J MED, V346, P549; HOSSMANN KA, 1988, CRIT CARE MED, V16, P964, DOI 10.1097/00003246-198810000-00007; KAMME F, 1995, EUR J NEUROSCI, V7, P2007, DOI 10.1111/j.1460-9568.1995.tb00623.x; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kumar K, 1995, METAB BRAIN DIS, V10, P283, DOI 10.1007/BF02109359; PENEL P, 1791, TRAITE MED PHILOS AL, P180; ROSOMOFF HL, 1956, J NEUROSURG, V13, P332; SAFAR P, 1988, CRIT CARE MED, V16, P923, DOI 10.1097/00003246-198810000-00003; SEALY WC, 1958, ANN SURG, V147, P603, DOI 10.1097/00000658-195805000-00004; SHAVER EG, 1995, STROKE, V26, P1273, DOI 10.1161/01.STR.26.7.1273; Solomon R A, 1994, Clin Neurosurg, V41, P351; SOLOMON RA, 1991, NEUROSURGERY, V29, P732, DOI 10.1227/00006123-199111000-00015; SPETZLER RF, 1988, J NEUROSURG, V68, P868, DOI 10.3171/jns.1988.68.6.0868; Stellar S, 1993, Surg Neurol, V39, P331, DOI 10.1016/0090-3019(93)90016-T; WESTIN B, 1971, AM J OBSTET GYNECOL, V110, P1134, DOI 10.1016/0002-9378(71)90313-9; WONG KC, 1936, HIST CHINESE MED, P54	29	29	34	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	MAY	2006	148	5					565	570		10.1007/s00701-006-0747-z			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	034GG	WOS:000236916400022	16489500				2021-06-18	
J	Hirose, H; Gill, IS; Malangoni, MA				Hirose, H; Gill, IS; Malangoni, MA			Nonoperative management of traumatic aortic injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						aortic injury; blunt trauma; management	THORACIC AORTA; BLUNT TRAUMA; RUPTURE; EXPERIENCE; ISTHMUS; REPAIR	Background: The standard management for patients with blunt aortic injury is surgery; however, a small number of patients have been medically managed. The outcome of these nonoperatively managed patients is unknown. Methods: Seven patients diagnosed as blunt aortic injury were managed without aortic surgery between January 1993 and April 2002, and their outcomes were retrospectively investigated. Results: There were three men and four women, with a mean age of 48.7 +/- 22.7 years and Injury Severity Score of 37.7 +/- 16.9. The reason for nonoperative management was refusal of surgery (2), do-not-resuscitate order (1), diffuse brain injury (2), small intimal tear (1), and technical difficulty (1). Two patients died resulting from associated injuries. Five patients are alive, and in three patients complete resolution of aortic injury was observed. Conclusion: In selected patients with multiple associated injuries or severe comorbidity, nonoperative management after blunt aortic injury can be a treatment of choice.	Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44109 USA; MetroHlth Med Ctr, Dept Surg, Cleveland, OH USA	Gill, IS (corresponding author), Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, ME90 3rd Floor,Hamann Bldg,2500 Metro Hlth Dr, Cleveland, OH 44109 USA.	gillis@ccf.org	Hirose, Hitoshi/B-2281-2008	Hirose, Hitoshi/0000-0001-5210-810X			AKINS CW, 1981, ANN THORAC SURG, V31, P305, DOI 10.1016/S0003-4975(10)60955-1; Camp PC, 1997, J TRAUMA, V43, P413, DOI 10.1097/00005373-199709000-00004; Fabian TC, 1998, ANN SURG, V227, P666, DOI 10.1097/00000658-199805000-00007; Fabian TC, 1997, J TRAUMA, V42, P374, DOI 10.1097/00005373-199703000-00003; FISHER RG, 1990, J TRAUMA, V30, P1562, DOI 10.1097/00005373-199012000-00022; Holmes JH, 2002, ANN THORAC SURG, V73, P1149, DOI 10.1016/S0003-4975(01)03585-8; Kasirajan K, 2003, ANN VASC SURG, V17, P589, DOI 10.1007/s10016-003-0066-2; Katsumata T, 1998, ANN THORAC SURG, V66, P774, DOI 10.1016/S0003-4975(98)00519-0; Kepros J, 2002, J TRAUMA, V52, P475, DOI 10.1097/00005373-200203000-00010; Kwon CC, 2002, ANN THORAC SURG, V74, pS1888, DOI 10.1016/S0003-4975(02)04148-6; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; Mattox K L, 2000, Chest Surg Clin N Am, V10, P167; Orford VP, 2003, ANN THORAC SURG, V75, P106, DOI 10.1016/S0003-4975(02)04331-X; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; Pate JW, 1999, WORLD J SURG, V23, P59, DOI 10.1007/s002689900565; PATE JW, 1995, WORLD J SURG, V19, P119, DOI 10.1007/BF00316994; Symbas PN, 2002, ANN SURG, V235, P796, DOI 10.1097/00000658-200206000-00006	17	29	29	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2006	60	3					597	601		10.1097/01.ta.0000205044.99771.44			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	026WX	WOS:000236374900030	16531860				2021-06-18	
J	Schutz, C; Stover, JF; Thompson, HJ; Hoover, RC; Morales, DM; Schouten, JW; McMillan, A; Soltesz, K; Motta, M; Spangler, Z; Neugebauer, E; McIntosh, TK				Schutz, C; Stover, JF; Thompson, HJ; Hoover, RC; Morales, DM; Schouten, JW; McMillan, A; Soltesz, K; Motta, M; Spangler, Z; Neugebauer, E; McIntosh, TK			Acute, transient hemorrhagic hypotension does not aggravate structural damage or neurologic motor deficits but delays the long-term cognitive recovery following mild to moderate traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						head injury; secondary brain damage; Morris water maze; hemorrhagic shock; fluid resuscitation	SEVERE HEAD-INJURY; CONTROLLED CORTICAL IMPACT; CEREBRAL-BLOOD-FLOW; HYPERTONIC FLUID RESUSCITATION; PERCUSSION MODEL; OXYGEN DELIVERY; RAT MODEL; SHOCK; EDEMA; HYPOXIA	Objectives: Posttraumatic hypotension is believed to increase morbidity and mortality in traumatically brain-injured patients. Using a clinically relevant model of combined traumatic brain injury with superimposed hemorrhagic hypotension in rats, the present study evaluated whether a reduction in mean arterial blood pressure aggravates regional brain edema formation, regional cell death, and neurologic motor/cognitive deficits associated with traumatic brain injury. Design: Experimental prospective, randomized study in rodents. Setting: Experimental laboratory at a university hospital. Subjects. One hundred nineteen male Sprague-Dawley rats weighing 350-385 g. Interventions. Experimental traumatic brain injury of mild to moderate severity was induced using the lateral fluid percussion brain injury model in anesthetized rats (n = 89). Following traumatic brain injury, in surviving animals one group of animals was subjected to pressure-controlled hemorrhagic hypotension, maintaining the mean arterial blood pressure at 50-60 mm Hg for 30 mins (n = 47). The animals were subsequently either resuscitated with lactated Ringer's solution (three times shed blood volume, n = 18) or left uncompensated (n = 29). Other groups of animals included those with isolated traumatic brain injury (n = 34), those with isolated hemorrhagic hypotension (n = 8), and sham-injured control animals receiving anesthesia and surgery alone (n = 22). Measurements and Main Results: The withdrawal of 6-7 mL of arterial blood significantly reduced mean arterial blood pressure by 50% without decreasing arterial oxygen saturation or PaO2. Brain injury induced significant cerebral edema (p <.001) in vulnerable brain regions and cortical tissue loss (p <.01) compared with sham-injured animals. Neither regional brain edema formation at 24 hrs postinjury nor the extent of cortical tissue loss assessed at 7 days postinjury was significantly aggravated by superimposed hemorrhagic hypotension. Brain injury-induced neurologic deficits persisted up to 20 wks after injury and were also not aggravated by the hemorrhagic hypotension. Cognitive dysfunction persisted for up to 16 wks postinjury. The superimposition of hemorrhagic hypotension significantly delayed the time course of cognitive recovery. Conclusions. A single, acute hypotensive event lasting 30 mins did not aggravate the short- and long-term structural and motor deficits but delayed the speed of recovery of cognitive function associated with experimental traumatic brain injury.	Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Cologne, Fac Med, Dept Surg, Biochem & Expt Div, D-5000 Cologne 41, Germany; Univ Washington, Seattle, WA 98195 USA; Policlin Hosp, Dept Anesthesiol & Crit Care Med, Milan, Italy	Schutz, C (corresponding author), Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA.		Schuetz, Christian/K-5234-2013	Schuetz, Christian/0000-0002-6828-4543; Morales, Diego/0000-0001-6672-9046	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM R01-34690, R01 GM034690-19] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS P50-08803, P50 NS008803-31] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32-NR07106, T32 NR007106-07, T32 NR007106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR007106] Funding Source: NIH RePORTER		Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Bray GA, 1999, DIABETES CARE, V22, P623; BULLOCK R, 1996, J NEUROTRAUM, V14, P639; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Eilig I, 2001, ANESTH ANALG, V92, P669, DOI 10.1213/00000539-200103000-00023; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GOBIET W, 1995, ZBL CHIR, V120, P544; HARTL R, 1995, SHOCK, V3, P274; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hobbs AJ, 2002, TRENDS PHARMACOL SCI, V23, P406, DOI 10.1016/S0165-6147(02)02067-9; Holtzer S, 2001, CRIT CARE MED, V29, P1609, DOI 10.1097/00003246-200108000-00018; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; LYETH BG, 1987, J NEUROSURG, V67, P110; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; PAXINOS G, 1990, STEREPTACTIC ATLAS R; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Riedel G, 1999, NAT NEUROSCI, V2, P898; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Save E, 2000, HIPPOCAMPUS, V10, P491, DOI 10.1002/1098-1063(2000)10:4<491::AID-HIPO16>3.3.CO;2-S; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; WANG P, 1994, AM J PHYSIOL, V266, pR368; Warner DS, 1996, ANESTHESIOLOGY, V84, P1475, DOI 10.1097/00000542-199606000-00024; Watford M, 2002, J NUTR, V132, P952; WELKERLING H, 1991, ZBL CHIR, V116, P1263; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	51	29	29	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2006	34	2					492	501		10.1097/01.CCM.0000198326.32049.7F			10	Critical Care Medicine	General & Internal Medicine	008UF	WOS:000235065500029	16424733	Green Accepted			2021-06-18	
J	Greve, KW; Bianchini, KJ				Greve, KW; Bianchini, KJ			Should the retention trial of the test of memory malingering be optional?	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; TOMM; symptom validity test; traumatic brain injury; chronic pain		The present study examined the false negative error rate associated with the optional use of the Retention trial the Test of Memory Malingering (TOMM). TOMM scores from 150 traumatic brain injury and 150 chronic pain patients were examined. Results indicated that early termination of the TOMM resulted in 3% of patients going undetected by the TOMM. The practical cost of this error was minimized by the inclusion of at least one other SVT. Clinical implications are discussed. (c) 2005 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, 2000 Lakefront, New Orleans, LA 70148 USA.	kgreve@uno.edu					Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; DOANE BM, CLIN NEUROPSYCHOLOGI; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260	9	29	29	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2006	21	1					117	119		10.1016/j.acn.2005.06.009			3	Psychology, Clinical; Psychology	Psychology	006EA	WOS:000234877100012	16111856				2021-06-18	
J	Hutchison, J; Ward, R; Lacroix, J; Hebert, P; Skippen, R; Barnes, M; Meyer, P; Morris, K; Kirpalani, H; Singh, R; Dirks, P; Bohn, D; Moher, D				Hutchison, J.; Ward, R.; Lacroix, J.; Hebert, P.; Skippen, P.; Barnes, M.; Meyer, P.; Morris, K.; Kirpalani, H.; Singh, R.; Dirks, P.; Bohn, D.; Moher, D.		HyP HIT Investigators; Canadian Critical Care Trials Grp	Hypothermia pediatric head injury trial: The value of a pretrial clinical evaluation phase	DEVELOPMENTAL NEUROSCIENCE			English	Article						pediatric severe traumatic brain injury; hypothermia therapy; multicenter trial	TRAUMATIC BRAIN-INJURY; MODERATE HYPOTHERMIA; INTENSIVE-CARE; CARDIAC-ARREST; CHILDREN	Background: The utility of a pretrial clinical evaluation or run-in phase prior to conducting trials of complex interventions such as hypothermia therapy following severe traumatic brain injury in children and adolescents has not been established. Methods: The primary objective of this study was to prospectively evaluate the ability of investigators to adhere to the clinical protocols of care including the cooling and rewarming procedures as well as management guidelines in patients with severe traumatic brain injury (Glasgow Coma Scale <= 8) treated with 24 h of hypothermia therapy. A secondary objective was to evaluate the ability of study research assistants to complete the study case report form using a procedures manual. The study was conducted at 18 sites in Canada, the United Kingdom and France prior to proceeding to a randomized controlled trial (RCT). After 2 patients were enrolled at each center, an independent clinical evaluation committee examined the process of care and the completeness of data collection. Centers were permitted to enroll patients in the RCT once they met pre-established adherence criteria. Results: Seventeen of the 18 centers completed the pretrial clinical evaluation phase demonstrating compliance with study procedures and proceeded to an RCT of hypothermia therapy. One center enrolled only 1 patient in the pretrial clinical evaluation phase due to small numbers of patients with traumatic brain injury, and therefore, did not proceed to the RCT. Three centers were required to enroll more than 2 patients in the pretrial clinical evaluation phase prior to proceeding to the RCT because of problems with adherence to the clinical protocols at two centers and the training of new study personnel at another center. Of the 39 patients enrolled during the pretrial clinical evaluation phase, 8 (20.5%) died and 22 (62.9%) had a good outcome defined as normal, mild or moderate disability assessed using the Pediatric Cerebral Performance Category score at 6 months following injury. Discussion: The pretrial clinical evaluation phase was useful to ensure compliance with complex hypothermia therapy and consensus-based clinical management guidelines of care successfully implemented across 17 of 18 centers. This study maneuver allowed us to complete a subsequent RCT in 225 children following severe traumatic brain injury. Copyright (c) 2006 S. Karger AG, Basel.	Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Neurosurg, Dept Surg, Toronto, ON M5G 1X8, Canada; Univ Toronto, Fac Med, Interdepartmental Div Crit Care, Toronto, ON, Canada; Hosp Sick Children, Res Inst, Integrat Biol Program, Toronto, ON M5G 1X8, Canada; Childrens Hosp Eastern Ontario, Res Inst, Chalmers Res Grp, Ottawa, ON, Canada; Ottawa Hosp, Dept Crit Care Med, Ottawa Hlth Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; Univ Ottawa, Fac Med, Dept Pediat, Ottawa, ON, Canada; Univ Ottawa, Fac Med, Dept Epidemiol & Community Med, Ottawa, ON, Canada; St Justine Hosp, Dept Pediat, Div Intens Care, Montreal, PQ, Canada; British Columbia Childrens Hosp, Dept Pediat, Div Intens Care, Vancouver, BC, Canada; Univ Guelph, Dept Psychol, Guelph, ON N1G 2W1, Canada; Childrens Hosp Hamilton, Dept Pediat, Hamilton, ON, Canada; Childrens Hosp Western Ontario, Dept Pediat, London, ON, Canada; Grp Hosp Necker Enfants Malades, Neurointens Care Unit, Paris, France; Birmingham Childrens Hosp, Intens Care Unit, Birmingham, W Midlands, England	Hutchison, J (corresponding author), Hosp Sick Children, Dept Crit Care Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	Jamie.Hutchison@sickkids.ca	Meyer, Philippe/ABE-4242-2020	Meyer, Philippe/0000-0002-3829-6631; skippen, peter/0000-0001-6716-0381; Moher, David/0000-0003-2434-4206			Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; [Anonymous], 2000, J Neurotrauma, V17, P537; Bernard S, 1996, ANAESTH INTENS CARE, V24, P382, DOI 10.1177/0310057X9602400315; Biagas Katherine V., 1998, Current Opinion in Pediatrics, V10, P271, DOI 10.1097/00008480-199806000-00009; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; Chambers S, 1999, Nurs Crit Care, V4, P112; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Cullen M L, 2001, Respir Care Clin N Am, V7, P59, DOI 10.1016/S1078-5337(05)70023-X; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; Gilliland MGF, 2001, AM J FOREN MED PATH, V22, P200, DOI 10.1097/00000433-200106000-00019; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; Linstone HA., 1975, DELPHI METHOD TECHNI; Marion DW, 1996, CRIT CARE MED, V24, pS81; MCINTYRE L, 2003, JAMA-J AM MED ASSOC, V89, P2992; Sambasivan M, 1999, NEUROL INDIA, V47, P255; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P1417, DOI 10.1001/jama.275.18.1417; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Tisherman SA, 1999, SURG CLIN N AM, V79, P1269, DOI 10.1016/S0039-6109(05)70077-3; Wechsler D., 1991, WECHSLER INTELLIGENC	30	29	31	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					291	301		10.1159/000094155			11	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600006	16943652				2021-06-18	
J	Jacoby, SF; Ackerson, TH; Richmond, TS				Jacoby, Sara F.; Ackerson, Theimann H.; Richmond, Therese S.			Outcome from serious injury in older adults	JOURNAL OF NURSING SCHOLARSHIP			English	Article						injury; trauma; outcome; older adult; geriatric	ELDERLY TRAUMA PATIENTS; INTENSIVE-CARE-UNIT; LONG-TERM SURVIVAL; GERIATRIC TRAUMA; MAJOR TRAUMA; PENETRATING TRAUMA; RIB FRACTURES; MORTALITY; DEPRESSION; SEVERITY	Purpose: To analyze the research published in peer-reviewed journals between 1996 and 2005 about factors affecting the physical outcomes of older adults after serious traumatic injury. Organizing Construct: Twenty-seven primary research studies published in the last 10 years pertained to in-hospital and long-term outcomes of serious injury among older adults. Research specific to isolated hip injury, traumatic brain injury, and burn trauma was excluded. Methods: An integrative review of research published between January 1996 and January 2005 was carried out to examine the relationship between older age and outcome from severe injury. MEDLINE, BIOSIS previews, CINAHL, and PsycINFO databases were searched using the MeSH terms: injury, serious injury, trauma and multiple trauma, and crossed with type, severity, medical/surgical management, complication, outcome, mortality, morbidity, survival, disability, quality of life, functional status, functional recovery, function, and placement. Findings: Older adults in these studies had higher short- and long-term mortality than did younger adults. The relationship between older age and poorer outcome persisted when adjusting for injury severity, number of injuries, comorbidities, and complications. At the same time, injury severity, number of injuries, complications, and gender each independently correlated with increased mortality among older adults. The body of research is limited by overreliance on retrospective data and heterogeneity in definitional criteria for the older adult population. Conclusions: Additional research is needed to clarify the contributory effect of variables such as psychosocial sequelae and physiologic resilience on injury outcome. The field of geriatric trauma would benefit from further population-based prospective investigation of the determinants of injury outcome in older adults in order to guide interventions and acute care treatment.	Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA	Richmond, TS (corresponding author), Univ Penn, Sch Nursing, 420 Guardian Dr, Philadelphia, PA 19104 USA.	terryr@nursing.upenn.edu	Jacoby, Sara F./X-7412-2019	Jacoby, Sara F./0000-0001-6206-5078			Albaugh G, 2000, AM SURGEON, V66, P978; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Battistella FD, 1998, J TRAUMA, V44, P618, DOI 10.1097/00005373-199804000-00010; Bergeron E, 2003, J TRAUMA, V54, P478, DOI 10.1097/01.TA.0000037095.83469.4C; Bulger EM, 2000, J TRAUMA, V48, P1040, DOI 10.1097/00005373-200006000-00007; *BUR CENS, 2001, AG 2000 CENS 2000 BR; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Copes W. S., 1990, P 33 ANN M ASS ADV A, P205; CUNNINGHAM C, 2001, IRISH MED J, V94, P168; Demetriades D, 2002, BRIT J SURG, V89, P1319, DOI 10.1046/j.1365-2168.2002.02210.x; Ferrera PC, 1999, AM J EMERG MED, V17, P629, DOI 10.1016/S0735-6757(99)90146-8; Ferrera PC, 2000, AM J EMERG MED, V18, P575, DOI 10.1053/ajem.2000.9266; Gallagher SF, 2003, AM J SURG, V185, P131, DOI 10.1016/S0002-9610(02)01208-4; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; Hannan EL, 2004, J TRAUMA, V56, P1297, DOI 10.1097/01.TA.0000075350.66739.53; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Holcomb JB, 2003, J AM COLL SURGEONS, V196, P549, DOI 10.1016/S1072-7515(02)01894-X; Hui T, 2002, AM SURGEON, V68, P1111; Inaba K, 2003, J TRAUMA, V54, P486, DOI 10.1097/01.TA.0000051588.05542.D6; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kempen GIJM, 2003, INT J GERIATR PSYCH, V18, P14, DOI 10.1002/gps.768; MACKENZIE EJ, 1990, J TRAUMA, V30, P1096, DOI 10.1097/00005373-199009000-00005; Mast BT, 1999, J GERONTOL A-BIOL, V54, pM607, DOI 10.1093/gerona/54.12.M607; McGwin G, 2000, J TRAUMA, V49, P470, DOI 10.1097/00005373-200009000-00014; McMahon DJ, 1996, WORLD J SURG, V20, P1113, DOI 10.1007/s002689900170; McMahon DJ, 2000, SURG CLIN N AM, V80, P1005, DOI 10.1016/S0039-6109(05)70110-9; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; Nagy KK, 2000, J TRAUMA, V49, P190, DOI 10.1097/00005373-200008000-00003; O'Brien DP, 2002, SURGERY, V132, P710, DOI 10.1067/msy.2002.127690; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Piccinelli M, 1999, J PSYCHOSOM RES, V46, P455, DOI 10.1016/S0022-3999(98)00126-3; Pickering SAW, 1999, INJURY, V30, P703, DOI 10.1016/S0020-1383(99)00188-6; Ponzetto M, 2003, ARCH GERONTOL GERIAT, V36, P83, DOI 10.1016/S0167-4943(02)00061-4; Pudelek Barbara, 2002, AACN Clin Issues, V13, P61; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Roth BJ, 2001, INJURY, V32, P551, DOI 10.1016/S0020-1383(01)00079-1; Scaf-Klomp W, 2003, AGE AGEING, V32, P88, DOI 10.1093/ageing/32.1.88; Taheri PA, 1997, J TRAUMA, V43, P565, DOI 10.1097/00005373-199710000-00001; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; TEASDALE G, 1974, LANCET, V2, P81; Tornetta P, 1999, J TRAUMA, V46, P702, DOI 10.1097/00005373-199904000-00024; van der Sluis CK, 1997, INJURY, V28, P588, DOI 10.1016/S0020-1383(97)00094-6; vanderSluis CK, 1996, J TRAUMA, V40, P78, DOI 10.1097/00005373-199601000-00015	43	29	31	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1527-6546	1547-5069		J NURS SCHOLARSHIP	J. Nurs. Scholarsh.		2006	38	2					133	140		10.1111/j.1547-5069.2006.00090.x			8	Nursing	Nursing	040QQ	WOS:000237395900016	16773916				2021-06-18	
J	Engel, DC; Slemmer, JE; Vlug, AS; Maas, AIR; Weber, JT				Engel, DC; Slemmer, JE; Vlug, AS; Maas, AIR; Weber, JT			Combined effects of mechanical and ischemic injury to cortical cells: Secondary ischemia increases damage and decreases effects of neuroprotective agents	NEUROPHARMACOLOGY			English	Article						cell culture; free radicals; neuronal injury; nitric oxide; superoxide; trauma	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; STRETCH-INDUCED INJURY; CEREBRAL-ISCHEMIA; IN-VITRO; SIGNAL-TRANSDUCTION; NEURONAL INJURY; HEAD-INJURY; LUBELUZOLE; DEATH	Traumatic brain injury (TBI) involves direct mechanical damage, which may be aggravated by secondary insults such as ischemia. We utilized an in vitro model of stretch-induced injury to investigate the effects of mechanical and combined mechanical/ ischemic insults to cultured mouse cortical cells. Stretch injury alone caused significant neuronal loss and increased uptake of the dye, propidium iodide, suggesting cellular membrane damage to both glia and neurons. Exposure of cultures to ischemic conditions for 24 h, or a combination of stretch and 24 h of ischemia, caused greater neuronal loss compared to stretch injury alone. Next, we tested the neuroprotective effects of superoxide dismutase (SOD), and the nitric oxide (NO) synthase inhibitors 7-nitroindazole (7-NINA) and lubeluzole. In general, these agents decreased neuronal loss following stretch injury alone, but were relatively ineffective against the combined injury paradigm. A combination of SOD with 7-NINA or lubeluzole offered no additional protection than single drug treatment against stretch alone or combined injury. These results suggest that the effects of primary mechanical damage and secondary ischemia to cortical neurons are cumulative, and drugs that scavenge superoxide or reduce NO production may not be effective for treating the secondary ischemia that often accompanies TBI. (c) 2005 Elsevier Ltd. All rights reserved.	Erasmus MC, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Neurosurg, NL-3000 DR Rotterdam, Netherlands	Weber, JT (corresponding author), Erasmus MC, Dept Neurosci, POB 1738, NL-3000 DR Rotterdam, Netherlands.	j.weber@erasmusmc.nl	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264			Cho S, 2005, J CEREBR BLOOD F MET, V25, P493, DOI 10.1038/sj.jcbfm.9600058; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Culmsee C, 1998, EUR J PHARMACOL, V342, P193, DOI 10.1016/S0014-2999(97)01499-4; Dawson VL, 1996, P SOC EXP BIOL MED, V211, P33; Dawson VL, 1999, P NATL ACAD SCI USA, V96, P10557, DOI 10.1073/pnas.96.19.10557; Diener HC, 2000, STROKE, V31, P2543, DOI 10.1161/01.STR.31.11.2543; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Glass TF, 2002, NEUROSCI LETT, V328, P133, DOI 10.1016/S0304-3940(02)00510-4; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hoffman WE, 1996, NEUROL RES, V18, P54, DOI 10.1080/01616412.1996.11740378; Huang HM, 2002, J CELL BIOCHEM, V84, P367, DOI 10.1002/jcb.10022; IKEDA J, 1994, ACTA NEUROCHIR, P94; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kamii H, 1996, J CEREBR BLOOD F MET, V16, P1153, DOI 10.1097/00004647-199611000-00009; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Kroppenstedt SN, 1999, J NEUROTRAUM, V16, P629, DOI 10.1089/neu.1999.16.629; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Liu PK, 2002, ANN NY ACAD SCI, V962, P226, DOI 10.1111/j.1749-6632.2002.tb04071.x; Maas A. I., 2000, CURR OPIN CRIT CARE, V6, P281; Maiese K, 1997, J NEUROCHEM, V68, P710; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Mueller RN, 2003, EXP BRAIN RES, V152, P329, DOI 10.1007/s00221-003-1539-9; O'Dell DM, 2000, RESTOR NEUROL NEUROS, V16, P127; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Raghupathi R, 1998, P W PHARMACOL SOC, V41, P241; Saito K, 1997, BRAIN RES, V763, P232, DOI 10.1016/S0006-8993(97)00414-9; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; SCHREIBER D, 1995, INT RES COMMITTEE BI, P233; Shanker G, 2003, MOL BRAIN RES, V110, P85, DOI 10.1016/S0169-328X(02)00642-3; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Toescu EC, 1998, CELL CALCIUM, V24, P387, DOI 10.1016/S0143-4160(98)90062-8; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	42	29	30	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	DEC	2005	49	7					985	995		10.1016/j.neuropharm.2005.05.021			11	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	984ZZ	WOS:000233347200004	16046227				2021-06-18	
J	Stokic, DS; Yablon, SA; Hayes, A				Stokic, DS; Yablon, SA; Hayes, A			Comparison of clinical and neurophysiologic responses to intrathecal baclofen bolus administration in moderate-to-severe spasticity after acquired brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	7th Annual Meeting of the American-Society-of-Neurorehabilitation	APR 27-29, 2000	SAN DIEGO, CA	Amer Soc Neurorehabilitat		baclofen; brain injuries; H-reflex; muscle spasticity; rehabilitation	MODIFIED ASHWORTH SCALE; H-REFLEX TESTS; CEREBRAL ORIGIN; SUPRASPINAL SPASTICITY; ADMINISTERED BACLOFEN; MUSCLE SPASTICITY; TIME-COURSE; F-WAVE; MANAGEMENT; HYPERTONIA	Objectives: To compare clinical and neurophysiologic responses to intrathecal baclofen (ITB) bolus injection in subjects with spasticity after acquired brain injury. Design: Prospective case series. Setting: Tertiary care rehabilitation center. Participants: Thirty consecutive ITB pump candidates with dysfunctional spasticity caused by traumatic brain injury, hypoxic encephalopathy, or stroke. Intervention: A single 50-mu g ITB bolus. Main Outcome Measures: Lower-extremity Ashworth Scale score at 2, 4, and 6 hours after ITB bolus; soleus Hoffmann reflex (H-reflex)/M-wave amplitude (H/M) ratio and abductor hallucis F-wave persistence and F/M ratio at 5 hours. Nonparametric repeated-measures analysis of variance and paired t test were used for statistical analyses. Results: The Ashworth score on the more involved side significantly decreased from 2.4 +/- 0.7 at baseline to 1.5 +/- 0.6 and 1.4 +/- 0.6 at 4- and 6-hour evaluations, respectively (P <.001). H/M ratio significantly decreased bilaterally (more involved side, 62% +/- 28% to 14% +/- 19%; less involved side, 59% +/- 26% to 11% +/- 20%; P < .001). F-wave persistence significantly decreased on the more involved side (86% +/- 17% to 75% +/- 13%, P < .05) with no change in F/M ratio. There was no significant correlation among these outcome measures before or after the ITB bolus injection. Conclusions: H/M ratio is more sensitive than the Ashworth score or F-wave persistence in detecting a physiologic response to ITB bolus. H-reflex is useful for verification of ITB bolus administration, as an adjunct to clinical evaluation, particularly among patients with moderate spasticity at rest or with small changes in Ashworth score. However, potential application of the marked sensitivity of the H-reflex to other clinically challenging situations, such as early detection of possible ITB system malfunction, awaits further investigation.	Methodist Rehabil Ctr, Ctr Neurosci & Neurol Recovery, Jackson, MS 39216 USA; Methodist Rehabil Ctr, Brain Injury Program, Jackson, MS 39216 USA	Stokic, DS (corresponding author), Methodist Rehabil Ctr, Ctr Neurosci & Neurol Recovery, 1350 W Eoodrow Wilson Dr, Jackson, MS 39216 USA.	dstokic@mmrcrehab.org		Stokic, Dobrivoje/0000-0002-1891-5730			Albright AL, 2003, J NEUROSURG, V98, P291, DOI 10.3171/jns.2003.98.2.0291; Albright AL, 1996, J CHILD NEUROL, V11, pS29, DOI 10.1177/0883073896011001S05; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; ALBRIGHT AL, 1997, INTRATHECAL BACLOFEN, P1; Allison SC, 1996, INT J REHABIL RES, V19, P67, DOI 10.1097/00004356-199603000-00007; ANGEL RW, 1963, ARCH NEUROL-CHICAGO, V8, P591, DOI 10.1001/archneur.1963.00460060021002; ASHWORTH B, 1964, PRACTITIONER, V192, P540; AZOUVI P, 1993, J NEUROL NEUROSUR PS, V56, P515, DOI 10.1136/jnnp.56.5.515; Bakheit AMO, 2003, J NEUROL NEUROSUR PS, V74, P646, DOI 10.1136/jnnp.74.5.646; Becher JG, 1999, J NEUROL, V246, P1080, DOI 10.1007/s004150050516; CAMPBELL SK, 1995, PHYS THER, V75, P352, DOI 10.1093/ptj/75.5.352; Dachy B, 2002, CLIN NEUROPHYSIOL, V113, P336, DOI 10.1016/S1388-2457(02)00010-X; Dario A, 2002, ACTA NEUROL SCAND, V105, P83, DOI 10.1034/j.1600-0404.2002.1o042.x; Detrembleur C, 2000, ARCH PHYS MED REHAB, V81, P279; DRESSNANDT J, 1995, MUSCLE NERVE, V18, P103, DOI 10.1002/mus.880180114; EISEN A, 1979, NEUROLOGY, V29, P1306, DOI 10.1212/WNL.29.9_Part_1.1306; FISHER MA, 1983, J NEUROL SCI, V62, P13, DOI 10.1016/0022-510X(83)90186-7; Gelber DA, 1999, NEUROREHAB NEURAL RE, V13, P5, DOI 10.1177/154596839901300103; Gilmartin R, 2000, J CHILD NEUROL, V15, P71, DOI 10.1177/088307380001500201; HARBURN KL, 1992, CAN J PUBLIC HEALTH, V83, pS41; Ivanhoe C B, 2001, Phys Med Rehabil Clin N Am, V12, P923; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P339, DOI 10.1016/0003-9993(92)90007-J; KOELMAN JHTM, 1993, J NEUROL NEUROSUR PS, V56, P776, DOI 10.1136/jnnp.56.7.776; KOELMAN JHTM, 1995, MOVEMENT DISORD, V10, P44, DOI 10.1002/mds.870100109; LATASH ML, 1989, EXP NEUROL, V103, P165, DOI 10.1016/0014-4886(89)90078-2; LEVIN MF, 1993, J NEUROL, V240, P63, DOI 10.1007/BF00858718; MACDONELL RAL, 1989, J NEUROL NEUROSUR PS, V52, P1110, DOI 10.1136/jnnp.52.9.1110; Meythaler JM, 1999, AM J PHYS MED REHAB, V78, P247, DOI 10.1097/00002060-199905000-00012; Meythaler JM, 2001, STROKE, V32, P2099, DOI 10.1161/hs0901.095682; MILANOV I G, 1992, Electromyography and Clinical Neurophysiology, V32, P11; MILANOV IG, 1992, ACTA NEUROL SCAND, V85, P305; Morris S, 2002, PHYS THER REV, V7, P53, DOI [10.1179/108331902125001770, DOI 10.1179/108331902125001770]; Murphy NA, 2002, ARCH PHYS MED REHAB, V83, P1721, DOI 10.1053/apmr.2002.36068; Nielsen J F, 1996, Mult Scler, V1, P296; Pandyan AD, 1999, CLIN REHABIL, V13, P373, DOI 10.1191/026921599677595404; Pandyan AD, 2003, CLIN REHABIL, V17, P290, DOI 10.1191/0269215503cr610oa; Parise M, 1997, ELECTROMYOGR MOTOR C, V105, P141, DOI 10.1016/S0924-980X(96)96555-8; Pisano F, 2000, CLIN NEUROPHYSIOL, V111, P1015, DOI 10.1016/S1388-2457(00)00289-3; Pohl M, 2003, J NEUROL, V250, P1195, DOI 10.1007/s00415-003-0178-1; Rawicki B, 1999, J NEUROSURG, V91, P733, DOI 10.3171/jns.1999.91.5.0733; Rifici C, 1994, Funct Neurol, V9, P29; Sabbahi M, 2003, CLIN NEUROPHYSIOL, V114, P288, DOI 10.1016/S1388-2457(02)00375-9; SCHILLER HH, 1978, J NEUROL NEUROSUR PS, V41, P45, DOI 10.1136/jnnp.41.1.45; SINKJAER T, 1994, BRAIN, V117, P355, DOI 10.1093/brain/117.2.355; STOKIC DS, 2000, NEUROREHAB NEURAL RE, V14, P77; STOKIC DS, 2001, NEUROREHAB NEURAL RE, V15, P327; THILMANN AF, 1991, BRAIN, V114, P233; Yablon SA, 2004, AM J PHYS MED REHAB, V83, pS10, DOI 10.1097/01.PHM.0000141126.11008.7D; YOUNG RR, 1989, NEW ENGL J MED, V320, P1553, DOI 10.1056/NEJM198906083202310	49	29	30	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2005	86	9					1801	1806		10.1016/j.apmr.2005.03.027			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	962QM	WOS:000231747300015	16181946				2021-06-18	
J	Tam, SF; Man, DWK; Chan, YP; Sze, PC; Wong, CM				Tam, SF; Man, DWK; Chan, YP; Sze, PC; Wong, CM			Evaluation of a computer-assisted, 2-D virtual reality system for training people with intellectual disabilities on how to shop	REHABILITATION PSYCHOLOGY			English	Article						computer-assisted system; virtual reality; shopping skills	TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION; LEARNING-DISABILITIES; ENVIRONMENTS; TECHNOLOGY; ATTENTION; EDUCATION; EFFICACY; THERAPY; FUTURE	Objective: To evaluate the effectiveness of a 2-D virtual reality (VR) program for training people with intellectual disabilities to shop. Study Design: Pretest and posttest quasi-experimental design. Participants: Sixteen persons with intellectual disabilities (age 17-23 years; IQ = 40-54). Intervention: A VR program or a conventional program training them in supermarket-shopping skills. Main Outcome Measure: Checklist for supermarket-shopping skills. Results: Participants in both training groups showed significant improvement. There was no significant difference in effectiveness between the two methods. Conclusions: The VR program appears effective in training people with intellectual disabilities in an important community living skill.	Hong Kong Polytech Univ, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China	Tam, SF (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China.	rsalan@polyu.edu.hk					ARMSTRONG C, 1989, COGNITIVE REHABILITA, V7, P10; Brooks BM, 2002, DISABIL REHABIL, V24, P622, DOI 10.1080/09638280110111397; Brooks BM, 1999, NEUROPSYCHOL REHABIL, V9, P63, DOI 10.1080/713755589; Browne C, 1997, NEURAL NETWORKS, V10, P1303, DOI 10.1016/S0893-6080(97)00063-4; BURDA PC, 1994, COMPUT HUM BEHAV, V10, P359, DOI 10.1016/0747-5632(94)90061-2; Burdea G, 1996, INT J HUM-COMPUT INT, V8, P5, DOI 10.1080/10447319609526138; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Cromby JJ, 1996, J INTELL DISABIL RES, V40, P489, DOI 10.1111/j.1365-2788.1996.tb00659.x; Cunningham D, 1999, Cyberpsychol Behav, V2, P19, DOI 10.1089/cpb.1999.2.19; ELKIND JS, 1998, CYBERPSYCHOLOGY BEHA, V1, P263, DOI DOI 10.1089/CPB.1998.1.263; GALIMBERTI C, 2001, CYBERPSYCHOLOGY MIND, P129; GOLDSTEIN AP, 1979, AM J OCCUP THER, V33, P635; Gontkovsky ST, 2002, NEUROREHABILITATION, V17, P195; GREEN RC, 1994, ARCH NEUROL-CHICAGO, V51, P779, DOI 10.1001/archneur.1994.00540200055017; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; *HONG KONG GOV, 1997, MENT HLTH AM ORD; Hong Kong Government, 1995, WHIT PAP REH POL SER; JOHNSON R, 1985, OCCUPATIONAL THERAPY, V48, P46; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; McComas J., 1998, CYBERPSYCHOL BEHAV, V1, P121, DOI [10.1089/cpb.1998.1.121, DOI 10.1089/CPB.1998.1.121]; MCGUIRE BE, 1990, IRISH J PSYCHOL, V11, P299, DOI 10.1080/03033910.1990.10557810; Moffat SD, 1998, EVOL HUM BEHAV, V19, P73, DOI 10.1016/S1090-5138(97)00104-9; Myers RL, 2000, CYBERPSYCHOL BEHAV, V3, P465, DOI 10.1089/10949310050078922; Popescu GV, 2002, HUM FAC ER, P435; Psotka J, 1995, INSTR SCI, V23, P405, DOI 10.1007/BF00896880; Pugnetti L., 1998, CYBERPSYCHOL BEHAV, V1, P151; Riva G, 1999, J BEHAV THER EXP PSY, V30, P221, DOI 10.1016/S0005-7916(99)00018-X; Riva G, 1997, ST HEAL T, V44, P71; Riva G, 1998, PERCEPT MOTOR SKILL, V86, P163, DOI 10.2466/pms.1998.86.1.163; Rizzo AA, 1998, ST HEAL T, V58, P21; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; Rose FD, 1998, ST HEAL T, V58, P233; Rose FD, 2002, DISABIL REHABIL, V24, P627, DOI 10.1080/09638280110111405; Rose FD, 1999, DISABIL REHABIL, V21, P548; Rose FD, 2000, ERGONOMICS, V43, P494, DOI 10.1080/001401300184378; Ruddle RA, 1997, J EXP PSYCHOL-APPL, V3, P143, DOI 10.1037/1076-898X.3.2.143; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; SKILBECK C, 1991, MICROCOMPUTERS CLIN, P95; SMART S, 1988, CLIN REHABIL, V2, P61; UNDERWOOD RL, 1997, DISS ABSTR INT A, V58, P520; VOCKELL EL, 1992, COMPUTER CLASSROOM; WATERS J, COGNITIVE REHABILITA, V425, P96; WESTLING DL, 1990, AM J MENT RETARD, V94, P616; Wickens C. D., 1995, VIRTUAL ENV ADV INTE; Wiederhold BK, 2000, CYBERPSYCHOL BEHAV, V3, P393, DOI 10.1089/10949310050078841	46	29	32	0	18	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2005	50	3					285	291		10.1037/0090-5550.50.3.285			7	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	962OD	WOS:000231741200013					2021-06-18	
J	Fritz, HG; Walter, B; Holzmayr, M; Brodhun, M; Patt, S; Bauer, R				Fritz, HG; Walter, B; Holzmayr, M; Brodhun, M; Patt, S; Bauer, R			A pig model with secondary increase of intracranial pressure after severe traumatic brain injury and temporary blood loss	JOURNAL OF NEUROTRAUMA			English	Article						fluid-percussion injury; hemorrhagic hypotension; intracranial pressure; piglets; secondary injury	CEREBRAL PERFUSION-PRESSURE; COLORED MICROSPHERE TECHNIQUE; FLUID-PERCUSSION MODEL; SEVERE HEAD-INJURY; NEWBORN PIGLETS; IMPACT INJURY; AXONAL INJURY; FLOW; METABOLISM; RAT	There is a lack of animal models of traumatic brain injury (TBI) that adequately simulate the long-term changes in intracranial pressure (ICP) increase following clinical TBI. We therefore reproduced the clinical scenario in an animal model of TBI and studied long-term postinjury changes in ICP and indices of brain injury. After induction of anesthesia, juvenile piglets were randomly traumatized using fluid-percussion injury (FPI) to induce either moderate (mTBI = 6 pigs: 3.2 +/- 0.6 atm) or severe (sTBI = 7 pigs: 4.1 +/- 1.0 atm) TBI. Injury was followed by a 30% withdrawal of blood volume. ICP and systemic hemodynamic were monitored continuously. Repeated measurements of global cerebral blood flow (CBF) and cerebral metabolic rate of oxygen (CMRO2) were performed at baseline, at the end of blood withdrawal, after volume replacement, and at 8 and 24 h postinjury. Histological and immunocytochemical studies have also performed. ICP peaked immediately following FPI (mTBI: 33 +/- 16 mm Hg; sTBI: 47 +/- 14 mm Hg, p < 0.05) in both groups. In the sTBI group, we noted a second peak at 5 +/- 1.5 h postinjury. This second ICP peak was accompanied by a 50% reduction in CBF (44 +/- 31 mL center dot min center dot 100 g(-1)) and CMRO2 (2.5 +/- 2.0 mL center dot min center dot 100 g(-1)). Moderate TBI typically resulted in focal pathological change whereas sTBI caused more diffuse change, particularly in terms of the ensuing axonal damage. We thus describe an animal model of severe TBI with a reproducible secondary ICP increase accompanied by patterns of diffuse brain damage. This model may be helpful in the study of pathogenetic relevance of concomitant affections and verify new therapeutic approaches in severe TBI.	Dept Anesthesiol & Intens Care Med, Halle An Der Saale, Germany; Matha Maria Hosp, Halle An Der Saale, Germany; Univ Jena, Univ Klinikum Jena, Dept Neurosurg, D-07740 Jena, Germany; Univ Jena, Univ Klinikum Jena, Inst Pathophysiol & Pathobiochem, D-07740 Jena, Germany; Univ Jena, Univ Klinikum Jena, Inst Pathol, D-07740 Jena, Germany	Bauer, R (corresponding author), Univ Jena, Inst Pathophysiol & Pathobiochem, D-07740 Jena, Germany.	Reinhard.Bauer@mti.uni-jena.de					Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 2002, DEV BRAIN RES, V139, P19, DOI 10.1016/S0165-3806(02)00511-4; Bauer R, 1999, PEDIATR NEUROSURG, V30, P62, DOI 10.1159/000028765; Bauer R, 2001, PEDIATR RES, V49, P474, DOI 10.1203/00006450-200104000-00007; Bauer R, 1996, EXP TOXICOL PATHOL, V48, P415; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Buki A, 2000, J NEUROSCI, V20, P2825; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CIRICILLO SF, 1992, J TRAUMA, V33, P899, DOI 10.1097/00005373-199212000-00018; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; COYLE MG, 1993, AM J PHYSIOL, V264, pH141; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; Felix B, 1999, BRAIN RES BULL, V49, P1, DOI 10.1016/S0361-9230(99)00012-X; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; LEFFLER CW, 1989, AM J PHYSIOL, V257, pH1917; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; LUNDBERG N, 1960, ACTA PSYCHIAT NEUROL, V149, P158; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Marmarou A, 1990, Adv Neurol, V52, P233; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; NILSSON F, 1995, ACTA ANAESTH SCAND, V39, P827, DOI 10.1111/j.1399-6576.1995.tb04179.x; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; POWNALL R, 1973, BRIT VET J, V129, P583, DOI 10.1016/S0007-1935(17)36340-6; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; Shackford SR, 1997, J TRAUMA, V42, pS48, DOI 10.1097/00005373-199705001-00009; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stern SA, 2000, J NEUROSURG, V93, P305, DOI 10.3171/jns.2000.93.2.0305; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Walter B, 1997, BASIC RES CARDIOL, V92, P191, DOI 10.1007/s003950050037; WARD JD, 1994, PEDIATR NEUROSURG, V20, P183, DOI 10.1159/000120784	50	29	29	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2005	22	7					807	821		10.1089/neu.2005.22.807			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	945VQ	WOS:000230530800008	16004583				2021-06-18	
J	Ley, JJ; Vigdorchik, A; Belayev, L; Zhao, WZ; Busto, R; Khoutorova, L; Becker, DA; Ginsberg, MD				Ley, JJ; Vigdorchik, A; Belayev, L; Zhao, WZ; Busto, R; Khoutorova, L; Becker, DA; Ginsberg, MD			Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat: Neurobehavior, histopathology, and pharmacokinetics	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							TRAUMATIC BRAIN INJURY; SPIN-TRAPPING AGENTS; ARTERY OCCLUSION; INTRALUMINAL SUTURE; THERAPEUTIC WINDOW; ACUTE STROKE; NXY-059; TRAPS; RADICALS; PBN	Stilbazulenyl nitrone (STAZN) is a potent lipophilic second-generation azulenyl nitrone antioxidant, which is highly neuroprotective in rodent models of cerebral ischemia and trauma. This study was conducted to establish whether the neuroprotection induced by STAZN persists with chronic survival and to characterize STAZN's pharmacokinetics. Physiologically regulated rats received a 2-h middle cerebral artery occlusion by intraluminal suture and were treated with either STAZN [four 0.6 mg/kg doses i.p. administered at 2 (i.e., onset of recirculation), 4, 24, and 48 h; n = 16] or dimethyl sulfoxide vehicle (n = 11). They received sequential neurobehavioral examinations followed by quantitative neuropathology at 30 days. STAZN improved neurological deficits compared with vehicle controls, beginning within < 2 h of the first dose and persisting throughout a 30-day survival. Large cystic necrotic infarcts were common in vehicle-treated rats but infrequent in STAZN-treated rats, and noninfarcted forebrain tissue was increased on average by 15%. In normal rats administered 5 mg/kg STAZN i.v. in Solutol HS 15/ethanol/saline vehicle, STAZN blood levels exhibited a biexponential decline, with an initial half-life of 28 min and a subsequent slow decay with half-life of similar to 7 h. STAZN tissue levels at 2 to 3 h were, on average, 2.5% of blood levels in forebrain, 56% in myocardium, and 41% in kidney. STAZN was concentrated in liver with initial concentrations averaging 5.2-fold above blood levels and a subsequent linear decline of 40% between 24 and 72 h. These results establish that STAZN confers enduring ischemic neuroprotection, has a long circulating half-life, and penetrates well into brain and other organs - characteristics favoring its potential therapeutic utility.	Univ Miami, Sch Med, Cerebral Vasc Dis Res Ctr, Dept Neurol, Miami, FL 33101 USA; Florida Int Univ, Dept Chem, Miami, FL 33199 USA	Ginsberg, MD (corresponding author), Univ Miami, Sch Med, Cerebral Vasc Dis Res Ctr, Dept Neurol, POB 016960, Miami, FL 33101 USA.	mdginsberg@stroke.med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS046295, P01NS005820] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 P01 NS05820, 1 U01 NS46295] Funding Source: Medline		Becker DA, 2002, J AM CHEM SOC, V124, P4678, DOI 10.1021/ja011507s; Becker DA, 1999, CELL MOL LIFE SCI, V56, P626, DOI 10.1007/s000180050457; Becker DA, 1998, ORG SYN TH, V4, P155; Becker DA, 1996, J AM CHEM SOC, V118, P905, DOI 10.1021/ja952895z; BECKER DA, 1998, J CHEM SOC P2, V6, P1289; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Belayev L, 2002, J NEUROSURG, V96, P1077, DOI 10.3171/jns.2002.96.6.1077; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; BUSTO R, 1998, CEREBROVASC DIS, P287; CARNEVALE NT, 1986, BRAIN RES BULL, V16, P137, DOI 10.1016/0361-9230(86)90022-5; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; CHEN GM, 1990, FREE RADICAL BIO MED, V9, P93, DOI 10.1016/0891-5849(90)90110-5; CHENG HY, 1993, FREE RADICAL BIO MED, V14, P243, DOI 10.1016/0891-5849(93)90021-L; COON JS, 1991, CANCER RES, V51, P897; Dehouck MP, 2002, BRAIN RES, V955, P229, DOI 10.1016/S0006-8993(02)03469-8; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Fujioka M, 2003, ANN NEUROL, V54, P732, DOI 10.1002/ana.10751; Ginsberg MD, 2003, ANN NEUROL, V54, P330, DOI 10.1002/ana.10659; Hensley K, 1997, INT REV NEUROBIOL, V40, P299; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; Klivenyi P, 1998, EXP NEUROL, V152, P163, DOI 10.1006/exnr.1998.6824; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Lame Mary E, 2004, Drug Metabol Drug Interact, V20, P11; Lees KR, 2003, STROKE, V34, P482, DOI 10.1161/01.STR.0000053032.14223.81; Lefer DJ, 2000, AM J MED, V109, P315, DOI 10.1016/S0002-9343(00)00467-8; Liu KJ, 1999, FREE RADICAL BIO MED, V27, P82, DOI 10.1016/S0891-5849(99)00042-8; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Mojumdar SC, 2004, J ORG CHEM, V69, P2929, DOI 10.1021/jo030390i; Nath KA, 2000, AM J MED, V109, P665, DOI 10.1016/S0002-9343(00)00612-4; Novelli G P, 1986, Free Radic Res Commun, V1, P321, DOI 10.3109/10715768609080971; Reinke LA, 2000, FREE RADICAL BIO MED, V28, P345, DOI 10.1016/S0891-5849(99)00248-8; SCHOENBERG MH, 1993, CRIT CARE MED, V21, P1376, DOI 10.1097/00003246-199309000-00023; Strickley RG, 2004, PHARM RES-DORDR, V21, P201, DOI 10.1023/B:PHAM.0000016235.32639.23; Strid S, 2002, EUR J CLIN PHARMACOL, V58, P409, DOI 10.1007/s00228-002-0478-x; Sydserff SG, 2002, BRIT J PHARMACOL, V135, P103, DOI 10.1038/sj.bjp.0704449; Trudeau-Lame ME, 2003, DRUG METAB DISPOS, V31, P147, DOI 10.1124/dmd.31.2.147; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Zhao WZ, 1996, STROKE, V27, P1112, DOI 10.1161/01.STR.27.6.1112	40	29	29	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JUN	2005	313	3					1090	1100		10.1124/jpet.105.083386			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	927OM	WOS:000229203200017	15716383				2021-06-18	
J	Meshorer, E; Biton, IE; Ben-Shaul, Y; Ben-Ari, S; Assaf, Y; Soreq, H; Cohen, Y				Meshorer, E; Biton, IE; Ben-Shaul, Y; Ben-Ari, S; Assaf, Y; Soreq, H; Cohen, Y			Chronic cholinergic imbalances promote brain diffusion and transport abnormalities	FASEB JOURNAL			English	Article						cholinergic neurotransmission; acetylcholinesterase; blood-brain barrier; aquaporin 4	ACETYLCHOLINESTERASE-TRANSGENIC MICE; POSTTRAUMATIC-STRESS-DISORDER; AQUAPORIN-4 WATER CHANNEL; CEREBRAL-ISCHEMIA; HEAD-INJURY; READTHROUGH ACETYLCHOLINESTERASE; BARRIER PERMEABILITY; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; UP-REGULATION	Cholinergic imbalances occur after traumatic effects and in the initial stages of neurodegenerative diseases, but their long-lasting effects remained largely unexplained. To address this, we used TgS transgenic mice constitutively overexpressing synaptic acetylcholinesterase (AChE-S) and presenting a complex phenotype of progressive neuro-deterioration. T-1- and T-2- weighted magnetic resonance (MR) brain images appeared similar. However, diffusion-weighted MRI showed decreased baseline water apparent diffusion coefficient in the brains of TgS animals. Furthermore, contrast-enhanced MRI after gadolinium diethylenetriaminepentaacetic acid (Gd- DTPA) injection demonstrated slower recovery of normal signals in the TgS brains than with controls. Perfusion MR imaging and difference T-1 maps calculated from pre- postcontrast T1- weighted MR images indicated accumulation of more Gd- DTPA molecules in the TgS brains than in the parent strain, reflecting impaired blood-brain barrier (BBB) functioning in these transgenic mice. To explore the molecular mechanism(s) underlying these global phenotypes, we performed microarray analysis in the stress-controlling prefrontal cortex of TgS vs. strain-matched wild-type animals. Profound overexpression of numerous ion channels, transporters, and adhesion genes was confirmed by real time RT-PCR tests. Immunohistochemical and immuno-blot analyses revealed corresponding increases in the level and cellular distributions of the chloride channel CLCN3 and the water channel AQP4, both of which contribute to BBB maintenance. Our study attributes to balanced cholinergic neurotransmission, a central role in the brain's maintenance of water diffusion and ion transport, and indicates that chronic impairments in this maintenance facilitate neurodeterioration through interference with BBB function.	Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Israel Ctr Neuronal Computat, IL-91904 Jerusalem, Israel; Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Chem, Ramat Aviv, Israel; Wohl Inst Adv Imaging, Tel Aviv Sourasky Med Ctr, Human Brain Imaging Unit, Tel Aviv, Israel	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@cc.huji.ac.il		assaf, yaniv/0000-0001-6828-7595; Soreq, Hermona/0000-0002-0955-526X; Meshorer, Eran/0000-0003-4777-986X			Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Andres C, 1997, P NATL ACAD SCI USA, V94, P8173, DOI 10.1073/pnas.94.15.8173; Arreola J, 2002, J PHYSIOL-LONDON, V545, P207, DOI 10.1113/jphysiol.2002.021980; BADAUT J, 2002, J CEREB BLOOD FLOW M, V22, P367, DOI DOI 10.1097/00004647-200204000-00001; Beeri R, 1997, J NEUROCHEM, V69, P2441; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; Benveniste H, 2002, PROG NEUROBIOL, V67, P393, DOI 10.1016/S0301-0082(02)00020-5; Birikh KR, 2003, P NATL ACAD SCI USA, V100, P283, DOI 10.1073/pnas.0135647100; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Cao H, 1996, BIOCHEM BIOPH RES CO, V227, P266, DOI 10.1006/bbrc.1996.1499; CHEN Y, 2003, P NATL ACAD SCI US; Cho H, 1998, EXP BRAIN RES, V122, P227, DOI 10.1007/s002210050510; Cohen O, 2002, MOL PSYCHIATR, V7, P874, DOI 10.1038/sj.mp.4001103; Darboux I, 1996, EMBO J, V15, P4835, DOI 10.1002/j.1460-2075.1996.tb00864.x; DELAESCALERA S, 1990, EMBO J, V9, P3593, DOI 10.1002/j.1460-2075.1990.tb07570.x; Erb C, 2001, J NEUROCHEM, V77, P638, DOI 10.1046/j.1471-4159.2001.00287.x; Esposito P, 2001, BRAIN RES, V888, P117, DOI 10.1016/S0006-8993(00)03026-2; Farchi N, 2003, J PHYSIOL-LONDON, V546, P165, DOI 10.1113/jphysiol.2002.030841; Forch P, 2001, APOPTOSIS, V6, P463, DOI 10.1023/A:1012441824719; Franklin KBJ, 2001, MOUSE BRAIN STEROTAX; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; Grauer E, 2001, LIFE SCI, V68, P985, DOI 10.1016/S0024-3205(00)01000-6; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HOSSMANN KA, 1995, CEREBROVAS BRAIN MET, V7, P187; Johnson MD, 2002, J BIOL CHEM, V277, P23000, DOI 10.1074/jbc.M201907200; Le Bihan D, 2002, NMR BIOMED, V15, P431, DOI 10.1002/nbm.798; Lu H, 2003, CHINESE MED J-PEKING, V116, P1063; Lupien SJ, 2001, BEHAV BRAIN RES, V127, P137, DOI 10.1016/S0166-4328(01)00361-8; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; McDaniel B, 2001, NEUROIMAGE, V14, P1244, DOI 10.1006/nimg.2001.0934; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Moghaddam B, 2002, BIOL PSYCHIAT, V51, P775, DOI 10.1016/S0006-3223(01)01362-2; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nico B, 2001, J CELL SCI, V114, P1297; Omori N, 2002, BRAIN RES, V954, P317, DOI 10.1016/S0006-8993(02)03366-8; Ovadia H, 2001, BRAIN RES, V905, P21, DOI 10.1016/S0006-8993(01)02361-7; Park SE, 2004, CANCER RES, V64, P2652, DOI 10.1158/0008-5472.CAN-04-0649; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; SCHAEFFER E, 1994, P NATL ACAD SCI USA, V91, P3882, DOI 10.1073/pnas.91.9.3882; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SHARMA HS, 1988, NEUROSCI RES, V5, P224, DOI 10.1016/0168-0102(88)90051-X; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Stark D, 1999, MAGNETIC RESONANCE I, V1; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Tomkins O, 2001, CELL MOL NEUROBIOL, V21, P675, DOI 10.1023/A:1015147920283; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; van Eden CG, 2000, PROG BRAIN RES, V126, P49; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wang GX, 2003, AM J PHYSIOL-HEART C, V285, pH1453, DOI 10.1152/ajpheart.00244.2003; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; Wilson JTL, 2003, J NEUROL NEUROSUR PS, V74, P841, DOI 10.1136/jnnp.74.7.841; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100; Yongbi MN, 1997, NMR BIOMED, V10, P79, DOI 10.1002/(SICI)1099-1492(199704)10:2<79::AID-NBM449>3.0.CO;2-K; Zhang ZG, 2001, J CEREBR BLOOD F MET, V21, P541, DOI 10.1097/00004647-200105000-00008	62	29	29	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					910	922		10.1096/fj.04-2957com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	WOS:000230207800038	15923401				2021-06-18	
J	Hellmich, HL; Garcia, JM; Shimamura, M; Shah, SA; Avila, MA; Uchida, T; Parsley, MA; Capra, BA; Eidson, KA; Kennedy, DR; Winston, JH; DeWitt, DS; Prough, DS				Hellmich, HL; Garcia, JM; Shimamura, M; Shah, SA; Avila, MA; Uchida, T; Parsley, MA; Capra, BA; Eidson, KA; Kennedy, DR; Winston, JH; DeWitt, DS; Prough, DS			Traumatic brain injury and hemorrhagic hypotension suppress neuroprotective gene expression in injured hippocampal neurons	ANESTHESIOLOGY			English	Article							NF-KAPPA-B; MICROARRAY ANALYSIS; NEUROTROPHIC FACTOR; CONSEQUENCES; ANTIOXIDANTS; ACTIVATION; MECHANISMS; RESPONSES; SHOCK	Background: After traumatic brain injury, memory dysfunction is due in part to damage to the hippocampus. To study the molecular mechanisms of this selective vulnerability, the authors used laser capture microdissection of neurons stained with Fluoro-Jade to directly compare gene expression in injured (Fluoro-jade-positive) and adjacent uninjured (FluoroJade-negative) rat hippocampal neurons after traumatic brain injury and traumatic brain injury plus hemorrhagic hypotension. Methods: Twelve isoflurane-anesthetized Sprague-Dawley rats underwent moderate (2.0 atm) fluid percussion traumatic brain injury followed by either normotension or hemorrhagic hypotension. Animals were killed 24 h after injury. Frozen brain sections were double stained with 1% cresyl violet and 0.001% Fluoro-Jade. RNA from 10 Fluoro-jade-positive neurons and 10 Fluoro-Jade-negative neurons, obtained from the hippocampal CA1, CA3, and dentate gyrus subfields using laser capture microdissection, was linearly amplified and analyzed by quantitative ribonuclease protection assay for nine neuroprotective and apoptosis-related genes. Results: In injured CA3 neurons, expression of the neuroprotective genes glutathione peroxidase 1, heme oxygenase 1, and brain-derived neurotrophic factor was significantly decreased compared with that of adjacent uninjured neurons. Superimposition of hemorrhagic hypotension was associated with downregulation of neuroprotective genes in both injured and uninjured neurons of all subregions. Expression of apoptosis-related genes did not vary between injured and uninjured neurons, with or without superimposed hemorrhage. Conclusions: The authors show, in the first direct comparison of messenger RNA levels in injured and uninjured hippocampal neurons, that injured neurons express lower levels of neuroprotective genes than adjacent uninjured neurons.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Off Biostat, Galveston, TX USA; Univ Texas, Med Branch, Div Gastroenterol, Dept Internal Med, Galveston, TX USA; Yokohama City Univ, Sch Med, Dept Neurol, Yokohama, Kanagawa, Japan	Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhellmic@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS 42849-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042849] Funding Source: NIH RePORTER		Ahlemeyer B, 2001, BRAIN RES, V890, P338, DOI 10.1016/S0006-8993(00)03202-9; Asahi M, 2001, J NEUROSCI, V21, P7724; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Bota M, 2003, NAT NEUROSCI, V6, P795, DOI 10.1038/nn1096; Cheng Y, 1997, ANN NEUROL, V41, P521, DOI 10.1002/ana.410410416; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Egan TD, 1999, ANESTHESIOLOGY, V91, P156, DOI 10.1097/00000542-199907000-00024; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a; Furling D, 2000, P NATL ACAD SCI USA, V97, P4351, DOI 10.1073/pnas.060574597; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; Ho YS, 1998, ENVIRON HEALTH PERSP, V106, P1219, DOI 10.2307/3433989; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Humphrey MF, 1997, EXP EYE RES, V64, P361, DOI 10.1006/exer.1996.0219; Kamme F, 2003, J NEUROSCI, V23, P3607; Kieran D, 2004, NAT MED, V10, P402, DOI 10.1038/nm1021; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Longo VD, 2002, CELL MOL LIFE SCI, V59, P903, DOI 10.1007/s00018-002-8477-8; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Maines MD, 2002, METHOD ENZYMOL, V353, P374; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; Martin-Villalba A, 1998, MOL BRAIN RES, V62, P158, DOI 10.1016/S0169-328X(98)00239-3; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McLaughlin B, 2003, P NATL ACAD SCI USA, V100, P715, DOI 10.1073/pnas.0232966100; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Pennypacker KR, 2001, EXP NEUROL, V172, P307, DOI 10.1006/exnr.2001.7817; Rossler OG, 2004, J NEUROCHEM, V88, P1240, DOI 10.1046/j.1471-4159.2003.02255.x; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sheng HX, 2002, DRUG NEWS PERSPECT, V15, P654, DOI 10.1358/dnp.2002.15.10.740236; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Szabo A, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r59; The SAS Institute, 1999, SAS STAT US GUID VER; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; ZENG YC, 1995, MECH AGEING DEV, V79, P169, DOI 10.1016/0047-6374(94)01559-5	50	29	29	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	APR	2005	102	4					806	814		10.1097/00000542-200504000-00017			9	Anesthesiology	Anesthesiology	910IG	WOS:000227923900016	15791111				2021-06-18	
J	Kurz, JE; Parsons, JT; Rana, A; Gibson, CJ; Hamm, RJ; Churn, SB				Kurz, JE; Parsons, JT; Rana, A; Gibson, CJ; Hamm, RJ; Churn, SB			A significant increase in both basal and maximal calcineurin activity following fluid percussion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						calcium; calmodulin; hippocampus; phosphatase; post-translational modification	TRAUMATIC BRAIN-INJURY; APOPTOTIC CELL-DEATH; GABA(A) RECEPTOR; NITRIC-OXIDE; KINASE-II; CALCIUM; PHOSPHORYLATION; NEURONS; PHOSPHATASE; MODEL	Calcineurin, a neuronally enriched, calcium-stimulated phosphatase, is an important modulator of many neuronal processes, including several that are physiologically related to the pathology of traumatic brain injury. This study examined the effects of moderate, central fluid percussion injury on the activity of this important neuronal enzyme. Animals were sacrificed at several time-points post-injury and cortical, hippocampal, and cerebellar homogenates were assayed for calcineurin activity by dephosphorylation of p-nitrophenol phosphate. A significant brain injury-dependent increase was observed in both hippocampal and cortical homogenates under both basal and maximally-stimulated reaction conditions. This increase persisted 2-3 weeks post-injury. Brain injury did not alter substrate affinity, but did induce a significant increase in the apparent maximal dephosphorylation rate. Unlike the other brain regions, no change in calcineurin activity was observed in the cerebellum following brain injury. No brain region tested displayed a significant change in calcineurin enzyme levels as determined by Western blot, demonstrating that increased enzyme synthesis was not responsible for the observed increase in activity. The data support the conclusion that fluid percussion injury results in increased calcineurin activity in the rat forebrain. This increased activity has broad physiological implications, possibly resulting in altered cellular excitability or a greater likelihood of neuronal cell death.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Churn, SB (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurol, Box 980599, Richmond, VA 23298 USA.	sbchurn@vcu.edu		Kurz, Jonathan/0000-0002-2259-4263	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS025630] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 07288, P01 NS 25630, R01 NS 399700] Funding Source: Medline		Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Amico C, 1998, NEUROSCIENCE, V84, P529, DOI 10.1016/S0306-4522(97)00555-1; Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; BAUGGRASS R, 2001, J BIOL CHEM, V276, P47914; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; CHEN QX, 1995, J PHYSIOL-LONDON, V482, P353, DOI 10.1113/jphysiol.1995.sp020522; CHEN QX, 1990, J PHYSIOL-LONDON, V420, P207, DOI 10.1113/jphysiol.1990.sp017908; CHURN SB, 1992, J CEREBR BLOOD F MET, V12, P784, DOI 10.1038/jcbfm.1992.109; CHURN SB, 1995, J NEUROSCI, V15, P3200; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EASTER SS, 1993, J NEUROSCI, V13, P285; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; Huang RQ, 1998, J PHARMACOL EXP THER, V286, P243; Jayaraman T, 2000, J BIOL CHEM, V275, P6417, DOI 10.1074/jbc.275.9.6417; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kurz JE, 2003, NEUROBIOL DIS, V14, P483, DOI 10.1016/j.nbd.2003.08.018; Kurz JE, 2001, J NEUROCHEM, V78, P304, DOI 10.1046/j.1471-4159.2001.00426.x; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; Lu YM, 2000, NEURON, V26, P197, DOI 10.1016/S0896-6273(00)81150-2; Luo Chun, 2002, Chin J Traumatol, V5, P24; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033; Matsuda T, 1998, J NEUROCHEM, V70, P2004; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; MONCADA S, 1991, PHARMACOL REV, V43, P109; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; PALLEN CJ, 1983, J BIOL CHEM, V258, P8550; PALLEN CJ, 1985, ARCH BIOCHEM BIOPHYS, V237, P281, DOI 10.1016/0003-9861(85)90279-6; Pyrzynska B, 2001, NEUROCHEM INT, V38, P409, DOI 10.1016/S0197-0186(00)00105-4; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Riedel G, 1999, CELL MOL LIFE SCI, V55, P549, DOI 10.1007/s000180050313; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; RINK A, 1995, AM J PATHOL, V147, P1575; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Springer JE, 2000, J NEUROSCI, V20, P7246; SZABO I, 1991, J BIOL CHEM, V266, P3376; TALLANT EA, 1988, BIOCHEMISTRY-US, V27, P2205, DOI 10.1021/bi00406a059; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Tymianski M, 1996, NEUROSURGERY, V38, P1176; WANG KKW, 1989, BIOCHEM CELL BIOL, V67, P703, DOI 10.1139/o89-105; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	62	29	30	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2005	22	4					476	490		10.1089/neu.2005.22.476			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	920YM	WOS:000228731400005	15853464				2021-06-18	
J	McNally, HA; Rajwa, B; Sturgis, J; Robinson, JP				McNally, HA; Rajwa, B; Sturgis, J; Robinson, JP			Comparative three-dimensional imaging of living neurons with confocal and atomic force microscopy	JOURNAL OF NEUROSCIENCE METHODS			English	Article						atomic force microscopy; confocal laser scanning microscopy; neurogenesis; neurotrauma; neurobiology	GLIAL-CELLS	Atomic force microscopy applications extend across a number of fields; however, limitations have reduced its effectiveness in live cell analysis. This report discusses the use of AFM to evaluate the three-dimensional (3-D) architecture of living chick dorsal root ganglia and sympathetic ganglia. These data sets were compared to similar images acquired with confocal laser scanning microscopy of identical cells. For this comparison we made use of visualization techniques which were applicable to both sets of data and identified several issues when coupling these technologies. These direct comparisons offer quantitative validation and confirmation of the character of novel images acquired by AFM. This paper is one in a series emphasizing various new applications of AFM in neurobiology. (C) 2004 Elsevier B.V. All rights reserved.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47906 USA; Purdue Univ, Sch Vet Med, Cytometry Labs, W Lafayette, IN 47907 USA; Purdue Univ, Sch Engn, Dept Biomed Engn, W Lafayette, IN 47907 USA	McNally, HA (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47906 USA.	menallyh@purdue.edu	Robinson, Joseph P/K-8492-2012; Robinson, Joseph/AAA-1001-2020; Rajwa, Bartek/B-3169-2009	Robinson, Joseph/0000-0001-8383-3240; Rajwa, Bartek/0000-0001-7540-8236			Abramoff MD, 2002, IEEE T MED IMAGING, V21, P296, DOI 10.1109/TMI.2002.1000254; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Gallant PE, 1997, J NEUROTRAUM, V14, P811, DOI 10.1089/neu.1997.14.811; HANSMA PK, 1994, APPL PHYS LETT, V64, P1738, DOI 10.1063/1.111795; Henderson E, 1993, Neuroimage, V1, P145, DOI 10.1006/nimg.1993.1007; Hennig AK, 1998, J NEUROSCI, V18, P3282; HIGGINS D, 1998, CULTURING NERVE CELL; Jena BP, 1997, CELL BIOL INT, V21, P683, DOI 10.1006/cbir.1997.0212; LAL R, 1995, AM J PHYSIOL-CELL PH, V269, pC275; LEVITAN IB, 1991, NEURON CELL MOL BIOL; MAHANTHAPPA NK, 1998, CUTURING NERVE CELLS; Matsumoto B., 2002, CELL BIOL APPL CONFO; McNally HA, 2004, J NEUROCYTOL, V33, P251, DOI 10.1023/B:NEUR.0000030700.48612.0b; Melling M, 2001, NEUROIMAGE, V14, P1348, DOI 10.1006/nimg.2001.0924; MORRIS VJ, 2001, ATOMIC FORCE MICROSC; Niell CM, 2004, ANNU REV PHYSIOL, V66, P771, DOI 10.1146/annurev.physiol.66.082602.095217; PARPURA V, 1993, J CELL SCI, V104, P427; Pawley J. B., 1995, HDB BIOL CONFOCAL MI; Peters A., 1991, FINE STRUCTURES NERV; Piston DW, 1998, BIOL BULL-US, V195, P1, DOI 10.2307/1542768; RICCI D, 2004, ATOMIC FORCE MICROSC; Ryan TA, 2001, CURR OPIN NEUROBIOL, V11, P544, DOI 10.1016/S0959-4388(00)00247-6; Ryan TA, 1997, NATURE, V388, P478, DOI 10.1038/41335; Sah R, 1999, J NEUROSCI, V19, P9209; SCHABERT F, 1994, ULTRAMICROSCOPY, V53, P147, DOI 10.1016/0304-3991(94)90005-1; Tojima T, 2000, NEUROSCIENCE, V101, P471, DOI 10.1016/S0306-4522(00)00320-1; VESENKA J, 1995, BIOTECHNIQUES, V19, P240; Weissmuller G, 2000, NEUROSCI RES, V38, P217, DOI 10.1016/S0168-0102(00)00159-0; Young IT, 1996, IEEE ENG MED BIOL, V15, P59, DOI 10.1109/51.482844	29	29	31	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAR 30	2005	142	2					177	184		10.1016/j.jneumeth.2004.08.018			8	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	901FT	WOS:000227269100002	15698657	Green Published			2021-06-18	
J	Arataki, S; Tomizawa, K; Moriwaki, A; Nishida, K; Matsushita, M; Ozaki, T; Kunisada, T; Yoshida, A; Inoue, H; Matsui, H				Arataki, S; Tomizawa, K; Moriwaki, A; Nishida, K; Matsushita, M; Ozaki, T; Kunisada, T; Yoshida, A; Inoue, H; Matsui, H			Calpain inhibitors prevent neuronal cell death and ameliorate motor disturbances after compression-induced spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; motor neuron; SCI; spinal cord; terminal deoxynucleotidyl transferase-uridine nucleotide end-labeling technique	TRAUMATIC BRAIN-INJURY; FODRIN PROTEOLYSIS; I ACTIVATION; APOPTOSIS; CASPASE-3; DEGRADATION; EXPRESSION; SURVIVAL; PRETREATMENT; RELEASE	Traumatic spinal cord injury (SCI) results in widespread neuronal cell death. Recent studies have suggested that activated calpain mediates neuronal cell death in the central nervous system. We conducted a study to determine whether calpain mediates neuronal cell death in the motor neurons of the spinal cord after SCI, and whether postinjury administration of the calpain inhibitors N-acetyl-Leu-Leu-Met-CHO (ALLM) and calpain inhibitor III (CI III) (MDL28170) reduces the motor disturbances in rats with a model of SCI. Adult male Wistar rats were subjected to SCI by application of a 20-g weight impactor probe to the spinal cord at T12 for 20 min. The rats were divided into three groups according to whether they were injected intravenously with 0.05-2.5 mg/kg ALLM, 10 mg/kg CI III, or 0.1% DMSO as a control every 24 h for I week after SCI. Calpain was activated in the spinal cord at 8 h, 24 h, and 5 days after SCI, and administration of ALLM inhibited its activation. ALLM, as compared to the DMSO vehicle alone, also significantly reduced the number of motor neurons in spinal-cord lesions that were positively labeled at 24 h after SCI with the terminal deoxynucleotidyl transferase-uridine nucleotide end-labeling (TUNEL) technique. Additionally, both the inclined plane test and footprint analysis showed markedly better motor activity after 4 weeks in rats injected with ALLM or CI III than in rats given vehicle only. These results suggest that activation of calpain plays a critical role in the neuronal cell death that follows SCI, and that calpain inhibitors may have benefit in treating the motor disturbances that follow SCI.	Okayama Univ, Grad Sch Med & Dent, Dept Physiol, Okayama, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Sci Funct Recovery & Reconstruct, Okayama, Japan	Tomizawa, K (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Physiol, 2-5-1 Shikata, Okayama, Japan.	tomikt@md.okayama-u.ac.jp	Tomizawa, Kazuhito/F-2405-2015; NISHIDA, Keiichiro/B-2014-2011	Tomizawa, Kazuhito/0000-0002-5663-2627; 	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17500212, 16500200, 17022028] Funding Source: KAKEN		Anthes DL, 1996, NEUROSURGERY, V39, P804, DOI 10.1097/00006123-199610000-00032; Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Dong HX, 2003, J NEUROSCI, V23, P8682; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; IIZUKA H, 1986, J NEUROSURG, V65, P92, DOI 10.3171/jns.1986.65.1.0092; IWASAKI Y, 1987, BRAIN RES, V406, P99, DOI 10.1016/0006-8993(87)90773-6; IWASAKI Y, 1985, BRAIN RES, V347, P124, DOI 10.1016/0006-8993(85)90897-2; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kitagawa K, 1999, J NEUROSCI RES, V55, P643, DOI 10.1002/(SICI)1097-4547(19990301)55:5<643::AID-JNR11>3.0.CO;2-V; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; NICHOLSON DW, 1997, TRENDS BIOCHEM SCI, V22, P229; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Ray SK, 2001, BRAIN RES, V916, P115, DOI 10.1016/S0006-8993(01)02874-8; Ray SK, 1999, ANN NY ACAD SCI, V890, P261, DOI 10.1111/j.1749-6632.1999.tb08001.x; Ray SK, 2000, BRAIN RES, V867, P80, DOI 10.1016/S0006-8993(00)02260-5; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Schaecher KE, 2001, NEUROCHEM RES, V26, P731, DOI 10.1023/A:1010903823668; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Shields DC, 1998, J NEUROSCI RES, V53, P482, DOI 10.1002/(SICI)1097-4547(19980815)53:4<482::AID-JNR10>3.0.CO;2-4; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Taoka Y, 1997, J NEUROSURG, V86, P1007, DOI 10.3171/jns.1997.86.6.1007; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Taoka Y, 1998, J NEUROSCI, V18, P1393; TATOR CH, 1991, NEUROCHIRURGIE, V37, P291; Tomizawa K, 2002, J NEUROSCI, V22, P2590, DOI 10.1523/JNEUROSCI.22-07-02590.2002; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wu HY, 2003, NEUROSCI RES, V47, P131, DOI 10.1016/S0168-0102(03)00195-0; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; Zhang SX, 2000, J NEUROPATH EXP NEUR, V59, P287, DOI 10.1093/jnen/59.4.287; Zhang SX, 2003, J NEUROTRAUM, V20, P59, DOI 10.1089/08977150360517182	38	29	34	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2005	22	3					398	406		10.1089/neu.2005.22.398			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	911QM	WOS:000228019500006	15785234				2021-06-18	
J	Isaksson, J; Farooque, M; Olsson, Y				Isaksson, J; Farooque, M; Olsson, Y			Improved functional outcome after spinal cord injury in iNOS-deficient mice	SPINAL CORD			English	Article						spinal cord injury; mouse; nitric oxide; iNOS	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; AMINOGUANIDINE TREATMENT; COMPRESSION INJURY; L-ARGININE; EXPRESSION; RATS; SUPEROXIDE; ROLES	Study design: Functional outcome was evaluated following experimental compression-type spinal cord injury (SCI) in wild-type mice and knockout mice, lacking the inducible nitric oxide synthase ( iNOS) gene. Objectives: To evaluate the role of the nitric oxide generating enzyme iNOS in SCI. Methods: The experimental animals were subjected to an extradural compression of the thoracic spinal cord. Functional outcome was studied during the first 2 weeks post-injury using a scoring system for assessment of hind limb motor function. Results: Injury resulted in initial paraplegia followed by gradual improvement of motor function in most cases. Mice lacking the iNOS gene ( iNOS -/-) clearly tended to have a better functional outcome than wild-type mice. The difference was significant on day 14 after injury. Conclusion: In accordance with a few earlier experimental studies, showing beneficial effects of pharmacological iNOS inhibition, the present report would indicate a destructive influence of iNOS following spinal cord trauma.	Univ Uppsala Hosp, Dept Genet & Pathol, Res Grp Neuropathol, Uppsala, Sweden; VA Med Ctr, Neurobiol Res Lab, Kansas City, MO USA	Isaksson, J (corresponding author), Karolinska Hosp, Dept Neurol, S-17176 Stockholm, Sweden.						BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Cohen TI, 1996, J NEUROTRAUM, V13, P361, DOI 10.1089/neu.1996.13.361; Farooque M, 2000, ACTA NEUROPATHOL, V100, P13, DOI 10.1007/s004010051187; Farooque M, 2001, J NEUROTRAUM, V18, P105, DOI 10.1089/089771501750055811; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323	17	29	30	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393			SPINAL CORD	Spinal Cord	MAR	2005	43	3					167	170		10.1038/sj.sc.3101672			4	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	902HF	WOS:000227344800004	15520837	Bronze			2021-06-18	
J	Skoglund, TS; Nellgard, B				Skoglund, TS; Nellgard, B			Long-time outcome after transient transtentorial herniation in patients with traumatic brain injury	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						outcome; transtentorial herniation; traumatic brain injury	HEAD-INJURY; THERAPY; SECONDARY; RECOVERY; SCALE; UNIT	Background: This study investigates mortality and morbidity in patients with traumatic brain injury (TBI) who developed episode(s) of transtentorial herniation. The transtentorial herniation was defined as a deterioration of consciousness accompanied by uni- or bilateral pupil dilatation. Methods: The medical records of all patients with traumatic brain injury admitted during 1999 to the Neuro- or General Intensive Care Units at Sahlgrenska University Hospital were analyzed, and patients with at least one episode of transtentoryal herniation were includInformation regarding patient age, gender, type of trauma, initial GCS, precipitating reason for herniation, uni-/bilateral pupil dilatation, treatment(s) and outcome after at least 6 months, assessed with the Glasgow Outcome Scale (GOS), was collected from medical records. Results: The study included 27 patients, average age 44 years (range 6-81), with a male proportion of 81%. The majority of the patients were victims of traffic accidents and falls. The results demonstrated that 16/27(59%) of the patients had a favorable outcome (GOS 4/5), 4/27(15%) were severely disabled (GOS 3), none was vegetative (GOS 2) and 7/27(26%) died (GOS 1). When analyzing patient subgroups, best outcome was found in children where 3/4 (75%) had a GOS 4/5. Conclusion: Transtentorial herniation is a serious consequence of supratentorial edema/mass lesions in patients with TBI. However, with aggressive neurointensive care and neurosurgical treatments we found a 59% patient incidence of a favorable outcome.	Sahlgrens Univ Hosp, Dept Neurosurg, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Anaesthesia & Intens Care Med, S-41345 Gothenburg, Sweden	Skoglund, TS (corresponding author), Sahlgrens Univ Hosp, Dept Neurosurg, Bla Straket 7, S-41345 Gothenburg, Sweden.	thomas.skoglund@vgregion.se					ANDREWS BT, 1988, J NEUROSURG, V69, P518, DOI 10.3171/jns.1988.69.4.0518; ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; BRENDLER SJ, 1970, BRAIN, V93, P381, DOI 10.1093/brain/93.2.381; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; JENNETT B, 1975, LANCET, V1, P480; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Meyer A, 1920, ARCH NEURO PSYCHIATR, V4, P387, DOI 10.1001/archneurpsyc.1920.02180220036003; Mirski MA, 2001, J NEUROSURG ANESTH, V13, P83, DOI 10.1097/00008506-200104000-00004; MUNRO D, 1952, NEW ENGL J MED, V247, P699, DOI 10.1056/NEJM195211062471901; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; NUSSBAUM ES, 1991, NEUROSURGERY, V29, P62, DOI 10.1227/00006123-199107000-00010; PLUM E, 1980, DIAGNOSIS STUPOR COM, P87; Qureshi AI, 2000, CRIT CARE MED, V28, P1556, DOI 10.1097/00003246-200005000-00049; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Verderber L, 1990, J Tenn Med Assoc, V83, P119; ZERVAS NT, 1972, NEW ENGL J MED, V286, P1075, DOI 10.1056/NEJM197205182862003	20	29	32	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2005	49	3					337	340		10.1111/j.1399-6576.2005.00624.x			4	Anesthesiology	Anesthesiology	902WI	WOS:000227387000013	15752399				2021-06-18	
J	David, M; Karmrodt, J; Weiler, N; Scholz, A; Markstaller, K; Eberle, B				David, M; Karmrodt, J; Weiler, N; Scholz, A; Markstaller, K; Eberle, B			High-frequency oscillatory ventilation in adults with traumatic brain injury and acute respiratory distress syndrome	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						acute respiratory distress syndrome; high-frequency oscillatory ventilation; intracranial pressure; traumatic brain injury	END-EXPIRATORY PRESSURE; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; MANAGEMENT	Background: This study observed adverse events of rescue treatment with high-frequency oscillatory ventilation (HFOV) in head-injured patients with acute respiratory distress syndrome (ARDS). Methods: Data of five male patients with ARDS and traumatic brain injury, median age 28 years, who failed to respond to conventional pressure-controlled ventilation (PCV) were analyzed retrospectively during HFOV. Adjusted mean airway pressure at initiation of HFOV was set to 5 cm H2O above the last measured mean airway pressure during PCV. Frequency of pulmonary air leak, mucus obstruction, tracheal injury, and need of HFOV termination due to increased intracranial pressure, decreased cerebral perfusion pressure, or deterioration in PaCO2 were analyzed. Results: During HFOV we found no complications. We recorded 390 datasets of intracranial pressure, cerebral perfusion pressure and PaCO2 simultaneously. Intracranial pressure increased (>25 mmHg) in 11 of 390 datasets, cerebral perfusion pressure was reduced (<70 mmHg) in 66 of 390 datasets, and PaCO2 variations (<4.7 kPa; >6.0 kPa) were observed in eight of 390 datasets after initiation of HFOV. All these alterations were responsive to treatment. PaO2/FIO2-ratio improved in four patients during HFOV. Conclusion: High-frequency oscillatory ventilation appears to be a promising alternative rescue treatment in head-injured patients with ARDS if continuous monitoring of intracranial pressure, cerebral perfusion pressure and PaCO2 are provided, in particular during initiation of HFOV.	Johannes Gutenberg Univ Mainz, Dept Anaesthesiol, D-55131 Mainz, Germany; Univ Kiel, Dept Anaesthesiol, Kiel, Germany; Univ Bern, Inselspital, Dept Anaesthesiol, CH-3010 Bern, Switzerland	David, M (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anaesthesiol, Langenbeckstr 1, D-55131 Mainz, Germany.	Matthias_David@gmx.de	Weiler, Norbert/E-5356-2010				*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Andersen FA, 2002, ACTA ANAESTH SCAND, V46, P1082, DOI 10.1034/j.1399-6576.2002.460905.x; Bein T, 2002, INTENS CARE MED, V28, P554, DOI 10.1007/s00134-002-1273-y; Bratton SL, 1997, NEUROSURGERY, V41, P1215, DOI 10.1097/00006123-199711000-00053; CHESNUT RM, 1997, J TRAUMA S, V42, P4; David M, 2003, INTENS CARE MED, V29, P1656, DOI 10.1007/s00134-003-1897-6; Derdak S, 2002, AM J RESP CRIT CARE, V166, P801, DOI 10.1164/rccm.2108052; Fort P, 1997, CRIT CARE MED, V25, P937, DOI 10.1097/00003246-199706000-00008; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Huynh T, 2002, J TRAUMA, V53, P488, DOI 10.1097/00005373-200209000-00016; LUCE JM, 1982, J APPL PHYSIOL, V52, P231; Marini JJ, 1996, CLIN CHEST MED, V17, P555, DOI 10.1016/S0272-5231(05)70331-2; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McGuire G, 1997, CRIT CARE MED, V25, P1059, DOI 10.1097/00003246-199706000-00025; Mehta S, 2001, CRIT CARE MED, V29, P1360, DOI 10.1097/00003246-200107000-00011; NISHIMURA M, 1992, CHEST, V101, P1681, DOI 10.1378/chest.101.6.1681; PINSKY M, 1991, AM REV RESPIR DIS, V143, P25, DOI 10.1164/ajrccm/143.1.25; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Videtta W, 2002, ACT NEUR S, V81, P93; 2000, J NEUROTRAUMA, V17, P479	21	29	32	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2005	49	2					209	214		10.1111/j.1399-6576.2004.00570.x			6	Anesthesiology	Anesthesiology	898FQ	WOS:000227062200014	15715623				2021-06-18	
J	Palmer, S; Bader, MK				Palmer, S; Bader, MK			Brain tissue oxygenation in brain death	NEUROCRITICAL CARE			English	Article						brain death; cerebral oxygen monitoring; traumatic brain injury; subarachnoid hemorrhage; neurosurgical critical care	DIAGNOSIS	Introduction: The value of brain tissue oxygenation (PbtO(2)) measurements in determining brain death is unknown. Methods: Eleven of 72 patients who had brain tissue oxygen monitors placed experienced brain death. Admission diagnoses included six severe traumatic brain injuries, one multiple trauma with cardiac arrest, one brain tumor, one subarachnoid hemorrhage, one intracerebral hemorrhage, and one cerebral stroke. Eleven males and zero females were studied, with an average age of 26 years (range: 20-70 years). Nine patients had Glasgow Coma Scores (GCS) of 3 on admission, one patient had a GCS of 5, and one patient had a GCS of 15. Results: Time from admission to declaration of brain death varied from 5 hours to 7 days; the most common interval was 1 or 2 days. Cerebral perfusion pressure (CPP) fell to 0 in eight patients, which indicated primary failure of cerebral perfusion. CPP stayed above 60 mmHg in three patients, indicating primary tissue failure, possibly of the cerebral microvasculature. PbtO(2) fell to 0 in all patients who experienced brain death, and all patients with PbtO(2) of 0 experienced brain death. None of the 61 patients who did not experience brain death had confirmed PbtO(2) readings of 0. Conclusion: PbtO(2) can be successfully and accurately used as a bedside adjunctive test for brain death. The use of PbtO(2) as a sole confirmatory test for brain death in the setting of an appropriate clinical examination will require the evaluation of a larger number of patients to assess its sensitivity and specificity.	Mission Hosp & Reg Med Ctr, Dept Neurosurg, Mission Viejo, CA 92651 USA	Palmer, S (corresponding author), Mission Hosp & Reg Med Ctr, Dept Neurosurg, NSMA 26732 Crown Valley Pkwy,Suite 561, Mission Viejo, CA 92651 USA.	sylvainpalmer@cox.net					[Anonymous], 1995, Neurology, V45, P1012; [Anonymous], 1976, BMJ-BRIT MED J, V2, P1187; [Anonymous], 1968, JAMA, V205, P337; BLACK PM, 1978, NEW ENGL J MED, V299, P338, DOI 10.1056/NEJM197808172990705; BULLOCK R, 1995, GUIDELINES MANAGEMEN; Capron AM, 2001, NEW ENGL J MED, V344, P1244, DOI 10.1056/NEJM200104193441611; Diaz-Reganon G, 2002, INTENS CARE MED, V28, P1724, DOI 10.1007/s00134-002-1543-8; Fisher C M, 1991, J Neurosci Nurs, V23, P330; Karakatsanis KG, 2002, ISSUES LAW MED, V18, P127; LANG CJG, 1995, NEUROLOGY, V45, P966, DOI 10.1212/WNL.45.5.966; Lovasik D, 2000, Crit Care Nurs Clin North Am, V12, P531; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; MOLLARET P., 1959, REV NEUROL [PARIS], V101, P3; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; PALMER S, 2001, EARLY CEREBRAL OXYGE; Swash M, 2002, NEUROLOGY, V58, P9, DOI 10.1212/WNL.58.1.9; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wijdicks EFM, 2002, NEUROLOGY, V58, P20, DOI 10.1212/WNL.58.1.20; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1003, DOI 10.1212/WNL.45.5.1003; 1976, BR MED J, V2, P1188	21	29	30	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2005	2	1					17	22		10.1385/NCC:2:1:017			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	945FU	WOS:000230489200004	16174963				2021-06-18	
J	Faden, AI; Knoblach, SM; Movsesyan, VA; Cernak, I				Faden, AI; Knoblach, SM; Movsesyan, VA; Cernak, I			Novel small peptides with neuroprotective and nootropic properties	JOURNAL OF ALZHEIMERS DISEASE			English	Article							TRAUMATIC BRAIN-INJURY; COGNITIVE RECOVERY; HORMONE TRH; ANALOG; METHYLPREDNISOLONE; NALOXONE; MOTOR; RATS	The tripeptide thyrotropin-releasing hormone (TRH) and/or related analogues have shown neuroprotective activity across multiple animal trauma models as well as in a small clinical trial of spinal cord injury. The metabolic product of TRH (cyclo-his-pro) retains physiological activity. We have developed a number of novel cyclic dipeptides that are structurally similar to cyclo-his-pro, and have examined their neuroprotective activity across multiple ire vitro models of neuronal injury and after traumatic brain injury (TB() in rodents. Four such compounds were found to reduce cell death after trophic withdrawal or traumatic injury in primary neuronal cultures; two also protected against glutamate or beta-amyloid neurotoxicity. All compounds significantly improved motor and cognitive recovery after controlled cortical impact injury in mice, and markedly reduced lesion volumes as shown by high field magnetic resonance imaging. Further, compound 35b, which is being developed for clinical trials, also showed considerable neuroprotection after fluid percussion induced TBI in rats, and improved cognitive function after daily administration in chronically brain injured rats. At a mechanistic level, the drugs attenuate both apoptotic and necrotic cell death in primary neuronal cultures, markedly reduce intracellular calcium accumulation after injury, and limit changes in mitochondrial membrane potential and associated cytochrome c release. In addition, microarray studies show that 356 reduces transcriptional changes after injury for a number of genes (and proteins) that may be associated with secondary injury, including cell cycle genes, aquaporins and cathepsins. It also upregulates brain-derived neurotrophic factor (BDNF), heat shock proteins (HSP) and hypoxia inducible factor (HIF). Thus, these novel dipeptides have multipotential actions that make them candidates for the treatment of both acute and chronic neurodegeneration.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA.	faden@gices.georgetown.edu	Cernak, Ibolja/A-6399-2008	Ibolja, Cernak/0000-0003-3214-698X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041119] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS41119] Funding Source: Medline		Allen JW, 2001, J NEUROSCI RES, V65, P45, DOI 10.1002/jnr.1126; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; FADEN AI, 1983, NEUROLOGY, V33, P673, DOI 10.1212/WNL.33.6.673; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FADEN AI, 1993, J NEUROTRAUM, V10, P101, DOI 10.1089/neu.1993.10.101; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1996, NEUROTRAUMA, P1479; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; KOSKINEN LOD, 1986, BRIT J PHARMACOL, V87, P509, DOI 10.1111/j.1476-5381.1986.tb10193.x; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; PRASAD C, 1995, PEPTIDES, V16, P151, DOI 10.1016/0196-9781(94)00017-Z; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8	18	29	30	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877			J ALZHEIMERS DIS	J. Alzheimers Dis.	DEC	2004	6	6		S			S93	S97					5	Neurosciences	Neurosciences & Neurology	900JT	WOS:000227211900014	15665420				2021-06-18	
J	Yune, TY; Lee, SM; Kim, SJ; Park, HK; Oh, YJ; Kim, YC; Markelonis, GJ; Oh, TH				Yune, TY; Lee, SM; Kim, SJ; Park, HK; Oh, YJ; Kim, YC; Markelonis, GJ; Oh, TH			Manganese superoxide dismutase induced by TNF-alpha is regulated transcriptionally by NF-kappa B after spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						Cu/ZnSOD; MnSOD; NF-kappa B; spinal cord injury; TNF-alpha; TNF-alpha neutralizing antibody	TUMOR-NECROSIS-FACTOR; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL CYTOCHROME-C; ENDOMETRIAL STROMAL CELLS; OXIDATIVE STRESS; TRANSGENIC MICE; MESSENGER-RNA; NEURODEGENERATIVE DISEASES; FUNCTIONAL RECOVERY	Antioxidant enzymes including superoxide dismutase (SOD) may play a role in the mechanism by which cells counteract the deleterious effects of reactive oxygen species (ROS) after spinal cord injury (SCI). Cu/Zn and MnSOD are especially potent scavengers of superoxide anion and likely serve important cytoprotective roles against cellular damage. We investigated expression of SOD after SCI to address its role during the early stages of injury. MnSOD activity was increased 4 h after SCI and persisted at elevated levels up to 24-48 h; by contrast, Cu/ZnSOD activity was not changed. `RT-PCR and Western blot analyses showed increased levels of MnSOD mRNA and protein, respectively, by 4 h and reached maximum levels by 24-48 h. Double immunostaining revealed that MnSOD protein was localized within neurons and oligodendrocytes. Tumor necrosis factor-alpha (TNFalpha) was administered locally into uninjured spinal cords to examine potential mechanisms for MnSOD induction after injury. TNF-alpha administered exogenously increased MnSOD expression in uninjured spinal cords. Western blot and immunostaining also revealed that a transcription factor, NF-kappaB, was activated and translocated into the nuclei of neurons and oligodendrocytes. By contrast, administration of neutralizing antibody against TNF-alpha into injured spinal cords attenuated the increase in MnSOD expression and activation of NF-kappaB. Double immunostaining revealed that MnSOD was co-localized with NF-kappaB in neurons and oligodendrocytes after SCI. These results suggest that TNF-alpha may be an inducer of NF-kappaB activation and MnSOD expression after SCI and that MnSOD expression induced by TNF-alpha is likely mediated through activation of NF-kappaB.	Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 136791, South Korea; Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Seoul Natl Univ, Coll Pharm, Seoul, South Korea; Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA	Yune, TY (corresponding author), Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 136791, South Korea.	rila@kist.re.kr					Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bethea JR, 1998, J NEUROSCI, V18, P3251; BEUTLER B, 1994, ANN NY ACAD SCI, V730, P118, DOI 10.1111/j.1749-6632.1994.tb44244.x; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; Blight AR, 1997, J NEUROTRAUM, V14, P89, DOI 10.1089/neu.1997.14.89; BLIGHT AR, 1992, J NEUROTRAUMA, V9, P83; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; BOWLING AC, 1995, LIFE SCI, V56, P1151, DOI 10.1016/0024-3205(95)00055-B; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Darville MI, 2000, ENDOCRINOLOGY, V141, P153, DOI 10.1210/en.141.1.153; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; DOUGALL WC, 1991, ENDOCRINOLOGY, V129, P2376, DOI 10.1210/endo-129-5-2376; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; EEARMJARDT JN, 2003, J NEUROTRAUM, V19, P1065; Fujimura M, 1999, J NEUROSCI, V19, P3414; Ghadge GD, 1997, J NEUROSCI, V17, P8756; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Guo Z, 2003, J BIOL CHEM, V278, P23570, DOI 10.1074/jbc.M303431200; HARRIS CA, 1991, J IMMUNOL, V147, P149; HASS MA, 1989, J CLIN INVEST, V83, P1241, DOI 10.1172/JCI114007; HASSAN HM, 1988, FREE RADICAL BIO MED, V5, P377, DOI 10.1016/0891-5849(88)90111-6; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; HO YS, 1987, NUCLEIC ACIDS RES, V15, P10070, DOI 10.1093/nar/15.23.10070; Hohmeier HE, 1998, J CLIN INVEST, V101, P1811, DOI 10.1172/JCI1489; Huang CY, 2001, J CEREBR BLOOD F MET, V21, P163, DOI 10.1097/00004647-200102000-00008; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Karube-Harada A, 2001, MOL HUM REPROD, V7, P1065, DOI 10.1093/molehr/7.11.1065; Keller JN, 1998, J NEUROSCI, V18, P687; Kim GM, 2001, J NEUROSCI, V21, P6617; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KINOUCHI K, 1991, BIOCHEM BIOPH RES CO, V181, P1532, DOI 10.1016/0006-291X(91)92113-X; Klivenyi P, 1998, NEUROBIOL DIS, V5, P253, DOI 10.1006/nbdi.1998.0191; Kondo T, 1997, J NEUROSCI, V17, P4180; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Li YQ, 1996, J CLIN INVEST, V97, P1605, DOI 10.1172/JCI118585; LIN PS, 1993, LYMPHOKINE CYTOK RES, V12, P303; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Liu XZ, 1997, J NEUROSCI, V17, P5395; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo J, 2002, SPINAL CORD, V40, P656, DOI 10.1038/sj.sc.3101363; Maehara K, 1999, FEBS LETT, V449, P115, DOI 10.1016/S0014-5793(99)00408-1; Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357-4310(00)01814-1; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Mu XJ, 2002, J NEUROTRAUM, V19, P917, DOI 10.1089/089771502320317078; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAKATA T, 1993, INT J CANCER, V55, P646, DOI 10.1002/ijc.2910550422; NELSON SK, 1995, J MOL CELL CARDIOL, V27, P223, DOI 10.1016/S0022-2828(08)80021-1; NOGAE C, 1995, J MOL CELL CARDIOL, V27, P2091, DOI 10.1016/S0022-2828(95)91155-3; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pan JZ, 2002, J NEUROSCI RES, V68, P315, DOI 10.1002/jnr.10215; Poynter ME, 2003, J IMMUNOL, V170, P6257, DOI 10.4049/jimmunol.170.12.6257; Rogers RJ, 2001, J BIOL CHEM, V276, P20419, DOI 10.1074/jbc.M008915200; Rosenfeld J, 1997, EXP NEUROL, V147, P37, DOI 10.1006/exnr.1997.6604; Saito A, 2003, J NEUROSCI, V23, P1710; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Siemankowski LM, 1999, FREE RADICAL BIO MED, V26, P919, DOI 10.1016/S0891-5849(98)00273-1; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Skaleric U, 2000, EUR J ORAL SCI, V108, P130, DOI 10.1034/j.1600-0722.2000.90771.x; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Sugino N, 2002, J CLIN ENDOCR METAB, V87, P3845, DOI 10.1210/jc.87.8.3845; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918; Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417; SYMONYAN MA, 1972, FEBS LETT, V28, P22, DOI 10.1016/0014-5793(72)80667-7; TAOKA Y, 1995, PARAPLEGIA, V33, P450, DOI 10.1038/sc.1995.98; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; VAN AD, 1996, SCIENCE, V274, P787; VISNER GA, 1990, J BIOL CHEM, V265, P2856; Wang CX, 2002, NEUROREPORT, V13, P1391, DOI 10.1097/00001756-200208070-00008; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150; WARNER GA, 1991, AM J PHYSIOL, V260, P296; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116	96	29	30	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1778	1794		10.1089/0897715042664858			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400009	15684769				2021-06-18	
J	Hinton-Bayre, AD; Geffen, G; Friis, P				Hinton-Bayre, AD; Geffen, G; Friis, P			Presentation and mechanisms of concussion in professional Rugby League football	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article								The present study prospectively recorded the circumstances, incidence, mechanisms, injury detection and presentation of concussion in Rugby League. Forty-three consecutive concussions were recorded over three competitive seasons in 175 professional Rugby League players. Data showed (i) the incidence of concussion ranged from 5.9 to 9.8 injuries/1000 player hours across grades - except when age-group players were mismatched (18.4); (ii) 'head-high tackles' accounted for a significant number of concussions; (iii) concussion rarely involved a loss of consciousness with the most common indicators of concussion being amnesia, headache and unsteadiness, with the mechanism of injury often missed; and (iv) concussion often occurs concurrently with other injuries. Concussion (including repeated episodes) is a common injury in Rugby League. Systematic mental status questioning is warranted whenever concussion is suspected. Coaches, trainers and players need more education in the recognition and management of concussion. Stricter penalties for illegal 'head-high' tackling are strongly recommended.	Univ Queensland, Cognit Psychol Lab, St Lucia, Qld 4067, Australia; Univ Queensland, Sch Med, St Lucia, Qld 4067, Australia; Holy Spirit Hosp, Brisbane Orthopaed & Sports Med Ctr, Brisbane, Qld, Australia	Hinton-Bayre, AD (corresponding author), Univ Queensland, Cognit Psychol Lab, St Lucia, Qld 4067, Australia.						Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Estell J, 1995, Aust J Sci Med Sport, V27, P95; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; *NAT HLTH MRC, 1994, FOOTB INJ HEAD NECK; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x	6	29	30	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	SEP	2004	7	3					400	404		10.1016/S1440-2440(04)80035-5			5	Sport Sciences	Sport Sciences	861CV	WOS:000224394600015	15518305				2021-06-18	
J	Hoane, MR; Lasley, LA; Akstulewicz, SL				Hoane, MR; Lasley, LA; Akstulewicz, SL			Middle age increases tissue vulnerability and impairs sensorimotor and cognitive recovery following traumatic brain injury in the rat	BEHAVIOURAL BRAIN RESEARCH			English	Article						aging; recovery of function; traumatic brain injury; rat; behavior; cognition	FACILITATE RECOVERY; FUNCTIONAL RECOVERY; MAGNESIUM THERAPY; NMDA ANTAGONISTS; CORTEX LESIONS; WATER MAZE; DEFICITS; ATROPHY; MODEL	With increasing age comes an increased risk for sustaining traumatic brain injuries (TBI). However, the effect of age is rarely studied in animal models of TBI. The present study evaluated the effect of increased age on recovery of function following bilateral medial frontal cortex injury. Groups of young (3 months) and middle-aged (14 months) rats received bilateral frontal cortex contusions or sham injuries. The rats were tested on a variety of tests to measure sensorimotor performance (bilateral tactile adhesive removal test), skilled forelimb use (staircase test), and the acquisition of reference and working memory in the Morris water maze. Results indicated that injury produced significant impairments on all behavioral tests compared to sham controls. Middle-aged rats that received cortical contusions were significantly impaired on the bilateral tactile adhesive removal test, acquisition of a reference memory task, and working memory compared to young-injured rats. Histological analysis showed that middle-aged rats developed significantly larger lesion cavities but did not show an increase in the number of glial fibrillary acidic protein (GFAP(+)) cells compared to young-injured rats. Age alone also significantly impaired function on the bilateral adhesive tactile removal test, skilled forelimb use, the acquisition of a reference memory task, and also increased the number of GFAP(+) cells compared to young rats. These results indicate that middle-aged rats respond to brain injury differently than young rats and that age is an important factor to consider in pre-clinical efficacy studies. (C) 2003 Elsevier B.V. All rights reserved.	E Carolina Univ, Dept Psychol, Brain Injury Lab, Greenville, NC 27858 USA; E Carolina Univ, Program Neurosci, Greenville, NC 27858 USA	Hoane, MR (corresponding author), E Carolina Univ, Dept Psychol, Brain Injury Lab, Rawl 217, Greenville, NC 27858 USA.	hoanem@mail.ecu.edu; lasleyl@mail.ecu.edu; akstulewicza@mail.ecu.edu		Hoane, Michael/0000-0001-7779-2657			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Albeck D, 2003, BRAIN RES, V967, P306, DOI 10.1016/S0006-8993(03)02272-8; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; BARTH TM, 1990, STROKE, V21, P153; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; FRICK KM, 1995, NEUROBIOL AGING, V16, P149, DOI 10.1016/0197-4580(94)00155-3; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2003, BRAIN RES BULL, V60, P105, DOI 10.1016/S0361-9230(03)00022-4; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Lifshitz J, 2003, J NEUROTRAUM, V20, P139, DOI 10.1089/08977150360547062; Lindner MD, 1997, NEUROBIOL LEARN MEM, V68, P203, DOI 10.1006/nlme.1997.3782; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lindner MD, 1999, BEHAV BRAIN RES, V102, P1, DOI 10.1016/S0166-4328(98)00160-0; Mukherjee SK, 1997, MOL CHEM NEUROPATHOL, V32, P59, DOI 10.1007/BF02815167; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Sandhu SK, 2002, BIOGERONTOLOGY, V3, P161, DOI 10.1023/A:1015643107449; SCHEFF SW, 2002, J NEUROTRAUM, V19, P1340; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tsay HJ, 2000, J BIOMED SCI, V7, P466; UNTERBERG A, 1994, ACTA NEUROCHIR, P431; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456	33	29	30	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	AUG 12	2004	153	1					189	197		10.1016/j.bbr.2003.11.012			9	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	840ST	WOS:000222880600021	15219720				2021-06-18	
J	Duong, TT; Englander, J; Wright, J; Cifu, DX; Greenwald, BD; Brown, AW				Duong, TT; Englander, J; Wright, J; Cifu, DX; Greenwald, BD; Brown, AW			Relationship between strength, balance, and swallowing deficits and outcome after traumatic brain injury: A multicenter analysis	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference of the International-Association-for-the-Study-of-Brain-Injury	MAY, 2001	Turin, ITALY	Int Assoc Study Brain Injury		balance; brain injuries; multicenter studies; rehabilitation; swallowing; treatment outcome	FUNCTIONAL INDEPENDENCE MEASURE; NIH STROKE SCALE; SYSTEMATIC BIAS; DYNAMIC BALANCE; SITTING BALANCE; FOLLOW-UP; RELIABILITY; REHABILITATION; INDIVIDUALS; ADMISSION	Objective: To examine the relation among strength, balance, and swallowing deficits, as measured on rehabilitation admission, and functional outcome at discharge and 1 year after traumatic brain injury (TBI). Design: Multicenter analysis of consecutive admissions to designated Traumatic Brain Injury Model Systems (TBIMS) facilities. Setting: Seventeen TBIMS centers. Participants: Adults and children older than 16 years of age with TBI (N = 2363) enrolled in the national database from January 1989 to November 2000. Interventions: Not applicable. Main Outcome Measures: Transfers, locomotion, stairs, lower-body dressing, grooming, bathing, upper-body dressing, toileting, and eating as measured by the FIM instrument at acute rehabilitation discharge and at 1 year after TBI. Results: Lower-extremity strength less than 3/5 on admission to acute rehabilitation was associated with increased need for assistance in locomotion, transfers, and lower-body dressing and less than 3/5 upper-extremity strength was associated with the need for assistance in self-care at rehabilitation discharge and at 1 year postinjury. Similar relations were found between impaired swallowing and assistance with eating, grossly impaired dynamic sitting, or standing balance and assistance with locomotion, transfers, eating, and self-care at rehabilitation discharge and at 1 year after TBI. Conclusions: Assessments of physical strength, swallowing ability, and dynamic balance on acute rehabilitation admission are helpful as screening tests in predicting the need for assistance of another person for mobility and self-care at rehabilitation discharge. This association remains strong at 1 year after TBI. By using this information, clinicians should initiate therapeutic interventions that optimize rehabilitation of the identified impairments and should make necessary arrangement for the patient's anticipated postdischarge needs. Further studies are necessary to delineate the amount of unique variance that these early physical examination findings contribute to outcome prediction. (C) 2004 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; Virginia Commonwealth Univ, Coll Med, Dept PM&R, Richmond, VA USA; CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA	Duong, TT (corresponding author), Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, 751 S Bascom Ave, San Jose, CA 95128 USA.	thao.duong@hhs.co.santa-clara.ca.us		Brown, Allen W./0000-0001-7228-3351; Cifu, David/0000-0003-1600-9387			ALBANESE MA, 1994, STROKE, V25, P1746, DOI 10.1161/01.STR.25.9.1746; BERG K, 1995, SCAND J REHABIL MED, V27, P27; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; Black K, 2000, BRAIN INJURY, V14, P141, DOI 10.1080/026990500120808; CIFU D, 2003, ARCH PHYS MED REHAB, V84, P1433; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Clark S, 2001, ARCH PHYS MED REHAB, V82, P468, DOI 10.1053/apmr.2001.21859; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Desrosiers J, 2003, CLIN REHABIL, V17, P666, DOI 10.1191/0269215503cr662oa; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hall KM, 1999, ARCH PHYS MED REHAB, V80, P1471, DOI 10.1016/S0003-9993(99)90260-5; Juneja G, 1998, AM J PHYS MED REHAB, V77, P388, DOI 10.1097/00002060-199809000-00005; KEENAN MA, 1984, CLIN ORTHOP RELAT R, P165; *KESS I REH, 1999, TRAUM BRAIN INJ MOD; Kinzey SJ, 1998, J ORTHOP SPORT PHYS, V27, P356, DOI 10.2519/jospt.1998.27.5.356; Marx RG, 1999, J HAND SURG-AM, V24A, P185; Nichols DS, 1996, ARCH PHYS MED REHAB, V77, P865, DOI 10.1016/S0003-9993(96)90271-3; Ramsey DJC, 2003, STROKE, V34, P1252, DOI 10.1161/01.STR.0000066309.06490.B8; *STAT U NEW YORK, 1997, GUID UN DAT SET MED; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	28	29	30	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2004	85	8					1291	1297		10.1016/j.apmr.2003.11.032			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	846CK	WOS:000223292200013	15295755				2021-06-18	
J	Radford, KA; Lincoln, NB; Murray-Leslie, C				Radford, KA; Lincoln, NB; Murray-Leslie, C			Validation of the stroke drivers screening assessment for people with traumatic brain injury	BRAIN INJURY			English	Article							DRIVING PERFORMANCE; FITNESS; BEHAVIOR	Cognitive impairments resulting from brain injury affect driving performance. The question of fitness to drive often arises during rehabilitation. Healthcare professionals need reliable criteria against which decisions about driving fitness can be made. Nouri et al. developed the Stroke Drivers Screening Assessment (SDSA), which was found predictive of on-road driving performance in stroke patients. The purpose of this study was to determine whether the SDSA, either alone or combined with other tests, predicted fitness to drive in brain injured people. Fifty-two participants were assessed on the SDSA plus additional cognitive tests. Their fitness to drive was examined on the public road. The SDSA predictions based on equations developed for stroke patients were not an accurate predictor of road test performance. Discriminant analysis was used to identify tests predictive of fitness to drive. Results indicated that a combination of the SDSA, the Stroop and the AMIPB Information Processing tasks correctly classified 87% of cases and may be useful predictors of driving fitness following brain injury. However, cross-validation on an independent sample of people with brain injury is required.	Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England	Radford, KA (corresponding author), Univ Nottingham, Sch Psychol, Univ Pk, Nottingham NG7 2RD, England.	kate.radford@nottingham.ac.uk	Radford, Kate A/F-8571-2013; Lincoln, Nadina B/B-9149-2009	Radford, Kate A/0000-0001-6246-3180; 			BARNES M, 1998, REHABILITATION TRAUM; Barnes MP, 1995, CLIN REHABIL, V9, P115; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; CHRISTIE N, 2001, 485 DEP ENV TRANSP R; CORNWELL M, 1999, FORUM REGIONAL MOBIL; COUGHLAN AK, 1985, ADULT MEMORY INFORMA; Fisk GD, 1998, BRAIN INJURY, V12, P683; FRYE A, 1995, GUIDE SERVICES DISAB; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; GRONWELL DMA, 1974, PSYCHOL EFFECTS CONC; HUNT LA, 1994, HDB DEMENTING ILLNES, P529; Johansson K, 1996, J AM GERIATR SOC, V44, P1198, DOI 10.1111/j.1532-5415.1996.tb01369.x; KERTESZ A, 1985, NEUROLOGY, V35, P662, DOI 10.1212/WNL.35.5.662; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Lundqvist A, 2001, BRAIN INJURY, V15, P981, DOI 10.1080/02699050110065637; Lundqvist A, 2001, NEUROPSYCHOL REHABIL, V11, P171, DOI 10.1080/09602010042000240; LUNDQVIST A, 2000, APPL COGNITIVE PSYCH, V135, P16; Lundqvist A, 1997, APPL NEUROPSYCHOL, V4, P220, DOI 10.1207/s15324826an0404_3; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; McKenna P., 1998, J MENT HEALTH, V7, P9; Nouri F M, 1987, Int Disabil Stud, V9, P110; Nouri F.M., 1992, CLIN REHABIL, V6, DOI [https://doi.org/10.1177/026921559200600402, DOI 10.1177/026921559200600402]; Nouri F. M., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; NOURI FM, 1993, BRIT MED J, V307, P482, DOI 10.1136/bmj.307.6902.482; NOURI FM, 1994, STROKE DRIVERS SCREE; PIDIKITI RD, 1991, ARCH PHYS MED REHAB, V72, P109; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; Radford KA, 2004, ARCH PHYS MED REHAB, V85, P324, DOI 10.1016/S0003-9993(03)00765-2; RADFORD KA, 2000, THESIS U NOTTINGHAM; RANNEY TA, 1994, ACCIDENT ANAL PREV, V26, P733, DOI 10.1016/0001-4575(94)90051-5; SHORE D, 1980, ARCH PHYS MED REHAB, V61, P481; SMITH T, 1980, THESIS CRANFIELD I T; The British Psychological Society, 2001, FITN DRIV COGN DOC M; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; WITHAAR FK, 2000, THESIS LEEUWARDEN	39	29	31	1	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2004	18	8					775	786		10.1080/02699050310001657394			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	826AN	WOS:000221801300004	15204318				2021-06-18	
J	Jones, NC; Constantin, D; Gibson, CL; Prior, MJW; Morris, PG; Marsden, CA; Murphy, S				Jones, NC; Constantin, D; Gibson, CL; Prior, MJW; Morris, PG; Marsden, CA; Murphy, S			A detrimental role for nitric oxide synthase-2 in the pathology resulting from acute cerebral injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						aseptic cryogenic cerebral injury; behavior; knockout mice; magnetic resonance imaging; NOS-2; trauma	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; CORTICAL IMPACT INJURY; NECROSIS-FACTOR-ALPHA; INOS-DEFICIENT MICE; FOCAL ISCHEMIA; KNOCKOUT MICE; TIME-COURSE; RAT-BRAIN; MEDIATED NEUROTOXICITY	Nitric oxide (NO) synthesized froth the inducible isoform of nitric oxide synthase (NOS-2) has been suggested to play both beneficial and deleterious roles in various neuropathologies. To define the role of nitric oxide in traumatic brain injury, we subjected male mice lacking a functional NOS-2 gene (NOS-2(-/-)) and their wild-type littermates (NOS-2(+/+)) to mild or severe aseptic cryogenic cerebral injury. Expression of NOS-2 mRNA and protein was observed in NOS-2(+/+) animals following injury. Lesion volume (as measured by histology and brain imaging) and neurological outcome (using motor and cognitive behavioral paradigms) were assessed at various times after injury. While magnetic resonance imaging revealed the extent of edema of the 2 genotypes to be similar, histology showed a reduced (32%) lesion volume in severely injured NOS2(-/-) compared with NOS-2(+/+) mice. In addition, NOS-2(-/-) mice showed significant improvements in both contralateral sensorimotor deficits (grid test: p = 0.011) and cognitive function (Morris water maze: p = 0.009) after severe injury compared to their wild-type littermates. This indicates that lesion volume is reduced and neurological recovery is improved after acute traumatic injury in mice lacking a functional NOS-2 gene, and strongly suggests that the post-trauma production of NO from this source contributes to neuropathology.	Univ Nottingham, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England; Univ Nottingham, Sir Peter Mansfield Magnet Resonance Ctr, Nottingham NG7 2UH, England; Univ Nottingham, Inst Neurosci, Nottingham NG7 2UH, England	Murphy, S (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England.	sean.murphy@nottingham.ac.uk	Jones, Nigel C/K-7773-2012	Jones, Nigel/0000-0002-1080-8439; Gibson, Claire/0000-0002-3358-7341			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Barker JE, 2001, J PATHOL, V194, P109, DOI 10.1002/path.845; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Boer R, 2000, MOL PHARMACOL, V58, P1026; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Cash D, 2001, BRAIN RES, V905, P91, DOI 10.1016/S0006-8993(01)02508-2; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cuzzocrea S, 2002, SHOCK, V18, P169, DOI 10.1097/00024382-200208000-00014; Dal Secco D, 2003, NITRIC OXIDE-BIOL CH, V9, P153, DOI 10.1016/j.niox.2003.11.001; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DE CR, 1995, J CLIN INVEST, V96, P60; Deitch EA, 2002, J GASTROINTEST SURG, V6, P599, DOI 10.1016/S1091-255X(01)00016-6; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gardner CR, 2002, TOXICOL APPL PHARM, V184, P27, DOI 10.1006/taap.2002.9474; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Grzybicki D, 1998, ACTA NEUROPATHOL, V95, P98, DOI 10.1007/s004010050770; HAMMOND BL, 1994, WORLD SCI C, V1, P1; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; Hesse M, 2000, AM J PATHOL, V157, P945, DOI 10.1016/S0002-9440(10)64607-X; Hickey MJ, 1997, FASEB J, V11, P955; Hines IN, 2002, MOL CELL BIOCHEM, V234, P229, DOI 10.1023/A:1015952926016; Huang PL, 1999, BRAZ J MED BIOL RES, V32, P1353, DOI 10.1590/S0100-879X1999001100005; Iadecola C, 1997, J NEUROSCI, V17, P9157; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; Kamada Kyousuke, 1995, Neurologia Medico-Chirurgica, V35, P1, DOI 10.2176/nmc.35.1; Kashii S, 1996, BRAIN RES, V711, P93, DOI 10.1016/0006-8993(95)01330-X; Kenyon NJ, 2002, AM J PHYSIOL-LUNG C, V282, pL540, DOI 10.1152/ajplung.00297.2001; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Kobayashi H, 2001, AM J RESP CELL MOL, V24, P390, DOI 10.1165/ajrcmb.24.4.4218; Kroppenstedt SN, 1999, J NEUROTRAUM, V16, P629, DOI 10.1089/neu.1999.16.629; Lecanu L, 1998, BRIT J PHARMACOL, V125, P584, DOI 10.1038/sj.bjp.0702119; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; Loihl AK, 1999, J BIOL CHEM, V274, P8844, DOI 10.1074/jbc.274.13.8844; Loihl AK, 1998, PROG BRAIN RES, V118, P253; Loihl AK, 1999, BRAIN RES, V830, P155, DOI 10.1016/S0006-8993(99)01388-8; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; McIntosh TK, 1996, LAB INVEST, V74, P315; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Murphy S, 2000, GLIA, V29, P1, DOI 10.1002/(SICI)1098-1136(20000101)29:1<1::AID-GLIA1>3.0.CO;2-N; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pearse DD, 2003, J NEUROPATH EXP NEUR, V62, P1096, DOI 10.1093/jnen/62.11.1096; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sirsjo A, 2003, J CARDIOVASC PHARM, V41, P897, DOI 10.1097/00005344-200306000-00010; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Trajkovic V, 2001, CURR DRUG METAB, V2, P315, DOI 10.2174/1389200013338405; Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yakovlev AG, 2001, MOL MED, V7, P205, DOI 10.1007/BF03401955; Zhao XR, 2003, BRAIN RES, V966, P308, DOI 10.1016/S0006-8993(02)04223-3; Zhu DY, 2003, J NEUROSCI, V23, P223	87	29	35	1	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUL	2004	63	7					708	720		10.1093/jnen/63.7.708			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	835LM	WOS:000222484700004	15290896	Bronze			2021-06-18	
J	Vreugdenhil, HJI; Van Zanten, GA; Brocaar, MP; Mulder, PGH; Weisglas-Kuperus, N				Vreugdenhil, HJI; Van Zanten, GA; Brocaar, MP; Mulder, PGH; Weisglas-Kuperus, N			Prenatal exposure to polychlorinated biphenyls and breastfeeding: opposing effects on auditory P300 latencies in 9-year-old Dutch children	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							EVENT-RELATED POTENTIALS; CLOSED-HEAD-INJURY; ENVIRONMENTAL EXPOSURE; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; BRAIN POTENTIALS; HUMAN-MILK; PCBS; AGE; SCHIZOPHRENIA	Prenatal exposure to polychlorinated biphenyls and breastfeeding: opposing effects on auditory P300 latencies in 9-year-old Dutch children.	Erasmus MC Sophia, Div Neonatol, Dept Paediat, NL-3000 CB Rotterdam, Netherlands; Erasmus MC, Dept Audiol, Rotterdam, Netherlands; Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands; Erasmus MC, Div Neonatol, Dept Paediat, Rotterdam, Netherlands	Weisglas-Kuperus, N (corresponding author), Erasmus MC Sophia, Div Neonatol, Dept Paediat, POB 2060, NL-3000 CB Rotterdam, Netherlands.	n.weisglas@erasmusmc.nl					Blackwood D, 2000, LANCET, V355, P771, DOI 10.1016/S0140-6736(99)00261-5; BLACKWOOD DHR, 1987, PSYCHOL MED, V17, P349, DOI 10.1017/S0033291700024892; Brouwer A, 1999, ENVIRON HEALTH PERSP, V107, P639, DOI 10.2307/3434557; BROUWER A, 1995, EUR J PHARM-ENVIRON, V293, P1; BRUDER GE, 1995, PSYCHOPHYSIOLOGY, V32, P373, DOI 10.1111/j.1469-8986.1995.tb01220.x; BRUDER GE, 1992, ANN NY ACAD SCI, V658, P205, DOI 10.1111/j.1749-6632.1992.tb22846.x; Caldwell B, 1984, HOME OBSERVATION ENV; CHEN YJ, 1994, DEV MED CHILD NEUROL, V36, P312, DOI 10.1111/j.1469-8749.1994.tb11851.x; FINLEY WW, 1985, NEUROLOGY, V35, P323, DOI 10.1212/WNL.35.3.323; Ford JM, 1999, BIOL PSYCHIAT, V46, P94, DOI 10.1016/S0006-3223(98)00290-X; Ford JM, 1999, PSYCHOPHYSIOLOGY, V36, P667, DOI 10.1111/1469-8986.3660667; HOLCOMB PJ, 1985, PSYCHOPHYSIOLOGY, V22, P656, DOI 10.1111/j.1469-8986.1985.tb01663.x; JACOBSON JL, 1990, J PEDIATR-US, V116, P38, DOI 10.1016/S0022-3476(05)81642-7; JACOBSON JL, 1992, DEV PSYCHOL, V28, P297, DOI 10.1037/0012-1649.28.2.297; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; Jeon YW, 2001, PSYCHIAT RES, V104, P61, DOI 10.1016/S0165-1781(01)00297-9; Kaneko WM, 1996, ALCOHOL CLIN EXP RES, V20, P35, DOI 10.1111/j.1530-0277.1996.tb01040.x; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; KOOPMANESSEBOOM C, 1994, CHEMOSPHERE, V29, P2327, DOI 10.1016/0045-6535(94)90401-4; KOOPMANESSEBOOM C, 1994, CHEMOSPHERE, V28, P1721, DOI 10.1016/0045-6535(94)90428-6; KoopmanEsseboom C, 1996, PEDIATRICS, V97, P700; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P171, DOI 10.1111/j.1469-8986.1984.tb00201.x; Mariussen E, 2001, TOXICOLOGY, V159, P11, DOI 10.1016/S0300-483X(00)00374-7; MARTIN LJ, 1988, SCAND AUDIOL, P105; MORROW LA, 1992, ARCH NEUROL-CHICAGO, V49, P315, DOI 10.1001/archneur.1992.00530270135031; Morrow LA, 1996, J NEUROPSYCH CLIN N, V8, P446; Morrow LA, 1998, NEUROPSY NEUROPSY BE, V11, P146; Morse DC, 1996, TOXICOL APPL PHARM, V139, P252, DOI 10.1006/taap.1996.0164; NESHIGE R, 1988, J NEUROL NEUROSUR PS, V51, P1120, DOI 10.1136/jnnp.51.9.1120; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; Patandin S, 1999, J PEDIATR-US, V134, P33, DOI 10.1016/S0022-3476(99)70369-0; Patandin S, 1997, AM J PUBLIC HEALTH, V87, P1711, DOI 10.2105/AJPH.87.10.1711; POLICH J, 1989, BIOMED PHARMACOTHER, V43, P493, DOI 10.1016/0753-3322(89)90110-8; POLICH J, 1991, ELECTROEN CLIN NEURO, P304; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; POLICH J, 1990, INT J PSYCHOPHYSIOL, V9, P237, DOI 10.1016/0167-8760(90)90056-J; Polich J, 2000, INT J PSYCHOPHYSIOL, V38, P3, DOI 10.1016/S0167-8760(00)00127-6; PRITCHARD WS, 1981, PSYCHOL BULL, V89, P506, DOI 10.1037/0033-2909.89.3.506; Rugg M. D., 1995, OX PSYCH S, V25, P27; Sangal RB, 1998, CLIN ELECTROENCEPHAL, V29, P1, DOI 10.1177/155005949802900105; SATTERFIELD JH, 1990, BIOL PSYCHIAT, V28, P879, DOI 10.1016/0006-3223(90)90569-N; SEEGAL RF, 1991, TOXICOLOGY, V66, P145, DOI 10.1016/0300-483X(91)90215-M; SEEGAL RF, 1989, NEUROTOXICOLOGY, V10, P757; SEEGAL RF, 1992, VULNERABLE BRAIN ENV, V2, P169; Steinhauer SR, 1997, BIOL PSYCHIAT, V42, P854, DOI 10.1016/S0006-3223(97)00285-0; STINISSEN J, 1970, DUTCH VERSION WECHSL; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; TAYLOR MJ, 1990, PSYCHOPHYSIOLOGY, V27, P318, DOI 10.1111/j.1469-8986.1990.tb00389.x; Tilson HA, 1998, NEUROTOXICOLOGY, V19, P517; Uauy R, 2001, NUTR REV, V59, pS34; Uauy R, 2001, LIPIDS, V36, P885, DOI 10.1007/s11745-001-0798-1; Van den Berg M, 1998, ENVIRON HEALTH PERSP, V106, P775, DOI 10.1289/ehp.98106775; Vreugdenhil HJI, 2004, NEUROPSYCHOLOGY, V18, P185, DOI 10.1037/0894-4105.18.1.185; Vreugdenhil HJI, 2002, J PEDIATR-US, V140, P48, DOI 10.1067/mpd.2002.119625; Walkowiak J, 2001, LANCET, V358, P1602, DOI 10.1016/S0140-6736(01)06654-5; Weisglas-Kuperus N, 1998, CHEMOSPHERE, V37, P1845, DOI 10.1016/S0045-6535(98)00250-1; Yanai I, 1997, J AFFECT DISORDERS, V46, P263, DOI 10.1016/S0165-0327(97)00100-6	58	29	29	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JUN	2004	46	6					398	405		10.1017/S0012162204000647			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	824OS	WOS:000221696500006	15174531				2021-06-18	
J	Watson, NF; Barber, JK; Doherty, MJ; Miller, JW; Temkin, NR				Watson, NF; Barber, JK; Doherty, MJ; Miller, JW; Temkin, NR			Does glucocorticoid administration prevent late seizures after head injury?	EPILEPSIA			English	Article						traumatic brain injury; seizures; glucocorticoids; prevention	TRAUMATIC BRAIN-INJURY; CORTICOSTERONE TREATMENT; CONTROLLED TRIALS; EPILEPSY; EPILEPTOGENESIS; STEROIDS	Purpose: preventing posttraumatic epilepsy has been a difficult challenge. In this study we evaluated the association between glucocorticoid administration after traumatic brain injury (TBI) and posttraumatic seizures. Methods: We examined a seizure-prevention trial database of 404 patients with severe TBI for exposure to glucocorticoids in the early (<1 week) posttraumatic period. After controlling for seizure risk, we compared the odds of developing first and second late posttraumatic seizures between those that received glucocorticoids and those that did not. Results: Patients dosed with glucocorticoids within 1 day of their TBI were more likely to develop first late seizures than were those without [p = 0.04; hazard ratio = 1.74; 95% confidence interval (CI), 1.01-2.98]; whereas those receiving glucocorticoids &GE;2 days after their injury had no similar association (p = 0.66 hazard ratio = 0.77; 95% CI, 0.23-2.56; p = 0.10 among the three groups). Receiving glucocorticoids within I day, or &GE;2 days after TBI was not associated with second late seizure development. Conclusions: Glucocorticoid treatment after TBI is not associated with decreased late posttraumatic seizures, and early treatment is associated with increased seizure activity.	Univ Washington, Neurol & Sleep Disorders Ctr, Seattle, WA 98104 USA; Univ Washington, Dept Biostat, Seattle, WA 98104 USA; Swedish Neurosci Inst, Epilepsy Ctr, Seattle, WA USA	Watson, NF (corresponding author), Univ Washington, Sleep Disorders Ctr, Box 359803,325 9th Ave, Seattle, WA 98104 USA.	nwatson@u.washington.edu					Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Frantseva MV, 2000, NEUROSCIENCE, V97, P431, DOI 10.1016/S0306-4522(00)00041-5; Goodman YD, 1996, J NEUROCHEM, V66, P1836; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; Hellsten J, 2002, EUR J NEUROSCI, V16, P283, DOI 10.1046/j.1460-9568.2002.02093.x; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; HOEPPNER TJ, 1986, EXP NEUROL, V94, P519, DOI 10.1016/0014-4886(86)90235-9; Karst H, 1999, EUR J NEUROSCI, V11, P889, DOI 10.1046/j.1460-9568.1999.00495.x; Mackay M, 2002, INT REV NEUROBIOL, V49, P157; Miller JD, 1996, SURG NEUROL, V45, P296; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P531; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954	15	29	30	0	0	BLACKWELL PUBLISHING INC	MALDEN	350 MAIN ST, MALDEN, MA 02148 USA	0013-9580			EPILEPSIA	Epilepsia	JUN	2004	45	6					690	694		10.1111/j.0013-9580.2004.59403.x			5	Clinical Neurology	Neurosciences & Neurology	828SI	WOS:000221992900018	15144437	Bronze			2021-06-18	
J	Wilson, S; Raghupathi, R; Saatman, KE; Mackinnon, MA; McIntosh, TK; Graham, DI				Wilson, S; Raghupathi, R; Saatman, KE; Mackinnon, MA; McIntosh, TK; Graham, DI			Continued in situ DNA fragmentation of microglia/macrophages in white matter weeks and months after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						human traumatic brain injury; TUNEL staining; Wallerian degeneration	SPINAL-CORD-INJURY; DIFFUSE AXONAL INJURY; MISSILE HEAD-INJURY; CONTROLLED CORTICAL IMPACT; VEGETATIVE STATE; CELL-DEATH; APOPTOSIS; RATS; NEUROPATHOLOGY; DAMAGE	Paraffin-embedded material from the pons of head-injured patients whose disability could be attributed to diffuse traumatic axonal injury, and controls, was identified from the department's archive. The cases were divided into three groups based on survival, viz Group I (n = 5) who survived for between 4 and 8 weeks, Group 2 (n = 5) for between 3 and 9 months, and Group 3 (n = 5) who survived for more that 12 months. Sections were stained by the TUNEL (TdT-mediated UTP nick end labelling) technique, and by H&E, LFB/CV and immunohistochemically for astrocytes (GFAP) and microglia/macrophages (CD68). Microscopic abnormalities were mapped onto line diagrams of two levels of the pons and quantitation of the response determined by an eye-piece graticule placed over the medial lemmisci, cortico-spinal and transverse fiber tracts. Data were pooled by region of interest. In the H&E and LFB/CV stained sections, there was variable pallor of staining in ascending and descending fiber tracts due to loss of myelin: within these same tracts there was an astrocytosis and increased numbers of microglia/macrophages compared with controls. In the white matter tracts of the controls, there was on average 1-2 TUNEL+ cells per unit area. In contrast, there were on average 2-16 TUNEL+ cells in the cortico-spinal tracts and in the medial lemnisci of all groups of head-injured patients. CD68(+) cells co-located with the TUNEL+, and their number mirrored the TUNEL I staining with on average 16-30 cells per unit area in Group 1, 14-27 cells per unit area in Group 2, and 12-14 cells per unit area in Group 3. There was a statistical association between the TUNEL+ and CD68(+) cells. Few changes were seen in the transverse fiber tracts of the pons. These findings indicate that most of the in situ DNA fragmentation occurred in microglia/macrophages in ascending and descending fiber tracts of the brain stem in which by conventional light microscopy there is Wallerian degeneration. However, in addition, a few TUNEL+ oligodendrocyte-like cells were also seen.	Univ Glasgow, Dept Neuropathol, Glasgow G12 8QQ, Lanark, Scotland; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Graham, DI (corresponding author), S Glasgow Hosp NHS Trust, So Gen Hosp, Acad Unit Neuropathol, Inst Neurol Sci, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.	D.Graham@clinmed.gla.ac.uk			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01-GN34690] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER		Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; BARRES BA, 1993, DEVELOPMENT, V118, P283; Beattie MS, 1998, NEUROSCIENTIST, V4, P163, DOI 10.1177/107385849800400312; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BUNGE RP, 1998, ADV NEUROL, V59, P75; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Fowler J, 2002, CLIN NEUROPATHOL, V21, P156; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; GEHRMANN J, 1992, LAB INVEST, V67, P100; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GRCEVIC H, 1977, RAD JUN AKAD ZNS VMJ, V402, P265; Hayes KC, 1997, J NEUROTRAUM, V14, P235, DOI 10.1089/neu.1997.14.235; KERR JFR, 1972, J PATHOL, V106, pPR11; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Liu XZ, 1997, J NEUROSCI, V17, P5395; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McLellan D, 1986, COMA TRAUMATIQUE, P165; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PETITO CK, 1995, J NEUROPATH EXP NEUR, V54, P761, DOI 10.1097/00005072-199511000-00002; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RINK A, 1995, AM J PATHOL, V147, P1575; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	54	29	29	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2004	21	3					239	250		10.1089/089771504322972031			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	806CI	WOS:000220411600002	15115599				2021-06-18	
J	Incoccia, C; Formisano, R; Muscato, P; Reali, G; Zoccolotti, P				Incoccia, C; Formisano, R; Muscato, P; Reali, G; Zoccolotti, P			Reaction and movement times in individuals with chronic traumatic brain injury with good motor recovery	CORTEX			English	Article						traumatic brain injury; attention; movement time	CLOSED-HEAD INJURY; ATTENTIONAL PROCESSES; DEFICITS; PATTERNS; SCALE	Reaction times and movement times were studied in 18 individuals with severe traumatic brain injury (TBI) and 36 matched normal controls. Reaction times depended on the type of task: in the case of simple visual stimuli (Alertness condition) they were similar in individuals with TBI and normal controls. In contrast, individuals with FBI were slower in a Go-no-go test. Regardless of task, movement times depended on movement length and were slower in individuals with TBI. These findings indicate the presence of a residual motor programming deficit in individuals with TBI even in the chronic stage and in the presence of good motor recovery, as assessed clinically.	IRCCS, Fdn Santa Lucia, Ctr Ric Neuropsicol, I-00179 Rome, Italy; Univ Roma La Sapienza, Dept Psychol, Rome, Italy	Incoccia, C (corresponding author), IRCCS, Fdn Santa Lucia, Ctr Ric Neuropsicol, Via Ardcatina 306, I-00179 Rome, Italy.	c.incoccia@hsantalucia.it	Zoccolotti, Pierluigi/H-4437-2019	Zoccolotti, Pierluigi/0000-0002-6351-2455; Incoccia, Chiara/0000-0003-4068-6548			ADAMS RJ, 1987, STROKE, V18, P665, DOI 10.1161/01.STR.18.3.665; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1974, J NEUROL NEUROSUR PS, V13, P81; JENNETT B, 1974, LANCET, V13, P81; KEELE SW, 1968, PSYCHOL BULL, V70, P387, DOI 10.1037/h0026739; KLAPP ST, 1975, J EXP PSYCHOL HUMAN, V104, P147; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; VANZOMEREN AH, 1994, CLIN NEUROPSCHOLOGY; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	13	29	29	0	4	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	FEB	2004	40	1					111	115		10.1016/S0010-9452(08)70924-9			5	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	807DU	WOS:000220483000010	15070006				2021-06-18	
J	Chesnut, RM				Chesnut, RM			Management of brain and spine injuries	CRITICAL CARE CLINICS			English	Article							SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; POSTTRAUMATIC INTRACRANIAL HYPERTENSION; 7.5-PERCENT SODIUM-CHLORIDE; RANDOMIZED CONTROLLED-TRIAL; VENA-CAVAL FILTERS; CORD-INJURY; CERVICAL-SPINE; TRAUMA PATIENTS; VENOUS THROMBOEMBOLISM	Over the past 30 years, remarkable progress has been made in improving outcome from traumatic brain injury (TBI). Overall mortalities from severe TBI have dropped from in the range of 36% in the late 1980s into the low-to-middle teens at specialized TBI centers [1,2]. Although many etiologies for such improvement have been suggested, it is unclear what changes actually affected the improvement in outcome. Despite the fervor for laboratory investigations of TBI models, it is sobering to recognize that no treatments have come from bench to bedside. As such, there are no magic bullets in the treatment of central nervous system (CNS) trauma in general, and TBI in particular. Instead, it appears to be a combination of many improvements in brain injury care, trauma systems, and critical care that has produced the decrease in mortality.	Oregon Hlth & Sci Univ, Dept Neurotrauma & Neurosurg Crit Care, Portland, OR 97201 USA	Chesnut, RM (corresponding author), Oregon Hlth & Sci Univ, Dept Neurotrauma & Neurosurg Crit Care, L-472,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	chesnutr@ohsu.edu					ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BIVINS HG, 1988, ANN EMERG MED, V17, P25, DOI 10.1016/S0196-0644(88)80498-0; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chesnut R M, 1995, New Horiz, V3, P581; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1998, CRIT CARE MED, V26, P210, DOI 10.1097/00003246-199802000-00009; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHESTNUT RM, 2000, HEAD INJURY, P229; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Cooper P R, 1976, Surg Neurol, V5, P25; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; DUH MS, 1994, NEUROSURGERY, V35, P240, DOI 10.1227/00006123-199408000-00009; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fehlings MG, 2001, SPINE, V26, pS101, DOI 10.1097/00007632-200112151-00017; FULTON RL, 1993, SURG GYNECOL OBSTET, V176, P327; GAAB MR, 1990, ACT NEUR S, V51, P326; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Ghajar J, 1995, New Horiz, V3, P395; GHAJAR JB, 1995, NEUROTRAUMA, P1007; Ghanta MK, 2002, AM SURGEON, V68, P563; GREEN D, 1991, SEMIN THROMB HEMOST, V17, P347, DOI 10.1055/s-2007-1002633; GREEN D, 1982, PARAPLEGIA, V20, P227, DOI 10.1038/sc.1982.41; GREEN D, 1988, JAMA-J AM MED ASSOC, V260, P1255, DOI 10.1001/jama.260.9.1255; Harris S, 1996, AM J PHYS MED REHAB, V75, P326, DOI 10.1097/00002060-199609000-00002; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Holzschuh M, 1998, ACT NEUR S, V71, P170; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; Hurlbert RJ, 2001, SPINE, V26, pS39, DOI 10.1097/00007632-200112151-00009; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; LEVI L, 1991, NEUROSURGERY, V29, P216, DOI 10.1227/00006123-199108000-00008; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1987, J NEUROSURG, V66, P400, DOI 10.3171/jns.1987.66.3.0400; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Maxwell RA, 2002, J TRAUMA, V52, P902, DOI 10.1097/00005373-200205000-00013; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Meguro K, 1988, Neurol Med Chir (Tokyo), V28, P34, DOI 10.2176/nmc.28.34; Mirza SK, 1999, CLIN ORTHOP RELAT R, P104, DOI 10.1097/00003086-199902000-00011; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Oertel M, 2002, ACT NEUR S, V81, P69; Pasquale M, 1998, J TRAUMA, V44, P941, DOI 10.1097/00005373-199806000-00001; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rogers FB, 2002, J TRAUMA, V53, P1032, DOI 10.1097/00005373-200211000-00045; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Schenarts PJ, 2001, J TRAUMA, V51, P663, DOI 10.1097/00005373-200110000-00007; Schneider GH, 2002, ACT NEUR S, V81, P77; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; TEASDALE G, 1974, LANCET, V2, P81; Vaccaro AR, 1997, SPINE, V22, P2609, DOI 10.1097/00007632-199711150-00006; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020; Velmahos GC, 2000, J TRAUMA, V49, P140, DOI 10.1097/00005373-200007000-00021; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; WAGNER FC, 1982, J NEUROSURG, V56, P699, DOI 10.3171/jns.1982.56.5.0699; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Winslow C, 2002, CHEST, V121, P1548, DOI 10.1378/chest.121.5.1548; 2000, J NEUROTRAUMA, V17, P479; 2001, J TRAUMA INJURY INFE, V51, pS3	85	29	30	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-0704	1557-8232		CRIT CARE CLIN	Crit. Care Clin.	JAN	2004	20	1					25	+		10.1016/S0749-0704(03)00090-3			32	Critical Care Medicine	General & Internal Medicine	848ID	WOS:000223460000004	14979328				2021-06-18	
J	Levy, DT; Mallonee, S; Miller, TR; Smith, GS; Spicer, RS; Romano, EO; Fisher, DA				Levy, DT; Mallonee, S; Miller, TR; Smith, GS; Spicer, RS; Romano, EO; Fisher, DA			Alcohol involvement in burn, submersion, spinal cord, and brain injuries	MEDICAL SCIENCE MONITOR			English	Article						alcohol; injury; intentional; unintentional; nonfatal	TRAUMA PATIENTS; EMERGENCY-ROOM; RISK FACTOR; ABUSE	Background : Alcohol is involved in many injuries, but estimates of this involvement vary considerably. Most information pertains to deaths although most injuries are nonfatal. Material/Method : The portion of fatal and nonfatal injuries involving alcohol was determined from a comprehensive Oklahoma surveillance system that tracks persons killed or hospitalized due to burns, submersions, spinal cord injuries (SCIs), and traumatic brain injuries (TBIs). Logistic regression was used to determine factors that explain the percentage of alcohol involvement in fatal versus nonfatal cases. Results : The victim was alcohol involved in 17% of fire burns, 4% of scald burns, 24% of submersions, 34% of SCIs, and 41% of TBIs where involvement was known. Large differences existed in total alcohol involvement between age and gender groups and between fatal and nonfatal cases of fire burns (31% vs. 1.1%) and submersions (33% vs. 6%). Large differences also existed in victim alcohol involvement between fatal and nonfatal cases of intentional SCIs (0% vs. 48%) and TBIs (38% vs. 70%). Those who imbibed during the day were not at excess risk of scald injury, but they were twice as likely to suffer a serious fire burn, 3 times as likely to suffer a spinal cord injury, 3.5 times as likely to suffer a submersion injury, and 2 to 4 times as likely to suffer a TBI. These excess risks persisted for all age groups between 15 and 64, with the excess risk especially high for underage drinkers aged 15 to 20. In contrast, people aged 65 and older did not appear to be at excess risk on days that they imbibed. Conclusion : A large percentage of fatal and nonfatal injuries as classified by diagnosis group involve alcohol. People who had been drinking were substantially more likely to suffer serious nonfatal and fatal injuries other than scald burns.	Univ Baltimore, Baltimore, MD 21201 USA; Pacific Inst Res & Evaluat, Beltsville, MD USA; Oklahoma Dept Hlth, Oklahoma City, OK USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA	Levy, DT (corresponding author), 14403 Sylvan Glade Dr, N Potomac, MD 20878 USA.	levy@pire.org			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA012208, R01AA009812] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01 AA12208-01, R01 AA09812-02] Funding Source: Medline		Blake R B, 1997, Am J Orthop (Belle Mead NJ), V26, P704; CHERPITEL CJ, 1995, ANN EMERG MED, V26, P158, DOI 10.1016/S0196-0644(95)70146-X; Cherpitel CJ, 1996, ALCOHOL CLIN EXP RES, V20, P338, DOI 10.1111/j.1530-0277.1996.tb01649.x; CHERPITEL CJ, 1993, ADDICTION, V88, P923, DOI 10.1111/j.1360-0443.1993.tb02110.x; HOWLAND J, 1988, ACCIDENT ANAL PREV, V20, P19, DOI 10.1016/0001-4575(88)90011-5; HOWLAND J, 1987, PUBLIC HEALTH REP, V102, P475; HOWLAND J, 1988, CONTEMP DRUG PROBL, P95; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Levy DT, 2002, ADDICTION, V97, P909, DOI 10.1046/j.1360-0443.2002.00133.x; Li GH, 1996, ALCOHOL CLIN EXP RES, V20, P1553, DOI 10.1111/j.1530-0277.1996.tb01698.x; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; MILLER TR, 1994, ACCIDENT ANAL PREV, V26, P583, DOI 10.1016/0001-4575(94)90020-5; *NIAAA, 1997, EFF ALC BEH SAF, P247; PAYNE SR, 1989, J TRAUMA, V29, P424, DOI 10.1097/00005373-198904000-00002; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; Roizen J, 1988, DRINKING CASUALTIES, P21; SMITH GS, 1988, ANNU REV PUBL HEALTH, V9, P99; Smith GS, 1999, ANN EMERG MED, V33, P659, DOI 10.1016/S0196-0644(99)70195-2; SMITH GS, 1999, EPIDEMIOLOGY ALCOHOL; SMITH GS, 1995, ADOLESC MED, V6, P153; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; WALLER JA, 1994, ACCIDENT ANAL PREV, V26, P635, DOI 10.1016/0001-4575(94)90025-6	22	29	30	1	5	INT SCIENTIFIC LITERATURE, INC	ALBERTSON	1125 WILLIS AVE, ALBERTSON, NY 11507 USA	1234-1010			MED SCI MONITOR	Med. Sci. Monitor	JAN	2004	10	1					CR17	CR24					8	Medicine, Research & Experimental	Research & Experimental Medicine	865XC	WOS:000224736500008	14704631				2021-06-18	
J	Walker, WC				Walker, WC			Pain pathoetiology after TBI - Neural and nonneural mechanisms	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acute pain; brain injury; chronic pain; pain assessment; trauma	TRAUMATIC BRAIN-INJURY; MOTOR-VEHICLE CRASHES; HEAD-INJURY; POSTTRAUMATIC HEADACHES; EPIDEMIOLOGY; PATHOGENESIS; DISABILITY; DISORDER	Individuals recovering from traumatic brain injury (YBI) frequently experience acute and chronic pain. Their pain experience is the net effect of many interacting and very complex physiologic, biochemical, and psychological mechanisms involving both the peripheral and central nervous system. This article reviews the basics of neural mechanisms and pathways of pain after TBI, and discusses clinical implications. Numerous intracranial and extracranial tissues must be considered in the evaluation of pain after TBI, with the specific mechanism of trauma influencing the anatomic distribution of injuries. The differential diagnosis usually falls into one of the following pathoetiologic classifications: primary or secondary musculoskeletal, vascular, visceral, and neural pain syndromes.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; McGuire VAMC, Def & Vet Brain Injury Ctr, Richmond, VA USA	Walker, WC (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, MCV Stn,Box 677, Richmond, VA 23298 USA.	wcwalker@mail2.vcu.edu	Walker, William C/N-3162-2014				Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Annoni J M, 1992, Disabil Rehabil, V14, P23; Ashina S, 2003, CEPHALALGIA, V23, P456, DOI 10.1046/j.1468-2982.2003.00559.x; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BENEDITTIS G, 1983, J NEUROSURG SCI, V27, P177; BIGLER ED, 2001, PHYS MED REHABIL STA, V15, P349; BONICA JJ, 2001, BONICAS MANAGEMENT P; Byers M. R., 2001, BONICAS MANAGEMENT P; CELENTANO DD, 1992, HEADACHE, V32, P223, DOI 10.1111/j.1526-4610.1992.hed3205223.x; Chapman CR, 1996, PROG BRAIN RES, V110, P63; CHUDLER EH, 2001, BONICAS MANAGEMENT P; Coda B, 2001, BONICAS MANAGEMENT P; Coderre TJ, 1997, BEHAV BRAIN SCI, V20, P404, DOI 10.1017/S0140525X97251484; Curatolo M, 2001, CLIN J PAIN, V17, P306, DOI 10.1097/00002508-200112000-00004; DISCHINGER PC, 1993, J TRAUMA, V35, P454, DOI 10.1097/00005373-199309000-00020; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Gabriel M, 1995, FRONTIER PAIN RES, P197; GALER BS, 2001, BONICAS MANAGEMENT P; GARLAND DE, 1981, CLIN ORTHOP RELAT R, V155, P162; GELLMAN H, 1992, PAIN, V51, P307, DOI 10.1016/0304-3959(92)90214-V; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; GOLDBERG G, 2001, PHYS MED REHABIL STA, V15, P363; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; HAM LP, 1994, CEPHALALGIA, V14, P118, DOI 10.1046/j.1468-2982.1994.1402118.x; HAMM RJ, 2000, NEUROPLASTICITY REOR, P46; Hasvold Toralf, 1993, Scandinavian Journal of Primary Health Care, V11, P219, DOI 10.3109/02813439308994834; JACOBSON L, 2001, BONICAS MANAGEMENT; JAY GW, 2001, CURRENT TREND DIAGNO; Jensen TS, 2001, ACTA ANAESTH SCAND, V45, P1128, DOI 10.1034/j.1399-6576.2001.450913.x; Kleppel JB, 2002, AM J PHYS MED REHAB, V81, P114, DOI 10.1097/00002060-200202000-00007; Kwan Oliver, 2002, Med Sci Monit, V8, pRA191; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Melzack R, 2001, J Dent Educ, V65, P1378; Miller L, 2000, NEUROREHABILITATION, V14, P25; MOSKOWITZ MA, 1993, NEUROLOGY, V43, P16; Nicholson K, 2000, NEUROREHABILITATION, V14, P3; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; RAJ PP, 1994, CURRENT REV PAIN, P21; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SIEGEL JH, 1993, J TRAUMA, V34, P736, DOI 10.1097/00005373-199305000-00017; Siegmund GP, 2001, SPINE, V26, P2095, DOI 10.1097/00007632-200110010-00010; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TASKER RR, 2001, BONICAS MANAGEMENT P; TERMAN GW, 2001, BONICAS MANAGEMENT P; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; VIJAYAN N, 1977, HEADACHE, V17, P19, DOI 10.1111/j.1526-4610.1977.hed1701019.x; VIJAYAN N, 1989, HEADACHE, V29, P502, DOI 10.1111/j.1526-4610.1989.hed2908502.x; Vogt BA, 1993, NEUROBIOLOGY CINGULA, P313; WALKER WC, 2002, ARCH PHYS MED REHAB, V83, P1643; WATANABE TK, 2001, PHYS MED REHABILITAT, V15, P283; ZHOU M, 2001, SCI WORLD J, V1, P204	54	29	30	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2004	19	1					72	81		10.1097/00001199-200401000-00007			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	768UT	WOS:000188554000007	14732832				2021-06-18	
J	Dixon, CE; Ma, XC; Kline, AE; Yan, HQ; Ferimer, H; Kochanek, PM; Wisniewski, SR; Jenkins, LW; Marion, DW				Dixon, CE; Ma, XC; Kline, AE; Yan, HQ; Ferimer, H; Kochanek, PM; Wisniewski, SR; Jenkins, LW; Marion, DW			Acute etomidate treatment reduces cognitive deficits and histopathology in rats with traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						controlled cortical impact; Morris water maze; recovery; spatial learning	EXCITATORY AMINO-ACIDS; CEREBROSPINAL-FLUID; GABA(A) RECEPTOR; GLUTAMATE; RELEASE; ISOFLURANE; CALCIUM; MODEL; ANESTHETICS; HYPOTHERMIA	Objective: To test the hypothesis that etomidate treatment improves functional, cognitive, and histologic outcome after experimental traumatic brain injury. Design: Controlled animal study. Setting: University research laboratory. Subjects: Male Sprague-Dawley rats. Interventions: Traumatic brain injury was produced by controlled cortical impact injury (4 m/sec, 2.6 mm of tissue deformation). Etomidate (2 mg/kg) was administered intravenously immediately before injury (n = 13) or 5 mins after injury (n = 12). Additional rats received saline treatment 5 mins after injury (n 12) or served as sham controls (n = 10). Measurements and Main Results. Rats were evaluated on beam balance and beam walk tasks on postoperative days 1-5 and then trained in the Morris water maze on postoperative days 14-18. On day 28, the rats were killed, and hippocampal CA(1) and CA(3) neuron counts and cortical lesion volume were measured in histologic brain sections. Preinjury etomidate attenuated beam balance deficits, water maze deficits, hippocampal CA(3) neuronal loss, and cortical tissue loss but did not attenuate beam walk deficits or hippocampal CA, neuronal loss. Postinjury etomidate attenuated water maze deficits, but it did not affect any other outcome measure. Conclusions. Administration of etomidate both before and after injury attenuates secondary injury resulting from traumatic brain injury, but the effect is more pronounced with pretreatment. The ineffectiveness of postinjury etomidate on motor and histologic tasks suggests a brief therapeutic treatment window in rats. However, the treatment window in humans is unknown. Lastly, postinjury etomidate did not exacerbate neurologic or histologic outcome.	Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurosurg, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	ecdixon@msx.upmc.edu	Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150, NS30318, NS40125] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150, P01NS030318, R01NS040125, P20NS030318, P50NS030318] Funding Source: NIH RePORTER		Adnet F, 1998, Eur J Emerg Med, V5, P415; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Belelli D, 1999, NEUROCHEM INT, V34, P447, DOI 10.1016/S0197-0186(99)00037-6; Bergen Joseph M., 1997, Journal of Emergency Medicine, V15, P221, DOI 10.1016/S0736-4679(96)00350-2; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; BULLOCK R, 1994, INTRACRANIAL PRESSUR, P264; CESHNUT RM, 1991, NEUROSURG CLIN N AM, V2, P267; CHOI DW, 1987, J NEUROSCI, V7, P357; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kindler CH, 1999, ANESTHESIOLOGY, V90, P1137, DOI 10.1097/00000542-199904000-00029; Kline AE, 2001, HEAD TRAUMA, P65; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Moody EJ, 1998, TOXICOL LETT, V101, P209, DOI 10.1016/S0378-4274(98)00187-8; Murugaiah KD, 1998, ANESTHESIOLOGY, V89, P919, DOI 10.1097/00000542-199810000-00017; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PATEL PM, 1995, ANESTH ANALG, V80, P933, DOI 10.1097/00000539-199505000-00013; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PRIOR JGL, 1983, INTENS CARE MED, V9, P313, DOI 10.1007/BF01692549; PUIL E, 1994, NEUROSCI LETT, V176, P63, DOI 10.1016/0304-3940(94)90872-9; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; Robertson SC, 1998, NEUROSURGERY, V43, P317, DOI 10.1097/00006123-199808000-00085; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Smith DC, 2000, J EMERG MED, V18, P13, DOI 10.1016/S0736-4679(99)00154-7; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; Swanson E R, 2001, Prehosp Emerg Care, V5, P142, DOI 10.1080/10903120190940001; Tentillier E, 2000, ANN FR ANESTH, V19, P275; WATSON JC, 1992, NEUROSURGERY, V30, P540; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	42	29	32	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2003	31	8					2222	2227		10.1097/01.CCM.0000080493.04978.73			6	Critical Care Medicine	General & Internal Medicine	712KV	WOS:000184797600021	12973183				2021-06-18	
J	Pachet, A; Friesen, S; Winkelaar, D; Gray, S				Pachet, A; Friesen, S; Winkelaar, D; Gray, S			Beneficial behavioural effects of lamotrigine in traumatic brain injury	BRAIN INJURY			English	Article							FUNCTIONAL ASSESSMENT MEASURE; INTERRATER RELIABILITY; VALPROIC ACID; CARBAMAZEPINE; AGITATION; MECHANISM; EPILEPSY; DRUGS	Anti-convulsant medications have been employed to treat behavioural disorders resulting from traumatic brain injury (TBI). However, there is a paucity of literature investigating the use of lamotrigine to treat aggression and agitation in patients with TBI. In a single case study design, the present study examined the effectiveness of lamotrigine to treat aggressive and agitated behaviour in a 40-year-old male who sustained a severe TBI. A substantial decrease in problematic behaviours and a significant improvement in neurobehavioural functioning were observed after lamotrigine treatment. This case study provides some support for the use of lamotrigine to treat aggression and agitation in patients with a TBI. Further research is needed to examine the relationship between lamotrigine and functional outcome after TBI.	Alberta Hosp Ponoka, Alberta Mental Hlth Board, Brain Injury Rehabil Prov Program, Edmonton, AB, Canada	Pachet, A (corresponding author), Columbia Hlth Ctr, Brain Injury Program, 2121 29th St NE, Calgary, AB T1Y 7H8, Canada.						Azouvi P, 1999, BRAIN INJURY, V13, P797, DOI 10.1080/026990599121188; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Brunbech L, 2002, DRUGS, V62, P593, DOI 10.2165/00003495-200262040-00004; Calabrese JR, 1999, AM J PSYCHIAT, V156, P1019; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; de la Cruz M, 1999, ARCH OTOLARYNGOL, V125, P225, DOI 10.1001/archotol.125.2.225; Devarajan S, 2000, AM J PSYCHIAT, V157, P1178, DOI 10.1176/appi.ajp.157.7.1178; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; ENTERS EK, 1992, BRAIN RES, V576, P271; Goldberg JF, 2001, J CLIN PSYCHIAT, V62, P27; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HORN LJ, 1987, J HEAD TRAUMA REHAB, V2, P18; Jette N, 2002, NEUROLOGY, V59, P275, DOI 10.1212/WNL.59.2.275; JOFFE RT, 1994, ANTICONVULSANTS MOOD; JULIEN RM, 1998, PRIMER DRUG ACTION; LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x; LEES G, 1993, BRAIN RES, V612, P190, DOI 10.1016/0006-8993(93)91660-K; Levine J, 2000, J CLIN PSYCHIAT, V61, P680, DOI 10.4088/JCP.v61n0914h; Maltese TM, 1999, AM J PSYCHIAT, V156, P1833; Martin R, 2001, EPILEPSIA, V42, P764, DOI 10.1046/j.1528-1157.2001.33300.x; MARTIN S, 2002, EPILSPSIA, V43, P482; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Meador KJ, 2001, NEUROLOGY, V56, P1177, DOI 10.1212/WNL.56.9.1177; MEYTHALER J, 1999, REHABILITATION PHARM, V10, P275; NEPPE V, 1998, J CLIN PSYCHIAT, V49, P4; OTTENBACHER KJ, 1996, ARCH PHYS MED REHAB, V7, P1226; Post RM, 1987, PSYCHOPHARMACOLOGY 3, P567; PRATT JA, 1984, J NEUROL NEUROSUR PS, V47, P1131, DOI 10.1136/jnnp.47.10.1131; Rhodes LJ, 2000, AM J PSYCHIAT, V157, P2058, DOI 10.1176/appi.ajp.157.12.2058; Ryan J M, 2000, Semin Clin Neuropsychiatry, V5, P238, DOI 10.1053/scnp.2000.9553; SHOWALTER C, 1996, J NEUROPSYCHIATRY CL, V8, P96; Showalter PEC, 2000, BRAIN INJURY, V14, P997; SMALL JG, 1991, ARCH GEN PSYCHIAT, V48, P915; Wroblewski BA, 1997, BRAIN INJURY, V11, P37, DOI 10.1080/026990597123791	34	29	30	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2003	17	8					715	722		10.1080/0269905031000110445			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691MF	WOS:000183609500009	12850956				2021-06-18	
J	Santhakumar, V; Voipio, J; Kaila, K; Soltesz, I				Santhakumar, V; Voipio, J; Kaila, K; Soltesz, I			Post-traumatic hyperexcitability is not caused by impaired buffering of extracellular potassium	JOURNAL OF NEUROSCIENCE			English	Article						potassium; buffering; head trauma; FPI; dentate gyrus; seizures	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; CENTRAL NERVOUS-SYSTEM; RAT DENTATE GYRUS; GLIAL-CELLS; HIPPOCAMPAL SLICES; IN-VITRO; ELECTROPHYSIOLOGICAL PROPERTIES; SYNAPTIC TRANSMISSION; EPILEPTIFORM ACTIVITY	Impaired extracellular potassium buffering has been proposed as one of the major mechanisms underlying the increased risk for temporal lobe epilepsy after brain injury (D'Ambrosio et al., 1999). The present study systematically tested this hypothesis by measuring the resting [K+](o) and recovery of the stimulation-evoked [K+](o) increases in the dentate gyrus after experimental head trauma, using a combination of whole-cell recordings and ion-selective microelectrode recordings in rat hippocampal slices. Despite the presence of hyperexcitability, the resting [K+](o) was not increased after injury. The faster rate of increase and larger amplitude of the orthodromically evoked [K+](o) elevation after head trauma occurred in association with a greater population spike with shorter response latency. Contrary to the assumption in previous studies that the evoked activity in control and injured neuronal circuits is the same during antidromic activation, stimulation of granule cell axons in glutamate receptor antagonists evoked a greater [K+](o) increase and a larger population spike. Although perforant path stimulation resulted in a larger [K+](o) elevation after injury, the rate of clearance of the [K+](o) transients evoked either by neuronal activity or by external application of potassium was not compromised. The [K+](o) increase evoked by activation of the presynaptic afferents in isolation was not increased. In addition, the postsynaptic neuronal depolarization and firing evoked by exogenous potassium application was decreased after trauma. These results show that the regulation of [K+](o) is not impaired after injury and indicate that the larger [K+](o) increase evoked by neuronal activity is a consequence, rather than the primary mechanism underlying post-traumatic hyperexcitability.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland	Santhakumar, V (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	vsanthak@uci.edu	Santhakumar, Vijayalakshmi/M-4192-2013; Kaila, Kai K/R-8528-2016; Santhakumar, Viji/K-4856-2019	Kaila, Kai K/0000-0003-0668-5955; Santhakumar, Viji/0000-0001-6278-4187; Voipio, Juha/0000-0001-7096-1286	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29 NS035915, R37 NS035915, R01 NS035915, NS35915] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035915, R37NS035915, R29NS035915] Funding Source: NIH RePORTER		AITKEN PG, 1986, BRAIN RES, V369, P163, DOI 10.1016/0006-8993(86)90524-X; Amzica F, 2002, J NEUROSCI, V22, P1042, DOI 10.1523/JNEUROSCI.22-03-01042.2002; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; BALLANYI K, 1984, NEUROSCIENCE, V12, P917, DOI 10.1016/0306-4522(84)90179-9; Bordey A, 1998, EPILEPSY RES, V32, P286, DOI 10.1016/S0920-1211(98)00059-X; Brickley SG, 2001, NEUROPHARMACOLOGY, V41, P730, DOI 10.1016/S0028-3908(01)00135-6; Bruton CJ, 1988, NEUROPATHOLOGY TEMPO; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; Chen K, 2001, NAT MED, V7, P331, DOI 10.1038/85480; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; DIETZEL I, 1986, ANN NY ACAD SCI, V481, P72, DOI 10.1111/j.1749-6632.1986.tb27140.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FISHER RS, 1976, ARCH NEUROL-CHICAGO, V33, P76, DOI 10.1001/archneur.1976.00500020004002; Golarai G, 2001, J NEUROSCI, V21, P8523; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; HEINEMANN U, 1975, BRAIN RES, V93, P63, DOI 10.1016/0006-8993(75)90286-3; HEINEMANN U, 1992, DENTATE GYRUS ITS S, V7, P273; HELEKAR SA, 1992, DEV BRAIN RES, V65, P205, DOI 10.1016/0165-3806(92)90180-5; HERTZ L, 1978, BRAIN RES, V145, P202, DOI 10.1016/0006-8993(78)90812-0; Hinterkeuser S, 2000, EUR J NEUROSCI, V12, P2087, DOI 10.1046/j.1460-9568.2000.00104.x; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412; HUXLEY AF, 1951, J PHYSIOL-LONDON, V112, P496, DOI 10.1113/jphysiol.1951.sp004546; Janigro D, 1997, J NEUROSCI, V17, P2813; JEFFERYS JGR, 1995, PHYSIOL REV, V75, P689; Jennett B, 1975, EPILEPSY NONMISSILE; Jones R.W., 1987, ADV PETROLEUM GEOCHE, V2, P1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Khawaled R, 1999, PFLUG ARCH EUR J PHY, V438, P314, DOI 10.1007/s004240050915; Largo C, 1996, J NEUROSCI, V16, P1219; LOTHMAN EW, 1992, EPILEPSY RES, P301; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUX HD, 1973, EXP BRAIN RES, V17, P190; Maccaferri G, 2002, NEUROPHARMACOLOGY, V43, P523, DOI 10.1016/S0028-3908(02)00161-2; MacFarlane SN, 1997, J NEUROSCI, V17, P7316; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; Masukawa L M, 1999, Adv Neurol, V79, P781; MCBAIN CJ, 1992, BRAIN RES, V592, P255, DOI 10.1016/0006-8993(92)91683-6; MCBAIN CJ, 1993, EPILEPSY MODELS MECH, P437; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MISGELD U, 1992, J NEUROPHYSIOL, V68, P1548; MOODY WJ, 1974, EXP NEUROL, V42, P248, DOI 10.1016/0014-4886(74)90023-5; NEWMAN EA, 1984, SCIENCE, V225, P1174, DOI 10.1126/science.6474173; Nicholson C, 2000, PROG BRAIN RES, V125, P129; Nicholson Charles, 1995, P387; NOEBELS JL, 1978, J NEUROPHYSIOL, V41, P1267; ONOZUKA M, 1987, BRAIN RES, V420, P259, DOI 10.1016/0006-8993(87)91246-7; ORKAND RK, 1966, J NEUROPHYSIOL, V29, P788; PEDLEY TA, 1976, FED PROC, V35, P1254; POLLEN D A, 1970, Science (Washington D C), V167, P1252, DOI 10.1126/science.167.3922.1252; POOLOS NP, 1987, J NEUROPHYSIOL, V58, P404; PRINCE DA, 1973, BRAIN RES, V50, P489, DOI 10.1016/0006-8993(73)90758-0; Ratzliff ADH, 2002, TRENDS NEUROSCI, V25, P140, DOI 10.1016/S0166-2236(00)02122-6; Rose CR, 1996, J PHYSIOL-LONDON, V491, P291, DOI 10.1113/jphysiol.1996.sp021216; Ross ST, 2001, P NATL ACAD SCI USA, V98, P8874, DOI 10.1073/pnas.141042398; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schroder W, 1999, GLIA, V28, P166, DOI 10.1002/(SICI)1098-1136(199911)28:2<166::AID-GLIA8>3.3.CO;2-K; Smirnov S, 1999, J NEUROSCI, V19, P9252; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOMJEN GG, 1985, J NEUROPHYSIOL, V53, P1098; SOMJEN GG, 1979, ANNU REV PHYSIOL, V41, P159, DOI 10.1146/annurev.ph.41.030179.001111; SOMJEN GG, 1984, ELECTROPHYSIOLOGY EP, P303; STASHEFF SF, 1993, J NEUROPHYSIOL, V70, P961; Steinhauser C, 2002, EUR J PHARMACOL, V447, P227, DOI 10.1016/S0014-2999(02)01846-0; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Toth Z, 1997, J NEUROSCI, V17, P8106; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259; Voipio J., 1994, MICROELECTRODE TECHN, P275; Walz W, 2000, NEUROCHEM INT, V36, P291, DOI 10.1016/S0197-0186(99)00137-0; Walz W, 1999, J NEUROSCI RES, V56, P595, DOI 10.1002/(SICI)1097-4547(19990615)56:6<595::AID-JNR5>3.3.CO;2-X; Xiong ZQ, 2000, J NEUROPHYSIOL, V83, P1443; Xiong ZQ, 1999, EUR J NEUROSCI, V11, P1677, DOI 10.1046/j.1460-9568.1999.00587.x	74	29	29	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 2	2003	23	13					5865	5876					12	Neurosciences	Neurosciences & Neurology	697CF	WOS:000183924100054	12843291				2021-06-18	
J	Lee, ZI; Byun, WM; Jang, SH; Ahn, SH; Moon, HK; Chang, YM				Lee, ZI; Byun, WM; Jang, SH; Ahn, SH; Moon, HK; Chang, YM			Diffusion tensor magnetic resonance imaging of microstructural abnormalities in children with brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						diffusion tensor imaging; microstructural abnormality; pediatric; brain injury; rehabilitation	BLUNT-HEAD TRAUMA; WHITE-MATTER; MOTOR RECOVERY; MRI; ORGANIZATION; ANISOTROPY	We present two pediatric cases demonstrating that diffusion tensor imaging is more efficient at revealing microstructural abnormalities of the brain than conventional magnetic resonance imaging because it enables measurements; of the directionality and integrity of white matter fiber tracts. One patient suffered from left hemiparesis, and the other had right hemiparesis. However, whereas conventional magnetic resonance imaging showed only the findings of traumatic contusional hemorrhages in the left temporal and parietal lobes of the first patient and focal encephalomalacia in the left anterior thalamus of the second patient, diffusion tensor imaging successfully disclosed microstructural abnormalities in the right cerebral peduncle of the midbrain of the first patient and in the posterior limb of the left internal capsule of the second. Theses two cases demonstrate that diffusion tensor imaging is more capable than magnetic resonance imaging at detecting the microstructural pathologic lesions that are responsible for clinical motor weakness, especially when conventional magnetic resonance imaging has failed to detect subtle structural abnormalities.	Yeungnam Univ, Dept Phys Med & Rehabil, Sch Med, Nam Ku, Taegu 705717, South Korea; Yeungnam Univ, Dept Diagnost Radiol, Sch Med, Taegu 705717, South Korea; Yeungnam Univ, Dept Pediat, Sch Med, Taegu 705717, South Korea; Kyungpook Natl Univ, Sch Med, Dept Diagnost Radiol, Taegu 702701, South Korea	Jang, SH (corresponding author), Yeungnam Univ, Dept Phys Med & Rehabil, Sch Med, Nam Ku, 317-1 Daemyungdong, Taegu 705717, South Korea.						Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Binkofski F, 1996, ANN NEUROL, V39, P460, DOI 10.1002/ana.410390408; Ciccarelli O, 2001, NEUROLOGY, V56, P926, DOI 10.1212/WNL.56.7.926; GENTRY LR, 1994, RADIOLOGY, V191, P1; Higano S, 2001, AM J NEURORADIOL, V22, P456; Huppi PS, 1998, PEDIATR RES, V44, P584; Huppi PS, 2001, PEDIATRICS, V107, P455, DOI 10.1542/peds.107.3.455; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Mamata H, 2002, AM J NEURORADIOL, V23, P67; MILLER G, 1998, CEREBRAL PALSIES CAU, P112; O'Sullivan M, 2001, NEUROLOGY, V57, P2307, DOI 10.1212/WNL.57.12.2307; Ono J, 1997, PEDIATR NEUROL, V16, P63, DOI 10.1016/S0887-8994(96)00249-4; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Shimony JS, 1998, RADIOLOGY, V209P, P240; Werring DJ, 1998, J NEUROL NEUROSUR PS, V65, P863, DOI 10.1136/jnnp.65.6.863; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; Wieshmann UC, 2001, J NEUROL NEUROSUR PS, V70, P521, DOI 10.1136/jnnp.70.4.521	22	29	29	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL	2003	82	7					556	559		10.1097/01.PHM.0000073830.15643.6A			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	694DC	WOS:000183757700009	12819543				2021-06-18	
J	Imberti, R; Bellinzona, G; Riccardi, F; Pagani, M; Langer, M				Imberti, R; Bellinzona, G; Riccardi, F; Pagani, M; Langer, M			Cerebral perfusion pressure and cerebral tissue oxygen tension in a patient during cardiopulmonary resuscitation	INTENSIVE CARE MEDICINE			English	Article						cardiac arrest; cardiopulmonary resuscitation; brain tissue partial pressure of oxygen; intracranial pressure; cerebral perfusion pressure; cerebral oxygen metabolism	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; BLOOD-FLOW; PO2; SATURATION; ARREST	Objective: To report on the effects of cardiopulmonary resuscitation (CPR) instituted immediately after a cardiac arrest on cerebral perfusion pressure (CPP) and cerebral tissue oxygen tension (PbrO(2)). Design: Case report. Setting: ICU of a university hospital. Patient: A head-injured 17-year-old man submitted to multimodal neurological monitoring underwent sudden cardiac arrest and successful CPR. Interventions: External chest compression, 100% oxygen ventilation, volume expansion and standard ACLS protocols. Measurements and results: Heart rate, ECG, mean arterial blood pressure (MABP), ETCO2, PaO2, intracranial pressure (ICP), CPP and PbrO(2) were continuously monitored during CPR and data recorded at 15-s intervals by a dedicated personal computer. At the onset of the cardiac arrest, PbrO(2) decreased to zero. The institution of CPR resulted in a progressive increase of MABP, CPP and PbrO(2). Assuming, on the basis of previous experimental and clinical reports, 8 mmHg PbrO(2) as a possible ischaemic/hypoxic threshold value, during the first 6.5 min of CPR, PbrO(2) values were below this threshold (range 0-7 mmHg) and CPP values were <25 mmHg for 81.5% of the time. In the following 5.5 min, more efficient CPR generated CPP values >25 mmHg for 77.3% of the time. These values were associated with a PbrO(2) >8 mmHg (range 8-28 mmHg) at all times. Conclusions: In the clinical setting of a witnessed cardiac arrest, immediate institution of CPR can be effective in generating PbrO(2) values above a supposed ischaemic/hypoxic threshold when CPP is >25 mmHg. PbrO(2) monitoring by the Licox system is sensitive and reliable, even at low values, and can be suitable for evaluating cerebral oxygenation during experimental CPR.	IRCCS, Policlin San Matteo, Serv Anestesia & Rianimaz 2, I-27100 Pavia, Italy	Imberti, R (corresponding author), IRCCS, Policlin San Matteo, Serv Anestesia & Rianimaz 2, I-27100 Pavia, Italy.	r.imberti@smatteo.pv.it	Shaheen, Ahmed/AAP-4054-2021	Shaheen, Ahmed/0000-0002-2216-1951			Bruzzone P, 1998, ACT NEUR S, V71, P111; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; FARRAR JK, 1991, J CEREB BLOOD FLOW M, V11, pS553; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; *INT GUID 2000 CPR, 2000, RESUSCITATION, V46, P1; KARIMAN K, 1983, J APPL PHYSIOL, V55, P1057; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Nozari A, 1999, RESUSCITATION, V40, P27, DOI 10.1016/S0300-9572(99)00003-9; SAFAR P, 1986, CIRCULATION, V74, P138; Shaffner DH, 1999, CRIT CARE MED, V27, P1335, DOI 10.1097/00003246-199907000-00026	12	29	29	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUN	2003	29	6					1016	1019		10.1007/s00134-003-1719-x			4	Critical Care Medicine	General & Internal Medicine	697GU	WOS:000183934800028	12664224				2021-06-18	
J	Morgan, A; Ward, E; Murdoch, B; Kennedy, B; Murisop, R				Morgan, A; Ward, E; Murdoch, B; Kennedy, B; Murisop, R			Incidence, characteristics, and predictive factors for dysphagia after pediatric traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; dysphagia; incidence; outcomes; pediatric	HEAD-INJURY; SWALLOWING DISORDERS; HEALTH-CARE; COMPLICATIONS; CHILDREN; ADULTS; MANAGEMENT; EMERGENCY; OUTCOMES; EBM	Objective: (1) To establish an incidence figure for dysphagia in a population of pediatric traumatic brain injury (TBI) cases; (2) to provide descriptive data on the admitting characteristics, patterns of resolution, and outcomes of children with and without dysphagia after TBI; and (3) to identify any factors present at admission that may predict dysphagia. Participants: A total of 1, 145 children consecutively admitted to an acute care setting for traumatic brain injury between July 1995 and July 2000. Main outcome measure: Medical parameters relating to dysphagia based on medical chart review. Results: (1) Dysphagia incidence figure of 5.3% across all pediatric head injury admissions. Incidence figures of 68% for severe TBI, 15% for moderate TBI, and only 1% for mild brain injury. (2) Statistically significant differences were found between the dysphagic and nondysphagic subgroups on the variables of length of stay, length of ventilation, Glasgow Coma Scale (GCS), computed tomography classification, duration of speech pathology intervention, supplemental feeding duration, duration until initiation of oral intake (DIOF), duration to total oral intake (DTOF), and period of time from the initiation of intake until achievement of total oral intake (DI-TOF). (3) Significant predictive factors for dysphagia included GCS < 8.5 and a ventilation period in excess of 1.5 days. Conclusion: The provision of incidence data and predictive factors for dysphagia will enable clinicians in acute care settings to allocate resources necessary to deal with the predicted number of dysphagia cases in a pediatric population, and assist in predicting patients who are at risk for dysphagia following TBI. Early detection of patients with swallowing dysfunction will be aided by these data, in turn helping to facilitate effective medical and speech pathology intervention via assisting the reduction of medical complications such as aspiration pneumonia.	Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia	Morgan, A (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia.		Ward, Elizabeth/F-9652-2010; Murdoch, Bruce E/C-1397-2012; Morgan, Angela/J-5235-2017	Ward, Elizabeth/0000-0002-2680-8978; Morgan, Angela/0000-0003-1147-7405			AITKEN M, 1990, STAT MODELLING GLIM; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; ANDERSON DW, 1980, J NEUROSURG      NOV, pS11; CHAN BSH, 1989, J TRAUMA, V29, P1540, DOI 10.1097/00005373-198911000-00014; Cherney LR, 1996, SEMIN NEUROL, V16, P349, DOI 10.1055/s-2008-1040993; Cherney LR, 1989, J HEAD TRAUMA REHAB, V4, P42; Deb S, 1999, BRAIN INJURY, V13, P369, DOI 10.1080/026990599121557; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Field L H, 1989, Brain Inj, V3, P19, DOI 10.3109/02699058909008069; FORTUNE N, 1999, 15 AIHW DIS; Foster M, 2000, BRAIN INJURY, V14, P1035; Gazarian M, 2001, MED J AUSTRALIA, V174, P586, DOI 10.5694/j.1326-5377.2001.tb143444.x; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hagen C, 1981, TOP LANG DIS, V1, P73; Halper AS, 1999, J HEAD TRAUMA REHAB, V14, P486, DOI 10.1097/00001199-199910000-00009; Hauck KA, 1999, TOP GERIATR REHABIL, V15, P56; Henry P C, 1992, J Neurosci Nurs, V24, P311; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LANZA DC, 1990, LARYNGOSCOPE, V100, P958; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; Little JM, 2001, MED J AUSTRALIA, V174, P641, DOI 10.5694/j.1326-5377.2001.tb143473.x; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; MCLEAN DE, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510000-00003; Mooney GH, 1997, MED J AUSTRALIA, V166, P575, DOI 10.5694/j.1326-5377.1997.tb123266.x; Morgan AS, 1999, J HEAD TRAUMA REHAB, V14, P454, DOI 10.1097/00001199-199910000-00006; MORGAN AS, 1992, J NATL MED ASSOC, V84, P1019; Morgan AT, 2001, ASIA PACIFIC J SPEEC, V6, P9; Morgan T. H., 1894, J MORPHOL, V9, P1, DOI [DOI 10.1002/JMOR.1050090102, 10.1002/jmor.1050090102]; Murgio A, 2001, CHILD NERV SYST, V17, P257, DOI 10.1007/s003810000403; Rowe LA, 1999, J HEAD TRAUMA REHAB, V14, P497, DOI 10.1097/00001199-199910000-00010; Schurr MJ, 1999, J TRAUMA, V46, P817, DOI 10.1097/00005373-199905000-00009; SHARPLES PM, 1990, BRIT MED J, V300, P89; Stoelwinder JU, 2001, MED J AUSTRALIA, V174, P644, DOI 10.5694/j.1326-5377.2001.tb143477.x; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; Tolep K, 1996, CHEST, V109, P167, DOI 10.1378/chest.109.1.167; Venables W. N., 2001, MODERN APPL STAT S P; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Woratyla S P, 1995, Conn Med, V59, P643; Ylvisaker M, 1989, J HEAD TRAUMA REHAB, V4, P51; YORKSTON KM, 1989, J HEAD TRAUMA REHAB, V4, P52	47	29	33	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2003	18	3					239	251		10.1097/00001199-200305000-00002			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	682HM	WOS:000183085700002	12802166				2021-06-18	
J	Blaha, M; Aaslid, R; Douville, CM; Correra, R; Newell, DW				Blaha, M; Aaslid, R; Douville, CM; Correra, R; Newell, DW			Cerebral blood flow and dynamic cerebral autoregulation during ethanol intoxication and hypercapnia	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						alcohol; autoregulation; cerebral blood flow; head injury; hypercapnia; transcranial Doppler ultrasonography	TRAUMATIC BRAIN INJURY; HEAD-INJURY; ALCOHOL; HUMANS; VELOCITY; DOPPLER; ABUSE	More than one-third of patients diagnosed with head injury are intoxicated with ethanol. Most clinical and animal studies have shown alcohol to have a deleterious impact in the setting of cerebrovascular trauma; however, there are also data showing neuroprotective effects in low ethanol doses. Human studies using imaging modalities suggest that small doses of alcohol produce cerebral vasodilatation and higher doses cerebral vasoconstriction. The aim of this study was to investigate the effect of ethanol intake on dynamic cerebral autoregulation and velocities in the middle cerebral arteries, and compare these changes with the effects of hypercapnia. Dynamic cerebral autoregulation and cerebral blood flow velocities were analysed before and after alcohol intake (1.1 g/kg of body weight) in six adult volunteers. Cerebral blood flow velocities in both middle cerebral arteries were monitored continuously by transcranial Doppler. A value for dynamic cerebral autoregulation was calculated from the rate of increase in middle cerebral artery velocities after a rapid-step decrease in arterial blood pressure. A sudden decrease in blood pressure was achieved by the release of previously inflated large blood pressure cuffs around the subject's thighs. Three volunteers were also tested before alcohol intake with CO2 challenge (breathing 6% CO2) during the autoregulation procedure. Blood alcohol level reached 90 mg/dl approximately 60 min after ethanol ingestion. Cerebral blood velocities increased by 8% from baseline for uncorrected end-tidal (et) CO2 and by 24% for correction to et CO2 = 40. Dynamic cerebral autoregulation measured as an autoregulation index decreased from 4.3 +/- 1.3 to 2.9 +/- 1.1 (p = 0.089), which did not reach statistical significance. During hypercapnic conditions, dynamic cerebral autoregulation dropped from 4 +/- 0.8 to 0.9 +/- 0.9. In conclusion, mild alcohol intoxication caused cerebral vasodilatation with a subsequent increase in cerebral blood flow of 8-24%. Dynamic cerebral autoregulation was not found to be significantly impaired by ethanol. Hypercapnia. almost completely destroys the physiological autoregulatory mechanism. A mild hyper-ventilation to etCO(2) = 34-36 may be a compensatory contrameasure for ethanol-induced vasodilatation in the setting of head trauma (C) 2003 Elsevier Science Ltd. All rights reserved.	Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA	Blaha, M (corresponding author), Royal Perth Hosp, Dept Neurosurg, Box X2213 GPO, Perth, WA 6847, Australia.			Blaha, Martin/0000-0002-9611-498X			AASLID R, 1991, STROKE, V22, P1148, DOI 10.1161/01.STR.22.9.1148; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; BERGLUND M, 1987, ACTA PSYCHIAT SCAND, V75, P202, DOI 10.1111/j.1600-0447.1987.tb02775.x; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V7, P93; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; MARKWALDER TM, 1984, J CEREBR BLOOD F MET, V4, P368, DOI 10.1038/jcbfm.1984.54; MATHEW RJ, 1991, AM J PSYCHIAT, V148, P292; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; SANO M, 1993, J STUD ALCOHOL, V54, P369, DOI 10.15288/jsa.1993.54.369; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; TIIHONEN J, 1994, AM J PSYCHIAT, V151, P1505; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1996, ALCOHOL CLIN EXP RES, V20, P1518, DOI 10.1111/j.1530-0277.1996.tb01693.x; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983	20	29	30	1	6	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	MAR	2003	10	2					195	198		10.1016/S0967-5868(02)00126-1			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	661EQ	WOS:000181878600011	12637048				2021-06-18	
J	Donders, J; Woodward, HR				Donders, J; Woodward, HR			Gender as a moderator of memory after traumatic brain injury in children	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						children; gender; memory; traumatic brain injury	HEAD-INJURY; WISC-III; ADOLESCENTS; MILD; RECOVERY; SEX	Objective: To explore the possibility that gender has a moderating effect on memory after pediatric traumatic brain injury (TBI). Design: Controlled group study. Gender effects between and within groups were evaluated by means of effect size comparisons and hierarchical regression analysis. Setting: Regional rehabilitation center. Participants: Seventy children with TBI, selected from a 4-year series of consecutive referrals, and 70 demographically matched controls. Main outcome measures: Screening version of the Wide Range Assessment of Memory and Learning (WRAML-S) and the Wechsler Intelligence Scale for Children-Third Edition (WISC-III). Results: Boys with TBI performed worse than girls with TBI, and worse than their counterparts in the control group, on the WRAML-S. There was no gender effect in the control group. Gender explained an additional 9% of the variance in WRAML-S performance over and above injury severity and age variables. However, gender differences were largely attenuated when speed of information processing, as assessed by the WISC-III, was used as a covariate. Conclusion: The effect of TBI on children's memory appears to be moderated by gender and may be mediated by speed of information processing.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; Pitt Cty Mem Hosp, Greenville, NC USA	Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson VA, 2000, BRAIN INJURY, V14, P679; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; DELIS D, 1994, CALIFORNIA VERBAL LE; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Donders J, 1996, CHILD NEUROPSYCHOL, V2, P185, DOI 10.1080/09297049608402251; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Holmbeck GN, 2002, J PEDIATR PSYCHOL, V27, P87, DOI 10.1093/jpepsy/27.1.87; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; MADIGAN KA, 1997, STUDENTS ACQUIRED BR, P123; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; Murphy KR, 1998, STAT POWER ANAL; RAZ S, 1995, DEV PSYCHOL, V31, P958, DOI 10.1037/0012-1649.31.6.958; RAZ S, 1994, PSYCHOBIOLOGY, V22, P244; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Sheslow D., 1990, WIDE RANGE ASSESSMEN; SHURTLEFF HA, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199510000-00008; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; WABER DP, 1992, J CLIN ONCOL, V10, P810, DOI 10.1200/JCO.1992.10.5.810; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1991, WECHSLER INTELLIGENC; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLIAMS J, 1995, DEV NEUROPSYCHOL, V11, P201, DOI 10.1080/87565649509540613; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Woodward H, 1998, APPL NEUROPSYCHOL, V5, P113, DOI 10.1207/s15324826an0503_1; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; YLVISAKER M, 1994, ED DIMENSIONS ACQUIR, P121	39	29	30	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2003	18	2					106	115		10.1097/00001199-200303000-00002			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	663DU	WOS:000181991600002	12802220				2021-06-18	
J	Mueller, CA; Schluesener, HJ; Conrad, S; Meyermann, R; Schwab, JM				Mueller, CA; Schluesener, HJ; Conrad, S; Meyermann, R; Schwab, JM			Lesional expression of a proinflammatory and antiangiogenic cytokine EMAP II confined to endothelium and microglia/macrophages during secondary damage following experimental traumatic brain injury	JOURNAL OF NEUROIMMUNOLOGY			English	Article						EMAP II; secondary brain damage; traumatic brain injury; inflammation; antiangiogenic	ACTIVATING POLYPEPTIDE-II; TUMOR-NECROSIS-FACTOR; SPINAL-CORD; INFLAMMATORY RESPONSE; VASCULAR ARCHITECTURE; MICROGLIAL CELLS; CORTICAL IMPACT; MACROPHAGES; RAT; ENCEPHALOMYELITIS	We analyzed expression of Endothelial Monocyte-Activating Polypeptide II (EMAP II), a proinflammatory, antiangiogenic cytokine in rat brains after stab wound injury and observed a highly significant (p<0.0001) lesional accumulation confined to microglia/macrophages. Maximum numbers were seen at day 5 declining until 21 days after injury. Further, EMAP II+ microglia/macrophages formed clusters in perivascular Virchow-Robin spaces. Prolonged accumulation of EMAP II+, EDI+ microglia/macrophages and increased lesional numbers of EMAP II+ endothelial/smooth muscle cells during the acute postinjury period might indicate that EMAP II enrich the proinflammatory and antiangiogenic repertoire of effector molecules expressed by activated microglia/macrophages during secondary damage. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Tubingen, Sch Med, Inst Brain Res, D-72076 Tubingen, Germany	Mueller, CA (corresponding author), Univ Tubingen, Sch Med, Inst Brain Res, Calwerstr 2, D-72076 Tubingen, Germany.	Christian-Andreas.Mueller@med.uni-tuebingen.de		Schwab, Jan/0000-0001-6784-4919			Adelson PD, 1998, ACT NEUR S, V71, P104; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bartholdi D, 1997, EUR J NEUROSCI, V9, P2549, DOI 10.1111/j.1460-9568.1997.tb01684.x; Berger AC, 2000, MICROVASC RES, V60, P70, DOI 10.1006/mvre.2000.2249; CARLOS TM, 1994, BLOOD, V84, P2068; Chang SY, 2002, J BIOL CHEM, V277, P8388, DOI 10.1074/jbc.M108792200; CHAO CC, 1992, J IMMUNOL, V149, P2736; COFFEY PJ, 1990, NEUROSCIENCE, V35, P121, DOI 10.1016/0306-4522(90)90126-O; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; ESIRI MM, 1990, J NEUROL SCI, V100, P3, DOI 10.1016/0022-510X(90)90004-7; Fujita T, 1998, ACTA NEUROCHIR, V140, P275, DOI 10.1007/s007010050095; Gerlach C, 1997, LAB INVEST, V77, P697; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hsu CY, 1996, NEUROTRAUMA, P1433; HUITINGA I, 1990, J EXP MED, V172, P1025, DOI 10.1084/jem.172.4.1025; ImperatoKalmar EL, 1997, EXP NEUROL, V145, P322, DOI 10.1006/exnr.1997.6449; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P25106; KAO J, 1994, J BIOL CHEM, V269, P9774; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; LOTAN M, 1994, FASEB J, V8, P1026; LU X, 1991, J NEUROSCI, V11, P972; MALLAT M, 1994, J LEUKOCYTE BIOL, V56, P416; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McIntosh TK, 1996, LAB INVEST, V74, P315; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; MULLIN JM, 1990, CANCER RES, V50, P2172; Murray JC, 2000, AM J PATHOL, V157, P2045, DOI 10.1016/S0002-9440(10)64843-2; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; RINK A, 1995, AM J PATHOL, V147, P1575; RIVADEPATY I, 1994, EXP NEUROL, V128, P77, DOI 10.1006/exnr.1994.1114; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Schwab ME, 1996, PHYSIOL REV, V76, P319; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; STREIT WJ, 1993, J CHEM NEUROANAT, V6, P261, DOI 10.1016/0891-0618(93)90047-8; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Tas MPR, 1996, INT J BIOCHEM CELL B, V28, P837, DOI 10.1016/1357-2725(96)00038-6; TERADA LS, 1992, INFLAMMATION, V16, P13, DOI 10.1007/BF00917511; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Zheng M, 2001, AM J PATHOL, V159, P1021, DOI 10.1016/S0002-9440(10)61777-4	67	29	30	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	FEB	2003	135	1-2					1	9		10.1016/S0165-5728(02)00427-7			9	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	651XW	WOS:000181349500001	12576219				2021-06-18	
J	Simmond, M; Fleming, J				Simmond, M; Fleming, J			Reliability of the self-awareness of deficits interview for adults with traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; IMPAIRED AWARENESS; BEHAVIORAL LIMITATIONS; REHABILITATION; DYSFUNCTION	Primary objective: This paper investigates the test-re-test reliability of the Self-Awareness of Deficits Interview (SADI) for assessing level of self-awareness in clients with traumatic brain injury (TBI). Research design: Twenty rehabilitation clients with TBI were interviewed using the SADI and re-test interviews were conducted 2-4 weeks later. Methods and procedures: Two checklists were used to collect collateral information on the client from significant others and rehabilitation staff. This information was used to assist in assigning SADI scores. Main outcomes and results: High test-re-test reliability was demonstrated for both total (ICC = 0.94) and sub-section scores (ICC = 0.85, 0.86 and 0.86). The results, combined with previous research indicating the high inter-rater reliability of the SADI, suggest the SADI is a reliable means of evaluating level of self-awareness. Further research is required to investigate other psychometric properties of the SADI and the two checklists.	Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia	Fleming, J (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.		Fleming, Jennifer M/B-4436-2011				Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Askenasy J. J. M., 1988, AM J PHYS MED, V66, P315; Barco P.P., 1991, COGNITIVE REHABILITA, P129; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BERQUIST TF, 1993, BRAIN INJURY, V7, P275; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Bowling A., 1997, RES METHODS HLTH INV; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cicerone K. D., 1986, CLIN NEUROPSYCHOLOGY, P59; CICERONE KD, 1989, REHABIL PSYCHOL, V34, P105, DOI 10.1037//0090-5550.34.2.105; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; FLEMING J, 1997, BRIT J OCCUPATIONAL, V60, P295, DOI DOI 10.1177/030802269706000703; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; JOHNSTON MV, 1992, ARCH PHYS MED REHAB, V73, P3; Katz N, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P323; Katz N., 1997, CANADIAN J OCCUPATIO, V64, P53, DOI DOI 10.1177/000841749706400201; KREBS DE, 1984, PHYS THER, V64, P1581; Kreutzer J S, 1988, Brain Inj, V2, P205, DOI 10.3109/02699058809150945; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; LEWIS L, 1991, AWARENESS DEFICIT BR, P63; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; MAHER C, 1993, AUST J PHYSIOTHER, V39, P5; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Newman AC, 2000, BRAIN INJURY, V14, P333; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OTTENBACHER KJ, 1993, AM J OCCUP THER, V47, P10, DOI 10.5014/ajot.47.1.10; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano G. P., 1992, NEUROPSYCHOL REHABIL, P55; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1991, AWARENESS DEFICIT BR, P3; Schlund MW, 1999, BRAIN INJURY, V13, P375, DOI 10.1080/026990599121566; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Toglia J, 2000, NEUROREHABILITATION, V15, P57	53	29	30	0	10	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2003	17	4					325	337		10.1080/0269905021000013219			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	660MP	WOS:000181837200005	12637184				2021-06-18	
J	Armstead, WM				Armstead, WM			Age dependent NMDA contribution to impaired hypotensive cerebral hemodynamics following brain injury	DEVELOPMENTAL BRAIN RESEARCH			English	Article						newborn; cerebral circulation; excitatory amino acid	SUPEROXIDE GENERATION CONTRIBUTES; CHANNEL FUNCTION IMPAIRMENT; NOC/OFQ-INDUCED IMPAIRMENT; HEAD-INJURY; BLOOD-FLOW; CEREBROVASODILATION; RAT; VASOPRESSIN; ENDOTHELIN; RESPONSES	Previous studies have observed that fluid percussion brain injury (FPI) impaired NMDA induced pial artery dilation (PAD) in an age dependent manner. Unrelated studies observed a similar age dependent impairment of hypotensive cerebral autoregulation after FPI. This study was designed to test the hypothesis that NMDA receptor activation contributes to impairment of cerebral autoregulation during hypotension after FPI in an age dependent manner. Therefore, the role of NMDA in impaired hypotensive cerebrovascular regulation after FPI was compared in newborn and juvenile pigs equipped with a closed cranial window. Ten minutes of hypotension (10-15 ml blood/kg) decreased mean arterial blood pressure uniformly in both groups (approximate to44%). In the newborn, hypotensive PAD was blunted within 1 h of FPI but partially protected by pretreatment with the NMDA antagonist MK801 (1 mg/kg i.v.) (34+/-1 vs. 8+/-1 vs. 25+/-2% for sham control, FPI, and FPI-MK801, respectively). Cerebral blood flow (CBF) was reduced during normotension by FPI, further reduced by hypotension, but both were partially protected by MK801 in the newborn (56+/-5, 35+/-2, and 16+/-1 vs. 62+/-6, 45+/-3, and 30+/-2 ml/min 100 g for normotension, nonnotension-FPI, and hypotension-FPI in the absence and presence of MK801, respectively). In contrast, blunted hypotensive PAD was protected significantly less by MK801 in the juvenile (32+/-2 vs. 7+/-2 vs. 16+/-2% for sham control, FPI, and FPI-MK801, respectively). Similarly, MK801 had less protective effect on normotensive and hypotensive CBF values post FPI in the juvenile. These data indicate that NMDA receptor activation contributes to impaired hypotensive cerebral hemodynamics following brain injury in an age dependent manner. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesia, 3400 Spruce St, Philadelphia, PA 19104 USA.						Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Armstead WM, 2000, AM J PHYSIOL-HEART C, V279, pH2188; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; Armstead WM, 2001, PEPTIDES, V22, P39, DOI 10.1016/S0196-9781(00)00354-5; Armstead WM, 2001, J NEUROTRAUM, V18, P615, DOI 10.1089/089771501750291855; Armstead WM, 2001, BRAIN RES, V910, P19, DOI 10.1016/S0006-8993(01)02716-0; Armstead WM, 2001, STROKE, V32, P1408, DOI 10.1161/01.STR.32.6.1408; Armstead WM, 2001, J NEUROTRAUM, V18, P1039, DOI 10.1089/08977150152693737; ARMSTEAD WM, 1999, AM J PHYSIOL, V274, pH1888; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Dobbing J, 1981, SCI F PAEDIATRICS, P744; FARACI FM, 1993, CIRC RES, V72, P476, DOI 10.1161/01.RES.72.2.476; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kulkarni M, 2000, STROKE, V31, P1990, DOI 10.1161/01.STR.31.8.1990; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MERCHANT RE, 1999, ANN NY ACAD SCI, V890, P41; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P625, DOI 10.1001/archpedi.1990.02150300019014; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Tepas J J 3rd, 1995, Semin Pediatr Surg, V4, P120; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	31	29	29	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-3806			DEV BRAIN RES	Dev. Brain Res.	NOV 15	2002	139	1					19	28	PII S0165-3806(02)00511-4	10.1016/S0165-3806(02)00511-4			10	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	618LV	WOS:000179420300003	12414090				2021-06-18	
J	Vela, JM; Yanez, A; Gonzalez, B; Castellano, B				Vela, JM; Yanez, A; Gonzalez, B; Castellano, B			Time course of proliferation and, elimination of microglia/macrophages in different neurodegenerative conditions	JOURNAL OF NEUROTRAUMA			English	Article						cell death; degeneration; inflammation; lesion; microglia; proliferation	CELL NUCLEAR ANTIGEN; DELAYED NEURONAL DEATH; BLOOD-BRAIN-BARRIER; SPINAL-CORD INJURY; MICROGLIAL CELLS; NERVOUS-SYSTEM; FLOW-CYTOMETRY; RAT-BRAIN; PHAGOCYTIC MICROGLIA; DNA FRAGMENTATION	Ablation of the hindlimb area of the sensorimotor cortex produces degeneration in the cortex (invasive traumatic injury) and leads to retrograde and/or anterograde degeneration in the thalamus (non-invasive injury, distal reaction). This provides an useful model to study the proliferation and elimination of microglia/macrophages in different neurodegenerative conditions. Changes in the morphology, distribution and numbers of microglia in the affected cortex and thalamus were analyzed at various time points (12 h to 30 days) after injury. In parallel, proliferation was determined by immunocytochemistry for the proliferating cell nuclear antigen and cell death, by the TUNEL method. Proliferation was an early event in the microglia/macrophage response (from 12 h in the cortex and from 2 days post-lesion in the thalamus) and persisted up to 30 days. The different microglia/macrophage phenotypes proliferated in a specific temporospatial pattern. In the lesioned cortex, early activation and proliferation of intrinsic microglia was accompanied, from the second post-lesion day, by monocyte entrance and proliferation of monocyte-derived cells. In contrast, accumulation of cells in the thalamus resulted from proliferation of intrinsic microglia, without apparent/significant monocytic recruitment. During the subsequent microglia/macrophages removal the majority of the cells in the cortex transformed into ameboid cells devoid of cell processes that progressively accumulated as fully-developed macrophages tissue within the lesion (3-14 days) ultimately migrating out to the meningeal connective tissue (14-30 days). Only some process-bearing cells, remaining in the cortical tissue bordering the lesion, underwent degeneration by 14-21 days post-lesion. In contrast, in the distal. affected thalamic nuclei, microglial cell death occurred by 14-30 days post-lesion. Altogether, this study shows that both the origin and fate of microglia/macrophages depend on the nature of the lesion.	Univ Autonoma Barcelona, Fac Med, Dept Biol Cellular Fisiol & Immunol, Unitat Histol, E-08193 Barcelona, Spain	Castellano, B (corresponding author), Univ Autonoma Barcelona, Fac Med, Dept Biol Cellular Fisiol & Immunol, Unitat Histol, Torre M-5, E-08193 Barcelona, Spain.	Bernardo.Castellano@uab.es	Castellano, Bernardo/G-1428-2010; Gonzalez, Berta/G-6250-2010; Gonzalez, Berta/G-1428-2010	Castellano, Bernardo/0000-0003-1976-971X; Gonzalez, Berta/0000-0002-1860-3980; Vela, Jose Miguel/0000-0002-6809-1477			ACARIN L, 1994, J HISTOCHEM CYTOCHEM, V42, P1033, DOI 10.1177/42.8.8027523; Acarin L, 2001, STROKE, V32, P2394, DOI 10.1161/hs1001.097243; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; ANGELOV DN, 1995, GLIA, V13, P113, DOI 10.1002/glia.440130205; AVANZI GC, 1991, CANCER RES, V51, P1741; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; Bignami Amico, 1995, P843; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Castano A, 1996, NEUROBIOL AGING, V17, P745; CHAMAK B, 1991, NEUROSCIENCE, V45, P513, DOI 10.1016/0306-4522(91)90267-R; CHAMAK B, 1994, J NEUROSCI RES, V38, P221, DOI 10.1002/jnr.490380213; Del Rio-Hortega P., 1932, CYTOLOGY CELLULAR PA, P481; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; Elkabes S, 1996, J NEUROSCI, V16, P2508; Faull RLM, 1985, RAT NERVOUS SYSTEM, V1, P129; GADBOIS DM, 1995, EXP CELL RES, V220, P220, DOI 10.1006/excr.1995.1309; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEHRMANN J, 1995, J NEUROPATH EXP NEUR, V54, P680, DOI 10.1097/00005072-199509000-00010; Gehrmann Jochen, 1995, P883; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, ADV NEUROL, V59, P315; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; GIULIAN D, 1993, STROKE, V24, pI84; Giulian Dana, 1995, P671; Hernandez JMV, 1997, BRAIN RES, V747, P130, DOI 10.1016/S0006-8993(96)01267-X; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; Jones LL, 1997, J NEUROCYTOL, V26, P755, DOI 10.1023/A:1018514415073; Kadota E, 2000, ACT NEUR S, V76, P69; Kalla R, 2001, J COMP NEUROL, V436, P182; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KURKI P, 1988, J IMMUNOL METHODS, V109, P49, DOI 10.1016/0022-1759(88)90441-3; LASSMANN H, 1991, REV NEUROL-FRANCE, V147, P763; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; LAWSON LJ, 1995, IMMUNE RESPONSES NER, P27; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; Leskovar A, 2001, CELL TISSUE RES, V304, P311, DOI 10.1007/s004410000325; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; LOHR F, 1995, CELL PROLIFERAT, V28, P93, DOI 10.1111/j.1365-2184.1995.tb00058.x; Lu J, 2001, J NEUROTRAUM, V18, P399, DOI 10.1089/089771501750170976; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; MATTHEWS DA, 1976, BRAIN RES, V115, P1, DOI 10.1016/0006-8993(76)90819-2; MCCORMICK D, 1992, HISTOPATHOLOGY, V21, P591, DOI 10.1111/j.1365-2559.1992.tb00454.x; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MILLIGAN CE, 1991, J COMP NEUROL, V314, P136, DOI 10.1002/cne.903140113; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Nakajima K, 2001, J BIOCHEM-TOKYO, V130, P169, DOI 10.1093/oxfordjournals.jbchem.a002969; NITATORI T, 1995, J NEUROSCI, V15, P1001; PAXINOS G, 1985, RAT NERVOUS SYSTEM, V1, P487; PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7; PERRY VH, 1992, NEUROPATH APPL NEURO, V18, P454, DOI 10.1111/j.1365-2990.1992.tb00811.x; Polazzi E, 2001, GLIA, V36, P271, DOI 10.1002/glia.1115; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; RIVADEPATY I, 1994, EXP NEUROL, V128, P77, DOI 10.1006/exnr.1994.1114; Shibata H, 1996, NEUROSCI RES, V26, P83, DOI 10.1016/0168-0102(96)01083-8; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; SKOFF RP, 1971, J COMP NEUROL, V141, P133, DOI 10.1002/cne.901410202; Snider BJ, 1999, ANN NY ACAD SCI, V893, P243, DOI 10.1111/j.1749-6632.1999.tb07829.x; Sorensen JC, 1996, EXP BRAIN RES, V112, P203; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Suzuki H, 2001, NEUROSCI LETT, V312, P95, DOI 10.1016/S0304-3940(01)02198-X; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TAKAHASHI T, 1993, J NEUROCYTOL, V22, P1096, DOI 10.1007/BF01235751; THOMPSON D, 1992, SIGHT SOUND, V1, P61; VANGROEN T, 1992, J COMP NEUROL, V324, P427, DOI 10.1002/cne.903240310; VELA JM, 1995, J COMP NEUROL, V361, P602, DOI 10.1002/cne.903610405; Vela JM, 1996, BRAIN RES, V712, P134, DOI 10.1016/0006-8993(95)01422-5; Wang Y, 1998, BRAIN RES, V781, P137, DOI 10.1016/S0006-8993(97)01223-7; WISE SP, 1977, J COMP NEUROL, V175, P129, DOI 10.1002/cne.901750202; Yamashita K, 2000, CELL MOL NEUROBIOL, V20, P541, DOI 10.1023/A:1007007710703; Yoshida Kazunari, 1997, Keio Journal of Medicine, V46, P55; Zietlow R, 1999, EUR J NEUROSCI, V11, P1657, DOI 10.1046/j.1460-9568.1999.00583.x; Zilles K., 1985, RAT NERVOUS SYSTEM, P375; ZIMMER J, 1982, NEUROSCIENCE, V7, P1905, DOI 10.1016/0306-4522(82)90006-9; ZOLZER F, 1994, CELL PROLIFERAT, V27, P685, DOI 10.1111/j.1365-2184.1994.tb01383.x	82	29	30	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2002	19	11					1503	1520		10.1089/089771502320914723			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	620JD	WOS:000179529500010	12490014				2021-06-18	
J	Bondanelli, M; Ambrosio, MR; Margutti, A; Boldrini, P; Basaglia, N; Franceschetti, P; Zatelli, MC; Uberti, ECD				Bondanelli, M; Ambrosio, MR; Margutti, A; Boldrini, P; Basaglia, N; Franceschetti, P; Zatelli, MC; Uberti, ECD			Evidence for integrity of the growth hormone/insulin-like growth factor-1 axis in patients with severe head trauma during rehabilitation	METABOLISM-CLINICAL AND EXPERIMENTAL			English	Article							SEVERE CRANIOCEREBRAL TRAUMA; HORMONE-RELEASING-FACTOR; BRAIN INJURY; CRITICAL ILLNESS; HYPOGONADISM; WITHDRAWAL; RESPONSES; PROGNOSIS; PROLACTIN; SECRETION	Severe traumatic head injury has been recognized to be associated with hypothalamo-hypophyseal impairment and subsequent abnormalities in hormone secretion, which can contribute to a prolonged clinical course and to hampered recovery in many head-injured patients. Most of the data on the growth hormone/insulin-like growth factor -1 (GH/IGF-1) axis function have been obtained early after head injury, whereas GH secretory pattern has not been fully elucidated after patients had left the intensive care unit. We examined the activity of the GH/IGF-1 axis in 16 severely closed head-injured (CHI) patients (14 males; age range, 17 to 47 years; body mass index [BMI], 21.4 +/- 0.8 kg/m(2)) during the rehabilitation period at least 1 month after leaving the intensive care unit and in 12 sex-, age-, and weight-matched healthy controls. The severity of trauma was assessed by the Glasgow Coma Scale (GCS) score (8 or less), posttraumatic amnesia (PTA, more than 24 hours), and initial computed tomography (CT) scan. The clinical picture at time of the study was evaluated by the Rancho Los Amigos Scale of Cognitive Functioning (CFS) and the Functional Independence Measure (FIM). In all subjects, we evaluated basal levels of anterior pituitary hormones, IGF-1, insulin-like growth factor-binding protein (IGFBP)-3, and IGFBP-1, as well as the GH responses to intravenous (IV) infusion of growth hormone-releasing hormone (GHRH) alone, GHRH plus arginine (ARG), and the GH release evoked by somatostatin (SRIH) infusion withdrawal, which is related to endogenous GHRH tone. In all subjects, nutritional parameters and nitrogen balance were normal. Basal plasma concentrations of GH, IGF-1, IGFBP-3, and IGFBP-1 did not significantly differ between CHI patients and controls. The GH responses to GHRH and GHRH plus ARG did not significantly differ between CHI patients (GH peak, 10.7 +/- 3.0 mug/L; area under the curve [AUC], 5.9 +/- 1.5 mug/L . min; and GH peak, 34.7 +/- 6.1 mug/L; AUC, 20.25 +/- 3.3 mug/L . min, respectively) and normal subjects (GH peak at 30 minutes, 7.23 +/- 1.35 mug/L; AUC, 4.7 +/- 0.8 mug/L . min; and GH peak at 60 minutes, 41.0 +/- 5.1 mug/L; AUC, 24.3 +/- 1.7 mug/L . min, respectively). SRIH withdrawal resulted in an unequivocal increase in plasma GH concentrations both in CHI patients and in controls, without any significant difference between the 2 groups. A negative correlation was found between the GH response (DeltaGH peak) to SRIH withdrawal and CFS (r = -.615, P <.005). In conclusion, our study indicates that patients receiving rehabilitation after leaving the intensive care unit for severe traumatic head injury have no significant changes of GH secretion with normal central regulation of the GH-IGF-1 axis. Copyright 2002, Elsevier Science (USA). All rights reserved.	Univ Ferrara, Endocrinol Sect, Dept Biomed Sci & Adv Therapies, I-44100 Ferrara, Italy; Arcispedale St Anna, Dept Rehabil Med, Ferrara, Italy	Uberti, ECD (corresponding author), Univ Ferrara, Endocrinol Sect, Dept Biomed Sci & Adv Therapies, Via Savonarola 9, I-44100 Ferrara, Italy.		Zatelli, Maria Chiara/Y-1160-2019; Zatelli, Maria Chiara/U-2649-2018	ambrosio, maria rosaria/0000-0002-7911-9770; Zatelli, Maria Chiara/0000-0001-8408-7796; Bondanelli, Marta/0000-0001-8071-6559; degli Uberti, Ettore/0000-0002-9441-7223			Baxter RC, 1999, GROWTH HORM IGF RES, V9, P67, DOI 10.1016/S1096-6374(99)80013-6; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Cappa M, 1999, J CLIN ENDOCR METAB, V84, P4426, DOI 10.1210/jc.84.12.4426; Cernak I, 1999, BRAIN INJURY, V13, P1005; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; De Marinis L, 1999, CLIN ENDOCRINOL, V50, P741; Della Corte F, 1998, CRIT CARE MED, V26, P1419; Giustina A, 1998, ENDOCR REV, V19, P717, DOI 10.1210/er.19.6.717; GOTTARDIS M, 1990, INTENS CARE MED, V16, P163, DOI 10.1007/BF01724795; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hatton J, 1997, J NEUROSURG, V86, P779, DOI 10.3171/jns.1997.86.5.0779; JACKSON RD, 1989, AM J PHYS MED REHAB, V68, P18, DOI 10.1097/00002060-198902000-00006; JEEVANANDAM M, 1995, METABOLISM, V44, P1205, DOI 10.1016/0026-0495(95)90017-9; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; MARSHALL LF, 1991, J NEUROSURG, V5, pS14; MELARVIE S, 1995, SURGERY, V117, P402, DOI 10.1016/S0039-6060(05)80060-1; MIKI N, 1988, J ENDOCRINOL, V117, P245, DOI 10.1677/joe.0.1170245; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; TEASDALE G, 1974, LANCET, V2, P81; Uberti ECD, 1997, J CLIN ENDOCR METAB, V82, P2885, DOI 10.1210/jc.82.9.2885; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; Welbourne TC, 1997, BAILLIERE CLIN ENDOC, V11, P699, DOI 10.1016/S0950-351X(97)80974-3; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011	29	29	32	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0026-0495	1532-8600		METABOLISM	Metab.-Clin. Exp.	OCT	2002	51	10					1363	1369		10.1053/meta.2002.34714			7	Endocrinology & Metabolism	Endocrinology & Metabolism	603XU	WOS:000178587200023	12370860				2021-06-18	
J	Lynch, B				Lynch, B			Historical review of computer-assisted cognitive retraining	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acquired brain injury; cognitive retraining software; computer-assisted cognitive retraining; microcomputers; personal digital assistants	TRAUMATIC BRAIN INJURY; REHABILITATION; MEMORY; REMEDIATION; RETENTION; DEFICITS	Objectives: This article details the introduction and development of the use of microcomputers as adjuncts to traditional cognitive rehabilitation of persons with acquired brain injury. Summary: The initial application of video games as therapeutic recreation in the late 1970s was soon followed in the early 1980s by the use of the first personal computers and available educational software. By the mid-1980s, both the IBM PC and Macintosh platforms were established, along with simplified programming languages that allowed individuals without extensive technical expertise to develop their own software. Several rehabilitation clinicians began to produce and market specially written cognitive retraining software for one or the other platform. Their work was detailed and reviewed, as was recently released software from commercial sources. The latter discussion included the latest developments in the rehabilitation applications of personal digital assistants and related organizing, reminding, and dictation devices. A summary of research on the general and specific efficacy of computer-assisted cognitive retraining illustrated the lingering controversy and skepticism that have been associated with this field since its inception. Conclusions: Computer-assisted cognitive retraining (CACR) can be an effective adjunct to a comprehensive program of cognitive rehabilitation. Training needs to be focused, structured, monitored, and as ecologically relevant as possible for optimum effect. Transfer or training or generalizabitity of skills remains a key issue in the field and should be considered the key criterion in evaluating whether to initiate or continue CACR.		Lynch, B (corresponding author), 133 Arch St,Suite 4, Redwood City, CA 94062 USA.						*AG HLTH CAR POL R, 1998, EV REP TECHN ASS; BENEDICT RHB, 1994, SCHIZOPHRENIA BULL, V20, P537, DOI 10.1093/schbul/20.3.537; BENEDICT RHB, 1989, BRIT J CLIN PSYCHOL, V28, P187, DOI 10.1111/j.2044-8260.1989.tb00832.x; BORTNER M, 1960, J NERV MENT DIS, V130, P49, DOI 10.1097/00005053-196001000-00008; BRACY O, 1998, PSSCOGREHAB ULTIMATE; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chen SHA, 1997, BRAIN INJURY, V11, P197; Chute DL, 1988, NEUROPSYCHOLOGY, V2, P41, DOI 10.1037//0894-4105.2.1.41; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cole E, 1999, NEUROREHABILITATION, V12, P39; COLE E, 1999, SW DISTORSION LEICHT; CRAINE JF, 1981, REHABILITATION BRAIN; DILLER L, 1976, CLINICAL PSYCHOLOGIS, V29, P13; Drew B., 1986, COGNITIVE REHABILITA, V4, P26; Engum E. S., 1988, COGNITIVE REHABILITA, V6, P34; ENGUM ES, 1989, COGNITIVE REHABILITA, V7, P22; Engum ES, 1990, COGNITIVE REHABILITA, V8, P20; GIANUTSOS R, 1981, COGREHAB 1; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; GUILMETTE TJ, 1997, POCKET GUIDE BRAIN I; HAGEN C, 1982, COGNITIVE REHABILITA; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; KIRSCH NL, 1987, J HEAD TRAUMA REHAB, V2, P77; LAMBERT EW, 1990, COGNITIVE REHABILITA, V8, P34; LAMBERT EW, 1992, J COGNITIVE REHABIL, V10, P32; Levinson R, 1997, J HEAD TRAUMA REHAB, V12, P85, DOI 10.1097/00001199-199704000-00010; LYNCH W, 1982, COGNITIVE REHABILITA; LYNCH W, 1992, J HEAD TRAUMA REHAB, V7, P106; Lynch W., 1986, COGNITIVE REHABILITA, V4, P14; LYNCH W, 1986, J HEAD TRAUMA REHAB, V1, P79; LYNCH W, 1983, COGN REHABIL, V1, P119; LYNCH W, 1983, VIDEO GAMES HUMAN DE; LYNCH W, 1984, BEHAV ASSESSMENT REH; LYNCH W, 1987, HDB CONTEMPORARY REH; LYNCH W, 1990, J HEAD TRAUMA REHAB, V5, P78; LYNCH W, 1992, J HEAD TRAUMA REHAB, V7, P36; Lynch WJ, 1998, J HEAD TRAUMA REHAB, V13, P91, DOI 10.1097/00001199-199810000-00011; Matthews E, 1991, GLOBAL BIOGEOCHEM CY, V5, P3, DOI 10.1029/90GB02311; McKitrick Leslie A., 1997, Clinical Gerontologist, V17, P58; MEEDER D, 1982, COGNITIVE REHABILITA; MIDDLETON DK, 1991, PERCEPT MOTOR SKILL, V72, P527, DOI 10.2466/PMS.72.2.527-530; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Ray EC, 1997, ARCH CLIN NEUROPSYCH, V12, P491; SANDFORD J, 1985, CAPTAIN COGNITIVE RE; SBORDONE RJ, 1986, PSYCHOTHERAPY PRIVAT, V4, P51; SOHLBERG MM, 1993, J HEAD TRAUMA REHAB, V8, P45, DOI DOI 10.1097/00001199-199303000-00006; STEELE RD, 1989, NEUROPSYCHOLOGIA, V27, P409, DOI 10.1016/0028-3932(89)90048-1; Stuss D., 1985, FRONTAL LOBES; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 2000, NEUROPSYCHOL REV, V10, P233, DOI 10.1023/A:1026464827874; Wood R L, 1987, Int Disabil Stud, V9, P149	56	29	39	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2002	17	5					446	457		10.1097/00001199-200210000-00006			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	610DD	WOS:000178944700006	12802254				2021-06-18	
J	Akasu, T; Muraoka, N; Hasuo, H				Akasu, T; Muraoka, N; Hasuo, H			Hyperexcitability of hippocampal CA1 neurons after fluid percussion injury of the rat cerebral cortex	NEUROSCIENCE LETTERS			English	Article						rat brain; fluid percussion injury; hippocampal CA1; optical recording; field potential; memory dysfunction; post-traumatic seizure	TRAUMATIC BRAIN INJURY; PATHWAY; MODEL	Effects of fluid percussion injury (FPI) of the parietal cerebral cortex on the neuronal activity in the temporal region of the rat hippocampal CA1 area were investigated by using optical and extracellular recording techniques. Application of moderate impact (1.5-2.0 atm) to the parietal cerebral cortex enhanced the optical signal of the neuronal activity in the ipsilateral hippocampal CA1 area. The field potential evoked by the Schaffer collaterals had multiple population spikes in the ipsilateral hippocampal CA1 pyramidal cell layer. Bicuculline (15 muM) increased the amplitude and the number of population spikes of the field potential even after the brain injury. These results suggest that FPI produces hyperexcitability of hippocampal CA1 neurons, probably by increasing the activity of the Schaffer collaterals of hippocampal CA3 neurons. (C) 2002 Published by Elsevier Science Ireland Ltd.	Kurume Univ, Sch Med, Dept Physiol, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Sch Med, Dept Neurosurg, Kurume, Fukuoka 8300011, Japan	Akasu, T (corresponding author), Kurume Univ, Sch Med, Dept Physiol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.						Amaral DG, 1987, HDB PHYSL NERVOUS SY, P211; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bruton CJ, 1988, NEUROPATHOLOGY TEMPO; BUCKMASTER PS, 1994, HIPPOCAMPUS, V4, P393, DOI 10.1002/hipo.450040402; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Golarai G, 2001, J NEUROSCI, V21, P8523; Hasuo H, 2001, NEUROSCI RES, V40, P265, DOI 10.1016/S0168-0102(01)00235-8; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nakagami Y, 1997, NEUROSCIENCE, V81, P1, DOI 10.1016/S0306-4522(97)00161-9; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1994, HIPPOCAMPUS, V4, P250, DOI 10.1002/hipo.450040304; Takeya M, 2002, NEUROSCI RES, V42, P175, DOI 10.1016/S0168-0102(01)00317-0; Toth Z, 1997, J NEUROSCI, V17, P8106	16	29	31	0	3	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	SEP 6	2002	329	3					305	308	PII S0304-3940(02)00707-3	10.1016/S0304-3940(02)00707-3			4	Neurosciences	Neurosciences & Neurology	595JA	WOS:000178104400014	12183037				2021-06-18	
J	Dumas, HM; Haley, SM; Ludlow, LH; Rabin, JP				Dumas, HM; Haley, SM; Ludlow, LH; Rabin, JP			Functional recover in pediatric traumatic brain injury during inpatient rehabilitation	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						inpatient; rehabilitation; pediatrics; outcome measure; brain injuries; function recovery	HEAD-INJURY; FOLLOW-UP; CHILDREN; SEVERITY	Objective: To examine changes in functional status of children with traumatic brain injury by identifying the pattern and amount of change between and within the domains of self-care, mobility, and social function during inpatient rehabilitation and to examine the relationships of age and injury severity to functional recovery. Design: Retrospective descriptive study. Seventy-nine children and adolescents with traumatic brain injury were assessed at inpatient rehabilitation hospital admission and discharge by using the Pediatric Evaluation of Disability Inventory's (PEDI) functional skills and caregiver assistance domains of self-care, mobility, and social function. Results: Admission self-care functional levels were significantly greater than mobility and social function for both PEDI scales. At discharge, significant improvement was noted within all three domains and the amount of change between domains was significantly greater for the mobility domain on both scales. Age was not related to the amount of recovery. Admission functional status was moderately negatively correlated to the change in PEDI scores (ranging from r = -0.432 to -0.681). Conclusions: Variations exist in the recovery of self-care, mobility, and social function capability and independence during inpatient rehabilitation. Self-care was the least affected. Participants showed significant improvement In all domains, with the most recovery in mobility. Children with greater functional deficits demonstrated greater functional gains.	Franciscan Childrens Hosp, Rehabil Ctr, Boston, MA 02135 USA; Res Ctr Children Special Hlth Care Needs, Boston, MA USA; Inpatient Phys Rehabil Program, Boston, MA USA; Boston Univ, Ctr Rehabil Effectiveness, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA; Boston Coll, Lynch Coll Educ, Chestnut Hill, MA 02167 USA	Dumas, HM (corresponding author), Franciscan Childrens Hosp, Rehabil Ctr, 30 Warren St, Boston, MA 02135 USA.						Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BURKE W H, 1990, Brain Injury, V4, P371, DOI 10.3109/02699059009026190; Clark E, 1996, J LEARN DISABIL, V29, P549, DOI 10.1177/002221949602900509; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; Emanuelson I, 1996, CHILD NERV SYST, V12, P460, DOI 10.1007/BF00261625; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Farmer JE, 1996, J LEARN DISABIL-US, V29, P532, DOI 10.1177/002221949602900508; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Haley S.M., 1992, PEDIAT EVALUATION DI; HALEY SM, 1992, PEDIAT PHYS THERAPY, V4, P24; HALEY SM, 1991, PEDIATRIC PHYSICAL T, V3, P177; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; KRIEL RL, 1993, PEDIATR NEUROL, V9, P362, DOI 10.1016/0887-8994(93)90104-K; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; Nichols D.S., 1996, PEDIATR PHYS THER, V8, DOI [https://doi.org/10.1097/00001577-199600810-00004, DOI 10.1097/00001577-199600810-00004]; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; RIVARA FP, 1994, PEDIATR ANN, V23, P12, DOI 10.3928/0090-4481-19940101-06; Swaine BR, 2000, AM J PHYS MED REHAB, V79, P412, DOI 10.1097/00002060-200009000-00002; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; Wright FV, 1993, CAN J REHABIL, V7, P41	29	29	29	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	SEP	2002	81	9					661	669		10.1097/00002060-200209000-00005			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	587UD	WOS:000177661000004	12172518				2021-06-18	
J	Takaoka, M; Tabuse, H; Kumura, E; Nakajima, S; Tsuzuki, T; Nakamura, K; Okada, A; Sugimoto, H				Takaoka, M; Tabuse, H; Kumura, E; Nakajima, S; Tsuzuki, T; Nakamura, K; Okada, A; Sugimoto, H			Semiquantitative analysis of corpus callosum injury using magnetic resonance imaging indicates clinical severity in patients with diffuse axonal injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN INJURY; CLOSED-HEAD INJURY; QUANTITATIVE-ANALYSIS; MRI; STEM; MODEL; COMA	Objective: To evaluate the hypothesis that the extent of corpus callosum injury indicates the depth of shearing lesions in the central brain structure and therefore relates to the clinical severity of diffuse axonal injury. Methods: A simple and objective procedure for semiquantitative analysis of magnetic resonance images (MRI)-the maximum signal intensity ratio (MSIR)-was employed prospectively in 21 patients with diffuse axonal injury but without apparent injury to the ventral pons. All were diagnosed using serial combination MRI scans of fluid attenuated inversion recovery (FLAIR) and T2* weighted gradient echo imaging during the initial two weeks after the injury. The signal intensity ratio between the two regions of interest-the corpus callosum and the normal appearing ventral pons-was calculated serially in mid-sagittal and parasagittal FLAIR image sections in each patient. The MSIR during the study period was determined as a semiquantitative index of corpus callosum injury in each patient. The correlations between MSIR and the duration of unconsciousness, Glasgow outcome scale at six months, and the presence of apparent midbrain injury were investigated. Results: The mean (SD) MSIR value was 1.12 (0.18) at 7.4 (3.1) days after the injury (n = 2 1). MSIR correlated strongly with the duration of unconsciousness (n = 19, R-2 = 0.74, p < 0.0001), and was higher in patients with both an unfavourable GOS outcome (p = 0.020) and apparent midbrain injury (p < 0.001). Conclusions: MSIR, which is a simple and objective procedure for semiquantitative analysis of corpus callosum damage in diffuse axonal injury, correlated with clinical severity. A high MSIR value may indicate the presence of concomitant midbrain injury.	Osaka Prefectural Nakakawachi Med Ctr Acute Med, Higashiosaka, Osaka 5780947, Japan; Osaka Univ, Sch Med, Dept Radiol, Osaka 553, Japan; Osaka Univ, Sch Med, Dept Traumatol, Osaka 553, Japan	Takaoka, M (corresponding author), Osaka Prefectural Nakakawachi Med Ctr Acute Med, 3-4-13 Nishiiwata, Higashiosaka, Osaka 5780947, Japan.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Coulthard A, 1999, BRIT J RADIOL, V72, P742, DOI 10.1259/bjr.72.860.10624339; Gean A, 1994, IMAGING HEAD TRAUMA; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; LAISSY JP, 1993, AM J NEURORADIOL, V14, P145; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Plum F, 1982, DIAGNOSIS STUPOR COM; Shibata Y, 2000, CLIN NEUROL NEUROSUR, V102, P124, DOI 10.1016/S0303-8467(00)00095-0; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Tokutomi T, 1997, ACT NEUR S, V70, P80; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	20	29	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2002	73	3					289	293		10.1136/jnnp.73.3.289			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	588LL	WOS:000177702900013	12185160	Bronze, Green Published			2021-06-18	
J	Auman, KM; Kufera, JA; Ballesteros, MF; Smialek, JE; Dischinger, PC				Auman, KM; Kufera, JA; Ballesteros, MF; Smialek, JE; Dischinger, PC			Autopsy study of motorcyclist fatalities: The effect of the 1992 Maryland motorcycle helmet use law	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							HEAD-INJURIES; IMPACT; COSTS; REPEAL; TRAUMA; RIDERS; CRASHES; USAGE; STATE	Objectives. This study sought to determine the impact of Maryland's all-rider motorcycle helmet law (enacted on October 1, 1992) on preventing deaths and traumatic brain injuries among motorcyclists. Methods. Statewide motorcyclist fatalities occurring during seasonally comparable 33-month periods immediately preceding and following enactment of the law were compared. Results. The motorcyclist fatality rate dropped from 10.3 per 10000 registered motorcycles prelaw to 4.5 postlaw despite almost identical numbers of registered motorcycles. Motorcyclists wearing helmets had a lower risk of traumatic brain injury than those not wearing helmets (odds ratio = 0.31, 95% confidence interval = 0.14. 0.68). Conclusions. Maryland's controversial motorcycle helmet law appears to be an effective public health policy and may be responsible for saving many lives.	Univ Maryland, Natl Study Ctr Trauma & EMS, Baltimore, MD 21201 USA; Off Chief Med Examiner, Baltimore, MD USA	Auman, KM (corresponding author), Univ Maryland, Natl Study Ctr Trauma & EMS, 701 W Pratt St,5th Floor, Baltimore, MD 21201 USA.						BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; CHENIER TC, 1987, ACCIDENT ANAL PREV, V19, P133, DOI 10.1016/0001-4575(87)90032-7; Conrad P, 1996, ACCIDENT ANAL PREV, V28, P193, DOI 10.1016/0001-4575(95)00056-9; Gopalakrishna G, 1998, ANN EMERG MED, V32, P425, DOI 10.1016/S0196-0644(98)70170-2; HEILMAN DR, 1982, ANN EMERG MED, V11, P659, DOI 10.1016/S0196-0644(82)80258-8; JOHNSON RM, 1995, J TRAUMA, V38, P876, DOI 10.1097/00005373-199506000-00008; KELLY P, 1991, ANN EMERG MED, V20, P852, DOI 10.1016/S0196-0644(05)81426-X; KRAUS JF, 1995, AM J PUBLIC HEALTH, V85, P96, DOI 10.2105/AJPH.85.1.96; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; LLOYD LE, 1987, TEX MED, V83, P30; LUNA GK, 1981, WESTERN J MED, V135, P89; May C, 1989, J Emerg Nurs, V15, P389; MCSWAIN NE, 1980, SURG GYNECOL OBSTET, V151, P215; MCSWAIN NE, 1990, J TRAUMA, V30, P1189, DOI 10.1097/00005373-199010000-00002; MUELLEMAN RL, 1992, ANN EMERG MED, V21, P266, DOI 10.1016/S0196-0644(05)80886-8; MURDOCK MA, 1991, WESTERN J MED, V155, P370; *NAT HIGHW TRAFF S, 1998, TRAFF SAF FACTS 1998; NELSON D, 1992, ANN EMERG MED, V21, P279, DOI 10.1016/S0196-0644(05)80888-1; OFFNER PJ, 1992, J TRAUMA, V32, P636, DOI 10.1097/00005373-199205000-00016; ORSAY E, 1995, ANN EMERG MED, V26, P455, DOI 10.1016/S0196-0644(95)70114-1; Peek-Asa C, 1999, ACCIDENT ANAL PREV, V31, P229, DOI 10.1016/S0001-4575(98)00071-2; PeekAsa C, 1997, ANN EMERG MED, V29, P630, DOI 10.1016/S0196-0644(97)70252-X; Rowland J, 1996, AM J PUBLIC HEALTH, V86, P41, DOI 10.2105/AJPH.86.1.41; SARKAR S, 1995, J TRAUMA, V38, P242, DOI 10.1097/00005373-199502000-00017; SHANKAR BS, 1992, ACCIDENT ANAL PREV, V24, P385, DOI 10.1016/0001-4575(92)90051-J; Thurman DJ., 1995, GUIDELINES SURVEILLA; TSAI YJ, 1995, AM J EPIDEMIOL, V142, P974, DOI 10.1093/oxfordjournals.aje.a117746; WATSON GS, 1980, AM J PUBLIC HEALTH, V70, P579, DOI 10.2105/AJPH.70.6.579	28	29	30	0	4	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	AUG	2002	92	8					1352	1355		10.2105/AJPH.92.8.1352			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	578GV	WOS:000177109800034	12144996	Green Published			2021-06-18	
J	Glenn, MB; Burke, DT; O'Neil-Pirozzi, T; Goldstein, R; Jacob, L; Kettell, J				Glenn, MB; Burke, DT; O'Neil-Pirozzi, T; Goldstein, R; Jacob, L; Kettell, J			Cutoff score on the apathy evaluation scale in subjects with traumatic brain injury	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; DISABILITY RATING-SCALE; RELIABILITY; DEPRESSION; VALIDITY; RECOVERY	This cross-sectional study was designed to determine a cutoff score on the Apathy Evaluation Scale (AES) that predicts a clinician's designation of a subject with TBI as apathetic or not. Forty-five outpatients with TBI completed the AES-S, and 37 family members, friends, or significant others filled out the AES-I. Three clinicians prospectively gave their impressions of the presence or absence of apathy and retrospectively chose the degree of apathy on a 7-point subjective rating scale. The data was analysed by logistic regression and Receiver Operating Characteristic (ROC) curve. Sensitivity and specificity were calculated. No cutoff score on the AES-S or AES-I was found to have reasonable sensitivity and specificity with respect to the ability to predict the clinician's designation of a subject as apathetic. The AES requires further study if it is to be used to measure apathy following TBI.	Spaulding Rehabil Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; Northeastern Univ, Sect Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA; Hebrew Rehabil Ctr Aged, Boston, MA 02131 USA	Glenn, MB (corresponding author), Spaulding Rehabil Hosp, 125 Nashua St, Boston, MA 02114 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980034-00] Funding Source: Medline		Beck A. T., 1996, BECK DEPRESSION INVE, VII; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; COREY MR, 1987, COGNITIVE REHABILITA, V5, P28; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; LAVECCHIO FA, 1996, FINAL REPORT MASSACH; Marin R.S., 1996, SEMIN CLIN NEUROPSYC, V1, P304, DOI [10.1053/SCNP00100304, DOI 10.1053/SCNP00100304]; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Okada K, 1997, STROKE, V28, P2437, DOI 10.1161/01.STR.28.12.2437; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Stuss DT., 2000, DIFFERENTIATION STAT, P340; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21	17	29	31	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2002	16	6					509	516		10.1080/02699050110119132			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	569RK	WOS:000176615800005	12119086				2021-06-18	
J	Rose, ME; Huerbin, MB; Melick, J; Marion, DW; Palmer, AM; Schiding, JK; Kochanek, PM; Graham, SH				Rose, ME; Huerbin, MB; Melick, J; Marion, DW; Palmer, AM; Schiding, JK; Kochanek, PM; Graham, SH			Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury	BRAIN RESEARCH			English	Article						brain microdialysis; glucose; glutamate; traumatic brain injury	TRAUMATIC BRAIN INJURY; HUMAN HEAD-INJURY; GLUTAMATE RELEASE; RAT; BW619C89; DAMAGE; ANTAGONISTS; LAMOTRIGINE; ASPARTATE; MECHANISM	Increases in brain interstitial excitatory amino acid (EAA(1)) concentrations after ischemia are ameliorated by use-dependent Na+ channel antagonists and by supplementing interstitial glucose, but the regulation of EAA, after traumatic brain injury (TBI) is unknown. We studied the regulation of EAA, after TBI using the controlled cortical impact model in rats. To monitor changes in EAA,. microdialysis probes were placed in the cortex adjacent to the contusion and in the ipsilateral hippocampus. Significant increases in dialysate EAA, after TBI were found compared to levels measured in sham controls. Treatment with the use-dependent Na+ channel antagonist 619C89 (30 mg/kg i.v.) did not significantly decrease dialysate glutamate compared to vehicle controls in hippocampus (10.4 +/- 2.4 vs. 11.9 +/- 1.6 muM), but there was significant decrease in dialysate glutamate in cortex after 619C89 treatment (19.3 +/- 3 vs. 12.6 +/- 1.1 muM P < 0.05). Addition of 30 mM glucose to the dialysate, a treatment that decreases EAA, after ischemia, had no significant effect upon dialysate glutamate after TBI in cortex (20.0 +/- 4.9 vs. 11.7 +/- 3.4 muM) or in hippocampus ( 10.9 +/- 2.0 vs. 8.9 +/- 2.4 muM). These results suggest that neither increased release of EAAs due to Na+ channel-mediated depolarization nor failure of glutamate reuptake due to glucose deprivation can explain the majority of the increase in EAA, following TBI. (C) 2002 Published by Elsevier Science B.V.	VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15240 USA; Cerebus Ltd, Wokingham, England; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA	Graham, SH (corresponding author), VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15240 USA.	sgra@pitt.edu	Palmer, Alan/AAP-8650-2020; Marion, Donald/AAR-5749-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS 30318] Funding Source: Medline		Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHOI DW, 1987, J NEUROSCI, V7, P357; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; EDWARDS MD, 1994, ANESTHESIOLOGY, V81, pA857; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; HAYES CG, 1989, ARBOVIRUSES EPIDEMIO, V5, P59; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; LEES G, 1993, BRAIN RES, V612, P190, DOI 10.1016/0006-8993(93)91660-K; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; RATAUD J, 1994, NEUROSCI LETT, V172, P19, DOI 10.1016/0304-3940(94)90652-1; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SMITH SE, 1993, NEUROREPORT, V4, P1339, DOI 10.1097/00001756-199309150-00013; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SWANSON RA, 1992, NEUROSCI LETT, V147, P143, DOI 10.1016/0304-3940(92)90580-Z; SWANSON RA, 1994, J CEREBR BLOOD F MET, V14, P1; SWANSON RA, 1994, BRAIN RES, V664, P94, DOI 10.1016/0006-8993(94)91958-5; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; Zauner A, 1996, ACT NEUR S, V67, P40	27	29	32	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 10	2002	935	1-2					40	46	PII S0006-8993(02)02445-9	10.1016/S0006-8993(02)02445-9			7	Neurosciences	Neurosciences & Neurology	555PN	WOS:000175802600006	12062471				2021-06-18	
J	Martin, RCG; Spain, DA; Richardson, JD				Martin, RCG; Spain, DA; Richardson, JD			Do facial fractures protect the brain or are they a marker for severe head injury?	AMERICAN SURGEON			English	Article							REHABILITATION	Facial fractures (FF) have been suggested to protect the brain from severe injury. However, others have stated that facial fractures are a marker for increased risk of brain injury. The aim of this study is to evaluate the association between facial fractures, brain injury, and functional outcome. A retrospective review of our prospective trauma database was performed for blunt trauma patients during a 7-year period (January 1993 through December 1999) at the University of Louisville Hospital. We identified 7324 blunt trauma patients at a Level 1 trauma center. Severity of head injury in patients with and without FF was compared. The severity of brain injury was evaluated by admission Glasgow Coma Score (GCS) as well as specific head, neck, cervical spine, and face Acute Injury Score (AIS). Length of intensive care unit (ICU) stay, hospital stay, and Functional Independence Measures (FIM) score were also identified. A total of 1068 (14.6%) patients were diagnosed with FF; of these 848 (79.4%) patients suffered some form of brain injury by CT abnormality, clinical examination, or both. A total of 2192 patients were treated for head injury without FF; 220 patients were treated for FF without head injury. FF with traumatic brain injury (TBI) were found to occur significantly greater than FFs without TBI (P < 0.001). The mean GCS on admission for FF with head injury was 12, which was similar to that of patients with head injury alone with a GCS of 10 but was significantly less than that of patients with FF alone with a GCS of 15 (P < 0.05). Injury Severity Score for patients with FF and head injury was significantly worse compared with patients with head injury alone and those with FF alone (P < 0.0001). Mean ICU stay and hospital stay were similar for all three groups (ranges 3-6 and 6-12 days); and were not significant (P < 0.06). FIM score was significantly lower for patients with FF and head injury compared with FF alone (P = 0.0003) and similar to that of patients with head injury. FF were found to have a significantly greater incidence of TBI. FF with TBI had a similar severity of head injury when compared with patients with head injury alone by demonstrating similar GCS, AIS of the head and neck, and early functional recovery. This analysis does not support the hypothesis that the face provides a protective effect for the brain and therefore leading to a more favorable short-term outcome. Thus patients with facial fractures should be treated with the same caution as patients with significant blunt head trauma.	Univ Louisville, Dept Surg, Louisville, KY 40292 USA; Univ Louisville Hosp, Trauma Inst, Louisville, KY USA	Martin, RCG (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.						ADEKEYE EO, 1980, ORAL SURG ORAL MED O, V49, P491, DOI 10.1016/0030-4220(80)90068-7; Chesnut R, 1999, EVIDENCE REPORT REHA, P1; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; HAUG RH, 1990, J ORAL MAXIL SURG, V48, P926, DOI 10.1016/0278-2391(90)90004-L; HAUG RH, 1992, J ORAL MAXILLOFAC SU, V530, P218; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; LIM LH, 1993, BRIT J PLAST SURG, V46, P635, DOI 10.1016/0007-1226(93)90191-D; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MORGAN B D G, 1972, British Journal of Plastic Surgery, V25, P147, DOI 10.1016/S0007-1226(72)80037-7; OLSON RA, 1982, J ORAL MAXIL SURG, V40, P23, DOI 10.1016/S0278-2391(82)80011-6; Plaisier BR, 2000, J ORAL MAXIL SURG, V58, P708, DOI 10.1053/joms.2000.7250; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SINCLAIR D, 1988, Journal of Emergency Medicine, V6, P109, DOI 10.1016/0736-4679(88)90148-5; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0	17	29	30	0	0	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	MAY	2002	68	5					477	481					5	Surgery	Surgery	549ER	WOS:000175432000017	12017150				2021-06-18	
J	Pettersen, JA				Pettersen, JA			Does rugby headgear prevent concussion? Attitudes of Canadian players and coaches	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INJURY; PERFORMANCE	Objectives: To examine the attitudes of players and coaches to the use of protective headgear, particularly with respect to the prevention of concussion. Methods: A questionnaire designed to assess attitudes to headgear was administered to 63 players from four different Canadian teams, each representing a different level of play (high school, university, community club, national). In addition, coaches from all four levels were questioned about team policies and their personal opinions about the use of headgear to prevent concussion. Results: Although the players tended to believe that the headgear could prevent concussion (62%), the coaches were less convinced (33%). Despite the players' belief that headgear offers protection against concussion, only a minority reported wearing headgear (27%) and few (24%) felt that its use should be made mandatory. Common reasons for not wearing headgear were "its use is not mandatory", "it is uncomfortable", and "it costs too much". Conclusion: Although most players in the study believe that rugby headgear may prevent concussion, only a minority reported wearing it. Coaches tended to be less convinced than the players that rugby headgear can prevent concussion.	Univ Toronto, Toronto, ON, Canada	Pettersen, JA (corresponding author), Foothills Prov Gen Hosp, Dept Clin Neurosci, 1403-29th St NW, Calgary, AB T2N 2T9, Canada.						Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GERRARD DF, 1994, BRIT J SPORT MED, V28, P229, DOI 10.1136/bjsm.28.4.229; GRONWALL D, 1975, LANCET, V2, P995; Gronwall D, 1989, MILD HEAD INJURY, P153; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; *IRB, 1996, LAW 4M 98G STAND PER; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MARIADAS AC, 1989, NIMHANS J, V7, P37; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Pettersen JA, 2000, PSYCHOBIOLOGY, V28, P81; ROY S, 1974, S AFR MED J, V2, P2321; Wilson BD, 1998, SPORTS MED, V25, P333, DOI 10.2165/00007256-199825050-00005	19	29	30	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	FEB	2002	36	1					19	22		10.1136/bjsm.36.1.19			4	Sport Sciences	Sport Sciences	521YU	WOS:000173869600009	11867487	Green Published, Bronze			2021-06-18	
J	Tolentino, PJ; DeFord, SM; Notterpek, L; Glenn, CC; Pike, BR; Wang, KKW; Hayes, RL				Tolentino, PJ; DeFord, SM; Notterpek, L; Glenn, CC; Pike, BR; Wang, KKW; Hayes, RL			Up-regulation of tissue-type transglutaminase after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						quantitative PCR; transglutaminase; traumatic brain injury	CORTICAL IMPACT INJURY; HUMAN HEAD-INJURY; CROSS-LINKING; ALZHEIMERS-DISEASE; BINDING PROTEIN; RAT-BRAIN; ALPHA-1-ADRENERGIC RECEPTOR; PHOSPHOLIPASE-C; AMYLOID PROTEIN; SPINAL-CORD	Tissue-type transglutaminase (tTG, EC 2.3.2.13) has been implicated in various disease paradigms including neurodegenerative disease. In these studies, tTG induction after traumatic brain injury was studied using a rat cortical impact model. Using western blots, two forms of tTG protein expression were identified - a similar to79-kDa primary form (tTG-L) and a less abundant similar to70-kDa form (tTG-S). Both forms of tTG protein were elevated after injury. In ipsilateral cortex, peak induction of tTG-L protein [561% +/- 80% of control (n = 5)] was observed five days after injury, with expression remaining elevated after two weeks. Peak induction of tTG-S protein [302% +/-81% of control (n = 5)] was observed three days after injury. Lesser tTG protein induction was observed in hippocampus. Northern blot analysis demonstrated two tTG transcripts in the ipsilateral cortex with peak induction of tTG-L mRNA three days after injury. However, tTG-S mRNA was not identified in control samples and only faintly detected in injured tissue. To facilitate analysis of low abundance transcripts in smaller tissue samples, a semiquantitative real-time PCR strategy was used. Semi-quantitative PCR analysis of tTG-L mRNA induction in ipsilateral cortex (peak after three days; 414% +/- 21% of control, n = 3) confirmed tTG-L mRNA induction determined by northern blot (410% of control).	Univ Florida, Dept Neurosci, Evelyn F & William L McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Gainesville, FL 32611 USA; Pfizer Inc, Dept Neurosci Therapeut, Ann Arbor, MI USA	Hayes, RL (corresponding author), Univ Florida, Dept Neurosci, Evelyn F & William L McKnight Brain Inst, Ctr Traumat Brain Injury Studies, 100 S Newell Dr,Box 100244, Gainesville, FL 32611 USA.			Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39091, R01 NS40182] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039091, R01NS040182] Funding Source: NIH RePORTER		ANDO M, 1993, BRAIN RES, V604, P64, DOI 10.1016/0006-8993(93)90352-N; Appelt DM, 1996, J HISTOCHEM CYTOCHEM, V44, P1421, DOI 10.1177/44.12.8985134; Appelt DM, 1997, BRAIN RES, V745, P21, DOI 10.1016/S0006-8993(96)01121-3; Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; DAS T, 1993, J BIOL CHEM, V268, P27398; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUDEK SM, 1993, J NEUROCHEM, V61, P1159, DOI 10.1111/j.1471-4159.1993.tb03636.x; DUDEK SM, 1994, BRAIN RES, V651, P129, DOI 10.1016/0006-8993(94)90688-2; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; Feng JF, 1999, BIOCHEMISTRY-US, V38, P2224, DOI 10.1021/bi9823176; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Fujita K, 1995, NEUROCHEM RES, V20, P1195, DOI 10.1007/BF00995383; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GILAD GM, 1985, J NEUROCHEM, V44, P1385, DOI 10.1111/j.1471-4159.1985.tb08774.x; GILAD GM, 1985, J NEUROCHEM, V45, P1522, DOI 10.1111/j.1471-4159.1985.tb07222.x; Gorza L, 1997, AM J PATHOL, V150, P2087; GREENBERG CS, 1991, FASEB J, V5, P3071; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; HO GJ, 1994, FEBS LETT, V349, P151, DOI 10.1016/0014-5793(94)00663-6; HUBSCHMANN OR, 1985, J NEUROSURG, V62, P698, DOI 10.3171/jns.1985.62.5.0698; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; IKURA K, 1993, FEBS LETT, V326, P109, DOI 10.1016/0014-5793(93)81772-R; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; MACCIONI RB, 1986, MOL CELL BIOCHEM, V69, P161; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MILLER ML, 1995, J NEUROCHEM, V65, P1760; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; Murthy SNP, 1998, J NEUROCHEM, V71, P2607; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nemes Z, 1997, J BIOL CHEM, V272, P20577, DOI 10.1074/jbc.272.33.20577; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Park ES, 1998, BIOCHEM J, V331, P283, DOI 10.1042/bj3310283; PERRY MJM, 1993, INT J DEV NEUROSCI, V11, P325, DOI 10.1016/0736-5748(93)90004-W; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; RINK A, 1995, AM J PATHOL, V147, P1575; Rostworowski M, 1997, J NEUROSCI, V17, P3664; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SELKOE DJ, 1982, P NATL ACAD SCI-BIOL, V79, P6070, DOI 10.1073/pnas.79.19.6070; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TETZLAFF W, 1988, BRAIN RES, V445, P142, DOI 10.1016/0006-8993(88)91083-9; WOODRING JH, 1991, J THORAC IMAG, V6, P1, DOI 10.1097/00005382-199104000-00003; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang W, 1998, ACTA NEUROPATHOL, V96, P395, DOI 10.1007/s004010050910	59	29	29	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	FEB	2002	80	4					579	588		10.1046/j.0022-3042.2001.00726.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	522NQ	WOS:000173903800004	11841565				2021-06-18	
J	Nandoe, RDS; Scheltens, P; Eikelenboom, P				Nandoe, Rishi D. S.; Scheltens, Philip; Eikelenboom, Piet			Head trauma and Alzheimer's disease A case report and review of the literature	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; head trauma; inflammation; atrophy; cholinesterase inhibitors; ApoE; amyloid		The authors describe a case of a 55 year old woman who was diagnosed with Alzheimer's disease 1.5 years after a car accident in which she experienced a mild concussion. Extensive history taking disclosed no cognitive changes prior to the car accident. The case is discussed in view of the inflammation hypothesis regarding Alzheimer's disease and the role of the apolipoprotein E4 genotype of the patient.	[Nandoe, Rishi D. S.; Scheltens, Philip] Vrije Univ, Dept Neurol, Med Ctr, POB 7057, NL-1007 MB Amsterdam, Netherlands; [Eikelenboom, Piet] Vrije Univ, Dept Psychiat, Med Ctr, Amsterdam, Netherlands	Scheltens, P (corresponding author), Vrije Univ, Dept Neurol, Med Ctr, POB 7057, NL-1007 MB Amsterdam, Netherlands.	p.scheltens@vumc.nl	Eikelenboom, Piet/AAF-6359-2020; Scheltens, Philip/AAL-9631-2020	Scheltens, Philip/0000-0002-1046-6408			ABRAHAM CR, 1989, BIO-TECHNOL, V7, P147, DOI 10.1038/nbt0289-147; ABRAHAM CR, 1992, RES IMMUNOL, V143, P631, DOI 10.1016/0923-2494(92)80047-O; ALLSOP D, 1986, NEUROSCI LETT, V68, P252, DOI 10.1016/0304-3940(86)90152-7; ANDERSEN K, 1995, NEUROLOGY, V45, P1441, DOI 10.1212/WNL.45.8.1441; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; Blain H., 1998, PRESSE MED, V15, P725; Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; Eikelenboom P, 1998, EXP NEUROL, V154, P89, DOI 10.1006/exnr.1998.6920; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GENTLEMAN SM, 1989, HISTOCHEMISTRY, V92, P355, DOI 10.1007/BF00500553; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Graham D.I., ACTA NEUROCHIR S, V73, P89; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Jorm A.F., MED J AUST, V167, P443; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MENDEZ MF, 1992, NEUROLOGY, V42, P770, DOI 10.1212/WNL.42.4.770; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Pasquier F, 1997, J NEUROL, V244, P135, DOI 10.1007/s004150050064; Perez M, 2002, EUR J BIOCHEM, V269, P1484, DOI 10.1046/j.1432-1033.2002.02794.x; PERRY G, 1998, PROGR HPLC, V7, P93; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; ROCCA WA, 1986, ANN NEUROL, V19, P415, DOI 10.1002/ana.410190502; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; TARDIFF B, 1994, CIRCULATION, V90, P201; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tokuda T, 1993, No To Shinkei, V45, P1109; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; vanDuijn CM, 1996, J NEUROL NEUROSUR PS, V60, P478, DOI 10.1136/jnnp.60.5.478; vanMuiswinkel FL, 1996, J NEUROCHEM, V66, P2468	37	29	30	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2002	4	4					303	308		10.3233/JAD-2002-4405			6	Neurosciences	Neurosciences & Neurology	VI5JU	WOS:000493366100005	12446932				2021-06-18	
J	Gorgulu, AK; Palaoglu, S; Ismailoglu, O; Tuncel, M; Surucu, MT; Erbil, M; Kilinc, K				Gorgulu, AK; Palaoglu, S; Ismailoglu, O; Tuncel, M; Surucu, MT; Erbil, M; Kilinc, K			Effect of melatonin on cerebral edema in rats	NEUROSURGERY			English	Article						cold injury; edema; melatonin	TRAUMATIC BRAIN-INJURY; OXYGEN-FREE-RADICALS; NITRIC-OXIDE; NEUROHORMONE MELATONIN; SCAVENGING ACTIVITY; ANTIOXIDANT; SUPEROXIDE; DAMAGE; CELL; PEROXYNITRITE	OBJECTIVE: Melatonin (5-methoxy-N-acetyltrypamine), a chemical naturally produced in the pineal gland, has been suggested to be a free radical scavenger and an antioxidant. In the present study, the effect of melatonin on cold-induced brain edema was evaluated by determination of cerebral water content, blood-brain barrier permeability, and areas of infarct; the effects were also studied histopathologically. METHODS: Brain edema was produced in rats by creating a lesion via cortical freezing. Animals were separated into four groups: sham-operated (craniectomy only); control (cold injury); sham-vehicle (cold injury plus saline); and melatonin treatment (cold injury plus melatonin). Melatonin was administered (50 mg/kg intraperitoneally) 15 minutes after the cold injury was induced. Twenty-four hours later, tissue samples from the core, from the periphery of the cold-injured hemisphere, and from the contralateral hemisphere symmetrical to the cold injury were obtained. RESULTS: Melatonin treatment reduced edema (mean +/- standard deviation; 86.22 +/- 1.54% in the control group versus 80.78 +/- 2.76% in the melatonin treatment group, P < 0.001) and blood-brain barrier permeability (45.34 +/- 2.75% in the control group versus 38.26 +/- 3.40% in the melatonin treatment group, P < 0.001) at the periphery of cold injury. Area of infarct reduced from 5.84 +/- 0.58% in the control group to 3.30 +/- 0.89% in the melatonin treatment group (P < 0.001). The effect of melatonin was also confirmed histopathologically. CONCLUSION: Melatonin was found to be neuroprotective in instances of cold-induced brain edema. Thus, melatonin may be a valuable therapeutic agent in the treatment of cerebral edema.	Trakya Univ, Tip Fak, Sch Med, Dept Neurosurg, TR-22030 Edirne, Turkey; Hacettepe Univ, Sch Med, Dept Neurosurg, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Anat, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Physiol, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Biochem, TR-06100 Ankara, Turkey	Gorgulu, AK (corresponding author), Trakya Univ, Tip Fak, Sch Med, Dept Neurosurg, TR-22030 Edirne, Turkey.	askingorgulu@hotmail.com	Gorgulu, Ahmet Orhan/W-1964-2018; Hayran, Murvet/H-5747-2013; Tuncer, Meltem/E-9982-2013	Hayran, Murvet/0000-0001-6058-6304; Tuncer, Meltem/0000-0003-0341-7277			Antolin I, 1996, FASEB J, V10, P882; BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bettahi I, 1996, J PINEAL RES, V20, P205, DOI 10.1111/j.1600-079X.1996.tb00260.x; CHAN PH, 1984, FED PROC, V43, P210; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; DEMURA N, 1995, NEUROSCI LETT, V192, P109, DOI 10.1016/0304-3940(95)11629-B; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; Guerrero JM, 1997, J PINEAL RES, V23, P24, DOI 10.1111/j.1600-079X.1997.tb00331.x; Houkin Kiyohiro, 1996, Neurologia Medico-Chirurgica, V36, P72, DOI 10.2176/nmc.36.72; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IKEDA Y, 1994, ACTA NEUROCHIR, P136; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; KIRKALI Z, 1995, J UROLOGY, V154, P1939, DOI 10.1016/S0022-5347(01)66830-7; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KUWASHIMA J, 1976, BRAIN RES, V110, P547, DOI 10.1016/0006-8993(76)90865-9; LEHOUX S, 1992, BRIT J PHARMACOL, V107, P996, DOI 10.1111/j.1476-5381.1992.tb13397.x; Manev H, 1996, FASEB J, V10, P1546; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; PALAOGLU S, 1994, ACTA NEUROCHIR, V128, P1, DOI 10.1007/BF01400645; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; PIERREFICHE G, 1995, EXP GERONTOL, V30, P213, DOI 10.1016/0531-5565(94)00036-3; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1995, J PINEAL RES, V18, P1, DOI 10.1111/j.1600-079X.1995.tb00133.x; Reiter RJ, 1997, ANN NY ACAD SCI, V825, P70, DOI 10.1111/j.1749-6632.1997.tb48415.x; REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014; REITER RJ, 1993, NEUROENDOCRINOL LETT, V15, P103; Reiter RJ, 1996, EUR J ENDOCRINOL, V134, P412, DOI 10.1530/eje.0.1340412; SELTZER A, 1992, ENDOCRINOLOGY, V130, P1896, DOI 10.1210/en.130.4.1896; TASDEMIR O, 1993, ANN THORAC SURG, V56, P305; TOMINAGA T, 1995, CENTRAL NERVOUS SYST, P85; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807	40	29	29	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2001	49	6					1434	1441					8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	497UU	WOS:000172474500036	11846944				2021-06-18	
J	Tate, RL; Perdices, M; Pfaff, A; Jurjevic, L				Tate, RL; Perdices, M; Pfaff, A; Jurjevic, L			Predicting duration of posttraumatic amnesia (PTA) from early PTA measurements	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive disorders; Galveston Orientation and Amnesia Test; Modified Oxford PTA Scale; posttraumatic amnesia; rehabilitation; traumatic brain injury	TRAUMATIC BRAIN INJURY; CLOSED-HEAD INJURY; POST-COMA DISTURBANCE; GALVESTON ORIENTATION; NONLINEAR PREDICTORS; PRACTICAL SCALE; RECOVERY; REHABILITATION; SEVERITY; MEMORY	Objectives: To determine a set of variables that would reliably predict duration of posttraumatic amnesia (PTA) in patients with traumatic brain injury and to test the efficacy of the model. Design: Simultaneous standard multiple regression analyses. Participants: Two independent samples of patients with traumatic brain injury who were in the early stages of PTA: a test sample (n = 61) and a cross-validation sample (n = 25). Main Outcome Measure: The Modified Oxford PTA Scale (MOPTAS) is a 12-item test measuring orientation (8 items) and anterograde memory (4 items). The Galveston Orientation and Amnesia Test (GOAT) was also used on a subset of the test sample. Procedure: Patients were examined daily until they emerged from PTA. Results: A statistically significant model, using three predictor variables, was derived that reliably predicted duration of PTA, accounting for 89% of the variance. A second model, using two predictor variables readily available to the clinician (day posttrauma on which PTA testing began and aggregate PTA scores over the first 5 days of testing) had comparable predictive accuracy. A third model, using GOAT data, was also statistically significant and successfully accounted for 72% of the variance. The MOPTAS model showed excellent application to an independent (validation) sample, with an intraclass correlation coefficient between observed and predicted durations of PTA of 0.95. Regression equations for all three models are provided to enable calculation of the predicted duration of PTA. Conclusions: These models can be readily applied in clinical practice and will provide clinically useful estimates of the duration of PTA within the first week of testing after admission to rehabilitation. This information will be important in terms of family counseling and planning of rehabilitation programs.	Univ Sydney, Royal Rehabil Ctr, Dept Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Univ Sydney, Royal N Shore Hosp, Dept Psychol Med, Dept Neurol, Sydney, NSW 2006, Australia; Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia	Tate, RL (corresponding author), Univ Sydney, Royal Rehabil Ctr, Dept Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia.		Perdices, Michael/AAW-4945-2020	Perdices, Michael/0000-0001-9198-011X			Ahmed S, 2000, BRAIN INJURY, V14, P765; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P675; Dowler RN, 2000, BRAIN INJURY, V14, P117, DOI 10.1080/026990500120781; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FORRESTER G, 1995, J FARR SERVICES POST; Garner A, 1999, AUST NZ J SURG, V69, P697, DOI 10.1046/j.1440-1622.1999.01688.x; GEFFEN GM, 1991, NEUROREPORT, V2, P105, DOI 10.1097/00001756-199102000-00010; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; HASLAM C, 1995, NEUROPSYCHOLOGY, V9, P599, DOI 10.1037/0894-4105.9.4.599; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Jain N, 2000, CLIN NEUROPSYCHOL, V14, P13, DOI 10.1076/1385-4046(200002)14:1;1-8;FT013; Jennett B, 1981, MANAGEMENT HEAD INJU; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MAROSSZEKY NEV, 1993, CLIN NEUROPSYCHOL, V7, P85, DOI 10.1080/13854049308401890; McFarland K, 2001, CLIN NEUROPSYCHOL, V15, P59, DOI 10.1076/clin.15.1.59.1916; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mysiw WJ, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199612000-00003; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; MYSIW WJ, 1996, MED REHABILITATION T, P53; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SANEDA D L, 1992, Brain Injury, V6, P167, DOI 10.3109/02699059209029655; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Snow P, 1995, TRAUMATIC BRAIN INJU, P33; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; Tate RL., 2000, BRAIN IMPAIR, V1, P116; TEASDALE G, 1974, LANCET, V2, P81; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	40	29	30	0	2	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2001	16	6					525	542		10.1097/00001199-200112000-00002			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	501AL	WOS:000172660800002	11732969				2021-06-18	
J	Nygren, C; Adami, J; Ye, W; Bellocco, R; af Geijerstam, JL; Borg, J; Nyren, O				Nygren, C; Adami, J; Ye, W; Bellocco, R; af Geijerstam, JL; Borg, J; Nyren, O			Primary brain tumors following traumatic brain injury - a population-based cohort study in Sweden	CANCER CAUSES & CONTROL			English	Article						brain tumor; epidemiology; risk factor; traumatic brain injury	LOS-ANGELES COUNTY; EXPLORATORY CASE-CONTROL; RISK-FACTORS; HEAD TRAUMA; ADULTS; CANCER; MENINGIOMAS; GLIOMA; EPIDEMIOLOGY	Objectives: The aim of this study was to explore the association between traumatic brain injury and brain tumor development. Methods: A cohort of patients hospitalized for traumatic brain injury during 1965-1994 was compiled using the Swedish Inpatient Register. Complete follow-up through 1995 was attained through record linkage with the Swedish Cancer Register, the Cause of Death Register, and the Emigration Register. Standardized incidence ratios (SIRs), defined as the ratios of the observed to the expected numbers of brain tumors, were used as the measure of relative risk. The expected number of brain tumors was calculated by multiplying the observed person-time by age-, gender- and calendar year-specific incidence-rates derived from the general Swedish population. Results: The cohort included 311,006 patients contributing 3,225,317 person-years. A total of 281 cases of brain tumors were diagnosed during follow-up. No associations were found between traumatic brain injury and the risk of primary brain tumors, neither overall (SIR: 1.0; 95% confidence interval (CI): 0.9-1.2), nor in analyses broken down by main groups of brain tumors. Stratified analyses according to age at entry into the cohort, year of follow-up, and severity of the brain injury all showed essentially the same null results. Conclusion: No association between traumatic head injury and primary brain tumors has been found.	Danderyd Hosp, Karolinska Inst, Dept Rehabil Med, SE-18288 Stockholm, Sweden; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden; Swedish Council Technol Assessment Hlth Care, Stockholm, Sweden	Nygren, C (corresponding author), Danderyd Hosp, Karolinska Inst, Dept Rehabil Med, SE-18288 Stockholm, Sweden.		Bellocco, Rino/E-7674-2018; Adami, Johanna/AAA-3312-2021; Ye, Weimin/A-5939-2008	Borg, Jorgen/0000-0002-2372-7478			BARNETT GH, 1986, NEUROSURGERY, V18, P75, DOI 10.1227/00006123-198601000-00012; BONDY M, 1994, J NEURO-ONCOL, V18, P69, DOI 10.1007/BF01324606; Breslow NE, 1987, IARC SCI PUBLICATION, V82; BURCH JD, 1987, J NATL CANCER I, V78, P601; CARPENTER AV, 1987, AM J PUBLIC HEALTH, V77, P1180, DOI 10.2105/AJPH.77.9.1180; CHOI NW, 1970, AM J EPIDEMIOL, V91, P467, DOI 10.1093/oxfordjournals.aje.a121158; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; HOCHBERG F, 1984, NEUROLOGY, V34, P1511, DOI 10.1212/WNL.34.11.1511; HOWE GR, 1989, CANCER RES, V49, P4349; Hu JF, 1998, CANCER DETECT PREV, V22, P100, DOI 10.1046/j.1525-1500.1998.CDOA22.x; Inskip PD, 1998, CANCER CAUSE CONTROL, V9, P109, DOI 10.1023/A:1008861722901; Inskip PD, 1995, EPIDEMIOL REV, V17, P382; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; *NAT BOARD HLTH WE, 1999, CANC INC SWED 1996 S; Nilsson A C, 1994, Lakartidningen, V91, P603; NYREN O, 1995, J NATL CANCER I, V87, P28, DOI 10.1093/jnci/87.1.28; Preston-Martin S, 1998, INT J EPIDEMIOL, V27, P579, DOI 10.1093/ije/27.4.579; PrestonMartin S, 1996, NEUROL CLIN, V14, P273, DOI 10.1016/S0733-8619(05)70256-5; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; PRESTONMARTIN S, 1980, JNCI-J NATL CANCER I, V65, P67; PRESTONMARTIN S, 1989, CANCER RES, V49, P6137; PRESTONMARTIN S, 1983, J NATL CANCER I, V70, P863; PrestonMartin S, 1996, CANC EPIDEMIOLOGY PR, P1231; Schlehofer B, 1999, INT J CANCER, V82, P155, DOI 10.1002/(SICI)1097-0215(19990719)82:2<155::AID-IJC1>3.3.CO;2-G; ZAMPIERI P, 1994, J NEURO-ONCOL, V19, P61, DOI 10.1007/BF01051049	25	29	30	0	3	KLUWER ACADEMIC PUBL	DORDRECHT	SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS	0957-5243			CANCER CAUSE CONTROL	Cancer Causes Control	OCT	2001	12	8					733	737		10.1023/A:1011227617256			5	Oncology; Public, Environmental & Occupational Health	Oncology; Public, Environmental & Occupational Health	460AA	WOS:000170282600007	11562113				2021-06-18	
J	Ercan, M; Inci, S; Kilinc, K; Palaoglu, S; Aypar, U				Ercan, M; Inci, S; Kilinc, K; Palaoglu, S; Aypar, U			Nimodipine attenuates lipid peroxidation during the acute phase of head trauma in rats	NEUROSURGICAL REVIEW			English	Article						head trauma; lipid peroxidation; nimodipine; oxygen free radicals	NERVOUS-SYSTEM TRAUMA; ANEURYSMAL SUBARACHNOID HEMORRHAGE; FOCAL CEREBRAL-ISCHEMIA; OXYGEN FREE-RADICALS; BLOOD-FLOW; ANTAGONIST NIMODIPINE; BRAIN PROTECTION; CALCIUM; INJURY; PHARMACOLOGY	Oxygen free radical-mediated lipid peroxidation is one of the major mechanisms of secondary damage in traumatic brain injury. We assessed the effects of nimodipine on lipid peroxidation 1 h after head trauma in rats. Nimodipine (1.5 mug/kg IV bolus injection) was given immediately after head trauma by either the carotid artery or the jugular vein. Placebo treated rats received saline by the same routes. Control rats received head trauma only. Sham-operated rats were the group without head trauma. Malondialdehyde (MDA), which is the end product of lipid peroxidation, was measured as an indicator of oxygen free radical formation in the brain tissue. The mean values for MDA in sham operated rats were 92.4 +/-4.9 nanomoles/gram wet weight (nmol/gww) of brain tissue. In the control group, MDA content of the brain tissue was 120.8 +/-9.4 nmol/gww. In placebo treated rats, the results were similar. In the groups receiving ni modipine via carotid artery or jugular vein, the mean values were 101.1 +/-6.9 and 106.5 +/-6.0 nmol/gww, respectively. These results indicate that nimodipine caused a significant decrease in lipid peroxidation when given in the acute phase of head trauma in rats. This occurred regardless of the route of injection.	Hacettepe Univ, Sch Med, Inst Anesthesiol & Reanimat, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Inst Biochem, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Inst Neurosurg, TR-06100 Ankara, Turkey	Inci, S (corresponding author), Emek Mah,4 Cad,70-8, TR-06510 Ankara, Turkey.						AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BAETHMANN A, 1986, EUR NEUROL, V25, P102, DOI 10.1159/000116105; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; FADEN AI, 1984, J NEUROSURG, V60, P796, DOI 10.3171/jns.1984.60.4.0796; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GISVOLD SE, 1991, CURR OPIN ANESTHESIO, V4, P229; GRISAR JM, 1995, J MED CHEM, V38, P453, DOI 10.1021/jm00003a008; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL R, 1990, CAN J ANAESTH, V37, P762, DOI 10.1007/BF03006535; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HOLLEY AE, 1993, BRIT MED BULL, V49, P494, DOI 10.1093/oxfordjournals.bmb.a072626; IKEDA Y, 1990, ACT NEUR S, V51, P74; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LANGLEY MS, 1989, DRUGS, V37, P669, DOI 10.2165/00003495-198937050-00004; LEBLANC R, 1991, CURR OPIN NEUROL NEU, V4, P63; MCCALDEN TA, 1984, STROKE, V15, P527, DOI 10.1161/01.STR.15.3.527; MEYER FB, 1986, J NEUROSURG, V64, P617, DOI 10.3171/jns.1986.64.4.0617; PEROUTKA SJ, 1983, J NEUROSURG, V59, P933, DOI 10.3171/jns.1983.59.6.0933; POZZILLI C, 1989, J NEUROL, V236, P199, DOI 10.1007/BF00314499; SCRIABINE A, 1988, ANN NY ACAD SCI, V522, P698; SIESJO BK, 1990, EUR NEUROL, V30, P3, DOI 10.1159/000117184; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SOLOMON RA, 1987, ARCH NEUROL-CHICAGO, V44, P769, DOI 10.1001/archneur.1987.00520190073018; TONI D, 1991, J CARDIOVASC PHARM, V18, pS10, DOI 10.1097/00005344-199118081-00004; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; VANZWIETEN PA, 1993, AM HEART J, V125, P566, DOI 10.1016/0002-8703(93)90204-M	33	29	30	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	JUL	2001	24	2-3					127	130		10.1007/PL00012396			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	450LF	WOS:000169743800015	11485234				2021-06-18	
J	Keren, O; Reznik, J; Groswasser, Z				Keren, O; Reznik, J; Groswasser, Z			Combined motor disturbances following severe traumatic brain injury: an integrative long-term treatment approach	BRAIN INJURY			English	Article							COMATOSE UNAWARENESS PATIENTS; BOTULINUM TOXIN-A; NEUTROPHIL FUNCTIONS; HEAD-INJURY; RECOVERY; STROKE	Patients surviving severe traumatic brain injury (TBI) often suffer from residual impairments in motor control, communication skills, cognition and social behaviour. These distinctly hamper their capability to return to their 'pre-trauma' activity. Comprehensive and integrated rehabilitation programmes initiate, during the acute phase, a prolonged treatment process which starts at the most sophisticated medical systems. There is no clear end point for the treatment of these patients, since the recovery process and the rehabilitation activity may continue for years, even after patients return home to live with their families. The inherent inability to make a firm early prediction regarding outcome of patients and the late appearance of additional symptoms stress the need for a comprehensive close long-term follow-up. The following presentation concerns the description of the treatment strategy and long-term improvement of a 22-year-old male who suffered from very severe TBI. On admission to the emergency room, he was in the decerebrated position and his Glasgow Coma Scale (GCS) was at the lowest (3). The focus of this presentation is on the recovery of motor function. The initial motor disabilities included weakness in all four limbs, in particular left hemiplegia, and right hemiparesis with severe bilateral ataxic elements and a marked tremor of the right arm. Range of motion was limited in hips, and he suffered from stiff trunk and neck. Goals of physiotherapy were directed towards improving range of motion (ROM) and active movement. Casting, use of orthoses, biofeedback, hydrotherapy, hippotherapy, medication and nerve blocks for reducing spasticity were timely applied during the process. The motor improvement in this very severe TBI patient who is now over 3 years postinjury still continues and has a functional meaning. He has succeeded in being able to stand up by himself from a chair and is able to walk unaided and without orthoses for very short distances-up to five steps. He is able to drink soup without assistance and play a few notes on the piano. Marked cognitive improvement occurred as well. It is concluded that motor improvement may be evident over long periods of time and various timely interventions may assist in the process.	Loewenstein Rehabil Hosp, Dept Brain Injury Rehabil, IL-43100 Raanana, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Groswasser, Z (corresponding author), Loewenstein Rehabil Hosp, Dept Brain Injury Rehabil, 278 Achuza St,POB 3, IL-43100 Raanana, Israel.			Reznik, Jacqueline/0000-0002-7324-9531			BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; DOLLY JO, 1984, NATURE, V307, P457, DOI 10.1038/307457a0; DOMOVY ML, 1988, ADV NEUROL, V47, P265; HALLETT M, 1995, ANN NEUROL, V38, P139, DOI 10.1002/ana.410380203; Hesse S, 1998, CLIN REHABIL, V12, P381, DOI 10.1191/026921598668275996; IWADATE Y, 1989, Neurosurgical Review, V12, P500, DOI 10.1007/BF01790695; JANCOVIC J, 1996, MOVEMENT DISORD, V11, P250; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Pantano P, 1996, BRAIN, V119, P1849, DOI 10.1093/brain/119.6.1849; Pullman SL, 1996, ARCH NEUROL-CHICAGO, V53, P617, DOI 10.1001/archneur.1996.00550070055012; RONDOT MD, 1998, ARCH NEUROL-CHICAGO, V19, P421; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; TROSCH RM, 1994, MOVEMENT DISORD, V9, P601, DOI 10.1002/mds.870090604; TWITCHELL TE, 1951, BRAIN, V74, P443, DOI 10.1093/brain/74.4.443; WALSHE FM, 1961, ARCH NEUROL-CHICAGO, V5, P119, DOI 10.1001/archneur.1961.00450140001001; WOLACH B, 1993, BRAIN INJURY, V7, P401, DOI 10.3109/02699059309029683; ZASLER ND, 1993, BRAIN INJURY, V7, P379, DOI 10.3109/02699059309029681	19	29	29	0	26	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2001	15	7					633	638		10.1080/02699050010009568			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	444PD	WOS:000169407900007	11429091				2021-06-18	
J	Allen, JW; Vicini, S; Faden, AI				Allen, JW; Vicini, S; Faden, AI			Exacerbation of neuronal cell death by activation of group 1 metabotropic glutamate receptors: Role of NMDA receptors and arachidonic acid release	EXPERIMENTAL NEUROLOGY			English	Article						CNS injury; ischemia; trauma; calcium; neuronal-glial culture; signal transduction	CEREBELLAR GRANULE CELLS; TRAUMATIC BRAIN INJURY; SPINAL-CORD INJURY; RAT HIPPOCAMPAL SLICES; D-ASPARTATE RECEPTORS; DORSAL HORN NEURONS; PROTEIN-KINASE-C; IN-VITRO; GLUCOSE DEPRIVATION; NEOCORTICAL NEURONS	Both ionotropic and metabotropic glutamate receptors have been implicated in the pathogenesis of neuronal injury, Activation of group I metabotropic glutamate receptors (mGluR) exacerbates neuronal cell death, whereas inhibition is neuroprotective. However, the mechanisms involved remain unknown. Activation of group I mGluR modulates multiple signal transduction pathways including stimulation of phosphoinositide hydrolysis, potentiation of NMDA receptor activity, and release of arachidonic acid. Here we demonstrate that whereas activation of group I mGluR by (S)-3,5-dihydroxyphenylglycine (DHPG) potentiates NMDA-induced currents and intracellular calcium increases in rat cortical neuronal cultures, partial effects of group I mGluR activation or inhibition on neuronal injury induced by oxygen-glucose deprivation remain despite NMDA receptor blockade. DHPG stimulation also increases basal arachidonic acid release from rat neuronal-glial cultures and potentiates injury-induced arachidonic acid release in these cultures. Thus, activation of group I mGluR may exacerbate neuronal injury through multiple mechanisms, which include positive modulation of NMDA receptors and enhanced release of arachidonic acid. (C) 2001 Academic Press.	Georgetown Univ, Dept Neurosci, Washington, DC 20007 USA; Georgetown Univ, Dept Phys & Biophys, Washington, DC 20007 USA; Georgetown Univ, Interdisciplinary Program Neurosci, Washington, DC 20007 USA; Georgetown Univ, Inst Cognit & Computat Sci, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Dept Neurosci, EP-12B Res Bldg,3970 Reservoir Rd, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu		Vicini, Stefano/0000-0001-8671-5194	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS37313] Funding Source: Medline		Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Allen JW, 1999, FASEB J, V13, P1875; ANIKSZTEJN L, 1992, EUR J NEUROSCI, V4, P500, DOI 10.1111/j.1460-9568.1992.tb00900.x; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BLEAKMAN D, 1992, MOL PHARMACOL, V42, P192; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CERNE R, 1992, NEUROSCI LETT, V144, P180, DOI 10.1016/0304-3940(92)90745-S; CHAVIS P, 1995, J NEUROSCI, V15, P135; COLWELL CS, 1994, NEUROSCIENCE, V61, P497, DOI 10.1016/0306-4522(94)90429-4; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Contractor A, 1998, P NATL ACAD SCI USA, V95, P8969, DOI 10.1073/pnas.95.15.8969; DEMEDIUK P, 1988, J NEUROSCI RES, V20, P115, DOI 10.1002/jnr.490200116; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; Doherty AJ, 1997, NEUROPHARMACOLOGY, V36, P265, DOI 10.1016/S0028-3908(97)00001-4; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1993, MOL PHARMACOL, V43, P976; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Fitzjohn SM, 1996, NEUROSCI LETT, V203, P211, DOI 10.1016/0304-3940(96)12301-6; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARVEY J, 1993, BRIT J PHARMACOL, V109, P1085, DOI 10.1111/j.1476-5381.1993.tb13733.x; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; Hirashima N, 1996, NEUROBIOL AGING, V17, P549; Holohean AM, 1999, BRIT J PHARMACOL, V126, P333, DOI 10.1038/sj.bjp.0702263; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; IKEDA M, 1986, J NEUROCHEM, V44, P465; KAKU DA, 1993, SCIENCE, V260, P1516, DOI 10.1126/science.8389056; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURASE K, 1989, NEUROSCI LETT, V103, P56, DOI 10.1016/0304-3940(89)90485-0; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Pisani A, 1997, BRIT J PHARMACOL, V120, P1007, DOI 10.1038/sj.bjp.0700999; QLLEN JW, 2000, CELL DEATH DIFFER, V7, P470; Rahman S, 1996, BRIT J PHARMACOL, V117, P675, DOI 10.1111/j.1476-5381.1996.tb15243.x; Riedel G, 1996, PROG NEURO-PSYCHOPH, V20, P1253, DOI 10.1016/S0278-5846(96)00110-8; SANFELIU C, 1990, BRAIN RES, V526, P241, DOI 10.1016/0006-8993(90)91228-9; Sayer RJ, 1998, J NEUROPHYSIOL, V80, P1981; SAYER RJ, 1992, J NEUROPHYSIOL, V68, P833; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; Ugolini A, 1999, NEUROPHARMACOLOGY, V38, P1569, DOI 10.1016/S0028-3908(99)00095-7; Ugolini A, 1997, NEUROPHARMACOLOGY, V36, P1047, DOI 10.1016/S0028-3908(97)00103-2; VERITY MA, 1993, ANN NY ACAD SCI, V679, P110; Viu E, 1998, J PHARMACOL EXP THER, V285, P527; YOSHIDA S, 1980, J NEUROSURG, V53, P323, DOI 10.3171/jns.1980.53.3.0323; Yu SP, 1997, J PHYSIOL-LONDON, V499, P721, DOI 10.1113/jphysiol.1997.sp021964; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	63	29	30	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2001	169	2					449	460		10.1006/exnr.2001.7672			12	Neurosciences	Neurosciences & Neurology	440TF	WOS:000169189800022	11358458				2021-06-18	
J	La Vaque, TJ; Rossiter, T				La Vaque, TJ; Rossiter, T			The ethical use of placebo controls in clinical research: The declaration of Helsinki	APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK			English	Article						ethics of clinical research; EEG biofeedback; sham treatment controls; placebo treatment controls; active treatment controls; ADHD; TBI; depression; Declaration of Helsink	ATTENTION-DEFICIT DISORDER; DOUBLE-BLIND; CONTROLLED-TRIALS; COGNITIVE THERAPY; MEDICAL-RESEARCH; HUMAN-RIGHTS; METHYLPHENIDATE; CHILDREN; TRANSMISSION; DEPRESSION	Medical ethicists have questioned the use of no-treatment (placebo and sham procedure) controlled studies of new therapies when safe and effective standard therapies are available for use as an active or "equivalence" control. Current ethical principles of conduct for biomedical research specifically prohibit designs that withhold or deny "the best proven diagnostic and therapeutic" treatment to any participant in a clinical study, including those individuals who consent to randomization into a control group. Studies of psychophysiological therapies are often criticized on the grounds they lack a placebo or sham treatment control group. This paper briefly reviews the history of the problem and discusses the ethical standards that govern human research as derived from the Nuremberg Code and the Declaration of Helsinki. An examination of the problem with regard to research involving EEG biofeedback therapy for Attention-Deficit/Hyperactivity Disorder Traumatic Brain Injury, and depression serves to highlight the issues. It is concluded that the active treatment control (treatment equivalence) design is most appropriate for those clinical studies examining disorders for which there is a known, effective treatment. Sham- or placebo-controlled studies are ethically acceptable for those disorders for which no effective treatment is available.	Stress Clin, Green Bay, WI 54301 USA; Rogers Mem Hosp, Clin Psychophysiol Ctr, Milwaukee, WI 53704 USA; Biofeedback Ctr, Green Bay, WI 54301 USA	La Vaque, TJ (corresponding author), Stress Clin, 125 S Jefferson,Ste 306, Green Bay, WI 54301 USA.	tlavaque@gbonline.com					ADDINGTON D, 1997, CAN J PSYCHIAT, V42, P6; Alderson P, 1996, J MED ETHICS, V22, P135, DOI 10.1136/jme.22.3.135; Alves WA, 1996, STROKE, V27, P1903, DOI 10.1161/01.STR.27.10.1903; Annas GJ, 1998, AM J PUBLIC HEALTH, V88, P560, DOI 10.2105/AJPH.88.4.560; Antonuccio DO, 1999, PSYCHOTHER PSYCHOSOM, V68, P3, DOI 10.1159/000012304; ANTONUCCIO DO, 1995, PROF PSYCHOL-RES PR, V26, P574, DOI 10.1037/0735-7028.26.6.574; Appelbaum PS, 1997, ARCH GEN PSYCHIAT, V54, P117; ARNOLD LE, 1998, NIH CONS DEV C DIAGN; ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844; Barkley R. A., 1992, CHADDER BOX, P5; Barkley RA, 1990, ATTENTION DEFICIT HY; BEARDSLEY T, 1998, SCI AM           JUL, P106; BENEDEK TG, 1978, J CHRON DIS, V31, P35, DOI 10.1016/0021-9681(78)90079-6; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Bloom BR, 1998, SCIENCE, V279, P186, DOI 10.1126/science.279.5348.186; Brawley OW, 1998, INT J RADIAT ONCOL, V40, P5, DOI 10.1016/S0360-3016(97)00835-3; Brennan TA, 1999, NEW ENGL J MED, V341, P527, DOI 10.1056/NEJM199908123410712; BROWN RT, 1986, J DEV BEHAV PEDIATR, V7, P163; BYMAN B, 1989, MINN MED, V72, P580; CALDWELL JG, 1973, J CHRON DIS, V26, P187, DOI 10.1016/0021-9681(73)90089-1; CAPLAN AL, 1992, HASTINGS CENT REP, V22, P29, DOI 10.2307/3562946; Capron AM, 1999, NEW ENGL J MED, V340, P1430, DOI 10.1056/NEJM199905063401812; Cobb W M, 1973, J Natl Med Assoc, V65, P345; COLLIER J, 1998, BRIT MED J, V311, P821; DeDeyn PP, 1996, J MED ETHICS, V22, P140, DOI 10.1136/jme.22.3.140; Dove A, 1999, NAT MED, V5, P598, DOI 10.1038/9431; EDGAR H, 1992, HASTINGS CENT REP, V22, P32, DOI 10.2307/3562947; Edwards SJ, 1998, HLTH TECHNOLOGY ASSE, V2, p[i, 1]; Fisher RL, 1996, J NERV MENT DIS, V184, P99, DOI 10.1097/00005053-199602000-00006; Freedman B, 1996, J LAW MED ETHICS, V24, P243, DOI 10.1111/j.1748-720X.1996.tb01859.x; Freedman B, 1996, J LAW MED ETHICS, V24, P252, DOI 10.1111/j.1748-720X.1996.tb01860.x; Freedman Benjamin, 1990, IRB, V12, P1, DOI 10.2307/3564541; Freeman TB, 1999, NEW ENGL J MED, V341, P988, DOI 10.1056/NEJM199909233411311; FUCHS T, 1999, AUFNERKSAMKEIT NEURO; Glantz LH, 1996, J AM ACAD CHILD PSY, V35, P1283, DOI 10.1097/00004583-199610000-00015; *HLTH HUM SERV, 1999, 01702401653S HLTH HU; Jacobson NS, 1996, J CONSULT CLIN PSYCH, V64, P74, DOI 10.1037/0022-006X.64.1.74; Jarrett RB, 1999, ARCH GEN PSYCHIAT, V56, P431, DOI 10.1001/archpsyc.56.5.431; LEHMANN HE, 1979, PROG NEURO-PSYCHOPHA, V3, P271, DOI 10.1016/0364-7722(79)90090-0; Lehrman NS, 1997, J MENT HEALTH ADMIN, V24, P227, DOI 10.1007/BF02898516; Levine RJ, 1998, J CLIN ETHIC, V9, P167; Levine RJ, 1999, NEW ENGL J MED, V341, P531, DOI 10.1056/NEJM199908123410713; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; LURIE P, 1999, COMMITTEE ADV SCI ED; Macklin R, 1999, NEW ENGL J MED, V341, P992, DOI 10.1056/NEJM199909233411312; Malone RP, 1998, PSYCHIATR SERV, V49, P1413, DOI 10.1176/ps.49.11.1413; Malt UF, 1999, BRIT MED J, V318, P1180; Marquis D, 1999, NEW ENGL J MED, V341, P691, DOI 10.1056/NEJM199908263410912; Michels R, 1999, NEW ENGL J MED, V340, P1427, DOI 10.1056/NEJM199905063401811; *NEJM BOARD ETH AR, 1997, SCIENCE, V278, P211; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Piot P, 1998, SCIENCE, V280, P1844, DOI 10.1126/science.280.5371.1844; Quitkin FM, 1999, AM J PSYCHIAT, V156, P829, DOI 10.1176/ajp.156.6.829; Ramsay S, 1999, LANCET, V354, P928, DOI 10.1016/S0140-6736(05)75680-4; RAPOPORT JL, 1978, SCIENCE, V199, P560, DOI 10.1126/science.341313; RAPOPORT JL, 1980, ARCH GEN PSYCHIAT, V37, P933; Rogers MF, 1999, NEW ENGL J MED, V341, P441, DOI 10.1056/NEJM199908053410609; Rossiter D.T.R., 1995, J NEUROTHERAPY, V1, P48, DOI DOI 10.1300/J184V01N01_; Rossiter T. R., 1998, J NEUROTHERAPY, V2, P54, DOI [10.1300/J184v02n04_04, DOI 10.1300/J184V02N04_04]; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SPENCER T, 1995, ARCH GEN PSYCHIAT, V52, P434; Stein CM, 1999, LANCET, V353, P400, DOI 10.1016/S0140-6736(98)01373-7; Striefel S., 1998, BIOFEEDBACK, V26, P12; Striefel S., 1998, BIOFEEDBACK, V26, P4; Studdert DM, 1998, MED J AUSTRALIA, V169, P545, DOI 10.5694/j.1326-5377.1998.tb123406.x; Swartwood MO, 1998, PEDIATR NEUROL, V18, P244, DOI 10.1016/S0887-8994(97)00205-1; Task Force on Promotion and Dissemination of Psychological Procedures, 1995, CLIN PSYCHOL-UK, V48, P3; TAUBES G, 1995, SCIENCE, V267, P25, DOI 10.1126/science.7809605; TEMPLE R, 1999, COMMITTEE ADV SCI ED; Temple RJ, 1997, CONTROL CLIN TRIALS, V18, P613, DOI 10.1016/S0197-2456(97)00058-5; Thatcher RW, 2000, CLIN ELECTROENCEPHAL, V31, P38, DOI 10.1177/155005940003100110; Weijer C, 1999, SCHIZOPHR RES, V35, P211, DOI 10.1016/S0920-9964(98)00127-3; WENDER PH, 1985, AM J PSYCHIAT, V142, P547; Woodman R, 1999, BRIT MED J, V319, P660, DOI 10.1136/bmj.319.7211.660a; Zeiner P, 1999, ACTA PAEDIATR, V88, P298, DOI 10.1080/08035259950170060; 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038	76	29	29	0	11	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1090-0586	1573-3270		APPL PSYCHOPHYS BIOF	Appl. Psychophysiol. Biofeedback	MAR	2001	26	1					23	37		10.1023/A:1009563504319			15	Psychology, Clinical	Psychology	433LQ	WOS:000168761200004	11387859				2021-06-18	
J	Runnerstam, M; Bao, F; Huang, YL; Shi, JS; Gutierrez, E; Hamberger, A; Hansson, HA; Viano, D; Haglid, K				Runnerstam, M; Bao, F; Huang, YL; Shi, JS; Gutierrez, E; Hamberger, A; Hansson, HA; Viano, D; Haglid, K			A new model for diffuse brain injury by rotational acceleration: II. Effects on extracellular glutamate, intracranial pressure, and neuronal apoptosis	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; glutamate; intracranial pressure; microdialysis; taurine; traumatic brain injury	EXCITATORY AMINO-ACIDS; SPINAL-CORD INJURY; HUMAN HEAD-INJURY; C-JUN EXPRESSION; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; METHYL-D-ASPARTATE; NERVE-CELL DEATH; AXONAL INJURY; RAT-BRAIN	The aim of this study is to monitor excitatory amino acids (EAAs) in the extracellular fluids of the brain and to characterize regional neuronal damage in a new experimental model for brain injury, in which rabbits were exposed to 180-260 krad/s(2) rotational head acceleration, This loading causes extensive subarachnoid hemorrhage, focal tissue bleeding, reactive astrocytosis, and axonal damage. Animals were monitored for intracranial pressure (ICP) and for amino acids in the extracellular fluids, Immunohistochemistry was used to study expression of the gene c-Jun and apoptosis with the terminal deoxynucleotidyl transferase nick-end labeling (TUNEL) technique. Extracellular glutamate, glycine, and taurine increased significantly in the hippocampus within a few hours and remained high after 24 h. Neuronal nuclei in the granule layers of the hippocampus and cerebellum were positive for c-Jun after 24 h. Little immunoreactivity was detected in the cerebral cortex. c-Jun-positive neuronal perikarya and processes were found in granule and pyramidal CA4 layers of the hippocampus and among the Purkinje cells of the cerebellum. Also some microglial cells stained positively for c-Jun. TUNEL reactivity was most intense at 10 days after trauma and was extensive in neurons of the cerebral cortex, hippocampus, and cerebellum. The initial response of the brain after rotational head injury involves brain edema after 24 h and an excitotoxic neuronal microenvironment in the first hour, which leads to extensive delayed neuronal cell death by apoptosis necrosis in the cerebral cortex, hippocampus and cerebellum.	Univ Gothenburg, Dept Anat & Cell Biol, SE-40530 Gothenburg, Sweden; Chalmers Univ Technol, Crash Safety Div, S-41296 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Neurosurg, S-41345 Gothenburg, Sweden; China Med Univ, Brain Res Inst, Shenyang, Peoples R China; Zhunyi Med Coll, Dept Pharmacol, Zhunyi, Peoples R China	Hamberger, A (corresponding author), Univ Gothenburg, Dept Anat & Cell Biol, Box 420, SE-40530 Gothenburg, Sweden.	anders.hamberger@anatcell.gu.se	Farewik, Elena M. Gutierrez/AAU-9832-2020; Gutierrez-Farewik, Elena/G-6945-2012; Farewik, Elena M Gutierrez/I-6842-2018	Farewik, Elena M. Gutierrez/0000-0001-5417-5939; Gutierrez-Farewik, Elena/0000-0001-5417-5939; Farewik, Elena M Gutierrez/0000-0001-5417-5939			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Buratta S, 1998, J NEUROCHEM, V71, P2145; Cheung NS, 1998, J NEUROSCI RES, V52, P69, DOI 10.1002/(SICI)1097-4547(19980401)52:1<69::AID-JNR7>3.3.CO;2-L; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DEFELIPE C, 1994, J NEUROSCI, V14, P2911; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; DRAGUNOW M, 1995, BRAIN RES REV, V21, P1, DOI 10.1016/0165-0173(95)00003-L; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Ferrer I, 1996, EUR J NEUROSCI, V8, P1286, DOI 10.1111/j.1460-9568.1996.tb01297.x; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRANDE PO, 1997, ACTA ANAESTH SCAND, V1100, P36; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HENNEBERRY RC, 1989, NEUROBIOL AGING, V10, P611, DOI 10.1016/0197-4580(89)90149-8; HERDEGEN T, 1991, NEUROSCIENCE, V45, P413, DOI 10.1016/0306-4522(91)90237-I; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; HUANG R, 1994, NEUROCHEM RES, V19, P257, DOI 10.1007/BF00971573; Humm JL, 1999, EXP NEUROL, V157, P349, DOI 10.1006/exnr.1999.7061; JENKINS R, 1993, NEUROSCIENCE, V53, P447, DOI 10.1016/0306-4522(93)90208-W; JENKINS R, 1991, NEUROSCI LETT, V129, P107, DOI 10.1016/0304-3940(91)90731-8; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Katoh H, 1998, ACT NEUR S, V71, P247; Koura SS, 1998, ACT NEUR S, V71, P244; KRESPAN B, 1982, J NEUROCHEM, V38, P509, DOI 10.1111/j.1471-4159.1982.tb08657.x; LEHMANN A, 1991, J NEUROCHEM, V56, P690, DOI 10.1111/j.1471-4159.1991.tb08204.x; LEHMANN A, 1983, J NEUROCHEM, V40, P1314, DOI 10.1111/j.1471-4159.1983.tb13572.x; LI Y, 1995, MOL BRAIN RES, V28, P164, DOI 10.1016/0169-328X(94)00220-9; Lieth E, 1998, DIABETES, V47, P815, DOI 10.2337/diabetes.47.5.815; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Liu XZ, 1997, J NEUROSCI, V17, P5395; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCCABE RT, 1993, J PHARMACOL EXP THER, V264, P1248; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; McKenna MC, 1996, DEV NEUROSCI-BASEL, V18, P380, DOI 10.1159/000111431; MOZZI R, 1990, NEUROSCI RES COMMUN, V7, P147; Nedelcu J, 1999, PEDIATR RES, V46, P297, DOI 10.1203/00006450-199909000-00008; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; OMMAYA AK, 1984, BIOMECHANICS IMPACT, P117; Oo TF, 1999, J NEUROCHEM, V72, P557, DOI 10.1046/j.1471-4159.1999.0720557.x; OTTERSEN OP, 1992, NEUROSCIENCE, V46, P519, DOI 10.1016/0306-4522(92)90141-N; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAPPIUS HM, 1989, IMPLICATIONS BLOOD B, P293; Pittman S, 1997, LEUKEMIA RES, V21, P491, DOI 10.1016/S0145-2126(97)00038-6; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; RINK A, 1995, AM J PATHOL, V147, P1575; Robert F, 1998, J CHROMATOGR A, V817, P195, DOI 10.1016/S0021-9673(98)00321-5; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; VIANO DC, 1997, INT J CRASHWORTHINES, V2, P191; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; WESTERGAARD N, 1995, NEUROSCI LETT, V185, P24, DOI 10.1016/0304-3940(94)11216-6; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F; Zauner A, 1996, ACT NEUR S, V67, P40; Zielke HR, 1998, J NEUROCHEM, V71, P1315	75	29	35	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2001	18	3					259	273		10.1089/08977150151070892			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	414EM	WOS:000167653000004	11284547				2021-06-18	
J	Thorley, RR; Wertsch, JJ; Klingbeil, GE				Thorley, RR; Wertsch, JJ; Klingbeil, GE			Acute hypothalamic instability in traumatic brain injury: A case report	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						autonomic nervous system diseases; catatonia; closed head injuries; malignant hyperthermia; neuroleptic malignant syndrome; rehabilitation	NEUROLEPTIC MALIGNANT SYNDROME; DIENCEPHALIC SEIZURES; HYPERTHERMIA SYNDROME; METOCLOPRAMIDE; THERAPY; BROMOCRIPTINE; WITHDRAWAL; DANTROLENE; LEVODOPA; PATIENT	Acute hypothalamic instability occurs in patients with traumatic brain injury (TBI). It usually occurs in the form of autonomic dysfunction syndrome (also known as diencephalic seizures or paroxysmal sympathetic storms); however, there are other causes of acute hypothalamic instability of which the clinician must be aware. Neuroleptic malignant syndrome, malignant hyperthermia, autonomic dysfunction syndrome, and lethal catatonia are all syndromes that clinically present as signs and symptoms of acute hypothalamic instability. Because of the lethal potential of these syndromes, clinicians who care for patients with TBI must be aware of the various syndromes, their clinical presentation, and their treatment. We present a case of life-threatening acute hypothalamic instability in a patient with TBI.	Med Coll Wisconsin, Dept Phys Med & Rehabil, Milwaukee, WI 53226 USA	Thorley, RR (corresponding author), Med Coll Wisconsin, Dept Phys Med & Rehabil, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.						BAKRI YN, 1992, GYNECOL ONCOL, V44, P189, DOI 10.1016/0090-8258(92)90037-J; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BROWER RD, 1989, J CHILD NEUROL, V4, P230, DOI 10.1177/088307388900400320; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; BURKE RE, 1981, NEUROLOGY, V31, P1022, DOI 10.1212/WNL.31.8.1022; CAROFF SN, 1980, J CLIN PSYCHIAT, V41, P79; DONNET A, 1991, BIOMED PHARMACOTHER, V45, P461, DOI 10.1016/0753-3322(91)90048-X; FEUERMAN T, 1988, J NEUROSURG, V68, P297, DOI 10.3171/jns.1988.68.2.0297; FIGATALAMANCA L, 1985, NEUROLOGY, V35, P258, DOI 10.1212/WNL.35.2.258; FLETCHER R, 1981, BRIT J ANAESTH, V53, P993, DOI 10.1093/bja/53.9.993; FRIEDMAN JH, 1985, JAMA-J AM MED ASSOC, V254, P2792, DOI 10.1001/jama.254.19.2792; FRIEDMAN LS, 1987, ARCH INTERN MED, V147, P1495, DOI 10.1001/archinte.147.8.1495; GRONERT GA, 1980, ANESTH ANALG, V59, P377; HENDERSON A, 1991, AUST NZ J MED, V21, P742, DOI 10.1111/j.1445-5994.1991.tb01381.x; KISH SJ, 1990, AM J PSYCHIAT, V147, P1358; LECOUTEUR DG, 1995, AUST NZ J MED, V25, P261; MANN SC, 1986, AM J PSYCHIAT, V143, P1374; Miranda A D, 1997, Am J Crit Care, V6, P368; MORGENSON J, 1974, LANCET, V1, P461; PATTERSON JF, 1988, SOUTHERN MED J, V81, P674, DOI 10.1097/00007611-198805000-00035; PEARLMAN CA, 1986, J CLIN PSYCHOPHARM, V6, P257; POLLOCK N, 1992, ANAESTH INTENS CARE, V20, P520, DOI 10.1177/0310057X9202000427; ROBINSON MB, 1985, J NEUROL NEUROSUR PS, V48, P1304, DOI 10.1136/jnnp.48.12.1304; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; Samie M R, 1987, Mov Disord, V2, P57, DOI 10.1002/mds.870020108; SHINTANI S, 1995, J NEUROL SCI, V128, P232, DOI 10.1016/0022-510X(94)00255-M; SIMPSON DM, 1984, AM J PSYCHIAT, V141, P796; WINGARD DW, 1974, LANCET, V2, P1450	28	29	32	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2001	82	2					246	249		10.1053/apmr.2001.18698			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	400AG	WOS:000166846000016	11239318				2021-06-18	
J	Beschorner, R; Schluesener, HJ; Nguyen, TD; Magdolen, V; Luther, T; Pedal, I; Mattern, R; Meyermann, R; Schwab, JM				Beschorner, R; Schluesener, HJ; Nguyen, TD; Magdolen, V; Luther, T; Pedal, I; Mattern, R; Meyermann, R; Schwab, JM			Lesion-associated accumulation of uPAR/CD87-expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						fibrinolysis; human; ischaemia; tissue remodelling; traumatic brain injury; urokinase-type plasminogen activator receptor	PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; MESSENGER-RNA; MATRIX METALLOPROTEINASES; CLINICAL-TRIALS; BRAIN EDEMA; U937 CELLS; EXPRESSION; MODULATION; SYSTEM	Urokinase-type plasminogen activator receptor (uPAR/CD87) together with its ligand, urokinase-type plasminogen activator (uPA), constitutes a proteolytic system associated with tissue remodelling and leucocyte infiltration. uPAR is a member of the glycosyl phosphatidyl inositol (GPI) anchored protein family. The functional role of uPAR comprises fibrinolysis by conversion of plasminogen to plasmin. In addition, uPAR promotes cell adhesion, migration, proliferation, re-organization of the actin cytoskeleton, and angiogenesis. Furthermore, uPAR is involved in prevention of scar formation and is chemoattractant to macrophages and leucocytes. In order to investigate the pathophysiological role of uPAR following human CNS injury we examined necrotic brain lesions resulting from traumatic brain injury (TBI; n = 28) and focal cerebral infarctions (FCI; n = 17) by immunohistochemistry. Numbers of uPAR(+) cells and uPAR(+) blood vessels were counted. Following brain damage, uPAR(+) cells increased significantly within 12 h, reached a maximum after 3-4 days and remained elevated until later stages. uPAR was expressed by infiltrating granulocytes, activated microglia/macrophages and endothelial cells. Numbers of uPAR(+) vessels increased in parallel subsiding earlier following FCI than post TBI. The restricted, lesion-associated accumulation of uPAR(+) cells in the brain parenchyma and upregulated expression by endothelial cells suggests a crucial role for the influx of inflammatory cells and blood-brain barrier (BBB) disturbance. Through a failure in BBB function, uPAR participates in formation of brain oedema and thus contributes to secondary brain damage. In conclusion, the study defines the localization, kinetic course and cellular source of uPAR as a potential pharmacological target following human TBI and FCI.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Tech Univ Munich, Klinikum Rechts Isar, Dept Gynecol, D-8000 Munich, Germany; Tech Univ Dresden, Inst Pathol, D-8027 Dresden, Germany	Beschorner, R (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	rudi.beschorner@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Beschorner, Rudi/0000-0003-1109-915X; Schwab, Jan/0000-0001-6784-4919			Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Cross AK, 1999, GLIA, V28, P183, DOI 10.1002/(SICI)1098-1136(199912)28:3<183::AID-GLIA2>3.3.CO;2-V; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Dietzmann K, 2000, PATHOL RES PRACT, V196, P15, DOI 10.1016/S0344-0338(00)80017-5; Fauser S, 2000, J NEUROIMMUNOL, V111, P234, DOI 10.1016/S0165-5728(00)00368-4; Fujimoto J, 1996, J STEROID BIOCHEM, V59, P1, DOI 10.1016/S0960-0760(96)00084-2; Heymans S, 1999, NAT MED, V5, P1135; Higazi AAR, 1996, BIOCHEMISTRY-US, V35, P6884, DOI 10.1021/bi9514774; HOOGERWERF WA, 1994, GENE CHROMOSOME CANC, V9, P88, DOI 10.1002/gcc.2870090203; KALIMO H, 1997, GREENFIELDS NEUROPAT, P315; LAN HY, 1995, J HISTOCHEM CYTOCHEM, V43, P97, DOI 10.1177/43.1.7822770; LAURSEN H, 1993, ACTA NEUROPATHOL, V86, P378, DOI 10.1007/BF00369451; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LUND LR, 1991, J BIOL CHEM, V266, P5177; Luther T, 1997, AM J PATHOL, V150, P1231; MAGDOLEN V, 1995, ELECTROPHORESIS, V16, P813, DOI 10.1002/elps.11501601134; MENZIES SA, 1993, J NEUROSURG, V78, P257, DOI 10.3171/jns.1993.78.2.0257; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Moser KL, 1998, P NATL ACAD SCI USA, V95, P14869, DOI 10.1073/pnas.95.25.14869; Nonaka T, 2000, J RHEUMATOL, V27, P997; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Peiretti F, 1996, BLOOD, V87, P162; Piguet PF, 1999, CIRCULATION, V99, P3315, DOI 10.1161/01.CIR.99.25.3315; PLOUG M, 1992, BLOOD, V79, P1447; Reid E, 2000, AM J HUM GENET, V66, P728, DOI 10.1086/302783; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; Reuning U, 1998, INT J ONCOL, V13, P893; Shetty S, 1998, ARCH BIOCHEM BIOPHYS, V356, P265, DOI 10.1006/abbi.1998.0789; Shimazaki C, 1999, BRIT J HAEMATOL, V104, P672, DOI 10.1111/j.1365-2141.1999.01239.x; Speth C, 1998, IMMUNOBIOLOGY, V199, P152, DOI 10.1016/S0171-2985(98)80071-5; Stichel CC, 1999, NEUROSCIENCE, V93, P321, DOI 10.1016/S0306-4522(99)00112-8; Stratakis CA, 1998, J CLIN ENDOCR METAB, V83, P2972, DOI 10.1210/jc.83.8.2972; TranThang C, 1996, BRIT J CANCER, V74, P846, DOI 10.1038/bjc.1996.447; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Washington RA, 1996, J NEUROSCI RES, V45, P392; YAMAMOTO M, 1994, CANCER RES, V54, P5016; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Yoshida E, 1996, INFLAMMATION, V20, P319, DOI 10.1007/BF01488206	40	29	35	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	DEC	2000	26	6					522	527		10.1046/j.0305-1846.2000.287.x			6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	384XL	WOS:000165972500005	11123718				2021-06-18	
J	Curtiss, G; Klemz, S; Vanderploeg, RD				Curtiss, G; Klemz, S; Vanderploeg, RD			Acute impact of severe traumatic brain injury on family structure and coping responses	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						circumplex model; coping; Coping Responses Inventory; Family Adaptability and Cohesion Evaluation Scales-II; family structure; traumatic brain injury	HEAD-INJURY; RELATIVES	Family stress following traumatic brain injury (TBI) is well documented. Previous studies have shown that family adaptation and the use of coping strategies moderate the stresses of TBI in the long term. However, relatively little is known about the impact on the family and family response during the acute stage of recovery. The present study used Olson's Circumplex Model to examine acute changes in family structure and examined changes in coping responses pre- and post-TBI. Wives of 20 male TBI survivors completed the Couples Version of the Family Adaptability and Cohesion Evaluation Scales-II (FACES-II) and the Coping Responses inventory (CRI). These questionnaires were completed retrospectively for a stressful event that occurred six months prior to the TBI, then for the current period following the TBI. Results found that 60% of all families experienced a significant change in structure following TBI. As predicted by the Circumplex Model, balanced families changed most, with 70% changing to the extreme type post-TBI. Focus of coping (problem versus emotion) and coping techniques (cognitive versus behavioral) also changed significantly from pre- to post-TBI and differed, depending on post-TBI family structure. Family interventions based on these differences in family structure and coping are presented.	James A Haley Vet Affairs Med Ctr, Dept Phys Med & Rehabil, Def & Vet Head Injury Program, Tampa, FL USA; James A Haley Vet Affairs Med Ctr, Dept Psychol, Def & Vet Head Injury Program, Tampa, FL USA	Curtiss, G (corresponding author), James A Haley Vet Affairs Med Ctr, Dept Phys Med & Rehabil, Def & Vet Head Injury Program, Tampa, FL USA.		Curtiss, Glenn/ABB-5566-2020				BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N., 1984, CLOSED HEAD INJURY P; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; GREER BG, 1992, HDB HEAD TRAUMA ACUT, P357; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Kosciulek J.F., 1998, J APPL REHABILITATIO, V29, P8; Kosciulek JF, 1996, J REHABIL, V62, P49; KOSCIULEK JF, 1993, J REHABIL, V59, P40; Kosciulek JF, 1999, INT J REHABIL RES, V22, P269, DOI 10.1097/00004356-199912000-00003; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCCUBBIN HI, 1981, F COPES FAMILY CRISE; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; Moos R, 1993, COPING RESPONSES INV; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; OLSON DH, 1982, FACES, V2; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; TEASDALE G, 1974, LANCET, V2, P81; Walsh F, 1993, NORMAL FAMILY PROCES, P104, DOI DOI 10.1016/J.APPET.2008.05.056; WILLIAMS J, 1991, HEAD INJURY FAMILY M	20	29	30	0	10	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2000	15	5					1113	1122		10.1097/00001199-200010000-00005			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	359DT	WOS:000089596800005	10970932				2021-06-18	
J	Shibata, Y; Matsumura, A; Meguro, K; Narushima, K				Shibata, Y; Matsumura, A; Meguro, K; Narushima, K			Differentiation of mechanism and prognosis of traumatic brain stem lesions detected by magnetic resonance imaging in the acute stage	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						brain stem; diffuse axonal injury; head injury; MRI	DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; MR; CT; DAMAGE; COMA	We retrospectively evaluated the MRI from 17 patients with primary brain stem injury obtained in the acute stage. Clinical and radiological findings were analyzed in these 17 patients. T2-weighted imaging proved to be most sensitive and specific for the diagnosis of primary brain stem injury. We found two patterns of brain stem injury. The good prognosis group showed ventral brain stem lesions or dorsal superficial brain stem lesions. On the other hand the poor prognosis group showed deep dorsal brain stem lesions. These acute stage findings are seen only temporally in many cases so that it is most important to examine MRI findings in the acute stage to evaluate the prognosis of the patient. MRI was valuable in predicting the outcome. The possible mechanism of brain stem injury in patients with head injury is briefly discussed. (C) 2000 Elsevier Science B.V. All rights reserved.	Tsukuba Med Ctr, Dept Neurosurg, Tsukuba, Ibaraki 305, Japan	Shibata, Y (corresponding author), Tsukuba Med Ctr, Dept Neurosurg, Tsukuba, Ibaraki 305, Japan.	y-shibata@amy.hi-ho.ne.jp					ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; MATSUMURA A, 1993, RECENT ADVANCES IN NEUROTRAUMATOLOGY, P192; MATSUMURA A, 1989, JPN J MAGN RESON MED, V8, P268; MITCHELL DE, 1973, LANCET, V2, P215; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; SAEKI N, 1990, NEUROTRAUMATOLOGY, V13, P101; TEASDALE G, 1974, LANCET, V2, P81	15	29	31	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	SEP	2000	102	3					124	128		10.1016/S0303-8467(00)00095-0			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	357LN	WOS:000089503300002	10996708				2021-06-18	
J	Durham, SR; Raghupathi, R; Helfaer, MA; Marwaha, S; Duhaime, AC				Durham, SR; Raghupathi, R; Helfaer, MA; Marwaha, S; Duhaime, AC			Age-related differences in acute physiologic response to focal traumatic brain injury in piglets	PEDIATRIC NEUROSURGERY			English	Article						trauma; age-dependent response to TBI; physiology; head injury; pediatric	CEREBRAL BLOOD-FLOW; COLORED MICROSPHERE TECHNIQUE; HEAD-INJURY; CHILDREN; METABOLISM; HYPEREMIA; PRESSURE; IMMATURE; NEWBORN; MATURE	Introduction: The goal of the present study was to determine whether age-related differences in the acute physiologic response to scaled cortical impact injury contribute to differences in vulnerability to traumatic brain injury (TBI), Methods: Heart rate (HR), mean arterial pressure (MAP), brain temperature (BrT) and cerebral blood flow (CBF) were measured in 22 piglets (7 of age 5 days, 8 of age 1 month, 7 of age 4 months) at baseline and for 3 h following scaled cortical impact injury. Results: There were no age-dependent variations from baseline in HR, MAP or BrT following injury, CBF increased in the 5-day-old animals following injury while CBF in the 1- and 4-month-old animals decreased following injury (p = 0.0049), Conclusion: CBF was shown to have a significant age-dependent response to TBI with the youngest animals exhibiting increased CBF following injury. Copyright (C) 2000 S. Karger AG, Basel.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Anesthesia Crit Care Med, Philadelphia, PA 19104 USA	Durham, SR (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.	durhamsr@mail.med.upenn.edu					Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Bauer R, 1999, PEDIATR NEUROSURG, V30, P62, DOI 10.1159/000028765; Bauer R, 1996, EXP TOXICOL PATHOL, V48, P415; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Cheng Y, 1997, ANN NEUROL, V41, P521, DOI 10.1002/ana.410410416; CHIRON C, 1992, J NUCL MED, V33, P696; DUHAIME A, IN PRESS J NEUROSURG; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HORIUCHI I, 1993, PEDIATR RES, V34, P385, DOI 10.1203/00006450-199309000-00028; ICHORD RN, 1991, STROKE, V22, P626, DOI 10.1161/01.STR.22.5.626; KETY S S, 1956, J Chronic Dis, V3, P478, DOI 10.1016/0021-9681(56)90146-1; KIRSCH JR, 1990, AM J PHYSIOL, V259, pH1551; MOLLER WD, 1978, EUR NEUROL, V17, P276, DOI 10.1159/000114958; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; Nagayama M, 1999, J CEREBR BLOOD F MET, V19, P661, DOI 10.1097/00004647-199906000-00009; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Takahashi T, 1999, AM J NEURORADIOL, V20, P917; Walter B, 1997, BASIC RES CARDIOL, V92, P191, DOI 10.1007/s003950050037; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	23	29	29	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	AUG	2000	33	2					76	82		10.1159/000028980			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	373NL	WOS:000165295500005	11070433				2021-06-18	
J	LeBlanc, JM; Hayden, ME; Paulman, RG				LeBlanc, JM; Hayden, ME; Paulman, RG			A comparison of neuropsychological and situational assessment for predicting employability after closed head injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adult closed head injury; cognitive neuropsychological assessment; ecological validity functioning; employment; executive functioning; situational assessment; vocational evaluation	TRAUMATIC BRAIN INJURY; EMPLOYMENT STATUS; FOLLOW-UP; IMPAIRMENT; RECOVERY; WORK	The relationships among neuropsychological assessment, situational assessment, and judgments of future employability in 127 survivors of moderate to severe closed head injury were evaluated. Participants received a comprehensive neuropsychological battery and a situational vocational evaluation. Two groups mere created, based on employment recommendation from the situational evaluation. a seven-factor model was found to account for the preponderance of variance within the neuropsychological battery used, and one factor mas predictive of group assignment from situational assessment. However, the present data reinforce the predominance of Endings in the literature that indicate that, in general, no individual neuropspchological test can be used to predict vocational performance in more environmentally relevant environments. Exceptions to this "rule" may occur when comparisons between results of formal neuropsychological tests and situational evaluation are limited to very simple, very circumscribed, and/or very well-defined functions. Thus, situational assessment is seen as a critical adjunct to neuropspchological assessment in making "real-world" predictions, The particular situational assessment used in this study was internally valid, an important finding given the importance of situational assessment in ecologically valid predictions.	Sabine Valley Ctr, Marshall Youth Serv, Marshall, TX 75670 USA; Pate Rehabil, Dallas, TX USA; Univ Texas, SW Med Ctr, Dallas, TX USA	LeBlanc, JM (corresponding author), Sabine Valley Ctr, Marshall Youth Serv, Marshall, TX 75670 USA.						ACKER MB, 1986, CLIN NEUROPSYCHOLOGY; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baum C, 1996, ARCH CLIN NEUROPSYCH, V11, P69, DOI 10.1016/0887-6177(95)00009-7; Benton A, 1989, MULTILINGUAL APHASIA; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BOLLER F, 1966, BRAIN, V89, P815, DOI 10.1093/brain/89.4.815; BRANDT GC, 1992, J CAN HIST ASSOC, V3, P3; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; BRUNSWICK E, 1955, PSYCHOL REV, V67, P193; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Christensen AL, 1979, LURIAS NEUROPSYCHOLO; CRISP R, 1992, J REHABIL, V58, P27; DEFILLIPIS NA, 1987, BOOKLET CATEGORY TES; DEPOY E, 1992, J COGN REHABIL   JAN, P30; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P1; DILLER L, 1970, Archives of Physical Medicine and Rehabilitation, V51, P358; DILLER L, 1991, NEUROBEHAVIORAL RECO; DILLER L, 1974, REHABILITATION MONOG, V50; FINUF P, 1995, INJ PREV CONTROL PRO; FORDYCE D, 1994, BRAIN INJURY REHABIL; Fraser R. T., 1991, J HEAD TRAUMA REHAB, V6, P46; Goldstein FC, 1995, CLIN NEUROPSYCHOLOGI; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; HART T, 1986, CLIN NEUROPSYCHOLOGY; Heaton R.K., 1991, COMPREHENSIVE NORMS; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JOHNSON EW, 1991, AM J PHYS MED REHAB, V70, P1, DOI 10.1097/00002060-199102000-00001; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; KARZMARK P, 1992, Brain Injury, V6, P213, DOI 10.3109/02699059209029662; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; LAM CS, 1991, REHABIL COUNS BULL, V35, P68; LEVIN H, 1987, NEUROBEHAVORIAL RECO; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LONG C, 1988, NP STUD NONFOCAL BRA; Long CJ., 1996, ECOLOGICAL VALIDITY; LORING DW, 1987, J CLIN EXP NEUROPSYC, V9, P340, DOI 10.1080/01688638708405055; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; Luria A. R., 1966, HIGHER CORTICAL FUNC; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; MAPOU R, 1992, HDB HEAD TRAUMA ACUT; MAPOU R, 1995, CLIN NP ASSESSESSMEN; MATHEWS CG, 1964, INSTRUCTION MANUAL A; MCCUE M, 1992, HDB HEAD TRAUMA ACUT; NEFF W, 1983, REHABILITATION CLIEN; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; ROBERTS R, 1992, HDB HEAD TRAUMA ACUT; SACHS PR, 1993, REHABIL PSYCHOL, V38, P87, DOI 10.1037/h0080294; SBORDONE R, 1992, PSYCHOTHER PRIVATE P, V10, P45; SCHENKENBERG T, 1980, NEUROLOGY, V30, P509, DOI 10.1212/WNL.30.5.509; SHALLICE T, 1991, FRONTAL LOBE FUNCTIO; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; SPECTOR J, 1995, CLIN NEUROPSYCHOLOGI; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stuss D. T., 1994, BRAIN INJURY REHABIL, P212; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TRAHAN D, 1986, CONTINUOUS VISUAL ME; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; VELOZO CA, 1993, AM J OCCUP THER, V47, P203, DOI 10.5014/ajot.47.3.203; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WESOLOWSKI MD, 1994, PRACTICAL GUIDE HEAD; WHEMAN P, 1989, J HEAD TRAUMA REHAB, V4, P66; WHEMAN P, 1990, ARCH PHYS MED REHAB, V71, P1047	70	29	29	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2000	15	4					1022	1040		10.1097/00001199-200008000-00005			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	340DK	WOS:000088517700005	10876173				2021-06-18	
J	Jaeger, M; Hertrich, I; Stattrop, U; Schonle, PW; Ackermann, H				Jaeger, M; Hertrich, I; Stattrop, U; Schonle, PW; Ackermann, H			Speech disorders following severe traumatic grain injury: Kinematic analysis of syllable repetitions using electromagnetic articulography	FOLIA PHONIATRICA ET LOGOPAEDICA			English	Article						traumatic brain injury; kinematic analysis; electromagnetic articulography; speech motor deficits; dysarthria; articulation	CLOSED-HEAD-INJURY; BRAIN INJURY; DYSFUNCTION; DYSARTHRIA; MOVEMENTS	Using electromagnetic articulography, the lips, the tip of the tongue, and the tongue dorsum were tracked during repetitions of the syllables [pa], [ta] and [ka] in 10 speakers with dysarthria following severe traumatic brain injury and in 10 age-matched control subjects. When asked to produce the syllable trains as fast as possible, the patient group showed a rather homogeneous pattern of movement abnormalities including prolonged syllable durations and reduced peak velocity/amplitude ratios. Most presumably, limited speed generation gives rise to the impaired ability to increase speech rate. During the habitual speaking condition, reduced velocity/amplitude ratios were restricted to the tongue tip and tongue dorsum. Obviously, the tongue and the lips are differentially affected in dysarthria following severe traumatic brain injury. Copyright (C) 2000 S. Karger AG, Basel.	Univ Konstanz, Lurija Inst Rehabil Sci & Hlth Res, Neurol Rehabil Ctr Schmieder, Allensbach, Germany; Univ Tubingen, Dept Neurol, D-7400 Tubingen, Germany	Jaeger, M (corresponding author), Kliniken Schmieder, Postfach 240, D-78473 Aliensbach, Germany.		Hertrich, Ingo/T-1154-2018	Hertrich, Ingo/0000-0001-8965-6249			ABBS J, 1985, SPEECH DISORDERS ADU; ACKERMANN H, 1995, FOLIA PHONIATR LOGO, V47, P15, DOI 10.1159/000266338; ACKERMANN H, 1995, J SPEECH HEAR RES, V38, P1252, DOI 10.1044/jshr.3806.1252; Ackermann H, 1997, MOVEMENT DISORD, V12, P1019, DOI 10.1002/mds.870120628; BARLOW SM, 1990, J SPEECH HEAR RES, V33, P660, DOI 10.1044/jshr.3304.660; BLUMBERGER J, 1995, BRAIN INJURY, V9, P797, DOI 10.3109/02699059509008235; BROWN SH, 1990, J NEUROL NEUROSUR PS, V53, P306, DOI 10.1136/jnnp.53.4.306; CAMPBELL TF, 1995, J SPEECH HEAR RES, V38, P864, DOI 10.1044/jshr.3804.864; Gennarelli TA, 1993, HEAD INJURY, P137; HERTRICH I, 1997, ACCURACY LIP MOVEMEN, V35, P165; Hoole P, 1993, FORSCHUNGSBERICHTE I, V31, P43; KELSO JAS, 1985, J ACOUST SOC AM, V77, P266, DOI 10.1121/1.392268; KENT RD, 1987, J SPEECH HEAR DISORD, V52, P367, DOI 10.1044/jshd.5204.367; LEFKOWITZ D, 1994, J MED SPEECH-LANG PA, V2, P1; MENNEL HD, 1997, SEVERE HEAD INJURIES, P19; Netsell R, 1992, ASHA SPECIAL INTERES, V2, P1; OSTRY DJ, 1985, J ACOUST SOC AM, V77, P457; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SCHONLE P, 1988, ELEKTROMAGNETISCHE A; THEODOROS D, 1993, BRAIN INJURY, V7, P59, DOI 10.3109/02699059309008157; THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; THEODOROS DG, 1995, BRAIN INJURY, V9, P237, DOI 10.3109/02699059509008196; THEODOROS DG, 1994, BRAIN INJURY, V8, P667, DOI 10.3109/02699059409151021; THEODOROS DG, 1995, BRAIN INJURY, V9, P671, DOI 10.3109/02699059509008225; VOGEL M, 1983, FOLIA PHONIATR, V35, P294, DOI 10.1159/000265705; YORKSTON KM, 1991, COMMUNICATION DISORD, P251; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173; ZYSKI BJ, 1987, J COMMUN DISORD, V20, P367, DOI 10.1016/0021-9924(87)90025-6	28	29	30	0	9	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7762			FOLIA PHONIATR LOGO	Folia Phoniatr. Logop.	JUL-AUG	2000	52	4					187	196		10.1159/000021533			10	Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation	Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation	314DW	WOS:000087040700004	10782011				2021-06-18	
J	Valadka, AB; Gopinath, SP; Robertson, CS				Valadka, AB; Gopinath, SP; Robertson, CS			Midline shift alter severe head injury: pathophysiologic implications	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	59th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 16-18, 1999	BOSTON, MA	Amer Assoc Surg Trauma		cerebral blood flow; cerebral metabolic rate of oxygen; head injury; intracranial pressure; midline shift; subdural hematoma; traumatic brain injury	ACUTE SUBDURAL-HEMATOMA; COMA DATA-BANK; CEREBRAL BLOOD-FLOW; ARTERIOVENOUS OXYGEN DIFFERENCE; COMPUTERIZED-TOMOGRAPHY; PROGNOSTIC FACTORS; CT SCAN; PREDICTION; DETERIORATE; INFARCTION	Objective:To investigate the mechanism of the adverse effect of midline shift after severe traumatic brain injury. Methods: This study compared averaged cerebral metabolic parameters of patients with midline shift > 5 mm (S) on initial computerized tomography scan to those of patients with shift less than or equal to 5 mm (NS). The effect of an acute subdural hematoma (SDH) was determined by separating patients into those with and those without SDH and then re-examining the effect of shift in these subgroups. Results: Four hundred fifty-four patients were studied. Cerebral metabolic rate of oxygen (CMRo(2), in mL/100 g per min) was always lower with shift: 1.74 for SDH-S versus 2.21 for SDH-NS (p < 0.001), and 1.80 for non-SDH-S versus 2.24 for non-SDB-NS (p < 0.001). No other major effects of shift were seen in SDH patients. Among non-SDH patients, shift was associated with higher intracranial pressure (ICP): 23.1 mm Hg versus 16.3 mm Hg (p < 0.001), Other differences between shift and nonshift patients in the non-SDH group were due at least in part to interventions to treat the elevated ICP. Conclusion:Midline shift after severe traumatic brain injury is associated with reduced CMRo(2), regardless of whether or not SDH is present. The deleterious effects of subdural blood may be related more to the mass effect of large SDHs than to the biochemical abnormalities caused by small amounts of blood in the subdural space.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Valadka, AB (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Suite 944, Houston, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-38660] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER		ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Athiappan S., 1993, Annals Academy of Medicine Singapore, V22, P452; COOK RJ, 1988, ACTA NEUROCHIR, V95, P90, DOI 10.1007/BF01790766; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Gibson J Y, 1994, J Neuroimaging, V4, P212; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; HARTUNG HJ, 1992, ANAESTHESIST, V41, P468; HAYASHI T, 1984, Neurological Surgery, V12, P1247; Ibrahim A W, 1989, Neurol Med Chir (Tokyo), V29, P816, DOI 10.2176/nmc.29.816; INGLIS FM, 1990, ACT NEUR S, V51, P277; JENKINS A, 1990, British Journal of Neurosurgery, V4, P45, DOI 10.3109/02688699009000681; JENNETT B, 1975, LANCET, V1, P480; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KASE CS, 1982, NEUROLOGY, V32, P1146, DOI 10.1212/WNL.32.10.1146; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Lehmann U, 1997, UNFALLCHIRURG, V100, P705, DOI 10.1007/s001130050180; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASE G, 1995, ACTA NEUROL SCAND, V91, P306, DOI 10.1111/j.1600-0404.1995.tb07011.x; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Paret G, 1996, J TRAUMA, V41, P859, DOI 10.1097/00005373-199611000-00017; QUATTROCCHI KB, 1991, SURG NEUROL, V35, P183, DOI 10.1016/0090-3019(91)90069-L; Rapenne T, 1997, PRESSE MED, V26, P1661; RIVAS JJ, 1988, NEUROSURGERY, V23, P44, DOI 10.1227/00006123-198807000-00010; ROBERTSON C, 1993, ACTA NEUROCHIR, P25; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SALVANT JB, 1993, NEUROSURGERY, V33, P387; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; SERVADEI F, 1985, NEUROCHIRURGIA, V28, P170; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SONAWALLA A B, 1992, JPMA (Journal of the Pakistan Medical Association), V42, P62; Takahashi H, 1989, Neurol Med Chir (Tokyo), V29, P192, DOI 10.2176/nmc.29.192; THIE A, 1988, FORTSCHR NEUROL PSYC, V56, P163, DOI 10.1055/s-2007-1001781; Valadka AB, 2000, J TRAUMA, V48, P296, DOI 10.1097/00005373-200002000-00017; WONG CW, 1995, ACTA NEUROCHIR, V135, P131, DOI 10.1007/BF02187756; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	48	29	30	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2000	49	1					1	8		10.1097/00005373-200007000-00001			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	335LH	WOS:000088244600001	10912851				2021-06-18	
J	Schootman, M; Fuortes, LJ				Schootman, M; Fuortes, LJ			Ambulatory care for traumatic brain injuries in the US, 1995-1997	BRAIN INJURY			English	Article							HEAD-INJURY; MILD; MANAGEMENT; PHYSICIANS; RISK	The burden of mild traumatic brain injury (TBI) is not well understood at the national level, but hospitalization rates show a decline over time. This paper describes ambulatory care for TBI patients at physician offices, hospital outpatient departments, and emergency departments (EDs) in comparison with non-TBI visits for the US during 1995-1997. An estimated 1.4 million visits for TBI were made each year for an average annual rate of 5.4/1000 population. A decline in annual visit rate was noted during 1995-1997. Visit rates were higher for those aged 0-14 and 75 and older. Falls (44%) and motor vehicles (28%) were the primary injury causes. Rural-urban differences were found, also in comparison with non-TBI. In 23% of visits to EDs, a CT scan was ordered or performed and in 33% a mental status exam was conducted. Further investigations are warranted to describe ambulatory care for TBI in more detail, particularly in light of a decline in hospitalization rates.	Iowa Dept Publ Hlth, Des Moines, IA 50319 USA; Univ Iowa, Dept Epidemiol, Iowa City, IA USA	Schootman, M (corresponding author), Washington Univ, Div Hlth Behav Res, Dept Pediat, 4444 Forest Pk Pkwy, St Louis, MO 63108 USA.	mschootm@im.wustl.edu	Schootman, Mario/AAF-3941-2019	Schootman, Mario/0000-0003-1162-8824	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-19TB 24-01, CCU703369-11] Funding Source: Medline		Aitken ME, 1998, ARCH PEDIAT ADOL MED, V152, P1176; Ashwal S, 1997, J HEAD TRAUMA REHAB, V12, P13, DOI 10.1097/00001199-199708000-00004; BASS JL, 1993, PEDIATRICS, V92, P544; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Clements AD, 1997, J REHABIL, V63, P3; Diamond PT, 1998, BRAIN INJURY, V12, P817, DOI 10.1080/026990598122052; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; HORNBROOK MC, 1994, GERONTOLOGIST, V34, P16, DOI 10.1093/geront/34.1.16; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; POTTHOFF RF, 1992, J AM STAT ASSOC, V87, P383, DOI 10.2307/2290269; Quinlan KP, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.5.e55; SCHAPPERT SM, 1997, NATL CTR HLTH STAT V, V13, P129; SCHAPPERT SM, 1998, NATL CTR HLTH STAT V, V13, P134; Schootman M, 1998, BIOM HLTH R, V21, P73; SCHOOTMAN M, 1999, IN PRESS BRAIN INJUR; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Torner James C., 1996, P19; WOODWELL D, 1997, NATL CTR HLTH STAT A, V305, P1999	23	29	29	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2000	14	4					373	381					9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	302UE	WOS:000086383400007	10815845				2021-06-18	
J	Klodell, CT; Carroll, M; Carrillo, EH; Spain, DA				Klodell, CT; Carroll, M; Carrillo, EH; Spain, DA			Routine intragastric feeding following traumatic brain injury is safe and well tolerated	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	28th Educational and Scientific Symposium of the Society-of-Critical-Care-Medicine	JAN 23-27, 1999	SAN FRANCISCO, CALIFORNIA	Soc Crit Care Med			PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; NUTRITIONAL SUPPORT; PATIENT; INTOLERANCE; COMPLICATIONS; TRACHEOSTOMY; MANAGEMENT; PASSAGE; TUBES	BACKGROUND: Delayed gastric emptying following traumatic brain injury (TBI) has led some to advocate jejunal feeding. Our purpose was to review our experience with percutaneous endoscopic gastrostomy (PEG) and intragastric feeding in TBI patients to assess safety and effectiveness. METHODS: Ail patients on a TBI clinical pathway at our institution were targeted for early PEG. After PEG, standard enteral nutrition was initiated. Abdominal examination and gastric residual volumes were used to assess tolerance. RESULTS: There were 118 patients with moderate to severe TBI. The average age was 36 years. Mean Injury Severity Score (ISS) was 25. Enteral access was obtained and intragastric feeding was initiated on day 3.6. Intragastric feeding was tolerated without complication in 111 of 114 (97%) patients. Five patients aspirated, but had no evidence of intolerance prior to the event. CONCLUSIONS: PEG provided reliable enteral access in moderate to severe TBI patients. Intragastric feeding was well tolerated with a low complication rate (4%). (C) 2000 by Excerpta Medica, Inc.	Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA; Univ Louisville Hosp, Trauma Program Surg, Louisville, KY USA; Vet Affairs Med Ctr, Louisville, KY USA	Spain, DA (corresponding author), Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA.						ALVERDY J, 1985, ANN SURG, V202, P681, DOI 10.1097/00000658-198512000-00003; BORZOTTA AP, 1993, SURG FORUM, V42, P29; Carrillo EH, 1997, SURG ENDOSC, V11, P1068, DOI 10.1007/s004649900531; Chendrasekhar A, 1996, AM SURGEON, V62, P887; DALY JM, 1995, ANN SURG, V221, P327, DOI 10.1097/00000658-199504000-00002; DAMELIO LF, 1994, AM SURGEON, V60, P180; FOX KA, 1995, AM J SURG, V170, P564, DOI 10.1016/S0002-9610(99)80016-6; Gianotti L, 1997, ARCH SURG-CHICAGO, V132, P1222, DOI 10.1001/archsurg.1997.01430350072012; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; HEYLAND DK, 1999, NUTR CLIN PRACT, V14, P23; LAZARUS BA, 1990, ARCH PHYS MED REHAB, V71, P46; MARIAN M, 1993, SURG GYNECOL OBSTET, V176, P475; MCCLAVE SA, 1992, JPEN-PARENTER ENTER, V16, P99, DOI 10.1177/014860719201600299; McClave SA, 1997, JPEN-PARENTER ENTER, V21, P14, DOI 10.1177/014860719702100114; MOORE FA, 1992, J TRAUMA, V33, P435, DOI 10.1097/00005373-199209000-00017; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; SAXE JM, 1994, J TRAUMA, V37, P581, DOI 10.1097/00005373-199410000-00010; SHAILESH LTC, 1992, AM J SURG, V164, P114, DOI 10.1016/S0002-9610(05)80367-8; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; STRONG RM, 1992, JPEN-PARENTER ENTER, V16, P59, DOI 10.1177/014860719201600159; Twyman D, 1997, CRIT CARE CLIN, V13, P39, DOI 10.1016/S0749-0704(05)70295-5; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131	27	29	35	0	5	CAHNERS PUBL CO	NEW YORK	249 WEST 17 STREET, NEW YORK, NY 10011 USA	0002-9610			AM J SURG	Am. J. Surg.	MAR	2000	179	3					168	171		10.1016/S0002-9610(00)00297-X			4	Surgery	Surgery	318LN	WOS:000087285700002	10827311				2021-06-18	
J	Minton, R; Murray, P; Stephenson, W; Galasko, CSB				Minton, R; Murray, P; Stephenson, W; Galasko, CSB			Whiplash injury - are current head restraints doing their job?	ACCIDENT ANALYSIS AND PREVENTION			English	Article; Proceedings Paper	World Congress on Whiplash Associated Disorders	1999	VANCOUVER, CANADA			whiplash; Whiplash Associated Disorder (WAD); head restraints		It is generally accepted that the incidence of whiplash associated disorders is increasing in all industrialised countries, despite the almost universal fitment of head restraints in at least the front seats of cars. This is usually attributed to the fact that few people can be observed to follow the standard recommendations as regards head restraint positioning, that is, level with the head vertically and as close to the head as possible horizontally. This study set out to determine whether any other factors, in addition to head restraint adjustment, could be found which would influence the severity of whiplash injury. This was done by linking medical assessment of real-world accident victims with engineering assessment of the accident vehicles. A random sample of road accident victims suffering from whiplash associated disorder was studied. The vehicles they had been travelling in were examined to assess impact severity and, where possible, measurements were made of seat and head restraint adjustment with the subject sitting in the vehicle. All subjects were interviewed to assess the disability resulting from their injuries, and their progress was followed for 12 months. The results were subjected to statistical analysis to try to determine relationships between severity of injury (as measured by resultant disability) and a number of occupant- and vehicle-related factors. A significant proportion of the sample had suffered lumbar strain injury in addition to whiplash, and these were excluded from the present analysis. Frontal impact victims suffered symptoms indistinguishable from those of rear impact victims. The beneficial effects of good head restraint adjustment could not be clearly demonstrated, and some trends, especially in rear impacts, where the benefits of a well-adjusted restraint should have been very clear, indicated that larger distances from head to restraint were associated with lower disability. The paper discusses these counter-intuitive results and their implications. (C) 2000 The Transport Research Laboratory. Published by Elsevier Science Ltd. All rights reserved.	Transport Res Lab, Crowthorne RG45 6AU, Berks, England; Univ Manchester, Hope Hosp, Dept Orthopaed Surg, Manchester, Lancs, England	Minton, R (corresponding author), Transport Res Lab, Crowthorne RG45 6AU, Berks, England.						BIGI D, 1998, P 16 ESV C WINDS CAN; BOGDUK N, 1986, CLIN BIOMECH, V1, P92, DOI 10.1016/0268-0033(86)90084-7; CULLEN E, 1996, P 1996 IRCOBI C DUBL; DIPPEL C, 1997, P 1997 IRCOBI C HANN; EICHBERGER A, 1996, P 1996 IRCOBI C DUBL; FORETBRUNO JY, 1991, P 13 ESV C PAR; HOPKIN JM, 1993, 379 TRL DEP TRANSP 1; LOVSUND P, 1988, P 1988 IRCOBI C BERG; LUNDELL B, 1998, P 16 ESV C WINDS CAN; LUNDELL B, 1988, SAE INT C EXP DETR; MAAG U, 1990, P 1990 IRCOBI C BRON; MINTON R, 1998, P 16 ESV C WINDS CAN; MINTON R, 1997, P 1997 IRCOBI C DUBL; MORRIS A, 1996, P 15 ESV C MELB; MURRAY PA, 1994, 106 TRL DEP TRANSP; MURRAY PA, 1993, 45 TRL DEP TRANSP; NYGREN A, 1985, P 10 ESV C OXF UK; NYGREN A, 1984, ACTA OTOLARYNGOLOG S, V395; OLSSON I, 1990, P 1990 IRCOBI C BRON; PARKIN S, 1994, P 14 ESV C MUN; RYAN GA, 1994, P 1994 IRCOBI C LYON; SEKIZUKA M, 1998, P 16 ESV C WINDS CAN; Spitzer W.O., 1995, SPINE S, V20, P8; Svensson MY, 1993, SAESP93963; VONKOCH M, 1995, P 1995 IRCOBI C BRUN	25	29	29	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575			ACCIDENT ANAL PREV	Accid. Anal. Prev.	MAR	2000	32	2					177	185		10.1016/S0001-4575(99)00092-5			9	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	282GG	WOS:000085209300006	10688474				2021-06-18	
J	Vilke, GM; Chan, TC; Guss, DA				Vilke, GM; Chan, TC; Guss, DA			Use of a complete neurological examination to screen for significant intracranial abnormalities in minor head injury	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						head; trauma; Glasgow Coma Scale; injury; minor; intracranial	CRANIAL COMPUTED-TOMOGRAPHY; SELECTION CRITERIA; TRAUMA; PREDICTORS; HEMATOMA; ALWAYS; SCANS	Indications for head computed tomography (CT) scans are unclear in patients with nonpenetrating head injury and Glasgow Coma Scale (GCS) scores of 15, We performed a prospective study to determine if significant intracranial injury could be excluded in patients with GCS-15 and a normal complete neurological examination. A prospective trial of clinically sober adult patients with GCS = 15 on emergency department (EO) presentation after closed head injury with loss of consciousness or amnesia was conducted from May 1996 through April 1997, All subjects underwent a standardized neurological examination including mental status evaluation, and assessment of motor, sensory, cerebellar and reflex function before CT scan. During the study period, 58 patients met inclusion criteria, Fifty five patients (95%) had normal CT scans and 23 (42%) had focal neurological abnormalities. Three patients (5%) had CT scan findings of acute intracranial injury, two of whom had normal neurological examinations, One patient had an acute subdural hematoma requiring emergent surgical decompression; the other had both an epidural hematoma and pneumocephalus that did not require surgery. Significant brain injury and need for CT scanning cannot be excluded in patients with minor head injury despite a GCS = 15 and normal complete neurological examination on presentation, (Am J Emerg Med 2000;18:159-163, Copyright (C) 2000 by W.B. Saunders Company).	Univ Calif San Diego, Med Ctr, Dept Emergency Med, San Diego, CA 92103 USA	Vilke, GM (corresponding author), Univ Calif San Diego, Med Ctr, Dept Emergency Med, 200 W Arbor Dr Mailcode 8676, San Diego, CA 92103 USA.						BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; FEURMAN T, 1988, NEUROSURGERY, V22, P449; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; MADDEN C, 1995, ACAD EMERG MED, V2, P248, DOI 10.1111/j.1553-2712.1995.tb03217.x; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; Price D J, 1986, Acta Neurochir Suppl (Wien), V36, P106; REINUS WR, 1993, ANN EMERG MED, V22, P1148, DOI 10.1016/S0196-0644(05)80981-3; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, J NEUROSURG, V69, P692, DOI 10.3171/jns.1988.69.5.0692; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	18	29	33	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAR	2000	18	2					159	163		10.1016/S0735-6757(00)90009-3			5	Emergency Medicine	Emergency Medicine	295YW	WOS:000085997100010	10750921				2021-06-18	
J	Black, K; Zafonte, R; Millis, S; Desantis, N; Harrison-Felix, C; Wood, D; Mann, N				Black, K; Zafonte, R; Millis, S; Desantis, N; Harrison-Felix, C; Wood, D; Mann, N			Sitting balance following brain injury: does it predict outcome?	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; ACUTE STROKE; REHABILITATION; INDIVIDUALS; RECOVERY	Balance dysfunction is commonly observed following traumatic brain injury. There are many proposed predictors of functional outcome in the traumatic brain injury population. It was hypothesized that the degree of balance dysfunction on admission to rehabilitation would be a significant predictor of the need for assistance at discharge, as measured by the Functional Independence Measure (FIM). This study involved 237 cases of traumatic brain injury patients admitted to a rehabilitation unit between November 1989 and September 1996. Using a multiple regression model, controlling for age, initial Glasgow Coma Score (GCS), rehabilitation admission strength, sitting balance and standing balance, it was found that the degree of impairment in sitting balance at admission to rehabilitation was a significant predictor of Discharge FIM-Total (FIM-T) score (p < 0.0001) and also of selected elements from the Discharge FIM-Motor (FIM-M) score (p < 0.0005). The combination of age, initial admission GCS, rehabilitation admission strength, standing balance and sitting balance accounted for 29% of the variance in the Discharge Total FIM score. Among these, sitting balance was the second most powerful predictor of both selected elements of the Discharge FIM motor score and discharge FIM-T. Sitting balance predictive capacity was exceeded in power only by age. Impairments in sitting balance appear to have a significant impact on functional outcome. Emphasis on unique rehabilitation techniques to treat balance dysfunction in the adult TBI population is warranted.	Wayne State Univ, Dept Phys Med & Rehabil, Inst Rehabil, Detroit, MI 48201 USA	Black, K (corresponding author), Wayne State Univ, Dept Phys Med & Rehabil, Inst Rehabil, 261 Mack Blvd, Detroit, MI 48201 USA.	KBLACK@DMK.org					ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Brosseau L, 1996, AM J PHYS MED REHAB, V75, P422, DOI 10.1097/00002060-199611000-00005; CARR JH, 1985, PHYS THER, V65, P175, DOI 10.1093/ptj/65.2.175; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; EISENBERG HM, 1983, INTRACRANIAL PRESSUR, V5, P549; Franchignoni FP, 1997, STROKE, V28, P1382, DOI 10.1161/01.STR.28.7.1382; FREGLY AR, 1968, AEROSPACE MED, V39, P277; GILCHRIST E, ARCH NEUROLOGY, V179, P355; GUERTS ACH, 1996, ARCH PHYSICAL MED RE, V77, P639; HAIN TC, 1994, VESTIBULAR REHABILIT, P15; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; Hillier SL, 1997, BRAIN INJURY, V11, P661; JENNETT B, 1976, LANCET, V1, P1031; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KEENAN MA, 1984, CLIN ORTHOP RELAT R, P165; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MILLETT D, 1987, PHYS THER, V65, P1697; Miyai I, 1997, NEUROLOGY, V48, P95, DOI 10.1212/WNL.48.1.95; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; Nichols DS, 1996, ARCH PHYS MED REHAB, V77, P865, DOI 10.1016/S0003-9993(96)90271-3; PRESCOTT RJ, 1982, STROKE, V13, P641, DOI 10.1161/01.STR.13.5.641; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; SANDIN KJ, 1990, STROKE, V21, P82, DOI 10.1161/01.STR.21.1.82; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; *UB FDN ACT, 1993, GUID UN DAT SET MED; WADE DT, 1983, ARCH PHYS MED REHAB, V64, P24; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; ZAFONTE RD, 1995, AM J PHYS MED REHABI, V74, P176	39	29	30	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2000	14	2					141	152		10.1080/026990500120808			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	281GW	WOS:000085151000004	10695570				2021-06-18	
J	Al-Samsam, RH; Alessandri, B; Bullock, R				Al-Samsam, RH; Alessandri, B; Bullock, R			Extracellular N-acetyl-aspartate as a biochemical marker of the severity of neuronal damage following experimental acute traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						N-acetyl-aspartate; high-performance liquid chromatography; microdialysis; traumatic brain injury	MAGNETIC-RESONANCE SPECTROSCOPY; CLOSED-HEAD INJURY; RAT-BRAIN; CEREBRAL-ISCHEMIA; AXONAL INJURY; ACETYLASPARTATE; MICRODIALYSIS; DYSFUNCTION; HYPOXIA	We evaluated the acute changes in interstitial and whole brain N-acetyl-aspartate (NAA) measured by high-performance liquid chromatography in animal models of isolated traumatic brain injury (TBI) and TBI combined with secondary insult (hypotension-hypoxia [HH]). The Marmarou impact-acceleration model was used. Four groups were studied: (1) sham-operated control, (2) TBI alone (TBI 500 gm, 2 m), (3) TBI plus 30 min of hypoxia (PaO2, similar to 40 mm Hg) and hypotension (mean arterial blood pressure, similar to 40 mm Hg) (THH), and (4) HH alone. The baseline value for dialysate NAA (NAA(d)) in the rats was 8.17 +/- 1 mu M. No significant difference between groups was found for this baseline value. The TBI group had a modest (100%) transient increase in NAA(d) after isolated TBI. The HH group had a transient (500%) increase in NAA(d) at 1 h, sustained for 2 h. In the THH group, there was a persistent increase in NAA(d) (800%) that peaked at 2.5 h. The whole brain NAA (NAA(w)) concentration in controls was 8.5 +/- 0.5 mmol/kg wet weight. There was no significant difference between TBI and controls; however, there was a significant decrease in NAA(w) in the THH and HH group compared to controls. Thus, in this animal model of TBI and TBI with secondary insult, we found that persistent, marked elevation in NAA is associated with TBI and secondary ischemic/hypoxic insult, but not with isolated TBI alone.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, MCV Stn, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Pediat Crit Care Med, Richmond, VA 23298 USA	Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, MCV Stn, Box 980631, Richmond, VA 23298 USA.	robulloc@hsc.vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		ABE K, 1995, STROKE, V26, P1478, DOI 10.1161/01.STR.26.8.1478; Al-Samsam R, 1999, CRIT CARE MED, V27, pA104, DOI 10.1097/00003246-199901001-00265; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; BERLINGUET L, 1996, CAN J BIOCHEM, V44, P783; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CENDES F, 1994, ANN NEUROL, V35, P211, DOI 10.1002/ana.410350213; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; DADAMO AF, 1966, J NEUROCHEM, V13, P961, DOI 10.1111/j.1471-4159.1966.tb10292.x; EBISU T, 1994, J CEREBR BLOOD F MET, V14, P373, DOI 10.1038/jcbfm.1994.48; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; GIDEON P, 1992, STROKE, V23, P1566, DOI 10.1161/01.STR.23.11.1566; Gotoh M, 1997, J NEUROCHEM, V69, P655; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; KOLLER KJ, 1984, J NEUROCHEM, V43, P1136, DOI 10.1111/j.1471-4159.1984.tb12854.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MOATS RA, 1994, MAGNET RESON MED, V32, P110, DOI 10.1002/mrm.1910320115; NADLER JV, 1972, J NEUROCHEM, V19, P2091, DOI 10.1111/j.1471-4159.1972.tb05119.x; Nakai A, 1997, NEUROBIOL DIS, V4, P288, DOI 10.1006/nbdi.1997.0146; PEDEN CJ, 1993, DEV MED CHILD NEUROL, V35, P502; Penrice J, 1996, PEDIATR RES, V40, P6, DOI 10.1203/00006450-199607000-00002; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; SAGER TN, 1995, J CEREBR BLOOD F MET, V15, P639, DOI 10.1038/jcbfm.1995.79; Sager TN, 1997, J NEUROCHEM, V68, P675; SCHELLER D, 1991, J NEUROSCI METH, V40, P31, DOI 10.1016/0165-0270(91)90114-F; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; TAYLOR DL, 1994, J NEUROCHEM, V62, P2349; TAYLOR DL, 1995, J NEUROCHEM, V65, P275; TSAI GC, 1995, PROG NEUROBIOL, V46, P531, DOI 10.1016/0301-0082(95)00014-M; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487	38	29	32	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2000	17	1					31	39		10.1089/neu.2000.17.31			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	278WR	WOS:000085012400003	10674756				2021-06-18	
J	Eijkenboom, M; Blokland, A; Van der Staay, FJ				Eijkenboom, M; Blokland, A; Van der Staay, FJ			Modelling cognitive dysfunctions with bilateral injections of ibotenic acid into the rat entorhinal cortex	NEUROSCIENCE			English	Article						electrolytic; excitotoxic; Morris water maze; parahippocampal area; replicability	WATER MAZE TASK; DENTATE GYRUS; KAINIC ACID; SPATIAL MEMORY; HIPPOCAMPAL DAMAGE; SUBDURAL-HEMATOMA; SELECTIVE LESIONS; RECOVERY; BEHAVIOR; PERFORMANCE	Neurodegenerative diseases, traumatic brain injury and stroke are likely to result in cognitive dysfunctioning. Animal models are needed in which these deficits and recovery of the affected functions can be investigated. In the present study, the entorhinal area was chosen as the target for lesioning and for assessing the lesion-induced deficits in the Morris water maze. The entorhinal cortex is regarded as an interface between the hippocampus and neocortex. Deafferentiating the hippocampus through entorhinal lesions impairs spatial learning. The effects of lesions, induced by either electrocoagulation (experiment 1) or ibotenate excitotoxicity (experiment 2), on spatial orientation behaviour were investigated. Water maze performance after unilateral or bilateral ibotenate injections into the entorhinal cortex was studied in the third experiment. In an additional study, the replicability of the spatial learning deficit after lesions induced by bilateral injections of ibotenic acid into the entorhinal cortex was assessed by comparing the results of nine experiments. We found that spatial learning was impaired after bilateral lesions aimed at the entorhinal cortex. The electrolytic lesion technique produced a relatively large sham effect, whereas the excitotoxic lesioning method did not. Unilateral injections of ibotenic acid into the entorhinal cortex did not affect spatial navigation. The ibotenate induced lesions replicably produced deficits in the Morris tasks. The degree of the induced spatial learning impairments and the effects on the rate of acquisition during training, however, differed between experiments. This result suggests that the fundamental biological diversity between shipments of rats can account for variation in the effects of parahippocampal damage on spatial learning even in highly standardized experimental set-ups. Rats lesioned by bilateral injections of ibotenic acid into the entorhinal cortex provide an interesting and reliable model for investigating cognitive dysfunctions in neurodegenerative diseases, stroke or traumatic brain injury. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Bayer AG, CNS Res, D-5600 Wuppertal, Germany; Maastricht Univ, Fac Psychol, Maastricht, Netherlands	Eijkenboom, M (corresponding author), Bayer AG, CNS Res, D-5600 Wuppertal, Germany.			van der Staay, F. Josef/0000-0002-8704-3366			AUBERT I, 1994, J NEUROSCI, V14, P2476; BARNES CA, 1990, PROGR BRAIN RES; Bobinski M, 1998, BRAIN RES, V805, P267, DOI 10.1016/S0006-8993(98)00759-8; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Cain DP, 1998, NEUROSCI BIOBEHAV R, V22, P181, DOI 10.1016/S0149-7634(97)00005-5; CHOI DW, 1988, J NEUROSCI, V8, P185; Cotman CW, 1998, MENT RETARD DEV D R, V4, P223, DOI 10.1002/(SICI)1098-2779(1998)4:3<223::AID-MRDD10>3.0.CO;2-X; Cotton JW., 1998, ANAL WITHIN SUBJECTS, V1; Crabbe JC, 1999, SCIENCE, V284, P1670, DOI 10.1126/science.284.5420.1670; Eijkenboom M, 1999, NEUROSCIENCE, V94, P373, DOI 10.1016/S0306-4522(99)00332-2; EIJKENBOOM M, 1998, P MEAS BEH 98 2 INT, P137; FREUND RJ, 1985, SAS LINEAR MODELS; Frotscher M, 1996, ANN ANAT, V178, P311, DOI 10.1016/S0940-9602(96)80080-X; Galani R, 1998, BEHAV BRAIN RES, V96, P1, DOI 10.1016/S0166-4328(97)00197-6; GLASIER MM, 1995, NEUROBIOL LEARN MEM, V64, P203, DOI 10.1006/nlme.1995.0003; Good M, 1997, BEHAV NEUROSCI, V111, P487, DOI 10.1037/0735-7044.111.3.487; GULDIN WO, 1982, J NEUROSCI METH, V5, P83, DOI 10.1016/0165-0270(82)90055-3; GULDIN WO, 1981, BRAIN RES, V225, P446, DOI 10.1016/0006-8993(81)90852-0; HAGAN JJ, 1992, PHYSIOL BEHAV, V51, P255, DOI 10.1016/0031-9384(92)90139-S; Hardman R, 1997, BRAIN RES, V758, P187, DOI 10.1016/S0006-8993(97)00223-0; HUNT ME, 1994, PSYCHOBIOLOGY, V22, P186; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; JARRARD LE, 1983, BEHAV NEUROSCI, V97, P873, DOI 10.1037/0735-7044.97.6.873; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P121, DOI 10.1016/S0149-7634(96)00001-2; KAHLE JS, 1993, BRAIN RES, V609, P201, DOI 10.1016/0006-8993(93)90874-M; KESSLAK JP, 1991, BRAIN RES, V557, P57, DOI 10.1016/0006-8993(91)90115-C; KIMBLE DP, 1965, J COMP PHYSIOL PSYCH, V60, P474, DOI 10.1037/h0022550; KOHLER C, 1979, NEUROSCI LETT, V15, P223, DOI 10.1016/0304-3940(79)96117-2; LEONARD BW, 1995, J NEUROSCI, V15, P5637; Miettinen R, 1998, BRAIN RES, V813, P9, DOI 10.1016/S0006-8993(98)00915-9; Miwa C, 1996, PSYCHIAT CLIN NEUROS, V50, P223, DOI 10.1111/j.1440-1819.1996.tb02746.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NYAKAS C, 1988, BRAIN RES BULL, V21, P285, DOI 10.1016/0361-9230(88)90243-2; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; PARENT A, 1994, NEUROSCIENCE, V61, P565, DOI 10.1016/0306-4522(94)90434-0; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PETERSON DA, 1994, J NEUROSCI, V14, P6872; RAMIREZ JJ, 1991, BEHAV BRAIN RES, V43, P99, DOI 10.1016/S0166-4328(05)80057-9; RAMIREZ JJ, 1984, BEHAV BRAIN RES, V13, P53, DOI 10.1016/0166-4328(84)90029-9; Ramirez JJ, 1998, RESTOR NEUROL NEUROS, V12, P203; Ramirez JJ, 1996, P NATL ACAD SCI USA, V93, P15512, DOI 10.1073/pnas.93.26.15512; RAMIREZ JJ, 1988, BRAIN RES, V459, P153, DOI 10.1016/0006-8993(88)90296-X; RASMUSSEN M, 1989, PSYCHOBIOLOGY, V17, P335; REEVES TM, 1987, BEHAV NEUROSCI, V101, P179; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; SCHENK F, 1985, EXP BRAIN RES, V58, P11; STEWARD O, 1983, J COMP NEUROL, V214, P370, DOI 10.1002/cne.902140403; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; TERRY P, 1990, PSYCHOBIOLOGY, V18, P404; THINUSBLANC C, 1991, BRAIN SPACE; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9; Zajaczkowski W, 1997, PHARMACOL BIOCHEM BE, V56, P21, DOI 10.1016/S0091-3057(96)00133-5; Zajaczkowski W, 1996, EUR J PHARMACOL, V296, P239, DOI 10.1016/0014-2999(95)00716-4	53	29	29	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	101	1					27	39		10.1016/S0306-4522(00)00342-0			13	Neurosciences	Neurosciences & Neurology	373AA	WOS:000165265200005	11068134				2021-06-18	
J	Nicholson, K				Nicholson, K			Pain, cognition and traumatic brain injury	NEUROREHABILITATION			English	Article							POSITRON-EMISSION-TOMOGRAPHY; MILD HEAD-INJURY; POST-CONCUSSIONAL SYNDROME; POSTTRAUMATIC HEADACHE; POSTCONCUSSION SYMPTOMS; TEST-PERFORMANCE; RISK-FACTORS; MEMORY; MIGRAINE; INFORMATION	There has been considerable controversy concerning the problem of the persisting post-concussive syndrome and whether cognitive or other sequelae might be attributed to the effects of brain injury or other causes. Headache is the predominant problem in virtually all surveys of the post-concussive syndrome. It is suggested that pain and related problems may account for most of the difficulties in those presenting with the persisting post-concussive syndrome or other cases in which mild to moderate brain injury is suspected. A survey of the literature concerning the relationship of pain, cognition and traumatic brain injury indicates that cognitive difficulties are common in acute or chronic pain, with or without any indication of brain injury. However, numerous methodological problems are apparent and there is clearly need for further study. Consideration is given both to psychosocial and neurobiological effects underlying any such relationships.	Toronto Western Hosp, Comprehens Pain Program, Toronto, ON M5T 2S8, Canada	Nicholson, K (corresponding author), Toronto Western Hosp, Comprehens Pain Program, 4BFell-150,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	keith@playfair.utoronto.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Andary MT, 1997, CLIN J PAIN, V13, P244, DOI 10.1097/00002508-199709000-00010; Aziz Q, 1997, GASTROENTEROLOGY, V113, P50, DOI 10.1016/S0016-5085(97)70079-9; Bell BD, 1999, ARCH CLIN NEUROPSYCH, V14, P389, DOI 10.1016/S0887-6177(98)00020-1; BERNARD JF, 1992, J NEUROPHYSIOL, V68, P551; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blume H G, 1990, Beitr Gerichtl Med, V48, P397; Branca B, 1996, HEADACHE, V36, P300, DOI 10.1046/j.1526-4610.1996.3605300.x; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; BRUYN GW, 1990, HDB CLIN NEUROLOGY, V13, P421; Burker E, 1989, NEUROPSYCHOLOGY, V3, P61, DOI 10.1037//0894-4105.3.2.61; CHEN ACN, 1993, PAIN, V54, P133, DOI 10.1016/0304-3959(93)90201-Y; Coghill RC, 1999, J NEUROPHYSIOL, V82, P1934; Crombez G, 1997, PAIN, V70, P149, DOI 10.1016/S0304-3959(96)03304-0; Crombez G, 1996, BEHAV RES THER, V34, P911, DOI 10.1016/S0005-7967(96)00058-7; CROMBEZ G, 1994, BEHAV RES THER, V32, P611, DOI 10.1016/0005-7967(94)90015-9; DANDREA G, 1989, CEPHALALGIA, V9, P25, DOI 10.1046/j.1468-2982.1989.0901025.x; DAVIDSON H, 1991 INT NEUR SOC AN; Denys P, 1996, BRAIN INJURY, V10, P149, DOI 10.1080/026990596124656; DERBYSHIRE SWG, 1994, J NEUROL NEUROSUR PS, V57, P1166, DOI 10.1136/jnnp.57.10.1166; Derbyshire SWG, 1997, PAIN, V73, P431, DOI 10.1016/S0304-3959(97)00138-3; Diener HC, 1997, HEADACHE, V37, P622, DOI 10.1046/j.1526-4610.1997.3710622.x; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIPIERO V, 1991, PAIN, V46, P9, DOI 10.1016/0304-3959(91)90026-T; DISTEFANO G, 1995, ACTA NEUROL SCAND, V91, P346; DUFTON BD, 1989, INT J PSYCHIAT MED, V19, P291, DOI 10.2190/JDJK-0795-5BFL-5N6K; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; ECCLESTON C, 1995, BEHAV RES THER, V33, P391, DOI 10.1016/0005-7967(94)00057-Q; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; EVANS RW, 1992, NEUROL CLIN, V10, P815; Farrell MJ, 1996, PAIN, V67, P7, DOI 10.1016/0304-3959(96)03041-2; FIORAVANTI M, 1983, CEPHALALGIA, V3, P221, DOI 10.1177/03331024830030S137; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GELLMAN H, 1992, PAIN, V51, P307, DOI 10.1016/0304-3959(92)90214-V; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; GRIGSBY J, 1994, ARCH CLIN NEUROPSYCH, V9, P135; HART RP, IN PRESS NEUROREHABI; HEBBEN N, 1981, NEUR ABSTR, V7, P235; HOOKER WD, 1986, ARCH NEUROL-CHICAGO, V43, P709, DOI 10.1001/archneur.1986.00520070065020; Hsieh JC, 1996, PAIN, V64, P303, DOI 10.1016/0304-3959(95)00129-8; HSIEH JC, 1996, INT C FUNCT MAPP HUM; IADAROLA MJ, 1995, PAIN, V63, P55, DOI 10.1016/0304-3959(95)00015-K; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; JAMISON RN, 1988, INT J PSYCHIAT MED, V18, P183; Jones AKP, 1996, ANN RHEUM DIS, V55, P411, DOI 10.1136/ard.55.7.411; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; KEWMAN DG, 1989, ARCH PHYSICAL MED RE; KOEHLER SM, 1991, J CLIN EXP NEUROPSYC, V13, P60; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lake AE, 1999, J HEAD TRAUMA REHAB, V14, P70, DOI 10.1097/00001199-199902000-00008; LEIJDEKKERS MLA, 1990, HEADACHE, V30, P352, DOI 10.1111/j.1526-4610.1990.hed3006352.x; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lorenz J, 1997, PSYCHOPHYSIOLOGY, V34, P436, DOI 10.1111/j.1469-8986.1997.tb02387.x; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MAZZUCCHI A, 1988, HEADACHE, V28, P488, DOI 10.1111/j.1526-4610.1988.hed2807488.x; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; MIDDELBOE T, 1992, J PERS DISORD, V6, P246, DOI 10.1521/pedi.1992.6.3.246; NICHOLSON K, NEUROREHABILITATION; NICHOLSON K, NEUROREHABILITION; PACKARD RC, 1993, HEADACHE, V33, P365, DOI 10.1111/j.1526-4610.1993.hed3307365.x; PATIL PG, 1995, PHYSIOL BEHAV, V58, P1281, DOI 10.1016/0031-9384(95)02071-3; PEYRON R, 1995, PAIN, V62, P275, DOI 10.1016/0304-3959(94)00211-V; Price DD, 1988, PSYCHOL NEURAL MECH, Vx; PUCA F, 1985, MIGRAINE CLIN RES AD, P1; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUTHERFORD WH, 1979, MILD HEAD INJURY, P217; SCHNURR RF, 1995, CLIN J PAIN, V11, P103, DOI 10.1097/00002508-199506000-00004; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; SELTZER SF, 1991, PAIN, V47, P47, DOI 10.1016/0304-3959(91)90010-U; Sepe C, 1993, Acta Neurol (Napoli), V15, P421; SHAPIRO AP, 1993, SPINE STATE ART REV, V7, P455; Silverman DHS, 1997, GASTROENTEROLOGY, V112, P64, DOI 10.1016/S0016-5085(97)70220-8; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x; Tsushima WT, 1996, HEADACHE, V36, P613, DOI 10.1046/j.1526-4610.1996.3610613.x; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; VERNONWILKINSON R, 1993 NAT AC NEUR ANN; Vogt BA, 1996, EUR J NEUROSCI, V8, P1461, DOI 10.1111/j.1460-9568.1996.tb01608.x; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; ZEITLIN C, 1984, BRIT J CLIN PSYCHOL, V23, P27, DOI 10.1111/j.2044-8260.1984.tb00623.x	89	29	31	1	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2000	14	2					95	103					9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	338AL	WOS:000088395900005					2021-06-18	
J	Kerr, ME; Weber, BB; Sereika, SM; Darby, J; Marion, DW; Orndoff, PA				Kerr, ME; Weber, BB; Sereika, SM; Darby, J; Marion, DW; Orndoff, PA			Effect of endotracheal suctioning on cerebral oxygenation in traumatic brain-injured patients	CRITICAL CARE MEDICINE			English	Article						endotracheal suctioning; cerebral oxygenation; head injury; transcranial Doppler ultrasound; jugular oxygen tension; intracranial pressure; arteriovenous oxygen difference	INTRACRANIAL-PRESSURE; HEAD-INJURY; FLOW VELOCITY; HYPERVENTILATION; ULTRASOUND; TRANSIENT; ADULTS	Objective: In patients with severe head injuries, brain damage occurs not only from the primary trauma but also secondarily from a reduction in cerebral oxygenation as a result of brain swelling, ischemia, and elevated intracranial pressure (ICP), However, routine interventions designed to maintain oxygenation, such as endotracheal suctioning (ETS), also may negatively affect the cerebrovascular status by increasing the ICP, The purpose of this study was to determine whether ETS influences cerebral oxygenation in patients with traumatic brain injury. Design: Descriptive, prospective, with repeated assessments within each patient. Setting: Ten-bed trauma intensive care unit in a university Level I trauma center. Subjects: Nineteen patients who were 16 yrs or older, had acute head injury, a Glasgow Coma Scale score less than or equal to 8, external ventricular drain and arterial pressure devices in place, and were intubated and mechanically ventilated. Interventions: ETS protocol consisting of administration of four ventilator-delivered breaths at 135% of the patients' actual tidal volume, 100% F-IO2, before and after suctioning with a standardized catheter at a 16-L flow rate. Measurements and Main Results: This study examined cerebrovascular responses as measured by the traditional measures of ICP and cerebral perfusion pressure, as well as middle cerebral artery velocity and jugular venous oxygen tension that occurred during ETS in head-injured adults. The results of this study show that both ICP and cerebral perfusion pressure are increased during ETS, In the majority of patients (84%), the ICP returned to baseline values within 2 mins, Conclusions: The increase in jugular venous oxygen tension associated with increases in middle cerebral artery velocity and mean arterial pressure suggests that cerebral oxygen delivery was maintained during ETS. Cerebral changes associated with ETS using the described protocol are consistent with the preservation of cerebral oxygenation.	Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA	Kerr, ME (corresponding author), Univ Pittsburgh, Sch Nursing, 360 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [1R03 NR03391-01] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R03NR003391] Funding Source: NIH RePORTER		AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Akaikei H., 1973, 2 INT S INFORM THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; BUSIJA DW, 1988, AM J PHYSIOL, V255, pH343; CONTANT CF, 1995, J NEUROSCI METH, V57, P15, DOI 10.1016/0165-0270(94)00106-Q; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; Diggle P., 1995, ANAL LONGITUDINAL DA; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GOSLING RG, 1974, P ROY SOC MED, V67, P447, DOI 10.1177/00359157740676P113; GRAHAM DI, 1971, LANCET, V1, P265; Graham DI, 1996, NEUROTRAUMA, P43; Kelly DF, 1996, NEUROTRAUMA, P71; Kerr M E, 1998, Am J Crit Care, V7, P205; Kerr ME, 1997, NURS RES, V46, P195, DOI 10.1097/00006199-199707000-00003; LASSEN NA, 1974, CIRC RES, V34, P749, DOI 10.1161/01.RES.34.6.749; March K, 1990, J Neurosci Nurs, V22, P375; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MITCHELL PH, 1978, NURS RES, V27, P4; PARSONS LC, 1984, HEART LUNG, V13, P372; Ropper Allan H., 1993, P11; RUDY EB, 1991, HEART LUNG, V20, P667; SANTBRINK H, 1996, NEUROSURGERY, V38, P21; SKELLEY BFH, 1980, HEART LUNG, V9, P316; URBAN BJ, 1969, ANESTHESIOLOGY, V31, P473, DOI 10.1097/00000542-196911000-00024; WINSOR T, 1945, P SOC EXP BIOL MED, V58, P165; Wisinger D, 1990, J Neurosci Nurs, V22, P365	29	29	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	DEC	1999	27	12					2776	2781		10.1097/00003246-199912000-00028			6	Critical Care Medicine	General & Internal Medicine	270EZ	WOS:000084523600028	10628625				2021-06-18	
J	Maxwell, WL; Donnelly, S; Sun, X; Fenton, T; Puri, N; Graham, DI				Maxwell, WL; Donnelly, S; Sun, X; Fenton, T; Puri, N; Graham, DI			Axonal cytoskeletal responses to nondisruptive axonal injury and the short-term effects of posttraumatic hypothermia	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia; microtubules; neurofilaments; traumatic axonal injury	TRAUMATIC BRAIN INJURY; AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; PIG OPTIC-NERVE; MODERATE HYPOTHERMIA; BEHAVIORAL DEFICITS; CORTICAL IMPACT; STRETCH-INJURY; PROTECTION; RAT	In human diffuse axonal injury (DAI), axons are exposed to transient tensile strain. Over thee ensuing several hours, injured axons enter a "pathological cascade" of events that lead to secondary axotomy. Use of animal models of traumatic axonal injury (TAI) has allowed description of a number of pathological changes before axotomy occurs, including structural and functional changes in the axolemma, disorientation, and/or loss of microtubules, either compaction and/or dispersion of neurofilaments together with focal compaction at sites where continuity of the axolemma is lost. Recent literature suggests that use of hypothermia may improve behavioral outcomes or reduce the number/density of injured axons in which axonal transport is altered after TAI. But there is presently no ultrastructural, pathological explanation as to how hypothermia may act at the level of the axon to reduce posttraumatic loss of axoplasmic transport. In this study, we tested the hypothesis that posttraumatic hypothermia may ameliorate (a) alteration of axonal transport and (b) early pathological changes in the axonal cytoskeleton prior to secondary axotomy. We have undertaken a pilot study within 4 h of stretch injury to adult guinea pig optic nerve axons as a model of TAI and applied stereological techniques to assess differences in pathology in animals either maintained at 37.5 degrees C or cooled to 32-32.5 degrees C for 2 or 4 h after injury. We provide quantitative evidence that posttraumatic hypothermia significantly reduces the number of axons labelled for beta-APP, a marker for disruption of fast axonal transport, and reduces the loss of microtubules and compaction of neurofilaments, which occurs in normothermic animals over the first 4 h after injury.	Univ Glasgow, Lab Human Anat, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Neuropathol, So Gen Hosp NHS Trust, Glasgow, Lanark, Scotland	Maxwell, WL (corresponding author), Univ Glasgow, Lab Human Anat, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.				Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		BAUR PS, 1977, J MICROSC-OXFORD, V109, P315, DOI 10.1111/j.1365-2818.1977.tb01145.x; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Eguchi Y, 1997, J NEUROTRAUM, V14, P109, DOI 10.1089/neu.1997.14.109; GENNARELLI TA, 1989, J NEUROSURG, V71, P315; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GUY J, 1989, J COMP NEUROL, V287, P446, DOI 10.1002/cne.902870404; Hyman BT, 1998, J NEUROPATH EXP NEUR, V57, P305, DOI 10.1097/00005072-199804000-00001; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WRIGLEY NG, 1968, J ULTRA MOL STRUCT R, V24, P454, DOI 10.1016/S0022-5320(68)80048-6	29	29	30	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1999	16	12					1225	1234		10.1089/neu.1999.16.1225			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266WC	WOS:000084322400009	10619200				2021-06-18	
J	Webster, G; Daisley, A; Rings, N				Webster, G; Daisley, A; Rings, N			Relationship and family breakdown following acquired brain injury: the role of the rehabilitation team	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; RELATIVES; CAREGIVERS; SUPPORT	Although the literature documents the considerable problems acquired brain injury causes for the survivors family and close relationships, and the corresponding significantly inflated rate of separation and divorce, few papers offer practical solutions. The objective of this paper is to respond to this gap in the literature by presenting some of the problems raised for the rehabilitation team when a family separates, and some suggestions for ways in which these problems could be overcome. The literature is reviewed briefly, followed by reflections and suggestions which are based on this review and on clinical experience. The discussion indicates that there are a number of practical dilemmas raised for the rehabilitation team when a family already involved in the rehabilitation process starts to break up. Some specific suggestions for addressing these issues are made; further research is needed to evaluate their effectiveness.	Rivermead Rehabil Ctr, Dept Clin Neuropsychol, Oxford OX1 4XD, England; Warneford Hosp, Isis Educ Ctr, Oxford Reg Training Course Clin Psychol, Oxford, England	Daisley, A (corresponding author), Rivermead Rehabil Ctr, Dept Clin Neuropsychol, Abingdon Rd, Oxford OX1 4XD, England.						Bond M R, 1979, Int Rehabil Med, V1, P155; BRANNEN J, 1982, MARRIAGES TROUBLE; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Frosch S, 1997, BRAIN INJURY, V11, P891; GLECKMAN AD, 1995, BRAIN INJURY, V9, P385, DOI 10.3109/02699059509005778; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Jackson A, 1991, COUNS PSYCHOL, V4, P355; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; Martin K M, 1994, J Neurosci Nurs, V26, P134; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; *MED DIS SOC, 1988, WORK PART REP MAN TR; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A., 1972, REHABILITATION, V38, P33; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Stilwell J, 1997, NATL TRAUMATIC BRAIN; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Testani-Dufour L, 1992, J Neurosci Nurs, V24, P317; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1988, NEW DEV CLIN PSYCHOL, V2, P189; TYERMAN A, 1991, COUNSELLING COMMUNIC, P115; WALKER J, 1988, FAMILY THERAPY BRITA, P241; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Woods B, 1997, AGING MENT HEALTH, V1, P11, DOI 10.1080/13607869757335	38	29	29	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	1999	13	8					593	603					11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	239YW	WOS:000082799200004	10901688				2021-06-18	
J	Weider, L; Hughes, K; Ciarochi, J; Dunn, E				Weider, L; Hughes, K; Ciarochi, J; Dunn, E			Early versus delayed repair of facial fractures in the multiply injured patient	AMERICAN SURGEON			English	Article							CRANIOFACIAL TRAUMA; INTERNAL-FIXATION; MANAGEMENT; MIDFACE	The management of facial fractures in the polytrauma patient requires the coordination of multiple surgical disciplines to optimize the functional and cosmetic outcome while minimizing overall morbidity and mortality. Although the plastic surgery literature historically advocates the early repair of facial fractures, the risk of general anesthesia in patients with associated injuries sometimes makes early repair unsafe. We compared early operative repair versus delayed operative repair of facial fractures in multitrauma patients. We specifically examined wound infection, overall complication rate, total length of hospital stay, days in the Intensive Care Unit (ICU), and days on the ventilator in the two groups. A 5-year (1991-1996) retrospective study of multitrauma patients with associated facial fractures was undertaken at an urban community hospital. We had a total of 82 patients, who were divided into three groups. Thirty-three patients did not have operative repair of the facial fractures during the initial admission and were followed by the plastic surgery service on an outpatient basis. These patients will not be discussed further. Seven patients underwent early operative repair, which was defined as repair within 48 hours of admission (group I). Forty-two patients had delayed operative repair, defined as repair more than 48 hours after admission (group II). The reasons for delayed repair included: excessive soft tissue swelling (16), intracranial injuries (12), unstable medical condition (8), and coordination of procedures with other services (6). Of the 49 patients who underwent operative repair, 43 were involved in motor vehicle accidents, 3 were injured by a fall from a height, 2 were involved in auto-pedestrian accidents, and 1 was a victim of assault. Forty-eight of the 49 patients were initially admitted to the ICU. Cumulative associated injuries were as follows: closed head injury (38), extremity fracture (21), blunt chest injuries (11), intra-abdominal injuries (5), vertebral column injuries (7), and ocular injuries (2). The average Injury Severity Score for Group I was 17.3 and for Group II, 18.1. In group I, there were no deaths, there were no wound infections, and the complication rate was 14.3 per cent. The average total number of days spent on the ventilator was 3.0, the average total number of days spent in the ICU was 5.0, and the average total hospital stay was 16.0 days. In group II, there were no deaths, the wound infection rate was 5 per cent, and the overall complication rate was 21 per cent. The average total number of days spent on the ventilator was 3.3, the average total number of days spent in the ICU was 5.8, and the average total days in the hospital was 14.8. Our results indicate that in a similar cohort of multitrauma patients, delayed repair did not increase length of ICU stay or hospital stay. The wound infection rate was negligible, and the complication rate was similar in the two groups. We conclude that a delay in repair of facial fractures in the critically ill patient has an acceptably low complication rate and may be advantageous in decreasing operative risk and minimizing cost by coordinating multiple procedures with various surgical subspecialties.	Methodist Hosp, Dept Surg, Dallas, TX 75265 USA	Dunn, E (corresponding author), Methodist Hosp, Dept Surg, POB 655999, Dallas, TX 75265 USA.						BENZIL DL, 1992, NEUROSURGERY, V30, P166, DOI 10.1227/00006123-199202000-00003; BRANDT KE, 1991, J TRAUMA, V31, P15, DOI 10.1097/00005373-199101000-00003; DERDYN C, 1990, PLAST RECONSTR SURG, V86, P238, DOI 10.1097/00006534-199008000-00005; DUFRESNE CR, 1992, CLIN PLAST SURG, V19, P207; Hartel J, 1991, Dtsch Z Mund Kiefer Gesichtschir, V15, P111; Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001; JETER TS, 1988, ORAL SURG ORAL MED O, V66, P416, DOI 10.1016/0030-4220(88)90257-5; KLOTCH DW, 1987, J TRAUMA, V27, P1136, DOI 10.1097/00005373-198710000-00008; MACIAS JD, 1993, ARCH OTOLARYNGOL, V119, P308; RAVEH J, 1988, J CRANIO MAXILL SURG, V16, P160, DOI 10.1016/S1010-5182(88)80042-8; REHM CG, 1995, J ORAL MAXIL SURG, V53, P522, DOI 10.1016/0278-2391(95)90063-2; THALLER SR, 1990, PLAST RECONSTR SURG, V85, P196, DOI 10.1097/00006534-199002000-00005; THALLER SR, 1992, PLAST RECONSTR SURG, V90, P562, DOI 10.1097/00006534-199210000-00003	13	29	30	0	0	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	AUG	1999	65	8					790	793					4	Surgery	Surgery	220MR	WOS:000081670200029	10432093				2021-06-18	
J	Gibbs, RW				Gibbs, RW			Interpreting what speakers say and implicate	BRAIN AND LANGUAGE			English	Article							BRAIN-DAMAGED PATIENTS; CLOSED-HEAD-INJURY; COMPREHENSION; RELEVANCE; REQUESTS; LANGUAGE; SARCASM; ABILITY; IDIOMS; AUTISM	The traditional view in pragmatic theory is that a distinction exists between what speakers say and what they mean, communicate, or implicate in context. For example, when uttering Jane has three children, a speaker might only say that "Jane has three children but may have more than three," but the speaker implicates that "Jane has exactly three children." Under this view, pragmatics plays only a small role in determining what speakers say and has a primary part in interpreting speaker's intended messages. My aim in this article is to challenge this view. I describe empirical work showing that pragmatics has a fundamental role in determining both what speakers say and implicate. Thus, when a speaker utters Jane has three children, enriched pragmatic information is used to infer that the speaker says "Jane has exactly three children" and that in specific contexts, the speaker can go on to express additional pragmatic meanings, such as ''Jane is married'' or "Jane is very busy because she has three children." I also describe work on the importance of complex pragmatic, metarepresentational reasoning in understanding irony and metaphor. Finally, I briefly discuss the relevance of these new developments in pragmatics for neurolinguistic research. (C) 1999 Academic Press.	Univ Calif Santa Cruz, Dept Psychol, Santa Cruz, CA 95064 USA	Gibbs, RW (corresponding author), Univ Calif Santa Cruz, Dept Psychol, Santa Cruz, CA 95064 USA.		Van Mulken, Margot/J-3567-2012	Van Mulken, Margot/0000-0002-0801-287X			BIHRLE AM, 1986, BRAIN COGNITION, V5, P399, DOI 10.1016/0278-2626(86)90042-4; BLASKO DG, 1993, J EXP PSYCHOL LEARN, V19, P295, DOI 10.1037/0278-7393.19.2.295; BROWNELL HH, 1983, BRAIN LANG, V18, P20, DOI 10.1016/0093-934X(83)90002-0; BROWNELL HH, 1990, NEUROPSYCHOLOGIA, V28, P375, DOI 10.1016/0028-3932(90)90063-T; CACCIARI C, 1988, J MEM LANG, V27, P668, DOI 10.1016/0749-596X(88)90014-9; CARSTON R, 1993, LINGUA, V90, P27, DOI 10.1016/0024-3841(93)90059-6; DASCAL M, 1987, COGNITIVE SCI, V11, P259, DOI 10.1207/s15516709cog1103_1; FRITH U, 1994, COGNITION, V50, P115, DOI 10.1016/0010-0277(94)90024-8; Gibbs Jr Raymond W, 1994, POETICS MIND FIGURAT; GIBBS R, IN PRESS METAREPRESE; GIBBS R, UNPUB METAREPRESENTA; Gibbs RW, 1997, COGNITION, V62, P51, DOI 10.1016/S0010-0277(96)00724-X; GIBBS RW, 1995, PSYCHOL BULL, V118, P133, DOI 10.1037/0033-2909.118.1.133; GIBBS RW, 1986, ACTA PSYCHOL, V62, P41, DOI 10.1016/0001-6918(86)90004-1; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; GIBBS RW, 1993, DISCOURSE PROCESS, V16, P387, DOI 10.1080/01638539309544846; GIBBS RW, 1986, DISCOURSE PROCESS, V9, P17, DOI 10.1080/01638538609544629; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; Grice H.P, 1989, STUDIES WAY WORDS; GROEFSEMA M, 1992, LINGUA, V87, P103, DOI 10.1016/0024-3841(92)90028-H; Happe F., 1994, METAPHOR SYMBOLIC AC, V10, P275; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; Katz A. N., 1998, FIGURATIVE LANGUAGE; Kempson, 1988, MENTAL REPRESENTATIO, P155; LEEKAM SR, 1994, J CHILD PSYCHOL PSYC, V35, P901, DOI 10.1111/j.1469-7610.1994.tb02301.x; Levinson S.C., 1987, PRAGMATIC PERSPECTIV, P61; Levinson S.C., 1983, PRAGMATICS; LUCARIELLO J, 1994, J EXP PSYCHOL GEN, V123, P129, DOI 10.1037/0096-3445.123.2.129; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; PAPAFRAGOU A, 1996, LINGUA, V94, P169; PEARCE S, 1995, J INT NEUROPSYCH SOC, V1, P342; Recanati F., 1993, DIRECT REFERENCE LAN; Recanati Francois, 1989, MIND LANG, V4, P295, DOI DOI 10.1111/J.1468-0017.1989.TB00258.X; Searle J., 1979, METAPHOR THOUGHT, P92; Searle J, 1983, INTENTIONALITY; Searle JR., 1978, ERKENNTNIS, V13, P207, DOI [10.1007/BF00160894, DOI 10.1007/BF00160894]; Sperber D., 1986, RELEVANCE COMMUNICAT; STEMMER B, 1994, BRAIN LANG, V46, P565, DOI 10.1006/brln.1994.1031; TABOSSI P, 1993, IDIOMS PROCESSING ST, P145; Van Lancker D, 1990, Behav Neurol, V3, P169, DOI 10.3233/BEN-1990-3304; WILSON D, 1993, LINGUA, V90, P1, DOI 10.1016/0024-3841(93)90058-5	43	29	32	0	12	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JUL	1999	68	3					466	485		10.1006/brln.1999.2123			20	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	226TE	WOS:000082037100006	10441189				2021-06-18	
J	Ponsford, J; Olver, J				Ponsford, J; Olver, J			Outcome measurement in an inpatient and outpatient traumatic brain injury rehabilitation programme	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							HEAD-INJURY; PROFILE	This paper outlines approaches taken to the measurement of outcome from a rehabilitation programme for individuals with traumatic brain injury (TBI). It describes methods used to evaluate progress made by individuals towards the attainment of goals within the programme, including the use of a Role Checklist and Goal Attainment Scaling. Maintenance of gains and long-term outcome in a range of life domains over 5 years after injury has been documented using a structured questionnaire, on which we obtained good inter-rater reliability. By 5 years after injury, the majority of individuals with TBI were in reasonable agreement with their close others regarding the presence of cognitive and behavioural changes. Standardised measures used in addition to the structured questionnaire have included the Sickness Impact Profile: the Craig Handicap Assessment and Reporting Technique (CHART), and the Leeds Scales for the Self-assessment of Anxiety and Depression. Findings and inter-correlations of all these measures are discussed. Emotional adjustment appears to have a significant influence upon self-reporting of problems and changes on measures such as the Sickness Impact Profile. It is therefore important to use more objective measures of handicap in a range of domains, such as the CHART, in addition to self-report measures.	Epworth Hosp, Bethesda Rehabil Ctr, Dept Psychol, Richmond, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia; Epworth Hosp, Bethesda Rehabil Unit, Melbourne, Vic, Australia				Olver, John/0000-0001-7069-1191			BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOAKE C, 1996, J PHYSICAL MED REHAB, V75, P1; Daniel A. E., 1983, POWER PRIVILEGE PRES; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Granger CV, 1987, UNIFORM DATA SET MED; JENNETT B, 1975, LANCET, V1, P480; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; OAKLEY F, 1986, OCCUP THER J RES, V6, P157, DOI 10.1177/153944928600600303; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Snaith RP, 1976, LEEDS SCALES SELF AS; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; World Health Organization, 1980, INT CLASS IMP DIS HA	20	29	29	0	2	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-OCT	1999	9	3-4					517	534		10.1080/096020199389563			18	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	242GV	WOS:000082932900024					2021-06-18	
J	Gurka, JA; Felmingham, KL; Baguley, IJ; Schotte, DE; Crooks, J; Marosszeky, JE				Gurka, JA; Felmingham, KL; Baguley, IJ; Schotte, DE; Crooks, J; Marosszeky, JE			Utility of the functional assessment measure after discharge from inpatient rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; INDEPENDENCE MEASURE; PERFORMANCE; VALIDATION	Objective: To assess the relationship between the Functional Independence Measure (FIM) and the Functional Assessment Measure (FAM), and community integration and return to work in patients with severe traumatic brain injuries (TBI). Design: A cross-sectional, prospective design was used to collect data at 6 and 24 months postdischarge. The Return to Work Scale (RTW) and Community Integration Questionnaire (CIQ) were selected to assess return to work and community functioning. Predictor variables included the motor and cognitive subscales of the FIM and the FAM. Setting: Follow-up database of an inpatient and community TBI Rehabilitation Unit. Participants: All consenting patients with TBI admitted to the unit, aged 16 or above. There were 88 patients at 6 and 79 patients at 24 month follow-up. Results: At 6 months follow-up, the FAM and the FIM were roughly equivalent in their ability to predict RTW and CIQ scores. At 24 months, FAM motor was the only significant predictor of CIQ, and FAM cognitive scores displayed an advantage over the FIM in predicting employment status. Conclusions: The FAM subscales produced only modest gains in prediction of employment status and community integration at 24 months postdischarge. This may reflect ceiling effects on the functional measures, a limited range on the RTW measure, poor ecologic validity of functional disability measures in assessing handicap, or a combination of these factors.	Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia; Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia; Westmead Hosp, Dept Rehabil Med, Westmead, NSW 2145, Australia	Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia.		Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705			CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HALL K, 1993, J HEAD TRAUMA REHAB, V8, P30; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, P10; KAPLAN CP, 1994, ARCH PHYS MED REHAB, V75, P643, DOI 10.1016/0003-9993(94)90186-4; Keith R, 1987, ADV CLIN REHABILITAT, V1, P10; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MAROSSZEKY JE, 1992, 12 ASM ACRM, P43; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; *STAT U NEW YORK, UN DAT SYST MED REH; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	18	29	29	0	4	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1999	14	3					247	256		10.1097/00001199-199906000-00005			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	203XY	WOS:000080734500005	10381977				2021-06-18	
J	Doder, M; Jahanshahi, M; Turjanski, N; Moseley, IF; Lees, AJ				Doder, M; Jahanshahi, M; Turjanski, N; Moseley, IF; Lees, AJ			Parkinson's syndrome after closed head injury: a single case report	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						parkinsonism; closed head injury; case report	ORDERED WORKING-MEMORY; FRONTAL-CORTEX; FOCAL LESIONS; BASAL GANGLIA; DISEASE; IMPAIRMENTS; MOVEMENTS; TASKS	A 36 year old man, who sustained a skull fracture in 1984, was unconscious for 24 hours, and developed signs of Parkinson's syndrome 6 weeks after the injury. When assessed in 1995, neuroimaging disclosed a cerebral infarction due to trauma involving the left caudate and lenticular nucleus. Parkinson's syndrome was predominantly right sided, slowly progressive, and unresponsive to levodopa therapy. Reaction time tests showed slowness of movement initiation and execution with both hands, particularly the right. Recording of movement related cortical potentials suggested bilateral deficits in movement preparation. Neuropsychological assessment disclosed no evidence of major deficits on tests assessing executive function or working memory, with the exception of selective impairments on the Stroop and on a test of self ordered random number sequences. There was evidence of abulia. The results are discussed in relation to previous literature on basal ganglia lesions and the effects of damage to different points of the frontostriatal circuits.	UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; Inst Neurol, MRC, Human Movement & Balance Unit, Dept Clin Neurol, London WC1N 3BG, England; Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0HS, England	Lees, AJ (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.		Lees, Andrew J/A-6605-2009	Lees, Andrew J/0000-0002-2476-4385	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ALTAR A, 1983, BRAIN RES, V279, P1, DOI 10.1016/0006-8993(83)90157-9; BATTIG K, 1991, J COMP PHYSIOL PSYCH, V13, P909; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Benton AL, 1978, MULTILINGUAL APHASIA; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; BROWN RG, 1993, J NEUROL NEUROSUR PS, V56, P295, DOI 10.1136/jnnp.56.3.295; CHAND RP, 1985, MED J MALAYSIA, V40, P335; CHANDULA.JA, 1970, EXP NEUROL, V29, P101, DOI 10.1016/0014-4886(70)90041-5; CHERAMY A, 1981, NEUROSCIENCE, V6, P2657, DOI 10.1016/0306-4522(81)90110-X; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; CROUZON O, 1929, PRESSE MED, V37, P1325; DE MORSIER G., 1960, PSYCHIAT ET NEUROL, V139, P60; DELLASALA S, 1990, ITAL J NEUROL SCI, V11, P65, DOI 10.1007/BF02334908; DIVAC I, 1967, J COMP PHYSIOL PSYCH, V63, P184, DOI 10.1037/h0024348; Dubois B, 1995, Adv Neurol, V65, P29; FACTOR SA, 1988, MOVEMENT DISORD, V3, P30, DOI 10.1002/mds.870030105; FACTOR SA, 1989, MOVEMENT DISORD, V4, P283; Fenelon G, 1997, MOVEMENT DISORD, V12, P1086, DOI 10.1002/mds.870120642; FOSTER JB, 1976, LANCET, V1, P981; Grimberg L, 1934, J NERV MENT DIS, V79, P14, DOI 10.1097/00005053-193401000-00002; JAHANSHAHI M, 1992, BRAIN, V115, P539, DOI 10.1093/brain/115.2.539; JENTZER A, 1947, SCHWEIZ ARCH NEUROL, V60, P388; LAWLER CP, 1995, SYNAPSE, V21, P299, DOI 10.1002/syn.890210404; LINDENBERG R, 1964, Dtsch Z Nervenheilkd, V185, P637; MILNER B, 1964, FRONTAL AGRANULAR CO; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OWEN AM, 1993, BRAIN, V116, P1159, DOI 10.1093/brain/116.5.1159; Parkinson J, 1817, ESSAY SHAKING PALSY; PETRIDES M, 1995, J NEUROSCI, V15, P359; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1964, EXAMEN CLIN PSYCHOL; Robbins TW, 1995, NEUROCASE, V1, P217; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; Schonell F., 1942, BACKWARDNESS BASIC S; SOURKES TL, 1965, NATURE, V207, P202, DOI 10.1038/207202a0; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Takeda M, 1991, Rinsho Shinkeigaku, V31, P842; TOUGE T, 1995, ANN NEUROL, V37, P791, DOI 10.1002/ana.410370613; Turjanski N, 1997, MOVEMENT DISORD, V12, P1035, DOI 10.1002/mds.870120630; Wechsler DW, ADULT INTELLIGENCE S; Weigl E, 1941, J ABNORM SOC PSYCH, V36, P3, DOI 10.1037/h0055544; WYKE M, 1967, NEUROLOGY, V17, P1113, DOI 10.1212/WNL.17.11.1113	44	29	32	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	1999	66	3					380	385		10.1136/jnnp.66.3.380			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	172MB	WOS:000078927200019	10084539	Green Published, Bronze			2021-06-18	
J	Lewen, A; Fredriksson, A; Li, GL; Olsson, Y; Hillered, L				Lewen, A; Fredriksson, A; Li, GL; Olsson, Y; Hillered, L			Behavioural and morphological outcome of mild cortical contusion trauma of the rat brain: Influence of NMDA-receptor blockade	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; rat; glutamate-receptors; recovery of function	PRECURSOR PROTEIN IMMUNOREACTIVITY; MICROTUBULE-ASSOCIATED PROTEIN-2; CEREBRAL-ISCHEMIA; AMINO-ACIDS; INJURY; MK-801; DEFICITS; GERBILS; IMPACT; HYPERACTIVITY	The authors studied the effect of a mild cortical contusion to the rat brain on behavioural and morphological outcome and the influence of NMDA-receptor blockade (MK-801, 0.5 mg/kg i.v. 30 min prior to trauma). Spontaneous motor activity was assessed 16-18 days post trauma. Saline treated traumatised rats showed a significant (p < 0.01) hyperactive behaviour compared to animals without injury. MK-SOI treated rats performed significantly better than the saline treated animals (p < 0.05). For histopathological evaluation hippocampal hilar neurons were counted, cortical thickness under the impact was measured and microtubule-associated protein 2 (MAP2) immunoreactivity in the dentate hilus was quantified 1, 3 and 21 days post trauma. In traumatised rats scattered loss of nerve cells, oedema and minute haemorrhages were present at the site of the impact one and three days after injury. At day 21 there was a significant reduction of cortical thickness at the site of impact. One day after trauma there was a bilateral, significant loss of neurons and MAP2. immunostaining in the dentate hilus of the hippocampus. MK-801 pretreated rats showed similar morphological changes. The disturbed spontaneous motor behaviour may be caused by hippocampal damage and a reduction of somatosensory cortical neurons. NMDA-receptor blockade improved the outcome assessed by the functional tests but failed to influence the morphological changes, suggesting that this behavioural test is a more sensitive indicator of outcome after mild traumatic brain injury (TBI).	Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Med, Uppsala, Sweden; Univ Uppsala Hosp, Dept Genet, Uppsala, Sweden; Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden	Lewen, A (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			ADAMS FS, 1994, PHYSIOL BEHAV, V55, P947, DOI 10.1016/0031-9384(94)90084-1; AMANO M, 1993, JPN J PHARMACOL, V63, P469, DOI 10.1254/jjp.63.469; ARCHER T, 1986, PSYCHOPHARMACOLOGY, V88, P141, DOI 10.1007/BF00652230; BUCHAN A, 1990, J NEUROSCI, V10, P311; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; DIDIER M, 1990, J NEUROSCI RES, V27, P25, DOI 10.1002/jnr.490270105; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feeney D M, 1987, Brain Inj, V1, P27, DOI 10.3109/02699058709034441; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FREDRIKSSON A, 1994, THESIS U UPSALIENSIS; GERHARDT SC, 1988, BEHAV NEUROSCI, V102, P301, DOI 10.1037/0735-7044.102.2.301; GOTTI B, 1990, BRAIN RES, V522, P290, DOI 10.1016/0006-8993(90)91473-T; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMBLE DP, 1975, HIPPOCAMPUS NEUROPHY, V2, P309; KUROIWA T, 1991, NEUROSCI LETT, V122, P141, DOI 10.1016/0304-3940(91)90842-H; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewis CA, 1997, J VASC INTERV RADIOL, V8, P475, DOI 10.1016/S1051-0443(97)70592-X; LIPTON SA, 1994, NEW ENGL J MED, V331, P274; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McCulloch J, 1993, Acta Neurochir Suppl (Wien), V57, P73; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NELLGARD B, 1991, ANESTHESIOLOGY, V75, P279, DOI 10.1097/00000542-199108000-00016; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; ROBINSON RG, 1986, PHARMACOL BIOCHEM BE, V25, P263, DOI 10.1016/0091-3057(86)90264-9; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; VALTYSSON J, 1994, ACTA NEUROCHIR, V129, P58, DOI 10.1007/BF01400874; YANG CR, 1987, NEUROSCIENCE, V23, P1041, DOI 10.1016/0306-4522(87)90179-5	56	29	30	0	4	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1999	141	2					193	202		10.1007/s007010050286			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	174MV	WOS:000079039700034	10189503				2021-06-18	
J	Miyakita, Y; Taguchi, Y; Sakakibara, Y; Matsuzawa, M; Kitagawa, H				Miyakita, Y; Taguchi, Y; Sakakibara, Y; Matsuzawa, M; Kitagawa, H			Transient mutism resolving into cerebellar speech after brain stem infarction following a traumatic injury of the vertebral artery in a child	ACTA NEUROCHIRURGICA			English	Article						mutism; child; trauma; midbrain; infarction	SUPPLEMENTARY MOTOR AREA; DYSARTHRIA; APHASIA; DISEASE	A 3.7-year-old girl presented with an anterior neck injury followed by progressive subcutaneous emphysema and loss of consciousness. After resuscitation, a laceration on the first tracheal cartilage was closed surgically. As she was extubated one week later, she was found to have right hemiplegia and muteness. MRI showed a T2-bright lesion on the tegmentum of the left midbrain down to the upper pens. Right vertebral angiography disclosed an intimal flap with stenosis at the C3 vertebral level presumably caused by a fracture of the right C3 transverse process later confirmed in a cervical 3D-CT scan. Her muteness lasted for 10 days, after which she began to utter some comprehensible words in a dysarthric fashion. Her neurological deficits showed improvement within 3 months of her admission. Transient mutism after brain stem infarction has not been reported previously. We discuss the anatomical bases for this unusual reversible disorder in the light of previous observations and conclude that bilateral damage to the dentatothalamocortical fibers at the decussation of the superior cerebellar peduncle may have been responsible for her transient mutism.	St Marianna Univ, Yokohama City Seibu Hosp, Div Neurosurg, Yokohama, Kanagawa, Japan; St Marianna Univ, Yokohama City Seibu Hosp, Div Paediat Surg, Yokohama, Kanagawa, Japan	Taguchi, Y (corresponding author), St Marianna Univ, Yokohama City Seibu Hosp, Div Neurosurg, Asahi Ku, 1197-1 Yasashi Cho, Kanagawa 2410811, Japan.						CRUTCHFIELD JS, 1994, J NEUROSURG, V81, P115, DOI 10.3171/jns.1994.81.1.0115; Ersahin Y, 1996, NEUROSURGERY, V38, P60; FRAIOLI B, 1975, APPL NEUROPHYSIOL, V38, P81; FRASER RAR, 1975, STROKE, V6, P153, DOI 10.1161/01.STR.6.2.153; FRIM DM, 1995, NEUROSURGERY, V36, P854, DOI 10.1227/00006123-199504000-00031; GESCHWIND N, 1971, NEW ENGL J MED, V284, P654, DOI 10.1056/NEJM197103252841206; HILTONJONES D, 1985, LANCET, V1, P1435; LECHTENBERG R, 1978, ANN NEUROL, V3, P285, DOI 10.1002/ana.410030402; LEINER HC, 1993, TRENDS NEUROSCI, V16, P444, DOI 10.1016/0166-2236(93)90072-T; MASDEU JC, 1978, NEUROLOGY, V28, P1220, DOI 10.1212/WNL.28.12.1220; MICKLE JP, 1995, NEUROSURGERY, V36, P854; PETERSEN SE, 1993, ANNU REV NEUROSCI, V16, P509, DOI 10.1146/annurev.ne.16.030193.002453; REA GL, 1996, PRINCIPLES SPINAL SU, P885; ROSS MK, 1984, ANN NEUROL, V16, P114; ROSTOMILY RC, 1991, J NEUROSURG, V75, P62, DOI 10.3171/jns.1991.75.1.0062; RYDING E, 1993, COGNITIVE BRAIN RES, V1, P94, DOI 10.1016/0926-6410(93)90015-W; SEGARRA JM, 1970, ARCH NEUROL-CHICAGO, V22, P408, DOI 10.1001/archneur.1970.00480230026003; TONKONOGY J, 1981, ARCH NEUROL-CHICAGO, V38, P486, DOI 10.1001/archneur.1981.00510080048005; VANDONGEN HR, 1994, NEUROLOGY, V44, P2040, DOI 10.1212/WNL.44.11.2040	19	29	29	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1999	141	2					209	213		10.1007/s007010050288			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	174MV	WOS:000079039700039	10189505				2021-06-18	
J	Trepagnier, CG				Trepagnier, CG			Virtual environments for the investigation and rehabilitation of cognitive and perceptual impairments	NEUROREHABILITATION			English	Article						virtual environments; rehabilitation; autism; aphasia; cognitive; impairment	DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN INJURY; WORKING-MEMORY; SPONTANEOUS-RECOVERY; EXECUTIVE FUNCTIONS; AUTISTIC-CHILDREN; APHASIA; ATTENTION; COMMUNICATION; THERAPY	Features of "virtual reality" (VR) systems and their value for the investigation and rehabilitation of cognitive and perceptual impairments are briefly described. Current and potential applications of VR technology to address six neurorehabilitation issues are discussed: (1) attention and the reduction of distraction, (2) assessment and remediation of executive function deficits, (3) investigation of impairments of coordinated movement, (4) study and rehabilitation of aphasia and other severe disorders of language, (5) task presentation for functional imaging studies of the brain, and (6) the measurement of mental load in the operation of assistive technology. Finally, a virtual reality system integrated with gaze angle sensing technology is described, and its potential for investigation and rehabilitation of face processing by individuals with autism is discussed.	Natl Rehabil Hosp, Assisted Technol Res Ctr, Rehabil Engn Serv, Washington, DC 20010 USA	Trepagnier, CG (corresponding author), Natl Rehabil Hosp, Assisted Technol Res Ctr, Rehabil Engn Serv, 102 Irving St NW, Washington, DC 20010 USA.	cyt1@mhg.edu					Aguirre GK, 1997, J NEUROSCI, V17, P2512; Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BAENNINGER M, 1994, J EXP CHILD PSYCHOL, V57, P377, DOI 10.1006/jecp.1994.1018; BAKER E, 1975, NATURE, V254, P509, DOI 10.1038/254509a0; BARTLETT JC, 1993, COGNITIVE PSYCHOL, V25, P281, DOI 10.1006/cogp.1993.1007; BOUCHER J, 1992, J CHILD PSYCHOL PSYC, V33, P843, DOI 10.1111/j.1469-7610.1992.tb01960.x; CHAPPELL PB, 1995, J AM ACAD CHILD PSY, V34, P1140, DOI 10.1097/00004583-199509000-00010; Cicerone KD, 1997, NEUROREHABILITATION, V8, P13, DOI 10.3233/NRE-1997-8103; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Cox CS, 1997, INT REV PSYCHIATR, V9, P45, DOI 10.1080/09540269775583; CULTON GL, 1969, J SPEECH HEAR RES, V12, P825, DOI 10.1044/jshr.1204.825; DeLuca J, 1996, DISABIL REHABIL, V18, P265, DOI 10.3109/09638289609166312; Denckla MB, 1996, J DEV BEHAV PEDIATR, V17, P114; ERICSSON KA, 1980, SCIENCE, V208, P1181, DOI 10.1126/science.7375930; Faillenot I, 1997, NEUROREPORT, V8, P859, DOI 10.1097/00001756-199703030-00010; GARDNER H, 1976, NEUROPSYCHOLOGIA, V14, P275, DOI 10.1016/0028-3932(76)90023-3; Georgiou N, 1997, MOVEMENT DISORD, V12, P386, DOI 10.1002/mds.870120318; GHAZIUDDIN M, 1994, J INTELL DISABIL RES, V38, P519; GILLBERG CL, 1992, J CHILD PSYCHOL PSYC, V33, P813, DOI 10.1111/j.1469-7610.1992.tb01959.x; Glantz K, 1996, PSYCHOTHERAPY, V33, P464, DOI 10.1037/0033-3204.33.3.464; GOLDENBERG G, 1994, BRAIN LANG, V47, P684, DOI 10.1006/brln.1994.1063; Goodenough-Trepagnier C, 1994, Assist Technol, V6, P3; GOODENOUGHTREPA.CX, 1990, P 1990 C IEEE ENG ME, V12, P1313; GOODENOUGHTREPAGNIER C, 1995, APHASIOLOGY, V9, P321, DOI 10.1080/02687039508248208; Granholm E, 1997, J ABNORM PSYCHOL, V106, P458, DOI 10.1037/0021-843X.106.3.458; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; GUNTHER W, 1992, EUR ARCH PSY CLIN N, V242, P152, DOI 10.1007/BF02191563; HOBSON RP, 1988, BRIT J PSYCHOL, V79, P441, DOI 10.1111/j.2044-8295.1988.tb02745.x; HOEKS B, 1993, BEHAV RES METH INSTR, V25, P16, DOI 10.3758/BF03204445; HYONA J, 1995, Q J EXP PSYCHOL-A, V48, P598; KRAAT AW, 1990, APHASIOLOGY, V4, P321, DOI 10.1080/02687039008249086; LENDREM W, 1985, J NEUROL NEUROSUR PS, V48, P743, DOI 10.1136/jnnp.48.8.743; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; LOVAAS OI, 1987, J CONSULT CLIN PSYCH, V55, P3, DOI 10.1037/0022-006X.55.1.3; Lundqvist A, 1997, APPL NEUROPSYCHOL, V4, P220, DOI 10.1207/s15324826an0404_3; Maguire EA, 1998, J COGNITIVE NEUROSCI, V10, P61, DOI 10.1162/089892998563789; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MCEACHIN JJ, 1993, AM J MENT RETARD, V97, P359; MENDOZZI L, 1998, CYBERPSYCHOLOGY BEHA, V1, P79, DOI DOI 10.1089/CPB.1998.1.79; Mialet JP, 1996, PSYCHOL MED, V26, P1009, DOI 10.1017/S0033291700035339; MIRSKY AF, 1992, J PSYCHIAT RES, V26, P383, DOI 10.1016/0022-3956(92)90042-M; Norman DA, 1993, THINGS MAKE US SMART; OCONNOR N, 1991, PSYCHOL MED, V21, P959, DOI 10.1017/S0033291700029949; Owen AM, 1997, PROG NEUROBIOL, V53, P431, DOI 10.1016/S0301-0082(97)00042-7; Ozonoff S, 1997, J AUTISM DEV DISORD, V27, P59, DOI 10.1023/A:1025821222046; OZONOFF S, 1994, J CHILD PSYCHOL PSYC, V35, P1015, DOI 10.1111/j.1469-7610.1994.tb01807.x; Parente R, 1997, NEUROREHABILITATION, V8, P3, DOI 10.3233/NRE-1997-8102; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Petheram B, 1996, APHASIOLOGY, V10, P267, DOI 10.1080/02687039608248412; Pulsifer M B, 1996, J Int Neuropsychol Soc, V2, P159; RAO SM, 1995, CURR OPIN NEUROL, V8, P216, DOI 10.1097/00019052-199506000-00010; Rizzo A.A., 1998, CYBERPSYCHOLOGY BEHA, V1, P59, DOI [10.1089/cpb.1998.1.59, DOI 10.1089/CPB.1998.1.59]; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; RUTTER M, 1994, J CHILD PSYCHOL PSYC, V35, P311, DOI 10.1111/j.1469-7610.1994.tb01164.x; STEEL RGT, 1986, PRINCIPLES PROCEDURE, P348; TACHI S, 1983, IEEE T BIO-MED ENG, V30, P571, DOI 10.1109/TBME.1983.325053; TANTAM D, 1989, J CHILD PSYCHOL PSYC, V30, P623, DOI 10.1111/j.1469-7610.1989.tb00274.x; Tinson D J, 1989, Int Disabil Stud, V11, P45; Todorov E, 1997, J MOTOR BEHAV, V29, P147, DOI 10.1080/00222899709600829; Towbin Kenneth E., 1997, Current Opinion in Pediatrics, V9, P361, DOI 10.1097/00008480-199708000-00010; TREPAGNIER C, 1996, FOCUS AUTISM OTHER D, V11, P170; WAISBREN SE, 1994, ACTA PAEDIATR, V83, P98, DOI 10.1111/j.1651-2227.1994.tb13464.x; Weinrich M, 1997, BRAIN LANG, V58, P23, DOI 10.1006/brln.1997.1757; Wilson PN, 1997, DISABIL REHABIL, V19, P213, DOI 10.3109/09638289709166530; WING L, 1976, EARLY CHILDHOOD AUTI	66	29	29	0	26	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		1999	12	1					63	72					10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	191WT	WOS:000080045100007					2021-06-18	
J	Keith, MS; Stanislav, SW; Wesnes, KA				Keith, MS; Stanislav, SW; Wesnes, KA			Validity of a cognitive computerized assessment system in brain-injured patients	BRAIN INJURY			English	Article							MINI-MENTAL-STATE; VALIDATION	The primary objective of the study was to investigate the criterion validity of the Cognitive Drug Research (CDR) computerized system in assessing cognitive functioning among persons with brain injury or other organic illness. Understanding the cognitive effects of pharmacotherapy is important in improving long-term rehabilitation outcomes in persons with organic disorders. The CDR system evaluates cognitive skills of attention, short-term or working memory, long-term memory, and visuomotor and motor functioning. For validity testing, correlation coefficients were obtained from an analysis of CDR scores to IQ and Folstein Mini-Mental State Exam (MMSE) scores. Subtests of the CDR system that correlated with the MMSE were choice reaction time (R = -0.542, p = 0.04), spatial working memory (R = 0.938, p = 0.01), and word recognition (R = -0.949, p = 0.01). These tests primarily measured attention and working memory. Correlations between the CDR and IQ scores were not evident. In summary, the data suggest the CDR assessment system has high patient acceptability by persons with traumatic brain injury, and is a useful tool in assessing certain domains of cognition, specifically short-term memory, discrimination, and identification skills.	Univ Texas, Coll Pharm, Austin, TX 78712 USA; Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA; Brown Sch Rehabil Ctr, Austin, TX USA; Cognit Drug Res, Reading, Berks, England	Keith, MS (corresponding author), Univ Texas, Coll Pharm, Austin, TX 78712 USA.		Wesnes, Keith A/D-7148-2018	Wesnes, Keith/0000-0002-4498-8511			CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Malloy PF, 1997, J NEUROPSYCH CLIN N, V9, P189; ROBINSON R, 1991, BIOL PSYCHIAT POSTER, V29, pS333; ROCCAFORTE WH, 1992, J AM GERIATR SOC, V40, P697, DOI 10.1111/j.1532-5415.1992.tb01962.x; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; SIMPSON PM, 1991, INT J GERIATR PSYCH, V6, P95, DOI 10.1002/gps.930060208; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Vogenthaler D R, 1987, Brain Inj, V1, P113; WESNES K, 1988, HUMAN PSYCHOPHARMACO, V3, P27, DOI DOI 10.1002/HUP.470030106; WESNES KA, COGNITIVE DRUG RES L	11	29	29	1	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	1998	12	12					1037	1043		10.1080/026990598121945			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	150BW	WOS:000077643400004	9876863				2021-06-18	
J	Armstead, WM				Armstead, WM			Brain injury impairs prostaglandin cerebrovasodilation	JOURNAL OF NEUROTRAUMA			English	Article						cerebral circulation; cyclic nucleotides; newborn; K(+) channel	K+ CHANNEL FUNCTION; PIAL ARTERY DILATION; POTASSIUM CHANNELS; NEWBORN PIGS; VASCULAR-RESPONSES; CEREBRAL-ARTERIES; HEAD-INJURY; RAT-BRAIN; ISCHEMIA; PIGLETS	Previous studies have observed that ATP- and calcium-sensitive K(+) (K(ATP) and K(ca)) channel function is impaired after fluid percussion brain injury (FPI). The present study was designed to characterize the effect of FPI on prostaglandin (PG)E(2) and I(2) pial artery dilation and the role of activation of these K(+) channels in that dilation in newborn pigs equipped with a closed cranial window, FPI of moderate severity (1.9-2.1 atm) was produced by using a pendulum to strike a piston on a saline-filled cylinder that was fluid coupled to the brain via a hollow screw inserted through the cranium. PGE(2) vasodilation was blunted by FPI (9 +/- 1%, 13 +/- 1%, and 19 +/- 1% vs. 2 +/- 1%, 5 +/- 1%, and 9 +/- 1%, for 1, 10, and 100 ng/ml PGE(2) before and after FPI, respectively). PGE(2) dilation was associated with increased CSF cGMP and cAMP concentration and such changes in cyclic nucleotides were blunted by FPI (448 +/- 10 and 793 +/- 38 vs, 316 +/- 11 and 403 +/- 27 fmol/ml for control and PGE(2) induced change in cGMP before and after FPI, respectively), PGI(2)-induced dilation and associated changes in CSF cyclic nucleotide concentration were similarly blunted by FPI. PGE(2) dilation was attenuated by either glibenclamide or iberiotoxin, K(ATP) and K(ca) channel antagonists, and coadministration of both K+ channel antagonists further decremented the dilator response (9 +/- 1%, 14 +/- 1%, and 21 +/- 1%; vs, 4 +/- 1%, 7 +/- 1%, and 12 +/- 1%; vs. 2 +/- 1%, 4 +/- 1%, and 7 +/- 1%, for 1, 10, and 100 ng/ml PGE(2) during control, after glibenclamide, and after combined glibenclamide and iberiotoxin, respectively). Glibenclamide and iberiotoxin had similar effects on PGI(2) dilation. These data show that prostaglandin dilation is attenuated after FPI. These data also show that prostaglandin dilation is dependent on activation of both K(ATP) and K(ca) channels. Further, these data suggest that attenuated prostaglandin dilation following FPI results from diminished prostaglandin-associated elevation in cyclic nucleotide concentration and impaired K(ATP) and K(ca) channel function.	Childrens Hosp Philadelphia, Dept Anesthesia, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	Armstead, WM (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesia, 34th & Civic Ctr Blvd, Philadelphia, PA 19104 USA.						Al-Turki A, 1998, CRIT CARE MED, V26, P917, DOI 10.1097/00003246-199805000-00029; ARMSTEAD WM, 1995, AM J PHYSIOL-HEART C, V268, pH1436; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH1272; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1996, AM J PHYSIOL-HEART C, V271, pH166; Armstead WM, 1997, BRAIN RES, V747, P252, DOI 10.1016/S0006-8993(96)01284-X; Armstead WM, 1997, BRAIN RES, V768, P177, DOI 10.1016/S0006-8993(97)00641-0; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH423; ARMSTEAD WM, 1992, P SOC EXP BIOL MED, V199, P149; ARMSTEAD WM, 1988, AM J PHYSIOL, V255, P401; AVELDANO MI, 1975, J NEUROCHEM, V25, P919, DOI 10.1111/j.1471-4159.1975.tb04432.x; Bari F, 1996, STROKE, V27, P1874, DOI 10.1161/01.STR.27.10.1874; Bari F, 1996, J CEREBR BLOOD F MET, V16, P1158, DOI 10.1097/00004647-199611000-00010; BAZAN NG, 1971, J NEUROCHEM, V18, P1387, DOI 10.1111/j.1471-4159.1971.tb00003.x; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ELLIS EF, 1989, J NEUROTRAUM, V6, P331; FREDRICKS KT, 1994, AM J PHYSIOL, V267, pH580; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hall E D, 1985, Cent Nerv Syst Trauma, V2, P75; KITAZONO T, 1995, STROKE, V26, P1713, DOI 10.1161/01.STR.26.9.1713; Kontos HA, 1996, AM J PHYSIOL-HEART C, V271, pH1498; Leffler CW, 1997, AM J PHYSIOL-HEART C, V272, pH1323; LEFFLER CW, 1987, AM J PHYSIOL, V252, pH687; LEFFLER CW, 1989, STROKE, V20, P541, DOI 10.1161/01.STR.20.4.541; LEFFLER CW, 1989, PEDIATR RES, V25, P180; LEFFLER CW, 1990, PROSTAGLANDINS, V40, P241, DOI 10.1016/0090-6980(90)90012-K; LEFFLER CW, 1985, PROSTAGLANDINS, V30, P811, DOI 10.1016/0090-6980(85)90009-7; LEFFLER CW, 1992, AM J PHYSIOL, V263, pH746; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NELSON MT, 1993, TRENDS CARDIOVAS MED, V3, P54, DOI 10.1016/1050-1738(93)90037-7; NELSON MT, 1995, AM J PHYSIOL, V268, P799; Quayle JM, 1997, PHYSIOL REV, V77, P1165; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SPINEDI A, 1990, J NEUROCHEM, V54, P778, DOI 10.1111/j.1471-4159.1990.tb02318.x; TEPAS JJ, 1995, PEDIAT SURG, V4, P120; Thorogood MC, 1996, ANESTHESIOLOGY, V84, P614, DOI 10.1097/00000542-199603000-00017; THOROGOOD MC, 1995, AM J PHYSIOL-HEART C, V269, pH1776; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2; ZALESKA MM, 1989, J NEUROCHEM, V52, P255, DOI 10.1111/j.1471-4159.1989.tb10925.x	45	29	29	0	0	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1998	15	9					721	729		10.1089/neu.1998.15.721			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	118ZT	WOS:000075871400007	9753219				2021-06-18	
J	Childers, MK; Rupright, J; Jones, PS; Merveille, O				Childers, MK; Rupright, J; Jones, PS; Merveille, O			Assessment of neuroendocrine dysfunction following traumatic brain injury	BRAIN INJURY			English	Article							DIABETES-INSIPIDUS; INAPPROPRIATE SECRETION; ANTIDIURETIC-HORMONE; HYPONATREMIA; HYPOPITUITARISM; AMANTADINE; POLYDIPSIA	Posttraumatic neuroendocrine pathology may be a clinically significant complication following traumatic blain injury (TBI). Metabolic abnormalities are described after TBI in two cases. A 21 year old male injured in a motor Vehicle accident admitted in a minimally responsive condition presented with fluctuating high sodium levels, undetectable serum testosterone, and depressed cortisol and thyroid function. Imaging revealed near complete avulsion of the pituitary stalk leading to panhypopituitarism. A 38 year old male admitted for occipital skull fractures and brain contusions presented with hyponatremia and low serum testosterone. Both patients required hormonal replacement and correction of electrolyte abnormalities. A screening protocol adapted for selected patients at risk for endocrine problems is described. While neuroendocrine screening is not advocated in all TBI patients, physicians should be aware of the importance of neuroendocrine dysfunction following TBI.	Univ Missouri, Dept PM&R, Howard A Rusk Rehabil Ctr, Columbia, MO 65212 USA; Missouri Rehabil Ctr, Mt Vernon, MO USA	Childers, MK (corresponding author), Univ Missouri, Dept PM&R, Howard A Rusk Rehabil Ctr, DC046-00,1 Hosp Dr, Columbia, MO 65212 USA.			Childers, Martin/0000-0003-4754-0883			BARRECA T, 1980, J CLIN ENDOCR METAB, V51, P1279, DOI 10.1210/jcem-51-6-1279; BARZILAY Z, 1988, J MED, V19, P47; COWELL LC, 1995, J HEAD TRAUMA REHAB, V10, P91, DOI 10.1097/00001199-199512000-00018; DIXON BS, 1988, AM REV RESPIR DIS, V138, P512, DOI 10.1164/ajrccm/138.3.512; EDWARDS OM, 1986, MEDICINE, V65, P281; Elovic E, 1996, NEUROREHABILITATION, V6, P57, DOI 10.3233/NRE-1996-6107; FARR RW, 1988, SOUTHERN MED J, V81, P677, DOI 10.1097/00007611-198805000-00037; GANDELMAN MS, 1994, PROG NEURO-PSYCHOPH, V18, P211, DOI 10.1016/0278-5846(94)90055-8; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; HAYCOCK GB, 1995, PEDIATR NEPHROL, V9, P375, DOI 10.1007/BF02254219; KAHN A, 1981, EUR J PEDIATR, V135, P293, DOI 10.1007/BF00442106; KLACHKO DM, 1968, J CLIN ENDOCR METAB, V28, P1768, DOI 10.1210/jcem-28-12-1768; KLINGBEIL GEG, 1985, ARCH PHYS MED REHAB, V66, P44; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; LABIB M, 1987, POSTGRAD MED J, V63, P33, DOI 10.1136/pgmj.63.735.33; LERAMO OB, 1987, CAN J SURG, V30, P53; Liu BA, 1996, CAN MED ASSOC J, V155, P519; Liu BA, 1996, CAN MED ASSOC J, V155, P1043; Miller M, 1997, Curr Ther Endocrinol Metab, V6, P206; NOTMAN DD, 1980, J TRAUMA, V20, P599, DOI 10.1097/00005373-198007000-00009; RALSTON C, 1990, ARCH DIS CHILD, V65, P896, DOI 10.1136/adc.65.8.896; Saito T, 1996, Nihon Jinzo Gakkai Shi, V38, P429; SHAH PJ, 1992, HOSP COMMUNITY PSYCH, V43, P509; Sihvonen T, 1997, ARCH PHYS MED REHAB, V78, P486, DOI 10.1016/S0003-9993(97)90161-1; Sterns Richard H., 1993, P225; WILCOX JA, 1990, NEUROPSYCHOBIOLOGY, V23, P144	26	29	33	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	1998	12	6					517	523		10.1080/026990598122476			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZU400	WOS:000074193300007	9638328				2021-06-18	
J	Kurtz, JE; Putnam, SH; Stone, C				Kurtz, JE; Putnam, SH; Stone, C			Stability of normal personality traits after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CLOSED HEAD-INJURY; SOCIAL RECOVERY; 5-FACTOR MODEL; FOLLOW-UP; ADJUSTMENT; CHILDREN	Objective: To test the hypothesis that changes in personality traits are evident after traumatic brain injury (TBI) using current models of normal adult personality variation. Design: Comparison of inception cohort and control group at two measurement occasions. Setting: A large urban academic medical center. Participants: Retrospective personality assessments were obtained from significant others of 21 TBI patients within 30 days of injury and at 6-month follow-up and from a control group of significant others of 25 persons without neurological history twice over a 6-month interval. Main Outcome Measures: Five scales-Neuroticism, Extraversion, Openness to Experience, Agreeableness, and Conscientiousness-from the revised NEO Personality Inventory (NEO PI-R), Form R, and an observer rating scale for retrospective estimates of change (REC). Results: Significant score changes were found for only one of the five trait domains in the patient sample; controls showed minimal changes overall. Patients' Extraversion scores declined to average levels at 6-month follow-up, diminishing premorbid differences between patients and controls on this dimension. Subjective change estimates made by raters after followup reflected perceptions of increased neuroticism in patients that were inconsistent with the serial NEO PI-R data the raters provided. Conclusions: The absence of systematic changes in personality trait scores among the patients cautions against presuming that such changes account for the behavior of TBI patients.	Villanova Univ, Dept Psychol, Villanova, PA 19085 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; Wayne State Univ, Sch Med, Rehabil Inst Michigan, Detroit, MI USA	Kurtz, JE (corresponding author), Villanova Univ, Dept Psychol, Villanova, PA 19085 USA.		Kurtz, John/AAR-2598-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007421] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T32 HD07421-04] Funding Source: Medline		Blumer D., 1975, PSYCHIAT ASPECTS NEU; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Costa P. T., 1991, REVISED NEO PERSONAL; DIGMAN JM, 1990, ANNU REV PSYCHOL, V41, P417, DOI 10.1146/annurev.ps.41.020190.002221; DODWELL D, 1988, PSYCHOL MED, V18, P495, DOI 10.1017/S0033291700008035; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GIANOTTI G, 1972, CORTEX, V8, P41; John O.P., 1990, HDB PERSONALITY THEO; LEE GP, 1993, INT J NEUROSCI, V72, P157, DOI 10.3109/00207459309024104; Lezak M., 1989, ASSESSMENT BEHAV CON; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MUTEN E, 1991, J PERS ASSESS, V57, P449, DOI 10.1207/s15327752jpa5703_5; NORMAN WT, 1963, J ABNORM PSYCHOL, V66, P574, DOI 10.1037/h0040291; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PRIGATANO GP, 1987, NEUROBEHAVIOURAL REC; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; STUSS DT, 1983, NEUROPSYCHOLOGY HUMA; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002	25	29	29	2	6	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1998	13	3					1	14		10.1097/00001199-199806000-00002			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZT046	WOS:000074042200002	9582175				2021-06-18	
J	Stewart-Scott, AM; Douglas, JM				Stewart-Scott, AM; Douglas, JM			Educational outcome for secondary and postsecondary students following traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; PREDICTING RETURN; PROFILE; SCHOOL; WORK	During the 12 month period of January-December 1991, 75 admissions were made to the Head Injury Unit at Bethesda Hospital, Melbourne, Australia. Approximately 26% (20) of these admissions were either secondary or postsecondary students. Thirteen of the 20 students were interviewed by telephone at approximately 3 years postinjury and demographic and medical information were obtained from their medical files. Outcome was documented in three areas: educational, medical and psychosocial status. At 3 years postinjury, 11 subjects (85%) had either completed a course or were still studying. The average lime for students to return to study was approximately 11 months postinjury. The students reported a number of changes including: enrolment in different courses, a reduction in course load to part-time study, altered educational and vocational goals and an increased need to utilize study skill strategies, individual tuition and special consideration. In addition, students reported changes to their relationships with peers and their involvement in extracurricular activities. It is apparent from these results that a number of factors need to be: considered when a student is planning to return to study following TBI and that a range of support services may be required. Future studies are needed to examine the factors which impede or enhance a student's progress following TBI.	La Trobe Univ, Fac Hlth Serv, Sch Human Commun Sci, Bundoora, Vic 3083, Australia; Bethesda Hosp, Speech Pathol Dept, Melbourne, Vic, Australia	Douglas, JM (corresponding author), La Trobe Univ, Fac Hlth Serv, Sch Human Commun Sci, Bundoora, Vic 3083, Australia.		Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624			BATES K, 1993, 2 INT C REC BRAIN IN; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BLOSSER JL, 1989, TOP LANG DISORD, V9, P66; BUETHE C, 1989, J COLL STUDENT DEV, V30, P172; COHEN SB, 1991, J HEAD TRAUMA REHAB, V6, P56; COOK J, 1991, J HEAD TRAUMA REHAB, V6, P64; DONDERS J, 1992, ANN M INT NEUR SOC S; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; HALL DE, 1986, COGNITIVE REHABI MAY, P6; HARRINGTON DE, 1990, REHABILITATION ADULT, P476; *HLTH DEP VICT COM, 1991, REP HEAD INJ IMP STU; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Kaplan S. P., 1988, J APPLIED REHABILITA, V19, P3; KAPLAN SP, 1993, REHABILITATION COUNS, V36, P152; KINSELLA G, 1995, J INT NEUROPSYCHOLOG, V1, P325; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; LANGE M, 1991, COGNITIVE REHABI JAN, P22; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MIRA MP, 1991, FOCUS EXCEPT CHILD, V23, P1; OCONNOR BA, 1995, AUSTR DISABILITY REV, V1, P31; Ponsford J., 1995, TRAUMATIC BRAIN INJU, P1; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Russell N, 1993, LANG SPEECH HEAR SER, V24, P67; SAVAGE R, 1988, COGNITIVE REHABI JUL, P10; Savage RC, 1987, J HEAD TRAUMA REHAB, V2, P1; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P65; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; Ylvisaker M, 1991, J HEAD TRAUMA REHAB, V6, P10, DOI DOI 10.1097/00001199-199103000-00006	36	29	30	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1998	12	4					317	331		10.1080/026990598122629			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZF942	WOS:000072948700008	9562914				2021-06-18	
J	Forbes, ML; Clark, RSB; Dixon, CE; Graham, SH; Marion, DW; DeKosky, ST; Schiding, JK; Kochanek, PM				Forbes, ML; Clark, RSB; Dixon, CE; Graham, SH; Marion, DW; DeKosky, ST; Schiding, JK; Kochanek, PM			Augmented neuronal death in CA3 hippocampus following hyperventilation early after controlled cortical impact	JOURNAL OF NEUROSURGERY			English	Article						head injury; hyperventilation; alkalosis; hippocampus; rat	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; PROLONGED HYPERVENTILATION; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; COMATOSE PATIENTS; CELL-DEATH; RATS; HYPOTHERMIA	Minimizing secondary injury after severe traumatic brain injury (TBI) is the primary goal of cerebral resuscitation. For more than two decades, hyperventilation has been one elf the most often used strategies in the management of TBI. Laboratory and clinical studies, however, have verified a post-TBI state of reduced cerebral perfusion that may increase the brain's vulnerability to secondary injury. In addition, it has been suggested in a clinical study that hyperventilation may worsen outcome after TBI. Object. Using the controlled cortical impact model in rats, the authors tested the hypothesis that aggressive hyperventilation applied immediately after TBI would worsen functional outcome, expand the contusion, and promote neuronal death in selectively vulnerable hippocampal neurons. Methods. Twenty-six intubated, mechanically ventilated, isoflurane-anesthetized male Sprague-Dawley rats were subjected to controlled cortical impact (4 m/second, 2.5-mm depth of deformation) and randomized after 10 minutes to either hyperventilation (PaCO2 = 20.3 +/- 0.7 mm Hg) or normal ventilation groups (PaCO2 = 34.9 +/- 0.3 mm Hg) containing 13 rats apiece and were treated for 5 hours. Beam balance and Morris water maze (MWM) performance latencies were measured in eight rats from each group on Days 1 to 5 and 7 to 11, respectively, after controlled cortical impact. The rats were killed at 14 days postinjury, and serial coronal sections of their brains were studied for contusion volume and hippocampal neuron counting (CA1, CA3) by an observer who was blinded to their treatment group. Mortality rates were similar in both groups (two of 13 in the normal ventilation compared with three of 13 in the hyperventilation group, not significant [NS]). There were no differences between the groups in mean arterial blood pressure, brain temperature, and serum glucose concentration. There were no differences between groups in performance latencies for both beam balance and MWM or contusion Volume (27.8 +/- 5.1 mm(3) compared with 27.8 +/- 3.3 mm(3), NS) in the normal ventilation compared with the hyperventilation groups, respectively. In brain sections cut from the center of the contusion, hippocampal neuronal survival in the CA1 region was similar in both groups; however, hyperventilation reduced the number of surviving hippocampal CA3 neurons (29.7 cells/hpf, range 24.2-31.7 in the normal ventilation group compared with 19.9 cells/hpf, range 17-23.7 in the hyperventilation group [25th-75th percentiles]; *p < 0.05, Mann-Whitney rank-sum test). Conclusions. Aggressive hyperventilation early after TBI augments CA3 hippocampal neuronal death; however, it did not impair functional outcome or expand the contusion. These data indicate that CA3 hippocampal neurons are selectively vulnerable to the effects of hyperventilation after TBI. Further studies delineating the mechanisms underlying these effects are needed, because the injudicious application of hyperventilation early after TBI may contribute to secondary neuronal injury.	Univ Pittsburgh, Brain Trauma Res Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Brain Trauma Res Ctr, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021; Forbes, MD, FAAP, Michael/C-4110-2009	Kochanek, Patrick M/0000-0002-2627-913X; Forbes, MD, FAAP, Michael/0000-0002-2612-5392; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS3198, NS30318] Funding Source: Medline		ARTRU AA, 1987, J CEREBR BLOOD F MET, V7, P471, DOI 10.1038/jcbfm.1987.90; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Bullock MR, 1996, J NEUROTRAUM, V13, P699; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; CROCKARD HA, 1973, BMJ-BRIT MED J, V4, P634, DOI 10.1136/bmj.4.5893.634; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; GIFFARD RG, 1992, STROKE, V23, P1817, DOI 10.1161/01.STR.23.12.1817; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HURN PD, 1995, J CEREB BLOOD FLO S1, V15, pS201; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P903, DOI 10.1038/jcbfm.1990.147; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KENNEALY JA, 1980, AM REV RESPIR DIS, V122, P407; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Kraemer PJ, 1996, BRAIN RES BULL, V39, P17, DOI 10.1016/0361-9230(95)02028-4; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MADSEN FF, 1990, ACTA NEUROCHIR, V106, P164, DOI 10.1007/BF01809461; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MEIS G, 1991, J CEREB BLOOD FLOW M, V11, P753; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, Q J EXP PSYCHOL-B, V38, P365; MOSER E, 1993, J NEUROSCI, V13, P3916; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OUYANG YB, 1994, BRAIN RES, V646, P65, DOI 10.1016/0006-8993(94)90058-2; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002; RINK A, 1995, AM J PATHOL, V147, P1575; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; TAKADERA T, 1992, BRAIN RES, V572, P126, DOI 10.1016/0006-8993(92)90460-Q; VANICKY I, 1992, NEUROSCI LETT, V135, P167, DOI 10.1016/0304-3940(92)90428-A; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087	58	29	29	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1998	88	3					549	556		10.3171/jns.1998.88.3.0549			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	YY305	WOS:000072133800018	9488311				2021-06-18	
J	Kadotani, H; Namura, S; Katsuura, G; Terashima, T; Kikuchi, H				Kadotani, H; Namura, S; Katsuura, G; Terashima, T; Kikuchi, H			Attenuation of focal cerebral infarct in mice lacking NMDA receptor subunit NR2C	NEUROREPORT			English	Article						binding assay; cerebral infarction; gene knockout; ischemic brain injury; MCA occlusion; mutant mice; NMDA receptor; stroke	D-ASPARTATE RECEPTOR; MOLECULAR DIVERSITY; GLUTAMATE RECEPTORS; BRAIN; RAT; ANTAGONIST; CHANNEL; BLOCKADE; PROTECT; DAMAGE	NEURONAL death following cerebral vascular occlusion may be caused in part by the action of glutamate acting through the NMDA receptor. Here we demonstrate that gene disruption of the NR2C subunit of the NMDA receptor attenuates focal cerebral ischemic injury after permanent MCA occlusion, and that a low level of NR2C is expressed and active in the cerebral cortex. NR2C-deficient mice do not show impairment of motor coordination or motor learning. Therefore the development of drugs selectively inhibiting NR2C may prove beneficial in the treatment of stroke and traumatic brain injuries. (C) 1998 Rapid Science Ltd.	Kyoto Univ, Fac Med, Dept Biol Sci, Kyoto 606, Japan; Shionogi & Co Ltd, Shionogi Res Labs, Shiga 52034, Japan; Kyoto Univ, Fac Med, Dept Neurosurg, Kyoto 606, Japan	Namura, S (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 149 13th St Room 6403, Charlestown, MA 02129 USA.		Kadotani, Hiroshi/A-7908-2015	Kadotani, Hiroshi/0000-0001-7474-3315			CHEN G, 1959, J PHARMACOL EXP THER, V127, P241; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; EDVINSSON L, 1993, CEREBRAL BLOOD FLOW, P410; FOSTER AC, 1987, BRIT J PHARMACOL, V91, P403, DOI 10.1111/j.1476-5381.1987.tb10295.x; HONORE T, 1985, NEUROSCI LETT, V54, P27, DOI 10.1016/S0304-3940(85)80113-0; ISHII T, 1993, J BIOL CHEM, V268, P2836; Kadotani H, 1996, J NEUROSCI, V16, P7859; Kishimoto Y, 1997, NEUROREPORT, V8, P3717, DOI 10.1097/00001756-199712010-00012; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LUBY ED, 1962, AM J PSYCHIAT, V119, P61, DOI 10.1176/ajp.119.1.61; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIKAWA E, 1997, J CEREB BLOOD FLOW M, V17, pS450; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; Small DL, 1997, NEUROSCI LETT, V232, P87, DOI 10.1016/S0304-3940(97)00592-2; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WARD R, 1990, J ANAT, V173, P87	23	29	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0959-4965			NEUROREPORT	Neuroreport	FEB 16	1998	9	3					471	475		10.1097/00001756-199802160-00021			5	Neurosciences	Neurosciences & Neurology	YZ263	WOS:000072236600022	9512392				2021-06-18	
J	Rapport, LJ; Farchione, TJ; Coleman, RD; Axelrod, BN				Rapport, LJ; Farchione, TJ; Coleman, RD; Axelrod, BN			Effects of coaching on malingered motor function profiles	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MILD HEAD-INJURY; TESTS; PROSPECTS; DEFICITS; VALIDITY	Measures of motor functioning were evaluated to assess a nonphysiological performance pattern initially revealed in a sample of litigating patients with postconcussive syndrome (grip strength < finger tapping < grooved pegs). The opposite pattern is observed in patients with traumatic brain injury, whose performance follows a gradient of increasing impairment corresponding to the sensory-motor complexity of these tasks. Naive and coached malingerers performed worse on all three motor tests relative to controls (N = 92); however, the presence of nonphysiologic configurations showed poor predictive accuracy among malingerers and controls. Exploratory analyses suggested that IQ may mediate the ability to dissimulate successfully. Although worthy of additional study, the use of pattern analysis in evaluation of malingered motor functioning has not been proven reliable or valid.	Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Dept Vet Affairs Med Ctr, Psychol Serv, Detroit, MI USA	Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ben-Porath Y. S., 1994, PSYCHOL ASSESSMENT, V6, P14; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERRY DTR, 1994, PSYCHOL ASSESSMENT, V6, P16; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; CRAWFORD JR, 1989, PERS INDIV DIFFER, V10, P585, DOI 10.1016/0191-8869(89)90043-3; CRAWFORD JR, 1992, DEV CLIN EXPT NEUROP; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Haaland K. Y., 1989, NEUROPSYCHOLOGICAL F, P219; Heaton R.K., 1991, COMPREHENSIVE NORMS; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK CK, 1994, J PSYCHOPATHOL BEHAV, V16, P95, DOI 10.1007/BF02232721; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MARTIN RC, 1992, FORENSIC REPORTS, V5, P393; MEISNER S, 1988, J PERS ASSESS, V52, P564, DOI 10.1207/s15327752jpa5203_19; MENSCH AJ, 1986, INT J CLIN NEUROPSYC, V8, P59; Reitan RM., 1985, HALSTEAD REITAN NEUR; Schretlen David, 1990, BEHAVIORAL SCI LAW, V8, P75, DOI DOI 10.1002/BSL.2370080109; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stebbins Glenn T, 1990, Clin Neuropsychol, V4, P18, DOI 10.1080/13854049008401493; Stebbins Glenn T, 1990, Clin Neuropsychol, V4, P64, DOI 10.1080/13854049008401497; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	25	29	29	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	1998	20	1					89	97		10.1076/jcen.20.1.89.1488			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	ZZ028	WOS:000074688100008	9672822				2021-06-18	
J	Tscherne, H; Regel, G; Pape, HC; Pohlemann, T; Krettek, C				Tscherne, H; Regel, G; Pape, HC; Pohlemann, T; Krettek, C			Internal fixation of multiple fractures in patients with polytrauma	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							EXTREMITY SEVERITY SCORE; PELVIC FRACTURES; TRAUMA; CLASSIFICATION; OSTEOSYNTHESIS; HEMORRHAGE; INJURIES; SALVAGE; STATE	Within the last decade understanding of the pathogenetic consequences of trauma has been improved significantly An additional reduction of lethality has been achieved that in part is related to increasing discrimination of complex injury patterns, Accordingly, additional staging in fracture management of these injuries has been developed, An overview of the current status of fracture management in polytrauma is given and certain regimens that are still controversially are discussed, The principles determined are based on the treatment experience of 4003 multiply injured patients within the past 23 years, The most important principles within the first hours after trauma represent adequate hemorrhage control, In fracture treatment the primary goal remains to perform primary stable osteosynthesis, In severe polytrauma with severe injuries to the extremities, the first decision is whether limb salvage can be achieved without risk of deterioration of the patient's condition, If this is the case, open fractures Grades III b and c usually can be stabilized primarily by unreamed intramedullary nailing or percutaneous plating, The priority pattern in multiple closed fractures is as follows: (1) tibia; (2) femur; (3) pelvis; (4) spine; and (5) upper extremity, Exceptions may ensue if severe head or thoracic trauma is present, Delayed treatment is performed for complex joint reconstruction, definitive treatment of maxillofacial injuries, and soft tissue reconstruction.	Hannover Med Sch, Dept Trauma Surg, D-30623 Hannover, Germany	Pape, HC (corresponding author), Hannover Med Sch, Dept Trauma Surg, D-30623 Hannover, Germany.			Pape, Hans-Christoph/0000-0002-2059-4980; Krettek, Christian/0000-0001-9807-0020			AEBI M, 1986, CLIN ORTHOP RELAT R, P244; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BEHRMAN SW, 1990, J TRAUMA, V30, P792, DOI 10.1097/00005373-199007000-00005; BONE L, 1986, J BONE JOINT SURG AM, V68A, P945, DOI 10.2106/00004623-198668060-00023; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; BROWN JJ, 1984, AM SURGEON, V50, P150; BROWNER BD, 1987, J TRAUMA, V27, P998, DOI 10.1097/00005373-198709000-00008; BURGESS AR, 1990, J TRAUMA, V30, P848, DOI 10.1097/00005373-199007000-00015; Cotler H B, 1988, J Orthop Trauma, V2, P222, DOI 10.1097/00005131-198802030-00008; CRYER HM, 1988, J TRAUMA, V28, P973, DOI 10.1097/00005373-198807000-00011; FAKHRY SM, 1994, J TRAUMA, V37, P255, DOI 10.1097/00005373-199408000-00018; GANZ R, 1991, CLIN ORTHOP RELAT R, P71; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HANSEN ST, 1987, J BONE JOINT SURG AM, V69A, P799, DOI 10.2106/00004623-198769060-00001; HELFET DL, 1990, CLIN ORTHOP RELAT R, P80; HOWE HR, 1987, AM SURGEON, V53, P205; HOYT DB, 1993, J TRAUMA, V35, P524, DOI 10.1097/00005373-199310000-00005; KRETTEK C, 1995, CLIN ORTHOP RELAT R, P34; Krettek C, 1996, INJURY, V27, P233, DOI 10.1016/0020-1383(96)00008-3; KRETTEK C, 1994, UNFALLCHIRURG, V97, P575; KROPFL A, 1995, J TRAUMA, V38, P717; MCNAMARA MG, 1994, J ORTHOP TRAUMA, V8, P81, DOI 10.1097/00005131-199404000-00001; MODRALL JG, 1993, ORTHOP CLIN N AM, V24, P557; MORENO C, 1986, J TRAUMA, V26, P987, DOI 10.1097/00005373-198611000-00005; PANETTA T, 1985, J TRAUMA, V25, P1021; PAPE HC, 1993, J TRAUMA, V35, P709, DOI 10.1097/00005373-199311000-00010; PAPE HC, 1993, J TRAUMA, V34, P72; Pape HC, 1996, TECH ORTHOP, V11, P2; PAPE HC, 1996, SCI PRACTICE INTRAME, P77; PELIAS ME, 1992, SURGERY, V111, P576; POHLEMANN T, 1994, CLIN ORTHOP RELAT R, P69; Pohlmann T, 1995, TECH ORTHOP, V9, P267, DOI DOI 10.1097/00013611-199400940-00004; QUABA AA, 1996, MANAGEMEN OPEN FRACT, P263; REGEL G, 1993, UNFALLCHIRURG, V96, P341; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; REGEL G, 1995, J TRAUMA, V38, P70, DOI 10.1097/00005373-199501000-00020; REGEL G, 1997, IN PRESS J ORTHOP TR; SEIBEL R, 1985, ANN SURG, V202, P283, DOI 10.1097/00000658-198509000-00003; Trentz O, 1993, Ther Umsch, V50, P491; TRUNKEY D, 1991, NEW ENGL J MED, V324, P1259; TSCHERNE H, 1987, CHIRURG, V58, P631; TSCHERNE H, 1982, UNFALLHEILKUNDE, V85, P111; TSCHERNE H, 1983, WORLD J SURG, V7, P80, DOI 10.1007/BF01655915; VANOS JP, 1994, J TRAUMA, V36, P495, DOI 10.1097/00005373-199404000-00006; Whitesides, 1996, J Am Acad Orthop Surg, V4, P209	45	29	31	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	FEB	1998		347					62	78					17	Orthopedics; Surgery	Orthopedics; Surgery	ZA795	WOS:000072402600010	9520876				2021-06-18	
J	Rayan, GM; Murray, D; Chung, KW; Rohrer, M				Rayan, GM; Murray, D; Chung, KW; Rohrer, M			The extensor retinacular system at the metacarpophalangeal joint - Anatomical and histological study	JOURNAL OF HAND SURGERY-BRITISH AND EUROPEAN VOLUME			English	Article								The anatomy of the sagittal bands was studied in 56 cadaver digits. The sagittal band is part of an extensor retinacular system which is integrated with the extrinsic and intrinsic musculotendinous structures. The extensor retinacular system is a single unit with radial and ulnar components and has transverse, sagittal and oblique fibres, The transverse-sagittal fibres, along with the palmar plate, form a closed cylindrical tube which surrounds the metacarpal head. The oblique fibres form the triangular lamina distal to the sagittal band. The radial component of the sagittal band is often thinner and longer than the ulnar component. The sagittal band envelops the extensor digitorum tendon and the superficial fibres are thinner than deep fibres, especially in the central digits. The central digits have palmar soft tissue confluence on each side consisting of the sagittal band, palmar plate, annular pulley and deep transverse metacarpal ligament. The sagittal band also appears to envelop the superficial interosseous tendons on both sides, Our findings explain the propensity for radial sagittal band injuries and suggest that the sagittal band is the primary stabilizer of the extensor digitorum at the meracarpophalangeal joint.	Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA	Rayan, GM (corresponding author), Physicians Bldg D,3366 NW Expressway 700, Oklahoma City, OK 73112 USA.						GARCIAELIAS M, 1991, J HAND SURG-AM, V16A, P1130, DOI 10.1016/S0363-5023(10)80079-6; HARRIS C, 1972, J BONE JOINT SURG AM, VA 54, P713, DOI 10.2106/00004623-197254040-00003; KAPLAN EMANUEL B., 1959, CLIN ORTHOPAED, V13, P24; KETTELKAMP DB, 1971, J BONE JOINT SURG AM, VA 53, P229, DOI 10.2106/00004623-197153020-00003; LANDSMEER JMF, 1949, ANAT REC, V104, P31, DOI 10.1002/ar.1091040105; LITTLER JW, 1967, SURG CLIN N AM, V47, P415; Milford LWJ, 1968, RETAINING LIGAMENTS; POSNER M, 1984, KAPLANS FUNCTIONAL S, P49; RAYAN GM, 1994, J HAND SURG-AM, V19A, P590, DOI 10.1016/0363-5023(94)90261-5; SCHULTZ RJ, 1981, J HAND SURG-AM, V6, P493, DOI 10.1016/S0363-5023(81)80110-4; TUBIANA R, 1964, SURG CLIN N AM, V44, P897; Zancolli EA, 1979, STRUCTURAL DYNAMIC B, P3	12	29	30	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0266-7681			J HAND SURG-BRIT EUR	J. Hand Surg.-Br. Eur. Vol.	OCT	1997	22B	5					585	590		10.1016/S0266-7681(97)80351-8			6	Orthopedics; Surgery	Orthopedics; Surgery	ZJ865	WOS:000073261500007	9752909				2021-06-18	
J	Naso, WB; Cure, J; Cuddy, BG				Naso, WB; Cure, J; Cuddy, BG			Retropharyngeal pseudomeningocele after atlanto-occipital dislocation: Report of two cases	NEUROSURGERY			English	Article							SPINAL PSEUDOMENINGOCELE	OBJECTIVE AND IMPORTANCE: We report two cases of retropharyngeal pseudomeningocele after atlanto-occipital dislocation. This is rare, with only one other reported case in the literature. CLINICAL PRESENTATION: We report two patients who presented after blunt cervical and head trauma. Plain films revealed that each patient had atlanto-occipital dislocation. Subsequent magnetic resonance imaging revealed the delayed development of retropharyngeal pseudomeningocele. Concomitant hydrocephalus was noted in both patients. INTERVENTION: The surviving patient showed marked neurological improvement and resolution of his pseudomeningocele after ventriculoperitoneal shunting. CONCLUSION: For patients with closed head injuries who develop posttraumatic pseudomeningocele, we recommend cranial computed tomography to assess for the presence of hydrocephalus. In patients with atlanto-occipital dislocation, delayed neurological deterioration warrants magnetic resonance imaging of the craniocervical junction to rule out posttraumatic pseudomeningocele.	MED UNIV S CAROLINA,DEPT NEUROSURG,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT RADIOL,CHARLESTON,SC 29425							COLLALTO PM, 1986, J BONE JOINT SURG AM, V68A, P1106, DOI 10.2106/00004623-198668070-00024; COOK DA, 1989, CLIN ORTHOPAEDICS, V247, P74; HELLE TL, 1981, NEUROSURGERY, V9, P314, DOI 10.1227/00006123-198109000-00018; HOFF JT, 1993, BRAIN SURG COMPLICAT, P108; HOROWITZ SW, 1990, AM J NEURORADIOL, V11, P784; KITCHEN N, 1992, SURG NEUROL, V38, P46, DOI 10.1016/0090-3019(92)90211-5; LOUW JA, 1991, S AFR J SURG, V29, P26; PRASAD VSSV, 1994, PARAPLEGIA, V32, P627, DOI 10.1038/sc.1994.100; SKLAR EML, 1990, AM J NEURORADIOL, V11, P1184; WILLIAMS MJ, 1995, J CLIN ANESTH, V7, P156, DOI 10.1016/0952-8180(94)00031-X	10	29	30	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUN	1997	40	6					1288	1290		10.1097/00006123-199706000-00033			3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	XC450	WOS:A1997XC45000088	9179904				2021-06-18	
J	Farooque, M; Hillered, L; Holtz, A; Olsson, Y				Farooque, M; Hillered, L; Holtz, A; Olsson, Y			Effects of moderate hypothermia on extracellular lactic acid and amino acids after severe compression injury of rat spinal cord	JOURNAL OF NEUROTRAUMA			English	Article						excitatory amino acids; glutamate; hypothermia; lactate; microdialysis; rat; spinal cord; trauma	TRAUMATIC BRAIN INJURY; CEREBRAL-ISCHEMIA; THERAPEUTIC HYPOTHERMIA; MILD HYPOTHERMIA; BLOOD-FLOW; TEMPERATURE; RELEASE; LACTATE; PROTECTION; GLUTAMATE	We evaluated in rats, the effect of moderate hypothermia (30-31 degrees C) on extracellular levels of amino acids, with special emphasis on the excitatory amino acids (EAAs) glutamate and aspartate, lactate and pyruvate, after severe spinal cord compression. A laminectomy of Th-7 and Th-8 was made. A probe was inserted in a dorsal horn and microdialysis was performed for 1.5 h before and 4 h after applying se vere compression for 5 min. Dialysate samples were collected at intervals of 10 min and analyzed by high-performance liquid chromatography. In normothermic (37.5 degrees C) animals there was a several-fold rise of glutamate that peaked in the first 10 min fraction after trauma. Hypothermic animals showed a similar increase after trauma, which was statistically significant until 20 min after injury. The level of glutamate was significantly higher in hypothermic animals from 20 to 70 min after injury, compared with normothermic animals. Aspartate also showed a marked increase following injury. The peak concentration was similar for both groups, whereas recovery was delayed in hypothermic animals. There was no significant difference between the normothermic and hypothermic animals for arginine, taurine, alanine, glutamine, histadine, glycine, threonine, tyrosine, and asparagine. No significant effect of hypothermia on lactate or lactate/pyruvate was noted. However, the mean level of lactate tended to be lower and recovery was quicker in hypothermic animals. The results of the present study suggest that moderate hypothermia does not attenuate extracellular accumulation of EAAs or markedly improve energy metabolism in our model. Instead, our findings raise the possibility that moderate hypothermia prolongs the duration of glutamate receptor overactivation. Since hypothermia effectively attenuates glutamate release in CNS and spinal cord ischemia models our results suggest different mechanisms of extracellular accumulation of EAAs in ischemia and trauma.	UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN	Farooque, M (corresponding author), UNIV UPPSALA HOSP,NEUROPATHOL LAB,S-75185 UPPSALA,SWEDEN.						ALLEN BT, 1994, J VASC SURG, V19, P332, DOI 10.1016/S0741-5214(94)70108-3; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BUISSON A, 1992, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1992, P417; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FAROOQUE M, 1992, ACTA NEUROPATHOL, V84, P613; FAROOQUE M, 1994, ACTA NEUROL SCAND, V89, P36; Farooque M, 1996, J NEUROCHEM, V66, P1125; FAROOQUE M, 1995, J NEUROTRAUM, V12, P41, DOI 10.1089/neu.1995.12.41; FAROOQUE M, 1996, J NEUROTRAUMA, V13, P535; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALL ED, 1993, RES P ARNMD, V71, P81; HALLSTROM A, 1989, J PHARMACOL METHOD, V22, P113; Hansebout R R, 1975, Surg Neurol, V4, P531; HOLTZ A, 1990, NEUROSURGERY, V26, P952, DOI 10.1227/00006123-199006000-00005; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kuchner E F, 1976, Surg Neurol, V6, P371; Li GL, 1996, ACTA NEUROPATHOL, V91, P155, DOI 10.1007/s004010050407; Li GL, 1996, ACTA NEUROPATHOL, V92, P19, DOI 10.1007/s004010050484; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; LI GL, 1995, RESTOR NEUROL NEUROS, V8, P189, DOI 10.3233/RNN-1995-8404; LIN BW, 1995, STROKE, V26, P1634, DOI 10.1161/01.STR.26.9.1634; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; LO EH, 1993, NEUROL RES, V15, P281; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; MELLERGARD P, 1990, British Journal of Neurosurgery, V4, P31, DOI 10.3109/02688699009000679; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; NATALE JE, 1989, STROKE, V20, P770, DOI 10.1161/01.STR.20.6.770; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P467, DOI 10.1111/j.1600-0404.1988.tb03689.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; SCHOUSBOE A, 1992, CAN J PHYSL PHARM, V70, P356; SHUAIB A, 1993, NEUROCHEM RES, V18, P663, DOI 10.1007/BF00966779; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V127, P533, DOI 10.1111/j.1748-1716.1986.tb07938.x	42	29	29	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	1997	14	1					63	69		10.1089/neu.1997.14.63			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WK032	WOS:A1997WK03200007	9048312				2021-06-18	
J	vandeMeent, HV; Hamers, FPT; Lankhorst, AJ; Joosten, EAJ; Gispen, WH				vandeMeent, HV; Hamers, FPT; Lankhorst, AJ; Joosten, EAJ; Gispen, WH			Beneficial effects of the melanocortin alpha-melanocyte-stimulating hormone on clinical and neurophysiological recovery after experimental spinal cord injury	NEUROSURGERY			English	Article						evoked potentials; melanocortins; neurological recovery; rat; spinal cord injury	METHYLPREDNISOLONE SODIUM SUCCINATE; BLOOD-FLOW; ACTH(4-9) ANALOG; MOLECULAR-CLONING; NERVE CRUSH; FUNCTIONAL RECOVERY; INDUCED NEUROPATHY; ACTH-(4-9) ANALOG; NUCLEUS ACCUMBENS; DOPAMINE SYSTEMS	OBJECTIVE: Melanocortins, peptides related to melanocyte-stimulating hormone (MSH) and corticotropin (ACTH), exhibit neurotrophic and neuroprotective activity in several established models of peripheral and central nervous system damage. The beneficial effects of melanocortins on functional recovery after experimental brain damage and central demyelinating diseases have prompted us to investigate alpha MSH treatment in a weight drop model of traumatic spinal cord injury in rats. METHODS: In two independent randomized blinded experiments, treatment with either alpha MSH (75 mu g/kg of body weight administered subcutaneously every 48 h for 3 weeks after trauma) or single high-dose (30 mg/kg, 30 min after injury) methylprednisolone was compared with saline treatment in rats subjected to a moderately severe 20-gcm weight drop injury. Spinal cord function was monitored using behavioral, electrophysiological, and histological parameters. RESULTS: In both experiments, alpha MSH significantly improved recovery, as illustrated by Tarlov scores, thoracolumbar height, and amplitude of rubrospinal motor evoked potentials. The magnitude of the alpha MSH effect on motor performance was comparable with the one observed after treatment with methylprednisolone. CONCLUSION: The reproducible neurological and electrophysiological improvement in spinal cord function of animals treated with alpha MSH suggests a new lead in the treatment of traumatic spinal cord injury.	UNIV UTRECHT HOSP, RES LAB NEUROL, UTRECHT, NETHERLANDS; UNIV UTRECHT, RUDOLF MAGNUS INST NEUROSCI, DEPT MED PHARMACOL, UTRECHT, NETHERLANDS							Adan RAH, 1996, MOL BRAIN RES, V36, P37, DOI 10.1016/0169-328X(95)00236-L; Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Anderson DK, 1991, J NEUROTRAUM, V8, P187, DOI 10.1089/neu.1991.8.187; BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; BEHRMANN DL, 1993, EXP NEUROL, V119, P258, DOI 10.1006/exnr.1993.1028; BIJLSMA WA, 1983, MUSCLE NERVE, V6, P104, DOI 10.1002/mus.880060205; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; CATANIA A, 1993, ENDOCR REV, V14, P564, DOI 10.1210/er.14.5.564; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; COLLINS WF, 1983, PARAPLEGIA, V21, P204, DOI 10.1038/sc.1983.34; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; DEKKER AJAM, 1987, PEPTIDES, V8, P1057, DOI 10.1016/0196-9781(87)90136-7; DEKONING P, 1987, EXP NEUROL, V97, P746, DOI 10.1016/0014-4886(87)90132-4; DELABAUME S, 1981, NEUROSCIENCE, V6, P315, DOI 10.1016/0306-4522(81)90125-1; Dohrmann G J, 1976, Surg Neurol, V5, P315; DUCKERS HJ, 1994, BRAIN, V117, P365, DOI 10.1093/brain/117.2.365; DUCKERS HJ, IN PRESS J NEUROSCI; EDWARDS PM, 1984, J NEUROL SCI, V64, P333, DOI 10.1016/0022-510X(84)90181-3; FADEN AI, 1988, BRAIN RES, V463, P63, DOI 10.1016/0006-8993(88)90527-6; FEHLINGS MG, 1989, J NEUROSURG, V71, P403, DOI 10.3171/jns.1989.71.3.0403; FERINGA ER, 1976, NEUROLOGY, V26, P839, DOI 10.1212/WNL.26.9.839; FORD RWJ, 1983, J NEUROSURG, V59, P268, DOI 10.3171/jns.1983.59.2.0268; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1994, BIOCHEM BIOPH RES CO, V200, P1214, DOI 10.1006/bbrc.1994.1580; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; GISPEN WH, 1994, PROG BRAIN RES, V100, P223; GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; HAMERS FPT, 1993, CANCER CHEMOTH PHARM, V32, P162, DOI 10.1007/BF00685621; HAMERS FPT, 1993, EUR J PHARMACOL, V233, P177, DOI 10.1016/0014-2999(93)90367-Q; HANNIGAN JH, 1985, PHARMACOL BIOCHEM BE, V23, P1019, DOI 10.1016/0091-3057(85)90109-1; HOL EM, 1993, NEUROREPORT, V4, P651, DOI 10.1097/00001756-199306000-00012; HOLTZ A, 1989, SURG NEUROL, V31, P350, DOI 10.1016/0090-3019(89)90066-9; HOLTZ A, 1990, ACTA NEUROL SCAND, V82, P68; HUNG TK, 1979, SURG NEUROL, V11, P470; ISAACSON RL, 1983, BEHAV NEURAL BIOL, V39, P52, DOI 10.1016/S0163-1047(83)90620-9; Joosten E. A. J., 1995, Journal of Neurotrauma, V12, P373; KAKULAS BA, 1987, PARAPLEGIA, V25, P212, DOI 10.1038/sc.1987.37; KOENIG G, 1977, J NEUROL NEUROSUR PS, V40, P1203, DOI 10.1136/jnnp.40.12.1203; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; NOBLE LJ, 1987, EXP NEUROL, V95, P530, DOI 10.1016/0014-4886(87)90162-2; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NYAKAS C, 1985, BRAIN RES BULL, V15, P257, DOI 10.1016/0361-9230(85)90148-0; PITSIKAS N, 1991, PHARMACOL BIOCHEM BE, V38, P931, DOI 10.1016/0091-3057(91)90267-6; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; STRAND FL, 1991, PHYSIOL REV, V71, P1017; STRAND FL, 1994, PHARMACOL THERAPEUT, V62, P1, DOI 10.1016/0163-7258(94)90002-7; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P588, DOI 10.1001/archneurpsyc.1954.02320410050004; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; ULENKATE HJLM, 1993, GLIA, V9, P219, DOI 10.1002/glia.440090307; VANDEMEENT H, 1995, EUR J NEUROSCI, V8, P197; VANDEMEENT H, IN PRESS J NEUROTRAU; VANDERHOOP RG, 1990, NEW ENGL J MED, V322, P89, DOI 10.1056/NEJM199001113220204; VANDERNEUT R, 1992, PEPTIDES, V13, P1109, DOI 10.1016/0196-9781(92)90015-U; VANDERZEE CEEM, 1988, EUR J PHARMACOL, V147, P351, DOI 10.1016/0014-2999(88)90168-9; VANREE JM, 1991, EUR NEUROPSYCHOPHARM, V1, P386; VERHAAGEN J, 1986, EXP NEUROL, V92, P451, DOI 10.1016/0014-4886(86)90098-1; VERHAAGEN J, 1987, PEPTIDES, V8, P581, DOI 10.1016/0196-9781(87)90028-3; WOLTERINK G, 1990, BRAIN RES, V507, P115, DOI 10.1016/0006-8993(90)90529-K; WOLTERINK G, 1990, BRAIN RES, V507, P109, DOI 10.1016/0006-8993(90)90528-J; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667	69	29	30	1	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	1997	40	1					122	130		10.1097/00006123-199701000-00028			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	VY973	WOS:A1997VY97300068	8971834				2021-06-18	
J	Brucia, J; Rudy, E				Brucia, J; Rudy, E			The effect of suction catheter insertion and tracheal stimulation in adults with severe brain injury	HEART & LUNG			English	Article							HEAD-INJURY; INTRACRANIAL HYPERTENSION; ENDOTRACHEAL; LIDOCAINE; PRESSURE	OBJECTIVE: To determine the effect of suction catheter insertion and tracheal stimulation on cerebrovascular and systemic vascular status in adults with severe traumatic brain injury. DESIGN: Quasi-experimental, within-subject design. SETTING: Two university-affiliated critical care units. SUBJECTS: Thirty intubated and mechanically ventilated adults with severe brain injury. The participants' average age was 31 +/- 15 years. OUTCOME MEASURES: Mean intracranial pressure (MICP), mean arterial pressure (MAP), cerebral perfusion pressure (CPP), and heart rate (HR) were measured. INTERVENTION: Endotracheal suction catheter insertion with tracheal stimulation was performed. RESULTS: Suction catheter insertion and tracheal stimulation, isolated from other components of the suctioning procedure, significantly increased MICP, MAP, and CPP. KR was not significantly increased. During the application of negative pressure for actual suctioning, MICP and HR significantly increased, whereas MAP and CPP did not significantly change compared with catheter insertion. CONCLUSION: Tracheal stimulation during suction catheter insertion initiates both cerebrovascular and systemic vascular responses during the suctioning procedure. Study findings suggest that a potentially productive direction for intervention research is to identify ways to minimize airway stimulation during the suctioning procedure.		Brucia, J (corresponding author), UNIV VIRGINIA,SCH NURSING,MCLEOD HALL,CHARLOTTESVILLE,VA 22903, USA.						BAUN M, 1977, American Review of Respiratory Disease, V115, P186; Baun M M, 1984, West J Nurs Res, V6, P213, DOI 10.1177/019394598400600206; Brucia J J, 1992, J Neurosci Nurs, V24, P205; CAMPBELL V, 1989, THESIS CASE W RES U; CHULAY M, 1988, HEART LUNG, V17, P654; Crosby L J, 1992, J Neurosci Nurs, V24, P40; DONEGAN MF, 1980, ANESTHESIOLOGY, V52, P516, DOI 10.1097/00000542-198006000-00014; ERSSON U, 1990, ACTA ANAESTH SCAND, V34, P99, DOI 10.1111/j.1399-6576.1990.tb03051.x; FELDMAN Z, 1993, HEAD INJURY, P247; FISHER DM, 1982, ANESTHESIOLOGY, V57, P416, DOI 10.1097/00000542-198211000-00013; HAMILL JF, 1981, ANESTHESIOLOGY, V55, P578, DOI 10.1097/00000542-198111000-00016; JOHANSON CE, 1995, NEUROSCIENCE MED, P171; KONTOS HA, 1978, AM J PHYSIOL, V234, pH582; KONTOS J, 1977, AM J PHYSIOL, V234, pH371; MARSHALL L, 1986, CLIN NEUR P C NEUR S; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PARSONS LC, 1984, HEART LUNG, V13, P372; PIERCE JB, 1987, HEART LUNG, V16, P34; RIGEL DF, 1989, CIRC RES, V64, P276, DOI 10.1161/01.RES.64.2.276; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; RUDY EB, 1991, HEART LUNG, V20, P667; SAUL T, 1986, CLIN NEUR P C NEUR S; SHAM JSK, 1993, J APPL PHYSIOL, V75, P772; SHAPIRO HM, 1975, ANESTHESIOLOGY, V43, P445, DOI 10.1097/00000542-197510000-00010; SIMARD JM, 1989, AM J CARDIOL, V63, pC32, DOI 10.1016/0002-9149(89)90403-7; SKELLEY BFH, 1980, HEART LUNG, V9, P316; STONE K, 1991, NURS RES, V76, P76; WHITE PF, 1982, ANESTHESIOLOGY, V57, P242, DOI 10.1097/00000542-198209000-00019; YANO M, 1986, ANESTHESIOLOGY, V64, P651, DOI 10.1097/00000542-198605000-00019	30	29	31	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0147-9563			HEART LUNG	Heart Lung	JUL-AUG	1996	25	4					295	303		10.1016/S0147-9563(96)80065-3			9	Cardiac & Cardiovascular Systems; Nursing; Respiratory System	Cardiovascular System & Cardiology; Nursing; Respiratory System	VA247	WOS:A1996VA24700005	8836745				2021-06-18	
J	Scremin, OU; Jenden, DJ				Scremin, OU; Jenden, DJ			Cholinergic control of cerebral blood flow in stroke, trauma and aging	LIFE SCIENCES			English	Article; Proceedings Paper	Scientific Festschrift on Cholinergic and Related Mechanisms in Aging and Disease - A Tribute to Donald J Jenden, MD	NOV 17-18, 1995	UNIV CALIF LOS ANGELES, LOS ANGELES, CA	Loyola Univ Chicago Stritch Sch Med, Neurosci & Aging Inst	UNIV CALIF LOS ANGELES	cerebrovascular circulation; acetylcholine; choline; brain injuries; aging	ALZHEIMERS-DISEASE; RAT-BRAIN; PLASMA CHOLINE; ACETYLCHOLINE; METABOLISM; DEMENTIA; VASODILATATION; AUTOREGULATION; STIMULATION; TURNOVER	Enhancing the availability of endogenous acetylcholine by inhibition of cholinesterase with physostigmine, eptastigmine or soman at sub-toxic doses increases cerebral blood flow (CBF) and the response of this variable to changes in PaCO2. These effects are not correlated with metabolic activation, suggesting that the function of the cholinergic vasodilatation is not merely to supply metabolic substrates. Since choline (Ch) can exchange between blood and the brain extracellular milieu the stage is set for possible feedback interactions between ACh synthesis and CBF. A negative feedback of CBF on ACh synthesis under conditions of a negative arteriovenous (A-V) difference for Ch across cerebral capillaries may contribute to stabilize CBF in ischemia. Eptastigmine and physostigmine significantly improve perfusion in experimental models of focal cerebral ischemia and traumatic brain injury respectively. During the short periods of time in which the A-V difference for Ch across the brain is positive, a positive feedback between cerebral free Ch and CBF may enhance the ability of the brain to recover Ch from the circulation for synthesis of membrane phospholipids. A loss of cholinergic cerebrovascular control may thus impair the survival of all cells within the CNS and contribute to the pathophysiology of dementia. Perhaps the view that the loss of cholinergic cells is the end point of Alzheimer's dementia could be modified to state that a cholinergic deficit may be the starting point of a decline in cerebral phospholipid turnover and cell membrane renewal that could lead to a generalized deterioration of cerebral function.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,SCH MED,DEPT MOLEC & MED PHARMACOL,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOMATH,LOS ANGELES,CA 90073	Scremin, OU (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,GERIATR RES & EDUC CLIN CTR,11301 WILSHIRE BLVD,LOS ANGELES,CA 90073, USA.						AOYAGI M, 1975, J NEUROSURG, V43, P689, DOI 10.3171/jns.1975.43.6.0689; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRODIE C, 1991, DEV BRAIN RES, V61, P183, DOI 10.1016/0165-3806(91)90130-B; CHOI RL, 1975, J NEUROCHEM, V24, P735, DOI 10.1111/j.1471-4159.1975.tb11672.x; DROSS K, 1972, N-S ARCH PHARMACOL, V274, P91, DOI 10.1007/BF00501010; FALGOUT JC, 1987, J CEREB BLOOD FLO S1, V7, pS405; FREEMAN JJ, 1975, J NEUROCHEM, V24, P729, DOI 10.1111/j.1471-4159.1975.tb03856.x; FREEMAN JJ, 1976, LIFE SCI, V19, P949, DOI 10.1016/0024-3205(76)90285-X; FUMEYA H, 1990, ACT NEUR S, V51, P283; GEANEY DP, 1990, LANCET, V335, P1484, DOI 10.1016/0140-6736(90)93028-N; GUSTAFSON L, 1987, J CEREB BLOOD FLO S1, V7, pS404; HUNTER R, 1990, LANCET, V336, P450, DOI 10.1016/0140-6736(90)92007-5; JAGUST WJ, 1990, ARCH NEUROL-CHICAGO, V47, P628, DOI 10.1001/archneur.1990.00530060036013; JENDEN DJ, 1991, B CLIN NEUROSCI, V55, P99; KAWAMURA Y, 1975, J NEUROSURG, V43, P676, DOI 10.3171/jns.1975.43.6.0676; KETY S S, 1956, J Chronic Dis, V3, P478, DOI 10.1016/0021-9681(56)90146-1; KLEIN J, 1992, J NEUROCHEM, V58, P870, DOI 10.1111/j.1471-4159.1992.tb09337.x; KLEIN J, 1990, J NEUROCHEM, V28, P897; KOMATANI A, 1988, J NUCL MED, V29, P1621; LAKHER M, 1987, BRAIN RES, V419, P131, DOI 10.1016/0006-8993(87)90576-2; LAVY S, 1978, ANN NEUROL, V4, P445, DOI 10.1002/ana.410040510; MONTALDI D, 1990, J NEUROL NEUROSUR PS, V53, P33, DOI 10.1136/jnnp.53.1.33; MOTULSKY HJ, 1987, FASEB J, V1, P365; PROHOVNIK I, 1988, NEUROLOGY, V38, P931, DOI 10.1212/WNL.38.6.931; REED BR, 1989, NEUROLOGY, V39, P1537, DOI 10.1212/WNL.39.11.1537; ROGERS RL, 1986, NEUROLOGY, V36, P1; ROVERE AA, 1973, STROKE, V4, P969, DOI 10.1161/01.STR.4.6.969; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; Scremin A M, 1992, J Stroke Cerebrovasc Dis, V2, P87, DOI 10.1016/S1052-3057(10)80212-5; Scremin O. U., 1995, Society for Neuroscience Abstracts, V21, P762; Scremin OU, 1973, STROKE, V4, P232, DOI 10.1161/01.STR.4.2.232; SCREMIN OU, 1983, J CEREBR BLOOD F MET, V3, P362, DOI 10.1038/jcbfm.1983.52; SCREMIN OU, 1989, STROKE, V20, P1524, DOI 10.1161/01.STR.20.11.1524; SCREMIN OU, 1982, J CEREBR BLOOD F MET, V2, P241, DOI 10.1038/jcbfm.1982.24; SCREMIN OU, 1988, NEUROPSYCHOPHARMACOL, V1, P297; SCREMIN OU, 1995, FASEB J, V9, pA381; SCREMIN OU, 1994, FASEB J, V8, pA828; SCREMIN OU, 1992, J NEUROCHEM, V59, P906, DOI 10.1111/j.1471-4159.1992.tb08329.x; SCREMIN OU, 1993, J CEREB BLOOD FLOW M, V130, P702; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SZERB JC, 1967, J PHYSIOL-LONDON, V192, P329, DOI 10.1113/jphysiol.1967.sp008303; TACHIBANA H, 1984, J AM GERIATR SOC, V32, P114, DOI 10.1111/j.1532-5415.1984.tb05850.x; WILSON K, 1991, BRIT J PSYCHIAT, V158, P558, DOI 10.1192/bjp.158.4.558; ZEISEL SH, 1981, ANNU REV NUTR, V1, P95, DOI 10.1146/annurev.nu.01.070181.000523	44	29	29	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0024-3205			LIFE SCI	Life Sci.	APR 26	1996	58	22					2011	2018		10.1016/0024-3205(96)00192-0			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	UH285	WOS:A1996UH28500015	8637431				2021-06-18	
J	Clifton, GL; Donovan, WH; Dimitrijevic, MM; Allen, SJ; Ku, A; Potts, JR; Moody, FG; Boake, C; Sherwood, AM; Edwards, JV				Clifton, GL; Donovan, WH; Dimitrijevic, MM; Allen, SJ; Ku, A; Potts, JR; Moody, FG; Boake, C; Sherwood, AM; Edwards, JV			Omental transposition in chronic spinal cord injury	SPINAL CORD			English	Article						spinal cord injury; omental transposition; MRI; neurophysiology; neurological examinations; neurological	SOMATOSENSORY EVOKED-POTENTIALS; EXPERIMENTAL CEREBRAL-ISCHEMIA; INTACT OMENTUM; BRAIN; NEOVASCULARIZATION; VASCULARIZATION; TRANSPLANTATION; PREVENTION; INFARCTION; SURFACE	The results of omental transposition in chronic spinal cord injury have been reported in 160 patients operated upon in the United States, Great Britain, China, Japan, India and Mexico, with detailed outcomes reported in few studies. Recovery of function to a greater degree than expected by natural history has been reported. In this series, 15 patients with chronic traumatic spinal cord injury (>1.5 years from injury) underwent transposition of pedicled omentum to the area of spinal cord injury. Of the first series of four patients who were operated upon in 1988, one died, one was lost to follow-up and two were followed with sequential neurological examinations and Magnetic Resonance Imaging (MRI) scans preoperatively, at 1 year post injury and 4 1/2 years post injury. Another 11 patients were operated in 1992 and underwent detailed neurological and neurophysiological examinations and had MRT scans preoperatively and every 4 months for at least 1 year after surgery. All patients completed a detailed self-report form. Of the total of 13 operated patients in both series followed for 1-4 1/2 years, six reported some enhanced function at 1 year and five of these felt the changes justified surgery primarily because of improved truncal control and decreased spasticity. MRI scans showed enlargement of the spinal cord as compared to preoperative scans in seven patients. Increased T2 signal intensity of the spinal cord was found by 1 year after surgery in eight of 13 operated patients. Neurophysiological examinations of 11 patients in the second series agreed with self-reports of increases or decreases in spasticity (r = 0.65, P < 0.03). Somatosensory evoked potentials and motor evoked potentials at 4 month intervals up to 1 year in these patients showed no change after surgery. Neurological testing, using the American Spinal Injury Association (ASIA) and International Medical Society of Paraplegia (IMSOP) international scoring standards, failed to show any significant changes when the I-year post operative examination was compared to the first preoperative examination except for decreased sensory function after surgery which approached statistical significance. When the 11 patients in the second series were compared to eight non-operated matched patients, followed for a similar length of time, no significant differences were found. Complications encountered in the operated patients from both series included one postoperative death from a pulmonary embolus, one postoperative pneumonia, three chronic subcutaneous cerebrospinal fluid (CSF) fistulae requiring wound revision, and one patient who developed biceps and wrist extensor weakness bilaterally requiring graft removal. We conclude that the omental graft remains viable over time and this operation can induce anatomical changes in the spinal cord as judged by MRI. Some patients reported subjective improvement but this was not supported by objective testing. We, therefore, find no justification for further clinical trials of this procedure in patients who have complete or sensory incomplete lesions. Further testing in motor incomplete patients would seem appropriate only with compelling supportive data.		Clifton, GL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,SCH MED,641 FANNIN,SUITE 7149,HOUSTON,TX 77030, USA.			Sherwood, Arthur/0000-0002-0110-4317			ABRAHAM J, 1980, PARAPLEGIA, V25, P44; ABRAHAM J, 1990, OMENTUM, P147; AZZENA GB, 1983, ACTA NEUROCHIR, V68, P63, DOI 10.1007/BF01406203; BERIC A, 1988, MUSCLE NERVE, V11, P621, DOI 10.1002/mus.880110615; BLIGHT AR, 1989, J NEUROL SCI, V91, P15, DOI 10.1016/0022-510X(89)90073-7; BLIGHT AR, 1989, J NEUROL SCI, V82, P145; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CARTIER R, 1990, J THORAC CARDIOV SUR, V99, P264; CUCCA GS, 1980, ACTA NEUROCHIR, V51, P253, DOI 10.1007/BF01406752; DELATORRE JC, 1990, ACTA NEUROCHIR, V102, P152, DOI 10.1007/BF01405432; DERIU PL, 1980, NEUROSURGERY, V7, P57, DOI 10.1227/00006123-198007000-00009; DIMITRIJEVIC MM, 1989, PHYS MED REHAB, V3, P64; DIMITRIJEVIC MR, 1992, ELECTROEN CLIN NEURO, V85, P365, DOI 10.1016/0168-5597(92)90049-H; DITUNNO JF, 1992, AM SPINAL INJURY ASS; FRACKOWIAK R, 1987, STROKE, V18, P46; GOLDSMITH HS, 1978, STROKE, V9, P224, DOI 10.1161/01.STR.9.3.224; GOLDSMITH HS, 1979, STROKE, V10, P471, DOI 10.1161/01.STR.10.4.471; GOLDSMITH HS, 1986, SURG GYNECOL OBSTET, V162, P579; GOLDSMITH HS, 1986, PARAPLEGIA, V24, P173, DOI 10.1038/sc.1986.23; GOLDSMITH HS, 1994, NEUROL RES, V16, P159; GOLDSMITH HS, 1975, AM J SURG, V129, P262, DOI 10.1016/0002-9610(75)90236-6; GOLDSMITH HS, 1973, ARCH SURG-CHICAGO, V106, P695; GOLDSMITH HS, 1975, AM J SURG, V130, P317, DOI 10.1016/0002-9610(75)90393-1; Goldsmith HS, 1990, OMENTUM RES CLIN APP, P45; KADABA MP, 1985, J ORTHOPAED RES, V3, P350, DOI 10.1002/jor.1100030312; KAKULAS A, 1988, PARAPLEGIA, V26, P371, DOI 10.1038/sc.1988.57; LIU JF, 1980, J NERV MENT DIS, V6, P321; MACMILLAN M, 1991, SPINE, V16, P176, DOI 10.1097/00007632-199102000-00014; MCINTOSH TK, 1990, OMENTUM RES CLIN APP, P75; MINSHU Z, 1990, OMENTUM, P173; MIYAMOTO S, 1990, OMENTUM, P159; NAGASHIMA C, 1991, Neurological Surgery, V19, P309; NI MS, 1983, CHINESE MED J-PEKING, V96, P787; OSHIO I, 1993, SPINE, V18, P1140; PAU A, 1982, ACTA NEUROCHIR, V66, P159, DOI 10.1007/BF02074502; PAU A, 1982, ACTA NEUROCHIR, V54, P213; PIEPMEIER JM, 1988, J NEUROSURG, V69, P399, DOI 10.3171/jns.1988.69.3.0399; RAFAEL H, 1992, ACTA NEUROCHIR, V114, P145, DOI 10.1007/BF01400604; ROSADINI G, 1990, OMENTUM, P109; SHERWOOD AM, 1981, IEEE T BIO-MED ENG, V28, P481, DOI 10.1109/TBME.1981.324733; SHERWOOD AM, 1992, J NEUROL SCI, V110, P90, DOI 10.1016/0022-510X(92)90014-C; SHERWOOD AM, 1992, 9 INT C ISEK FLOR IT, P95; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SIEK GC, 1990, OMENTUM RES CLIN APP, P83; SONG MF, 1990, CHUNG HUA WAI KO TSA, V28, P342; WAXMAN SG, 1989, J NEUROL SCI, V91, P1, DOI 10.1016/0022-510X(89)90072-5; YOUNG W, 1987, FRONTIERS CLIN NEURO, V10, P156; ZHANG C, 1983, CHUNG HUA SHEN CHING, V16, P23; ZHU ZC, 1982, CHUNG HUA WAI KO TSA, V20, P11; ZOU XW, 1985, CHIN J NEUROSURG, V1, P107	50	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	1362-4393			SPINAL CORD	Spinal Cord	APR	1996	34	4					193	203		10.1038/sc.1996.38			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UR611	WOS:A1996UR61100003	8963963	Bronze			2021-06-18	
J	SALAZAR, AM; SCHWAB, K; GRAFMAN, JH				SALAZAR, AM; SCHWAB, K; GRAFMAN, JH			PENETRATING INJURIES IN THE VIETNAM-WAR - TRAUMATIC UNCONSCIOUSNESS, EPILEPSY, AND PSYCHOSOCIAL OUTCOME	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article							HEAD-INJURY; PROGNOSTIC FACTORS; BRAIN; MORTALITY; PHENYTOIN; VETERANS; SEIZURES; CARE	The WF Caveness Vietnam Head Injury Study includes over a thousand men who survived penetrating head injuries during the Vietnam War and on whom detailed medical and follow-up data are available. This population offers unique opportunities for the study of recovery from brain injury and of brain structure-function relationships. The authors briefly review long-term outcome in this cohort with respect to traumatic unconsciousness, posttraumatic epilepsy, and elements of psychologic and psychosocial function, including returning to work.	NINCDS,BETHESDA,MD 20892	SALAZAR, AM (corresponding author), WALTER REED ARMY MED CTR,DEFENSE & VET HEAD INJURY PROGRAM,BLDG 7,ROOM 224,WASHINGTON,DC 20307, USA.						ALBERT ML, 1976, ARCH NEUROL-CHICAGO, V33, P453, DOI 10.1001/archneur.1976.00500060059013; CAREY ME, 1987, MIL MED, V152, P6; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CAVENESS WF, 1974, HDB NEUROLOGY, P274; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; Credner L, 1930, Z GESAMTE NEUROL PSY, V126, P721, DOI 10.1007/BF02864129; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; GRAFMAN J, 1986, J NEUROSCI, V6, P301; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; Harlow JM, 1848, BOSTON MED SURG J, V39, P389, DOI DOI 10.1056/NEJM184812130392001; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Jennett B, 1981, MANAGEMENT HEAD INJU; KAUFMAN HH, 1991, SURG NEUROL, V36, P370, DOI 10.1016/0090-3019(91)90026-6; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; LURIA AR, 1978, CONSCIOUSNESS SELF R, P1; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; PARENTI G, 1991, PHARM PROPHYLAXIS PO, P43; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; SALAZAR A, 1987, ADV EPILEPTOL, P753; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1987, PROGR CLIN NEUROSCIE, V1, P225; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; SCHWARTZ B, 1967, ACTA NEUROL SCAND, V43, P513, DOI 10.1111/j.1600-0404.1967.tb05757.x; SERAFETINIDES EA, 1965, BRAIN, V88, P107, DOI 10.1093/brain/88.1.107; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; TUCKER DM, 1984, PSYCHOL REV, V91, P185, DOI 10.1037/0033-295X.91.2.185; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; WILLMORE LJ, 1990, EPILEPSIA, V31, P67; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236	33	29	30	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	1042-3680			NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	1995	6	4					715	&					0	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	RZ142	WOS:A1995RZ14200012	8527913				2021-06-18	
J	LEWIS, SB; MYBURGH, JA; REILLY, PL				LEWIS, SB; MYBURGH, JA; REILLY, PL			DETECTION OF CEREBRAL VENOUS DESATURATION BY CONTINUOUS JUGULAR BULB OXIMETRY FOLLOWING ACUTE NEUROTRAUMA	ANAESTHESIA AND INTENSIVE CARE			English	Article						MEASUREMENT TECHNIQUES; CONTINUOUS JUGULAR BULB OXIMETRY; INTRACRANIAL PRESSURE; CEREBRAL PERFUSION PRESSURE; CAPNOGRAPHY; BRAIN; VENOUS DESATURATION; TRAUMA	ACUTE BRAIN INJURY; SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL HYPERTENSION; COMATOSE PATIENTS; OXYGENATION; HYPERVENTILATION; HYPOXIA; DAMAGE	A prospective observational study was performed to assess the reliability of fibreoptic oximetric catheters and to identify the incidence and causes of jugular bulb oxygen desaturation in patients with acute closed head injury. There were twenty-five patients (30+/-16 years) with GCS less than or equal to 8 in this study. Jugular bulb oximetry, mean arterial pressure, intracranial pressure, end-tidal CO2 and pulse oximetry were monitored continuously. Catheter calibration against a laboratory oximeter was performed post insertion and thereafter eight-hourly Cerebral venous desaturation was defined as a jugular bulb oxygen saturation < 55% of > 10 minutes duration. There was a poor correlation for the first in vivo calibration (r(2)=0.602, P < 0.001, n=25). Thereafter a close correlation between jugular bulb catheter and oximetry values was demonstrated (r(2)=0.868, P<0.001, n=205). forty-two episodes of jugular bulb oxygen desaturation of 88 minutes mean duration (range 10 to 555) were observed. 83% occurred within 48 hours following injury. Hypocapnia was associated in 45% of episodes; hypoperfusion in 22%; raised ICP in 9% and a combination of the above in 24%. Validation with a laboratory oximeter is essential prior to continuous jugular bulb oximetry. Sustained episodes of cerebral venous desaturation are frequent within the first 48 hours following acute head injury. Factors such as hypocapnia and cerebral hypoperfusion that primarily reduce cerebral blood flow are predominant.	ROYAL ADELAIDE HOSP,DEPT INTENS CARE,ADELAIDE,SA,AUSTRALIA	LEWIS, SB (corresponding author), ROYAL ADELAIDE HOSP,DEPT NEUROSURG,N TERRACE,ADELAIDE,SA 5000,AUSTRALIA.						ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1993, CRIT CARE MED, V21, P1242, DOI 10.1097/00003246-199308000-00027; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; JONES RR, 1993, WORLD WATCH, V6, P4; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38	20	29	30	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	JUN	1995	23	3					307	314		10.1177/0310057X9502300307			8	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	RB451	WOS:A1995RB45100007	7573917	Bronze			2021-06-18	
J	VAKIL, E; WEISZ, H; JEDWAB, L; GROSWASSER, Z; ABERBUCH, S				VAKIL, E; WEISZ, H; JEDWAB, L; GROSWASSER, Z; ABERBUCH, S			STROOP COLOR-WORD TASKS AS A MEASURE OF SELECTIVE ATTENTION - EFFICIENCY IN CLOSED-HEAD-INJURED PATIENTS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MECHANISMS; SYMPTOMS; DEFICITS	Deficits in attention and concentration are reported to be among the most common symptoms following head injury. Various underlying mechanisms of selective attention such as excitation, inhibition, and habituation have been isolated in recent studies. In the present study 27 control and 25 closed-head-injured (CHI) subjects were compared on four conditions based on the Stroop color-word task (neutral, habituation, Stroop, and negative priming). Cross-comparison of the different tasks enables examination of the various components of selective attention. The hypothesis that the control group's overall reading time would be faster than that of the CHI group was confirmed. Also confirmed was the hypothesis that the overall reading time pattern between task conditions would be neutral < habituation < Stroop < negative priming. The prediction that the CHI patients, due to their impaired inhibitory mechanism, would not show a slower reading time on the negative priming as compared to the Stroop condition, was confirmed as well. The theoretical and diagnostic implications of the results are discussed.	LOEWENSTEIN HOSP & REHABIL CTR,RAANANA,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL	VAKIL, E (corresponding author), BAR ILAN UNIV,DEPT PSYCHOL,IL-52900 RAMAT GAN,ISRAEL.						BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HASHER L, 1988, J EXPT PSYCHOL LEARN, V17, P163; Jennett B, 1981, MANAGEMENT HEAD INJU; LORCH EP, 1986, J EXPT CHILD PSYCHOL, V41, P84; LOWE DG, 1985, MEM COGNITION, V13, P74, DOI 10.3758/BF03198446; MATTSON AJ, 1990, J NERV MENT DIS, V178, P82; McDowd J. M., 1991, J GERONTOL B-PSYCHOL, V46, P340; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NEILL WT, 1977, J EXP PSYCHOL HUMAN, V3, P444, DOI 10.1037/0096-1523.3.3.444; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Stroop JR, 1935, AM J PSYCHOL, V47, P499, DOI 10.2307/1416349; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TIPPER SP, 1989, J EXP CHILD PSYCHOL, V48, P353, DOI 10.1016/0022-0965(89)90047-7; TIPPER SP, 1985, Q J EXP PSYCHOL-A, V37, P591, DOI 10.1080/14640748508400921; TIPPER SP, 1985, Q J EXP PSYCHOL-A, V37, P571, DOI 10.1080/14640748508400920; Van Zomeren A. H., 1981, REACTION TIME ATTENT; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	24	29	31	0	2	SWETS ZEITLINGER BV	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1995	17	3					335	342		10.1080/01688639508405127			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	RA265	WOS:A1995RA26500002	7650097				2021-06-18	
J	MCCLELLAND, RJ; FENTON, GW; RUTHERFORD, W				MCCLELLAND, RJ; FENTON, GW; RUTHERFORD, W			THE POSTCONCUSSIONAL-SYNDROME REVISITED	JOURNAL OF THE ROYAL SOCIETY OF MEDICINE			English	Article						POSTCONCUSSION SYNDROME; EEG; BRAIN-STEM EVOKED POTENTIALS; LIFE EVENTS AND SOCIAL DIFFICULTIES	MINOR HEAD-INJURY; CONCUSSION		UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT PSYCHIAT,DUNDEE DD1 9SY,SCOTLAND; ROYAL VICTORIA HOSP,DEPT ACCID & EMERGENCY,BELFAST,NORTH IRELAND	MCCLELLAND, RJ (corresponding author), QUEENS UNIV BELFAST,DEPT MENTAL HLTH,BELFAST,NORTH IRELAND.						Barth JT, 1989, MILD HEAD INJURY; Brown GW., 1978, SOCIAL ORIGINS DEPRE; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; FENTON GW, 1992, BRIT J PSYCHIAT, V16, P416; GRONWALL D, 1975, LANCET, V2, P995; JENKINS A, 1986, LANCET, V2, P445; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIDVALL HF, 1974, ACTA NEUROL SCAND  S, V56, P1; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MCKINLEY WW, 1993, J NEUROSURG PSYCHIAT, V46, P1084; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1978, INJURY, V10, P225; RUTHERFORD WH, 1988, ARCH EMERG MED, V5, P12; TAYLOR AR, 1966, LANCET, V2, P178; WATSON MR, 1994, IN PRESS BR J PSYCHI; Wing J. K., 1978, PSE ID CATEGO SYSTEM; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	25	29	30	0	1	ROYAL SOC MEDICINE SERVICES LTD	LONDON	1 WIMPOLE STREET, LONDON, ENGLAND W1M 8AE	0141-0768			J ROY SOC MED	J. R. Soc. Med.	SEP	1994	87	9					508	510					3	Medicine, General & Internal	General & Internal Medicine	PF125	WOS:A1994PF12500006	7932452				2021-06-18	
J	ANDERSON, CV; BIGLER, ED				ANDERSON, CV; BIGLER, ED			THE ROLE OF CAUDATE-NUCLEUS AND CORPUS-CALLOSUM ATROPHY IN TRAUMA-INDUCED ANTERIOR HORN DILATION	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; DEGENERATIVE CHANGES; BRAIN INJURY; RESONANCE; MORPHOLOGY	Day-of-injury computerized tomography (CT) scans were compared to post-injury (at least 6 weeks) magnetic resonance (MR) imaging of 30 traumatic brain-injured (TBI) patients. Scans were matched as closely as possible at the head of the caudate nucleus (CN), a grey matter structure, and the anterior horns (AH) of the lateral ventricle. The CN and AH surface areas and width of the corpus callosum (CC), a white-matter structure, were measured. Results demonstrated a non-significant change in CN surface area, while AH showed a significant increase. CC showed a significant decrease in width. Lack of significant change in the CN, combined with a significant decrease in CC width, suggests that AH dilation is probably due to surrounding white as opposed to grey-matter atrophy.	BRIGHAM YOUNG UNIV,DEPT PSYCHOL,1086 SWKT,PROVO,UT 84602							BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1993, IN PRESS BRAIN INJUR; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; DALPAN GJ, 1992, NEUROLOGY, V42, P2125, DOI 10.1212/WNL.42.11.2125; Hall S, 1989, Arch Clin Neuropsychol, V4, P79; JOHNSON SC, IN PRESS NEUROPSYCHO; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; MACNAMARA SE, 1992, ARCH CLIN NEUROPSYCH, V7, P275, DOI 10.1016/0887-6177(92)90169-N; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; SANDOR T, 1992, ARCH NEUROL-CHICAGO, V49, P381, DOI 10.1001/archneur.1992.00530280069024; YEO RA, 1991, J CLIN EXP NEUROPSYC, V13, P63	12	29	29	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG-SEP	1994	8	6					565	569		10.3109/02699059409151008			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	PE682	WOS:A1994PE68200008	7987292				2021-06-18	
J	WANG, JY; CHEN, JL				WANG, JY; CHEN, JL			GLYCEROL DEHYDRATES EDEMATOUS AS WELL AS NORMAL BRAIN IN DOGS	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY			English	Article						CEREBRAL WATER CONTENT; CRYOGENIC EDEMA; DOG; GLYCEROL; NORMAL BRAIN; TRAUMATIC EDEMA	INTRA-CRANICAL HYPERTENSION; INTRAVENOUS GLYCEROL; CEREBRAL EDEMA; DOUBLE-BLIND; ACUTE STROKE; RANDOMIZED TRIAL; ORAL GLYCEROL; WATER-CONTENT; INFUSION; PRESSURE	1. Although the effect of glycerol on reducing intracranial pressure has been widely investigated, only a few studies have reported its dehydrating effect on brain oedema caused by infarction, ischaemia, microembolism and cold injury, but none on traumatic oedema. In this study the effects of glycerol (1 g/kg, i.v. bolus infusion at a rate of 0.04 g/kg per min) on traumatic and cryogenic cerebral oedema and on normal brain were compared in the anaesthetized dog. The tissue water content was measured with the gravimetric method. 2. Oedema resulting from mechanical trauma was initiated 4 h prior to treatment with glycerol (8 dogs) or vehicle (5 dogs) by closed head contusion with fixed force under general anaesthesia. Tissue samples underneath the region of contusion were taken, before and 1 h after infusion of glycerol or vehicle, for the measurement of water content. 3. Glycerol infusion decreased the water content in white matter of the traumatic brain model from 76.54 +/- 1.70% to 70.73 +/- 1.54% (P<0.001). In normal brain the reduction was from 68.42 +/- 0.48% to 65.36 +/- 0.39% (P<0.001). Neither vehicle nor glycerol infusion resulted in significant changes in specific gravity of the gray matter. 4. Cryogenic oedema was initiated 3 h prior to the infusion of glycerol or vehicle by applying unilaterally a brass conical cup (bottom diameter 1 cm) filled with dry ice-acetone (-65 degrees C) to the exposed dura for 1 min. The contralateral hemisphere, which was not subjected to cold injury, was used for determination of water content of normal gray and white matter. 5. Glycerol infusion decreased the water content in the white matter of the cold-injured region from 75.38 +/- 0.69% to 72.57 +/- 0.58% (P<0.001). In the normal white matter the reduction was from 68.63 +/- 0.34% to 65.48 +/- 0.49% (P<0.001). 6. Our data indicate that glycerol decreases water content of the white matter in traumatic and cold-injured oedematous brain as well as in normal brain.	TRISERV GEN HOSP, DEPT SURG, DIV NEUROSURG, TAIPEI, TAIWAN	WANG, JY (corresponding author), NATL DEF MED CTR, DEPT PHYSIOL, POB 90048-503, 10713 TAIPEI, TAIWAN.						ABSOLON MJ, 1966, BRIT J OPHTHALMOL, V50, P683, DOI 10.1136/bjo.50.12.683; ARAKAWA M, 1977, FOLIA PHARMACOL JPN, V73, P541, DOI 10.1254/fpj.73.541; BAETHMAN A, 1978, NEUROSURG REV, V1, P85; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BAYER AJ, 1987, LANCET, V1, P405; BRALET J, 1983, STROKE, V14, P597, DOI 10.1161/01.STR.14.4.597; CASSEN B, 1960, AM J PHYSIOL, V198, P1296; CHEN JL, 1989, CLIN SCI, V77, P535, DOI 10.1042/cs0770535; DODSON RF, 1975, J NEUROL SCI, V26, P235, DOI 10.1016/0022-510X(75)90035-0; FRANK MSB, 1981, PHARMACOTHERAPY, V1, P147; FREI A, 1987, STROKE, V18, P373, DOI 10.1161/01.STR.18.2.373; GUISADO R, 1974, AM J PHYSIOL, V227, P865; GUISADO R, 1976, NEUROLOGY, V26, P69, DOI 10.1212/WNL.26.1.69; Kashiwagi F, 1990, Adv Neurol, V52, P541; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KUMANA CR, 1991, STROKE, V22, P1608, DOI 10.1161/str.22.12.1608a; KUMANA CR, 1990, BRIT J CLIN PHARMACO, V29, P347, DOI 10.1111/j.1365-2125.1990.tb03646.x; MACDONALD JT, 1982, NEUROLOGY, V32, P437, DOI 10.1212/WNL.32.4.437; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MEYER JS, 1975, CIRCULATION, V51, P701, DOI 10.1161/01.CIR.51.4.701; MEYER JS, 1971, LANCET, V2, P993; NAU R, 1992, EUR J CLIN PHARMACOL, V42, P181, DOI 10.1007/BF00278481; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; Node Y, 1990, Adv Neurol, V52, P359; Ohta K, 1990, Adv Neurol, V52, P275; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAKES PS, 1985, NIH PUBLICATION, V8523; PITLICK WH, 1982, CLIN PHARMACOL THER, V31, P466, DOI 10.1038/clpt.1982.61; QUADBECK G, 1955, Z NATURFORSCH PT B, V10, P168, DOI 10.1515/znb-1955-0310; REINGLASS JL, 1974, NEUROLOGY, V24, P743, DOI 10.1212/WNL.24.8.743; RINDER L, 1968, ACTA NEUROPATHOL, V11, P201; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; ROTTENBERG DA, 1977, NEUROLOGY, V27, P600, DOI 10.1212/WNL.27.7.600; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; Suga S, 1990, Adv Neurol, V52, P185; Tornheim P A, 1976, Surg Neurol, V5, P171; TORNHEIM PA, 1981, J NEUROSURG, V55, P407, DOI 10.3171/jns.1981.55.3.0407; TSUBOKAWA T, 1989, Neurological Research, V11, P249; WALD SL, 1982, J NEUROSURG, V56, P323, DOI 10.3171/jns.1982.56.3.0323; WATERHOUSE JM, 1970, J NEUROL SCI, V10, P305, DOI 10.1016/0022-510X(70)90157-7; WOSTER PS, 1990, CLIN PHARMACY, V9, P762; YU YL, 1992, STROKE, V23, P967, DOI 10.1161/01.STR.23.7.967	43	29	30	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1440-1681			CLIN EXP PHARMACOL P	Clin. Exp. Pharmacol. Physiol.	APR	1994	21	4					263	270		10.1111/j.1440-1681.1994.tb02511.x			8	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	NU288	WOS:A1994NU28800001	7923891				2021-06-18	
J	BERNARD, LC; MCGRATH, MJ; HOUSTON, W				BERNARD, LC; MCGRATH, MJ; HOUSTON, W			DISCRIMINATING BETWEEN SIMULATED MALINGERING AND CLOSED-HEAD INJURY ON THE WECHSLER-MEMORY-SCALE-REVISED	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							DEFICITS; PROSPECTS	We tested the hypothesis that malingering is distinguished by poorer performance on recognition relative to recall tasks by evaluating the ability of discriminant functions to distinguish between 89 subjects simulating malingering and 44 subjects with a history of closed head injury (CHI) on the Wechsler Memory Scale Revised (WMS-R). Functions with good accuracy in discriminating between simulated malingerers and controls in prior studies did not have adequate specificity when applied to the CHI group. A newly derived discriminant function achieved overall classification accuracy of 79% for the malingering versus CHI groups on cross-validation, with 79% sensitivity (true positives for malingering) and 80% specificity (true negatives for closed head injured). A complex performance pattern on seven WMS-R subtests distinguished malingering subjects from those with CHI, but did not support the recognition versus recall hypothesis. The malingering pattern involved. (a) poorer performance on two relatively (but inconspicuously) easy tasks dependent on immediate recall (Visual Reproduction I and Visual Memory Span); (b) better performance on two relatively (but inconspicuously) easy tasks dependent on immediate recall (Visual Paired Associates I and Digit Span); (c) poorer performance an two relatively difficult delayed tasks (Logical Memory II and Visual Paired Associates II); and (d) better performance on another difficult task involving delayed recall (Visual Reproduction II).	ROYAL C JOHNSON VET MEM HOSP,SIOUX FALLS,SD	BERNARD, LC (corresponding author), LOYOLA MARYMOUNT UNIV,DEPT PSYCHOL,7101 W 80TH ST,LOS ANGELES,CA 90045, USA.						BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; BRANDT J, 1985, ANN NY ACAD SCI, V444, P502, DOI 10.1111/j.1749-6632.1985.tb37625.x; Haughton P M, 1979, Br J Audiol, V13, P135, DOI 10.3109/03005367909078888; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Klecka WR, 1980, DISCRIMINANT ANAL; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LORING DW, 1989, CLIN NEUROPSYCHOL, V3, P59, DOI DOI 10.1080/13854048908404077; OBERG RGE, 1985, ENV HLTH SERIES; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1979, J CONSULT CLIN PSYCH, V47, P409, DOI 10.1037/0022-006X.47.2.409; PANKRATZ L, 1987, ARCH NEUROL-CHICAGO, V44, P798, DOI 10.1001/archneur.1987.00520200006007; Pankratz L., 1990, CLIN NEUROPSYCHOL, V4, P379; Piotrowski C., 1989, HEALTH PSYCHOL, V11, P1; Reitan R., 1985, NEUROANATOMY NEUROPA; Reitan RM, 1988, TRAUMATIC BRAIN INJU, VII; ROGERS R, 1988, CLIN ASSESSMENT MALI, P293; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; Tabachnick B.G., 1989, USING MULTIVARIATE S; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wolfson D., 1993, HALSTEAD REITAN NEUR	21	29	29	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV-DEC	1993	8	6					539	551		10.1016/0887-6177(93)90054-5			13	Psychology, Clinical; Psychology	Psychology	MN089	WOS:A1993MN08900008	14591993				2021-06-18	
J	SHIBATA, M; EINHAUS, S; SCHWEITZER, JB; ZUCKERMAN, S; LEFFLER, CW				SHIBATA, M; EINHAUS, S; SCHWEITZER, JB; ZUCKERMAN, S; LEFFLER, CW			CEREBRAL BLOOD-FLOW DECREASED BY ADRENERGIC-STIMULATION OF CEREBRAL VESSELS IN ANESTHETIZED NEWBORN PIGS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article						FLUID-PERCUSSION BRAIN INJURY; CEREBRAL BLOOD FLOW; SYMPATHETIC NERVOUS SYSTEM; NEWBORN PIG	SHAKEN BABY SYNDROME; HEAD-INJURY; PIAL-ARTERIES; METABOLISM; RELEASE; DAMAGE; NOREPINEPHRINE; NORADRENALINE; RECOVERY; CORTEX	Changes in cerebral blood flow (CBF), pial arteriolar diameter, and arterial blood pressure, gases, and pH were examined before and for 3 hours after fluid-percussion brain injury in a-chloralose-anesthetized piglets. The brain injury was induced by a percussion of 2.28 +/- 0.06 atm applied for 23.7 +/- 0.5 msec to the right parietal cortex. Regional CBF was measured with radiolabeled microspheres, and changes in pial arteriolar diameter were monitored in the left parietal cortex using closed cranial windows. Immediately following brain injury, mean blood pressure transiently (for approximately 10 minutes) either increased or decreased and then exhibited a prolonged decrease in all of the animals. The brains showed changes consistent with traumatic brain injury such as subarachnoid hemorrhage, contusions, or reactive axonal swelling; none showed histological evidence of a global alternative pathogenetic mechanism such as hypoxic ischemic damage. While CBF of uninjured control animals did not change over a 3-hour observation period, after brain injury blood flow decreased 30% +/- 1% below the baseline level within 10 minutes and remained there for 2 to 3 hours posttrauma. After adrenergic blockade, CBF did not decrease at any time during the 3-hour period in either the uninjured control or the injured animals. Concomitant with the decreased blood flow after brain injury, pial arteriolar diameter decreased 14% below the preinjury level. However, in piglets treated with adrenoceptor antagonists, uninjured control and brain-injured animals did not show a decrease in pial arteriolar diameter. The present results support the hypothesis that increased sympathetic outflow to the cephalic vasculature following the fluid-percussion brain injury causes cerebral vasoconstriction decreasing pial arteriolar diameter and regional CBF.	UNIV TENNESSEE CTR HLTH SCI, DEPT NEUROSURG, MEMPHIS, TN 38163 USA; ST JUDE CHILDRENS RES HOSP, DIV CRIT CARE MED, MEMPHIS, TN USA	SHIBATA, M (corresponding author), UNIV TENNESSEE CTR HLTH SCI, BRAIN INJURY RES CTR, DEPT PHYSIOL & BIOPHYS, MEMPHIS, TN 38163 USA.				NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL34059, HL42851, HL42875] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL034059, R01HL042875, R37HL042851, R29HL042875, R01HL042851] Funding Source: NIH RePORTER		ARAKI T, 1989, ACTA NEUROL SCAND, V80, P451, DOI 10.1111/j.1600-0404.1989.tb03908.x; BIAGAS K V, 1992, Pediatric Research, V31, p27A; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BUSIJA DW, 1985, PEDIATR RES, V19, P1210, DOI 10.1203/00006450-198511000-00020; BUSIJA DW, 1987, DEV PHARMACOL THERAP, V10, P36, DOI 10.1159/000457726; CROCKARD HA, 1977, SURG NEUROL, V7, P281; CROWDER JM, 1987, EUR J PHARMACOL, V143, P343, DOI 10.1016/0014-2999(87)90458-4; DELANGEN CDJ, 1980, BRAIN RES, V185, P399; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FLETCHER AM, 1989, AM J VET RES, V50, P754; FRIEDMAN AH, 1980, BRAIN RES, V183, P89, DOI 10.1016/0006-8993(80)90121-3; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HARIK SI, 1981, J CEREBR BLOOD F MET, V1, P329, DOI 10.1038/jcbfm.1981.36; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; LAPTOOK AR, 1983, BRAIN RES, V276, P51, DOI 10.1016/0006-8993(83)90547-4; LEFFLER CW, 1985, PEDIATR RES, V19, P1160, DOI 10.1203/00006450-198511000-00009; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; LYNCH MA, 1986, NEUROPHARMACOLOGY, V25, P493, DOI 10.1016/0028-3908(86)90173-5; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MEYER JS, 1973, BRAIN, V96, P277, DOI 10.1093/brain/96.2.277; MILLEN JE, 1980, J APPL PHYSIOL, V49, P856; MILLEN JE, 1983, J APPL PHYSIOL, V54, P666; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROSNER MJ, 1985, CENTRAL NERVOUS SYST, P405; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; WAGERLE LC, 1985, FED PROC, V44, P1008; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YONAS H, 1989, NEUROSURGERY, V24, P368, DOI 10.1227/00006123-198903000-00010	46	29	29	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	1993	79	5					696	704		10.3171/jns.1993.79.5.0696			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	MD733	WOS:A1993MD73300008	8105043				2021-06-18	
J	GUTLING, E; GONSER, A; REGARD, M; GLINZ, W; LANDIS, T				GUTLING, E; GONSER, A; REGARD, M; GLINZ, W; LANDIS, T			DISSOCIATION OF FRONTAL AND PARIETAL COMPONENTS OF SOMATOSENSORY-EVOKED POTENTIALS IN SEVERE HEAD-INJURY	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article						SOMATOSENSORY EVOKED POTENTIALS; SEVERE HEAD INJURY; GLASGOW OUTCOME SCALE; FRONTAL SEP COMPONENTS	OUTCOME PREDICTION; BRAIN-FUNCTION; FINGER STIMULATION; COMATOSE PATIENTS; CONDUCTION TIME; TRAUMA; N20; P22; RESPONSES; LESIONS	Reports on the topography of SEPs in non-comatose patients have drawn attention to a second thalamo-cortical loop connecting the thalamus with the frontal cortex, which has a close anatomical relation to the fronto-limbic structures frequently damaged in severe head injury (SHI). We studied whether the frontal component (P20/22) of the somatosensory evoked response (SEP), known to be due to a generator different from that of the traditionally analysed parietal SEP component (N20), would be differently affected by SHI. Moreover, we examined whether its analysis would improve the prognostic evaluation in the Glasgow outcome scale (GOS) after 3-6 months. In 50 patients examined within 72 h after the injury we found a dissociated impairment of frontal and parietal components in 24% of the recorded SEPs. When both frontal and parietal components were used as predictors, discriminant analysis correctly classified 94% of the patients into good (GOS good recovery and moderate disability) or poor (GOS severe disability, persistent vegetative state or death) outcome groups. Classification was less accurate and misclassifications grosser when considering parietal or frontal parameters alone. Our results show that (i) the evaluation of frontal components provides information different from that of the parietal SEPs, confirming the presence of different generators, and (ii) a combined analysis of the two components improves the prognostic evaluation with regard to the global outcome.	UNIV HOSP ZURICH,DEPT NEUROL,CH-8091 ZURICH,SWITZERLAND; UNIV HOSP ZURICH,DEPT SURG,CH-8091 ZURICH,SWITZERLAND							AHMED I, 1988, CLIN ELECTROENCEPHAL, V19, P78, DOI 10.1177/155005948801900209; ALLISON T, 1980, PROGR CLIN NEUROPHYS, V7, P51; ALLISON T, 1982, ANN NY ACAD SCI, V338, P671; BROUGHTON RJ, 1969, NASA SP191, P79; CHERON G, 1987, ELECTROEN CLIN NEURO, V67, P537, DOI 10.1016/0013-4694(87)90056-3; COHEN LG, 1985, NEUROLOGY, V35, P691, DOI 10.1212/WNL.35.5.691; DEIBER MP, 1986, ELECTROEN CLIN NEURO, V65, P321, DOI 10.1016/0168-5597(86)90012-2; DESMEDT JE, 1981, ELECTROEN CLIN NEURO, V52, P553, DOI 10.1016/0013-4694(81)91430-9; DESMEDT JE, 1987, ELECTROEN CLIN NEURO, V68, P1, DOI 10.1016/0168-5597(87)90065-7; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GREENBERG RP, 1982, ANN NY ACAD SCI, V388, P683, DOI 10.1111/j.1749-6632.1982.tb50835.x; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HUME AL, 1979, ANN NEUROL, V5, P379, DOI 10.1002/ana.410050412; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1984, CLOSED HEAD INJURY P, P37; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; MAUGUIERE F, 1983, BRAIN, V106, P271, DOI 10.1093/brain/106.2.271; MAUGUIERE F, 1991, ANN NEUROL, V30, P71, DOI 10.1002/ana.410300113; MAUGUIERE F, 1989, ANN NEUROL, V26, P724, DOI 10.1002/ana.410260607; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NOGUEIRA MC, 1989, NEUROLOGY, V39, P1210, DOI 10.1212/WNL.39.9.1210; PAPAKOSTOPOULOS D, 1980, PROGR CLIN NEUROPHYS, V7, P15; RIFFEL B, 1987, EEG-EMG-Z ELEK ELEKT, V18, P192; ROSSINI PM, 1989, ELECTROEN CLIN NEURO, V74, P277, DOI 10.1016/0168-5597(89)90058-0; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; Urasaki E, 1986, No To Shinkei, V38, P973; VANDESTEEN A, 1991, NEUROLOGY, V41, P913, DOI 10.1212/WNL.41.6.913; WALSER H, 1986, J NEUROL, V233, P34, DOI 10.1007/BF00313989	30	29	29	0	3	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.	SEP-OCT	1993	88	5					369	376		10.1016/0168-5597(93)90013-F			8	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	MC725	WOS:A1993MC72500003	7691561				2021-06-18	
J	SILVERMAN, IE; GALETTA, SL; GRAY, LG; MOSTER, M; ATLAS, SW; MAURER, AH; ALAVI, A				SILVERMAN, IE; GALETTA, SL; GRAY, LG; MOSTER, M; ATLAS, SW; MAURER, AH; ALAVI, A			SPECT IN PATIENTS WITH CORTICAL VISUAL-LOSS	JOURNAL OF NUCLEAR MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; CEREBRAL METABOLISM; ALZHEIMERS-DISEASE; STATUS EPILEPTICUS; STIMULATION; CORTEX; SYSTEM	Single-photon emission computed tomography (SPECT) with Tc-99m-hexamethyl propyleneamine oxime (HMPAO) was used to investigate changes in cerebral blood flow in seven patients with cortical visual impairment. Traumatic brain injury (TBI) was the cause of cortical damage in two patients, cerebral ischemia in two patients and carbon monoxide (CO) poisoning, status epilepticus and Alzheimer's Disease (AD) each in three separate patients. The SPECT scans of the seven patients were compared to T2-weighted magnetic resonance image (MRI) scans of the brain to determine the correlation between functional and anatomical findings. In six of the seven patients, the qualitative interpretation of the SPECT studies supported the clinical findings (i.e., the visual field defect) by revealing altered regional cerebral blood flow (rCBF) in the appropriate regions of the visual pathway. MR scans in all of the patients, on the other hand, were either normal or disclosed smaller lesions than those detected by SPECT. We conclude that SPECT may reveal altered rCBF in patients with cortical visual impairment of various etiologies, even when MRI studies are normal or nondiagnostic.	TEMPLE UNIV, DEPT NEUROL & NUCL MED, PHILADELPHIA, PA 19122 USA; UNIV PENN, DEPT NEUROL, DIV NEURORADIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT RADIOL, DIV NUCL MED, PHILADELPHIA, PA 19104 USA					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T35HD007217] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T35-HD-07217-11] Funding Source: Medline		Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; ALAVI A, 1991, SEMIN NUCL MED, V21, P58, DOI 10.1016/S0001-2998(05)80079-0; BAUER J, 1989, J NEUROL, V236, P296, DOI 10.1007/BF00314460; BOSLEY TM, 1985, NEUROLOGY, V35, P470, DOI 10.1212/WNL.35.4.470; BRYAN RN, 1991, MAGNETIC RESONANCE I, P411; CELESIA GG, 1991, NEUROLOGY, V41, P862, DOI 10.1212/WNL.41.6.862; FUJIWARA T, 1991, EPILEPSIA, V32, P650, DOI 10.1111/j.1528-1157.1991.tb04704.x; GENTRY LR, 1991, MAGNETIC RESONANCE I, P439; HOLMAN BL, 1992, J NUCL MED, V33, P181; JIBIKI I, 1991, EUR NEUROL, V31, P149, DOI 10.1159/000116665; KIYOSAWA M, 1989, OPHTHALMOLOGY, V96, P1077; KUMAR A, 1991, INT J GERIATR PSYCH, V6, P775, DOI 10.1002/gps.930061104; KUSHNER MJ, 1988, NEUROLOGY, V38, P89, DOI 10.1212/WNL.38.1.89; Kuwabara Y, 1990, Ann Nucl Med, V4, P75; PHELPS ME, 1981, NEUROLOGY, V31, P517, DOI 10.1212/WNL.31.5.517; STECKER MM, 1992, J NUCL MED, V35, P928; WOODS SW, 1991, J NUCL MED, V32, P210	17	29	29	0	1	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	SEP	1993	34	9					1447	1451					5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	LU701	WOS:A1993LU70100016	8355062				2021-06-18	
J	JAFFE, KM; MASSAGLI, TL; MARTIN, KM; RIVARA, JMB; FAY, GC; POLISSAR, NL				JAFFE, KM; MASSAGLI, TL; MARTIN, KM; RIVARA, JMB; FAY, GC; POLISSAR, NL			PEDIATRIC TRAUMATIC BRAIN INJURY - ACUTE AND REHABILITATION COSTS	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						ECONOMIC COSTS; PEDIATRIC TRAUMATIC BRAIN INJURY	HEAD		SEATTLE UNIV,SCH NURSING,SEATTLE,WA; UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,SEATTLE,WA 98195	JAFFE, KM (corresponding author), CHILDRENS HOSP & MED CTR,POB 5371,4800 SAND POINT WAY NE,SEATTLE,WA 98105, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49-CCR002299] Funding Source: Medline		ANDERSON DW, 1980, J NEUROSURG, V53, pS11; BENNETT BR, 1989, J TRAUMA, V29, P556, DOI 10.1097/00005373-198905000-00003; Conover W.J., 1980, PRACTICAL NONPARAMET; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KRAUS JF, 1987, PEDIATRICS, V79, P501; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MACKENZIE EJ, 1988, JAMA-J AM MED ASSOC, V260, P3290, DOI 10.1001/jama.260.22.3290; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; Rice D P, 1985, Health Care Financ Rev, V7, P61; RIVARA FP, 1988, JAMA-J AM MED ASSOC, V260, P221; Rivara Frederick P., 1986, J HEAD TRAUMA REHAB, V1, P7; SAYWELL RM, 1989, J AM GERIATR SOC, V37, P625, DOI 10.1111/j.1532-5415.1989.tb01253.x; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; 1990, REPORT TASK FORCE ME; 1985, ABBREVIATED INJURY S	18	29	29	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	1993	74	7					681	686		10.1016/0003-9993(93)90024-5			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	LM079	WOS:A1993LM07900001	8328886				2021-06-18	
J	SHARMA, HS; NYBERG, F; THORNWALL, M; OLSSON, Y				SHARMA, HS; NYBERG, F; THORNWALL, M; OLSSON, Y			MET-ENKEPHALIN-ARG(6)-PHE(7) IN SPINAL-CORD AND BRAIN FOLLOWING TRAUMATIC INJURY TO THE SPINAL-CORD - INFLUENCE OF P-CHLOROPHENYLALANINE - AN EXPERIMENTAL-STUDY IN THE RAT USING RADIOIMMUNOASSAY TECHNIQUE	NEUROPHARMACOLOGY			English	Article						MET-ENKEPHALIN-ARG(6)-PHE(7); OPIOID PEPTIDES; SEROTONIN; SPINAL CORD TRAUMA; P-CHLOROPHENYL-ALANINE (P-CPA); BRAIN	HUMAN CEREBROSPINAL-FLUID; MET-ENKEPHALIN-LIKE; OPIOID-PEPTIDES; SUBSTANCE-P; EDEMA; IMMUNOREACTIVITY; PROENKEPHALIN; SEROTONIN; NEURONS; TISSUES	The possibility that trauma to the dorsal horn may affect the release and distribution of enkephalin was examined using the opioid peptide Met-Enk-Arg6-Phe7 (MEAP) as a marker in a rat model. The peptide content of samples of spinal cord and whole brain was measured using a radioimmunoassay (RIA) technique. In addition, the possible functional relation between this peptide and serotonin was evaluated using a pharmacological approach that included depletion of endogenous serotonin. A focal trauma to the fight dorsal horn in the T10-11 segments (2 mm deep and 5 mm long) markedly modified the content of MEAP of the adjacent rostral and caudal segments of the cord, as well as the content of MEAP of the brain. Depletion of serotonin with p-CPA (an inhibitor of the synthesis of serotonin) significantly elevated the content of MEAP in the whole brain without affecting the regions of the spinal cord (except T9 level which showed a 25% decrease from an intact control group). Trauma to the spinal cord in the serotonin-depleted animals did not alter the content of MEAP further, as compared to a p-CPA-treated but untraumatized group. These results indicate that enkephalin (i) participates in the pathophysiology of spinal cord trauma and (ii) suggest that the peptide is somehow functionally related with serotonin.	UNIV UPPSALA, CTR BIOMED, DEPT PHARMACOL, S-75123 UPPSALA, SWEDEN	SHARMA, HS (corresponding author), UNIV HOSP UPPSALA, NEUROPATHOL LAB, S-75185 UPPSALA, SWEDEN.		Sharma, Aruna/D-4430-2011				BASBAUM AI, 1988, SOMATOSENS MOT RES, V5, P177, DOI 10.3109/07367228809144625; BOARDER MR, 1982, J NEUROCHEM, V38, P299, DOI 10.1111/j.1471-4159.1982.tb08629.x; CHRISTENSSONNYLANDER I, 1985, REGUL PEPTIDES, V11, P65, DOI 10.1016/0167-0115(85)90032-1; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; Gibson S. J., 1986, IMMUNOCYTOCHEMISTRY, P360; GIRAUD P, 1983, J NEUROCHEM, V41, P154, DOI 10.1111/j.1471-4159.1983.tb11827.x; GUBLER U, 1982, NATURE, V295, P206, DOI 10.1038/295206a0; HOGAN EL, 1985, HDB NEUROCHEMISTRY, V10, P285; HOKFELT T, 1979, NEUROSCI LETT, V14, P55, DOI 10.1016/0304-3940(79)95343-6; HOKFELT T, 1987, PSYCHOPHARMACOLOGY 3, P401; HOKFELT T, 1978, PSYCHOPHARMACOLOGY G, P39; Hunt S. P., 1983, CHEM NEUROANATOMY, P53; JACOBS BL, 1992, PHYSIOL REV, V72, P165; Johansson O, 1978, Adv Biochem Psychopharmacol, V18, P51; KOJIMA K, 1982, ARCH BIOCHEM BIOPHYS, V215, P638, DOI 10.1016/0003-9861(82)90125-4; Lee S, 1990, J Neural Transm Suppl, V30, P45; MORLEY JE, 1985, HDB NEUROCHEM, V8, P43; NYBERG F, 1986, J CHROMATOGR, V359, P541, DOI 10.1016/0021-9673(86)80105-4; NYBERG F, 1990, PROG CLIN BIOL RES, V328, P261; Nyberg F, 1988, BASIC MECHANISMS HEA, P241; OLSON GA, 1991, PEPTIDES, V12, P1407, DOI 10.1016/0196-9781(91)90227-G; OLSSON Y, 1990, ACTA NEUROPATHOL, V79, P595, DOI 10.1007/BF00294236; OLSSON Y, 1992, PROG BRAIN RES, V91, P197; Petrusz P., 1985, Handbook of Chemical Neuroanatomy, V4, P273; RUZICKA BB, 1990, BRAIN RES, V536, P227, DOI 10.1016/0006-8993(90)90029-B; SHARMA HS, 1990, NEUROSCIENCE, V38, P205, DOI 10.1016/0306-4522(90)90386-I; SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U; SHARMA HS, 1990, ACTA NEUROPATHOL, V80, P12, DOI 10.1007/BF00294216; SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D; SHARMA HS, 1992, NEUROSCI RES, V14, P195; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; TANG J, 1982, NEUROPHARMACOLOGY, V21, P595, DOI 10.1016/0028-3908(82)90054-5; TASHIRO T, 1989, BRAIN RES, V491, P360, DOI 10.1016/0006-8993(89)90071-1; TERENIUS L, 1988, INT REV NEUROBIOL, V30, P101; WILLIAMS RG, 1982, BRAIN RES, V240, P167, DOI 10.1016/0006-8993(82)90657-6	35	29	29	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	JUL	1993	32	7					711	717		10.1016/0028-3908(93)90085-H			7	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	LK305	WOS:A1993LK30500012	8361583				2021-06-18	
J	MOORE, A; STAMBROOK, M; PETERS, L				MOORE, A; STAMBROOK, M; PETERS, L			CENTRIPETAL AND CENTRIFUGAL FAMILY-LIFE CYCLE FACTORS IN LONG-TERM OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; QUALITY; PREDICTORS; ADJUSTMENT; SCALE	The family life cycle model categorizes stresses on family systems in terms of their source and their effects on family members. Centripetal forces bring members together while centrifugal forces lead to loosened intrafamilial ties. This study examined the association of normative, developmental and centripetal illness-related family forces with patient outcome. Hypothesized centripetal and centrifugal forces acting on 65 families of married male TBI patients were used as independent variables in stepwise multiple regressions with criterion measures of quality of life outcome used as dependent measures. Centripetal variables included measures of family coping, marital adjustment, and number of years married. Centrifugal variables included number of children, age of oldest child, and amount of perceived financial strain. Regression equations obtained had multiple R's ranging from 0.623 to 0.407 (p values <0.017). Results suggest that families normatively dealing with the developmental stage of the family with young children may face unique challenges when a husband sustains a TBI, particularly when financial strain exists. Stages in family development involving conflict between centripetal and centrifugal forces may be most problematic for families to resolve, and potentially the most effective periods for intervention.	UNIV MANITOBA,DEPT PSYCHOL,WINNIPEG R3A 1R9,MB,CANADA; UNIV MANITOBA,HLTH SCI CLIN RES CTR,DEPT PSYCHIAT,NEUROPSYCHOL RES UNIT,WINNIPEG R3A 1R9,MB,CANADA; UNIV MANITOBA,SOC MANITOBANS DISABILITIES,DEPT PSYCHIAT,WINNIPEG R3A 1R9,MB,CANADA; UNIV MANITOBA,SOC MANITOBANS DISABILITIES,DEPT MED,WINNIPEG R3A 1R9,MB,CANADA; UNIV MANITOBA,SOC MANITOBANS DISABILITIES,DEPT PSYCHOL,WINNIPEG R3A 1R9,MB,CANADA							BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BERROL S, 1989, MILD MODERATE HEAD I, P135; Carter B., 1989, CHANGING FAMILY LIFE; COMBRINCKGRAHAM L, 1985, FAM PROCESS, V24, P139, DOI 10.1111/j.1545-5300.1985.00139.x; FRANK R G, 1990, Brain Injury, V4, P289, DOI 10.3109/02699059009026179; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; KASSUM DA, 1984, CAN J SURG, V27, P64; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MCCUBBIN HE, 1985, FAMILY CRISIS ORIENT; McGoldrick, 1980, FAMILY LIFE CYCLE FR; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McNair DM, 1971, EITS MANUAL PROFILE; Miller WG, 1986, NEUROPSYCHOLOGY HDB, P347; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; Rolland J. S., 1989, CHANGING FAMILY LIFE, P433; Spanbock P., 1987, COGNITIVE REHABILITA, V5, P12; SPANIER GB, 1976, J MARRIAGE FAM, V38, P15, DOI 10.2307/350547; STAMBROOK M, 1990, CAN J SURG, V33, P115; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; STAMBROOK M, 1989, CANADIAN J REHABILIT, V3, P87; STAMBROOK M, UNPUB BRAIN INJURY R; TEASDALE G, 1974, LANCET, V2, P81	26	29	29	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1993	7	3					247	255		10.3109/02699059309029677			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	MA170	WOS:A1993MA17000006	8508181				2021-06-18	
J	VINK, R				VINK, R			NUCLEAR-MAGNETIC-RESONANCE CHARACTERIZATION OF SECONDARY MECHANISMS FOLLOWING TRAUMATIC BRAIN INJURY	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						MAGNESIUM; EXCITATORY AMINO ACIDS; GLUTAMATE; BIOENERGETICS	INTRACELLULAR FREE MAGNESIUM; ENERGY PHOSPHATE-METABOLISM; PHOSPHOLIPASE-C ACTIVITY; FLUID-PERCUSSION MODEL; P-31 NMR-SPECTROSCOPY; AMINO-ACID RECEPTORS; FREE MG-2+; CENTRAL NEURONS; SPINAL-CORD; RATS	Much of the injury that occurs following a traumatic insult to the central nervous system is the result of physiological and biochemical processes initiated by the primary traumatic event. These processes occur over a period of hours to days following the insult, and although a number of factors have been identified as being associated with this secondary injury process, their role and interrelationship with one another is unclear. Nuclear magnetic resonance spectroscopy has been utilized to characterize many of these secondary factors and their relationship to eventual neurological outcome. In particular, the role of high energy phosphates, pH, lactic acid, excitatory amino acids, and magnesium has been investigated, along with pharmacotherapies directed toward altering the status of these factors following traumatic injury. This review critically examines the role that each of these factors may play in the secondary injury process, and proposes a scheme which theoretically accounts for the interrelationships among the various factors.		VINK, R (corresponding author), JAMES COOK UNIV N QUEENSLAND, DEPT CHEM & BIOCHEM, TOWNSVILLE, QLD 4811, AUSTRALIA.		Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667			ALTURA B M, 1985, Magnesium, V4, P245; ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; ALVAREZLEEFMANS FJ, 1987, CAN J PHYSIOL PHARM, V65, P915, DOI 10.1139/y87-147; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; Bara M, 1984, MAGNESIUM, V3, P212; BYGRAVE FL, 1978, BIOL REV, V53, P43, DOI 10.1111/j.1469-185X.1978.tb00992.x; Cavaliere F, 1985, Recenti Prog Med, V76, P563; CHAUDRY IH, 1986, MAGNESIUM, V5, P211; CHAUDRY IH, 1983, AM J PHYSIOL, V245, pR117; CHOI DW, 1987, J NEUROSCI, V7, P369; COHEN Y, 1991, MAGNET RESON MED, V17, P225, DOI 10.1002/mrm.1910170125; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; DIDYMAYFIELD JE, 1991, J NEUROCHEM, V56, P1536; DIXON CE, 1987, J NEUROSURG, V65, P615; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; EDGAR AD, 1982, J NEUROCHEM, V39, P1111, DOI 10.1111/j.1471-4159.1982.tb11503.x; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P608; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FLINK EB, 1986, ALCOHOL CLIN EXP RES, V10, P590, DOI 10.1111/j.1530-0277.1986.tb05150.x; GARFINKEL L, 1984, BIOCHEMISTRY-US, V23, P3547, DOI 10.1021/bi00310a025; GILL R, 1988, NEUROSCIENCE, V25, P847, DOI 10.1016/0306-4522(88)90040-1; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Henneberry R C, 1989, Prog Clin Biol Res, V317, P143; HOEK JB, 1992, FASEB J, V6, P2386; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P173; KIRKELS JH, 1989, J MOL CELL CARDIOL, V21, P1209, DOI 10.1016/0022-2828(89)90697-4; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LEMKE M, 1990, MOL CHEM NEUROPATHOL, V12, P147, DOI 10.1007/BF03159941; LEVY DI, 1990, NEUROSCI LETT, V110, P291, DOI 10.1016/0304-3940(90)90862-4; LONDON RE, 1991, ANNU REV PHYSIOL, V53, P251; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; McGuigan J.A.S., 1991, MG2 PLUS EXCITABLE M, P1; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MOSHER TJ, 1992, MAGNET RESON MED, V24, P163, DOI 10.1002/mrm.1910240117; NICOLL RA, 1990, PHYSIOL REV, V70, P513; NIGAM S, 1986, PROSTAG LEUKOTR ESS, V23, P1, DOI 10.1016/0262-1746(86)90070-3; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NORDSTROM CH, 1990, PROTECTION BRAIN ISC, P49; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PECASENS M, 1991, CURR ASP NEUROSCI, V3, P104; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SELECKI BR, 1981, INJURIES HEAD SPINE; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VINK R, 1991, AM J PHYSIOL, V261, pR1527; VINK R, 1989, BIOCHEM BIOPH RES CO, V165, P913, DOI 10.1016/S0006-291X(89)80053-1; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1990, J NEUROSCI, V10, P3524; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; VINK R, 1993, IN PRESS METABOLISM; VINK R, 1991, MG2PLUS EXCITABLE ME, P125; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087; YOUNG W, 1992, CENTRAL NERVOUS SYST, P9	76	29	29	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	APR	1993	18	3					279	297		10.1007/BF03160120			19	Neurosciences; Pathology	Neurosciences & Neurology; Pathology	KZ118	WOS:A1993KZ11800007	8507306				2021-06-18	
J	SCHMOKER, JD; SHACKFORD, SR; WALD, SL; PIETROPAOLI, JA				SCHMOKER, JD; SHACKFORD, SR; WALD, SL; PIETROPAOLI, JA			AN ANALYSIS OF THE RELATIONSHIP BETWEEN FLUID AND SODIUM ADMINISTRATION AND INTRACRANIAL-PRESSURE AFTER HEAD-INJURY	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	22ND ANNUAL MEETING OF THE WESTERN TRAUMA ASSOC	FEB 29-MAR 07, 1992	STEAMBOAT SPRINGS, CO	W TRAUMA ASSOC			BRAIN; TRAUMA; SYSTEM; CATECHOLAMINES; HYPONATREMIA; MANAGEMENT; EDEMA	Severe head injury is the leading cause of traumatic death. When a severe head injury is combined with hypotension the mortality doubles. The use of asanguineous salt solutions to maintain blood pressure, however, may contribute to cerebral swelling and intracranial hypertension. For this reason, restrictions of fluids (FLD) and sodium (Na) have been advocated. To our knowledge, however, there are no clinical data to support this recommendation. We hypothesized that in adult patients sustaining severe head injuries (Glasgow Coma Scale score less-than-or-equal-to 8) with or without associated injuries: (1) FLD balance and total Na administered during the initial 72 hours of hospital admission are positively and significantly correlated with each other, and (2) total FLD, FLD balance, and total Na administration during the initial 72 hours are significantly and positively correlated with changes in ICP and adverse outcome. We retrospectively studied 40 adult trauma patients with severe head injuries. We found a significant correlation between total Na and FLD balance (R2 = 0.54; p < 0.05). However, we found no significant correlation between total FLD and maximum ICP (R2 = 0.081), ICP score (R2 = 0.01), or outcome (R2 = 0.066), no significant correlation between FLD balance and maximum ICP (R2 = 0.000), ICP score (R2 = 0.000), or outcome (R2 = 0.01), and no significant correlation between total Na and maximum ICP (R2 = 0.000), ICP score (R 2 = 0.001), or outcome (R2 = 0.02). We conclude that Na and FLD administration are not independent determinants of ICP during the initial 72 hours after brain injury.	UNIV VERMONT,COLL MED,DEPT SURG,BURLINGTON,VT 05405; UNIV VERMONT,COLL MED,DIV NEUROSURG,BURLINGTON,VT 05405					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030324] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS30324-01] Funding Source: Medline		[Anonymous], 1990, ABBREVIATED INJURY S; BECKER DP, 1972, INTRACRANIAL PRESSUR, V1, P309; BIRKHAHN RH, 1980, SURGERY, V88, P294; BLAND JE, 1968, NEUROLOGY, V18, P821, DOI 10.1212/WNL.18.8.821; BOUZARTH WF, 1982, LANCET, V1, P1061; BOWERS SA, 1980, NEUROSURGERY, V6, P237; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CLIFTON GL, 1985, CENTRAL NERVOUS SYST, P139; EISENBERG H, 1983, INTRACRANIAL PRESSUR, P549; FEUSTEL PJ, 1990, J TRAUMA, V30, P1259, DOI 10.1097/00005373-199010000-00011; FOX JL, 1971, J NEUROSURG, V34, P506, DOI 10.3171/jns.1971.34.4.0506; GO KG, 1972, J NEUROL SCI, V16, P209, DOI 10.1016/0022-510X(72)90090-1; Go KG, 1991, CEREBRAL PATHOPHYSIO, P66; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; JENNETT B, 1972, LANCET, V1, P734; KIEN CL, 1978, ANN SURG, V187, P3837; KINNEY VM, 1966, P C ENERGY METABOLIS, P173; MCLAURIN RL, 1960, SURG GYNECOL OBSTET, V110, P282; MEYER WJ, 1983, SURG CLIN N AM, V63, P401; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Parent A D, 1972, J Neurosurg Nurs, V4, P9; REULEN HJ, 1976, BRIT J ANAESTH, V48, P741, DOI 10.1093/bja/48.8.741; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SCALEA T, 1991, J TRAUMA, V31, P1720; SCHMOKER J, 1991, Journal of Trauma, V31, P1038, DOI 10.1097/00005373-199107000-00091; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SHENKIN HA, 1976, J NEUROSURG, V45, P432, DOI 10.3171/jns.1976.45.4.0432; Shoemaker W C, 1974, Crit Care Med, V2, P317, DOI 10.1097/00003246-197411000-00006; SHOEMAKER WC, 1982, CRIT CARE MED, V10, P398, DOI 10.1097/00003246-198206000-00015; Starling E H, 1896, J Physiol, V19, P312; TEASDALE G, 1974, LANCET, V2, P81; WALD S, 1991, Journal of Trauma, V31, P1041, DOI 10.1097/00005373-199107000-00102; WILMORE DW, 1974, ANN SURG, V180, P653, DOI 10.1097/00000658-197410000-00031; ZHUANG J, 1991, J TRAUMA, V31, P1722	37	29	31	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	1992	33	3					476	481		10.1097/00005373-199209000-00024			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	JR171	WOS:A1992JR17100024	1404521				2021-06-18	
J	ZENTNER, J; ROHDE, V; FRIEDMAN, WA; DAUBE, JR				ZENTNER, J; ROHDE, V; FRIEDMAN, WA; DAUBE, JR			THE PROGNOSTIC VALUE OF SOMATOSENSORY AND MOTOR EVOKED-POTENTIALS IN COMATOSE PATIENTS	NEUROSURGERY			English	Article						COMA; MOTOR EVOKED POTENTIAL; SOMATOSENSORY EVOKED POTENTIAL	SEVERE HEAD-INJURY; MAGNETIC STIMULATION; CONDUCTION TIME; BRAIN; CORTEX	SOMATOSENSORY AND MOTOR evoked potentials (SEP and MEP) were examined in a total of 213 patients in traumatic (n = 140) and nontraumatic (n = 73) coma. It was the aim of this study to compare the prognostic value of MEP elicited by both electrical and magnetoelectric transcranial stimulation with the use of SEP alone. According to the presence or absence of responses and the duration of central conduction time, SEP and MEP obtained during Days 1 through 3 after the onset of coma were divided into four categories and correlated with the outcome of the patients, as assessed by the Glasgow Outcome Scale. Our results clearly show that in terms of prognostic value, SEP are superior to MEP, with normal findings indicating a favorable outcome and absent responses an unfavorable outcome. On the other hand, patients with normal electromyographic responses after both electrical and magnetoelectric stimulation had favorable and unfavorable outcomes about equally. Thus, unlike SEP, normal MEP do not allow any prognostic conclusions. Only the bilateral absence of MEP in response to electrical stimulation was a definitely unfavorable prognostic sign because all of these patients died. In contrast, with magnetoelectric stimulation, neither normal nor absent responses allowed any prognostic conclusions. Therefore, the prognostic value of electrically evoked motor responses is limited, and magnetoelectric stimulation cannot be recommended in this context.	UNIV TUBINGEN,SCH MED,DEPT MINERAL & PETROL,W-7400 TUBINGEN 1,GERMANY							BARKER AT, 1985, LANCET, V1, P1106; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; DAY BL, 1987, NEUROSCI LETT, V75, P101, DOI 10.1016/0304-3940(87)90083-8; GOODWIN SR, 1991, CRIT CARE MED, V19, P518, DOI 10.1097/00003246-199104000-00011; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HUME AL, 1979, ANN NEUROL, V5, P379, DOI 10.1002/ana.410050412; JENNETT B, 1975, LANCET, V1, P480; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; MERTON PA, 1980, NATURE, V285, P227, DOI 10.1038/285227a0; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OBESO J A, 1980, Electromyography and Clinical Neurophysiology, V20, P343; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; TEASDALE G, 1974, LANCET, V2, P81; WALSER H, 1985, ARCH NEUROL-CHICAGO, V42, P32, DOI 10.1001/archneur.1985.04060010038013; ZENTNER J, 1989, ADV NEUROSURG, V17, P287	15	29	30	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	SEP	1992	31	3					429	434		10.1227/00006123-199209000-00007			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	JN834	WOS:A1992JN83400007	1407425				2021-06-18	
J	KIRSCHNER, CE; GRANTZ, A; MULLEN, MW				KIRSCHNER, CE; GRANTZ, A; MULLEN, MW			IMPACT ORIGIN OF THE AVAK STRUCTURE, ARCTIC ALASKA, AND GENESIS OF THE BARROW GAS-FIELDS	AAPG BULLETIN-AMERICAN ASSOCIATION OF PETROLEUM GEOLOGISTS			English	Article								Geophysical and subsurface geologic data suggest that the Avak structure. which underlies the Arctic Costal Plain 12 km southeast of Barrow, Alaska, is a hypervelocity meteorite or comet impact structure. The structure is a roughly circular area of uplifted, chaotically deformed Upper Triassic to Lower Cretaceous sedimentary rocks 8 km in diameter that is bounded by a ring of anastomosing, inwardly dipping, listric normal faults 12 km in diameter. A zone of gently outward-dipping sedimentary country rocks forms a discontinuous ring of "rim anticlines" within the peripheral ring of normal faults. Beyond these anticlines, the sedimentary rocks are almost flat-living. Basement consists of strongly deformed ordovician and Silurian argillite. Density and acoustic impedance contrasts between the argillite and the overlying strata produce gravity and seismic-reflection signatures that define a ring of anticlines around the disturbed zone and a structural high surrounded by an annular structural low at its center. In the adjacent Barrow gas fields, the tops of the informally named Neocomian "pebble shale" unit and the gas-producing Lower Jurassic Barrow sand (local usage) lie at average subsea depths of 488 m and 670 m, respectively. In the Avak 1 well, drilled on the central high, the pebble shale and the Barrow sand lie near the surface, documenting more than 500 m of relative uplift at the high. The cores in this well have steep dips (30-90-degrees), mixed breccia with Franklinian argillite clasts 10 and 90 m above basement, quartz grains with shock mosaicism and multiple sets of shock lamellae, oriented concussion fractures in sand-size quartz grains, and shatter cones resembling those found in the peripheral zones of well-documented impact structures. In addition, above-background levels of fractured quartz grains in Barrow sand were found as far as 19 km beyond the rim of the Avak structure. Data concerning the age of the Avak structure are not definitive. If submarine landslide deposits in the upper part of the Aptian and Albian Torok Formation, in the subsurface 200 km to the east, were triggered by the Avak event, then the Avak meteorite struck a submerged marine shelf about 100 +/- 5 Ma. However, the impact features found at Avak (shatter cones, concussion fractures, shock lamellae and shock mosaicism in quartz grains, and widespread cataclasis) characterize, the distal zones of meteorite impact structures. Fused rocks, plastic deformation. and shock-metamorphic minerals found in more proximal zones of impact structures are apparently missing. These observations. and the lack of Avak ejecta in cuttings and cores from the Torok Formation and Nanushuk Group (Albian to middle Cenomanian) in surrounding test wells, indicate that the impact event postdated these beds. In this case, the Avak meteorite Struck a Late Cretaceous or Tertiary marine shelf or coastal plain between the Cenomanian (ca. 95 Ma), and deposition of the basal beds of the overlying late Pliocene and Quaternary Gubik Formation (ca. 3 Ma).	US GEOL SURVEY,MENLO PK,CA 94025	KIRSCHNER, CE (corresponding author), US GEOL SURVEY,POB 154,UNION,WA 98592, USA.						BRUYNZEEL JW, 1982, PETROLEUM EXPLORATIO; CARTER C, 1975, AAPG BULL, V59, P457; CARTER NL, 1965, AM J SCI, V263, P747, DOI 10.2475/ajs.263.9.747; Collins F. R., 1961, US GEOLOGICAL SURVEY, P569; COLLINS FR, 1967, USGS287 OP FIL REP; Dence MR, 1968, SHOCK METAMORPHISM N, P169; Dietz R. S., 1968, SHOCK METAMORPHISM N, P267; DIETZ RS, 1960, SCIENCE, V131, P1781, DOI 10.1126/science.131.3416.1781; DIETZ RS, 1947, SCIENCE, V105, P42, DOI 10.1126/science.105.2715.42; Eardley A. J., 1951, STRUCTURAL GEOLOGY N; Grantz A., 1990, ARCTIC OCEAN REGION, VL, P257; GUTMAN SI, 1982, GRAVITY MAGNETIC INV; IZETT GA, 1990, 249 GEOL SOC AM SP P; KIEFFER SW, 1971, J GEOPHYS RES, V76, P5449, DOI 10.1029/JB076i023p05449; KIRSCHNER CE, 1988, USGS1399 PROF PAP; KIRSCHNER CE, 1990, AAPG BULL, V74, P696; KIRSCHNER CE, 1983, USGS911 CIRC, P24; KIRSCHNER CE, 1984, GEOLOGICAL SOC AM, P293; LANTZ RJ, 1981, OIL GAS J, V79, P197; MICKEY MB, 1987, ALASKAN N SLOPE GEOL, V1, P397; MILTON DJ, 1972, SCIENCE, V175, P1199, DOI 10.1126/science.175.4027.1199; MOLENAAR CM, 1987, ALASKAN N SLOPE GEOL, V1, P513; MOLENAAR CM, 1981, USGS811084 OP FIL RE; PALMER AR, 1983, DECADE N AM GEOLOGY; ROCKWELL DW, 1981, USGS1408000116474 HU; Stoffler D., 1972, FORTSCHR MINERAL, V49, P50; THURSTON DK, 1991, GEOLOGY, V19, P477, DOI 10.1130/0091-7613(1991)019<0477:SEOEDI>2.3.CO;2; WEIMER P, 1987, ALASKAN N SLOPE GEOL, V1, P481; WILSHIRE HG, 1972, USGS599H PROF PAP; WILSON CW, 1968, TENNESSEE DIV GEOL B, V68; WOOLSON JR, 1962, USGS304A PROF PAP	31	29	29	0	4	AMER ASSOC PETROLEUM GEOLOGIST	TULSA	1444 S BOULDER AVE, PO BOX 979, TULSA, OK 74101	0149-1423			AAPG BULL	AAPG Bull.-Am. Assoc. Petr. Geol.	MAY	1992	76	5					651	679					29	Geosciences, Multidisciplinary	Geology	HR238	WOS:A1992HR23800005					2021-06-18	
J	CREMONAMETEYARD, SL; CLARK, CR; WRIGHT, MJ; GEFFEN, GM				CREMONAMETEYARD, SL; CLARK, CR; WRIGHT, MJ; GEFFEN, GM			COVERT ORIENTATION OF VISUAL-ATTENTION AFTER CLOSED HEAD-INJURY	NEUROPSYCHOLOGIA			English	Article								The ability to orient visual attention covertly was studied in 11 patients who had suffered a moderate or severe closed head injury (CHI) at least 1 year previously. Their performance was compared to nine matched controls using a cued reaction time (RT) task which measured the RT benefit of valid directional cueing and the RT cost of miscueing. The CHI and control groups did not differ in overall RT. Relative to controls, the CHI group showed normal cost but hardly any benefit, indicating that the normal capacity to pre-align attention with a cued location was impaired.	UNIV QUEENSLAND, DEPT PSYCHOL, COGNIT PSYCHOPHYSIOL LAB, ST LUCIA, QLD 4067, AUSTRALIA			Wright, Margaret J/H-3308-2014; clark, christopher richard/B-3525-2012; Wright, Margaret Jane/A-4560-2016	Wright, Margaret Jane/0000-0001-7133-4970			BROOKWS H, 1984, CLOSED HEAD INJURY P; CLARK CR, 1989, NEUROPSYCHOLOGIA, V27, P131, DOI 10.1016/0028-3932(89)90166-8; DFRIVER J, 1989, J EXP PSYCHOL HUMAN, V16, P448; ERIKSEN CW, 1987, PERCEPT PSYCHOPHYS, V42, P299, DOI 10.3758/BF03203082; GAZZANIGA MS, 1962, P NATL ACAD SCI USA, V48, P1765, DOI 10.1073/pnas.48.10.1765; GEFFEN GM, 1991, J CLIN EXP NEUROPSYC, V13, P423; KEPPEL S, 1982, DESIGN ANAL RES HDB; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MILLER E, 1969, CORTEX, V6, P132; MOUNTCASTLE VB, 1978, J ROY SOC MED, V71, P14; PETERSEN SE, 1985, J NEUROPHYSIOL, V54, P867; Posner M.I., 1975, INFORM PROCESSING CO, P55; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1982, MODES PERCEIVING PRO, V298, P197; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; SHUM DHK, 1988, J CLIN EXPT NEUROPSY, V12, P125; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Vogenthaler D R, 1987, Brain Inj, V1, P113; WRIGHT MJ, 1990, NEUROPSYCHOLOGIA, V28, P151, DOI 10.1016/0028-3932(90)90097-8; WURTZ RH, 1980, PROGR PSYCHOBIOLOGY, V9, P43	24	29	29	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	FEB	1992	30	2					123	132		10.1016/0028-3932(92)90022-E			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	HG882	WOS:A1992HG88200002	1560891				2021-06-18	
J	KRAUSS, GL; NIEDERMEYER, E				KRAUSS, GL; NIEDERMEYER, E			ELECTROENCEPHALOGRAM AND SEIZURES IN CHRONIC-ALCOHOLISM	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article						ALCOHOLISM; EEG; LOW VOLTAGE RECORDS; WITHDRAWAL (FROM ALCOHOL); EPILEPTIC SEIZURES; MAGNESIUM; CNS COMPLICATIONS (OF ALCOHOLISM)	EEG; ABUSE	CNS complications of chronic alcoholism are frequently difficult to assess due to the variety of direct and secondary conditions which can result from alcoholic drinking and lifestyles. The influence of alcoholism and alcohol-related factors on the EEG of patients with chronic alcoholism was studied in 213 patients (15.4% of all adults who had EEGs) using visual analysis. The influence of a variety of alcohol-related factors - drinking history, clinical complications, traumatic head injuries, head CT findings and laboratory results - on the EEG and alcohol-related seizures was studied. The effect of EEG results on the decision to treat alcohol-related seizures was also assessed. 152 of the patients had seizures, mostly (90% of those with defined seizure types) generalized tonic-clonic seizures. 53% of all seizures occurred in the early withdrawal period (8 h to 7 days abstinence). A history of partial seizures was significantly associated with findings of focal EEG abnormalities, a history of head injuries and structural lesions on CT. The clinical significance of these findings was unclear, however, as the majority of patients who had focal EEG abnormalities or structural brain lesions still appeared to have generalized withdrawal seizures. The EEG and CT appeared to be complementary tests: for most patients, focal abnormalities were demonstrated on only one of the two tests. The majority of patients (56%) with normal EEGs had predominantly low voltage recordings (< 25-mu-V), compared with 13.9% of 1167 patients without a history of alcoholism (P < 0.001). Other alcoholism-related factors, such as head injuries and structural abnormalities on CT and age, did not influence the occurrence of low voltage recordings. A slight increase in frequency of low voltage records occurred in patients with cortical atrophy identified on CT. These findings were verified in a smaller controlled, prospective study of 24 patients. Several other clinical findings in patients with alcohol-related seizures included hypoglycemia in two patients, and the finding of lower serum magnesium levels in patients with seizures (mean 1.36 +/- 0.04 mEq/l) compared with those who had delirium or other diagnosis (mean 1.6 +/- 0.10 mEq/l, P < 0.05). Hypomagnesemia did not appear to be a precipitating factor in the development of alcohol-related seizures, as patients in various stages of abstinence had similar magnesium levels. One-half of patients were treated chronically with anticonvulsants and only one maintained therapeutic drug levels and two had overdosages. A history of recurring seizures (and particularly of partial seizures) was a more important factor in the decision to treat with chronic anticonvulsant therapy than was the results of EEG. The finding of low voltage EEG is useful in detecting alcoholism, although this finding is not specific for alcoholism. The role of EEG in chronic alcoholism is more contributory to the clinical evaluation than it is widely assumed.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	KRAUSS, GL (corresponding author), JOHNS HOPKINS UNIV HOSP,DEPT NEUROL,600 N WOLFE ST,BALTIMORE,MD 21205, USA.						ARENTSEN K, 1963, ACTA PSYCHIAT SCAND, V39, P370; AVOLI M, 1987, BRAIN RES, V417, P199, DOI 10.1016/0006-8993(87)90201-0; Begleiter Henri, 1972, BIOL ALCOHOL, V2, P293; BICKFORD RG, 1952, ELECTROEN CLIN NEURO, V4, P275, DOI 10.1016/0013-4694(52)90052-7; CHAN AWK, 1985, EPILEPSIA, V26, P323, DOI 10.1111/j.1528-1157.1985.tb05658.x; CHARNESS ME, 1989, NEW ENGL J MED, V321, P442, DOI 10.1056/NEJM198908173210706; COGER RW, 1978, BIOL PSYCHIAT, V13, P729; Davis PA, 1941, Q J STUD ALCOHOL, V1, P626; DEISENHAMMER E, 1984, EPILEPSIA, V25, P526, DOI 10.1111/j.1528-1157.1984.tb03455.x; DREYFUS PM, 1961, AM J CLIN NUTR, V9, P414, DOI 10.1093/ajcn/9.4.414; EARNEST MP, 1988, NEUROLOGY, V38, P1561, DOI 10.1212/WNL.38.10.1561; EHLERS CL, 1989, NEUROPHYSIOL, V73, P179; ENGEL GL, 1945, ARCH NEURO PSYCHIATR, V53, P44, DOI 10.1001/archneurpsyc.1945.02300010054004; FEUSSNER JR, 1981, ANN INTERN MED, V494, P519; FISCH B, 1986, NEUROPHYSIOL, V64, P76; FOURNET A, 1956, Rev Neurol (Paris), V94, P644; FRANTZEN E, 1966, ACTA NEUROL SCAND, V42, P426; GERSON IM, 1979, CLIN ELECTROENCEPHAL, V10, P40, DOI 10.1177/155005947901000105; Giove G, 1965, Rev Neurol (Paris), V113, P347; Greenblatt M, 1944, ARCH NEURO PSYCHIATR, V52, P290, DOI 10.1001/archneurpsyc.1944.02290340037003; HAUSER WA, 1988, EPILEPSIA, V29, pS66, DOI 10.1111/j.1528-1157.1988.tb05800.x; HILLBOM ME, 1980, EPILEPSIA, V21, P459, DOI 10.1111/j.1528-1157.1980.tb04296.x; HUDOLIN V, 1967, BRIT J ADDICT, V62, P55; JOHANNESSON G, 1982, ACTA PSYCHIAT SCAND, V65, P148, DOI 10.1111/j.1600-0447.1982.tb00834.x; KELLEY JT, 1983, EEG EVOKED POTENTIAL; KOUFEN H, 1980, NERVENARZT, V51, P100; LITTLE SC, 1952, ELECTROEN CLIN NEURO, V4, P245; MAGNES J, 1961, NATURE SLEEP, P57; Magni F, 1959, ARCH ITAL BIOL, V97, P33; Mattson R.H., 1983, EPILEPSY DIAGNOSIS M, P325; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; NEWMAN SE, 1978, ANN NEUROL, V3, P299, DOI 10.1002/ana.410030404; NIEDERMEYER E, 1981, CLIN ELECTROENCEPHAL, V12, P113, DOI 10.1177/155005948101200304; NIEDERMEYER E, 1963, NEUROLOGY, V13, P412, DOI 10.1212/WNL.13.5.412; NIEDERMEYER E, 1987, Epilepsia, V28, P605; NIEDERMEYER E, 1987, ELECTROENCEPHALOGRAP, P275; REILLY EL, 1979, CLIN ELECTROENCEPHAL, V10, P69, DOI 10.1177/155005947901000204; SAINIO K, 1976, NEUROPHYSIOL, V40, P535; SCHEAR HE, 1985, CLIN ELECTROENCEPHAL, V16, P30, DOI 10.1177/155005948501600105; SOKYA M, 1989, J EPILEPSY, V2, P109; VANSWEDEN B, 1983, CLIN NEUROL NEUROSUR, V85, P12, DOI 10.1016/0303-8467(83)90019-7; VANSWEDEN B, 1983, CLIN NEUROL NEUROSUR, V85, P3, DOI 10.1016/0303-8467(83)90018-5; Verceletto P, 1965, Rev Neurol (Paris), V113, P344; VICTOR M., 1967, EPILEPSIA, V8, P1; VICTOR M, 1970, EPILEPSY RECENT VIEW, P185; VOSSLER DG, 1988, EPILEPSIA, V29, P494; WESSELY P, 1974, WIEN KLIN WOCHENSCHR, V86, P618; WIKLER A, 1956, AM J PSYCHIAT, V113, P106, DOI 10.1176/ajp.113.2.106; ZILM DH, 1980, CLIN TOXICOL, V16, P345, DOI 10.3109/15563658008989958	50	29	29	0	6	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.	FEB	1991	78	2					97	104		10.1016/0013-4694(91)90108-G			8	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	EY029	WOS:A1991EY02900002	1704841				2021-06-18	
J	WERNER, RA; VANDERZANT, CW				WERNER, RA; VANDERZANT, CW			MULTIMODALITY EVOKED-POTENTIAL TESTING IN ACUTE MILD CLOSED HEAD-INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						EVOKED POTENTIALS; AUDITORY; EVOKED POTENTIALS; SOMATOSENSORY; EVOKED POTENTIALS; VISUAL; HEAD INJURIES	BRAIN-STEM RESPONSES; CONCUSSION; SYMPTOMS; PROGNOSIS	Multimodality evoked potential (MEP) testing, including brainstem auditory, visual, and somatosensory evoked potentials, have been reported to be useful in predicting outcome i in severe closed head injury. Brainstem auditory evoked potentials have been demonstrated to be abnormal in 10% to 40% of acute mild head injury. A prospective study of 18 patients with mild closed head injury was undertaken to determine the usefulness of MEP screening within two weeks of the acute event. Long latency event-related potentials (P300s), in response to auditory stimuli with an oddball paradigm, were included in the screening. The subjects had several symptoms consistent with the postconcussive syndrome at the time of the evoked potential testing. Only one patient had an abnormal evoked potential response (greater than three standard deviations from the mean) from all the testing done. The standard methods of MEP testing were insensitive to quantifying the possible physiologic changes that are associated with memory deficits, lethargy, and emotional irritability after mild closed head injury.	UNIV MICHIGAN,MED CTR,DEPT NEUROL,ANN ARBOR,MI 48109	WERNER, RA (corresponding author), UNIV MICHIGAN,MED CTR,DEPT PHYS MED & REHABIL,BOX 0042,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.						BENNA P, 1982, ITAL J NEUROL SCI, V3, P281, DOI 10.1007/BF02043575; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CHIAPPA KH, 1982, NEW ENGL J MED, V306, P1140, DOI 10.1056/NEJM198205133061904; DRAKE ME, 1987, CLIN EVOKED POTENTIA, V5, P19; Greenberg R P, 1979, Acta Neurochir Suppl (Wien), V28, P50; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NEWLON PG, 1985, NEUROL CLIN, V3, P675, DOI 10.1016/S0733-8619(18)31029-6; NORDBY HK, 1984, ACTA NEUROCHIR, V71, P205, DOI 10.1007/BF01401315; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P138, DOI 10.1016/0013-4694(86)90007-6; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P167, DOI 10.1177/155005948101200403; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; RUTH RA, 1982, 1982 AM SPEECH HEAR; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; SCHOENHUBER R, 1988, J NEUROSURG, V68, P742, DOI 10.3171/jns.1988.68.5.0742; Schoenhuber R, 1983, J Neurosurg Sci, V27, P157; SCHOENHUBER R, 1985, EVOKED POTENTIALS NE, P237; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; 1984, J CLIN NEUROPHYSL, V1, P3	26	29	30	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1991	72	1					31	34					4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	ET653	WOS:A1991ET65300008	1985621				2021-06-18	
J	SARAN, A				SARAN, A			ANTIDEPRESSANTS NOT EFFECTIVE IN HEADACHE ASSOCIATED WITH MINOR CLOSED HEAD-INJURY	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article									HIGHLAND VIEW HOSP,CLEVELAND,OH	SARAN, A (corresponding author), CLEVELAND METROPOLITAN GEN HOSP,3395 SCRANTON RD,CLEVELAND,OH 44109, USA.						ALCOFF J, 1982, J FAM PRACTICE, V14, P841; BAKAL DA, 1976, HEADACHE, V11, P123; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; CARASSO RL, 1979, INT J NEUROSCI, V9, P191, DOI 10.3109/00207457909147672; CASSIDY WL, 1957, JAMA-J AM MED ASSOC, V164, P1535, DOI 10.1001/jama.1957.02980140011003; COUCH MR, 1978, ARCH NEUROLOGY, V36, P695; DIAMOND S, 1971, HEADACHE, V11, P110, DOI 10.1111/j.1526-4610.1971.hed1103110.x; DIAMOND S, 1964, Headache, V4, P255, DOI 10.1111/j.1526-4610.1964.hed0403255.x; FEIGHNER JP, 1972, ARCH GEN PSYCHIAT, V26, P57, DOI 10.1001/archpsyc.1972.01750190059011; GARVEY MJ, 1983, BRIT J PSYCHIAT, V143, P544, DOI 10.1192/bjp.143.6.544; GERSHON S, 1981, J CLIN PSYCHOPHARM S, V1, P39; JACOBSON SA, 1969, LATE EFFECTS HEAD IN; KOZOL HL, 1946, ARCH NEURO PSYCHIATR, V56, P245, DOI 10.1001/archneurpsyc.1946.02300200002001; LANCE JW, 1964, LANCET, V1, P1236; LIEBOWITZ MR, 1984, J CLIN PSYCHIAT, V45, P22; LISHMAN WA, 1978, PSYCHOL CONSEQUENCES, P191; MARTIN MJ, 1978, MED CLIN N AM, V62, P559, DOI 10.1016/S0025-7125(16)31793-X; MATHEW NT, 1981, HEADACHE, V21, P105, DOI 10.1111/j.1526-4610.1981.hed2103105.x; RUTHERFORD WH, 1977, LANCET, V1, P1; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SCOTT WA, 1969, PRACTITIONER     JUN, P802; SHERWIN D, 1979, AM J PSYCHIAT, V136, P1181; TAUB A, 1973, J NEUROSURG, V39, P235, DOI 10.3171/jns.1973.39.2.0235; TYLER GS, 1980, HEADACHE, V20, P213, DOI 10.1111/j.1526-4610.1980.hed2004213.x; WARD N, 1984, J CLIN PSYCHIAT, V45, P54; WARD NG, 1982, J CLIN PSYCHIAT, V43, P32; WARD NG, 1979, PAIN, V7, P331, DOI 10.1016/0304-3959(79)90089-7	27	29	29	0	2	BAYWOOD PUBL CO INC	AMITYVILLE	26 AUSTIN AVE, AMITYVILLE, NY 11701	0091-2174			INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		1988	18	1					75	83		10.2190/15AH-JB7Q-U94T-JEAF			9	Psychiatry	Psychiatry	N5275	WOS:A1988N527500007	3294202				2021-06-18	
J	Li, D; Huang, S; Yin, ZY; Zhu, JL; Ge, XT; Han, ZL; Tan, J; Zhang, SS; Zhao, J; Chen, FL; Wang, HC; Lei, P				Li, Dai; Huang, Shan; Yin, Zhenyu; Zhu, Jialin; Ge, Xintong; Han, Zhaoli; Tan, Jin; Zhang, Shishuang; Zhao, Jing; Chen, Fanglian; Wang, Haichen; Lei, Ping			Increases in miR-124-3p in Microglial Exosomes Confer Neuroprotective Effects by Targeting FIP200-Mediated Neuronal Autophagy Following Traumatic Brain Injury	NEUROCHEMICAL RESEARCH			English	Article						Traumatic brain injury; Exosomes; Autophagy; miRNA; Microglia	NEGATIVELY REGULATE AUTOPHAGY; MESENCHYMAL STROMAL CELLS; EXTRACELLULAR VESICLES; MICRORNA EXPRESSION; TUMOR-SUPPRESSOR; DOWN-REGULATION; IN-VITRO; APOPTOSIS; PATHWAY; CANCER	In our recent study, we observed consistent increases in miR-124-3p levels in exosomes derived from cultured BV2 microglia which was treated with repetitive traumatic brain injury (rTBI) mouse model brain extracts. To clarify the mechanisms underlying increases in microglia-derived exosomal miR-124-3p and their role in regulating neuronal autophagy after TBI, we investigated the impact of exosomal miR-124-3p on neuronal autophagy in scratch-injured HT22 neurons and rTBI mice. We harvested injured brain extracts from rTBI mice at 3 to 21days post injury (DPI) for the treatment of cultured BV2 microglia in vitro. We observed significant induction of autophagy following TBI in vitro, and that inhibition of activated neuronal autophagy could protect against trauma-induced injury. Our results indicated that co-culture of injured HT22 neurons with miR-124-3p overexpressing BV2 microglia exerted a protective effect by inhibiting neuronal autophagy in scratch-injured neurons. Further research revealed that these effects were achieved mainly via upregulation of exosomal miR-124-3p, and that Focal adhesion kinase family-interacting protein of 200kDa (FIP200) plays a key role in trauma-induced autophagy. Injection of exosomes into the vena caudalis in in vivo experiments revealed that exosomal miR-124-3p was associated with decreases in the modified neurological severity score (mNSS) and improvements in Morris water maze (MWM) test results in rTBI mice. Altogether, our results indicate that increased miR-124-3p in microglial exosomes following TBI may inhibit neuronal autophagy and protect against nerve injury via their transfer into neurons. Thus, treatment with microglial exosomes enriched with miR-124-3p may represent a novel therapeutic strategy for the treatment of nerve injury after TBI.	[Li, Dai; Huang, Shan; Yin, Zhenyu; Ge, Xintong; Han, Zhaoli; Tan, Jin; Zhang, Shishuang; Zhao, Jing; Lei, Ping] Tianjin Med Univ Gen Hosp, Tianjin Geriatr Inst, Lab Neuro Trauma & Neurodegenerat Disorders, Tianjin 300052, Peoples R China; [Li, Dai; Huang, Shan; Yin, Zhenyu; Han, Zhaoli; Tan, Jin; Zhang, Shishuang; Zhao, Jing; Lei, Ping] Tianjin Med Univ Gen Hosp, Dept Geriatr, Tianjin 300052, Peoples R China; [Ge, Xintong] Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Ge, Xintong; Chen, Fanglian] Tianjin Med Univ Gen Hosp, Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin 300052, Peoples R China; [Ge, Xintong; Chen, Fanglian] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Zhu, Jialin] Tianjin Med Univ Canc Inst & Hosp, Dept Ultrasound Diag & Treatment, Tianjin 300060, Peoples R China; [Wang, Haichen] Duke Univ, Dept Neurol, Med Ctr, Durham, NC 27710 USA; [Lei, Ping] Tianjin Med Univ Gen Hosp, Tianjin Geriatr Inst, Dept Geriatr, Lab Neurotrauma & Neurodegenerat Disorders, Anshan Rd, Tianjin 300054, Peoples R China	Lei, P (corresponding author), Tianjin Med Univ Gen Hosp, Tianjin Geriatr Inst, Lab Neuro Trauma & Neurodegenerat Disorders, Tianjin 300052, Peoples R China.; Lei, P (corresponding author), Tianjin Med Univ Gen Hosp, Dept Geriatr, Tianjin 300052, Peoples R China.; Lei, P (corresponding author), Tianjin Med Univ Gen Hosp, Tianjin Geriatr Inst, Dept Geriatr, Lab Neurotrauma & Neurodegenerat Disorders, Anshan Rd, Tianjin 300054, Peoples R China.	luke88956@163.com	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81772060, 81471252]; Tianjin Science FoundationNatural Science Foundation of Tianjin [16JCYBJC27200, 16JCQNJC11000, 16JCYBJC26900, 18ZXDBSY00090]; Tianjin Medical University General Hospital Youth Cultivation Foundation [ZYYFY2016001, ZYYFY2014025]	This research was supported by Grants from the National Natural Science Foundation of China (Grant Nos. 81772060, 81471252), Tianjin Science Foundation (Grant Nos. 16JCYBJC27200, 16JCQNJC11000, 16JCYBJC26900, 18ZXDBSY00090), Tianjin Medical University General Hospital Youth Cultivation Foundation (Grant Nos. ZYYFY2016001, ZYYFY2014025). The authors appreciate Li Liu, Weiyun Cui and Lei Zhou from Tianjin Neurological Institute for their technical support.	Abbi S, 2002, MOL BIOL CELL, V13, P3178, DOI 10.1091/mbc.E02-05-0295; An FM, 2017, ONCOTARGET, V8, P114065, DOI 10.18632/oncotarget.23119; Antonucci F, 2012, EMBO J, V31, P1231, DOI 10.1038/emboj.2011.489; Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Au AK, 2017, NEUROCRIT CARE, V26, P348, DOI 10.1007/s12028-016-0351-x; Ban BK, 2013, MOL CELL BIOL, V33, P3907, DOI 10.1128/MCB.00627-13; Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Dong RF, 2018, J CELL BIOCHEM, V119, P269, DOI 10.1002/jcb.26170; Fineberg SK, 2009, NEURON, V64, P303, DOI 10.1016/j.neuron.2009.10.020; Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266; Gabrielli M, 2015, EMBO REP, V16, P213, DOI 10.15252/embr.201439668; Gao HB, 2017, BRAIN RES, V1657, P1, DOI 10.1016/j.brainres.2016.11.028; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2018, J NEUROSCI METH, V308, P162, DOI 10.1016/j.jneumeth.2018.07.021; Ge XT, 2019, J NEUROTRAUM, V36, P1291, DOI 10.1089/neu.2018.5728; Ge XT, 2016, BRAIN RES, V1650, P31, DOI 10.1016/j.brainres.2016.07.015; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Gong X, 2016, AM J TRANSL RES, V8, P2127; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hooper C, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-144; Huang S, 2018, FASEB J, V32, P2315, DOI 10.1096/fj.201700673RERR; Jiang, 2012, J NEUROTRAUM, DOI DOI 10.1089/NEU.2011.2134; Jiang JY, 2013, INJURY, V44, P1453, DOI 10.1016/j.injury.2012.08.045; Jiang M, 2018, CELL PHYSIOL BIOCHEM, V47, P864, DOI [10.1159/000490078, 10.1159/000490078and]; Johnson WD, 2017, LANCET NEUROL, V16, P949, DOI 10.1016/S1474-4422(17)30362-9; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kim J, 2015, GENE, V558, P173, DOI 10.1016/j.gene.2015.01.001; Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a; Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351; Kramer-Albers EM, 2016, CURR OPIN NEUROBIOL, V39, P101, DOI 10.1016/j.conb.2016.04.016; Legakis JE, 2007, AUTOPHAGY, V3, P422, DOI 10.4161/auto.4129; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Levin H, 2013, LANCET NEUROL, V12, P15, DOI 10.1016/S1474-4422(12)70300-9; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li SF, 2016, LIFE SCI, V147, P143, DOI 10.1016/j.lfs.2016.01.044; Liao WT, 2014, J PATHOL, V232, P415, DOI 10.1002/path.4309; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Martinez B, 2017, NEURAL REGEN RES, V12, P1749, DOI 10.4103/1673-5374.219025; Mehta AK, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aam6291; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Menghini R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.556; Osier N, 2018, MOL NEUROBIOL, V55, P9280, DOI 10.1007/s12035-018-1054-4; Osier N, 2016, METHODS MOL BIOL, V1462, P177, DOI 10.1007/978-1-4939-3816-2_11; Paolicelli RC, 2019, NEUROSCIENCE, V405, P148, DOI 10.1016/j.neuroscience.2018.04.003; Potolicchio A, 2005, J IMMUNOL, V175, P2237, DOI 10.4049/jimmunol.175.4.2237; Rajendran L, 2014, J NEUROSCI, V34, P15482, DOI 10.1523/JNEUROSCI.3258-14.2014; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Su ZY, 2015, ONCOTARGET, V6, P8474, DOI 10.18632/oncotarget.3523; Sun LQ, 2018, BEHAV BRAIN RES, V340, P126, DOI 10.1016/j.bbr.2016.09.020; Sun LQ, 2017, BIOCHEM BIOPH RES CO, V482, P1141, DOI 10.1016/j.bbrc.2016.12.001; Sun LQ, 2015, BEHAV BRAIN RES, V291, P315, DOI 10.1016/j.bbr.2015.05.049; Taj SH, 2016, BIOMATERIALS, V91, P151, DOI 10.1016/j.biomaterials.2016.03.025; Tamboli IY, 2010, J BIOL CHEM, V285, P37405, DOI 10.1074/jbc.M110.149468; Thompson AG, 2016, NAT REV NEUROL, V12, P346, DOI 10.1038/nrneurol.2016.68; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Vuokila N, 2018, CELL MOL LIFE SCI, V75, P4557, DOI 10.1007/s00018-018-2911-z; Wang DY, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0019629, 10.1371/journal.pone.0019835]; Wang F, 2013, STEM CELL RES, V11, P657, DOI 10.1016/j.scr.2013.04.005; World Health Organization, 2017, NEUR DIS PUBL HLTH C; Wu H, 2012, CELL SIGNAL, V24, P2179, DOI 10.1016/j.cellsig.2012.07.001; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang Y, 2017, MOL NEUROBIOL, V54, P2659, DOI 10.1007/s12035-016-9851-0; Zhao G, 2013, MOL CANCER THER, V12, P83, DOI 10.1158/1535-7163.MCT-12-0534-T; Zheng TT, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00012; Zhou X, 2010, LAB INVEST, V90, P144, DOI 10.1038/labinvest.2009.126	75	28	30	2	10	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	AUG	2019	44	8					1903	1923		10.1007/s11064-019-02825-1			21	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	IL9EY	WOS:000477589200012	31190315				2021-06-18	
J	Li, QC; Jiang, Y; Su, ZB				Li, Qing-Chun; Jiang, Yun; Su, Zhen-Bo			Prophylactic treatment with MSC-derived exosomes attenuates traumatic acute lung injury in rats	AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY			English	Article						exosomes; inflammatory response; mesenchymal stem cells; microRNA-124-3p; oxidative stress injury; purinergic receptor P2X ligand-gated ion channel 7; traumatic acute lung injury	MESENCHYMAL STEM-CELLS; P2X(7) RECEPTOR; MIR-124-3P; EXPRESSION; STRESS; BRAIN; INFLAMMATION; CONTRIBUTES; RESPONSES; PROTECTS	The mesenchymal stern cell (MSC) is a potential strategy in the pretreatment of traumatic acute lung injury (ALI), a disease that causes inflammation and oxidative stress. This study aimed to investigate whether MSC-exosomal microRNA-124-3p (miR-124-3p) affects traumatic ALI. Initially, a traumatic ALI rat model was established using the weight-drop method. Then, exosomes were obtained from MSCs of Sprague-Dawley rats, which were injected into the traumatic ALI rats. We found that miR-124-3p was abundantly-expressed in MSCs-derived exosomes and could directly target purinergic receptor P2X ligand-gated ion channel 7 (P2X7), which was overexpressed in traumatic ALI rats. After that, a loss- and gain-of-function study was performed in MSCs and traumatic ALI rats to investigate the role of miR-124-3p and P2X7 in traumatic ALI. MSC-derived exosomal miR-124-3p or silenced P2X7 was observed to increase the survival rate of traumatic ALI rats and enhance the glutathione/superoxide dismutase activity in their lung tissues. However, the wet/dry weight of lung tissues, activity of methylenedioxyamphetamine and H2O2, and levels of inflammatory factors (TNF-a, IL-6, and IL-8) were reduced. Similarly. the numbers of total cells, macrophages. neutrophils, and lymphocytes in bronchoalveolar lavage fluid were also reduced when treated with exosomal miR-124-3p or silenced P2X7. In conclusion, the results provide evidence that miR-124-3p transferred by MSC-derived exosomes inhibited P2X7 expression, thus improving oxidative stress injury and suppressing inflammatory response in traumatic ALI, highlighting a potential pretreatment for traumatic ALI.	[Li, Qing-Chun] Jilin Univ, China Japan Union Hosp, Dept Gastrointestinal Colorectal & Anal Surg, Changchun, Jilin, Peoples R China; [Jiang, Yun] Jilin Univ, China Japan Union Hosp, Ctr Phys Examinat, Changchun, Jilin, Peoples R China; [Su, Zhen-Bo] Jilin Univ, China Japan Union Hosp, Dept Anesthesiol, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China	Su, ZB (corresponding author), Jilin Univ, China Japan Union Hosp, Dept Anesthesiol, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China.	suzb@jlu.edu.cn			Department of Science and Technology of Jilin Province [20190701068GH]	This study was supported by Department of Science and Technology of Jilin Province (No. 20190701068GH).	Ahmad SB, 2017, J TRAUMA ACUTE CARE, V82, P587, DOI 10.1097/TA.0000000000001352; Aliotta JM, 2016, CARDIOVASC RES, V110, P319, DOI 10.1093/cvr/cvw054; Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Arslan F, 2013, STEM CELL RES, V10, P301, DOI 10.1016/j.scr.2013.01.002; Arulkumaran N, 2011, EXPERT OPIN INV DRUG, V20, P897, DOI 10.1517/13543784.2011.578068; Barbera-Cremades M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00862; Beninson LA, 2015, IMMUNOL LETT, V163, P187, DOI 10.1016/j.imlet.2014.10.019; Cai ZY, 2016, ARCH PHARM RES, V39, P499, DOI 10.1007/s12272-016-0713-0; El Agha E, 2017, CELL STEM CELL, V21, P166, DOI 10.1016/j.stem.2017.07.011; Farooq RK, 2018, PSYCHONEUROENDOCRINO, V97, P120, DOI 10.1016/j.psyneuen.2018.07.016; Galam L, 2016, AM J PHYSIOL-LUNG C, V310, pL572, DOI 10.1152/ajplung.00417.2015; Geng LJ, 2017, EXP BIOL MED, V242, P1757, DOI 10.1177/1535370217734492; Goodarzi P, 2018, ADV EXP MED BIOL, V1119, P119, DOI 10.1007/5584_2018_251; Gore AV, 2015, J TRAUMA ACUTE CARE, V78, P767, DOI 10.1097/TA.0000000000000592; Gu M, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/5381290; Guo Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.254; Hayes M, 2012, CRIT CARE, V16, DOI 10.1186/cc10570; Hoth JJ, 2014, J TRAUMA ACUTE CARE, V76, P601, DOI 10.1097/TA.0000000000000129; Hu LY, 2018, EUR REV MED PHARMACO, V22, P1402, DOI 10.26355/eurrev_201803_14486; Huang LZ, 2015, ARCH VIROL, V160, P979, DOI 10.1007/s00705-015-2351-0; Huang S, 2018, FASEB J, V32, P512, DOI 10.1096/fj.201700673R; Li T, 2013, LUNG, V191, P207, DOI 10.1007/s00408-012-9449-x; Liu F, 2018, BIOMED REP, V9, P147, DOI 10.3892/br.2018.1113; Liu Y, 2017, CELL PHYSIOL BIOCHEM, V41, P2037, DOI 10.1159/000475434; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu WN, 2017, J NEUROCHEM, V141, P436, DOI 10.1111/jnc.13998; Ma B, 2016, SCI REP-UK, V6, DOI 10.1038/srep32971; Ma J, 2017, STEM CELL TRANSL MED, V6, P51, DOI 10.5966/sctm.2016-0038; Moniruzzaman M, 2018, ECOTOX ENVIRON SAFE, V163, P37, DOI 10.1016/j.ecoenv.2018.07.053; Nojehdehi S, 2018, J CELL BIOCHEM, V119, P9433, DOI 10.1002/jcb.27260; Nong KT, 2016, CYTOTHERAPY, V18, P1548, DOI 10.1016/j.jcyt.2016.08.002; Pan Y, 2018, DOMEST ANIM ENDOCRIN, V65, P17, DOI 10.1016/j.domaniend.2018.05.002; Raghavendran K, 2005, ANESTH ANALG, V101, P1482, DOI 10.1213/01.ANE.0000180201.25746.1F; Ren XF, 2015, TOXICOL APPL PHARM, V283, P198, DOI 10.1016/j.taap.2015.01.014; Riteau N, 2010, AM J RESP CRIT CARE, V182, P774, DOI 10.1164/rccm.201003-0359OC; Sayed DA, 2018, BIOMED PHARMACOTHER, V107, P90, DOI 10.1016/j.biopha.2018.07.173; Shamili FH, 2018, INT J PHARMACEUT, V549, P218, DOI 10.1016/j.ijpharm.2018.07.067; Shieh CH, 2014, GLIA, V62, P592, DOI 10.1002/glia.22628; Sormann P, 2017, INJURY, V48, P2400, DOI 10.1016/j.injury.2017.08.041; Tong L, 2016, SCI REP-UK, V6, DOI 10.1038/srep21642; van den Boogaard FE, 2017, J AEROSOL MED PULM D, V30, P91, DOI 10.1089/jamp.2016.1317; Wang YB, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2862-4; Wong SP, 2015, PHARMACOL THERAPEUT, V151, P107, DOI 10.1016/j.pharmthera.2015.03.006; Wu CR, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0537-9; Xu XP, 2018, BBA-MOL BASIS DIS, V1864, P1663, DOI 10.1016/j.bbadis.2018.02.011; Young CNJ, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00248; Zhang D, 2017, AM J PHYSIOL-LUNG C, V312, pL110, DOI 10.1152/ajplung.00423.2016; Zhang W, 2018, FEBS OPEN BIO, V8, P325, DOI 10.1002/2211-5463.12345; Zhang YY, 2014, TOXICOL APPL PHARM, V281, P1, DOI 10.1016/j.taap.2014.09.016; Zhou LY, 2008, J BIOL CHEM, V283, P28274, DOI 10.1074/jbc.M802663200; Zhou ZC, 2016, CELL PHYSIOL BIOCHEM, V38, P258, DOI 10.1159/000438627	51	28	28	0	16	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	1040-0605	1522-1504		AM J PHYSIOL-LUNG C	Am. J. Physiol.-Lung Cell. Mol. Physiol.	JUN	2019	316	6					L1107	L1117		10.1152/ajplung.00391.2018			11	Physiology; Respiratory System	Physiology; Respiratory System	ID7QI	WOS:000471877000005	30892077	Bronze			2021-06-18	
J	Ge, XT; Li, WZ; Huang, S; Yin, ZY; Yang, MC; Han, ZY; Han, ZL; Chen, FL; Wang, HC; Lei, P; Zhang, JN				Ge, Xintong; Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Yang, Mengchen; Han, Zhenying; Han, Zhaoli; Chen, Fanglian; Wang, Haichen; Lei, Ping; Zhang, Jianning			Increased miR-21-3p in Injured Brain Microvascular Endothelial Cells after Traumatic Brain Injury Aggravates Blood-Brain Barrier Damage by Promoting Cellular Apoptosis and Inflammation through Targeting MAT2B	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; blood-brain barrier; inflammation; miRNA; traumatic brain injury	MICRORNA EXPRESSION; SIGNALING PATHWAY; DOWN-REGULATION; IN-VITRO; NEUROINFLAMMATION; PROLIFERATION; CONTRIBUTES; HYPOTHERMIA; MIRNA-21; CORTEX	Our recent articles have reported that increased miR-21-5p in brain after traumatic brain injury (TBI) could improve the neurological outcome through alleviating blood-brain barrier (BBB) damage. miR-21-3p is another mature miRNA derived from pre-miR-21 after Dicer Procession other than miR-21-5p. Its roles in various diseases, such as tumors and myocardial disease, aroused great interest for research in recent years. To further explore the function and underlying mechanism of miR-21, especially miR-21-3p, in regulating the pathological development of BBB damage after TBI, we designed this research and focused on studying the impact of miR-21-3p on apoptosis and inflammation in brain microvascular endothelial cells (BMVECs), the major cellular component of BBB. We performed controlled cortical impact on mouse brain and employed the oxygen glucose deprivation/reoxygenation (OGD)-treated bEnd.3 cells injury model. We found that the miR-21-3p level in BMVECs from injured cerebral cortex of controlled cortical impact (CCI) mice and bEnd.3 cells with OGD treatment were both increased after injury. For in vitro experiments, downregulation on the miR-21-3p level by transfecting miR-21-3p antagomir in cultured cells alleviated OGD-induced BBB damage, characterized by decreased BBB leakage and increased expression of tight junction proteins. Besides, miR-21-3p antagomir could suppress cell death by anti-apoptosis and control inflammatory response by inhibiting the activity of NF-kappa B signaling. Using luciferase reporter assay and a MAT2B-silenced shRNA vector, we further proved that miR-21-3p exerted the above functions through targeting MAT2B. In addition, in vivo experiments also confirmed that intracerebroventricular infusion of miR-21-3p antagomir could alleviate BBB leakage after TBI. It reduced Evans Blue extravasation and promoted the expression of tight junction proteins, thus contributed to improve the neurological outcome of CCI mice. Taken together, increased miR-21-3p in BMVECs after TBI was bad for restoration of injured BBB. Downregulation on the miR-21-3p level in injured brain could be a promising therapeutic strategy for BBB damage after TBI.	[Ge, Xintong; Yang, Mengchen; Han, Zhenying; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Chen, Fanglian] Tianjin Med Univ, Gen Hosp, Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin, Peoples R China; [Yang, Mengchen; Han, Zhenying; Chen, Fanglian; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China; [Ge, Xintong; Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Han, Zhaoli; Lei, Ping] Tianjin Med Univ, Gen Hosp, Tianjin Geriatr Inst, Lab Neurotrauma & Neurodegenerat Disorders, Tianjin, Peoples R China; [Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Han, Zhaoli; Lei, Ping] Tianjin Med Univ, Gen Hosp, Dept Geriatr, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Wang, Haichen] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA	Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin 300052, Peoples R China.; Lei, P (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Geriatr, 154 Anshan Rd, Tianjin 300052, Peoples R China.	leiping1974@163.com; jianningzhang@hotmail.com	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X			Baez-Vega PM, 2016, ONCOTARGET, V7, P36321, DOI 10.18632/oncotarget.9216; Cavallini A, 2017, ONCOTARGET, V8, P41866, DOI 10.18632/oncotarget.16383; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.135; Chen X, 2014, J NEUROL SCI, V342, P93, DOI 10.1016/j.jns.2014.04.032; Chen X, 2013, CRIT CARE, V17, DOI 10.1186/cc13067; Chen XW, 2013, J MEMBRANE BIOL, V246, P7, DOI 10.1007/s00232-012-9495-6; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Degueurce G, 2016, EMBO MOL MED, V8, P919, DOI 10.15252/emmm.201505384; Dietrich WD, 2016, BRAIN RES, V1640, P94, DOI 10.1016/j.brainres.2015.12.034; Edwards P, 2005, LANCET, V365, P1957; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Frau M, 2013, J HEPATOL, V59, P830, DOI 10.1016/j.jhep.2013.04.031; Ge X., 2015, RNA DIS, V2, pe642; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2016, BRAIN RES, V1650, P31, DOI 10.1016/j.brainres.2016.07.015; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Gordillo GM, 2014, J BIOL CHEM, V289, P9027, DOI 10.1074/jbc.M113.519264; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Haseloff RF, 2015, SEMIN CELL DEV BIOL, V38, P16, DOI 10.1016/j.semcdb.2014.11.004; Huang S, 2018, FASEB J, V32, P512, DOI 10.1096/fj.201700673R; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Leger M, 2013, NAT PROTOC, V8, P2531, DOI 10.1038/nprot.2013.155; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lei Y, 2016, INT J ONCOL, V49, P981, DOI 10.3892/ijo.2016.3603; Levin H, 2013, LANCET NEUROL, V12, P15, DOI 10.1016/S1474-4422(12)70300-9; Lin L, 2018, MOL NEUROBIOL, V55, P3131, DOI 10.1007/s12035-017-0544-0; Lo TF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075628; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Miao W, 2015, BRAZ J MED BIOL RES, V48, P433, DOI [10.1590/1414-431X20144012, 10.1590/1414-431x20144012]; Nasser M, 2016, CNS NEUROL DISORD-DR, V15, P1030, DOI 10.2174/1871527315666160815093525; Pan YB, 2017, NEUROSCIENCE, V367, P189, DOI 10.1016/j.neuroscience.2017.10.046; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Rizwan H, 2017, INT J NANOMED, V12, P5841, DOI 10.2147/IJN.S141839; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Ruck T, 2014, JOVE-J VIS EXP, DOI 10.3791/52204; Sandhir R, 2014, NEUROCHEM INT, V78, P117, DOI 10.1016/j.neuint.2014.09.009; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Temiz-Resitoglu M, 2017, EUR J PHARMACOL, V802, P7, DOI 10.1016/j.ejphar.2017.02.034; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Wang Q, 2008, WORLD J GASTROENTERO, V14, P4633, DOI 10.3748/wjg.14.4633; Xu X, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0934-2; Yan MW, 2015, CARDIOVASC RES, V105, P340, DOI 10.1093/cvr/cvu254; Yang HP, 2008, GASTROENTEROLOGY, V134, P281, DOI 10.1053/j.gastro.2007.10.027; Yang HP, 2013, J BIOL CHEM, V288, P23161, DOI 10.1074/jbc.M113.487157; Yang Y, 2016, INT J BIOCHEM CELL B, V79, P222, DOI 10.1016/j.biocel.2016.08.040; Zacharek A, 2006, NEUROSCI LETT, V404, P28, DOI 10.1016/j.neulet.2006.05.027	58	28	30	1	32	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2019	36	8					1291	1305		10.1089/neu.2018.5728			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HS4DK	WOS:000463812000008	29695199	Bronze			2021-06-18	
J	Denning, JH; Shura, RD				Denning, John H.; Shura, Robert D.			Cost of malingering mild traumatic brain injury-related cognitive deficits during compensation and pension evaluations in the veterans benefits administration	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						Malingering; medical symptom validity test; neuropsychology; test of memory malingering; traumatic brain injury; veterans	POSTTRAUMATIC-STRESS-DISORDER; PERFORMANCE VALIDITY TESTS; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; WORD MEMORY TEST; PERSISTENT POSTCONCUSSIVE SYMPTOMS; IRAQI FREEDOM VETERANS; TRIAL 1; OEF/OIF VETERANS; SERVICE MEMBERS; TEST FAILURE	Given the high rates of exaggeration in those claiming long-term cognitive deficits as a result of mild traumatic brain injury (mTBI), the aim of this study was to evaluate the rates of malingering in those seeking disability through the Veterans Benefits Administration and estimate the financial burden of disability payments for those receiving compensation despite exaggerated mTBI-related cognitive deficits. Retrospective review included 74 veterans seen for Compensation and Pension evaluations for mTBI. Rates of malingering were based on failure of the Medical Symptom Validity Test (MSVT) and/or the Test of Memory Malingering (TOMM) trial 1 <= 40. Total estimated compensation was based on the level of disability awarded and the number of individuals found to be malingering cognitive deficits. Overall, 33-52% of the sample was found to be malingering mTBI-related cognitive deficits. The malingering groups were receiving approximately $71,000-$121,000/year ($6,390-$7,063 per year, per veteran on average). Estimated nationwide disability payments for those possibly malingering mTBI-related cognitive deficits would be $136-$235 million/year (projected costs from 2015-2020 = $700 million-$1.2 billion). It is critical that providers and administrative officials identify those exaggerating disability claims attributed to mTBI. The cost of malingering impacts society in general as well as veterans themselves, as it diverts needed funds/resources away from those legitimately impaired by their military service.	[Denning, John H.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Dept Vet Affairs, Charleston, SC USA; [Denning, John H.] Med Univ South Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA; [Shura, Robert D.] Midatlantic Mental Illness Res Educ & Clin Ctr, Salisbury, NC USA; [Shura, Robert D.] WG Bill Hefner Vet Affairs Med Ctr VAMC, Mental Hlth & Behav Sci Serv Line, Salisbury, NC USA; [Shura, Robert D.] Wake Forest Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC USA	Denning, JH (corresponding author), Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv Line, 109 Bee St, Charleston, SC 29401 USA.	john.denning@va.gov	Shura, Robert D/J-6749-2019	Shura, Robert/0000-0002-9505-0080	Office of Research and Development, Medical Research Service, Department of Veterans AffairsUS Department of Veterans Affairs	This work was supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, and the Mid-Atlantic MIRECC.	Adams C., 2013, MCCLATCHY NEWSPAPERS; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Armistead-Jehle P, 2018, ARCH CLIN NEUROPSYCH, V33, P120, DOI 10.1093/arclin/acx031; Armistead-Jehle P, 2016, APPL NEUROPSYCH-ADUL, V23, P264, DOI 10.1080/23279095.2015.1055564; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Ashendorf L, 2017, CLIN NEUROPSYCHOL, V31, P857, DOI 10.1080/13854046.2017.1285961; Ashendorf L, 2016, CLIN NEUROPSYCHOL, V30, P599, DOI 10.1080/13854046.2016.1172668; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benitez A, 2011, ARCH CLIN NEUROPSYCH, V26, P184, DOI 10.1093/arclin/acr001; Bolzenius JD, 2015, APPL NEUROPSYCH-ADUL, V22, P79, DOI 10.1080/23279095.2013.845823; Boone, 2007, ASSESSMENT FEIGNED C; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Carone D.A., 2013, MILD TRAUMATIC BRAIN; Carone DA, 2014, CLIN NEUROPSYCHOL, V28, P146, DOI 10.1080/13854046.2013.861019; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chafetz M, 2013, ARCH CLIN NEUROPSYCH, V28, P633, DOI 10.1093/arclin/act038; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; Clark AL, 2016, J HEAD TRAUMA REHAB, V31, P346, DOI 10.1097/HTR.0000000000000183; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Combs HL, 2015, J NEUROTRAUM, V32, P956, DOI 10.1089/neu.2014.3585; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Cook CM, 2016, CLIN NEUROPSYCHOL, V30, P284, DOI 10.1080/13854046.2016.1139186; Cooper DB, 2014, J REHABIL RES DEV, V51, P1023, DOI [10.1682/JRRD.2013.05.0104, 10.1682/JRRD.2013.05.0140]; Defense and Veterans Brain Injury Center, 2016, DOD NUMB TRAUM BRAIN; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Denning JH, 2014, APPL NEUROPSYCH-ADUL, V21, P269, DOI 10.1080/23279095.2013.811076; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dretsch MN, 2015, J NEUROTRAUM, V32, P1217, DOI 10.1089/neu.2014.3637; Fazio RL, 2017, CLIN NEUROPSYCHOL, V31, P251, DOI 10.1080/13854046.2016.1213316; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Fox DD, 2011, CLIN NEUROPSYCHOL, V25, P488, DOI 10.1080/13854046.2011.554443; Franke LM, 2015, J HEAD TRAUMA REHAB, V30, pE34, DOI 10.1097/HTR.0000000000000042; Gfeller JD, 2013, BEHAV SCI LAW, V31, P833, DOI 10.1002/bsl.2084; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Green, 2004, GREENS MED SYMPTOM V; Green P., 2006, INT J FORENSIC PSYCH, V1, P1; Green P, 2016, APPL NEUROPSYCH-CHIL, V5, P25, DOI 10.1080/21622965.2014.935378; Grills CE, 2016, APPL NEUROPSYCH-ADUL, V23, P295, DOI 10.1080/23279095.2015.1079713; Guilmette T. J., 2013, MILD TRAUMATIC BRAIN, P31; Hanson KL, 2016, J CLIN EXP NEUROPSYC, V38, P1115, DOI 10.1080/13803395.2016.1198468; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Heltemes KJ, 2011, MIL MED, V176, P132, DOI 10.7205/MILMED-D-09-00238; Hetherington HP, 2014, MAGN RESON MED, V71, P1358, DOI 10.1002/mrm.24814; Heyanka DJ, 2015, ARCH CLIN NEUROPSYCH, V30, P369, DOI 10.1093/arclin/acv025; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horner MD, 2017, ARCH CLIN NEUROPSYCH, V32, P228, DOI 10.1093/arclin/acw094; Horner MD, 2014, CLIN NEUROPSYCHOL, V28, P703, DOI 10.1080/13854046.2014.925143; Ioachimescu AG, 2015, PITUITARY, V18, P535, DOI 10.1007/s11102-014-0606-5; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P697, DOI 10.1007/978-0-387-76978-3_22; Jak AJ, 2015, J CLIN EXP NEUROPSYC, V37, P379, DOI 10.1080/13803395.2015.1020769; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1373, DOI 10.1080/13854046.2013.851740; Jones A, 2012, CLIN NEUROPSYCHOL, V26, P790, DOI 10.1080/13854046.2012.693202; Kehle-Forbes SM, 2017, J HEAD TRAUMA REHAB, V32, pE16, DOI 10.1097/HTR.0000000000000227; King PR, 2014, J NERV MENT DIS, V202, P231, DOI 10.1097/NMD.0000000000000103; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee G.J., 2012, FORENSIC NEUROPSYCHO; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; Larson EB, 2013, J INT NEUROPSYCH SOC, V19, P88, DOI 10.1017/S1355617712000999; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lippa SM, 2017, APPL NEUROPSYCH-ADUL, V24, P73, DOI 10.1080/23279095.2015.1100617; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Macciocchi SN, 2017, ARCH CLIN NEUROPSYCH, V32, P339, DOI 10.1093/arclin/acw112; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; McCormick CL, 2013, ARCH CLIN NEUROPSYCH, V28, P808, DOI 10.1093/arclin/act050; McNally RJ, 2013, J ANXIETY DISORD, V27, P520, DOI 10.1016/j.janxdis.2013.07.002; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mendez MF, 2013, BRAIN INJURY, V27, P10, DOI 10.3109/02699052.2012.722252; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Morel KR, 2008, CLIN NEUROPSYCHOL, V22, P350, DOI 10.1080/13854040701300531; Morgan J. E., 2009, NEUROPSYCHOLOGY MALI; Neipert L, 2014, BRAIN INJURY, V28, P1667, DOI 10.3109/02699052.2014.947623; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Office of Inspector General, 2014, SEM REP C, P72; Office of the Inspector General, 2013, SEM REP C; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Reslan S, 2017, APPL NEUROPSYCH-ADUL, V24, P132, DOI 10.1080/23279095.2015.1107565; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Roth RS, 2013, J PALLIAT CARE MED, V1, P105, DOI DOI 10.4172/2329-9096.1000105; Russo AC, 2012, ARCH CLIN NEUROPSYCH, V27, P840, DOI 10.1093/arclin/acs090; Salmi L Rachid, 2014, Arch Phys Med Rehabil, V95, pS95, DOI 10.1016/j.apmr.2013.10.026; Schroeder RW, 2013, ARCH CLIN NEUROPSYCH, V28, P21, DOI 10.1093/arclin/acs094; Schutte C, 2011, CLIN NEUROPSYCHOL, V25, P454, DOI 10.1080/13854046.2010.550635; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2017, BRAIN INJURY, V31, P32, DOI 10.1080/02699052.2016.1218546; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Stenclik JH, 2013, APPL NEUROPSYCH-ADUL, V20, P243, DOI 10.1080/09084282.2012.704603; Storzbach D, 2015, J INT NEUROPSYCH SOC, V21, P353, DOI 10.1017/S1355617715000326; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Tombaugh TN, 1996, TEST MEMORY MALINGER; Troyanskaya M, 2015, MIL MED, V180, P285, DOI 10.7205/MILMED-D-14-00256; US Department of Veterans Affairs, COMPENSATION; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Veterans Benefits Administration, 2014, REG 3 310 1 DIS AR P; Veterans Benefits Administration, 2016, VBA ANN BEN REP FISC; Whitney KA, 2013, ARCH CLIN NEUROPSYCH, V28, P222, DOI 10.1093/arclin/act012; Whitney KA, 2010, APPL NEUROPSYCHOL, V17, P196, DOI 10.1080/09084282.2010.499787; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P263, DOI 10.1093/arclin/acp034; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Wisdom NM, 2012, ARCH CLIN NEUROPSYCH, V27, P208, DOI 10.1093/arclin/acr107; Worthen MD, 2011, PSYCHOL INJ LAW, V4, P187, DOI 10.1007/s12207-011-9115-2; Wrocklage KM, 2016, J INT NEUROPSYCH SOC, V22, P399, DOI 10.1017/S1355617716000059; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083	133	28	28	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult	JAN 2	2019	26	1					1	16		10.1080/23279095.2017.1350684			16	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	HR3RQ	WOS:000463057500001	28816502				2021-06-18	
J	Adams, JW; Alvarez, VE; Mez, J; Huber, BR; Tripodis, Y; Xia, WM; Meng, GY; Kubilus, CA; Cormier, K; Kiernan, PT; Daneshvar, DH; Chua, AS; Svirsky, S; Nicks, R; Abdolmohammadi, B; Evers, L; Solomon, TM; Cherry, JD; Aytan, N; Mahar, I; Devine, S; Auerbach, S; Alosco, ML; Nowinski, CJ; Kowall, NW; Goldstein, LE; Dwyer, B; Katz, DI; Cantu, RC; Stern, RA; Au, R; McKee, AC; Stein, TD				Adams, Jason W.; Alvarez, Victor E.; Mez, Jesse; Huber, Bertrand R.; Tripodis, Yorghos; Xia, Weiming; Meng, Gaoyuan; Kubilus, Caroline A.; Cormier, Kerry; Kiernan, Patrick T.; Daneshvar, Daniel H.; Chua, Alicia S.; Svirsky, Sarah; Nicks, Raymond; Abdolmohammadi, Bobak; Evers, Laney; Solomon, Todd M.; Cherry, Jonathan D.; Aytan, Nurgul; Mahar, Ian; Devine, Sherral; Auerbach, Sanford; Alosco, Michael L.; Nowinski, Christopher J.; Kowall, Neil W.; Goldstein, Lee E.; Dwyer, Brigid; Katz, Douglas I.; Cantu, Robert C.; Stern, Robert A.; Au, Rhoda; McKee, Ann C.; Stein, Thor D.			Lewy Body Pathology and Chronic Traumatic Encephalopathy Associated With Contact Sports	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						American football; Chronic traumatic encephalopathy (CTE); Lewy body disease; Mild traumatic brain injury; Parkinson disease; Repetitive head impacts	ALPHA-SYNUCLEIN; BRAIN-INJURY; PARKINSON DISEASE; NATIONAL INSTITUTE; ALZHEIMERS-DISEASE; AMERICAN FOOTBALL; CONCUSSION; DIAGNOSIS; PLAYERS; TAU	Traumatic brain injury has been associated with increased risk of Parkinson disease and parkinsonism, and parkinsonism and Lewy body disease (LBD) can occur with chronic traumatic encephalopathy (CTE). To test whether contact sports and CTE are associated with LBD, we compared deceased contact sports athletes (n = 269) to cohorts from the community (n 164) and the Boston University Alzheimer disease (AD) Center (n = 261). Participants with CTE and LBD were more likely to have 3-amyloid deposition, dementia, and parkinsonism than CTE alone (p < 0.05). Traditional and hierarchical clustering showed a similar pattern of LBD distribution in CTE compared to LBD alone that was most frequently neocortical, limbic, or brainstem. In the community-based cohort, years of contact sports play were associated with neocortical LBD (OR = 1.30 per year, p = 0.0112), and in a pooled analysis a threshold of >8 years of play best predicted neocortical LBD (ROC analysis, OR = 6.24, 95% CI = 1.5 25, p = 0.011), adjusting for age, sex, and APOE allele status. Clinically, dementia was significantly associated with neocortical LBD, CTE stage, and AD; parkinsonism was associated with LBD pathology but not CTE stage. Contact sports participation may increase risk of developing neocortical LBD, and increased LBD frequency may partially explain extrapyramidal motor symptoms sometimes observed in CTE.	[Adams, Jason W.; Alvarez, Victor E.; Mez, Jesse; Huber, Bertrand R.; Tripodis, Yorghos; Kubilus, Caroline A.; Cormier, Kerry; Kiernan, Patrick T.; Daneshvar, Daniel H.; Svirsky, Sarah; Nicks, Raymond; Abdolmohammadi, Bobak; Evers, Laney; Solomon, Todd M.; Cherry, Jonathan D.; Aytan, Nurgul; Mahar, Ian; Alosco, Michael L.; Nowinski, Christopher J.; Kowall, Neil W.; Goldstein, Lee E.; Stern, Robert A.; Au, Rhoda; McKee, Ann C.; Stein, Thor D.] Boston Univ, Alzheimers Dis & CTE Ctr, Boston, MA 02215 USA; [Alvarez, Victor E.; Mez, Jesse; Devine, Sherral; Auerbach, Sanford; Alosco, Michael L.; Au, Rhoda; McKee, Ann C.; Stein, Thor D.] Boston Univ, Sch Med, Framingham Heart Study, Boston, MA 02118 USA; [Alvarez, Victor E.; Huber, Bertrand R.; Meng, Gaoyuan; Kowall, Neil W.; McKee, Ann C.; Stein, Thor D.] VA Boston Healthcare Syst, Boston, MA USA; [Tripodis, Yorghos; Chua, Alicia S.; Au, Rhoda] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Xia, Weiming; Meng, Gaoyuan; McKee, Ann C.; Stein, Thor D.] Dept Vet Affairs Med Ctr, Bedford, MA USA; [Nowinski, Christopher J.; Cantu, Robert C.] Boston Univ, Sch Med, Concuss Legacy Fdn, Boston, MA 02118 USA; [Goldstein, Lee E.; McKee, Ann C.; Stein, Thor D.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Dwyer, Brigid; Katz, Douglas I.] Braintree Rehabil Hosp, Brain Injury Program, Braintree, MA USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Au, Rhoda] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	Stein, TD (corresponding author), VA Boston Healthcare Syst, Dept Pathol & Lab Med, 150 S Huntington Ave, Boston, MA 02130 USA.	tdstein@bu.edu	, Bob/ABA-8507-2020; Mahar, Ian/R-8226-2017; Dwyer, Brigid/AAI-6199-2020; Lang, Steven/AAE-8102-2021; Chua, Alicia/AAA-3628-2019; Kowall, Neil/M-5378-2019	Mahar, Ian/0000-0002-8792-0437; Dwyer, Brigid/0000-0002-6446-8054; Lang, Steven/0000-0003-1669-9146; Kowall, Neil/0000-0002-6624-0213; Chua, Alicia/0000-0001-6908-8539; Tripodis, Yorghos/0000-0003-2190-7608	Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award [I01-CX001038]; Veterans Affairs Biorepository [BX002466]; Alzheimer's AssociationAlzheimer's Association [NIRG-305779, NIRG-362697]; National Institute of AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [RF1AG054156, R56AG057768, K23AG046377, R01AG016495, R01AG008122, R01AG033040]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659, F32NS096803, R01NS017950]; National Institute of Aging Boston University AD Center [P30AG13846, 0572063345-5]; Department of Defense Peer Reviewed Alzheimer's Research Program (PRARP) [13267017]; National Heart, Lung, and Blood Institute, Framingham Heart Study [N01-HC-25195, HHSN268201500001I]; Concussion Legacy Foundation; Fonds de Recherche du Quebec-Sante (FRQS) postdoctoral scholar; Andlinger Foundation; WWE; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS017950, K23NS102399, U01NS086659, F32NS096803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033040, RF1AG054156, P30AG013846, K23AG046377] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX003527, I01CX001038] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award (I01-CX001038); Veterans Affairs Biorepository (BX002466); Alzheimer's Association (NIRG-305779, NIRG-362697); National Institute of Aging (RF1AG054156, R56AG057768, K23AG046377, R01AG016495, R01AG008122, R01AG033040); National Institute of Neurological Disorders and Stroke (U01NS086659, F32NS096803, R01NS017950); National Institute of Aging Boston University AD Center (P30AG13846; supplement 0572063345-5); Department of Defense Peer Reviewed Alzheimer's Research Program (PRARP #13267017); National Heart, Lung, and Blood Institute, Framingham Heart Study (N01-HC-25195, HHSN268201500001I); Concussion Legacy Foundation. IM receives funding as a Fonds de Recherche du Quebec-Sante (FRQS) postdoctoral scholar. This work was also supported by unrestricted gifts from the Andlinger Foundation and WWE.	Alosco ML, 2018, ANN NEUROL, V83, P886, DOI 10.1002/ana.25245; Barnes DE, 2018, JAMA NEUROL, V2018, DOI [10.1001/jamaneurol, DOI 10.1001/JAMANEUROL]; Beekly DL, 2007, ALZ DIS ASSOC DIS, V21, P249, DOI 10.1097/WAD.0b013e318142774e; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Burre J, 2010, SCIENCE, V329, P1663, DOI 10.1126/science.1195227; Campbell BCV, 2000, NEUROBIOL DIS, V7, P192, DOI 10.1006/nbdi.2000.0286; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Colom-Cadena M, 2017, J NEUROPATH EXP NEUR, V76, P216, DOI 10.1093/jnen/nlx002; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Darby A, 2015, J NEUROPATHOL EXP NE, V74, P588; Gardner RC, 2018, NEUROLOGY, V90, pE1771, DOI 10.1212/WNL.0000000000005522; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Greenland S, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1981; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Logan T, 2017, NAT NEUROSCI, V20, P681, DOI 10.1038/nn.4529; Mackenzie IRA, 2010, ACTA NEUROPATHOL, V119, P1, DOI 10.1007/s00401-009-0612-2; MAWDSLEY C, 1963, LANCET, V2, P795; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Mollenhauer B, 2011, LANCET NEUROL, V10, P230, DOI 10.1016/S1474-4422(11)70014-X; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Mukaetova-Ladinska EB, 2013, J NEUROPATH EXP NEUR, V72, P53, DOI 10.1097/NEN.0b013e31827c5710; Nauman EA, 2015, DEV NEUROPSYCHOL, V40, P85, DOI 10.1080/87565641.2015.1016161; Pearson ES, 1931, BIOMETRIKA, V23, P114, DOI 10.1093/biomet/23.1-2.114; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Postupna N, 2015, J NEUROPATH EXP NEUR, V74, P100, DOI 10.1097/NEN.0000000000000153; Rose G, 2001, INT J EPIDEMIOL, V30, P427, DOI 10.1093/ije/30.3.427; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Toledo JB, 2016, ACTA NEUROPATHOL, V131, P393, DOI 10.1007/s00401-015-1526-9; Toledo JB, 2013, ACTA NEUROPATHOL, V126, P683, DOI 10.1007/s00401-013-1148-z; Uchikado H, 2006, J NEUROPATH EXP NEUR, V65, P685, DOI 10.1097/01.jnen.0000225908.90052.07; Vallortigara J, 2016, J ALZHEIMERS DIS, V50, P101, DOI 10.3233/JAD-150707; Vonsattel JPG, 2008, ACTA NEUROPATHOL, V115, P509, DOI 10.1007/s00401-007-0311-9	47	28	28	0	34	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	SEP	2018	77	9					757	768		10.1093/jnen/nly065			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	GS3TJ	WOS:000443544600002	30053297	Green Published, Bronze			2021-06-18	
J	Threlkeld, ZD; Bodien, YG; Rosenthal, ES; Giacino, JT; Nieto-Castanon, A; Wu, O; Whitfield-Gabrieli, S; Edlow, BL				Threlkeld, Zachary D.; Bodien, Yelena G.; Rosenthal, Eric S.; Giacino, Joseph T.; Nieto-Castanon, Alfonso; Wu, Ona; Whitfield-Gabrieli, Susan; Edlow, Brian L.			Functional networks reemerge during recovery of consciousness after acute severe traumatic brain injury	CORTEX			English	Article						Coma; Consciousness; Traumatic brain injury; Default mode network; Resting-state functional MRI	DEFAULT-MODE NETWORK; RESTING-STATE; BOLD SIGNAL; CONNECTIVITY; FMRI; DISORDERS; AWARENESS; FLUCTUATIONS; INVOLVEMENT; DIAGNOSIS	Integrity of the default mode network (DMN) is believed to be essential for human consciousness. However, the effects of acute severe traumatic brain injury (TBI) on DMN functional connectivity are poorly understood. Furthermore, the temporal dynamics of DMN reemergence during recovery of consciousness have not been studied longitudinally in patients with acute severe TBI. We performed resting-state functional magnetic resonance imaging (rs-fMRI) to measure DMN connectivity in 17 patients admitted to the intensive care unit (ICU) with acute severe TBI and in 16 healthy control subjects. Eight patients returned for follow-up rs-fMRI and behavioral assessment six months post-injury. At each time point, we analyzed DMN connectivity by measuring intra-network correlations (i.e. positive correlations between DMN nodes) and inter-network anticorrelations (i.e. negative correlations between the DMN and other resting-state networks). All patients were comatose upon arrival to the ICU and had a disorder of consciousness (DoC) at the time of acute rs-fMRI (9.2 +/- 4.6 days post-injury): 2 coma, 4 unresponsive wakefulness syndrome, 7 minimally conscious state, and 4 post-traumatic confusional state. We found that, while DMN anticorrelations were absent in patients with acute DoC, patients who recovered from coma to a minimally conscious or confusional state while in the ICU showed partially preserved DMN correlations. Patients who remained in coma or unresponsive wakefulness syndrome in the ICU showed no DMN correlations. All eight patients assessed longitudinally recovered beyond the confusional state by 6 months post-injury and showed normal DMN correlations and anticorrelations, indistinguishable from those of healthy subjects. Collectively, these findings suggest that recovery of consciousness after acute severe TBI is associated with partial preservation of DMN correlations in the ICU, followed by long-term normalization of DMN correlations and anticorrelations. Both intra-network DMN correlations and inter-network DMN anticorrelations may be necessary for full recovery of consciousness after acute severe TBI. (C) 2018 Elsevier Ltd. All rights reserved.	[Threlkeld, Zachary D.; Bodien, Yelena G.; Edlow, Brian L.] Harvard Med Sch, Ctr Neurotechnol & Neurorecovery, Massachusetts Gen Hosp, Boston, MA USA; [Threlkeld, Zachary D.; Bodien, Yelena G.; Rosenthal, Eric S.; Edlow, Brian L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA; [Bodien, Yelena G.; Giacino, Joseph T.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Charlestown, MA USA; [Nieto-Castanon, Alfonso] Boston Univ, Dept Speech Language & Hearing Sci, Boston, MA 02215 USA; [Wu, Ona; Edlow, Brian L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA; [Whitfield-Gabrieli, Susan] MIT, McGovern Inst Brain Res, Martinos Imaging Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Edlow, BL (corresponding author), Massachusetts Gen Hosp, Ctr Neurotechnol & Neurorecovery, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.	zthrelkeld@mgh.harvard.edu; ybodien@mgh.harvard.edu; erosenthal@mgh.harvard.edu; jgiacino@mgh.harvard.edu; alfnie@gmail.com; ona@nmr.mgh.harvard.edu; swg@mit.edu; bedlow@mgh.harvard.edu	Giacino, Joseph/AAF-1952-2021; Rosenthal, Eric Scott/A-2085-2017	Giacino, Joseph/0000-0002-7916-9698; Rosenthal, Eric Scott/0000-0003-3900-356X; Wu, Ona/0000-0002-5509-9461; Bodien, Yelena/0000-0003-4858-2903	NIH National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS094538]; Center for Integration of Medicine & Innovative Technology (Boston, MA, USA); American Academy of Neurology/American Brain Foundation; James S. McDonnell Foundation; Massachusetts General Hospital Department of Neurology and Division of Neurocritical Care and Emergency Neurology; National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR), Administration for Community Living [90DP0039]; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMOUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U48DP000039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS105950, K23NS094538] Funding Source: NIH RePORTER	The authors thank the nursing staff of the Massachusetts General Hospital Neurosciences ICU, Multidisciplinary ICU, and Surgical ICU. We are grateful to the patients and families in this study for their participation and support. We acknowledge Dylan Tisdall and Andre van der Kouwe (Athinoula A. Martinos Center for Biomedical Imaging) and Himanshu Bhat (Siemens Medical Center) for the provision of WIP711D (vNav Motion-Corrected Multiecho MPRAGE) used to acquire MEMPRAGE data. This work was supported by grants from the NIH National Institute of Neurological Disorders and Stroke (K23NS094538), the Center for Integration of Medicine & Innovative Technology (Boston, MA, USA), the American Academy of Neurology/American Brain Foundation, the James S. McDonnell Foundation, the Massachusetts General Hospital Department of Neurology and Division of Neurocritical Care and Emergency Neurology, and the National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR), Administration for Community Living (90DP0039, Spaulding-Harvard TBI Model System). The contents of this manuscript do not necessarily represent the policy of the U.S. Department of Health and Human Services, and endorsement by the federal government should not be assumed.	Amico E, 2017, NEUROIMAGE, V148, P201, DOI 10.1016/j.neuroimage.2017.01.020; Andrews-Hanna JR, 2010, J NEUROPHYSIOL, V104, P322, DOI 10.1152/jn.00830.2009; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Birn RM, 2013, NEUROIMAGE, V83, P550, DOI 10.1016/j.neuroimage.2013.05.099; Bodien YG, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00688; Bodien YG, 2017, SEMIN NEUROL, V37, P485, DOI 10.1055/s-0037-1607310; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Braga RM, 2017, NEURON, V95, P457, DOI 10.1016/j.neuron.2017.06.038; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Crone JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026373; Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; Demertzi A, 2015, BRAIN, V138, P2619, DOI 10.1093/brain/awv169; Di Perri C, 2016, LANCET NEUROL, V15, P830, DOI 10.1016/S1474-4422(16)00111-3; Di X, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00493; Edlow BL, 2017, BRAIN, V140, P2399, DOI 10.1093/brain/awx176; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Golland Y, 2007, CEREB CORTEX, V17, P766, DOI 10.1093/cercor/bhk030; Greicius MD, 2008, HUM BRAIN MAPP, V29, P839, DOI 10.1002/hbm.20537; He JH, 2014, NMR BIOMED, V27, P880, DOI 10.1002/nbm.3130; Horovitz SG, 2009, P NATL ACAD SCI USA, V106, P11376, DOI 10.1073/pnas.0901435106; Keller CJ, 2013, J NEUROSCI, V33, P6333, DOI 10.1523/JNEUROSCI.4837-12.2013; Kirsch M, 2017, ANESTH ANALG, V124, P588, DOI 10.1213/ANE.0000000000001721; Kondziella D, 2017, NEUROCRIT CARE, V27, P401, DOI 10.1007/s12028-017-0407-6; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; Muschelli J, 2014, NEUROIMAGE, V96, P22, DOI 10.1016/j.neuroimage.2014.03.028; Norton L, 2012, NEUROLOGY, V78, P175, DOI 10.1212/WNL.0b013e31823fcd61; Qin PM, 2015, ANN NEUROL, V78, P594, DOI 10.1002/ana.24479; Raichle ME, 2011, BRAIN CONNECT, V1, P3, DOI 10.1089/brain.2011.0019; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rosazza C, 2016, ANN NEUROL, V79, P841, DOI 10.1002/ana.24634; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Sair HI, 2017, RADIOLOGY, DOI [10.1148/radio1.2017162161, DOI 10.1148/RADIO1.2017162161]; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Silva S, 2015, NEUROLOGY, V85, P2036, DOI 10.1212/WNL.0000000000002196; Spadone S, 2015, P NATL ACAD SCI USA, V112, P8112, DOI 10.1073/pnas.1415439112; Stamatakis EA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014224; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Symonds CP, 1928, BRIT MED J, V1928, P829, DOI 10.1136/bmj.2.3540.829; Tagliazucchi E, 2014, NEURON, V82, P695, DOI 10.1016/j.neuron.2014.03.020; van der Kouwe AJW, 2008, NEUROIMAGE, V40, P559, DOI 10.1016/j.neuroimage.2007.12.025; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Wannez S, 2017, ANN NEUROL, V81, P883, DOI 10.1002/ana.24962; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Whitfield-Gabrieli S, 2011, NEUROIMAGE, V55, P225, DOI 10.1016/j.neuroimage.2010.11.048; Woo CW, 2014, NEUROIMAGE, V91, P412, DOI 10.1016/j.neuroimage.2013.12.058; Wu XH, 2015, J NEUROSCI, V35, P12932, DOI 10.1523/JNEUROSCI.0415-15.2015	53	28	29	0	7	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	SEP	2018	106						299	308		10.1016/j.cortex.2018.05.004			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	GV3HO	WOS:000445985200023	29871771	Bronze, Green Accepted			2021-06-18	
J	Vay, SU; Flitsch, LJ; Rabenstein, M; Rogall, R; Blaschke, S; Kleinhaus, J; Reinert, N; Bach, A; Fink, GR; Schroeter, M; Rueger, MA				Vay, Sabine Ulrike; Flitsch, Lea Jessica; Rabenstein, Monika; Rogall, Rebecca; Blaschke, Stefan; Kleinhaus, Judith; Reinert, Noemie; Bach, Annika; Fink, Gereon Rudolf; Schroeter, Michael; Rueger, Maria Adele			The plasticity of primary microglia and their multifaceted effects on endogenous neural stem cells in vitro and in vivo	JOURNAL OF NEUROINFLAMMATION			English	Article						Neuroinflammation; Neuroprotection; Stem cell-mediated regeneration; M1 microglia; M2 microglia; Hybrid microglia; Cerebral ischemia	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; M2 MICROGLIA; NEURODEGENERATIVE DISEASES; MACROPHAGE ACTIVATION; STEM/PROGENITOR CELLS; REACTIVE ASTROCYTES; CHRONIC PHASE; WHITE-MATTER	Background: Microglia-the resident immune cells of the brain-are activated after brain lesions, e.g., cerebral ischemia, and polarize towards a classic "M1" pro-inflammatory or an alternative "M2" anti-inflammatory phenotype following characteristic temporo-spatial patterns, contributing either to secondary tissue damage or to regenerative responses. They closely interact with endogenous neural stem cells (NSCs) residing in distinct niches of the adult brain. The current study aimed at elucidating the dynamics of microglia polarization and their differential effects on NSC function. Results: Primary rat microglia in vitro were polarized towards a M1 phenotype by LPS, or to a M2 phenotype by IL4, while simultaneous exposure to LPS plus IL4 resulted in a hybrid phenotype expressing both M1- and M2-characteristic markers. M2 microglia migrated less but exhibit higher phagocytic activity than M1 microglia. Defined mediators switched microglia from one polarization state to the other, a process more effective when transforming M2 microglia towards M1 than vice versa. Polarized microglia had differential effects on the differentiation potential of NSCs in vitro and in vivo, with M1 microglia promoting astrocytogenesis, while M2 microglia supported neurogenesis. Regardless of their polarization, microglia inhibited NSC proliferation, increased NSC migration, and accelerated NSC differentiation. Conclusion: Overall, this study shed light on the complex conditions governing microglia polarization and the effects of differentially polarized microglia on critical functions of NSCs in vitro and in vivo. Refining the understanding of microglia activation and their modulatory effects on NSCs is likely to facilitate the development of innovative therapeutic concepts supporting the innate regenerative capacity of the brain.	[Vay, Sabine Ulrike; Flitsch, Lea Jessica; Rabenstein, Monika; Rogall, Rebecca; Blaschke, Stefan; Kleinhaus, Judith; Reinert, Noemie; Bach, Annika; Fink, Gereon Rudolf; Schroeter, Michael; Rueger, Maria Adele] Univ Hosp Cologne, Dept Neurol, Kerpener Str 62, D-50924 Cologne, Germany; [Blaschke, Stefan; Fink, Gereon Rudolf; Schroeter, Michael; Rueger, Maria Adele] Res Ctr Juelich, Inst Neurosci & Med INM 3, Cognit Neurosci, Julich, Germany	Vay, SU (corresponding author), Univ Hosp Cologne, Dept Neurol, Kerpener Str 62, D-50924 Cologne, Germany.	sabine.vay@uk-koeln.de	Fink, Gereon R./E-1616-2012; Vay, Sabine Ulrike/AAP-3842-2020; Blaschke, Stefan/AAM-9468-2021	Fink, Gereon R./0000-0002-8230-1856; Vay, Sabine Ulrike/0000-0002-3289-7807; 	Marga-und-Walter-Boll-Foundation [210-10-15]; "Koeln Fortune Program"/Faculty of Medicine, University of Cologne, Germany [339/2015]	This research work was supported by the "Marga-und-Walter-Boll-Foundation" (#210-10-15) and by the "Koeln Fortune Program"/Faculty of Medicine, University of Cologne, Germany (339/2015).	Aarum J, 2003, P NATL ACAD SCI USA, V100, P15983, DOI 10.1073/pnas.2237050100; Ajmone-Cat MA, 2013, GLIA, V61, P1698, DOI 10.1002/glia.22550; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Dooley D, 2014, PHARMACOL THERAPEUT, V141, P21, DOI 10.1016/j.pharmthera.2013.08.001; Ekdahl CT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00041; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Franco R, 2015, PROG NEUROBIOL, V131, P65, DOI 10.1016/j.pneurobio.2015.05.003; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Ghisletti S, 2010, IMMUNITY, V32, P317, DOI 10.1016/j.immuni.2010.02.008; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Girard S, 2013, GLIA, V61, P813, DOI 10.1002/glia.22478; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Kokaia Z, 2012, NAT NEUROSCI, V15, P1078, DOI 10.1038/nn.3163; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; L'Episcopo F, 2018, STEM CELLS, V36, P1179, DOI 10.1002/stem.2827; L'Episcopo F, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00012; L'Episcopo F, 2013, J NEUROSCI, V33, P1462, DOI 10.1523/JNEUROSCI.3206-12.2013; L'Episcopo F, 2012, J NEUROSCI, V32, P2062, DOI 10.1523/JNEUROSCI.5259-11.2012; Lam D, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0941-3; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Martino G, 2011, PHYSIOL REV, V91, P1281, DOI 10.1152/physrev.00032.2010; MATTHEWS MA, 1974, CELL TISSUE RES, V148, P477; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Michelucci A, 2009, J NEUROIMMUNOL, V210, P3, DOI 10.1016/j.jneuroim.2009.02.003; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Mosher KI, 2012, NAT NEUROSCI, V15, P1485, DOI 10.1038/nn.3233; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nayak D, 2014, ANNU REV IMMUNOL, V32, P367, DOI 10.1146/annurev-immunol-032713-120240; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Osman AM, 2019, NEUROSCIENCE, V405, P92, DOI 10.1016/j.neuroscience.2017.10.034; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Rabenstein M, 2016, J NEUROIMMUNOL, V299, P130, DOI 10.1016/j.jneuroim.2016.09.009; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Rivest Serge, 2011, Expert Rev Neurother, V11, P783, DOI 10.1586/ern.11.64; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Rueger MA, 2010, J NEUROSCI, V30, P6454, DOI 10.1523/JNEUROSCI.6092-09.2010; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Shechter R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027969; Sierra A, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00240; Sierra A, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/610343; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011; Vay SU, 2016, J NEUROSCI RES, V94, P149, DOI 10.1002/jnr.23686; Vogel DYS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-35; Walberer M, 2014, BRAIN RES, V1581, P80, DOI 10.1016/j.brainres.2014.05.030; Walberer Maureen, 2010, Exp Transl Stroke Med, V2, P22, DOI 10.1186/2040-7378-2-22; Walter HL, 2015, NEUROSCIENCE, V292, P71, DOI 10.1016/j.neuroscience.2015.02.024; Xu HZ, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/5405104; Yuan JC, 2017, ONCOTARGET, V8, P19855, DOI 10.18632/oncotarget.15774	70	28	30	1	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 13	2018	15								226	10.1186/s12974-018-1261-y			21	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	GQ2QW	WOS:000441501400001	30103769	DOAJ Gold, Green Published			2021-06-18	
J	Katz, BP; Kudela, M; Harezlak, J; McCrea, M; McAllister, T; Broglio, SP				Katz, Barry P.; Kudela, Maria; Harezlak, Jaroslaw; McCrea, Michael; McAllister, Thomas; Broglio, Steven P.		CARE Consortium Investigators	Baseline Performance of NCAA Athletes on a Concussion Assessment Battery: A Report from the CARE Consortium	SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; NEUROCOGNITIVE FUNCTION; STANDARDIZED ASSESSMENT; FOOTBALL PLAYERS; SPORT; STATEMENT; SYMPTOMS; POSITION; HISTORY; RELIABILITY	Background Sport-related concussion and repetitive head impact exposure in contact sports continue to receive increased attention in public and medical spheres. The Concussion Assessment, Research and Education (CARE) Consortium, a multicenter cooperative, was established to study the natural history of concussion in National Collegiate Athletic Association (NCAA) collegiate student-athletes across 29 colleges and universities in the United States. The purpose of this investigation is to provide normative data from the CARE Consortium and evaluate for differences between sport categories. Methods NCAA student-athletes were evaluated annually for general demographics and sport-specific characteristics before the start of the competitive season. We collected demographic and medical history information and evaluated each student-athlete's neurocognitive function, neurological status, postural stability, and self-reported symptoms. Sports were categorized by the amount of contact typically associated with the sport (i. e., contact, limited contact, non-contact). Comparisons between the three sport categories for the evaluated variables were made using linear or zero inflated negative binomial regression models adjusted for gender, concussion history, and household income. Results Over a 2-year period (August 2014-July 2016), 15,681 NCAA athletes completed preseason evaluations. Overall, 53% of the athletes were in the contact sport group, 31% were in the limited contact group and 17% were in the non-contact group. After adjusting for covariates, there were statistically significant differences found between athlete groups, although the differences and effect sizes were small and not clinically significant. The contact sport group had better scores on Immediate Post- Concussion Assessment Testing (ImPACT similar to) visual and verbal memory, Sport Concussion Assessment Tool (SCAT) symptom checklist, and Brief Symptom Inventory-18 (BSI-18), but slower ImPACT reaction time and worse scores on Standardized Assessment of Concussion (SAC). Further, the data indicate that some ImPACT score distributions were noticeably different from those presented in the technical manual. Conclusions In this large, racially and socio-economically diverse cohort of male and female college athletes, we found no evidence that student-athletes participating in contact sports have clinically meaningful deficits in preseason cognitive and balance testing. They also did not report significantly more symptoms of psychological distress when compared with student-athletes in non-contact or limited contact sports. In addition, the data suggest potential limitations when using published ImPACT norms when evaluating injured athletes.	[Katz, Barry P.] Indiana Univ, Indiana Univ Sch Med, Dept Biostat, 410 West Tenth St, Indianapolis, IN 46260 USA; [Katz, Barry P.; Kudela, Maria] Richard M Fairbanks Sch Publ Hlth, Dept Biostat, Indianapolis, IN 46202 USA; [Harezlak, Jaroslaw] Indiana Univ, Dept Epidemiol & Biostat, Bloomington, IN USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [McAllister, Thomas] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Broglio, Steven P.] Univ Michigan, Univ Michigan Injury Ctr, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA	Katz, BP (corresponding author), Indiana Univ, Indiana Univ Sch Med, Dept Biostat, 410 West Tenth St, Indianapolis, IN 46260 USA.; Katz, BP (corresponding author), Richard M Fairbanks Sch Publ Hlth, Dept Biostat, Indianapolis, IN 46202 USA.	bkatz@iu.edu	; Harezlak, Jaroslaw/P-8557-2014	Cameron, Kenneth/0000-0002-6276-4482; Harezlak, Jaroslaw/0000-0002-3070-7686	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - National Collegiate Athletic Association (NCAA); Department of Defense (DoD)United States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]; Department of DefenseUnited States Department of Defense	Contributing investigators include Scott Anderson, ATC (University of Oklahoma); Jeffrey Bazarian, MD, MPH (University of Rochester); Christopher Todd Bullers, MD (Wake Forest University); Christopher Giza, MD (University of California-Los Angeles); Kevin Guskiewicz, PhD, ATC (University of North Carolina); Jessica Dysart Myles, PhD, ATC (University of North Georgia); Patrick O'Donnell, MHA (United States Coast Guard Academy); Steven J. Svoboda, MD (United States Military Academy); and Ryan Tierney, PhD, ATC (Temple University). The authors would also like to thank Jody Harland, Janetta Matesan, Larry Riggen, and Shi Zhao (Indiana University); Ashley and Ellie Rettmann (University of Michigan); Melissa Koschnitzke (Medical College of Wisconsin); Michael Jarrett, Vibeke Brinck and Bianca Byrne (Quesgen); Thomas Dompier, Melissa Niceley Baker, and Sara Dalton (Datalys Center for Sports Injury Research and Prevention); and the research and medical staff at each of the participating sites. This publication was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded by the National Collegiate Athletic Association (NCAA) and the Department of Defense (DoD). The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014, is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award NO W81XWH-14-2-0151. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense (DHP funds).	Barr WB, 2001, J ATHL TRAINING, V36, P297; Broglio SP, 2017, SPORTS MED; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cameron KL, 2012, J NEUROTRAUM, V29, P1313, DOI 10.1089/neu.2011.2168; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hintze JL, 1998, AM STAT, V52, P181, DOI 10.2307/2685478; ImPACT Applications Inc, IMPACT VERS 2 0 CLIN, P1; ImPACT Applications Inc, 2011, IMM POSTC ASS TEST I, P1; Kaplan GA, 2001, INT J EPIDEMIOL, V30, P256, DOI 10.1093/ije/30.2.256; Kerr ZY, 2015, AM J SPORT MED, V43, P606, DOI 10.1177/0363546514562180; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kontos AP, 2010, ARCH CLIN NEUROPSYCH, V25, P734, DOI 10.1093/arclin/acq068; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; Loeys T, 2012, BRIT J MATH STAT PSY, V65, P163, DOI 10.1111/j.2044-8317.2011.02031.x; Matheson GO, 2011, CLIN J SPORT MED, V21, P25, DOI 10.1097/JSM.0b013e3182095f92; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Ulfarsson T, 2014, BRAIN INJURY, V28, P328, DOI 10.3109/02699052.2013.865274; Zimmer A, 2013, J ATHL TRAINING, V48, P659, DOI 10.4085/1062-6050-48.5.06	36	28	28	0	10	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	AUG	2018	48	8					1971	1985		10.1007/s40279-018-0875-7			15	Sport Sciences	Sport Sciences	HF7XO	WOS:000454455500014	29498030				2021-06-18	
J	Cnossen, MC; van der Naalt, J; Spikman, JM; Nieboer, D; Yue, JK; Winkler, EA; Manley, GT; von Steinbuechel, N; Polinder, S; Steyerberg, EW; Lingsma, HF				Cnossen, Maryse C.; van der Naalt, Joukje; Spikman, Joke M.; Nieboer, Daan; Yue, John K.; Winkler, Ethan A.; Manley, Geoffrey T.; von Steinbuechel, Nicole; Polinder, Suzanne; Steyerberg, Ewout W.; Lingsma, Hester F.			Prediction of Persistent Post-Concussion Symptoms after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						external validation; mild traumatic brain injury; post-concussion symptoms; prediction model	POSTCONCUSSION SYNDROME; EXTERNAL VALIDATION; PROGNOSTIC MODELS; EVENT SCALE; QUESTIONNAIRE; DIAGNOSIS; IMPACT	Persistent post-concussion symptoms (PPCS) occur frequently after mild traumatic brain injury (mTBI). The identification of patients at risk for poor outcome remains challenging because valid prediction models are missing. The objectives of the current study were to assess the quality and clinical value of prediction models for PPCS and to develop a new model based on the synthesis of existing models and addition of complaints at the emergency department (ED). Patients with mTBI (Glasgow Coma Scale score 13-15) were recruited prospectively from three Dutch level I trauma centers between 2013 and 2015 in the UPFRONT study. PPCS were assessed using the Head Injury Severity Checklist at six months post-injury. Two prediction models (Stulemeijer 2008; Cnossen 2017) were examined for calibration and discrimination. The final model comprised variables of existing models with the addition of headache, nausea/vomiting, and neck pain at ED, using logistic regression and bootstrap validation. Overall, 591 patients (mean age 51years, 41% female) were included; PPCS developed in 241 (41%). Existing models performed poorly at external validation (area under the curve [AUC]: 0.57-0.64). The newly developed model included female sex (odds ratio [OR] 1.48, 95% confidence interval [CI] [1.01-2.18]), neck pain (OR 2.58, [1.39-4.78]), two-week post-concussion symptoms (OR 4.89, [3.19-7.49]) and two-week post-traumatic stress (OR 2.98, [1.88-4.73]) as significant predictors. Discrimination of this model was adequate (AUC after bootstrap validation: 0.75). Existing prediction models for PPCS perform poorly. A new model performs reasonably with predictive factors already discernible at ED warranting further external validation. Prediction research in mTBI should be improved by standardizing definitions and data collection and by using sound methodology.	[Cnossen, Maryse C.; Nieboer, Daan; Polinder, Suzanne; Steyerberg, Ewout W.; Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [van der Naalt, Joukje; Spikman, Joke M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [Spikman, Joke M.] Univ Groningen, Univ Med Ctr Groningen, Dept Clin & Dev Neuropsychol, Groningen, Netherlands; [Yue, John K.; Winkler, Ethan A.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Yue, John K.; Winkler, Ethan A.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [von Steinbuechel, Nicole] Georg August Univ, Inst Med Psychol & Med Sociol, Gottingen, Germany; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands	Cnossen, MC (corresponding author), Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	m.c.cnossen@erasmusmc.nl	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Spikman, Jacoba/0000-0002-6477-0763	Dutch Brain Foundation [Ps-2012-06]; European Union FP 7th Framework program [602150]	The UPFRONT study was funded by the Dutch Brain Foundation (Ps-2012-06). The authors M.C. Cnossen, S. Polinder, H.F. Lingsma, S. Polinder, D. Nieboer, and E.W. Steyerberg were funded by the European Union FP 7th Framework program (grant 602150).	Akaike H, 1973, 2 INT S INF THEOR; Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cnossen M.C., 2017, J NEUROTRAUMA; Collins G.S., 2014, BMJ-BRIT MED J, P350; Collins GS, 2016, STAT MED, V35, P214, DOI 10.1002/sim.6787; de Koning ME, 2017, BRAIN INJURY, V31, P1102, DOI 10.1080/02699052.2017.1296193; de Koning ME, 2016, INJURY, V47, P2041, DOI 10.1016/j.injury.2016.04.036; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Foks K.A., 2017, J NEUROTRAUMA; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; King NS, 2013, BRAIN IMPAIR, V14, P235, DOI 10.1017/BrImp.2013.17; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kristman V, 2014, BRAIN INJURY, V28, P817; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Marshall CM, 2015, PHYSICIAN SPORTSMED, V43, P274, DOI 10.1080/00913847.2015.1064301; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Reuben A, 2014, EMERG MED J, V31, P72, DOI 10.1136/emermed-2012-201667; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Steyerberg EW., 2009, CLIN PREDICTION MODE; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Vergouwe Y, 2005, J CLIN EPIDEMIOL, V58, P475, DOI 10.1016/j.jclinepi.2004.06.017; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Warren AM, 2015, J TRAUMA ACUTE CARE, V79, P1062, DOI 10.1097/TA.0000000000000875	42	28	28	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2018	35	22					2691	2698		10.1089/neu.2017.5486		JUL 2018	8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GZ0MO	WOS:000439664000001	29690799				2021-06-18	
J	Korley, FK; Yue, JK; Wilson, DH; Hrusovsky, K; Diaz-Arrastia, R; Ferguson, AR; Yuh, EL; Mukherjee, P; Wang, KKW; Valadka, AB; Puccio, AM; Okonkwo, DO; Manley, GT				Korley, Frederick K.; Yue, John K.; Wilson, David H.; Hrusovsky, Kevin; Diaz-Arrastia, Ramon; Ferguson, Adam R.; Yuh, Esther L.; Mukherjee, Pratik; Wang, Kevin K. W.; Valadka, Alex B.; Puccio, Ava M.; Okonkwo, David O.; Manley, Geoffrey T.			Performance Evaluation of a Multiplex Assay for Simultaneous Detection of Four Clinically Relevant Traumatic Brain Injury Biomarkers	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; glial fibrillary acidic protein; multiplex immunoassay; neurofilament light chain; total tau; traumatic brain injury; ubiquitin c-terminal hydrolase L1	COMMON DATA ELEMENTS; SERUM NEUROFILAMENT LIGHT; TRANSFORMING RESEARCH; CEREBROSPINAL-FLUID; GFAP; KNOWLEDGE; PROTEINS	Traumatic brain injury (TBI) results in heterogeneous pathology affecting multiple cells and tissue types in the brain. It is likely that assessment of such complexity will require simultaneous measurement of multiple molecular biomarkers in a single sample of biological fluid. We measured glial fibrillary acidic protein (GFAP), ubiquitin c-terminal hydrolase L1 (UCH-L1), neurofilament light chain (NF-L) and total tau in plasma samples obtained from 107 subjects enrolled in the Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot (TRACK-TBI Pilot) Study using the Quanterix Simoa 4-Plex assay. We also measured NF-L using the Simoa singleplex assay. We computed the correlation between the different biomarkers and calculated the discriminative value of each biomarker for distinguishing between subjects with abnormal versus normal head computed tomography (CT). We found a strong correlation between NF-L values derived from the multiplex and singleplex assays (correlation coefficient=0.997). Among biomarker values derived from the multiplex assay, the strongest correlation was between the axonal and neuronal markers, NF-L and UCH-L1 (coefficient=0.71). The weakest correlation was between the glial marker GFAP and the axonal marker tau (coefficient=0.06). The areas under the curves for distinguishing between subjects with/without abnormal head CT for multiplex GFAP, UCH-L1, NF-L, and total tau were: 0.88 (95% confidence interval 0.81-0.95), 0.86 (0.79-0.93), 0.84 (0.77-0.92), and 0.77 0.67-0.86), respectively. We conclude that the multiplex assay provides simultaneous quantification of GFAP, UCH-L1, NF-L, and tau, and may be clinically useful in the diagnosis of TBI as well as identifying different types of cellular injury.	[Korley, Frederick K.] Univ Michigan, Dept Emergency Med, 1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA; [Yue, John K.; Ferguson, Adam R.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Wilson, David H.; Hrusovsky, Kevin] Quanterix Corp, Lexington, MA USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Traumat Brain Injury Clin Res Ctr, Penn Presbyterian Med Ctr, Philadelphia, PA 19104 USA; [Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Wang, Kevin K. W.] Univ Florida, Ctr Neuroprote & Biomarkers Res, Dept Psychiat, McKnight Brain Inst, Gainesville, FL USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA USA; [Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA	Korley, FK (corresponding author), Univ Michigan, Dept Emergency Med, 1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.	korley@med.umich.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Wang, Kevin/0000-0002-9343-6473; Ferguson, Adam/0000-0001-7102-1608	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [UG3NS106899] Funding Source: NIH RePORTER		Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Bagnato S, 2017, J NEUROTRAUM, V34, P2475, DOI 10.1089/neu.2016.4837; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; Korley FK, 2016, J NEUROTRAUM, V33, P215, DOI 10.1089/neu.2015.3949; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; Liu Q, 2004, CELL MOL LIFE SCI, V61, P3057, DOI 10.1007/s00018-004-4268-8; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; National Institutes of Neurologic Diseases and Stroke (NINDS) Common Data Elements, 2015, PATH TERMS DEF TBI L; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Oliver JM, 2016, J NEUROTRAUM, V33, P1784, DOI 10.1089/neu.2015.4295; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Paziana K, 2015, FUTUR NEUROL, V10, P281, DOI 10.2217/FNL.15.13; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Yuan AD, 2012, J CELL SCI, V125, P3257, DOI 10.1242/jcs.104729; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	25	28	28	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2019	36	1					182	187		10.1089/neu.2017.5623		JUL 2018	6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HF0PB	WOS:000439642700001	29690824	Green Published			2021-06-18	
J	Ellenbogen, RG; Batjer, H; Cardenas, J; Berger, M; Bailes, J; Pieroth, E; Heyer, R; Theodore, N; Hsu, W; Nabel, E; Maroon, J; Cantu, R; Barnes, R; Collins, J; Putukian, M; Lonser, R; Solomon, G; Sills, A				Ellenbogen, Richard G.; Batjer, Hunt; Cardenas, Javier; Berger, Mitchel; Bailes, Julian; Pieroth, Elizabeth; Heyer, Robert; Theodore, Nicholas; Hsu, Wellington; Nabel, Elizabeth; Maroon, Joe; Cantu, Robert; Barnes, Ronnie; Collins, James; Putukian, Margot; Lonser, Russell; Solomon, Gary; Sills, Allen			National Football League Head, Neck and Spine Committee's Concussion Diagnosis and Management Protocol: 2017-18 season	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INTERNATIONAL-CONFERENCE; SPORT; STATEMENT	One of the National Football League's (NFL) Head, Neck and Spine Committee's principal goals is to create a 'best practice' protocol for concussion diagnosis and management for its players. The science related to concussion diagnosis and management continues to evolve, thus the protocol has evolved contemporaneously. The Fifth International Conference on Concussion in Sport was held in Berlin in 2016, and guidelines for sports concussion diagnosis and management were revised and refined. The NFL Head, Neck and Spine Committee has synthesised the most recent empirical evidence for sports concussion diagnosis and management including the Berlin consensus statement and tailored it to the game played in the NFL. One of the goals of the Committee is to provide a standardised, reliable, efficient and evidence-based protocol for concussion diagnosis and management that can be applied in this professional sport during practice and game day. In this article, the end-of-season version of the 2017-18 NFL Concussion Diagnosis and Management Protocol is described along with its clinical rationale. Immediate actions for concussion programme enhancement and research are reviewed. It is the Committee's expectation that the protocol will undergo refinement and revision over time as the science and clinical practice related to concussion in sports crystallise	[Ellenbogen, Richard G.] Univ Washington, Sch Med, Seattle, WA USA; [Batjer, Hunt] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Cardenas, Javier] Barrow Neurol Inst, Phoenix, AZ 85013 USA; [Berger, Mitchel] Univ Calif San Francisco, San Francisco Sch Med, San Francisco, CA 94143 USA; [Bailes, Julian; Pieroth, Elizabeth] NorthShore Univ Hlth Syst, Chicago, IL USA; [Bailes, Julian] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; [Heyer, Robert] Carolinas Med Ctr, Charlotte, NC 28203 USA; [Theodore, Nicholas] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Hsu, Wellington] Northwestern Univ, Sch Med, Chicago, IL USA; [Nabel, Elizabeth] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Maroon, Joe] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Cantu, Robert] Boston Univ, Sch Med, Boston, MA 02118 USA; [Barnes, Ronnie] New York Giants Football Club, New York, NY USA; [Collins, James] Los Angeles Chargers Football Club, Los Angeles, CA USA; [Putukian, Margot] Princeton Univ Hlth Serv, Princeton, NJ USA; [Lonser, Russell] Ohio State Univ, Sch Med, Columbus, OH 43210 USA; [Solomon, Gary] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Sills, Allen] Natl Football League, Dept Hlth & Safety, New York, NY USA	Solomon, G (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.	gary.solomon@vanderbilt.edu	Solomon, Gary/K-9011-2019				Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Feddermann-Demont N, 2017, BRIT J SPORT MED, V51, P903, DOI 10.1136/bjsports-2016-097403; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J ATHL TRAINING, P36; McCrory P, 2017, BRIT J SPORT MED, V51, P837, DOI 10.1136/bjsports-2017-097878; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; NFL Head Neck & Spine Committee, 2013, PROT REG DIAGN MAN C; Sungwon K., 2017, J LEGAL ASPECTS SPOR, V27, P162, DOI DOI 10.1123/JLAS.2016-0007; Tagliabue P, 2003, NEUROSURGERY, V53, P796, DOI 10.1227/01.NEU.0000083559.68424.3F	17	28	28	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUL	2018	52	14					894	902		10.1136/bjsports-2018-099203			9	Sport Sciences	Sport Sciences	GO2XV	WOS:000439845300011	29549147	Bronze			2021-06-18	
J	Haarbauer-Krupa, J; Arbogast, KB; Metzger, KB; Greenspan, AI; Kessler, R; Curr, AE; Bell, JM; DePadilla, L; Pfeiffer, MR; Zonfrillo, MR; Master, CL				Haarbauer-Krupa, Juliet; Arbogast, Kristy B.; Metzger, Kristina B.; Greenspan, Arlene, I; Kessler, Ronni; Curr, Allison E.; Bell, Jeneita M.; DePadilla, Lara; Pfeiffer, Melissa R.; Zonfrillo, Mark R.; Master, Christina L.			Variations in Mechanisms of Injury for Children with Concussion	JOURNAL OF PEDIATRICS			English	Article							EMERGENCY-DEPARTMENT VISITS; TRAUMATIC BRAIN-INJURY; SPORTS; RISK; BIOMECHANICS; SYMPTOMS; FOOTBALL; TRENDS	Objectives To assess the distribution of injury mechanisms and activities among children with concussions in a large pediatric healthcare system. Study design All patients, age 0-17 years, who had at least 1 clinical encounter with an International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis of concussion in the Children's Hospital of Philadelphia's electronic health record system from July 1,2012 to June 30, 2014, were selected (N = 8233) and their initial concussion-related visit identified. Approximately, 20% of the patients (n = 1625) were randomly selected for manual record review to examine injury mechanisms and activities. Results Overall, 70% of concussions were sports related; however, this proportion varied by age. Only 18% of concussions sustained by children aged 0-4 were sports related, compared with greater proportions for older children (67% for age 5-11,77% for age 12-14, and 73% for age 15-17). When the concussion was not sports related, the primary mechanisms of injury were struck by an object (30%) and falls (30%). Conclusions Sports-related injuries in children older than 6 years of age contributed to the majority of concussions in this cohort; however, it is important to note that approximately one-third of concussions were from non-sports-related activities. Although there is increased participation in community and organized sports activities among children, a focus on prevention efforts in other activities where concussions occur is needed.	[Haarbauer-Krupa, Juliet; Greenspan, Arlene, I; Bell, Jeneita M.; DePadilla, Lara] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; [Arbogast, Kristy B.; Metzger, Kristina B.; Kessler, Ronni; Curr, Allison E.; Pfeiffer, Melissa R.; Master, Christina L.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Arbogast, Kristy B.; Curr, Allison E.; Master, Christina L.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.] Brown Univ, Hasbro Childrens Hosp, Providence, RI 02912 USA; [Zonfrillo, Mark R.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA; [Master, Christina L.] Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Philadelphia, PA 19104 USA	Haarbauer-Krupa, J (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, 4770 Buford Highway NE,MS-F62, Atlanta, GA 30341 USA.	JHaarbauerKrupa@cdc.gov	Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563; Arbogast, Kristy/0000-0002-1694-4562; Curry, Allison/0000-0001-7076-3538; Master, Christina/0000-0002-6717-4270	US Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; Children's Hospital of Philadelphia	Supported by an intergovernmental personnel act agreement between the US Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) and the Children's Hospital of Philadelphia. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. The authors declare no conflicts of interest.	Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention (CDC), 2011, YOUTH RISK BEH SURV; Centers for Medicare and Medicaid Services & the National Center for Health Statistics (NCHS), 2011, ICD 9 CM OFF GUID CO; Cheng TA, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2721; Comstock D, HIGH SCH RIO REPORTI; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; DURANT RH, 1991, AM J DIS CHILD, V145, P1119, DOI 10.1001/archpedi.1991.02160100051022; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Falcone RA, 2008, J PEDIATR SURG, V43, P1858, DOI 10.1016/j.jpedsurg.2008.01.058; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Howard Ivory, 2005, Ethn Dis, V15, pS5; Institute of Medicine (IOM) and National Research Council (NRC), 2013, SPORTS RELATED CONCU; Jayanthi N, 2013, SPORTS HEALTH, V5, P251, DOI 10.1177/1941738112464626; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Marin JR, 2014, JAMA-J AM MED ASSOC, P311; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Metzl JD, 2006, PEDIATRICS, V117, P1813, DOI 10.1542/peds.2006-0480; National Council of Youth Sports, REP TRENDS PART ORG; Schwebel DC, 2014, J ATHL TRAINING, V49, P780, DOI 10.4085/1062-6050-49.3.41; Seiger A, 2015, J HEAD TRAUMA REHAB, V30, pE52, DOI 10.1097/HTR.0000000000000051; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Theisen D, 2013, J SCI MED SPORT, V16, P200, DOI 10.1016/j.jsams.2012.07.007; Turner Robert W, 2015, Glob Pediatr Health, V2, p2333794X15577944, DOI 10.1177/2333794X15577944; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Washington RL, 2001, PEDIATRICS, V107, P1205; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek RL, 2017, J PEDIATR-US, V181, P222, DOI 10.1016/j.jpeds.2016.10.067; Zonfrillo MR, 2015, ACAD EMERG MED, V22, P872, DOI 10.1111/acem.12696	35	28	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JUN	2018	197						241	+		10.1016/j.jpeds.2018.01.075			9	Pediatrics	Pediatrics	GG9UR	WOS:000433047100043	29627189	Green Accepted			2021-06-18	
J	Leung, A; Metzger-Smith, V; He, YF; Cordero, J; Ehlert, B; Song, D; Lin, L; Shahrokh, G; Tsai, A; Vaninetti, M; Rutledge, T; Polston, G; Sheu, R; Lee, R				Leung, Albert; Metzger-Smith, Valerie; He, Yifan; Cordero, James; Ehlert, Brandon; Song, David; Lin, Lisa; Shahrokh, Golshan; Tsai, Alice; Vaninetti, Michael; Rutledge, Thomas; Polston, Greg; Sheu, Robert; Lee, Roland			Left Dorsolateral Prefrontal Cortex rTMS in Alleviating MTBI Related Headaches and Depressive Symptoms	NEUROMODULATION			English	Article						Chronic posttraumatic headaches; MTBI; MTBI-HA; neuropathic pain; rTMS; transcranial magnetic stimulation; traumatic brain injury	TRAUMATIC BRAIN-INJURY; TRANSCRANIAL MAGNETIC STIMULATION; ELECTRICAL-STIMULATION; YOUNG-PATIENTS; CENTRAL PAIN; CONNECTIVITY; VETERANS; NEUROPSYCHOLOGY; INTELLIGENCE; PREVALENCE	ObjectivePersistent mild traumatic brain injury related headache (MTBI-HA) represents a neuropathic pain state. This study tested the hypothesis that repetitive transcranial magnetic stimulation (rTMS) at the left prefrontal cortex can alleviate MTBI-HA and associated neuropsychological dysfunctions. Methods and MaterialsVeterans with MTBI-HA were randomized to receive four sessions of either real (REAL group) or sham (SHAM group) high frequency rTMS delivered at 10 Hz, 80% of resting motor threshold and 2000 pulses per session at >24 and <72 hours apart. Pre-treatment, post-treatment 1-week and 4-week headache and neuropsychological assessments were conducted. ResultsTwenty nine out of forty-four consented subjects completed the study. A two-factor (visit x treatment) repeated measures ANOVA showed a significant (p=0.002, F=11.63, df=1) interaction for the average daily persistent headache intensity with the REAL group exhibiting a significant (p<0.0001) average reduction (SD) of 25.3 +/- 16.8% and 23.0 +/- 17.7% reduction in their numerical rating scale at the one-week and four-week post-treatment assessments in comparison to <1 +/- 11.7% and 2.3 +/- 14.5% reduction found in the SHAM group. In addition, a significant (p<0.01) 50% and 57% reduction was found in the prevalence of persistent headache in the REAL group at the one-week and four-week assessments in comparison to 7% and 20% reduction found in the SHAM group. Furthermore, the REAL group demonstrated a significant (p=0.033) improvement (from 22.3 +/- 6.4 at pre-treatment to 19.0 +/- 5.0 at post-treatment one-week) in the Hamilton Rating Scale for Depression score, while the SHAM group's score remained largely unchanged (from 25.33 +/- 8.43 to 24.64 +/- 5.03) in the same time frame. This trend of improvement, although not statistically significant, continues to the post-treatment four-week assessment. ConclusionA short-course rTMS at the left DLPFC can alleviate MTBI-HA symptoms and provide a transient mood enhancing benefit. Further studies are required to establish a clinical protocol balancing both treatment efficacy and patient compliance.	[Leung, Albert; Vaninetti, Michael; Polston, Greg] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Leung, Albert; Metzger-Smith, Valerie; He, Yifan; Cordero, James; Ehlert, Brandon; Song, David; Lin, Lisa; Tsai, Alice; Vaninetti, Michael; Rutledge, Thomas; Polston, Greg] Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA; [Song, David] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Shahrokh, Golshan] Vet Med Res Fdn, San Diego, CA USA; [Rutledge, Thomas] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Sheu, Robert] Naval Med Ctr, San Diego, CA USA; [Lee, Roland] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA	Leung, A (corresponding author), Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA.; Leung, A (corresponding author), Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	ayleung@ucsd.edu			VA Rehabilitation and Research Development SPIRE Awards [21RX001359, 21RX002366]; Department of Defense Congressionally Directed Medical Research Program GrantUnited States Department of Defense [W81XWH-16-1-0754]	The authors thank the funding support from the following agencies: VA Rehabilitation and Research Development SPIRE Awards (21RX001359, 21RX002366) and Department of Defense Congressionally Directed Medical Research Program Grant (W81XWH-16-1-0754).	Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; de Oliveira RAA, 2014, J PAIN, V15, P1271, DOI 10.1016/j.jpain.2014.09.009; Bormann JE, 2014, MED CARE, V52, pS13, DOI 10.1097/MLR.0000000000000200; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Brooks BL, 2011, ASSESSMENT, V18, P156, DOI 10.1177/1073191110385316; Caeyenberghs K, 2015, BRAIN CONNECT, V5, P423, DOI 10.1089/brain.2014.0293; Chan F, 2008, BRAIN INJURY, V22, P471, DOI 10.1080/02699050802084886; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; de Andrade DC, 2011, PAIN, V152, P320, DOI 10.1016/j.pain.2010.10.032; Defrin R, 2014, J MAN MANIP THER, V22, P36, DOI 10.1179/2042618613Y.0000000053; DiTommaso C, 2014, HEADACHE, V54, P511, DOI 10.1111/head.12254; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Joubert Jacques, 2005, Aust Fam Physician, V34, P621; Khedr EM, 2005, J NEUROL NEUROSUR PS, V76, P833, DOI 10.1136/jnnp.2004.055806; Klein MM, 2015, PAIN; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Leung A, 2014, HEADACHE, V54, P57; Leung A, 2015, NEUROMODULATION; Leung A, 2016, MOL PAIN, V12, DOI 10.1177/1744806916662661; Leung A, 2016, PAIN PHYSICIAN, V19, pE347; Leung A, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-18; Leung A, 2009, J PAIN, V10, P1205, DOI 10.1016/j.jpain.2009.03.010; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700; Ljubisavljevic M, 1996, ELECTROMYOGR MOTOR C, V101, P281, DOI 10.1016/0924-980X(96)95627-1; Lorenz J, 2003, BRAIN, V126, P1079, DOI 10.1093/brain/awg102; Lorenz J, 2002, NEURON, V35, P383, DOI 10.1016/S0896-6273(02)00767-5; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Marshall KR, 2012, MIL MED, V177, P67, DOI 10.7205/MILMED-D-12-00110; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Misra UK, 2013, J NEUROL, V260, P2793, DOI 10.1007/s00415-013-7072-2; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; O'Neil-Pirozzi TM, 2012, BRAIN INJURY, V26, P1425, DOI 10.3109/02699052.2012.694561; Ohn SH, 2012, NEUROREHAB NEURAL RE, V26, P344, DOI 10.1177/1545968311423110; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pal D, 2012, CLIN NEUROL NEUROSUR, V114, P564, DOI 10.1016/j.clineuro.2011.12.002; Pal E, 2010, MOVEMENT DISORD, V25, P2311, DOI 10.1002/mds.23270; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Paus T, 2001, EUR J NEUROSCI, V14, P1405, DOI 10.1046/j.0953-816x.2001.01757.x; Peng HJ, 2012, J AFFECT DISORDERS, V136, P249, DOI 10.1016/j.jad.2011.12.006; PEYRON R, 1995, PAIN, V62, P275, DOI 10.1016/0304-3959(94)00211-V; PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schmidt-Wilcke T, 2014, NEUROIMAGE-CLIN, V6, P252, DOI 10.1016/j.nicl.2014.09.007; Schmidt-Wilcke T, 2014, PAIN MED, V15, P1346, DOI 10.1111/pme.12460; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Taylor JJ, 2013, NEUROPSYCHOPHARMACOL, V38, P1189, DOI 10.1038/npp.2013.13; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Wu E, 2015, J HEAD TRAUMA REHABI	56	28	28	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	JUN	2018	21	4					390	401		10.1111/ner.12615			12	Medicine, Research & Experimental; Clinical Neurology	Research & Experimental Medicine; Neurosciences & Neurology	GL9WF	WOS:000437692500010	28557049				2021-06-18	
J	Archer, DB; Vaillancourt, DE; Coombes, SA				Archer, Derek B.; Vaillancourt, David E.; Coombes, Stephen A.			A Template and Probabilistic Atlas of the Human Sensorimotor Tracts using Diffusion MRI	CEREBRAL CORTEX			English	Article						diffusion; movement; sensorimotor; tractography; white matter template	PREDICTS MOTOR IMPAIRMENT; TRAUMATIC BRAIN-INJURY; CORTICOSPINAL TRACT; DESCENDING PATHWAYS; FRONTAL-LOBE; SPINAL-CORD; TOPOGRAPHIC ORGANIZATION; LATERAL SURFACE; STROKE; AREAS	The purpose of this study was to develop a high-resolution sensorimotor area tract template (SMATT) which segments corticofugal tracts based on 6 cortical regions in primary motor cortex, dorsal premotor cortex, ventral premotor cortex, supplementary motor area (SMA), pre-supplementary motor area (preSMA), and primary somatosensory cortex using diffusion tensor imaging. Individual probabilistic tractography analyses were conducted in 100 subjects using the highest resolution data currently available. Tractography results were refined using a novel algorithm to objectively determine slice level thresholds that best minimized overlap between tracts while preserving tract volume. Consistent with tracing studies in monkey and rodent, our observations show that cortical topography is generally preserved through the internal capsule, with the preSMA tract remaining most anterior and the primary somatosensory tract remaining most posterior. We combine our results into a freely available white matter template named the SMATT. We also provide a probabilistic SMATT that quantifies the extent of overlap between tracts. Finally, we assess how the SMATT operates at the individual subject level in another independent data set, and in an individual after stroke. The SMATT and probabilistic SMATT provide new tools that segment and label sensorimotor tracts at a spatial resolution not previously available.	[Archer, Derek B.; Vaillancourt, David E.; Coombes, Stephen A.] Univ Florida, Dept Appl Physiol & Kinesiol, Lab Rehabil Neurosci, POB 118206, Gainesville, FL 32611 USA; [Vaillancourt, David E.] Univ Florida, Dept Neurol, Coll Med, Gainesville, FL 32611 USA; [Vaillancourt, David E.] Univ Florida, Dept Biomed Engn, Gainesville, FL 32611 USA	Coombes, SA (corresponding author), Univ Florida, Dept Appl Physiol & Kinesiol, Lab Rehabil Neurosci, POB 118206, Gainesville, FL 32611 USA.	scoombes@ufl.edu			American Heart AssociationAmerican Heart Association [15GRNT25700431]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS058487]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U54MH091657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG047266] Funding Source: NIH RePORTER	The American Heart Association (contract grant number 15GRNT25700431) and the National Institutes of Health (contract grant number R01 NS058487).	Andersson JLR, 2016, NEUROIMAGE, V125, P1063, DOI 10.1016/j.neuroimage.2015.10.019; Andersson JLR, 2015, NEUROIMAGE, V122, P166, DOI 10.1016/j.neuroimage.2015.07.067; Archer DB, 2016, HUM BRAIN MAPP, V37, P2039, DOI 10.1002/hbm.23155; BARNARD JW, 1956, J COMP NEUROL, V105, P25, DOI 10.1002/cne.901050103; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2006, NEUROIMAGE, V30, P220, DOI 10.1016/j.neuroimage.2005.09.036; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Clatworthy PL, 2010, NEUROIMAGE, V49, P2001, DOI 10.1016/j.neuroimage.2009.10.083; Coleman KA, 1997, J COMP NEUROL, V381, P143, DOI 10.1002/(SICI)1096-9861(19970505)381:2<143::AID-CNE3>3.0.CO;2-3; Coombes SA, 2012, CEREB CORTEX, V22, P616, DOI 10.1093/cercor/bhr141; Coombes SA, 2011, NEUROIMAGE, V54, P2226, DOI 10.1016/j.neuroimage.2010.10.003; Coombes SA, 2010, J NEUROPHYSIOL, V103, P2114, DOI 10.1152/jn.00920.2009; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; DUM RP, 1991, J NEUROSCI, V11, P667; Dum RP, 2005, J NEUROSCI, V25, P1375, DOI 10.1523/JNEUROSCI.3902-04.2005; Feinberg DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015710; Frazier JA, 2005, AM J PSYCHIAT, V162, P1256, DOI 10.1176/appi.ajp.162.7.1256; FRIES W, 1993, BRAIN, V116, P369, DOI 10.1093/brain/116.2.369; GALEA MP, 1994, CEREB CORTEX, V4, P166, DOI 10.1093/cercor/4.2.166; Goldstein JM, 2007, BIOL PSYCHIAT, V61, P935, DOI 10.1016/j.biopsych.2006.06.027; Groisser BN, 2014, NEUROREHAB NEURAL RE, V28, P751, DOI 10.1177/1545968314521896; HE SQ, 1995, J NEUROSCI, V15, P3284; HE SQ, 1993, J NEUROSCI, V13, P952; HEFFNER RS, 1983, BRAIN BEHAV EVOLUT, V23, P165, DOI 10.1159/000121494; Hou JM, 2016, HUM BRAIN MAPP, V37, P2195, DOI 10.1002/hbm.23163; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jang SH, 2016, J NEUROTRAUM, V33, P1790, DOI 10.1089/neu.2015.4298; Jang SH, 2015, NEUROSCI LETT, V585, P77, DOI 10.1016/j.neulet.2014.11.030; Jang SH, 2009, NEUROREHABILITATION, V24, P285, DOI 10.3233/NRE-2009-0480; Jaspers E, 2016, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00112; Jbabdi S, 2015, NAT NEUROSCI, V18, P1546, DOI 10.1038/nn.4134; Jbabdi S, 2012, MAGN RESON MED, V68, P1846, DOI 10.1002/mrm.24204; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johansen-Berg H, 2009, ANNU REV NEUROSCI, V32, P75, DOI 10.1146/annurev.neuro.051508.135735; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; KEIZER K, 1989, EXP BRAIN RES, V74, P311; Lehericy S, 2004, ANN NEUROL, V55, P522, DOI 10.1002/ana.20030; Lehericy S, 2004, CEREB CORTEX, V14, P1302, DOI 10.1093/cercor/bhh091; Lemon RN, 2005, MUSCLE NERVE, V32, P261, DOI 10.1002/mus.20333; Leunissen I, 2013, HUM BRAIN MAPP, V34, P1254, DOI 10.1002/hbm.21508; Lindenberg R, 2010, NEUROLOGY, V74, P280, DOI 10.1212/WNL.0b013e3181ccc6d9; Lindenberg R, 2012, HUM BRAIN MAPP, V33, P1040, DOI 10.1002/hbm.21266; LUPPINO G, 1994, NEUROREPORT, V5, P2545, DOI 10.1097/00001756-199412000-00035; Maier MA, 2002, CEREB CORTEX, V12, P281, DOI 10.1093/cercor/12.3.281; Makris N, 2006, SCHIZOPHR RES, V83, P155, DOI 10.1016/j.schres.2005.11.020; Mayka MA, 2006, NEUROIMAGE, V31, P1453, DOI 10.1016/j.neuroimage.2006.02.004; Misra G., 2016, CEREB CORTEX; Misra G, 2015, CEREB CORTEX, V25, P1906, DOI 10.1093/cercor/bhu001; Moeller S, 2010, MAGN RESON MED, V63, P1144, DOI 10.1002/mrm.22361; Morecraft RJ, 2015, J COMP NEUROL, V523, P669, DOI 10.1002/cne.23703; Muggeo VMR, 2003, STAT MED, V22, P3055, DOI 10.1002/sim.1545; Newton JM, 2006, BRAIN, V129, P1844, DOI 10.1093/brain/awl106; NUDO RJ, 1990, J COMP NEUROL, V296, P559, DOI 10.1002/cne.902960405; NUDO RJ, 1990, J COMP NEUROL, V296, P584, DOI 10.1002/cne.902960406; Park CH, 2013, NEUROIMAGE-CLIN, V2, P521, DOI 10.1016/j.nicl.2013.04.002; Park JK, 2008, KOREAN J RADIOL, V9, P191, DOI 10.3348/kjr.2008.9.3.191; Plow EB, 2015, NEUROSCIENTIST, V21, P225, DOI 10.1177/1073858414537381; Potter-Baker KA, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00079; Rouiller EM, 1998, EUR J NEUROSCI, V10, P729, DOI 10.1046/j.1460-9568.1998.00075.x; Sach M, 2004, BRAIN, V127, P340, DOI 10.1093/brain/awh041; Schaechter JD, 2008, NEUROIMAGE, V39, P1370, DOI 10.1016/j.neuroimage.2007.09.071; Schaechter JD, 2009, HUM BRAIN MAPP, V30, P3461, DOI 10.1002/hbm.20770; Schulz R, 2012, STROKE, V43, P2248, DOI 10.1161/STROKEAHA.112.662619; Setsompop K, 2012, MAGN RESON MED, V67, P1210, DOI 10.1002/mrm.23097; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Sotiropoulos SN, 2013, MAGN RESON MED, V70, P1682, DOI 10.1002/mrm.24623; Sotiropoulos SN, 2013, NEUROIMAGE, V80, P125, DOI 10.1016/j.neuroimage.2013.05.057; Stinear CM, 2007, BRAIN, V130, P170, DOI 10.1093/brain/awl333; Stinear CM, 2012, BRAIN, V135, P2527, DOI 10.1093/brain/aws146; Tovar-Moll F, 2015, J NEUROIMAGING, V25, P200, DOI 10.1111/jon.12171; TRAVIS AM, 1955, BRAIN, V78, P155, DOI 10.1093/brain/78.2.155; van Baarsen KM, 2016, NEUROIMAGE, V124, P724, DOI 10.1016/j.neuroimage.2015.09.014; Van Essen DC, 2013, NEUROIMAGE, V80, P62, DOI 10.1016/j.neuroimage.2013.05.041; Vos SB, 2011, NEUROIMAGE, V55, P1566, DOI 10.1016/j.neuroimage.2011.01.048; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Zhu LL, 2010, STROKE, V41, P910, DOI 10.1161/STROKEAHA.109.577023	82	28	28	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	MAY	2018	28	5					1685	1699		10.1093/cercor/bhx066			15	Neurosciences	Neurosciences & Neurology	GF3XH	WOS:000431890800010	28334314	Bronze, Green Published			2021-06-18	
J	Patricios, JS; Ardern, CL; Hislop, MD; Aubry, M; Bloomfield, P; Broderick, C; Clifton, P; Echemendia, RJ; Ellenbogen, RG; Falvey, EC; Fuller, GW; Grand, J; Hack, D; Harcourt, PR; Hughes, D; McGuirk, N; Meeuwisse, W; Miller, J; Parsons, JT; Richiger, S; Sills, A; Moran, KB; Shute, J; Raftery, M				Patricios, Jon S.; Ardern, Clare L.; Hislop, Michael David; Aubry, Mark; Bloomfield, Paul; Broderick, Carolyn; Clifton, Patrick; Echemendia, Ruben J.; Ellenbogen, Richard G.; Falvey, Eanna Cian; Fuller, Gordon Ward; Grand, Julie; Hack, Dallas; Harcourt, Peter Rex; Hughes, David; McGuirk, Nathan; Meeuwisse, Willem; Miller, Jeffrey; Parsons, John T.; Richiger, Simona; Sills, Allen; Moran, Kevin B.; Shute, Jenny; Raftery, Martin			Implementation of the 2017 Berlin Concussion in Sport Group Consensus Statement in contact and collision sports: a joint position statement from 11 national and international sports organisations	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article								The 2017 Berlin Concussion in Sport Group Consensus Statement provides a global summary of best practice in concussion prevention, diagnosis and management, underpinned by systematic reviews and expert consensus. Due to their different settings and rules, individual sports need to adapt concussion guidelines according to their specific regulatory environment. At the same time, consistent application of the Berlin Consensus Statement's themes across sporting codes is likely to facilitate superior and uniform diagnosis and management, improve concussion education and highlight collaborative research opportunities. This document summarises the approaches discussed by medical representatives from the governing bodies of 10 different contact and collision sports in Dublin, Ireland in July 2017. Those sports are: American football, Australian football, basketball, cricket, equestrian sports, football/soccer, ice hockey, rugby league, rugby union and skiing. This document had been endorsed by 11 sport governing bodies/national federations at the time of being published.	[Patricios, Jon S.] Univ Pretoria, Sect Sports Med, Fac Hlth Sci, Johannesburg, South Africa; [Patricios, Jon S.] Univ Witwatersrand, Fac Hlth Sci, Dept Emergency Med, Johannesburg, South Africa; [Ardern, Clare L.] Linkoping Univ, Dept Physiotherapy, Linkoping, Sweden; [Ardern, Clare L.] La Trobe Univ, Sch Allied Hlth, Melbourne, Vic, Australia; [Hislop, Michael David; Raftery, Martin] World Rugby, Dublin, Ireland; [Aubry, Mark; Richiger, Simona] Int Ice Hockey Federat, Zurich, Switzerland; [Bloomfield, Paul; Broderick, Carolyn; McGuirk, Nathan] Natl Rugby League, Sydney, NSW, Australia; [Clifton, Patrick; Harcourt, Peter Rex; Hughes, David] Australian Football League, Melbourne, Vic, Australia; [Clifton, Patrick; Hughes, David] Australian Inst Sport, Canberra, ACT, Australia; [Echemendia, Ruben J.; Grand, Julie; Meeuwisse, Willem] Natl Hockey League, New York, NY USA; [Echemendia, Ruben J.] Univ Orthoped Ctr, Concuss Care Clin, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA; [Ellenbogen, Richard G.; Miller, Jeffrey; Sills, Allen] Natl Football League, New York, NY USA; [Ellenbogen, Richard G.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Falvey, Eanna Cian] Irish Rugby Football Union, Dublin, Ireland; [Fuller, Gordon Ward] Univ Sheffield, Sch Hlth & Related Res, Ctr Urgent & Emergency Care Res, Sheffield, S Yorkshire, England; [Hack, Dallas; Parsons, John T.] Natl Coll Athlet Assoc, Indianapolis, IN USA; [Sills, Allen] Federat Equestre Int, Lausanne, Switzerland; [Moran, Kevin B.] Gael Athlet Assoc, Dublin, Ireland; [Shute, Jenny] Federat Int Ski, Oberhofen, Switzerland; [Shute, Jenny] Federat Int Ski, Thunersee, Switzerland	Patricios, JS (corresponding author), Univ Pretoria, Fac Hlth Sci, Sect Sports Med, ZA-2121 Pretoria, South Africa.	jpat@mweb.co.za	Echemendia, Ruben/R-6939-2019; Hislop, Michael David/I-2339-2019	Fuller, Gordon Ward/0000-0001-8532-3500; Broderick, Carolyn/0000-0003-0096-796X; Echemendia, Ruben/0000-0001-6116-8462; Hughes, David/0000-0002-4194-2147; Patricios, Jon/0000-0002-6829-4098; Ardern, Clare/0000-0001-8102-3631	National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2015-04-005] Funding Source: researchfish		Bruce JM, 2018, BRIT J SPORT MED, V52, DOI 10.1136/bjsports-2016-097091; Davis GA, 2017, BRIT J SPORT MED, V51, P859, DOI 10.1136/bjsports-2017-097492; Davis GA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097415; Echemendia RJ, 2017, BRIT J SPORT MED, V51; Echemendia RJ., 2017, BR J SPORTS MED; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P895, DOI 10.1136/bjsports-2016-097466; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P870, DOI 10.1136/bjsports-2017-097508; Emery CA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097452; Feddermann-Demont N, 2017, BRIT J SPORT MED, V51, P903, DOI 10.1136/bjsports-2016-097403; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Makdissi M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097470; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrory P, 2016, BRIT J SPORT MED, V2017, P838, DOI DOI 10.1136/BJSP0RTS-2017-097699; McCrory P, 2017, BRIT J SPORT MED, V51, P877, DOI 10.1136/bjsports-2016-097393; Patricios J, 2017, BRIT J SPORT MED, V51; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475	22	28	28	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2018	52	10					635	641		10.1136/bjsports-2018-099079			7	Sport Sciences	Sport Sciences	GE7FP	WOS:000431399000011	29500252	Other Gold, Green Published, Green Accepted			2021-06-18	
J	Prexl, O; Bruckbauer, M; Voelckel, W; Grottke, O; Ponschab, M; Maegele, M; Schochl, H				Prexl, Oliver; Bruckbauer, Martin; Voelckel, Wolfgang; Grottke, Oliver; Ponschab, Martin; Maegele, Marc; Schoechl, Herbert			The impact of direct oral anticoagulants in traumatic brain injury patients greater than 60-years-old	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						DOAC; Vitamin K antagonist; Brain trauma; Mortality; Intracranial haematoma	PROTHROMBIN COMPLEX CONCENTRATE; PREINJURY WARFARIN USE; INTRACRANIAL HEMORRHAGE; REVERSAL; DABIGATRAN; COMPLICATIONS; RIVAROXABAN; MANAGEMENT; MORTALITY; SURGERY	Background: Traumatic brain injury (TBI) is the leading cause of death among trauma patients. Patients under antithrombotic therapy (ATT) carry an increased risk for intracranial haematoma (ICH) formation. There is a paucity of data about the role of direct oral anticoagulants (DOACs) among TBI patients. Methods: In this retrospective study, we investigated all TBI patients >= 60-years-old who were admitted to the intensive care unit (ICU) from January 2014 until May 2017. Patients were grouped into those receiving vitamin K antagonists (VKA), platelet inhibitors (PI), DOACs and no antithrombotic therapy (no-ATT). Results: One-hundred-eighty-six, predominantly male (52.7%) TBI patients with a median age of 79 years (range: 70-85 years) were enrolled in the study. Glasgow Coma Scale and S-100 beta were not different among the groups. Patients on VKA and DOACs had a higher Charlson Comorbidity Index compared to the PI group and no-ATT group (p = 0.0021). The VKA group received reversal agents significantly more often than the other groups (p < 0.0001). Haematoma progression in the follow-up cranial computed tomography (CCT) was lowest in the DOAC group. The number of CCT and surgical interventions were low with no differences between the groups. No relevant differences in ICU and hospital length of stay were observed. Mortality in the VKA group was significantly higher compared to DOAC, PI and no-ATT group (p = 0.047). Discussion: Data from huge registry studies displayed higher efficacy and lower fatal bleeding rates for DOACs compared to VKAs. The current study revealed comparable results. Despite the fact that TBI patients on VKAs received reversal agents more often than patients on DOACs (84.4% vs. 24.2%, p < 0.001), mortality rate was significantly higher in the VKA group (p = 0.047). Conclusion: In patients >= 60 years suffering from TBI, anticoagulation with DOACs appears to be safer than with VKA. Anti-thrombotic therapy with VKA resulted in a worse outcome compared to DOACs and PI. Further studies are warranted to confirm this finding.	[Prexl, Oliver; Bruckbauer, Martin; Voelckel, Wolfgang; Schoechl, Herbert] Paracelsus Med Univ, Acad Teaching Hosp, AUVA Trauma Ctr Salzburg, Dept Anaesthesiol & Intens Care Med, Dr Franz Rehrl Pl 5, A-5020 Salzburg, Austria; [Prexl, Oliver; Bruckbauer, Martin] Paracelsus Med Univ, Salzburg, Austria; [Grottke, Oliver] RWTH Aachen Univ Hosp, Dept Anaesthesiol, Aachen, Germany; [Ponschab, Martin] Paracelsus Med Univ, Acad Teaching Hosp, AUVA Trauma Ctr Linz, Dept Anaesthesiol & Intens Care Med, Salzburg, Austria; [Maegele, Marc] UW H, CMMC, Dept Trauma & Orthopaed Surg, Campus Cologne Merheim, Cologne, Germany; [Schoechl, Herbert] Ludwig Boltzmann Inst Expt & Clin Traumatol, AUVA Trauma Res Ctr, Vienna, Austria	Schochl, H (corresponding author), Paracelsus Med Univ, Acad Teaching Hosp, AUVA Trauma Ctr Salzburg, Dept Anaesthesiol & Intens Care Med, Dr Franz Rehrl Pl 5, A-5020 Salzburg, Austria.; Schochl, H (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, AUVA Trauma Res Ctr, Vienna, Austria.	herbert.schoechl@auva.at		Grottke, Oliver/0000-0002-0722-3122			Barletta JF, 2017, EUR J TRAUMA EMERG S, V43, P445, DOI 10.1007/s00068-017-0772-z; Barnes GD, 2015, AM J MED, V128, P1300, DOI 10.1016/j.amjmed.2015.05.044; Beynon C, 2015, THROMB RES, V136, P560, DOI 10.1016/j.thromres.2015.07.001; Brown KS, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1422-2; Chai-Adisaksopha C, 2014, BLOOD, V124, P2450, DOI 10.1182/blood-2014-07-590323; Collins CE, 2014, AM J SURG, V208, P544, DOI 10.1016/j.amjsurg.2014.05.019; Connolly SJ, 2016, NEW ENGL J MED, V375, P1131, DOI 10.1056/NEJMoa1607887; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Dossett LA, 2011, ARCH SURG-CHICAGO, V146, P565, DOI 10.1001/archsurg.2010.313; Douxfils J, 2017, SEMIN THROMB HEMOST, V43, P277, DOI 10.1055/s-0036-1597296; Feeney JM, 2017, INJURY, V48, P47, DOI 10.1016/j.injury.2016.08.016; Frontera JA, 2016, NEUROCRIT CARE, V24, P6, DOI 10.1007/s12028-015-0222-x; Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907; Goldstein JN, 2015, LANCET, V385, P2077, DOI 10.1016/S0140-6736(14)61685-8; Gonsalves WI, 2013, MAYO CLIN PROC, V88, P495, DOI 10.1016/j.mayocp.2013.03.006; Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Kirchhof P, 2016, EUR J CARDIO-THORAC, V50, pE1, DOI 10.1093/ejcts/ezw313; Kobayashi L, 2017, J TRAUMA ACUTE CARE, V82, P827, DOI 10.1097/TA.0000000000001414; Le Roux P, 2014, J NEUROSURG, V121, P1, DOI 10.3171/2014.8.paradigm; Luchette F, 2010, SURGERY, V148, P729; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; Maung AA, 2016, J TRAUMA ACUTE CARE, V81, P652, DOI 10.1097/TA.0000000000001189; Myers SP, 2017, J TRAUMA ACUTE CARE, V82, P542, DOI 10.1097/TA.0000000000001340; Nishijima DK, 2013, ACAD EMERG MED, V20, P140, DOI 10.1111/acem.12074; Pabinger I, 2008, J THROMB HAEMOST, V6, P622, DOI 10.1111/j.1538-7836.2008.02904.x; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Pollack CV, 2017, NEW ENGL J MED, V377, P431, DOI 10.1056/NEJMoa1707278; Pozzessere A, 2015, AM SURGEON, V81, P1039; Rossaint R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1265-x; Sarode R, 2013, CIRCULATION, V128, P1234, DOI 10.1161/CIRCULATIONAHA.113.002283; Siracuse JJ, 2010, SURGERY, V148, P724, DOI 10.1016/j.surg.2010.07.014; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Wood B, 2017, SCAND J TRAUMA RESUS, V25, DOI 10.1186/s13049-017-0420-y	35	28	28	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	MAR 27	2018	26								20	10.1186/s13049-018-0487-0			7	Emergency Medicine	Emergency Medicine	GB2XN	WOS:000428919300001	29580268	DOAJ Gold, Green Published			2021-06-18	
J	Cole, JH; Jolly, A; de Simoni, S; Bourke, N; Patel, MC; Scott, G; Sharp, DJ				Cole, James H.; Jolly, Amy; de Simoni, Sara; Bourke, Niall; Patel, Maneesh C.; Scott, Gregory; Sharp, David J.			Spatial patterns of progressive brain volume loss after moderate-severe traumatic brain injury	BRAIN			English	Article						traumatic brain injury; voxel-based morphometry; longitudinal; neurodegeneration; brain atrophy	TENSOR-BASED MORPHOMETRY; WHITE-MATTER INJURY; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; LONGITUDINAL CHANGES; DIFFUSION-TENSOR; ATROPHY RATES; FOLLOW-UP; TAU-PET; MILD	Traumatic brain injury leads to significant loss of brain volume, which continues into the chronic stage. This can be sensitively measured using volumetric analysis of MRI. Here we: (i) investigated longitudinal patterns of brain atrophy; (ii) tested whether atrophy is greatest in sulcal cortical regions; and (iii) showed how atrophy could be used to power intervention trials aimed at slowing neurodegeneration. In 61 patients with moderate-severe traumatic brain injury (mean age = 41.55 years +/- 12.77) and 32 healthy controls (mean age = 34.22 years +/- 10.29), cross-sectional and longitudinal (1-year follow-up) brain structure was assessed using voxel-based morphometry on T1-weighted scans. Longitudinal brain volume changes were characterized using a novel neuroimaging analysis pipeline that generates a Jacobian determinant metric, reflecting spatial warping between baseline and follow-up scans. Jacobian determinant values were summarized regionally and compared with clinical and neuropsychological measures. Patients with traumatic brain injury showed lower grey and white matter volume in multiple brain regions compared to controls at baseline. Atrophy over 1 year was pronounced following traumatic brain injury. Patients with traumatic brain injury lost a mean (+/- standard deviation) of 1.55% +/- 2.19 of grey matter volume per year, 1.49% +/- 2.20 of white matter volume or 1.51% +/- 1.60 of whole brain volume. Healthy controls lost 0.55% +/- 1.13 of grey matter volume and gained 0.26% +/- 1.11 of white matter volume; equating to a 0.22% +/- 0.83 reduction in whole brain volume. Atrophy was greatest in white matter, where the majority (84%) of regions were affected. This effect was independent of and substantially greater than that of ageing. Increased atrophy was also seen in cortical sulci compared to gyri. There was no relationship between atrophy and time since injury or age at baseline. Atrophy rates were related to memory performance at the end of the follow-up period, as well as to changes in memory performance, prior to multiple comparison correction. In conclusion, traumatic brain injury results in progressive loss of brain tissue volume, which continues for many years postinjury. Atrophy is most prominent in the white matter, but is also more pronounced in cortical sulci compared to gyri. These findings suggest the Jacobian determinant provides a method of quantifying brain atrophy following a traumatic brain injury and is informative in determining the long-term neurodegenerative effects after injury. Power calculations indicate that Jacobian determinant images are an efficient surrogate marker in clinical trials of neuroprotective therapeutics.	[Cole, James H.; Jolly, Amy; de Simoni, Sara; Bourke, Niall; Patel, Maneesh C.; Scott, Gregory; Sharp, David J.] Imperial Coll London, Computat Cognit & Clin Neuroimaging Lab, Div Brain Sci, Hammersmith Hosp, London, England	Cole, JH (corresponding author), Imperial Coll London, Computat Cognit & Clin Neuroimaging Lab, Hammersmith Hosp, 3rd Floor Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	james.cole@imperial.ac.uk	Sharp, David J/A-2119-2013; Cole, James H/I-5197-2019	Cole, James H/0000-0003-1908-5588; Scott, Gregory/0000-0001-8063-5871; Jolly, Amy/0000-0002-7413-9772	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/L022141/1]; Imperial College London National Institute of Health (NIHR) Biomedical Research Centre; National Institute of Health Research Professorship [RP-011-048]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1769568] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	J.H.C. is funded by a research grant to Imperial College London from the Medical Research Council (MR/L022141/1). D.J.S. has a National Institute of Health Research Professorship: RP-011-048. The work was also supported by the Imperial College London National Institute of Health (NIHR) Biomedical Research Centre.	Ashburner J., 2000, NEUROIMAGE S, V11, pS465; Ashburner J, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00197; Beckett LA, 2000, STAT MED, V19, P1469, DOI 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1469::AID-SIM439>3.0.CO;2-J; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bonner-Jackson A, 2013, J INT NEUROPSYCH SOC, V19, P739, DOI 10.1017/S1355617713000507; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Brezova V, 2014, NEUROIMAGE-CLIN, V5, P128, DOI 10.1016/j.nicl.2014.03.012; Cash DM, 2015, NEUROIMAGE, V123, P149, DOI 10.1016/j.neuroimage.2015.07.087; Cash David M, 2014, Alzheimers Res Ther, V6, P87, DOI 10.1186/s13195-014-0087-9; CHEVAN A, 1991, AM STAT, V45, P90, DOI 10.2307/2684366; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Doody RS, 2014, NEW ENGL J MED, V370, P311, DOI 10.1056/NEJMoa1312889; Fagerholm ED, 2015, BRAIN, V138, P1696, DOI 10.1093/brain/awv075; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Green REA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00067; Gutman BA, 2015, NEUROBIOL AGING, V36, pS69, DOI 10.1016/j.neurobiolaging.2014.05.038; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Holmes HE, 2016, NEUROBIOL AGING, V39, P184, DOI 10.1016/j.neurobiolaging.2015.12.001; Hua X, 2016, NEUROBIOL AGING, V37, P26, DOI 10.1016/j.neurobiolaging.2015.09.018; Hua X, 2010, NEUROIMAGE, V51, P63, DOI 10.1016/j.neuroimage.2010.01.104; Hua X, 2009, NEUROIMAGE, V48, P668, DOI 10.1016/j.neuroimage.2009.07.011; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Kim J, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00052; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Landman BA, 2011, NEUROIMAGE, V54, P2854, DOI 10.1016/j.neuroimage.2010.11.047; LaPoint MR, 2017, NEUROIMAGE, V157, P612, DOI 10.1016/j.neuroimage.2017.05.049; Leow AD, 2009, NEUROIMAGE, V45, P645, DOI 10.1016/j.neuroimage.2009.01.004; Leow AD, 2006, NEUROIMAGE, V31, P627, DOI 10.1016/j.neuroimage.2005.12.013; Maass A, 2017, NEUROIMAGE, V157, P448, DOI 10.1016/j.neuroimage.2017.05.058; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Rohrer JD, 2011, BRAIN, V134, P2565, DOI 10.1093/brain/awr198; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Sarro L, 2016, BRAIN, V139, P2740, DOI 10.1093/brain/aww193; Scahill RI, 2002, P NATL ACAD SCI USA, V99, P4703, DOI 10.1073/pnas.052587399; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sluimer JD, 2008, NEUROLOGY, V70, P1836, DOI 10.1212/01.wnl.0000311446.61861.e3; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; Tomaiuolo F, 2012, BRAIN RES BULL, V87, P373, DOI 10.1016/j.brainresbull.2012.01.008; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Vannorsdall TD, 2010, J NEUROPSYCH CLIN N, V22, P173, DOI 10.1176/appi.neuropsych.22.2.173; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	72	28	28	1	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR	2018	141		3				822	836		10.1093/brain/awx354			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FY4RP	WOS:000426813600026	29309542	Green Published, Other Gold			2021-06-18	
J	Lalonde, G; Bernier, A; Beaudoin, C; Gravel, J; Beauchamp, MH				Lalonde, Gabrielle; Bernier, Annie; Beaudoin, Cindy; Gravel, Jocelyn; Beauchamp, Miriam H.			Investigating social functioning after early mild TBI: the quality of parent-child interactions	JOURNAL OF NEUROPSYCHOLOGY			English	Article						paediatric; traumatic brain injury; concussion; parent-child; social interactions; outcome; social skills	TRAUMATIC-BRAIN-INJURY; MUTUALLY RESPONSIVE ORIENTATION; EXECUTIVE FUNCTION OUTCOMES; YOUNG-CHILDREN; FAMILY BURDEN; MOTHER-CHILD; PSYCHOSOCIAL OUTCOMES; PRESCHOOL-CHILDREN; FOLLOW-UP; BEHAVIOR	The young brain is particularly vulnerable to injury due to inherent physiological and developmental factors, and even mild forms of traumatic brain injury (mTBI) can sometimes result in cognitive and behavioural difficulties. Despite the high prevalence of paediatric mTBI, little is known of its impact on children's social functioning. Parent-child relationships represent the centre of young children's social environments and are therefore ideal contexts for studying the potential effects of mTBI on children's social functioning. The aim of this study was to assess the quality of parent-child interactions after mTBI using observational assessment methods and parental report. The sample included 130 children (18-60months at recruitment) divided into three groups: children with uncomplicated mTBI (n=47), children with orthopaedic injury (OI, n=27), and non-injured children (NI, n=56). The quality of parent-child interactions was assessed 6months post-injury using the Mutually Responsive Orientation (MRO) scale, an observational measure which focuses on the dyadic nature of parent-child exchanges, and the Parental Stress Index questionnaire (Parent-Child Dysfunctional Interaction (PCDI) domain). Significant differences with medium effect sizes were found between the mTBI group and the NI group on the MRO, but not between the OI group and the other two groups. PCDI scores did not differ across groups, suggesting that observational measures may be more sensitive to changes in parent-child interactions after TBI. The current findings have implications for children's post-injury social development and highlight the importance of monitoring social outcomes even after minor head injuries.	[Lalonde, Gabrielle; Beaudoin, Cindy; Gravel, Jocelyn; Beauchamp, Miriam H.] Ste Justine Res Ctr, Montreal, PQ, Canada; [Lalonde, Gabrielle; Bernier, Annie; Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Gravel, Jocelyn] Ste Justine Hosp, Montreal, PQ, Canada	Beauchamp, MH (corresponding author), CP 6128 Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	miriam.beauchamp@umontreal.ca					Abidin RR., 1995, PARENTING STRESS IND; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Aksan N, 2006, DEV PSYCHOL, V42, P833, DOI 10.1037/0012-1649.42.5.833; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Aspland Helen, 2003, Child Adolesc Ment Health, V8, P136, DOI 10.1111/1475-3588.00061; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bakermans-Kranenburg MJ, 2003, PSYCHOL BULL, V129, P195, DOI 10.1037/0033-2909.129.2.195; Bayley N., 2006, BAYLEY SCALES INFANT; Beauchamp M., 2010, PRINCIPLES PRACTICE, P315, DOI 10.1017/CBO9780511674815.024; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bellerose J, 2015, J INT NEUROPSYCH SOC, V21, P483, DOI 10.1017/S1355617715000569; Belsky J., 1988, CLIN IMPLICATIONS AT, P45; Bendikas EA, 2011, REHABIL PSYCHOL, V56, P374, DOI 10.1037/a0025634; Bernier A, 2012, DEVELOPMENTAL SCI, V15, P12, DOI 10.1111/j.1467-7687.2011.01093.x; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Biringen Z, 2000, Attach Hum Dev, V2, P188; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; Bordeleau S, 2012, J FAM PSYCHOL, V26, P254, DOI 10.1037/a0027366; Boss P, 2014, ENCY QUALITY LIFE WE, P2202; CAMPBELL SB, 1995, DEV PSYCHOL, V31, P349, DOI 10.1037/0012-1649.31.3.349; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Clark Alex, 2008, Clin Child Psychol Psychiatry, V13, P565, DOI 10.1177/1359104508090607; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cowan P.A., 2003, NORMAL FAMILY PROCES, P424; Crowe LM, 2013, CHILD NEUROPSYCHOL, V19, P113, DOI 10.1080/09297049.2011.651079; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; DeKeyser R. M., 2000, STUDIES 2 LANGUAGE A, V22, P499, DOI [DOI 10.1017/S0272263100004022, 10.1017/S0272263100004022]; Dennis M., 1988, CLIN NEUROPSYCHOLOGY, P85; Deonandan R., 2000, CHRONIC DIS CANADA, V21, P1; Eddy JM, 1998, J ABNORM CHILD PSYCH, V26, P53, DOI 10.1023/A:1022634807098; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Fairbanks JM, 2013, REHABIL PSYCHOL, V58, P223, DOI 10.1037/a0033119; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FERGUSSON DM, 1993, J ABNORM CHILD PSYCH, V21, P245, DOI 10.1007/BF00917534; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Haskett ME, 2006, J CLIN CHILD ADOLESC, V35, P302, DOI 10.1207/s15374424jccp3502_14; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Huelke DF, 1998, P ANN C ASS, P93; Josie KL, 2008, J HEAD TRAUMA REHAB, V23, P357, DOI 10.1097/01.HTR.0000341431.29133.a8; Kaldoja ML, 2012, BRAIN INJURY, V26, P1005, DOI 10.3109/02699052.2012.660516; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Knudsen EI, 2004, J COGNITIVE NEUROSCI, V16, P1412, DOI 10.1162/0898929042304796; Kochanska G, 2005, J CHILD PSYCHOL PSYC, V46, P19, DOI 10.1111/j.1469-7610.2004.00348.x; Kochanska G, 2002, CURR DIR PSYCHOL SCI, V11, P191, DOI 10.1111/1467-8721.00198; Kochanska G, 1997, CHILD DEV, V68, P94, DOI 10.2307/1131928; Kochanska G, 2000, CHILD DEV, V71, P417, DOI 10.1111/1467-8624.00154; Kochanska G, 2008, CHILD DEV, V79, P30, DOI 10.1111/j.1467-8624.2007.01109.x; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Locke LM, 2002, CLIN PSYCHOL REV, V22, P895, DOI 10.1016/S0272-7358(02)00133-2; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McKay JM, 1996, CURR PSYCHOL, V15, P223, DOI 10.1007/BF02686879; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; MEGA MS, 2001, FRONTAL LOBES NEUROP, P15; Morsbach SK, 2006, CLIN CHILD FAM PSYCH, V9, P1, DOI 10.1007/s10567-006-0001-5; MoutonSimien P, 1997, J ABNORM CHILD PSYCH, V25, P59, DOI 10.1023/A:1025759408417; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Paniak C, 2000, BRAIN INJURY, V14, P219; Poggi G, 2005, BRAIN INJURY, V19, P777, DOI 10.1080/0269905500110132; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Reynolds C.R., 1992, BEHAV ASSESSMENT SYS; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Sonnenberg LK, 2010, BRAIN INJURY, V24, P1003, DOI 10.3109/02699052.2010.489033; SPARROW SS, 1984, INTERVIEW EDITION EX; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Tarabulsy GM, 2005, DEV PSYCHOL, V41, P212, DOI 10.1037/0012-1649.41.1.212; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Thurber S., 2012, ARCH ASSESSMENT PSYC, V2, P73; Trenchard SO, 2013, BRAIN INJURY, V27, P1217, DOI 10.3109/02699052.2013.812240; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Wade SL, 2010, NEUROREHABILITATION, V27, P63, DOI 10.3233/NRE-2010-0581; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wechsler, 2002, WECHSLER PRESCHOOL P; Woods DT, 2011, DEV NEUROREHABIL, V14, P274, DOI 10.3109/17518423.2011.586371; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zareie S., 2014, THESIS	94	28	28	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1748-6645	1748-6653		J NEUROPSYCHOL	J. Neuropsychol.	MAR	2018	12	1					1	22		10.1111/jnp.12104			22	Psychology; Psychology, Experimental	Psychology	FY2GG	WOS:000426632900001	27012315				2021-06-18	
J	Huang, YN; Yang, LY; Greig, NH; Wang, YC; Lai, CC; Wang, JY				Huang, Ya-Ni; Yang, Ling-Yu; Greig, Nigel H.; Wang, Yu-Chio; Lai, Chien-Cheng; Wang, Jia-Yi			Neuroprotective effects of pifithrin-alpha against traumatic brain injury in the striatum through suppression of neuroinflammation, oxidative stress, autophagy, and apoptosis	SCIENTIFIC REPORTS			English	Article							CELL-DEATH; FUNCTIONAL OUTCOMES; ANTIOXIDANT THERAPIES; GLIAL ACTIVATION; HEME OXYGENASE-1; GENE-EXPRESSION; NERVOUS-SYSTEM; NEURONAL DEATH; DNA-DAMAGE; P53	Cortical and hippocampal neuronal damages caused by traumatic brain injury (TBI) are associated with motor and cognitive impairments; however, only little attention paid to the striatal damage. It is known that the p53 tumor-suppressor transcription factor participated in TBI-induced secondary brain damage. We investigated how the p53 inactivator pifithrin (PFT)-alpha affected TBI-induced striatal neuronal damage at 24 h post-injury. Sprague-Dawley rats subjected to a controlled cortical impact were used as TBI models. We observed that p53 mRNA significantly increased, whereas p53 protein expression was distributed predominantly in neurons but not in glia cells in striatum after TBI. PFT-alpha improved motor deficit following TBI. PFT-alpha suppressed TBI-induced striatal glial activation and expression of proinflammatory cytokines. PFT-alpha alleviated TBI-induced oxidative damage TBI induced autophagy was evidenced by increased protein expression of Beclin-1 and shift of microtubule-associated light chain (LC) 3-I to LC3-II, and decreased p62. These effects were reduced by PFT-alpha. Post-injury PFT-alpha treatment reduced the number of degenerating (FJC-positive) and apoptotic neurons. Our results suggest that PFT-alpha may provide neuroprotective effects via p53-dependent or -independent mechanisms depending on the cell type and timing after the TBI and can possibly be developed into a novel therapy to ameliorate TBI-induced neuronal damage.	[Huang, Ya-Ni] Hsin Sheng Jr Coll Med Care & Management, Dept Nursing, Taoyuan, Taiwan; [Huang, Ya-Ni] Hsin Sheng Jr Coll Med Care & Management, Dept Optometry, Taoyuan, Taiwan; [Yang, Ling-Yu; Wang, Yu-Chio; Wang, Jia-Yi] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan; [Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Wang, Yu-Chio] Taipei Med Univ, Coll Med, Sch Med, Taipei, Taiwan; [Lai, Chien-Cheng] Far Eastern Mem Hosp, Div Orthoped, Dept Surg, New Taipei, Taiwan; [Wang, Jia-Yi] Taipei Med Univ, Coll Med, Dept Physiol, Taipei, Taiwan	Wang, JY (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan.; Wang, JY (corresponding author), Taipei Med Univ, Coll Med, Dept Physiol, Taipei, Taiwan.	jywang2010@tmu.edu.tw		Wang, Jia-Yi/0000-0002-9106-3351	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST104-2923-B-038-001-MY3]; Taipei Medical University, Taiwan [104-5432-010-111]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000311] Funding Source: NIH RePORTER	This work was supported by a grant (MOST104-2923-B-038-001-MY3) to JYW from the Ministry of Science and Technology, Taiwan, and a grant (104-5432-010-111) to YNH from Taipei Medical University, Taiwan.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bales JW, 2011, EXP NEUROL, V229, P300, DOI 10.1016/j.expneurol.2011.02.013; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barone E, 2015, J NEUROSCI RES, V93, P1728, DOI 10.1002/jnr.23627; Budanov Andrei V, 2014, Subcell Biochem, V85, P337, DOI 10.1007/978-94-017-9211-0_18; Chen CJ, 2010, J GEN VIROL, V91, P1028, DOI 10.1099/vir.0.013565-0; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chen T, 2017, CELL MOL NEUROBIOL, V37, P43, DOI 10.1007/s10571-016-0341-8; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Chung YH, 2002, NEUROL RES, V24, P324, DOI 10.1179/016164102101199828; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Davenport CM, 2010, J NEUROCHEM, V112, P552, DOI 10.1111/j.1471-4159.2009.06485.x; Dijsselbloem N, 2007, J IMMUNOL, V178, P5048, DOI 10.4049/jimmunol.178.8.5048; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Engle MR, 2004, TOXICOL APPL PHARM, V194, P296, DOI 10.1016/j.taap.2003.10.001; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Ferrandiz ML, 2008, CURR PHARM DESIGN, V14, P473, DOI 10.2174/138161208783597399; Fleiss B, 2015, DEV NEUROSCI-BASEL, V37, P363, DOI 10.1159/000370031; Gao Z., 2017, MOL NEUROBIOLOGY; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Harmon JL, 2017, J NEUROTRAUM, V34, P487, DOI 10.1089/neu.2015.4395; Hoagland MS, 2005, J PHARMACOL EXP THER, V314, P603, DOI 10.1124/jpet.105.084186; Hong MY, 2012, CHINESE MED J-PEKING, V125, P2019, DOI 10.3760/cma.j.issn.0366-6999.2012.11.032; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Jayadev S, 2011, GLIA, V59, P1402, DOI 10.1002/glia.21178; Jebelli J, 2014, NEUROSCI LETT, V583, P92, DOI 10.1016/j.neulet.2014.08.049; Jebelli JD, 2012, GLIA, V60, P515, DOI 10.1002/glia.22268; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Karve I. P., 2015, BRIT J PHARM; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Kourtis N, 2009, CELL DEATH DIFFER, V16, P21, DOI 10.1038/cdd.2008.120; Kumar A., 2012, BRAIN BEHAV IMMUNITY, V26; LANGEVELD CH, 1995, NEUROSCI LETT, V192, P13, DOI 10.1016/0304-3940(95)11596-O; Leker RR, 2004, EXP NEUROL, V187, P478, DOI 10.1016/j.expneurol.2004.01.030; Li L., 2015, CELL MOL NEUROBIOL; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Long J, 2013, NEURAL REGEN RES, V8, P1491, DOI 10.3969/j.issn.1673-5374.2013.16.006; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Mancuso C, 2004, ANTIOXID REDOX SIGN, V6, P878, DOI 10.1089/1523086041798097; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Morrison R. S., 2000, CELL DEATH DIFFERENT, V7; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Murphy PJM, 2004, J BIOL CHEM, V279, P30195, DOI 10.1074/jbc.M403539200; Nijboer CH, 2011, ANN NEUROL, V70, P255, DOI 10.1002/ana.22413; Nopparat C, 2010, J PINEAL RES, V49, P382, DOI 10.1111/j.1600-079X.2010.00805.x; O'Callaghan JP, 2008, ANN NY ACAD SCI, V1139, P318, DOI 10.1196/annals.1432.032; Petronilho F, 2010, J SURG RES, V164, P316, DOI 10.1016/j.jss.2009.04.031; Pietrancosta N., 2006, J MED CHEM, V49; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Potucek YD, 2006, NEUROCHEM INT, V49, P204, DOI 10.1016/j.neuint.2006.04.005; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Reed TT, 2009, J NEUROSCI RES, V87, P408, DOI 10.1002/jnr.21872; Rock RB, 2006, J NEUROIMMUNE PHARM, V1, P117, DOI 10.1007/s11481-006-9012-8; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Sauerbeck A, 2012, EXP NEUROL, V234, P85, DOI 10.1016/j.expneurol.2011.12.012; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; Senol N, 2014, NEUROCHEM RES, V39, P685, DOI 10.1007/s11064-014-1255-9; Shin SS, 2012, J NEUROTRAUM, V29, P843, DOI 10.1089/neu.2011.1966; Shin SS, 2011, BRAIN RES, V1369, P208, DOI 10.1016/j.brainres.2010.10.096; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Smith CM, 2011, NEUROBIOL DIS, V43, P52, DOI 10.1016/j.nbd.2010.09.014; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Sohn D, 2009, CELL DEATH DIFFER, V16, P869, DOI 10.1038/cdd.2009.17; Sparfel L, 2006, CARCINOGENESIS, V27, P656, DOI 10.1093/carcin/bgi256; Stoica BA, 2014, J NEUROTRAUM, V31, P758, DOI 10.1089/neu.2013.3194; Su W, 2014, J IMMUNOL, V192, P358, DOI 10.4049/jimmunol.1301397; Wagner AK, 2014, J CEREBR BLOOD F MET, V34, P1328, DOI 10.1038/jcbfm.2014.87; Wan CH, 2013, J MOL NEUROSCI, V51, P695, DOI 10.1007/s12031-013-0050-4; Wang DB, 2014, BBA-MOL BASIS DIS, V1842, P1186, DOI 10.1016/j.bbadis.2013.12.015; Wang JY, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0631-6; Webster KM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0457-7; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xu Fa-Lin, 2006, Zhongguo Dang Dai Er Ke Za Zhi, V8, P137; Ya JC, 2015, MOL MED REP, V12, P6591, DOI 10.3892/mmr.2015.4292; Yang LY, 2015, EXP NEUROL, V269, P56, DOI 10.1016/j.expneurol.2015.03.015; Yang LY, 2016, NEUROBIOL DIS, V96, P216, DOI 10.1016/j.nbd.2016.08.012; Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0	98	28	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	FEB 5	2018	8								2368	10.1038/s41598-018-19654-x			17	Multidisciplinary Sciences	Science & Technology - Other Topics	FU8FC	WOS:000424087700040	29402897	DOAJ Gold, Green Published			2021-06-18	
J	Dolle, JP; Jaye, A; Anderson, SA; Ahmadzadeh, H; Shenoy, VB; Smith, DH				Dolle, Jean-Pierre; Jaye, Andrew; Anderson, Stewart A.; Ahmadzadeh, Hossein; Shenoy, Vivek B.; Smith, Douglas H.			Newfound sex differences in axonal structure underlie differential outcomes from in vitro traumatic axonal injury	EXPERIMENTAL NEUROLOGY			English	Article						Sexual dimorphism; Traumatic axonal injury; Undulations; Calcium; Axon diameter; Microtubules	PLURIPOTENT STEM-CELLS; DYNAMIC STRETCH INJURY; BRAIN-INJURY; WHITE-MATTER; CORPUS-CALLOSUM; UNMYELINATED AXONS; SODIUM-CHANNELS; CALCIUM INFLUX; UNITED-STATES; TAU PROTEINS	Since traumatic axonal injury (TAI) is implicated as a prominent pathology of concussion, we examined potential sex differences in axon structure and responses to TAI. Rat and human neurons were used to develop micro patterned axon tracts in vitro that were genetically either male or female. Ultrastructural analysis revealed for the first time that female axons were consistently smaller with fewer microtubules than male axons. Computational modeling of TAI showed that these structural differences place microtubules in female axons at greater risk of failure during trauma under the same applied loads than in male axons. Likewise, in an in vitro model of TAI, dynamic stretch-injury to axon tracts induced greater pathophysiology of female axons than male axons, including more extensive undulation formations resulting from mechanical breaking of microtubules, and greater calcium influx shortly after the same level of injury. At 24 h post-injury, female axons exhibited significantly more swellings and greater loss of calcium signaling function than male axons. Accordingly, sexual dimorphism of axon structure in the brain may also contribute to more extensive axonal pathology in females compared to males exposed to the same mechanical injury.	[Dolle, Jean-Pierre; Jaye, Andrew] Univ Penn, Dept Neurosurg, Penn Ctr Brain Injury & Repair, 220 South 33rd St,283 Towne Bldg, Philadelphia, PA 19104 USA; [Anderson, Stewart A.] Childrens Hosp Philadelphia, Dept Psychiat, Philadelphia, PA 19104 USA; [Ahmadzadeh, Hossein; Shenoy, Vivek B.] Univ Penn, Res Struct Matter Lab, Dept Mat Sci & Engn, 3231 Walnut St,Room 309, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Dept Neurosurg, Perm Ctr Brain Injury & Repair, 3320 Smith Walk Hayden Hall 105, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, Perm Ctr Brain Injury & Repair, 3320 Smith Walk Hayden Hall 105, Philadelphia, PA 19104 USA.	dollej@pennmedicine.upenn.edu; andrew.h.jaye@gmail.com; sande@pennmedicine.upenn.edu; hossein@seas.upenn.edu; vshenoy@seas.upenn.edu; smithdou@pennmedicine.upenn.edu			Paul G. Allen Family Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS092398, NS038104, EB021293, MH110185]; US Department of DefenseUnited States Department of Defense [PT110785]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB021293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH110185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092398, R01NS038104, T32NS043126, R01NS094003] Funding Source: NIH RePORTER	This work was supported by the Paul G. Allen Family Foundation, National Institutes of Health grants NS092398 (D.H.S), NS038104 (D.H.S), EB021293 (D.H.S and V.B.S), MH110185 (S.A.A) and the US Department of Defense Grant PT110785 (D.H.S).	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Ahmadzadeh H, 2015, BIOPHYS J, V109, P2328, DOI 10.1016/j.bpj.2015.09.010; Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; Alexander DC, 2010, NEUROIMAGE, V52, P1374, DOI 10.1016/j.neuroimage.2010.05.043; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Covassin T, 2003, J ATHL TRAINING, V38, P238; DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410; Espuny-Camacho I, 2013, NEURON, V77, P440, DOI 10.1016/j.neuron.2012.12.011; Fairbanks SL, 2013, JOVE-J VIS EXP, DOI 10.3791/50758; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Gaw CE, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0071-8; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Gur RC, 1999, J NEUROSCI, V19, P4065; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Lin MY, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0366-0; Lu W, 2016, P NATL ACAD SCI USA, V113, pE4995, DOI 10.1073/pnas.1522424113; MACK CM, 1995, BRAIN RES, V697, P152, DOI 10.1016/0006-8993(95)00804-Y; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MIYATA Y, 1986, J BIOL CHEM, V261, P3026; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; Ozdogmus O, 2009, ANAT SCI INT, V84, P2, DOI 10.1007/s12565-008-0001-2; Paus T, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.014.2009; Pedrosa E, 2011, J NEUROGENET, V25, P88, DOI 10.3109/01677063.2011.597908; Perrin JS, 2009, NEUROIMAGE, V45, P1055, DOI 10.1016/j.neuroimage.2009.01.023; Perrin JS, 2008, J NEUROSCI, V28, P9519, DOI 10.1523/JNEUROSCI.1212-08.2008; Pesaresi M, 2015, NEUROIMAGE, V115, P191, DOI 10.1016/j.neuroimage.2015.04.048; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sendek A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104965; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Staal JA, 2011, J NEUROTRAUM, V28, P841, DOI 10.1089/neu.2010.1658; Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Vorstman JAS, 2006, HUM MUTAT, V27, P814, DOI 10.1002/humu.20330; Wang SSH, 2008, J NEUROSCI, V28, P4047, DOI 10.1523/JNEUROSCI.5559-05.2008; Wegmann S, 2011, J BIOL CHEM, V286, P20512, DOI 10.1074/jbc.M111.237875; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yuan A, 2017, COLD SPRING HARB PER, P9; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhang YS, 2013, NEURON, V78, P785, DOI 10.1016/j.neuron.2013.05.029	53	28	28	1	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2018	300						121	134		10.1016/j.expneurol.2017.11.001			14	Neurosciences	Neurosciences & Neurology	FT1JZ	WOS:000422893300013	29104114	Green Accepted			2021-06-18	
J	Rowson, S; Duma, SM; Stemper, BD; Shah, A; Mihalik, JP; Harezlak, J; Riggen, LD; Giza, CC; DiFiori, JP; Brooks, A; Guskiewicz, K; Campbell, D; McGinty, G; Svoboda, SJ; Cameron, KL; Broglio, SP; McAllister, TW; McCrea, M				Rowson, Steven; Duma, Stefan M.; Stemper, Brian D.; Shah, Alok; Mihalik, Jason P.; Harezlak, Jaroslaw; Riggen, Larry D.; Giza, Christopher C.; DiFiori, John P.; Brooks, Alison; Guskiewicz, Kevin; Campbell, Darren; McGinty, Gerald; Svoboda, Steven J.; Cameron, Kenneth L.; Broglio, Steven P.; McAllister, Thomas W.; McCrea, Michael			Correlation of Concussion Symptom Profile with Head Impact Biomechanics: A Case for Individual-Specific Injury Tolerance	JOURNAL OF NEUROTRAUMA			English	Article						acceleration; CARE; exposure; HITS; risk; SCAT3	HIGH-SCHOOL FOOTBALL; BRAIN-INJURY; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; SPORT HELD; PLAYERS; COLLEGIATE; EXPOSURE; ACCELERATION; KINEMATICS	Concussion is a brain injury induced by biomechanical forces that is broadly defined as a complex pathophysiological process affecting the brain. The intricate link between biomechanical input and concussion injury response is poorly understood. We aimed to test the hypothesis that greater biomechanical forces would result in the presentation of more concussion-related symptoms that would take longer to resolve. The objective of this study was to investigate the relationship between an array of biomechanical parameters measured for concussive impacts and the presentation and resolution of concussion symptoms. A total of 319 collegiate football players from six universities were recruited to participate in this study. Certified athletic trainers and/or team physicians at each site diagnosed and treated concussions sustained by subjects through participation in football. The subjects' helmets were instrumented with accelerometer arrays that measured linear and rotational head accelerations for each impact experienced during games and practices. Correlations between biomechanical measurements associated with concussion symptom presentation and recovery were quantified. A total of 22 subjects collectively sustained 25 concussions, with three subjects sustaining two concussions each. Biomechanical measures associated with injury were not found to be correlated with number of symptoms, Sport Concussion Assessment Tool 3 Symptom Severity Score, or time to symptom resolution. Linear and rotational accelerations associated with injury were not correlated with symptom severity for any of the 22 individual symptoms evaluated. Further, we found no association between impact location and presence of any individual symptom when ignoring severity grade. While concussive impacts did not stand out relative to impacts that did not result in injury, concussive impacts were among the most severe for each individual player. This suggests tolerance to head acceleration might be individual-specific, meaning similar biomechanical inputs can produce different injury presentations between individuals. Future investigations should consider individual-specific analyses of tolerance to head acceleration and injury response.	[Rowson, Steven; Duma, Stefan M.] Virginia Tech, Dept Biomed Engn & Mech, Blacksburg, VA 24061 USA; [Stemper, Brian D.; Shah, Alok; McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Mihalik, Jason P.; Guskiewicz, Kevin] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Harezlak, Jaroslaw] Indiana Univ, Bloomington Sch Publ Hlth, Dept Epidemiol & Biostat, Bloomington, IN USA; [Riggen, Larry D.] Indiana Univ, Sch Med, Dept Biostat, Bloomington, IN USA; [Giza, Christopher C.] Univ Calif Los Angeles, Sch Med, Pediat & Neurosurg, Los Angeles, CA USA; [DiFiori, John P.] Univ Calif Los Angeles, UCLA Div Sports Med, Los Angeles, CA USA; [Brooks, Alison] Univ Wisconsin, Madison, WI USA; [Campbell, Darren; McGinty, Gerald] US Air Force Acad, Dept Sports Med, Colorado Springs, CO 80840 USA; [Svoboda, Steven J.; Cameron, Kenneth L.] US Mil Acad, Keller Army Community Hosp, West Point, PA USA; [Broglio, Steven P.] Univ Michigan, Dept Kinesiol, Ann Arbor, MI 48109 USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA	Rowson, S (corresponding author), Virginia Tech, Dept Biomed Engn & Mech, Blacksburg, VA 24061 USA.	rowson@vt.edu	Rowson, Steven/B-1270-2012; Stemper, Brian/AAX-7611-2020; Harezlak, Jaroslaw/P-8557-2014	Rowson, Steven/0000-0002-3227-0596; Cameron, Kenneth/0000-0002-6276-4482; Harezlak, Jaroslaw/0000-0002-3070-7686	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - National Collegiate Athletic Association (NCAA); Department of Defense (DoD)United States Department of Defense; U.S. Army Medical Research Acquisition Activity; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]; Department of Defense (DHP funds)	This investigation was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded, by the National Collegiate Athletic Association (NCAA) and the Department of Defense (DoD). The U.S. Army Medical Research Acquisition Activity is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award NO W81XWH-14-2-0151. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense (DHP funds.)	Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Cantu R, 2004, LANCET NEUROL, V3, P437; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Cormier J, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004248; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Danelson KA, 2008, STAPP CAR C, V52, P59; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Funk JR, 2011, ANN BIOMED ENG, V39, P766, DOI 10.1007/s10439-010-0183-3; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Greenwald RM, 2012, CLIN J SPORT MED, V22, P83, DOI 10.1097/JSM.0b013e31824cc5d3; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hirsch Arthur E., 1970, STAPP CAR CRASH J, P144; Hodgson V., 1983, 27 STAPP CAR CRASH C, P22; Kemper Andrew R, 2010, Ann Adv Automot Med, V54, P15; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mertz Harold J, 2003, Stapp Car Crash J, V47, P155; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1967, P 11 STAPP CAR CRASH, P670906; Ommaya AK, 1966, P 10 STAPP CAR CRASH, V10, P314; Ommaya AK, 1985, BIOMECHANICS TRAUMA; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2016, SPORTS MED ARTHROSC, V24, P100, DOI 10.1097/JSA.0000000000000121; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Unterharnscheidt F. J, 1971, P 15 STAPP CAR CRASH; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	43	28	28	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2018	35	4					681	690		10.1089/neu.2017.5169			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FV3OH	WOS:000424477100008	29132269				2021-06-18	
J	Singh, R; Mason, S; Lecky, F; Dawson, J				Singh, Rajiv; Mason, Suzanne; Lecky, Fiona; Dawson, Jeremy			Prevalence of depression after TBI in a prospective cohort: The SHEFBIT study	BRAIN INJURY			English	Article						traumatic brain injury; depression; outcome; follow-up; cohort; rehabilitation	TRAUMATIC BRAIN-INJURY; HOSPITAL ANXIETY; HEAD-INJURY; PSYCHIATRIC-DISORDERS; RATING-SCALE; DSM-IV; SYMPTOMS; VALIDITY; COMORBIDITY; MODERATE	Objective: The objective is to measure the prevalence of depression after traumatic brain injury (TBI) and the features associated with increased risk in a cohort that reflects clinical practice. Methods: Prospective TBI admissions to a large Teaching Hospital Emergency Department were recruited over a 2-year period. Assessments for depression and other psychosocial and global outcomes were completed at 3 months post-injury. Comparisons were made with demographic and injury features of interest to establish any associations of depression risk. Results: Out of 827 individuals, 774 (94%) successfully attended follow-up. A percentage of 56.3 had depression using a HADS-D > 8. Depressed individuals had higher levels of post-concussion symptoms and worse psychosocial and global outcome ratings. In multivariable analysis, features associated with depression were TBI severity, previous psychiatric history, alcohol intoxication at time of injury, female gender and nonwhite ethnicity. Those with a normal CT scan showed higher risk than those with only mild abnormality and were comparable to those with much more marked CT changes. Conclusion: The 3-month prevalence of depression after TBI is very high and associated with several injury and demographic features. Future long-term follow-up of this cohort aims to confirm the features that increase risk; this may allow the earlier targeting of susceptible individuals for depression interventions.	[Singh, Rajiv] Sheffield Teaching Hosp, Dept Rehabil Med, Osborn Neurorehabilitat Unit, Sheffield S5 7AU, S Yorkshire, England; [Singh, Rajiv; Mason, Suzanne; Lecky, Fiona] Univ Sheffield, Sch Hlth & Related Res ScHARR, Hlth Serv Res, Emergency Med Res Sheffield EMRiS, Sheffield, S Yorkshire, England; [Dawson, Jeremy] Univ Sheffield, Management Sch, Inst Work Psychol, Sheffield, S Yorkshire, England	Singh, R (corresponding author), Sheffield Teaching Hosp, Dept Rehabil Med, Osborn Neurorehabilitat Unit, Sheffield S5 7AU, S Yorkshire, England.	rajiv.singh@sth.nhs.uk		Mason, Suzanne/0000-0002-1701-0577; singh, rajiv/0000-0002-3173-9591			[Anonymous], 2014, HEAD INJ TRIAG ASS I; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Chandola T, 2000, J PUBLIC HEALTH MED, V22, P182, DOI 10.1093/pubmed/22.2.182; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dyer JR, 2016, J HEAD TRAUMA REHAB, V31, P225, DOI 10.1097/HTR.0000000000000177; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; First MB., 2002, STRUCTURED CLIN INTE; Gertler P, 2015, COCHRANE DATABASE SY, V12; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Guillamondegui OD, 2011, AHRQ PUBLICATION; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Huang DB, 2005, BRAIN INJURY, V19, P903, DOI 10.1080/02699050400004773; Hudak AM, 2012, J HEAD TRAUMA REHAB, V27, P87, DOI 10.1097/HTR.0b013e3182114efd; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9; LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532-5415.1968.tb02103.x; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meltzer H, 1995, PREVALENCE PSYCHIAT; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Sigurdardottir S, 2013, J REHABIL MED, V45, P808, DOI 10.2340/16501977-1156; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Siponkoski ST, 2013, J REHABIL MED, V45, P835, DOI 10.2340/16501977-1189; Ulfarsson T, 2014, BRAIN INJURY, V28, P1675, DOI 10.3109/02699052.2014.947625; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	48	28	28	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	1					84	90		10.1080/02699052.2017.1376756			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FY7VS	WOS:000427072300009	29190146				2021-06-18	
J	Rivera-Lara, L; Geocadin, R; Zorrilla-Vaca, A; Healy, R; Radzik, BR; Palmisano, C; Mirski, M; Ziai, WC; Hogue, C				Rivera-Lara, Lucia; Geocadin, Romergryko; Zorrilla-Vaca, Andres; Healy, Ryan; Radzik, Batya R.; Palmisano, Caitlin; Mirski, Marek; Ziai, Wendy C.; Hogue, Charles			Validation of Near-Infrared Spectroscopy for Monitoring Cerebral Autoregulation in Comatose Patients	NEUROCRITICAL CARE			English	Article						Cerebral oximetry; Transcranial Doppler; Blood flow velocity; Cerebral perfusion; Near-infrared spectroscopy; Cerebral autoregulation	BLOOD-FLOW AUTOREGULATION; TRAUMATIC BRAIN-INJURY; TRANSCRANIAL DOPPLER; CEREBROVASCULAR AUTOREGULATION; SUBARACHNOID HEMORRHAGE; CARDIAC-SURGERY; PRESSURE; HYPOTENSION; ULTRASOUND; REACTIVITY	Transcranial Doppler (TCD) noninvasively measures cerebral blood flow (CBF) velocity and is a well-studied method to monitor cerebral autoregulation (CA). Near-infrared spectroscopy (NIRS) has emerged as a promising noninvasive method to determine CA continuously by using regional cerebral oxygen saturation (rSO(2)) as a surrogate for CBF. Little is known about its accuracy to determine CA in patients with intracranial lesions. The purpose of this study was to assess the accuracy of rSO(2)-based CA monitoring with TCD methods in comatose patients with acute neurological injury. Thirty-three comatose patients were monitored at the bedside to measure CA using both TCD and NIRS. Patients were monitored daily for up to three days from coma onset. The cerebral oximetry index (COx) was calculated as the moving correlation between the slow waves of rSO(2) and mean arterial pressure (MAP). The mean velocity index (Mx) was calculated as a similar coefficient between slow waves of TCD-measured CBF velocity and MAP. Optimal blood pressure was defined as the MAP with the lowest Mx and COx. Averaged Mx and COx as well as optimal MAP, based on both Mx and COx, were compared using Pearson's correlation. Bias analysis was performed between these same CA metrics. The median duration of monitoring was 60 min (interquartile range [IQR] 48-78). There was a moderate correlation between the averaged values of COx and Mx (R = 0.40, p = 0.005). Similarly, there was a strong correlation between optimal MAP calculated for COx and Mx (R = 0.87, p < 0.001). Bland-Altman analysis showed moderate agreement with bias (+/- standard deviation) of -0.107 (+/- 0.191) for COx versus Mx and good agreement with bias of 1.90 (+/- 7.94) for optimal MAP determined by COx versus Mx. Monitoring CA with NIRS-derived COx is correlated and had good agreement with previously validated TCD-based method. These results suggest that COx may be an acceptable substitute for Mx monitoring in patients with acute intracranial injury.	[Rivera-Lara, Lucia; Geocadin, Romergryko; Ziai, Wendy C.] Johns Hopkins Univ, Sch Med, Dept Neurol Anesthesiol & Crit Care Med, 600 N Wolfe St,Phipps 455, Baltimore, MD 21287 USA; [Rivera-Lara, Lucia; Geocadin, Romergryko; Zorrilla-Vaca, Andres; Healy, Ryan; Radzik, Batya R.; Palmisano, Caitlin; Mirski, Marek; Ziai, Wendy C.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Zorrilla-Vaca, Andres] Univ Valle, Sch Med, Fac Hlth, Cali, Colombia; [Hogue, Charles] Northwestern Univ, Dept Anesthesiol, Feinberg Sch Med, Chicago, IL 60611 USA	Rivera-Lara, L (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol Anesthesiol & Crit Care Med, 600 N Wolfe St,Phipps 455, Baltimore, MD 21287 USA.; Rivera-Lara, L (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA.	lriver14@jhmi.edu	Rivera-Lara, Lucia/AAX-8233-2020; Zorrilla Vaca, Andres/I-9274-2014	Rivera-Lara, Lucia/0000-0002-9053-2283; Zorrilla Vaca, Andres/0000-0001-8140-8486	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL 92259]; Medtronic/Covidien, Dublin, IR; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL092259] Funding Source: NIH RePORTER	Dr. Hogue is the PI on an NIH-sponsored clinical study (R01 HL 92259). Dr. Rivera Lara is the PI on an American Academy of Neurology/American Brain Foundation and grant from Medtronic/Covidien, Dublin, IR.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aries MJH, 2010, STROKE, V41, P2697, DOI 10.1161/STROKEAHA.110.594168; Bazan R, 2015, ULTRASOUND MED BIOL, V41, P2131, DOI 10.1016/j.ultrasmedbio.2015.04.008; Berg RMG, 2016, SCAND J CLIN LAB INV, V76, P88, DOI 10.3109/00365513.2015.1091495; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Budohoski KP, 2013, J CEREBR BLOOD F MET, V33, P449, DOI 10.1038/jcbfm.2012.189; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Hori D, 2016, INTERACT CARDIOV TH, V22, P445, DOI 10.1093/icvts/ivv371; Hori D, 2015, ANN THORAC SURG, V100, P487, DOI 10.1016/j.athoracsur.2015.03.036; Howlett JA, 2013, PEDIATR RES, V74, P525, DOI 10.1038/pr.2013.132; Hughes CG, 2012, CURR OPIN CRIT CARE, V18, P518, DOI 10.1097/MCC.0b013e328357effa; LINDEGAARD KF, 1987, STROKE, V18, P1025, DOI 10.1161/01.STR.18.6.1025; NEWELL DW, 1992, CEREBROVAS BRAIN MET, V4, P122; Olsen KS, 1996, J NEUROSURG ANESTH, V8, P280, DOI 10.1097/00008506-199610000-00004; Ono M, 2013, ANESTH ANALG, V116, P198, DOI 10.1213/ANE.0b013e318271fb10; Reinhard M, 2006, J NEUROL SCI, V250, P103, DOI 10.1016/j.jns.2006.07.011; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Stevens RD, 2006, CRIT CARE MED, V34, P31, DOI 10.1097/01.CCM.0000194534.42661.9F; Tsuji M, 2000, PEDIATRICS, V106, P625, DOI 10.1542/peds.106.4.625; Tsuji M, 1998, PEDIATR RES, V44, P591, DOI 10.1203/00006450-199810000-00020; Vernieri F, 2008, CEPHALALGIA, V28, P689, DOI 10.1111/j.1468-2982.2008.01579.x; Vretzakis G, 2014, J THORAC DIS, V6, pS60, DOI 10.3978/j.issn.2072-1439.2013.10.22; Wang XH, 2012, ASAIO J, V58, P122, DOI 10.1097/MAT.0b013e318241abd3; Weerakkody RA, 2010, ACTA NEUROCHIR, V152, P1763, DOI 10.1007/s00701-010-0748-9; Yoshitani K, 2002, ANESTH ANALG, V94, P586, DOI 10.1097/00000539-200203000-00020; Zweifel C, 2010, STROKE, V41, P1963, DOI 10.1161/STROKEAHA.109.577320	29	28	29	0	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2017	27	3					362	369		10.1007/s12028-017-0421-8			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	FN7DT	WOS:000416179300009	28664392	Green Accepted			2021-06-18	
J	Du Preez, EJ; Graham, KS; Gan, TY; Moses, B; Ball, C; Kuah, DE				Du Preez, Etienne J.; Graham, Kenneth S.; Gan, Thomas Y.; Moses, Bassam; Ball, Chris; Kuah, Donald E.			Depression, Anxiety, and Alcohol Use in Elite Rugby League Players Over a Competitive Season	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						rugby league; prevalence; depression; anxiety; alcohol use	PROFESSIONAL FOOTBALL PLAYERS; MENTAL-HEALTH; RISK-FACTORS; CES-D; PHQ-9; PREVALENCE; SYMPTOMS; POPULATION; DISORDERS; VALIDITY	Objective: To assess the prevalence of symptoms of depression, anxiety, and rates of alcohol misuse in elite rugby league players in Australasia. Design: A cross-sectional, epidemiological study with repeated measures. Setting: Surveys were conducted during the 2015 preseason and in-season. Participants: Four hundred four elite rugby league players participated preseason and 278 players in-season. Main Outcome Measures: Symptoms of depression were measured using the Patient Health Questionnaire-9 scale, symptoms of generalized anxiety disorder (GAD) with the GAD-7 scale, and the Alcohol Use Disorders Identification Test Consumption scale was used to assess hazardous alcohol use. Results: The overall prevalence of depression was 12.6% preseason and 10.1% in-season. Generalized anxiety disorder had a prevalence of 14.6% and 10.1% for these 2 periods. Overall, 68.6% of players had hazardous levels of alcohol use preseason, and 62.8% in-season. There was no significant difference for any of the main outcomes between the periods. Players with a history of mental illnesses had 5.62 greater odds (95% confidence interval [CI], 2.62-12.04) of depression than those without during preseason, and 22.08 greater odds (95% CI, 7.77-62.71) in-season. Players reporting >= 3 previous concussions had 2.02 greater odds (95% CI, 1.07-3.82) of depression than those reporting <= 2 in the preseason sample. Conclusions: Rugby league players have a lower prevalence of depression compared with studies of the general population and other athletes, but a higher prevalence of GAD, and high rates of alcohol misuse. Clubs may consider implementing regular screening for these conditions. Further prospective research to determine causality of independent factors is required.	[Du Preez, Etienne J.] Australasian Coll Sport & Exercise Phys, Sydney, NSW, Australia; [Graham, Kenneth S.] New South Wales Inst Sport, Appl Res Program, Sydney, NSW, Australia; [Gan, Thomas Y.] Narrabeen Sports Med Ctr, Sydney, NSW, Australia; [Moses, Bassam] Southern Cross Orthopaed & Sports Clin, Sydney, NSW, Australia; [Ball, Chris] Sports Clin NQ, North Ward, Australia; [Kuah, Donald E.] New South Wales Inst Sport, Sydney Sports Med Ctr, Sydney, NSW, Australia	Du Preez, EJ (corresponding author), Stadium Sports Med Clin, Sheridan Bldg,Moore Pk Rd, Moore Pk, NSW 2021, Australia.	etdupreez@gmail.com					American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Australian Bureau of Statistics, 2009, NAT SURV MENT HLTH W; Badel P, 2015, QUEENSLANDS NRL STAR; Begg SJ, 2008, MED J AUSTRALIA, V188, P36, DOI 10.5694/j.1326-5377.2008.tb01503.x; Bradley KA, 2007, ALCOHOL CLIN EXP RES, V31, P1208, DOI 10.1111/j.1530-0277.2007.00403.x; Carey M, 2014, FAM PRACT, V31, P483, DOI 10.1093/fampra/cmu018; Choi SW, 2014, PSYCHOL ASSESSMENT, V26, P513, DOI 10.1037/a0035768; Downey RG, 1998, J GEN PSYCHOL, V125, P175, DOI 10.1080/00221309809595542; Garry C, 2015, RUGBY LEAGUE COMMUNI; Gouttebarge V, 2015, OCCUP MED-OXFORD, V65, P190, DOI 10.1093/occmed/kqu202; Gulliver A, 2015, J SCI MED SPORT, V18, P255, DOI 10.1016/j.jsams.2014.04.006; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hingson RW, 2009, J STUD ALCOHOL DRUGS, P12, DOI 10.15288/jsads.2009.s16.12; Jorm AF, 2012, MED J AUSTRALIA, V196, P118, DOI 10.5694/mja11.10041; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kokaua Jesse, 2009, Pac Health Dialog, V15, P9; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093; Milette K, 2010, RHEUMATOLOGY, V49, P789, DOI 10.1093/rheumatology/kep443; National Rugby League, 2014, BUILD STRONG GAM ANN; Ong AD, 2000, J APPL SOC PSYCHOL, V30, P1691, DOI 10.1111/j.1559-1816.2000.tb02462.x; Sareen J, 2005, ARCH GEN PSYCHIAT, V62, P1249, DOI 10.1001/archpsyc.62.11.1249; Schaal K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019007; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Wolanin A, 2016, BRIT J SPORT MED, V50, P167, DOI 10.1136/bjsports-2015-095756; Yang JZ, 2007, CLIN J SPORT MED, V17, P481, DOI 10.1097/JSM.0b013e31815aed6b	28	28	28	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2017	27	6					530	535					6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	FN2KO	WOS:000415821300006	28107218				2021-06-18	
J	Kroshus, E; Rivara, FP; Whitlock, KB; Herring, SA; Chrisman, SPD				Kroshus, Emily; Rivara, Frederick P.; Whitlock, Kathryn B.; Herring, Stanley A.; Chrisman, Sara P. D.			Disparities in Athletic Trainer Staffing in Secondary School Sport: Implications for Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; health disparities; athletic trainer; high school	TRAUMATIC BRAIN-INJURY; PROLONGED RECOVERY; EPIDEMIOLOGY; MANAGEMENT; STATEMENT; BENCHMARK; EDUCATION	Objective: First, to assess whether teams at schools with an athletic trainer (AT) on staff had a higher number of diagnosed concussions than teams without medical personnel present. Second, to assess whether the variability in employment of a certified AT by Washington state high schools is patterned by socioeconomic and demographic characteristics. Design: Cross-sectional survey. Setting: Washington state public high schools. Participants: Stratified random sample of football and soccer coaches (n = 270 teams, 144 schools). Independent Variables: Presence of an AT and school characteristics (percentage of students qualifying for free or reduced price lunch, rural location, enrollment). Results: Football and boys' soccer teams at schools with an AT had a significantly greater number of athletes with diagnosed concussions compared to teams at schools without an AT (P < 0.05). There was no difference in number of athletes with diagnosed concussions by AT staffing for girls' soccer. Schools with an AT on staff were significantly more likely than schools without an AT to be in an urban location (P < 0.001), to have an enrollment of 1000 students or more (P < 0.001), and to have a smaller proportion of students eligible for school lunch (P = 0.005). Conclusions: The present study provides empirical support for the benefit of ATs in diagnosing concussions in high school sport and underscores the challenges to AT staffing in lower resource settings. These findings cause us to critically reflect on the threshold for medical oversight in contact and collision sport from the perspective of risk prevention, and the extent to which disparities in this medical oversight are acceptable in the public school setting. Clinical Relevance: Strategies for increasing AT staffing in high school sports settings should be explored given their demonstrated benefit in diagnosing concussions.	[Kroshus, Emily; Rivara, Frederick P.; Whitlock, Kathryn B.; Chrisman, Sara P. D.] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, 2001 8th Ave,Suite 400, Seattle, WA 98121 USA; [Kroshus, Emily; Rivara, Frederick P.; Whitlock, Kathryn B.; Chrisman, Sara P. D.] Univ Washington, Dept Pediat, 2001 8th Ave,Suite 400, Seattle, WA 98121 USA; [Rivara, Frederick P.; Whitlock, Kathryn B.; Chrisman, Sara P. D.] Harborview Injury Prevent & Res Ctr, Seattle, WA USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98121 USA	Kroshus, E (corresponding author), Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, 2001 8th Ave,Suite 400, Seattle, WA 98121 USA.; Kroshus, E (corresponding author), Univ Washington, Dept Pediat, 2001 8th Ave,Suite 400, Seattle, WA 98121 USA.	ekroshus@u.washington.edu		Chrisman, Sara/0000-0001-5373-7223	Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF); Public Health Law Research (PHLR) program	Data used in this study were funded by the Robert Wood Johnson Foundation, Public Health Law Research (PHLR) program.	Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Casa DJ, 2013, J ATHL TRAINING, V48, P546, DOI 10.4085/1062-6050-48.4.12; Chrisman SP, 2014, AM J SPORT MED, V42, P1190, DOI 10.1177/0363546513519073; Comstock RD, 2016, INJURY PEDIAT ADOLES, P51; Condron DJ, 2003, SOCIOL EDUC, V76, P18, DOI 10.2307/3090259; Courson R, 2014, J ATHL TRAINING, V49, P128, DOI 10.4085/1062-6050-49.1.06; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Hailu A, 2009, GUIDELINES USING RUR; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Kerr Zachary Y, 2014, Inj Epidemiol, V1, P28; LaBella CR, 2013, CLIN J SPORT MED, V23, P149; Leachman Michael, 2014, MOST STATES STILL FU; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Mazerolle SM, 2015, J ATHL TRAINING, V50, P1059, DOI 10.4085/1062-6050-50.10.01; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McLeod TCV, 2013, J ATHL TRAINING, V48, P483, DOI 10.4085/1062-6050-48.4.04; Meehan WP, 2013, PEDIATR EMERG CARE, V29, P624, DOI 10.1097/PEC.0b013e31828e9cea; Office of the Superintendent of Public Instruction, WASH STAT REP CARD 2; Posey-Maddox L, 2013, AM J EDUC, V119, P235, DOI 10.1086/668754; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Pryor RR, 2015, J ATHL TRAINING, V50, P156, DOI 10.4085/1062-6050-50.2.03; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; United States Department of Agriculture-Economic Research Service (USDA-ERS), RUR POV WELL BEING; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	27	28	28	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2017	27	6					542	547					6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	FN2KO	WOS:000415821300008	28742604				2021-06-18	
J	Kennedy, E; Heron, J; Munafo, M				Kennedy, Eleanor; Heron, Jon; Munafo, Marcus			Substance use, criminal behaviour and psychiatric symptoms following childhood traumatic brain injury: findings from the ALSPAC cohort	EUROPEAN CHILD & ADOLESCENT PSYCHIATRY			English	Article						Traumatic brain injury; Head injury; Risk behaviour; Crime; Substance use	BIRTH COHORT; ABUSE; QUESTIONNAIRE; EPIDEMIOLOGY; ADOLESCENTS; DISORDERS; ALCOHOL; HEALTH; RISK	Recent research suggests a link between traumatic brain injury (TBI) in youth and later risk behaviour. We explored the association between mild TBI and psychiatric symptoms, substance use and criminal behaviour using data from a longitudinal birth cohort. Participants with mild TBI (n = 800), orthopaedic injuries (n = 2305) and no injuries (n = 8307) were identified from self and parent reports up to age 16 years. Self-report measures of substance use (alcohol, tobacco and cannabis) and criminal behaviours, and parent-reported psychiatric symptoms were collected at age 17 years. Analyses were adjusted for pre-birth and early childhood confounders. Participants with a TBI showed increased odds of hazardous alcohol use compared to those with no injury and those with an orthopaedic injury. Relative to those with no injury, participants with a TBI showed increased odds of problematic use of tobacco and cannabis, being in trouble with the police and having more parent-reported conduct problems. Sustaining either a TBI or an orthopaedic injury increased the odds of offending behaviour compared to having no injuries. There was no clear evidence of association between orthopaedic injury and the other risk outcomes. The increased odds of risk behaviour associated with TBI relative to no injury replicated previous research. However, the inclusion of a non-brain-related injury group adds evidence for a possible causal pathway between mild TBI in youth and later hazardous alcohol use only. This highlights the importance of including an additional negative control injury group in mild TBI research.	[Kennedy, Eleanor; Munafo, Marcus] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England; [Kennedy, Eleanor; Munafo, Marcus] Univ Bristol, Sch Expt Psychol, Bristol, Avon, England; [Heron, Jon] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England; [Kennedy, Eleanor; Munafo, Marcus] Sch Expt Psychol, 12a Priory Rd, Bristol BS8 1TU, Avon, England	Kennedy, E (corresponding author), Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England.; Kennedy, E (corresponding author), Univ Bristol, Sch Expt Psychol, Bristol, Avon, England.; Kennedy, E (corresponding author), Sch Expt Psychol, 12a Priory Rd, Bristol BS8 1TU, Avon, England.	e.kennedy@bristol.ac.uk	Munafo, Marcus/AAE-2306-2020; Heron, Jon/D-5884-2011	Munafo, Marcus/0000-0002-4049-993X; Heron, Jon/0000-0001-6199-5644	UK Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Wellcome TrustWellcome TrustEuropean Commission [092731]; University of Bristol; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_UU_12013/6]; Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECI-PHer), a UKCRC Public Health Research Centre of ExcellenceAustralian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme; British Heart FoundationBritish Heart Foundation [MR/KO232331/1]; Cancer Research UKCancer Research UK; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; Welsh Government; Wellcome Trust under UK Clinical Research CollaborationWellcome Trust; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_PC_15018, G9815508] Funding Source: researchfish	We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. This publication is the work of the authors who will serve as guarantors for the contents of this paper. The UK Medical Research Council and Wellcome Trust (Grant Ref: 092731) and the University of Bristol provide core support for ALSPAC. This work was supported by a University of Bristol postgraduate research scholarship to EK, and the Medical Research Council (MC_UU_12013/6). The work was undertaken with the support of The Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECI-PHer), a UKCRC Public Health Research Centre of Excellence. Joint funding (MR/KO232331/1) from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, the Welsh Government and the Wellcome Trust, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged. All authors are part of the MRC Integrative Epidemiology Unit (IEU) at the University of Bristol.	Babor TF, 2001, GUIDE USE PRIM CARE, V2, P1; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Cho SB, 2014, ALCOHOL CLIN EXP RES, V38, P2024, DOI 10.1111/acer.12446; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dewan MC, 2016, WORLD NEUROSURG, V91, P497, DOI 10.1016/j.wneu.2016.03.045; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Gage SH, 2016, ANNU REV PSYCHOL, V67, P567, DOI 10.1146/annurev-psych-122414-033352; Goodman A, 2011, SOC PSYCH PSYCH EPID, V46, P521, DOI 10.1007/s00127-010-0219-x; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Ilie G, 2014, BULLYING OTHER CONDU, V9, P10, DOI DOI 10.1371/J0URNAL.P0NE.0094936; Ilie G, 2017, INJURY, V48, P285, DOI 10.1016/j.injury.2016.09.030; Ilie G, 2015, J HEAD TRAUMA REHAB, V30, P293, DOI 10.1097/HTR.0000000000000101; Kennedy E, 2017, J HEAD TRAUMA REHAB, V32, P425, DOI 10.1097/HTR.0000000000000289; Legleye S, 2013, INT J METH PSYCH RES, V22, P16, DOI 10.1002/mpr.1378; Mawson AR, 1996, AM J EPIDEMIOL, V144, P463; Max JE, 1998, BRAIN INJURY, V12, P41; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; McKinlay A, 2014, J HEAD TRAUMA REHAB, V29, P498, DOI 10.1097/HTR.0000000000000001; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Moore E, 2014, J HEAD TRAUMA REHAB, V29, P239, DOI 10.1097/HTR.0b013e31828f9876; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Sariaslan A, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002103; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Tonks James, 2011, Clin Child Psychol Psychiatry, V16, P185, DOI 10.1177/1359104511403583; Williams R, 2006, STATA J, V6, P58, DOI 10.1177/1536867X0600600104; Williams WH, 2015, J HEAD TRAUMA REHAB, V30, P69, DOI 10.1097/HTR.0000000000000134; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; Winqvist S, 2008, BRAIN INJURY, V22, P780, DOI 10.1080/02699050802339397; Winqvist S, 2007, BRAIN INJURY, V21, P1079, DOI 10.1080/02699050701553221; World Health Organization, 2006, NEUR DIS PUBL HLTH C	34	28	28	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1018-8827	1435-165X		EUR CHILD ADOLES PSY	Eur. Child Adolesc. Psych.	OCT	2017	26	10					1197	1206		10.1007/s00787-017-0975-1			10	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	FK7OR	WOS:000413697300006	28314984	Green Published, Other Gold			2021-06-18	
J	Patel, RK; Prasad, N; Kuwar, R; Haldar, D; Abdul-Muneer, PM				Patel, Rachel K.; Prasad, Nithisha; Kuwar, Ram; Haldar, Debanjan; Abdul-Muneer, P. M.			Transforming growth factor-beta 1 signaling regulates neuroinflammation and apoptosis in mild traumatic brain injury	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Transforming growth factor-beta 1; Smad proteins; Transfection; Oxidative stress; Neuroinflammation; Apoptosi	TGF-BETA; TRANSCRIPTIONAL REGULATION; CEREBROSPINAL-FLUID; OXIDATIVE STRESS; RAT-BRAIN; IN-VITRO; MODEL; INFLAMMATION; MECHANISMS; INHIBITION	Mild traumatic brain injury (mTBI) is a low-level injury, which often remains undiagnosed, and in most cases it leads to death and disability as it advances as secondary injury. Therefore, it is important to study the underlying signaling mechanisms of mTBI-associated neurological ailments. While transforming growth factor-betal (TGF-beta 1) has a significant role in inflammation and apoptosis in myriads of other pathophysiological conditions, the precise function of increased TGF-beta 1 after mTBI is unknown. In this study, our objective is to study the physiological relevance and associated mechanisms of TGF-beta 1-mediated inflammation and apoptosis in mTBI. Using an in vitro stretch-injury model in rat neuronal cultures and the in vivo fluid percussion injury (FPI) model in rats, we explored the significance of TGF-beta 1 activation in mTBI. Our study demonstrated that the activation of TGF-beta 1 in mTBI correlated with the induction of free radical generating enzyme NADPH oxidase 1 (NOX1). Further, using TGF-beta type I receptor (TGF-(beta RI) inhibitor SB431542 and transfection of TGF-beta 1 siRNA and TGF-beta antagonist Smad7, we established the neuroinflammatory and apoptotic role of TGF-beta 1 in mTBI. Inhibition of TGF-beta RI or TGF-beta 1 diminished TGF-beta 1-induced inflammation and apoptosis. Further, the enhanced TGF-beta 1 activation increased the phosphorylation of R-Smads including Smad2 and Smad3 proteins. By immunofluorescence, western blotting, ELISA and TUNEL experiments, we demonstrated the up-regulation of pro inflammatory cytokines IL-1 beta and TNE-alpha and apoptotic cell death in neurons. In conclusion, this study could establish the significance of TGF-beta 1 in transforming the pathophysiology of mTBI into secondary injury. (C) 2017 Elsevier Inc. All rights reserved.	[Patel, Rachel K.; Prasad, Nithisha; Kuwar, Ram; Haldar, Debanjan; Abdul-Muneer, P. M.] JFK Med Ctr, Neurosci Inst, Lab CNS Injury & Repair, 65 James St, Edison, NJ 08820 USA	Abdul-Muneer, PM (corresponding author), JFK Med Ctr, Neurosci Inst, Lab CNS Injury & Repair, 65 James St, Edison, NJ 08820 USA.	pmamuneer@gmail.com		Haldar, Debanjan/0000-0002-5061-0953; Abdul-Muneer, P. M/0000-0001-8231-4385	Neuroscience Institute at JFK Medical Center, Edison NJ	This work was funded by the Neuroscience Institute at JFK Medical Center, Edison NJ to P.M. Abdul-Muneer.	Abdul Muneer P. M., 2005, THESIS; Abdul-Muneer PM, 2017, BRAIN BEHAV IMMUN, V59, P190, DOI 10.1016/j.bbi.2016.09.002; Abdul-Muneer PM, 2016, MOL NEUROBIOL, V53, P6106, DOI 10.1007/s12035-015-9520-8; Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Abdul-Muneer P.M., 2016, MOL NEUROBIOL; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Ben-Gigi L, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0078-14.2015; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Chen S, 2005, IMMUNOLOGY, V114, P565, DOI 10.1111/j.1365-2567.2004.02110.x; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heinemann U, 2012, GLIA, V60, P1251, DOI 10.1002/glia.22311; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Jain M, 2013, J BIOL CHEM, V288, P770, DOI 10.1074/jbc.M112.431973; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Krstic J, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/654594; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Lanz TV, 2010, J CLIN INVEST, V120, P2782, DOI 10.1172/JCI41709; Lim H, 2006, CELL MOL LIFE SCI, V63, P2584, DOI 10.1007/s00018-006-6085-8; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Luo J, 2006, P NATL ACAD SCI USA, V103, P18326, DOI 10.1073/pnas.0605077103; Manaenko A, 2014, STROKE, V45, P828, DOI 10.1161/STROKEAHA.113.003754; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; McMillin MA, 2015, LAB INVEST, V95, P903, DOI 10.1038/labinvest.2015.70; Meng XM, 2012, KIDNEY INT, V81, P266, DOI 10.1038/ki.2011.327; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Nicoletti F, 1998, CLIN EXP IMMUNOL, V113, P96, DOI 10.1046/j.1365-2249.1998.00604.x; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nirogi R, 2009, J NEUROSCI METH, V178, P116, DOI 10.1016/j.jneumeth.2008.12.001; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Prat A, 2001, GLIA, V36, P145, DOI 10.1002/glia.1104; Rustenhoven J, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0503-0; Saghazadeh A, 2016, REV NEUROSCIENCE, V27, P635, DOI 10.1515/revneuro-2015-0059; Salvador E, 2013, JOVE-J VIS EXP, DOI 10.3791/50928; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Shen WY, 2011, EUR J CELL BIOL, V90, P323, DOI 10.1016/j.ejcb.2010.10.013; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Soares HD, 1995, J NEUROSCI, V15, P8223; Spender LC, 2009, CELL DEATH DIFFER, V16, P593, DOI 10.1038/cdd.2008.183; Swardfager W, 2010, BIOL PSYCHIAT, V68, P930, DOI 10.1016/j.biopsych.2010.06.012; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Vogel T, 2010, CEREB CORTEX, V20, P661, DOI 10.1093/cercor/bhp134; Walsh JG, 2008, P NATL ACAD SCI USA, V105, P12815, DOI 10.1073/pnas.0707715105; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Zhang D. B., 2013, YANGTZE RIVER, V1, P1, DOI DOI 10.1371/J0URNAL.P0NE.0065044; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127	68	28	28	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	AUG	2017	64						244	258		10.1016/j.bbi.2017.04.012			15	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	EZ1XR	WOS:000404504600024	28433746				2021-06-18	
J	Brody, AL; Hubert, R; Enoki, R; Garcia, LY; Mamoun, MS; Okita, K; London, ED; Nurmi, EL; Seaman, LC; Mandelkern, MA				Brody, Arthur L.; Hubert, Robert; Enoki, Ryutaro; Garcia, Lizette Y.; Mamoun, Michael S.; Okita, Kyoji; London, Edythe D.; Nurmi, Erika L.; Seaman, Lauren C.; Mandelkern, Mark A.			Effect of Cigarette Smoking on a Marker for Neuroinflammation: A [C-11]DAA1106 Positron Emission Tomography Study	NEUROPSYCHOPHARMACOLOGY			English	Article							PERIPHERAL BENZODIAZEPINE-RECEPTOR; NICOTINIC ACETYLCHOLINE-RECEPTORS; PROTEIN 18 KDA; TRAUMATIC BRAIN-INJURY; LIGAND DAA1106 BINDS; IN-VIVO BINDING; TRANSLOCATOR PROTEIN; ALZHEIMERS-DISEASE; MICROGLIAL ACTIVATION; DOPAMINE RELEASE	In the brain, microglia continuously scan the surrounding extracellular space in order to respond to damage or infection by becoming activated and participating in neuroinflammation. When activated, microglia increase the expression of translocator protein (TSPO) 18 kDa, thereby making the TSPO expression a marker for neuroinflammation. We used the radiotracer [C-11] DAA1106 (a ligand for TSPO) and positron emission tomography (PET) to determine the effect of smoking on availability of this marker for neuroinflammation. Forty-five participants (30 smokers and 15 non-smokers) completed the study and had usable data. Participants underwent a dynamic PET scanning session with bolus injection of [C-11] DAA1106 (with smokers in the satiated state) and blood draws during PET scanning to determine TSPO affinity genotype and plasma nicotine levels. Whole-brain standardized uptake values (SUVs) were determined, and analysis of variance was performed, with group (smoker vs non-smoker) and genotype as factors, thereby controlling for genotype. Smokers and non-smokers differed in whole-brain SUVs (P = 0.006) owing to smokers having 16.8% lower values than non-smokers. The groups did not differ in injected radiotracer dose or body weight, which were used to calculate SUV. An inverse association was found between whole-brain SUV and reported cigarettes per day (P<0.05), but no significant relationship was found for plasma nicotine. Thus, smokers have less [C-11] DAA1106 binding globally than non-smokers, indicating less microglial activation. Study findings are consistent with much prior research demonstrating that smokers have impaired inflammatory functioning compared with non-smokers and that constituents of tobacco smoke other than nicotine affect inflammatory processes.	[Brody, Arthur L.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Brody, Arthur L.] VA San Diego Healthcare Syst, Dept Psychiat, San Diego, CA USA; [Hubert, Robert; Enoki, Ryutaro; Garcia, Lizette Y.; Mamoun, Michael S.; Okita, Kyoji] VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA USA; [Okita, Kyoji; London, Edythe D.; Nurmi, Erika L.; Seaman, Lauren C.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA; [Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA USA	Brody, AL (corresponding author), Univ Calif San Diego, Dept Psychiat, VA San Diego Healthcare Syst, 3350 La Jolla Village Dr,116A, San Diego, CA 92161 USA.	abrody@ucsd.edu	Nurmi, Erika/AAX-1625-2020; Nurmi, Erika L/P-4627-2014	Nurmi, Erika/0000-0003-4893-8957; Nurmi, Erika L/0000-0003-4893-8957	Tobacco-Related Disease Research ProgramUniversity of California System [23XT-0002]; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01 DA20872]; Department of Veterans Affairs, Office of Research and Development (CSR&D Merit Review Award) [I01 CX000412]; DOMONKAI fund from the Department of Psychiatry, Graduate School of Medicine, at Chiba University; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 DA024635]; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA024635] Funding Source: NIH RePORTER	This study was supported by the Tobacco-Related Disease Research Program (to ALB (23XT-0002)), the National Institute on Drug Abuse (to ALB (R01 DA20872)), and the Department of Veterans Affairs, Office of Research and Development (CSR&D Merit Review Award I01 CX000412 (to ALB)). This research was also supported, in part, by the DOMONKAI fund from the Department of Psychiatry, Graduate School of Medicine, at Chiba University (to KO), endowments from the Thomas P. and Katherine K. Pike Chair in Addiction Studies (to EDL) and Marjorie M. Green Trust (to EDL), and the National Institutes of Health (T32 DA024635 (to LCS)). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The authors declare no conflict of interest.	Abobo CV, 2012, NICOTINE TOB RES, V14, P801, DOI 10.1093/ntr/ntr287; Anthony DC, 2013, MOL CELL NEUROSCI, V53, P1, DOI 10.1016/j.mcn.2012.11.005; Arimilli S, 2015, JOVE-J VIS EXP, DOI 10.3791/52351; Baker RR, 2004, FOOD CHEM TOXICOL, V42, pS53, DOI 10.1016/j.fct.2004.01.001; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; BENOWITZ NL, 1994, CLIN PHARMACOL THER, V56, P483, DOI 10.1038/clpt.1994.169; Brody AL, 2004, AM J PSYCHIAT, V161, P1211, DOI 10.1176/appi.ajp.161.7.1211; Brody AL, 2002, ARCH GEN PSYCHIAT, V59, P1162, DOI 10.1001/archpsyc.59.12.1162; Brody AL, 2006, ARCH GEN PSYCHIAT, V63, P808, DOI 10.1001/archpsyc.63.7.808; Brody AL, 2006, ARCH GEN PSYCHIAT, V63, P907, DOI 10.1001/archpsyc.63.8.907; Brody AL, 2013, INT J NEUROPSYCHOPH, V16, P957, DOI 10.1017/S1461145712001022; Brody AL, 2011, ARCH GEN PSYCHIAT, V68, P953, DOI 10.1001/archgenpsychiatry.2011.51; Brody AL, 2009, INT J NEUROPSYCHOPH, V12, P305, DOI 10.1017/S146114570800922X; Brody AL, 2009, NEUROPSYCHOPHARMACOL, V34, P282, DOI 10.1038/npp.2008.87; Chaki S, 1999, EUR J PHARMACOL, V371, P197, DOI 10.1016/S0014-2999(99)00118-1; Chauveau F, 2008, EUR J NUCL MED MOL I, V35, P2304, DOI 10.1007/s00259-008-0908-9; Colasanti A, 2016, BIOL PSYCHIAT, V80, P62, DOI 10.1016/j.biopsych.2015.11.022; Cosgrove KP, 2009, ARCH GEN PSYCHIAT, V66, P666, DOI 10.1001/archgenpsychiatry.2009.41; Coughlin JM, 2014, J NEUROVIROL, V20, P219, DOI 10.1007/s13365-014-0239-5; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; Fan Z, 2015, BRAIN, V138, P3685, DOI 10.1093/brain/awv288; First M., 1995, STRUCTURED CLIN INTE; Fowles J, 2003, TOB CONTROL, V12, P424, DOI 10.1136/tc.12.4.424; Gandhi KK, 2009, INT J CLIN PRACT, V63, P360, DOI 10.1111/j.1742-1241.2008.01969.x; Gao Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107979; Goncalves RB, 2011, INFLAMM RES, V60, P409, DOI 10.1007/s00011-011-0308-7; Green CR, 1996, RECENT ADV TOBACCO S, V22, P131; Haarman BCM, 2016, BRAIN BEHAV IMMUN, V56, P21, DOI 10.1016/j.bbi.2015.09.004; Hafizi S, 2017, AM J PSYCHIAT, V174, P118, DOI 10.1176/appi.ajp.2016.16020171; Hamelin L, 2016, BRAIN, V139, P1252, DOI 10.1093/brain/aww017; Hannestad J, 2013, BRAIN BEHAV IMMUN, V33, P131, DOI 10.1016/j.bbi.2013.06.010; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Henderson BJ, 2015, NEUROPHARMACOLOGY, V96, P178, DOI 10.1016/j.neuropharm.2015.01.022; Hines CS, 2013, J NUCL MED, V54, P64, DOI 10.2967/jnumed.112.106872; Ikoma Y, 2007, J CEREBR BLOOD F MET, V27, P173, DOI 10.1038/sj.jcbfm.9600325; Kalra R, 2004, CLIN DIAGN LAB IMMUN, V11, P563, DOI 10.1128/CDLI.11.3.563-568.2004; Khanna A, 2013, J NEUROIMMUNOL, V254, P69, DOI 10.1016/j.jneuroim.2012.09.006; Koshimori Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138721; Kreisl WC, 2016, NEUROBIOL AGING, V44, P53, DOI 10.1016/j.neurobiolaging.2016.04.011; Kreisl WC, 2013, BRAIN, V136, P2228, DOI 10.1093/brain/awt145; Lartey FM, 2014, MOL IMAGING BIOL, V16, P109, DOI 10.1007/s11307-013-0664-5; Lyoo CH, 2015, J NUCL MED, V56, P701, DOI 10.2967/jnumed.114.146027; Maeda J, 2004, SYNAPSE, V52, P283, DOI 10.1002/syn.20027; Mizrahi R, 2012, J CEREBR BLOOD F MET, V32, P968, DOI 10.1038/jcbfm.2012.46; Muscat JE, 2009, CANCER EPIDEM BIOMAR, V18, P35, DOI 10.1158/1055-9965.EPI-08-0744; Nair A, 2016, EJNMMI RES, V6, DOI 10.1186/s13550-016-0226-3; Narendran R, 2014, J NEUROSCI, V34, P9945, DOI 10.1523/JNEUROSCI.0928-14.2014; Nayak D, 2014, ANNU REV IMMUNOL, V32, P367, DOI 10.1146/annurev-immunol-032713-120240; Okubo T, 2004, BIOORGAN MED CHEM, V12, P423, DOI 10.1016/j.bmc.2003.10.050; Okuyemi KS, 2007, ADDICTION, V102, P1979, DOI 10.1111/j.1360-0443.2007.02010.x; Ory D, 2015, NUCL MED BIOL, V42, P753, DOI 10.1016/j.nucmedbio.2015.06.010; Owen DR, 2012, J CEREBR BLOOD F MET, V32, P1, DOI 10.1038/jcbfm.2011.147; Owen DRJ, 2011, J NUCL MED, V52, P24, DOI 10.2967/jnumed.110.079459; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; Piao WH, 2009, ACTA PHARMACOL SIN, V30, P715, DOI 10.1038/aps.2009.67; Pletcher MJ, 2006, ARCH INTERN MED, V166, P1915, DOI 10.1001/archinte.166.17.1915; Pluvy I, 2015, ANN CHIR PLAST ESTH, V60, pE3, DOI 10.1016/j.anplas.2014.06.011; Reuther WJ, 2014, BRIT J ORAL MAX SURG, V52, P102, DOI 10.1016/j.bjoms.2013.11.003; Rinker Brian, 2013, Ann Plast Surg, V70, P599, DOI 10.1097/SAP.0b013e3182764fcd; Rizzo G, 2014, J CEREBR BLOOD F MET, V34, P1060, DOI 10.1038/jcbfm.2014.55; Sajja RK, 2016, J CEREBR BLOOD F MET, V36, P539, DOI 10.1177/0271678X15616978; SAMHSA, 2009, SUBST AB MENT HLTH S; Sandiego CM, 2015, P NATL ACAD SCI USA, V112, P12468, DOI 10.1073/pnas.1511003112; Setiawan E, 2015, JAMA PSYCHIAT, V72, P268, DOI 10.1001/jamapsychiatry.2014.2427; SHIFFMAN SM, 1976, PSYCHOPHARMACOLOGY, V50, P35, DOI 10.1007/BF00634151; Sorensen LT, 2012, ARCH SURG-CHICAGO, V147, P373, DOI 10.1001/archsurg.2012.5; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Staley JK, 2006, J NEUROSCI, V26, P8707, DOI 10.1523/JNEUROSCI.0546-06.2006; Surendranathan A, 2015, PARKINSONISM RELAT D, V21, P1398, DOI 10.1016/j.parkreldis.2015.10.009; Suridjan I, 2015, MOL PSYCHIATR, V20, P1579, DOI 10.1038/mp.2015.1; Suridjan I, 2014, NEUROIMAGE, V84, P868, DOI 10.1016/j.neuroimage.2013.09.021; Takano A, 2010, INT J NEUROPSYCHOPH, V13, P943, DOI 10.1017/S1461145710000313; Tilp C, 2016, CLIN EXP ALLERGY, V46, P957, DOI 10.1111/cea.12665; Toth M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125917; Towler J, 2000, J Wound Care, V9, P100; Turkheimer FE, 2015, BIOCHEM SOC T, V43, P586, DOI 10.1042/BST20150058; Varrone A, 2015, EUR J NUCL MED MOL I, V42, P438, DOI 10.1007/s00259-014-2955-8; Venneti S, 2008, J NEUROPATH EXP NEUR, V67, P1001, DOI 10.1097/NEN.0b013e318188b204; Venneti S, 2007, EXP NEUROL, V207, P118, DOI 10.1016/j.expneurol.2007.06.003; Venneti S, 2007, J NEUROCHEM, V102, P2118, DOI 10.1111/j.1471-4159.2007.04690.x; Walberer M, 2014, BRAIN RES, V1581, P80, DOI 10.1016/j.brainres.2014.05.030; Walker MD, 2015, J CEREBR BLOOD F MET, V35, P1331, DOI 10.1038/jcbfm.2015.54; Wang M, 2012, APPL RADIAT ISOTOPES, V70, P965, DOI 10.1016/j.apradiso.2012.03.011; Wang Y, 2014, EUR J NUCL MED MOL I, V41, P1440, DOI 10.1007/s00259-014-2727-5; Williams JM, 2007, NICOTINE TOB RES, V9, P873, DOI 10.1080/14622200701484995; Yasuno F, 2012, PSYCHIAT RES-NEUROIM, V203, P67, DOI 10.1016/j.pscychresns.2011.08.013; Yasuno F, 2008, BIOL PSYCHIAT, V64, P835, DOI 10.1016/j.biopsych.2008.04.021; Yoder KK, 2015, NUCL MED BIOL, V42, P305, DOI 10.1016/j.nucmedbio.2014.11.003; Yoder KK, 2013, J NUCL MED, V54, P1320, DOI 10.2967/jnumed.112.118885; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196; Zhang MR, 2003, NUCL MED BIOL, V30, P513, DOI 10.1016/S0969-8051(03)00016-7; Zurcher NR, 2015, NEUROIMAGE-CLIN, V7, P409, DOI 10.1016/j.nicl.2015.01.009	92	28	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	JUL	2017	42	8					1630	1639		10.1038/npp.2017.48			10	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	EX4WL	WOS:000403235600008	28262740	Green Published, Bronze			2021-06-18	
J	Wright, DK; Johnston, LA; Kershaw, J; Ordidge, R; O'Brien, TJ; Shultz, SR				Wright, David K.; Johnston, Leigh A.; Kershaw, Jeff; Ordidge, Roger; O'Brien, Terence J.; Shultz, Sandy R.			Changes in Apparent Fiber Density and Track-Weighted Imaging Metrics in White Matter following Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; biomarkers; DTI; MRI	PROTEIN PHOSPHATASE 2A; DIFFUSE AXONAL INJURY; HYPERPHOSPHORYLATED TAU; SPHERICAL-DECONVOLUTION; SODIUM SELENATE; TENSOR; MILD; RAT; MRI; OUTCOMES	Traumatic brain injury (TBI) has been assessed with diffusion tensor imaging (DTI), a commonly used magnetic resonance imaging (MRI) marker for white matter integrity. However, given that the DTI model only fits a single fiber orientation, results can become confounded in regions of "crossing'' white matter fibers. In contrast, constrained spherical deconvolution estimates a fiber orientation distribution directly from high angular resolution diffusion-weighted images. Consequently, constrained spherical deconvolution-based measures, such as apparent fiber density (AFD) and track-weighted imaging (TWI) metrics (including tract density imaging, average pathlength mapping, and mean curvature), may be more sensitive than DTI metrics to white matter injury post-TBI. As such, this study administered the lateral fluid percussion injury (FPI) model of TBI, assessed for changes in AFD and TWI metrics, and compared these results to the DTI metrics, fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD). Rats received either an FPI (n = 11) or sham injury (n = 9) and after a recovery period of 12 weeks underwent MRI. AFD was calculated as described previously and statistical testing was performed using connectivity-based fixel enhancement. TWI and DTI metrics were assessed using voxel-wise nonparametric permutation testing. We found that rats given an FPI had significantly reduced AFD, tract density, average pathlength, and mean curvature when compared to sham-injured rats and significant changes in DTI metrics, including reduced FA and increased MD, RD, and AD. However, the latter DTI metrics identified fewer voxels affected by TBI. Additionally, analysis of AFD with connectivity-based fixel enhancement was the only method that identified damage within the corticospinal tract of rats given an FPI. These results support the use of constrained spherical deconvolution, in conjunction with DTI metrics, to better assess disease progression and treatment post-TBI.	[Wright, David K.; Ordidge, Roger] Univ Melbourne, Anat & Neurosci, Parkville, Vic, Australia; [Wright, David K.; Johnston, Leigh A.] Florey Inst Neurosci & Mental Hlth, 30 Royal Parade, Parkville, Vic 3052, Australia; [Johnston, Leigh A.] Univ Melbourne, Dept Elect & Elect Engn, Parkville, Vic, Australia; [Kershaw, Jeff] Natl Inst Radiol Sci, Appl MRI Res, QST, Chiba, Japan; [O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia	Wright, DK (corresponding author), Florey Inst Neurosci & Mental Hlth, 30 Royal Parade, Parkville, Vic 3052, Australia.	david.wright@florey.edu.au	Johnston, Leigh A/D-7102-2014	Johnston, Leigh A/0000-0002-5032-4674; O'Brien, Terence/0000-0002-7198-8621; Wright, David/0000-0002-7535-8651	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Victorian Neurotrauma Initiative project	This work was supported by funding to S.S. and T.O. from the Australian National Health and Medical Research Council, the Canadian Institute of Health Research, and Victorian Neurotrauma Initiative project. The authors acknowledge the facilities, and the scientific and technical assistance, of the National Imaging Facility at the Florey Institute of Neuroscience and Mental Health (Parkville, VIC, Australia).	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Calamante F, 2012, NEUROIMAGE, V59, P2494, DOI 10.1016/j.neuroimage.2011.08.099; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jeurissen B, 2013, HUM BRAIN MAPP, V34, P2747, DOI 10.1002/hbm.22099; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laitinen T, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.7015.00128, 10.3389/fnins.2015.00128]; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Liu SJ, 2016, BRAIN, V139, P1919, DOI 10.1093/brain/aww116; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Pannek K, 2011, NEUROIMAGE, V55, P133, DOI 10.1016/j.neuroimage.2010.12.010; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raffelt D, 2012, NEUROIMAGE, V59, P3976, DOI 10.1016/j.neuroimage.2011.10.045; Raffelt D, 2011, NEUROIMAGE, V56, P1171, DOI 10.1016/j.neuroimage.2011.02.014; Raffelt DA, 2015, NEUROIMAGE, V117, P40, DOI 10.1016/j.neuroimage.2015.05.039; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Smith RE, 2013, NEUROIMAGE, V67, P298, DOI 10.1016/j.neuroimage.2012.11.049; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Tan XL, 2016, NEUROPHARMACOLOGY, V108, P382, DOI 10.1016/j.neuropharm.2016.05.001; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; Webster KM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0457-7; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Willats L, 2014, NEUROIMAGE, V87, P18, DOI 10.1016/j.neuroimage.2013.11.016; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Wright DK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28713; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739	42	28	28	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2017	34	13					2109	2118		10.1089/neu.2016.4730			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EZ2HM	WOS:000404530400449	28152648				2021-06-18	
J	Sanderson, J; Weathers, M; Snedaker, K; Gramlich, K				Sanderson, Jimmy; Weathers, Melinda; Snedaker, Katherine; Gramlich, Kelly			"I Was Able to Still Do My Job on the Field and Keep Playing": An Investigation of Female and Male Athletes' Experiences With (Not) Reporting Concussions	COMMUNICATION & SPORT			English	Article						concussions; pain principle; hegemonic masculinity; gender and sport; muted group theory	SCHOOL; MASCULINITY; PERFORMANCE; KNOWLEDGE; IDENTITY	This research applied muted group theory to investigate female and male athletes' experiences with not reporting concussions sustained during athletic competition. Using snowball-sampling techniques, a total of 365 women and 247 men completed an online open-ended questionnaire about their reasons for not reporting a concussion. Results indicated that male athletes were more likely to continue to play through and not report a concussion than female athletes. Participants also indicated that they did not report concussions due to (a) perceived lack of resources, (b) perceived lack of severity, (c) conformance to sport cultural norms, which was comprised of two subthemes: adherence to the pain principle and team allegiance. The results suggest that efforts to address concussion management in sport need to focus on the communicative and structural elements that privilege hegemonic masculinity and playing through pain, as they contribute to muting athletes in advocating for their health.	[Sanderson, Jimmy] Clemson Univ, Clemson Online, Clemson, SC USA; [Weathers, Melinda; Gramlich, Kelly] Clemson Univ, Dept Commun Studies, Clemson, SC USA; [Snedaker, Katherine] Pink Concuss, Stamford, CT USA	Sanderson, J (corresponding author), Clemson Univ, Clemson Online, Snowflake, AZ 85937 USA.	jsande6@clemson.edu		Snedaker, Katherine/0000-0002-3865-3926			Anderson E, 2012, MEN MASC, V15, P152, DOI 10.1177/1097184X11430127; Ardener S., 1978, DEFINING FEMALES NAT; Ardener Shirley, 1975, PERCEIVING WOMEN; Bagilhole B, 2006, J GENDER STUD, V15, P35, DOI 10.1080/09589230500486900; Bandura A., 1986, SOCIAL FDN THOUGHT A; Beck CS, 2014, HEALTH COMMUN, V29, P244, DOI 10.1080/10410236.2012.741668; Bloom GA, 2008, EUR J SPORT SCI, V8, P295, DOI 10.1080/17461390802251836; Branch J., 2011, DEREK BOOGARD BRAIN; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Cantu R., 2012, CONCUSSIONS OUR KIDS; Caswell SV, 2012, AM J SPORT MED, V40, P756, DOI 10.1177/0363546512436647; Charlesworth H., 2004, SPORTING BODIES, P163; Connell RW, 1995, MASCULINITIES; Cournoyer J, 2014, J ATHL TRAINING, V49, P654, DOI 10.4085/1062-6050-49.3.34; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Cream A, 2003, INT J LANG COMM DIS, V38, P379, DOI 10.1080/13682820310001598166; Diamond D., 2013, HEAD INJURY PRACTICE; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gal S., 1994, WOMEN LANGUAGE DEBAT, P407; Gee S, 2009, SOCIOL SPORT J, V26, P578, DOI 10.1123/ssj.26.4.578; Gerschick T., 1994, MASCULINITIES, V2, P34, DOI [10.1177/1097184X12439879, DOI 10.1177/1097184X12439879]; Graham T., 2014, BROKE AND BROKEN; Henley N. M., 1994, WOMEN LANGUAGE DEBAT, P383; Hogg MA, 2006, COMMUN THEOR, V16, P7, DOI 10.1111/j.1468-2885.2006.00003.x; Hopmann DN, 2012, COMMUN METHODS MEAS, V6, P145, DOI 10.1080/19312458.2012.703832; Houston M., 1991, DISCOURSE SOC, V2, P387; Kassing JW, 2009, WESTERN J COMM, V73, P182, DOI 10.1080/10570310902856063; Katzowitz J., 2013, REACTIONS FRONTLINE; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kirk M., 2013, LEAGUE DENIAL DOCUME; Lindlof T.R., 2011, QUALITATIVE COMMUNIC; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Meares M. M., 2003, ANN C INT COMM ASS S; Meares MM, 2004, J APPL COMMUN RES, V32, P4, DOI 10.1080/0090988042000178121; Messner M. A., 1990, International Review for the Sociology of Sport, V25, P203, DOI 10.1177/101269029002500303; Messner M.A., 2002, TAKING FIELD WOMEN M; Messner Michael, 1994, SEX VIOLENCE POWER S; Messner MA, 2014, SOCIOL SPORT J, V31, P102, DOI 10.1123/ssj.2013-0111; Orbe M., 1998, CONSTRUCTING COCULTU; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Roderick M., 2000, INT REV SOCIOL SPORT, V35, P67; Rodgers K., 2014, NFL CRITICAL CULTURA, P142; Sabo D., 1994, ANN M NAT ATHL TRAIN; Sabo D., 2004, SPORTING BODIES DAMA, P59; Sage G., 2013, SOCIOLOGY N AM SPORT; Sanderson J, 2016, COMMUN SPORT, V4, P3, DOI 10.1177/2167479514536982; Sheridan B. (Producer), 2012, HEAD GAMES DOCUMENTA; Steinfeldt M, 2012, J APPL SPORT PSYCHOL, V24, P115, DOI 10.1080/10413200.2011.603405; Strauss A., 1998, BASICS QUALITATIVE R; Suter EA, 2006, J SOC PERS RELAT, V23, P349, DOI 10.1177/0265407506064201; Svokos A., 2014, MAJORITY HIGH SCH KI; TRUJILLO N, 1991, CRIT STUD MASS COMM, V8, P290, DOI 10.1080/15295039109366799; Wall CJ, 1999, EUR J WOMENS STUD, V6, P21, DOI 10.1177/135050689900600103; Weber AF, 2013, J ATHL TRAINING, V48, P153, DOI 10.4085/1062-6050-48.1.07; Wolverton B., 2013, COACH MAKES CALL ATH; Ye Hee Lee M., 2014, MORE ATHLETIC TRAINE; Young K., 1995, Journal of Sport and Social Issues, V19, P45, DOI 10.1177/019372395019001004; YOUNG K, 1994, SOCIOL SPORT J, V11, P175, DOI 10.1123/ssj.11.2.175	59	28	28	2	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2167-4795	2167-4809		COMMUN SPORT	Commun. Sport	JUN	2017	5	3					267	287		10.1177/2167479515623455			21	Communication; Hospitality, Leisure, Sport & Tourism	Communication; Social Sciences - Other Topics	FG7US	WOS:000410631200001					2021-06-18	
J	Watson, PMD; Kavanagh, E; Allenby, G; Vassey, M				Watson, P. Marc D.; Kavanagh, Edel; Allenby, Gary; Vassey, Matthew			Bioengineered 3D Glial Cell Culture Systems and Applications for Neurodegeneration and Neuroinflammation	SLAS DISCOVERY			English	Article						Glial cell; neurodegenerative diseases; neuroinflammation; CNS and PNS diseases; 3D	IN-VITRO MODEL; PLURIPOTENT STEM-CELL; 3-DIMENSIONAL CULTURE; SNAPSHOT GENETICS; ASTROCYTE INTERACTIONS; EXTRACELLULAR-MATRIX; INDUCE RAMIFICATION; BRAIN-DEVELOPMENT; GFAP EXPRESSION; DRUG-DELIVERY	Neurodegeneration and neuroinflammation are key features in a range of chronic central nervous system (CNS) diseases such as Alzheimer's and Parkinson's disease, as well as acute conditions like stroke and traumatic brain injury, for which there remains significant unmet clinical need. It is now well recognized that current cell culture methodologies are limited in their ability to recapitulate the cellular environment that is present in vivo, and there is a growing body of evidence to show that three-dimensional (3D) culture systems represent a more physiologically accurate model than traditional two-dimensional (2D) cultures. Given the complexity of the environment from which cells originate, and their various cell-cell and cell-matrix interactions, it is important to develop models that can be controlled and reproducible for drug discovery. 3D cell models have now been developed for almost all CNS cell types, including neurons, astrocytes, microglia, and oligodendrocyte cells. This review will highlight a number of current and emerging techniques for the culture of astrocytes and microglia, glial cell types with a critical role in neurodegenerative and neuroinflammatory conditions. We describe recent advances in glial cell culture using electrospun polymers and hydrogel macromolecules, and highlight how these novel culture environments influence astrocyte and microglial phenotypes in vitro, as compared to traditional 2D systems. These models will be explored to illuminate current trends in the techniques used to create 3D environments for application in research and drug discovery focused on astrocytes and microglial cells.	[Watson, P. Marc D.; Kavanagh, Edel] Cerevance, 418 Cambridge Sci Pk Milton Rd, Cambridge CB4 0PZ, England; [Allenby, Gary; Vassey, Matthew] Aurelia Biosci, Pennyfoot St, Nottingham NG1 1GF, England	Watson, PMD (corresponding author), Cerevance, 418 Cambridge Sci Pk Milton Rd, Cambridge CB4 0PZ, England.; Vassey, M (corresponding author), Aurelia Biosci, Pennyfoot St, Nottingham NG1 1GF, England.	marc.watson@cerevance.com; vassey@aureliabio.com					Abbott A, 2003, NATURE, V424, P870, DOI 10.1038/424870a; Alves MH, 2011, MACROMOL BIOSCI, V11, P1293, DOI 10.1002/mabi.201100145; Andersen Therese, 2015, Microarrays (Basel), V4, P133, DOI 10.3390/microarrays4020133; Andreasson KI, 2016, J NEUROCHEM, V138, P653, DOI 10.1111/jnc.13667; Baiguera S, 2010, J MATER SCI-MATER M, V21, P1353, DOI 10.1007/s10856-009-3944-5; Balasubramanian S, 2016, TISSUE ENG PT A, V22, P885, DOI [10.1089/ten.tea.2016.0103, 10.1089/ten.TEA.2016.0103]; Barata D, 2016, ACTA BIOMATER, V34, P1, DOI 10.1016/j.actbio.2015.09.009; Bayraktar OA, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020362; Bergstrom JS, 2016, ANN BIOMED ENG, V44, P330, DOI 10.1007/s10439-015-1455-8; Bernardinelli Y, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/232105; Beutner C, 2013, GLIA, V61, P1429, DOI 10.1002/glia.22524; Bonneh-Barkay D, 2009, BRAIN PATHOL, V19, P573, DOI 10.1111/j.1750-3639.2008.00195.x; BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97; Bras J, 2015, CELL, V160, P570, DOI 10.1016/j.cell.2015.01.019; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Caliari SR, 2016, NAT METHODS, V13, P405, DOI 10.1038/nmeth.3839; Cao HQ, 2012, MACROMOL BIOSCI, V12, P666, DOI 10.1002/mabi.201100436; Casano AM, 2015, DEV CELL, V32, P469, DOI 10.1016/j.devcel.2015.01.018; Chen Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep13708; Chiu IM, 2013, CELL REP, V4, P385, DOI 10.1016/j.celrep.2013.06.018; Choi J, 2015, BIOTECHNOL J, V10, P1682, DOI 10.1002/biot.201500092; Choi Se Hoon, 2015, US Neurol, V11, P102; Choi SH, 2014, NATURE, V515, P274, DOI 10.1038/nature13800; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Cruz-Acuna R., 2017, MATRIX BIOL; Dash TK, 2012, MOL PHARMACEUT, V9, P2365, DOI 10.1021/mp3001952; Dash TK, 2012, J CONTROL RELEASE, V158, P15, DOI 10.1016/j.jconrel.2011.09.064; Daud MFB, 2012, BIOMATERIALS, V33, P5901, DOI 10.1016/j.biomaterials.2012.05.008; Doorn KJ, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3339/fncel.2015.00084, 10.3389/fncel.2015.00084]; Du F, 2010, J CELL BIOCHEM, V109, P30, DOI 10.1002/jcb.22375; Duke DC, 2004, DEV NEUROSCI-BASEL, V26, P30, DOI 10.1159/000080709; Durafourt Bryce A, 2013, Methods Mol Biol, V1041, P199, DOI 10.1007/978-1-62703-520-0_19; East E, 2013, REGEN MED, V8, P739, DOI 10.2217/rme.13.61; East E, 2012, TISSUE ENG PART C-ME, V18, P526, DOI [10.1089/ten.tec.2011.0587, 10.1089/ten.TEC.2011.0587]; East E, 2010, TISSUE ENG PT A, V16, P3173, DOI 10.1089/ten.tea.2010.0017; East E, 2009, J TISSUE ENG REGEN M, V3, P634, DOI 10.1002/term.209; Figuera-Losada M, 2014, J BIOMOL SCREEN, V19, P17, DOI 10.1177/1087057113499406; Foo LC, 2011, NEURON, V71, P799, DOI 10.1016/j.neuron.2011.07.022; Ge D, 2013, APPL BIOCHEM BIOTECH, V170, P406, DOI 10.1007/s12010-013-0211-5; Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114; Grabert K, 2016, NAT NEUROSCI, V19, P504, DOI 10.1038/nn.4222; Grodecki J, 2015, BIOTECHNOL PROGR, V31, P1406, DOI 10.1002/btpr.2123; Grubman A, 2016, J MOL NEUROSCI, V60, P390, DOI 10.1007/s12031-016-0825-5; Guerreiro R, 2015, CELL, V160, P798, DOI 10.1016/j.cell.2015.01.052; Guerreiro R, 2013, CELL, V155, P968, DOI 10.1016/j.cell.2013.10.037; Guerrini R, 2014, NEUROTHERAPEUTICS, V11, P269, DOI 10.1007/s13311-014-0267-0; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Hansen E, 2010, J ALZHEIMERS DIS, V19, P451, DOI 10.3233/JAD-2010-1233; Haw RTY, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-134; Hawkins BT, 2015, BRAIN RES, V1608, P167, DOI 10.1016/j.brainres.2015.02.025; Haycock JW, 2011, METHODS MOL BIOL, V695, P1, DOI 10.1007/978-1-60761-984-0_1; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Heppner FL, 1998, GLIA, V22, P180, DOI 10.1002/(SICI)1098-1136(199802)22:2<180::AID-GLIA9>3.0.CO;2-B; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Hoing S, 2012, CELL STEM CELL, V11, P620, DOI 10.1016/j.stem.2012.07.005; Hong S, 2016, CURR OPIN NEUROBIOL, V36, P128, DOI 10.1016/j.conb.2015.12.004; Hongisto V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077232; Hopkins AM, 2015, PROG NEUROBIOL, V125, P1, DOI 10.1016/j.pneurobio.2014.11.003; Howes AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108283; Hristovska I, 2016, FRONT INTEGR NEUROSC, V9, DOI 10.3389/fnint.2015.00073; Hunt NC, 2010, BIOTECHNOL LETT, V32, P733, DOI 10.1007/s10529-010-0221-0; Jo J, 2016, CELL STEM CELL, V19, P248, DOI 10.1016/j.stem.2016.07.005; Joers V., 2017, PROG NEUROBIOL; Jose S, 2015, CELL BIOL INT, V39, P1355, DOI 10.1002/cbin.10516; Joshi P, 2015, BIOSENSORS-BASEL, V5, P768, DOI 10.3390/bios5040768; Jung SM, 2012, IN VITRO CELL DEV-AN, V48, P633, DOI 10.1007/s11626-012-9566-0; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Khakh BS, 2015, NAT NEUROSCI, V18, P942, DOI 10.1038/nn.4043; Khorshidi S, 2016, J TISSUE ENG REGEN M, V10, P715, DOI 10.1002/term.1978; Kierdorf K, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00044; Kim SH, 2012, COLLOID SURFACE B, V90, P113, DOI 10.1016/j.colsurfb.2011.10.004; Kim YH, 2015, NAT PROTOC, V10, P985, DOI 10.1038/nprot.2015.065; Knight E, 2015, J ANAT, V227, P746, DOI 10.1111/joa.12257; Labour MN, 2016, ACTA BIOMATER, V37, P38, DOI 10.1016/j.actbio.2016.04.001; Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517; Lange SC, 2012, NEUROCHEM RES, V37, P2569, DOI 10.1007/s11064-012-0868-0; Langer G, 2016, HANDB EXP PHARMACOL, V232, P171, DOI 10.1007/164_2015_18; Lau CL, 2014, J NEUROCHEM, V130, P215, DOI 10.1111/jnc.12702; Lee Jae-Kyung, 2013, Methods Mol Biol, V1041, P17, DOI 10.1007/978-1-62703-520-0_3; Lins L. C., 2017, BIOMACROMOLECULES; Liu ZW, 2014, J ZHEJIANG UNIV-SC B, V15, P1013, DOI 10.1631/jzus.B1400163; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lozano R, 2015, BIOMATERIALS, V67, P264, DOI 10.1016/j.biomaterials.2015.07.022; Macaya DJ, 2013, BIOMATERIALS, V34, P3591, DOI 10.1016/j.biomaterials.2012.12.050; Maclean FL, 2016, NEUROCHEM RES, V41, P589, DOI 10.1007/s11064-015-1697-8; Mandrycky C, 2016, BIOTECHNOL ADV, V34, P422, DOI 10.1016/j.biotechadv.2015.12.011; Matyash V, 2010, BRAIN RES REV, V63, P2, DOI 10.1016/j.brainresrev.2009.12.001; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McKenzie JL, 2004, BIOMATERIALS, V25, P1309, DOI 10.1016/j.biomaterials.2003.08.006; Medda X, 2016, J BIOMOL SCREEN, V21, P804, DOI 10.1177/1087057116638029; Meli L, 2014, STEM CELL RES, V13, P36, DOI 10.1016/j.scr.2014.04.004; Min SK, 2015, IN VITRO CELL DEV-AN, V51, P933, DOI 10.1007/s11626-015-9925-8; Min SK, 2015, SCI REP-UK, V5, DOI 10.1038/srep14418; Min SK, 2013, J BIOMED MATER RES A, V101, P3467, DOI 10.1002/jbm.a.34654; Min SK, 2013, J BIOMED MATER RES B, V101, P1267, DOI 10.1002/jbm.b.32939; Min SK, 2013, NEUROSCI LETT, V534, P80, DOI 10.1016/j.neulet.2012.11.015; Mollers S, 2009, TISSUE ENG PT A, V15, P461, DOI 10.1089/ten.tea.2007.0107; Montanez-Sauri SI, 2015, CELL MOL LIFE SCI, V72, P237, DOI 10.1007/s00018-014-1738-5; Moran LB, 2004, NEUROGENETICS, V5, P95, DOI 10.1007/s10048-004-0172-5; Muffat J, 2016, NAT MED, V22, P1358, DOI 10.1038/nm.4189; Nam KH, 2015, JALA-J LAB AUTOM, V20, P201, DOI 10.1177/2211068214557813; Nath S, 2016, PHARMACOL THERAPEUT, V163, P94, DOI 10.1016/j.pharmthera.2016.03.013; Nierode G, 2016, J MICROBIOL BIOTECHN, V26, P213, DOI 10.4014/jmb.1508.08007; Nierode GJ, 2016, STEM CELL REP, V7, P970, DOI 10.1016/j.stemcr.2016.10.001; Noel G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017559; Novak U, 2000, J CLIN NEUROSCI, V7, P280, DOI 10.1054/jocn.1999.0212; O'Connor SM, 2000, J NEUROSCI METH, V102, P187, DOI 10.1016/S0165-0270(00)00303-4; O'Shea RD, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00050; Oberheim NA, 2006, TRENDS NEUROSCI, V29, P547, DOI 10.1016/j.tins.2006.08.004; Oberheim NA, 2012, METHODS MOL BIOL, V814, P23, DOI 10.1007/978-1-61779-452-0_3; Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009; Ooms F, 2002, BBA-MOL BASIS DIS, V1587, P118, DOI 10.1016/S0925-4439(02)00074-1; Park J, 2015, LAB CHIP, V15, P141, DOI 10.1039/c4lc00962b; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Peretz H, 2007, TISSUE ENG, V13, P461, DOI 10.1089/ten.2005.0522; Phillips JB, 2014, METHODS MOL BIOL, V1162, P113, DOI 10.1007/978-1-4939-0777-9_9; Phillips MJ, 2011, INVEST OPHTH VIS SCI, V52, P1439, DOI 10.1167/iovs.10-6400; Pires LR, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2014.1224; Pottler M, 2006, NEUROSCI LETT, V410, P137, DOI 10.1016/j.neulet.2006.09.082; Prasad A, 2016, REGEN MED, V11, P181, DOI 10.2217/rme.16.5; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Puschmann TB, 2014, J NEUROCHEM, V128, P878, DOI 10.1111/jnc.12519; Puschmann TB, 2013, GLIA, V61, P432, DOI 10.1002/glia.22446; Raja WK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161969; Ransohoff RM, 2016, SCIENCE, V353, P777, DOI 10.1126/science.aag2590; Ransohoff RM, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a020560; Ransom BR, 2012, METHODS MOL BIOL, V814, P3, DOI 10.1007/978-1-61779-452-0_1; Rao SS, 2013, ACS APPL MATER INTER, V5, P9276, DOI 10.1021/am402097j; Reilly JF, 1998, GLIA, V22, P202, DOI 10.1002/(SICI)1098-1136(199802)22:2<202::AID-GLIA11>3.0.CO;2-1; Renton AE, 2014, NAT NEUROSCI, V17, P17, DOI 10.1038/nn.3584; Reyes RC, 2012, ASN NEURO, V4, P33, DOI 10.1042/AN20110059; Rezaie P, 2002, EXP CELL RES, V274, P68, DOI 10.1006/excr.2001.5431; Rocha DN, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3389/fncel.2015.00577, 10.3389/fncel.2015.00377]; Rosenstiel P, 2001, MICROSC RES TECHNIQ, V54, P18, DOI 10.1002/jemt.1116; Ruedinger F, 2015, APPL MICROBIOL BIOT, V99, P623, DOI 10.1007/s00253-014-6253-y; Ryan SL, 2016, ASSAY DRUG DEV TECHN, V14, P19, DOI 10.1089/adt.2015.670; Sawcer S, 2014, LANCET NEUROL, V13, P700, DOI 10.1016/S1474-4422(14)70041-9; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Schafer DP, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020545; Schilling T, 2001, EUR J NEUROSCI, V14, P463, DOI 10.1046/j.0953-816x.2001.01661.x; Schwartz MP, 2015, P NATL ACAD SCI USA, V112, P12516, DOI 10.1073/pnas.1516645112; Shan JL, 2014, CELL BIOL INT, V38, P1233, DOI 10.1002/cbin.10325; Shi W, 2016, ACTA BIOMATER, V45, P247, DOI 10.1016/j.actbio.2016.09.001; Singh S, 2007, J NANOSCI NANOTECHNO, V7, P2596, DOI 10.1166/jnn.2007.909; Singh V, 2014, CHEM RES TOXICOL, V27, P895, DOI 10.1021/tx500046k; Slepko N, 1996, GLIA, V16, P241; Smith I, 2015, NEUROSCI LETT, V609, P198, DOI 10.1016/j.neulet.2015.10.044; Sofroniew MV, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020420; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Song Q, 2014, BIOMATERIALS, V35, P6930, DOI 10.1016/j.biomaterials.2014.05.002; Sreekanthreddy Peddagangannagari, 2015, F1000Res, V4, P1279, DOI 10.12688/f1000research.7142.1; Sun YQ, 2016, ACS APPL MATER INTER, V8, P2348, DOI 10.1021/acsami.5b11473; Swinney DC, 2011, NAT REV DRUG DISCOV, V10, P507, DOI 10.1038/nrd3480; Tang-Schomer MD, 2014, P NATL ACAD SCI USA, V111, P13811, DOI 10.1073/pnas.1324214111; Thorne N, 2016, STEM CELL TRANSL MED, V5, P613, DOI 10.5966/sctm.2015-0170; Tieng V, 2014, STEM CELLS DEV, V23, P1535, DOI 10.1089/scd.2013.0442; Tiryaki VM, 2015, NANOMEDICINE-UK, V10, P529, DOI 10.2217/nnm.14.33; Tiryaki VM, 2012, INT J NANOMED, V7, P3891, DOI 10.2147/IJN.S32681; Tunesi M, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00146; Tyzack G, 2016, CURR STEM CELL REP, V2, P236, DOI 10.1007/s40778-016-0049-1; Ugbode CI, 2016, NEUROCHEM RES, V41, P1857, DOI 10.1007/s11064-016-1911-3; Wang JD, 2016, MOL PHARMACEUT, V13, P895, DOI 10.1021/acs.molpharmaceut.5b00805; Wang P. Y., 2017, ACTA BIOMATERIAL; Watanabe K, 2007, RESTOR NEUROL NEUROS, V25, P109; Wes PD, 2016, GLIA, V64, P1710, DOI 10.1002/glia.22988; Wiebe J, 2015, CURR OPIN CARDIOL, V30, P650, DOI 10.1097/HCO.0000000000000229; Wollmer MA, 2001, J NEUROIMMUNOL, V115, P19, DOI 10.1016/S0165-5728(01)00257-0; Wu YW, 2015, TRENDS IMMUNOL, V36, P605, DOI 10.1016/j.it.2015.08.008; Xia Haijian, 2014, Nan Fang Yi Ke Da Xue Xue Bao, V34, P1569; Yip PK, 2009, J NEUROSCI METH, V183, P223, DOI 10.1016/j.jneumeth.2009.07.002; Yu PP, 2012, METHODS MOL BIOL, V814, P327, DOI 10.1007/978-1-61779-452-0_21; Zhang Y, 2016, NEURON, V89, P37, DOI 10.1016/j.neuron.2015.11.013; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014]; Zhang Y, 2010, CURR OPIN NEUROBIOL, V20, P588, DOI 10.1016/j.conb.2010.06.005; Zhao Y, 2015, BIOFABRICATION, V7, DOI 10.1088/1758-5090/7/4/045002; Zhou K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151589; Zhu JM, 2010, BIOMATERIALS, V31, P4639, DOI 10.1016/j.biomaterials.2010.02.044; Zierler S, 2005, BRAIN RES, V1039, P162, DOI 10.1016/j.brainres.2005.01.086; Zorn S, 2016, NAT REV DRUG DISCOV, V15, P302, DOI 10.1038/nrd.2016.70; Zuidema JM, 2014, BIOMATERIALS, V35, P1439, DOI 10.1016/j.biomaterials.2013.10.079	183	28	28	1	24	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2472-5552	2472-5560		SLAS DISCOV	SLAS Discov.	JUN	2017	22	5			SI		583	601		10.1177/2472555217691450			19	Biochemical Research Methods; Biotechnology & Applied Microbiology; Chemistry, Analytical	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry	EV4KF	WOS:000401727800013	28346104	Bronze			2021-06-18	
J	Braun, M; Vaibhav, K; Saad, N; Fatima, S; Brann, DW; Vender, JR; Wang, LP; Hoda, MN; Baban, B; Dhandapani, KM				Braun, Molly; Vaibhav, Kumar; Saad, Nancy; Fatima, Sumbul; Brann, Darrell W.; Vender, John R.; Wang, Lei P.; Hoda, Md Nasrul; Baban, Babak; Dhandapani, Krishnan M.			Activation of Myeloid TLR4 Mediates T Lymphocyte Polarization after Traumatic Brain Injury	JOURNAL OF IMMUNOLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; MYELIN BASIC-PROTEIN; GROUP BOX PROTEIN-1; CLOSED-HEAD INJURY; TH17 CELLS; WHITE-MATTER; IMMUNE-RESPONSE; INTERLEUKIN-23 PROMOTES; MACROPHAGE POLARIZATION; AUTOIMMUNE INFLAMMATION	Traumatic brain injury (TBI) is a major public health issue, producing significant patient mortality and poor long-term outcomes. Increasing evidence suggests an important, yet poorly defined, role for the immune system in the development of secondary neurologic injury over the days and weeks following a TBI. In this study, we tested the hypothesis that peripheral macrophage infiltration initiates long-lasting adaptive immune responses after TBI. Using a murine controlled cortical impact model, we used adoptive transfer, transgenic, and bone marrow chimera approaches to show increased infiltration and proinflammatory (classically activated [M1]) polarization of macrophages for up to 3 wk post-TBI. Monocytes purified from the injured brain stimulated the proliferation of naive T lymphocytes, enhanced the polarization of T effector cells (T(H)1/T(H)17), and decreased the production of regulatory T cells in an MLR. Similarly, elevated T effector cell polarization within blood and brain tissue was attenuated by myeloid cell depletion after TBI. Functionally, C3H/HeJ (TLR4 mutant) mice reversed Ml macrophage and T(H)1/T(H)17 polarization after TBI compared with C3H/OuJ (wild-type) mice. Moreover, brain monocytes isolated from C3H/HeJ mice were less potent stimulators of T lymphocyte proliferation and T(H)1/T(H)17 polarization compared with C3H/OuJ monocytes. Taken together, our data implicate TLR4-dependent, Ml macrophage trafficking/polarization into the CNS as a key mechanistic link between acute TBI and long-term, adaptive immune responses.	[Braun, Molly; Vaibhav, Kumar; Vender, John R.; Dhandapani, Krishnan M.] Augusta Univ, Dept Neurosurg, Med Coll Georgia, BI-3088,1120 15th St, Augusta, GA 30912 USA; [Vaibhav, Kumar; Fatima, Sumbul; Hoda, Md Nasrul] Augusta Univ, Dept Med Lab Imaging & Radiol Sci, Coll Allied Hlth Sci, Augusta, GA 30912 USA; [Saad, Nancy; Baban, Babak] Augusta Univ, Dept Oral Biol, Dent Coll Georgia, Augusta, GA 30912 USA; [Fatima, Sumbul; Hoda, Md Nasrul; Baban, Babak] Augusta Univ, Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA; [Brann, Darrell W.] Augusta Univ, Med Coll Georgia, Dept Neurosci & Regenerat Med, Augusta, GA 30912 USA; [Brann, Darrell W.; Hoda, Md Nasrul; Dhandapani, Krishnan M.] Charlie Norwood VA Med Ctr, Augusta, GA 30912 USA; [Wang, Lei P.] Augusta Univ, Dept Psychiat, Med Coll Georgia, Augusta, GA 30912 USA; [Baban, Babak] Augusta Univ, Dept Surg, Med Coll Georgia, Augusta, GA 30912 USA	Dhandapani, KM (corresponding author), Augusta Univ, Dept Neurosurg, Med Coll Georgia, BI-3088,1120 15th St, Augusta, GA 30912 USA.	kdhandapani@augusta.edu	Vaibhav, Kumar/H-4120-2019	Vaibhav, Kumar/0000-0002-4206-3830; Dhandapani, Krishnan/0000-0001-7044-1117	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS095154, NS084228]; Veterans Affairs Merit Review Award Program [BX001117]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172, R21NS095154, R03NS084228] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX001117] Funding Source: NIH RePORTER	This work was supported in part by the National Institutes of Health (Grants NS095154 and NS084228 to K.M.D.) and by the Veterans Affairs Merit Review Award Program (Grant BX001117 to D.W.B.).	Achyut BR, 2016, CANCER BIOL THER, V17, P280, DOI 10.1080/15384047.2016.1139243; Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Arnold CE, 2015, IMMUNOBIOLOGY, V220, P10, DOI 10.1016/j.imbio.2014.09.022; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Baban B, 2005, INT IMMUNOL, V17, P909, DOI 10.1093/intimm/dxh271; Baban B, 2013, EXP MOL PATHOL, V95, P288, DOI 10.1016/j.yexmp.2013.09.002; Baxi EG, 2015, J NEUROSCI, V35, P8626, DOI 10.1523/JNEUROSCI.3817-14.2015; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Boivin A, 2007, J NEUROSCI, V27, P12565, DOI 10.1523/JNEUROSCI.3027-07.2007; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chow A, 2011, NAT REV IMMUNOL, V11, P788, DOI 10.1038/nri3087; Crome SQ, 2010, J IMMUNOL, V185, P3199, DOI 10.4049/jimmunol.1000557; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; Ding JW, 2016, J ATHEROSCLER THROMB, V23, P737, DOI 10.5551/jat.31088; Duan LH, 2011, LAB INVEST, V91, P43, DOI 10.1038/labinvest.2010.141; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Flohe SB, 2008, INNATE IMMUN-LONDON, V14, P333, DOI 10.1177/1753425908100016; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Frei R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008808; Gagliani N, 2015, NATURE, V523, P221, DOI 10.1038/nature14452; Gimsa U, 2001, J NEUROIMMUNOL, V119, P73, DOI 10.1016/S0165-5728(01)00343-5; Gonzalez H, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0201-8; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Green REA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00067; Gutcher I, 2007, J CLIN INVEST, V117, P1119, DOI 10.1172/JCI31720; Hedegaard CJ, 2008, IMMUNOLOGY, V125, P161, DOI 10.1111/j.1365-2567.2008.02837.x; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P1, DOI 10.1016/j.coi.2006.11.018; Kawamata T, 2006, ACTA NEUROCHIR SUPPL, V96, P3; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; King MD, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09223; Konoeda F, 2010, BIOCHEM BIOPH RES CO, V402, P500, DOI 10.1016/j.bbrc.2010.10.058; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lv M, 2011, NEUROSCIENCE, V176, P162, DOI 10.1016/j.neuroscience.2010.11.066; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; Messmer D, 2004, J IMMUNOL, V173, P307, DOI 10.4049/jimmunol.173.1.307; Miljkovic D, 2007, J NEUROSCI RES, V85, P3598, DOI 10.1002/jnr.21453; Miller- Graziano C. L., 2002, IMMUNE RESPONSES CRI, P247; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Murphy AC, 2010, BRAIN BEHAV IMMUN, V24, P641, DOI 10.1016/j.bbi.2010.01.014; Mus AMC, 2010, ARTHRITIS RHEUM-US, V62, P1043, DOI 10.1002/art.27336; Niebling Johannes, 2014, F1000Res, V3, P169, DOI 10.12688/f1000research.4439.1; Pizzolla A, 2011, EUR J IMMUNOL, V41, P403, DOI 10.1002/eji.201040598; Prajeeth CK, 2014, BRAIN BEHAV IMMUN, V37, P248, DOI 10.1016/j.bbi.2014.01.001; Qin HW, 2012, J IMMUNOL, V189, P3439, DOI 10.4049/jimmunol.1201168; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; Raposo C, 2014, J NEUROSCI, V34, P10141, DOI 10.1523/JNEUROSCI.0076-14.2014; Sharma MD, 2010, IMMUNITY, V33, P942, DOI 10.1016/j.immuni.2010.11.022; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Su E., 2016, TRANSLATIONAL RES TR; Tobin RP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0143-5; Vergelli M, 1997, EUR J IMMUNOL, V27, P941, DOI 10.1002/eji.1830270421; Walsh JT, 2014, J IMMUNOL, V193, P5013, DOI 10.4049/jimmunol.1302401; Walsh JT, 2014, IMMUNOLOGY, V141, P340, DOI 10.1111/imm.12187; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang KY, 2012, CLIN CHIM ACTA, V413, P1737, DOI 10.1016/j.cca.2012.07.002; Weckbach S, 2012, J NEUROTRAUM, V29, P1233, DOI 10.1089/neu.2011.2169; Wolf SA, 2002, J NEUROIMMUNOL, V133, P72, DOI 10.1016/S0165-5728(02)00367-3; Yang D, 2014, J NEUROSCI, V34, P16467, DOI 10.1523/JNEUROSCI.2582-14.2014; Yang NL, 2015, FASEB J, V29, P3954, DOI 10.1096/fj.15-273664; Yasuno F, 2014, PSYCHOGERIATRICS, V14, P213, DOI 10.1111/psyg.12084; Zhang ZY, 2007, J CELL MOL MED, V11, P307, DOI 10.1111/j.1582-4934.2007.00019.x	76	28	29	1	6	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	MAY 1	2017	198	9					3615	3626		10.4049/jimmunol.1601948			12	Immunology	Immunology	EU6HN	WOS:000401135200029	28341672	Green Accepted, Bronze			2021-06-18	
J	Cooper, DB; Bowles, AO; Kennedy, JE; Curtiss, G; French, LM; Tate, DF; Vanderploeg, RD				Cooper, Douglas B.; Bowles, Amy O.; Kennedy, Jan E.; Curtiss, Glenn; French, Louis M.; Tate, David F.; Vanderploeg, Rodney D.			Cognitive Rehabilitation for Military Service Members With Mild Traumatic Brain Injury: A Randomized Clinical Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast injuries; clinical trial; cognitive rehabilitation; concussion; mild TBI; postconcussive syndrome; posttraumatic stress disorder; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; ROUTINE FOLLOW-UP; HEAD-INJURY; SYMPTOMS; PILOT; VETERANS; INTERVENTION; PREVALENCE; PERSONNEL; MODERATE	Objective: To compare cognitive rehabilitation (CR) interventions for mild traumatic brain injury (mTBI) with standard of care management, including psychoeducation and medical care for noncognitive symptoms. Setting: Military medical center. Participants: A total of 126 service members who received mTBI from 3 to 24 months before baseline evaluation and reported ongoing cognitive difficulties. Interventions: Randomized clinical trial with treatment outcomes assessed at baseline, 3-week, 6-week, 12-week, and 18-week follow-ups. Participants were randomly assigned to one of four 6-week treatment arms: (1) psychoeducation, (2) computer-based CR, (3) therapist-directed manualized CR, and (4) integrated therapist-directed CR combined with cognitive-behavioral psychotherapy (CBT). Treatment dosage was constant (10 h/wk) for intervention arms 2 to 4. Measures: Paced Auditory Serial Addition Test (PASAT); Symptom Checklist-90 Revised (SCL-90-R); Key Behaviors Change Inventory (KBCI). Results: No differences were noted between treatment arms on demographics, injury-related characteristics, or psychiatric comorbidity apart from education, with participants assigned to the computer arm having less education. Using mixed-model analysis of variance, all 4 treatment groups showed a significant improvement over time on the 3 primary outcome measures. Treatment groups showed equivalent improvement on the PASAT. The therapist-directed CR and integrated CR treatment groups had better KBCI outcomes compared with the psychoeducation group. Improvements on primary outcome measures during treatment were maintained at follow-up with no differences among arms. Conclusions: Both therapist-directed CR and integrated CR with CBT reduced functional cognitive symptoms in service members after mTBI beyond psychoeducation and medical management alone.	[Cooper, Douglas B.; Kennedy, Jan E.; Curtiss, Glenn; French, Louis M.; Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, Silver Spring, MD USA; [Cooper, Douglas B.; Kennedy, Jan E.] Brooke Army Med Ctr, Dept Neurol, San Antonio, TX USA; [Bowles, Amy O.] Brooke Army Med Ctr, Dept Rehabil Med, San Antonio, TX USA; [Cooper, Douglas B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Bowles, Amy O.] Uniformed Serv Univ Hlth Sci, Dept Phys Med & Rehabil, Bethesda, MD 20814 USA; [Curtiss, Glenn; Vanderploeg, Rodney D.] James A Haley VA Med Ctr, Tampa, FL USA; [Curtiss, Glenn; Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat & Behav Neurosci, Tampa, FL USA; [French, Louis M.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Tate, David F.] Univ Missouri St Louis, Missouri Inst Mental Hlth, Berkeley, CA USA	Cooper, DB (corresponding author), Brooke Army Med Ctr, Def & Vet Brain Injury Ctr, MCHE MDU DVBIC, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	douglas.b.cooper.ctr@mail.mil	french, louis/AAB-2083-2020; Curtiss, Glenn/ABB-5566-2020; Tate, David F/I-3963-2013	Tate, David F/0000-0003-0213-1920; french, louis/0000-0002-9451-0604	Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development ServiceUS Department of Veterans Affairs [VA HSRD IIR 13-196-1]; Clinical Sciences Research and Development [VA CSRDW81XWH-13-2-0095]; TATRC research grant (ERMS) [12286030]	This work is the result of work supported with resources and the use of the facilities at Brooke Army Medical Center (BAMC), Joint Base San Antonio. Research staff and resources were provided in part by the Defense and Veterans Brain Injury Centers (DVBIC) and the Telemedicine and Advanced Technology Research Center. Individuals providing the interventions were Department of the Army civilian employees. Psychoeducational materials were based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service (VA HSR&D IIR 13-196-1), and Clinical Sciences Research and Development (VA CSRDW81XWH-13-2-0095). Data management was supported by TATRC research grant (ERMS#12286030) to David Tate, PhD.	Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Belanger HG, 2015, MIL MED, V180, P192, DOI 10.7205/MILMED-D-14-00388; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Carroll LJ, 2004, J REHABIL MED S, P106; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Citrome L, 2016, J AFFECT DISORDERS, V196, P225, DOI 10.1016/j.jad.2016.02.042; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Cuijpers P, 2014, PSYCHOL MED, V44, P685, DOI 10.1017/S0033291713000457; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; Department of Veterans Affairs & Department of Defense, 2009, J REHABIL RES DEV, V46; Derogatis LR, 1994, SYMPTOM CHECKLIST 90; EGAN V, 1988, PERS INDIV DIFFER, V9, P179, DOI 10.1016/0191-8869(88)90046-3; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HEITJAN DF, 1991, J R STAT SOC C-APPL, V40, P13; Helmick K, 2010, NEUROREHABILITATION, V26, P239, DOI 10.3233/NRE-2010-0560; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huckans M, 2010, J REHABIL RES DEV, V47, P43, DOI 10.1682/JRRD.2009.02.0019; Institute of Medicine (IOM), 2011, COGN REH THER TRAUM; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Janak JC, 2017, J HEAD TRAUMA REHAB, V32, P1, DOI 10.1097/HTR.0000000000000202; King EG, 2013, REHABIL PSYCHOL, V58, P272, DOI 10.1037/a0033116; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Langlois JA, 2006, TRAUMATIC BRAIN INJU; MCCAFFREY RJ, 1995, ARCH CLIN NEUROPSYCH, V10, P241, DOI 10.1016/0887-6177(94)00048-U; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Nelson LA, 2013, NEUROPSYCHOLOGY, V27, P666, DOI 10.1037/a0034117; O'Neil ME, 2014, J INT NEUROPSYCH SOC, V20, P249, DOI [10.1017/S1355617714000204, 10.1017/S135561771300146X]; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Schenker N, 1996, COMPUT STAT DATA AN, V22, P425, DOI 10.1016/0167-9473(95)00057-7; Schmitt JS, 2004, J CLIN EPIDEMIOL, V57, P1008, DOI 10.1016/j.jclinepi.2004.02.007; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Sullivan KW, 2012, STUD HEALTH TECHNOL, V181, P71, DOI 10.3233/978-1-61499-121-2-71; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Tombaugh TN, 1996, TEST MEMORY MALINGER; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Walter KH, 2012, REHABIL PSYCHOL, V57, P13, DOI 10.1037/a0026254; Weathers F. W, 1993, PCL M FOR DSM IV; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Zickefoose S, 2013, BRAIN INJURY, V27, P707, DOI 10.3109/02699052.2013.775484	64	28	28	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2017	32	3					E1	E15		10.1097/HTR.0000000000000254			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EV4GM	WOS:000401716900008	27603763				2021-06-18	
J	Oberlander, TJ; Olson, BL; Weidauer, L				Oberlander, Tyler J.; Olson, Bernadette L.; Weidauer, Lee			Test-Retest Reliability of the King-Devick Test in an Adolescent Population	JOURNAL OF ATHLETIC TRAINING			English	Article						sport concussion; oculomotor function; saccadic rhythm	MILD HEAD-INJURY; SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; VISUAL SCREENING TOOL; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; EPIDEMIOLOGY; BALANCE; PLAYERS; VISION	Context: The King-Devick (KD) test is a screening tool designed to assess cognitive visual impairments, namely saccadic rhythm, postconcussion. Test-retest reliability of the KD in a healthy adolescent population has not yet been established. Objective: To investigate the overall test-retest reliability of the KD among a sample of healthy adolescents. Additionally, we sought to determine if sex and age influenced reliability. Design: Cross-sectional study. Setting: Secondary school. Patients or Other Participants: Sixty-eight healthy adolescents, 41 boys (age = 15.4 +/- 1.9 years) and 27 girls (age = 15.4 +/- 1.9 years). Main Outcome Measure(s): Participants completed the KD (version 1) at 3 testing sessions (days 1, 30, and 45) following standard instructions. We recorded total time to complete the reading of 3 cards for each participant during each testing session. Two-way random-effects intraclass correlation coefficients (ICCs) using single measurements repeated over time and repeatability coefficients were calculated. Linear mixed models were used to determine whether differences existed at each testing time and to examine whether changes that took place among visits were different by sex or age. Results: Adolescents who completed the KD demonstrated acceptable reliability (ICC = 0.81; 95% confidence interva = 0.73, 0.87); however, the repeatability coefficient was large (68.76 seconds). The sample demonstrated improvements between visits 1 and 2 (mean +/- standard error = 4.3 +/- 0.5 seconds, P < .001) and between visits 2 and 3 (2.4 +/- 0.5 seconds, P < .001) for a total improvement of 6.9 seconds over 3 tests. No significant visit-by-sex or visit-by-age interactions were observed. Conclusions: Despite the ICC being clinically acceptable, providers using the KD test for serial assessment of concussion in adolescents should be cautious in interpreting the results due to a large learning effect. Incorporating multiple measures can ensure accurate detection of sport concussion.	[Oberlander, Tyler J.] Great Plains Hlth Sports & Therapy, North Platte, NE USA; [Olson, Bernadette L.; Weidauer, Lee] South Dakota State Univ, Hlth & Nutrit Sci, Box 2203,SIM 116, Brookings, SD 57007 USA	Olson, BL (corresponding author), South Dakota State Univ, Hlth & Nutrit Sci, Box 2203,SIM 116, Brookings, SD 57007 USA.	bernie.olson@sdstate.edu					Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Comstock D, SUMMARY REPORT NATL; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davies EC, 2012, NEUROLOGY, V78, pE103, DOI 10.1212/WNL.0b013e318251833d; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Graham R., 2014, SPORTS RELATED CONCU; Greenwald RM, 2012, CLIN J SPORT MED, V22, P83, DOI 10.1097/JSM.0b013e31824cc5d3; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Jinguji TM, 2011, PHYS MED REH CLIN N, V22, P565, DOI 10.1016/j.pmr.2011.08.001; Keightley M, 2009, BMJ CASE REP, V2009; Khurana VG, 2012, J CLIN NEUROSCI, V19, P1, DOI 10.1016/j.jocn.2011.08.002; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; Krumholtz I, 2000, Optometry, V71, P426; Kulp M T, 1997, J Am Optom Assoc, V68, P589; Kulp MT, 1997, OPTOMETRY VISION SCI, V74, P37, DOI 10.1097/00006324-199701000-00018; Kulp MT, 1998, OPTOMETRY VISION SCI, V75, P284, DOI 10.1097/00006324-199804000-00026; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Leong Danielle F, 2015, J Optom, V8, P131, DOI 10.1016/j.optom.2014.12.005; Leong DF, 2014, CLIN PEDIATR, V53, P858, DOI 10.1177/0009922814532520; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marinides Z, 2015, NEUROL CLIN PRACT, V5, P25, DOI DOI 10.1212/CPJ.000000000; Marshall Cameron M, 2012, J Can Chiropr Assoc, V56, P299; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2015, BRAIN INJURY, V29, P175, DOI 10.3109/02699052.2014.965206; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Okonkwo David O, 2014, Neurosurgery, V75 Suppl 4, pS82, DOI 10.1227/NEU.0000000000000493; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Portney LG, 2009, FDN CLIN RES APPL PR; Purves D., 2001, NEUROSCIENCE; Riemann BL, 1997, J SPORT REHABIL, V6, P283, DOI 10.1123/jsr.6.3.283; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Sussman ES, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15610; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Vaz S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073990; Ventura RE, 2015, J NEURO-OPHTHALMOL, V35, P73, DOI 10.1097/WNO.0000000000000223; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	55	28	28	0	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAY	2017	52	5					439	445		10.4085/1062-6050-52.2.12			7	Sport Sciences	Sport Sciences	EY7ED	WOS:000404150400005	28362161	Green Published, Bronze			2021-06-18	
J	Senthinathan, A; Mainwaring, LM; Hutchison, M				Senthinathan, Arrani; Mainwaring, Lynda M.; Hutchison, Michael			Heart Rate Variability of Athletes Across Concussion Recovery Milestones: A Preliminary Study	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						mild traumatic brain injury; concussion; athletes; heart rate variability	TRAUMATIC BRAIN-INJURY; SAMPLE ENTROPY; BLOOD-PRESSURE; MENTAL STRESS; WORK; REST; RISK	Objective: To assess heart rate variability (HRV) in athletes with concussion across three phases of recovery. Design: A prospective matched control group design included the collection of HRV and symptoms measured by the Rivermead Post-Concussion Questionnaire. These measures were taken at 3 phases of recovery [(1) symptomatic; (2). asymptomatic; and (3) one-week after return-to-play (RTP)]. The same protocol was completed by noninjured athletes. Setting: Interuniversity sports teams at a single institution. Participants: 11 athletes, across 7 sports, diagnosed with concussion, and 11 matched-athlete controls volunteered for the study. Intervention: Physician diagnosed concussion and a sitting to standing protocol for HRV monitoring. Main Outcome Measures: The frequency, time, and nonlinear domains of HRV were assessed along with the absolute difference between sitting and standing for each. Results: A 2 x 3 (group x phase) repeated-measures analysis of variance revealed significant interactions for sitting High Frequency (HF) norm, sitting Low Frequency (LF) norm, the difference between sitting and standing HF norm, and difference between sitting and standing LF norm. Acutely, athletes with concussion displayed increased LF norm and decreased HF norm while sitting and a decreased change in their HF and LF norm measures between sitting and standing. A significant group effect for sample entropy when standing was detected, with the concussed group displaying decreased values compared with the matched controls. Conclusions: Athletes with concussion displayed autonomic dysfunction in some measures of HRV that persisted beyond RTP and were related to a previous history of concussion.	[Senthinathan, Arrani; Mainwaring, Lynda M.; Hutchison, Michael] Univ Toronto, Fac Kinesiol & Phys Educ, Exercise Sci, Toronto, ON, Canada	Mainwaring, LM (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	lynda.mainwaring@utoronto.ca			Canadian Institute for Health ResearchCanadian Institutes of Health Research (CIHR); Ontario Neurotrauma Foundation; Faculty of Kinesiology and Physical Education	This study was funded by the Canadian Institute for Health Research, the Ontario Neurotrauma Foundation, and the Faculty of Kinesiology and Physical Education.	Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; Al-Angari HM, 2007, IEEE T BIO-MED ENG, V54, P1900, DOI 10.1109/TBME.2006.889772; Aubert AE, 2003, SPORTS MED, V33, P889, DOI 10.2165/00007256-200333120-00003; Beaumont LD, 2011, HDB SPORT NEUROPSYCH, P155; Bigler ED, 2012, NEUROSCI LETT, V509, P1, DOI 10.1016/j.neulet.2011.12.009; Bilchick KC, 2006, J CARDIOVASC ELECTR, V17, P691, DOI 10.1111/j.1540-8167.2006.00501.x; Billman GE, 2006, J APPL PHYSIOL, V100, P896, DOI 10.1152/japplphysiol.01328.2005; Billman GE, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00026; Boullosa DA, 2012, EUR J APPL PHYSIOL, V112, P2233, DOI 10.1007/s00421-011-2202-y; Buchheit M, 2010, EUR J APPL PHYSIOL, V109, P571, DOI 10.1007/s00421-010-1385-y; Camm AJ, 1996, EUR HEART J, V17, P354; Frodl T, 2013, NEUROBIOL DIS, V52, P24, DOI 10.1016/j.nbd.2012.03.012; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Griesbach G. S, 2011, AM ACAD PHYS MED S1, V3, P64; Henden PL, 2014, J NEUROSURG ANESTH, V26, P50, DOI 10.1097/ANA.0b013e3182a47b62; Hjortskov N, 2004, EUR J APPL PHYSIOL, V92, P84, DOI 10.1007/s00421-004-1055-z; Kahn AAS, 2013, INT C INF EL VIS, P17; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; King ML, 1997, BRAIN INJURY, V11, P445; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; La Fountaine MF, 2011, J ATHL TRAINING, V46, P230; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Lewis MJ, 2007, PHYSIOL MEAS, V28, P731, DOI 10.1088/0967-3334/28/6/011; McCraty Rollin, 2015, Glob Adv Health Med, V4, P46, DOI 10.7453/gahmj.2014.073; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Renu C. H., 2010, INT J COMPUTER THEOR, V2, P1793; RenuMadhavi C.H., 2010, INT J COMPUTER APPL, V8, P10; Thayer JF, 2010, INT J CARDIOL, V141, P122, DOI 10.1016/j.ijcard.2009.09.543; Uusitalo A, 2011, APPL ERGON, V42, P830, DOI 10.1016/j.apergo.2011.01.005; Vrijkotte TGM, 2000, HYPERTENSION, V35, P880, DOI 10.1161/01.HYP.35.4.880; Vuksanovic V, 2007, MED ENG PHYS, V29, P344, DOI 10.1016/j.medengphy.2006.05.011; Yarnell J, 2008, EUR HEART J, V29, P579, DOI 10.1093/eurheartj/ehm641; Young FLS, 2011, APPL PHYSIOL NUTR ME, V36, P210, DOI [10.1139/h10-103, 10.1139/H10-103]	37	28	28	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2017	27	3					288	295		10.1097/JSM.0000000000000337			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	ET9NV	WOS:000400635100009	27379659				2021-06-18	
J	Fu, WW; Fu, TS; Jing, R; McFaull, SR; Cusimano, MD				Fu, Wayne W.; Fu, Terence S.; Jing, Rowan; McFaull, Steven R.; Cusimano, Michael D.			Predictors of falls and mortality among elderly adults with traumatic brain injury: A nationwide, population-based study	PLOS ONE			English	Article							OLDER-ADULTS; MULTIFACTORIAL INTERVENTION; REDUCE FALLS; RISK; AGE; HOSPITALIZATION; EPIDEMIOLOGY; METAANALYSIS; PREVENTION; SEVERITY	Background Elderly adults are at particular risk of sustaining a traumatic brain injury (TBI), and tend to suffer worse outcomes compared to other age groups. Falls are the leading cause of TBI among the elderly. Methods We examined nationwide trends in TBI hospitalizations among elderly adults (ages 65 and older) between April 2006 and March 2011 using a population-based database that is mandatory for all hospitals in Canada. Trends in admission rates were analyzed using linear regression. Predictors of falls and in-hospital mortality were identified using logistic regression. Results Between 2006 and 2011, there were 43,823 TBI hospitalizations resulting in 6,939 deaths among elderly adults in Canada. Over the five-year study period, the overall rate of TBI admissions increased by an average of 6% per year from 173.2 to 214.7 per 100,000, while the rate of fall-related TBI increased by 7% annually from 138.6 to 179.2 per 100,000. There were significant trends towards increasing age and comorbidity level (p< 0.001 and p = 0.002). Advanced age, comorbidity, and injury severity were independent predictors of both TBI-related falls and mortality on multivariate analysis. Conclusion Prevention efforts should be targeted towards vulnerable demographics including the "older old" (ages 85 and older) and those with multiple medical comorbidities. Additionally, hospitals and long-term care facilities should be prepared to manage the burgeoning population of older patients with more complex comorbidities.	[Fu, Wayne W.] Albany Med Coll, Albany, NY USA; [Fu, Terence S.; Jing, Rowan; Cusimano, Michael D.] St Michaels Hosp, Dept Surg, Div Neurosurg, Toronto, ON, Canada; [Fu, Terence S.; Jing, Rowan; Cusimano, Michael D.] Keenan Res Ctr, Li Ka Shing Knowledge Inst, Injury Prevent Res Off, Toronto, ON, Canada; [Fu, Terence S.; Jing, Rowan; Cusimano, Michael D.] Univ Toronto, Toronto, ON, Canada; [McFaull, Steven R.] Publ Hlth Agcy Canada, Hlth Surveillance & Epidemiol Div, Injury Sect, Ottawa, ON, Canada; [Cusimano, Michael D.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada	Cusimano, MD (corresponding author), St Michaels Hosp, Dept Surg, Div Neurosurg, Toronto, ON, Canada.; Cusimano, MD (corresponding author), Keenan Res Ctr, Li Ka Shing Knowledge Inst, Injury Prevent Res Off, Toronto, ON, Canada.; Cusimano, MD (corresponding author), Univ Toronto, Toronto, ON, Canada.; Cusimano, MD (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.	injuryprevention@smh.ca	Cusimano, Michael/X-4059-2019		Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation	This research was supported by the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research #TIR-103946 and the Ontario Neurotrauma Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambrose AF, 2013, MATURITAS, V75, P51, DOI 10.1016/j.maturitas.2013.02.009; Bohnert N, 2014, POPULATION PROJECTIO; Campbell AJ, 2007, AGE AGEING, V36, P656, DOI 10.1093/ageing/afm122; Centers for Disease Control and Prevention, 2010, EXT CAUS INJ MORT MA; Chan V, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-97; Chang JT, 2004, BRIT MED J, V328, P680, DOI 10.1136/bmj.328.7441.680; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CIoHI, 2012, CIHI DAT QUAL STUD 2; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Coronado VG, 2012, EPIDEMIOLOGY PREVENT, P45; Cryer C, 2006, INJURY PREV, V12, P67, DOI 10.1136/ip.2006.011668; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; de Vries OJ, 2010, ARCH INTERN MED, V170, P1110, DOI 10.1001/archinternmed.2010.169; Donohue JT, 2007, J TRAUMA, V62, P419, DOI 10.1097/01.ta.0000219286.88179.18; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Fu TS, 2015, J TRAUMA ACUTE CARE, V79, P449, DOI 10.1097/TA.0000000000000733; Fu TS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145469; Giannoudis PV, 2009, INJURY, V40, P362, DOI 10.1016/j.injury.2008.10.016; Gillespie LD, 2012, COCHRANE DATABASE SY, V9, DOI 1002/14651858.CD007146.pub3; Hajjar Emily R, 2007, Am J Geriatr Pharmacother, V5, P345, DOI 10.1016/j.amjopharm.2007.12.002; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Huang AR, 2012, DRUG AGING, V29, P359, DOI 10.2165/11599460-000000000-00000; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kenny RAM, 2011, J AM GERIATR SOC, V59, P148, DOI 10.1111/j.1532-5415.2010.03234.x; Korhonen N, 2013, JAMA-J AM MED ASSOC, V309, P1891, DOI 10.1001/jama.2013.3356; McIntyre A, 2013, BRAIN INJURY, V27, P31, DOI 10.3109/02699052.2012.700086; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Murphy TE, 2014, J GERONTOL GERIATR R, V3, P3; Ortman JM., 2014, AGING NATION OLDER P, P25; Perula LA, 2012, ARCH PHYS MED REHAB, V93, P1677, DOI 10.1016/j.apmr.2012.03.035; Petridou ET, 2009, J AGING HEALTH, V21, P713, DOI 10.1177/0898264309338298; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Rubenstein LZ, 2006, AGE AGEING, V35, P37, DOI 10.1093/ageing/afl084; Selassie AW, 2014, J HEAD TRAUMA REHAB, V29, pE8, DOI 10.1097/HTR.0b013e3182976ad3; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Stephenson S, 2004, INJURY PREV, V10, P379, DOI 10.1136/ip.2004.005561; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thurman DKJRC, 1995, STANDARDS SURVEILLAN; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151	46	28	29	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2017	12	4							e0175868	10.1371/journal.pone.0175868			15	Multidisciplinary Sciences	Science & Technology - Other Topics	ES9KN	WOS:000399876100019	28430782	DOAJ Gold, Green Published			2021-06-18	
J	Laskowitz, DT; Wang, HC; Chen, T; Lubkin, DT; Cantillana, V; Tu, TM; Kernagis, D; Zhou, GN; Macy, G; Kolls, BJ; Dawson, HN				Laskowitz, Daniel T.; Wang, Haichen; Chen, Tony; Lubkin, David T.; Cantillana, Viviana; Tu, Tian Ming; Kernagis, Dawn; Zhou, Guanen; Macy, Gary; Kolls, Bradley J.; Dawson, Hana N.			Neuroprotective pentapeptide CN-105 is associated with reduced sterile inflammation and improved functional outcomes in a traumatic brain injury murine model	SCIENTIFIC REPORTS			English	Article							NECROSIS-FACTOR-ALPHA; LONG-TERM DISABILITY; E-MIMETIC PEPTIDES; PROTEIN 88 MYD88; APOLIPOPROTEIN-E; UNITED-STATES; APOE GENOTYPE; MULTIPLE PATHWAYS; MOTOR DEFICITS; RECEPTOR	At present, there are no proven pharmacological treatments demonstrated to improve long term functional outcomes following traumatic brain injury (TBI). In the setting of non-penetrating TBI, sterile brain inflammatory responses are associated with the development of cerebral edema, intracranial hypertension, and secondary neuronal injury. There is increasing evidence that endogenous apolipoprotein E (apoE) modifies the neuroinflammatory response through its role in downregulating glial activation, however, the intact apoE holoprotein does not cross the blood-brain barrier due to its size. To address this limitation, we developed a small 5 amino acid apoE mimetic peptide (CN-105) that mimics the polar face of the apoE helical domain involved in receptor interactions. The goal of this study was to investigate the therapeutic potential of CN-105 in a murine model of closed head injury. Treatment with CN-105 was associated with a durable improvement in functional outcomes as assessed by Rotarod and Morris Water Maze and a reduction in positive Fluoro-Jade B stained injured neurons and microglial activation. Administration of CN-105 was also associated with reduction in mRNA expression of a subset of inflammatory and immune-related genes.	[Laskowitz, Daniel T.; Wang, Haichen; Chen, Tony; Lubkin, David T.; Cantillana, Viviana; Tu, Tian Ming; Kernagis, Dawn; Zhou, Guanen; Macy, Gary; Kolls, Bradley J.; Dawson, Hana N.] Duke Univ, Sch Med, Dept Neurol, Durham, NC 27710 USA; [Laskowitz, Daniel T.] Duke Univ, Sch Med, Dept Neurobiol, Durham, NC 27710 USA; [Laskowitz, Daniel T.] Aegis CN LLC, Durham, NC 27705 USA; [Tu, Tian Ming] Tan Tock Seng Hosp, Natl Neurosci Inst, Dept Neurol, Singapore, Singapore; [Kernagis, Dawn] Florida Inst Human & Machine Cognit, Pensacola, FL 32502 USA; [Zhou, Guanen] Huanhu Hosp, Dept Neurol, Tianjin 300060, Peoples R China	Laskowitz, DT (corresponding author), Duke Univ, Sch Med, Dept Neurol, Durham, NC 27710 USA.; Laskowitz, DT (corresponding author), Duke Univ, Sch Med, Dept Neurobiol, Durham, NC 27710 USA.; Laskowitz, DT (corresponding author), Aegis CN LLC, Durham, NC 27705 USA.	daniel.laskowitz@dm.duke.edu	Tu, Tian Ming/AAI-3949-2020; Kolls, Brad/R-9154-2019	Tu, Tian Ming/0000-0002-7175-0357; 	North Carolina Biotechnology Center [2014-794 CFG-8004, W81XWH-16-C-0142]	The study was supported by a grant from the North Carolina Biotechnology Center (2014-794 CFG-8004 and CDMRP#W81XWH-16-C-0142).	ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Amor S, 2014, IMMUNOLOGY, V141, P287, DOI 10.1111/imm.12134; Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Barish GD, 2012, CELL METAB, V15, P554, DOI 10.1016/j.cmet.2012.02.012; Barish GD, 2010, GENE DEV, V24, P2760, DOI 10.1101/gad.1998010; Basso K, 2010, BLOOD, V115, P975, DOI 10.1182/blood-2009-06-227017; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; Biffi A, 2011, LANCET NEUROL, V10, P702, DOI 10.1016/S1474-4422(11)70148-X; Can A, 2011, GENES BRAIN BEHAV, V10, P434, DOI 10.1111/j.1601-183X.2011.00682.x; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Croy JE, 2004, BIOCHEMISTRY-US, V43, P7328, DOI 10.1021/bi036208p; Dawson HN, 2007, J NEUROSCI, V27, P9155, DOI 10.1523/JNEUROSCI.5492-06.2007; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Flanagan SR, 2015, ARCH PHYS MED REHAB, V96, P1753, DOI 10.1016/j.apmr.2015.07.001; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gonias SL, 2014, AM J PATHOL, V184, P18, DOI 10.1016/j.ajpath.2013.08.029; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Hoe HS, 2005, J NEUROCHEM, V93, P145, DOI 10.1111/j.1471-4159.2004.03007.x; Iyer SS, 2012, CRIT REV IMMUNOL, V32, P23, DOI 10.1615/CritRevImmunol.v32.i1.30; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; Kassam I, 2016, J NEUROL NEUROSUR PS, V87, P433, DOI 10.1136/jnnp-2015-310500; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Koedel U, 2007, AM J PATHOL, V171, P200, DOI 10.2353/ajpath.2007.060821; Lanterna LA, 2007, NEUROLOGY, V69, P766, DOI 10.1212/01.wnl.0000267640.03300.6b; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Lawrence DW, 2015, BRAIN INJURY, V29, P1018, DOI 10.3109/02699052.2015.1005131; Le Thuc O, 2015, ANN NY ACAD SCI, V1351, P127, DOI 10.1111/nyas.12855; Lei BL, 2016, SCI REP-UK, V6, DOI 10.1038/srep34834; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Li LZ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002028; Li W, 2013, J SURG RES, V180, P133, DOI 10.1016/j.jss.2012.10.928; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P409, DOI 10.1007/978-3-211-85578-2_80; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; MACLEOD JN, 1987, XENOBIOTICA, V17, P1095, DOI 10.3109/00498258709044208; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Mesis Rachel G, 2006, Neurosurg Focus, V21, pE4; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Mora J, 2016, J MOL CELL BIOL, V8, P426, DOI 10.1093/jmcb/mjw006; Morris PG, 2004, ACTA NEUROL SCAND, V109, P205, DOI 10.1034/j.1600-0404.2003.00206.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nishitsuji K, 2011, J BIOL CHEM, V286, P17536, DOI 10.1074/jbc.M111.225532; Ophir G, 2003, NEUROBIOL DIS, V12, P56, DOI 10.1016/S0969-9961(02)00005-0; Petraglia Anthony L, 2014, Neurosurgery, V75 Suppl 4, pS34, DOI 10.1227/NEU.0000000000000472; Pocivavsek A, 2009, J NEUROIMMUNOL, V214, P25, DOI 10.1016/j.jneuroim.2009.06.010; Pocivavsek A, 2009, GLIA, V57, P444, DOI 10.1002/glia.20772; Qiu Z, 2003, NEUROSCIENCE, V122, P291, DOI 10.1016/j.neuroscience.2003.08.017; Said-Sadier Najwane, 2012, Biomed J, V35, P437, DOI 10.4103/2319-4170.104408; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sheng ZY, 2008, NEUROPHARMACOLOGY, V55, P204, DOI 10.1016/j.neuropharm.2008.05.016; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; van de Veerdonk FL, 2012, P NATL ACAD SCI USA, V109, P3001, DOI 10.1073/pnas.1121534109; Wang H, 2013, EXP NEUROL, V241, P67, DOI 10.1016/j.expneurol.2012.11.027; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Westermark GT, 2008, NEW ENGL J MED, V359, P977, DOI 10.1056/NEJMc0802893; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yu L, 2010, J CELL MOL MED, V14, P2592, DOI 10.1111/j.1582-4934.2010.01127.x; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Yuan XL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/807976; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	83	28	28	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	APR 21	2017	7								46461	10.1038/srep46461			16	Multidisciplinary Sciences	Science & Technology - Other Topics	ET0WX	WOS:000399986800001	28429734	DOAJ Gold, Green Published			2021-06-18	
J	Cebak, JE; Singh, IN; Hill, RL; Wang, JA; Hall, ED				Cebak, John E.; Singh, Indrapal N.; Hill, Rachel L.; Wang, Juan A.; Hall, Edward D.			Phenelzine Protects Brain Mitochondrial Function In Vitro and In Vivo following Traumatic Brain Injury by Scavenging the Reactive Carbonyls 4-Hydroxynonenal and Acrolein Leading to Cortical Histological Neuroprotection	JOURNAL OF NEUROTRAUMA			English	Article						4-hydroxynonenal; acrolein; brain mitochondria; lipid peroxidation; neuroprotection; phenelzine; traumatic brain injury	SPINAL-CORD-INJURY; MEDIATED OXIDATIVE DAMAGE; LIPID-PEROXIDATION; ANTIOXIDANT THERAPIES; UNITED-STATES; FREE-RADICALS; CNS INJURY; PEROXYNITRITE; DYSFUNCTION; STRESS	Lipid peroxidation (LP) is a key contributor to the pathophysiology of traumatic brain injury (TBI). Traditional antioxidant therapies are intended to scavenge the free radicals responsible for either initiation or propagation of LP. A more recently explored approach involves scavenging the terminal LP breakdown products that are highly reactive and neurotoxic carbonyl compounds, 4-hydroxynonenal (4-HNE) and acrolein (ACR), to prevent their covalent modification and rendering of cellular proteins nonfunctional leading to loss of ionic homeostasis, mitochondrial failure, and subsequent neuronal death. Phenelzine (PZ) is a U.S. Food and Drug Administration-approved monoamine oxidase (MAO) inhibitor (MAO-I) used for treatment of refractory depression that possesses a hydrazine functional group recently discovered by other investigators to scavenge reactive carbonyls. We hypothesized that PZ will protect mitochondrial function and reduce markers of oxidative damage by scavenging LP-derived aldehydes. In a first set of in vitro studies, we found that exogenous application of 4-HNE or ACR significantly reduced respiratory function and increased markers of oxidative damage (p < 0.05) in isolated noninjured rat brain cortical mitochondria, whereas PZ pretreatment significantly prevented mitochondrial dysfunction and oxidative modification of mitochondrial proteins in a concentration-related manner (p < 0.05). This effect was not shared by a structurally similar MAO-I, pargyline, which lacks the hydrazine group, confirming that the mitochondrial protective effects of PZ were related to its carbonyl scavenging and not to MAO inhibition. In subsequent in vivo studies, we documented that PZ treatment begun at 15 min after controlled cortical impact TBI significantly attenuated 72-h post-injury mitochondrial respiratory dysfunction. The cortical mitochondrial respiratory protection occurred together with a significant increase in cortical tissue sparing.	[Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, BBSRB Room 477,741 South Limestone St, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, BBSRB Room 477,741 South Limestone St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		National Institute of Neurological Disorder and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01 NS083405, 5R01 NS084857, 5P30 NS051220, 2T32 NS077889]; Kentucky Spinal Cord & Head Injury Research Trust (KSCHIRT); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS084857, T32NS077889] Funding Source: NIH RePORTER	This work was supported by National Institute of Neurological Disorder and Stroke 5R01 NS083405, 5R01 NS084857, 5P30 NS051220, and 2T32 NS077889 and funding from the Kentucky Spinal Cord & Head Injury Research Trust (KSCHIRT).	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Burcham PC, 2004, MOL PHARMACOL, V65, P655, DOI 10.1124/mol.65.3.655; Burcham PC, 2006, MOL PHARMACOL, V69, P1056, DOI 10.1124/mol.105.018168; Burcham PC, 2002, TOXICOLOGY, V181, P229, DOI 10.1016/S0300-483X(02)00287-1; Burcham PC, 2008, CHEM RES TOXICOL, V21, P779, DOI 10.1021/tx700399q; CDC, 2003, REP C MILD TRAUM BRA; Communications M. O. o. S, 2013, DOD NUMB TRAUM BRAIN; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Dranka BP, 2011, FREE RADICAL BIO MED, V51, P1621, DOI 10.1016/j.freeradbiomed.2011.08.005; Ferrick DA, 2008, DRUG DISCOV TODAY, V13, P268, DOI 10.1016/j.drudis.2007.12.008; Galvani S, 2008, FREE RADICAL BIO MED, V45, P1457, DOI 10.1016/j.freeradbiomed.2008.08.026; Gerencser AA, 2009, ANAL CHEM, V81, P6868, DOI 10.1021/ac900881z; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hamann K, 2009, J NEUROCHEM, V111, P1348, DOI 10.1111/j.1471-4159.2009.06395.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lai J C, 1979, Methods Enzymol, V55, P51; LoPachin RM, 2009, CHEM RES TOXICOL, V22, P1499, DOI 10.1021/tx900147g; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P373; Miller DM, 2014, J NEUROTRAUM, V31, P1194, DOI 10.1089/neu.2013.3218; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Rogers GW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021746; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; Stevens JF, 2008, MOL NUTR FOOD RES, V52, P7, DOI 10.1002/mnfr.200700412; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toninello A, 2004, AMINO ACIDS, V26, P339, DOI 10.1007/s00726-004-0080-x; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Wood PL, 2006, BRAIN RES, V1122, P184, DOI 10.1016/j.brainres.2006.09.003; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025; Zhu Q, 2009, CHEM RES TOXICOL, V22, P1721, DOI 10.1021/tx900221s	50	28	29	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	7					1302	1317		10.1089/neu.2016.4624			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ER0FB	WOS:000398461600002	27750484	Green Published			2021-06-18	
J	Salzar, RS; Treichler, D; Wardlaw, A; Weiss, G; Goeller, J				Salzar, Robert S.; Treichler, Derrick; Wardlaw, Andrew; Weiss, Greg; Goeller, Jacques			Experimental Investigation of Cavitation as a Possible Damage Mechanism in Blast-Induced Traumatic Brain Injury in Post-Mortem Human Subject Heads	JOURNAL OF NEUROTRAUMA			English	Article						brain; bTBI; cavitation; DYSMAS; pressure	MILITARY; MODEL; SYSTEM; IMPACT; SHELL; RISK	The potential of blast-induced traumatic brain injury from the mechanism of localized cavitation of the cerebrospinal fluid (CSF) is investigated. While the mechanism and criteria for non-impact blast-induced traumatic brain injury is still unknown, this study demonstrates that local cavitation in the CSF layer of the cranial volume could contribute to these injuries. The cranial contents of three post-mortem human subject (PMHS) heads were replaced with both a normal saline solution and a ballistic gel mixture with a simulated CSF layer. Each were instrumented with multiple pressure transducers and placed inside identical shock tubes at two different research facilities. Sensor data indicates that cavitation may have occurred in the PMHS models at pressure levels below those for a 50% risk of blast lung injury. This study points to skull flexion, the result of the shock wave on the front of the skull leading to a negative pressure in the contrecoup, as a possible mechanism that contributes to the onset of cavitation. Based on observation of intracranial pressure transducer data from the PMHS model, cavitation onset is thought to occur from approximately a 140 kPa head-on incident blast.	[Salzar, Robert S.] Univ Virginia, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA; [Treichler, Derrick; Wardlaw, Andrew; Goeller, Jacques] Adv Technol & Res, Columbia, MD USA; [Weiss, Greg] Appl Res Associates Inc, Littleton, CO USA	Salzar, RS (corresponding author), Univ Virginia, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA.	salzar@virginia.edu			SBIR Enhancement Program by the Defense Research Project Agency (DARPA); US Army Medical Research and Materiel Command (MRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W911NF-10-C-0044]	The work was jointly funded under and SBIR Enhancement Program by the Defense Research Project Agency (DARPA) and the US Army Medical Research and Materiel Command (MRMC; contract W911NF-10-C-0044). The authors would like to acknowledge the support provided by Dr. Judah Goldwasser of DARPA/DSO, and Dr. Kenneth Curley of MRMC. The effort was administered by Dr. Ralph Anthenien of the Army Research Office. The authors would also like to acknowledge the support provided by Dr. Carol Chancey and Mr. Tyler Rooks of the USAARL in completing the PMHS shock tube tests, and Dr. Daniel Tollin of the University of Colorado for providing CT scan support.	Abdul-Muneer PM, 2016, MOL NEUROBIOL, V53, P6106, DOI 10.1007/s12035-015-9520-8; Aihaiti M., 2008, EQUATION STATE BALLI; Bailey M. R., 2003, ACOUST PHYS, P49; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Brenner M., 2007, JSR07200 JASON MITR; BRUNO LA, 1987, CLIN SPORT MED, V6, P17; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chafi S. M., 2007, ASME P, P211; EDBERG S, 1963, LAB INVEST, V12, P1305; ENGIN AE, 1978, AVIAT SPACE ENVIR MD, V49, P120; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FISCHER HANNAH, 2015, GUIDE US MILITARY CA; Ganpule S, 2012, COMPUT METHOD BIOMEC, V15, P1233, DOI 10.1080/10255842.2011.597353; Gennarelli T.A., 1972, STAPP CAR CRASH J, P296; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; HICKLING R, 1973, J BIOMECH, V6, P115, DOI 10.1016/0021-9290(73)90081-X; IREMONGER MJ, 1997, SCI FDN TRAUMA, P189; Johnson E., 2006, SAE TECH PAPERS; LINDENBERG R, 1960, ARCH PATHOL, V69, P440; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss W.C., 2009, J ACOUST SOC AM, V125, P2650; Nicholas N, 2004, I NONLETHAL DEFENSE; NUSHOLTZ GS, 1995, J NEUROTRAUM, V12, P707, DOI 10.1089/neu.1995.12.707; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Reid MW, 2015, MOL CELL NEUROSCI, V66, P123, DOI 10.1016/j.mcn.2015.03.014; Sotudeh-Chafi M., 2007, ASME 2007 INT MECH E, V2, P211; SUH C, 1972, J BIOMECH, V5, P181, DOI 10.1016/0021-9290(72)90054-1; Ward C, 1980, P 24 STAPP CAR CRASH; WARD JW, 1948, SCIENCE, V107, P349, DOI 10.1126/science.107.2779.349; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wardlaw A, 2010, IFMBE PROC, V32, P34, DOI 10.1007/978-3-642-14998-6_9; Wardlaw Jr A.B, 2500 NSWCIH; Young F. R., 1999, CAVITATION, V4, P143; Young LA, 2015, SEMIN NEUROL, V35, P5, DOI 10.1055/s-0035-1544242; Ziejewski M., 2007, BRAIN INJ PROF, V4, P10	41	28	32	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	8					1589	1602		10.1089/neu.2016.4600			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ES1ZM	WOS:000399325500011	27855566				2021-06-18	
J	Wang, FS; Wang, XW; Shapiro, LA; Cotrina, ML; Liu, WM; Wang, EW; Gu, SM; Wang, W; He, XS; Nedergaard, M; Huang, JH				Wang, Fushun; Wang, Xiaowei; Shapiro, Lee A.; Cotrina, Maria L.; Liu, Weimin; Wang, Ernest W.; Gu, Simeng; Wang, Wei; He, Xiaosheng; Nedergaard, Maiken; Huang, Jason H.			NKCC1 up-regulation contributes to early post-traumatic seizures and increased post-traumatic seizure susceptibility	BRAIN STRUCTURE & FUNCTION			English	Article						Traumatic brain injury; In vivo electrophysiology; TGF; Bumetanide	TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR-BETA; NEONATAL SEIZURES; EPILEPTIFORM ACTIVITY; SIGNALING PATHWAY; MOUSE MODEL; HEAD-INJURY; IN-VIVO; EPILEPSY; MICE	Traumatic brain injury (TBI) is not only a leading cause for morbidity and mortality in young adults (Bruns and Hauser, Epilepsia 44(Suppl 10):210, 2003), but also a leading cause of seizures. Understanding the seizure-inducing mechanisms of TBI is of the utmost importance, because these seizures are often resistant to traditional first- and second-line anti-seizure treatments. The early post-traumatic seizures, in turn, are a contributing factor to ongoing neuropathology, and it is critically important to control these seizures. Many of the available anti-seizure drugs target gamma-aminobutyric acid (GABA(A)) receptors. The inhibitory activity of GABA(A) receptor activation depends on low intracellular Cl-, which is achieved by the opposing regulation of Na+-K+-Cl- cotransporter 1 (NKCC1) and K+-Cl--cotransporter 2 (KCC2). Up-regulation of NKCC1 in neurons has been shown to be involved in neonatal seizures and in ammonia toxicity-induced seizures. Here, we report that TBI-induced up-regulation of NKCC1 and increased intracellular Cl- concentration. Genetic deletion of NKCC1 or pharmacological inhibition of NKCC1 with bumetanide suppresses TBI-induced seizures. TGF beta expression was also increased after TBI and competitive antagonism of TGF beta reduced NKKC1 expression, ameliorated reactive astrocytosis, and inhibited seizures. Thus, TGF beta might be an important pathway involved in NKCC1 up-regulation after TBI. Our findings identify neuronal up-regulation of NKCC1 and its mediation by TGF beta, as a potential and important mechanism in the early post-traumatic seizures, and demonstrate the therapeutic potential of blocking this pathway.	[Wang, Fushun; Gu, Simeng; Wang, Wei] Nanjing Univ Chinese Med, Nanjing 210023, Jiangsu, Peoples R China; [Wang, Fushun; Wang, Xiaowei; Cotrina, Maria L.; Liu, Weimin; Nedergaard, Maiken] Univ Rochester, Div Glial Dis & Therapeut, Ctr Translat Neuromed, 601 Elmwood Ave, Rochester, NY 14642 USA; [Wang, Xiaowei] Univ Rochester, Neurosci Grad Program, 601 Elmwood Ave, Rochester, NY 14642 USA; [Wang, Fushun; Shapiro, Lee A.; Huang, Jason H.] Texas A&M Univ, Dept Surg, Hlth Sci Ctr, Coll Med, Temple, TX 76504 USA; [Wang, Fushun; Wang, Ernest W.; Huang, Jason H.] Baylor Scott & White Hlth, Dept Neurosurg, Neurosci Inst, Cent Div, Temple, TX 76508 USA; [He, Xiaosheng] 4th Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian, Peoples R China	Shapiro, LA; Huang, JH (corresponding author), Texas A&M Univ, Dept Surg, Hlth Sci Ctr, Coll Med, Temple, TX 76504 USA.; Huang, JH (corresponding author), Baylor Scott & White Hlth, Dept Neurosurg, Neurosci Inst, Cent Div, Temple, TX 76508 USA.	lshapiro@medicine.tamhsc.edu; jhuang@sw.org	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168	University of Rochester Institutional grant; Jiangsu Specially Appointed professorship foundation; priority academic program development of Jiangsu Higher Education Institute (PAPD); Jiangsu Natural Science FoundationNatural Science Foundation of Jiangsu Province [BK20151565]; Jiangsu Traditional Chinese Medicine Foundation [ZD201501]; Jiangsu Six Talent Peak [2015-YY-006];  [NIH-R01-NS-067435];  [NIH- R01DE022743];  [NS078304];  [NS078167];  [NS075177]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE022743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078304, R01NS067435, R01NS078167, R01NS075177, R01NS100366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG048769] Funding Source: NIH RePORTER	This work was supported, in part, by a University of Rochester Institutional grant (JHH), by NIH-R01-NS-067435 (JHH) and NIH- R01DE022743 (MN), NS078304(MN), NS078167 (MN), and NS075177(MN), and Jiangsu Specially Appointed professorship foundation (FW) and also the priority academic program development of Jiangsu Higher Education Institute (PAPD), and also Jiangsu Natural Science Foundation (BK20151565), and Jiangsu Traditional Chinese Medicine Foundation (ZD201501), and Jiangsu Six Talent Peak (2015-YY-006).	Abidin I, 2011, BRAIN RES BULL, V86, P159, DOI 10.1016/j.brainresbull.2011.06.015; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Arndt DH, 2013, EPILEPSIA, V54, P1780, DOI 10.1111/epi.12369; Beamer E, 2012, EUR J NEUROSCI, V36, P3194, DOI 10.1111/j.1460-9568.2012.08234.x; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Bergstrom RA, 2013, SCI REP-UK, V3, DOI 10.1038/srep01483; Brionne TC, 2003, NEURON, V40, P1133, DOI 10.1016/S0896-6273(03)00766-9; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carmo KB, 2005, J PAEDIATR CHILD H, V41, P313, DOI 10.1111/j.1440-1754.2005.00638.x; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; Dohgu S, 2005, BRAIN RES, V1038, P208, DOI 10.1016/j.brainres.2005.01.027; Dombeck DA, 2007, NEURON, V56, P43, DOI 10.1016/j.neuron.2007.08.003; Dzhala VI, 2005, NAT MED, V11, P1205, DOI 10.1038/nm1301; Dzhala VI, 2003, J NEUROSCI, V23, P1840; Dzhala VI, 2008, ANN NEUROL, V63, P222, DOI 10.1002/ana.21229; Dzhala VI, 2010, J NEUROSCI, V30, P11745, DOI 10.1523/JNEUROSCI.1769-10.2010; Ferrie CD, 2005, EPILEPSIA, V46, P91, DOI 10.1111/j.1528-1167.2005.00319.x; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Fu PC, 2015, BRAIN RES, V1613, P110, DOI 10.1016/j.brainres.2015.04.006; Heinemann U, 2012, GLIA, V60, P1251, DOI 10.1002/glia.22311; Huang JH, 2013, NEUROL RES, V35, P221, DOI 10.1179/1743132813Y.0000000178; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Kahle KT, 2008, NAT CLIN PRACT NEURO, V4, P490, DOI 10.1038/ncpneuro0883; Lee BH, 2007, J BIOL CHEM, V282, P17985, DOI 10.1074/jbc.M702664200; Lee HK, 2014, SPINE J, V14, P777, DOI 10.1016/j.spinee.2013.06.100; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Mannix Rebekah C, 2012, Int J Alzheimers Dis, V2012, P608732, DOI 10.1155/2012/608732; Medina-Ceja L, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-78; Mesples B, 2005, NEUROBIOL DIS, V18, P193, DOI 10.1016/j.nbd.2004.09.018; Modol L, 2015, J NEUROSCI, V35, P7414, DOI 10.1523/JNEUROSCI.4079-14.2015; Oberheim NA, 2008, J NEUROSCI, V28, P3264, DOI 10.1523/JNEUROSCI.4980-07.2008; Perillan PR, 2002, J BIOL CHEM, V277, P1974, DOI 10.1074/jbc.M107984200; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Petridis AK, 2012, CLINICS PRACT, V2, P164, DOI 10.4081/cp.2012.e66; Phillips DJ, 2006, J NEUROTRAUM, V23, P1283, DOI 10.1089/neu.2006.23.1283; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Rennie JM, 2003, CURR OPIN NEUROL, V16, P177, DOI 10.1097/00019052-200304000-00010; Richardson C, 2008, J CELL SCI, V121, P3293, DOI 10.1242/jcs.029223; Rodgers KM, 2015, J NEUROSCI, V35, P9194, DOI 10.1523/JNEUROSCI.0919-15.2015; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Staley K, 2001, NAT NEUROSCI, V4, P674, DOI 10.1038/89439; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Thrane VR, 2012, NEUROSCIENCE, V220, P247, DOI 10.1016/j.neuroscience.2012.06.022; Thrane VR, 2013, NAT MED, V19, P1643, DOI 10.1038/nm.3400; Tollner K, 2014, ANN NEUROL, V75, P550, DOI 10.1002/ana.24124; Tong J, 2014, NEUROSURGERY, V75, P51, DOI 10.1227/NEU.0000000000000337; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wang FS, 2012, P NATL ACAD SCI USA, V109, P7911, DOI 10.1073/pnas.1120380109; Wang FS, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002334; Wang HQ, 2013, EPILEPSY RES, V107, P272, DOI 10.1016/j.eplepsyres.2013.10.006; WILCOX KS, 1994, J NEUROSCI, V14, P1775; Yamada J, 2004, J PHYSIOL-LONDON, V557, P829, DOI 10.1113/jphysiol.2004.062471	56	28	31	0	7	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	APR	2017	222	3					1543	1556		10.1007/s00429-016-1292-z			14	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	ER6QH	WOS:000398930700028	27586142	Green Published			2021-06-18	
J	Bretzin, AC; Mansell, JL; Tierney, RT; McDevitt, JK				Bretzin, Abigail C.; Mansell, Jamie L.; Tierney, Ryan T.; McDevitt, Jane K.			Sex Differences in Anthropometrics and Heading Kinematics Among Division I Soccer Athletes: A Pilot Study	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						biomechanics; head injuries/concussion; neck strength; cervical musculature	TRAUMATIC BRAIN-INJURY; SEGMENT DYNAMIC STABILIZATION; DESCRIPTIVE EPIDEMIOLOGY; SURVEILLANCE SYSTEM; MUSCLE STRENGTH; NECK STRENGTH; PLAYERS; ACCELERATION; CONCUSSION; BIOMECHANICS	Background: Soccer players head the ball repetitively throughout their careers; this is also a potential mechanism for a concussion. Although not all soccer headers result in a concussion, these subconcussive impacts may impart acceleration, deceleration, and rotational forces on the brain, leaving structural and functional deficits. Stronger neck musculature may reduce head-neck segment kinematics. Hypothesis: The relationship between anthropometrics and soccer heading kinematics will not differ between sexes. The relationship between anthropometrics and soccer heading kinematics will not differ between ball speeds. Study Design: Pilot, cross-sectional design. Methods: Division I soccer athletes (5 male, 8 female) were assessed for head-neck anthropometric and neck strength measurements in 6 directions (ie, flexion, extension, right and left lateral flexions and rotations). Participants headed the ball 10 times (25 or 40 mph) while wearing an accelerometer secured to their head. Kinematic measurements (ie, linear acceleration and rotational velocity) were recorded at 2 ball speeds. Results: Sex differences were observed in neck girth (t = 5.09, P < 0.001), flexor and left lateral flexor strength (t = 3.006, P = 0.012 and t = 4.182, P = 0.002, respectively), and rotational velocity at both speeds (t = -2.628, P = 0.024 and t = -2.227, P = 0.048). Neck girth had negative correlations with both linear acceleration (r = -0.599, P = 0.031) and rotational velocity at both speeds (r = -0.551, P = 0.012 and r = -0.652, P = 0.016). Also, stronger muscle groups had lower linear accelerations at both speeds (P < 0.05). Conclusion: There was a significant relationship between anthropometrics and soccer heading kinematics for sex and ball speeds.	[Bretzin, Abigail C.] Michigan State Univ, Dept Kinesiol, 308 West Circle Dr, E Lansing, MI 48824 USA; [Mansell, Jamie L.; Tierney, Ryan T.] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [McDevitt, Jane K.] East Stroudsburg Univ, Dept Athlet Training, East Stroudsburg, PA USA	Bretzin, AC (corresponding author), Michigan State Univ, Dept Kinesiol, 308 West Circle Dr, E Lansing, MI 48824 USA.	bretzina@msu.edu		Bretzin, Abigail/0000-0003-3730-2849			Aagaard P, 2001, J PHYSIOL-LONDON, V534, P613, DOI 10.1111/j.1469-7793.2001.t01-1-00613.x; Agel J, 2007, J ATHL TRAINING, V42, P270; ALWAY SE, 1989, J APPL PHYSIOL, V66, P2725; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; De Witt JK, 2012, SPORT BIOMECH, V11, P382, DOI 10.1080/14763141.2012.661757; Dezman ZDW, 2013, SPORTS HEALTH, V5, P320, DOI 10.1177/1941738113480935; Dick R, 2007, J ATHL TRAINING, V42, P278; Eckner JT, 2014, AM J SPORT MED, V42, P566, DOI 10.1177/0363546513517869; Ferraz R, 2012, J HUM KINET, V35, P97, DOI 10.2478/v10078-012-0083-8; Gilchrist MD, 2004, STRAIN, V40, P180, DOI 10.1111/j.1475-1305.2004.00168.x; Gutierrez GM, 2014, PEDIATR EXERC SCI, V26, P33, DOI 10.1123/pes.2013-0102; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lisman P., 2012, INT J SPORTS SCI ENG, V6, P131; MACDOUGALL JD, 1979, MED SCI SPORT EXER, V11, P164; Mansell J, 2005, J ATHL TRAINING, V40, P310; Mansell JL, 2010, BRAIN INJURY, V24, P1070, DOI 10.3109/02699052.2010.494589; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PLAGENHOEF S, 1983, RES Q EXERCISE SPORT, V54, P169, DOI 10.1080/02701367.1983.10605290; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Zaumseil F., 2011, FOOTWEAR SCI S1, V3, pS172	33	28	28	1	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	MAR-APR	2017	9	2					168	173		10.1177/1941738116678615			6	Sport Sciences	Sport Sciences	EY5WQ	WOS:000404052200010	28225689	Green Published			2021-06-18	
J	Rizoli, SB; Jaja, BNR; Di Battista, AP; Rhind, SG; Neto, AC; da Costa, L; Inaba, K; da Luz, LT; Nascimento, B; Perez, A; Baker, AJ; Manoel, ALD				Rizoli, Sandro B.; Jaja, Blessing N. R.; Di Battista, Alex P.; Rhind, Shawn G.; Neto, Antonio Capone; da Costa, Leodante; Inaba, Kenji; da Luz, Luis Teodoro; Nascimento, Bartolomeu; Perez, Adic; Baker, Andrew J.; Manoel, Airton Leonardo de Oliveira			Catecholamines as outcome markers in isolated traumatic brain injury: the COMA-TBI study	CRITICAL CARE			English	Article						Traumatic brain injury; Catecholamines; Epinephrine; Norepinephrine; Functional outcome	SEVERE HEAD-INJURY; CARDIOPULMONARY-RESUSCITATION; CARDIAC SEQUELAE; SCALE; EPIDEMIOLOGY; EPINEPHRINE; THERAPY; SYSTEM; EDEMA; DEATH	Background: Elevated catecholamine levels might be associated with unfavorable outcome after traumatic brain injury (TBI). We investigated the association between catecholamine levels in the first 24 h post-trauma and functional outcome in patients with isolated moderate-to-severe TBI. Methods: A cohort of 174 patients who sustained isolated blunt TBI was prospectively enrolled from three Level-1 Trauma Centers. Epinephrine (Epi) and norepinephrine (NE) concentrations were measured at admission (baseline), 6, 12 and 24 h post-injury. Outcome was assessed at 6 months by the extended Glasgow Outcome Scale (GOSE) score. Fractional polynomial plots and logistic regression models (fixed and random effects) were used to study the association between catecholamine levels and outcome. Effect size was reported as the odds ratio (OR) associated with one logarithmic change in catecholamine level. Results: At 6 months, 109 patients (62.6%) had an unfavorable outcome (GOSE 5-8 vs. 1-4), including 51 deaths (29.3%). Higher admission levels of Epi were associated with a higher risk of unfavorable outcome (OR, 2.04, 95% CI: 1.31-3.18, p = 0.002) and mortality (OR, 2.86, 95% CI: 1.62-5.01, p = 0.001). Higher admission levels of NE were associated with higher risk of unfavorable outcome (OR, 1.59, 95% CI: 1.07-2.35, p = 0.022) but not mortality (OR, 1. 45, 95% CI: 0.98-2.17, p = 0.07). There was no relationship between the changes in Epi levels over time and mortality or unfavorable outcome. Changes in NE levels with time were statistically associated with a higher risk of mortality, but the changes had no relation to unfavorable outcome. Conclusions: Elevated circulating catecholamines, especially Epi levels on hospital admission, are independently associated with functional outcome and mortality after isolated moderate-to-severe TBI.	[Rizoli, Sandro B.; Perez, Adic; Baker, Andrew J.; Manoel, Airton Leonardo de Oliveira] St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Jaja, Blessing N. R.; Baker, Andrew J.; Manoel, Airton Leonardo de Oliveira] St Michaels Hosp, Keenan Res Ctr Biomed Sci, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Rizoli, Sandro B.; Di Battista, Alex P.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Rhind, Shawn G.] Toronto Res Ctr, DRDC, Toronto, ON, Canada; [Neto, Antonio Capone] Hosp Israelita Albert Einstein, Ave Albert Einstein,627-701 Morumbi, BR-05652900 Sao Paulo, SP, Brazil; [da Costa, Leodante; da Luz, Luis Teodoro; Nascimento, Bartolomeu; Perez, Adic] Univ Toronto, Dept Surg, Sunnybrook Hlth Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada; [Inaba, Kenji] Univ Southern Calif, IPT, 2051 Marengo St,C5L100, Los Angeles, CA 90033 USA; [Jaja, Blessing N. R.; Baker, Andrew J.; Manoel, Airton Leonardo de Oliveira] St Michaels Hosp, Li Ka Shing Knowledge Inst, Neurosci Res Program, Keenan Res Ctr, 30 Bond St, Toronto, ON M5B 1W8, Canada	Manoel, ALD (corresponding author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.; Manoel, ALD (corresponding author), St Michaels Hosp, Keenan Res Ctr Biomed Sci, 30 Bond St, Toronto, ON M5B 1W8, Canada.; Manoel, ALD (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Neurosci Res Program, Keenan Res Ctr, 30 Bond St, Toronto, ON M5B 1W8, Canada.	airtonleo.manoel@gmail.com	INABA, KENJI/AAC-8532-2020; de Oliveira Manoel, Airton Leonardo/C-4724-2018	de Oliveira Manoel, Airton Leonardo/0000-0002-9593-1013; Rhind, Shawn/0000-0003-2300-0620; Di Battista, Alex/0000-0002-3325-6833	Physician's Services Incorporation Foundation	This study was funded by a Research Grant awarded to Dr. Sandro Rizoli by the Physician's Services Incorporation Foundation.	Alali AS, 2014, NEUROCRIT CARE, V20, P514, DOI 10.1007/s12028-013-9903-5; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Di Battista AP, 2016, SHOCK, V46, P96, DOI 10.1097/SHK.0000000000000642; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Diaz EC, 2015, BURNS, V41, P649, DOI 10.1016/j.burns.2014.10.010; Dunser MW, 2009, CRIT CARE, V13, DOI 10.1186/cc8167; Dunser Martin W, 2009, J Intensive Care Med, V24, P293, DOI 10.1177/0885066609340519; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Herndon DN, 2001, NEW ENGL J MED, V345, P1223, DOI 10.1056/NEJMoa010342; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LARREMORE T, 1983, BRIT HEART J, V49, P101; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MCLEOD AA, 1982, BRIT HEART J, V47, P221; Molina PE, 2005, SHOCK, V24, P3, DOI 10.1097/01.shk.0000167112.18871.5c; Monk DN, 1996, ANN SURG, V223, P395, DOI 10.1097/00000658-199604000-00008; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Ristagno G, 2007, CRIT CARE MED, V35, P2145, DOI 10.1097/01.CCM.0000280427.76175.D2; Ristagno G, 2009, CRIT CARE MED, V37, P1408, DOI 10.1097/CCM.0b013e31819cedc9; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Simon RJ, 2004, J TRAUMA, V56, P269; TEASDALE G, 1974, LANCET, V2, P81; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899	35	28	29	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	FEB 23	2017	21								37	10.1186/s13054-017-1620-6			10	Critical Care Medicine	General & Internal Medicine	EM5HD	WOS:000395341700001	28228155	DOAJ Gold, Green Published			2021-06-18	
J	Lim, SW; Shiue, YL; Liao, JC; Wee, HY; Wang, CC; Chio, CC; Chang, CH; Hu, CY; Kuo, JR				Lim, Sher-Wei; Shiue, Yow-Ling; Liao, Jen-Chieh; Wee, Hsiao-Yue; Wang, Che-Chuan; Chio, Chung-Ching; Chang, Chin-Hung; Hu, Chiao-Ya; Kuo, Jinn-Rung			Simvastatin Therapy in the Acute Stage of Traumatic Brain Injury Attenuates Brain Trauma-Induced Depression-Like Behavior in Rats by Reducing Neuroinflammation in the Hippocampus	NEUROCRITICAL CARE			English	Article						Fluid percussion injury; Depression-Like behavior; Forced swim; Hippocampus; Maximal angle; Microglia; Tumor necrosis factor-alpha; Simvastatin	LATERAL FLUID-PERCUSSION; NECROSIS-FACTOR-ALPHA; MICROGLIAL ACTIVATION; NEURONAL INJURY; NITRIC-OXIDE; LIPID-LEVELS; STATINS; MODEL; INCREASE; DEGENERATION	The antidepressant-like effects of simvastatin on traumatic brain injury (TBI) remain unclear. The present study aimed to investigate the neuroprotective effects of simvastatin and determine whether simvastatin attenuates TBI-induced depression-like behavior and, more specifically, acts as an antineuroinflammatory. Anesthetized male Sprague-Dawley rats were divided into five groups: sham-operated controls, TBI controls, and TBI treatment with simvastatin 4, 10, or 20 mg/kg. Simvastatin was intraperitoneally injected 0, 24, and 48 h after TBI. The motor function was measured using an inclined plane, and depression-like behavior was evaluated using forced swimming tests. Neuronal apoptosis (markers: NeuN, TUNEL, caspase-3), microglia (marker: OX42) and astrocyte (marker: GFAP) activation, and TNF-alpha expression in the microglia and astrocytes of the hippocampal CA3 area were investigated using immunofluorescence assay. All parameters were measured on the 4th, 8th, and 15th day, or only on the 15th day after TBI. TBI-induced depression-like behavior, which increased duration of immobility, was significantly attenuated by 20 mg simvastatin therapy on day 15 after TBI. TBI-induced neuronal apoptosis, microglia and astrocyte activation, and TNF-alpha expression in the microglia and astrocytes of the CA3 area of the hippocampus were significantly reduced by simvastatin treatment, particularly when 20 mg/kg was administered for 3 days. Intraperitoneal injection of simvastatin attenuated TBI in rats during the acute stage by reducing neuronal apoptosis, microglia, and TNF-alpha expression, thereby resulting in a reduction of depressive-like behavior. Our results suggest that simvastatin may be a promising treatment for TBI-induced depression-like behavior.	[Lim, Sher-Wei; Shiue, Yow-Ling] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan; [Lim, Sher-Wei; Liao, Jen-Chieh; Wee, Hsiao-Yue; Wang, Che-Chuan; Chio, Chung-Ching; Chang, Chin-Hung; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan; [Wang, Che-Chuan] Southern Taiwan Univ Sci & Technol, Dept Child Care, Tainan, Taiwan; [Kuo, Jinn-Rung] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Hu, Chiao-Ya; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Lim, Sher-Wei] Min Hwei Coll Hlth Care Management, Dept Nursing, Tainan, Taiwan; [Kuo, Jinn-Rung] Chi Mei Med Ctr, 901 Chung Hwa Rd, Tainan, Taiwan	Kuo, JR (corresponding author), Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan.; Kuo, JR (corresponding author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.; Kuo, JR (corresponding author), Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.; Kuo, JR (corresponding author), Chi Mei Med Ctr, 901 Chung Hwa Rd, Tainan, Taiwan.	kuojinnrung@gmail.com			 [CHMFHR10357]	The authors thank all of the researchers, especially Chio-Ya Hu, who participated in this study. Research has been funded by CHMFHR10357 grants.	Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Ancelin ML, 2010, BIOL PSYCHIAT, V68, P125, DOI 10.1016/j.biopsych.2010.04.011; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Basso AM, 2005, NEUROPSYCHOPHARMACOL, V30, P1257, DOI 10.1038/sj.npp.1300677; BORSINI F, 1988, PSYCHOPHARMACOLOGY, V94, P147; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Chio CC, 2015, CURR MED CHEM, V22, P759, DOI 10.2174/0929867321666141106124657; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Chuang CS, 2014, GEN HOSP PSYCHIAT, V36, P497, DOI 10.1016/j.genhosppsych.2014.05.008; Chuang TJ, 2012, J TRAUMA ACUTE CARE, V73, P1161, DOI 10.1097/TA.0b013e318265d128; Cucchiara B, 2001, J NEUROL SCI, V187, P81, DOI 10.1016/S0022-510X(01)00529-9; Fang CY, 2013, J BEHAV MED, V36, P143, DOI 10.1007/s10865-012-9409-1; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Kaster MP, 2012, NEUROPHARMACOLOGY, V62, P419, DOI 10.1016/j.neuropharm.2011.08.018; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Laskowitz DT, 2008, NEUROCRIT CARE, V8, P3, DOI 10.1007/s12028-007-9040-0; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Lindberg C, 2005, J NEUROSCI RES, V82, P10, DOI 10.1002/jnr.20615; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; MAURO VF, 1993, CLIN PHARMACOKINET, V24, P195, DOI 10.2165/00003088-199324030-00002; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Morales K, 2006, J AM GERIATR SOC, V54, P70, DOI 10.1111/j.1532-5415.2005.00542.x; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Rikitake Y, 2005, CIRC RES, V97, P1232, DOI 10.1161/01.RES.0000196564.18314.23; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; Shirayama Y, 2002, J NEUROSCI, V22, P3251, DOI 10.1523/JNEUROSCI.22-08-03251.2002; Tsai YT, 2014, J SURG RES, V189, P106, DOI 10.1016/j.jss.2014.02.009; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang CC, 2013, J SURG RES, V184, P1045, DOI 10.1016/j.jss.2013.04.059; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang KW, 2014, ANN CLIN LAB SCI, V44, P145; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4	45	28	29	0	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2017	26	1					122	132		10.1007/s12028-016-0290-6			11	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	EI2AI	WOS:000392287900019	27406816				2021-06-18	
J	Brickell, TA; Lippa, SM; French, LM; Kennedy, JE; Bailie, JM; Lange, RT				Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.; Kennedy, Jan E.; Bailie, Jason M.; Lange, Rael T.			Female Service Members and Symptom Reporting after Combat and Non-Combat-Related Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						gender; military; TBI	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; MENTAL-HEALTH DIAGNOSES; POST-CONCUSSION SYNDROME; OPERATION IRAQI FREEDOM; MILITARY SEXUAL TRAUMA; COMPLAINT BASE RATES; GENDER-DIFFERENCES; AFGHANISTAN VETERANS; HEAD-INJURY	Females are often excluded from military-related mild traumatic brain injury (mTBI) research because of its relatively low prevalence in this population. The purpose of this study was to focus on outcome from mTBI in female service members, compared with males. Participants were 172 United States military service members selected from a larger sample that had sustained an mTBI, and were evaluated within 24 months of injury (Age: mean =28.9, SD=8.1) at one of six military medical centers. Eighty-six women were matched to 86 men on nine key variables: TBI severity, mechanism of injury, bodily injury severity, days post-injury, age, number of deployments, theater where wounded, branch of service, and rank. Participants completed the Neurobehavioral Symptom Inventory (NSI) and the Posttraumatic Stress Disorder Checklist (PCL-C). There were no meaningful gender differences across all demographic and injury-related variables (p > 0.05). There were significant group differences and medium effect sizes for the NSI total score and all four NSI cluster scores. Symptoms most affected related to nausea, sensitivity to light, change in taste/smell, change in appetite, fatigue, and poor sleep. There were significant group differences and small-medium effect sizes for the PCL-C total score and two of the three PCL-C cluster scores. Symptoms most affected related to poor concentration, trouble remembering a stressful event, and disturbing memories/thoughts/images. Females consistently experienced more symptoms than males. As females become more active in combat-related deployments, it is critical that future studies place more emphasis on this important military population.	[Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.; Kennedy, Jan E.; Bailie, Jason M.; Lange, Rael T.] Def & Vet Brain Injury Ctr, Silver Spring, MD USA; [Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.; Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.; Lange, Rael T.] Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Kennedy, Jan E.] San Antonio Mil Med Ctr, San Antonio, TX USA; [Bailie, Jason M.] Naval Hosp Camp Pendleton, San Diego, CA USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC, Canada	Lange, RT (corresponding author), Natl Intrepid Ctr Excellence, Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.	rael.lange@gmail.com	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			Amara J, 2014, WOMEN HEALTH ISS, V24, pE171, DOI 10.1016/j.whi.2013.12.004; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baker DG, 2009, MIL MED, V174, P773; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Burrelli D.F., 2013, WOMEN COMBAT ISSUES; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Crum-Cianflone NF, 2014, EPIDEMIOL REV, V36, P5, DOI 10.1093/epirev/mxt005; Department of Defense, 2014, 2013 DEM PROF MIL CO; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Dutra L, 2011, J TRAUMA DISSOCIATIO, V12, P25, DOI 10.1080/15299732.2010.496141; Eisen SV, 2012, AM J PUBLIC HEALTH, V102, pS66, DOI 10.2105/AJPH.2011.300609; Evans CT, 2013, PM&R, V5, P210, DOI 10.1016/j.pmrj.2012.12.004; Farace E, 2000, Neurosurg Focus, V8, pe6; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Fox AB, 2016, PSYCHOL TRAUMA-US, V8, P135, DOI 10.1037/tra0000033; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Haskell SG, 2011, WOMEN HEALTH ISS, V21, P92, DOI 10.1016/j.whi.2010.08.001; Haskell SG, 2010, J WOMENS HEALTH, V19, P267, DOI 10.1089/jwh.2008.1262; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2010, RET HOM IR AFGH PREL; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Iverson KM, 2013, J WOMENS HEALTH, V22, P267, DOI 10.1089/jwh.2012.3755; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kimerling R, 2010, AM J PUBLIC HEALTH, V100, P1409, DOI 10.2105/AJPH.2009.171793; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P329, DOI 10.1093/arclin/acu013; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; LeardMann CA, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1273; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Luxton DD, 2010, DEPRESS ANXIETY, V27, P1027, DOI 10.1002/da.20730; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Maguen S, 2012, J PSYCHIATR RES, V46, P311, DOI 10.1016/j.jpsychires.2011.11.007; Maguen S, 2012, WOMEN HEALTH ISS, V22, pE61, DOI 10.1016/j.whi.2011.07.010; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; Managment of Concussion/nTBI Working Group, 2009, VA DOD CLIN PRACT GU; Mattocks KM, 2012, SOC SCI MED, V74, P537, DOI 10.1016/j.socscimed.2011.10.039; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moon Cronk T., 2016, OFFICIALS DESCRIBE P; Mulrine A., 2013, 8 OTHER NATIONS THAT; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Peterson AL, 2011, J CLIN PSYCHOL MED S, V18, P164, DOI 10.1007/s10880-011-9238-3; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Renshaw KD, 2009, ANXIETY STRESS COPIN, V22, P101, DOI 10.1080/10615800802354000; Rona RJ, 2007, INT J EPIDEMIOL, V36, P319, DOI 10.1093/ije/dyl273; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Skopp NA, 2011, J TRAUMA STRESS, V24, P277, DOI 10.1002/jts.20632; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; Street AE, 2013, J GEN INTERN MED, V28, pS556, DOI 10.1007/s11606-013-2333-4; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vogt D, 2011, J ABNORM PSYCHOL, V120, P797, DOI 10.1037/a0023452; Vogt DS, 2005, J TRAUMA STRESS, V18, P271; Wallace D, 2009, AUSTRALAS PSYCHIATRY, V17, P218, DOI 10.1080/10398560902878679; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Wojcik BE, 2009, MIL MED, V174, P1010, DOI 10.7205/MILMED-D-01-6108; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Zinzow HM, 2007, TRAUMA VIOLENCE ABUS, V8, P384, DOI 10.1177/1524838007307295; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257	96	28	28	1	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					300	312		10.1089/neu.2016.4403			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800005	27368356				2021-06-18	
J	Ashendorf, L; Clark, EL; Sugarman, MA				Ashendorf, Lee; Clark, Erika L.; Sugarman, Michael A.			Performance validity and processing speed in a VA Polytrauma sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						Validity; effort; processing speed; veterans	TRAUMATIC BRAIN-INJURY; ADULT INTELLIGENCE SCALE; DIGIT SPAN; TRAIL; SPECIFICITY; STRATEGIES; INDEXES; RATES	Objective: While recognition memory has been the primary tool for the assessment of performance validity in neuropsychological evaluations, some consideration has also been given to embedded measures from other cognitive domains, including processing speed. The present study evaluated the classification accuracy of several speed-based measures in a Veterans Affairs Medical Center Polytrauma sample. Method: The present sample consisted of 114 military veterans (Mean age=35.5, SD=9.4) referred for a suspected history of mild traumatic brain injury who were administered a full neuropsychological protocol that included several validity checks. Veterans were assigned to Valid (n=80) or Invalid (n=34) groups based on outcomes of performance validity measures (PVMs). Results: Several processing speed measures yielded acceptable or excellent classification accuracy; sensitivity values ranged from 29 to 53% with specificity values above 90%. Efforts to identify an improved algorithm that would collapse across multiple processing speed PVMs were unsuccessful compared to classification based on single measures. Conclusions: Processing speed measures can serve as efficient performance validity assessment tools.	[Ashendorf, Lee; Clark, Erika L.; Sugarman, Michael A.] Edith Nourse Rogers Mem Vet Hosp, Bedford, MA 01730 USA; [Ashendorf, Lee] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Clark, Erika L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Clark, Erika L.] Home Base, Boston, MA USA	Ashendorf, L (corresponding author), Edith Nourse Rogers Mem Vet Hosp, Bedford, MA 01730 USA.; Ashendorf, L (corresponding author), Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.	Lee.Ashendorf@va.gov	Ashendorf, Lee/R-7206-2019	Ashendorf, Lee/0000-0003-0479-4023	Department of Veterans Affairs, Veterans Health AdministrationUS Department of Veterans Affairs	This study was supported by salary and research support from the Department of Veterans Affairs, Veterans Health Administration. The authors report no financial relationships with commercial interests.	American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Ashendorf L, 2016, CLIN NEUROPSYCHOL, V30, P599, DOI 10.1080/13854046.2016.1172668; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Boone, 2007, ASSESSMENT FEIGNED C; Boone K., 2002, DOT COUNTING TEST; Carone D. A., 2012, MILD TRAUMATIC BRAIN; Cottingham ME, 2014, CLIN NEUROPSYCHOL, V28, P1030, DOI 10.1080/13854046.2014.951397; Curtis KL, 2009, ASSESSMENT, V16, P401, DOI 10.1177/1073191109338161; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Erdodi L. A., PSYCHOL ASS IN PRESS; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Hosmer D. W., 2000, APPL LOGISTIC REGRES, DOI [10. 1002/0471722146, DOI 10.1002/0471722146, 10.1002/0471722146]; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Meyers J., 1995, REY COMPLEX FIGURE T; Mitrushina M., 2005, HDB NORMATIVE DATA N; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; O'Bryant SE, 2003, CLIN NEUROPSYCHOL, V17, P69, DOI 10.1076/clin.17.1.69.15624; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; Ruff R.M., 1996, RUFF 2 7 SELECTIVE A; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Van Dyke SA, 2013, CLIN NEUROPSYCHOL, V27, P1234, DOI 10.1080/13854046.2013.835447; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wechsler D., 2001, WECHSLER TEST ADULT; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE	43	28	28	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	5					857	866		10.1080/13854046.2017.1285961			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	EY2WQ	WOS:000403833900004	28276866				2021-06-18	
J	Black, AM; Sergio, LE; Macpherson, AK				Black, Amanda M.; Sergio, Lauren E.; Macpherson, Alison K.			The Epidemiology of Concussions: Number and Nature of Concussions and Time to Recovery Among Female and Male Canadian Varsity Athletes 2008 to 2011	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						incidence; athletic injuries; concussion; female; male; recovery of function; neuropsychological tests; students; universities	HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; SPORT; INJURIES; PREVENTION; STATEMENT; FOOTBALL; IMPACT; RATES	Objective: To provide incidence rates and days to symptom resolution and cognitive recovery stratified by sex and sport at a Canadian institution. Study Design: A retrospective chart analysis. Subjects: Seven hundred fifty-nine varsity level athletes competing in men's football, men's and women's soccer, men's and women's volleyball, men's and women's basketball, men's and women's ice hockey, women's field hockey, women's rugby, men's and women's tennis, men's and women's water polo, men's and women's swimming, badminton, cross-country, and track and field in the 2008 to 2009 season through the 2010 to 2011 season. Main Outcome Measures: Incidence of concussion, days to symptom recovery, and days to cognitive recovery as measured by clinical interpretation using the sports concussion assessment tool (SCAT)/SCAT2 and Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) with baseline and follow-up data. Results: A total of 81 concussions were reported and diagnosed among 759 athletes. Significantly, more female athletes were concussed than male athletes (13.08%-7.53%, respectively; P = 0.014) with the highest rates in women's rugby [incidence density (ID) = 20.00 concussions per athlete-season], women's ice hockey (ID = 18.67 per athlete-season), and men's basketball (ID = 20.00 per athlete-season). Sex differences in symptom recovery and cognitive recovery were not significant. Conclusions: The incidence of concussion across multiple sports in a Canadian varsity athlete population is of concern. There are inconsistencies found between the time an athlete claims to have no symptoms and the time of neurocognitive recovery as measured by computerized neurocognitive testing. Therefore, objective computerized testing is recommended to ensure that athletes are functionally recovered before return to play.	[Black, Amanda M.; Sergio, Lauren E.; Macpherson, Alison K.] York Univ, Sch Kinesiol & Hlth Sci, Fac Hlth, Toronto, ON, Canada; [Black, Amanda M.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada	Black, AM (corresponding author), Sport Injury Res Prevent Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	ablack@ucalgary.ca	Sergio, Lauren/AAK-3274-2020; Black, Amanda/O-7675-2017	Black, Amanda/0000-0001-5668-9706			Bloom GA, 2008, EUR J SPORT SCI, V8, P295, DOI 10.1080/17461390802251836; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Johnson EW, 2011, CLIN SPORT MED, V30, P73, DOI 10.1016/j.csm.2010.08.007; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mayers L, 2008, ARCH NEUROL-CHICAGO, V65, P1158, DOI 10.1001/archneur.65.9.1158; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meeuwisse WH, 2000, AM J SPORT MED, V28, P516, DOI 10.1177/03635465000280041201; Rishiraj N, 2009, J SPORT MED PHYS FIT, V49, P159; Underhill J, 2006, CHRONIC DIS CAN, V27, P163	21	28	28	1	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2017	27	1					52	56		10.1097/JSM.0000000000000308			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	EH9OP	WOS:000392101000010	26862834				2021-06-18	
J	Erdodi, L; Roth, R				Erdodi, Laszlo; Roth, Robert			Low scores on BDAE Complex Ideational Material are associated with invalid performance in adults without aphasia	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						Aphasia examination; aphasia screening; Boston Diagnostic Complex Ideational Material; embedded validity indicators; performance validity assessment; receptive language	TRAUMATIC BRAIN-INJURY; PRIMARY PROGRESSIVE APHASIA; LEARNING TEST-II; ALZHEIMERS-DISEASE; DIGIT SPAN; CLASSIFICATION ACCURACY; LANGUAGE IMPAIRMENT; INCOMPLETE EFFORT; EFFORT INDICATORS; RESPONSE BIAS	Complex Ideational Material (CIM) is a sentence comprehension task designed to detect pathognomonic errors in receptive language. Nevertheless, patients with apparently intact language functioning occasionally score in the impaired range. If these instances reflect poor test taking effort, CIM has potential as a performance validity test (PVT). Indeed, in 68 adults medically referred for neuropsychological assessment, CIM was a reliable marker of psychometrically defined invalid responding. A raw score <= 9 or T-score <= 29 achieved acceptable combinations of sensitivity (.34-.40) and specificity (.82-.90) against two reference PVTs, and produced a zero overall false positive rate when scores on all available PVTs were considered. More conservative cutoffs (<= 8/<= 23) with higher specificity (.95-1.00) but lower sensitivity (.14-.17) may be warranted in patients with longstanding, documented neurological deficits. Overall, results indicate that in the absence of overt aphasia, poor performance on CIM is more likely to reflect invalid responding than true language impairment. The implications of the clinical interpretation of CIM are discussed.	[Erdodi, Laszlo] Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Roth, Robert] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA	Erdodi, L (corresponding author), Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com					Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; BLONDER LX, 1989, BRAIN COGNITION, V9, P244, DOI 10.1016/0278-2626(89)90034-1; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; BOROD J C, 1980, Journal of Clinical Neuropsychology, V2, P209, DOI 10.1080/01688638008403793; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Chapman SB, 1997, APHASIOLOGY, V11, P337, DOI 10.1080/02687039708248475; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Davis JJ, 2012, CLIN NEUROPSYCHOL, V26, P850, DOI 10.1080/13854046.2012.686631; Drummond SS, 2004, BRAIN INJURY, V18, P41, DOI 10.1080/0269905031000149461; Eaton KP, 2008, NEUROIMAGE, V41, P311, DOI 10.1016/j.neuroimage.2008.02.033; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; GERMANI MJ, 1995, APHASIOLOGY, V9, P1, DOI 10.1080/02687039508248685; Giovannetti T, 2008, J INT NEUROPSYCH SOC, V14, P542, DOI 10.1017/S1355617708080715; Goodglass H., 1972, BOSTON DIAGNOSTIC AP; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Goodglass H., 2001, BOSTON DIAGNOSTIC AP; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Heaton RK, 2004, REVISED COMPREHENSIV; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kiewel NA, 2012, CLIN NEUROPSYCHOL, V26, P965, DOI 10.1080/13854046.2012.694478; Kuljic-Obradovic DC, 2003, EUR J NEUROL, V10, P445, DOI 10.1046/j.1468-1331.2003.00604.x; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Mapstone M, 2003, NEUROPSYCHOLOGIA, V41, P1396, DOI 10.1016/S0028-3932(03)00043-5; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; PAYNEJOHNSON JC, 1986, J COMMUN DISORD, V19, P237, DOI 10.1016/0021-9924(86)90030-4; Pearson, 2009, ADV CLIN SOLUTIONS W; Rogalski E, 2007, COGN BEHAV NEUROL, V20, P38, DOI 10.1097/WNN.0b013e31802e3bae; Rosso C, 2015, NEUROREHAB NEURAL RE, V29, P287, DOI 10.1177/1545968314543926; Saykin A J, 1995, Appl Neuropsychol, V2, P79, DOI 10.1207/s15324826an0202_5; SAYKIN AJ, 1995, EPILEPSIA, V36, P1071, DOI 10.1111/j.1528-1157.1995.tb00464.x; Seniow J, 2009, J NEUROL SCI, V283, P214, DOI 10.1016/j.jns.2009.02.336; Siedlecki KL, 2008, NEUROPSYCHOLOGY, V22, P400, DOI 10.1037/0894-4105.22.3.400; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Stenclik JH, 2013, APPL NEUROPSYCH-ADUL, V20, P243, DOI 10.1080/09084282.2012.704603; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Tombaugh TN, 1996, TEST MEMORY MALINGER; ULATOWSKA HK, 1983, BRAIN LANG, V19, P317, DOI 10.1016/0093-934X(83)90074-3; Vuorinen E, 2000, ALZ DIS ASSOC DIS, V14, P81, DOI 10.1097/00002093-200004000-00005; WALLACE GL, 1991, ARCH PHYS MED REHAB, V72, P674; Warrington EK., 1984, RECOGNITION MEMORY T; Wicklund AH, 2004, J CLIN EXP NEUROPSYC, V26, P347, DOI 10.1080/13803390490510077; Wilde MC, 2006, CLIN NEUROPSYCHOL, V20, P702, DOI 10.1080/13854040500246901; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	53	28	28	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult		2017	24	3					264	274		10.1080/23279095.2016.1154856			11	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	ES5VJ	WOS:000399613800006	27101354				2021-06-18	
J	Scheenen, ME; Spikman, JM; de Koning, ME; van der Horn, HJ; Roks, G; Hageman, G; van der Naalt, J				Scheenen, Myrthe E.; Spikman, Jacoba M.; de Koning, Myrthe E.; van der Horn, Harm J.; Roks, Gerwin; Hageman, Gerard; van der Naalt, Joukje			Patients "At Risk'' of Suffering from Persistent Complaints after Mild Traumatic Brain Injury: The Role of Coping, Mood Disorders, and Post-Traumatic Stress	JOURNAL OF NEUROTRAUMA			English	Article						neuropsychology; recovery; rehabilitation; traumatic brain injury	SYMPTOMS FOLLOWING MILD; QUALITY-OF-LIFE; POSTCONCUSSIVE SYMPTOMS; EVENT SCALE; ANXIETY; PREDICTORS; DEPRESSION; PREVALENCE; VALIDATION; RECOVERY	Although most patients recover fully following mild traumatic brain injury (mTBI), a minority (15-25%) of all patients develop persistent post-traumatic complaints (PTC) that interfere with the resumption of previous activities. An early identification of patients who are at risk for PTC is currently performed by measuring the number of complaints in the acute phase. However, only part of this group will actually develop persisting complaints, stressing the need for studies on additional risk factors. This study aimed to compare this group of patients with many complaints with patients with few and no complaints to identify potential additional discriminating characteristics and to evaluate which of these factors have the most predictive value for being at risk. We evaluated coping style, presence of psychiatric history, injury characteristics, mood-related symptoms, and post-traumatic stress. We included 820 patients (Glasgow Coma Scale [GCS] score 13-15) admitted to three level-1 trauma centers as part of the UPFRONT-study. At 2 weeks after injury, 60% reported three or more complaints (PTC-high), 25% reported few complaints (PTC-low), and 15% reported no complaints (PTC-zero). Results showed that PTC-high consisted of more females (78% vs. 73% and 52%, p < 0.001), were more likely to have a psychiatric history (7% vs. 2% and 5%), and had a higher number of reported depression (22% vs. 6% and 3%, p < 0.001), anxiety (25% vs. 7% and 5%), and post-traumatic stress (37% vs. 27% and 19%, p < 0.001) than the PTC-low and PTC-zero groups. We conclude that in addition to reported complaints, psychological factors such as coping style, depression, anxiety, and post-traumatic stress symptoms had the highest predictive value and should be taken into account in the identification of at-risk patients for future treatment studies.	[Scheenen, Myrthe E.; Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neuropsychol, Groningen, Netherlands; [de Koning, Myrthe E.; van der Horn, Harm J.; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands; [Roks, Gerwin] St Elizabeth Hosp, Dept Neurol, Tilburg, Netherlands; [Hageman, Gerard] Med Spectrum Twente Enschede, Dept Neurol, Enschede, Netherlands	van der Naalt, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	j.van.der.naalt@umcg.nl		Spikman, Jacoba/0000-0002-6477-0763			Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Feinstein A, 2000, BRAIN COGNITION, V44, P78; Ford AH, 2015, BRIT J PSYCHIAT, V207, P286, DOI 10.1192/bjp.bp.115.166595; Gregorio GW, 2014, J HEAD TRAUMA REHAB, V29, pE43, DOI 10.1097/HTR.0b013e318292fb00; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; IBM. Corp, 2013, IBM SPSS STAT WINDOW; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Maestas KL, 2014, J HEAD TRAUMA REHAB, V29, P407, DOI 10.1097/HTR.0b013e31828654b4; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Matuseviciene G., 2015, J REHABIL MED, V48, P1977; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Paniak C, 2000, BRAIN INJURY, V14, P219; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; SCHREURS PJG, 1984, GEDRAG GEZOND, V12, P101; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Snell DL, 2013, NEUROPSYCHOL REHABIL, V23, P333, DOI 10.1080/09658211.2012.758419; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; STAVRAKAKI C, 1986, BRIT J PSYCHIAT, V149, P7, DOI 10.1192/bjp.149.1.7; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; van der Ploeg E, 2004, PSYCHOL ASSESSMENT, V16, P16, DOI 10.1037/1040-3590.16.1.16; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	44	28	28	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					31	37		10.1089/neu.2015.4381			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100005	27560623				2021-06-18	
J	Duan, HM; Li, XG; Wang, C; Hao, P; Song, W; Li, ML; Zhao, W; Gao, YD; Yang, ZY				Duan, Hongmei; Li, Xiaoguang; Wang, Cong; Hao, Peng; Song, Wei; Li, Manli; Zhao, Wen; Gao, Yudan; Yang, Zhaoyang			Functional hyaluronate collagen scaffolds induce NSCs differentiation into functional neurons in repairing the traumatic brain injury	ACTA BIOMATERIALIA			English	Article						Traumatic brain injury; Neural stem cell; bFGF; Neuron; Functional neural network	CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; HUMAN FIBROBLASTS; STEM-CELLS; MULTIELECTRODE ARRAY; GROWTH-FACTOR; LONG-TERM; CONVERSION; MOUSE; RECOVERY	The traumatic brain injury (TBI) usually causes brain tissue defects, including neuronal death or loss, which ultimately results in dysfunction in some degree. The cell replacement therapy is now one of the most promising methods for such injury. There are currently various methods to induce the differentiation of stem cells into neurons, but all extremely complex, slow and unstable. Here we report that the sodium hyaluronate collagen scaffold loaded with bFGF (bFGF-controlled releasing system, bFGF-CRS) can induce neural stem cells (NSCs) to differentiate into multi-type and mature functional neurons at a high percentage of 82 +/- 1.528% in two weeks. The quantitative real-time (QRT) PCR results reveal that a long-term activation of bFGF receptors could up-regulate ERK/MAPK signal pathways, thus facilitating the formation of presynaptic and postsynaptic structure among the induced neuronal cells (iN cells). The functional synaptic connections established among iN cells were detected by the planar multielectrode dish system. When jointly transplanting the bFGF-CRS and NSCs into the CA1 zone of the rat TBI area, the results suggested that bFGF-CRS provided an optimal microenvironment, which promoted survival, neuronal differentiation of transplanted NSCs and functional synapse formation not only among iN cells but also between iN cells and the host brain tissue in TBI rats, consequently leading to the cognitive function recovery of TBI rats. These findings in vitro and in vivo may lay a foundation for the application of bFGF-CRS and shed light on the delivery of exogenous cells or nutrients to the CNS injury or disease area. Statement of Significance A sodium hyaluronate collagen scaffold was specifically functionalized with nutrient-bFGF which can induce the differentiation of neural stem cells (NSCs) into multi-type and mature functional neurons at a high percentage in two week. When jointly transplanting the bFGF-CRS and NSCs into the CA1 zone of the traumatic brain injured area of adult rats, the bFGF-CRS could provide an optimal microenvironment, which promoted survival, migration and neuronal differentiation of transplanted NSCs and functional synapse formation among iN cells, as well as between iN cells and host brain tissue in TBI rats, consequently leading to the cognitive function recovery of TBI rats. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Duan, Hongmei; Li, Xiaoguang; Wang, Cong; Hao, Peng; Zhao, Wen; Gao, Yudan; Yang, Zhaoyang] Captial Med Univ, Sch Basic Med Sci, Dept Neurobiol, Beijing 100069, Peoples R China; [Song, Wei] Captial Med Univ, Sch Rehabil Med, Beijing 100068, Peoples R China; [Song, Wei] China Rehabil Res Ctr, Beijing 100068, Peoples R China; [Li, Manli] Beihang Univ, Sch Biol Sci & Med Engn, Dept Biomed Engn, Beijing 100191, Peoples R China	Yang, ZY (corresponding author), Captial Med Univ, Sch Basic Med Sci, Dept Neurobiol, Beijing 100069, Peoples R China.	wack_lily@163.com		Duan, Hongmei/0000-0003-2261-2182; hao, peng/0000-0002-8509-8232	State Key Program of National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31130022, 31320103903, 31271037]; National Science and Technology Pillar Program of China [2012BAI17B04]; International Cooperation in Science and Technology Projects of the Ministry of Science Technology of China [2014DFA30640]; National Ministry of Education Special Fund for Excellent Doctoral Dissertation [201356]; Special Funds for Excellent Doctoral Dissertation of Beijing, China [20111000601]	We express heartfelt thanks to Hui Qiao (Ningxia Medical University) and Liwei Zhang (Science China Press) for their kind help and constructive comments. This work was supported by the State Key Program of National Natural Science Foundation of China (Grants 31130022, 31320103903 & 31271037), the National Science and Technology Pillar Program of China (Grant 2012BAI17B04), the International Cooperation in Science and Technology Projects of the Ministry of Science Technology of China (Grant 2014DFA30640), the National Ministry of Education Special Fund for Excellent Doctoral Dissertation (Grant 201356), and the Special Funds for Excellent Doctoral Dissertation of Beijing, China (Grant 20111000601).	Ambasudhan R, 2011, CELL STEM CELL, V9, P113, DOI 10.1016/j.stem.2011.07.002; Bateup HS, 2013, NEURON, V78, P510, DOI 10.1016/j.neuron.2013.03.017; Caiazzo M, 2011, NATURE, V476, P224, DOI 10.1038/nature10284; Cao ZY, 2012, HUM MOL GENET, V21, P2923, DOI 10.1093/hmg/dds118; Cooke MJ, 2011, BIOMATERIALS, V32, P5688, DOI 10.1016/j.biomaterials.2011.04.032; Duan HM, 2015, P NATL ACAD SCI USA, V112, P13360, DOI 10.1073/pnas.1510176112; Gao YD, 2016, REGEN BIOMATER, V3, P115, DOI 10.1093/rb/rbw004; Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107; Ito D, 2013, BRAIN RES, V1534, P22, DOI 10.1016/j.brainres.2013.08.004; Jeon O, 2006, BIOMATERIALS, V27, P1598, DOI 10.1016/j.biomaterials.2005.08.030; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Johnson MA, 2007, J NEUROSCI, V27, P3069, DOI 10.1523/JNEUROSCI.4562-06.2007; Kang CE, 2009, TISSUE ENG PT A, V15, P595, DOI 10.1089/ten.tea.2007.0349; Leong C, 2013, STEM CELL RES, V11, P1314, DOI 10.1016/j.scr.2013.09.002; Lessard A, 2010, EXP NEUROL, V223, P634, DOI 10.1016/j.expneurol.2010.02.013; Li XG, 2009, BIOMATERIALS, V30, P4978, DOI 10.1016/j.biomaterials.2009.05.047; Mekhoubad S, 2012, CELL STEM CELL, V10, P595, DOI 10.1016/j.stem.2012.02.014; Mo LH, 2010, BIOMATERIALS, V31, P2184, DOI 10.1016/j.biomaterials.2009.11.078; Oka H, 1999, J NEUROSCI METH, V93, P61, DOI 10.1016/S0165-0270(99)00113-2; Pang ZPP, 2011, NATURE, V476, P220, DOI 10.1038/nature10202; Pimashkin A, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00087; Qiang L, 2011, CELL, V146, P359, DOI 10.1016/j.cell.2011.07.007; Qu XB, 2015, CELL MOL NEUROBIOL, V35, P913, DOI 10.1007/s10571-015-0186-6; Rang C. E., 2010, J CONTROL RELEASE, V144, P25; Riedel G, 1999, NAT NEUROSCI, V2, P898; Son EY, 2011, CELL STEM CELL, V9, P205, DOI 10.1016/j.stem.2011.07.014; Su ZD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4338; Tam RY, 2014, NEUROPSYCHOPHARMACOL, V39, P169, DOI 10.1038/npp.2013.237; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wu H, 2007, P NATL ACAD SCI USA, V104, P13821, DOI 10.1073/pnas.0706199104; Xu Y, 2006, NEUROSCI LETT, V397, P174, DOI 10.1016/j.neulet.2005.12.051; Yang ZY, 2015, P NATL ACAD SCI USA, V112, P13354, DOI 10.1073/pnas.1510194112; Yang ZY, 2010, BIOMATERIALS, V31, P4846, DOI 10.1016/j.biomaterials.2010.02.015; Yoo AS, 2011, NATURE, V476, P228, DOI 10.1038/nature10323; Zhang HY, 2013, MOL NEUROBIOL, V48, P452, DOI 10.1007/s12035-013-8432-8; Zhao XY, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-55	36	28	33	2	42	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	NOV	2016	45						182	195		10.1016/j.actbio.2016.08.043			14	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	EB3VZ	WOS:000387298300013	27562609				2021-06-18	
J	Li, Q; Yu, P; Zeng, QT; Luo, B; Cai, SQ; Hui, KL; Yu, G; Zhu, CS; Chen, XD; Duan, ML; Sun, XJ				Li, Qian; Yu, Pan; Zeng, Qiuting; Luo, Bing; Cai, Shenquan; Hui, Kangli; Yu, Gao; Zhu, Changsong; Chen, Xingdong; Duan, Manlin; Sun, Xuejun			Neuroprotective Effect of Hydrogen-Rich Saline in Global Cerebral Ischemia/Reperfusion Rats: Up-Regulated Tregs and Down-Regulated miR-21, miR-210 and NF-kappa B Expression	NEUROCHEMICAL RESEARCH			English	Article						Global cerebral ischemia/reperfusion; Neuroprotection; Hydrogen; Regulatory T cells; MiRNA; Immuno-inflammatory response	TRAUMATIC BRAIN-INJURY; ISCHEMIA-REPERFUSION INJURY; MOLECULAR-HYDROGEN; OXIDATIVE DAMAGE; PROSTATE-CANCER; CARDIAC-ARREST; T-CELLS; PROTECTS; MODEL; INFLAMMATION	Recently, it has been suggested that molecular hydrogen (H-2) can selectively reduce the levels of hydroxyl radicals (.OH), and ameliorate oxidative and inflammatory injuries to organs in global cerebral ischemia reperfusion models. Global cerebral ischemia/reperfusion (I/R) can induce a sudden activation of inflammatory cytokines and later influence the systemic immunoreactivity which may contribute to a worse outcome. Regulatory T cells (Tregs) are involved in several pathological aspects of cerebral I/R. In addition, miRNA took part in the processes of cellular response to hypoxia. Since the expression of a specific set of miRNA called "hypoxamirs" is upregulated by hypoxia. Therefore, the aim of this study was to analyze the effect of HRS on I/R inducing cerebral damage, Tregs, and specific miRNA. Our results showed that rats undergone global cerebral I/R and treated with HRS have milder injury than I/R animals without HRS treatment. miR-210 expression in the hippocampus of the I/R group at 6, 24 and 96 h after reperfusion was significantly increased at each time point, while its expression in the group treated with HRS was significantly decreased. In addition, Tregs number in group I/R was decreased at each time points, while its number in the group treated with HRS was increased at 24 and 96 h after reperfusion. We focus on the relationship among Tregs, TGF-beta 1, TNF-alpha and NF-kappa B at 24 h, and we found that there is a high correlation among them. Therefore, our results indicated that the brain resuscitation mechanism in the HRS-treated rats may be related with the effect of upregulating the number of Treg cells.	[Li, Qian; Luo, Bing; Cai, Shenquan; Hui, Kangli; Yu, Gao; Zhu, Changsong; Chen, Xingdong; Duan, Manlin] Jinling Hosp, Dept Anesthesia, 305 Zhongshan East Rd, Nanjing 210002, Jiangsu, Peoples R China; [Yu, Pan] Jinling Hosp, Dept Burn & Plast Surg, 305 Zhongshan East Rd, Nanjing 210002, Jiangsu, Peoples R China; [Zeng, Qiuting] Southeast Univ, Zhongda Hosp, Dept Anesthesia, 87 Hunan Rd, Nanjing 210002, Jiangsu, Peoples R China; [Sun, Xuejun] Second Mil Med Univ, Fac Naval Med, Dept Naval Aeromed, Shanghai 200433, Peoples R China	Chen, XD; Duan, ML (corresponding author), Jinling Hosp, Dept Anesthesia, 305 Zhongshan East Rd, Nanjing 210002, Jiangsu, Peoples R China.	mengguren_cxd@163.com; dml9001@163.com	sun, xuejun/A-5561-2010	sun, xuejun/0000-0003-2387-5531	Medical technology innovation Foundation of Nanjing Military [MS120]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81401602]; Medical Technology Foundation of the PLA [CNJ13J006]; Medical Foundation of Nanjing General Hospital of Nanjing Military Command [2015069]	This research was supported by the Medical technology innovation Foundation of Nanjing Military (MS120, 2013), the National Natural Science Foundation of China (No. 81401602), the Medical Technology Foundation of the PLA (No. CNJ13J006) and Medical Foundation of Nanjing General Hospital of Nanjing Military Command (No. 2015069).	Aggarwal BB, 2010, ANNU REV NUTR, V30, P173, DOI 10.1146/annurev.nutr.012809.104755; Albertsmeier M, 2007, RESUSCITATION, V74, P552, DOI 10.1016/j.resuscitation.2007.01.040; Assadiasl S, 2014, IRAN J IMMUNOL, V11, P139, DOI IJIv11i3A1; Bik W, 2008, NEUROENDOCRINOL LETT, V29, P359; Cai JM, 2009, BRAIN RES, V1256, P129, DOI 10.1016/j.brainres.2008.11.048; Chan SY, 2010, CELL CYCLE, V9, P1072, DOI 10.4161/cc.9.6.11006; Chang LL, 2011, BRAIN BEHAV IMMUN, V25, P260, DOI 10.1016/j.bbi.2010.09.017; Chen H, 2010, BIOCHEM BIOPH RES CO, V393, P308, DOI 10.1016/j.bbrc.2010.02.005; Cui YM, 2014, J SURG RES, V192, P564, DOI 10.1016/j.jss.2014.05.060; Devlin C, 2011, IUBMB LIFE, V63, P94, DOI [10.1002/iub.00427, 10.1002/iub.427]; Fayyad-Kazan H, 2012, J BIOL CHEM, V287, P9910, DOI 10.1074/jbc.M111.337154; Fu Y, 2009, NEUROSCI LETT, V453, P81, DOI 10.1016/j.neulet.2009.02.016; Ha Tai-You, 2011, Immune Netw, V11, P11, DOI [10.4110/in.2011.11.3.135, 10.4110/in.2011.11.1.11]; Han L, 2015, BRAIN RES, V1615, P129, DOI 10.1016/j.brainres.2015.04.038; Harms H, 2011, CEREBROVASC DIS, V32, P552, DOI 10.1159/000331922; Hayashida K, 2014, CIRCULATION, V130, P2173, DOI 10.1161/CIRCULATIONAHA.114.011848; Hayashida K, 2008, BIOCHEM BIOPH RES CO, V373, P30, DOI 10.1016/j.bbrc.2008.05.165; Hotchkiss RS, 2009, NEW ENGL J MED, V361, P1570, DOI 10.1056/NEJMra0901217; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Huang YF, 2007, CELL IMMUNOL, V248, P4, DOI 10.1016/j.cellimm.2007.03.009; Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736; Ji Q, 2011, SURG RES, V168, P95; Ji XT, 2012, J SURG RES, V178, pE9, DOI 10.1016/j.jss.2011.12.038; Jiang Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117982; Lee JC, 2015, FREE RADICAL BIO MED, V79, P78, DOI 10.1016/j.freeradbiomed.2014.11.022; Liu J, 2012, CHIN J TRAUMATOL, V15, P13, DOI 10.3760/cma.j.issn.1008-1275.2012.01.003; Liu P, 2013, CLIN TRANSL ONCOL, V15, P741, DOI 10.1007/s12094-012-0999-4; Lu L, 2012, ACTA PHARMACOL SIN, V33, P531, DOI 10.1038/aps.2011.180; Ma L., 2015, ANN OPER RES, V2015, P1, DOI DOI 10.11817/J.ISSN.1672-7347.2015.11.002]; Mano Y, 2014, FREE RADICAL BIO MED, V69, P324, DOI 10.1016/j.freeradbiomed.2014.01.037; Mei Y, 2013, J CELL BIOCHEM, V114, P1374, DOI 10.1002/jcb.24479; Merlo A, 2012, J CLIN ENDOCR METAB, V97, pE2194, DOI 10.1210/jc.2012-2410; Miko I, 2010, CLIN HEMORHEOL MICRO, V45, P281, DOI 10.3233/CH-2010-1307; Nakao A, 2010, J HEART LUNG TRANSPL, V29, P544, DOI 10.1016/j.healun.2009.10.011; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Pulsinelli WA, 1988, STROKE, V199, P13; Quero L, 2011, RADIOTHER ONCOL, V101, P203, DOI 10.1016/j.radonc.2011.05.063; Singhal AB, 2008, STROKE, V39, P289, DOI 10.1161/STROKEAHA.107.511485; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; Sun HY, 2011, J HEPATOL, V54, P471, DOI 10.1016/j.jhep.2010.08.011; Tian RF, 2016, BRAIN RES, V1637, P1, DOI 10.1016/j.brainres.2016.01.029; Toda S, 2002, ACTA NEUROCHIR, V144, P1297, DOI 10.1007/s00701-002-1010-x; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Wang Y, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0110-3; Xu WH, 2012, J CLIN IMMUNOL, V32, P975, DOI 10.1007/s10875-012-9685-0; Yang L.-X., 2012, DISCRETE DYN NAT SOC, V2012, P1, DOI DOI 10.1186/1471-2229-13-53; Yin J, 2013, BRAIN RES, V1491, P188, DOI 10.1016/j.brainres.2012.10.046	47	28	32	1	10	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	OCT	2016	41	10					2655	2665		10.1007/s11064-016-1978-x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EA1TY	WOS:000386376000016	27386874	Green Published, Other Gold			2021-06-18	
J	Rizzo, JR; Hudson, TE; Dai, WW; Birkemeier, J; Pasculli, RM; Selesnick, I; Balcer, LJ; Galetta, SL; Rucker, JC				Rizzo, John-Ross; Hudson, Todd E.; Dai, Weiwei; Birkemeier, Joel; Pasculli, Rosa M.; Selesnick, Ivan; Balcer, Laura J.; Galetta, Steven L.; Rucker, Janet C.			Rapid number naming in chronic concussion: eye movements in the King-Devick test	ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; SUPERIOR COLLICULUS; 1ST YEAR; SACCADES; OCULOMOTOR; DEFICITS; NEURONS; STATEMENT; RECOVERY	ObjectiveThe King-Devick (KD) test, which is based on rapid number naming speed, is a performance measure that adds vision and eye movement assessments to sideline concussion testing. We performed a laboratory-based study to characterize ocular motor behavior during the KD test in a patient cohort with chronic concussion to identify features associated with prolonged KD reading times. MethodsTwenty-five patients with a concussion history (mean age: 31) were compared to control participants with no concussion history (n = 42, mean age: 32). Participants performed a computerized KD test under infrared-based video-oculography. ResultsAverage intersaccadic intervals for task-specific saccades were significantly longer among concussed patients compared to controls (324.4 85.6 msec vs. 286.1 +/- 49.7 msec, P = 0.027). Digitized KD reading times were prolonged in concussed participants versus controls (53.43 +/- 14.04 sec vs. 43.80 +/- 8.55 sec, P = 0.004) and were highly correlated with intersaccadic intervals. Concussion was also associated with a greater number of saccades during number reading and larger average deviations of saccade endpoint distances from the centers of the to-be-read numbers (1.22 +/- 0.29 degrees vs. 0.98 +/- 0.27 degrees, P = 0.002). There were no differences in saccade peak velocity, duration, or amplitude. InterpretationProlonged intersaccadic intervals, greater numbers of saccades, and larger deviations of saccade endpoints underlie prolonged KD reading times in chronic concussion. The KD test relies upon a diffuse neurocognitive network that mediates the fine control of efferent visual function. One sequela of chronic concussion may be disruption of this system, which may produce deficits in spatial target selection and planning of eye movements.	[Rizzo, John-Ross; Hudson, Todd E.; Birkemeier, Joel; Pasculli, Rosa M.] NYU Sch Med, Dept Phys Med & Rehabil, New York, NY USA; [Rizzo, John-Ross; Hudson, Todd E.; Balcer, Laura J.; Galetta, Steven L.; Rucker, Janet C.] NYU Sch Med, Dept Neurol, New York, NY USA; [Dai, Weiwei; Selesnick, Ivan] NYU Tandon Sch Engn, Dept Elect & Comp Engn, New York, NY USA; [Balcer, Laura J.] NYU Sch Med, Dept Populat Hlth, New York, NY USA; [Balcer, Laura J.; Galetta, Steven L.] NYU Sch Med, Dept Ophthalmol, New York, NY USA	Rucker, JC (corresponding author), Ctr Ambulatory Care, Dept Neurol, Neurol, 240 East 38th St,20th Floor, New York, NY 10016 USA.	janet.rucker@nyumc.org		Rizzo, John-Ross/0000-0002-4084-0085; Rucker, Janet/0000-0002-0397-0999	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K12HDOO1097]; NCMRR, National Institutes of Health Rehabilitation Medicine Scientist Training Program; Empire Clinical Research Investigator Program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001073] Funding Source: NIH RePORTER	This work was supported by 5K12HDOO1097 NICHD and NCMRR, National Institutes of Health Rehabilitation Medicine Scientist Training Program (JRR) and Empire Clinical Research Investigator Program (ECRIP).	[Anonymous], TBI ID METH; Barker-Collo S, 2015, BRAIN INJURY, V29, P1604, DOI 10.3109/02699052.2015.1075143; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Carpenter RHS, 2000, CURR BIOL, V10, pR291, DOI 10.1016/S0960-9822(00)00430-9; Clarke LA, 2012, BRAIN INJURY, V26, P298, DOI 10.3109/02699052.2012.654588; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta K.M., 2015, CONCUSSION, V1, P1; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Horn AKE, 2003, ANN NY ACAD SCI, V1004, P19, DOI 10.1196/annals.1303.003; HORN AKE, 1995, J COMP NEUROL, V359, P350, DOI 10.1002/cne.903590212; KEATING EG, 1986, BEHAV BRAIN RES, V22, P191, DOI 10.1016/0166-4328(86)90064-1; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Kulp MT, 1996, OPTOMETRY VISION SCI, V73, P283, DOI 10.1097/00006324-199604000-00011; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leigh R.J., 2015, NEUROLOGY EYE MOVEME; Leigh RJ, 2004, BRAIN, V127, P460, DOI 10.1093/brain/awh035; Leong Danielle F, 2015, J Optom, V8, P131, DOI 10.1016/j.optom.2014.12.005; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Mangione C.M., 2000, NATL EYE I 25 ITEM V; Maruta J, 2014, PROG NEUROL SURG, V28, P226, DOI 10.1159/000358786; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; OHTSUKA K, 1991, NEUROSCI RES, V10, P290, DOI 10.1016/0168-0102(91)90086-E; PIERROTDESEILLIGNY C, 1991, BRAIN, V114, P1473, DOI 10.1093/brain/114.3.1473; PIERROTDESEILLIGNY C, 1991, J NEUROL NEUROSUR PS, V54, P1106, DOI 10.1136/jnnp.54.12.1106; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Raphael BA, 2006, AM J OPHTHALMOL, V142, P1026, DOI 10.1016/j.ajo.2006.06.060; Rizzo JR, 2016, J NEUROL SCI, V362, P232, DOI 10.1016/j.jns.2016.01.045; Roos JCP, 2008, EXP BRAIN RES, V187, P283, DOI 10.1007/s00221-008-1304-1; Sachdev PS, 2014, NAT REV NEUROL, V10, P634, DOI 10.1038/nrneurol.2014.181; Servadei P, 1994, J Neurosurg Sci, V38, P129; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Ventura RE, 2016, J NEUROL SCI, V361, P79, DOI 10.1016/j.jns.2015.12.010; Williams IM, 1997, J CLIN NEUROSCI, V4, P186, DOI 10.1016/S0967-5868(97)90072-2	48	28	28	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2328-9503			ANN CLIN TRANSL NEUR	Ann. Clin. Transl. Neurol.	OCT	2016	3	10					801	811		10.1002/acn3.345			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DZ2IZ	WOS:000385666800006	27752515	DOAJ Gold, Green Published			2021-06-18	
J	Lopiz, Y; Gonzalez, A; Garcia-Fernandez, C; Garcia-Coiradas, J; Marco, F				Lopiz, Yaiza; Gonzalez, Ana; Garcia-Fernandez, Carlos; Garcia-Coiradas, Javier; Marco, Fernando			Comminuted fractures of the radial head: resection or prosthesis?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Radial head fracture; Metal prosthesis; Radial head resection; Elbow instability	TERM-FOLLOW-UP; LONG-TERM; INTERNAL-FIXATION; CLOSED FRACTURE; DEFICIENT ELBOW; III FRACTURES; EXCISION; ARTHROPLASTY; REPLACEMENT; NECK	Introduction: At present, surgical treatment of comminuted radial head fractures without associated instability continues to be controversial. When anatomical reconstruction is not possible, radial head excision is performed. However, the appearance of long-term complications with this technique, along with the development of new radial head implants situates arthroplasty as a promising surgical alternative. The purpose of the present study was to compare the mid-term functional outcomes of both techniques. Materials and Methods: A retrospective study was performed between 2002 and 2011 on 25 Mason type-III fractures, 11 patients treated with primary radial head resection and 14 who received treatment of the fracture with metal prosthesis. At the end of follow-up, patients were contacted and outcomes evaluated according to: Mayo Elbow Performance Score (MEPS), the Disabilities of the Arm, Shoulder and Hand score (DASH) and strength measurement. Radiographic assessment (proximal migration of the radius, osteoarthritic changes, and signs of prosthesis loosening) was also performed. Results: The average age of the sample was 53.7 years in the resection group, and 54.4 years in the replacement group, with a mean follow-up of 60.3 and 42 months respectively. According to the MEPS scale, there were 6 excellent cases, 3 good and 2 acceptable in the resection group, and 6 excellent cases, 3 good, 3 acceptable, and 2 poor in the prosthesis group. The mean DASH score were 13.5, and 24.8 for the resection and the replacement group respectively. We found one postoperative complication in the resection group (stiffness and valgus instability) and 6 in the replacement group: 3 of joint stiffness, 1 case of prosthesis breakage, and 2 neurological injuries. Conclusions: Although this is a retrospective study, the high complication rate occurring after radial head replacement in comparison with radial head resection, as well as good functional results obtained with this last technique, leads us to recommend it for comminuted radial head fractures without associated instability. (C) 2016 Elsevier Ltd. All rights reserved.	[Lopiz, Yaiza; Gonzalez, Ana; Garcia-Fernandez, Carlos; Garcia-Coiradas, Javier; Marco, Fernando] Univ Complutense Madrid, Clin San Carlos Hosp, Dept Orthopaed Surg, Shoulder & Elbow Unit, Madrid, Spain	Lopiz, Y (corresponding author), Hosp Clin San Carlos, Serv Traumatol & Cirugia Ortoped, Plaza Cristo Rey S-N, Madrid 28040, Spain.	yaizalopiz@gmail.com		/0000-0002-0678-5086			Antuna SA, 2000, REV ORTOP TRAUMATOL, V44, P67; Antuna SA, 2010, J BONE JOINT SURG AM, V92A, P558, DOI 10.2106/JBJS.I.00332; Ashwood N, 2004, J BONE JOINT SURG AM, V86A, P274, DOI 10.2106/00004623-200402000-00009; Bain G I, 2005, J Bone Joint Surg Am, V87 Suppl 1, P136, DOI 10.2106/JBJS.D.02710; BAKALIM G, 1970, ACTA ORTHOP SCAND, V41, P320, DOI 10.3109/17453677008991518; Beingessner DM, 2004, J BONE JOINT SURG AM, V86A, P1730, DOI 10.2106/00004623-200408000-00018; BERGER M, 1991, ANN RADIOL, V34, P330; BROBERG MA, 1986, J BONE JOINT SURG AM, V68A, P669, DOI 10.2106/00004623-198668050-00005; Charalambous CP, 2006, INJURY, V37, P849, DOI 10.1016/j.injury.2006.04.125; Chen X, 2011, INT ORTHOP, V35, P1071, DOI 10.1007/s00264-010-1107-4; Cheung EV, 2009, J AM ACAD ORTHOP SUR, V17, P325, DOI 10.5435/00124635-200905000-00007; Faldini C, 2012, J ORTHOP TRAUMA, V26, P236, DOI 10.1097/BOT.0b013e318220af4f; Giannicola G, 2014, INJURY, V45, P428, DOI 10.1016/j.injury.2013.09.019; GOLDBERG I, 1986, J BONE JOINT SURG AM, V68A, P675, DOI 10.2106/00004623-198668050-00006; GORDON M, 1982, J BONE JOINT SURG AM, V64, P574, DOI 10.2106/00004623-198264040-00013; Harrington IJ, 2001, J TRAUMA, V50, P46, DOI 10.1097/00005373-200101000-00009; HASTINGS H, 1994, HAND CLIN, V10, P417; Herbertsson P, 2004, J BONE JOINT SURG AM, V86A, P1925, DOI 10.2106/00004623-200409000-00010; Herbertsson P, 2004, J BONE JOINT SURG AM, V86A, P569, DOI 10.2106/00004623-200403000-00016; Hotchkiss RN, 1998, AAOS INSTR COURS LEC, V47, P173; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; Iftimie PP, 2011, J SHOULDER ELB SURG, V20, P45, DOI 10.1016/j.jse.2010.09.005; Ikeda M, 2005, J BONE JOINT SURG AM, V87A, P76, DOI 10.2106/JBJS.C.01323; Ikeda Masayoshi, 2006, J Bone Joint Surg Am, V88 Suppl 1 Pt 1, P11; Janssen RPA, 1998, J BONE JOINT SURG BR, V80B, P231, DOI 10.1302/0301-620X.80B2.8255; Jensen SL, 1999, J SHOULDER ELB SURG, V8, P238, DOI 10.1016/S1058-2746(99)90135-0; Kachooei AR, 2016, INJURY, V47, P1253, DOI 10.1016/j.injury.2016.02.023; Liu Bifeng, 2010, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V24, P900; MANN FA, 1992, RADIOLOGY, V184, P15, DOI 10.1148/radiology.184.1.1609073; Martin-Fuentes A M, 2013, Rev Esp Cir Ortop Traumatol, V57, P217, DOI 10.1016/j.recot.2013.02.005; MASON ML, 1954, BRIT J SURG, V42, P123, DOI 10.1002/bjs.18004217203; MAYHALL WST, 1981, J BONE JOINT SURG AM, V63, P459, DOI 10.2106/00004623-198163030-00022; Maynou C, 1996, Acta Orthop Belg, V62 Suppl 1, P105; Moro JK, 2001, J BONE JOINT SURG AM, V83A, P1201, DOI 10.2106/00004623-200108000-00010; MORREY BF, 1991, CLIN ORTHOP RELAT R, P187; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P454, DOI 10.2106/00004623-198163030-00021; MORREY BF, 1979, J BONE JOINT SURG AM, V61, P63, DOI 10.2106/00004623-197961010-00012; Morrey BF, 1985, ELBOW ITS DISORDERS, P62; Obert L, 2005, Chir Main, V24, P17, DOI 10.1016/j.main.2004.11.009; Pavic R, 2015, INJURY, V46, pS119, DOI 10.1016/j.injury.2015.10.050; Pilato G, 2004, Chir Organi Mov, V89, P213; Popovic N, 2000, J ORTHOP TRAUMA, V14, P171, DOI 10.1097/00005131-200003000-00004; Sanchez Gomez P, 2010, REV ESP CIR ORTOP TR, V54, P280; Sanchez-Sotelo J, 2000, J ORTHOP TRAUMA, V14, P354, DOI 10.1097/00005131-200006000-00009; Saus Milan N, 2012, REV ESPANOLA CIRUGIA, V47, P151; Schnetzke M, 2014, INT ORTHOP, V38, P2295, DOI 10.1007/s00264-014-2478-8; Shepard MF, 2001, J BONE JOINT SURG AM, V83A, P92, DOI 10.2106/00004623-200101000-00013; Shin R, 2007, J BONE JOINT SURG AM, V89A, P1108, DOI 10.2106/JBJS.F.00594; Smets S, 2000, Acta Orthop Belg, V66, P353; Smits AJ, 2014, INJURY, V45, P1564, DOI 10.1016/j.injury.2014.05.034; SOWA DT, 1995, CLIN ORTHOP RELAT R, P106; STEPHEN IBM, 1981, ACTA ORTHOP SCAND, V52, P409, DOI 10.3109/17453678109050121; Stoffelen D V, 1994, Acta Orthop Belg, V60, P402; TROUSDALE RT, 1992, J BONE JOINT SURG AM, V74A, P1486, DOI 10.2106/00004623-199274100-00007; Van Glabbeek F, 2005, MED ENG PHYS, V27, P336, DOI 10.1016/j.medengphy.2004.04.011; Van Glabbeek F, 2004, J BONE JOINT SURG AM, V86A, P2629, DOI 10.2106/00004623-200412000-00007; Yalcinkaya M, 2013, ORTHOPEDICS, V36, pE1358, DOI 10.3928/01477447-20131021-15; Zarattini G, 2012, J ORTHOP TRAUMA, V26, P229, DOI 10.1097/BOT.0b013e318220a227; Zhao JJ, 2007, J HUAZHONG U SCI-MED, V27, P681, DOI 10.1007/s11596-007-0616-x; Zwingmann J, 2013, INJURY, V44, P1540, DOI 10.1016/j.injury.2013.04.003	60	28	30	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2016	47			3			S29	S34		10.1016/S0020-1383(16)30603-9			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	EF7VW	WOS:000390538400006	27692103				2021-06-18	
J	Yin, TC; Voorhees, JR; Genova, RM; Davis, KC; Madison, AM; Britt, JK; Cintron-Perez, CJ; McDaniel, L; Harper, MM; Pieper, AA				Yin, Terry C.; Voorhees, Jaymie R.; Genova, Rachel M.; Davis, Kevin C.; Madison, Ashley M.; Britt, Jeremiah K.; Cintron-Perez, Coral J.; McDaniel, Latisha; Harper, Matthew M.; Pieper, Andrew A.			Acute Axonal Degeneration Drives Development of Cognitive, Motor, and Visual Deficits after Blast-Mediated Traumatic Brain Injury in Mice	ENEURO			English	Article						axonal degeneration; nicotinamide adenine dinucleotide; neurodegeneration; traumatic brain injury; WldS mouse	WALLERIAN DEGENERATION; NEUROPROTECTIVE EFFICACY; AMINOPROPYL CARBAZOLES; CELLULAR REACTIONS; GENETIC INFLUENCES; SELF-DESTRUCTION; MUTATION WLD(S); MOUSE MODEL; ACTIVATION; PROTECTION	Axonal degeneration is a prominent feature of many forms of neurodegeneration, and also an early event in blast-mediated traumatic brain injury (TBI), the signature injury of soldiers in Iraq and Afghanistan. It is not known, however, whether this axonal degeneration is what drives development of subsequent neurologic deficits after the injury. The Wallerian degeneration slow strain (WldS) of mice is resistant to some forms of axonal degeneration because of a triplicated fusion gene encoding the first 70 amino acids of Ufd2a, a ubiquitin-chain assembly factor, that is linked to the complete coding sequence of nicotinamide mononucleotide adenylyltransferase 1 (NMAT1). Here, we demonstrate that resistance of WldS mice to axonal degeneration after blast-mediated TBI is associated with preserved function in hippocampal-dependent spatial memory, cerebellar-dependent motor balance, and retinal and optic nerve-dependent visual function. Thus, early axonal degeneration is likely a critical driver of subsequent neurobehavioral complications of blast-mediated TBI. Future therapeutic strategies targeted specifically at mitigating axonal degeneration may provide a uniquely beneficial approach to treating patients suffering from the effects of blast-mediated TBI.	[Yin, Terry C.; Genova, Rachel M.; Davis, Kevin C.; Madison, Ashley M.; Britt, Jeremiah K.; Cintron-Perez, Coral J.; McDaniel, Latisha; Pieper, Andrew A.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA; [Voorhees, Jaymie R.] Univ Iowa, Dept Psychiat, Interdisciplinary Grad Program Human Toxicol, Carver Coll Med, Iowa City, IA 52242 USA; [Harper, Matthew M.] Univ Iowa, Carver Coll Med, Ctr Prevent & Treatment Visual Loss, Dept Vet Affairs, Iowa City, IA 52242 USA; [Harper, Matthew M.] Univ Iowa, Dept Ophthalmol & Visual Sci, Carver Coll Med, Iowa City, IA 52242 USA; [Pieper, Andrew A.] Univ Iowa, Dept Neurol, Carver Coll Med, Iowa City, IA 52242 USA; [Pieper, Andrew A.] Univ Iowa, Dept Free Radical & Radiat Biol, Carver Coll Med, Iowa City, IA 52242 USA; [Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Vet Affairs, Iowa City, IA 52242 USA; [Pieper, Andrew A.] Cornell Univ, Weill Cornell Autism Res Program, Weill Cornell Med, New York, NY 10065 USA	Pieper, AA (corresponding author), Univ Iowa, Carver Coll Med, Dept Vet Affairs, Neurol & Free Radical & Radiat Biol, 415 Newton Rd, Iowa City, IA 52242 USA.	andrew-pieper@uiowa.edu	Pieper, Andrew A/R-5552-2016	Harper, Matthew/0000-0003-3395-2406; Pieper, Andrew/0000-0001-6299-6577; Davis, Kevin/0000-0002-0258-077X	Calico LLC (California Life Company); Mary Alice Smith Fund for Neuropsychiatry Research; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15K21603, 15H01300] Funding Source: KAKEN	This work was supported by funds from Calico LLC (California Life Company) and from an anonymous donor to the Mary Alice Smith Fund for Neuropsychiatry Research to A.A.P.	Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; BALDOCK RA, 1993, J MICROSC-OXFORD, V172, P49, DOI 10.1111/j.1365-2818.1993.tb03392.x; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Coleman MP, 1998, P NATL ACAD SCI USA, V95, P9985, DOI 10.1073/pnas.95.17.9985; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; De Jesus-Cortes H., 2016, NEUROGENESIS; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; De Jesus-Cortest H, 2015, NPJ PARKINSON DIS, V1, DOI 10.1038/npjparkd.2015.10; Dutca LM, 2014, INVEST OPHTH VIS SCI, V55, P8330, DOI 10.1167/iovs.14-15468; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Fujiki M, 1996, J COMP NEUROL, V371, P469; Goffus AM, 2010, OXID MED CELL LONGEV, V3, P145, DOI 10.4161/oxim.3.2.11315; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Henninger N, 2016, BRAIN, V139, P1094, DOI 10.1093/brain/aww001; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horste GMZ, 2011, NEUROBIOL DIS, V42, P1, DOI 10.1016/j.nbd.2010.12.006; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kemp SWP, 2015, NEUROSCIENCE, V284, P202, DOI 10.1016/j.neuroscience.2014.10.005; Lee AS, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0006-16.2016; Lemke S, 2013, JAMA OPHTHALMOL, V131, P1602, DOI 10.1001/jamaophthalmol.2013.5028; Lingor P, 2012, CELL TISSUE RES, V349, P289, DOI 10.1007/s00441-012-1362-3; Lorber B, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-56; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Luong TN, 2011, JOVE-J VIS EXP, DOI 10.3791/2376; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; MacMillan KS, 2011, J AM CHEM SOC, V133, P1428, DOI 10.1021/ja108211m; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Naidoo J, 2014, J MED CHEM, V57, P3746, DOI 10.1021/jm401919s; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Paxinos G., 1997, MOUSE BRAIN STEREOTA; Pieper AA, 2014, CHEM SOC REV, V43, P6716, DOI 10.1039/c3cs60448a; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Porciatti V, 2007, DOC OPHTHALMOL, V115, P145, DOI 10.1007/s10633-007-9059-8; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Sajadi A, 2004, CURR BIOL, V14, P326, DOI 10.1016//j.cub.2004.01.053; Sasaki Y, 2006, J NEUROSCI, V26, P8484, DOI 10.1523/JNEUROSCI.2320-06.2006; Schauwecker PE, 1997, J COMP NEUROL, V380, P82, DOI 10.1002/(SICI)1096-9861(19970331)380:1<82::AID-CNE6>3.0.CO;2-P; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Stoica BA, 2014, J NEUROTRAUM, V31, P758, DOI 10.1089/neu.2013.3194; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Walker AK, 2015, MOL PSYCHIATR, V20, P500, DOI 10.1038/mp.2014.34; Wang G, 2014, CELL, V158, P1324, DOI 10.1016/j.cell.2014.07.040; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; Wang JT, 2015, P NATL ACAD SCI USA, V112, P10093, DOI 10.1073/pnas.1508337112; Wang JT, 2012, CURR BIOL, V22, pR221, DOI 10.1016/j.cub.2012.02.056; Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Won SJ, 2012, J NEUROTRAUM, V29, P1401, DOI 10.1089/neu.2011.2228; Yin TC, 2014, CELL REPORTS, V8, P10; Zhang ZY, 1996, J COMP NEUROL, V371, P485	60	28	28	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	2373-2822			ENEURO	eNeuro	SEP-OCT	2016	3	5								10.1523/ENEURO.0220-16.2016			11	Neurosciences	Neurosciences & Neurology	EH7CL	WOS:000391930400034		DOAJ Gold, Green Published			2021-06-18	
J	Simon-O'Brien, E; Gauthier, D; Riban, V; Verleye, M				Simon-O'Brien, Emmanuelle; Gauthier, Delphine; Riban, Veronique; Verleye, Marc			Etifoxine improves sensorimotor deficits and reduces glial activation, neuronal degeneration, and neuroinflammation in a rat model of traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; Etifoxine; Neuroinflammation; TSPO; Neurosteroids; Functional recovery; Cytokines; Astrogliosis; Neuronal degeneration; Microglia	PERIPHERAL BENZODIAZEPINE-RECEPTOR; CONTROLLED CORTICAL IMPACT; TUMOR-NECROSIS-FACTOR; PROTEIN 18 KDA; CELL-DEATH; INFLAMMATORY RESPONSE; ANXIOLYTIC ETIFOXINE; GABA(A) RECEPTORS; TEMPORAL PROFILE; NERVOUS-SYSTEM	Background: Traumatic brain injury (TBI) results in important neurological impairments which occur through a cascade of deleterious physiological events over time. There are currently no effective treatments to prevent these consequences. TBI is followed not only by an inflammatory response but also by a profound reorganization of the GABAergic system and a dysregulation of translocator protein 18 kDa (TSPO). Etifoxine is an anxiolytic compound that belongs to the benzoxazine family. It potentiates GABAergic neurotransmission, either through a positive allosteric effect or indirectly, involving the activation of TSPO that leads to an increase in neurosteroids synthesis. In several models of peripheral nerve injury, etifoxine has been demonstrated to display potent regenerative and anti-inflammatory properties and to promote functional recovery. Prior study also showed etifoxine efficacy in reducing brain edema in rats. In light of these positive results, we used a rat model of TBI to explore etifoxine treatment effects in a central nervous system injury, from functional outcomes to the underlying mechanisms. Methods: Male Sprague-Dawley rats received contusion (n = 18) or sham (n = 19) injuries centered laterally to bregma over the left sensorimotor cortex. They were treated with etifoxine (50 mg/kg, i.p.) or its vehicle 30 min following injury and every day during 7 days. Rats underwent behavioral testing to assess sensorimotor function. In another experiment, injured rats (n = 10) or sham rats (n = 10) received etifoxine (EFX) (50 mg/kg, i.p.) or its vehicle 30 min post-surgery. Brains were then dissected for analysis of neuroinflammation markers, glial activation, and neuronal degeneration. Results: Brain-injured rats exhibited significant sensorimotor function deficits compared to sham-injured rats in the bilateral tactile adhesive removal test, the beam walking test, and the limb-use asymmetry test. After 2 days of etifoxine treatment, behavioral impairments were significantly reduced. Etifoxine treatment reduced pro-inflammatory cytokines levels without affecting anti-inflammatory cytokines levels in injured rats, reduced macrophages and glial activation, and reduced neuronal degeneration. Conclusions: Our results showed that post-injury treatment with etifoxine improved functional recovery and reduced neuroinflammation in a rat model of TBI. These findings suggest that etifoxine may have a therapeutic potential in the treatment of TBI.	[Simon-O'Brien, Emmanuelle; Gauthier, Delphine; Riban, Veronique; Verleye, Marc] Biocodex, Dept Pharmacol, Chemin Armancourt, F-60200 Compiegne, France	Simon-O'Brien, E (corresponding author), Biocodex, Dept Pharmacol, Chemin Armancourt, F-60200 Compiegne, France.	e.simonobrien@biocodex.fr					Akk G, 2007, PHARMACOL THERAPEUT, V116, P35, DOI 10.1016/j.pharmthera.2007.03.004; Almeida-Suhett CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102627; Anderson GD, 2011, J NEUROTRAUM, V28, P1827, DOI 10.1089/neu.2011.1911; Ansari MA, 2015, J NEUROL SCI, V357, P41, DOI 10.1016/j.jns.2015.06.062; Baratz R, 2015, J NEUROINFLAMM, V7, P12; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Chauveau F, 2011, EUR J NUCL MED MOL I, V38, P509, DOI 10.1007/s00259-010-1628-5; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Daugherty DJ, 2013, EMBO MOL MED, V5, P891, DOI 10.1002/emmm.201202124; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; do Rego JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120473; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Ferzaz B, 2002, J PHARMACOL EXP THER, V301, P1067, DOI 10.1124/jpet.301.3.1067; Fleming SM, 2004, J NEUROSCI, V24, P9434, DOI 10.1523/JNEUROSCI.3080-04.2004; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Freret T, 2006, EUR J NEUROSCI, V23, P1757, DOI 10.1111/j.1460-9568.2006.04699.x; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Girard C, 2012, J NEUROENDOCRINOL, V24, P71, DOI 10.1111/j.1365-2826.2011.02215.x; Girard C, 2008, P NATL ACAD SCI USA, V105, P20505, DOI 10.1073/pnas.0811201106; Girard P, 2009, CLIN EXP PHARMACOL P, V36, P655, DOI 10.1111/j.1440-1681.2008.05127.x; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hamon A, 2003, NEUROPHARMACOLOGY, V45, P293, DOI 10.1016/S0028-3908(03)00187-4; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; Kaufman NA, 2010, BEHAV BRAIN RES, V214, P395, DOI 10.1016/j.bbr.2010.06.017; Khateb A, 1998, NEUROSCIENCE, V86, P937, DOI 10.1016/S0306-4522(98)00094-3; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Nguyen N, 2006, HUM PSYCHOPHARM CLIN, V21, P139, DOI 10.1002/hup.757; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Papadopoulos V, 2006, NEUROSCIENCE, V138, P749, DOI 10.1016/j.neuroscience.2005.05.063; Papadopoulos V, 2009, EXP NEUROL, V219, P53, DOI 10.1016/j.expneurol.2009.04.016; Patel HC, 2003, ANN NY ACAD SCI, V992, P39, DOI 10.1111/j.1749-6632.2003.tb03136.x; Perego C, 2013, JOVE-J VIS EXP, DOI 10.3791/50605; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pu BF, 2015, MOL MED REP, V12, P3704, DOI 10.3892/mmr.2015.3830; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raivich G, 2002, EXP NEUROL, V178, P186, DOI 10.1006/exnr.2002.8024; Ravikumar B, 2016, NEUROPHARMACOLOGY, V108, P229, DOI 10.1016/j.neuropharm.2016.03.053; Robertson CS, 2013, J NEUROTRAUM, V30, P765, DOI 10.1089/neu.2012.2431; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Romanides AJ, 1999, NEUROSCIENCE, V92, P97, DOI 10.1016/S0306-4522(98)00747-7; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Ryu JK, 2005, NEUROBIOL DIS, V20, P550, DOI 10.1016/j.nbd.2005.04.010; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; SCHALLERT T, 1983, PHARMACOL BIOCHEM BE, V18, P753, DOI 10.1016/0091-3057(83)90019-9; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; Schlichter R, 2000, NEUROPHARMACOLOGY, V39, P1523, DOI 10.1016/S0028-3908(99)00253-1; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schumacher M, 2014, PROG NEUROBIOL, V113, P6, DOI 10.1016/j.pneurobio.2013.09.004; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Servant D, 1998, ENCEPHALE, V24, P569; Shafer RA, 1997, GLIA, V21, P370, DOI 10.1002/(SICI)1098-1136(199712)21:4<370::AID-GLIA4>3.0.CO;2-7; Stein DJ, 2015, ADV THER, V32, P57, DOI 10.1007/s12325-015-0176-6; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Streit WJ, 1996, NEUROTOXICOLOGY, V17, P671; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; TANAKA M, 1994, J NEUROCHEM, V63, P266; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Torres SR, 2000, EUR J PHARMACOL, V408, P199, DOI 10.1016/S0014-2999(00)00760-3; Toth M, 2016, BRAIN STRUCT FUNCT, V221, P1279, DOI 10.1007/s00429-014-0970-y; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Veiga S, 2005, J NEUROSCI RES, V80, P129, DOI 10.1002/jnr.20430; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; Verleye M, 2005, PHARMACOL BIOCHEM BE, V82, P712, DOI 10.1016/j.pbb.2005.11.013; Verleye M, 2004, PHYSIOL BEHAV, V82, P891, DOI 10.1016/j.physbeh.2004.07.010; Verleye M, 2002, NEUROSCI RES, V44, P167, DOI 10.1016/S0168-0102(02)00121-9; Verleye M, 1999, NEUROREPORT, V10, P3207, DOI 10.1097/00001756-199910190-00015; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang Y, 2014, EUR J NUCL MED MOL I, V41, P1440, DOI 10.1007/s00259-014-2727-5; Wei LC, 2002, DEV BRAIN RES, V139, P9, DOI 10.1016/S0165-3806(02)00509-6; Wolf L, 2015, PHARMACOPSYCHIATRY, V48, P72, DOI 10.1055/s-0034-1398507; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Woodlee MT, 2005, EXP NEUROL, V191, P310, DOI 10.1016/j.expneurol.2004.09.005; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	106	28	28	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 26	2016	13								203	10.1186/s12974-016-0687-3			15	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DV4EN	WOS:000382878200006	27565146	DOAJ Gold, Green Published			2021-06-18	
J	Lipponen, A; Paananen, J; Puhakka, N; Pitkanen, A				Lipponen, Anssi; Paananen, Jussi; Puhakka, Noora; Pitkanen, Asla			Analysis of Post-Traumatic Brain Injury Gene Expression Signature Reveals Tubulins, Nfe2l2, Nfkb, Cd44, and S100a4 as Treatment Targets	SCIENTIFIC REPORTS			English	Article							RAT CEREBRAL-CORTEX; CHEMOKINE EXPRESSION; CELL-DEATH; HIPPOCAMPAL; RESPONSES; NEUROPROTECTION; ACTIVATION; MECHANISMS; PATTERNS; EPILEPSY	We aimed to define the chronically altered gene expression signature of traumatic brain injury (TBI-sig) to discover novel treatments to reverse pathologic gene expression or reinforce the expression of recovery-related genes. Genome-wide RNA-sequencing was performed at 3 months post-TBI induced by lateral fluid-percussion injury in rats. We found 4964 regulated genes in the perilesional cortex and 1966 in the thalamus (FDR < 0.05). TBI-sig was used for a LINCS analysis which identified 11 compounds that showed a strong connectivity with the TBI-sig in neuronal cell lines. Of these, celecoxib and sirolimus were recently reported to have a disease-modifying effect in in vivo animal models of epilepsy. Other compounds revealed by the analysis were BRD-K91844626, BRD-A11009626, NO-ASA, BRD-K55260239, SDZ-NKT-343, STK-661558, BRD-K75971499, ionomycin, and desmethylclomipramine. Network analysis of overlapping genes revealed the effects on tubulins (Tubb2a, Tubb3, Tubb4b), Nfe2l2, S100a4, Cd44, and Nfkb2, all of which are linked to TBI-relevant outcomes, including epileptogenesis and tissue repair. Desmethylclomipramine modulated most of the gene targets considered favorable for TBI outcome. Our data demonstrate long-lasting transcriptomics changes after TBI. LINCS analysis predicted that these changes could be modulated by various compounds, some of which are already in clinical use but never tested in TBI.	[Lipponen, Anssi; Puhakka, Noora; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, POB 1627, FIN-70211 Kuopio, Finland; [Paananen, Jussi] Univ Eastern Finland, Inst Biomed, FIN-70211 Kuopio, Finland; [Paananen, Jussi] Univ Eastern Finland, Bioinformat Ctr, FIN-70211 Kuopio, Finland	Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitkanen@uef.fi		Lipponen, Anssi/0000-0002-4403-9084; Paananen, Jussi/0000-0001-5100-4907	Academy of FinlandAcademy of FinlandEuropean Commission; EpiGENet EUROEPINOMICS; FP7-HEALTH project [602102]; ERA-NET Neuron [TBI Epilepsy]	This study was supported by the Academy of Finland (A.P.), EpiGENet EUROEPINOMICS (A.P.), FP7-HEALTH project 602102 (EPITARGET), ERA-NET Neuron [TBI Epilepsy]. We thank Mr. Jarmo Hartikainen and Mrs. Merja Lukkari for their excellent technical assistance. We also grateful to Mr. Juha Kekalainen, for his excellent help in bioinformatics analysis.	Andrews S., FastQC a quality control tool for high throughput sequence data; Chattopadhyay M, 2010, J PHARMACOL EXP THER, V335, P443, DOI 10.1124/jpet.110.171017; Colak T, 2012, INJURY, V43, P1264, DOI 10.1016/j.injury.2012.01.021; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; Cushion TD, 2014, AM J HUM GENET, V94, P634, DOI 10.1016/j.ajhg.2014.03.009; Das M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-148; DELEON M, 1991, J NEUROSCI RES, V29, P155; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dmytriyeva O, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2202; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dolenec P, 2015, J NEUROPATH EXP NEUR, V74, P512, DOI 10.1097/NEN.0000000000000194; Dougall D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009221.pub2; Faul M., 2010, BRAIN INJURY US EMER; Gallorini M, 2015, BIOMATERIALS, V56, P114, DOI 10.1016/j.biomaterials.2015.03.047; Goodman JC, 2008, ACTA NEUROCHIR SUPPL, V102, P389, DOI 10.1007/978-3-211-85578-2_75; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Hardingham GE, 2016, NAT REV NEUROSCI, V17, P1, DOI 10.1038/nrn.2015.19; Hellmich HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053230; Ishikawa Y, 2006, ACTA NEUROCHIR SUPPL, V96, P163; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kukacka J, 2006, NEUROENDOCRINOL LETT, V27, P116; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIU CM, 1978, J BIOL CHEM, V253, P5892; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mazzuferi M, 2013, ANN NEUROL, V74, P560, DOI 10.1002/ana.23940; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; Pitkanen A, 2014, EPILEPSY BEHAV, V38, P19, DOI 10.1016/j.yebeh.2014.01.013; Pitkanen A, 2014, NEUROBIOL DIS, V72, P224, DOI 10.1016/j.nbd.2014.05.037; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Renato B., 2015, J NEUROL NEUROPHYSIO; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Samal BB, 2015, J MOL NEUROSCI, V57, P282, DOI 10.1007/s12031-015-0626-2; Sandberg M, 2014, NEUROPHARMACOLOGY, V79, P298, DOI 10.1016/j.neuropharm.2013.11.004; Satoh T, 2006, P NATL ACAD SCI USA, V103, P768, DOI 10.1073/pnas.0505723102; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sirota M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001318; Stylli SS, 2000, J CLIN NEUROSCI, V7, P137, DOI 10.1054/jocn.1999.0187; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Vonder Haar C, 2014, J NEUROTRAUM, V31, P961, DOI 10.1089/neu.2013.3119; Wacker SA, 2012, NAT CHEM BIOL, V8, P235, DOI [10.1038/NCHEMBIO.779, 10.1038/nchembio.779]; White TE, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2412-0; White TE, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-282; Wong YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020216; Zhang XY, 2014, GENET MOL RES, V13, P9220, DOI 10.4238/2014.November.7.9	55	28	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 17	2016	6								31570	10.1038/srep31570			9	Multidisciplinary Sciences	Science & Technology - Other Topics	DT4YH	WOS:000381487000001	27530814	DOAJ Gold, Green Published			2021-06-18	
J	Bigler, ED				Bigler, Erin D.			Systems Biology, Neuroimaging, Neuropsychology, Neuroconnectivity and Traumatic Brain Injury	FRONTIERS IN SYSTEMS NEUROSCIENCE			English	Article						traumatic brain injury (TBI); neuroimaging; computed tomography (CT); magnetic resonance imaging (MRI); systems biology; connectivity; neuropsychology; quantitative image analysis	WHITE-MATTER; STRUCTURAL CONNECTOME; STATE; MILD; CONSEQUENCES; DAMAGE; NEUROPATHOLOGY; ORGANIZATION; CONNECTIVITY; PERFORMANCE	The patient who sustains a traumatic brain injury (TBI) typically undergoes neuroimaging studies, usually in the form of computed tomography (CT) and magnetic resonance imaging (MRI). In most cases the neuroimaging findings are clinically assessed with descriptive statements that provide qualitative information about the presence/absence of visually identifiable abnormalities; though little if any of the potential information in a scan is analyzed in any quantitative manner, except in research settings. Fortunately, major advances have been made, especially during the last decade, in regards to image quantification techniques, especially those that involve automated image analysis methods. This review argues that a systems biology approach to understanding quantitative neuroimaging findings in TBI provides an appropriate framework for better utilizing the information derived from quantitative neuroimaging and its relation with neuropsychological outcome. Different image analysis methods are reviewed in an attempt to integrate quantitative neuroimaging methods with neuropsychological outcome measures and to illustrate how different neuroimaging techniques tap different aspects of TBI-related neuropathology. Likewise, how different neuropathologies may relate to neuropsychological outcome is explored by examining how damage influences brain connectivity and neural networks. Emphasis is placed on the dynamic changes that occur following TBI and how best to capture those pathologies via different neuroimaging methods. However, traditional clinical neuropsychological techniques are not well suited for interpretation based on contemporary and advanced neuroimaging methods and network analyses. Significant improvements need to be made in the cognitive and behavioral assessment of the brain injured individual to better interface with advances in neuroimaging-based network analyses. By viewing both neuroimaging and neuropsychological processes within a systems biology perspective could represent a significant advancement for the field.	[Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Ctr Neurosci, Provo, UT 84602 USA	Bigler, ED (corresponding author), Brigham Young Univ, Ctr Neurosci, Dept Psychol, Provo, UT 84602 USA.	erin_bigler@byu.edu			National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5R01HD048946, 3R01HD048946-05S1]; Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-13-2-0095]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	Parts of the research written about in this review were supported by the National Institute of Child Health and Human Development (Grant Nos. 5R01HD048946 and 3R01HD048946-05S1) and the USA. Army Medical Research and Material Command under Award No. W81XWH-13-2-0095 (Chronic Effects of Neurotrauma Consortium). The views and opinions expressed in this article are those of the author and do not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred. EDB co-directs the Neuropsychological Assessment and Research Laboratory at Brigham Young University which provides forensic consultation. Tracy Abildskov, Naomi Goodrich-Hunsaker, Ph.D. and Trevor Huff assisted with creating some of the images used in this review and Jo Ann Petrie, Ph.D. also provided assistance with manuscript preparation.	Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306; An G, 2012, INT J BURNS TRAUMA, V2, P1; Armstrong RC, 2016, NEUROPHARMACOLOGY, V110, P654, DOI 10.1016/j.neuropharm.2015.04.029; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Avants BB, 2011, NEUROINFORMATICS, V9, P381, DOI 10.1007/s12021-011-9109-y; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Barkhof F, 2014, RADIOLOGY, V272, P28, DOI 10.1148/radiol.14132388; Bayly PV, 2012, ANNU REV BIOMED ENG, V14, P369, DOI [10.1146/annurev-bioeng-071811-150032, 10.1146/annurev.bioeng-071811-150032]; Benarroch EE, 2015, NEUROLOGY, V85, P1417, DOI 10.1212/WNL.0000000000002044; Bigler E. D., 2016, SPORTS MED IN PRESS; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P442, DOI 10.1017/S1355617704103111; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler E, 2015, NEUROPSYCHOL REV, V25, P224, DOI 10.1007/s11065-015-9290-0; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bigler ED, 2009, NEUROPSYCHOL REV, V19, P9, DOI 10.1007/s11065-009-9086-1; Binet, 1904, ANN PSYCHOL, V11, P191, DOI [10.3406/psy.1904.3675, DOI 10.3406/PSY.1904.3675]; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004; Catani M, 2012, CORTEX, V48, P1262, DOI 10.1016/j.cortex.2012.07.001; CHAPPELL PM, 1992, RADIOLOGY, V183, P719, DOI 10.1148/radiology.183.3.1584926; CIPOLOTTI L, 1995, J NEUROL NEUROSUR PS, V58, P655, DOI 10.1136/jnnp.58.6.655; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Cole MW, 2013, NAT NEUROSCI, V16, P1348, DOI 10.1038/nn.3470; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; Cromwell HC, 2011, NEUROSCI BIOBEHAV R, V35, P2026, DOI 10.1016/j.neubiorev.2011.02.008; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Currie S, 2016, POSTGRAD MED J, V92, P41, DOI 10.1136/postgradmedj-2014-133211; Das S, 2016, NEUROIMAGE, V124, P1188, DOI 10.1016/j.neuroimage.2015.08.076; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P338, DOI 10.1017/S1355617712001440; Dockree PM, 2011, INT J PSYCHOPHYSIOL, V82, P53, DOI 10.1016/j.ijpsycho.2011.01.004; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Filley CM, 2011, NEUROL CLIN, V29, P81, DOI 10.1016/j.ncl.2010.10.003; Filley CM, 2010, NEUROPSYCHOL REV, V20, P158, DOI 10.1007/s11065-010-9127-9; Finn ES, 2015, NAT NEUROSCI, V18, P1664, DOI 10.1038/nn.4135; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Gean A, 1994, IMAGING HEAD TRAUMA; Gean A. D., 2015, BRAIN INJURY APPL WA; Gozzi A, 2016, NEUROIMAGE, V127, P496, DOI 10.1016/j.neuroimage.2015.12.017; Hayes JP, 2016, J INT NEUROPSYCH SOC, V22, P120, DOI 10.1017/S1355617715000740; Insel TR, 2013, NEURON, V80, P561, DOI 10.1016/j.neuron.2013.09.041; Irimia A, 2015, NEUROPSYCH DIS TREAT, V11, DOI 10.2147/NDT.S79174; Jang SH, 2015, AM J PHYS MED REHAB, V94, P250, DOI 10.1097/PHM.0000000000000274; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jokinen H, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00455; Khan AR, 2015, NEUROBIOL AGING, V36, pS60, DOI 10.1016/j.neurobiolaging.2014.04.036; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kim J, 2014, J INT NEUROPSYCH SOC, V20, P887, DOI 10.1017/S1355617714000812; Kloppel S, 2012, NEUROIMAGE, V61, P457, DOI 10.1016/j.neuroimage.2011.11.002; Koerte I.K., 2016, TRANSLATIONAL RES TR; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; Kuceyeski A, 2015, HUM BRAIN MAPP, V36, P2147, DOI 10.1002/hbm.22761; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; Lisman J, 2015, NEURON, V86, P864, DOI 10.1016/j.neuron.2015.03.032; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; Masel BE, 2015, J NEUROTRAUM, V32, P1833, DOI 10.1089/neu.2015.29004.bm; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Maxwell W.L., 2015, BRAIN NEUROTRAUMA MO; McAndrews MP, 2014, NEUROIMAG CLIN N AM, V24, P585, DOI 10.1016/j.nic.2014.07.008; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Mirzaalian H, 2016, NEUROIMAGE, V135, P311, DOI 10.1016/j.neuroimage.2016.04.041; Mitra J, 2016, NEUROIMAGE, V129, P247, DOI 10.1016/j.neuroimage.2016.01.056; Nave KA, 2010, NAT REV NEUROSCI, V11, P275, DOI 10.1038/nrn2797; Nilsson J, 2014, J INT NEUROPSYCH SOC, V20, P262, DOI 10.1017/S1355617713001458; Olesen J, 2003, EUR J NEUROL, V10, P471, DOI 10.1046/j.1468-1331.2003.00682.x; Parsons TD, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00660; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Ross L, 1990, Arch Clin Neuropsychol, V5, P273, DOI 10.1016/0887-6177(90)90026-L; Ross L K, 1990, Arch Clin Neuropsychol, V5, P347, DOI 10.1016/0887-6177(90)90014-G; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; Schrag M, 2010, ACTA NEUROPATHOL, V119, P291, DOI 10.1007/s00401-009-0615-z; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smitherman E, 2016, J NEUROTRAUM, V33, P35, DOI 10.1089/neu.2014.3801; Sorg C, 2015, CLIN NEURORADIOL, V25, P177, DOI 10.1007/s00062-015-0438-3; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Sullivan E, 2015, NEUROPSYCHOL REV, V25, P221, DOI 10.1007/s11065-015-9296-7; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Sundman M, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00334; Toga AW, 2015, J AM MED INFORM ASSN, V22, P1126, DOI 10.1093/jamia/ocv077; Tracy JI, 2015, CURR OPIN NEUROL, V28, P158, DOI 10.1097/WCO.0000000000000178; Tustison NJ, 2014, NEUROIMAGE, V99, P166, DOI 10.1016/j.neuroimage.2014.05.044; Ueda Y, 2016, MED BIOL ENG COMPUT, V54, P1341, DOI 10.1007/s11517-015-1380-x; van der Helm PA, 2012, COGN PROCESS, V13, P13, DOI 10.1007/s10339-011-0425-9; Vodovotz Y., 2015, TRANSLATIONAL SYSTEM; Wilde E. A., BRAIN INJ IN PRESS; Wilde EA, 2015, BRAIN IMAGING BEHAV, V9, P367, DOI 10.1007/s11682-015-9444-y; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Wu MJ, 2017, NEUROIMAGE, V145, P254, DOI 10.1016/j.neuroimage.2016.02.016; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531; Yu C, 2015, BRAIN NEUROTRAUMA MO; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhao W, 2016, J NEUROTRAUM, V33, P1834, DOI 10.1089/neu.2015.4239	102	28	28	0	25	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5137		FRONT SYST NEUROSCI	Front. Syst. Neurosci.	AUG 9	2016	10								55	10.3389/fnsys.2016.00055			23	Neurosciences	Neurosciences & Neurology	DT0OW	WOS:000381183900001	27555810	DOAJ Gold, Green Published			2021-06-18	
J	Gellatly, R; Beck, AT				Gellatly, Resham; Beck, Aaron T.			Catastrophic Thinking: A Transdiagnostic Process Across Psychiatric Disorders	COGNITIVE THERAPY AND RESEARCH			English	Article						Catastrophic belief; Risk prediction; Transdiagnostic; Mediation; Intervention	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; THOUGHT-ACTION FUSION; LOW-BACK-PAIN; COGNITIVE EMOTION REGULATION; FEAR-AVOIDANCE BELIEFS; HEALTH ANXIETY; SOCIAL PHOBIA; RISK-FACTOR; POSTCONCUSSIVE SYMPTOMS	Since the description of catastrophizing by Ellis (Reason and emotion in psychotherapy. Lyle Stuart, Oxford, 1962) as a general factor in psychopathology, numerous studies have explored this construct and its association with many common disorders. This paper investigates the role of catastrophic thinking across psychiatric disorders. We conducted a comprehensive review of the literature on the role of catastrophic beliefs as a predictor and correlate of psychopathological disorders including panic, phobia, health anxiety, obsessive-compulsive disorder, posttraumatic stress disorder, pain, and traumatic brain injury. The literature suggests that catastrophic thinking has been demonstrated to play a role in a wide variety of disorders and has been a focal point for prevention and psychotherapeutic intervention. While the process of catastrophic thinking is transdiagnostic, content is unique for each disorder. We propose a model for the catastrophic cycle and discuss the utility of including catastrophic beliefs in an alternative diagnostic scheme based on cognitive theory. We offer recommendations for prevention and psychotherapeutic interventions that have targeted catastrophic thinking and led to improvement in each particular disorder. We conclude with recommendations for further research on the role of mediation, as well further investigation of disorders such as psychosis and irritable bowel syndrome, which emerging evidence suggests may be related to catastrophic beliefs.	[Gellatly, Resham; Beck, Aaron T.] Univ Penn, Aaron T Beck Psychopathol Res Ctr, Perelman Sch Med, 3535 Market St,Room 2032, Philadelphia, PA 19104 USA	Gellatly, R (corresponding author), Univ Penn, Aaron T Beck Psychopathol Res Ctr, Perelman Sch Med, 3535 Market St,Room 2032, Philadelphia, PA 19104 USA.	resham.gellatly@gmail.com					Amir N, 1998, J ABNORM PSYCHOL, V107, P285, DOI 10.1037/0021-843X.107.2.285; Austin DW, 2001, BEHAV RES THER, V39, P1277, DOI 10.1016/S0005-7967(00)00095-4; Beck A., 1979, COGNITIVE THERAPY EM; Beck A. T., 1986, ANXIETY DISORDERS PS, P115; Beck A. T., 1984, FDN COGNITIVE THERAP, P155, DOI DOI 10.1007/978-1-4613-2641-0_7; Beck A. T., 1999, PRISONERS HATE COGNI; BECK AT, 1964, ARCH GEN PSYCHIAT, V10, P561; BECK AT, 1963, ARCH GEN PSYCHIAT, V9, P324; Beck AT, 1997, BEHAV RES THER, V35, P49, DOI 10.1016/S0005-7967(96)00069-1; BECK AT, 1970, J NERV MENT DIS, V150, P3, DOI 10.1097/00005053-197001000-00002; Beck AT, 1988, PANIC PSYCHOL PERSPE, P91; Beck AT, 1985, ANXIETY DISORDERS PH; BELFER PL, 1992, J ANXIETY DISORD, V6, P133, DOI 10.1016/0887-6185(92)90012-V; Berle D, 2005, CLIN PSYCHOL REV, V25, P263, DOI 10.1016/j.cpr.2004.12.001; Berman NC, 2012, BEHAV RES THER, V50, P761, DOI 10.1016/j.brat.2012.09.002; Berman NC, 2011, BEHAV RES THER, V49, P695, DOI 10.1016/j.brat.2011.07.010; Bryant RA, 2005, PSYCHOL SCI, V16, P749, DOI 10.1111/j.1467-9280.2005.01608.x; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Bryant RA, 2007, J CONSULT CLIN PSYCH, V75, P812, DOI 10.1037/0022-006X.75.5.812; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Buchbinder R, 2001, BRIT MED J, V322, P1516, DOI 10.1136/bmj.322.7301.1516; Buer N, 2002, PAIN, V99, P485, DOI 10.1016/S0304-3959(02)00265-8; Calkins AW, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0357-4; Clark D.A., 2011, COGNITIVE THERAPY AN; Clark DM, 2002, BIOL PSYCHIAT, V51, P92, DOI 10.1016/S0006-3223(01)01296-3; CLARK DM, 1986, BEHAV RES THER, V24, P461, DOI 10.1016/0005-7967(86)90011-2; CLARK DM, 1988, HDB ANXIETY DISORDER, P362; CLARK DM, 1988, PANIC PSYCHOL PERSPE, P71; Clohessy S, 1999, BRIT J CLIN PSYCHOL, V38, P251, DOI 10.1348/014466599162836; Craske MG, 2014, BEHAV RES THER, V58, P10, DOI 10.1016/j.brat.2014.04.006; Day S, 2004, MEMORY, V12, P416, DOI 10.1080/09658210444000034; Drossman D. A., 1999, AM J MED, V107, P41, DOI DOI 10.1016/S0002-9343(99)00081-9; Dunmore E, 1999, BEHAV RES THER, V37, P809, DOI 10.1016/S0005-7967(98)00181-8; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Ehlers A, 1998, J TRAUMA STRESS, V11, P457, DOI 10.1023/A:1024448511504; Ellis A., 1962, REASON EMOTION PSYCH; Ellis A., 1975, NEW GUIDE RATIONAL L; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Garnefski N, 2001, PERS INDIV DIFFER, V30, P1311, DOI 10.1016/S0191-8869(00)00113-6; Geisser ME, 1999, PAIN FORUM, V8, P161, DOI 10.1016/S1082-3174(99)70001-2; Geisser ME, 1998, J OCCUP REHABIL, V8, P73, DOI 10.1023/A:1023060616201; GOLDSTEIN AJ, 1978, BEHAV THER, V9, P47, DOI 10.1016/S0005-7894(78)80053-7; Granot M, 2005, CLIN J PAIN, V21, P439, DOI 10.1097/01.ajp.0000135236.12705.2d; Greenberg R. L., 1988, COGNITIVE THERAPY CL, P25; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Hadjistavropoulos HD, 1998, BEHAV RES THER, V36, P149, DOI 10.1016/S0005-7967(98)00014-X; Haenen MA, 2000, BEHAV RES THER, V38, P819, DOI 10.1016/S0005-7967(99)00128-X; Harms P.D., 2013, COMPREHENSIVE SOLDIE; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; HARVEY JM, 1993, COGNITIVE THER RES, V17, P235, DOI 10.1007/BF01172948; Hofmann SG, 2005, BEHAV RES THER, V43, P885, DOI 10.1016/j.brat.2004.07.002; HOFMANN SG, 2002, ANXIETY ITS DISORDER, P454; Hofmann SG, 2014, BEHAV THER, V45, P576, DOI 10.1016/j.beth.2014.03.001; Hofmann SG, 2013, BEHAV THER, V44, P199, DOI 10.1016/j.beth.2009.01.007; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOGG JA, 1986, J COLL STUDENT DEV, V27, P349; Hunt MG, 2009, J COGN PSYCHOTHER, V23, P160, DOI 10.1891/0889-8391.23.2.160; Hunt MG, 2014, COGNITIVE THER RES, V38, P472, DOI 10.1007/s10608-014-9607-y; INGRAM RE, 1987, COGNITIVE THER RES, V11, P523, DOI 10.1007/BF01183856; Iversen A, 2007, CLIN PSYCHOL REV, V27, P842, DOI 10.1016/j.cpr.2007.07.006; KHAWAJA NG, 1992, J ANXIETY DISORD, V6, P305, DOI 10.1016/0887-6185(92)90002-O; Kraemer HC, 2001, AM J PSYCHIAT, V158, P848, DOI 10.1176/appi.ajp.158.6.848; MACLEOD C, 1986, J ABNORM PSYCHOL, V95, P15, DOI 10.1037/0021-843X.95.1.15; Marcus DK, 2007, CLIN PSYCHOL REV, V27, P127, DOI 10.1016/j.cpr.2006.09.003; Marcus DK, 2003, J PSYCHOSOM RES, V54, P543, DOI 10.1016/S0022-3999(02)00526-3; Martin RC, 2005, PERS INDIV DIFFER, V39, P1249, DOI 10.1016/j.paid.2005.06.004; MCCRACKEN LM, 1993, CLIN J PAIN, V9, P253, DOI 10.1097/00002508-199312000-00006; McLaughlin KA, 2014, DEPRESS ANXIETY, V31, P834, DOI 10.1002/da.22284; MCNALLY RJ, 1990, PSYCHOL BULL, V108, P403, DOI 10.1037/0033-2909.108.3.403; Merckelbach H, 1996, CLIN PSYCHOL REV, V16, P337, DOI 10.1016/0272-7358(96)00014-1; Muse K, 2010, BEHAV RES THER, V48, P792, DOI 10.1016/j.brat.2010.05.008; Ottaviani R, 1987, J ANXIETY DIORD, V1, P15, DOI DOI 10.1016/0887-6185; Pavlin DJ, 2005, CLIN J PAIN, V21, P83, DOI 10.1097/00002508-200501000-00010; Rachman S, 1998, BEHAV RES THER, V36, P385, DOI 10.1016/S0005-7967(97)10041-9; Rachman S, 2012, BEHAV RES THER, V50, P502, DOI 10.1016/j.brat.2012.05.001; Rachman S, 1997, BEHAV RES THER, V35, P793, DOI 10.1016/S0005-7967(97)00040-5; Rapee RM, 1997, BEHAV RES THER, V35, P741, DOI 10.1016/S0005-7967(97)00022-3; Reivich KJ, 2011, AM PSYCHOL, V66, P25, DOI 10.1037/a0021897; Richards JC, 2001, COGNITIVE THER RES, V25, P235, DOI 10.1023/A:1010783427196; Rief W, 1998, J ABNORM PSYCHOL, V107, P587, DOI 10.1037/0021-843X.107.4.587; Rief W, 2015, CURR OPIN PSYCHIATR, V28, P378, DOI 10.1097/YCO.0000000000000184; SALKOVSKIS PM, 1986, BEHAV RES THER, V24, P597, DOI 10.1016/0005-7967(86)90041-0; SALKOVSKIS PM, 1985, BEHAV RES THER, V23, P571, DOI 10.1016/0005-7967(85)90105-6; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schneier FR., 1995, SOCIAL PHOBIA DIAGNO, P69, DOI DOI 10.1017/S1352465808004487; Shafran R, 1996, J ANXIETY DISORD, V10, P379, DOI 10.1016/0887-6185(96)00018-7; Shah A., 2014, THINK YOU ACT NEW AP; SHERMAN SJ, 1985, PERS SOC PSYCHOL B, V11, P118, DOI 10.1177/0146167285111011; Sokol-Kessler L., 1987, AM PSYCH ASS CHIC IL; Spevak C, 2011, CURR PAIN HEADACHE R, V15, P124, DOI 10.1007/s11916-011-0173-7; Spinhoven P, 2004, EUR J PAIN, V8, P211, DOI 10.1016/j.ejpain.2003.08.003; Startup H, 2007, BEHAV RES THER, V45, P523, DOI 10.1016/j.brat.2006.04.006; Steil R, 2000, BEHAV RES THER, V38, P537, DOI 10.1016/S0005-7967(99)00069-8; Stopa L, 2000, BEHAV RES THER, V38, P273, DOI 10.1016/S0005-7967(99)00043-1; Sullivan MJL, 1998, PAIN, V77, P253, DOI 10.1016/S0304-3959(98)00097-9; Sullivan MJL, 2001, CLIN J PAIN, V17, P52, DOI 10.1097/00002508-200103000-00008; Susan H, 2002, AM J EPIDEMIOL, V156, P1028, DOI 10.1093/aje/kwf136; Swartz JR, 2015, NEURON, V85, P505, DOI 10.1016/j.neuron.2014.12.055; Tang NKY, 2007, BEHAV RES THER, V45, P2821, DOI 10.1016/j.brat.2007.05.004; Thompson-Hollands J, 2013, J NERV MENT DIS, V201, P407, DOI 10.1097/NMD.0b013e31828e102c; Turner JA, 2007, PAIN, V127, P276, DOI 10.1016/j.pain.2006.09.005; VASEY MW, 1992, COGNITIVE THER RES, V16, P505, DOI 10.1007/BF01175138; VLAEYEN JWS, 1995, PAIN, V62, P363, DOI 10.1016/0304-3959(94)00279-N; Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0; Wells A., 1993, BEHAV COGN PSYCHOTH, V21, P265, DOI [https://doi.org/10.1017/S1352465800010511, DOI 10.1017/S1352465800010511]; Winterowd C., 2003, COGNITIVE THERAPY CH; Woby SR, 2004, BEHAV RES THER, V42, P761, DOI 10.1016/S0005-7967(03)00195-5; ZWEMER WA, 1984, J COUNS PSYCHOL, V31, P391	112	28	28	0	26	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0147-5916	1573-2819		COGNITIVE THER RES	Cogn. Ther. Res.	AUG	2016	40	4					441	452		10.1007/s10608-016-9763-3			12	Psychology, Clinical	Psychology	DR7OM	WOS:000380089600001					2021-06-18	
J	Hanninen, T; Tuominen, M; Parkkari, J; Vartiainen, M; Ohman, J; Iverson, GL; Luoto, TM				Hanninen, Timo; Tuominen, Markku; Parkkari, Jari; Vartiainen, Matti; Ohman, Juha; Iverson, Grant L.; Luoto, Teemu M.			Sport concussion assessment tool-3rd edition - normative reference values for professional ice hockey players	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Brain concussion; Head injuries; Baseline survey; Clinical assessment	BASE-LINE VALUES; HIGH-SCHOOL; SCAT2; STATEMENT; SIDELINE; HISTORY; MENS	Objectives: To determine normative reference values for the Sport Concussion Assessment Tool-3rd Edition (SCAT3) using a large sample of professional male ice hockey players. Design: A descriptive cross-sectional study. Methods: Preseason baseline testing was administered individually to 304 professional male ice hockey players. Results: The participants were aged between 16 and 40 with a mean (M) age of 25.3 years. Over 60% of the athletes reported previous concussion, almost 20% had been hospitalized or medically imaged following a head trauma. Of the players, 48% reported no symptoms. The symptom score median (Md) was 1.0 (M=1.5) and severity median was 1.0 (M=2.3). The median of the SAC score was 27.0 (M= 27.0). The median of the M-BESS was 1.0 (M=2.0). The Tandem gait median was 10.9 s (M=10.8 s). The most common baseline symptom was neck pain (24%). Delayed recall was the most difficult component of the SAC (Md=4); only 24% performed it flawlessly. All athletes completed the double-leg stance of the M-BESS without errors, but there was performance variability in the tandem stance (Md=0, M=0.6, range = 0-10) and single-leg stance (Md=1.0, M = 1.4, range = 0-10). Conclusions: Representative normative reference values for the SCAT3 among professional male ice hockey players are provided. (C) 2015 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Hanninen, Timo; Parkkari, Jari] UKK Inst Hlth Promot Res, Tampere Res Ctr Sports Med, Tampere, Finland; [Tuominen, Markku] Int Ice Hockey Federat IIHF, Med Comm, Zurich, Switzerland; [Tuominen, Markku] Liiga Finnish Ice Hockey Assoc, Liiga, Finland; [Tuominen, Markku] Medisport Ltd, Tampere, Finland; [Vartiainen, Matti] Univ Helsinki, Div Cognit Psychol & Neuropsychol, Inst Behav Sci, Helsinki, Finland; [Ohman, Juha; Luoto, Teemu M.] Tampere Univ Hosp, Dept Neurosurg, Tampere, Finland; [Iverson, Grant L.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Children Sport Concuss Program, Boston, MA 02114 USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA	Hanninen, T (corresponding author), UKK Inst Hlth Promot Res, Tampere Res Ctr Sports Med, Tampere, Finland.	timo.hanninen@fimnet.fi	Luoto, Teemu/W-6468-2018	Luoto, Teemu/0000-0002-7329-3284; Ohman, Juha/0000-0002-6592-1367; Iverson, Grant/0000-0001-7348-9570	Finnish Ministry of Education and Culture and Finnish Hockey League; Finnish Hockey League; Finnish Ice Hockey Association (FIHA); Finnish Hockey Player Association (FHPA)	This study was financially supported by the Finnish Ministry of Education and Culture and Finnish Hockey League. We greatly appreciate the cooperation of all the team physicians and physiotherapists (Davies Paul, Huttunen Jussi, Hyde Jacob, Hamalainen Jari, Ikonen Juhani, Isotupa Juha, Kuosmanen Mika, Kuutamoinen Ville, Lahtinen Teppo, Mali Hero, Piekkola Ville, Pihkoluoma Tomi, Pohjonen Veli-Matti, Puustinen Vesa, Tikanto Jukka, Toivanen Tero, Tahkapaa Mikko, Uotila Toni, Vahtera Ville, Virtala Mika, Vaisanen Jonne) who volunteered their time to collect the data for this project. We sincerely thank Mr. Kari Tokola, M.Sc., for the statistical advice, Ms. Birgitta Jarvinen, M.Sc. for help in conducting literature searches and research assistant Anne Simi for her contribution in data collection. We would like to thank the Finnish Hockey League, Finnish Ice Hockey Association (FIHA) and Finnish Hockey Player Association (FHPA) for all their support. This study was partly presented at the Ice Hockey Summit II-Action on Concussion in Rochester, MN, USA, in October 2013.	Agel J, 2010, CAN J SURG, V53, P319; Concussion in Sport Group, 2013, BRIT J SPORT MED, V47, P259; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Glaviano NR, 2015, CLIN J SPORT MED, V25, P373, DOI 10.1097/JSM.0000000000000154; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson GL, 2013, BRAIN INJURY, V27, P596, DOI 10.3109/02699052.2013.772237; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Luoto TM, 2014, J NEUROTRAUM, V31, P728, DOI 10.1089/neu.2013.3174; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Ruhe A, 2014, BRIT J SPORT MED, V48, P102, DOI 10.1136/bjsports-2012-091609; Schneider KJ, 2013, CLIN J SPORT MED, V23, P267, DOI 10.1097/JSM.0b013e318281f09f; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Schneiders AG, 2010, J SCI MED SPORT, V13, P196, DOI 10.1016/j.jsams.2009.05.004; Swaine BR, 2005, ARCH PHYS MED REHAB, V86, P1665, DOI 10.1016/j.apmr.2004.11.021; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; Zimmer A, 2013, J ATHL TRAINING, V48, P659, DOI 10.4085/1062-6050-48.5.06	29	28	28	0	15	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	AUG	2016	19	8					636	641		10.1016/j.jsams.2015.08.005			6	Sport Sciences	Sport Sciences	DQ7FI	WOS:000379371900007	26383876				2021-06-18	
J	Riesberg, LA; Weed, SA; McDonald, TL; Eckerson, JM; Drescher, KM				Riesberg, Lisa A.; Weed, Stephanie A.; McDonald, Thomas L.; Eckerson, Joan M.; Drescher, Kristen M.			Beyond muscles: The untapped potential of creatine	INTERNATIONAL IMMUNOPHARMACOLOGY			English	Article						Creatine; Immune response; Immunomodulation; Neuroprotection	MITOCHONDRIAL PERMEABILITY TRANSITION; TRAUMATIC BRAIN-INJURY; INTERLEUKIN-1-BETA CONVERTING-ENZYME; ALLERGIC LUNG INFLAMMATION; TRANSGENIC ANIMAL-MODEL; CYTOCHROME-C RELEASE; NEURONAL CELL-DEATH; L-DOPA TREATMENT; NF-KAPPA-B; HUNTINGTONS-DISEASE	Creatine is widely used by both elite and recreational athletes as an ergogenic aid to enhance anaerobic exercise performance. Older individuals also use creatine to prevent sarcopenia and, accordingly, may have therapeutic benefits for muscle wasting diseases. Although the effect of creatine on the musculoskeletal system has been extensively studied, less attention has been paid to its potential effects on other physiological systems. Because there is a significant pool of creatine in the brain, the utility of creatine supplementation has been examined in vitro as well as in vivo in both animal models of neurological disorders and in humans. While the data are preliminary, there is evidence to suggest that individuals with certain neurological conditions may benefit from exogenous creatine supplementation if treatment protocols can be optimized. A small number of studies that have examined the impact of creatine on the immune system have shown an alteration in soluble mediator production and the expression of molecules involved in recognizing infections, specifically toll-like receptors. Future investigations evaluating the total impact of creatine supplementation are required to better understand the benefits and risks of creatine use, particularly since there is increasing evidence that creatine may have a regulatory impact on the immune system. (C) 2016 Elsevier B.V. All rights reserved.	[Riesberg, Lisa A.; Weed, Stephanie A.; Drescher, Kristen M.] Creighton Univ, Dept Med Microbiol & Immunol, 2500 Calif Plaza, Omaha, NE 68178 USA; [McDonald, Thomas L.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, 986495 Nebraska Med Ctr, Omaha, NE 68198 USA; [Eckerson, Joan M.] Creighton Univ, Dept Exercise Sci & Prehlth Profess, 2500 Calif Plaza, Omaha, NE 68178 USA	Drescher, KM (corresponding author), Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, 2500 Calif Plaza,Criss 2,Room 424, Omaha, NE 68178 USA.	kristendrescher@creighton.edu			National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1 C06 RR17417-01]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR017417] Funding Source: NIH RePORTER	This work was performed in a facility supported by Grant Number 1 C06 RR17417-01 from the National Center for Research Resources (KMD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.	Alam Q., 2015, CURR PHARM DES; Andersson M, 1999, NEUROBIOL DIS, V6, P461, DOI 10.1006/nbdi.1999.0259; Andreassen OA, 2001, NEUROBIOL DIS, V8, P479, DOI 10.1006/nbdi.2001.0406; Andreassen OA, 2001, J NEUROCHEM, V77, P383, DOI 10.1046/j.1471-4159.2001.00188.x; Andres RH, 2005, CELL TRANSPLANT, V14, P537, DOI 10.3727/000000005783982756; Andres RH, 2005, NEUROSCIENCE, V133, P701, DOI 10.1016/j.neuroscience.2005.03.004; Andres RH, 2008, BRAIN RES BULL, V76, P329, DOI 10.1016/j.brainresbull.2008.02.035; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; ARBORELIUS M, 1984, EUR J RESPIR DIS, V65, P25; avada B.S., 2015, INFLAMM RES; Azeredo R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139967; BALSOM PD, 1994, SPORTS MED, V18, P268, DOI 10.2165/00007256-199418040-00005; Bamberger M., 1998, SPORTS ILLUSTRATED, V88, P58; Bassit RA, 2008, AMINO ACIDS, V35, P425, DOI 10.1007/s00726-007-0582-4; Beal MF, 2011, AMINO ACIDS, V40, P1305, DOI 10.1007/s00726-011-0851-0; Bemben MG, 2010, J NUTR HEALTH AGING, V14, P155, DOI 10.1007/s12603-009-0124-8; Bemben MG, 2005, SPORTS MED, V35, P107, DOI 10.2165/00007256-200535020-00002; Bender A, 2006, NEUROLOGY, V67, P1262, DOI 10.1212/01.wnl.0000238518.34389.12; Bender A, 2005, J NEUROL, V252, P36, DOI 10.1007/s00415-005-0595-4; Bender A, 2008, NUTR RES, V28, P172, DOI 10.1016/j.nutres.2008.01.001; Beraud D., 2012, PARKINSONISM RELAT D, V18S1, pS17; Berjaoui S, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/573784; Beutler BA, 2009, BLOOD, V113, P1399, DOI 10.1182/blood-2008-07-019307; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Bian MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039953; Borthakur A, 2012, BBA-MOL BASIS DIS, V1822, P1300, DOI 10.1016/j.bbadis.2012.05.001; Bosco C, 1997, INT J SPORTS MED, V18, P369, DOI 10.1055/s-2007-972648; Braak H., 2002, J NEUROL, V249, pIII/1, DOI DOI 10.1007/S00415-002-1301-4; Braissant O, 2001, MOL BRAIN RES, V86, P193, DOI 10.1016/S0169-328X(00)00269-2; Brasier AR, 2006, CARDIOVASC TOXICOL, V6, P111, DOI 10.1385/CT:6:2:111; Brustovetsky N, 2003, J NEUROSCI, V23, P4858; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Buki A, 2000, J NEUROSCI, V20, P2825; Burke DG, 2008, INT J SPORT NUTR EXE, V18, P389, DOI 10.1123/ijsnem.18.4.389; Burns RD, 2004, J AM DIET ASSOC, V104, P246, DOI 10.1016/j.jada.2003.11.013; Calfee R, 2006, PEDIATRICS, V117, pE577, DOI 10.1542/peds.2005-1429; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Cenci MA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00242; Choudhary M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/474616; Chu WM, 2013, CANCER LETT, V328, P222, DOI 10.1016/j.canlet.2012.10.014; Chung YC, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/370526; Dawson B, 1995, Aust J Sci Med Sport, V27, P56; Dean ED, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039227; Dedeoglu A, 2003, J NEUROCHEM, V85, P1359, DOI 10.1046/j.1471-4159.2003.01706.x; Degraaf AJ, 2014, AM J RESP CELL MOL, V51, P242, DOI 10.1165/rcmb.2013-0495OC; DELANGHE J, 1989, CLIN CHEM, V35, P1802; Demant TW, 1999, SPORTS MED, V28, P49, DOI 10.2165/00007256-199928010-00005; DHAWAN BN, 1973, BRIT J PHARMACOL, V49, P64, DOI 10.1111/j.1476-5381.1973.tb08268.x; Dolder M, 2003, J BIOL CHEM, V278, P17760, DOI 10.1074/jbc.M208705200; Droge W, 2002, PHYSIOL REV, V82, P47; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Eddouks M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/142087; Elm JJ, 2012, MOVEMENT DISORD, V27, P1513, DOI 10.1002/mds.25175; Fanelli A, 2007, MED SCI SPORT EXER, V39, P1474, DOI 10.1249/mss.0b013e3180d099ad; Ferger B, 1999, J NEUROCHEM, V73, P1329, DOI 10.1046/j.1471-4159.1999.0731329.x; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; Ferreira SC, 2010, INT J SPORTS MED, V31, P906, DOI 10.1055/s-0030-1267160; Field ML, 1996, CARDIOVASC RES, V31, P174, DOI 10.1016/S0008-6363(95)00225-1; Fifel K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086240; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; GAI WP, 1994, J NEUROL NEUROSUR PS, V57, P1039, DOI 10.1136/jnnp.57.9.1039; Garcia-Delgado M, 2001, J AM SOC NEPHROL, V12, P1819, DOI 10.1681/ASN.V1291819; Gastin PB, 2001, SPORTS MED, V31, P725, DOI 10.2165/00007256-200131100-00003; Gerecke KM, 2010, BRAIN RES, V1341, P72, DOI 10.1016/j.brainres.2010.01.053; Gerlach M, 2011, J NEURAL TRANSM, V118, P1659, DOI 10.1007/s00702-011-0728-0; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Goodall Emily F., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406010854; GREENE JG, 1993, J NEUROCHEM, V61, P1151, DOI 10.1111/j.1471-4159.1993.tb03634.x; Greenhaff PL, 1997, J NUTR BIOCHEM, V8, P610, DOI 10.1016/S0955-2863(97)00116-2; Grindstaff PD, 1997, INT J SPORT NUTR, V7, P330, DOI 10.1123/ijsn.7.4.330; Groeneveld GJ, 2003, ANN NEUROL, V53, P437, DOI 10.1002/ana.10554; Guan J, 2000, BRAIN RES, V859, P286, DOI 10.1016/S0006-8993(00)01988-0; Guay J, 2004, J BIOL CHEM, V279, P24866, DOI 10.1074/jbc.M403106200; Gufford Brandon T., 2013, Journal of Dietary Supplements, V10, P241, DOI 10.3109/19390211.2013.822453; Gufford Brandon T., 2010, Journal of Dietary Supplements, V7, P240, DOI 10.3109/19390211.2010.491507; Guidi C, 2008, BBA-GEN SUBJECTS, V1780, P16, DOI 10.1016/j.bbagen.2007.09.018; GUIMBAL C, 1993, J BIOL CHEM, V268, P8418; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; HARRIS RC, 1992, CLIN SCI, V83, P367, DOI 10.1042/cs0830367; Helenius I, 2000, J ALLERGY CLIN IMMUN, V106, P444, DOI 10.1067/mai.2000.107749; HENRIKSEN JM, 1983, ACTA PAEDIATR SCAND, V72, P31, DOI 10.1111/j.1651-2227.1983.tb09659.x; Hersch S. M., 1997, MOVEMENT DISORDERS N, P503; Hultman E, 1996, J APPL PHYSIOL, V81, P232; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Ikonomidou C, 1996, CRIT REV NEUROBIOL, V10, P239; Jing X., 2015, NEUROCHEM RES; Juhn MS, 1998, CLIN J SPORT MED, V8, P298, DOI 10.1097/00042752-199810000-00007; Kadoguchi N, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-79; Kaithwas Gaurav, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P185, DOI 10.1016/S2221-1691(12)60039-2; Kaithwas Gaurav, 2010, Inflammopharmacology, V18, P127, DOI 10.1007/s10787-010-0033-9; Karimian J, 2011, J RES MED SCI, V16, P1347; Khalaf H, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-26; KHANNA NK, 1978, ARCH INT PHARMACOD T, V231, P340; Kieburtz K, 2008, CLIN NEUROPHARMACOL, V31, P141, DOI 10.1097/WNF.0b013e3181342f32; Kieburtz K, 2015, JAMA-J AM MED ASSOC, V313, P584, DOI 10.1001/jama.2015.120; Kim SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027566; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Klivenyi P, 2003, J MOL NEUROSCI, V21, P191, DOI 10.1385/JMN:21:3:191; Kochanek Kenneth D, 2014, NCHS Data Brief, P1; Koenig KA, 2014, BRAIN CONNECT, V4, P535, DOI 10.1089/brain.2014.0271; Kowal SL, 2013, MOVEMENT DISORD, V28, P311, DOI 10.1002/mds.25292; Kreider R., 1998, THE J, V1, P7; Kreider R.B., 1999, ENERGY YEILDING MACR, P213; Kreider RB, 2003, MOL CELL BIOCHEM, V244, P89, DOI 10.1023/A:1022465203458; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; Lawler JM, 2002, BIOCHEM BIOPH RES CO, V290, P47, DOI 10.1006/bbrc.2001.6164; Le Floc'h N, 2004, LIVEST PROD SCI, V87, P37, DOI 10.1016/j.livprodsci.2003.09.005; LEES P, 1985, EQUINE VET J, V17, P83, DOI 10.1111/j.2042-3306.1985.tb02056.x; Lefavi R. G., 1998, J STRENGTH COND RES, V12, P275; Leland KM, 2011, INT IMMUNOPHARMACOL, V11, P1341, DOI 10.1016/j.intimp.2011.04.018; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LI TM, 1988, J NEUROL NEUROSUR PS, V51, P778, DOI 10.1136/jnnp.51.6.778; Lyck R, 2015, CURR OPIN HEMATOL, V22, P53, DOI 10.1097/MOH.0000000000000103; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Macedo S B, 2004, Homeopathy, V93, P84, DOI 10.1016/j.homp.2004.02.006; MACKAY RJ, 1983, AM J VET RES, V44, P774; MacKenzie JR, 2001, J IMMUNOL, V167, P3146, DOI 10.4049/jimmunol.167.6.3146; MADAN B R, 1979, Indian Journal of Physiology and Pharmacology, V23, P1; Madan B.R., 1976, IND J PHYSL PHARM, V8, P227; Mandrioli J, 2003, NEUROLOGY, V60, P683, DOI 10.1212/01.WNL.0000048208.54755.78; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martin LJ, 2014, NEUROBIOL AGING, V35, P1132, DOI 10.1016/j.neurobiolaging.2013.11.008; Martin LJ, 2011, J BIOENERG BIOMEMBR, V43, P569, DOI 10.1007/s10863-011-9395-y; Martin LJ, 2009, EXP NEUROL, V218, P333, DOI 10.1016/j.expneurol.2009.02.015; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mason M A, 2001, Iowa Orthop J, V21, P43; Matsui JT, 2015, HUM BRAIN MAPP, V36, P3717, DOI 10.1002/hbm.22835; Matsumoto I, 1999, THORAX, V54, P196, DOI 10.1136/thx.54.3.196; Matthews RT, 1998, J NEUROSCI, V18, P156; Matthews RT, 1999, EXP NEUROL, V157, P142, DOI 10.1006/exnr.1999.7049; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; McCormack AL, 2008, J NEUROPATH EXP NEUR, V67, P793, DOI 10.1097/NEN.0b013e318180f0bd; McGuine TA, 2001, CLIN J SPORT MED, V11, P247, DOI 10.1097/00042752-200110000-00007; McGuine Timothy A, 2002, WMJ, V101, P25; McNair ND, 1999, NURS CLIN N AM, V34, P637; Metzl JD, 2001, PEDIATRICS, V108, P421, DOI 10.1542/peds.108.2.421; Mihic S, 2000, MED SCI SPORT EXER, V32, P291, DOI 10.1097/00005768-200002000-00007; MING L, 1995, J TOXICOL-CLIN TOXIC, V33, P363, DOI 10.3109/15563659509028924; Moldoveanu AI, 2001, SPORTS MED, V31, P115, DOI 10.2165/00007256-200131020-00004; Montal M, 1998, BBA-BIOENERGETICS, V1366, P113, DOI 10.1016/S0005-2728(98)00124-8; Mosley RL, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009381; MOUATTPRIGENT A, 1994, BRAIN RES, V668, P62, DOI 10.1016/0006-8993(94)90511-8; Nasrallah F, 2010, PEDIATR NEUROL, V42, P163, DOI 10.1016/j.pediatrneurol.2009.07.015; Necas J, 2013, VET MED-CZECH, V58, P187, DOI 10.17221/6758-VETMED; Neves M, 2011, APPL PHYSIOL NUTR ME, V36, P419, DOI [10.1139/h11-014, 10.1139/H11-014]; NICKERSON BG, 1983, PEDIATRICS, V71, P147; Nomura A, 2003, BRIT J PHARMACOL, V139, P715, DOI 10.1038/sj.bjp.0705316; Nony PA, 1999, METAB BRAIN DIS, V14, P83, DOI 10.1023/A:1020753629477; Orsenigo MN, 2005, J MEMBRANE BIOL, V207, P183, DOI 10.1007/s00232-005-0813-0; Ostrowski K, 1999, J PHYSIOL-LONDON, V515, P287, DOI 10.1111/j.1469-7793.1999.287ad.x; Parashos SA, 2014, JAMA NEUROL, V71, P710, DOI 10.1001/jamaneurol.2014.391; Pavelko KD, 2003, J NEUROSCI, V23, P481; Pearlman JP, 2006, NUTR REV, V64, P80, DOI [10.1301/nmr.2006.feb.80-88, 10.1111/j.1753-4887.2006.tb00191.x]; Pedersen BK, 2000, BRIT J SPORT MED, V34, P246, DOI 10.1136/bjsm.34.4.246; Cunha MP, 2014, ASN NEURO, V6, DOI 10.1177/1759091414554945; Peral MJ, 2002, J PHYSIOL-LONDON, V545, P133, DOI 10.1113/jphysiol.2002.026377; Poortmans JR, 2000, SPORTS MED, V30, P155, DOI 10.2165/00007256-200030030-00002; Przedborski Serge, 2003, Curr Neurol Neurosci Rep, V3, P70, DOI 10.1007/s11910-003-0041-x; Quintanilla RA, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-45; Ram FS, 2005, COCHRANE DB SYST REV, V4; Ravina B, 2006, NEUROLOGY, V66, P664; Rawson ES, 2011, AMINO ACIDS, V40, P1349, DOI 10.1007/s00726-011-0855-9; Razonable RR, 2005, ANTIMICROB AGENTS CH, V49, P3546, DOI 10.1128/AAC.49.8.3546-3549.2005; ROSA MD, 1971, J PHARM PHARMACOL, V23, P297, DOI 10.1111/j.2042-7158.1971.tb08661.x; Rosas HD, 2014, NEUROLOGY, V82, P850, DOI 10.1212/WNL.0000000000000187; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rosenfeld J, 2008, AMYOTROPH LATERAL SC, V9, P266, DOI 10.1080/17482960802028890; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Ryu H, 2005, PHARMACOL THERAPEUT, V108, P193, DOI 10.1016/j.pharmthera.2005.04.008; Sakellaris G, 2006, J TRAUMA, V61, P322, DOI 10.1097/01.ta.0000230269.46108.d5; Sakellaris G, 2008, ACTA PAEDIATR, V97, P31, DOI 10.1111/j.1651-2227.2007.00529.x; SAKS VA, 1991, AM J PHYSIOL, V261, P30, DOI 10.1152/ajplung.1991.261.4.L30; Salama M, 2012, CNS NEUROL DISORD-DR, V11, P836, DOI 10.2174/1871527311201070836; Santos RVT, 2004, LIFE SCI, V75, P1917, DOI 10.1016/j.lfs.2003.11.036; SCHIATTI P, 1970, Bollettino Chimico Farmaceutico, V109, P33; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Schulze A, 2003, MOL CELL BIOCHEM, V244, P143, DOI 10.1023/A:1022443503883; Sestili P, 2006, FREE RADICAL BIO MED, V40, P837, DOI 10.1016/j.freeradbiomed.2005.10.035; Sestito S. E., 2015, PHARMACOL RES S, VS1043-6618, P30004; Sgambato-Faure V, 2005, J NEUROPATH EXP NEUR, V64, P936, DOI 10.1097/01.jnen.0000186922.42592.b7; Shefner JM, 2004, NEUROLOGY, V63, P1656, DOI 10.1212/01.WNL.0000142992.81995.F0; Shomrat A, 2000, EUR J APPL PHYSIOL, V82, P321, DOI 10.1007/s004210000222; Siddique T, 1996, CLIN NEUROSCI, V3, P338; Silva L.A., 2013, J SPORTS SCI, P1; Simon DK, 2015, CLIN NEUROPHARMACOL, V38, P163, DOI 10.1097/WNF.0000000000000102; Smith J, 2000, MAYO CLIN PROC, V75, P1257, DOI 10.4065/75.12.1257; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; Snow RJ, 2001, MOL CELL BIOCHEM, V224, P169, DOI 10.1023/A:1011908606819; Speer O, 2004, MOL CELL BIOCHEM, V256, P407, DOI 10.1023/B:MCBI.0000009886.98508.e7; Stackler-Ipsiroglu S., 2012, INBORN METABOLIC DIS, P240; Stavrovskaya IG, 2005, FREE RADICAL BIO MED, V38, P687, DOI 10.1016/j.freeradbiomed.2004.11.032; Stefanis L, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009399; Stefanova N, 2004, NEUROBIOL DIS, V15, P630, DOI 10.1016/j.nbd.2003.11.025; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; SZENTAGOTHAI K, 1987, PEDIATR PULM, V3, P166, DOI 10.1002/ppul.1950030310; Tabrez S, 2012, CNS NEUROL DISORD-DR, V11, P395, DOI 10.2174/187152712800792785; Tabrizi SJ, 2012, LANCET NEUROL, V11, P42, DOI 10.1016/S1474-4422(11)70263-0; Tabrizi SJ, 2003, NEUROLOGY, V61, P141, DOI 10.1212/01.WNL.0000070186.97463.A7; Taes YEC, 2008, NEPHROL DIAL TRANSPL, V23, P1330, DOI 10.1093/ndt/gfm793; Terjung RL, 2000, MED SCI SPORT EXER, V32, P706, DOI 10.1097/00005768-200003000-00024; Tian LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132064; Tibbs RE, 1998, ANAT REC, V253, P167; TILZ GP, 1993, IMMUNOBIOLOGY, V188, P194, DOI 10.1016/S0171-2985(11)80497-3; Valastro B, 2009, BEHAV BRAIN RES, V197, P90, DOI 10.1016/j.bbr.2008.08.004; Valayannopoulos V, 2012, J INHERIT METAB DIS, V35, P151, DOI 10.1007/s10545-011-9358-9; van der Brug MP, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8280; Veech RL, 2012, IUBMB LIFE, V64, P203, DOI 10.1002/iub.590; Verbessem P, 2003, NEUROLOGY, V61, P925, DOI 10.1212/01.WNL.0000090629.40891.4B; Vieira RP, 2009, INT J SPORTS MED, V30, P684, DOI 10.1055/s-0029-1224176; Vieira RP, 2007, AM J RESP CELL MOL, V37, P660, DOI 10.1165/rcmb.2007-0108OC; Vieira RP, 2007, AM J RESP CRIT CARE, V176, P871, DOI 10.1164/rccm.200610-1567OC; Volek J.S., 1996, J STRENGTH COND RES, V10, P200, DOI 10.1519/00124278-199608000-00014; Volek JS, 1999, MED SCI SPORT EXER, V31, P1147, DOI 10.1097/00005768-199908000-00011; Vuckovic MG, 2008, NEUROBIOL DIS, V32, P319, DOI 10.1016/j.nbd.2008.07.015; Walker J B, 1979, Adv Enzymol Relat Areas Mol Biol, V50, P177; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; Weiler JM, 2000, J ALLERGY CLIN IMMUN, V106, P267, DOI 10.1067/mai.2000.108605; Westin JE, 2001, EUR J NEUROSCI, V14, P1171, DOI 10.1046/j.0953-816x.2001.01743.x; White RJ, 1996, J NEUROSCI, V16, P5688; Williams JK, 2015, NEUROPSYCHOLOGY, V29, P255, DOI 10.1037/neu0000102; Worms PA, 2001, J NEUROL SCI, V191, P3, DOI 10.1016/S0022-510X(01)00630-X; Wyss M, 2000, PHYSIOL REV, V80, P1107; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xu Z, 2012, J INFLAMM-LOND, V9, DOI 10.1186/1476-9255-9-2; Yang LC, 2009, J NEUROCHEM, V109, P1427, DOI 10.1111/j.1471-4159.2009.06074.x; Yar RA, 2015, BRAIN RES, V1595, P92, DOI 10.1016/j.brainres.2014.11.017; Young L, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00089; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100; Zhu S, 2004, J NEUROSCI, V24, P5909, DOI 10.1523/JNEUROSCI.1278-04.2004	237	28	29	0	61	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1567-5769	1878-1705		INT IMMUNOPHARMACOL	Int. Immunopharmacol.	AUG	2016	37				SI		31	42		10.1016/j.intimp.2015.12.034			12	Immunology; Pharmacology & Pharmacy	Immunology; Pharmacology & Pharmacy	DQ3LE	WOS:000379103000006	26778152	Green Accepted			2021-06-18	
J	Ahn, SM; Kim, HN; Kim, YR; Choi, YW; Kim, CM; Shin, HK; Choi, BT				Ahn, Sung Min; Kim, Ha Neui; Kim, Yu Ri; Choi, Young Whan; Kim, Cheol Mm; Shin, Hwa Kyoung; Choi, Byung Tae			Emodin from Polygonum multiflorum ameliorates oxidative toxicity in HT22 cells and deficits in photothrombotic ischemia	JOURNAL OF ETHNOPHARMACOLOGY			English	Article						Emodin; Polygonum multiflorum; Neuroprotection; Oxidative toxicity; Ischemia	GLUTAMATE-INDUCED APOPTOSIS; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; IN-VITRO; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; NEURONAL CELLS; UP-REGULATION; HIPPOCAMPAL; ACTIVATION	Ethnopharmacological relevance: Polygonum multiflorum Thunb. has been used widely in East Asia in treatment of diseases associated with aging. Emodin, an active component from Polygonum multiflorum Thunb., provides benefits for brain disturbances induced by severe cerebral injury. Aim of the study: We investigated the neuroprotective effect of emodin from Polygonum multiflorum Thunb. against glutamate-induced oxidative toxicity and cerebral ischemia. Materials and methods: For examination of neuroprotective effects of emodin, cell viability, cytotoxicity, flow cytometry, and Western blot were performed in HT22 cells and infarct volume, behavioral tests and Western blot in a mouse model of photothrombotic ischemic stroke. Results: Pretreatment with emodin resulted in significantly reduced glutamate-induced apoptotic cell death in HT22 cells. However, blocking of phosphatidylinositol-3 kinase (PI3K) activity with LY294002 resulted in significantly inhibited cell survival by emodin. Exposure of glutamate-treated cells to emodin induced an increase in the level of Bcl-2 expression, whereas the expression of Bax and active caspase-3 proteins was significantly reduced. In addition, treatment with emodin resulted in increased phosphorylation of Akt and cAMP response element binding protein (CREB), and expression of mature brain derived neurotrophic factor (BDNF). This expression by emodin was also significantly inhibited by blocking of PI3K activity. In a photothrombotic ischemic stroke model, treatment with emodin resulted in significantly reduced infarct volume and improved motor function. We confirmed the critical role of the expression levels of Bcl-2/Bax, active caspase-3, phosphorylated (p)Akt, p-CREB, and mature BDNF for potent neuroprotective effects of emodin in cerebral ischemia. Conclusions: These results suggest that emodin may afford a significant neuroprotective effect against glutamate-induced apoptosis through activation of the PI3K/Akt signaling pathway, and subsequently enhance behavioral function in cerebral ischemia. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Ahn, Sung Min; Kim, Ha Neui; Kim, Yu Ri; Choi, Byung Tae] Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan 50612, South Korea; [Ahn, Sung Min; Choi, Young Whan; Kim, Cheol Mm; Shin, Hwa Kyoung; Choi, Byung Tae] Pusan Natl Univ, Res Ctr Antiaging Technol Dev, Busan 46241, South Korea; [Kim, Ha Neui; Shin, Hwa Kyoung; Choi, Byung Tae] Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan 50612, South Korea; [Choi, Young Whan] Pusan Natl Univ, Dept Hort Biosci, Coll Nat Resource & Life Sci, Miryang 50463, South Korea; [Kim, Cheol Mm] Pusan Natl Univ, Dept Biochem, Coll Med, Yangsan 50612, South Korea; [Shin, Hwa Kyoung; Choi, Byung Tae] Pusan Natl Univ, Sch Korean Med, Div Meridian & Struct Med, Yangsan 50612, South Korea	Choi, BT (corresponding author), Pusan Natl Univ, Dept Korean Med Sci, Sch Korean Med, Yangsan 626870, South Korea.	choibt@pusan.ac.kr	Choi, Young-Whan/AAO-4826-2021	Kim, Haneui/0000-0002-5651-4727	R&D program of MOTIE/KIAT [N0000697]; National Research Foundation of Korea (NRF) - Korean government (MSIP, South Korea) [2014R1A5A2009936]	This work was supported by the R&D program of MOTIE/KIAT (N0000697, Establishment of Infra Structure for Anti-aging Industry Support). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP, South Korea) (2014R1A5A2009936).	Ahn SM, 2015, AM J CHINESE MED, V43, P637, DOI 10.1142/S0192415X15500391; Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Carloni S, 2009, EXP NEUROL, V220, P82, DOI 10.1016/j.expneurol.2009.07.026; Chang MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050291; Chu X, 2005, J CHROMATOGR A, V1097, P33, DOI 10.1016/j.chroma.2005.08.008; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Ferrer Isidro, 2006, Cerebrovasc Dis, V21 Suppl 2, P9, DOI 10.1159/000091699; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; Fukui M, 2010, FREE RADICAL BIO MED, V49, P800, DOI 10.1016/j.freeradbiomed.2010.06.002; Fukui M, 2009, EUR J PHARMACOL, V617, P1, DOI 10.1016/j.ejphar.2009.06.059; Girard S, 2014, BEHAV BRAIN RES, V270, P18, DOI 10.1016/j.bbr.2014.05.008; Gu JW, 2000, CHINESE MED J-PEKING, V113, P529; Gu JW, 2005, NEUROPHARMACOLOGY, V49, P103, DOI 10.1016/j.neuropharm.2005.02.003; Jackson TC, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.187; Jain V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062235; Jang JY, 2013, J ETHNOPHARMACOL, V145, P261, DOI 10.1016/j.jep.2012.10.061; Jeong GS, 2011, EUR J PHARMACOL, V654, P226, DOI 10.1016/j.ejphar.2010.12.027; Lee MS, 2013, MOLECULES, V18, P354, DOI 10.3390/molecules18010354; Lee SV, 2014, MOL MED REP, V9, P1415, DOI 10.3892/mmr.2014.1943; Lin LF, 2015, J HAZARD MATER, V299, P249, DOI 10.1016/j.jhazmat.2015.06.014; Lin LF, 2015, J ETHNOPHARMACOL, V159, P158, DOI 10.1016/j.jep.2014.11.009; Lin SP, 2012, J ETHNOPHARMACOL, V144, P671, DOI 10.1016/j.jep.2012.10.009; Liu T, 2010, BRAIN RES, V1347, P149, DOI 10.1016/j.brainres.2010.05.079; Liu X, 1999, MOL BRAIN RES, V71, P210, DOI 10.1016/S0169-328X(99)00186-2; Liu ZL, 2011, NAT PROD COMMUN, V6, P55; Lou A., 2010, PFLUG ARCH, V460, P525; Maher P, 1996, J NEUROSCI, V16, P6394; Park SJ, 2015, NEUROSCI LETT, V588, P101, DOI 10.1016/j.neulet.2015.01.001; Paschen W, 1996, ACTA NEUROBIOL EXP, V56, P313; Qin R, 2011, TOXICOL LETT, V202, P1, DOI 10.1016/j.toxlet.2011.01.001; Qiu XH, 2013, J CHROMATOGR A, V1292, P121, DOI 10.1016/j.chroma.2012.11.051; Ravati A, 2000, BRAIN RES, V866, P23, DOI 10.1016/S0006-8993(00)02210-1; Sakamoto K, 2011, J NEUROCHEM, V116, P1, DOI 10.1111/j.1471-4159.2010.07080.x; Tamokou JD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055880; Tobaben S, 2011, CELL DEATH DIFFER, V18, P282, DOI 10.1038/cdd.2010.92; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Wang CY, 2007, EUR J PHARMACOL, V577, P58, DOI 10.1016/j.ejphar.2007.08.033; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xu J., 2011, NEUROBIOL AGING, V32, pe2325, DOI DOI 10.1016/J.NEUR0BI0LAGING.2011.06.017; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yu JQ, 2013, PHYTOTHER RES, V27, P251, DOI 10.1002/ptr.4703; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhang YM, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-49; Zhou XP, 2011, IMMUNOPHARM IMMUNOT, V33, P594, DOI 10.3109/08923973.2010.549135	46	28	30	0	25	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-8741			J ETHNOPHARMACOL	J. Ethnopharmacol.	JUL 21	2016	188						13	20		10.1016/j.jep.2016.04.058			8	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	DQ9WU	WOS:000379560800002	27151150				2021-06-18	
J	Kuo, C; Wu, LC; Hammoor, BT; Luck, JF; Cutcliffe, HC; Lynall, RC; Kait, JR; Campbell, KR; Mihalik, JP; Bass, CR; Camarillo, DB				Kuo, Calvin; Wu, Lyndia C.; Hammoor, Brad T.; Luck, Jason F.; Cutcliffe, Hattie C.; Lynall, Robert C.; Kait, Jason R.; Campbell, Kody R.; Mihalik, Jason P.; Bass, Cameron R.; Camarillo, David B.			Effect of the mandible on mouthguard measurements of head kinematics	JOURNAL OF BIOMECHANICS			English	Article						Instrumented mouthguard; Mild traumatic brain injury; Head kinematics; Drop test	PROFESSIONAL FOOTBALL; CONCUSSION; IMPACTS; HELMET	Wearable sensors are becoming increasingly popular for measuring head motions and detecting head impacts. Many sensors are worn on the skin or in headgear and can suffer from motion artifacts introduced by the compliance of soft tissue or decoupling of headgear from the skull. The instrumented mouthguard is designed to couple directly to the upper dentition, which is made of hard enamel and anchored in a bony socket by stiff ligaments. This gives the mouthguard superior coupling to the skull compared with other systems. However, multiple validation studies have yielded conflicting results with respect to the mouthguard's head kinematics measurement accuracy. Here, we demonstrate that imposing different constraints on the mandible (lower jaw) can alter mouthguard kinematic accuracy in dummy headform testing. In addition, post mortem human surrogate tests utilizing the worst-case unconstrained mandible condition yield 40% and 80% normalized root mean square error in angular velocity and angular acceleration respectively. These errors can be modeled using a simple spring-mass system in which the soft mouthguard material near the sensors acts as a spring and the mandible as a mass. However, the mouthguard can be designed to mitigate these disturbances by isolating sensors from mandible loads, improving accuracy to below 15% normalized root mean square error in all kinematic measures. Thus, while current mouthguards would suffer from measurement errors in the worst case unconstrained mandible condition, future mouthguards should be designed to account for these disturbances and future validation testing should include unconstrained mandibles to ensure proper accuracy. (C) 2016 Elsevier Ltd. All rights reserved.	[Kuo, Calvin; Camarillo, David B.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Wu, Lyndia C.; Hammoor, Brad T.; Camarillo, David B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Luck, Jason F.; Cutcliffe, Hattie C.; Kait, Jason R.; Bass, Cameron R.] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA; [Lynall, Robert C.; Campbell, Kody R.; Mihalik, Jason P.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA	Kuo, C (corresponding author), 443 Via Ortega, Stanford, CA 94305 USA.	calvink@stanford.edu	Wu, Lyndia/AAQ-1106-2020; Kuo, Calvin/AAH-1933-2019; Lynall, Robert/M-2888-2014	Wu, Lyndia/0000-0002-8236-032X; Kuo, Calvin/0000-0001-8401-9136; Lynall, Robert/0000-0002-0785-6640; Cutcliffe, Hattie/0000-0001-8456-1996; Campbell, Kody/0000-0002-4534-5497	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [3R21EB01761101S1]; National Institute of Bio-medical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB01761101S1]; Stanford Child Health Research Institute Transdisciplinary Initiatives Program; Stanford Bio-X Graduate Research Fellowship Program; University of Pennsylvania Prime; US Army Research Office [W911NF-10-1-0526]; Duke University Pratt School of Engineering	This study was supported by the National Institutes of Health (NIH) (Grant number 3R21EB01761101S1) National Institute of Bio-medical Imaging and Bioengineering (NIBIB) 3R21EB01761101S1, the Stanford Child Health Research Institute Transdisciplinary Initiatives Program, and the Stanford Bio-X Graduate Research Fellowship Program. The authors appreciate additional funding from the University of Pennsylvania Prime, US Army Research Office W911NF-10-1-0526 and the Duke University Pratt School of Engineering.	Abramowitz M, 1965, HDB MATH FUNCTIONS F, V55; Bartsch Adam, 2014, Stapp Car Crash J, V58, P1; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Elliott MR, 2015, J BIOMECH, V48, P3059, DOI 10.1016/j.jbiomech.2015.07.026; Ferrario VF, 2004, J ORAL REHABIL, V31, P18, DOI 10.1046/j.0305-182X.2003.01179.x; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hernandez F., 2014, ANN BIOMED ENG, V43, P1; Hernandez F., 2015, J BIOMECH; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Kang YS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4005427; KING AI, 1995, J TRAUMA, V38, P564, DOI 10.1097/00005373-199504000-00016; Luck J., 2014, WORLD C BIOM; NOYES DH, 1973, J BIOMECH, V6, P439, DOI 10.1016/0021-9290(73)90002-X; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Siegmund G.P., 2015, ANN BIOMED ENG; Siegmund GP, 2014, ANN BIOMED ENG, V42, P1834, DOI 10.1007/s10439-014-1052-2; Society of Automotive Engineers, 2007, TECHNICAL REPORT; Stammen JA, 2001, BIOMATERIALS, V22, P799, DOI 10.1016/S0142-9612(00)00242-8; Viano DC, 2012, ANN BIOMED ENG, V40, P47, DOI 10.1007/s10439-011-0399-x; Walker L.B., 1973, P 17 STAPP CAR CRASH, P523; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Wonnacott M., 2010, SAE TECHNICAL PAPER; Wu L.C., 2015, ANN BIOMED ENG	27	28	28	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JUN 14	2016	49	9					1845	1853		10.1016/j.jbiomech.2016.04.017			9	Biophysics; Engineering, Biomedical	Biophysics; Engineering	DO4DE	WOS:000377731200058	27155744				2021-06-18	
J	Failla, MD; Juengst, SB; Arenth, PM; Wagner, AK				Failla, Michelle D.; Juengst, Shannon B.; Arenth, Patricia M.; Wagner, Amy K.			Preliminary Associations Between Brain-Derived Neurotrophic Factor, Memory Impairment, Functional Cognition, and Depressive Symptoms Following Severe TBI	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; depression; cognitive impairment; BDNF; biomarker; rehabilomics	FACTOR BDNF; BLOOD-BRAIN; INDEPENDENCE MEASURE; EXECUTIVE FUNCTION; FUTURE-DIRECTIONS; SELF-AWARENESS; OLDER-ADULTS; SHORT-TERM; INJURY; SERUM	Background. Traumatic brain injury (TBI) often leads to mood and cognitive complications, affecting functional recovery. Understanding neurobiological alterations common in post-TBI depression (PTD) and cognition may identify novel biomarkers for TBI complications. Brain-derived neurotrophic factor (BDNF) is a likely target based on evidence of reduced BDNF signaling in experimental TBI and depression models and its role in learning and memory. Objective. To evaluate BDNF as a biomarker for PTD, cognitive impairment, and functional cognition in a prospective cohort with severe TBI. Methods. Participants with TBI (n = 113) were evaluated for PTD (Patient Health Questionnaire-9 [PHQ-9]), cognitive impairment (cognitive composite score), and functional cognition (Functional Independence Measure-Cognition, FIM-Cog). BDNF levels were measured in cerebrospinal fluid and serum at 0 to 6 days postinjury and in serum at 6 and 12 months postinjury. Results. Serum BDNF was reduced after TBI versus controls at all time points. Acute serum BDNF positively correlated with memory composites (6 months: r = 0.43, P = .019, n = 30; 12 months: r = 0.53, P = .005, n = 26) and FIM-Memory scores (6 months: r = 0.35, P = .019, n = 45; 12 months: r = 0.38, P = .018, n = 38). Acute serum BDNF negatively correlated with 12-month PHQ-9 scores (r = -0.38; P = .044; n = 29). At 12 months, chronic serum BDNF tended to be lower in participants with PTD (P = .07) and correlated with PHQ-9 scores (r = -0.41; P = .019; n = 32). Conclusions. Acute BDNF associations with memory recovery may implicate hippocampal damage/degeneration. Comparatively, BDNF associations with PTD status were not as strong as associations with PTD severity. Further investigation may delineate longitudinal BDNF patterns, and BDNF responsive treatments, reflecting mood and cognitive recovery following TBI.	[Failla, Michelle D.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Juengst, Shannon B.; Arenth, Patricia M.; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Neurosci, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Phys Med & Rehabil, 3471 Fifth Ave Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Failla, Michelle/AAI-3788-2021; Juengst, Shannon B/AAC-5891-2019	Failla, Michelle/0000-0001-9734-3373; Juengst, Shannon/0000-0003-4709-545X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048162]; NIDRR [H133A120087]; University of Pittsburgh Women's Studies Faculty Research Fund [CDC R49 CCR 323155];  [DODW81XWH-071-0701]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by NIH R01 HD048162; NIDRR H133A120087; DODW81XWH-071-0701; CDC R49 CCR 323155, University of Pittsburgh Women's Studies Faculty Research Fund.	Alonso M, 2002, HIPPOCAMPUS, V12, P551, DOI 10.1002/hipo.10035; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bath KG, 2006, COGN AFFECT BEHAV NE, V6, P79, DOI 10.3758/CABN.6.1.79; Bekinschtein P, 2008, NEUROSCIENTIST, V14, P147, DOI 10.1177/1073858407305850; Bekinschtein P, 2008, P NATL ACAD SCI USA, V105, P2711, DOI 10.1073/pnas.0711863105; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; D'Sa C, 2002, BIPOLAR DISORD, V4, P183, DOI 10.1034/j.1399-5618.2002.01203.x; Dawood T, 2007, MOL PSYCHIATR, V12, P981, DOI 10.1038/sj.mp.4002059; Dawson JD, 2010, J AM GERIATR SOC, V58, P1090, DOI 10.1111/j.1532-5415.2010.02872.x; Delis DC, 2000, CALIFORNIA VERBAL LE; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Failla MD, 2016, NEUROREHAB NEURAL RE, V30, P83, DOI 10.1177/1545968315586465; Failla MD, 2015, J HEAD TRAUMA REHAB, V30, pE54, DOI 10.1097/HTR.0000000000000118; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fleming J, 1999, BRAIN INJURY, V13, P417; Gass P, 2010, INT J NEUROPSYCHOPH, V13, P1, DOI 10.1017/S1461145709991039; Gotlib IH, 2010, ANNU REV CLIN PSYCHO, V6, P285, DOI 10.1146/annurev.clinpsy.121208.131305; Goverover Y, 2014, BRAIN INJURY, V28, P174, DOI 10.3109/02699052.2013.860474; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griffin EW, 2011, PHYSIOL BEHAV, V104, P934, DOI 10.1016/j.physbeh.2011.06.005; Gunstad J, 2008, J GERIATR PSYCH NEUR, V21, P166, DOI 10.1177/0891988708316860; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hashimoto K, 2010, PSYCHIAT CLIN NEUROS, V64, P341, DOI 10.1111/j.1440-1819.2010.02113.x; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoffman JM, 2010, PM&R, V2, P911, DOI 10.1016/j.pmrj.2010.06.008; Juengst S, 2013, ARCH PHYS MED REHAB, V94, P74, DOI 10.1016/j.apmr.2012.07.025; Kalish H, 2010, J CHROMATOGR B, V878, P194, DOI 10.1016/j.jchromb.2009.10.022; Karege F, 2005, BIOL PSYCHIAT, V57, P1068, DOI 10.1016/j.biopsych.2005.01.008; Karege F, 2002, PSYCHIAT RES, V109, P143, DOI 10.1016/S0165-1781(02)00005-7; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Kovalchuk Y, 2002, SCIENCE, V295, P1729, DOI 10.1126/science.1067766; LARRABEE GJ, 1995, J CLIN EXP NEUROPSYC, V17, P536, DOI 10.1080/01688639508405144; Larsson J, 2013, J REHABIL MED, V45, P765, DOI 10.2340/16501977-1184; Levin RL, 2007, COGNITIVE THER RES, V31, P211, DOI 10.1007/s10608-007-9128-z; Lewis Frank D, 2013, J Spec Oper Med, V13, P56; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Lommatzsch M, 2005, NEUROBIOL AGING, V26, P115, DOI 10.1016/j.neurobiolaging.2004.03.002; Martinowich K, 2007, NAT NEUROSCI, V10, P1089, DOI 10.1038/nn1971; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; Nettiksimmons J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091339; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Osterrieth P, 1944, ARCH PSYCHOL, V20, P206; Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Petzold A, 2015, NEUROBIOL LEARN MEM, V120, P52, DOI 10.1016/j.nlm.2015.02.009; Piccinni A, 2008, J AFFECT DISORDERS, V105, P279, DOI 10.1016/j.jad.2007.05.005; Pittenger C, 2008, NEUROPSYCHOPHARMACOL, V33, P88, DOI 10.1038/sj.npp.1301574; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Rasmussen P, 2009, EXP PHYSIOL, V94, P1062, DOI 10.1113/expphysiol.2009.048512; Reitan RM., 1985, HALSTEAD REITAN NEUR; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Siuciak JA, 1997, PHARMACOL BIOCHEM BE, V56, P131, DOI 10.1016/S0091-3057(96)00169-4; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Terracciano A, 2013, WORLD J BIOL PSYCHIA, V14, P583, DOI 10.3109/15622975.2011.616533; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; van Veelen NMJ, 2010, SCHIZOPHR RES, V120, P191, DOI 10.1016/j.schres.2010.04.011; Dias VV, 2009, BIPOLAR DISORD, V11, P663, DOI 10.1111/j.1399-5618.2009.00733.x; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Wagner AK, 2012, BRAIN INJURY, V26, P1226, DOI 10.3109/02699052.2012.667594; Wise EK, 2012, ARCH PHYS MED REHAB, V93, P1319, DOI 10.1016/j.apmr.2012.05.009; Yang LL, 2011, INT J GERIATR PSYCH, V26, P495, DOI 10.1002/gps.2552; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	77	28	28	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUN	2016	30	5					419	430		10.1177/1545968315600525			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DL6BR	WOS:000375723200004	26276123	Green Accepted			2021-06-18	
J	Khalaj, AJ; Hasselmann, J; Augello, C; Moore, S; Tiwari-Woodruff, SK				Khalaj, Anna J.; Hasselmann, Jonathan; Augello, Catherine; Moore, Spencer; Tiwari-Woodruff, Seema K.			Nudging oligodendrocyte intrinsic signaling to remyelinate and repair: Estrogen receptor ligand effects	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article; Proceedings Paper	8th International Meeting on Steroids and Nervous System	2015	Torino, ITALY			Estrogen receptor ligands; Multiple sclerosis; Demyelination; Remyelination; Experimental autoimmune; encephalomyelitis; Axon degeneration	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS LESIONS; BETA-AGONIST; PROGENITOR CELLS; SELECTIVE LIGANDS; MAMMALIAN TARGET; GENE-EXPRESSION; ERK1/2 MAPK; MOUSE MODEL; IN-VIVO	Demyelination in multiple sclerosis (MS) leads to significant, progressive axonal and neuronal degeneration. Currently existing immunosuppressive and immunomodulatory therapies alleviate MS symptoms and slow, but fail to prevent or reverse, disease progression. Restoration of damaged myelin sheath by replenishment of mature oligodendrocytes (OLs) should not only restore saltatory axon conduction, but also provide a major boost to axon survival. Our previous work has shown that therapeutic treatment with the modestly selective generic estrogen receptor (ER) beta agonist diarylpropionitrile (DPN) confers functional neuroprotection in a chronic experimental autoimmune encephalomyelitis (EAE) mouse model of MS by stimulating endogenous remyelination. Recently, we found that the more potent, selective ER beta agonist indazole-chloride (Ind-Cl) improves clinical disease and motor performance. Importantly, electrophysiological measures revealed improved corpus callosal conduction and reduced axon refractoriness. This Ind-Cl treatment-induced functional remyelination was attributable to increased OL progenitor cell (OPC) and mature OL numbers. At the intracellular signaling level, transition of early to late OPCs requires ERK1/2 signaling, and transition of immature to mature OLs requires mTOR signaling; thus, the PI3K/Akt/mTOR pathway plays a major role in the late stages of OL differentiation and myelination. Indeed, therapeutic treatment of EAE mice with various ER beta agonists results in increased brain-derived neurotrophic factor (BDNF) and phosphorylated (p) Akt and p-mTOR levels. It is notable that while DPN's neuroprotective effects occur in the presence of peripheral and central inflammation, Ind-Cl is directly neuroprotective, as demonstrated by remyelination effects in the cuprizone-induced demyelination model, as well as immunomodulatory. Elucidating the mechanisms by which ER agonists and other directly remyelinating agents modulate endogenous OPC and OL regulatory signaling is critical to the development of effective remyelinating drugs. The discovery of signaling targets to induce functional remyelination will valuably contribute to the treatment of demyelinating neurological diseases, including MS, stroke, and traumatic brain and spinal cord injury. Published by Elsevier Ltd.	[Khalaj, Anna J.; Hasselmann, Jonathan; Augello, Catherine; Moore, Spencer; Tiwari-Woodruff, Seema K.] Univ Calif Riverside, Sch Med, Div Biomed Sci, Rm 205,311 Sch Med Res Bldg,900 Univ Ave, Riverside, CA 92521 USA; [Tiwari-Woodruff, Seema K.] Univ Calif Riverside, Neurosci Grad Program, Riverside, CA 92521 USA	Tiwari-Woodruff, SK (corresponding author), Univ Calif Riverside, Sch Med, Div Biomed Sci, Rm 205,311 Sch Med Res Bldg,900 Univ Ave, Riverside, CA 92521 USA.	seema.tiwari-woodruff@ucr.edu		Hasselmann, Jonathan/0000-0003-2630-9850; Moore, Spencer/0000-0001-9811-9007	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS075198, R01 NS081141] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS081141, R21NS075198] Funding Source: NIH RePORTER		ABRAMSKY O, 1994, ANN NEUROL, V36, pS38, DOI 10.1002/ana.410360712; Aggarwal S, 2011, TRENDS CELL BIOL, V21, P585, DOI 10.1016/j.tcb.2011.06.004; ALMAZAN G, 1985, DEV NEUROSCI-BASEL, V7, P45, DOI 10.1159/000112275; Amantea D, 2005, PHARMACOL RES, V52, P119, DOI 10.1016/j.phrs.2005.03.002; Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856; Beagley KW, 2003, FEMS IMMUNOL MED MIC, V38, P13, DOI 10.1016/S0928-8244(03)00202-5; Bebo BF, 2001, J IMMUNOL, V166, P2080, DOI 10.4049/jimmunol.166.3.2080; Bhatt A, 2014, NEURAL REGEN RES, V9, P1347, DOI 10.4103/1673-5374.137586; Bibollet-Bahena O, 2009, J NEUROCHEM, V109, P1440, DOI 10.1111/j.1471-4159.2009.06071.x; Blakemore WF, 2008, J NEUROL SCI, V265, P43, DOI 10.1016/j.jns.2007.08.004; Blaschuk KL, 2000, DEVELOPMENT, V127, P1961; Bonetti A, 2009, J NEUROIMMUNOL, V208, P119, DOI 10.1016/j.jneuroim.2009.01.003; Bonora M, 2014, CELL DEATH DIFFER, V21, P1198, DOI 10.1038/cdd.2014.35; Bourikas D, 2010, MOL CELL NEUROSCI, V45, P363, DOI 10.1016/j.mcn.2010.07.009; Browne P, 2014, NEUROLOGY, V83, P1022, DOI 10.1212/WNL.0000000000000768; Burns KA, 2012, ARCH TOXICOL, V86, P1491, DOI 10.1007/s00204-012-0868-5; Carroll VM, 2012, J MED CHEM, V55, P528, DOI 10.1021/jm201436k; CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O; Charles P, 2002, BRAIN, V125, P1972, DOI 10.1093/brain/awf216; Choi SR, 2012, BRAIN, V135, P2925, DOI 10.1093/brain/aws189; Christaki E, 2010, J INFECT DIS, V201, P1250, DOI 10.1086/651276; Clarner T, 2012, GLIA, V60, P1468, DOI 10.1002/glia.22367; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Crawford DK, 2010, BRAIN, V133, P2999, DOI 10.1093/brain/awq237; Cunningham M., 2016, CLIN REV ALLERG IMMU, V40, P66; Cvoro A, 2008, J IMMUNOL, V180, P630, DOI 10.4049/jimmunol.180.1.630; DASILVA JAP, 1992, CLIN RHEUMATOL, V11, P189, DOI 10.1007/BF02207955; De Angelis M, 2005, J MED CHEM, V48, P1132, DOI 10.1021/jm049223g; Denic Aleksandar, 2011, Pathophysiology, V18, P21, DOI 10.1016/j.pathophys.2010.04.004; DSouza SD, 1996, J NEUROSCI RES, V43, P289, DOI 10.1002/(SICI)1097-4547(19960201)43:3<289::AID-JNR4>3.0.CO;2-F; Dubois-Dalcq M, 2000, PATHOL BIOL, V48, P80; Elloso MM, 2005, J ENDOCRINOL, V185, P243, DOI 10.1677/joe.1.06063; Fancy S. P., 2016, ANNU REV NEUROSCI, V34, P21; Fancy SPJ, 2004, MOL CELL NEUROSCI, V27, P247, DOI 10.1016/j.mcn.2004.06.015; FFRENCHCONSTANT C, 1986, NATURE, V319, P499, DOI 10.1038/319499a0; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Franklin RJM, 2008, J NEUROL, V255, P19, DOI 10.1007/s00415-008-1004-6; FRESSINAUD C, 1995, J NEUROSCI RES, V40, P285, DOI 10.1002/jnr.490400302; Friese MA, 2009, ANN NEUROL, V66, P132, DOI 10.1002/ana.21744; Frischer JM, 2009, BRAIN, V132, P1175, DOI 10.1093/brain/awp070; Goverman J, 2009, NAT REV IMMUNOL, V9, P393, DOI 10.1038/nri2550; Guardiola-Diaz HM, 2012, GLIA, V60, P476, DOI 10.1002/glia.22281; HAMMERLING GJ, 1991, IMMUNOL REV, V122, P47, DOI 10.1111/j.1600-065X.1991.tb00596.x; Harris H. A., 2016, E SCHERING FDN S P, V2006, P149; Harris HA, 2003, ENDOCRINOLOGY, V144, P4241, DOI 10.1210/en.2003-0550; Harris HA, 2005, HUM REPROD, V20, P936, DOI 10.1093/humrep/deh711; Hellwig K, 2014, EUR NEUROL, V72, P39, DOI 10.1159/000367640; Hinks GL, 1999, MOL CELL NEUROSCI, V14, P153, DOI 10.1006/mcne.1999.0771; Hirahara Y, 2009, GLIA, V57, P153, DOI 10.1002/glia.20742; Hohlfeld R., 2015, LANCET NEUROL; Hollenbach JA, 2015, J AUTOIMMUN, V64, P13, DOI 10.1016/j.jaut.2015.06.010; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Hu QD, 2003, CELL, V115, P163, DOI 10.1016/S0092-8674(03)00810-9; Ishii A, 2014, J NEUROSCI, V34, P16031, DOI 10.1523/JNEUROSCI.3360-14.2014; JANSSON L, 1994, J NEUROIMMUNOL, V53, P203, DOI 10.1016/0165-5728(94)90030-2; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Juarez A. Lopez, 2015, BRAIN RES IN PRESS; Kessaris N, 2006, NAT NEUROSCI, V9, P173, DOI 10.1038/nn1620; Khalaj AJ, 2013, P NATL ACAD SCI USA, V110, P19125, DOI [10.1073/pnas.311763110, 10.1073/pnas.1311763110]; Kim S, 1999, NEUROLOGY, V52, P1230, DOI 10.1212/WNL.52.6.1230; Kipp M, 2012, CNS NEUROL DISORD-DR, V11, P506, DOI 10.2174/187152712801661248; Kipp M, 2012, FRONT NEUROENDOCRIN, V33, P1, DOI 10.1016/j.yfrne.2012.01.001; Kuhlmann T, 2008, BRAIN, V131, P1749, DOI 10.1093/brain/awn096; Kumar S, 2013, NEUROBIOL DIS, V56, P131, DOI 10.1016/j.nbd.2013.04.005; Lebel C, 2012, NEUROIMAGE, V60, P340, DOI 10.1016/j.neuroimage.2011.11.094; Liu F, 2008, NAT NEUROSCI, V11, P334, DOI 10.1038/nn2057; Liu ZJ, 2007, DEV BIOL, V302, P683, DOI 10.1016/j.ydbio.2006.10.007; Lopez-Diego RS, 2008, NAT REV DRUG DISCOV, V7, P909, DOI 10.1038/nrd2358; Lucchinetti C, 1999, BRAIN, V122, P2279, DOI 10.1093/brain/122.12.2279; Maeda Y, 2001, ANN NEUROL, V49, P776, DOI 10.1002/ana.1015; Mahad DH, 2015, LANCET NEUROL, V14, P183, DOI 10.1016/S1474-4422(14)70256-X; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; MCMORRIS FA, 1988, J NEUROSCI RES, V21, P199, DOI 10.1002/jnr.490210212; Meltser I, 2008, J CLIN INVEST, V118, P1563, DOI 10.1172/JCI32796; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Miller DH, 2014, MULT SCLER J, V20, P527, DOI 10.1177/1352458513519840; Miller RH, 2002, PROG NEUROBIOL, V67, P451, DOI 10.1016/S0301-0082(02)00058-8; Minutolo F, 2011, MED RES REV, V31, P364, DOI 10.1002/med.20186; Mohler ML, 2010, EXPERT OPIN THER PAT, V20, P507, DOI 10.1517/13543771003657164; Moore SM, 2014, P NATL ACAD SCI USA, V111, P18061, DOI 10.1073/pnas.1411294111; Morales LBJ, 2006, J NEUROSCI, V26, P6823, DOI 10.1523/JNEUROSCI.0453-06.2006; Mosyak L, 2006, J BIOL CHEM, V281, P36378, DOI 10.1074/jbc.M607314200; Najm FJ, 2015, NATURE, V522, P216, DOI 10.1038/nature14335; Nakatani H, 2013, J NEUROSCI, V33, P9752, DOI 10.1523/JNEUROSCI.0805-13.2013; Narayanan SP, 2009, J NEUROSCI, V29, P6860, DOI 10.1523/JNEUROSCI.0232-09.2009; Nicoletti F, 2010, AUTOIMMUN DIS, V2010, DOI 10.4061/2010/757432; Nielsen HH, 2006, GLIA, V54, P105, DOI 10.1002/glia.20357; NOLL E, 1993, DEVELOPMENT, V118, P563; Paruthiyil S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006271; Patel JR, 2010, P NATL ACAD SCI USA, V107, P11062, DOI 10.1073/pnas.1006301107; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; Preston M, 2013, ANN NEUROL, V73, P266, DOI 10.1002/ana.23788; PRINEAS JW, 1993, ANN NEUROL, V33, P137, DOI 10.1002/ana.410330203; Pringle NP, 1998, NEURON, V20, P883, DOI 10.1016/S0896-6273(00)80470-5; Prokai L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1290; Qi YC, 2002, TRENDS NEUROSCI, V25, P223, DOI 10.1016/S0166-2236(02)02145-8; Raine CS, 1999, ANN NEUROL, V46, P144, DOI 10.1002/1531-8249(199908)46:2<144::AID-ANA3>3.0.CO;2-K; RASCOL A, 1982, REV NEUROL, V138, P921; Roman-Blas JA, 2010, ARTHRIT CARE RES, V62, P1588, DOI 10.1002/acr.20275; Rubinfeld H, 2005, MOL BIOTECHNOL, V31, P151, DOI 10.1385/MB:31:2:151; Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Sherman DL, 2012, J NEUROSCI, V32, P1817, DOI 10.1523/JNEUROSCI.4814-11.2012; Shimizu T, 2005, DEV BIOL, V282, P397, DOI 10.1016/j.ydbio.2005.03.020; Sicotte NL, 2002, ANN NEUROL, V52, P421, DOI 10.1002/ana.10301; Sirn FJ, 2006, ANN NEUROL, V59, P763, DOI 10.1002/ana.20812; Spence RD, 2013, J NEUROSCI, V33, P10924, DOI 10.1523/JNEUROSCI.0886-13.2013; Srivastava DP, 2010, J NEUROSCI, V30, P13454, DOI 10.1523/JNEUROSCI.3264-10.2010; Stovall DW, 2009, CURR OPIN INVEST DR, V10, P365; Takao T, 2004, J NEUROCHEM, V89, P660, DOI 10.1111/j.1471-4159.2004.02370.x; Takebayashi H, 2015, GLIA, V63, P1350, DOI 10.1002/glia.22863; Tedesco R, 2001, CHEM BIOL, V8, P277, DOI 10.1016/S1074-5521(01)00006-0; Tiwari-Woodruff S, 2007, P NATL ACAD SCI USA, V104, P14813, DOI 10.1073/pnas.0703783104; Tiwari-Woodruff S, 2009, J NEUROL SCI, V286, P81, DOI 10.1016/j.jns.2009.04.023; Tyler WA, 2009, J NEUROSCI, V29, P6367, DOI 10.1523/JNEUROSCI.0234-09.2009; van der Valk P, 2000, NEUROPATH APPL NEURO, V26, P2, DOI 10.1046/j.1365-2990.2000.00217.x; Van't Veer A, 2009, J NEUROSCI RES, V87, P69, DOI 10.1002/jnr.21841; VANDERPAL RHM, 1988, J NEUROSCI RES, V19, P483, DOI 10.1002/jnr.490190412; Vondran MW, 2010, GLIA, V58, P848, DOI 10.1002/glia.20969; Voskuhl RR, 2016, LANCET NEUROL, V15, P35, DOI 10.1016/S1474-4422(15)00322-1; Wang Ling, 2002, Sci STKE, V2002, ppe29, DOI 10.1126/stke.2002.138.pe29; Wang XL, 2009, MOL IMMUNOL, V46, P2413, DOI 10.1016/j.molimm.2009.04.014; WAXMAN SG, 1980, MUSCLE NERVE, V3, P141, DOI 10.1002/mus.880030207; Weiser MJ, 2009, ENDOCRINOLOGY, V150, P1817, DOI 10.1210/en.2008-1355; Wood TL, 2013, ASN NEURO, V5, P63, DOI 10.1042/AN20120092; Wu WF, 2013, P NATL ACAD SCI USA, V110, P3543, DOI 10.1073/pnas.1300313110; Zeger M, 2007, GLIA, V55, P400, DOI 10.1002/glia.20469; Zhang YJ, 2015, EXP NEUROL, V266, P68, DOI 10.1016/j.expneurol.2015.02.006; Zhang Z, 2004, J NEUROCHEM, V89, P674, DOI 10.1111/j.1471-4159.2004.02388.x; Zhao LQ, 2015, AGEING RES REV, V24, P178, DOI 10.1016/j.arr.2015.08.001	133	28	28	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	JUN	2016	160				SI		43	52		10.1016/j.jsbmb.2016.01.006			10	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	DN1QM	WOS:000376840500007	26776441	Green Accepted			2021-06-18	
J	Nicholson, AM; Finch, NA; Almeida, M; Perkerson, RB; van Blitterswijk, M; Wojtas, A; Cenik, B; Rotondo, S; Inskeep, V; Almasy, L; Dyer, T; Peralta, J; Jun, G; Wood, AR; Frayling, TM; Fuchsberger, C; Fowler, S; Teslovich, TM; Manning, AK; Kumar, S; Curran, J; Lehman, D; Abecasis, G; Duggirala, R; Pottier, C; Zahir, HA; Crook, JE; Karydas, A; Mitic, L; Sun, Y; Dickson, DW; Bu, GJ; Herz, J; Yu, G; Miller, BL; Ferguson, S; Petersen, RC; Graff-Radford, N; Blangero, J; Rademakers, R				Nicholson, Alexandra M.; Finch, NiCole A.; Almeida, Marcio; Perkerson, Ralph B.; van Blitterswijk, Marka; Wojtas, Aleksandra; Cenik, Basar; Rotondo, Sergio; Inskeep, Venette; Almasy, Laura; Dyer, Thomas; Peralta, Juan; Jun, Goo; Wood, Andrew R.; Frayling, Timothy M.; Fuchsberger, Christian; Fowler, Sharon; Teslovich, Tanya M.; Manning, Alisa K.; Kumar, Satish; Curran, Joanne; Lehman, Donna; Abecasis, Goncalo; Duggirala, Ravindranath; Pottier, Cyril; Zahir, Haaris A.; Crook, Julia E.; Karydas, Anna; Mitic, Laura; Sun, Ying; Dickson, Dennis W.; Bu, Guojun; Herz, Joachim; Yu, Gang; Miller, Bruce L.; Ferguson, Shawn; Petersen, Ronald C.; Graff-Radford, Neill; Blangero, John; Rademakers, Rosa			Prosaposin is a regulator of progranulin levels and oligomerization	NATURE COMMUNICATIONS			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; TRAUMATIC BRAIN-INJURY; DISEASE MOUSE MODELS; NEUROTROPHIC FACTOR; NEURITE OUTGROWTH; GENE-EXPRESSION; RISK-FACTOR; PROTEIN; DEMENTIA; SORTILIN	Progranulin (GRN) loss-of-function mutations leading to progranulin protein (PGRN) haploinsufficiency are prevalent genetic causes of frontotemporal dementia. Reports also indicated PGRN-mediated neuroprotection in models of Alzheimer's and Parkinson's disease; thus, increasing PGRN levels is a promising therapeutic for multiple disorders. To uncover novel PGRN regulators, we linked whole-genome sequence data from 920 individuals with plasma PGRN levels and identified the prosaposin (PSAP) locus as a new locus significantly associated with plasma PGRN levels. Here we show that both PSAP reduction and overexpression lead to significantly elevated extracellular PGRN levels. Intriguingly, PSAP knockdown increases PGRN monomers, whereas PSAP overexpression increases PGRN oligomers, partly through a protein-protein interaction. PSAP-induced changes in PGRN levels and oligomerization replicate in human-derived fibroblasts obtained from a GRN mutation carrier, further supporting PSAP as a potential PGRN-related therapeutic target. Future studies should focus on addressing the relevance and cellular mechanism by which PGRN oligomeric species provide neuroprotection.	[Nicholson, Alexandra M.; Finch, NiCole A.; Perkerson, Ralph B.; van Blitterswijk, Marka; Wojtas, Aleksandra; Pottier, Cyril; Zahir, Haaris A.; Crook, Julia E.; Dickson, Dennis W.; Bu, Guojun; Rademakers, Rosa] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Almeida, Marcio; Almasy, Laura; Dyer, Thomas; Peralta, Juan; Kumar, Satish; Curran, Joanne; Duggirala, Ravindranath; Blangero, John] Univ Texas Rio Grande Valley Sch Med, South Texas Diabet & Obes Inst, Brownsville, TX 78520 USA; [Cenik, Basar] Univ Texas Southwestern Med Ctr, Dept Neurosci Mol Genet & Psychiat, Dallas, TX 75390 USA; [Rotondo, Sergio; Ferguson, Shawn] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; [Rotondo, Sergio; Ferguson, Shawn] Yale Univ, Sch Med, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06510 USA; [Inskeep, Venette; Sun, Ying] Cincinnati Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH 45229 USA; [Jun, Goo] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA; [Wood, Andrew R.; Frayling, Timothy M.] Univ Exeter, Sch Med, Genet Complex Traits, St Lukes Campus, Exeter EX1 2LU, Devon, England; [Fuchsberger, Christian; Teslovich, Tanya M.; Abecasis, Goncalo] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA; [Fowler, Sharon] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Manning, Alisa K.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; [Lehman, Donna] Univ Texas Hlth Sci Ctr, Dept Med Cardiol & Cellular & Struct Biol, San Antonio, TX 78229 USA; [Karydas, Anna; Mitic, Laura; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA; [Herz, Joachim; Yu, Gang] Univ Texas SW Med Ctr Dallas, Dept Mol Genet Neurosci Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Petersen, Ronald C.] Mayo Clin, Dept Neurol, Rochester, MN 55902 USA; [Graff-Radford, Neill] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA	Rademakers, R (corresponding author), Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA.	rademakers.rosa@mayo.edu	van Blitterswijk, Marka/H-7274-2012; Jun, Goo/F-1941-2017; Jun, Goo/M-5235-2016; Almasy, Laura/V-3156-2019; van Blitterswijk, Marka/AAL-4126-2021	van Blitterswijk, Marka/0000-0002-3054-7053; Jun, Goo/0000-0003-0891-0204; Jun, Goo/0000-0003-0891-0204; van Blitterswijk, Marka/0000-0002-3054-7053; Curran, Joanne/0000-0002-6898-155X; Peralta, Juan Manuel/0000-0002-8811-5579; Afonso de Almeida, Marcio Augusto/0000-0002-8114-3892; Blangero, John/0000-0001-6250-5723	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS076471, P50 AG016574, UO1 AG006786, U01 DK085524, U01 DK085584, U01 DK085501, U01 DK085526, U01 DK085545, P01 HL045222, R01 DK047482, R01 DK053889]; Younkin Scholarship; Consortium for Frontotemporal Degeneration Research; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR020547] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01DK085501, U01DK085545, U01DK085524, U01DK085584, U01DK085526, R01DK047482, R01DK053889] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS093382, R01NS076471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG016574, U01AG006786] Funding Source: NIH RePORTER	We are deeply indebted to Richard Gibson (deceased) for his many years of commitment to science, the Department of Molecular Genetics at UT Southwestern and for his help with producing anti-progranulin antibodies. We thank the T2D-GENES consortium for sequencing data sharing. This work was funded by NIH grants R01 NS076471, P50 AG016574 and UO1 AG006786 awarded to Rosa Rademakers, the Younkin Scholarship awarded to Alexandra Nicholson, and the Consortium for Frontotemporal Degeneration Research. T2D-GENES Consortium is supported by NIH grants U01 DK085524, U01 DK085584, U01 DK085501, U01 DK085526 and U01 DK085545. The San Antonio Family Studies is supported by NIH grants P01 HL045222, R01 DK047482 and R01 DK053889.	Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; Almasy Laura, 2014, BMC Proc, V8, pS2, DOI 10.1186/1753-6561-8-S1-S2; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Banzhaf-Strathmann J, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-16; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; BHANDARI V, 1992, BIOCHEM BIOPH RES CO, V188, P57, DOI 10.1016/0006-291X(92)92349-3; Bossu P, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-65; Brouwers N, 2008, NEUROLOGY, V71, P656, DOI 10.1212/01.wnl.0000319688.89790.7a; Capell A, 2011, J NEUROSCI, V31, P1885, DOI 10.1523/JNEUROSCI.5757-10.2011; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Carrasquillo MM, 2010, AM J HUM GENET, V87, P890, DOI 10.1016/j.ajhg.2010.11.002; Cenik B, 2012, J BIOL CHEM, V287, P32298, DOI 10.1074/jbc.R112.399170; Cenik B, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.193433; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Daniel R, 2003, DEV DYNAM, V227, P593, DOI 10.1002/dvdy.10341; Dickson DW, 2010, NEURODEGENER DIS, V7, P170, DOI 10.1159/000289231; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; Gao X, 2010, PROTEIN CELL, V1, P552, DOI 10.1007/s13238-010-0067-1; Gass J, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-33; Gotzl JK, 2014, ACTA NEUROPATHOL, V127, P845, DOI 10.1007/s00401-014-1262-6; He ZH, 1999, CANCER RES, V59, P3222; Hiesberger T, 1998, EMBO J, V17, P4617, DOI 10.1093/emboj/17.16.4617; Hsiung GYR, 2011, J NEUROL SCI, V300, P28, DOI 10.1016/j.jns.2010.10.009; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Jawaid A, 2009, NEURODEGENER DIS, V6, P219, DOI 10.1159/000258704; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Kohlschutter A, 2009, BRAIN DEV-JPN, V31, P499, DOI 10.1016/j.braindev.2008.12.008; Laird AS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013368; Lefrancois S, 2003, EMBO J, V22, P6430, DOI 10.1093/emboj/cdg629; Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653; Mateo I, 2013, EUR J NEUROL, V20, P1571, DOI 10.1111/ene.12090; Meyer RC, 2014, BRAIN RES, V1585, P1, DOI 10.1016/j.brainres.2014.08.022; Minami SS, 2014, NAT MED, V20, P1157, DOI 10.1038/nm.3672; Mitchell BD, 1996, CIRCULATION, V94, P2159, DOI 10.1161/01.CIR.94.9.2159; Nguyen AD, 2013, J BIOL CHEM, V288, P8627, DOI 10.1074/jbc.M112.441949; Nicholson AM, 2014, NEUROLOGY, V82, P1871, DOI 10.1212/WNL.0000000000000445; Nuytemans K, 2008, NEUROLOGY, V71, P1147, DOI 10.1212/01.wnl.0000327563.10320.2b; OBRIEN JS, 1995, FASEB J, V9, P681; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OBRIEN JS, 1991, FASEB J, V5, P301; Okura H, 2010, J ATHEROSCLER THROMB, V17, P568, DOI 10.5551/jat.3921; Petersen RC, 2010, NEUROLOGY, V75, P889, DOI 10.1212/WNL.0b013e3181f11d85; Rademakers R, 2008, HUM MOL GENET, V17, P3631, DOI 10.1093/hmg/ddn257; RECKLIES AD, 1985, BIOCHEM BIOPH RES CO, V131, P402, DOI 10.1016/0006-291X(85)91816-9; Roberts RO, 2008, NEUROEPIDEMIOLOGY, V30, P58, DOI 10.1159/000115751; Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790; Schulze H, 2014, BBA-MOL CELL BIOL L, V1841, P799, DOI 10.1016/j.bbalip.2013.10.015; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Sleegers K, 2009, ANN NEUROL, V65, P603, DOI 10.1002/ana.21621; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Sun Y, 2005, J LIPID RES, V46, P2102, DOI 10.1194/jlr.M500202-JLR200; Sun Y, 2002, MOL GENET METAB, V76, P271, DOI 10.1016/S1096-7192(02)00114-2; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; WERB Z, 1974, J EXP MED, V140, P1482, DOI 10.1084/jem.140.6.1482; Xu SQ, 1998, J BIOL CHEM, V273, P20078, DOI 10.1074/jbc.273.32.20078; Yuan LB, 2010, J HISTOCHEM CYTOCHEM, V58, P287, DOI 10.1369/jhc.2009.955203	63	28	29	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	JUN	2016	7								11992	10.1038/ncomms11992			14	Multidisciplinary Sciences	Science & Technology - Other Topics	DQ3NN	WOS:000379109100001	27356620	DOAJ Gold, Green Published			2021-06-18	
J	Nolin, P; Stipanicic, A; Henry, M; Lachapelle, Y; Lussier-Desrochers, D; Rizzo, A; Allain, P				Nolin, Pierre; Stipanicic, Annie; Henry, Mylene; Lachapelle, Yves; Lussier-Desrochers, Dany; Rizzo, Albert Skip; Allain, Philippe			ClinicaVR: Classroom-CPT: A virtual reality tool for assessing attention and inhibition in children and adolescents	COMPUTERS IN HUMAN BEHAVIOR			English	Article						ClinicaVR; Classroom-CPT; Inhibition; Validity; Reliability; Children; Virtual reality; Virtual classroom	CONTINUOUS PERFORMANCE-TEST; TRAUMATIC BRAIN-INJURY; DEFICIT HYPERACTIVITY DISORDER; ECOLOGICAL VALIDITY; REHABILITATION; ENVIRONMENT; TASK; ADHD; SCENARIO	Having garnered interest both in clinic and research areas, the Virtual Classroom (Rizzo et al., 2000) assesses children's attention in a virtual context. The Digital MediaWorks team (www.dmw.ca) has evolved the original basic classroom concept over a number of iterations to form the ClinicaVR Suite containing the Classroom-CPT as one of its components. The present study has three aims: investigate certain validity and reliability aspects of the tool; examine the relationship between performance in the virtual test and the attendant sense of presence and cybersickness experienced by participants; assess potential effects of gender and age on performance in the test. The study was conducted with 102 children and adolescents from Grade 2 to Grade 10. All participants were enrolled in a regular school program. Results support both concurrent and construct validity as well as temporal stability of ClinicaVR: Classroom-Continuous Performance Test (CPT). Gender exerted no effect on performance, while age did. The test did not cause much cybersickness. We recommend ClinicaVR: Classroom-CPT as an assessment tool for selective and sustained attention, and inhibition, in clinic and research domains. (C) 2016 Elsevier Ltd. All rights reserved.	[Nolin, Pierre; Stipanicic, Annie; Henry, Mylene; Lachapelle, Yves; Lussier-Desrochers, Dany] Univ Quebec Trois Rivieres, Lab Rech Interdisciplinaire Real Virtuelle LARI R, Quebec City, PQ, Canada; [Nolin, Pierre; Stipanicic, Annie; Henry, Mylene; Lachapelle, Yves; Lussier-Desrochers, Dany] Univ Quebec Trois Rivieres, Chaire Rech Technol Soutien Autodeterminat, Chaire TSA, Quebec City, PQ, Canada; [Rizzo, Albert Skip] Univ So Calif, Dept Psychiat, Inst Creat Technol, Playa Vista, CA USA; [Rizzo, Albert Skip] Univ So Calif, Sch Gerontol, Playa Vista, CA USA; [Allain, Philippe] Univ Angers, LUNAM, Lab Psychol Pays de la Loire, EA 4638, Angers, France	Nolin, P (corresponding author), Univ Quebec Trois Rivieres, Dept Psychoeduc, Lab Rech Interdisciplinaire Real Virtuelle, CP 500, Trois Rivieres, PQ G9A 5H7, Canada.	pierre.nolin@uqtr.ca			Canada Foundation for Innovation (FCI)Canada Foundation for InnovationFonds der Chemischen Industrie [1842]; Ministere de l'Economie, de l'Innovation et des Exportations du Quebec (MDEIE); Fond de Developpement Academique du Roseau de l'Universite du Quebec (FODAR); Fonds Institutionnel de Recherche (FIR) de l'Universite du Quebec a Trois-Rivieres (UQTR)	This research was supported by Canada Foundation for Innovation (FCI, No. 1842), The Ministere de l'Economie, de l'Innovation et des Exportations du Quebec (MDEIE), the Fond de Developpement Academique du Roseau de l'Universite du Quebec (FODAR), and Fonds Institutionnel de Recherche (FIR) de l'Universite du Quebec a Trois-Rivieres (UQTR). The authors would like to thank Roman Mitura and Dean Klimchuk from the Digital MediaWorks company for allowing them to use the Virtual Classroom and ClinicaVR: Classroom. The authors would also like to thank the following people for their valuable contributions to this research project: the staff of the Academie les Estacades de Trois-Rivieres, particularly Mrs. Rosemarie Boucher, Mrs. Luce Mongrain and Mr. Michel Boutin; Dr. David Fecteau of the Centre Hospitalier Regional de Trois-Rivieres; Mr. Fernand Bouchard of the St. Maurice Physiotherapy Clinic; Mrs Nancy Mignault, directrice du Conseil du Loisir Scientifique - Trois-Rivieres, and all research assistants from our laboratory.	Adams R, 2009, CHILD NEUROPSYCHOL, V15, P120, DOI 10.1080/09297040802169077; Albani G, 2010, ANN REV CYBERTHERAPY, V8, P73; Allain P., 2011, J CYBERTHERAPY REHAB, V4, P278; Aymerich-Franch L, 2010, CYBERPSYCH BEH SOC N, V13, P649, DOI 10.1089/cyber.2009.0412; Baumgartner T, 2006, CYBERPSYCHOL BEHAV, V9, P30, DOI 10.1089/cpb.2006.9.30; Betts J, 2006, CHILD NEUROPSYCHOL, V12, P205, DOI 10.1080/09297040500488522; Bouchard S, 2007, ANN REV CYBERTHERAPY, V5, P128; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Cegalis JA, 1991, VIGIL SOFTWARE TESTI; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Egeland J, 2010, J ATTEN DISORD, V13, P339, DOI 10.1177/1087054708323019; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Gutierrez-Maldonado J, 2009, ANU PSICOL, V40, P211; Jovanovski D, 2012, APPL NEUROPSYCH-ADUL, V19, P207, DOI 10.1080/09084282.2011.643956; Kennedy R. S., 1993, Int'l. J. Aviat. Psychol., V3, P203, DOI [DOI 10.1207/S15327108IJAP0303_3, 10.1207/s15327108ijap0303_3]; Klinger E, 2009, ANN REV CYBERTHERAPY, V7, P248; Knight RG, 2009, BRAIN IMPAIR, V10, P3, DOI 10.1375/brim.10.1.3; Larson EB, 2011, BRAIN INJURY, V25, P274, DOI 10.3109/02699052.2010.551648; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Long CJ., 1996, ECOLOGICAL VALIDITY; Marcotte T., 2010, NEUROPSYCHOLOGY EVER; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; Moreau G, 2006, ANN REV CYBERTHERAPY, V4, P59; Nolin P, 2009, ANN REV CYBERTHERAPY, V7, P240; Parsons T., 2015, VIRTUAL REALITY TECH, P177; Parsons TD, 2005, AGING NEUROPSYCHOL C, V12, P78, DOI 10.1080/13825580590925125; Parsons TD, 2008, CYBERPSYCHOL BEHAV, V11, P17, DOI 10.1089/cpb.2007.9934; Parsons TD, 2007, CHILD NEUROPSYCHOL, V13, P363, DOI 10.1080/13825580600943473; Parsons TD, 2009, DEV NEUROREHABIL, V12, P224, DOI 10.1080/17518420902991719; Parsons TD, 2008, ANN REV CYBERTHERAPY, V6, P23; Penn PR, 2009, DEV NEUROREHABIL, V12, P32, DOI 10.1080/17518420902739365; Pollak Y, 2010, CNS SPECTRUMS, V15, P125, DOI 10.1017/S109285290002736X; Pollak Y, 2009, J DEV BEHAV PEDIATR, V30, P2, DOI 10.1097/DBP.0b013e3181969b22; Pugnetti L., 1998, CYBERPSYCHOL BEHAV, V1, P151; Raspelli S., 2009, J CYBERTHERAPY REHAB, V2, P299; Riva G, 2007, CYBERPSYCHOL BEHAV, V10, P45, DOI 10.1089/cpb.2006.9993; Rizzo AA, 2006, CNS SPECTRUMS, V11, P35, DOI 10.1017/S1092852900024196; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Rizzo AA, 2002, HUM FAC ER, P1027; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; Robillard G, 2002, 25 C SOC QUEB RECH P; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; Sbordone R.J., 2008, NEUROPSYCHOLOGY HDB, V3rd ed., P367; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P378, DOI 10.1097/00001199-200210000-00002; Sheridan T., 1992, PRESENCE TELEOP VIRT, V1, P120, DOI [10.1162/pres.1992.1.1.120, DOI 10.1162/PRES.1992.1.1.120]; Tarr MJ, 2002, NAT NEUROSCI, V5, P1089, DOI 10.1038/nn948; Trepagnier CG, 1999, NEUROREHABILITATION, V12, P63; van der Linden WJ, 2008, Z PSYCHOL, V216, P3, DOI 10.1027/0044-3409.216.1.3; van der Linden WJ, 2008, Z PSYCHOL, V216, P1, DOI 10.1027/0044-3409.216.1.1; Wang M, 2011, NEUROEPIDEMIOLOGY, V36, P2, DOI 10.1159/000320847; Witmer BG, 1998, PRESENCE-TELEOP VIRT, V7, P225, DOI 10.1162/105474698565686; Yen HL, 2007, ANN ACAD MED SINGAP, V36, P62	52	28	31	1	48	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0747-5632	1873-7692		COMPUT HUM BEHAV	Comput. Hum. Behav.	JUN	2016	59						327	333		10.1016/j.chb.2016.02.023			7	Psychology, Multidisciplinary; Psychology, Experimental	Psychology	DI8KB	WOS:000373748800035					2021-06-18	
J	Ponsford, JL; Spitz, G; McKenzie, D				Ponsford, Jennie L.; Spitz, Gershon; McKenzie, Dean			Using Post-Traumatic Amnesia To Predict Outcome after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						outcome prediction; post-traumatic amnesia; traumatic brain injury	GLASGOW COMA SCALE; HEAD-INJURY; MULTICENTER; SEVERITY; DURATION; UTILITY	Duration of post-traumatic amnesia (PTA) has emerged as a strong measure of injury severity after traumatic brain injury (TBI). Despite the growing international adoption of this measure, there remains a lack of consistency in the way in which PTA duration is used to classify severity of injury. This study aimed to establish the classification of PTA that would best predict functional or productivity outcomes. We conducted a cohort study of 1041 persons recruited from inpatient admissions to a TBI rehabilitation center between 1985 and 2013. Participants had a primary diagnosis of TBI, emerged from PTA before discharge from inpatient hospital, and engaged in productive activities before injury. Eight models that classify duration of PTA were evaluatedsix that were based on the literature and two that were statistically driven. Models were assessed using area under the receiver operating characteristic curve (AUC) as well as model-based Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) statistics. All categorization models showed longer PTA to be associated with a greater likelihood of being nonproductive at 1 year after TBI. Classification systems with a greater number of categories performed better than two-category systems. The dimensional (continuous) form of PTA resulted in the greatest AUC, and lowest AIC as well as BIC, of the classification systems examined. This finding indicates that the greatest accuracy in prognosis is likely to be achieved using PTA as a continuous variable. This enables the probability of productive outcomes to be estimated with far greater precision than that possible using a classification system. Categorizing PTA to classify severity of injury may be reducing the precision with which clinicians can plan the treatment of patients after TBI.	[Ponsford, Jennie L.; Spitz, Gershon] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Ponsford, Jennie L.; Spitz, Gershon] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [McKenzie, Dean] Epworth Healthcare, Res Dev & Governance, Melbourne, Vic, Australia; [McKenzie, Dean] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia.	Jennie.Ponsford@monash.edu			Transport Accident Commission (TAC), through the Institute for Safety, Compensation and Recovery Research (ISCRR)	This project is funded by the Transport Accident Commission (TAC), through the Institute for Safety, Compensation and Recovery Research (ISCRR).	Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; Brown AW, 2010, BRAIN INJURY, V24, P472, DOI 10.3109/02699051003610466; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Chatterjee S, 2012, REGRESSION ANAL EXAM; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Field A., 2013, DISCOVERING STAT USI, V4; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Jennett B, 1981, MANAGEMENT HEAD INJU; MacCallum RC, 2002, PSYCHOL METHODS, V7, P19, DOI 10.1037//1082-989X.7.1.19; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; Olshen RA, 1984, CLASSIFICATION REGRE; Osborne JasonW., 2015, BEST PRACTICES LOGIS; Ponsford J, 2012, TRAUMATIC BRAIN INJU; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Salford Systems, 2013, CART VERS 7; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; StataCorp, 2011, STAT STAT SOFTW REL; Symonds C., 1943, LANCET, V241, P7, DOI DOI 10.1016/S0140-6736(00)70687-8; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Williams JS, 2011, J HEALTH SERV RES PO, V16, P147, DOI 10.1258/jhsrp.2010.010063	32	28	28	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2016	33	11					997	1004		10.1089/neu.2015.4025			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DN3SU	WOS:000376984600003	26234939				2021-06-18	
J	Schmidt, JL; Tweten, DJ; Benegal, AN; Walker, CH; Portnoi, TE; Okamoto, RJ; Garbow, JR; Bayly, PV				Schmidt, J. L.; Tweten, D. J.; Benegal, A. N.; Walker, C. H.; Portnoi, T. E.; Okamoto, R. J.; Garbow, J. R.; Bayly, P. V.			Magnetic resonance elastography of slow and fast shear waves illuminates differences in shear and tensile moduli in anisotropic tissue	JOURNAL OF BIOMECHANICS			English	Article						MR Elastography; Shear waves; Anisotropy; Transversely isotropic material	VISCOELASTIC PROPERTIES; MR ELASTOGRAPHY; IN-VIVO; MECHANICAL-PROPERTIES; BRAIN-TISSUE; PARAMETERS; INVERSION	Mechanical anisotropy is an important property of fibrous tissues; for example, the anisotropic mechanical properties of brain white matter may play a key role in the mechanics of traumatic brain injury (TBI). The simplest anisotropic material model for small deformations of soft tissue is a nearly incompressible, transversely isotropic (M) material characterized by three parameters: minimum shear modulus (mu), shear anisotropy (phi = (mu 1)/(mu) - 1) and tensile anisotropy (zeta= (E1)/(E2) - 1). These parameters can be determined using magnetic resonance elastography (MRE) to visualize shear waves, if the angle between the shear-wave propagation direction and fiber direction is known. Most MRE studies assume isotropic material models with a single shear (mu) or tensile (E) modulus. In this study, two types of shear waves, "fast" and "slow", were analyzed for a given propagation direction to estimate anisotropic parameters mu, phi, and zeta in two fibrous soft materials: turkey breast ex vivo and aligned fibrin gels. As expected, the speed of slow shear waves depended on the angle between fiber direction and propagation direction. Fast shear waves were observed when the deformations due to wave motion induced stretch in the fiber direction. Finally, MRE estimates of anisotropic mechanical properties in turkey breast were compared to estimates from direct mechanical tests. (C) 2016 Elsevier Ltd. All rights reserved.	[Schmidt, J. L.; Tweten, D. J.; Okamoto, R. J.; Bayly, P. V.] Washington Univ, Mech Engn & Mat Sci, 1 Brookings Dr, St Louis, MO 63105 USA; [Benegal, A. N.; Walker, C. H.; Bayly, P. V.] Washington Univ, Biomed Engn, St Louis, MO 63105 USA; [Portnoi, T. E.] MIT, Elect Engn, Cambridge, MA 02139 USA; [Garbow, J. R.] Washington Univ, Radiol, Biomed Magnet Resonance Lab, St Louis, MO 63105 USA	Bayly, PV (corresponding author), Washington Univ, Mech Engn & Mat Sci, 1 Brookings Dr, St Louis, MO 63105 USA.	pvb@wustl.edu		Okamoto, Ruth/0000-0002-3085-3878	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055951]; NSFNational Science Foundation (NSF) [CMMI-1332433]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055951] Funding Source: NIH RePORTER	This study was supported by NIH Grant NS055951 (Bayly) and NSF Grant CMMI-1332433 (Bayly).	Aristizabal S, 2014, PHYS MED BIOL, V59, P7735, DOI 10.1088/0031-9155/59/24/7735; Asbach P, 2008, MAGN RESON MED, V60, P373, DOI 10.1002/mrm.21636; Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Auld BA., 1990, ACOUSTIC FIELDS WAVE; Clayton EH, 2011, PHYS MED BIOL, V56, P2391, DOI 10.1088/0031-9155/56/8/005; Feng Y, 2013, J BIOMECH, V46, P863, DOI 10.1016/j.jbiomech.2012.12.024; Feng Y, 2013, J MECH BEHAV BIOMED, V23, P117, DOI 10.1016/j.jmbbm.2013.04.007; Fitzgibbon A, 1999, IEEE T PATTERN ANAL, V21, P476, DOI 10.1109/34.765658; Flugge W., 1975, VISCOELASTICITY; Gennisson JL, 2003, J ACOUST SOC AM, V114, P536, DOI 10.1121/1.1579008; Green MA, 2013, NMR BIOMED, V26, P1387, DOI 10.1002/nbm.2964; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; Guo J., 2015, MAGN RESON MED; Johnson CL, 2013, MAGN RESON MED, V70, P404, DOI 10.1002/mrm.24473; Klatt D, 2010, PHYS MED BIOL, V55, P6445, DOI 10.1088/0031-9155/55/21/007; Klatt D, 2010, BIORHEOLOGY, V47, P133, DOI 10.3233/BIR-2010-0565; Manduca A, 2003, MED IMAGE ANAL, V7, P465, DOI 10.1016/S1361-8415(03)00038-0; Mariappan YK, 2009, MAGN RESON MED, V62, P1457, DOI 10.1002/mrm.22091; Murphy MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081668; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Muthupillai R, 1996, NAT MED, V2, P601, DOI 10.1038/nm0596-601; Namani R, 2012, J BIOMECH ENG-T ASME, V134, DOI 10.1115/1.4006848; Namani R, 2009, J BIOMECH, V42, P2047, DOI 10.1016/j.jbiomech.2009.06.007; Okamoto RJ, 2011, PHYS MED BIOL, V56, P6379, DOI 10.1088/0031-9155/56/19/014; Papazoglou S, 2006, MAGN RESON MED, V56, P489, DOI 10.1002/mrm.20993; Qin EC, 2014, RADIOLOGY, V273, P726, DOI 10.1148/radiol.14132661; Qin EC, 2013, J MAGN RESON IMAGING, V37, P217, DOI 10.1002/jmri.23797; Riek K, 2011, J BIOMECH, V44, P1380, DOI 10.1016/j.jbiomech.2010.12.031; Romano A, 2014, MAGN RESON MED, V72, P1755, DOI 10.1002/mrm.25067; Romano A, 2012, MAGN RESON MED, V68, P1410, DOI 10.1002/mrm.24141; Rouze NC, 2013, J BIOMECH, V46, P2761, DOI 10.1016/j.jbiomech.2013.09.008; Royer D, 2011, J ACOUST SOC AM, V129, P2757, DOI 10.1121/1.3559681; Sack I, 2008, NMR BIOMED, V21, P265, DOI 10.1002/nbm.1189; Sinkus R, 2005, MAGNET RESON MED, V53, P372, DOI 10.1002/mrm.20355; Tweten DJ, 2015, J BIOMECH, V48, P4002, DOI 10.1016/j.jbiomech.2015.09.009; Wang M, 2013, IEEE T MED IMAGING, V32, P1671, DOI 10.1109/TMI.2013.2262948	36	28	28	1	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	MAY 3	2016	49	7					1042	1049		10.1016/j.jbiomech.2016.02.018			8	Biophysics; Engineering, Biomedical	Biophysics; Engineering	DM0RB	WOS:000376052400009	26920505	Bronze, Green Accepted			2021-06-18	
J	Koutsoudaki, PN; Papastefanaki, F; Stamatakis, A; Kouroupi, G; Xingi, E; Stylianopoulou, F; Matsas, R				Koutsoudaki, Paraskevi N.; Papastefanaki, Florentia; Stamatakis, Antonios; Kouroupi, Georgia; Xingi, Evangelia; Stylianopoulou, Fotini; Matsas, Rebecca			Neural stem/progenitor cells differentiate into oligodendrocytes, reduce inflammation, and ameliorate learning deficits after transplantation in a mouse model of traumatic brain injury	GLIA			English	Article						insulin-like growth factor-I (IGF-I); mechanical brain trauma; hippocampus; astrogliosis; Morris Water Maze	GROWTH-FACTOR-I; SPINAL-CORD-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; PROMOTE FUNCTIONAL RECOVERY; CENTRAL-NERVOUS-SYSTEM; TEMPORAL-LOBE EPILEPSY; WHITE-MATTER INJURY; STEM-CELLS; PROGENITOR CELLS; MULTIPLE-SCLEROSIS	The central nervous system has limited capacity for regeneration after traumatic injury. Transplantation of neural stem/progenitor cells (NPCs) has been proposed as a potential therapeutic approach while insulin-like growth factor I (IGF-I) has neuroprotective properties following various experimental insults to the nervous system. We have previously shown that NPCs transduced with a lentiviral vector for IGF-I overexpression have an enhanced ability to give rise to neurons in vitro but also in vivo, upon transplantation in a mouse model of temporal lobe epilepsy. Here we studied the regenerative potential of NPCs, IGF-I-transduced or not, in a mouse model of hippocampal mechanical injury. NPC transplantation, with or without IGF-I transduction, rescued the injury-induced spatial learning deficits as revealed in the Morris Water Maze. Moreover, it had beneficial effects on the host tissue by reducing astroglial activation and microglial/macrophage accumulation while enhancing generation of endogenous oligodendrocyte precursor cells. One or two months after transplantation the grafted NPCs had migrated towards the lesion site and in the neighboring myelin-rich regions. Transplanted cells differentiated toward the oligodendroglial, but not the neuronal or astrocytic lineages, expressing the early and late oligodendrocyte markers NG2, Olig2, and CNPase. The newly generated oligodendrocytes reached maturity and formed myelin internodes. Our current and previous observations illustrate the high plasticity of transplanted NPCs which can acquire injury-dependent phenotypes within the host CNS, supporting the fact that reciprocal interactions between transplanted cells and the host tissue are an important factor to be considered when designing prospective cell-based therapies for CNS degenerative conditions. GLIA 2016;64:763-779	[Koutsoudaki, Paraskevi N.; Papastefanaki, Florentia; Kouroupi, Georgia; Matsas, Rebecca] Hellenic Pasteur Inst, Lab Cellular & Mol Neurobiol, 127 Vas Sofias Ave, Athens 11521, Greece; [Stamatakis, Antonios; Stylianopoulou, Fotini] Univ Athens, Fac Nursing, Dept Basic Sci, Biol Biochem Lab, Athens 11527, Greece; [Xingi, Evangelia] Hellenic Pasteur Inst, Light Microscopy Unit, Athens 11521, Greece	Matsas, R (corresponding author), Hellenic Pasteur Inst, Lab Cellular & Mol Neurobiol, 127 Vas Sofias Ave, Athens 11521, Greece.	rmatsa@pasteur.gr	STYLIANOPOULOU, FOTINI/B-1403-2008; Stamatakis, A./J-5294-2019; Xingi, Evangelia/AAA-4882-2020	Stamatakis, A./0000-0003-2480-5578; Koutsoudaki, Paraskevi N./0000-0003-4765-3730	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [FP7 REGPOT Neurosign 264083]; Greek Ministry of Education, Research and Religious Affairs [09SYN-21-969, Excellence I-2272, KRIPIS MIS450598]; Empeirikion Foundation; Theodore-Theochari Cozzika Foundation	Grant sponsor: European Commission; Grant number: FP7 REGPOT Neurosign 264083; Grant sponsor: Greek Ministry of Education, Research and Religious Affairs; Grant number: 09SYN-21-969, Excellence I-2272, KRIPIS MIS450598; Grant sponsor: Empeirikion Foundation.; F. Papastefanaki was recipient of a fellowship from the Theodore-Theochari Cozzika Foundation. The authors have no conflict of interest to declare.	Aberg ND, 2003, J NEUROSCI RES, V74, P12, DOI 10.1002/jnr.10734; Altemus KL, 1997, HIPPOCAMPUS, V7, P403, DOI 10.1002/(SICI)1098-1063(1997)7:4<403::AID-HIPO6>3.0.CO;2-J; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Barkas LJ, 2010, BEHAV BRAIN RES, V208, P535, DOI 10.1016/j.bbr.2009.12.035; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; Blaya MO, 2015, EXP NEUROL, V264, P67, DOI 10.1016/j.expneurol.2014.11.014; CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O; Cendes F, 2014, ACTA NEUROPATHOL, V128, P21, DOI 10.1007/s00401-014-1292-0; Chesik D, 2007, INT REV NEUROBIOL, V79, P203, DOI 10.1016/S0074-7742(07)79009-8; Cossetti C, 2014, MOL CELL, V56, P193, DOI 10.1016/j.molcel.2014.08.020; Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]; Crocker SJ, 2011, NEUROPATH APPL NEURO, V37, P643, DOI 10.1111/j.1365-2990.2011.01165.x; Curt A, 2012, EXPERT OPIN BIOL TH, V12, P271, DOI 10.1517/14712598.2012.655722; Cusimano M, 2012, BRAIN, V135, P447, DOI 10.1093/brain/awr339; Drago D, 2013, BIOCHIMIE, V95, P2271, DOI 10.1016/j.biochi.2013.06.020; Ebert AD, 2008, EXP NEUROL, V209, P213, DOI 10.1016/j.expneurol.2007.09.022; Einstein O, 2009, J NEUROSCI, V29, P15694, DOI 10.1523/JNEUROSCI.3364-09.2009; Enomoto M, 2003, EUR J NEUROSCI, V17, P1223, DOI 10.1046/j.1460-9568.2003.02555.x; Fernandez AM, 2012, NAT REV NEUROSCI, V13, P225, DOI 10.1038/nrn3209; Franklin KBJ, 2001, MOUSE BRAIN STEREOTA; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gerlai RT, 2002, BRAIN RES BULL, V57, P3, DOI 10.1016/S0361-9230(01)00630-X; Gold AE, 2005, HIPPOCAMPUS, V15, P808, DOI 10.1002/hipo.20103; Groticke I, 2007, EXP NEUROL, V207, P329, DOI 10.1016/j.expneurol.2007.06.021; Hsieh J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/jcb.200308101; Hwang DH, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-117; Kalladka D, 2014, STEM CELLS CLONING, V7, P31, DOI 10.2147/SCCAA.S38003; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Katsimpardi L, 2008, STEM CELLS, V26, P1796, DOI 10.1634/stemcells.2007-0921; Kazanis I, 2004, EXP NEUROL, V186, P221, DOI 10.1016/j.expneurol.2003.12.004; Kazanis I, 2003, BRAIN RES, V991, P34, DOI 10.1016/S0006-8993(03)03525-X; Kesner RP, 2004, REV NEUROSCIENCE, V15, P333; Kim DS, 2010, STEM CELLS, V28, P2099, DOI 10.1002/stem.526; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Kouroupi G, 2010, J NEUROCHEM, V115, P460, DOI 10.1111/j.1471-4159.2010.06939.x; Koutsoudaki PN, 2009, NEUROSCI LETT, V451, P83, DOI 10.1016/j.neulet.2008.11.058; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Laterza C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3597; Levine JB, 1999, GLIA, V28, P215; Li MF, 2013, CELL PHYSIOL BIOCHEM, V32, P1776, DOI 10.1159/000356611; Liu X, 1995, Mult Scler, V1, P2; Livingstone SA, 2007, BEHAV BRAIN RES, V185, P21, DOI 10.1016/j.bbr.2007.07.015; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Makri G, 2010, STEM CELLS, V28, P127, DOI 10.1002/stem.258; Mallucci G, 2015, PROG NEUROBIOL, V127, P1, DOI 10.1016/j.pneurobio.2015.02.003; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; Miltiadous P, 2013, STEM CELL TRANSL MED, V2, P185, DOI 10.5966/sctm.2012-0074; Miltiadous P, 2011, EXP NEUROL, V231, P223, DOI 10.1016/j.expneurol.2011.06.014; Miltiadous P, 2010, CELL MOL NEUROBIOL, V30, P347, DOI 10.1007/s10571-009-9457-4; Mitome M, 2001, BRAIN, V124, P2147, DOI 10.1093/brain/124.11.2147; Muller CJ, 2009, EXP NEUROL, V219, P284, DOI 10.1016/j.expneurol.2009.05.035; Muller FJ, 2006, NAT REV NEUROSCI, V7, P75, DOI 10.1038/nrn1829; Nudi ET, 2015, J NEUROTRAUM, V32, P1117, DOI 10.1089/neu.2014.3618; Papastefanaki F, 2007, BRAIN, V130, P2159, DOI 10.1093/brain/awm155; Papastefanaki F, 2015, GLIA, V63, P1101, DOI 10.1002/glia.22809; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Plemel JR, 2011, GLIA, V59, P1891, DOI 10.1002/glia.21232; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Pluchino S, 2013, GLIA, V61, P1379, DOI 10.1002/glia.22500; Politi LS, 2007, STEM CELLS, V25, P2583, DOI 10.1634/stemcells.2007-0037; Poltavtseva RA, 2012, B EXP BIOL MED+, V153, P586, DOI 10.1007/s10517-012-1772-y; Porambo M, 2015, GLIA, V63, P452, DOI 10.1002/glia.22764; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sakowski SA, 2009, AMYOTROPH LATERAL SC, V10, P63, DOI 10.1080/17482960802160370; Salewski RP, 2015, STEM CELL TRANSL MED, V4, P743, DOI 10.5966/sctm.2014-0236; Samanta J, 2015, NATURE, V526, P448, DOI 10.1038/nature14957; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; Schwarzmaier SM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00358; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Skardelly M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00318; Sun Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057534; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Toft A, 2013, GLIA, V61, P513, DOI 10.1002/glia.22452; Torres-Aleman I, 2007, EXPERT OPIN THER TAR, V11, P1535, DOI 10.1517/14728222.11.12.1535; van der Staay FJ, 2000, PHYSIOL BEHAV, V68, P599, DOI 10.1016/S0031-9384(99)00236-X; van Praag H, 1998, BEHAV BRAIN RES, V92, P21, DOI 10.1016/S0166-4328(97)00117-4; Vargas MR, 2010, NEUROTHERAPEUTICS, V7, P471, DOI 10.1016/j.nurt.2010.05.012; Vicario-Abejon C, 2003, J NEUROSCI, V23, P895; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Wallenquist U, 2009, RESTOR NEUROL NEUROS, V27, P323, DOI 10.3233/RNN-2009-0481; Wang JY, 2013, CNS NEUROL DISORD-DR, V12, P413, DOI 10.2174/1871527311312030014; Whitman LM, 2012, EXP NEUROL, V235, P380, DOI 10.1016/j.expneurol.2012.03.003; Yan J, 2007, PLOS MED, V4, P318, DOI 10.1371/journal.pmed.0040039; Yasuda A, 2011, STEM CELLS, V29, P1983, DOI 10.1002/stem.767; Ye P, 2004, J NEUROSCI RES, V78, P472, DOI 10.1002/jnr.20288; Yokota K, 2015, STEM CELL REP, V5, P264, DOI 10.1016/j.stemcr.2015.06.004; Zawadzka M, 2010, CELL STEM CELL, V6, P578, DOI 10.1016/j.stem.2010.04.002	90	28	29	0	38	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAY	2016	64	5					763	779		10.1002/glia.22959			17	Neurosciences	Neurosciences & Neurology	DI0OR	WOS:000373197000007	26712314				2021-06-18	
J	Dams-O'Connor, K; Gibbons, LE; Landau, A; Larson, EB; Crane, PK				Dams-O'Connor, Kristen; Gibbons, Laura E.; Landau, Alexandra; Larson, Eric B.; Crane, Paul K.			Health Problems Precede Traumatic Brain Injury in Older Adults	JOURNAL OF THE AMERICAN GERIATRICS SOCIETY			English	Article						traumatic brain injury; health; older adults	RISK; AGE; DISEASE; EPIDEMIOLOGY; MORTALITY; DEMENTIA; FALLS	ObjectivesTo evaluate whether indices of preinjury health and functioning are associated with risk of incident traumatic brain injury (TBI) with loss of consciousness (LOC) and to evaluate health-related factors associated with mortality in individuals with incident TBI. DesignProspective community cohort study. SettingGroup Health, Seattle, Washington. ParticipantsIndividuals aged 65 and older with no self-reported prior TBI with LOC (N = 3,363) were enrolled and followed every 2 years for an average of 7.5 years (range 0-18 years). MeasurementsWeibull survival models were used to evaluate baseline and time-varying predictors of incident TBI with LOC, including measures of depression, activities of daily living (ADLs), cerebrovascular disease, and disease comorbidity. ResultsIn an adjusted multivariate model, baseline depression symptoms as measured according to Center for Epidemiologic Studies Depression Scale (CES-D) score (hazard ratio (HR) for 4 points = 1.23, 95% confidence interval (CI) = 1.02-1.49, P = .03) and baseline activity of daily living (ADL) impairment (HR = 2.37, 95% CI = 1.24-4.53, P = .009) were associated with incident TBI. In a model that included time-dependent covariates, cerebrovascular disease at the previous visit (HR = 2.28, 95% CI = 1.37-3.78, P < .001), CES-D score the previous visit (HR for 4 points = 1.23, 95% CI = 1.02-1.49, P < .04) and baseline ADL impairment (HR 2.14, 95% CI = 1.11-4.13, P = .02) predicted incident TBI. Of factors considered, cerebrovascular disease and ADL impairment were associated with earlier mortality in participants with incident TBI with LOC. ConclusionIndices of health, mood, and functional status predict incident TBI with LOC in older adults. These findings may have implications for injury prevention and postinjury clinical management.	[Dams-O'Connor, Kristen; Landau, Alexandra] Icahn Sch Med Mt Sinai, Dept Rehabil Med, One Gustave L Levy Pl,Box 1240, New York, NY 10029 USA; [Gibbons, Laura E.; Crane, Paul K.] Univ Washington, Sch Med, Div Gen Internal Med, Seattle, WA 98195 USA; [Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA	Dams-O'Connor, K (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, One Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.	kristen.dams-o'connor@mountsinai.org			National Institutes of Health (NIH), National Institute on Aging (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG006781]; NIH, National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651-01A1]; NIH, NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG05136]; NIH, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS086625]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005136, U01AG006781] Funding Source: NIH RePORTER	This project was supported by Grants U01 AG006781 (Larson, National Institutes of Health (NIH), National Institute on Aging (NIA)), K01HD074651-01A1 (DamsO'Connor, NIH, National Institute of Child Health and Human Development), P50 AG05136 (Montine, NIH, NIA), and U01 NS086625 (PI Wayne Gordon, NIH, National Institute of Neurological Disorders and Stroke).	Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Eaton W.W., 2004, USE PSYCHOL TESTING, P363, DOI DOI 10.1111/J.1083-6101.2007.00367.X; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fishman PA, 2003, MED CARE, V41, P84, DOI 10.1097/00005650-200301000-00011; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Gray SL, 2013, J GERONTOL A-BIOL, V68, P1083, DOI 10.1093/gerona/glt013; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Koepsell TD, 2004, J AM GERIATR SOC, V52, P1495, DOI 10.1111/j.1532-5415.2004.52412.x; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Leibson CL, 2012, J NEUROTRAUM, V29, P2038, DOI 10.1089/neu.2010.1713; Lindsey JC, 1998, STAT MED, V17, P219, DOI 10.1002/(SICI)1097-0258(19980130)17:2<219::AID-SIM735>3.0.CO;2-O; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McMillan TM, 2014, J NEUROL NEUROSUR PS, V85, P1214, DOI 10.1136/jnnp-2013-307279; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Nordstrom A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f723; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Rockhill CM, 2010, BRAIN INJURY, V24, P1051, DOI 10.3109/02699052.2010.494586; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shumway-Cook A, 2009, PHYS THER, V89, P324, DOI 10.2522/ptj.20070107; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Wang L, 2002, J AM GERIATR SOC, V50, P1525, DOI 10.1046/j.1532-5415.2002.50408.x	29	28	29	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0002-8614	1532-5415		J AM GERIATR SOC	J. Am. Geriatr. Soc.	APR	2016	64	4					844	848		10.1111/jgs.14014			5	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	DK1WO	WOS:000374705900016	26925541	Green Accepted, Bronze			2021-06-18	
J	Li, XW; Tzeng, SY; Liu, XY; Tammia, M; Cheng, YH; Rolfe, A; Sun, D; Zhang, N; Green, JJ; Wen, XJ; Mao, HQ				Li, Xiaowei; Tzeng, Stephany Y.; Liu, Xiaoyan; Tammia, Markus; Cheng, Yu-Hao; Rolfe, Andrew; Sun, Dong; Zhang, Ning; Green, Jordan J.; Wen, Xuejun; Mao, Hai-Quan			Nanoparticle-mediated transcriptional modification enhances neuronal differentiation of human neural stem cells following transplantation in rat brain	BIOMATERIALS			English	Article						Nanoparticles; Transfection; Neurogenin-2; Neuronal differentiation; Traumatic brain injury	GENE DELIVERY; PRECURSOR CELLS; GROWTH-FACTOR; DNA DELIVERY; TRANSFECTION; SURVIVAL; ADULT; EXPRESSION; GENERATION; VECTORS	Strategies to enhance survival and direct the differentiation of stem cells in vivo following transplantation in tissue repair site are critical to realizing the potential of stem cell-based therapies. Here we demonstrated an effective approach to promote neuronal differentiation and maturation of human fetal tissue derived neural stem cells (hNSCs) in a brain lesion site of a rat traumatic brain injury model using biodegradable nanoparticle-mediated transfection method to deliver key transcriptional factor neurogenin-2 to hNSCs when transplanted with a tailored hyaluronic acid (HA) hydrogel, generating larger number of more mature neurons engrafted to the host brain tissue than non-transfected cells. The nanoparticle-mediated transcription activation method together with an HA hydrogel delivery matrix provides a translatable approach for stem cell-based regenerative therapy. (C) 2016 Elsevier Ltd. All rights reserved.	[Li, Xiaowei; Tzeng, Stephany Y.; Tammia, Markus; Cheng, Yu-Hao; Green, Jordan J.; Mao, Hai-Quan] Johns Hopkins Sch Med, Translat Tissue Engn Ctr, Baltimore, MD 21287 USA; [Li, Xiaowei; Tammia, Markus; Green, Jordan J.; Mao, Hai-Quan] Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA; [Tzeng, Stephany Y.; Green, Jordan J.] Johns Hopkins Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; [Liu, Xiaoyan; Zhang, Ning] Virginia Commonwealth Univ, Sch Engn, Dept Biomed Engn, Richmond, VA 23284 USA; [Rolfe, Andrew; Sun, Dong] Virginia Commonwealth Univ, Dept Neurosurg, Med Coll Virginia, Richmond, VA 23298 USA; [Green, Jordan J.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; [Wen, Xuejun] Virginia Commonwealth Univ, Sch Engn, Dept Chem & Life Sci Engn, Richmond, VA 23284 USA; [Wen, Xuejun] Virginia Commonwealth Univ, 601 West Main St, Richmond, VA 23284 USA	Mao, HQ (corresponding author), Johns Hopkins Univ, 113 Maryland Hall,3400 N Charles St, Baltimore, MD 21218 USA.	xwen@vcu.edu; hmao@jhu.edu	Green, Jordan/B-9001-2009; Cheng, Yu-Hao/D-3686-2016	Green, Jordan/0000-0003-4176-3808; Mao, Hai-Quan/0000-0002-4262-9988; Cheng, Yu-Hao/0000-0002-7472-8518	U.S. National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS085714, R21NS078710-02]; National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [1R01EB016721]; U.S. National Science FoundationNational Science Foundation (NSF) [CBET 1312970]; Stiftelsen Olle Engkvist ByggmastareSwedish Research Council; Foundation Blanceflor Boncompagni-Ludovisi, nee Bildt; Hans Werthen fonden; Maryland Stem Cell Research Fund [2013MSCRF-00042169]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY001765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB016721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078710, R21NS085714] Funding Source: NIH RePORTER; Directorate For EngineeringNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [1312970] Funding Source: National Science Foundation	This work was supported by the U.S. National Institute of Neurological Disorders and Stroke (R21NS085714 to H.-Q. M. and R21NS078710-02 to D. S.), National Institute of Biomedical Imaging and Bioengineering (1R01EB016721 to J. J. G.), and the U.S. National Science Foundation Faculty Early Career Awards (CBET 1312970 to N.Z.). M.T. acknowledges partial support by fellowships from Stiftelsen Olle Engkvist Byggmastare, the Foundation Blanceflor Boncompagni-Ludovisi, nee Bildt, and Hans Werthen fonden. X.-W. L acknowledges a postdoctoral fellowship from the Maryland Stem Cell Research Fund (2013MSCRF-00042169).	Aldskogius H, 2009, STEM CELLS, V27, P1592, DOI 10.1002/stem.77; Bharali DJ, 2005, P NATL ACAD SCI USA, V102, P11539, DOI 10.1073/pnas.0504926102; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; Chen X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031547; DeKosky ST, 2004, J NEUROTRAUM, V21, P491, DOI 10.1089/089771504774129838; Delcroix GJR, 2010, BIOMATERIALS, V31, P2105, DOI 10.1016/j.biomaterials.2009.11.084; Deng B, 2013, BIOMATERIALS, V34, P8786, DOI 10.1016/j.biomaterials.2013.07.076; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gonzalez F, 2009, P NATL ACAD SCI USA, V106, P8918, DOI 10.1073/pnas.0901471106; Guerrero-Cazares H, 2014, ACS NANO, V8, P5141, DOI 10.1021/nn501197v; Hester ME, 2011, MOL THER, V19, P1905, DOI 10.1038/mt.2011.135; Hicks AU, 2009, EUR J NEUROSCI, V29, P562, DOI 10.1111/j.1460-9568.2008.06599.x; Hovakimyan M, 2012, ANN ANAT, V194, P429, DOI 10.1016/j.aanat.2012.05.003; Jandial R, 2008, MOL THER, V16, P450, DOI 10.1038/sj.mt.6300402; Johanson C, 2011, J NEURAL TRANSM, V118, P115, DOI 10.1007/s00702-010-0498-0; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Li X., 2013, METHODS COMPOSITIONS; Li XW, 2014, STEM CELL TRANSL MED, V3, P662, DOI 10.5966/sctm.2013-0015; Li XW, 2013, FASEB J, V27, P1127, DOI 10.1096/fj.12-211151; Li XW, 2012, MED HYPOTHESES, V79, P274, DOI 10.1016/j.mehy.2012.05.010; Liu ML, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3183; Lynn DM, 2001, J AM CHEM SOC, V123, P8155, DOI 10.1021/ja016288p; Montserrat N, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.168013; Mothe AJ, 2008, CELL TRANSPLANT, V17, P735, DOI 10.3727/096368908786516756; Nauta A, 2013, MOL THER, V21, P445, DOI 10.1038/mt.2012.234; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Pang ZPP, 2011, NATURE, V476, P220, DOI 10.1038/nature10202; Pickard MR, 2011, BIOMATERIALS, V32, P2274, DOI 10.1016/j.biomaterials.2010.12.007; Sunshine J, 2009, ADV MATER, V21, P4947, DOI 10.1002/adma.200901718; Sunshine JC, 2011, THER DELIV, V2, P493, DOI 10.4155/TDE.11.14; Tammia M., 2012, DMSO SHOCK YIELDS HI; Tseng TC, 2014, BIOMATERIALS, V35, P2630, DOI 10.1016/j.biomaterials.2013.12.021; Tzeng SY, 2013, J BIOMED MATER RES A, V101, P1837, DOI 10.1002/jbm.a.34616; Tzeng SY, 2013, ADV HEALTHC MATER, V2, P468, DOI 10.1002/adhm.201200257; Tzeng SY, 2012, BIOMATERIALS, V33, P8142, DOI 10.1016/j.biomaterials.2012.07.036; Tzeng SY, 2011, BIOMATERIALS, V32, P5402, DOI 10.1016/j.biomaterials.2011.04.016; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang F, 2009, GENE THER, V16, P533, DOI 10.1038/gt.2008.182; Yi SH, 2008, MOL THER, V16, P1873, DOI 10.1038/mt.2008.189	39	28	29	1	71	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	APR	2016	84						157	166		10.1016/j.biomaterials.2016.01.037			10	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	DF5BT	WOS:000371367500014	26828681	Green Accepted, Bronze			2021-06-18	
J	Kumar, RG; Rubin, JE; Berger, RP; Kochanek, PM; Wagner, AK				Kumar, Raj G.; Rubin, Jonathan E.; Berger, Rachel P.; Kochanek, Patrick M.; Wagner, Amy K.			Principal components derived from CSF inflammatory profiles predict outcome in survivors after severe traumatic brain injury	BRAIN BEHAVIOR AND IMMUNITY			English	Article						TBI; Inflammation; Principal component analysis; Cluster analysis; Interleukins; Cytokines; Soluble cell surface markers; Outcome; Prognosis; Rehabilomics	CEREBROSPINAL-FLUID; HORMONE-LEVELS; MARKERS; REHABILITATION; NEUTRALIZATION; ASSOCIATIONS; PROGNOSIS; BIOMARKER; CYTOKINE; IMPACT	Studies have characterized absolute levels of multiple inflammatory markers as significant risk factors for poor outcomes after traumatic brain injury (TBI). However, inflammatory marker concentrations are highly inter-related, and production of one may result in the production or regulation of another. Therefore, a more comprehensive characterization of the inflammatory response post-TBI should consider relative levels of markers in the inflammatory pathway. We used principal component analysis (PCA) as a dimension-reduction technique to characterize the sets of markers that contribute independently to variability in cerebrospinal (CSF) inflammatory profiles after TBI. Using PCA results, we defined groups (or clusters) of individuals (n = 111) with similar patterns of acute CSF inflammation that were then evaluated in the context of outcome and other relevant CSF and serum biomarkers collected days 0-3 and 4-5 post-injury. We identified four significant principal components (PC1-PC4) for CSF inflammation from days 0-3, and PC1 accounted for the greatest (31%) percentage of variance. PC1 was characterized by relatively higher CSF sICAM-1, sFAS, IL-10, IL-6, sVCAM-1, IL-5, and IL-8 levels. Cluster analysis then defined two distinct clusters, such that individuals in cluster 1 had highly positive PC1 scores and relatively higher levels of CSF cortisol, progesterone, estradiol, testosterone, brain derived neurotrophic factor (BDNF), and S100b; this group also had higher serum cortisol and lower serum BDNF. Multinomial logistic regression analyses showed that individuals in cluster I had a 10.9 times increased likelihood of GOS scores of 2/3 vs. 4/5 at 6 months compared to cluster 2, after controlling for covariates. Cluster group did not discriminate between mortality compared to GOS scores of 4/5 after controlling for age and other covariates. Cluster groupings also did not discriminate mortality or 12 month outcomes in multivariate models. PCA and cluster analysis establish that a subset of CSF inflammatory markers measured in days 0-3 post-TBI may distinguish individuals with poor 6-month outcome, and future studies should prospectively validate these findings. PCA of inflammatory mediators after TBI could aid in prognostication and in identifying patient subgroups for therapeutic interventions. (C) 2015 Elsevier Inc. All rights reserved.	[Kumar, Raj G.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15260 USA; [Rubin, Jonathan E.] Univ Pittsburgh, Dept Math, 301 Thackeray Hall, Pittsburgh, PA 15260 USA; [Berger, Rachel P.; Kochanek, Patrick M.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Berger, Rachel P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15260 USA.; Rubin, JE (corresponding author), Univ Pittsburgh, Dept Math, 301 Thackeray Hall, Pittsburgh, PA 15260 USA.	jonrubin@pitt.edu; wagnerak@upmc.edu	RUBIN, JONATHAN/AAD-9071-2019	Rubin, Jonathan/0000-0002-1513-1551	CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CCR 323155]; DODUnited States Department of Defense [W81XWH-071-0701]; NIDILRRUnited States Department of Health & Human Services [90DP0041-02-01]; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMOUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U48DP000041] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER	The authors wish to thank the UPMC Trauma Registry for providing some elements of data collection. The authors also wish to thank the University of Pittsburgh Cancer Institute for Luminex services. This work was supported in part by: CDC: R49 CCR 323155, DOD: W81XWH-071-0701, NIDILRR 90DP0041-02-01.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bryant F B, 1995, PRINCIPAL COMPONENTS; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CDC, NAT VIT STAT SYST MO; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Crownover J, 2012, CURR GERIATR REP, V1, P149, DOI 10.1007/s13670-012-0021-6; Daun S, 2008, J CRIT CARE, V23, P585, DOI 10.1016/j.jcrc.2008.02.003; De Guise E., 2015, BRAIN INJURY, P1; Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Failla M.D., 2015, NEUROREHABIL NEURAL; Friedland-Leuner K, 2014, PROG MOL BIOL TRANSL, V127, P183, DOI 10.1016/B978-0-12-394625-6.00007-6; Garringer JA, 2013, J NEUROTRAUM, V30, P1415, DOI 10.1089/neu.2012.2565; GERMANN T, 1993, EUR J IMMUNOL, V23, P1762, DOI 10.1002/eji.1830230805; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Grimm L.G., 1995, READING UNDERSTANDIN; HALLENBECK JM, 1977, NEUROLOGY, V27, P3, DOI 10.1212/WNL.27.1.3; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; JENNETT B, 1975, LANCET, V1, P480; Jeong Hey-Kyeong, 2013, Exp Neurobiol, V22, P59, DOI 10.5607/en.2013.22.2.59; Juengst S.B., 2014, J HEAD TRAUMA REHABI; Kaiser H.F., 1960, ED PSYCHOL MEAS; Kirchhoff C, 2006, J NEUROTRAUM, V23, P943, DOI 10.1089/neu.2006.23.943; Kumar R., 2014, J HEAD TRAUMA REHABI; Lourbopoulos A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00054; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Machado RF, 2005, AM J RESP CRIT CARE, V171, P1286, DOI 10.1164/rccm.200409-1184OC; MacQueen J., 1967, P 5 BERK S MATH STAT, P281; Mocchegiani E, 2014, AGEING RES REV, V14, P81, DOI 10.1016/j.arr.2014.01.001; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nettleton JA, 2007, AM J CLIN NUTR, V85, P1615; Norden D., 2014, NEUROPHARMACOLOGY; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roe C, 2013, J REHABIL MED, V45, P734, DOI 10.2340/16501977-1198; Salminen LE, 2014, REV NEUROSCIENCE, V25, P805, DOI 10.1515/revneuro-2014-0046; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Suhr DD, 2005, P SUGI, P203, DOI DOI 10.1177/096228029200100105; Tadevosyan-Leyfer O, 2003, J AM ACAD CHILD PSY, V42, P864, DOI 10.1097/01.CHI.0000046870.56865.90; WAGNER A, 2015, J NEUROTRAUM, V32, pA92, DOI DOI 10.1089/NEU.2015.29000.ABSTRACTS; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xu K, 2008, ADV EXP MED BIOL, V614, P379, DOI 10.1007/978-0-387-74911-2_42	51	28	30	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAR	2016	53						183	193		10.1016/j.bbi.2015.12.008			11	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	DG9BJ	WOS:000372377500019	26705843	Bronze, Green Accepted			2021-06-18	
J	Nordin, LE; Moller, MC; Julin, P; Bartfai, A; Hashim, F; Li, TQ				Nordin, Love Engstrom; Moller, Marika Christina; Julin, Per; Bartfai, Aniko; Hashim, Farouk; Li, Tie-Qiang			Post mTBI fatigue is associated with abnormal brain functional connectivity	SCIENTIFIC REPORTS			English	Article							ANTERIOR CINGULATE CORTEX; DEFAULT-MODE NETWORK; RESTING-STATE; INJURY; MRI; CONCUSSION; DISRUPTION; ATTENTION; SELECTION; RECOVERY	This study set out to investigate the behavioral correlates of changes in resting-state functional connectivity before and after performing a 20 minute continuous psychomotor vigilance task (PVT) for patients with chronic post-concussion syndrome. Ten patients in chronic phase after mild traumatic brain injury (mTBI) with persisting symptoms of fatigue and ten matched healthy controls participated in the study. We assessed the participants' fatigue levels and conducted resting-state fMRI before and after a sustained PVT. We evaluated the changes in brain functional connectivity indices in relation to the subject's fatigue behavior using a quantitative data-driven analysis approach. We found that the PVT invoked significant mental fatigue and specific functional connectivity changes in mTBI patients. Furthermore, we found a significant linear correlation between self-reported fatigue and functional connectivity in the thalamus and middle frontal cortex. Our findings indicate that resting-state fMRI measurements may be a useful indicator of performance potential and a marker of fatigue level in the neural attentional system.	[Nordin, Love Engstrom; Li, Tie-Qiang] Karolinska Univ Hosp Huddinge, Dept Diagnost Med Phys, Stockholm, Sweden; [Nordin, Love Engstrom; Hashim, Farouk; Li, Tie-Qiang] Karolinska Inst, Div Med Imaging & Technol, Dept Clin Sci Intervent & Technol, Stockholm, Sweden; [Moller, Marika Christina; Julin, Per; Bartfai, Aniko] Karolinska Inst, KIDS, Danderyd Hosp, Dept Clin Sci, Solnavagen 1, S-17177 Solna, Sweden; [Moller, Marika Christina] Uppsala Univ, Ctr Clin Res, Sormland, Uppsala, Sweden; [Julin, Per] Stora Skondal Fdn, Neurol Rehabil Clin, Stockholm, Sweden; [Hashim, Farouk] Karolinska Univ Hosp, Dept Radiol, Stockholm, Sweden	Nordin, LE (corresponding author), Karolinska Univ Hosp Huddinge, Dept Diagnost Med Phys, Stockholm, Sweden.; Nordin, LE (corresponding author), Karolinska Inst, Div Med Imaging & Technol, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.	love.engstrom-nordin@karolinska.se	Moller, Marika/S-5427-2019; MAller, Marika C/N-8782-2016	Moller, Marika/0000-0001-8700-5186; MAller, Marika C/0000-0001-8700-5186; Hashim, Farouk/0000-0003-1656-4217; Li, Tie-Qiang/0000-0002-4866-5904	Swedish Research CouncilSwedish Research CouncilEuropean Commission; ALF Medicine in Stockholm; Centre for Clinical Research Sormland and Promobilia; Karolinska InstituteKarolinska Institutet; Karolinska University HospitalKarolinska Institutet	This study was supported by research grants from the Swedish Research Council, ALF Medicine in Stockholm, Centre for Clinical Research Sormland and Promobilia. The authors also would like to acknowledge the support from Karolinska Institute and Karolinska University Hospital.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Brzezicka A, 2013, BEHAV BRAIN SCI, V36, P682, DOI 10.1017/S0140525X13000940; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Dobryakova E., 2013, J INT NEUROPSYCH SOC, V19, P1; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gronwall D, 1989, MILD HEAD INJURY, P153; Hetherington H, 2015, Handb Clin Neurol, V127, P309, DOI 10.1016/B978-0-444-52892-6.00020-9; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kiviniemi V, 2009, HUM BRAIN MAPP, V30, P3865, DOI 10.1002/hbm.20813; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Leung HC, 2002, J COGNITIVE NEUROSCI, V14, P659, DOI 10.1162/08989290260045882; Li T. Q., 2015, P ISMRM, P1256; Lim J, 2010, NEUROIMAGE, V49, P3426, DOI 10.1016/j.neuroimage.2009.11.020; Mastropasqua C, 2015, BRAIN TOPOGR, V28, P548, DOI 10.1007/s10548-014-0422-2; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Moller MC, 2014, J CLIN EXP NEUROPSYC, V36, P716, DOI 10.1080/13803395.2014.933779; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Park HJ, 2013, SCIENCE, V342, P579, DOI 10.1126/science.1238411; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shin SS, 2014, PROG NEUROL SURG, V28, P86, DOI 10.1159/000358767; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Sours C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134019; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; van der Linden D, 2003, ACTA PSYCHOL, V113, P45, DOI 10.1016/S0001-6918(02)00150-6; Wang YL, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00259; Wang YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076315; Yuan R, 2016, BRAIN STRUCT FUNCT, V221, P1971, DOI 10.1007/s00429-015-1018-7; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	51	28	28	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	FEB 16	2016	6								21183	10.1038/srep21183			12	Multidisciplinary Sciences	Science & Technology - Other Topics	DD8KV	WOS:000370176300003	26878885	DOAJ Gold, Green Published			2021-06-18	
J	Meier, TB; Bellgowan, PSF; Bergamino, M; Ling, JM; Mayer, AR				Meier, Timothy B.; Bellgowan, Patrick S. F.; Bergamino, Maurizio; Ling, Josef M.; Mayer, Andrew R.			Thinner Cortex in Collegiate Football Players With, but not Without, a Self-Reported History of Concussion	JOURNAL OF NEUROTRAUMA			English	Article						anterior cingulate; concussion; cortical thickness; football; fractional anisotropy	TRAUMATIC BRAIN-INJURY; CORTICAL THICKNESS; NEUROCOGNITIVE PERFORMANCE; DEPRESSIVE SYMPTOMS; ABNORMALITIES; DYSFUNCTION; VALIDATION; DISORDER; VALIDITY; VOLUME	Emerging evidence suggests that a history of sports-related concussions can lead to long-term neuroanatomical changes. The extent to which similar changes are present in young athletes is undetermined at this time. Here, we tested the hypothesis that collegiate football athletes with (n=25) and without (n=24) a self-reported history of concussion would have cortical thickness differences and altered white matter integrity relative to healthy controls (n=27) in fronto-temporal regions that appear particularly susceptible to traumatic brain injury. Freesurfer software was used to estimate cortical thickness, fractional anisotropy was calculated in a priori white matter tracts, and behavior was assessed using a concussion behavioral battery. Groups did not differ in self-reported symptoms (p>0.10) or cognitive performance (p>0.10). Healthy controls reported significantly higher happiness levels than both football groups (all p<0.01). Contrary to our hypothesis, no differences in fractional anisotropy were observed between our groups (p>0.10). However, football athletes with a history of concussion had significantly thinner cortex in the left anterior cingulate cortex, orbital frontal cortex, and medial superior frontal cortex relative to healthy controls (p=0.02, d= -0.69). Further, football athletes with a history of concussion had significantly thinner cortex in the right central sulcus and precentral gyrus relative to football athletes without a history of concussion (p=0.03, d= -0.71). No differences were observed between football athletes without a history of concussion and healthy controls. These results suggest that previous concussions, but not necessarily football exposure, may be associated with cortical thickness differences in collegiate football athletes.	[Meier, Timothy B.; Ling, Josef M.; Mayer, Andrew R.] Mind Res Network, Lovelace Biomed & Environm Res Inst, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA; [Meier, Timothy B.; Bergamino, Maurizio] Laureate Inst Brain Res, Tulsa, OK USA; [Bellgowan, Patrick S. F.] NINDS, NIH, North Bethesda, MD USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Meier, TB (corresponding author), Mind Res Network, Lovelace Biomed & Environm Res Inst, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	tmeier@mrn.org	Meijer, Anna/K-5118-2016				Albaugh M. D., 2014, J PEDIAT, V166, P394; Alosco ML, 2014, BRAIN INJURY, V28, P472, DOI 10.3109/02699052.2014.887145; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Etkin A, 2011, TRENDS COGN SCI, V15, P85, DOI 10.1016/j.tics.2010.11.004; Euston DR, 2012, NEURON, V76, P1057, DOI 10.1016/j.neuron.2012.12.002; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Iverson G. L., 2014, J NEUROTRAUMA; Johnson DR, 2008, ARCH CLIN NEUROPSYCH, V23, P73, DOI 10.1016/j.acn.2007.10.001; Jones TB, 2010, NEUROIMAGE, V49, P401, DOI 10.1016/j.neuroimage.2009.07.051; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mori S, 2007, AM J PSYCHIAT, V164, P1005, DOI 10.1176/appi.ajp.164.7.1005; Narr KL, 2009, J AM ACAD CHILD PSY, V48, P1014, DOI 10.1097/CHI.0b013e3181b395c0; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pardoe HR, 2013, HUM BRAIN MAPP, V34, P3000, DOI 10.1002/hbm.22120; Porto L, 2011, EUR J PAEDIATR NEURO, V15, P493, DOI 10.1016/j.ejpn.2011.06.004; Proal E, 2011, ARCH GEN PSYCHIAT, V68, P1122, DOI 10.1001/archgenpsychiatry.2011.117; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Roebuck-Spencer TM, 2013, ARCH CLIN NEUROPSYCH, V28, P700, DOI 10.1093/arclin/act055; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shaw P, 2006, ARCH GEN PSYCHIAT, V63, P540, DOI 10.1001/archpsyc.63.5.540; Short P, 2007, ARCH CLIN NEUROPSYCH, V22, pS63, DOI 10.1016/j.acn.2006.10.012; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Talairach J., 1988, COPLANAR STEREOTAXIC; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Turken And U, 2009, BMC Med Imaging, V9, P20, DOI 10.1186/1471-2342-9-20; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	57	28	28	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2016	33	4					330	338		10.1089/neu.2015.3919			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DD2NH	WOS:000369758800002	26061068	Green Published			2021-06-18	
J	Jarrett, M; Tam, R; Hernandez-Torres, E; Martin, N; Perera, W; Zhao, YS; Shahinfard, E; Dadachanji, S; Taunton, J; Li, DKB; Rauscher, A				Jarrett, Michael; Tam, Roger; Hernandez-Torres, Enedino; Martin, Nancy; Perera, Warren; Zhao, Yinshan; Shahinfard, Elham; Dadachanji, Shiroy; Taunton, Jack; Li, David K. B.; Rauscher, Alexander			A Prospective Pilot Investigation of Brain Volume, White Matter Hyperintensities, and Hemorrhagic Lesions after Mild Traumatic Brain Injury	FRONTIERS IN NEUROLOGY			English	Article						concussion; mTBI; MRI; neuroimaging; brain volume; susceptibility-weighted imaging; white matter hyperintensities	ROBUST; SPORT; ENCEPHALOPATHY; OPTIMIZATION; REGISTRATION; DEHYDRATION; PREVALENCE; MRI	Traumatic brain injury (TBI) is among the most common neurological disorders. Hemorrhagic lesions and white matter hyperintensities (VVMH) are radiological features associated with moderate and severe TBI. Brain volume reductions have also been observed during the months following injury. In concussion, no signs of injury are observed on conventional magnetic resonance imaging (MRI), which may be a true feature of concussion or merely due to the limited sensitivity of imaging techniques used so far. Moreover, it is not known whether volume reductions are due to the resolution of trauma related edema or a true volume loss. Forty-five collegiate-level ice hockey players (20 females) and 15 controls (9 females), 40 players underwent 3-T MRI for hemorrhages [multi-echo susceptibility-weighted imaging (SWI)], WMH (three-dimensional fluid-attenuated inversion recovery), and brain volume at the beginning and the end of the hockey season. Concussed athletes underwent additional imaging and neuropsychological testing at 3 days, 2 weeks, and 2 months after injury. At the end of the hockey season, brain volume was reduced compared to controls by 0.32% (p < 0.034) in the whole cohort and by 0.26% (p < 0.09) in the concussed athletes. Two weeks and 2 months after concussion, brain volume was reduced by 0.08% (p = 0.027) and 0.23% (p = 0.035), respectively. In athletes, the WMH were significantly closer to the interface between gray matter and white matter compared to controls. No significant changes in the number of WMH over the duration of the study were found in athletes. No microhemorrhages were detected as a result of concussion or playing a season of ice hockey. We conclude that mild TBI does not lead to transient increases in brain volume and no new microbleeds or WMH are detectable after concussion. Brain volume reductions appear by 2 weeks after concussion and persist until at least 2 months after concussion. Brain volume is reduced between the beginning and the end of the ice hockey season.	[Jarrett, Michael; Hernandez-Torres, Enedino; Li, David K. B.; Rauscher, Alexander] Univ British Columbia, UBC MRI Res Ctr, Vancouver, BC V5Z 1M9, Canada; [Tam, Roger; Li, David K. B.] Univ British Columbia, Dept Radiol, Vancouver, BC, Canada; [Tam, Roger; Li, David K. B.] Univ British Columbia, MS MRI Res Grp, Vancouver, BC V5Z 1M9, Canada; [Martin, Nancy] Richmond Hosp, Dept Radiol, Richmond, BC, Canada; [Martin, Nancy] Burnaby Hosp, Dept Radiol, Burnaby, BC, Canada; [Martin, Nancy] Delta Hosp, Dept Radiol, Delta, BC, Canada; [Perera, Warren] St Vincents Hosp, Dept Med Imaging, Melbourne, Vic, Australia; [Zhao, Yinshan; Shahinfard, Elham] Univ British Columbia, Dept Med, Div Neurol, Vancouver, BC V6T 1W5, Canada; [Dadachanji, Shiroy; Taunton, Jack] Univ British Columbia, Fac Med, Div Sports Med, Vancouver, BC, Canada; [Rauscher, Alexander] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V5Z 1M9, Canada; [Rauscher, Alexander] Univ British Columbia, Dept Pediat, Div Neurol, Vancouver, BC V6T 1W5, Canada	Rauscher, A (corresponding author), Univ British Columbia, UBC MRI Res Ctr, Vancouver, BC V5Z 1M9, Canada.; Rauscher, A (corresponding author), Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V5Z 1M9, Canada.; Rauscher, A (corresponding author), Univ British Columbia, Dept Pediat, Div Neurol, Vancouver, BC V6T 1W5, Canada.	rauscher@physics.ubc.ca	Hernandez-Torres, Enedino/AAG-2483-2019	Hernandez-Torres, Enedino/0000-0003-2873-5693; Shahinfard, Elham/0000-0002-3526-0086; Jarrett, Michael/0000-0002-3702-2014; Rauscher, Alexander/0000-0002-1961-8252	London Drugs Award for Research Excellence; Canadian Institutes for Health Research New Investigator AwardCanadian Institutes of Health Research (CIHR); CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT)	Funding was provided by the London Drugs Award for Research Excellence. AR is supported by a Canadian Institutes for Health Research New Investigator Award. EH-T is supported by a grant from CONACYT.	Baayen R. H., 2008, ANAL LINGUISTIC DATA; Bates D., 2014, LME4 LINEAR MIXED EF; Bigler E.D, 2015, BRAIN NEUROTRAUMA MO, P433; Biller A, 2015, AM J NEURORADIOL, V36, P2277, DOI 10.3174/ajnr.A4508; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Denk C, 2010, J MAGN RESON IMAGING, V31, P185, DOI 10.1002/jmri.21995; Duning T, 2005, NEUROLOGY, V64, P548, DOI 10.1212/01.WNL.0000150542.16969.CC; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gunter JL, 2009, MED PHYS, V36, P2193, DOI 10.1118/1.3116776; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Hartwigsen G, 2010, J COMPUT ASSIST TOMO, V34, P596, DOI 10.1097/RCT.0b013e3181d9c2bb; Hopkins RO, 2006, J NEUROIMAGING, V16, P243, DOI 10.1111/j.1552-6569.2006.00047.x; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kempton MJ, 2009, HUM BRAIN MAPP, V30, P291, DOI 10.1002/hbm.20500; Koennecke HC, 2006, NEUROLOGY, V66, P165, DOI 10.1212/01.wnl.0000194266.55694.1e; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2011, J SPORT REHABIL, V20, P46, DOI 10.1123/jsr.20.1.46; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Watson P, 2010, MED SCI SPORT EXER, V42, P2197, DOI 10.1249/MSS.0b013e3181e39788; Wiggermann V, 2016, AM J NEURORADIOL, V37, P259, DOI 10.3174/ajnr.A4514; Wilcox BJ, 2014, J ATHL TRAINING, V49, P514, DOI 10.4085/1062-6050-49.3.19; Wilson D, 2014, EXPERT REV NEUROTHER, V14, P661, DOI 10.1586/14737175.2014.918506; Zagorchev L, 2016, J NEUROTRAUM, V33, P29, DOI 10.1089/neu.2014.3831; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	36	28	29	0	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	FEB 12	2016	7								11	10.3389/fneur.2016.00011			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DE2CB	WOS:000370432700001	26903944	DOAJ Gold, Green Published			2021-06-18	
J	Lin, CM; Tseng, YC; Hsu, HL; Chen, CJ; Chen, DYT; Yan, FX; Chiu, WT				Lin, Che-Ming; Tseng, Ying-Chi; Hsu, Hui-Ling; Chen, Chi-Jen; Chen, David Yen-Ting; Yan, Feng-Xian; Chiu, Wen-Ta			Arterial Spin Labeling Perfusion Study in the Patients with Subacute Mild Traumatic Brain Injury	PLOS ONE			English	Article							CEREBRAL BLOOD-VOLUME; SEVERE HEAD-INJURY; TECHNETIUM-99M-HMPAO SPECT; ISCHEMIA; FLOW; MRI; 3T; CT	Background This study uses a MRI technique, three-dimension pulse continuous arterial spin labeling (3D-PCASL), to measure the patient's cerebral blood flow (CBF) at the subacute stage of mild traumatic brain injury (MTBI) in order to analyze the relationship between cerebral blood flow and neurocognitive deficits. Objective To provide the relationship between cortical CBF and neuropsychological dysfunction for the subacute MTBI patients. Methods After MTBI, perfusion MR imaging technique (3D-PCASL) measures the CBF of MTBI patients (n = 23) within 1 month and that of normal controls (n = 22) to determine the quantity and location of perfusion defect. The correlation between CBF abnormalities and cognitive deficits was elucidated by combining the results of the neuropsychological tests of the patients. Result We observed a substantial reduction in CBF in the bilateral frontal and left occipital cortex as compared with the normal persons. In addition, there were correlation between post concussive symptoms (including dizziness and simulator sickness) and CBF in the hypoperfused areas. The more severe symptom was correlated with higher CBF in bilateral frontal and left occipital lobes. Conclusion First, this study determined that despite no significant abnormality detected on conventional CT and MRI studies, hypoperfusion was observed in MTBI group using 3D-PCASL technique in subacute stage, which suggested that this approach may increase sensitivity to MTBI. Second, the correlation between CBF and the severity of post concussive symptoms suggested that changes in cerebral hemodynamicsmay play a role in pathophysiology underlies the symptoms.	[Lin, Che-Ming; Tseng, Ying-Chi; Hsu, Hui-Ling; Chen, Chi-Jen; Chen, David Yen-Ting; Yan, Feng-Xian; Chiu, Wen-Ta] Taipei Med Univ, Shuang Ho Hosp, Dept Diagnost Radiol, New Taipei, Taiwan; [Lin, Che-Ming; Tseng, Ying-Chi; Hsu, Hui-Ling; Chen, Chi-Jen; Chen, David Yen-Ting; Yan, Feng-Xian; Chiu, Wen-Ta] Taipei Med Univ, Shuang Ho Hosp, Brain & Consciousness Res Ctr, New Taipei, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei, Taiwan; [Lin, Che-Ming; Tseng, Ying-Chi; Hsu, Hui-Ling; Chen, Chi-Jen; Chen, David Yen-Ting; Yan, Feng-Xian] Taipei Med Univ, Sch Med, Dept Radiol, Coll Med, New Taipei, Taiwan; [Chen, Chi-Jen] Minist Hlth & Welf, Chia Yi Hosp, Chiayi, Taiwan	Hsu, HL (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Dept Diagnost Radiol, New Taipei, Taiwan.; Hsu, HL (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Brain & Consciousness Res Ctr, New Taipei, Taiwan.; Hsu, HL (corresponding author), Taipei Med Univ, Sch Med, Dept Radiol, Coll Med, New Taipei, Taiwan.	anne.hlh@gmail.com					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Audenaert K., 2003, MED SCI MONITOR, V9, P112; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BOUMA GJ, 1993, ACTA NEUROCHIR, P34; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Chang TY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076072; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Davis P, 2012, EXPERT PANEL ON NEUR, V14; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2009, J MAGN RESON IMAGING, V29, P1425, DOI 10.1002/jmri.21794; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Nariai T, 2001, J NEUROTRAUM, V18, P1323, DOI 10.1089/08977150152725623; Piker EG, 2008, J AM ACAD AUDIOL, V19, P337, DOI 10.3766/jaaa.19.4.6; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Wong AM, 2014, J MAGN RESON IMAGING, V39, P427, DOI 10.1002/jmri.24178	32	28	28	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2016	11	2							e0149109	10.1371/journal.pone.0149109			11	Multidisciplinary Sciences	Science & Technology - Other Topics	DD6SI	WOS:000370054100107	26871696	DOAJ Gold, Green Published			2021-06-18	
S	Jayakumar, AR; Norenberg, MD		Schousboe, A; Sonnewald, U		Jayakumar, Arumugam R.; Norenberg, Michael D.			Glutamine Synthetase: Role in Neurological Disorders	GLUTAMATE/GABA-GLUTAMINE CYCLE: AMINO ACID NEUROTRANSMITTER HOMEOSTASIS	Advances in Neurobiology		English	Article; Book Chapter						Ammonia; Astrocytes; Glutamine synthetase; Glutamine; Excitotoxicity; Neurological disorders; Neurotoxicity; Therapy	FIBRILLARY ACIDIC PROTEIN; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; FULMINANT HEPATIC-FAILURE; METHIONINE-S-SULFOXIMINE; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; ORNITHINE-L-ASPARTATE; ACUTE LIVER-FAILURE; ALZHEIMERS-DISEASE	Glutamine synthetase (GS) is an ATP-dependent enzyme found in most species that synthesizes glutamine from glutamate and ammonia. In brain, GS is exclusively located in astrocytes where it serves to maintain the glutamate-glutamine cycle, as well as nitrogen metabolism. Changes in the activity of GS, as well as its gene expression, along with excitotoxicity, have been identified in a number of neurological conditions. The literature describing alterations in the activation and gene expression of GS, as well as its involvement in different neurological disorders, however, is incomplete. This review summarizes changes in GS gene expression/activity and its potential contribution to the pathogenesis of several neurological disorders, including hepatic encephalopathy, ischemia, epilepsy, Alzheimer's disease, amyotrophic lateral sclerosis, traumatic brain injury, Parkinson's disease, and astroglial neoplasms. This review also explores the possibility of targeting GS in the therapy of these conditions.	[Jayakumar, Arumugam R.; Norenberg, Michael D.] Vet Affairs Med Ctr, Neuropathol Lab, Miami, FL 33125 USA; [Norenberg, Michael D.] Univ Miami, Sch Med, Dept Pathol, POB 016960, Miami, FL 33101 USA	Norenberg, MD (corresponding author), Vet Affairs Med Ctr, Neuropathol Lab, Miami, FL 33125 USA.; Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu			NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK063311] Funding Source: Medline		Agostinho P, 2010, CURR PHARM DESIGN, V16, P2766, DOI 10.2174/138161210793176572; Akinmoladun AC, 2015, NEUROCHEM RES, V40, P777, DOI 10.1007/s11064-015-1527-z; Aksenov MY, 1996, J NEUROCHEM, V66, P2050; Allen RS, 2014, EXP NEUROL, V254, P206, DOI 10.1016/j.expneurol.2014.02.005; Anlauf Enrico, 2013, Front Endocrinol (Lausanne), V4, P144, DOI 10.3389/fendo.2013.00144; Babu CS, 2009, PHARMACOL BIOCHEM BE, V92, P424, DOI 10.1016/j.pbb.2009.01.010; Bak LK, 2006, J NEUROCHEM, V98, P641, DOI 10.1111/j.1471-4159.2006.03913.x; Bame M, 2012, GENDER MED, V9, P524, DOI 10.1016/j.genm.2012.10.014; Battaglia F, 2007, BIOL PSYCHIAT, V62, P1405, DOI 10.1016/j.biopsych.2007.02.027; BAUDRY M, 1986, J NEUROSCI, V6, P3430; Behrens PF, 2002, BRAIN, V125, P1908, DOI 10.1093/brain/awf180; Bender AS, 1996, NEUROCHEM RES, V21, P567, DOI 10.1007/BF02527755; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bernstein HG, 2013, CNS NEUROL DISORD-DR, V12, P900, DOI 10.2174/18715273113129990091; BLEI AT, 1994, HEPATOLOGY, V19, P1437, DOI 10.1002/hep.1840190619; Bondy SC, 1998, MOL CHEM NEUROPATHOL, V34, P219, DOI 10.1007/BF02815081; Bristol LA, 1996, ANN NEUROL, V39, P676, DOI 10.1002/ana.410390519; Bruneau EG, 2005, SCHIZOPHR RES, V75, P27, DOI 10.1016/j.schres.2004.12.012; Burbaeva GS, 2005, NEUROCHEM RES, V30, P1443, DOI 10.1007/s11064-005-8654-x; Butterfield DA, 1997, J NEUROCHEM, V68, P2451; CAPOCACCIA L, 1991, DIGEST DIS SCI, V36, P775, DOI 10.1007/BF01311236; Cardenas-Rodriguez N, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/759293; CARTER CJ, 1983, LIFE SCI, V32, P1949, DOI 10.1016/0024-3205(83)90046-2; CARTER CJ, 1982, LIFE SCI, V31, P1151, DOI 10.1016/0024-3205(82)90090-X; CARTER CJ, 1981, LANCET, V1, P782; Castegna A, 2011, NEUROSCIENCE, V185, P97, DOI 10.1016/j.neuroscience.2011.04.041; CHAO CC, 1992, J CLIN INVEST, V90, P1786, DOI 10.1172/JCI116053; Chatauret N, 2006, J HEPATOL, V44, P1083, DOI 10.1016/j.jhep.2005.11.048; Chiu IM, 2009, P NATL ACAD SCI USA, V106, P20960, DOI 10.1073/pnas.0911405106; Chiu IM, 2008, P NATL ACAD SCI USA, V105, P17913, DOI 10.1073/pnas.0804610105; Choudary PV, 2005, P NATL ACAD SCI USA, V102, P15653, DOI 10.1073/pnas.0507901102; CHUNG SH, 1984, PROC R SOC SER B-BIO, V221, P145, DOI 10.1098/rspb.1984.0028; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Crunelli V, 2015, NEUROSCIENTIST, V21, P62, DOI 10.1177/1073858414523320; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Dam G, 2011, AM J PHYSIOL-GASTR L, V301, pG269, DOI 10.1152/ajpgi.00062.2011; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Desjardins P, 1999, METAB BRAIN DIS, V14, P273, DOI 10.1023/A:1020741226752; DiGiacomo C, 1997, NEUROCHEM RES, V22, P1145, DOI 10.1023/A:1027321420075; Dorfman D, 2013, EXP NEUROL, V240, P146, DOI 10.1016/j.expneurol.2012.11.017; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; Dugan L.L., 1999, BASIC NEUROCHEMISTRY, V6th; Dutuit M, 2000, GLIA, V32, P15, DOI 10.1002/1098-1136(200010)32:1<15::AID-GLIA20>3.0.CO;2-#; EDE RJ, 1986, SEMIN LIVER DIS, V6, P107, DOI 10.1055/s-2008-1040594; Eid T, 2013, NEUROCHEM INT, V63, P670, DOI 10.1016/j.neuint.2013.06.008; Eid T, 2008, BRAIN, V131, P2061, DOI 10.1093/brain/awn133; Fernandez DC, 2009, J NEUROCHEM, V111, P488, DOI 10.1111/j.1471-4159.2009.06334.x; FLOYD RA, 1990, FASEB J, V4, P2587; FOLBERGROVA J, 1993, J CEREBR BLOOD F MET, V13, P145, DOI 10.1038/jcbfm.1993.17; Fujioka M, 2003, ANN NEUROL, V54, P732, DOI 10.1002/ana.10751; Garrett R. H., 2007, BIOCHEMISTRY; Ghoddoussi F, 2010, J NEUROL SCI, V290, P41, DOI 10.1016/j.jns.2009.11.013; GIRARD G, 1993, METAB BRAIN DIS, V8, P207, DOI 10.1007/BF01001062; Gorovits R, 1996, MOL BRAIN RES, V43, P321, DOI 10.1016/S0169-328X(96)00213-6; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRIFFITH OW, 1978, J BIOL CHEM, V253, P2333; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Haussinger D, 2005, METAB BRAIN DIS, V20, P285, DOI 10.1007/s11011-005-7908-2; HAWKINS RA, 1993, J NEUROCHEM, V60, P1000, DOI 10.1111/j.1471-4159.1993.tb03247.x; Hensley K, 2006, ANTIOXID REDOX SIGN, V8, P2075, DOI 10.1089/ars.2006.8.2075; HERBERG LJ, 1992, EPILEPSY RES, V11, P3, DOI 10.1016/0920-1211(92)90015-L; Hertz L, 2004, TRENDS NEUROSCI, V27, P735, DOI 10.1016/j.tins.2004.10.008; Hertz Leif, 2013, Front Endocrinol (Lausanne), V4, P59, DOI 10.3389/fendo.2013.00059; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; Hilgier W, 1981, Neuropatol Pol, V19, P351; Hirata T, 1996, STROKE, V27, P729, DOI 10.1161/01.STR.27.4.729; Hirata T, 1999, AM J PHYSIOL-HEART C, V276, pH456; Holownia Adam, 1994, Materia Medica Polona, V26, P25; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; Itzen A, 2011, TRENDS BIOCHEM SCI, V36, P219, DOI 10.1016/j.tibs.2010.12.004; Jalan R, 2007, MED HYPOTHESES, V69, P1064, DOI 10.1016/j.mehy.2006.12.061; Jarrett SG, 2008, J NEUROCHEM, V106, P1044, DOI 10.1111/j.1471-4159.2008.05460.x; JOHNSON WL, 1965, ELECTROEN CLIN NEURO, V18, P229, DOI 10.1016/0013-4694(65)90089-1; Jones EA, 1997, J NEUROL NEUROSUR PS, V63, P279, DOI 10.1136/jnnp.63.3.279; Justin A, 2014, PHARMACOL BIOCHEM BE, V122, P61, DOI 10.1016/j.pbb.2014.03.009; Kalkman HO, 2011, MED HYPOTHESES, V76, P905, DOI 10.1016/j.mehy.2011.03.005; KANAMORI K, 1993, NMR BIOMED, V6, P21, DOI 10.1002/nbm.1940060104; Kim S, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-413; Klempan TA, 2009, MOL PSYCHIATR, V14, P175, DOI 10.1038/sj.mp.4002110; Kosenko E, 2003, NEUROCHEM INT, V43, P493, DOI 10.1016/S0197-0186(03)00039-1; Kruchkova Y, 2001, J NEUROCHEM, V77, P1641, DOI 10.1046/j.1471-4159.2001.00390.x; LAVOIE J, 1987, METAB BRAIN DIS, V2, P283, DOI 10.1007/BF00999698; Lee A, 2010, J CHEM NEUROANAT, V39, P211, DOI 10.1016/j.jchemneu.2009.12.002; Lee DR, 2003, BRAIN RES, V989, P221, DOI 10.1016/S0006-8993(03)03373-0; Lee Y, 2013, J PSYCHIATR NEUROSCI, V38, P183, DOI 10.1503/jpn.120024; Leite MC, 2006, BRAIN RES BULL, V70, P179, DOI 10.1016/j.brainresbull.2006.05.003; LEPRINCE G, 1995, NEUROCHEM RES, V20, P859, DOI 10.1007/BF00969698; LEVENTAL M, 1972, ARCH INT PHYSIOL BIO, V80, P861; LIAW SH, 1994, BIOCHEMISTRY-US, V33, P675, DOI 10.1021/bi00169a007; LOCKWOOD AH, 1991, J CEREBR BLOOD F MET, V11, P337, DOI 10.1038/jcbfm.1991.67; Loeppen S, 2002, CANCER RES, V62, P5685; Master S, 1999, HEPATOLOGY, V30, P876, DOI 10.1002/hep.510300428; Matos M, 2008, NEUROSCIENCE, V156, P898, DOI 10.1016/j.neuroscience.2008.08.022; Matsumoto M, 2008, SURG NEUROL, V70, P122, DOI 10.1016/j.surneu.2007.07.011; MCCORMICK D, 1990, NEUROPATH APPL NEURO, V16, P205, DOI 10.1111/j.1365-2990.1990.tb01157.x; Miguel-Hidalgo JJ, 2002, BRAIN RES, V958, P210, DOI 10.1016/S0006-8993(02)03731-9; Miguel-Hidalgo JJ, 2010, J AFFECT DISORDERS, V127, P230, DOI 10.1016/j.jad.2010.06.003; Nagele RG, 2004, NEUROBIOL AGING, V25, P663, DOI 10.1016/j.neurobiolaging.2004.01.007; Nakajima K, 2015, NEUROSCI LETT, V591, P99, DOI 10.1016/j.neulet.2015.02.021; NAKAMURA K, 1984, P NATL ACAD SCI-BIOL, V81, P2011, DOI 10.1073/pnas.81.7.2011; Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x; Nielsen HM, 2009, GLIA, V57, P978, DOI 10.1002/glia.20822; Norenberg MD, 2007, METAB BRAIN DIS, V22, P219, DOI 10.1007/s11011-007-9062-5; NORENBERG MD, 1977, LAB INVEST, V36, P618; NORENBERG MD, 1979, J HISTOCHEM CYTOCHEM, V27, P756, DOI 10.1177/27.3.39099; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; Norenberg MD, 1983, GLUTAMINE GLUTAMATE, P95; Olabarria M, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-55; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PAHLMARK K, 1993, STROKE, V24, P731, DOI 10.1161/01.STR.24.5.731; Pascual JM, 1998, STROKE, V29, P1048, DOI 10.1161/01.STR.29.5.1048; PERRY TL, 1981, LANCET, V1, P1261; PETITO CK, 1992, BRAIN RES, V569, P275, DOI 10.1016/0006-8993(92)90639-Q; PHILLIS JW, 1994, PROG NEUROBIOL, V42, P441, DOI 10.1016/0301-0082(94)90046-9; Pike CJ, 1996, EXP NEUROL, V139, P167, DOI 10.1006/exnr.1996.0091; PILKINGTON GJ, 1982, NEUROPATH APPL NEURO, V8, P227, DOI 10.1111/j.1365-2990.1982.tb00277.x; PROLER M, 1962, EPILEPSIA, V3, P117, DOI 10.1111/j.1528-1157.1962.tb05237.x; PROLER ML, 1965, NEUROLOGY, V15, P931, DOI 10.1212/WNL.15.10.931; Radford RA, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00414; Rajkowska G, 2013, CURR DRUG TARGETS, V14, P1225; Rao KVR, 2012, NEUROCHEM INT, V61, P575, DOI 10.1016/j.neuint.2012.01.012; REINER L, 1950, ARCH BIOCHEM, V25, P447; Revett TJ, 2013, J PSYCHIATR NEUROSCI, V38, P6, DOI 10.1503/jpn.110190; RICHMAN PG, 1973, J BIOL CHEM, V248, P6684; Robinson SR, 2000, NEUROCHEM INT, V36, P471, DOI 10.1016/S0197-0186(99)00150-3; Rosati A, 2013, NEURO-ONCOLOGY, V15, P618, DOI 10.1093/neuonc/nos338; Rosati A, 2009, J NEURO-ONCOL, V93, P319, DOI 10.1007/s11060-008-9794-z; Rose C, 1998, METAB BRAIN DIS, V13, P147, DOI 10.1023/A:1020613314572; Rose C, 1999, HEPATOLOGY, V30, P636, DOI 10.1002/hep.510300311; ROWE WB, 1970, P NATL ACAD SCI USA, V66, P500, DOI 10.1073/pnas.66.2.500; Safwen K, 2015, INT J STROKE, V10, P415, DOI 10.1111/ijs.12391; SALLANON M, 1992, CR ACAD SCI III-VIE, V315, P109; SCHATZ RA, 1975, J NEUROCHEM, V24, P63, DOI 10.1111/j.1471-4159.1975.tb07628.x; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Sequeira A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006585; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Shin JY, 2005, J CELL BIOL, V171, P1001, DOI 10.1083/jcb.200508072; Silvestrin RB, 2013, BRAIN RES, V1495, P52, DOI 10.1016/j.brainres.2012.11.048; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Stryer L, 2007, BIOCHEMISTRY-US, P679; Suarez I, 1997, NEUROPATH APPL NEURO, V23, P254, DOI 10.1046/j.1365-2990.1997.9198091.x; Suarez I, 1996, METAB BRAIN DIS, V11, P369, DOI 10.1007/BF02029497; Suarez I, 2002, NEUROCHEM INT, V41, P123, DOI 10.1016/S0197-0186(02)00033-5; Sugimoto H, 1997, J CEREBR BLOOD F MET, V17, P44, DOI 10.1097/00004647-199701000-00006; Sun HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066885; Sunil AG, 2011, BRAIN RES BULL, V84, P394, DOI 10.1016/j.brainresbull.2011.01.008; TAKAHASHI H, 1991, AM J PHYSIOL, V261, pH825; TAKAHASHI H, 1992, CIRC RES, V71, P1220, DOI 10.1161/01.RES.71.5.1220; TAKAHASHI K, 1993, NEUROSCI LETT, V151, P51, DOI 10.1016/0304-3940(93)90043-K; TANAKA H, 1992, EXP NEUROL, V116, P264, DOI 10.1016/0014-4886(92)90006-C; Tanigami H, 2005, NEUROSCIENCE, V131, P437, DOI 10.1016/j.neuroscience.2004.10.045; THOMAS JW, 1988, METAB BRAIN DIS, V3, P81, DOI 10.1007/BF01001011; Thompson MD, 2011, J HEPATOL, V54, P506, DOI 10.1016/j.jhep.2010.07.020; THORN W, 1958, J NEUROCHEM, V2, P166, DOI 10.1111/j.1471-4159.1958.tb12361.x; Thurman DJ, 2011, EPILEPSIA, V52, P2, DOI 10.1111/j.1528-1167.2011.03121.x; TIFFANYCASTIGLIONI EC, 1990, J NEUROSCI RES, V25, P223, DOI 10.1002/jnr.490250210; Toro CT, 2006, NEUROSCI LETT, V404, P276, DOI 10.1016/j.neulet.2006.05.067; Torres-Vega MA, 2015, GENE THER, V22, P58, DOI 10.1038/gt.2014.89; Tumani H, 1999, ARCH NEUROL-CHICAGO, V56, P1241, DOI 10.1001/archneur.56.10.1241; van den Berg C. J, 1970, HANDBOOK NEUROCHEMIS, P355; van der Hel WS, 2005, NEUROLOGY, V64, P326, DOI 10.1212/01.WNL.0000149636.44660.99; van der Vos KE, 2012, AUTOPHAGY, V8, P1862, DOI 10.4161/auto.22152; van der Vos KE, 2012, NAT CELL BIOL, V14, P829, DOI 10.1038/ncb2536; van Gassen KLI, 2009, GENES BRAIN BEHAV, V8, P290, DOI 10.1111/j.1601-183X.2008.00471.x; VARDIMON L, 1988, P NATL ACAD SCI USA, V85, P5981, DOI 10.1073/pnas.85.16.5981; Veerhuis R, 2011, CURR ALZHEIMER RES, V8, P34, DOI 10.2174/156720511794604589; Verma R, 2010, EUR J PHARMACOL, V638, P65, DOI 10.1016/j.ejphar.2010.04.021; Walker FO, 2007, LANCET, V369, P218, DOI 10.1016/S0140-6736(07)60111-1; Walls AB, 2015, NEUROCHEM RES, V40, P402, DOI 10.1007/s11064-014-1473-1; Wang XF, 2013, NEUROSCI LETT, V549, P69, DOI 10.1016/j.neulet.2013.06.013; Wang Y, 2009, EXP NEUROL, V220, P293, DOI 10.1016/j.expneurol.2009.08.034; WANIEWSKI RA, 1992, J NEUROCHEM, V58, P167, DOI 10.1111/j.1471-4159.1992.tb09292.x; WARREN KS, 1964, J LAB CLIN MED, V64, P442; WillardMack CL, 1996, NEUROSCIENCE, V71, P589, DOI 10.1016/0306-4522(95)00462-9; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; YAMAMOTO T, 1989, ACTA NEUROPATHOL, V77, P357, DOI 10.1007/BF00687370; ZHANG HY, 1991, J BIOL CHEM, V266, P24332; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; ZIEVE L, 1986, METAB BRAIN DIS, V1, P25, DOI 10.1007/BF00998474; Zou J, 2011, NEUROCHEM INT, V58, P404, DOI 10.1016/j.neuint.2010.12.018	181	28	33	0	4	SPRINGER INT PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	2190-5215		978-3-319-45096-4; 978-3-319-45094-0	ADV NEUROBIOL	Adv. Neurobiol.		2016	13						327	350		10.1007/978-3-319-45096-4_13	10.1007/978-3-319-45096-4		24	Biology; Neurosciences	Life Sciences & Biomedicine - Other Topics; Neurosciences & Neurology	BH5HC	WOS:000400933900013	27885636				2021-06-18	
J	Nathanson, JT; Connolly, JG; Yuk, F; Gometz, A; Rasouli, J; Lovell, M; Choudhri, T				Nathanson, John T.; Connolly, James G.; Yuk, Frank; Gometz, Alex; Rasouli, Jonathan; Lovell, Mark; Choudhri, Tanvir			Concussion Incidence in Professional Football: Position-Specific Analysis With Use of a Novel Metric	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						concussion; mTBI; National Football League; athlete exposures; game positions; position plays; risk assessment; concussion incidence	PLAYERS; EPIDEMIOLOGY; COLLEGIATE	Background: In the United States alone, millions of athletes participate in sports with potential for head injury each year. Although poorly understood, possible long-term neurological consequences of repetitive sports-related concussions have received increased recognition and attention in recent years. A better understanding of the risk factors for concussion remains a public health priority. Despite the attention focused on mild traumatic brain injury (mTBI) in football, gaps remain in the understanding of the optimal methodology to determine concussion incidence and position-specific risk factors. Purpose: To calculate the rates of concussion in professional football players using established and novel metrics on a group and position-specific basis. Study Design: Case-control study; Level of evidence, 3. Methods: Athletes from the 2012-2013 and 2013-2014 National Football League (NFL) seasons were included in this analysis of publicly available data. Concussion incidence rates were analyzed using established (athlete exposure [AE], game position [GP]) and novel (position play [PP]) metrics cumulatively, by game unit and position type (offensive skill players and linemen, defensive skill players and linemen), and by position. Results: In 480 games, there were 292 concussions, resulting in 0.61 concussions per game (95% CI, 0.54-0.68), 6.61 concussions per 1000 AEs (95% CI, 5.85-7.37), 1.38 concussions per 100 GPs (95% CI, 1.22-1.54), and 0.17 concussions per 1000 PPs (95% CI, 0.15-0.19). Depending on the method of calculation, the relative order of at-risk positions changed. In addition, using the PP metric, offensive skill players had a significantly greater rate of concussion than offensive linemen, defensive skill players, and defensive linemen (P < .05). Conclusion: For this study period, concussion incidence by position and unit varied depending on which metric was used. Compared with AE and GP, the PP metric found that the relative risk of concussion for offensive skill players was significantly greater than other position types. The strengths and limitations of various concussion incidence metrics need further evaluation. Clinical Relevance: A better understanding of the relative risks of the different positions/units is needed to help athletes, team personnel, and medical staff make optimal player safety decisions and enhance rules and equipment.	[Nathanson, John T.; Connolly, James G.; Yuk, Frank; Gometz, Alex; Rasouli, Jonathan; Lovell, Mark; Choudhri, Tanvir] Icahn Sch Med Mt Sinai, New York, NY 10029 USA	Choudhri, T (corresponding author), Icahn Sch Med Mt Sinai, Dept Neurosurg, One Gustave L Levy Pl, New York, NY 10029 USA.	tanvir.choudhri@mountsinai.org	Rasouli, Jonathan/AAF-2742-2020	Rasouli, Jonathan/0000-0002-5085-8422			[Anonymous], 2014, 2013 14 HIGH SCH SPO; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Clay MB, 2013, J CHIROPR MED, V12, P230, DOI 10.1016/j.jcm.2012.11.005; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lillibridge M., 2013, ANATOMY 53 MAN ROSTE; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Myer GD, 2014, J ORTHOP SPORT PHYS, V44, P164, DOI 10.2519/jospt.2014.5298; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54	11	28	28	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2325-9671			ORTHOP J SPORTS MED	Orthop. J. Sports Med.	JAN	2016	4	1							2325967115622621	10.1177/2325967115622621			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DE2AG	WOS:000370427900002	26848481	DOAJ Gold, Green Published			2021-06-18	
J	Singh, K; Trivedi, R; Devi, MM; Tripathi, RP; Khushu, S				Singh, Kavita; Trivedi, Richa; Devi, M. Memita; Tripathi, Rajendra P.; Khushu, Subash			Longitudinal changes in the DTI measures, anti-GFAP expression and levels of serum inflammatory cytokines following mild traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Mild traumatic brain injury; TNF-alpha; IL-10; Diffusion tensor imaging; Glial fibrillary acidic protein; Cortex; Mean diffusivity; Radial diffusivity	FIBRILLARY ACIDIC PROTEIN; WHITE-MATTER; HEAD-INJURY; COGNITIVE DEFICITS; EXPERIMENTAL-MODEL; RATS; CONCUSSION; RECOVERY; WATER; LONG	The majority of human mild traumatic brain injuries (mTBI; 70%) lack radiological evidence of injury, yet may present long term cognitive, and behavioral dysfunctions. With the hypothesis of evident damaged neural tissue and immunological consequences during acute phase of mTBI, we used closed skull weight-drop TBI model to address human mTBI condition. Serum cytokines (TNF-alpha, IL-10) and glial fibrillary acidic protein (GFAP) expression were examined at day 0 (control, pre-injury), 4 h, day 1, day 3 and day 5 post injury (PI). Diffusion tensor imaging (DTI) was performed at similar timepoints to identify neuroinflammation translation into imaging abnormalities and monitor injury progression. DTI indices including mean diffusivity (MD), radial diffusivity (RD), fractional anisotropy and axial diffusivity values were quantified from cortex (CTX), hippocampus and corpus callosum regions. One way ANOVA showed significant increase in TNF-alpha. at 4 h and IL-10 at day 1 PI as compared to control. GFAP(+) cells were significantly increased at day 3 and day 5 as compared to control in CTX. Repeated measures ANOVA revealed significant decreases in MD, RD values in CTX at day 3 and day 5 as compared to day 0. A significant, inverse correlation was observed between cortical MD (r = -0.74, p = 0.01), AD (r = -0.60, p = 0.03) and RD (r = -0.72, p = 0.01) values with mean GFAP(+) cells in the cortical region. These findings suggest that mTBI leads to elevated cytokine expression and subsequent hypertrophy of astrocytic processes. The increased numbers of reactive glial cells contribute diffusion restrictions in the CNS leading to reduced MD and RD values. These findings are in line with the deficits and pathologies associated with clinical mTBI, and support the use of mTBI model to address pathology and therapeutic options. (C) 2015 Elsevier Inc. All rights reserved.	[Singh, Kavita; Trivedi, Richa; Devi, M. Memita; Tripathi, Rajendra P.; Khushu, Subash] Inst Nucl Med & Allied Sci, NMR Res Ctr, Delhi 110054, India	Trivedi, R (corresponding author), Inst Nucl Med & Allied Sci, NMR Res Ctr, Delhi 110054, India.	triricha@gmail.com			Department of Science and Technology (DST), New Delhi, IndiaDepartment of Science & Technology (India)	Ms. Kavita Singh would like to acknowledge the fellowship grant from Department of Science and Technology (DST), New Delhi, India. We acknowledge Dr. I Namita for her assistance with histological study.	Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bignami A., 1991, DISCUSS NEUROSCI, V111, P9; Blumenfeld-Katzir T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020678; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control, 2003, NAT CTR INJ PREV CON; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; CHOI DW, 1987, J NEUROSCI, V7, P357; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; De Mulder G, 2000, ACT NEUR S, V76, P409; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; Fujiki M, 2008, J CLIN NEUROSCI, V15, P791, DOI 10.1016/j.jocn.2007.07.002; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Jacobs A, 1996, J NUCL MED, V37, P1605; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; KIMELBERG HK, 1994, NEUROBIOLOGY CENTRAL, P193; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Le Bihan D, 1991, Magn Reson Q, V7, P1; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McKeating EG, 1998, BRIT J ANAESTH, V80, P77; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Olsson B, 2011, PROG NEUROBIOL, V95, P520, DOI 10.1016/j.pneurobio.2011.04.006; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Peled S, 2007, IEEE T MED IMAGING, V26, P1448, DOI 10.1109/TMI.2007.906787; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rooker S, 2002, J NEUROSCI METH, V119, P83, DOI 10.1016/S0165-0270(02)00183-8; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Simard M, 2004, NEUROSCIENCE, V129, P877, DOI 10.1016/j.neuroscience.2004.09.053; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Theodosis DT, 2008, PHYSIOL REV, V88, P983, DOI 10.1152/physrev.00036.2007; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Trivedi R, 2012, J NEUROSCI RES, V90, P2009, DOI 10.1002/jnr.23073; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vorisek I, 2002, MAGNET RESON MED, V48, P994, DOI 10.1002/mrm.10305; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	80	28	30	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2016	275		3		SI		427	435		10.1016/j.expneurol.2015.07.016			9	Neurosciences	Neurosciences & Neurology	DB2ED	WOS:000368320200012	26216663				2021-06-18	
J	von Steinbuechel, N; Covic, A; Polinder, S; Kohlmann, T; Cepulyte, U; Poinstingl, H; Backhaus, J; Bakx, W; Bullinger, M; Christensen, AL; Formisano, R; Gibbons, H; Hofer, S; Koskinen, S; Maas, A; Neugebauer, E; Powell, J; Sarajuuri, J; Sasse, N; Schmidt, S; Muhlan, H; von Wild, K; Zitnay, G; Truelle, JL				von Steinbuechel, Nicole; Covic, Amra; Polinder, Suzanne; Kohlmann, Thomas; Cepulyte, Ugne; Poinstingl, Herbert; Backhaus, Joy; Bakx, Wilbert; Bullinger, Monika; Christensen, Anne-Lise; Formisano, Rita; Gibbons, Henning; Hoefer, Stefan; Koskinen, Sanna; Maas, Andrew; Neugebauer, Edmund; Powell, Jane; Sarajuuri, Jaana; Sasse, Nadine; Schmidt, Silke; Muehlan, Holger; von Wild, Klaus; Zitnay, George; Truelle, Jean-Luc			Assessment of Health-Related Quality of Life after TBI: Comparison of a Disease-Specific (QOLIBRI) with a Generic (SF-36) Instrument	BEHAVIOURAL NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; HOSPITAL ANXIETY; ITEM BANKS; 1ST YEAR; DEPRESSION; MODERATE; MILD; SCALE; INDIVIDUALS; EQ-5D	Psychosocial, emotional, and physical problems can emerge after traumatic brain injury (TBI), potentially impacting health-related quality of life (HRQoL). Until now, however, neither the discriminatory power of disease-specific (QOLIBRI) and generic (SF-36) HRQoL nor their correlates have been compared in detail. These aspects as well as some psychometric item characteristics were studied in a sample of 795 TBI survivors. The Shannon H' index absolute informativity, as an indicator of an instrument's power to differentiate between individuals within a specific group or health state, was investigated. Psychometric performance of the two instruments was predominantly good, generally higher, and more homogenous for the QOLIBRI than for the SF-36 subscales. Notably, the SF-36 "Role Physical," " Role Emotional," and "Social Functioning" subscales showed less satisfactory discriminatory power than all other dimensions or the sum scores of both instruments. The absolute informativity of disease-specific as well as generic HRQoL instruments concerning the different groups defined by different correlates differed significantly. When the focus is on how a certain subscale or sum score differentiates between individuals in one specific dimension/health state, the QOLIBRI can be recommended as the preferable instrument.	[von Steinbuechel, Nicole; Covic, Amra; Cepulyte, Ugne; Poinstingl, Herbert; Backhaus, Joy; Gibbons, Henning; Hoefer, Stefan; Sasse, Nadine] Univ Med Gottingen, Inst Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany; [Polinder, Suzanne] Erasmus Med Coll, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Kohlmann, Thomas] Ernst Moritz Arndt Univ Greifswald, Sect Methods Community Med, Inst Community Med, Walther Rathenau Str 48, D-17475 Greifswald, Germany; [Bakx, Wilbert] Hoensbroeck Rehabil Ctr, Postbus 88, NL-6430 AB Hoensbroek, Netherlands; [Bakx, Wilbert] Maastricht Univ, POB 616, NL-6200 MD Maastricht, Netherlands; [Bullinger, Monika] Univ Hosp Eppendorf, Dept Med Psychol, Martinistr 52, D-20251 Hamburg, Germany; [Christensen, Anne-Lise] Univ Copenhagen, Ctr Rehabil Brain Injury, Njalsgade 88, DK-2300 Copenhagen, Denmark; [Christensen, Anne-Lise] Univ Copenhagen, Ctr Cognit & Memory, Njalsgade 88, DK-2300 Copenhagen, Denmark; [Formisano, Rita] Santa Lucia Fdn, Rehabil Hosp, IRCCS, Via Ardeatina 306-354, I-00179 Rome, Italy; [Gibbons, Henning] Univ Bonn, Dept Psychol, Kaiser Karl Ring 9, D-53111 Bonn, Germany; [Hoefer, Stefan] Med Univ Innsbruck, Dept Med Psychol, Schopfstr 23a, A-6020 Innsbruck, Austria; [Koskinen, Sanna] Univ Helsinki, Inst Behav Sci, Siltavuorenpenger 5 A,POB 9, FIN-00014 Helsinki, Finland; [Maas, Andrew] Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstraat 10, B-2650 Antwerp, Belgium; [Maas, Andrew] Univ Antwerp, Wilrijkstraat 10, B-2650 Antwerp, Belgium; [Neugebauer, Edmund] Private Univ ofWitten Herdecke, IFOM, Ostmerheimer Str 200, D-51109 Cologne, Germany; [Powell, Jane] Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; [Sarajuuri, Jaana] Validia Rehabil, Dept Clin Neuropsychol & Psychol, Mannerheimintie 107, Helsinki 00280, Finland; [Schmidt, Silke; Muehlan, Holger] Ernst Moritz Arndt Univ Greifswald, Dept Hlth & Prevent, Inst Psychol, D-17475 Greifswald, Germany; [von Wild, Klaus] Univ Munster, Fac Med, Domagkstr 3, D-48149 Munster, Germany; [Zitnay, George] Martha Jefferson Assoc Hosp, 459 Locust Ave, Charlottesville, VA 22902 USA; [Truelle, Jean-Luc] Hop Raymond Poincare, Serv Phys Med & Rehabil MPR, 104 Blvd Raymond Poincare, F-92380 Garches, France	von Steinbuechel, N (corresponding author), Univ Med Gottingen, Inst Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany.	nvsteinbuechel@med.uni-goettingen.de	Hofer, Stefan/N-8253-2019; Hofer, Stefan/B-8393-2008; Sarajuuri, Jaana/AAD-8665-2019	Hofer, Stefan/0000-0002-6128-3687; Hofer, Stefan/0000-0002-6128-3687; Sarajuuri, Jaana/0000-0002-6432-0295; Bullinger, Monika/0000-0001-8876-0159; Koskinen, Sanna/0000-0002-3453-5084	ZNS-Hannelore Kohl Stiftung [2008014/2008019]	The authors are grateful to all researchers who helped in collecting data in each country and to the patients who provided them. They wish to cordially thank Dr. Ralph Telgmann for revision of the paper and technical assistance in the preparation. This work was generously founded by the ZNS-Hannelore Kohl Stiftung, Grants 2008014/2008019.	Almeida OP, 2015, INT J GERIATR PSYCH, V30, P1215, DOI 10.1002/gps.4276; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Bullinger M, 2001, CURR PROB E, V16, P277; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Cella D., 2007, MED CARE S1, V45, p3S3; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; George D., 2010, SPSS WINDOWS STEP ST, V10; Gershon RC, 2012, QUAL LIFE RES, V21, P475, DOI 10.1007/s11136-011-9958-8; Giustini M, 2014, FUNCT NEUROL, V29, P167, DOI 10.11138/FNeur/2014.29.3.167; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Janssen MF, 2008, VALUE HEALTH, V11, P275, DOI 10.1111/j.1524-4733.2007.00230.x; Janssen MFB, 2007, QUAL LIFE RES, V16, P895, DOI 10.1007/s11136-006-9160-6; LILLIEFORS HW, 1967, J AM STAT ASSOC, V62, P399, DOI 10.2307/2283970; Lin YN, 2014, J HEAD TRAUMA REHAB, V29, pE37, DOI 10.1097/HTR.0b013e3182816363; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; Nutt DJ, 2004, J CLIN PSYCHIAT, V65, P11; Olsson I, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-46; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Perez Lori, 2007, J Neurosci Nurs, V39, P342; Polinder S, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0037-1; Polinder S, 2010, INJURY PREV, V16, P147, DOI 10.1136/ip.2009.022418; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Power M, 2005, QUAL LIFE RES, V14, P2197, DOI 10.1007/s11136-005-7380-9; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Reeve BB, 2007, MED CARE, V45, pS22, DOI 10.1097/01.mlr.0000250483.85507.04; Royston P, 1992, STAT COMPUT, V2, P117, DOI [DOI 10.1007/BF01891203, 10.1007/BF01891203]; Sasse N, 2013, J HEAD TRAUMA REHAB, V28, P464, DOI 10.1097/HTR.0b013e318263977d; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; SCHRIESHEIM CA, 1981, EDUC PSYCHOL MEAS, V41, P1101, DOI 10.1177/001316448104100420; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Siponkoski ST, 2013, J REHABIL MED, V45, P835, DOI 10.2340/16501977-1189; Soberg HL, 2013, J REHABIL MED, V45, P785, DOI 10.2340/16501977-1158; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Sukraeny N., 2014, SONGKLANAGARIND NU S, V34, P119; Sullivan-Singh SJ, 2014, ARCH PHYS MED REHAB, V95, P1100, DOI 10.1016/j.apmr.2014.02.001; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023; TEASDALE G, 1974, LANCET, V2, P81; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Ware J. E., 2008, SF 36V2 HLTH SURVEY; Ware JE, 1993, MANUAL INTERPRETATIO; Williamson M. L., 2015, J HEAD TRAUMA REHABI; Williamson MLC, 2013, BRAIN INJURY, V27, P992, DOI 10.3109/02699052.2013.801512; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	65	28	28	1	23	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0953-4180	1875-8584		BEHAV NEUROL	Behav. Neurol.		2016	2016								7928014	10.1155/2016/7928014			14	Clinical Neurology	Neurosciences & Neurology	DD9TR	WOS:000370269100001	27022207	DOAJ Gold, Green Published			2021-06-18	
J	Zagorchev, L; Meyer, C; Stehle, T; Wenzel, F; Young, S; Peters, J; Weese, J; Paulsen, K; Garlinghouse, M; Ford, J; Roth, R; Flashman, L; McAllister, T				Zagorchev, Lyubomir; Meyer, Carsten; Stehle, Thomas; Wenzel, Fabian; Young, Stewart; Peters, Jochen; Weese, Juergen; Paulsen, Keith; Garlinghouse, Matthew; Ford, James; Roth, Robert; Flashman, Laura; McAllister, Thomas			Differences in Regional Brain Volumes Two Months and One Year after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; MRI; subcortical structures; volume	GRAY-MATTER ABNORMALITIES; SEGMENTATION; ATROPHY; MODEL	Conventional structural imaging is often normal after mild traumatic brain injury (mTBI). There is a need for structural neuroimaging biomarkers that facilitate detection of milder injuries, allow recovery trajectory monitoring, and identify those at risk for poor functional outcome and disability. We present a novel approach to quantifying volumes of candidate brain regions at risk for injury. Compared to controls, patients with mTBI had significantly smaller volumes in several regions including the caudate, putamen, and thalamus when assessed 2 months after injury. These differences persisted but were reduced in magnitude 1 year after injury, suggesting the possibility of normalization over time in the affected regions. More pronounced differences, however, were found in the amygdala and hippocampus, suggesting the possibility of regionally specific responses to injury.	[Zagorchev, Lyubomir] Philips Res North Amer, Briarcliff Manor, NY 10510 USA; [Zagorchev, Lyubomir; Paulsen, Keith] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Meyer, Carsten; Stehle, Thomas; Wenzel, Fabian; Young, Stewart; Peters, Jochen; Weese, Juergen] Philips Res Hamburg, Digital Imaging, Hamburg, Germany; [Garlinghouse, Matthew; Ford, James; Roth, Robert; Flashman, Laura; McAllister, Thomas] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA	Zagorchev, L (corresponding author), Philips Res North Amer, 345 Scarborough Rd, Briarcliff Manor, NY 10510 USA.	lyubomir.zagorchev@philips.com	Ford, James/AAF-7039-2020		Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176] Funding Source: NIH RePORTER	The TBI study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, R01 HD048176: Role of Candidate Alleles in Cognitive Outcome After TBI. The authors would like to gratefully acknowledge the assistance of Mary Hynes, RN, for her help with numerous phases of the data collection.	ARNDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; Babalola KO, 2009, NEUROIMAGE, V47, P1435, DOI 10.1016/j.neuroimage.2009.05.029; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Ecabert O, 2008, IEEE T MED IMAGING, V27, P1189, DOI 10.1109/TMI.2008.918330; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Weese J., 2001, Information Processing in Medical Imaging. 17th International Conference, IPMI 2001. Proceedings (Lecture Notes in Computer Science Vol.2082), P380; Weese J., 2014, SHAPE ANAL MED IMAGE, P151; Zagorchev L, 2011, LECT NOTES COMPUT SC, V7012, P52, DOI 10.1007/978-3-642-24446-9_7; Zagorchev L, 2011, LECT NOTES COMPUT SC, V7012, P118, DOI 10.1007/978-3-642-24446-9_15; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	20	28	29	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					29	34		10.1089/neu.2014.3831			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200004	25970552	Green Published			2021-06-18	
J	Hammond, TR; McEllin, B; Morton, PD; Raymond, M; Dupree, J; Gallo, V				Hammond, Timothy R.; McEllin, Brian; Morton, Paul D.; Raymond, Matthew; Dupree, Jeff; Gallo, Vittorio			Endothelin-B Receptor Activation in Astrocytes Regulates the Rate of Oligodendrocyte Regeneration during Remyelination	CELL REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; CELLS; MYELINATION; LESIONS; BETA; CNS	Reactive astrogliosis is an essential and ubiquitous response to CNS injury, but in some cases, aberrant activation of astrocytes and their release of inhibitory signaling molecules can impair endogenous neural repair processes. Our lab previously identified a secreted intercellular signaling molecule, called endothelin-1 (ET-1), which is expressed at high levels by reactive astrocytes in multiple sclerosis (MS) lesions and limits repair by delaying oligodendrocyte progenitor cell (OPC) maturation. However, as ET receptors are widely expressed on neural cells, the cell-and receptor-specific mechanisms of OPC inhibition by ET-1 action remain undefined. Using pharmacological approaches and cell-specific endothelin receptor (EDNR) ablation, we show that ET-1 acts selectively through EDNRB on astrocytes-and not OPCs-to indirectly inhibit remyelination. These results demonstrate that targeting specific pathways in reactive astrocytes represents a promising therapeutic target in diseases with extensive reactive astrogliosis, including MS.	[Hammond, Timothy R.; McEllin, Brian; Morton, Paul D.; Raymond, Matthew; Dupree, Jeff; Gallo, Vittorio] Childrens Natl Med Ctr, Childrens Res Inst, Ctr Neurosci Res, Washington, DC 20010 USA	Gallo, V (corresponding author), Childrens Natl Med Ctr, Childrens Res Inst, Ctr Neurosci Res, Washington, DC 20010 USA.	vgallo@cnmc.org			National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG4019, R01NS090383]; Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Centers [P30HD40677]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS090383] Funding Source: NIH RePORTER	We thank Drs. Li-Jin Chew and Joseph Scafidi for discussion and critically reading the manuscript. This work was supported by the National Multiple Sclerosis Society (grant RG4019 to V.G.), R01NS090383 (V.G.), and Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Centers (P30HD40677 to V.G.).	Aguirre A, 2007, NAT NEUROSCI, V10, P990, DOI 10.1038/nn1938; Armstead WM, 2011, NEUROL RES, V33, P133, DOI 10.1179/016164111X12881719352174; BIGAUD M, 1992, BRIT J PHARMACOL, V107, P912, DOI 10.1111/j.1476-5381.1992.tb13385.x; Brosnan CF, 2013, GLIA, V61, P453, DOI 10.1002/glia.22443; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; D'haeseleer M, 2013, P NATL ACAD SCI USA, V110, P5654, DOI 10.1073/pnas.1222560110; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Gadea A, 2008, J NEUROSCI, V28, P2394, DOI 10.1523/JNEUROSCI.5652-07.2008; Gadea A, 2009, J NEUROSCI, V29, P10047, DOI 10.1523/JNEUROSCI.0822-09.2009; Ganat YM, 2006, J NEUROSCI, V26, P8609, DOI 10.1523/JNEUROSCI.2532-06.2006; Guo J, 2014, INT J MOL MED, V34, P74, DOI 10.3892/ijmm.2014.1751; Guo YW, 2014, J NEUROIMMUNOL, V276, P64, DOI 10.1016/j.jneuroim.2014.08.616; Hammond TR, 2014, NEURON, V81, P588, DOI 10.1016/j.neuron.2013.11.015; Horinouchi T, 2013, J PHARMACOL SCI, V123, P85, DOI 10.1254/jphs.13R02CR; Johnston DA, 2009, GENE, V435, P36, DOI 10.1016/j.gene.2009.01.003; Jung KJ, 2011, J KOREAN MED SCI, V26, P92, DOI 10.3346/jkms.2011.26.1.92; Koyama Y, 1999, GLIA, V26, P268, DOI 10.1002/(SICI)1098-1136(199905)26:3<268::AID-GLIA8>3.0.CO;2-G; Moldes O, 2012, NEUROPHARMACOLOGY, V63, P1279, DOI 10.1016/j.neuropharm.2012.08.019; Palmer JC, 2012, J ALZHEIMERS DIS, V29, P853, DOI 10.3233/JAD-2012-111760; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Rogers SD, 2003, GLIA, V41, P180, DOI 10.1002/glia.10173; RUBANYI GM, 1991, FASEB J, V5, P2713; Schinelli S, 2001, J NEUROSCI, V21, P8842, DOI 10.1523/JNEUROSCI.21-22-08842.2001; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Stiles JD, 1997, J NEUROPATH EXP NEUR, V56, P435, DOI 10.1097/00005072-199704000-00012; Torbidoni V, 2005, EXP EYE RES, V81, P265, DOI 10.1016/j.exer.2004.12.024; Williams A, 2007, GLIA, V55, P1300, DOI 10.1002/glia.20546; Wolswijk G, 1998, J NEUROSCI, V18, P601; Yuen TJ, 2013, BRAIN, V136, P1035, DOI 10.1093/brain/awt024; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012	33	28	28	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	DEC 15	2015	13	10					2090	2097		10.1016/j.celrep.2015.11.002			8	Cell Biology	Cell Biology	CY6QQ	WOS:000366534300007	26628380	DOAJ Gold			2021-06-18	
J	Scott, G; Hellyer, PJ; Ramlackhansingh, AF; Brooks, DJ; Matthews, PM; Sharp, DJ				Scott, Gregory; Hellyer, Peter J.; Ramlackhansingh, Anil F.; Brooks, David J.; Matthews, Paul M.; Sharp, David J.			Thalamic inflammation after brain trauma is associated with thalamo-cortical white matter damage	JOURNAL OF NEUROINFLAMMATION			English	Article						Microglia; Translocator protein; Positron emission tomography; Traumatic brain injury; Traumatic axonal injury; PK11195; Thalamus	MICROGLIAL ACTIVATION; AXONAL INJURY; ISCHEMIC-STROKE; IN-VIVO; NEUROINFLAMMATION; SINGLE	Background: Traumatic brain injury can trigger chronic neuroinflammation, which may predispose to neurodegeneration. Animal models and human pathological studies demonstrate persistent inflammation in the thalamus associated with axonal injury, but this relationship has never been shown in vivo. Findings: Using [C-11]-PK11195 positron emission tomography, a marker of microglial activation, we previously demonstrated thalamic inflammation up to 17 years after traumatic brain injury. Here, we use diffusion MRI to estimate axonal injury and show that thalamic inflammation is correlated with thalamo-cortical tract damage. Conclusions: These findings support a link between axonal damage and persistent inflammation after brain injury.	[Scott, Gregory; Hellyer, Peter J.; Ramlackhansingh, Anil F.; Brooks, David J.; Matthews, Paul M.; Sharp, David J.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Brain Sci, London, England; [Hellyer, Peter J.] Kings Coll London, Ctr Neuroimaging Sci, IoPPN, London WC2R 2LS, England; [Brooks, David J.] Aarhus Univ, Inst Clin Med, Aarhus, Denmark; [Sharp, David J.] Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, London W12 0NN, England	Sharp, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Brain Sci, Hammersmith Hosp Campus, London, England.	david.sharp@imperial.ac.uk	Hellyer, Peter J/F-7112-2013; Sharp, David J/A-2119-2013	Hellyer, Peter J/0000-0002-5139-3401; Brooks, David/0000-0003-2602-2518; Scott, Gregory/0000-0001-8063-5871	Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme; MS Society of Great Britain; Progressive MS Alliance; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); GlaxoSmithKlineGlaxoSmithKline; Edmund J. Safra Foundation; Lily Safra; MRC (UK) Clinician Scientist Fellowship; National Institute for Health Research (NIHR) Imperial Biomedical Research Centre; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/K501013/1, MR/L022141/1, MC_U120036861, G0900897, G1100810, G0701951] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048, NF-SI-0514-10022] Funding Source: researchfish	GS was supported by a clinical research fellowship awarded in the Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme. The Medical Research Council (UK) supported PH. PM has research support from the MS Society of Great Britain, the Progressive MS Alliance, the MRC and GlaxoSmithKline and personal support from the Edmund J. Safra Foundation and from Lily Safra. DJS has been supported by an MRC (UK) Clinician Scientist Fellowship and currently holds a National Institute of Health Research Professorship-RP-011-048 (DJS). The research was also supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Banati RB, 2001, NEUROREPORT, V12, P3439, DOI 10.1097/00001756-200111160-00012; Banati RB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6452; Cagnin A, 2001, BRAIN, V124, P2014, DOI 10.1093/brain/124.10.2014; Cagnin Annachiara, 2003, P379; Folkersma H, 2011, J NUCL MED, V52, P1235, DOI 10.2967/jnumed.110.084061; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Gerhard A, 2005, NEUROIMAGE, V24, P591, DOI 10.1016/j.neuroimage.2004.09.034; Graeber MB, 2014, BRAIN PATHOL, V24, P620, DOI 10.1111/bpa.12192; Grieve SM, 2007, AM J NEURORADIOL, V28, P226; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones EG, 2012, THALAMUS; Liu GJ, 2014, BRAIN PATHOL, V24, P631, DOI 10.1111/bpa.12196; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Pappata S, 2000, NEUROLOGY, V55, P1052, DOI 10.1212/WNL.55.7.1052; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; Thiel A, 2010, J NUCL MED, V51, P1404, DOI 10.2967/jnumed.110.076612; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246	27	28	28	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	DEC 1	2015	12								224	10.1186/s12974-015-0445-y			5	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CX5ZY	WOS:000365782200001	26627199	DOAJ Gold, Green Published			2021-06-18	
J	Bohrer, C; Pfurr, S; Mammadzada, K; Schildge, S; Plappert, L; Hils, M; Pous, L; Rauch, KS; Dumit, VI; Pfeifer, D; Dengjel, J; Kirsch, M; Schachtrup, K; Schachtrup, C				Bohrer, Christian; Pfurr, Sabrina; Mammadzada, Koenuel; Schildge, Sebastian; Plappert, Leandra; Hils, Miriam; Pous, Lauriane; Rauch, Katharina S.; Dumit, Veronica I.; Pfeifer, Dietmar; Dengjel, Joern; Kirsch, Matthias; Schachtrup, Kristina; Schachtrup, Christian			The balance of Id3 and E47 determines neural stem/precursor cell differentiation into astrocytes	EMBO JOURNAL			English	Article						astrocyte-specific genes; basic helix-loop-helix transcription factor; bone morphogenetic protein; traumatic brain injury; vascular damage	TRANSCRIPTION FACTOR OLIG2; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; SUBVENTRICULAR ZONE; TGF-BETA; POSTNATAL NEUROGENESIS; ADULT NEUROGENESIS; BRAIN; PROTEINS; NICHE	Adult neural stem/precursor cells (NSPCs) of the subventricular zone (SVZ) are an endogenous source for neuronal replacement in CNS disease. However, adult neurogenesis is compromised after brain injury in favor of a glial cell fate, which is mainly attributed to changes in the NSPC environment. Yet, it is unknown how this unfavorable extracellular environment translates into a transcriptional program altering NSPC differentiation. Here, we show that genetic depletion of the transcriptional regulator Id3 decreased the number of astrocytes generated from SVZ-derived adult NSPCs in the cortical lesion area after traumatic brain injury. Cortical brain injury resulted in rapid BMP-2 and Id3 up-regulation in the SVZ stem cell niche. Id3(-/-) adult NSPCs failed to differentiate into BMP-2-induced astrocytes, while NSPCs deficient for the Id3-controlled transcription factor E47 readily differentiated into astrocytes in the absence of BMP-2. Mechanistically, E47 repressed the expression of several astrocyte-specific genes in adult NSPCs. These results identify Id3 as the BMP-2-induced transcriptional regulator, promoting adult NSPC differentiation into astrocytes upon CNS injury and reveal a molecular link between environmental changes and NSPC differentiation in the CNS after injury.	[Bohrer, Christian; Pfurr, Sabrina; Mammadzada, Koenuel; Schildge, Sebastian; Plappert, Leandra; Pous, Lauriane; Kirsch, Matthias; Schachtrup, Christian] Univ Freiburg, Inst Anat & Cell Biol, D-79106 Freiburg, Germany; [Bohrer, Christian; Pfurr, Sabrina; Mammadzada, Koenuel; Schildge, Sebastian; Plappert, Leandra; Hils, Miriam; Pous, Lauriane; Rauch, Katharina S.] Univ Freiburg, Fac Biol, D-79106 Freiburg, Germany; [Hils, Miriam; Rauch, Katharina S.; Schachtrup, Kristina] Univ Freiburg, Univ Med Ctr Freiburg, CCI, D-79106 Freiburg, Germany; [Dumit, Veronica I.; Dengjel, Joern] Univ Freiburg, Dept Dermatol, Med Ctr,BIOSS Ctr Biol Signalling Studies, Freiburg Inst Adv Studies FRIAS,ZBSA Ctr Biol Sys, D-79106 Freiburg, Germany; [Pfeifer, Dietmar] Univ Freiburg, Univ Med Ctr Freiburg, Dept Hematol Oncol & Stem Cell Transplantat, D-79106 Freiburg, Germany	Schachtrup, C (corresponding author), Univ Freiburg, Inst Anat & Cell Biol, Hugstetter Str 55, D-79106 Freiburg, Germany.	christian.schachtrup@anat.uni-freiburg.de	Kirsch, Matthias/G-7227-2015; Dengjel, Joern/AAI-3682-2020	Kirsch, Matthias/0000-0002-2090-8556; Dengjel, Joern/0000-0002-9453-4614; Schachtrup, Kristina/0000-0002-9385-8254	International Graduate Academy Fellowship; German Academic Exchange Service Fellowship; Fazit Foundation Graduate Fellowship; European Commission FP7 Grant [PIRG08-GA-2010-276989, PIRG08-GA-2010-276906]; NEUREX; German Research FoundationGerman Research Foundation (DFG) [SCHA 1442/3-2]; German Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF) [BMBF 01EO1303]	We are grateful to Cornelis Murre for the Id3<SUP>-/-</SUP> mice. We thank Meike Ast-Dumbach for outstanding technical assistance and Gary Howard for editorial assistance. This work was supported by the International Graduate Academy Fellowship to C.B. and K.S.R., a German Academic Exchange Service Fellowship to K.M., the Fazit Foundation Graduate Fellowship to S.S., the European Commission FP7 Grant PIRG08-GA-2010-276989, NEUREX, and the German Research Foundation Grant SCHA 1442/3-2 to C.S., the European Commission FP7 Grant PIRG08-GA-2010-276906 and the German Federal Ministry of Education and Research (BMBF 01EO1303) to K.S.	ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Beck K, 2009, J EXP MED, V206, P2271, DOI 10.1084/jem.20090756; Belvindrah R, 2009, REV NEUROSCIENCE, V20, P331, DOI 10.1515/REVNEURO.2009.20.5-6.331; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Bonaguidi MA, 2005, DEVELOPMENT, V132, P5503, DOI 10.1242/dev.02166; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chen Y, 2008, J NEUROSCI, V28, P10983, DOI 10.1523/JNEUROSCI.3545-08.2008; Codega P, 2014, NEURON, V82, P545, DOI 10.1016/j.neuron.2014.02.039; Colak D, 2008, J NEUROSCI, V28, P434, DOI 10.1523/JNEUROSCI.4374-07.2008; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Emsley JG, 2003, EXP NEUROL, V183, P298, DOI 10.1016/S0014-4886(03)00129-8; Freeman MR, 2010, SCIENCE, V330, P774, DOI 10.1126/science.1190928; Fuentealba LC, 2012, CELL STEM CELL, V10, P698, DOI 10.1016/j.stem.2012.05.012; Gage FH, 2013, NEURON, V80, P588, DOI 10.1016/j.neuron.2013.10.037; Gajera CR, 2010, J CELL SCI, V123, P1922, DOI 10.1242/jcs.065912; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; Hampton DW, 2007, EUR J NEUROSCI, V26, P3024, DOI 10.1111/j.1460-9568.2007.05940.x; Havrda MC, 2008, J NEUROSCI, V28, P14074, DOI 10.1523/JNEUROSCI.3188-08.2008; He YB, 2014, NAT NEUROSCI, V17, P943, DOI 10.1038/nn.3732; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Ihrie RA, 2011, NEURON, V70, P674, DOI 10.1016/j.neuron.2011.05.004; Jung S, 2010, STEM CELLS DEV, V19, P831, DOI 10.1089/scd.2009.0093; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kessaris N, 2008, PHILOS T R SOC B, V363, P71, DOI 10.1098/rstb.2006.2013; Kitajima K, 2006, BRAIN RES, V1073, P93, DOI 10.1016/j.brainres.2005.12.048; Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638; Li L, 2010, GLIA, V58, P1610, DOI 10.1002/glia.21033; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960; Liu F, 2009, J NEUROSCI, V29, P5075, DOI 10.1523/JNEUROSCI.0201-09.2009; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Marshall CAG, 2005, J NEUROSCI, V25, P7289, DOI 10.1523/JNEUROSCI.1924-05.2005; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mira H, 2010, CELL STEM CELL, V7, P78, DOI 10.1016/j.stem.2010.04.016; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; Morales-Garcia JA, 2011, GLIA, V59, P293, DOI 10.1002/glia.21101; Murre C, 2005, NAT IMMUNOL, V6, P1079, DOI 10.1038/ni1260; Nam HS, 2009, CELL STEM CELL, V5, P515, DOI 10.1016/j.stem.2009.08.017; Niola F, 2012, NAT CELL BIOL, V14, P477, DOI 10.1038/ncb2490; Obernier K, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00162; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Picard-Riera N, 2002, P NATL ACAD SCI USA, V99, P13211, DOI 10.1073/pnas.192314199; Porlan E, 2013, NAT NEUROSCI, V16, P1567, DOI 10.1038/nn.3545; Qi XA, 2010, EXP NEUROL, V221, P353, DOI 10.1016/j.expneurol.2009.12.003; Raponi E, 2007, GLIA, V55, P165, DOI 10.1002/glia.20445; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Schachtrup C, 2007, P NATL ACAD SCI USA, V104, P11814, DOI 10.1073/pnas.0704045104; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Schildge S, 2014, CURR MED CHEM, V21, P2190, DOI 10.2174/0929867321666131227162215; Stipursky J, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00393; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tzeng SF, 1999, GLIA, V26, P139, DOI 10.1002/(SICI)1098-1136(199904)26:2<139::AID-GLIA5>3.0.CO;2-1; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013	70	28	29	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0261-4189	1460-2075		EMBO J	Embo J.	NOV 12	2015	34	22					2804	2819		10.15252/embj.201591118			16	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	CY7QR	WOS:000366604300010	26438726	Green Published			2021-06-18	
J	Honan, CA; McDonald, S; Gowland, A; Fisher, A; Randall, RK				Honan, Cynthia A.; McDonald, Skye; Gowland, Alison; Fisher, Alana; Randall, Rebekah K.			Deficits in comprehension of speech acts after TBI: The role of theory of mind and executive function	BRAIN AND LANGUAGE			English	Article						Traumatic brain injury; Executive function; Theory of mind; Social cognition; Pragmatic language	TRAUMATIC BRAIN-INJURY; ASSESSING SOCIAL-PERCEPTION; DIFFUSE AXONAL INJURY; EMOTION RECOGNITION; FRONTAL LOBES; EYES TEST; IMPAIRMENTS; COGNITION; ADULTS; PERFORMANCE	Theory of mind (TOM) is critical to effective communication following traumatic brain injury (TBI) however, whether impairments are specific to social cognition, or reflective of executive demands is unclear. This study examined whether ToM impairments are predicted by executive function difficulties using everyday conversation tasks. Twenty-five individuals with severe-TBI were compared to 25 healthy controls on low- and high-ToM tasks across four conditions: (1) low cognitive load, (2) high flexibility, (3) high working memory (WM) and (4) high inhibition. TBI individuals were impaired on high-ToM tasks in the WM condition. When the WM demands of the task were controlled, the impairments were no longer apparent. TBI individuals were not impaired on high-TOM tasks in the inhibition and flexibility conditions, suggesting these tasks may not have been sufficiently demanding of ToM abilities. The results suggest that ToM impairments in everyday communication may arise due to WM demands, in individuals with TBI. (C) 2015 Elsevier Inc. All rights reserved.	[Honan, Cynthia A.; McDonald, Skye; Gowland, Alison] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Honan, Cynthia A.; McDonald, Skye] Moving Ahead Ctr Res Excellence Brain Recovery, Sydney, NSW, Australia; [Fisher, Alana] Univ Sydney, Ctr Med Psychol & Evidence Based Decis Making CeM, Sch Psychol, Sydney, NSW 2006, Australia; [Randall, Rebekah K.] Univ Melbourne, Sch Psychol Sci, Melbourne, Vic, Australia	Honan, CA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	c.honan@unsw.edu.au; s.mcdonald@unsw.edu.au; Alison.gowland@gmail.com; a.fisher@sydney.edu.au; Rebekah.k.randall@gmail.com	Fisher, Alana/T-1869-2019; Honan, Cynthia/O-6332-2017	Gowland, Alison/0000-0002-6578-4112; Fisher, Alana/0000-0002-6027-659X; Honan, Cynthia/0000-0001-5735-4270	Australian Research CouncilAustralian Research Council [DP09886689]	This research was supported by the Australian Research Council with an ARC Discovery Project Grant [number DP09886689]. We are grateful to the Royal Ryde Rehabilitation Centre who assisted with recruitment. We are particularly grateful to the people with traumatic brain injuries and our control participants who gave willingly of their time to assist this research.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Bach LJ, 2000, COGN NEUROPSYCHIATRY, V5, P175, DOI DOI 10.1080/13546800050083520; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Benton A., 1994, MULTILINGUAL APHASIA; Benton AL., 1983, CONTRIBUTION NEUROPS; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Brownell H, 1998, RIGHT HEMISPHERE LANGUAGE COMPREHENSION, P309; Bull R, 2008, COGNITION, V107, P663, DOI 10.1016/j.cognition.2007.07.015; Byom LJ, 2012, INT J LANG COMM DIS, V47, P310, DOI 10.1111/j.1460-6984.2011.00102.x; Carlson SM, 2002, INFANT CHILD DEV, V11, P73, DOI 10.1002/icd.298; Carrington SJ, 2009, HUM BRAIN MAPP, V30, P2313, DOI 10.1002/hbm.20671; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Channon S, 2010, NEUROPSYCHOL REHABIL, V20, P739, DOI 10.1080/09602011003794583; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Courville CB, 1945, PATHOLOGY NERVOUS SY; D'Argembeau A, 2007, J COGNITIVE NEUROSCI, V19, P935, DOI 10.1162/jocn.2007.19.6.935; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Dress ML, 2008, J LANG SOC PSYCHOL, V27, P71, DOI 10.1177/0261927X07309512; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HADLEY DM, 1988, CLIN RADIOL, V39, P131; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hughes C, 1998, BRIT J DEV PSYCHOL, V16, P233, DOI 10.1111/j.2044-835X.1998.tb00921.x; Johnco C, 2013, J ANXIETY DISORD, V27, P576, DOI 10.1016/j.janxdis.2012.10.004; Johnston L, 2008, AUST J PSYCHOL, V60, P135, DOI 10.1080/00049530701449521; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kortte Kathleen Bechtold, 2002, Appl Neuropsychol, V9, P106, DOI 10.1207/S15324826AN0902_5; LEUKEL F, 1972, INTRO PHYSL PSYCHOL; Levy N. K., 2014, CHILD NEUROPSYCHOLOG; Linacre JM, 2006, USERS GUIDE WINSTEPS; Lough S, 2006, NEUROPSYCHOLOGIA, V44, P950, DOI 10.1016/j.neuropsychologia.2005.08.009; Lovibond SH, 1995, MANUAL DEPRESSION AN; Maehara Y, 2011, ACTA PSYCHOL, V138, P367, DOI 10.1016/j.actpsy.2011.09.009; Marcovitch S, 2015, COGNITIVE DEV, V33, P40, DOI 10.1016/j.cogdev.2014.07.001; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; Mathias JL, 2007, BRIT J CLIN PSYCHOL, V46, P457, DOI 10.1348/014466507X190197; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S., 2011, AWARENESS SOCIAL INF; McDonald S, 2014, NEUROPSYCHOLOGY, V28, P801, DOI 10.1037/neu0000089; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; McDonald S, 2012, AUST PSYCHOL, V47, P39, DOI 10.1111/j.1742-9544.2011.00054.x; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Morris PG, 2005, BRIT J CLIN PSYCHOL, V44, P209, DOI 10.1348/014466505X34174; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Ochsner KN, 2001, AM PSYCHOL, V56, P717, DOI 10.1037//0003-066X.56.9.717; Perner J, 1999, TRENDS COGN SCI, V3, P337, DOI 10.1016/S1364-6613(99)01362-5; Pickup GJ, 2008, PSYCHOPATHOLOGY, V41, P206, DOI 10.1159/000125554; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Psychological Corporation, 2001, WECHSLER TEST ADULT; Reitan R. M, 1992, TRAIL MAKING TEST; Ruby P, 2004, J COGNITIVE NEUROSCI, V16, P988, DOI 10.1162/0898929041502661; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Shallice, 1997, HAYLING BRIXTON TEST; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062	80	28	30	1	39	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	NOV	2015	150						69	79		10.1016/j.bandl.2015.08.007			11	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	CY1EG	WOS:000366148900008	26335998				2021-06-18	
J	Jenkins, MM; Colvonen, PJ; Norman, SB; Afari, N; Allard, CB; Drummond, SPA				Jenkins, Melissa M.; Colvonen, Peter J.; Norman, Sonya B.; Afari, Niloofar; Allard, Carolyn B.; Drummond, Sean P. A.			Prevalence and Mental Health Correlates of Insomnia in First-Encounter Veterans with and without Military Sexual Trauma	SLEEP			English	Article						insomnia; military sexual trauma; prevalence; veterans	COGNITIVE-BEHAVIORAL THERAPY; POSTTRAUMATIC-STRESS-DISORDER; SLEEP DISTURBANCE; SERVICE; IRAQ; DISSEMINATION; EPIDEMIOLOGY; ASSOCIATION; VALIDATION; DEPRESSION	Study Objectives: There is limited information about prevalence of insomnia in general populations of veterans of recent wars in Iraq and Afghanistan. No studies have examined insomnia in veterans with military sexual trauma (MST). We assess prevalence of insomnia, identify types of services sought by veterans with insomnia, and examine correlates of insomnia in veterans with and without MST. Design: A cross-sectional study of first-encounter veterans registering to establish care. Setting: Veteran Affairs San Diego Healthcare System. Participants: Nine hundred seventeen veterans completed questionnaires assessing insomnia, MST, service needs, traumatic brain injury, resilience, and symptoms of depression, posttraumatic stress disorder (PTSD), pain, alcohol misuse, and hypomania. Interventions: N/A. Measurements and Results: 53.1% of veterans without MST and 60.8% of veterans with MST had clinically significant insomnia symptoms, with the MST subsample reporting more severe symptoms, P < 0.05. Insomnia was more prevalent than depression, hypomania, PTSD, and substance misuse. Veterans with insomnia were more likely to seek care for physical health problems and primary care versus mental health concerns, P < 0.001. For the veteran sample without MST, age, combat service, traumatic brain injury, pain, and depression were associated with worse insomnia, P < 0.001. For the MST subsample, employment status, pain, and depression were associated with worse insomnia, P < 0.001. Conclusions: Study findings indicate a higher rate of insomnia in veterans compared to what has been found in the general population. Insomnia is more prevalent, and more severe, in veterans with military sexual trauma. Routine insomnia assessments and referrals to providers who can provide evidence-based treatment are crucial.	[Jenkins, Melissa M.; Norman, Sonya B.; Afari, Niloofar; Allard, Carolyn B.; Drummond, Sean P. A.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Jenkins, Melissa M.; Norman, Sonya B.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Colvonen, Peter J.; Norman, Sonya B.; Afari, Niloofar; Allard, Carolyn B.; Drummond, Sean P. A.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA; [Colvonen, Peter J.; Norman, Sonya B.; Afari, Niloofar; Allard, Carolyn B.; Drummond, Sean P. A.] Ctr Excellence Stress & Mental Hlth CESAMH, San Diego, CA USA; [Norman, Sonya B.] Natl Ctr PTSD, White River Jct, VT USA; [Drummond, Sean P. A.] Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia	Drummond, SPA (corresponding author), Monash Univ, Sch Psychol Sci, Clin Neurosci, Clayton, Vic 3800, Australia.	sean.drummond@monash.edu	Allard, Carolyn B./B-3521-2013	Allard, Carolyn B./0000-0002-7803-2243; Drummond, Sean/0000-0002-9815-626X	Department of Veterans Affairs Center of Excellence for Stress and Mental Health (CESAMH)US Department of Veterans Affairs; Veterans Affairs Center for Innovation; VA San Diego Healthcare SystemUS Department of Veterans Affairs; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH018399] Funding Source: NIH RePORTER	This was not an industry supported study. Dr. Drummond has received fees from Arena Pharmaceuticals and grants from Actelion Clinical Research, Inc., unrelated to this paper. The other authors have indicated no financial conflicts of interest. This material is based upon work supported by the Department of Veterans Affairs Center of Excellence for Stress and Mental Health (CESAMH) and the Veterans Affairs Center for Innovation. This material also is the result of work supported with resources of the VA San Diego Healthcare System. The views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Veterans Affairs or any of the institutions with which the authors are affiliated. The funding source did not play a role in the study design, in the collection, analysis, and interpretation of data, in the writing of the manuscript, or in the decision to submit the paper for publication.	Agha Z, 2000, ARCH INTERN MED, V160, P3252, DOI 10.1001/archinte.160.21.3252; Allard CB, 2011, J TRAUMA DISSOCIATIO, V12, P324, DOI 10.1080/15299732.2011.542609; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; [Anonymous], 2005, SLEEP, V28, P1049; Bernert RA, 2014, JAMA PSYCHIAT, V71, P1129, DOI 10.1001/jamapsychiatry.2014.1126; Bjorngaard JH, 2011, SLEEP, V34, P1155, DOI 10.5665/SLEEP.1228; Bradley KA, 2007, ALCOHOL CLIN EXP RES, V31, P1208, DOI 10.1111/j.1530-0277.2007.00403.x; Bramoweth AD, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0401-4; Bryant RA, 2010, SLEEP, V33, P69, DOI 10.1093/sleep/33.1.69; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Cozza S. J., 2004, IRAQ WAR CLIN GUIDE, DOI DOI 10.7205/MILMED-D-14-00686; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Edinger JD, 2001, JAMA-J AM MED ASSOC, V285, P1856, DOI 10.1001/jama.285.14.1856; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Hermes E, 2014, SLEEP MED, V15, P508, DOI 10.1016/j.sleep.2013.12.010; Hirschfeld RMA, 2000, AM J PSYCHIAT, V157, P1873, DOI 10.1176/appi.ajp.157.11.1873; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Karlin BE, 2015, INT J GERIATR PSYCH, V30, P308, DOI 10.1002/gps.4143; Karlin BE, 2013, J CONSULT CLIN PSYCH, V81, P912, DOI 10.1037/a0032554; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LeBlanc M, 2007, J PSYCHOSOM RES, V63, P157, DOI 10.1016/j.jpsychores.2007.03.004; Leger D, 2002, SLEEP, V25, P625; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Manber R, 2012, J CLIN SLEEP MED, V8, P209, DOI 10.5664/jcsm.1786; Manber R, 2011, J CLIN SLEEP MED, V7, P645, DOI 10.5664/jcsm.1472; Margolies SO, 2013, J CLIN PSYCHOL, V69, P1026, DOI 10.1002/jclp.21970; McIntyre LM, 1999, J GEN INTERN MED, V14, P186, DOI 10.1046/j.1525-1497.1999.00311.x; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Morin CM, 2013, SLEEP MED CLIN, V8, P281, DOI 10.1016/j.jsmc.2013.05.002; Morin CM, 2012, LANCET, V379, P1129, DOI 10.1016/S0140-6736(11)60750-2; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Morin CM, 2009, JAMA-J AM MED ASSOC, V301, P2005, DOI 10.1001/jama.2009.682; Mustafa Masroor, 2005, Sleep Breath, V9, P57, DOI 10.1007/s11325-005-0016-z; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Niebuhr RE, 1997, SEXUAL HARASSMENT TH, P250; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Ohayon MM, 2003, J PSYCHIAT RES, V37, P9, DOI 10.1016/S0022-3956(02)00052-3; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Simon GE, 1997, AM J PSYCHIAT, V154, P1417; Sivertsen B, 2012, PSYCHOSOM MED, V74, P758, DOI 10.1097/PSY.0b013e3182648619; Smith MT, 2004, SLEEP MED REV, V8, P119, DOI 10.1016/S1087-0792(03)00044-3; Suris A, 2008, TRAUMA VIOLENCE ABUS, V9, P250, DOI 10.1177/1524838008324419; Taylor MK, 2014, MIL MED, V179, P744, DOI 10.7205/MILMED-D-13-00551; Trockel M, 2014, BEHAV RES THER, V53, P41, DOI 10.1016/j.brat.2013.11.006; Weathers F.W., 1994, PCL C FOR DSM 4; Yaeger D, 2006, J GEN INTERN MED, V21, pS65, DOI 10.1111/j.1525-1497.2006.00377.x	49	28	28	0	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA		1550-9109		SLEEP	Sleep	OCT 1	2015	38	10					1547	1554		10.5665/sleep.5044			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CT3CP	WOS:000362684500005	26085301	Green Published			2021-06-18	
J	Martinez-Valverde, T; Vidal-Jorge, M; Martinez-Saez, E; Castro, L; Arikan, F; Cordero, E; Radoi, A; Poca, MA; Simard, JM; Sahuquillo, J				Martinez-Valverde, Tamara; Vidal-Jorge, Marian; Martinez-Saez, Elena; Castro, Lidia; Arikan, Fuat; Cordero, Esteban; Radoi, Andreea; Poca, Maria-Antonia; Simard, J. Marc; Sahuquillo, Juan			Sulfonylurea Receptor 1 in Humans with Post-Traumatic Brain Contusions	JOURNAL OF NEUROTRAUMA			English	Article						brain contusion; brain edema; human; immunofluorescence; sulfonyurea receptor 1	SENSITIVE POTASSIUM CHANNELS; CEREBRAL CONTUSION; SUBARACHNOID HEMORRHAGE; INJURY; ATP; GLIBENCLAMIDE; EDEMA; MODEL; BARRIER; DAMAGE	Post-traumatic brain contusions (PTBCs) are traditionally considered primary injuries and can increase in size, generate perilesional edema, cause mass effect, induce neurological deterioration, and cause death. Most patients experience a progressive increase in pericontusional edema, and nearly half, an increase in the hemorrhagic component itself. The underlying molecular pathophysiology of contusion-induced brain edema and hemorrhagic progression remains poorly understood. The aim of this study was to investigate sulfonylurea 1/transient receptor potential melastatin 4 (SUR1-TRPM4) ion channel SUR1 expression in various cell types (neurons, astrocytes, endothelial cells, microglia, macrophages, and neutrophils) of human brain contusions and whether SUR1 up-regulation was related to time postinjury. Double immunolabeling of SUR1 and cell-type- specific proteins was performed in 26 specimens from traumatic brain injury patients whose lesions were surgically evacuated. Three samples from limited brain resections performed for accessing extra-axial skull-base tumors or intraventricular lesions were controls. We found SUR1 was significantly overexpresed in all cell types and was especially prominent in neurons and endothelial cells (ECs). The temporal pattern depended on cell type: 1) In neurons, SUR1 increased within 48h of injury and stabilized thereafter; 2) in ECs, there was no trend; 3) in glial cells and microglia/macrophages, a moderate increase was observed over time; and 4) in neutrophils, it decreased with time. Our results suggest that up-regulation of SUR1 in humans point to this channel as one of the important molecular players in the pathophysiology of PTBCs. Our findings reveal opportunities to act therapeutically on the mechanisms of growth of traumatic contusions and therefore reduce the number of patients with neurological deterioration and poor neurological outcomes.	[Martinez-Valverde, Tamara; Vidal-Jorge, Marian; Castro, Lidia; Arikan, Fuat; Radoi, Andreea; Poca, Maria-Antonia; Sahuquillo, Juan] Univ Autonoma Barcelona, Neurotraumatol & Neurosurg Res Unit UNINN, Barcelona 08035, Spain; [Martinez-Saez, Elena] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Pathol, Barcelona 08035, Spain; [Arikan, Fuat; Cordero, Esteban; Poca, Maria-Antonia; Sahuquillo, Juan] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Neurosurg, Barcelona 08035, Spain; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	Sahuquillo, J (corresponding author), Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Neurosurg, Paseo Vall dHebron 119-129, Barcelona 08035, Spain.	sahuquillo@neurotrauma.net	Martinez-Saez, Elena/E-9097-2018; Radoi, Andreea/N-5613-2019; Radoi, Andreea/C-9682-2016; Poca, Maria A./B-8475-2008; Castro, Lidia/J-3976-2017; Arikan, Fuat/F-8900-2016; Sahuquillo, Juan/B-3577-2008; Vidal-Jorge, Marian/D-4402-2017	Martinez-Saez, Elena/0000-0001-6004-5364; Radoi, Andreea/0000-0002-0677-3544; Poca, Maria A./0000-0002-3831-0536; Castro, Lidia/0000-0001-8513-7388; Arikan, Fuat/0000-0002-9459-0915; Sahuquillo, Juan/0000-0003-0713-5875; Vidal-Jorge, Marian/0000-0002-3459-9336	Fondo de Investigacion Sanitaria (Instituto de Salud Carlos III)Instituto de Salud Carlos III [PI10/00302, PI11/00700]; European Regional DevelopmentEuropean Commission; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission [FI11/00195]; Fundacio Institut de Recerca HUVH [PRED-VHIR-2012-26]	This work was supported, in part, by the Fondo de Investigacion Sanitaria (Instituto de Salud Carlos III) with grants PI10/00302 and PI11/00700, which were cofinanced by the European Regional Development and awarded to Dr. Poca and Dr. Sahuquillo, respectively. T. Martinez-Valverde and A. Raloi are recipients of a predoctoral grant from the Instituto de Salud Carlos III (grant no.: FI11/00195) and from Fundacio Institut de Recerca HUVH (grant no.: PRED-VHIR-2012-26), respectively.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Aittoniemi J, 2009, PHILOS T R SOC B, V364, P257, DOI 10.1098/rstb.2008.0142; Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Chen MK, 2001, J NEUROSCI, V21, P6512; Clancy B, 1998, J NEUROSCI METH, V83, P97, DOI 10.1016/S0165-0270(98)00066-1; Davis ME, 2004, J BIOL CHEM, V279, P163, DOI 10.1074/jbc.M307528200; Eriskat J., 1994, INTRACRANIAL PRESSUR, P339; Fox J., 2011, R COMPANION APPL REG, V2; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; Iaccarino C, 2014, J NEUROSURG, V120, P908, DOI 10.3171/2013.12.JNS131090; Katayama Y, 1998, ACT NEUR S, V71, P289; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kawamata T, 2007, PROG BRAIN RES, V161, P235, DOI 10.1016/S0079-6123(06)61016-9; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kunte H, 2012, ANN NEUROL, V72, P799, DOI 10.1002/ana.23680; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Latchman DS, 1997, INT J BIOCHEM CELL B, V29, P1305, DOI 10.1016/S1357-2725(97)00085-X; LINDENBERG R, 1957, ARCH PATHOL, V63, P23; Liss B, 2001, NEWS PHYSIOL SCI, V16, P214; Maeda T, 2003, ACT NEUR S, V86, P329; Marion DW, 2006, NEUROSURGERY, V58, P655; Mehta RI, 2013, J NEUROPATH EXP NEUR, V72, P871, DOI 10.1097/NEN.0b013e3182a32e40; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; R Development Core Team, 2013, R LANG ENV STAT COMP; Rosenberg GA, 2012, J CEREBR BLOOD F MET, V32, P1139, DOI 10.1038/jcbfm.2011.197; RStudio, 2013, RSTUDIO INT DEV ENV; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard JM, 2010, STROKE, V41, P531, DOI 10.1161/STROKEAHA.109.572644; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2008, PEDIATR RES, V64, P648, DOI 10.1203/PDR.0b013e318186e5a9; Simard PF, 2011, TRANSL STROKE RES, V2, P227, DOI 10.1007/s12975-011-0070-8; Spitzer N, 2011, J NEUROSCI METH, V197, P48, DOI 10.1016/j.jneumeth.2011.01.029; SULLIVAN HC, 1993, BRAIN RES, V612, P336, DOI 10.1016/0006-8993(93)91682-I; Tosun C, 2013, STROKE, V44, P3522, DOI 10.1161/STROKEAHA.113.002904; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Verstraeten SV, 2010, BBA-BIOMEMBRANES, V1798, P1739, DOI 10.1016/j.bbamem.2010.06.010; Vilalta A, 2006, J NEUROTRAUM, V23, P772; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Wu HM, 2013, J NEUROTRAUM, V30, P352, DOI 10.1089/neu.2012.2610; Yokota Hiroyuki, 2007, Journal of Nippon Medical School, V74, P332, DOI 10.1272/jnms.74.332; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	54	28	29	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2015	32	19					1478	1487		10.1089/neu.2014.3706			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CR8NC	WOS:000361609500006	26398596	Green Published			2021-06-18	
J	Xia, Y; Kong, L; Yao, YJ; Jiao, YA; Song, J; Tao, ZY; You, Z; Yang, JX				Xia, Yang; Kong, Liang; Yao, Yingjia; Jiao, Yanan; Song, Jie; Tao, Zhenyu; You, Zhong; Yang, Jingxian			Osthole confers neuroprotection against cortical stab wound injury and attenuates secondary brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Osthole; Cortical stab wound injury; Secondary brain injury; Anti-inflammation; Anti-apoptosis	NEURAL STEM-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; BCL-2 PROTEIN FAMILY; INFLAMMATORY RESPONSE; BONE-MARROW; SPINAL-CORD; ANTIINFLAMMATORY MECHANISM; NATURAL COUMARIN	Background: Neuroendoscopy is an innovative technique for neurosurgery that can nonetheless result in traumatic brain injury. The accompanying neuroinflammation may lead to secondary tissue damage, which is the major cause of delayed neuronal death after surgery. The present study investigated the capacity of osthole to prevent secondary brain injury and the underlying mechanism of action in a mouse model of stab wound injury. Methods: A mouse model of cortical stab wound injury was established by inserting a needle into the cerebral cortex for 20 min to mimic neuroendoscopy. Mice received an intraperitoneal injection of osthole 30 min after surgery and continued for 14 days. Neurological severity was evaluated 12 h and up to 21 days after the trauma. Brains were collected 3-21 days post-injury for histological analysis, immunocytochemistry, quantitative real-time PCR, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and enzyme-linked immunosorbent assays. Results: Neurological function improved in mice treated with osthole and was accompanied by reduced brain water content and accelerated wound closure relative to untreated mice. Osthole treatment reduced the number of macrophages/microglia and peripheral infiltrating of neutrophils and lowered the level of the proinflammatory cytokines interleukin-6 and tumor necrosis factor a in the lesioned cortex. Osthole-treated mice had fewer TUNEL + apoptotic neurons surrounding the lesion than controls, indicating increased neuronal survival. Conclusions: Osthole reduced secondary brain damage by suppressing inflammation and apoptosis in a mouse model of stab wound injury. These results suggest a new strategy for promoting neuronal survival and function after neurosurgery to improve long-term patient outcome.	[Xia, Yang; You, Zhong] Univ Oxford, Dept Engn, Oxford OX1 3LZ, England; [Kong, Liang; Yao, Yingjia; Jiao, Yanan; Song, Jie; Tao, Zhenyu; Yang, Jingxian] Liaoning Univ Tradit Chinese Med, Sch Pharm, Dalian 116600, Peoples R China	Yang, JX (corresponding author), Liaoning Univ Tradit Chinese Med, Sch Pharm, Dalian 116600, Peoples R China.	jingxianyang@yahoo.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81173580]	This work was supported by the National Natural Science Foundation of China (grant No. 81173580).	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bitto A, 2012, CRIT CARE MED, V40, P945, DOI 10.1097/CCM.0b013e318236efde; Bjornsson CS, 2006, J NEURAL ENG, V3, P196, DOI 10.1088/1741-2560/3/3/002; Casanova F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094919; Casanova F, 2014, J NEUROSCI METH, V237, P79, DOI 10.1016/j.jneumeth.2014.08.012; Chao XD, 2010, BRAIN RES, V1363, P206, DOI 10.1016/j.brainres.2010.09.052; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen XH, 2010, EUR J PHARMACOL, V629, P40, DOI 10.1016/j.ejphar.2009.12.008; Chen ZW, 2015, NEUROCHEM RES, V40, P186, DOI 10.1007/s11064-014-1483-z; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Ding D, 2015, J CLIN NEUROSCI, DOI [10.1016/jjocn.2015.01.004, DOI 10.1016/JJOCN.2015.01.004]; Fan J, 2010, NEUROSCI LETT, V473, P196, DOI 10.1016/j.neulet.2010.02.045; Farkas G, 1998, NEUROSCI LETT, V242, P147, DOI 10.1016/S0304-3940(98)00060-3; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Gao Z, 2014, J PHARMACOL SCI, V124, P54, DOI 10.1254/jphs.13144FP; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hirjak D, 2013, NEUROPSYCHOBIOLOGY, V68, P91, DOI 10.1159/000350999; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; Hu Y, 2013, BIOL PHARM BULL, V36, P1950, DOI 10.1248/bpb.b13-00561; Ji HJ, 2010, EUR J PHARMACOL, V636, P96, DOI 10.1016/j.ejphar.2010.03.038; Kassam AB, 2009, J NEUROSURG, V110, P116, DOI 10.3171/2008.7.JNS08226; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; KELLY PJ, 1988, J NEUROSURG, V69, P301, DOI 10.3171/jns.1988.69.2.0301; Kotipatruni RR, 2011, NEUROCHEM RES, V36, P2063, DOI 10.1007/s11064-011-0530-2; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu SJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-66; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Nishihara T, 2000, J NEUROSURG, V92, P1053, DOI 10.3171/jns.2000.92.6.1053; Okamoto T, 2001, JPN J PHARMACOL, V85, P95, DOI 10.1254/jjp.85.95; Perrot R, 2008, MOL NEUROBIOL, V38, P27, DOI 10.1007/s12035-008-8033-0; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Schaible EV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071056; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Su ZD, 2010, GLIA, V58, P901, DOI 10.1002/glia.20972; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Takarada-Iemata M, 2014, J NEUROCHEM, V130, P374, DOI 10.1111/jnc.12729; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Villapol S, 2013, EXP NEUROL, V250, P353, DOI 10.1016/j.expneurol.2013.10.008; Wagshul ME, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-5; Wallenquist U, 2012, RESTOR NEUROL NEUROS, V30, P9, DOI 10.3233/RNN-2011-0606; Wang HH, 2012, NEUROIMMUNOMODULAT, V19, P304, DOI 10.1159/000339302; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; Waran V, 2009, J NEUROSURG, V111, P1127, DOI 10.3171/2009.4.JNS081506; Xia L, 2012, J NEUROSCI RES, V90, P1424, DOI 10.1002/jnr.22811; Xie F, 2013, TOXICOL APPL PHARM, V272, P598, DOI 10.1016/j.taap.2013.07.020; Yabe JT, 2001, CELL MOTIL CYTOSKEL, V50, P1, DOI 10.1002/cm.1037; Yang JX, 2014, MOL THER, V22, P440, DOI 10.1038/mt.2013.241; Yang JX, 2010, AM J PATHOL, V177, P1989, DOI 10.2353/ajpath.2010.091203; Yang JX, 2009, J CLIN INVEST, V119, P3678, DOI 10.1172/JCI37914; Yang JX, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002864; Yang LL, 2003, PLANTA MED, V69, P1091, DOI 10.1055/s-2003-45188; Yin F, 2014, BRAIN RES, V1561, P1, DOI 10.1016/j.brainres.2014.02.047; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; You L, 2009, NAT PROD COMMUN, V4, P297; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhang N, 2013, INT J MOL SCI, V14, P18657, DOI 10.3390/ijms140918657; Zhang N, 2012, EUR J PHARMACOL, V697, P32, DOI 10.1016/j.ejphar.2012.10.008; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	72	28	29	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	SEP 4	2015	12								155	10.1186/s12974-015-0373-x			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CQ7LT	WOS:000360786300001	26337552	DOAJ Gold, Green Published			2021-06-18	
J	Boltz, MM; Podany, AB; Hollenbeak, CS; Armen, SB				Boltz, Melissa M.; Podany, Abigail B.; Hollenbeak, Christopher S.; Armen, Scott B.			Injuries and outcomes associated with traumatic falls in the elderly population on oral anticoagulant therapy	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Elderly; Trauma; Falls; Oral anticoagulation	BRAIN-INJURY; PREINJURY WARFARIN; INTRACRANIAL HEMORRHAGE; HEAD-INJURY; MORTALITY; RISK; ANTIPLATELET; CLOPIDOGREL; INCREASE; IMPACT	Introduction: Fall risk for older adults is a multi-factorial public health problem as 90% of geriatric injuries are caused by traumatic falls. The CDC estimated 33% of adults >65 years incurred a fall in 2011, with 30% resulting in moderate injury. While much has been written about overall risk to trauma patients on oral anticoagulant (OAC) therapy, less has been reported on outcomes in the elderly trauma population. We used data from the National Trauma Data Bank (NTDB) to identify the types of injury and complications incurred, length of stay, and mortality associated with OACs in elderly patients sustaining a fall. Methods: Using standard NTDB practices, data were collected on elderly patients (>= 65 years) on OACs with diagnosis of fall as the primary mechanism of injury from 2007 to 2010. Univariate analysis was used to determine patient variables influencing risk of fall on OACs. Odds ratios were calculated for types of injury sustained and post-trauma complications. Logistic regression was used to determine mortality associated with type of injury incurred. Results: Of 118,467 elderly patients sampled, OAC use was observed in 444. Predisposing risk factors for fall on OACs were >1 comorbidity (p < 0.0001). Patients on OACs were 188% and 370% more likely to develop 2 and >3 complications (p < 0.0001); the most significant being ARDS and ARF (p < 0.0001). The mortality rate on OACs was 16%. Injuries to the GI tract, liver, spleen, and kidney (p < 0.0002) were more likely to occur. However, if patients suffered a mortality, the most significant injuries were skull fractures and intracranial haemorrhage (p < 0.0001). Conclusions: Risks of anticoagulation in elderly trauma patients are complex. While OAC use is a predictor of 30-day mortality after fall, the injuries sustained are markedly different between the elderly who die and those who do not. As a result there is a greater need for healthcare providers to identify preventable and non-preventable risks factors indicative of falls in the anti-coagulated elderly patient. (C) 2015 Elsevier Ltd. All rights reserved.	[Boltz, Melissa M.; Podany, Abigail B.; Hollenbeak, Christopher S.; Armen, Scott B.] Penn State Univ, Coll Med, Dept Surg, Hershey, PA 17033 USA; [Hollenbeak, Christopher S.] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA 17033 USA	Hollenbeak, CS (corresponding author), Penn State Univ, Coll Med, Dept Surg, 500 Univ Dr,H151, Hershey, PA 17033 USA.	boltzm@ccf.org; apodany@hmc.psu.edu; chollenbeak@psu.edu; sarmen@hmc.psu.edu	Hollenbeak, Christopher S./A-5309-2019	Hollenbeak, Christopher S./0000-0002-3362-814X			Bradburn E, 2012, J TRAUMA ACUTE CARE, V73, P435, DOI 10.1097/TA.0b013e31825c7cf4; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Heinze G, 2006, STAT MED, V25, P4216, DOI 10.1002/sim.2687; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Karni A, 2001, AM SURGEON, V67, P1098; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; National Trauma Data Bank, 2013, ANN REP 2012; National Trauma Data Bank, 2013, DAT DICT 2013; Ott MM, 2010, J TRAUMA, V68, P560, DOI 10.1097/TA.0b013e3181ad6600; Pieracci FM, 2007, J TRAUMA, V63, P519, DOI 10.1097/TA.0b013e31812e519b; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880; Sellers MB, 2011, AM HEART J, V161, P241, DOI 10.1016/j.ahj.2010.11.002; Williams TM, 2008, J TRAUMA, V65, P772, DOI 10.1097/TA.0b013e3181877ff7; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	19	28	28	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2015	46	9					1765	1771		10.1016/j.injury.2015.06.013			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	CS9LO	WOS:000362412800013	26117415				2021-06-18	
J	Kilbaugh, TJ; Karlsson, M; Byro, M; Bebee, A; Ralston, J; Sullivan, S; Duhaime, AC; Hansson, MJ; Elmer, E; Margulies, SS				Kilbaugh, Todd J.; Karlsson, Michael; Byro, Melissa; Bebee, Ashley; Ralston, Jill; Sullivan, Sarah; Duhaime, Ann-Christine; Hansson, Magnus J.; Elmer, Eskil; Margulies, Susan S.			Mitochondrial bioenergetic alterations after focal traumatic brain injury in the immature brain	EXPERIMENTAL NEUROLOGY			English	Article						Pediatric traumatic brain injury; Mitochondria; Axonal injury; Bioenergetics; Contusion; Swine	MATURATION-DEPENDENT RESPONSE; ELECTRON-TRANSPORT CHAIN; COMMON DATA ELEMENTS; METABOLIC CRISIS; POSTNATAL-DEVELOPMENT; UNITED-STATES; CELL-DEATH; RAT; DYSFUNCTION; ISCHEMIA	Traumatic brain injury (TBI) is one of the leading causes of death in children worldwide. Emerging evidence suggests that alterations in mitochondrial function are critical components of secondary injury cascade initiated by TBI that propogates neurodegeneration and limits neuroregeneration. Unfortunately, there is very little known about the cerebral mitochondrial bioenergetic response from the immature brain triggered by traumatic biomechanical forces. Therefore, the objective of this study was to perform a detailed evaluation of mitochondrial bioenergetics using high-resolution respirometry in a high-fidelity large animal model of focal controlled cortical impact injury (CCI) 24 h post-injury. This novel approach is directed at analyzing dysfunction in electron transport, ADP phosphorylation and leak respiration to provide insight into potential mechanisms and possible interventions for mitochondrial dysfunction in the immature brain in focal TBI by delineating targets within the electron transport system (ETS). Development and application of these methodologies have several advantages, and adds to the interpretation of previously reported techniques, by having the added benefit that any toxins or neurometabolites present in the ex-vivo samples are not removed during the mitochondrial isolation process, and simulates the in situ tricarboxylic acid (TCA) cycle by maximizing key substrates for convergent flow of electrons through both complexes I and II To investigate alterations in mitochondrial function after CCI, ipsilateral tissue near the focal impact site and tissue from the corresponding contralateral side were examined. Respiration per mg of tissue was also related to citrate synthase activity (CS) and calculated flux control ratios (FCR), as an attempt to control for variability in mitochondrial content. Our biochemical analysis of complex interdependent pathways of electron flow through the electron transport system, by most measures, reveals a bilateral decrease in complex I-driven respiration and an increase in complex II-driven respiration 24 h after focal TBI. These alterations in convergent electron flow though both complex I and II-driven respiration resulted in significantly lower maximal coupled and uncoupled respiration in the ipsilateral tissue compared to the contralateral side, for all measures. Surprisingly, increases in complex II and complex IV activities were most pronounced in the contralateral side of the brain from the focal injury, and where oxidative phosphoryladon was increased significantly compared to sham values. We conclude that 24 h after focal TBI in the immature brain, there are significant alterations in cerebral mitochondrial bioenergetics, with pronounced increases in complex II and complex IV respiration in the contralateral hemisphere. These alterations in mitochondrial bioenergetics present multiple targets for therapeutic intervention to limit secondary brain injury and support recovery. (C) 2015 Elsevier Inc. All rights reserved.	[Kilbaugh, Todd J.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Karlsson, Michael; Hansson, Magnus J.; Elmer, Eskil] Lund Univ, Dept Clin Sci, Mitochondrial Med, SE-22184 Lund, Sweden; [Byro, Melissa; Bebee, Ashley; Ralston, Jill; Sullivan, Sarah; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Duhaime, Ann-Christine] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA	Kilbaugh, TJ (corresponding author), 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	kilbaugh@chop.edu; michael.karlsson@med.lu.se; melissa.byro@gmail.com; ashley.n.durban@gmail.com; ralstonjm@gmail.com; sarahsul@seas.upenn.edu; aduhaime@partners.org; magnus.hansson@med.lu.se; eskil.elmer@med.lu.se; margulie@seas.upenn.edu	Karlsson, Michael/AAL-8743-2020; Elmer, Eskil/F-9341-2014; Hansson, Magnus/G-4486-2014	Karlsson, Michael/0000-0002-7247-2133; Elmer, Eskil/0000-0001-7901-1826; Hansson, Magnus/0000-0002-0201-0638; Kilbaugh, Todd/0000-0002-4959-3092	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UO1 NS069545]; Endowed Chair of Critical Care Medicine at the Children's Hospital of Philadelphia; Stephenson Fund Department of Bioengineering the University of Pennsylvania; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS069545] Funding Source: NIH RePORTER	The authors would like to thank Albana Shahini and Saori Morota for their invaluable technical support. The Oroboros Oxygraph used in the study was a loan from NeuroVive Pharmaceutical AB, Lund Sweden. Studies were supported by the NIH UO1 NS069545, Endowed Chair of Critical Care Medicine at the Children's Hospital of Philadelphia, and Stephenson Fund Department of Bioengineering the University of Pennsylvania.	Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; ALMEIDA A, 1995, DEV NEUROSCI-BASEL, V17, P212, DOI 10.1159/000111289; Armstead William M, 2005, Pathophysiology, V12, P5, DOI 10.1016/j.pathophys.2005.01.002; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Balan IS, 2013, J NEUROTRAUM, V30, P367, DOI 10.1089/neu.2012.2339; BATES TE, 1994, DEV NEUROSCI-BASEL, V16, P321, DOI 10.1159/000112126; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Chepelev NL, 2009, J ENZYM INHIB MED CH, V24, P1319, DOI 10.3109/14756360902852586; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DELMAESTRO R, 1987, MECH AGEING DEV, V41, P29, DOI 10.1016/0047-6374(87)90051-0; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Durham SR, 2007, J NEUROTRAUM, V24, P5, DOI 10.1089/neu.2006.0054; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Gnaiger E, 2009, INT J BIOCHEM CELL B, V41, P1837, DOI 10.1016/j.biocel.2009.03.013; Grate LL, 2003, J NEUROSCI METH, V123, P201, DOI 10.1016/S0165-0270(02)00361-8; Hagen CM, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071904, 10.1371/currents.hd.d8917b4862929772c5a2f2a34ef1c201]; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hattori N, 2003, J NUCL MED, V44, P1709; Karlsson M, 2013, INT J BIOCHEM CELL B, V45, P151, DOI 10.1016/j.biocel.2012.08.008; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Kunz WS, 2000, ANN NEUROL, V48, P766, DOI 10.1002/1531-8249(200011)48:5<766::AID-ANA10>3.0.CO;2-M; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185; Lemieux H, 2011, INT J BIOCHEM CELL B, V43, P1729, DOI 10.1016/j.biocel.2011.08.008; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Loor G, 2011, BBA-MOL CELL RES, V1813, P1382, DOI 10.1016/j.bbamcr.2010.12.008; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Miller AC, 2012, J NEUROTRAUM, V29, P634, DOI 10.1089/neu.2011.1932; Missios S, 2009, J NEUROTRAUM, V26, P1943, DOI [10.1089/neu.2009.0956, 10.1089/neu.2009-0956]; Navarro A, 2009, J BIOENERG BIOMEMBR, V41, P517, DOI 10.1007/s10863-009-9250-6; Niatsetskaya ZV, 2012, J NEUROSCI, V32, P3235, DOI 10.1523/JNEUROSCI.6303-11.2012; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Pecinova A, 2011, MITOCHONDRION, V11, P722, DOI 10.1016/j.mito.2011.05.006; Picard M, 2011, J PHYSIOL-LONDON, V589, P4413, DOI 10.1113/jphysiol.2011.212712; Picard M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018317; Ragan DK, 2013, J CEREBR BLOOD F MET, V33, P48, DOI 10.1038/jcbfm.2012.130; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Saito A, 2005, MOL NEUROBIOL, V31, P105, DOI 10.1385/MN:31:1-3:105; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; SIMS NR, 1986, J NEUROCHEM, V47, P496; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Suchadolskiene O, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-2; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Watson William D, 2013, Front Neuroenergetics, V5, P12, DOI 10.3389/fnene.2013.00012; Weeks D, 2014, J NEUROTRAUM, V31, P206, DOI 10.1089/neu.2013.3113; Wright MJ, 2013, BRAIN IMAGING BEHAV, V7, P307, DOI 10.1007/s11682-013-9231-6; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	57	28	29	1	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2015	271						136	144		10.1016/j.expneurol.2015.05.009			9	Neurosciences	Neurosciences & Neurology	CT2JG	WOS:000362627200015	26028309	Green Accepted			2021-06-18	
J	Zhao, ZR; Sabirzhanov, B; Wu, JF; Faden, AI; Stoica, BA				Zhao, Zaorui; Sabirzhanov, Boris; Wu, Junfang; Faden, Alan I.; Stoica, Bogdan A.			Voluntary Exercise Preconditioning Activates Multiple Antiapoptotic Mechanisms and Improves Neurological Recovery after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						exercise; traumatic brain injury; controlled cortical impact; neuroprotection	SPINAL-CORD-INJURY; CONTROLLED CORTICAL IMPACT; TAIL SUSPENSION TEST; TREADMILL EXERCISE; PROGRESSIVE NEURODEGENERATION; NEURONAL APOPTOSIS; RECOGNITION MEMORY; BH3-ONLY PROTEINS; PHYSICAL-EXERCISE; CDK INHIBITOR	Physical activity can attenuate neuronal loss, reduce neuroinflammation, and facilitate recovery after brain injury. However, little is known about the mechanisms of exercise-induced neuroprotection after traumatic brain injury (TBI) or its modulation of post-traumatic neuronal cell death. Voluntary exercise, using a running wheel, was conducted for 4 weeks immediately preceding (preconditioning) moderate-level controlled cortical impact (CCI), a well-established experimental TBI model in mice. Compared to nonexercised controls, exercise preconditioning (pre-exercise) improved recovery of sensorimotor performance in the beam walk task, as well as cognitive/affective functions in the Morris water maze, novel object recognition, and tail-suspension tests. Further, pre-exercise reduced lesion size, attenuated neuronal loss in the hippocampus, cortex, and thalamus, and decreased microglial activation in the cortex. In addition, exercise preconditioning activated the brain-derived neurotrophic factor pathway before trauma and amplified the injury-dependent increase in heat shock protein 70 expression, thus attenuating key apoptotic pathways. The latter include reduction in CCI-induced up-regulation of proapoptotic B-cell lymphoma 2 (Bcl-2)-homology 3-only Bcl-2 family molecules (Bid, Puma), decreased mitochondria permeabilization with attenuated release of cytochrome c and apoptosis-inducing factor (AIF), reduced AIF translocation to the nucleus, and attenuated caspase activation. Given these neuroprotective actions, voluntary physical exercise may serve to limit the consequences of TBI.	[Stoica, Bogdan A.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA	Stoica, BA (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Bressler Res Bldg,655 West Baltimore St, Baltimore, MD 21201 USA.	bstoica@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Faden, Alan I./0000-0003-0128-2348	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS037313, R01 NS052568]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568, R01NS037313] Funding Source: NIH RePORTER	The authors thank Titilola Akintola for expert technical assistance and Dr. David Loane for critical review of the manuscript. This work was supported by National Institutes of Health grants R01 NS037313 and R01 NS052568 (to A.I.F.).	Abelson-Mitchell N, 2008, J CLIN NURS, V17, P46, DOI 10.1111/j.1365-2702.2007.01941.x; Almeida S, 2009, NEUROBIOL DIS, V35, P448, DOI 10.1016/j.nbd.2009.06.006; Archer T, 2012, ACTA NEUROL SCAND, V125, P293, DOI 10.1111/j.1600-0404.2011.01638.x; Bao TH, 2014, J MOL NEUROSCI, V54, P622, DOI 10.1007/s12031-014-0344-1; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Chen YW, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2006.033829; Clark RE, 2000, J NEUROSCI, V20, P8853; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; De Biase A, 2005, PHYSIOL GENOMICS, V22, P368, DOI 10.1152/physiolgenomics.00081.2005; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gresack JE, 2007, BRAIN RES, V1160, P91, DOI 10.1016/j.brainres.2007.05.033; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gu YL, 2014, NEUROSCI LETT, V570, P86, DOI 10.1016/j.neulet.2014.04.004; Heck TG, 2011, CELL BIOCHEM FUNCT, V29, P215, DOI 10.1002/cbf.1739; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Jacotte-Simancas A, 2015, J NEUROTRAUM, V32, P739, DOI 10.1089/neu.2014.3502; Johnson EM, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00044; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; Kim JY, 2013, NEUROBIOL DIS, V58, P289, DOI 10.1016/j.nbd.2013.06.012; Kim SE, 2010, EXP GERONTOL, V45, P357, DOI 10.1016/j.exger.2010.02.005; Liebelt B, 2010, NEUROSCIENCE, V166, P1091, DOI 10.1016/j.neuroscience.2009.12.067; Liu X, 2010, NEUROSCI LETT, V476, P99, DOI 10.1016/j.neulet.2010.04.011; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lomonosova E, 2008, ONCOGENE, V27, pS2, DOI 10.1038/onc.2009.39; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mota BC, 2012, NEUROTOX RES, V21, P175, DOI 10.1007/s12640-011-9257-8; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Quadrato G, 2012, P NATL ACAD SCI USA, V109, pE1499, DOI 10.1073/pnas.1202068109; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Sabirzhanov B, 2012, J NEUROCHEM, V123, P542, DOI 10.1111/j.1471-4159.2012.07927.x; Shamas-Din A, 2011, BBA-MOL CELL RES, V1813, P508, DOI 10.1016/j.bbamcr.2010.11.024; Shen XF, 2013, INT J MOL SCI, V14, P21598, DOI 10.3390/ijms141121598; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Smith RS, 2007, DNA SEQUENCE, V18, P47, DOI 10.1080/10425170601060707; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Stoica BA, 2005, MOL CELL NEUROSCI, V29, P355, DOI 10.1016/j.mcn.2005.02.009; Stoica BA, 2010, ACUTE NEURONAL INJURY: THE ROLE OF EXCITOTOXIC PROGRAMMED CELL DEATH MECHANISMS, P169, DOI 10.1007/978-0-387-73226-8_12; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Stranahan AM, 2009, HIPPOCAMPUS, V19, P951, DOI 10.1002/hipo.20577; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023; Turturici G, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/618127; Yang JL, 2014, NEUROMOL MED, V16, P161, DOI 10.1007/s12017-013-8270-x; Zhang HT, 2008, NEUROPSYCHOPHARMACOL, V33, P1611, DOI 10.1038/sj.npp.1301537; Zhao ZR, 2013, J CEREBR BLOOD F MET, V33, P1897, DOI 10.1038/jcbfm.2013.144; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zhao ZR, 2010, P NATL ACAD SCI USA, V107, P5605, DOI 10.1073/pnas.0910578107	65	28	29	2	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2015	32	17					1347	1360		10.1089/neu.2014.3739			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CP0KP	WOS:000359564500008	25419789	Green Published			2021-06-18	
J	Dang, H; Stayman, JW; Sisniega, A; Xu, J; Zbijewski, W; Wang, X; Foos, DH; Aygun, N; Koliatsos, VE; Siewerdsen, JH				Dang, H.; Stayman, J. W.; Sisniega, A.; Xu, J.; Zbijewski, W.; Wang, X.; Foos, D. H.; Aygun, N.; Koliatsos, V. E.; Siewerdsen, J. H.			Statistical reconstruction for cone-beam CT with a post-artifact-correction noise model: application to high-quality head imaging	PHYSICS IN MEDICINE AND BIOLOGY			English	Article						cone-beam CT; traumatic brain injury; intracranial hemorrhage; model-based iterative reconstruction; artifact correction; measurement noise model; soft-tissue image quality	X-RAY CT; FLAT-PANEL IMAGERS; COMPUTED-TOMOGRAPHY; DIAGNOSTIC-RADIOLOGY; SCATTER CORRECTION; ORDERED SUBSETS; BREAST CT; OPTIMIZATION; PERFORMANCE; DETECTABILITY	Non-contrast CT reliably detects fresh blood in the brain and is the current front-line imaging modality for intracranial hemorrhage such as that occurring in acute traumatic brain injury (contrast similar to 40-80 HU, size > 1 mm). We are developing flat-panel detector (FPD) cone-beam CT (CBCT) to facilitate such diagnosis in a low-cost, mobile platform suitable for point-of-care deployment. Such a system may offer benefits in the ICU, urgent care/concussion clinic, ambulance, and sports and military theatres. However, current FPD-CBCT systems face significant challenges that confound low-contrast, soft-tissue imaging. Artifact correction can overcome major sources of bias in FPD-CBCT but imparts noise amplification in filtered backprojection (FBP). Model-based reconstruction improves soft-tissue image quality compared to FBP by leveraging a high-fidelity forward model and image regularization. In this work, we develop a novel penalized weighted least-squares (PWLS) image reconstruction method with a noise model that includes accurate modeling of the noise characteristics associated with the two dominant artifact corrections (scatter and beam-hardening) in CBCT and utilizes modified weights to compensate for noise amplification imparted by each correction. Experiments included real data acquired on a FPD-CBCT test-bench and an anthropomorphic head phantom emulating intra-parenchymal hemorrhage. The proposed PWLS method demonstrated superior noise-resolution tradeoffs in comparison to FBP and PWLS with conventional weights (viz. at matched 0.50 mm spatial resolution, CNR = 11.9 compared to CNR = 5.6 and CNR = 9.9, respectively) and substantially reduced image noise especially in challenging regions such as skull base. The results support the hypothesis that with high-fidelity artifact correction and statistical reconstruction using an accurate post-artifact-correction noise model, FPD-CBCT can achieve image quality allowing reliable detection of intracranial hemorrhage.	[Dang, H.; Stayman, J. W.; Sisniega, A.; Xu, J.; Zbijewski, W.; Siewerdsen, J. H.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA; [Wang, X.; Foos, D. H.] Carestream Hlth, Rochester, NY 14608 USA; [Aygun, N.; Siewerdsen, J. H.] Johns Hopkins Univ, Russell H Morgan Dept Radiol, Baltimore, MD 21205 USA; [Koliatsos, V. E.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA	Dang, H (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA.	jeff.siewerdsen@jhu.edu	Dang, Hao/U-4865-2018	Dang, Hao/0000-0001-5861-6535; Stayman, Joseph/0000-0003-4358-378X; Sisniega, Alejandro/0000-0003-2030-2711	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-CA-112163]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA112163] Funding Source: NIH RePORTER	This work was supported by NIH R01-CA-112163 and the academic-industry partnership with Carestream Health (Rochester, NY). The authors also thank Dr Adam Wang and Mr Nicholas Uebele (Johns Hopkins University, Baltimore, MD) for assistance with the head phantom and simulated intracranial hemmorrhage.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Barrett HH., 2004, FDN IMAGE SCI; Benaroya H, 2005, PROBABILITY MODELS E; Boone JM, 2001, RADIOLOGY, V221, P657, DOI 10.1148/radiol.2213010334; BOONE JM, 1988, MED PHYS, V15, P721, DOI 10.1118/1.596186; Centers for Disease Control and Prevention, 2010, TRAUM BRAIN INJ US F; Dang H, 2015, PROC SPIE, V9412, DOI 10.1117/12.2082075; Dang H, 2014, PHYS MED BIOL, V59, P4799, DOI 10.1088/0031-9155/59/17/4799; DUBLIN AB, 1977, RADIOLOGY, V122, P365, DOI 10.1148/122.2.365; Erdogan H, 1999, PHYS MED BIOL, V44, P2835, DOI 10.1088/0031-9155/44/11/311; Fessler JA, 1996, IEEE T IMAGE PROCESS, V5, P1346, DOI 10.1109/83.535846; Gang GJ, 2014, MED PHYS, V41, P260, DOI 10.1118/1.4883816; Greenberg MS, 2006, HDB NEUROSURGERY; Hsieh J, 2000, MED PHYS, V27, P23, DOI 10.1118/1.598853; JOSEPH PM, 1978, J COMPUT ASSIST TOMO, V2, P100, DOI 10.1097/00004728-197801000-00017; Kachelriess M, 2001, MED PHYS, V28, P475, DOI 10.1118/1.1358303; Kim D, 2015, IEEE T MED IMAGING, V34, P167, DOI 10.1109/TMI.2014.2350962; Kim D, 2013, IEEE T MED IMAGING, V32, P1965, DOI 10.1109/TMI.2013.2266898; Koskinen SK, 2013, SKELETAL RADIOL, V42, P649, DOI 10.1007/s00256-012-1516-0; Kwan ALC, 2006, MED PHYS, V33, P391, DOI 10.1118/1.2163388; La Riviere PJ, 2006, IEEE T MED IMAGING, V25, P1022, DOI 10.1109/TMI.2006.875429; Li TF, 2004, IEEE T NUCL SCI, V51, P2505, DOI 10.1109/TNS.2004.834824; Long Y, 2010, IEEE T MED IMAGING, V29, P1839, DOI 10.1109/TMI.2010.2050898; Ning R, 2004, MED PHYS, V31, P1195, DOI 10.1118/1.1711475; Parizel PM, 2001, EUR RADIOL, V11, P1770, DOI 10.1007/s003300000800; Penninger RT, 2011, OTOL NEUROTOL, V32, P453, DOI 10.1097/MAO.0b013e31820d962c; PETERS TM, 1981, IEEE T NUCL SCI, V28, P3641, DOI 10.1109/TNS.1981.4331812; SAUER K, 1993, IEEE T SIGNAL PROCES, V41, P534, DOI 10.1109/78.193196; SIDDON RL, 1985, MED PHYS, V12, P252, DOI 10.1118/1.595715; Siewerdsen JH, 2006, MED PHYS, V33, P187, DOI 10.1118/1.2148916; Siewerdsen JH, 1997, MED PHYS, V24, P71, DOI 10.1118/1.597919; Siewerdsen JH, 1998, P SOC PHOTO-OPT INS, V3336, P546, DOI 10.1117/12.317057; Siewerdsen JH, 1999, MED PHYS, V26, P2635, DOI 10.1118/1.598803; Siewerdsen JH, 2001, MED PHYS, V28, P220, DOI 10.1118/1.1339879; Sisniega A, 2015, PHYS MED BIOL, V60, P1415, DOI 10.1088/0031-9155/60/4/1415; Sisniega A, 2013, MED PHYS, V40, DOI 10.1118/1.4801895; Stayman JW, 2014, PROC SPIE, V9033, DOI 10.1117/12.2043067; Stayman JW, 2013, PHYS MED BIOL, V58, P7563, DOI 10.1088/0031-9155/58/21/7563; Thibault JB, 2007, MED PHYS, V34, P4526, DOI 10.1118/1.2789499; Tilley Steven 2nd, 2014, Conf Proc Int Conf Image Form Xray Comput Tomogr, V2014, P363; Tward DJ, 2007, MED PHYS, V34, P4459, DOI 10.1118/1.2790586; Tward DJ, 2008, MED PHYS, V35, P5510, DOI 10.1118/1.3002414; Wang AS, 2015, MED PHYS, V42, P2699, DOI 10.1118/1.4914378; Wang AS, 2014, PHYS MED BIOL, V59, P1005, DOI 10.1088/0031-9155/59/4/1005; Wunderlich A, 2008, PHYS MED BIOL, V53, P2471, DOI 10.1088/0031-9155/53/10/002; Xu J, 2012, MED PHYS, V39, P4932, DOI 10.1118/1.4736805; Yang WT, 2007, AM J ROENTGENOL, V189, P1312, DOI 10.2214/AJR.07.2403; Zbijewski W, 2011, MED PHYS, V38, P4700, DOI 10.1118/1.3611039; Zbijewski W, 2009, P SPIE MED IMAGING, V7258; Zhu L, 2006, IEEE T MED IMAGING, V25, P1573, DOI 10.1109/TMI.2006.884636; Zhu L, 2009, MED PHYS, V36, P741, DOI 10.1118/1.3063001	51	28	28	0	10	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0031-9155	1361-6560		PHYS MED BIOL	Phys. Med. Biol.	AUG 21	2015	60	16					6153	6175		10.1088/0031-9155/60/16/6153			23	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Engineering; Radiology, Nuclear Medicine & Medical Imaging	CR0ZO	WOS:000361052600003	26225912	Green Accepted			2021-06-18	
J	Wei, WT; Wang, HD; Wu, Y; Ding, K; Li, T; Cong, ZX; Xu, JG; Zhou, ML; Huang, LT; Ding, H; Wu, HM				Wei, Wuting; Wang, Handong; Wu, Yong; Ding, Ke; Li, Tao; Cong, Zixiang; Xu, Jianguo; Zhou, Mengliang; Huang, Litian; Ding, Hui; Wu, Heming			Alpha lipoic acid inhibits neural apoptosis via a mitochondrial pathway in rats following traumatic brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article						Alpha lipoic acid; Apoptosis; Traumatic brain injury; Mitochondria	EXPERIMENTAL SUBARACHNOID HEMORRHAGE; REDUCING OXIDATIVE STRESS; CELL-DEATH; NRF2-ARE PATHWAY; CYTOCHROME-C; SYNAPTIC PROTEINS; NEUROPROTECTION; PROTECTS; ACTIVATION; DYSFUNCTION	Alpha lipoic acid (ALA) is a powerful antioxidant that has proven protective effects against brain damage following a traumatic brain injury (TBI) in rats. However, the molecular mechanisms underlying these effects are not well understood. This study investigated the effect of ALA on neural apoptosis and the potential mechanism of these effects in the weight-drop model of TBI in male Sprague-Dawley rats that were treated with ALA (20 or 100 mg/kg) or vehicle via intragastric administration 30 min after TBI. Brain samples were collected 48 h later for analysis. ALA treatment resulted in a downregulation of caspase-3 expression, reduced the number of positive cells in the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay and improved neuronal survival. Furthermore, the level of malondialdehyde and glutathione peroxidase activity were restored, while Bcl-2-associated X protein translocation to mitochondria and cytochrome c release into the cytosol were reduced by ALA treatment. These results demonstrate that ALA improves neurological outcome in rats by protecting neural cell against apoptosis via a mechanism that involves the mitochondria following TBI. (C) 2015 Elsevier Ltd. All rights reserved.	[Wei, Wuting; Wang, Handong; Huang, Litian; Ding, Hui] Southern Med Univ Guangzhou, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Wu, Yong; Ding, Ke; Li, Tao; Cong, Zixiang; Xu, Jianguo; Zhou, Mengliang; Wu, Heming] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357, 81301180]; Jiangsu Planned Projects for Postdoctoral Research Funds [1401002A]	This work was supported by grants from the National Natural Science Foundation of China (nos. 81371357, 81301180) and Jiangsu Planned Projects for Postdoctoral Research Funds (1401002A).	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Cahill J, 2007, NEUROSURGERY, V60, P531, DOI 10.1227/01.NEU.0000249287.99878.9B; Chen JY, 2014, J PINEAL RES, V56, P12, DOI 10.1111/jpi.12086; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Feeney D. M., 1981, BRAIN RES, V211, P66; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gloryy A, 2014, INT J HYPERTHER, V30, P502, DOI 10.3109/02656736.2014.968641; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Paradies G, 2014, WORLD J GASTROENTERO, V20, P14205, DOI 10.3748/wjg.v20.i39.14205; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Reed LJ, 1998, PROTEIN SCI, V7, P220, DOI 10.1002/pro.5560070125; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Simpkins JW, 2010, BBA-GEN SUBJECTS, V1800, P1113, DOI 10.1016/j.bbagen.2009.11.013; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Smith AR, 2004, CURR MED CHEM, V11, P1135, DOI 10.2174/0929867043365387; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Tirosh O, 2003, BIOFACTORS, V17, P297, DOI 10.1002/biof.5520170129; Toklu HZ, 2009, FREE RADICAL RES, V43, P658, DOI 10.1080/10715760902988843; Wang R, 2014, CELL PHYSIOL BIOCHEM, V34, P854, DOI 10.1159/000366304; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xie F, 2014, INT J CLIN EXP MED, V7, P2009; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, BRAIN INJURY, V22, P802, DOI 10.1080/02699050802372174; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zhang D, 2013, NEUROSCIENCE, V238, P209, DOI 10.1016/j.neuroscience.2013.02.022; Zhuang Z, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-47	39	28	28	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	AUG	2015	87						85	91		10.1016/j.neuint.2015.06.003			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CO7HO	WOS:000359330400009	26055972				2021-06-18	
J	Wolf, GK; Kretzmer, T; Crawford, E; Thors, C; Wagner, HR; Strom, TQ; Eftekhari, A; Klenk, M; Hayward, L; Vanderploeg, RD				Wolf, Gregory K.; Kretzmer, Tracy; Crawford, Eric; Thors, Christina; Wagner, H. Ryan; Strom, Thad Q.; Eftekhari, Afsoon; Klenk, Megan; Hayward, Laura; Vanderploeg, Rodney D.			Prolonged Exposure Therapy With Veterans and Active Duty Personnel Diagnosed With PTSD and Traumatic Brain Injury	JOURNAL OF TRAUMATIC STRESS			English	Article							POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH-SERVICES; PSYCHOMETRIC PROPERTIES; AFGHANISTAN VETERANS; CHECKLIST PCL; IRAQ; SYMPTOMS; VALIDITY; VICTIMS; HISTORY	The present study used archival clinical data to analyze the delivery and effectiveness of prolonged exposure (PE) and ancillary services for posttraumatic stress disorder (PTSD) among Operation Enduring Freedom, Operation Iraqi Freedom, and Operation New Dawn veterans (N = 69) with histories of mild to severe traumatic brain injury (TBI). Data from standard clinical assessments of veterans and active duty personnel treated in both inpatient and outpatient programs at 2 Department of Veteran Affairs medical centers were examined. Symptoms were assessed with self-report measures of PTSD (PTSD Checklist) and depression (Beck Depression Inventory-II) before and throughout therapy. Mixed linear models were utilized to determine the slope of reported symptoms throughout treatment, and the effects associated with fixed factors such as site, treatment setting (residential vs. outpatient), and TBI severity were examined. Results demonstrated significant decreases in PTSD, B = -3.00, 95% CI [-3.22, -2.78]; t(210) = -13.5; p < .001, and in depressive symptoms, B = -1.46, 95% CI [-1.64, -1.28]; t(192) = -8.32; p < .001. The effects of PE treatment did not differ by clinical setting and participants with moderate to severe injuries reported more rapid gains than those with a history of mild TBI. The results provide evidence that PE may well be effective for veterans with PTSD and TBI.	[Wolf, Gregory K.; Kretzmer, Tracy; Thors, Christina; Vanderploeg, Rodney D.] James A Haley VA Med Ctr, MHBS, Tampa, FL 33612 USA; [Crawford, Eric; Wagner, H. Ryan] VA Mid Atlantic Reg Mental Illness Res Educ & Cli, Durham, NC USA; [Crawford, Eric; Wagner, H. Ryan; Klenk, Megan] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; [Strom, Thad Q.] Dept Vet Affairs Med Ctr, Mental Hlth Serv Minneapolis, Minneapolis, MN USA; [Strom, Thad Q.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Eftekhari, Afsoon] VA Palo Alto HCS, Natl Ctr PTSD, Disseminat & Training Div, Menlo Pk, CA USA; [Hayward, Laura] Syracuse VA Med Ctr, Dept Psychol, Syracuse, NY USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat & Neurosci, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA	Wolf, GK (corresponding author), James A Haley VA Med Ctr, MHBS, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Gregory.Wolf2@va.gov		Strom, Thad/0000-0001-6743-9999			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2011, SUICIDE LIFE-THREAT, V41, P416, DOI 10.1111/j.1943-278X.2011.00041.x; Cahill S.P., 2003, J COGN PSYCHOTHER, V17, P113, DOI [DOI 10.1891/JCOP.17.2.113.57434, 10.1891/jcop.17.2.113.57434]; Cook JM, 2013, J TRAUMA STRESS, V26, P56, DOI 10.1002/jts.21769; Corrigan JD, 2012, BRAIN INJURY, V26, P139, DOI 10.3109/02699052.2011.648705; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Erbes C, 2007, MIL MED, V172, P359, DOI 10.7205/MILMED.172.4.359; Foa EB, 1999, J CONSULT CLIN PSYCH, V67, P194, DOI 10.1037/0022-006X.67.2.194; Foa EB, 2005, J CONSULT CLIN PSYCH, V73, P953, DOI 10.1037/0022-006X.73.5.953; Foa EB, 2002, J CONSULT CLIN PSYCH, V70, P1022, DOI 10.1037//0022-006X.70.4.1022; Foa EB, 2007, PROLONGED EXPOSURE T; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Goodson JT, 2013, J TRAUMA STRESS, V26, P419, DOI 10.1002/jts.21830; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258; Karlin BE, 2010, J TRAUMA STRESS, V23, P663, DOI 10.1002/jts.20588; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; Monson CM, 2008, PSYCHOL ASSESSMENT, V20, P131, DOI 10.1037/1040-3590.20.2.131; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Rauch SAM, 2009, DEPRESS ANXIETY, V26, P732, DOI 10.1002/da.20518; Rauch SAM, 2009, J TRAUMA STRESS, V22, P60, DOI 10.1002/jts.20380; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; Resick PA, 2014, COGNITIVE PROCESSING; Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2010, J TRAUMA STRESS, V23, P5, DOI 10.1002/jts.20493; Sripada RK, 2013, J TRAUMA STRESS, V26, P369, DOI 10.1002/jts.21813; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Tuerk PW, 2013, PSYCHOL SERV, V10, P401, DOI 10.1037/a0030549; Tuerk PW, 2011, J ANXIETY DISORD, V25, P397, DOI 10.1016/j.janxdis.2010.11.002; U.S. Department of Veteran Affairs and Department of Defense, 2010, TRAUM BRAIN INJ VET; U.S. Department of Veterans Affairs, 2010, VA CONS C PRACT REC; U.S. Department of Veterans Affairs and Department of Defense (VA/DoD), 2009, VA DOD CLIN PRACT GU; U.S. Department of Veterans Affairs and Department of Defense (VA/DoD), 2010, VA DOD CLIN PRACT GU; US Department of Defense, 2012, US MIL CAS STAT OP N; VansMinnen A., 2012, EUROPEAN J PSYCHOTRA, V3, DOI [10.3402/ejpt.v3i0.18805, DOI 10.3402/EJPT.V3I0.18805]; Verbeke G., 2000, LINEAR MIXED MODELS; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Wolf GK, 2012, J HEAD TRAUMA REHAB, V27, P26, DOI 10.1097/HTR.0b013e31823cd01f	45	28	28	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	AUG	2015	28	4					339	347		10.1002/jts.22029			9	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	CP5HR	WOS:000359912400010	26201688				2021-06-18	
J	Diamond, ML; Ritter, AC; Failla, MD; Boles, JA; Conley, YP; Kochanek, PM; Wagner, AK				Diamond, Matthew L.; Ritter, Anne C.; Failla, Michelle D.; Boles, Jennifer A.; Conley, Yvette P.; Kochanek, Patrick M.; Wagner, Amy K.			IL-1 beta associations with posttraumatic epilepsy development: A genetics and biomarker cohort study	EPILEPSIA			English	Article						Posttraumatic epilepsy; Inflammation; Traumatic brain injury; Genetic variation; IL-1 beta		ObjectivePosttraumatic epilepsy (PTE) is a significant complication following traumatic brain injury (TBI), yet the role of genetic variation in modulating PTE onset is unclear. We hypothesized that TBI-induced inflammation likely contributes to seizure development. We assessed whether genetic variation in the interleukin-1beta (IL-1) gene, Il-1 levels in cerebral spinal fluid (CSF) and serum, and CSF/serum IL-1 ratios would predict PTE development post-TBI. MethodsWe investigated PTE development in 256 Caucasian adults with moderate-to-severe TBI. IL-1 tagging and functional single nucleotide polymorphisms (SNPs) were genotyped. Genetic variance and PTE development were assessed. Serum and CSF IL-1 levels were collected from a subset of subjects (n=59) during the first week postinjury and evaluated for their associations with IL-1 gene variants, and also PTE. Temporally matched CSF/serum IL-1 ratios were also generated to reflect the relative contribution of serum IL-1 to CSF IL-1. ResultsMultivariate analysis showed that higher CSF/serum IL-1 ratios were associated with increased risk for PTE over time (p=0.008). Multivariate analysis for rs1143634 revealed an association between the CT genotype and increased PTE risk over time (p=0.005). The CT genotype group also had lower serum IL-1 levels (p=0.014) and higher IL-1 CSF/serum ratios (p=0.093). SignificanceThis is the first report implicating IL-1 gene variability in PTE risk and linking (1) IL-1 gene variation with serum IL-1 levels observed after TBI and (2) IL-1 ratios with PTE risk. Given these findings, we propose that genetic and IL-1 ratio associations with PTE may be attributable to biologic variability with blood-brain barrier integrity during TBI recovery. These results provide a rationale for further studies (1) validating the impact of genetic variability on IL-1 production after TBI, (2) assessing genetically mediated signaling mechanisms that contribute to IL-1 CSF/serum associations with PTE, and (3) evaluating targeted IL-1 therapies that reduce PTE. A PowerPoint slide summarizing this article is available for download in the Supporting Information section . This article was previously published: IL-1 associations with posttraumatic epilepsy development: A genetics and biomarker cohort study Vol. 55, Issue 7, 1109-1119, Article first published online: 22 APR 2014	[Diamond, Matthew L.; Ritter, Anne C.; Failla, Michelle D.; Boles, Jennifer A.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Failla, Michelle D.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Hlth Promot & Dev, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Safar Ctr Resuscitat Res, Rehabil Res, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Failla, Michelle/AAI-3788-2021	Failla, Michelle/0000-0001-9734-3373; Conley, Yvette/0000-0002-1784-6067	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048162-02, R01NR008424, 5P01NS030318];  [DODW81XWH-071-0701]	This work was supported by DODW81XWH-071-0701, NIH R01 HD048162-02, NIH R01NR008424, and NIH 5P01NS030318. Thanks to Sandra Deslouche for support with genotyping, and the subjects and their families for their generous participation. Thanks to the UPMC Trauma Registry for providing some elements of data collection. Thanks to the University of Pittsburgh Cancer Institute for Luminex services.		0	28	32	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUL	2015	56	7					991	1001		10.1111/epi.13100			11	Clinical Neurology	Neurosciences & Neurology	CM5LD	WOS:000357728400005	26149793	Bronze			2021-06-18	
J	Herou, E; Romner, B; Tomasevic, G				Herou, Erik; Romner, Bertil; Tomasevic, Gregor			Acute Traumatic Brain Injury: Mortality in the Elderly	WORLD NEUROSURGERY			English	Article						aSDH; Craniotomy; Elderly; Head injury; TBI; Trauma	GLASGOW COMA SCALE; REACTION LEVEL SCALE; PROGNOSTIC VALUE; ADMISSION CHARACTERISTICS; INTRACRANIAL HEMORRHAGE; IMPACT; AGE; OUTCOMES; ANTIPLATELET; VALIDATION	OBJECTIVE: Despite recent progress, prognosis for the elderly (defined as aged >= 70 years) afflicted by traumatic brain injury (TBI) is unfavorable and surgical intervention remains controversial. Research during the past decade on the mortality rates or prognostic factors for survival in the elderly is limited. METHODS: We analyzed 97 patients aged >= 70 years who were treated surgically for closed TBI at our neurosurgical unit between January 1, 2003 and December 31, 2012. In addition, we analyzed 22 patients aged >= 70 years who had sustained a closed TBI and on whom no neurosurgical intervention was performed. Outcome in both groups was measured as 30-, 90- and 180-day mortality. RESULTS: Surgically treated patients: median age, 76 years' 30- day overall mortality rate, 36%. Higher mortality was seen with lower level of consciousness, high energy trauma, one pupil fixed and dilated, and more extensive intracranial pathology. Presence of warfarin, more advanced age, or degree of midline shift were not associated with worsened outcome. Patients not treated neurosurgically: median age. 81.5 years; 30-day overall mortality rate, 23%. Mortality for patients with Glasgow coma scale (GCS) 10-15 was 6%, GCS 6-9 67%, and GCS 3-5 100%. CONCLUSIONS: Selected patients aged >= 70 years can benefit from surgical intervention for closed TBI. Level of consciousness, radiologic type of injury, mechanism of injury, and pupil abnormalities should be carefully evaluated. There also seems to exist a group of patients in whom surgical intervention offers little benefit, as mortality rate is low without surgical intervention.	[Herou, Erik; Romner, Bertil; Tomasevic, Gregor] Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden	Herou, E (corresponding author), Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden.	Erik.Herou@skane.se			Lund University Medical School [31434411014]	This work was funded by grants from Lund University Medical School (fund no. 31434411014).	Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Borger V, 2012, ACTA NEUROCHIR, V154, P1549, DOI 10.1007/s00701-012-1434-x; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; *CDCP, TRAUM BRAIN INJ US; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Hanley JP, 2004, J CLIN PATHOL, V57, P1132, DOI 10.1136/jcp.2003.008904; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Inamasu J, 2010, NEUROL MED-CHIR, V50, P1051, DOI 10.2176/nmc.50.1051; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Taussky P, 2012, WORLD NEUROSURG, V78, P306, DOI 10.1016/j.wneu.2011.10.030; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P597, DOI [10.1089/neu.2000.17.597, DOI 10.1089/NEU.2000.17.597]; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P591; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P583; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J Neurotrauma, V17, P563, DOI 10.1089/neu.2000.17.563; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Walther SM, 2003, INTENS CARE MED, V29, P933, DOI 10.1007/s00134-003-1757-4	32	28	28	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUN	2015	83	6					996	1001		10.1016/j.wneu.2015.02.023			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CK3TN	WOS:000356138800021	25731794				2021-06-18	
J	Agrawal, R; Noble, E; Tyagi, E; Zhuang, YM; Ying, Z; Gomez-Pinilla, F				Agrawal, Rahul; Noble, Emily; Tyagi, Ethika; Zhuang, Yumei; Ying, Zhe; Gomez-Pinilla, Fernando			Flavonoid derivative 7,8-DHF attenuates TBI pathology via TrkB activation	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						Cognition; 7,8-Dihydroxyflavone; Metabolism; Plasticity; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL TRANSCRIPTION FACTOR; NEUROTROPHIC FACTOR; MEMORY DEFICITS; COPY NUMBER; MOUSE MODEL; PGC-1-ALPHA; 7,8-DIHYDROXYFLAVONE; BDNF; PLASTICITY	Traumatic brain injury (TBI) is followed by a state of metabolic dysfunction, affecting the ability of neurons to use energy and support brain plasticity: there is no effective therapy to counteract the TBI pathology. Brain-derived neurotrophic factor (BDNF) has an exceptional capacity to support metabolism and plasticity, which highly contrasts with its poor pharmacological profile. We evaluated the action of a flavonoid derivative 7,8-dihydroxyflavone (7,8-DHF), a BDNF receptor (TrkB) agonist with the pharmacological profile congruent for potential human therapies. Treatment with 7,8-DHF (5 mg/kg, ip, daily for 7 days) was effective to ameliorate the effects of TBI on plasticity markers (CREB phosphorylation, GAP-43 and syntaxin-3 levels) and memory function in Barnes maze test. Treatment with 7,8-DHF restored the decrease in protein and phenotypic expression of TrkB phosphorylation after TBI. In turn, intrahippocampal injections of K252a, a TrkB antagonist, counteracted the 7,8-DHF induced TrkB signaling activation and memory improvement in TBI, suggesting the pivotal role of TrkB signaling in cognitive performance after brain injury. A potential action of 7,8-DHF on cell energy homeostasis was corroborated by the normalization in levels of PGC-1 alpha, TFAM, COII AMPK and SIRT1 in animals subjected to TBI. Results suggest a potential mechanism by which 7,8-DHF counteracts TBI pathology via activation of the TrkB receptor and engaging the interplay between cell energy management and synaptic plasticity. Since metabolic dysfunction is an important risk factor for the development of neurological and psychiatric disorders, these results set a precedent for the therapeutic use of 7,8-DHF in a larger context.. (C) 2015 Elsevier B.V. All rights reserved.	[Agrawal, Rahul; Noble, Emily; Tyagi, Ethika; Ying, Zhe; Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA; [Zhuang, Yumei; Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Integrat Biol & Physiol, 621 Charles E Young Dr South, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu	Agrawal, Rahul/F-6412-2015	Agrawal, Rahul/0000-0001-8128-3724; Noble, Emily/0000-0002-7483-031X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS050465]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R21DA037689] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant NS050465. There is no conflict of interest for any of the contributing authors.	Alonso M, 2002, CELL MOL NEUROBIOL, V22, P663, DOI 10.1023/A:1021848706159; Andero R, 2012, HIPPOCAMPUS, V22, P399, DOI 10.1002/hipo.20906; Anglin RE, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.107; Autry AE, 2012, PHARMACOL REV, V64, P238, DOI 10.1124/pr.111.005108; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Benito E, 2010, TRENDS NEUROSCI, V33, P230, DOI 10.1016/j.tins.2010.02.001; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Burkhalter J, 2003, J NEUROSCI, V23, P8212; Campbell CT, 2012, BBA-GENE REGUL MECH, V1819, P921, DOI 10.1016/j.bbagrm.2012.03.002; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Chen J, 2011, NEUROSCI LETT, V499, P181, DOI 10.1016/j.neulet.2011.05.054; Chen SD, 2011, INT J MOL SCI, V12, P7199, DOI 10.3390/ijms12107199; Cheng AW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2238; Devi L, 2012, NEUROPSYCHOPHARMACOL, V37, P434, DOI 10.1038/npp.2011.191; Eakins James, 2009, J Diabetes Sci Technol, V3, P1373; Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Griesdale DEG, 2009, NEUROCRIT CARE, V11, P311, DOI 10.1007/s12028-009-9249-1; Gupta SK, 2009, CELL DEATH DIFFER, V16, P624, DOI 10.1038/cdd.2008.188; Gupta VK, 2013, INT J MOL SCI, V14, P10122, DOI 10.3390/ijms140510122; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jang SW, 2010, P NATL ACAD SCI USA, V107, P2687, DOI 10.1073/pnas.0913572107; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kimura R, 2009, NEUROBIOL DIS, V33, P229, DOI 10.1016/j.nbd.2008.10.006; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; Liu X, 2010, J MED CHEM, V53, P8274, DOI 10.1021/jm101206p; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; Markham A, 2004, EUR J NEUROSCI, V20, P1189, DOI 10.1111/j.1460-9568.2004.03578.x; Martin-Martin B, 1999, J LEUKOCYTE BIOL, V65, P397; Rafaeloff-Phail R, 2004, J BIOL CHEM, V279, P52934, DOI 10.1074/jbc.M409574200; Real CC, 2013, NEUROSCIENCE, V237, P118, DOI 10.1016/j.neuroscience.2013.01.060; Riddle DR, 1997, BIOTECHNIQUES, V23, P928, DOI 10.2144/97235rr02; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Thomson DM, 2008, J APPL PHYSIOL, V104, P429, DOI 10.1152/japplphysiol.00900.2007; Valle I, 2005, CARDIOVASC RES, V66, P562, DOI 10.1016/j.cardiores.2005.01.026; Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001; Ventura-Clapier R, 2008, CARDIOVASC RES, V79, P208, DOI 10.1093/cvr/cvn098; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Wareski P, 2009, J BIOL CHEM, V284, P21379, DOI 10.1074/jbc.M109.018911; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]	46	28	30	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-4439	0006-3002		BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	MAY	2015	1852	5					862	872		10.1016/j.bbadis.2015.01.018			11	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CG3JJ	WOS:000353176200016	25661191	Green Accepted, Bronze			2021-06-18	
J	Green, GA; Pollack, KM; D'Angelo, J; Schickendantz, MS; Caplinger, R; Weber, K; Valadka, A; McAllister, TW; Dick, RW; Mandelbaum, B; Curriero, FC				Green, Gary A.; Pollack, Keshia M.; D'Angelo, John; Schickendantz, Mark S.; Caplinger, Roger; Weber, Kathleen; Valadka, Alex; McAllister, Thomas W.; Dick, Randall W.; Mandelbaum, Bert; Curriero, Frank C.			Mild Traumatic Brain Injury in Major and Minor League Baseball Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						professional baseball; traumatic brain injury; sports injury; concussion	SURVEILLANCE SYSTEM; HIGH-SCHOOL; CONCUSSION; EPIDEMIOLOGY; SPORTS; RATES; HEAD	Background: Although mild traumatic brain injury (MTBI) is not as common in professional baseball as in collision sports, it does occur and frequently results in significant loss of time away from the sport. To date, no study has investigated MTBI among an entire cohort of professional baseball players. Purpose: To investigate MTBIs in major and minor league baseball players to determine the most common mechanisms of injury, activity at time of injury, position, level of play, and time lost, as well as ultimately inform prevention efforts. A secondary objective was to document the association between MTBI and return to play using several different measures. Study Design: Descriptive epidemiologic study. Methods: Data were captured from a newly implemented league-wide injury surveillance system that records injuries among all professional baseball players as entered by certified athletic trainers and physicians. The MTBIs were identified with respect to level of play, activity, field location, and mechanism of injury. Time loss was assessed by 3 measures of return to play, and MTBI game rates were reported as injuries per 1000 athlete-exposures. Data were combined over the 2011-2012 seasons for analysis, and results were presented separately for minor and major league players. Chi-square tests were used to test the hypothesis of equal proportions between the various categories of MTBI injury characteristics. Results: There were 41 reported MTBIs in the major leagues and 266 in the minor leagues over the 2-year period under study. The overall MTBI game rate across both major and minor league ball clubs was 0.42 per 1000 athlete-exposures. The median time lost was 9 days. Mild traumatic brain injury accounted for 1% of all injuries resulting in time lost from play. For MTBIs that occurred while fielding, catchers were significantly overrepresented. No differences were noted among the 3 measures of time lost. Conclusion: Mild traumatic brain injury is an important problem in professional baseball players, especially for catchers. This study provides a foundation for future inquiry to reduce the incidence of MTBI in those positions at greatest risk and to provide a baseline as rules and equipment evolve.	Major League Baseball, New York, NY USA; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	Green, GA (corresponding author), Pacific Palisades Med Grp, 15200 Sunset Blvd,Suite 107, Pacific Palisades, CA 90272 USA.	ggreen@mednet.ucla.edu			Office of the Commissioner of Major League Baseball; Major League Baseball Players Association	The authors acknowledge the contribution and the research support by the Office of the Commissioner of Major League Baseball and Jon Coyles, as well as the Major League Baseball Players Association and Drs Stephen Fealy and John Golfinos for their support and review of the manuscript. Finally, the authors acknowledge the dedication of the ATCs in collecting and entering data.	Ahmad CS, 2014, AM J SPORT MED, V42, P1464, DOI 10.1177/0363546514529083; Associated Press, 2007, CONC SYMPT FORC MATH; Athiviraham A, 2012, AM J SPORT MED, V40, P2808, DOI 10.1177/0363546512461754; Dick R, 2007, J ATHL TRAINING, V42, P183; Dick R, 2007, J ATHL TRAINING, V42, P173; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kilcoyne KG, 2014, SPORTS HEALTH, V6, P402, DOI 10.1177/1941738113491545; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; National Research Council, 2014, SPORT REL CONC YOUTH; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; R Core Team, 2013, R LANG ENV STAT COMP; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Rosenbaum DA, 2014, INT J SPORTS MED, V35, P704, DOI 10.1055/s-0033-1363253; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Stevens ST, 2006, J SCI MED SPORT, V9, P238, DOI 10.1016/j.jsams.2006.03.025; Stovitz SD, 2012, BRIT J SPORT MED, V46, P960, DOI 10.1136/bjsports-2011-090693; Weinbaum W, 2014, PITCHERS PROTECTIVE	19	28	28	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2015	43	5					1118	1126		10.1177/0363546514568089			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CH4CV	WOS:000353980000017	25660188				2021-06-18	
J	Wang, FY; Di, HB; Hu, XH; Jing, S; Thibaut, A; Di Perri, C; Huang, WS; Nie, YZ; Schnakers, C; Laureys, S				Wang, Fuyan; Di, Haibo; Hu, Xiaohua; Jing, Shan; Thibaut, Aurore; Di Perri, Carol; Huang, Wangshan; Nie, Yunzhi; Schnakers, Caroline; Laureys, Steven			Cerebral response to subject's own name showed high prognostic value in traumatic vegetative state	BMC MEDICINE			English	Article						Functional MRI; Own name; Prognosis; Traumatic brain injury; Vegetative state/unresponsive wakefulness syndrome	BRAIN; DISORDERS; ACTIVATION; RECOVERY	Background: Previous studies have shown the prognostic value of stimulation elicited blood-oxygen-level-dependent (BOLD) signal in traumatic patients in vegetative state/unresponsive wakefulness syndrome (VS/UWS). However, to the best of our knowledge, no studies have focused on the relevance of etiology and level of consciousness in patients with disorders of consciousness (DOC) when explaining the relationship between BOLD signal and both outcome and signal variability. We herein propose a study in a large sample of traumatic and non-traumatic DOC patients in order to ascertain the relevance of etiology and level of consciousness in the variability and prognostic value of a stimulation-elicited BOLD signal. Methods: 66 patients were included, and the response of each subject to his/her own name said by a familiar voice (SON-FV) was recorded using fMRI; 13 patients were scanned twice in the same day, respecting the exact same conditions in both cases. A behavioral follow-up program was carried out at 3, 6, and 12 months after scanning. Results: Of the 39 VS/UWS patients, 12 (75%) out of 16 patients with higher level activation patterns recovered to minimally conscious state (MCS) or emergence from MCS (EMCS) and 17 (74%) out of 23 patients with lower level activation patterns or no activation had a negative outcome. Taking etiology into account for VS/UWS patients, a higher positive predictive value was assigned to traumatic patients, i.e., up to 92% (12/13) patients with higher level activation pattern achieved good recovery whereas 11 out of 13 (85%) non-traumatic patients with lower level activation or without activation had a negative clinical outcome. The reported data from visual analysis of fMRI activation patterns were corroborated using ROC curve analysis, which supported the correlation between auditory cortex activation volume and VS/UWS patients' recovery. The average brain activity overlap in primary and secondary auditory cortices in patients scanned twice was 52%. Conclusions: The activation type and volume in auditory cortex elicited by SON-FV significantly correlated with VS/UWS patients' prognosis, particularly in patients with traumatic etiology, however, this could not be established in MCS patients. Repeated use of this simple fMRI task might help obtain more reliable prognostic information.	[Wang, Fuyan; Di, Haibo; Hu, Xiaohua; Huang, Wangshan; Nie, Yunzhi] Hangzhou Normal Univ, Int Vegetat State & Consciousness Sci Inst, Hangzhou, Zhejiang, Peoples R China; [Wang, Fuyan] Hangzhou Normal Univ, Affiliated Hosp, Dept Radiol, Hangzhou, Zhejiang, Peoples R China; [Hu, Xiaohua; Jing, Shan] Hangzhou Wujing Hosp, Dept Rehabil, Hangzhou, Zhejiang, Peoples R China; [Di, Haibo; Thibaut, Aurore; Di Perri, Carol; Schnakers, Caroline; Laureys, Steven] Univ Liege, Coma Sci Grp, GIGA Res, Liege, Belgium; [Di, Haibo; Thibaut, Aurore; Di Perri, Carol; Schnakers, Caroline; Laureys, Steven] Univ Hosp Liege, Liege, Belgium; [Schnakers, Caroline] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA	Di, HB (corresponding author), Hangzhou Normal Univ, Int Vegetat State & Consciousness Sci Inst, Hangzhou, Zhejiang, Peoples R China.	Dihaibo19@aliyun.com	Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011; Wang, Fuyan/AAE-9666-2019; Thibaut, Aurore/U-8101-2019	Laureys, Steven/0000-0002-3096-3807; Di Perri, Carol/0000-0003-0284-770X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [KG14086, KG08027, KG13007]; Science and Technology Department of Zhejiang Province [KZ09037]; Hangzhou Normal University [JTAS2011-01-016]	This paper is funded by the National Natural Science Foundation of China (KG14086, KG08027, KG13007), Science and Technology Department of Zhejiang Province (KZ09037), Hangzhou Normal University (JTAS2011-01-016). We thank Professor Yizhang Chen, Professor Xuchu Weng, Dr. Zirui Huang, Professor Shizheng Zhang, Dr. Lianhe zhang, Dr. Shenmin Yu, Dr. Jingqi Li, Lijuan Cheng, Professor Jianping Ding, Ying Zhang, Xiaojing Yu, and Lizette Heine for their kind help.	Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Bronkhorst AW, 2000, ACUSTICA, V86, P117; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; CAMPAIN R, 1976, BRAIN LANG, V3, P318, DOI 10.1016/0093-934X(76)90026-2; Chen LK, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-154; Coleman MR, 2009, PROG BRAIN RES, V177, P231, DOI 10.1016/S0079-6123(09)17716-6; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cruse D, 2012, NEUROLOGY, V78, P816, DOI 10.1212/WNL.0b013e318249f764; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Di HB, 2008, CLIN MED, V8, P502, DOI 10.7861/clinmedicine.8-5-502; Emmorey K, 2003, P NATL ACAD SCI USA, V100, P10049, DOI 10.1073/pnas.1730169100; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Gosseries O, 2014, ANNU REV NEUROSCI, V37, P457, DOI 10.1146/annurev-neuro-062012-170339; Holeckova I, 2006, BRAIN RES, V1082, P142, DOI 10.1016/j.brainres.2006.01.089; JANCKE L, 1994, NEUROREPORT, V5, P1161; Jennett B, 2002, J NEUROL NEUROSUR PS, V73, P355, DOI 10.1136/jnnp.73.4.355; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Monti MM, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3765; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Owen AM, 2005, NEUROPSYCHOL REHABIL, V15, P290, DOI 10.1080/09602010443000579; PANDYA DN, 1995, REV NEUROL, V151, P486; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Sherer M, 2009, ARCH PHYS MED REHAB, V90, P1749, DOI 10.1016/j.apmr.2009.05.011; ZWEIG MH, 1993, CLIN CHEM, V39, P561	32	28	31	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1741-7015			BMC MED	BMC Med.	APR 15	2015	13								83	10.1186/s12916-015-0330-7			13	Medicine, General & Internal	General & Internal Medicine	CG4LN	WOS:000353257200001	25880206	DOAJ Gold, Green Published			2021-06-18	
J	Kroshus, E; Baugh, CM; Hawrilenko, M; Daneshvar, DH				Kroshus, Emily; Baugh, Christine M.; Hawrilenko, Matt; Daneshvar, Daniel H.			Pilot Randomized Evaluation of Publically Available Concussion Education Materials: Evidence of a Possible Negative Effect	HEALTH EDUCATION & BEHAVIOR			English	Article						behavior change; concussion; education; injury; sport	TRAUMATIC BRAIN-INJURY; ICE HOCKEY; KNOWLEDGE; COLLEGE; EPIDEMIOLOGY; SYMPTOMS; BEHAVIOR; PLAYERS; MODELS; IMPACT	Many states and sports leagues are instituting concussion policies aimed at reducing risk of morbidity and mortality; many include mandates about the provision of concussion education to youth athletes. However, there is limited evidence if educational materials provided under these typically vague mandates are in fact effective in changing concussion risk-related behavior or any cognition predictive of risk-related behavior. The purpose of this pilot randomized controlled study was to conduct a theory-driven evaluation of three publically available concussion education materials: two videos and one informational handout. Participants were 256 late adolescent males from 12 teams in a single league of ice hockey competition in the United States. Randomization of educational condition occurred at the team level. Written surveys assessing postimpact symptom reporting behavior, concussion knowledge, and concussion reporting cognitions were completed by participants immediately before receiving their educational intervention, 1 day after, and 1 month after. Results indicated no change in any measure over any time interval, with the exception of perceived underreporting norms. In one of the video conditions, perceived underreporting norms increased significantly 1 day after viewing the video. Possible content and viewing environment-related reasons for this increase are discussed. Across all conditions, perceived underreporting norms increased 1 month after intervention receipt, raising the possibility that late in the competitive season underreporting may be perceived as normative. The need for the development of theory-driven concussion education materials, drawing on best practices from health behavior scholars, is discussed.	[Kroshus, Emily] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Baugh, Christine M.; Daneshvar, Daniel H.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Hawrilenko, Matt] Clark Univ, Worcester, MA 01610 USA	Kroshus, E (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave, Boston, MA 02115 USA.	emk329@mail.harvard.edu	Meijer, Anna/K-5118-2016; Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Daneshvar, Daniel/0000-0003-3691-9513	Head Games, The Movie	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Christine M. Baugh and Daniel H. Daneshvar received funding from Head Games, The Movie.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; [Anonymous], 2013, 2013 14 NCAA SPORTS; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; BANDURA A, 1982, AM PSYCHOL, V37, P122, DOI 10.1037/0003-066X.37.2.122; Baugh C. M., J LAW MED E IN PRESS; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Centers for Disease Control and Prevention, 2013, HEADS CONC HIGH SCH; Chan DKC, 2012, SPORTS MED, V42, P725, DOI 10.2165/11633040-000000000-00000; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Cusimano MD, 2014, BRIT J SPORT MED, V48, P141, DOI 10.1136/bjsports-2012-091660; Cusimano MD, 2013, CAN MED ASSOC J, V185, pE57, DOI 10.1503/cmaj.112017; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Gielen AC, 2003, EPIDEMIOL REV, V25, P65, DOI 10.1093/epirev/mxg004; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Hedeker D, 1997, PSYCHOL METHODS, V2, P64, DOI 10.1037/1082-989X.2.1.64; James S., 2012, HEAD GAMES MOTION PI; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Keats MR, 2012, SPORTS MED, V42, P175, DOI 10.2165/11597050-000000000-00000; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kroshus E., 2014, NORMS ATHLETIC UNPUB; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; MLL Communications, 2013, SPORTS LEG I PARTN M; National Athletic Trainers' Association/National Academy of Neuropsychology, CONC HOCK SIGNS SYMP; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Sarris CE, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12224; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Verhagen EALM, 2010, SPORTS MED, V40, P899, DOI 10.2165/11536890-000000000-00000; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	40	28	28	0	23	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1090-1981	1552-6127		HEALTH EDUC BEHAV	Health Educ. Behav.	APR	2015	42	2					153	162		10.1177/1090198114543011			10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CF0IX	WOS:000352228000003	25128434				2021-06-18	
J	Heyer, GL; Weber, KD; Rose, SC; Perkins, SQ; Schmittauer, CE				Heyer, Geoffrey L.; Weber, Kevin D.; Rose, Sean C.; Perkins, Sara Q.; Schmittauer, Caitlin E.			High School Principals' Resources, Knowledge, and Practices regarding the Returning Student with Concussion	JOURNAL OF PEDIATRICS			English	Article							EDUCATION; SPORTS; STATEMENT; CONSENSUS; RECOVERY; COACHES; PLAY	Objective To determine high school principals' self-reported resources, knowledge, and practices regarding the management of students returning to school following concussion. Study design A cross-sectional survey of public high school principals in the state of Ohio assessed respondent and school demographics, respondent concussion training, school resources, and monitoring and accommodation practices for students with concussion. Results Of the 695 eligible high school principals, 465 (66.9%) completed the survey. Over one-third of principals (37.2%) had some form of concussion training in the past year. Those with training were more likely to promote training of other school faculty (57.4% vs 30.6%, P < .001). Principals were asked to identify school personnel who are designated as case managers for students with concussion. Schools without a designated case manager were less likely to have an athletic trainer (P < .001) and had fewer students (median 424.5 vs 599) than schools with a case manager. Principals could list at least 1 faculty designee who communicates with health professionals more often for student-athletes than for nonathletes (P < .001). Most principals were willing to provide students with short-term academic accommodations, but 30.1% required a health professional's note prior to making any academic changes. Only 32% of principals reported providing families with a written academic plan following concussion. Conclusions Schools differ in their resources and management strategies for students returning to school after concussion. Understanding these differences can help health professionals to overcome potential barriers in managing their school-aged patients with concussion.	[Heyer, Geoffrey L.; Rose, Sean C.; Schmittauer, Caitlin E.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA; [Heyer, Geoffrey L.; Rose, Sean C.] Nationwide Childrens Hosp, Dept Neurol, Columbus, OH 43205 USA; [Heyer, Geoffrey L.; Rose, Sean C.] Ohio State Univ, Columbus, OH 43210 USA; [Weber, Kevin D.] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA; [Perkins, Sara Q.] Miami Univ, Ctr Human Psychophysiol, Oxford, OH 45056 USA	Heyer, GL (corresponding author), Nationwide Childrens Hosp, Dept Pediat, 700 Childrens Dr,ED-5, Columbus, OH 43205 USA.	geoffrey.heyer@nationwidechildrens.org	Heyer, Geoffrey/E-3243-2011	Rose, Sean/0000-0001-5177-7715; Weber, Kevin/0000-0002-8405-828X; Heyer, Geoffrey/0000-0001-9334-3739			[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; *CDCP, HEADS CONC YOUTH SPO; Chrisman SP, 2014, AM J SPORT MED, V42, P1190, DOI 10.1177/0363546513519073; Esquivel A, 2013, SPORTS HEALTH, V5, P258, DOI 10.1177/1941738113476850; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; The National Football League, HLTH SAF CONC LEG ST; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	23	28	28	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	MAR	2015	166	3					594	U878		10.1016/j.jpeds.2014.09.038			13	Pediatrics	Pediatrics	CC2ZL	WOS:000350213600022	25444011				2021-06-18	
J	Jang, SH; Kim, SH; Lim, HW; Yeo, SS				Jang, Sung Ho; Kim, Seong Ho; Lim, Hyoung Won; Yeo, Sang Seok			Recovery of Injured Lower Portion of the Ascending Reticular Activating System in a Patient with Traumatic Brain Injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Diffusion Tensor Imaging; Ascending Reticular Activating System; Consciousness	AROUSAL SYSTEM; CONSCIOUSNESS; DISORDERS; COMA	The authors report on a patient with traumatic brain injury who showed recovery of an injured lower portion of the ascending reticular activating system (ARAS) between the pontine reticular formation and the thalamus. A 57-yr-old male patient experienced head trauma. After 4 mos from onset, he exhibited impaired alertness, with a score of 7 on the Glasgow Coma Scale. At 40 mos after onset, the patient had a full Glasgow Coma Scale score of 15. The lower portion of the ARAS was reconstructed using the probabilistic tractography method. On 4-mo diffusion tensor tractography, the fractional anisotropy and the tract volume of the lower portion of the right ARAS were lower by more than 2 SDs of those of control subjects. By contrast, on 40-mo diffusion tensor tractography, the fractional anisotropy and the tract volume values of the lower portion of the right ARAS were within 2 SDs of those of the control subjects. The increment fractional anisotropy and the FV value of the lower portion of the right ARAS on 40-mo diffusion tensor tractography indicated recovery of the injured lower ARAS. As a result, recovery of an injured lower portion of the ARAS in a patient with traumatic brain injury was demonstrated.	[Jang, Sung Ho] Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, Taegu, South Korea; [Kim, Seong Ho] Yeungnam Univ, Coll Med, Dept Neurosurg, Taegu, South Korea; [Lim, Hyoung Won; Yeo, Sang Seok] Dankook Univ, Coll Hlth Sci, Dept Phys Therapy, Cheonan Si 330714, Chungnam, South Korea	Yeo, SS (corresponding author), Dankook Univ, Coll Hlth Sci, Dept Phys Therapy, 119 Dandae Ro, Cheonan Si 330714, Chungnam, South Korea.						Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Edlow BL, 2013, J NEUROPATH EXP NEUR, V72, P505, DOI 10.1097/NEN.0b013e3182945bf6; Edlow BL, 2012, J NEUROPATH EXP NEUR, V71, P531, DOI 10.1097/NEN.0b013e3182588293; Godbolt AK, 2013, J REHABIL MED, V45, P741, DOI 10.2340/16501977-1167; Hesse S, 2003, CNS DRUGS, V17, P1093, DOI 10.2165/00023210-200317150-00004; Kwon HG, 2012, J REHABIL MED, V44, P280, DOI 10.2340/16501977-0931; Lovstad M, 2014, J HEAD TRAUMA REHAB, V29, pE31, DOI 10.1097/HTR.0000000000000017; Seo JP, 2013, AM J NEURORADIOL, V34, P1359, DOI 10.3174/ajnr.A3389; TEASDALE G, 1974, LANCET, V2, P81; Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165; Yeo SS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00416	11	28	29	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAR	2015	94	3					250	253		10.1097/PHM.0000000000000274			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CC2VT	WOS:000350203500011	25700167				2021-06-18	
J	Santarsieri, M; Kumar, RG; Kochanek, PM; Berga, S; Wagner, AK				Santarsieri, M.; Kumar, R. G.; Kochanek, P. M.; Berga, S.; Wagner, A. K.			Variable neuroendocrine-immune dysfunction in individuals with unfavorable outcome after severe traumatic brain injury	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Traumatic brain injury; Cerebrospinal fluid; Cortisol; Hypothalamic-pituitary-axis; Inflammation; Cytokines; Cell adhesion molecule; GOS; Trajectory analysis; Rehabilomics	PITUITARY-ADRENAL AXIS; CENTRAL-NERVOUS-SYSTEM; INFLAMMATORY RESPONSE; HPA AXIS; GLUCOCORTICOID REGULATION; CEREBROSPINAL-FLUID; CYTOKINE PRODUCTION; CRITICAL ILLNESS; STRESS-RESPONSE; P-GLYCOPROTEIN	Bidirectional communication between the immune and neuroendocrine systems is not well understood in the context of traumatic brain injury (TBI). The purpose of this study was to characterize relationships between cerebrospinal fluid (CSF) cortisol and inflammation after TB!, and to determine how these relationships differ by outcome. CSF samples were collected from 91 subjects with severe TBI during days 0-6 post-injury, analyzed for cortisol and inflammatory markers, and compared to healthy controls (n = 13 cortisol, n = 11 inflammatory markers). Group-based trajectory analysis (TRAJ) delineated subpopulations with similar longitudinal CSF cortisol profiles (high vs. low cortisol). Glasgow Outcome Scale (GOS) scores at 6 months served as the primary outcome measure reflecting global outcome. Inflammatory markers that displayed significant bivariate associations with both GOS and cortisol TRAJ (interleukin [IL]-6, IL-10, soluble Fas [sFas], soluble intracellular adhesion molecule [sICAM]-1, and tumor necrosis factor alpha [TNF]-(alpha) were used to generate a cumulative inflammatory load score (ILS). Subsequent analysis revealed that cortisol TRAJ group membership mediated ILS effects on outcome (indirect effect estimate = -0.253, 95% CI (-0.481, -0.025), p = 0.03). Correlational analysis between mean cortisol levels and ILS were examined separately within each cortisol TRAJ group and by outcome. Within the low cortisol TRAJ group, subjects with unfavorable 6-month outcome displayed a negative correlation between ILS and mean cortisol (r = -0.562, p = 0.045). Conversely, subjects with unfavorable outcome in the high cortisol TRAJ group displayed a positive correlation between ILS and mean cortisol (r = 0.391, p = 0.006). Our results suggest that unfavorable outcome after TBI may result from dysfunctional neuroendocrine-immune communication wherein an adequate immune response is not mounted or, alternatively, neurinflammation is prolonged. Importantly, the nature of neuroendocrine-immune dysfunction differs between cortisol TRAJ groups. These results present a novel biomarker-based index from which to discriminate outcome and emphasize the need for evaluating tailored treatments targeting inflammation early after injury. (C) 2014 Elsevier Inc. All rights reserved.	[Santarsieri, M.; Kumar, R. G.; Wagner, A. K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, A. K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kochanek, P. M.; Wagner, A. K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kochanek, P. M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Berga, S.] Wake Forest Univ, Dept Obstet & Gynecol, Winston Salem, NC 27109 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	martina.santarsieri@gmail.com; kumarr4@upmc.edu; kochanekpm@ccm.upmc.edu; sberga@wakehealth.edu; wagnerak@upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	DODUnited States Department of Defense [W81XWH-071-0701]; CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CCR 323155]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01NS030318]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER	This work was supported by DOD W81XWH-071-0701, CDC R49 CCR 323155, and NIH 5P01NS030318. The authors would like to thank the University of Pittsburgh Cancer Institute and their Luminex Facility for assay performance. Special thanks to Dr. Anna Lokshin and John Snyder for input on data scaling for inflammatory markers.	AHMED SA, 1985, AM J PATHOL, V121, P531; Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Andaluz-Ojeda D, 2012, CYTOKINE, V57, P332, DOI 10.1016/j.cyto.2011.12.002; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Banks WA, 2005, CURR PHARM DESIGN, V11, P973, DOI 10.2174/1381612053381684; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Becher B, 2000, GLIA, V29, P293; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BESEDOVSKY HO, 1991, J STEROID BIOCHEM, V40, P613, DOI 10.1016/0960-0760(91)90284-C; Besedovsky HO, 2000, Z RHEUMATOL, V59, P26, DOI 10.1007/s003930070014; Besedovsky HO, 2011, NEUROCHEM RES, V36, P1, DOI 10.1007/s11064-010-0252-x; Bird MD, 2008, CELL IMMUNOL, V252, P57, DOI 10.1016/j.cellimm.2007.09.007; BOELEN A, 1995, J CLIN ENDOCR METAB, V80, P971, DOI 10.1210/jc.80.3.971; Brand RE, 2011, CLIN CANCER RES, V17, P805, DOI 10.1158/1078-0432.CCR-10-0248; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; CARROLL BJ, 1976, ARCH GEN PSYCHIAT, V33, P1039; Chantong B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-260; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cohen S, 2012, P NATL ACAD SCI USA, V109, P5995, DOI 10.1073/pnas.1118355109; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Correia LCL, 2010, CLIN CHIM ACTA, V411, P540, DOI 10.1016/j.cca.2010.01.011; Cousar JL, 2013, NEUROCRIT CARE, V19, P192, DOI 10.1007/s12028-013-9881-7; Dardiotis E., 2012, TRAUMATIC BRAIN INJU; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Dinkel K, 2003, J NEUROCHEM, V84, P705, DOI 10.1046/j.1471-4159.2003.01604.x; Dinkel K, 2002, J NEUROVIROL, V8, P513, DOI 10.1080/13550280290100914; Dooms H, 2013, J AUTOIMMUN, V45, P40, DOI 10.1016/j.jaut.2013.06.007; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; Elenkov IJ, 2004, ANN NY ACAD SCI, V1024, P138, DOI 10.1196/annals.1321.010; Elenkov IJ, 2008, NEUROCHEM INT, V52, P40, DOI 10.1016/j.neuint.2007.06.037; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Grund B, 2010, CURR OPIN HIV AIDS, V5, P473, DOI 10.1097/COH.0b013e32833ed742; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hickey WF, 1999, SEMIN IMMUNOL, V11, P125, DOI 10.1006/smim.1999.0168; Hildreth AN, 2008, J TRAUMA, V65, P573, DOI 10.1097/TA.0b013e31818255e8; Holub M, 2007, CRIT CARE, V11, DOI 10.1186/cc5729; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Jabbi M, 2007, MOL PSYCHIATR, V12, P483, DOI 10.1038/sj.mp.4001975; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; JENNETT B, 1975, LANCET, V1, P480; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Jozefowski S, 2003, INT IMMUNOPHARMACOL, V3, P865, DOI 10.1016/S1567-5769(03)00072-9; Juengst S.B., 2014, J HEAD TRAUMA REHABI; Karssen AM, 2001, ENDOCRINOLOGY, V142, P2686, DOI 10.1210/en.142.6.2686; Kirchhoff C, 2008, EUR J MED RES, V13, P464; KIRSCHBAUM C, 1995, PSYCHOSOM MED, V57, P468, DOI 10.1097/00006842-199509000-00009; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kumar R., 2014, J HEAD TRAUMA REHABI; Kumar RG, 2014, AM J PHYS MED REHAB, V93, P687, DOI 10.1097/PHM.0000000000000077; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Llompart-Pou JA, 2007, J ENDOCRINOL INVEST, V30, P393, DOI 10.1007/BF03346316; Loscher Wolfgang, 2005, NeuroRx, V2, P86, DOI 10.1602/neurorx.2.1.86; Lowenstein Daniel H, 2009, Ann Neurol, V66, pA7, DOI 10.1002/ana.21876; MacKinnon DP, 2004, MULTIVAR BEHAV RES, V39, P99, DOI 10.1207/s15327906mbr3901_4; MacPherson A, 2005, EXP NEUROL, V194, P376, DOI 10.1016/j.expneurol.2005.02.021; Mahon PB, 2013, PSYCHOPHARMACOLOGY, V227, P231, DOI 10.1007/s00213-012-2956-x; Maier SF, 2003, BRAIN BEHAV IMMUN, V17, P69, DOI 10.1016/S0889-1591(03)00032-1; Maier SF, 1998, ANN NY ACAD SCI, V840, P289, DOI 10.1111/j.1749-6632.1998.tb09569.x; MASTORAKOS G, 1993, J CLIN ENDOCR METAB, V77, P1690, DOI 10.1210/jc.77.6.1690; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MUNCK A, 1994, ANN NY ACAD SCI, V746, P115, DOI 10.1111/j.1749-6632.1994.tb39221.x; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nagin D., 2005, GROUP BASED MODELING; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; Pace TWW, 2007, BRAIN BEHAV IMMUN, V21, P9, DOI 10.1016/j.bbi.2006.08.009; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Pearson A., 2010, BMC RES NOTES, V8, P3; Phelps C., 2008, NEUROIMMUNE, V6; Rahman A, 2009, ANTIOXID REDOX SIGN, V11, P823, DOI [10.1089/ars.2008.2204, 10.1089/ARS.2008.2204]; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130; REICHLIN S, 1993, NEW ENGL J MED, V329, P1246; REINCKE M, 1993, J CLIN ENDOCR METAB, V77, P151, DOI 10.1210/jc.77.1.151; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Roubenoff R, 1998, J GERONTOL A-BIOL, V53, pM20, DOI 10.1093/gerona/53A.1.M20; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Santarsieri M., 2014, J NEUROTRAUMA; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; Sapolsky R., 1992, STRESS AGING BRAIN M; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Schinkel AH, 1999, ADV DRUG DELIVER REV, V36, P179, DOI 10.1016/S0169-409X(98)00085-4; Schwartz M, 2010, NAT REV NEUROL, V6, P405, DOI 10.1038/nrneurol.2010.71; Silverman MN, 2012, ANN NY ACAD SCI, V1261, P55, DOI 10.1111/j.1749-6632.2012.06633.x; Sorrells SF, 2007, BRAIN BEHAV IMMUN, V21, P259, DOI 10.1016/j.bbi.2006.11.006; Sorrells SF, 2009, NEURON, V64, P33, DOI 10.1016/j.neuron.2009.09.032; Stamatovic SM, 2008, CURR NEUROPHARMACOL, V6, P179, DOI 10.2174/157015908785777210; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P2374, DOI 10.1073/pnas.86.7.2374; Stoffel-Wagner B, 2003, ANN NY ACAD SCI, V1007, P64, DOI 10.1196/annals.1286.007; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; TRASKMAN L, 1980, ARCH GEN PSYCHIAT, V37, P761; Turnbull AV, 1995, BRAIN BEHAV IMMUN, V9, P253, DOI 10.1006/brbi.1995.1026; Turnbull AV, 1999, PHYSIOL REV, V79, P1, DOI 10.1152/physrev.1999.79.1.1; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P1827, DOI 10.1210/jc.83.6.1827; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wakelkamp IMMJ, 2003, CLIN ENDOCRINOL, V58, P280, DOI 10.1046/j.1365-2265.2003.01708.x; Wang XS, 2013, CLIN RHEUMATOL, V32, P1703, DOI 10.1007/s10067-013-2360-x; WIEGERS GJ, 1995, J IMMUNOL, V155, P1893; Wiegers GJ, 1998, TRENDS PHARMACOL SCI, V19, P317, DOI 10.1016/S0165-6147(98)01229-2; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yeager MP, 2011, DOSE-RESPONSE, V9, P332, DOI 10.2203/dose-response.10-013.Yeager; Yeager MP, 2004, ACTA ANAESTH SCAND, V48, P799, DOI 10.1111/j.1399-6576.2004.00434.x; Yu L, 2002, MOL CELL ENDOCRINOL, V190, P9, DOI 10.1016/S0303-7207(02)00041-2; Yu S, 2014, J ALLERGY CLIN IMMUN, V133, P943, DOI 10.1016/j.jaci.2014.02.015; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015	121	28	30	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAR	2015	45						15	27		10.1016/j.bbi.2014.09.003			13	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	CC7BX	WOS:000350523800003	25218898	Green Accepted			2021-06-18	
J	Svaldi, DO; Joshi, C; Robinson, ME; Shenk, TE; Abbas, K; Nauman, EA; Leverenz, LJ; Talavage, TM				Svaldi, Diana O.; Joshi, Chetas; Robinson, Meghan E.; Shenk, Trey E.; Abbas, Kausar; Nauman, Eric A.; Leverenz, Larry J.; Talavage, Thomas M.			Cerebrovascular Reactivity Alterations in Asymptomatic High School Football Players	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	2nd Annual Meeting of the CIC/Big Ten/Ivy League Traumatic Brain Injury Summit	JUL 16-17, 2014	Philadelphia, PA				CHRONIC TRAUMATIC ENCEPHALOPATHY; INJURY; CO2	Cerebrovascular reactivity (CVR) is impaired following brain injury, increasing susceptibility to subsequent injury. CVR was tracked in football and non-collision athletes throughout one season. CVR transiently decreased in football athletes during the first half of the season. Results indicate the brain adapts slowly to increases in loading, increasing risk for injury.	[Svaldi, Diana O.; Robinson, Meghan E.; Nauman, Eric A.; Talavage, Thomas M.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Joshi, Chetas; Shenk, Trey E.; Abbas, Kausar; Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Robinson, Meghan E.] VA Boston Hlth Care Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Neuroimaging Res Vet NeRVe Ctr, Boston, MA USA; [Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Nauman, Eric A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA	Svaldi, DO (corresponding author), Purdue Univ, Biomed Engn, 465 Northwestern Ave, W Lafayette, IN 47907 USA.	dianaotero7@gmail.com					Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; Golding E. M., 1999, J AM PHYSL SOC, V99; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kastrup A, 2001, MAGN RESON IMAGING, V19, P13, DOI 10.1016/S0730-725X(01)00227-2; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len T. K., 2013, MED SCI SPORTS EXERC, V43, P2241; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512	10	28	28	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	FEB 17	2015	40	2			SI		80	84		10.1080/87565641.2014.973959			5	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	CH6UW	WOS:000354172800006	25961590				2021-06-18	
J	Ogata, K; Sumida, K; Miyata, K; Kushida, M; Kuwamura, M; Yamate, J				Ogata, Keiko; Sumida, Kayo; Miyata, Kaori; Kushida, Masahiko; Kuwamura, Mitsuru; Yamate, Jyoji			Circulating miR-9*and miR-384-5p as Potential Indicators for Trimethyltin-induced Neurotoxicity	TOXICOLOGIC PATHOLOGY			English	Article						microRNAs; biomarker; serum; neurotoxicity; trimethyltin; hippocampus	CHROMATIN-REMODELING COMPLEXES; HIPPOCAMPAL DENTATE GYRUS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; ADULT MICE; MICRORNAS; RAT; EXPRESSION; CELLS; APOPTOSIS	Circulating microRNAs (miRNAs) show promise as biomarkers due to their tissue-specific expression and high stability. This study was conducted to investigate whether nervous system-enriched miR-9* and hippocampus-enriched miR-384-5p could be indicators of neurotoxicity in serum. Rats were given a single administration of trimethyltin (TMT) chloride at 6, 9, or 12 mg/kg by gavage, and brain and serum were collected 1, 4, and 7 days after administration. MiR-9* and miR-384-5p levels in serum and hippocampus were analyzed by reverse transcriptase polymerase chain reaction (RT-PCR), and their neurotoxicity detection sensitivities were compared with nervous symptoms, auditory response, and histopathology. TMT caused tremor, hypersensitivity, and decreased auditory response at 12 mg/kg on day 1 and at 9 mg/kg on day 4. Histopathologically, neural cell death and glial reaction were observed in brain (mainly hippocampus) at 12 mg/kg on day 1, 4, and 7 and at 6 and 9 mg/kg on day 4 and 7. MiR-9* and miR-384-5p levels were elevated in serum at 9 and 12 mg/kg on days 4 and 7 (at 9 mg/kg on day 7, miR-9* only) but were not changed in hippocampus. These miRNAs were considered to be elevated with the evolution of neural cell death and were thus considered possible novel indicators of neurotoxicity.	[Ogata, Keiko; Sumida, Kayo; Miyata, Kaori; Kushida, Masahiko] Sumitomo Chem Co Ltd, Environm Hlth Sci Lab, Osaka 5548558, Japan; [Ogata, Keiko; Kuwamura, Mitsuru; Yamate, Jyoji] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Div Vet Sci, Lab Vet Pathol, Osaka, Japan	Ogata, K (corresponding author), Sumitomo Chem Co Ltd, Environm Hlth Sci Lab, Konohana Ku, 1-98,Kasugadenaka 3 Chome, Osaka 5548558, Japan.	ogatak2@sc.sumitomo-chem.co.jp					Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; BALABAN CD, 1988, NEUROSCIENCE, V26, P337, DOI 10.1016/0306-4522(88)90150-9; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Bao YY, 2013, APOPTOSIS, V18, P260, DOI 10.1007/s10495-013-0802-1; BOULDIN TW, 1981, AM J PATHOL, V104, P237; BROWN AW, 1979, AM J PATHOL, V97, P59; BUSHNELL PJ, 1985, TOXICOL APPL PHARM, V79, P134, DOI 10.1016/0041-008X(85)90375-8; Corvino V, 2005, BRAIN RES BULL, V65, P471, DOI 10.1016/j.brainresbull.2005.02.031; Corvino V, 2013, NEUROCHEM RES, V38, P240, DOI 10.1007/s11064-012-0932-9; CROFTON KM, 1990, TOXICOL APPL PHARM, V105, P123, DOI 10.1016/0041-008X(90)90364-Z; Cuk K, 2013, INT J CANCER, V132, P1602, DOI 10.1002/ijc.27799; Davis TH, 2008, J NEUROSCI, V28, P4322, DOI 10.1523/JNEUROSCI.4815-07.2008; Dogini DB, 2008, J MOL NEUROSCI, V35, P331, DOI 10.1007/s12031-008-9068-4; DYER RS, 1982, NEUROBEH TOXICOL TER, V4, P127; EASTMAN CL, 1987, NEUROTOXICOL TERATOL, V9, P329, DOI 10.1016/0892-0362(87)90026-2; Edbauer D, 2010, NEURON, V65, P373, DOI 10.1016/j.neuron.2010.01.005; FECHTER LD, 1986, HEARING RES, V23, P275, DOI 10.1016/0378-5955(86)90116-4; Fiedorowicz A, 2001, BRAIN RES, V912, P116, DOI 10.1016/S0006-8993(01)02675-0; Figiel I, 2002, NEUROTOXICOLOGY, V23, P77, DOI 10.1016/S0161-813X(02)00006-2; Geloso MC, 2011, NEUROCHEM INT, V58, P729, DOI 10.1016/j.neuint.2011.03.009; Hannafon BN, 2013, INT J MOL SCI, V14, P14240, DOI 10.3390/ijms140714240; Haramati S, 2010, P NATL ACAD SCI USA, V107, P13111, DOI 10.1073/pnas.1006151107; He XJ, 2007, ACTA BIOCH BIOPH SIN, V39, P708, DOI 10.1111/j.1745-7270.2007.00324.x; Ishida N, 1997, NEUROSCIENCE, V81, P1183, DOI 10.1016/S0306-4522(97)00220-0; Jenkins SM, 2004, TOXICOL LETT, V147, P63, DOI 10.1016/j.toxlet.2003.10.023; Junn E, 2012, PHARMACOL THERAPEUT, V133, P142, DOI 10.1016/j.pharmthera.2011.10.002; Kaur P, 2012, J TOXICOLOGY, V2012, P1, DOI [10.2353/ajpath.2010.091202, DOI 10.2353/AJPATH.2010.091202]; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Krichevsky AM, 2006, STEM CELLS, V24, P857, DOI 10.1634/stemcells.2005-0441; Little AR, 2012, NEUROTOXICOL TERATOL, V34, P72, DOI 10.1016/j.ntt.2011.09.012; Liu Y, 1996, TOXICOL IN VITRO, V10, P567, DOI 10.1016/S0887-2333(96)00036-7; Margis R, 2011, J BIOTECHNOL, V152, P96, DOI 10.1016/j.jbiotec.2011.01.023; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Morita M, 2008, NEUROSCIENCE, V153, P1135, DOI 10.1016/j.neuroscience.2008.01.078; Nass D, 2009, BRAIN PATHOL, V19, P375, DOI 10.1111/j.1750-3639.2008.00184.x; Ogita K, 2005, J NEUROSCI RES, V82, P609, DOI 10.1002/jnr.20678; Ogita Kiyokazu, 2012, JAPANESE JOURNAL OF NEUROPSYCHOPHARMACOLOGY, V32, P281; Omar F. L., 2009, CLIN CHEM, V55, P1977; Packer AN, 2008, J NEUROSCI, V28, P14341, DOI 10.1523/JNEUROSCI.2390-08.2008; Perretta G, 1993, Ann Ist Super Sanita, V29, P167; Qing Y, 2013, ARCH TOXICOL, V87, P1273, DOI 10.1007/s00204-013-1021-9; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; RUPPERT PH, 1984, TOXICOL LETT, V22, P33, DOI 10.1016/0378-4274(84)90042-0; Schraivogel D, 2011, EMBO J, V30, P4309, DOI 10.1038/emboj.2011.301; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Shintani N, 2007, YAKUGAKU ZASSHI, V127, P451, DOI 10.1248/yakushi.127.451; Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Su YW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037395; Sukata T, 2011, TOXICOL LETT, V200, P46, DOI 10.1016/j.toxlet.2010.10.013; Tal TL, 2012, NEUROTOXICOLOGY, V33, P530, DOI 10.1016/j.neuro.2012.02.013; Tokarz P, 2012, ACTA BIOCHIM POL, V59, P467; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; Wanet A, 2012, NUCLEIC ACIDS RES, V40, P4742, DOI 10.1093/nar/gks151; Wang ES, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-165; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Wang XX, 2010, J ENVIRON SCI HEAL B, V45, P648, DOI 10.1080/03601234.2010.502435; Wei XW, 2013, NEUROCHEM RES, V38, P1605, DOI 10.1007/s11064-013-1062-8; Yokota Takanori, 2009, Brain and Nerve (Tokyo), V61, P167; Yoo AS, 2009, NATURE, V460, P642, DOI 10.1038/nature08139; YOUNG JS, 1986, TOXICOL APPL PHARM, V82, P87, DOI 10.1016/0041-008X(86)90441-2; Zhang ZP, 2010, INT J BIOCHEM CELL B, V42, P367, DOI 10.1016/j.biocel.2009.11.023; Zhao JJ, 2006, CHILD NERV SYST, V22, P1419, DOI 10.1007/s00381-006-0173-9	65	28	29	1	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	FEB	2015	43	2					198	208		10.1177/0192623314530533			11	Pathology; Toxicology	Pathology; Toxicology	CC4RO	WOS:000350341100004	24777749				2021-06-18	
J	Xu, DY; Huang, P; Yte, ZS; Xing, DH; Ouyang, S; Xing, GQ				Xu, Dongying; Huang, Ping; Yte, Zhaosheng; Xing, Daniel H.; Ouyang, Shuai; Xing, Guoqiang			Efficacy and safety of Panax notoginseng saponin therapy for acute intracerebral hemorrhage, meta-analysis, and mini review of potential mechanisms of action	FRONTIERS IN NEUROLOGY			English	Article						notoginsenosides; botanical medicine; nutraceutica Is; TBI and stroke recovery; randomized controlled clinical trials; hemostasis; anti-coagulation; pharmacological mechanisms	ISCHEMIA-REPERFUSION INJURY; TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; NF-KAPPA-B; GINSENOSIDE RG1; STEM-CELLS; RAT MODEL; GLUCOCORTICOID-RECEPTOR; PERIHEMATOMAL EDEMA; INDUCED APOPTOSIS	Intracranial/intracerebral hemorrhage (ICH) is a leading cause of death and disability in people with traumatic brain injury (TBI) and stroke. No proven drug is available for ICH. Panax notoginseng (total saponin extraction, PNS) is one of the most valuable herb medicines for stroke and cerebralvascular disorders in China. We searched for randomized controlled clinical trials (RCTs) involving PNS injection to treat cerebral hemorrhage for meta-analysis from various databases including the Chinese Stroke Trials Register, the trials register of the Cochrane Complementary Medicine Field, the Cochrane Central Register of Controlled Trials, MEDLINE, Chinese BioMedical disk, and China Doctorate/Master Dissertations Databases. The quality of the eligible trials was assessed by Jadad's scale. Twenty (20) of the 24 identified randomized controlled trials matched the inclusive criteria including 984 ICH patients with PNS injection and 907 ICH patients with current treatment (CT). Compared to the CT groups, PNS-treated patients showed better outcomes in the effectiveness rate (ER), neurological deficit score, intracranial hematoma volume, intracerebral edema volume, Barthel index, the number of patients died, and incidence of adverse events. Conclusion: PNS injection is superior to CT for acute ICH. A review of the literature shows that PNS may exert multiple protective mechanisms against ICH-induced brain damage including hemostasis, anti-coagulation, anti-thromboembolism, cerebral vasodilation, invigorated blood dynamics, anti-inflammation, antioxidation, and anti-hyperglycemic effects. Since vitamin C and other brain cell activators (BCA) that are not considered common practice were also used as parts of the CT in several trials, potential PNS and BCA interactions could exist that may have made the effect of PNS therapy less or more impressive than by PNS therapy alone. Future PNS trials with and without the inclusion of such controversial BCAs as part of the CT could clarify the situation. As PNS has a long clinical track record in Asia, it could potentially become a therapy option to treat ICH in the US and Europe. Further clinical trials with better experimental design could determine the long-term effects of PNS treatment for TB I and stroke.	[Xu, Dongying; Huang, Ping] Guangxi Univ Chinese Med, Fac Nursing, Nanning 530022, Guangxi, Peoples R China; [Yte, Zhaosheng] Huanggang Hosp Tradit Chinese Med, Dept Oncol, Huanggang, Peoples R China; [Xing, Daniel H.] Thomas Wootton High Sch, Rockville, MD USA; [Ouyang, Shuai] Univ Alberta, Sch Business, Edmonton, AB, Canada; [Xing, Guoqiang] Lotus Biotech Com LLC, Rockville, MD USA	Xu, DY (corresponding author), Guangxi Univ Chinese Med, Fac Nursing, 61 Dongge Rd, Nanning 530022, Guangxi, Peoples R China.	donnaxu_cn@hotmail.com; gxing99@yahoo.com	Xing, Guoqiang/ABA-8450-2020		Department of Education, Guangxi Zhuang Autonomous Region, P.R. China (New Century Higher Education Reform program in Guangxi: Research and Practice of English Curriculum System in Nursing at Guangxi Traditional Chinese Medicine College) [2011JGZD. 014]	Ms. Jillian W. Wen edited the manuscript. Mr. Zhongjian Chen of Panax Notoginseng Research Institute of Wenshan State/Region, Yunnan Province, China provided the artistic drawing of noto-ginseng. This study is supported, in part, by a grant from the Department of Education, Guangxi Zhuang Autonomous Region, P.R. China (New Century Higher Education Reform program in Guangxi: Research and Practice of English Curriculum System in Nursing at Guangxi Traditional Chinese Medicine College) (2011JGZD. 014) (to Dongying Xu).	Abou-Chebl A, 2007, CATHETER CARDIO INTE, V69, P690, DOI 10.1002/ccd.20693; Abou-Chebl A, 2010, STROKE, V41, P1996, DOI 10.1161/STROKEAHA.110.578997; Adu-Bonsaffoh K, 2013, INT J GYNECOL OBSTET, V123, P110, DOI 10.1016/j.ijgo.2013.05.017; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; An DS, 2011, INT J SYST EVOL MICR, V61, P2606, DOI 10.1099/ijs.0.028431-0; Anderson CS, 2010, STROKE, V41, P307, DOI 10.1161/STROKEAHA.109.561795; [Anonymous], 2013, J Mol Med (Berl), V91, P645, DOI 10.1007/s00109-013-1018-0; Arauz A, 2014, CURR OPIN NEUROL, V27, P8, DOI 10.1097/WCO.0000000000000045; Aung HH, 2007, CANCER CHEMOTH PHARM, V59, P369, DOI 10.1007/s00280-006-0278-6; Auriat A, 2005, J CEREBR BLOOD F MET, V25, P247, DOI 10.1038/sj.jcbfm.9600026; Bai YL, 2012, J CLIN NEUROSCI, V19, P1376, DOI 10.1016/j.jocn.2011.10.021; Balami JS, 2012, LANCET NEUROL, V11, P101, DOI 10.1016/S1474-4422(11)70264-2; Balsevich JJ, 2009, PHYTOCHEM ANALYSIS, V20, P38, DOI 10.1002/pca.1095; Berek L, 2001, IN VIVO, V15, P151; Cadilhac DA, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-49; Chai H, 2009, J SURG RES, V157, P193, DOI 10.1016/j.jss.2008.07.005; Chan CM, 2010, CRIT CARE, V14, DOI 10.1186/cc8996; Chan ECY, 2007, RAPID COMMUN MASS SP, V21, P519, DOI 10.1002/rcm.2864; Chang SH, 2007, CLIN NUTR, V26, P785, DOI 10.1016/j.clnu.2007.07.008; Chang Y, 2006, J THORAC CARDIOV SUR, V132, P867, DOI 10.1016/j.jtcvs.2006.06.029; Chen C, 2014, ACTA PHARMACOL SIN, V35, P143, DOI 10.1038/aps.2013.136; Chen Gang, 2011, Zhongguo Zhong Yao Za Zhi, V36, P1815; Chen GT, 2007, J NAT PROD, V70, P1203, DOI 10.1021/np070053v; Chen Hui-zhen, 2012, Zhejiang Da Xue Xue Bao Yi Xue Ban, V41, P32; Chen J, 2011, TRADIT CHIN EMERG ME, V20, P1273; Chen KZ, 2013, HUNAN J TRADIT CHIN, V29, P41; Chen SX, 2011, J ETHNOPHARMACOL, V137, P263, DOI 10.1016/j.jep.2011.05.011; Chen SL, 2006, CHIN J INTEGR MED CA, V4, P80; Chen W, 2000, Se Pu, V18, P439; Chen XF, 2011, J CLIN NEURO, V24, P191; Cheng WD, 2013, INT ORTHOP, V37, P2065, DOI 10.1007/s00264-013-1990-6; Cheng Y, 2005, ACTA PHARMACOL SIN, V26, P143, DOI 10.1111/j.1745-7254.2005.00034.x; Cheung LWT, 2011, CARDIOVASC RES, V89, P419, DOI 10.1093/cvr/cvq300; Chiu CD, 2013, STROKE, V44, P1682, DOI 10.1161/STROKEAHA.113.675983; CNS TtCNCoN, 1996, CHIN J NEUROL SCI, V29, P379; Cui Han-ming, 2009, Zhong Yao Cai, V32, P1810; Cui X, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006556.pub2; Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99; Ding HY, 2008, NEURAL INJ FUNCT REC, V3, P386; Ding HY, 2010, CHINA MOD MED, V17, P56; Dong YH, 2006, J MED THEORY PRACT, V19, P253; Edwards P, 2005, LANCET, V365, P1957; Emiru T, 2013, CLIN APPL THROMB-HEM, V19, P652, DOI 10.1177/1076029612454938; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Bernal EF, 2013, MED INTENSIVA, V37, P327, DOI 10.1016/j.medin.2012.05.015; FUJII Y, 1994, NEUROSURGERY, V35, P592, DOI 10.1227/00006123-199410000-00003; Gao B, 2014, BRIT J PHARMACOL, V171, P214, DOI 10.1111/bph.12435; Gao B, 2014, LIFE SCI, V108, P63, DOI 10.1016/j.lfs.2014.05.010; Gao L, 2012, J NEUROL SCI, V323, P236, DOI 10.1016/j.jns.2012.09.028; [高颖 Gao Ying], 2011, [中成药, Chinese Traditional Patent Medicine], V33, P1851; Garrett MC, 2009, BRAIN RES, V1298, P171, DOI 10.1016/j.brainres.2009.04.047; Gebel JM, 2000, STROKE, V31, P596, DOI 10.1161/01.STR.31.3.596; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gong Wan, 2013, Zhongguo Zhong Yao Za Zhi, V38, P1046; Gong Y, 2008, ACTA NEUROCHIR SUPPL, V105, P67; Gu P, 2006, J CHIN CLIN MED, V13, P527; Guo XF, 2002, CHIN J MISDIAGN, V2, P1355; Han DH, 2012, METABOLISM, V61, P1615, DOI 10.1016/j.metabol.2012.04.008; Hanlon RE, 2005, BRAIN INJURY, V19, P257, DOI 10.1080/02699050400004955; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Hashimoto R, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/693717; He D, 2002, CHIN J INTEGR TRADIT, V9, P27; He W, 2011, J ASIAN NAT PROD RES, V13, P1, DOI 10.1080/10286020.2010.535519; Huang LF, 2014, THROMB RES, V133, P848, DOI 10.1016/j.thromres.2014.02.009; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jia D, 2014, INT J BIOL MACROMOL, V63, P177, DOI 10.1016/j.ijbiomac.2013.10.034; Kim DH, 2013, J GINSENG RES, V37, P54, DOI 10.5142/jgr.2013.37.54; Kim EJ, 2009, BMB REP, V42, P194, DOI 10.5483/BMBRep.2009.42.4.194; Korivi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/932165; Lan TH, 2011, BIOCHEM PHARMACOL, V82, P148, DOI 10.1016/j.bcp.2011.04.001; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lau J, 2006, BMJ-BRIT MED J, V333, P597, DOI 10.1136/bmj.333.7568.597; Lauer A, 2011, J CEREBR BLOOD F MET, V31, P1736, DOI 10.1038/jcbfm.2011.22; Lee HM, 2012, PHYTOTHER RES, V26, P1017, DOI 10.1002/ptr.3686; Lee IA, 2012, J AGR FOOD CHEM, V60, P9595, DOI 10.1021/jf301372g; Lee KT, 2011, ARCH PHARM RES, V34, P1201, DOI 10.1007/s12272-011-0719-6; Leung KW, 2011, ANGIOGENESIS, V14, P515, DOI 10.1007/s10456-011-9235-z; Leys Didier, 2012, Rev Prat, V62, P1239; Li C, 2014, AM J PHYSIOL-GASTR L, V306, pG111, DOI 10.1152/ajpgi.00123.2013; Li H, 2004, CHIN J INTEGR TRADIT, V11, P50; Li H, 2014, UROL INT, V93, P92, DOI 10.1159/000354878; Li L, 2004, BIOMED CHROMATOGR, V18, P849, DOI 10.1002/bmc.400; Li Q, 2004, CHIN J MISDIAGN, V4, P262; Li WH, 2014, J ETHNOPHARMACOL, V151, P686, DOI 10.1016/j.jep.2013.11.035; Li XY, 2010, CLIN EXP PHARMACOL P, V37, P199, DOI 10.1111/j.1440-1681.2009.05286.x; Li XY, 2007, BIOMED CHROMATOGR, V21, P735, DOI 10.1002/bmc.813; Li XY, 2007, BIOL PHARM BULL, V30, P847, DOI 10.1248/bpb.30.847; Liang XH, 1998, CHIN J PHARM TOXICOL, V12, P40; [林力 LIN Li], 2009, [中国药学杂志, Chinese Pharmaceutical Journal], V44, P373; Lin N, 2014, CELL BIOCHEM BIOPHYS, V68, P189, DOI 10.1007/s12013-013-9688-3; Lin T, 2012, J ETHNOPHARMACOL, V142, P754, DOI 10.1016/j.jep.2012.05.057; Lin WM, 2007, J NEURAL TRANSM-SUPP, P105; Liu DH, 2012, J CARDIOVASC PHARM, V59, P222, DOI 10.1097/FJC.0b013e31823c1d34; Liu H Z, 1982, Yao Xue Xue Bao, V17, P801; Liu HF, 2009, DRUG METAB DISPOS, V37, P2290, DOI 10.1124/dmd.109.029819; Liu JF, 2012, NEUROCHEM RES, V37, P2738, DOI 10.1007/s11064-012-0866-2; Liu L, 2011, BRAIN RES, V1382, P147, DOI 10.1016/j.brainres.2011.01.051; Liu QA, 2011, NEUROCHEM INT, V58, P119, DOI 10.1016/j.neuint.2010.11.004; Liu RY, 2014, NEUROSCI BULL, V30, P90, DOI 10.1007/s12264-013-1371-6; Liu YW, 2012, PHARMACOL BIOCHEM BE, V101, P93, DOI 10.1016/j.pbb.2011.12.003; Liu ZC, 2013, MOL MED REP, V8, P1397, DOI 10.3892/mmr.2013.1658; Loftspring MC, 2009, J CEREBR BLOOD F MET, V29, P137, DOI 10.1038/jcbfm.2008.114; Lok J, 2011, ACTA NEUROCHIR SUPPL, V111, P63, DOI 10.1007/978-3-7091-0693-8_11; Lu TT, 2011, BIOL PHARM BULL, V34, P1319, DOI 10.1248/bpb.34.1319; Luo FC, 2010, J ETHNOPHARMACOL, V127, P419, DOI 10.1016/j.jep.2009.10.023; Luo PD, 2008, J PREV MED, V35, P4307; Ma JX, 2010, NEUROSCI LETT, V478, P66, DOI 10.1016/j.neulet.2010.04.064; Ma LY, 1998, CHINESE PHARMACOL B, V14, P27; Ma Xiaofen, 2010, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V27, P342; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Meng X, 2014, FREE RADICAL RES, V48, P445, DOI 10.3109/10715762.2014.885117; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Na JY, 2012, J GINSENG RES, V36, P242, DOI 10.5142/jgr.2012.36.3.242; Ning MH, 2004, J TRADIT CHIN MED, V8, P592; Ogata T, 2008, J NEUROL SCI, V272, P83, DOI 10.1016/j.jns.2008.04.032; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Qian YH, 2009, NEUROL RES, V31, P663, DOI 10.1179/174313209X385572; Revel-Vilk S, 2004, J PEDIATR-US, V144, P490, DOI 10.1016/j.jpeds.2003.12.016; Rodriguez-Yanez M, 2013, NEUROLOGIA, V28, P236, DOI 10.1016/j.nrl.2011.03.010; Shen KK, 2014, BIOCHEM PHARMACOL, V88, P66, DOI 10.1016/j.bcp.2014.01.007; Shen KK, 2012, BIOCHEM PHARMACOL, V84, P784, DOI 10.1016/j.bcp.2012.05.024; Shi YH, 2011, PHARM BIOL, V49, P900, DOI 10.3109/13880209.2011.554845; Skolarus LE, 2013, J STROKE CEREBROVASC, V22, P15, DOI 10.1016/j.jstrokecerebrovasdis.2011.05.025; Song Y, 2008, CHIN J MISDIAGN, V8, P8875; Sun Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080859; Tan Zhen-Yuan, 2013, Zhong Yao Cai, V36, P1121; Tang BZ, 2011, CNS NEUROL DISORD-DR, V10, P235, DOI 10.2174/187152711794480456; Tang JL, 2000, J CLIN EPIDEMIOL, V53, P477, DOI 10.1016/S0895-4356(99)00204-8; Tang YH, 2007, MOD J INTEGR TRADIT, V16, P4285; Tian ZX, 2004, J PRACT TRADIT CHIN, V18, P68; Tveiten A, 2014, ACTA NEUROL SCAND, V129, P269, DOI 10.1111/ane.12185; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; Vogel T, 2008, UNFALLCHIRURG, V111, P898, DOI 10.1007/s00113-008-1502-0; Wang De-Jian, 2011, Sichuan Da Xue Xue Bao Yi Xue Ban, V42, P503; Wang JH, 2007, SHAANXI TRADIT CHIN, V28, P1314; Wang J, 2009, NEUROCHEM INT, V54, P43, DOI 10.1016/j.neuint.2008.10.003; Wang P, 2014, PHYTOMEDICINE, V21, P177, DOI 10.1016/j.phymed.2013.08.021; Wang YL, 2011, NEUROSCI LETT, V487, P70, DOI 10.1016/j.neulet.2010.09.076; Wu JY, 2013, NEUROCHEM INT, V62, P92, DOI 10.1016/j.neuint.2012.09.016; Wu Wei, 2011, Zhongguo Zhong Xi Yi Jie He Za Zhi, V31, P799; Xia R, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/767930; Xia W, 2011, PHYTOMEDICINE, V18, P516, DOI 10.1016/j.phymed.2010.09.007; Xie GQ, 2005, CHIN J INTEGR MED CA, V3, P496; Xie XS, 2009, CHIN J INTEGR MED, V15, P133, DOI 10.1007/s11655-009-0133-9; Xie X, 2010, MOL MED REP, V3, P635, DOI 10.3892/mmr_00000308; Xiong Y, 2010, DIABETES, V59, P2505, DOI 10.2337/db10-0315; Xu DY, 2005, ZHONGGUO ZHONG YAO Z, V30, P1465; Xu H. L., 1997, Yaoxue Xuebao, V32, P502; Xu QF, 2003, J ETHNOPHARMACOL, V84, P187, DOI 10.1016/S0378-8741(02)00317-3; Xu YQ, 2003, INNER MONGOL J TRADI, V22, P41; Yan JP, 2013, J ETHNOPHARMACOL, V147, P456, DOI 10.1016/j.jep.2013.03.039; Yang NQ, 2012, ACTA BIOCH BIOPH SIN, V44, P999, DOI 10.1093/abbs/gms092; Yao Xiao-hao, 2002, Zhongguo Zhongyao Zazhi, V27, P371; Ye RD, 2011, NEUROTHERAPEUTICS, V8, P515, DOI 10.1007/s13311-011-0051-3; Ye RD, 2011, NEUROPHARMACOLOGY, V61, P815, DOI 10.1016/j.neuropharm.2011.05.029; Ye RD, 2011, NEUROCHEM INT, V58, P391, DOI 10.1016/j.neuint.2010.12.015; Yong-Xin X, 2013, INDIAN J MED RES, V137, P151; Yoshikawa M, 1997, CHEM PHARM BULL, V45, P1039, DOI 10.1248/cpb.45.1039; Yoshikawa M, 2001, CHEM PHARM BULL, V49, P1452, DOI 10.1248/cpb.49.1452; Yu SH, 2012, J INT SOC SPORT NUTR, V9, DOI 10.1186/1550-2783-9-23; Yuan KZ, 2010, CHIN COMMUNITY DOCTO, V12, P136; Yuan Y, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005569.pub2; Zhang X, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00152; Zhang Y, 2007, JPMT, V14, P1877; Zhang YX, 2013, INT IMMUNOPHARMACOL, V17, P1094, DOI 10.1016/j.intimp.2013.10.013; Zhang ZG, 2014, MOL MED REP, V9, P989, DOI 10.3892/mmr.2013.1870; ZHAO GQ, 1986, CHINESE TRADITIONAL, V17, P34; Zhao XS, 2013, INT TRADIT CHIN MED, V8, P787; Zheng HZ, 2013, J ETHNOPHARMACOL, V147, P595, DOI 10.1016/j.jep.2013.03.043; Zheng XD, 2007, J MOD CLIN MED, V33, P112; Zhou Q, 2014, THROMB RES, V133, P57, DOI 10.1016/j.thromres.2013.10.032; Zhou YH, 2007, CHIN J INTEGR MED CA, V5, P69; Zhou YJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/374963; Zou Y, 2013, J SURG RES, V183, P760, DOI 10.1016/j.jss.2013.01.068; 李俊明, 2003, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V23, P546	177	28	31	2	29	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JAN 7	2015	5								274	10.3389/fneur.2014.00274			19	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU7VB	WOS:000363748800001	25620952	DOAJ Gold, Green Published			2021-06-18	
J	Rousseau, P; Hoshizaki, TB				Rousseau, Philippe; Hoshizaki, Thomas B.			Defining the effective impact mass of elbow and shoulder strikes in ice hockey	SPORTS BIOMECHANICS			English	Article						sports biomechanics; impact reconstruction; Head injury	PROFESSIONAL FOOTBALL; HEAD IMPACTS; CONCUSSION; BIOMECHANICS; INJURIES; PLAYERS; RECONSTRUCTION; SPORTS; TRAUMA; BRAIN	Reconstruction of real-life events can be used to investigate the relationship between the mechanical parameters of the impact and concussion risk. Striking mass has typically been approximated as being the mass of the body part coming into contact with the head without accounting for the force applied by the striking athlete. Thus, the purpose of this study was to measure the effective impact mass of three common striking techniques in ice hockey. Fifteen participants were instructed to strike a suspended 50th percentile Hybrid III headform at least three times with their elbow or shoulder. Effective impact mass was calculated by measuring the change in velocity of the player and the headform. Mean effective impact mass for the extended elbow, tucked-in elbow, and shoulder check conditions were 4.8, 3.0, and 12.9kg, respectively. Peak linear accelerations were lower than the values associated with concussion in American football which could be a reflection of the methodology used in this study as well as inherent differences between both sports.	[Rousseau, Philippe; Hoshizaki, Thomas B.] Univ Ottawa, Neurotrauma Impact Sci Lab, Fac Hlth Sci, Ottawa, ON K1N 6N5, Canada	Rousseau, P (corresponding author), Univ Ottawa, Neurotrauma Impact Sci Lab, Fac Hlth Sci, A106-200 Lees Ave, Ottawa, ON K1N 6N5, Canada.	philippe.rousseau@uottawa.ca					Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Budescu E. I., 2008, P INT C COMP EXP ENG; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Foster J., 1974, HYBRID, P49; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Gabbett TJ, 2008, J STRENGTH COND RES, V22, P625, DOI 10.1519/JSC.0b013e3181635a6a; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hubbard R., 1974, HYBRID 3 1 HUMAN CRA, P95; Hutchison M. H., 2011, THESIS U TORONTO CAN; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; Jorgensen U, 1986, Br J Sports Med, V20, P7; Karton C., 2012, THESIS U OTTAWA CANA; Karton CM, 2014, AM SOC TEST MATER, V1552, P23, DOI 10.1520/STP155220120175; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Mao H., 2010, INT J NUMERICAL METH, V27, P357; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Mertz H. J., 1985, P 29 STAPP CAR CRASH; Morrison III B., 2003, P 47 STAPP CAR CRASH; Newman J. A., 1999, P INT RES COUNC BIOM; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; Smith MS, 2000, J SPORT SCI, V18, P445, DOI 10.1080/02640410050074377; Society of Automotive Engineer International, 2007, J2111 SAE INT; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; USA Hockey, 2009, CHECK RIGHT WAY YOUT; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Walsh ES, 2011, SPORTS ENG, V13, P135, DOI 10.1007/s12283-011-0060-9; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; WHITING WC, 1988, AM J SPORT MED, V16, P130, DOI 10.1177/036354658801600207; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Yu Z., 2009, BIOM SCI ENG C 1 ANN; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	49	28	27	0	4	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1476-3141	1752-6116		SPORT BIOMECH	Sport. Biomech.	JAN 2	2015	14	1					57	67		10.1080/14763141.2015.1025236			11	Engineering, Biomedical; Sport Sciences	Engineering; Sport Sciences	CH4YD	WOS:000354039000005	25895554				2021-06-18	
J	Holubkov, R; Clark, AE; Moler, FW; Slomine, BS; Christensen, JR; Silverstein, FS; Meert, KL; Pollack, MM; Dean, JM				Holubkov, Richard; Clark, Amy E.; Moler, Frank W.; Slomine, Beth S.; Christensen, James R.; Silverstein, Faye S.; Meert, Kathleen L.; Pollack, Murray M.; Dean, J. Michael			Efficacy Outcome Selection in the Therapeutic Hypothermia After Pediatric Cardiac Arrest Trials	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cardiac arrest; clinical trials; hypothermia; randomized; simulations	TRAUMATIC BRAIN-INJURY; ENCEPHALOPATHY	Objectives: The Therapeutic Hypothermia After Pediatric Cardiac Arrest trials will determine whether therapeutic hypothermia improves survival with good neurobehavioral outcome, as assessed by the Vineland Adaptive Behavior Scales Second Edition, in children resuscitated after cardiac arrest in the in-hospital and out-of-hospital settings. We describe the innovative efficacy outcome selection process during Therapeutic Hypothermia After Pediatric Cardiac Arrest protocol development. Design/Setting: Consensus assessment of potential outcomes and evaluation timepoints. Interventions: None. Measurements and Main Results: We evaluated practical and technical advantages of several follow-up timepoints and continuous/categorical outcome variants. Simulations estimated power assuming varying hypothermia benefit on mortality and on neurobehavioral function among survivors. Twelve months after arrest was selected as the optimal assessment timepoint for pragmatic and clinical reasons. Change in Vineland Adaptive Behavior Scales Second Edition from prearrest level, measured as quasicontinuous with death and vegetative status being worst-possible levels, yielded optimal statistical power. However, clinicians preferred simpler multicategorical or binary outcomes because of easier interpretability and favored outcomes based solely on postarrest status because of concerns about accurate parental assessment of prearrest status and differing clinical impact of a given Vineland Adaptive Behavior Scales Second Edition change depending on prearrest status. Simulations found only modest power loss from categorizing or dichotomizing quasicontinuous outcomes because of high expected mortality. The primary outcome selected was survival with 12-month Vineland Adaptive Behavior Scales Second Edition no less than two SD below a reference population mean (70 points), necessarily evaluated only among children with prearrest Vineland Adaptive Behavior Scales Second Edition greater than or equal to 70. Two secondary efficacy outcomes, 12-month survival and quasicontinuous Vineland Adaptive Behavior Scales Second Edition change from prearrest level, will be evaluated among all randomized children, including those with compromised function prearrest. Conclusions: Extensive discussion of optimal efficacy assessment timing, and of the advantages versus drawbacks of incorporating prearrest status and using quasicontinuous versus simpler outcomes, was highly beneficial to the final Therapeutic Hypothermia After Pediatric Cardiac Arrest design. A relatively simple, binary primary outcome evaluated at 12 months was selected, with two secondary outcomes that address the potential disadvantages of primary outcome.	[Holubkov, Richard; Clark, Amy E.; Dean, J. Michael] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Moler, Frank W.; Silverstein, Faye S.] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Slomine, Beth S.] Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA; [Slomine, Beth S.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; [Christensen, James R.] Kennedy Krieger Inst, Dept Pediat Rehabil Med, Baltimore, MD USA; [Christensen, James R.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Christensen, James R.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Meert, Kathleen L.] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA; [Pollack, Murray M.] Childrens Natl Med Ctr, Dept Crit Care Med, Washington, DC 20010 USA; [Pollack, Murray M.] George Washington Univ, Dept Pediat, Sch Hlth Sci, Washington, DC 20052 USA	Holubkov, R (corresponding author), Intermt Injury Control Res Ctr, 295 Chipeta Way,Suite 2E600, Salt Lake City, UT 84158 USA.	rich.holubkov@hsc.utah.edu		Holubkov, Richard/0000-0003-0431-3381	Pediatric Emergency Care Applied Research Network (PECARN) from the Emergency Medical Services for Children program of the Maternal and Child Health Bureau of the Health Resources and Services Administration [UO3MC00001, UO3MC00003, UO3MC00006, UO3MC00007, UO3MC00008]; National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network (CPCCRN) [U10HD500009, U1OHD050096, U10HD049981, U10HD049945, U10HD049983, U1OHD050012, UO1HD049934]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Heart, Lung, and Blood Institute (NHLBI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI); Eunice Kennedy Shriver National Institute of Child Health and Human Development [NICHD]United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21 HD044955, R34 HD 050531]; NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01 HL094339, U01 HL094345, HL094345]; NHLBI, NICHD;  [HD073692]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U10HD049983, R21HD073692, U10HD049981, U01HD049934, UG1HD049981, UG1HD050096, U10HD050096, UG1HD049983, U10HD050012] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U10HD049945, U10HD050009, R21HD044955, R34HD050531] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL094339, U01HL094345] Funding Source: NIH RePORTER	Supported, in part, by the Pediatric Emergency Care Applied Research Network (PECARN) under cooperative agreements UO3MC00001, UO3MC00003, UO3MC00006, UO3MC00007, and UO3MC00008 from the Emergency Medical Services for Children program of the Maternal and Child Health Bureau of the Health Resources and Services Administration, and from the National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network (CPCCRN) under cooperative agreements U10HD500009, U1OHD050096, U10HD049981, U10HD049945, U10HD049983, U1OHD050012, and UO1HD049934.; Dr. Holubkov served as board member for Pfizer and the American Burn Association (Data and Safety Monitoring Board [DSMB] memberships), consulted for St. Jude Medical and the Physicians Committee for Responsible Medicine (Biostatistical consultancies) and received support for article research from the National Institutes of Health (NIH). Dr. Holubkov and his institution received grant support from the National Heart, Lung, and Blood Institute (NHLBI; chief biostatistician for Therapeutic Hypothermia After Pediatric Cardiac Arrest [THAPCA]). His institution received support for travel from the NHLBI (THAPCA planning meeting). Ms. Clark received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Moler received support for article research from the NIH. His institution received grant support, support for travel, and support for participation in review activities (R21 HD044955 and R34 HD 050531 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development [NICHD], and by U01 HL094339 [Dr. Dean] and U01 HL094345 [Dr. Moler] from the NHLBI). Dr. Slomine received support for writing/reviewing the article from the NHLBI (U01HL094345/co-investigator), received support from the NHLBI (grant pays for administrative support and overhead), served as board member for the American Board of Clinical Neuropsychology (travel expenses as oral examiner), consulted for the University of Michigan (Executive Committee for Planning Grant) and University of California, Davis (DSMB Member), is employed by Kennedy Krieger Institute, provided expert testimony for private practice, lectured for St. Joseph's Hospital (presentation at Grand Rounds), and received support for article research from the NIH. Dr. Slomine and her institution received support for travel from the NHLBI (U01HL094345/co-investigator). Her institution received grant support from the NHLBI (U01HL094345/co-investigator). Dr. Christensen is employed by Kennedy Krieger Institute and received support for article research from the NIH. His institution received grant support, support for travel, and support for writing/reviewing the article from the NHLBI (U01HL094345/co-investigator) and received support from the NHLBI (grant pays for administrative support and overhead). Dr. Silverstein received support for travel from the March of Dimes (scientific advisory board) and received support for article research from the NIH. Her institution received grant support from the NHLBI (funding for role as co-investigator on grant U01 HL094345) and from the NICHD (effort funded on an unrelated project HD073692) and received support for travel from the NHLBI (investigator meeting HL094345). Dr. Meert received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Pollack received support for article research from the NIH. His institution received grant support Dr. Dean's institution received grant support from the NHLBI, NICHD, and NIH.	Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bruininks R.H., 1996, SCALES INDEPENDENT B; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Harrison P., 2003, ADAPTIVE BEHAV ASSES; HOLM S, 1979, SCAND J STAT, V6, P65; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hothorn T, 2014, EXACTRANKTESTS EXACT; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Jennison C, 2000, GROUP SEQUENTIAL MET; Lachenbruch PA, 2001, STAT MED, V20, P1215, DOI 10.1002/sim.790; Limperopoulos Catherine, 2006, Phys Occup Ther Pediatr, V26, P115, DOI 10.1300/J006v26n01_08; Moler FW, 2013, PEDIATR CRIT CARE ME, V14, pE304, DOI 10.1097/PCC.0b013e31828a863a; Moler FW, 2009, CRIT CARE MED, V37, P2259, DOI 10.1097/CCM.0b013e3181a00a6a; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; R Development Core Team, R LANG ENV STAT COMP; Sauve M J, 1996, Am J Crit Care, V5, P127; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sparrow S, 2005, VINELAND ADAPTIVE BE	20	28	28	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2015	16	1					1	10		10.1097/PCC.0000000000000272			10	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	AZ1DW	WOS:000347981400002	25268768	Green Accepted			2021-06-18	
J	Lange, RT; Brickell, TA; Lippa, SM; French, LM				Lange, Rael T.; Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.			Clinical utility of the Neurobehavioral Symptom Inventory validity scales to screen for symptom exaggeration following traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Validity-10; NIM5; LOW6; Military; Traumatic brain injury; Symptom exaggeration	PERSONALITY-ASSESSMENT INVENTORY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; POSTTRAUMATIC-STRESS-DISORDER; SERVICE MEMBERS; INDICATORS; SPECIFICITY; SENSITIVITY; VALIDATION; COMPLAINTS	The purpose of this study was to examine the clinical utility of three recently developed validity scales (Validity-10, NIM5, and LOW6) designed to screen for symptom exaggeration using the Neurobehavioral Symptom Inventory (NSI). Participants were 272 U. S. military service members who sustained a mild, moderate, severe, or penetrating traumatic brain injury (TBI) and who were evaluated by the neuropsychology service at Walter Reed Army Medical Center within 199 weeks post injury. Participants were divided into two groups based on the Negative Impression Management scale of the Personality Assessment Inventory: (a) those who failed symptom validity testing (SVT-fail; n = 27) and (b) those who passed symptom validity testing (SVT-pass; n = 245). Participants in the SVT-fail group had significantly higher scores (p<.001) on the Validity-10, NIM5, LOW6, NSI total, and Personality Assessment Inventory (PAI) clinical scales (range: d = 0.76 to 2.34). Similarly high sensitivity, specificity, positive predictive power (PPP), and negative predictive (NPP) values were found when using all three validity scales to differentiate SVT-fail versus SVT-pass groups. However, the Validity-10 scale consistently had the highest overall values. The optimal cutoff score for the Validity-10 scale to identify possible symptom exaggeration was = 19 (sensitivity =.59, specificity =.89, PPP =.74, NPP =.80). For the majority of people, these findings provide support for the use of the Validity-10 scale as a screening tool for possible symptom exaggeration. When scores on the Validity-10 exceed the cutoff score, it is recommended that (a) researchers and clinicians do not interpret responses on the NSI, and (b) clinicians follow up with a more detailed evaluation, using well-validated symptom validity measures (e. g., Minnesota Multiphasic Personality Inventory-2 Restructured Form, MMPI-2-RF, validity scales), to seek confirmatory evidence to support an hypothesis of symptom exaggeration.	[Lange, Rael T.; Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Dept Rehabil, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.] Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA	Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bldg 8,Room 2264,8901 Wisconsin Ave, Bethesda, MD 20814 USA.	rael.lange@gmail.com	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Calhoun PS, 2000, J PERS ASSESS, V75, P338, DOI 10.1207/S15327752JPA7502_11; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cooper DB, 2011, ARCH CLIN NEUROPSYCH, V26, P718, DOI 10.1093/arclin/acr070; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson G., 2006, PSYCHOL INJURIES FOR, P76; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P325, DOI 10.1080/13803395.2015.1013021; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; LEESHALEY PR, 2002, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Liljequist L, 1998, J PERS ASSESS, V71, P322, DOI 10.1207/s15327752jpa7103_3; Morey L. C., 1991, PERSONALITY ASSESSME; ROGERS R, 1993, J PERS ASSESS, V60, P554, DOI 10.1207/s15327752jpa6003_12; Rogers R, 1996, J PERS ASSESS, V67, P629, DOI 10.1207/s15327752jpa6703_15; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; SILVERTON L, 1998, MALINGERING PROBABIL; Smith GP, 1997, J AM ACAD PSYCHIATRY, V25, P183; Strauss E, 2006, COMPENDIUM NEUROPSYC, P3; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e	22	28	29	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2015	37	8					853	862		10.1080/13803395.2015.1064864			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	DD3FP	WOS:000369807800007	26245293				2021-06-18	
J	Peters-Libeu, C; Campagna, J; Mitsumori, M; Poksay, KS; Spilman, P; Sabogal, A; Bredesen, DE; John, V				Peters-Libeu, Clare; Campagna, Jesus; Mitsumori, Michael; Poksay, Karen S.; Spilman, Patricia; Sabogal, Alex; Bredesen, Dale E.; John, Varghese			sA beta PP alpha is a Potent Endogenous Inhibitor of BACE1	JOURNAL OF ALZHEIMERS DISEASE			English	Article						A beta; sA beta PP alpha; sA beta PP beta; allosteric; BACE; BACE1; endogenous; inhibitor; SAXS	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; SECRETASE ACTIVITY; CLEAVAGE; HYPOXIA; EXPRESSION; APP; ASTROCYTES; INJURY; SS	Proteolytic cleavage of the amyloid-beta protein precursor (A beta PP) by the enzyme BACE1 (BACE) is the initial step in production of amyloid-beta peptide (A beta), and as such has been a major target of Alzheimer's disease (AD) drug discovery efforts. Overproduction of A beta results in neuronal cell death and accumulation of amyloid plaques in AD and in traumatic brain injury, and is also associated with stroke due to cerebral amyloid angiopathy. Herein we report for the first time that sA beta PP alpha, the product of the cleavage of A beta PP by alpha-secretase, is a potent endogenous direct inhibitor of the BACE enzyme, and that its inhibition is likely by an allosteric mechanism. Furthermore, using small-angle X-ray scattering, we show that sA beta PP beta, which is identical to sA beta PP alpha except for a 16-amino acid truncation at the carboxy terminus, adopts a completely different structure than sA beta PP alpha and does not inhibit BACE. Our data thus reveal a novel mechanistic role played by sA beta PP alpha in regulating overproduction of A beta and restoring neuronal homeostasis and neuroprotection. Identification of sA beta PP alpha as a direct BACE inhibitor may lead to design of new therapeutics targeting pathologies associated with overproduction of A beta.	[Peters-Libeu, Clare; Mitsumori, Michael; Poksay, Karen S.; Sabogal, Alex; Bredesen, Dale E.; John, Varghese] Buck Inst Res Aging, Novato, CA 94945 USA; [Campagna, Jesus; Spilman, Patricia; Bredesen, Dale E.; John, Varghese] UCLA, Dept Neurol, Drug Discovery Lab, Los Angeles, CA 90025 USA; [Bredesen, Dale E.; John, Varghese] UCLA, Easton Ctr Alzheimers Dis Res, Los Angeles, CA 90025 USA	John, V (corresponding author), UCLA, Easton Ctr Alzheimers Dis Res, Los Angeles, CA 90025 USA.	clibeu@buckinstitute.org; vjohn@mednet.ucla.edu			Ellen and Douglas Rosenberg Foundation; Rosenberg Alzheimer's Project	This research was supported by a grant from the Ellen and Douglas Rosenberg Foundation and the Rosenberg Alzheimer's Project. We thank Rowena Abulencia for her assistance in preparation of the manuscript.	Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Auerbach ID, 2006, J NEUROPATH EXP NEUR, V65, P610, DOI 10.1097/00005072-200606000-00009; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Bredesen DE, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-27; CHANG LS, 1994, J PROTEIN CHEM, V13, P635, DOI 10.1007/BF01890462; Chasseigneaux S, 2012, J NEUROCHEM, V120, P99, DOI 10.1111/j.1471-4159.2011.07584.x; Cole SL, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-22; Corrigan F, 2012, BRAIN RES, V1451, P87, DOI 10.1016/j.brainres.2012.02.045; Dahms SO, 2010, P NATL ACAD SCI USA, V107, P5381, DOI 10.1073/pnas.0911326107; EFTINK MR, 1982, BIOCHEMISTRY-US, V21, P117, DOI 10.1021/bi00530a021; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Garcia-Matas S, 2010, J ALZHEIMERS DIS, V20, P229, DOI 10.3233/JAD-2010-1365; Gralle M, 2006, J MOL BIOL, V357, P493, DOI 10.1016/j.jmb.2005.12.053; Guglielmotto M, 2009, J NEUROCHEM, V108, P1045, DOI 10.1111/j.1471-4159.2008.05858.x; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Lakowicz JR., 2006, PRINCIPLES FLUORESCE, V3rd ed, DOI [10.1007/978-0-387-46312-4, DOI 10.1007/978-0-387-46312-4]; Lee HH, 2010, BIOCHEM BIOPH RES CO, V399, P600, DOI 10.1016/j.bbrc.2010.07.121; Lee S, 2011, BIOCHEMISTRY-US, V50, P5453, DOI 10.1021/bi101846x; Li M, 2000, NAT STRUCT BIOL, V7, P113; Li QY, 2010, NEUROSCI LETT, V481, P154, DOI 10.1016/j.neulet.2010.06.076; Libeu CAP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040027; Libeu CP, 2011, J ALZHEIMERS DIS, V25, P547, DOI 10.3233/JAD-2011-101938; Lu DC, 2003, J NEUROCHEM, V87, P733, DOI 10.1046/j.1471-4159.2003.02059.x; Mannix RC, 2013, BRAIN INJURY, V27, P743, DOI 10.3109/02699052.2013.771797; Mannix RC, 2011, J NEUROTRAUM, V28, P1855, DOI 10.1089/neu.2011.1759; Mondello S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06446; Moussavi Nik Seyyed Hani, 2012, J Alzheimers Dis, V28, P515, DOI 10.3233/JAD-2011-110533; Nalivaeva NN, 2013, FEBS LETT, V587, P2046, DOI 10.1016/j.febslet.2013.05.010; Nallamsetty S, 2005, PROTEIN SCI, V14, P2964, DOI 10.1110/ps.051718605; Ng KKS, 2000, NAT STRUCT BIOL, V7, P653, DOI 10.1038/77950; Nikolaev A, 2009, NATURE, V457, P981, DOI 10.1038/nature07767; Obregon D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1781; Pan XD, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-45; Petoukhov MV, 2012, J APPL CRYSTALLOGR, V45, P342, DOI 10.1107/S0021889812007662; Petoukhov MV, 2005, BIOPHYS J, V89, P1237, DOI 10.1529/biophysj.105.064154; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Soscia SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009505; Stamford AW, 2012, ACS MED CHEM LETT, V3, P897, DOI 10.1021/ml3001165; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tian YA, 2010, J BIOL CHEM, V285, P32549, DOI 10.1074/jbc.M110.128439; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang WR, 2013, CURR OPIN STRUC BIOL, V23, P797, DOI 10.1016/j.sbi.2013.08.001; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhang H, 2012, J NEUROCHEM, V120, P9, DOI 10.1111/j.1471-4159.2011.07519.x; Zhang X, 2007, J BIOL CHEM, V282, P10873, DOI 10.1074/jbc.M608856200; Zhao J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-150; ZHONG ZY, 1994, J BIOL CHEM, V269, P627	50	28	29	0	8	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2015	47	3					545	555		10.3233/JAD-150282			11	Neurosciences	Neurosciences & Neurology	CQ9JN	WOS:000360930700003	26401691				2021-06-18	
J	Rundhaug, NP; Moen, KG; Skandsen, T; Schirmer-Mikalsen, K; Lund, SB; Hara, S; Vik, A				Rundhaug, Nils Petter; Moen, Kent Goran; Skandsen, Toni; Schirmer-Mikalsen, Kari; Lund, Stine B.; Hara, Sozaburo; Vik, Anne			Moderate and severe traumatic brain injury: effect of blood alcohol concentration on Glasgow Coma Scale score and relation to computed tomography findings	JOURNAL OF NEUROSURGERY			English	Article						ethanol; craniocerebral trauma; x-ray computed tomography; intracranial hypertension; consciousness disorders; traumatic brain injury	SEVERE HEAD-INJURY; INTOXICATION; CLASSIFICATION; GUIDELINES; MANAGEMENT; OUTCOMES; LEVEL	OBJECT The influence of alcohol is assumed to reduce consciousness in patients with traumatic brain injury (TBI), but research findings are divergent. The aim of this investigation was to study the effects of different levels of blood alcohol concentration (BAC) on the Glasgow Coma Scale (GCS) scores in patients with moderate and severe TBI and to relate the findings to brain injury severity based on the admission CT scan. METHODS In this cohort study, 265 patients (age range 16-70 years) who were admitted to St. Olavs University Hospital with moderate and severe TBI during a 7-year period were prospectively registered. Of these, 217 patients (82%) had measured BAC. Effects of 4 BAC groups on GCS score were examined with ordinal logistic regression analyses, and the GCS scores were inverted to give an OR > 1. The Rotterdam CT score based on admission CT scan was used to adjust for brain injury severity (best score 1 and worst score 6) by stratifying patients into 2 brain injury severity groups (Rotterdam CT scores of 1-3 and 4-6). RESULTS Of all patients with measured BAC, 91% had intracranial CT findings and 43% had BAC > 0 mg/dl. The median GCS score was lower in the alcohol-positive patients (6.5, interquartile range [ION 4-10) than in the alcohol-negative patients (9, IQR 6-13; p < 0.01). No significant differences were found between alcohol-positive and alcohol-negative patients regarding other injury severity variables. Increasing BAC was a significant predictor of lower GCS score in a dose-dependent manner in age-adjusted analyses, with OR 2.7 (range 1.4-5.0) and 3.2 (range 1.5-6.9) for the 2 highest BAC groups (p < 0.01). Subgroup analyses showed an increasing effect of BAC group on GCS scores in patients with Rotterdam CT scores of 1-3: OR 3.1 (range 1.4-6.6) and 6.7 (range 2.7-16.7) for the 2 highest BAC groups (p < 0.01). No such relationship was found in patients with Rotterdam CT scores of 4-6 (p = 0.14-0.75). CONCLUSIONS Influence of alcohol significantly reduced the GCS score in a dose-dependent manner in patients with moderate and severe TBI and with Rotterdam CT scores of 1-3. In patients with Rotterdam CT scores of 4-6, and therefore more CT findings indicating increased intracranial pressure, the brain injury itself seemed to overrun the depressing effect of the alcohol on the CNS. This finding is in agreement with the assumption of many clinicians in the emergency situation.	[Rundhaug, Nils Petter; Moen, Kent Goran; Skandsen, Toni; Vik, Anne] Norwegian Univ Sci & Technol, Dept Neurosci, N-7491 Trondheim, Norway; [Schirmer-Mikalsen, Kari] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway; [Moen, Kent Goran; Lund, Stine B.; Hara, Sozaburo; Vik, Anne] Univ Trondheim Hosp, Dept Neurosurg, Trondheim, Norway; [Skandsen, Toni] Univ Trondheim Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Schirmer-Mikalsen, Kari] Univ Trondheim Hosp, St Olavs Hosp, Dept Anaesthesia & Acute Med, Trondheim, Norway	Moen, KG (corresponding author), Norwegian Univ Sci & Technol, Dept Neurosci, Postboks 3250 Sluppen, N-7491 Trondheim, Norway.	kent.g.moen@ntnu.no			Liaison Committee	During part of the study period, Dr. Schirmer-Mikalsen received a research grant from the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bratton SL, 2008, J NEUROTRAUM, V25, P276; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Farshchian N, 2012, J INJ VIOLENCE RE S1, V4; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; Lange RT, 2010, BRAIN INJURY, V24, P919, DOI 10.3109/02699052.2010.489794; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Rosenberg JB, 2011, NEUROCRIT CARE, V15, P599, DOI 10.1007/s12028-011-9545-4; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shahin H, 2010, J TRAUMA, V69, P1176, DOI 10.1097/TA.0b013e3181edbd47; Skandsen T, 2012, MANAGEMENT SEVERE TR, P389; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Sperry JL, 2006, J TRAUMA, V61, P1305, DOI 10.1097/01.ta.0000240113.13552.96; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; SULLIVAN JB, 1987, J FORENSIC SCI, V32, P1660; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50	26	28	29	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2015	122	1					211	218		10.3171/2014.9.JNS14322			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AX5DQ	WOS:000346947600030	25361494	Bronze			2021-06-18	
J	Scicchitano, F; Constanti, A; Citraro, R; De Sarro, G; Russo, E				Scicchitano, Francesca; Constanti, Andrew; Citraro, Rita; De Sarro, Giovambattista; Russo, Emilio			Statins and Epilepsy: Preclinical Studies, Clinical Trials and Statin-Anticonvulsant Drug Interactions	CURRENT DRUG TARGETS			English	Article						Adverse effects; atorvastatin; epileptogenesis; fluvastatin; lovastatin; pravastatin; seizures; simvastatin; statin-antiepileptic drug (AED) interactions; statins	COA REDUCTASE INHIBITORS; ATORVASTATIN TREATMENT; INDUCED EXCITOTOXICITY; ANTIEPILEPTIC DRUGS; STATUS-EPILEPTICUS; INDUCED SEIZURES; NITRIC-OXIDE; CELL-DEATH; RAT MODEL; SIMVASTATIN	3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins) are potent cholesterol-lowering drugs which also possess beneficial antioxidant, antiinflammatory, immunomodulatory, and antiexcitotoxic effects. In addition, statins have proven neuroprotective effects in several neurological diseases: stroke, cerebral ischemia, Alzheimer's and Parkinson's disease, multiple sclerosis and traumatic brain injury. Relatively few studies have investigated the potential anti-seizure properties of statins in epilepsy and the possible underlying protective mechanisms that may be involved. This review summarizes the currently available data concerning statin effects in modulating seizure activity (sometimes adversely) and epileptogenesis in different experimental models as well as in clinical studies. Furthermore, we analyze the consequences of some of the more commonly reported statin-anticonvulsant drug interactions in the literature, discuss some of the adverse effects of statins encountered in clinical practice and comment on the potential future usefulness of statins in epilepsy therapy.	[Scicchitano, Francesca; Citraro, Rita; De Sarro, Giovambattista; Russo, Emilio] Magna Graecia Univ Catanzaro, Sch Med, Dept Hlth Sci, Catanzaro, Italy; [Constanti, Andrew] UCL Sch Pharm, Dept Pharmacol, London, England	Russo, E (corresponding author), Univ Catanzaro, Sch Med, Dept Hlth Sci, Via T Campanella 115, I-88100 Catanzaro, Italy.	erusso@unicz.it	Russo, Emilio/G-5241-2010; gallelli, luca/A-5180-2011	Russo, Emilio/0000-0002-1279-8123; gallelli, luca/0000-0003-0858-7902; De Sarro, Giovambattista/0000-0002-7629-6579; Citraro, Rita/0000-0001-6746-6751	Commission European Social Fund; Region of Calabria (Italy)	The Commission European Social Fund and Region of Calabria (Italy) are kindly acknowledged for student economical support.	Agarwal R, 2006, AM J CARDIOL, V97, P748, DOI 10.1016/j.amjcard.2005.09.110; Albayda J, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926-014-0433-8; Arntz HR, 2000, AM J CARDIOL, V86, P1293, DOI 10.1016/S0002-9149(00)01230-3; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Bellosta S, 2004, CIRCULATION, V109, P50, DOI 10.1161/01.CIR.0000131519.15067.1f; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Bravo AER, 2005, DRUG SAFETY, V28, P263; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; Bullman J, 2011, EPILEPSIA, V52, P1351, DOI 10.1111/j.1528-1167.2011.03118.x; Candrilli SD, 2010, EPILEPSY RES, V91, P260, DOI 10.1016/j.eplepsyres.2010.07.021; Canevini MP, 2010, EPILEPSIA, V51, P797, DOI 10.1111/j.1528-1167.2010.02520.x; Caron G, 2007, PHARM RES-DORDR, V24, P480, DOI 10.1007/s11095-006-9199-7; Citraro R, 2014, EPILEPSIA, V55, P1284, DOI 10.1111/epi.12686; Clarke RM, 2008, J BIOL CHEM, V283, P1808, DOI 10.1074/jbc.M707442200; Cucchiara B, 2001, J NEUROL SCI, V187, P81, DOI 10.1016/S0022-510X(01)00529-9; D'Ambrosio R, 2013, EXPERT REV NEUROTHER, V13, P615, DOI [10.1586/ERN.13.54, 10.1586/ern.13.54]; Dedeurwaerdere S, 2012, EPILEPSIA, V53, P1113, DOI 10.1111/j.1528-1167.2012.03520.x; Etminan M, 2010, NEUROLOGY, V75, P1496, DOI 10.1212/WNL.0b013e3181f96253; Eyal S, 2014, EPILEPSY BEHAV, V31, P369, DOI 10.1016/j.yebeh.2013.09.041; Falcao A, 2013, EPILEPSY RES, V106, P244, DOI 10.1016/j.eplepsyres.2013.04.009; Friedman A, 2011, EPILEPSIA, V52, P33, DOI 10.1111/j.1528-1167.2011.03034.x; Funck VR, 2011, EPILEPSIA, V52, P2094, DOI 10.1111/j.1528-1167.2011.03261.x; Gouveia TLF, 2011, EPILEPSY BEHAV, V20, P1, DOI 10.1016/j.yebeh.2010.10.001; Gazzerro P, 2012, PHARMACOL REV, V64, P102, DOI 10.1124/pr.111.004994; Gidal BE, 2009, NEUROLOGY, V72, P419, DOI 10.1212/01.wnl.0000341789.77291.8d; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gorter JA, 2006, J NEUROSCI, V26, P11083, DOI 10.1523/JNEUROSCI.2766-06.2006; Gotto AM, 2012, AM J CARDIOL, V110, p15A, DOI 10.1016/j.amjcard.2012.04.003; Heverin M, 2012, BRAIN RES, V1480, P81, DOI 10.1016/j.brainres.2012.08.018; Huang WJ, 2013, MOL MED REP, V8, P1337, DOI 10.3892/mmr.2013.1660; Ifergan I, 2006, ANN NEUROL, V60, P45, DOI 10.1002/ana.20875; Kesim M, 2012, J PAK MED ASSOC, V62, P1187; Khandwala HM, 2006, SOUTH MED J, V99, P1385, DOI 10.1097/01.smj.0000251470.39036.ea; Kulkarni SK, 2009, DRUG TODAY, V45, P135, DOI 10.1358/dot.2009.45.2.1322481; Landmark CJ, 2012, EXPERT REV CLIN PHAR, V5, P281, DOI [10.1586/ECP.12.10, 10.1586/ecp.12.10]; Lee CY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038789; Lee JK, 2008, NEUROSCI LETT, V440, P260, DOI 10.1016/j.neulet.2008.05.112; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Ma T, 2009, J NEUROSCI, V29, P11226, DOI 10.1523/JNEUROSCI.6150-08.2009; Marchi N, 2007, EPILEPSIA, V48, P732, DOI 10.1111/j.1528-1167.2007.00988.x; Miesbach W, 2005, J NEUROL SCI, V238, P93, DOI 10.1016/j.jns.2005.06.008; Miller AE, 2008, PHARMACOTHERAPY, V28, P553, DOI 10.1592/phco.28.5.553; Minder CM, 2013, CURR OPIN CARDIOL, V28, P554, DOI 10.1097/HCO.0b013e32836429e6; Mirhadi K., 2011, Global Veterinaria, V7, P386; Mlodinow SG, 2014, J FAM PRACTICE, V63, P497; Moazzami K, 2013, FUND CLIN PHARMACOL, V27, P387, DOI 10.1111/j.1472-8206.2012.01038.x; Moezi L, 2012, EPILEPSY BEHAV, V23, P399, DOI 10.1016/j.yebeh.2012.02.001; Naval NS, 2009, NEUROL RES, V31, P425, DOI 10.1179/174313208X353686; Nejm MB, 2013, EPILEPSY BEHAV, V28, P10, DOI 10.1016/j.yebeh.2013.03.024; Neuhaus O, 2004, LANCET NEUROL, V3, P369, DOI 10.1016/S1474-4422(04)00770-7; Osterweil EK, 2013, NEURON, V77, P243, DOI 10.1016/j.neuron.2012.01.034; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Patel AM, 2013, ANN INTERN MED, V158, P869, DOI 10.7326/0003-4819-158-12-201306180-00004; Piermartiri TCB, 2010, EXP NEUROL, V226, P274, DOI 10.1016/j.expneurol.2010.08.030; Ponce J, 2008, STROKE, V39, P1269, DOI 10.1161/STROKEAHA.107.498923; Preiss D, 2011, JAMA-J AM MED ASSOC, V305, P2556, DOI 10.1001/jama.2011.860; Ramirez C, 2011, J ALZHEIMERS DIS, V24, P161, DOI 10.3233/JAD-2010-101653; Rangel P, 2005, ARQ NEURO-PSIQUIAT, V63, P972, DOI 10.1590/S0004-282X2005000600013; Ravizza T, 2011, NEUROSCI LETT, V497, P223, DOI 10.1016/j.neulet.2011.02.040; Reiss AB, 2009, THESCIENTIFICWORLDJO, V9, P1242, DOI 10.1100/tsw.2009.141; Riazi K, 2010, EPILEPSY RES, V89, P34, DOI 10.1016/j.eplepsyres.2009.09.004; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Russo E, 2013, PHARMACOL RES, V70, P1, DOI 10.1016/j.phrs.2012.12.002; Sasa M, 2006, J PHARMACOL SCI, V100, P487, DOI 10.1254/jphs.CPJ06010X; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; Serbanescu I, 2004, J LIPID RES, V45, P2038, DOI 10.1194/jlr.M400097-JLR200; Shafaroodi H, 2012, NEUROL RES, V34, P847, DOI 10.1179/1743132812Y.0000000080; Sierra-Marcos A, 2015, EUR J NEUROL, V22, P402, DOI 10.1111/ene.12428; Simic I, 2015, CURR PHARM DESIGN, V21, P1220, DOI 10.2174/1381612820666141013134447; Staffa JA, 2002, NEW ENGL J MED, V346, P539, DOI 10.1056/NEJM200202143460721; Stepien KM, 2012, EUR J PHARMACOL, V674, P20, DOI 10.1016/j.ejphar.2011.10.030; Sun JH, 2012, INT J MOL MED, V30, P739, DOI 10.3892/ijmm.2012.1076; Tan KM, 2008, BRIT J CLIN PHARMACO, V65, P147, DOI 10.1111/j.1365-2125.2007.02982.x; Turkoglu OF, 2009, SURG NEUROL, V72, P146, DOI 10.1016/j.surneu.2008.07.004; Turrin NP, 2004, NEUROBIOL DIS, V16, P321, DOI 10.1016/j.nbd.2004.03.010; Ucar M, 2004, EUR J CLIN PHARMACOL, V59, P879, DOI 10.1007/s00228-003-0700-5; Uzum G, 2010, EPILEPSY BEHAV, V19, P284, DOI 10.1016/j.yebeh.2010.07.024; van Vliet EA, 2011, EPILEPSIA, V52, P1319, DOI 10.1111/j.1528-1167.2011.03073.x; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Vezzani A, 2013, NEUROPHARMACOLOGY, V69, P16, DOI 10.1016/j.neuropharm.2012.04.004; Vezzani A, 2013, EXP NEUROL, V244, P11, DOI 10.1016/j.expneurol.2011.09.033; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; Wang LN, 2010, NEUROSCI LETT, V471, P152, DOI 10.1016/j.neulet.2010.01.030; Weber MS, 2006, J NEUROIMMUNOL, V178, P140, DOI 10.1016/j.jneuroim.2006.06.006; Williams D, 2002, CLIN PHARMACOKINET, V41, P343, DOI 10.2165/00003088-200241050-00003; Wood WG, 2010, ANN NY ACAD SCI, V1199, P69, DOI 10.1111/j.1749-6632.2009.05359.x; Xie CC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024966; Yanuck D, 2012, INT J NEUROSCI, V122, P619, DOI 10.3109/00207454.2012.704455; Zacco A, 2003, J NEUROSCI, V23, P11104	89	28	28	0	11	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1389-4501	1873-5592		CURR DRUG TARGETS	Curr. Drug Targets		2015	16	7					747	756		10.2174/1389450116666150330114850			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CN9QV	WOS:000358784800006	25901524				2021-06-18	
J	Monaco, CM; Gebhardt, KM; Chlebowski, SM; Shaw, KE; Cheng, JP; Henchir, JJ; Zupa, MF; Kline, AE				Monaco, Christina M.; Gebhardt, Kory M.; Chlebowski, Sarah M.; Shaw, Kaitlyn E.; Cheng, Jeffrey P.; Henchir, Jeremy J.; Zupa, Margaret F.; Kline, Anthony E.			A Combined Therapeutic Regimen of Buspirone and Environmental Enrichment Is More Efficacious than Either Alone in Enhancing Spatial Learning in Brain-Injured Pediatric Rats	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; controlled cortical impact (CCI); functional recovery; learning and memory; behavior; Morris water maze; 5-HT1A receptor agonist, beam-walking; traumatic brain injury	RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; MEDIATED FUNCTIONAL IMPROVEMENT; COGNITIVE DEFICITS; NEUROBEHAVIORAL BENEFIT; YOUNG-CHILDREN; UNITED-STATES; HEAD-INJURY; 5-HT1A; RECOVERY; 8-OH-DPAT	Buspirone, a 5-HT1A receptor agonist, and environmental enrichment (EE) enhance cognition and reduce histopathology after traumatic brain injury (TBI) in adult rats, but have not been fully evaluated after pediatric TBI, which is the leading cause of death in children. Hence, the aims of this study were to assess the efficacy of buspirone alone (Experiment 1) and in combination with EE (Experiment 2) in TBI postnatal day-17 male rats. The hypothesis was that both therapies would confer cognitive and histological benefits when provided singly, but their combination would be more efficacious. Anesthetized rats received a cortical impact or sham injury and then were randomly assigned to receive intraperitoneal injections of buspirone (0.08 mg/kg, 0.1 mg/kg, and 0.3 mg/kg) or saline vehicle (1.0 mL/kg) 24 h after surgery and once daily for 16 days (Experiment 1). Spatial learning and memory were assessed using the Morris water maze (MWM) on post-operative days 11-16, and cortical lesion volume was quantified on day 17. Sham controls for each condition were significantly better than all TBI groups. In the TBI groups, buspirone (0.1 mg/kg) enhanced MWM performance versus vehicle and buspirone (0.08 mg/kg and 0.3 mg/kg) (p<0.05) and reduced lesion volume relative to vehicle (p=0.038). In Experiment 2, buspirone (0.1 mg/kg) or vehicle was combined with EE after TBI, and the data were compared to the standard (STD)-housed groups from Experiment 1. EE lead to a significant enhancement of spatial learning and a reduction in lesion size versus STD. Moreover, the combined treatment group (buspirone+EE) performed markedly better than the buspirone+STD and vehicle+EE groups, which suggests an additive effect and supports the hypothesis. The data replicate previous studies assessing these therapies in adult rats. These novel findings may have important rehabilitation-relevant implications for clinical pediatric TBI.	[Monaco, Christina M.; Gebhardt, Kory M.; Chlebowski, Sarah M.; Shaw, Kaitlyn E.; Cheng, Jeffrey P.; Kline, Anthony E.] Univ Pittsburgh, Pittsburgh, PA 15213 USA; [Monaco, Christina M.; Gebhardt, Kory M.; Chlebowski, Sarah M.; Shaw, Kaitlyn E.; Cheng, Jeffrey P.; Henchir, Jeremy J.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Zupa, Margaret F.] SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14260 USA	Kline, AE (corresponding author), Univ Pittsburgh, 3471 Fifth Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	NIH grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD046700, NS060005, HD069620]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	Supported, in part, by NIH grants HD046700, NS060005, and HD069620 (AEK).	Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Bondi CO, 2014, J NEUROTRAUM, V31, P873, DOI 10.1089/neu.2014.3328; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Cheng JP, 2012, J NEUROTRAUM, V29, P2684, DOI 10.1089/neu.2012.2560; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Harkany T, 2001, NEUROSCIENCE, V108, P629, DOI 10.1016/S0306-4522(01)00444-4; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Herlenius E, 2004, EXP NEUROL, V190, pS8, DOI 10.1016/j.expneurol.2004.03.027; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2012, J NEUROTRAUM, V29, P1960, DOI 10.1089/neu.2012.2385; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Lippert-Gruener M, 2007, EXP NEUROL, V203, P82, DOI 10.1016/j.expneurol.2006.07.025; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; Meneses A, 2007, NEUROSCI BIOBEHAV R, V31, P705, DOI 10.1016/j.neubiorev.2007.02.001; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Olsen AS, 2012, J NEUROTRAUM, V29, P1898, DOI 10.1089/neu.2012.2358; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Sakaue M, 2000, BRIT J PHARMACOL, V129, P1028, DOI 10.1038/sj.bjp.0703139; Garcia AS, 2011, J INVEST ALLERG CLIN, V21, P1; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; TEYLER TJ, 1989, NEUROPSYCHOLOGIA, V27, P31, DOI 10.1016/0028-3932(89)90088-2; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Xu L., 2010, TRAUMATIC BRAIN INJU; Yelleswarapu NK, 2012, NEUROSCI LETT, V515, P153, DOI 10.1016/j.neulet.2012.03.033	57	28	28	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2014	31	23					1934	1941		10.1089/neu.2014.3541			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AT6US	WOS:000345075500006	25050595	Green Published			2021-06-18	
J	Shimada, SL; Brandt, CA; Feng, H; McInnes, DK; Rao, SR; Rothendler, JA; Haggstrom, DA; Abel, EA; Cioffari, LS; Houston, TK				Shimada, Stephanie Leah; Brandt, Cynthia A.; Feng, Hua; McInnes, D. Keith; Rao, Sowmya R.; Rothendler, James A.; Haggstrom, David A.; Abel, Erica A.; Cioffari, Lisa S.; Houston, Thomas K.			Personal Health Record Reach in the Veterans Health Administration: A Cross-Sectional Analysis	JOURNAL OF MEDICAL INTERNET RESEARCH			English	Article						personal health records; patient characteristics; medical conditions; veterans	POSTTRAUMATIC-STRESS-DISORDER; PRIMARY-CARE CLINICS; MENTAL-HEALTH; RANDOMIZED-TRIAL; AFGHANISTAN VETERANS; PHYSICIAN REMINDERS; SELF-MANAGEMENT; PATIENT ACCESS; SERVICE USE; PREVALENCE	Background: My HealtheVet (MHV) is the personal health record and patient portal developed by the United States Veterans Health Administration (VA). While millions of American veterans have registered for MHV, little is known about how a patient's health status may affect adoption and use of the personal health record. Objective: Our aim was to characterize the reach of the VA personal health record by clinical condition. Methods: This was a cross-sectional analysis of all veterans nationwide with at least one inpatient admission or two outpatient visits between April 2010 and March 2012. We compared adoption (registration, authentication, opt-in to use secure messaging) and use (prescription refill and secure messaging) of MHV in April 2012 across 18 specific clinical conditions prevalent in and of high priority to the VA. We calculated predicted probabilities of adoption by condition using multivariable logistic regression models adjusting for sociodemographics, comorbidities, and clustering of patients within facilities. Results: Among 6,012,875 veterans, 6.20% were women, 61.45% were Caucasian, and 26.31% resided in rural areas. The mean age was 63.3 years. Nationwide, 18.64% had registered for MHV, 11.06% refilled prescriptions via MHV, and 1.91% used secure messaging with their clinical providers. Results from the multivariable regression suggest that patients with HIV, hyperlipidemia, and spinal cord injury had the highest predicted probabilities of adoption, whereas those with schizophrenia/schizoaffective disorder, alcohol or drug abuse, and stroke had the lowest. Variation was observed across diagnoses in actual (unadjusted) adoption and use, with registration rates ranging from 29.19% of patients with traumatic brain injury to 14.18% of those with schizophrenia/schizoaffective disorder. Some of the variation in actual reach can be explained by facility-level differences in MHV adoption and by differences in patients' sociodemographic characteristics (eg, age, race, income) by diagnosis. Conclusions: In this phase of early adoption, opportunities are being missed for those with specific medical conditions that require intensive treatment and self-management, which could be greatly supported by functions of a tethered personal health record.	[Shimada, Stephanie Leah; Feng, Hua; McInnes, D. Keith; Rao, Sowmya R.; Rothendler, James A.; Cioffari, Lisa S.; Houston, Thomas K.] Edith Nourse Rogers Mem VA Med Ctr, eHlth Qual Enhancement Res Initiat, Ctr Healthcare Org & Implementat Res, Bedford, MA 01730 USA; [Shimada, Stephanie Leah; McInnes, D. Keith; Rothendler, James A.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Shimada, Stephanie Leah; Feng, Hua; Cioffari, Lisa S.; Houston, Thomas K.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Div Hlth Informat & Implementat Sci, Worcester, MA USA; [Brandt, Cynthia A.; Abel, Erica A.] VA Connecticut Healthcare Syst, Pain Res Informat Multi Morbid & Educ Ctr, West Haven, CT USA; [Brandt, Cynthia A.; Abel, Erica A.] Yale Univ, Sch Med, Yale Ctr Med Informat, New Haven, CT USA; [Brandt, Cynthia A.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA; [Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Div Biostat, Worcester, MA USA; [Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Hlth Serv Res, Worcester, MA USA; [Haggstrom, David A.] Richard L Roudebush Vet Adm Med Ctr, Ctr Hlth Informat & Commun, Indianapolis, IN 46202 USA; [Haggstrom, David A.] Indiana Univ Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Indianapolis, IN 46202 USA	Shimada, SL (corresponding author), Edith Nourse Rogers Mem VA Med Ctr, eHlth Qual Enhancement Res Initiat, Ctr Healthcare Org & Implementat Res, 200 Springs Rd 152, Bedford, MA 01730 USA.	stephanie.shimada@va.gov			Department of Veterans Affairs (VA) Health Services Research and Development Service, Quality Enhancement Research Initiative [RRP 11-404]; VA Health Services Research and Development Career Development Award (CDA) [10-210]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000142] Funding Source: NIH RePORTER	( The research reported here was supported by the Department of Veterans Affairs (VA) Health Services Research and Development Service, Quality Enhancement Research Initiative (RRP 11-404). In addition, Dr Shimada was supported by a VA Health Services Research and Development Career Development Award (CDA# 10-210). The views expressed in this paper are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.	Ahern DK, 2011, AM J PREV MED, V40, pS162, DOI 10.1016/j.amepre.2011.01.005; Amante DJ, 2014, DIABETES TECHNOL THE, V16, P784, DOI 10.1089/dia.2014.0078; Ansseau M, 2004, J AFFECT DISORDERS, V78, P49, DOI 10.1016/S0165-0327(02)00219-7; Archer N, 2011, J AM MED INFORM ASSN, V18, P515, DOI 10.1136/amiajnl-2011-000105; Ayanian JZ, 2008, J GEN INTERN MED, V23, P762, DOI 10.1007/s11606-008-0576-2; Bali RK, 2010, STUD HEALTH TECHNOL, V156, P138, DOI 10.3233/978-1-60750-565-5-138; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Chumbler NR, 2011, MED CARE, V49, pS36, DOI 10.1097/MLR.0b013e3181d558f9; Cohen BE, 2010, J GEN INTERN MED, V25, P18, DOI 10.1007/s11606-009-1117-3; Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW, P164; Davison KP, 2000, AM PSYCHOL, V55, P205, DOI 10.1037/0003-066X.55.2.205; Department of Veterans Affairs, 2013, MY HEALTHEVET ACC TY; Detmer D, 2008, BMC MED INFORM DECIS, V8, DOI 10.1186/1472-6947-8-45; Druss BG, 2014, AM J PSYCHIAT, V171, P360, DOI 10.1176/appi.ajp.2013.13070913; Frueh BC, 2007, AM J GERIAT PSYCHIAT, V15, P660, DOI 10.1097/JGP.0b013e3180487cc2; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Golub A, 2013, MIL MED, V178, P107, DOI 10.7205/MILMED-D-12-00131; Goulet JL, 2007, CLIN INFECT DIS, V45, P1593, DOI 10.1086/523577; Grubaugh AL, 2006, WOMEN HEALTH, V43, P41, DOI 10.1300/J013v43n03_03; Hall AK, 2015, HEALTH EDUC BEHAV, V42, P202, DOI 10.1177/1090198114547815; Jonas BS, 2003, SOC PSYCH PSYCH EPID, V38, P618, DOI 10.1007/s00127-003-0682-8; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lorig KR, 2008, ARTHRIT RHEUM-ARTHR, V59, P1009, DOI 10.1002/art.23817; Lorig KR, 2006, MED CARE, V44, P964, DOI 10.1097/01.mlr.0000233678.80203.c1; Lorig KR, 2008, CHRONIC ILLN, V4, P247, DOI 10.1177/1742395308098886; LURIE N, 1992, HOSP COMMUNITY PSYCH, V43, P69; Magruder KM, 2005, GEN HOSP PSYCHIAT, V27, P169, DOI 10.1016/j.genhosppsych.2004.11.001; Mattocks KM, 2010, J WOMENS HEALTH, V19, P2159, DOI 10.1089/jwh.2009.1892; Miller Holly, 2007, J Healthc Inf Manag, V21, P44; Nazi KM, 2013, MED CARE, V51, pS52, DOI 10.1097/MLR.0b013e31827808db; Nazi KM, 2010, J GEN INTERN MED, V25, P62, DOI 10.1007/s11606-009-1114-6; Palen TE, 2012, JAMA-J AM MED ASSOC, V308, P2012, DOI 10.1001/jama.2012.14126; Riolo SA, 2005, AM J PUBLIC HEALTH, V95, P998, DOI 10.2105/AJPH.2004.047225; Roblin DW, 2009, J AM MED INFORM ASSN, V16, P683, DOI 10.1197/jamia.M3169; Seal KH, 2010, J TRAUMA STRESS, V23, P5, DOI 10.1002/jts.20493; Sequist TD, 2009, ARCH INTERN MED, V169, P364, DOI 10.1001/archinternmed.2008.564; Shimada SL, 2013, MED CARE, V51, pS21, DOI 10.1097/MLR.0b013e3182780917; Song H, 2015, AM J MENS HEALTH, V9, P235, DOI 10.1177/1557988314539502; Stone EG, 2002, ANN INTERN MED, V136, P641, DOI 10.7326/0003-4819-136-9-200205070-00006; Tang PC, 2006, J AM MED INFORM ASSN, V13, P121, DOI 10.1197/jamia.M2025; Tsai J, 2012, J AM MED INFORM ASSN, V19, P1089, DOI 10.1136/amiajnl-2012-000971; US Department of Health and Human Services. The National Infrastructure Workgroup of the National Committee on Vital Statistics (NICVHS), 2006, NAT INFR WORKGR NAT; Veterans Health Administration Office of Health Information Product Effectiveness, 2009, MY HEALTHEVET SHEP S; Walkup JT, 2004, MED CARE, V42, P756, DOI 10.1097/01.mlr.0000132749.20897.46; Weingart SN, 2008, INT J MED INFORM, V77, P161, DOI 10.1016/j.ijmedinf.2007.04.007; Weingart SN, 2006, J AM MED INFORM ASSN, V13, P91, DOI 10.1197/jamia.M1833; Woods SS, 2013, J MED INTERNET RES, V15, P182, DOI 10.2196/jmir.2356; Yamin CK, 2011, ARCH INTERN MED, V171, P568, DOI 10.1001/archinternmed.2011.34; Yoon J, 2014, MED CARE, V52, pS31, DOI 10.1097/MLR.0000000000000061	49	28	28	0	27	JMIR PUBLICATIONS, INC	TORONTO	59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA	1438-8871			J MED INTERNET RES	J. Med. Internet Res.	DEC	2014	16	12					165	177		10.2196/jmir.3751			13	Health Care Sciences & Services; Medical Informatics	Health Care Sciences & Services; Medical Informatics	AW2TH	WOS:000346141400014	25498515	DOAJ Gold, Green Published			2021-06-18	
J	Villalba, N; Sonkusare, SK; Longden, TA; Tran, TL; Sackheim, AM; Nelson, MT; Wellman, GC; Freeman, K				Villalba, Nuria; Sonkusare, Swapnil K.; Longden, Thomas A.; Tran, Tram L.; Sackheim, Adrian M.; Nelson, Mark T.; Wellman, George C.; Freeman, Kalev			Traumatic Brain Injury Disrupts Cerebrovascular Tone Through Endothelial Inducible Nitric Oxide Synthase Expression and Nitric Oxide Gain of Function	JOURNAL OF THE AMERICAN HEART ASSOCIATION			English	Article						cerebral artery; endothelium-derived factors; myogenic tone; nitric oxide; traumatic brain injury; vascular endothelial function; vascular reactivity		Background-Traumatic brain injury (TBI) has been reported to increase the concentration of nitric oxide (NO) in the brain and can lead to loss of cerebrovascular tone; however, the sources, amounts, and consequences of excess NO on the cerebral vasculature are unknown. Our objective was to elucidate the mechanism of decreased cerebral artery tone after TBI. Methods and Results-Cerebral arteries were isolated from rats 24 hours after moderate fluid-percussion TBI. Pressure-induced increases in vasoconstriction (myogenic tone) and smooth muscle Ca2+ were severely blunted in cerebral arteries after TBI. However, myogenic tone and smooth muscle Ca2+ were restored by inhibition of NO synthesis or endothelium removal, suggesting that TBI increased endothelial NO levels. Live native cell NO, indexed by 4,5-diaminofluorescein (DAF-2 DA) fluorescence, was increased in endothelium and smooth muscle of cerebral arteries after TBI. Clamped concentrations of 20 to 30 nmol/L NO were required to simulate the loss of myogenic tone and increased (DAF-2T) fluorescence observed following TBI. In comparison, basal NO in control arteries was estimated as 0.4 nmol/L. Consistent with TBI causing enhanced NO-mediated vasodilation, inhibitors of guanylyl cyclase, protein kinase G, and large-conductance Ca2+-activated potassium (BK) channel restored function of arteries from animals with TBI. Expression of the inducible isoform of NO synthase was upregulated in cerebral arteries isolated from animals with TBI, and the inducible isoform of NO synthase inhibitor 1400W restored myogenic responses following TBI. Conclusions-The mechanism of profound cerebral artery vasodilation after TBI is a gain of function in vascular NO production by 60-fold over controls, resulting from upregulation of the inducible isoform of NO synthase in the endothelium.	[Villalba, Nuria; Sonkusare, Swapnil K.; Longden, Thomas A.; Nelson, Mark T.; Wellman, George C.; Freeman, Kalev] Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA; [Tran, Tram L.; Sackheim, Adrian M.; Freeman, Kalev] Univ Vermont, Dept Surg, Burlington, VT 05405 USA; [Nelson, Mark T.] Univ Manchester, Inst Cardiovasc Sci, Manchester, Lancs, England	Freeman, K (corresponding author), Univ Vermont, Given E301, Burlington, VT 05405 USA.	Kalev.Freeman@uvm.edu		Longden, Thomas/0000-0002-7950-7677; Nelson, Mark/0000-0002-6608-8784	American Heart Association fellowshipsAmerican Heart Association [13POST14820015, 12POST12090001]; Totman Medical Research Trust; Fondation LeducqLeducq Foundation; Peter A. Martin Brain Aneurysm Research Fund; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20-RR-16435, P01-HL-095488, UM1-HL-120877-01, R01-HL-044455, R01-HL-098243, R37-DK-053832, P30-RR-032135-02, P30-GM-103498-02, K08-GM-098795-01, K99-HL-121484-01, R01-HL-121706-01]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016435, P30RR032135] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL044455, K99HL121484, R01HL121706, UM1HL120877, P01HL095488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R37DK053832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08GM098795, P30GM103498] Funding Source: NIH RePORTER	American Heart Association fellowships to Drs Villalba, Longden (13POST14820015, 12POST12090001); and additional funding from the Totman Medical Research Trust, Fondation Leducq, Peter A. Martin Brain Aneurysm Research Fund, and National Institutes of Health (P20-RR-16435, P01-HL-095488, UM1-HL-120877-01, R01-HL-044455, R01-HL-098243, R37-DK-053832, P30-RR-032135-02, P30-GM-103498-02, K08-GM-098795-01, K99-HL-121484-01, R01-HL-121706-01).	Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC; Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; Bellamy TC, 2002, J BIOL CHEM, V277, P31801, DOI 10.1074/jbc.M205936200; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cheng JJ, 1999, CHINESE J PHYSIOL, V42, P103; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; DACEY RG, 1982, AM J PHYSIOL, V243, pH598; Faraci FM, 1998, PHYSIOL REV, V78, P53; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; Foley LM, 2013, J CEREBR BLOOD F MET, V33, P129, DOI 10.1038/jcbfm.2012.145; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Golding EA, 2003, J CEREBR BLOOD F MET, V23, P210, DOI 10.1097/01.WCB.0000044739.64940.B5; Golding EM, 1998, J NEUROTRAUM, V15, P973, DOI 10.1089/neu.1998.15.973; Golding EM, 2001, J NEUROTRAUM, V18, P691, DOI 10.1089/089771501750357636; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; Griffiths C, 2003, MOL PHARMACOL, V64, P1349, DOI 10.1124/mol.64.6.1349; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hah JM, 2001, J MED CHEM, V44, P2667, DOI 10.1021/jm0101491; Hall CN, 2009, NITRIC OXIDE-BIOL CH, V21, P92, DOI 10.1016/j.niox.2009.07.002; Hannah RM, 2011, J CEREBR BLOOD F MET, V31, P1175, DOI 10.1038/jcbfm.2010.214; Held KF, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00130; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Hishikawa K, 1997, CIRCULATION, V96, P3610; Hofmann F, 2000, J CELL SCI, V113, P1671; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; Kojima H, 1998, CHEM PHARM BULL, V46, P373; Larson BE, 2012, J SURG RES, V173, pE73, DOI 10.1016/j.jss.2011.09.056; Ledoux J, 2008, P NATL ACAD SCI USA, V105, P9627, DOI 10.1073/pnas.0801963105; Li Q, 2013, STROKE, V44, P3183, DOI 10.1161/STROKEAHA.113.002073; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Longden TA, 2014, P NATL ACAD SCI USA, V111, P7462, DOI 10.1073/pnas.1401811111; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NELSON MT, 1990, NATURE, V344, P770, DOI 10.1038/344770a0; Nystoriak MA, 2011, AM J PHYSIOL-HEART C, V300, pH803, DOI 10.1152/ajpheart.00760.2010; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; PELLIGRINO DA, 1993, J CEREBR BLOOD F MET, V13, P80, DOI 10.1038/jcbfm.1993.10; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Porter VA, 1998, AM J PHYSIOL-CELL PH, V274, pC1346; Rafols D, 2004, NEUROSCI LETT, V362, P154, DOI 10.1016/j.neulet.2004.03.021; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sonkusare SK, 2012, SCIENCE, V336, P597, DOI 10.1126/science.1216283; Takimoto Y, 2002, CIRCULATION, V105, P490, DOI 10.1161/hc0402.102662; Terpolilli NA, 2013, J CEREBR BLOOD F MET, V33, P311, DOI 10.1038/jcbfm.2012.176; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wei L, 2014, CLIN EXP PHARMACOL P, V41, P134, DOI 10.1111/1440-1681.12186; Wellman GC, 2003, CELL CALCIUM, V34, P211, DOI 10.1016/S0143-4160(03)00124-6; Wellman GC, 1996, CIRC RES, V79, P1024, DOI 10.1161/01.RES.79.5.1024; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yi FX, 2002, AM J PHYSIOL-HEART C, V283, pH2725, DOI 10.1152/ajpheart.00428.2002; Yu GX, 2014, J NEUROTRAUM, V31, P739, DOI 10.1089/neu.2013.3187; YUAN X-Q, 1990, Journal of Neurotrauma, V7, P141, DOI 10.1089/neu.1990.7.141; Zhang P, 2007, CIRC RES, V100, P1089, DOI 10.1161/01.RES.0000264081.78659.45	69	28	29	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2047-9980			J AM HEART ASSOC	J. Am. Heart Assoc.	DEC	2014	3	6							e001474	10.1161/JAHA.114.001474			17	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	V61EX	WOS:000210882600036	25527626	DOAJ Gold, Green Published			2021-06-18	
J	Lu, P; Kamboj, A; Gibson, SB; Anderson, CM				Lu, Ping; Kamboj, Amit; Gibson, Spencer B.; Anderson, Christopher M.			Poly(ADP-Ribose) Polymerase-1 Causes Mitochondrial Damage and Neuron Death Mediated by Bnip3	JOURNAL OF NEUROSCIENCE			English	Article						apoptosis-inducing factor; Bnip3; ischemia; mitochondrial permeability; PARP; sirtuin	TRAUMATIC BRAIN INJURY; CELL-DEATH; NAD(+) DEPLETION; TRANSCRIPTION FACTOR; DNA DAMAGE; APOPTOSIS; INHIBITION; METABOLISM; SIRT1; PARP	Excessive pathophysiological activity of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP1) causes neuron death in brain hypoxia/ischemia by inducing mitochondrial permeability transition and nuclear translocation of apoptosis-inducing factor (AIF). Bcl-2/adenovirus E1B 19 kDa-interacting protein (Bnip3) is a prodeath BH3-only Bcl-2 protein family member that is induced in hypoxia, and has effects on mitochondrial permeability and neuronal survival similar to those caused by PARP1 activation. We hypothesized that Bnip3 is a critical mediator of PARP1-induced mitochondrial dysfunction and neuron death. Hypoxic death of mouse cortical neuron cultures was mitigated by deletion of either PARP1 or Bnip3, indicating that both factors are involved. Direct normoxic PARP1 activation by a DNA alkylating agent enhanced Bnip3 expression, and caused Bnip3-dependent mitochondrial membrane permeability, AIF translocation, and neuron death. Hypoxia produced PARP1-dependent depletion of nicotinamide adenine dinucleotide (NAD(+)) and inhibition of the NAD(+)-dependent class III histone deactelyase (HDAC) sirtuin-1 (SIRT1). This, in turn, led to hyperacetylation and nuclear localization of the forkhead box (Fox) protein FoxO3a, followed by enhanced association of FoxO3a with the Bnip3 upstream promoter region, increased levels of Bnip3 transcript, and elevated mitochondrial Bnip3 immunoreactivity. Finally, FoxO3a silencing using a lentiviral short hairpin RNA approach significantly reduced hypoxic Bnip3 expression, mitochondrial damage, and neuron death. Together, these data illustrate a direct PARP1-mediated hypoxic signaling pathway involving NAD(+) depletion, SIRT1 inhibition, FoxO3a-driven Bnip3 generation, and mitochondrial AIF release.	[Lu, Ping; Kamboj, Amit; Anderson, Christopher M.] Univ Manitoba, Winnipeg Hlth Sci Ctr, Kleysen Inst Adv Med, Neurosci Res Program, Winnipeg, MB R3E 0Z3, Canada; [Lu, Ping; Kamboj, Amit; Anderson, Christopher M.] Univ Manitoba, Coll Med, Winnipeg, MB R3E 0Z3, Canada; [Lu, Ping; Kamboj, Amit; Anderson, Christopher M.] Univ Manitoba, Coll Med, Dept Pharmacol & Therapeut, Winnipeg, MB R3E 0T6, Canada; [Gibson, Spencer B.] Manitoba Inst Cell Biol, Winnipeg, MB R3E 0T3, Canada	Anderson, CM (corresponding author), Kleysen Inst Adv Med, Hlth Sci Ctr, Neurosci Res Program, 710 William Ave,SR452, Winnipeg, MB R3E 0Z3, Canada.	chris.anderson@med.umanitoba.ca		Anderson, Christopher/0000-0003-0678-3002; Gibson, Spencer/0000-0003-0119-732X	Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Research Manitoba	This work was supported by the Heart and Stroke Foundation of Canada. P.L. and A.K. were supported by postdoctoral fellowships from Research Manitoba. C.M.A. holds a Manitoba Research Chair from Research Manitoba. We thank Dr. Gerald Dorn for providing bnip3<SUP>-/-</SUP> mice, and Dr. Jiming Kong for providing the Bnip3 antibody.	Akhter R, 2014, J BIOL CHEM, V289, P10812, DOI 10.1074/jbc.M113.519355; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; Almeida A, 1998, BRAIN RES PROTOC, V2, P209, DOI 10.1016/S1385-299X(97)00044-5; Althaus J, 2006, NEUROCHEM INT, V48, P687, DOI 10.1016/j.neuint.2005.12.008; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Andrabi SA, 2014, P NATL ACAD SCI USA, V111, P10209, DOI 10.1073/pnas.1405158111; Bai P, 2011, CELL METAB, V13, P461, DOI 10.1016/j.cmet.2011.03.004; Baxter P, 2014, TRANSL STROKE RES, V5, P136, DOI 10.1007/s12975-013-0283-0; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chen Y, 2010, P NATL ACAD SCI USA, V107, P9035, DOI 10.1073/pnas.0914013107; Chinnadurai G, 2008, ONCOGENE, V27, pS114, DOI 10.1038/onc.2009.49; COHEN A, 1987, ARCH BIOCHEM BIOPHYS, V258, P498, DOI 10.1016/0003-9861(87)90371-7; Cosi C, 1999, ANN NY ACAD SCI, V890, P227, DOI 10.1111/j.1749-6632.1999.tb07998.x; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Diwan A, 2007, J CLIN INVEST, V117, P2825, DOI 10.1172/JCI32490; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Fatokun AA, 2014, BRIT J PHARMACOL, V171, P2000, DOI 10.1111/bph.12416; Ghosh AP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039586; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Hagenbuchner J, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00147; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hunt WT, 2010, J NEUROCHEM, V115, P123, DOI 10.1111/j.1471-4159.2010.06908.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Pillai JB, 2005, J BIOL CHEM, V280, P43121, DOI 10.1074/jbc.M506162200; Qi YM, 2012, J CELL BIOL, V198, P103, DOI 10.1083/jcb.201111063; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Tang KS, 2010, GLIA, V58, P446, DOI 10.1002/glia.20936; Thompson JW, 2012, LIFE SCI, V91, P223, DOI 10.1016/j.lfs.2012.03.034; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wang F, 2013, STEM CELL RES, V11, P657, DOI 10.1016/j.scr.2013.04.005; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Won SJ, 2012, J NEUROTRAUM, V29, P1401, DOI 10.1089/neu.2011.2228; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang ZF, 2007, STROKE, V38, P1606, DOI 10.1161/STROKEAHA.106.475129; Zhang ZF, 2011, FEBS J, V278, P134, DOI 10.1111/j.1742-4658.2010.07939.x	47	28	31	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 26	2014	34	48					15975	15987		10.1523/JNEUROSCI.2499-14.2014			13	Neurosciences	Neurosciences & Neurology	AU9OJ	WOS:000345923600015	25429139	Green Published, Bronze			2021-06-18	
J	Roberts, RM; Mathias, JL; Rose, SE				Roberts, R. M.; Mathias, J. L.; Rose, S. E.			Diffusion Tensor Imaging (DTI) Findings Following Pediatric Non-Penetrating TBI: A Meta-Analysis	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; BEHAVIOR RELATIONSHIPS; HEAD-INJURY; CHILDREN; MODERATE; CHILDHOOD; MEMORY; ABNORMALITIES; ADOLESCENTS	This study meta-analyzed research examining Diffusion Tensor Imaging following pediatric non-penetrating traumatic brain injury to identify the location and extent of white matter changes. Fractional anisotropy (FA) and apparent diffusion coefficient (ADC) data from 20 studies were analyzed. FA increased and ADC decreased in most white matter tracts in the short-term (moderate-to-large effects), and FA decreased and ADC increased in the medium- to long-term (moderate-to-very-large effects). Whole brain (short-term), cerebellum and corpus callosum (medium- to long-term) FA values have diagnostic potential, but the impact of age/developmental stage and injury severity on FA/ADC, and the predictive value, is unclear.	[Roberts, R. M.; Mathias, J. L.] Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia; [Rose, S. E.] Royal Brisbane & Womens Hosp, Australian E Hlth Res Ctr, CSIRO Digital Prod & Serv Flagship, Herston, Qld, Australia	Roberts, RM (corresponding author), Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia.	rachel.roberts@adelaide.edu.au	Meijer, Anna/K-5118-2016; Roberts, Rachel Margaret/AAE-5712-2020; Rose, Stephen/C-8044-2009	Roberts, Rachel Margaret/0000-0002-9547-9995; Mathias, Jane/0000-0001-8957-8594			Adamson C, 2013, BRAIN INJURY, V27, P454, DOI 10.3109/02699052.2012.750756; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Asarnow R, 1995, TRAUMATIC BRAIN INJU, P117; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Duckworth JL, 2010, CURR OPIN CRIT CARE, V16, P92, DOI 10.1097/MCC.0b013e3283374900; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fleisher GR., 2010, TXB PEDIAT EMERGENCY, VSixth ed.; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hessen E., 2010, PEDIAT TRAUMATIC BRA, P118; Imperati D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023437; Jeurissen B, 2013, HUM BRAIN MAPP, V34, P2747, DOI 10.1002/hbm.22099; Johnson CP, 2011, J INT NEUROPSYCH SOC, V17, P663, DOI 10.1017/S1355617711000464; Jones DK, 2010, NMR BIOMED, V23, P803, DOI 10.1002/nbm.1543; Juranek J, 2012, BRAIN IMAGING BEHAV, V6, P36, DOI 10.1007/s11682-011-9140-5; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Koestler J, 2001, J EMERG MED, V21, P145, DOI 10.1016/S0736-4679(01)00363-8; Kurowski B, 2009, J PEDIATR REHAB MED, V2, P273, DOI 10.3233/PRM-2009-0093; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lee Bruce, 2005, NeuroRx, V2, P372; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Liegeois F, 2013, NEUROLOGY, V80, P926, DOI 10.1212/WNL.0b013e3182840c6d; Lipsey M.W., 2001, PRACTICAL META ANAL; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Mathias JL, 2013, BRAIN INJURY, V27, P887, DOI 10.3109/02699052.2013.793398; Max JE, 2012, J AM ACAD CHILD PSY, V51, P1208, DOI 10.1016/j.jaac.2012.08.026; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; Mills KL, 2014, DEV COGN NEUROS-NETH, V9, P172, DOI 10.1016/j.dcn.2014.04.004; Mori S., 2007, INTRO DIFFUSION TENS; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; ROSENTHAL R, 1995, PSYCHOL BULL, V118, P183, DOI 10.1037/0033-2909.118.2.183; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheibel RS, 2011, SOC NEUROSCI-UK, V6, P582, DOI 10.1080/17470919.2011.588844; Schmidt AT, 2013, BRAIN INJURY, V27, P1528, DOI 10.3109/02699052.2013.828851; Tasker RC, 2010, DEV NEUROSCI-BASEL, V32, P374, DOI 10.1159/000316806; Taylor H. G., 2010, PEDIAT TRAUMATIC BRA, P145; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wardlaw JM, 2012, EUR RADIOL, V22, P2295, DOI 10.1007/s00330-012-2500-8; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Winston GP, 2012, QUANT IMAGING MED SU, V2, P254, DOI 10.3978/j.issn.2223-4292.2012.12.05; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Xu D, 2013, PEDIATR RADIOL, V43, P55, DOI 10.1007/s00247-012-2481-4; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE	67	28	28	1	13	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	NOV 17	2014	39	8					600	637		10.1080/87565641.2014.973958			38	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	AU6AS	WOS:000345685100003	25470224	Green Published, Bronze			2021-06-18	
J	Arbour, C; Choiniere, M; Topolovec-Vranic, J; Loiselle, CG; Puntillo, K; Gelinas, C				Arbour, Caroline; Choiniere, Manon; Topolovec-Vranic, Jane; Loiselle, Carmen G.; Puntillo, Kathleen; Gelinas, Celine			Detecting Pain in Traumatic Brain-injured Patients With Different Levels of Consciousness During Common Procedures in the ICU Typical or Atypical Behaviors?	CLINICAL JOURNAL OF PAIN			English	Article						traumatic brain injury; pain; behaviors; pain assessment; intensive care unit	INTENSIVE-CARE-UNIT; CRITICALLY-ILL; OBSERVATION TOOL; RELIABILITY; SCALE; VALIDATION; ADULT; PREVALENCE; SEVERITY; VALIDITY	Purpose: Pain behaviors such as grimacing and muscle rigidity are recommended for pain assessment in nonverbal populations. However, these behaviors may not be appropriate for critically ill patients with a traumatic brain injury (TBI) depending on their level of consciousness (LOC). This study aimed to validate the use of behaviors for assessing pain of critically ill TBI adults with different LOC. Methods: Using a repeated measure within subject design, participants (N = 45) were observed for 1 minute before (baseline), during, and 15 minutes after 2 procedures: (1) noninvasive blood pressure: NIBP (non-nociceptive); and (2) turning (nociceptive). A behavioral checklist combining 50 items from existing pain assessment tools and video recording were used to describe participants' behaviors. Intrarater and interrater agreements of observed behaviors were also examined. Results: Overall, pain behaviors were observed more frequently during turning (median = 4; T = -5.336; P <= 0.001) than at baseline (median = 1), or during noninvasive blood pressure (median = 0). TBI patients' pain behaviors were mostly "atypical" and included uncommon responses such as flushing, sudden eye opening, eye weeping, and flexion of limbs. These behaviors were observed in >= 25.0% of TBI participants during turning independent of their LOC, and in 22.2% to 66.7% of conscious participants who reported the presence of pain. Agreements were > 92% among and between the 2 raters. Conclusions: This study support previous findings that critically ill TBI patients could exhibit atypical behaviors when exposed to nociceptive procedures. As such, use of current recommended pain behaviors as part of standardized scales may not be optimal for assessing the analgesic needs of this vulnerable group.	[Arbour, Caroline; Loiselle, Carmen G.; Gelinas, Celine] McGill Univ, Ingram Sch Nursing, Montreal, PQ H3A 2A7, Canada; [Arbour, Caroline; Loiselle, Carmen G.; Gelinas, Celine] McGill Univ, Jewish Gen Hosp, Centre Nursing Res, Montreal, PQ H3T 1E2, Canada; [Arbour, Caroline; Loiselle, Carmen G.; Gelinas, Celine] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; [Arbour, Caroline; Loiselle, Carmen G.; Gelinas, Celine] Quebec Nursing Intervent Res Network RRISIQ, Montreal, PQ, Canada; [Arbour, Caroline; Gelinas, Celine] McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ H3A 2A7, Canada; [Choiniere, Manon] Univ Montreal, CRCHUM, Montreal, PQ, Canada; [Topolovec-Vranic, Jane] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Trauma & Neurosurg Program, Toronto, ON M5B 1W8, Canada; [Puntillo, Kathleen] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA	Gelinas, C (corresponding author), McGill Univ, Ingram Sch Nursing, 3506 Univ St, Montreal, PQ H3A 2A7, Canada.	celine.gelinas@mcgill.ca	Topolovec-Vranic, Jane/A-5293-2013	Topolovec-Vranic, Jane/0000-0001-7695-4212; Loiselle, Carmen/0000-0002-1981-2645	Louise and Alan Edwards Foundation; Canadian Institutes of Health Research (CIHR), CanadaCanadian Institutes of Health Research (CIHR) [258 867]; Fonds de la Recherche du Quebec-Sante (FRQ-S), Montreal, Qc, Canada [25094]; Quebec Nursing Intervention Research Network (RRISIQ), Montreal, Qc, Canada; Louise and Alan Edwards; FRQ-S; Quebec Ministry of Education (FRESIQ-MELS program)	This study was initially funded by a pilot research grant from the Louise and Alan Edwards Foundation, and is part of a larger research program funded by the Canadian Institutes of Health Research (CIHR #258 867), Canada; and the Fonds de la Recherche du Quebec-Sante (FRQ-S #25094), Montreal, Qc, Canada; held by the principal investigator (C. G.). Part of this study was also funded by a research grant from the Quebec Nursing Intervention Research Network (RRISIQ), Montreal, Qc, Canada; and 3 PhD studentship awards (C. A.) from the Louise and Alan Edwards, the FRQ-S, and by the Quebec Ministry of Education (FRESIQ-MELS program). The authors declare no conflict of interest.	Ahlers SJGM, 2010, ANESTH ANALG, V110, P127, DOI 10.1213/ANE.0b013e3181c3119e; Aissaoui Y, 2005, ANESTH ANALG, V101, P1470, DOI 10.1213/01.ANE.0000182331.68722.FF; American Pain Society, 2003, PRINC AN US TREATM A; Arbour C, 2013, RECH SOINS INFIRM, P46, DOI 10.3917/rsi.112.0046; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Benditt JO, 2006, RESPIR CARE, V51, P829; Berben SAA, 2008, INJURY, V39, P578, DOI 10.1016/j.injury.2007.04.013; Chahine LM, 2006, EPILEPSY BEHAV, V8, P610, DOI 10.1016/j.yebeh.2006.01.017; Dunwoody Colleen J, 2008, J Perianesth Nurs, V23, pS15, DOI 10.1016/j.jopan.2007.11.007; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Gelinas C, 2008, PAIN MANAG NURS, V9, P120, DOI 10.1016/j.pmn.2007.12.001; Gelinas Celine, 2007, Perspect Infirm, V4, P12; Gelinas C, 2007, CLIN J PAIN, V23, P497, DOI 10.1097/ajp.0b013e31806a23fb; Gelinas C, 2006, AM J CRIT CARE, V15, P420; Gelinas C, 2013, SEMIN RESP CRIT CARE, V34, P153, DOI 10.1055/s-0033-1342970; Gelinas C, 2011, INT J NURS STUD, V48, P1495, DOI 10.1016/j.ijnurstu.2011.03.012; Gelinas C, 2009, J CRIT CARE, V24, DOI 10.1016/j.jcrc.2009.01.013; GOODWIN LD, 1981, RES NURS HEALTH, V4, P323, DOI 10.1002/nur.4770040308; Haidet KK, 2009, RES NURS HEALTH, V32, P465, DOI 10.1002/nur.20334; Herr K, 2011, PAIN MANAG NURS, V12, P230, DOI 10.1016/j.pmn.2011.10.002; Kastrup M, 2009, J INT MED RES, V37, P1267, DOI 10.1177/147323000903700502; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kreipke CW, 2009, J CELL MOL MED, V13, P262, DOI 10.1111/j.1582-4934.2008.00508.x; Le Q, 2013, PAIN MANAG NURS, V14, pE251, DOI 10.1016/j.pmn.2012.02.005; Marmo L, 2010, PAIN MANAG NURS, V11, P134, DOI 10.1016/j.pmn.2009.05.007; McHugh ML, 2011, BIOCHEM MEDICA, V21, P203; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; Puntillo K A, 2001, Am J Crit Care, V10, P238; Puntillo KA, 2004, CRIT CARE MED, V32, P421, DOI 10.1097/01.CCM.0000108875.35298.D2; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; Samuel M. L., 2012, STAT LIFE SCI; Schnakers C, 2010, PAIN, V148, P215, DOI 10.1016/j.pain.2009.09.028; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Stanik-Hutt J A, 2001, Am J Crit Care, V10, P252; Streiner D.L., 2008, HLTH MEASUREMENT SCA; TEASDALE G, 1974, LANCET, V2, P81	38	28	29	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	NOV	2014	30	11					960	969		10.1097/AJP.0000000000000061			10	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	AR0GG	WOS:000343247000005	24480910				2021-06-18	
J	Gershengorn, HB; Wunsch, H; Scales, DC; Zarychanski, R; Rubenfeld, G; Garland, A				Gershengorn, Hayley B.; Wunsch, Hannah; Scales, Damon C.; Zarychanski, Ryan; Rubenfeld, Gordon; Garland, Allan			Association Between Arterial Catheter Use and Hospital Mortality in Intensive Care Units	JAMA INTERNAL MEDICINE			English	Article							CRITICALLY-ILL PATIENTS; CENTRAL VENOUS CATHETER; RANDOMIZED CONTROLLED-TRIAL; BLOOD-PRESSURE-MEASUREMENT; DISCOVERED ADRENAL MASSES; TRAUMATIC BRAIN-INJURY; PULMONARY-ARTERY; STREAM INFECTION; SEPTIC SHOCK; HIGH-RISK	IMPORTANCE Arterial catheters are used frequently in intensive care units (ICUs). Clinical effectiveness and adverse events associated with the use of the catheters have not been formally evaluated in clinical studies. OBJECTIVE To determine whether an association exists between arterial catheter use and hospital mortality in ICU patients. DESIGN, SETTING, AND PARTICIPANTS Propensity-matched cohort analysis of data in the Project IMPACT database, from 2001 to 2008. A total of 139 ICUs in the United States were included. Participants were ICU patients 18 years or older. EXPOSURE Arterial catheter use. MAIN OUTCOMES AND MEASURES Our main outcome was hospital mortality. We assessed a primary cohort of medical patients requiring mechanical ventilation and 9 secondary cohorts. We used propensity score-matched pairs as the primary analytic strategy. Sensitivity analyses included 4 alternative methods of comparison in the primary cohort: multivariate modeling without propensity adjustment, mixed-effects multivariate logistic regression without propensity adjustment, multivariate modeling with propensity adjustment, and stratification based on propensity quintiles. RESULTS Our primary cohort consisted of 60 975 patients; 24 126 of these patients (39.6%) had an arterial catheter in place during their ICU stay, and analyses were based on 13 603 propensity score-matched pairs. We found no association between arterial catheter use and hospital mortality in medical patients requiring mechanical ventilation in the primary analysis (odds ratio [OR], 0.98; 95% CI, 0.93-1.03; P = .40) or the 4 sensitivity analyses (P >= .58 for all). In 8 of 9 secondary cohorts we were unable to detect an association between arterial catheter use and hospital mortality. In the cohort of patients receiving vasopressors, arterial catheter use was associated with an increased odds of death (OR, 1.08; 95% CI, 1.02-1.14; P = .008). CONCLUSIONS AND RELEVANCE In this propensity-matched cohort analysis, arterial catheters were not associated with improvements in hospital mortality in medical ICU patients requiring mechanical ventilation. Given the costs and potential harms associated with invasive catheters, randomized clinical trials are needed to further evaluate the usefulness of these frequently used devices.	[Gershengorn, Hayley B.] Montefiore Med Ctr, Div Crit Care Med, Bronx, NY 10467 USA; [Wunsch, Hannah] Columbia Univ, Dept Anesthesiol, New York, NY USA; [Wunsch, Hannah] Columbia Univ, Dept Epidemiol, New York, NY USA; [Scales, Damon C.] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada; [Rubenfeld, Gordon] Univ Toronto, Sch Med, Dept Med, Toronto, ON, Canada; [Rubenfeld, Gordon] Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON M4N 3M5, Canada; [Garland, Allan] Univ Manitoba, Dept Med & Community Hlth Sci, Winnipeg, MB, Canada	Gershengorn, HB (corresponding author), Montefiore Med Ctr, Div Crit Care Med, 111 E 210th St,Gold Zone,Main Floor, Bronx, NY 10467 USA.	hgershen@montefiore.org		Zarychanski, Ryan/0000-0001-9455-6138; Garland, Allan/0000-0001-7129-936X	Physicians' Services Incorporated Foundation	Dr Scales is supported by a fellowship in Translational Health Research from the Physicians' Services Incorporated Foundation.	American Society of Anesthesiologists, STAND PRACT PAR STAN; [Anonymous], 1871, BMJ-BRIT MED J, V1, P283, DOI DOI 10.1136/BMJ.1.533.283; [Anonymous], 2003, DAT COLL THER DRUGS, P77; Arpino B, 2011, COMPUT STAT DATA AN, V55, P1770, DOI 10.1016/j.csda.2010.11.008; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Blackstone EH, 2002, J THORAC CARDIOV SUR, V123, P8, DOI 10.1067/mtc.2002.120329; Brady WJ, 2011, RESUSCITATION, V82, P845, DOI 10.1016/j.resuscitation.2011.02.028; Branco BC, 2012, INJURY, V43, P78, DOI 10.1016/j.injury.2010.12.003; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; Bur A, 2003, CRIT CARE MED, V31, P793, DOI 10.1097/01.CCM.0000053650.12025.1A; Bur A, 2000, CRIT CARE MED, V28, P371, DOI 10.1097/00003246-200002000-00014; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cleverley K, 2013, RESUSCITATION, V84, P878, DOI 10.1016/j.resuscitation.2013.01.038; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; COCHRAN WG, 1968, BIOMETRICS, V24, P295, DOI 10.2307/2528036; Coldman AJ, 2012, CAN J PUBLIC HEALTH, V103, pE420, DOI 10.1007/BF03405630; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Cook SF, 2002, CRIT CARE MED, V30, P2765, DOI 10.1097/00003246-200212000-00024; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Esteve F, 2011, J INFECTION, V63, P139, DOI 10.1016/j.jinf.2011.05.020; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Fraser, 2010, PROPENSITY SCORE ANA; Gaertner WB, 2010, ANN VASC SURG, V24, DOI 10.1016/j.avsg.2009.07.039; Garland A, 2010, AM J RESP CRIT CARE, V182, P133, DOI 10.1164/rccm.201003-0410ED; Gershengorn HB, 2014, ANESTHESIOLOGY, V120, P650, DOI 10.1097/ALN.0000000000000008; Gershengorn HB, 2013, CRIT CARE MED, V41, P2667, DOI 10.1097/CCM.0b013e318298a41e; Gowardman JR, 2010, J HOSP INFECT, V75, P12, DOI 10.1016/j.jhin.2010.01.005; Harvey S, 2005, LANCET, V366, P472, DOI 10.1016/S0140-6736(05)67061-4; Higgins TL, 2007, CRIT CARE MED, V35, P827, DOI 10.1097/01.CCM.0000257337.63529.9F; Hubbard RA, 2011, ANN INTERN MED, V155, P481, DOI 10.7326/0003-4819-155-8-201110180-00004; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Koh DBC, 2008, CRIT CARE MED, V36, P397, DOI 10.1097/CCM.0b013e318161f74b; Koo KKY, 2011, CRIT CARE MED, V39, P1613, DOI 10.1097/CCM.0b013e318218a045; Kumar A, 2010, CRIT CARE MED, V38, P1773, DOI 10.1097/CCM.0b013e3181eb3ccd; Lakhal K, 2012, CRIT CARE MED, V40, P1207, DOI 10.1097/CCM.0b013e31823dae42; Lee JE, 1998, SURGERY, V124, P1115, DOI 10.1067/msy.1998.92009; Leuven E., PSMATCH2 STATA MODUL; LOW LL, 1995, CHEST, V108, P216, DOI 10.1378/chest.108.1.216; Lucet JC, 2010, CRIT CARE MED, V38, P1030, DOI 10.1097/CCM.0b013e3181d4502e; Lumachi F, 2007, TUMORI, V93, P269; Lunt M., PBALCHK STATA MODULE; Maki DG, 2006, MAYO CLIN PROC, V81, P1159, DOI 10.4065/81.9.1159; Manios E, 2007, BLOOD PRESS MONIT, V12, P149, DOI 10.1097/MBP.0b013e3280b083e2; MANTEL N, 1959, J NATL CANCER I, V22, P719; Marrie RA, 2009, J CLIN EPIDEMIOL, V62, P511, DOI 10.1016/j.jclinepi.2008.05.015; Mettes TG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003879.pub3; MUAKKASSA FF, 1990, J TRAUMA, V30, P1087, DOI 10.1097/00005373-199009000-00004; Nazeri A, 2011, ACTA CLIN BELG, V66, P223, DOI 10.2143/ACB.66.3.2062552; O'Horo JC, 2014, CRIT CARE MED, V42, P1334, DOI 10.1097/CCM.0000000000000166; Pedersen T, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002013.pub2; Prasad V, 2013, JAMA-J AM MED ASSOC, V309, P241, DOI 10.1001/jama.2012.96867; Quayle FJ, 2007, SURGERY, V142, P497, DOI 10.1016/j.surg.2007.07.013; Richard C, 2003, JAMA-J AM MED ASSOC, V290, P2713, DOI 10.1001/jama.290.20.2713; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; Schull MJ, 2000, ACAD EMERG MED, V7, P647, DOI 10.1111/j.1553-2712.2000.tb02038.x; SHINOZAKI T, 1983, JAMA-J AM MED ASSOC, V249, P223, DOI 10.1001/jama.249.2.223; Smith JA, 2005, J ECONOMETRICS, V125, P305, DOI 10.1016/j.jeconom.2004.04.011; Suissa S, 2007, PHARMACOEPIDEM DR S, V16, P241, DOI 10.1002/pds.1357; Sweet BV, 2011, J MANAGE CARE PHARM, V17, P40, DOI 10.18553/jmcp.2011.17.1.40; Thoemmes FJ, 2011, MULTIVAR BEHAV RES, V46, P514, DOI 10.1080/00273171.2011.569395; Traore O, 2005, CRIT CARE MED, V33, P1276, DOI 10.1097/01.CCM.0000166350.90812.D4; Valentine RJ, 2005, J AM COLL SURGEONS, V201, P18, DOI 10.1016/j.jamcollsurg.2005.01.011; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213; Wiener RS, 2007, JAMA-J AM MED ASSOC, V298, P423, DOI 10.1001/jama.298.4.423; Zarychanski R, 2008, CRIT CARE MED, V36, P2973, DOI 10.1097/CCM.0b013e31818b8c6b; Zhou Z, 2005, AM J EPIDEMIOL, V162, P1016, DOI 10.1093/aje/kwi307; Zimmerman JE, 1997, CRIT CARE MED, V25, P737, DOI 10.1097/00003246-199705000-00006; Zuur A, 2003, ZERO TRUNCATED ZERO, P261	69	28	28	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6106	2168-6114		JAMA INTERN MED	JAMA Intern. Med.	NOV	2014	174	11					1746	1754		10.1001/jamainternmed.2014.3297			9	Medicine, General & Internal	General & Internal Medicine	AU9KA	WOS:000345909900011	25201069	Bronze			2021-06-18	
J	Wu, LC; Zarnescu, L; Nangia, V; Cam, B; Camarillo, DB				Wu, Lyndia C.; Zarnescu, Livia; Nangia, Vaibhav; Cam, Bruce; Camarillo, David B.			A Head Impact Detection System Using SVM Classification and Proximity Sensing in an Instrumented Mouthguard	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						Impact detection; infrared proximity sensing; support vector machines (SVMs); traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; BRAIN-INJURY; CONCUSSION; EXPOSURE; VALIDATION; KINEMATICS	Injury from blunt head impacts causes acute neurological deficits and may lead to chronic neurodegeneration. A head impact detection device can serve both as a research tool for studying head injury mechanisms and a clinical tool for real-time trauma screening. The simplest approach is an acceleration thresholding algorithm, which may falsely detect high-acceleration spurious events such as manual manipulation of the device. We designed a head impact detection system that distinguishes head impacts from nonimpacts through two subsystems. First, we use infrared proximity sensing to determine if the mouthguard is worn on the teeth to filter out all off-teeth events. Second, on-teeth, non-impact events are rejected using a support vector machine classifier trained on frequency domain features of linear acceleration and rotational velocity. The remaining events are classified as head impacts. In a controlled laboratory evaluation, the present system performed substantially better than a 10-g acceleration threshold in head impact detection (98% sensitivity, 99.99% specificity, 99% accuracy, and 99.98% precision, compared to 92% sensitivity, 58% specificity, 65% accuracy, and 37% precision). Once adapted for field deployment by training and validation with field data, this system has the potential to effectively detect head trauma in sports, military service, and other high-risk activities.	[Wu, Lyndia C.; Zarnescu, Livia; Camarillo, David B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Nangia, Vaibhav; Cam, Bruce] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA	Camarillo, DB (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.	lyndiacw@stanford.edu; liviaz@stanford.edu; vnangia@stanford.edu; bcam@stanford.edu; dcamarillo@stanford.edu	Wu, Lyndia/AAQ-1106-2020	Wu, Lyndia/0000-0002-8236-032X	Stanford Department of Athletics	The authors would like to thank the Stanford Department of Athletics for their support in this research. A patent application has been filed for the technology described in this paper and will be assigned to Stanford University [49]. Royalties gained from any intellectual property granted for this work will be shared among the inventors, the department, and the school, according to Stanford's technology licensing policies.	Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Asada G., 1998, ESSCIRC '98. Proceedings of the 24th European Solid-State Circuits Conference, P9; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Benet G, 2002, ROBOT AUTON SYST, V40, P255, DOI 10.1016/S0921-8890(02)00271-3; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Cam B., 2014, U.S. Patent, Patent No. [14/199 716, 14199716]; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010; Fawcett Tom., 2004, MACH LEARN, V31, P1, DOI DOI 10.1016/J.PATREC.2005.10.010; FRIED D, 1995, APPL OPTICS, V34, P1278, DOI 10.1364/AO.34.001278; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; GEISSER S, 1975, J AM STAT ASSOC, V70, P320, DOI 10.2307/2285815; Greenwald R. M., 2005, U.S. Patent, Patent No. [11/031 970, 11031970]; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guyon I., 2003, Journal of Machine Learning Research, V3, P1157, DOI 10.1162/153244303322753616; Gwin J. T., 2009, J ASTM INT, V6, P1; Hinckley K., 2000, UIST. Proceedings of the 13th Annual ACM Symposium on User Interface Software and Technology, P91; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hummel JB, 2005, MED PHYS, V32, P2371, DOI 10.1118/1.1944327; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Joiner A, 2004, J DENT, V32, P3, DOI 10.1016/j.jdent.2003.10.013; Jordan BD, 1996, AM J SPORT MED, V24, P704, DOI 10.1177/036354659602400526; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kim Y, 2009, IEEE T GEOSCI REMOTE, V47, P1328, DOI 10.1109/TGRS.2009.2012849; LANGER R, 1981, J BIOMED MATER RES, V15, P267, DOI 10.1002/jbm.820150212; Magne P, 2003, J PROSTHET DENT, V89, P453, DOI 10.1016/S0022-3913(03)00125-2; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; Ravi Nishkam, 2005, AAAI, P1541, DOI DOI 10.1007/978-3-642-02481-8_120; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schuldt C, 2004, INT C PATT RECOG, P32, DOI 10.1109/ICPR.2004.1334462; Wang SQ, 2005, PROCEEDINGS OF THE 2005 INTERNATIONAL CONFERENCE ON NEURAL NETWORKS AND BRAIN, VOLS 1-3, P1212; Westerman B, 2002, DENT TRAUMATOL, V18, P24, DOI 10.1034/j.1600-9657.2002.180103.x; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Xu QS, 2001, CHEMOMETR INTELL LAB, V56, P1, DOI 10.1016/S0169-7439(00)00122-2	47	28	28	0	25	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9294	1558-2531		IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	NOV	2014	61	11					2659	2668		10.1109/TBME.2014.2320153			10	Engineering, Biomedical	Engineering	AS2AS	WOS:000344082000001	24800918				2021-06-18	
J	Ryan, ME; Palasis, S; Saigal, G; Singer, AD; Karmazyn, B; Dempsey, ME; Dillman, JR; Dory, CE; Garber, M; Hayes, LL; Iyer, RS; Mazzola, CA; Raske, ME; Rice, HE; Rigsby, CK; Sierzenski, PR; Strouse, PJ; Westra, SJ; Wootton-Gorges, SL; Coley, BD				Ryan, Maura E.; Palasis, Susan; Saigal, Gaurav; Singer, Adam D.; Karmazyn, Boaz; Dempsey, Molly E.; Dillman, Jonathan R.; Dory, Christopher E.; Garber, Matthew; Hayes, Laura L.; Iyer, Ramesh S.; Mazzola, Catherine A.; Raske, Molly E.; Rice, Henry E.; Rigsby, Cynthia K.; Sierzenski, Paul R.; Strouse, Peter J.; Westra, Sjirk J.; Wootton-Gorges, Sandra L.; Coley, Brian D.			ACR Appropriateness Criteria Head Trauma-Child	JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY			English	Article						Appropriateness criteria; head trauma; nonaccidental injury; pediatric; CT; MRI	MAGNETIC-RESONANCE SPECTROSCOPY; PEDIATRIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; CERVICAL-SPINE; NEUROBEHAVIORAL OUTCOMES; INTRACRANIAL INJURY; RADIATION-EXPOSURE; UNIQUE FEATURES; DECISION RULE; SKULL	Head trauma is a frequent indication for cranial imaging in children. CT is considered the first line of study for suspected intracranial injury because of its wide availability and rapid detection of acute hemorrhage. However, the majority of childhood head injuries occur without neurologic complications, and particular consideration should be given to the greater risks of ionizing radiation in young patients in the decision to use CT for those with mild head trauma. MRI can detect traumatic complications without radiation, but often requires sedation in children, owing to the examination length and motion sensitivity, which limits rapid assessment and exposes the patient to potential anesthesia risks. MRI may be helpful in patients with suspected nonaccidental trauma, with which axonal shear injury and ischemia are more common and documentation is critical, as well as in those whose clinical status is discordant with CT findings. Advanced techniques, such as diffusion tensor imaging, may identify changes occult by standard imaging, but data are currently insufficient to support routine clinical use. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.	[Ryan, Maura E.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Palasis, Susan] Childrens Hosp Atlanta, Atlanta, GA USA; [Saigal, Gaurav] Univ Miami Hlth Syst, Miami, FL USA; [Singer, Adam D.] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA; [Karmazyn, Boaz] Indiana Univ, James Whitcomb Riley Hosp Children, Indianapolis, IN USA; [Dempsey, Molly E.] Texas Scottish Rite Hosp Crippled Children, Dallas, TX USA; [Dillman, Jonathan R.; Strouse, Peter J.] CS Mott Childrens Hosp, Ann Arbor, MI USA; [Dory, Christopher E.] Childrens Hosp, San Diego, CA USA; [Garber, Matthew] Div Gen & Hosp Pediat, Columbia, SC USA; [Garber, Matthew] Amer Acad Pediat, Elk Grove Village, IL USA; [Hayes, Laura L.] Childrens Healthcare Atlanta, Atlanta, GA USA; [Iyer, Ramesh S.] Seattle Childrens Hosp, Seattle, WA USA; [Mazzola, Catherine A.] New Jersey Pediat Neurosci Inst, Morristown, NJ USA; [Mazzola, Catherine A.] Amer Assoc Neurol Surg, Rolling Meadows, IL USA; [Mazzola, Catherine A.] Illinois Congress Neurol Surg, Schaumburg, IL USA; [Raske, Molly E.] St Paul Radiol PA, St Paul, MN USA; [Rice, Henry E.] Duke Univ, Med Ctr, Durham, NC USA; [Rice, Henry E.] Amer Pediat Surg Assoc, Deerfield, IL USA; [Rigsby, Cynthia K.] Childrens Mem Hosp, Chicago, IL 60614 USA; [Sierzenski, Paul R.] Christiana Care Hlth Syst, Newark, DE USA; [Sierzenski, Paul R.] Amer Coll Emergency Phys, Irving, TX USA; [Westra, Sjirk J.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Wootton-Gorges, Sandra L.] Univ Calif Davis, Sacramento, CA 95817 USA; [Coley, Brian D.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA	Ryan, ME (corresponding author), Ann & Robert H Lurie Childrens Hosp Chicago, 225 E Chicago Ave, Chicago, IL 60611 USA.	mryan@luriechildrens.org	Rigsby, Cynthia/AAC-9351-2019; Palasis, Susan/AAD-3550-2019; Hayes, Laura L./AAS-5574-2020	Coley, Brian/0000-0003-0354-4727; Rigsby, Cynthia/0000-0003-1224-2333	Siemens Medical	Boaz K Karmazyn, MD, receives grant funding for research into CT dose and dose reduction techniques from Siemens Medical, but does not have any ownership in or receive any direct compensation from Siemens Medical.	Amodio J, 2005, PEDIATR RADIOL, V35, P1113, DOI 10.1007/s00247-005-1503-x; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Ashwal S, 2010, DEV NEUROSCI-BASEL, V32, P343, DOI 10.1159/000316801; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bainbridge J, 2012, BRIT J RADIOL, V85, P183, DOI 10.1259/bjr/56169980; BALL WS, 1989, RADIOLOGY, V173, P609, DOI 10.1148/radiology.173.3.2813759; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brown RL, 2001, J PEDIATR SURG, V36, P1107, DOI 10.1053/jpsu.2001.25665; Chen CY, 1996, RADIOLOGY, V201, P389, DOI 10.1148/radiology.201.2.8888229; Teruel GC, 2007, J PEDIATR SURG, V42, P1903, DOI 10.1016/j.jpedsurg.2007.07.020; Crowe L, 2010, ARCH DIS CHILD, V95, P1017, DOI 10.1136/adc.2009.174854; Datta S, 2005, ARCH DIS CHILD, V90, P947, DOI 10.1136/adc.2002.021154; Davis PC, ACR APPROPRIATENESS; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Faul M, TRAUMATIC BRAIN INJU; Ghatan S, 2002, NEUROSURG CLIN N AM, V13, P227, DOI 10.1016/S1042-3680(01)00002-X; Gorelick MH, 2008, ACAD EMERG MED, V15, P812, DOI 10.1111/j.1553-2712.2008.00206.x; Goshen E, 1996, NUCL MED COMMUN, V17, P418, DOI 10.1097/00006231-199605000-00011; Halley Michelle K, 2004, Pediatr Crit Care Med, V5, P230, DOI 10.1097/01.PCC.0000123543.40224.73; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; HOBBS CJ, 1984, ARCH DIS CHILD, V59, P246, DOI 10.1136/adc.59.3.246; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P57; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Holmes JF, 2011, ANN EMERG MED, V58, P315, DOI 10.1016/j.annemergmed.2011.03.060; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jones TS, 2012, AM J SURG, V204, P7, DOI 10.1016/j.amjsurg.2011.07.015; Kadom N, 2014, PEDIATR RADIOL, V44, P839, DOI 10.1007/s00247-014-2874-7; Keiper MD, 1998, NEURORADIOLOGY, V40, P359, DOI 10.1007/s002340050599; Kemp AM, 2011, ARCH DIS CHILD, V96, P1103, DOI 10.1136/archdischild-2011-300630; Kemp AM, 2009, CLIN RADIOL, V64, P473, DOI 10.1016/j.crad.2008.11.011; Kopelman TR, 2011, J TRAUMA, V71, P559, DOI 10.1097/TA.0b013e318226eadd; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Laskey AL, 2004, J PEDIATR-US, V144, P719, DOI 10.1016/j.jpeds.2004.02.023; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Mogbo KI, 1998, RADIOLOGY, V208, P521, DOI 10.1148/radiology.208.2.9680586; Mortazavi MM, 2011, CHILD NERV SYST, V27, P2045, DOI 10.1007/s00381-011-1409-x; Munson S, 2006, PEDIATRICS, V117, P1372, DOI 10.1542/peds.2005-0826; Nakahara K, 2011, J TRAUMA, V70, P180, DOI 10.1097/TA.0b013e3181d76737; Nigrovic LE, 2012, ARCH PEDIAT ADOL MED, V166, P356, DOI 10.1001/archpediatrics.2011.1156; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Pickering A, 2011, ARCH DIS CHILD, V96, P414, DOI 10.1136/adc.2010.202820; Pinto PS, 2012, J NEUROIMAGING, V22, pe18, DOI 10.1111/j.1552-6569.2011.00690.x; Pinto PS, 2012, J NEUROIMAGING, V22, pe1, DOI 10.1111/j.1552-6569.2011.00688.x; Prabhu SP, 2013, PEDIATR RADIOL, V43, P575, DOI 10.1007/s00247-012-2546-4; Reed MJ, 2005, ARCH DIS CHILD, V90, P859, DOI 10.1136/adc.2004.053603; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Schachar JL, 2011, PEDIATR RADIOL, V41, P971, DOI 10.1007/s00247-011-2032-4; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Sepelyak K, 2010, EUR J PEDIATR, V169, P557, DOI 10.1007/s00431-009-1066-1; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Stence NV, 2011, CURR TREAT OPTION NE, V13, P636, DOI 10.1007/s11940-011-0149-2; Tavarez MM, 2012, CURR OPIN PEDIATR, V24, P307, DOI 10.1097/MOP.0b013e3283531ce6; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Willis AP, 2008, CLIN RADIOL, V63, P165, DOI 10.1016/j.crad.2007.05.027; WORLEY G, 1995, DEV MED CHILD NEUROL, V37, P213	68	28	28	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1546-1440			J AM COLL RADIOL	J. Am. Coll. Radiol.	OCT	2014	11	10					939	947		10.1016/j.jacr.2014.07.017			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	AQ1FY	WOS:000342528500008	25164794				2021-06-18	
J	Eroglu, B; Kimbler, DE; Pang, JF; Choi, J; Moskophidis, D; Yanasak, N; Dhandapani, KM; Mivechi, NF				Eroglu, Binnur; Kimbler, Donald E.; Pang, Junfeng; Choi, Justin; Moskophidis, Demetrius; Yanasak, Nathan; Dhandapani, Krishnan M.; Mivechi, Nahid F.			Therapeutic inducers of the HSP70/HSP110 protect mice against traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						BGP-15; celastrol; closed cortical impact; Hsp110; Hsp70; knockout mice	GROWTH-HORMONE GH; HEAT-SHOCK; C-JUN; EXPRESSION; STRESS; HSP70; GENE; P53; ACCUMULATION; CHAPERONES	Traumatic brain injury (TBI) induces severe harm and disability in many accident victims and combat-related activities. The heat-shock proteins Hsp70/Hsp110 protect cells against death and ischemic damage. In this study, we used mice deficient in Hsp110 or Hsp70 to examine their potential requirement following TBI. Data indicate that loss of Hsp110 or Hsp70 increases brain injury and death of neurons. One of the mechanisms underlying the increased cell death observed in the absence of Hsp110 and Hsp70 following TBI is the increased expression of reactive oxygen species-induced p53 target genes Pig1, Pig8, and Pig12. To examine whether drugs that increase the levels of Hsp70/Hsp110 can protect cells against TBI, we subjected mice to TBI and administered Celastrol or BGP-15. In contrast to Hsp110- or Hsp70i-deficient mice that were not protected following TBI and Celastrol treatment, there was a significant improvement of wild-type mice following administration of these drugs during the first week following TBI. In addition, assessment of neurological injury shows significant improvement in contextual and cued fear conditioning tests and beam balance in wild- type mice that were treated with Celastrol or BGP-15 following TBI compared to TBI-treated mice. These studies indicate a significant role of Hsp70/Hsp110 in neuronal survival following TBI and the beneficial effects of Hsp70/Hsp110 inducers toward reducing the pathological consequences of TBI.	[Eroglu, Binnur; Mivechi, Nahid F.] CNVAMC, Augusta, GA 30904 USA; [Eroglu, Binnur; Kimbler, Donald E.; Pang, Junfeng; Choi, Justin; Moskophidis, Demetrius; Yanasak, Nathan; Dhandapani, Krishnan M.; Mivechi, Nahid F.] Georgia Regents Univ, Augusta, GA 30912 USA; [Eroglu, Binnur; Choi, Justin; Moskophidis, Demetrius; Mivechi, Nahid F.] Georgia Regents Univ, Ctr Canc, Augusta, GA 30912 USA; [Eroglu, Binnur; Kimbler, Donald E.; Pang, Junfeng; Choi, Justin; Moskophidis, Demetrius; Yanasak, Nathan; Dhandapani, Krishnan M.; Mivechi, Nahid F.] Med Coll Georgia, Augusta, GA 30912 USA; [Kimbler, Donald E.; Dhandapani, Krishnan M.] Georgia Regents Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA; [Yanasak, Nathan; Mivechi, Nahid F.] Georgia Regents Univ, Med Coll Georgia, Dept Radiol, Augusta, GA 30912 USA	Mivechi, NF (corresponding author), CNVAMC, One Freedom Way, Augusta, GA 30904 USA.	nahid.mivechi@va.gov	Pang, Junfeng/I-9148-2014	Dhandapani, Krishnan/0000-0001-7044-1117	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA121951, R01CA062130, R01CA132640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX000161] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA121951, R01 CA132640, CA062130, R01 CA121951, CA132640, R01 CA062130] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS065172, NS065172] Funding Source: Medline; BLRD VA [I01 BX000161] Funding Source: Medline		Abbas HA, 2010, CELL STEM CELL, V7, P606, DOI 10.1016/j.stem.2010.09.013; Beck IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069115; Beere HM, 2000, NAT CELL BIOL, V2, P469; Bonner HP, 2010, J NEUROCHEM, V114, P606, DOI 10.1111/j.1471-4159.2010.06790.x; Buschmann JP, 2012, J MOL NEUROSCI, V48, P66, DOI 10.1007/s12031-012-9773-x; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Covey MV, 2007, NEUROSCIENCE, V148, P501, DOI 10.1016/j.neuroscience.2007.06.015; Devesa J, 2013, HORM BEHAV, V63, P331, DOI 10.1016/j.yhbeh.2012.02.022; Engel T, 2012, FASEB J, V26, P1616, DOI 10.1096/fj.11-196089; Eroglu B, 2010, MOL CELL BIOL, V30, P4626, DOI 10.1128/MCB.01493-09; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; GARCIAARAGON J, 1992, DEVELOPMENT, V114, P869; Gehrig SM, 2012, NATURE, V484, P394, DOI 10.1038/nature10980; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gombos I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028818; Haldimann P, 2011, J BIOL CHEM, V286, P18784, DOI 10.1074/jbc.M111.234773; Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317; Homma S, 2007, J NEUROSCI, V27, P7974, DOI 10.1523/JNEUROSCI.0006-07.2007; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang L, 2001, MOL CELL BIOL, V21, P8575, DOI 10.1128/MCB.21.24.8575-8591.2001; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Januchowski R, 2013, BIOMED PHARMACOTHER, V67, P240, DOI 10.1016/j.biopha.2012.11.011; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kim JY, 2013, NEUROBIOL DIS, V58, P289, DOI 10.1016/j.nbd.2013.06.012; Kim MG, 2014, KIDNEY INT, V85, P62, DOI 10.1038/ki.2013.277; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lee H, 2013, HUM GENE THER, V24, P655, DOI 10.1089/hum.2013.001; Lee SH, 1999, BBA-GENE STRUCT EXPR, V1446, P389, DOI 10.1016/S0167-4781(99)00112-8; Lehar SM, 1996, ONCOGENE, V12, P1181; Li YH, 2012, BRAIN RES, V1464, P8, DOI 10.1016/j.brainres.2012.04.054; Literati-Nagy B, 2009, HORM METAB RES, V41, P374, DOI 10.1055/s-0028-1128142; LIU FT, 1995, AM J PATHOL, V147, P1016; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Narayan N, 2012, NATURE, V492, P199, DOI 10.1038/nature11700; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Polier S, 2008, CELL, V133, P1068, DOI 10.1016/j.cell.2008.05.022; Qi DS, 2012, J NEUROL SCI, V317, P123, DOI 10.1016/j.jns.2012.02.011; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saleh A, 2000, NAT CELL BIOL, V2, P476; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Szabados E, 2000, BIOCHEM PHARMACOL, V59, P937, DOI 10.1016/S0006-2952(99)00418-9; Trott A, 2008, MOL BIOL CELL, V19, P1104, DOI 10.1091/mbc.E07-10-1004; TUPPER DE, 1980, ACTA NEUROBIOL EXP, V40, P999; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Wilson CA, 2013, PHARMACOL BIOCHEM BE, V104, P47, DOI 10.1016/j.pbb.2012.12.015; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xu LJ, 2011, NEUROSCI LETT, V488, P279, DOI 10.1016/j.neulet.2010.11.047; Zhao ZR, 2013, J CEREBR BLOOD F MET, V33, P1897, DOI 10.1038/jcbfm.2013.144	52	28	33	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	SEP	2014	130	5					626	641		10.1111/jnc.12781			16	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AN4EF	WOS:000340539700003	24903326	Green Accepted, Bronze			2021-06-18	
J	Krasny-Pacini, A; Limond, J; Evans, J; Hiebel, J; Bendjelida, K; Chevignard, M				Krasny-Pacini, Agata; Limond, Jenny; Evans, Jonathan; Hiebel, Jean; Bendjelida, Karim; Chevignard, Mathilde			Context-Sensitive Goal Management Training for Everyday Executive Dysfunction in Children After Severe Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						child; daily life activities; ecological; executive functions; Goal Management Training; intervention; prospective memory; traumatic/acquired brain injury	BEHAVIOR RATING INVENTORY; PROSPECTIVE MEMORY; COGNITIVE REHABILITATION; ECOLOGICAL ASSESSMENT; YOUNG-CHILDREN; FRONTAL-LOBE; FUNCTION DEFICITS; PEDIATRIC TBI; TEST SCORE; OUTCOMES	Objectives: To assess the effectiveness of a metacognitive training intervention, based on an adapted Goal Management Training and Ylvisaker's principles, on 3 activity domains of executive functions: (1) prospective memory (PM) performance in ecological setting, (2) complex cooking task management, and (3) daily executive functioning (EF) at home and at school. Participants: Five children aged 8 to 14 years, who were 3 to 11 years post-severe traumatic brain injury, experiencing severe EF difficulties in daily life. Design: Single-case experimental design and assessment of EF twice prior to intervention, postintervention, and 3 and 6 months postintervention. Progress was monitored by a weekly ecological PM score. The effect on EF was assessed using the Children's Cooking Task. Transfer to the child's natural context was assessed by parental and teacher questionnaires and Goal Attainment Scaling. Results: All children improved both on the measure of PM and on questionnaires of daily EF. Two children improved on the Children's Cooking Task but returned to their preintervention level in a novel cooking task at follow-up. Participation of school personnel and parents in the program was low. Conclusions: It is feasible but challenging to use Goal Management Training in children with traumatic brain injury. Further research is needed in relation to how to promote generalization and how to increase the involvement of the child's "everyday people" in the intervention.	[Krasny-Pacini, Agata; Hiebel, Jean] Inst Univ Readaptat Clemenceau Strasbourg, F-67082 Strasbourg, France; [Krasny-Pacini, Agata; Hiebel, Jean] Hautepierre Univ Hosp, Dept Paediat Surg, Strasbourg, France; [Chevignard, Mathilde] Hop St Maurice, Rehabil Dept Children Acquired Brain Injury, St Maurice, France; [Limond, Jenny; Evans, Jonathan] Univ Glasgow, Inst Hlth & Wellbeing, Gartnavel Royal Hosp, Glasgow, Lanark, Scotland; [Krasny-Pacini, Agata; Chevignard, Mathilde] Univ Paris 06, Pitie Salpetriere Hosp, ER UPMC 6, Paris, France; [Bendjelida, Karim] Hop Hasenrain, EMOI TC 68, Mulhouse, France	Krasny-Pacini, A (corresponding author), Inst Univ Readaptat Clemenceau Strasbourg, 45 Bd Clemenceau, F-67082 Strasbourg, France.	agata.krasny@ugecam-alsace.fr			"SOFMER"(French Society of Physical and Rehabilitation Medicine); "SFERHE" (French Research Society against Children's handicap); "Fondation Gueules Cassees"	This study was supported by scholarships from the "SOFMER"(French Society of Physical and Rehabilitation Medicine), the "SFERHE" (French Research Society against Children's handicap), and the "Fondation Gueules Cassees."	Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 2001, Pediatr Rehabil, V4, P119, DOI 10.1080/13638490110091347; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bjorklund D. F., 2011, CHILDRENS THINKING C; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Burden V., 2003, BEHAV ASSESSMENT DYS; Burgess PW, 2011, NEUROPSYCHOLOGIA, V49, P2246, DOI 10.1016/j.neuropsychologia.2011.02.014; Butler RW, 2008, J CONSULT CLIN PSYCH, V76, P367, DOI 10.1037/0022-006X.76.3.367; Catroppa C, 2009, DEV NEUROREHABIL, V12, P361, DOI 10.3109/17518420903087335; Chan DYK, 2011, DISABIL REHABIL, V33, P2023, DOI 10.3109/09638288.2011.556207; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; Chevignard MP, 2012, BRAIN INJURY, V26, P1033, DOI 10.3109/02699052.2012.666366; Chevignard MP, 2010, BRAIN IMPAIR, V11, P125, DOI 10.1375/brim.11.2.125; Chevignard MP, 2009, DEV NEUROREHABIL, V12, P76, DOI 10.1080/17518420902777019; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COHEN MJ, 2001, ECHELLE MEMOIRE ENFA; Cole WR, 2009, DEV DISABIL RES REV, V15, P159, DOI 10.1002/ddrr.58; Corbett C, 2009, THESIS U CAPE TOWN S; Crawford JR, 2002, NEUROPSYCHOLOGIA, V40, P1196, DOI 10.1016/S0028-3932(01)00224-X; Crawford JR, 1998, CLIN NEUROPSYCHOL, V12, P482, DOI 10.1076/clin.12.4.482.7241; Denckla M.B., 1994, FRAMES REFERENCE ASS, P117; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Feeney TJ, 2010, J HEAD TRAUMA REHAB, V25, P416, DOI 10.1097/HTR.0b013e3181fbc0a2; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fish J, 2010, NEUROPSYCHOL REHABIL, V20, P161, DOI 10.1080/09602010903126029; Ford RM, 2012, J EXP CHILD PSYCHOL, V111, P468, DOI 10.1016/j.jecp.2011.10.006; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Graham JE, 2012, ARCH PHYS MED REHAB, V93, pS111, DOI 10.1016/j.apmr.2011.12.017; Jansen LMC, 2003, DEV MED CHILD NEUROL, V45, P58, DOI 10.1017/S0012162203000112; Kerns KA, 2000, J INT NEUROPSYCH SOC, V6, P62, DOI 10.1017/S1355617700611074; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Krasny-Pacini A., 2013, Annals of Physical and Rehabilitation Medicine, V56, P212, DOI 10.1016/j.rehab.2013.02.002; Krasny-Pacini A, GOAL MANAGEMENT TRAI; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; Lewis MW, 2011, NEUROPSYCHOL REHABIL, V21, P145, DOI 10.1080/09602011.2010.543867; Limond J, 2005, J CHILD PSYCHOL PSYC, V46, P339, DOI 10.1111/j.1469-7610.2004.00397.x; Mackinlay RJ, 2009, J EXP CHILD PSYCHOL, V102, P251, DOI 10.1016/j.jecp.2008.08.006; Mahy CEV, 2011, COGNITIVE DEV, V26, P269, DOI 10.1016/j.cogdev.2011.06.002; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; McCauley SR, 2011, J CLIN EXP NEUROPSYC, V33, P639, DOI 10.1080/13803395.2010.547844; McCauley SR, 2009, NEUROPSYCHOLOGY, V23, P201, DOI 10.1037/a0014192; Miotto EC, 2009, NEUROPSYCHOL REHABIL, V19, P517, DOI 10.1080/09602010802332108; Missiuna C, 2010, PHYS OCCUP THER PEDI, V30, P205, DOI 10.3109/01942631003761554; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Parker RI, 2009, BEHAV THER, V40, P357, DOI 10.1016/j.beth.2008.10.006; Perdices M, 2009, NEUROPSYCHOL REHABIL, V19, P904, DOI 10.1080/09602010903040691; Philips L., 1997, METHODOLOGY FRONTAL, P200; Rabbitt P., METHODOLOGY FRONTAL; Ross KA, 2011, DEV MED CHILD NEUROL, V53, P692, DOI 10.1111/j.1469-8749.2011.03976.x; Rous R, 2012, 9 INT BRAIN INJ C MA; Schlosser RW, 2004, J COMMUN DISORD, V37, P217, DOI 10.1016/j.jcomdis.2003.09.003; Selznick L, 2000, BEHAV INTERVENT, V15, P243, DOI 10.1002/1099-078X(200007/09)15:3<243::AID-BIN59>3.0.CO;2-1; Servant V, 2009, EVALUATION; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; Simons J.S., 2005, EFFECTIVENESS REHABI, V211, DOI [10.1093/acprof:oso/9780198526544.003.0018, DOI 10.1093/ACPROF:OSO/9780198526544.001.0001]; Slomine B, 2009, DEV DISABIL RES REV, V15, P133, DOI 10.1002/ddrr.56; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Suzman KB, 1997, J BEHAV THER EXP PSY, V28, P203, DOI 10.1016/S0005-7916(97)00023-2; Tamm L, 2012, J ATTENTION DISORD; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Walker AJ, 2005, BRAIN INJURY, V19, P1237, DOI 10.1080/02699050500309411; Ward H, 2004, BRAIN INJURY, V18, P471, DOI 10.1080/02699050310001646107; Ward H, 2007, CHILD NEUROPSYCHOL, V13, P219, DOI 10.1080/09297040600910003; Wechsler D., 2005, WISC 4 ECHELLE INTEL; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU	82	28	28	0	43	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2014	29	5					E49	E64		10.1097/HTR.0000000000000015			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AP2GW	WOS:000341891700005	24495918				2021-06-18	
J	Brown, HJ; Siegmund, GP; Guskiewicz, KM; Van den Doel, K; Cretu, E; Blouin, JS				Brown, Harrison J.; Siegmund, Gunter P.; Guskiewicz, Kevin M.; Van den Doel, Kees; Cretu, Edmond; Blouin, Jean-Sebastien			Development and Validation of an Objective Balance Error Scoring System	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						STANDING BALANCE; POSTURAL CONTROL; CONCUSSION EVALUATION; BALANCE ERROR SCORING SYSTEM	COLLEGIATE FOOTBALL PLAYERS; MILD HEAD-INJURY; POSTURAL STABILITY; CONCUSSION; SPORT; MANAGEMENT; RELIABILITY; SCHOOL	Introduction: Limited access to sophisticated technology and the unreliability of simple tools prevent accurate and reliable human standing balance assessments outside research laboratory settings. The goal of this study was to develop and validate a simple objective balance assessment tool that provides an accurate, reliable, and affordable alternative to currently available laboratory and clinical methods. Methods: Thirty healthy subjects were filmed performing the Balance Error Scoring System (BESS) while wearing inertial measurement units (IMU) measuring linear accelerations and angular velocities from seven locations of the body: forehead, sternum, waist, right and left wrist, and right and left shin. Each video was scored by four experienced BESS raters, whose mean scores were used to develop an algorithm computing objective BESS (oBESS) scores solely from IMU data. Interrater reliability and accuracy of oBESS scores were assessed using intraclass correlations (ICC). Results: Raters displayed low variability in scoring (ICC3,1 = 0.91). The oBESS was able to produce scores with accurate fit to raters (ICC3,1 = 0.92) and predicted individual BESS scores (ICC3,1 = 0.90) using data from one IMU placed at the forehead. oBESS was unable to produce accurate scores (ICC3,1 = 0.68) when using IMU data from the subset of conditions (firm surface only) used in popular concussion identification protocols. Conclusion: The oBESS can reliably predict total BESS scores in healthy subjects. Pending further validation, oBESS could represent a valid tool to assess balance by offering an objective and reliable alternative to the current scoring methods of the BESS.	[Brown, Harrison J.; Siegmund, Gunter P.; Blouin, Jean-Sebastien] Univ British Columbia, Sch Kinesiol, Vancouver, BC V6T 1Z1, Canada; [Siegmund, Gunter P.] MEA Forens Engineers & Scientists, Richmond, BC, Canada; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Van den Doel, Kees] Univ British Columbia, Dept Comp Sci, Vancouver, BC V6T 1Z1, Canada; [Cretu, Edmond] Univ British Columbia, Dept Elect & Comp Engn, Vancouver, BC V6T 1Z1, Canada	Blouin, JS (corresponding author), Univ British Columbia, Sch Kinesiol, 210-6081 Univ Blvd, Vancouver, BC V6T 1Z1, Canada.	jsblouin@mail.ubc.ca	Siegmund, Gunter P/B-7003-2013	Siegmund, Gunter/0000-0003-2387-941X; Guskiewicz, Kevin/0000-0002-8682-2130	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR; Canadian Institutes of Health Research/Canadian Chiropractic Research FoundationCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research	This work was supported by the Natural Sciences and Engineering Research Council of Canada grant to J. S. Blouin and G. P. Siegmund. J. S. Blouin received salary support from the Canadian Institutes of Health Research/Canadian Chiropractic Research Foundation and the Michael Smith Foundation for Health Research. G. P. Siegmund owns shares in a consulting company, and both he and the company may derive benefit from being associated with this work.	[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Barela JA, 2011, RES DEV DISABIL, V32, P1814, DOI 10.1016/j.ridd.2011.03.011; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Clark RA, 2010, GAIT POSTURE, V31, P307, DOI 10.1016/j.gaitpost.2009.11.012; Davis GA, 2009, BRIT J SPORT MED, V43, P136; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Johnson EW, 2011, CLIN SPORT MED, V30, P73, DOI 10.1016/j.csm.2010.08.007; Lafond D, 2004, J BIOMECH, V37, P1421, DOI 10.1016/S0021-9290(03)00251-3; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; MacInnis MJ, 2012, HIGH ALT MED BIOL, V13, P93, DOI 10.1089/ham.2011.1085; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; McLeod TCV, 2009, J SPORT REHABIL, V18, P465, DOI 10.1123/jsr.18.4.465; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Onate JA, 2007, J ATHL TRAINING, V42, P446; Osborne JW, 2007, BEST PRACTICES QUANT, P48; Paloski WH, 2006, GAIT POSTURE, V23, P315, DOI 10.1016/j.gaitpost.2005.04.009; Portney LG, 1993, FDN CLIN RES APPL PR, P514; Randolph C, 2005, J ATHL TRAINING, V40, P139; Riemann BL, 2000, J ATHL TRAINING, V35, P19; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Valovich McLeod TC, 2003, J ATHL TRAINING, V38, P51; Zammit E, 2005, PHYS THER SPORT, V6, P116, DOI 10.1016/j.ptsp.2005.05.002	31	28	28	1	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	AUG	2014	46	8					1610	1616		10.1249/MSS.0000000000000263			7	Sport Sciences	Sport Sciences	AL6RF	WOS:000339259700017	24500539	Green Published			2021-06-18	
J	Mutch, WAC; Ellis, MJ; Graham, MR; Wourms, V; Raban, R; Fisher, JA; Mikulis, D; Leiter, J; Ryner, L				Mutch, W. Alan C.; Ellis, Michael J.; Graham, M. Ruth; Wourms, Vincent; Raban, Roshan; Fisher, Joseph A.; Mikulis, David; Leiter, Jeffrey; Ryner, Lawrence			Brain MRI CO2 Stress Testing: A Pilot Study in Patients with Concussion	PLOS ONE			English	Article							CEREBROVASCULAR RESPONSE; WHITE-MATTER; SPORTS; RECOVERY; KNOWLEDGE; INJURY	Background: There is a real need for quantifiable neuro-imaging biomarkers in concussion. Here we outline a brain BOLD-MRI CO2 stress test to assess the condition. Methods: This study was approved by the REB at the University of Manitoba. A group of volunteers without prior concussion were compared to post-concussion syndrome (PCS) patients - both symptomatic and recovered asymptomatic. Five 3-minute periods of BOLD imaging at 3.0 T were studied - baseline 1 (BL1- at basal CO2 tension), hypocapnia (CO2 decreased similar to 5 mmHg), BL2, hypercapnia (CO2 increased similar to 10 mmHg) and BL3. Data were processed using statistical parametric mapping (SPM) for 1st level analysis to compare each subject's response to the CO2 stress at the p = 0.001 level. A 2nd level analysis compared each PCS patient's response to the mean response of the control subjects at the p = 0.05 level. Results: We report on 5 control subjects, 8 symptomatic and 4 asymptomatic PCS patients. Both increased and decreased response to CO2 was seen in all PCS patients in the 2nd level analysis. The responses were quantified as reactive voxel counts: whole brain voxel counts (2.0 +/- 1.6%, p = 0.012 for symptomatic patients for CO2 response < controls and 3.0 +/- 5.1%, p = 0.139 for CO2 response > controls: 0.49 +/- 0.31%, p = 0.053 for asymptomatic patients for CO2 response < controls and 4.4 +/- 6.8%, p = 0.281 for CO2 response > controls). Conclusions: Quantifiable alterations in regional cerebrovascular responsiveness are present in concussion patients during provocative CO2 challenge and BOLD MRI and not in healthy controls. Future longitudinal studies must aim to clarify the relationship between CO2 responsiveness and individual patient symptoms and outcomes.	[Mutch, W. Alan C.; Graham, M. Ruth; Wourms, Vincent; Raban, Roshan] Univ Manitoba, Hlth Sci Ctr, Dept Anesthesia & Perioperat Med, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Dept Surg, Hlth Sci Ctr, Neurosurg Sect, Winnipeg, MB R3T 2N2, Canada; [Fisher, Joseph A.] Univ Toronto, Toronto Gen Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5G 1L7, Canada; [Mikulis, David] Univ Toronto, Toronto Western Hosp, Dept Radiol, Sect Neuroimaging, Toronto, ON M5T 2S8, Canada; [Leiter, Jeffrey] Univ Manitoba, Dept Surg, Pan Am Clin, Winnipeg, MB R3T 2N2, Canada; [Ryner, Lawrence] Univ Manitoba, Dept Phys & Astron, Winnipeg, MB, Canada	Mutch, WAC (corresponding author), Univ Manitoba, Hlth Sci Ctr, Dept Anesthesia & Perioperat Med, Winnipeg, MB, Canada.	wacmutch@shaw.ca	Mikulis, David J/H-5167-2019	Mikulis, David/0000-0003-3956-0892; Mutch, W. Alan/0000-0001-7174-7839	Anesthesia Oversight Committee	Anesthesia Oversight Committee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Ashburner J, 2012, NEUROIMAGE, V62, P791, DOI 10.1016/j.neuroimage.2011.10.025; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Burke MJ, 2012, CAN J NEUROL SCI, V39, P763, DOI 10.1017/S0317167100015584; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Fierstra J, 2013, J PHYSIOL-LONDON, V591, P5809, DOI 10.1113/jphysiol.2013.259150; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; He BJ, 2009, TRENDS COGN SCI, V13, P302, DOI 10.1016/j.tics.2009.04.004; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kiebel SJ, 2004, NEUROIMAGE, V22, P503, DOI 10.1016/j.neuroimage.2004.02.013; Kim SG, 2012, J CEREBR BLOOD F MET, V32, P1188, DOI 10.1038/jcbfm.2012.23; Kitzbichler MG, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000314; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Langlois JA, 2008, J HEAD TRAUMA REHAB, V21, P375; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mardimae A, 2012, PFLUG ARCH EUR J PHY, V464, P345, DOI 10.1007/s00424-012-1148-1; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; Mutch WAC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057881; Mutch WAC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047443; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Prisman E, 2008, J MAGN RESON IMAGING, V27, P185, DOI 10.1002/jmri.21102; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Raichle ME, 2009, J NEUROSCI, V29, P12729, DOI 10.1523/JNEUROSCI.4366-09.2009; Regan RE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070751; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Sobczyk O, 2014, NEUROIMAGE, V92, P56, DOI 10.1016/j.neuroimage.2014.01.051; Tormenti M, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12282; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005	38	28	28	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2014	9	7							e102181	10.1371/journal.pone.0102181			10	Multidisciplinary Sciences	Science & Technology - Other Topics	AL8VR	WOS:000339418300039	25032707	DOAJ Gold, Green Published			2021-06-18	
J	Colletti, G; Battista, VMA; Allevi, F; Giovanditto, F; Rabbiosi, D; Biglioli, F				Colletti, Giacomo; Battista, Valeria Marinella Augusta; Allevi, Fabiana; Giovanditto, Federica; Rabbiosi, Dimitri; Biglioli, Federico			Extraoral approach to mandibular condylar fractures: Our experience with 100 cases	JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY			English	Article						Condylar fracture; Extraoral approach; Retromandibular access; Mini-retromandibular access	MINI-RETROMANDIBULAR ACCESS; CLOSED TREATMENT; SUBCONDYLAR FRACTURES; FIXATION	Introduction: Mandibular condylar fractures are very common. The current literature contains many indications and methods of treatment. Extraoral approaches are complicated by the need to avoid injury to the facial nerve. On the other hand intraoral approaches can make fracture reduction and/or fixation difficult. The mini-retromandibular approach provides an excellent view of the surgical field, minimises the risk of injury to the facial nerve, and allows rapid and easy management of condylar fractures. We have collected and reviewed our first 100 condylar fractures treated by means of a mini-retromandibular approach. Patients and methods: Between June 2006 and June 2012, Eighty-seven patients with extracapsular condylar fractures underwent open reduction and rigid fixation for 100 extracapsular condylar fractures via a mini-retromandibular approach. Results: Dental occlusion and anatomic reduction were restored in all 100 condylar fractures. Postoperative infection developed in three patients. There was one sialocele and one case of plate fracture. Four patients experienced transient palsy of the buccal branch of the facial nerve. No permanent deficit of any facial nerve branch was observed. No patient showed condylar head resorption. Conclusions: Our experience with the treatment of the first 100 condylar fractures using the mini-retromandibular approach has demonstrated that this technique has allowed the Authors to safely manage extracapsular condylar fractures at all levels. (C) 2013 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.	[Colletti, Giacomo; Battista, Valeria Marinella Augusta; Allevi, Fabiana; Giovanditto, Federica; Rabbiosi, Dimitri; Biglioli, Federico] Univ Milan, San Paolo Hosp, Dept Maxillo Facial Surg, I-20100 Milan, Italy	Colletti, G (corresponding author), Piazza Repubbl 1-A, I-20121 Milan, Italy.	giacomo.colletti@gmail.com	Colletti, Giacomo/G-8620-2012; Allevi, Fabiana/AAO-2330-2020	Colletti, Giacomo/0000-0001-6975-495X; ALLEVI, FABIANA/0000-0002-5012-4031; Rabbiosi, Dimitri/0000-0001-5207-2055			Arcuri F, 2012, J CRANIOFAC SURG, V23, pE196, DOI 10.1097/SCS.0b013e31824de328; Biglioli F, 2010, Minerva Stomatol, V59, P603; Biglioli F, 2008, J CRANIO MAXILL SURG, V36, P378, DOI 10.1016/j.jcms.2008.05.001; Biglioli F, 2009, J ORAL MAXIL SURG, V67, P2418, DOI 10.1016/j.joms.2009.04.066; Brusati R, 2005, RIV ITAL CHIR MAXILL, V16, P15; Brusati R, 2010, J CRANIO MAXILL SURG, V38, P179, DOI 10.1016/j.jcms.2009.04.010; Choi KY, 2012, ARCH PLAST SURG-APS, V39, P291, DOI 10.5999/aps.2012.39.4.291; Chrcanovic BR, 2012, ORAL MAXILLOFAC SURG, V16, P245, DOI 10.1007/s10006-012-0344-7; Chrcanovic BR, 2012, ORAL MAXILLOFAC SURG, V16, P257, DOI 10.1007/s10006-012-0337-6; CLEMENTSCHITSCH F, 1955, Dtsch Zahnarztl Z, V10, P380; Colletti G, 2012, J CRANIOFAC SURG, V23, pE400, DOI 10.1097/SCS.0b013e31825bd004; Danda AK, 2010, J ORAL MAXIL SURG, V68, P1238, DOI 10.1016/j.joms.2009.09.042; Delaire J, 1975, Rev Stomatol Chir Maxillofac, V76, P331; Eckelt U, 2006, J CRANIO MAXILL SURG, V34, P306, DOI 10.1016/j.jcms.2006.03.003; Ellis E, 2000, J ORAL MAXIL SURG, V58, P719, DOI 10.1053/joms.2000.7253; ELLIS E, 1985, ORAL SURG ORAL MED O, V59, P120, DOI 10.1016/0030-4220(85)90002-7; Ellis E, 2000, J ORAL MAXIL SURG, V58, P260, DOI 10.1016/S0278-2391(00)90047-8; Eulert S, 2007, ANN ANAT, V189, P377, DOI 10.1016/j.aanat.2007.02.010; Handschel J, 2012, J CRANIOMAXILLOFAC S; Hovinga J, 1999, INT J ORAL MAX SURG, V28, P429, DOI 10.1034/j.1399-0020.1999.280606.x; IIZUKA T, 1991, ORAL SURG ORAL MED O, V72, P400, DOI 10.1016/0030-4220(91)90547-P; Jacobovicz J, 1998, PLAST RECONSTR SURG, V101, P437, DOI 10.1097/00006534-199802000-00030; Kellman RM, 2009, FACIAL PLAST SURG, V25, P23, DOI 10.1055/s-0028-1112228; Kohler A, 1956, DTSCH STOMATOL, V6, P561; Kokemueller H, 2012, J ORAL MAXIL SURG, V70, P384, DOI 10.1016/j.joms.2011.02.035; Landes CA, 2008, ORAL MAXILLOFAC SURG, V12, P79, DOI 10.1007/s10006-008-0108-6; Mueller Reid V, 2006, Facial Plast Surg Clin North Am, V14, P1; Myall RWT, 1994, CONTROVERSIES ORAL M, V17, P191; Rabbiosi D, 2012, MINERVA STOMATOL, V61, P431; Schmelzeisen R, 2009, J ORAL MAXIL SURG, V67, P147, DOI 10.1016/j.joms.2008.09.019; SILVENNOINEN U, 1992, J ORAL MAXIL SURG, V50, P1032, DOI 10.1016/0278-2391(92)90484-H; Silverman SL, 1925, DENT COSMOS, V67, P876; Steinhauser E, 1964, DTSCH ZAHNARZTL Z, V19, P694; Throckmorton GS, 2000, INT J ORAL MAX SURG, V29, P421, DOI 10.1034/j.1399-0020.2000.290605.x; Vesnaver A, 2011, J CRANIOMAXILLOFAC S; Wa&beta;mund M, 1934, DTSCH KIEFERCHIR, V1, P27; Zachariades N, 2006, J CRANIO MAXILL SURG, V34, P421, DOI 10.1016/j.jcms.2006.07.854	37	28	30	0	4	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1010-5182	1878-4119		J CRANIO MAXILL SURG	J. Cranio-MaxilloFac. Surg.	JUL	2014	42	5					E186	E194		10.1016/j.jcms.2013.08.005			9	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	AX5NH	WOS:000346973000021	24099654				2021-06-18	
J	Mierzwa, AJ; Sullivan, GM; Beer, LA; Ahn, S; Armstrong, RC				Mierzwa, Amanda J.; Sullivan, Genevieve M.; Beer, Laurel A.; Ahn, Sohyun; Armstrong, Regina C.			Comparison of Cortical and White Matter Traumatic Brain Injury Models Reveals Differential Effects in the Subventricular Zone and Divergent Sonic Hedgehog Signaling Pathways in Neuroblasts and Oligodendrocyte Progenitors	ASN NEURO			English	Article						neuroblast; oligodendrocyte progenitor; sonic hedgehog; stem cell; subventricular zone; traumatic brain injury	NEURAL STEM-CELL; IMPACT INJURY; ADULT BRAIN; MICE; MOUSE; PROLIFERATION; DEMYELINATION; MAINTENANCE; POPULATIONS; ASTROCYTES	The regenerative capacity of the central nervous system must be optimized to promote repair following traumatic brain injury (TBI) and may differ with the site and form of damage. Sonic hedgehog (Shh) maintains neural stem cells and promotes oligodendrogenesis. We examined whether Shh signaling contributes to neuroblast (doublecortin) or oligodendrocyte progenitor (neural/glial antigen 2 [NG2]) responses in two distinct TBI models. Shh-responsive cells were heritably labeled in vivo using Gli1-CreER (T2); R26-YFP bitransgenic mice with tamoxifen administration on Days 2 and 3 post-TBI. Injury to the cerebral cortex was produced with mild controlled cortical impact. Yellow fluorescent protein (YFP) cells decreased in cortical lesions. Total YFP cells increased in the subventricular zone (SVZ), indicating Shh pathway activation in SVZ cells, including doublecortin-labeled neuroblasts. The alternate TBI model produced traumatic axonal injury in the corpus callosum. YFP cells decreased within the SVZ and were rarely double labeled as NG2 progenitors. NG2 progenitors increased in the cortex, with a similar pattern in the corpus callosum. To further test the potential of NG2 progenitors to respond through Shh signaling, Smoothened agonist was microinjected into the corpus callosum to activate Shh signaling. YFP cells and NG2 progenitors increased in the SVZ but were not double labeled. This result indicates that either direct Smoothened activation in NG2 progenitors does not signal through Gli1 or that Smoothened agonist acts indirectly to increase NG2 progenitors. Therefore, in all conditions, neuroblasts exhibited differential Shh pathway utilization compared with oligodendrocyte progenitors. Notably, cortical versus white matter damage from TBI produced opposite responses of Shh-activated cells within the SVZ.	[Mierzwa, Amanda J.; Sullivan, Genevieve M.; Beer, Laurel A.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Mierzwa, Amanda J.; Sullivan, Genevieve M.; Beer, Laurel A.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Sullivan, Genevieve M.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Program Mol & Cell Biol, Bethesda, MD 20814 USA; [Ahn, Sohyun] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA	Armstrong, RC (corresponding author), Uniformed Serv Univ Hlth Sci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	regina.armstrong@usuhs.edu	Sullivan, Genevieve/AAK-7415-2021	Sullivan, Genevieve/0000-0002-3561-223X	National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG4675]; Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM)	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Multiple Sclerosis Society (RG4675) and the Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM).	Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023; Alvarez JI, 2011, SCIENCE, V334, P1727, DOI 10.1126/science.1206936; Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009; Badea TC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007859; Balordi F, 2007, J NEUROSCI, V27, P5936, DOI 10.1523/JNEUROSCI.1040-07.2007; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Ferent J, 2013, J NEUROSCI, V33, P1759, DOI 10.1523/JNEUROSCI.3334-12.2013; Garcia ADR, 2010, J NEUROSCI, V30, P13597, DOI 10.1523/JNEUROSCI.0830-10.2010; Hughes EG, 2013, NAT NEUROSCI, V16, P668, DOI 10.1038/nn.3390; Ihrie RA, 2011, NEURON, V71, P250, DOI 10.1016/j.neuron.2011.05.018; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Ming XT, 2013, J NEUROSCI, V33, P12528, DOI 10.1523/JNEUROSCI.0536-13.2013; Palma V, 2005, DEVELOPMENT, V132, P335, DOI 10.1242/dev.01567; Petrova R, 2013, J NEUROSCI, V33, P17490, DOI 10.1523/JNEUROSCI.2042-13.2013; Radomski KL, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-142; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sirko S, 2013, CELL STEM CELL, V12, P426, DOI 10.1016/j.stem.2013.01.019; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Wang Y, 2008, ANN NEUROL, V64, P417, DOI 10.1002/ana.21457; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Yi JH, 2012, J COMP NEUROL, V520, P3295, DOI 10.1002/cne.23156; Yi X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070306	30	28	28	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1759-0914			ASN NEURO	ASN Neuro	JUL-SEP	2014	6	5							1759091414551782	10.1177/1759091414551782			16	Neurosciences	Neurosciences & Neurology	AR7IP	WOS:000343753200001	25290062	DOAJ Gold, Green Published			2021-06-18	
J	Simpson, JR				Simpson, Joseph R.			DSM-5 and Neurocognitive Disorders	JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW			English	Article							TRAUMATIC BRAIN-INJURY; OPERATION IRAQI FREEDOM	The newest edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) introduces several changes in the diagnostic criteria for dementia and other cognitive disorders. Some of these changes may prove helpful for clinical and forensic practitioners, particularly when evaluating less severe cognitive impairments. The most substantial change is that the cognitive disorder-not otherwise specified category found in prior editions has been eliminated. Those disorders that do not cause sufficient impairment to qualify for a diagnosis of dementia are now defined as neurocognitive disorders and placed on a spectrum with the more severe conditions. The concept of social cognition is also introduced as one of the core functional domains that can be affected by a neurocognitive disorder. This concept may be particularly significant in the evaluation of patients with non-Alzheimer's dementias, such as frontotemporal dementia. With the aging of the population and the increasing recognition of the possibility of long-lasting cognitive deficits after traumatic brain injury, the need for assessment of cognitive disorders in medicolegal contexts is certain to increase. Forensic psychiatrists who perform these evaluations should understand the conceptualization of Neurocognitive Disorders as presented in DSM-5 and how it differs from prior diagnostic systems.	[Simpson, Joseph R.] Univ So Calif, Keck Sch Med, Los Angeles Cty Jail Mental Hlth Serv, Los Angeles, CA 90033 USA; [Simpson, Joseph R.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA	Simpson, JR (corresponding author), POB 818, Hermosa Beach, CA 90254 USA.	jrsimpsonmd@gmail.com					American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gordon C, 2013, EXPERT REV NEUROTHER, V13, P1247, DOI 10.1586/14737175.2013.856265; Korngold C, 2013, J AM ACAD PSYCHIATRY, V41, P430; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; McCrea M, 2008, MILD TRAUMATIC BRAIN; Mendez MF, 2010, J AM ACAD PSYCHIATRY, V38, P318; Wallace D, 2009, AUSTRALAS PSYCHIATRY, V17, P218, DOI 10.1080/10398560902878679	12	28	30	0	2	AMER ACAD PSYCHIATRY & LAW	BLOOMFIELD	ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA	1093-6793	1943-3662		J AM ACAD PSYCHIATRY	J. Am. Acad. Psychiatry Law	JUN 1	2014	42	2					159	164					6	Law; Psychiatry	Government & Law; Psychiatry	AN8LW	WOS:000340856700005	24986342				2021-06-18	
J	Neher, MD; Rich, MC; Keene, CN; Weckbach, S; Bolden, AL; Losacco, JT; Patane, J; Flierl, MA; Kulik, L; Holers, M; Stahel, PF				Neher, Miriam D.; Rich, Megan C.; Keene, Chesleigh N.; Weckbach, Sebastian; Bolden, Ashley L.; Losacco, Justin T.; Patane, Jenee; Flierl, Michael A.; Kulik, Liudmila; Holers, Michael; Stahel, Philip F.			Deficiency of complement receptors CR2/CR1 in Cr2(-/-) mice reduces the extent of secondary brain damage after closed head injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Closed head injury; Neuroinflammation; Complement receptor; Cr2(-/-) mice; Secondary brain injury	NATURAL ANTIBODIES; TISSUE-INJURY; ACTIVATION; SYSTEM; IMMUNITY; C3; COMPLEMENT-RECEPTOR-2; NEUROPROTECTION; AUTOANTIBODIES; ACCUMULATION	Complement activation at the C3 convertase level has been associated with acute neuroinflammation and secondary brain injury after severe head trauma. The present study was designed to test the hypothesis that Cr2(-/-) mice, which lack the receptors CR2/CD21 and CR1/CD35 for complement C3-derived activation fragments, are protected from adverse sequelae of experimental closed head injury. Adult wild-type mice and Cr2(-/-) mice on a C57BL/6 genetic background were subjected to focal closed head injury using a standardized weight-drop device. Head-injured Cr2(-/-) mice showed significantly improved neurological outcomes for up to 72 hours after trauma and a significantly decreased post-injury mortality when compared to wild-type mice. In addition, the Cr2(-/-) genotype was associated with a decreased extent of neuronal cell death at seven days post-injury. Western blot analysis revealed that complement C3 levels were reduced in the injured brain hemispheres of Cr2(-/-) mice, whereas plasma C3 levels remained unchanged, compared to wild-type mice. Finally, head-injured Cr2(-/-) had an attenuated extent of post-injury C3 tissue deposition, decreased astrocytosis and microglial activation, and attenuated immunoglobulin M deposition in injured brains compared to wild-type mice. Targeting of these receptors for complement C3 fragments (CR2/CR1) may represent a promising future approach for therapeutic immunomodulation after traumatic brain injury.	[Neher, Miriam D.; Rich, Megan C.; Keene, Chesleigh N.; Weckbach, Sebastian; Bolden, Ashley L.; Losacco, Justin T.; Patane, Jenee; Flierl, Michael A.; Stahel, Philip F.] Univ Colorado, Sch Med, Dept Orthoped Surg, Denver Hlth Med Ctr, Denver, CO 80204 USA; [Kulik, Liudmila; Holers, Michael] Univ Colorado, Barbara Davis Ctr, Dept Med, Aurora, CO 80045 USA; [Kulik, Liudmila; Holers, Michael] Univ Colorado, Barbara Davis Ctr, Dept Immunol, Aurora, CO 80045 USA; [Stahel, Philip F.] Univ Colorado, Sch Med, Dept Neurosurg, Denver Hlth Med Ctr, Denver, CO 80204 USA	Stahel, PF (corresponding author), Univ Colorado, Sch Med, Dept Orthoped Surg, Denver Hlth Med Ctr, 777 Bannock St, Denver, CO 80204 USA.	philip.stahel@dhha.org		Losacco, Justin/0000-0001-7867-1152	Colorado Traumatic Brain Injury Trust Fund/Colorado Brain Injury Program; German Research Foundation (DFG)German Research Foundation (DFG); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AR051749]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR051749] Funding Source: NIH RePORTER	This study was supported by a project grant from The Colorado Traumatic Brain Injury Trust Fund/Colorado Brain Injury Program to PFS and MAF. SW was supported by a Research Fellowship by the German Research Foundation (DFG). VMH was supported by an R01 grant from the NIH (Number AR051749). We are indebted to our long-time friend, Dr Scott R. Barnum (University of Alabama at Birmingham, Alabama, United States) for critical review of this manuscript, and for his continuing leadership and mentorship in the field of 'neuro-complementology'.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Ankeny DP, 2010, TRENDS IMMUNOL, V31, P332, DOI 10.1016/j.it.2010.06.006; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Bellander BM, 2010, EXP BRAIN RES, V205, P103, DOI 10.1007/s00221-010-2342-z; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Carroll MC, 2012, IMMUNITY, V37, P199, DOI 10.1016/j.immuni.2012.08.002; Ehrenstein MR, 2010, NAT REV IMMUNOL, V10, P778, DOI 10.1038/nri2849; Elvington A, 2012, J IMMUNOL, V188, P1460, DOI 10.4049/jimmunol.1102132; Fleming SD, 2004, J IMMUNOL, V173, P7055, DOI 10.4049/jimmunol.173.11.7055; Fleming SD, 2006, AUTOIMMUNITY, V39, P379, DOI 10.1080/08916930600739381; Fleming SD, 2012, ADV EXP MED BIOL, V750, P174, DOI 10.1007/978-1-4614-3461-0_13; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gasque P, 1996, J IMMUNOL, V156, P2247; Glushakov AV, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-132; Griffiths MR, 2009, J NEUROPATH EXP NEUR, V68, P217, DOI 10.1097/NEN.0b013e3181996688; Holers VM, 2007, MOL IMMUNOL, V44, P64, DOI 10.1016/j.molimm.2006.07.003; Holers VM, 2013, ADV EXP MED BIOL, V735, P137, DOI 10.1007/978-1-4614-4118-2_9; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kaveri SV, 2012, J IMMUNOL, V188, P939, DOI 10.4049/jimmunol.1102107; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kelso ML, 2013, CURR PHARM DES; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kulik L, 2009, J IMMUNOL, V182, P5363, DOI 10.4049/jimmunol.0803980; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Menet C, 1999, J VIROL, V73, P7722, DOI 10.1128/JVI.73.9.7722-7733.1999; MOLINA H, 1990, J IMMUNOL, V145, P2974; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moriyama M, 2011, J NEUROSCI, V31, P3981, DOI 10.1523/JNEUROSCI.3617-10.2011; Neher MD, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-90; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Schwulst SJ, 2013, J TRAUMA ACUTE CARE, V75, P780, DOI 10.1097/TA.0b013e318299616a; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Weckbach S, 2012, J NEUROTRAUM, V29, P1233, DOI 10.1089/neu.2011.2169; Xu ZL, 2013, NAT MED, V19, P452, DOI 10.1038/nm.3107	39	28	28	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 24	2014	11								95	10.1186/1742-2094-11-95			13	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	AI9MU	WOS:000337257500001	24885042	DOAJ Gold, Green Published			2021-06-18	
J	Gill, J; Lee, H; Barr, T; Baxter, T; Heinzelmann, M; Rak, H; Mysliwiec, V				Gill, Jessica; Lee, Hyunhwa; Barr, Taura; Baxter, Tristin; Heinzelmann, Morgan; Rak, Hannah; Mysliwiec, Vincent			Lower health related quality of life in US military personnel is associated with service-related disorders and inflammation	PSYCHIATRY RESEARCH			English	Article						IL-6; Post-traumatic stress disorder; Depression; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SELF-RATED HEALTH; CARDIOVASCULAR EVENTS; PTSD; DEPRESSION; MORTALITY; RISK; BIOMARKERS; SYMPTOMS	Military personnel who have combat exposures are at increased risk for the service-related disorders of post-traumatic stress disorder (PTSD), depression, sleep disturbances and decreased health related quality of life (HRQOL). Those with a traumatic brain injury (TBI) are at even greater risk. Inflammation is associated with these disorders and may underlie the risk for health declines. We evaluated 110 recently deployed, military personnel presenting with sleep disturbances for service-related disorders (TBI, PTSD, and depression) as well as HRQOL. ANOVA models were used to examine differences among military personnel with two or more service-related disorders (high comorbid group), or one or no disorders (low comorbid group). Logistic regression models were used to determine associations among interleukin-6 (IL-6) to HRQOL and service-related disorders. Approximately one-third of the sample had two or more service-related disorders. HRQOL was lower and IL-6 concentrations were higher in military personnel with PTSD or depression, with the most profound differences in those with more service-related disorders, regardless of sleep disorder. Having symptoms of depression and PTSD resulted in a 3.5-fold risk to be in the lower quartile of HRQOL and the highest quartile of IL-6. In a linear regression model, 41% of the relationship between HRQOL and IL-6 concentrations was mediated by PTSD and depression. Military personnel with PTSD and depression are at high risk for lower HRQOL, and higher IL-6 concentrations. Comprehensive treatment is required to address co-occurring service-related disorders in military personnel to promote health and well-being. (C) 2014 Published by Elsevier Ireland Ltd.	[Gill, Jessica; Lee, Hyunhwa; Heinzelmann, Morgan; Rak, Hannah] NINR, NIH, Bethesda, MD 20892 USA; [Barr, Taura] W Virginia Univ, Morgantown, WV 26506 USA; [Baxter, Tristin; Mysliwiec, Vincent] Madigan Army Med Ctr, Tacoma, WA 98431 USA	Gill, J (corresponding author), NINR, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	gillj@mail.nih.gov	Gill, Gill M/Q-2020-2017	Heinzelmann, Morgan/0000-0002-4399-6229; Lee, Hyunhwa/0000-0002-5625-3141	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [60855]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000027] Funding Source: NIH RePORTER	This study was funded, in part, by the Center for Neuroscience and Regenerative Medicine (Grant 60855). The opinions and assertions in this manuscript are those of the authors and do not necessarily represent those of the Department of the Army, Department of Defense, U.S. Government, or the Center for Neuroscience and Regenerative Medicine.	Agaku Israel, 2012, Morbidity and Mortality Weekly Report, V61, P889; American Congress of Rehabilitation Medicine, DEF MILD TRAUM BRAIN; Andersen K, 2008, HORM METAB RES, V40, P635, DOI 10.1055/s-0028-1083810; Aversa LH, 2013, QUAL LIFE RES, V22, P1381, DOI 10.1007/s11136-012-0280-x; Bhasin MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062817; Boscarino JA, 2006, MED CARE, V44, P454, DOI 10.1097/01.mlr.0000207435.10138.36; Boscarino JA, 2008, PSYCHOSOM MED, V70, P668, DOI 10.1097/PSY.0b013e31817bccaf; Boscarino JA, 2012, PREV MED, V54, P363, DOI 10.1016/j.ypmed.2012.01.001; Boscarino JA, 2010, PSYCHOSOM MED, V72, P481, DOI 10.1097/PSY.0b013e3181d9a80c; Boyko EJ, 2010, DIABETES CARE, V33, P1771, DOI 10.2337/dc10-0296; Britt TW, 2007, MIL MED, V172, P157, DOI 10.7205/MILMED.172.2.157; Celik T, 2013, BLOOD PRESSURE, V22, P94, DOI 10.3109/08037051.2012.716580; Edwards R.D., 2010, NBER WORKING PAPER N, DOI [10.3386/w16163, DOI 10.3386/W16163]; FERRER CF, 1995, AVIAT SPACE ENVIR MD, V66, P571; Fisher H., 2010, CRS REP C; Germain A, 2012, J PSYCHOSOM RES, V72, P89, DOI 10.1016/j.jpsychores.2011.11.010; Gill J, 2010, BIOL PSYCHIAT, V68, P999, DOI 10.1016/j.biopsych.2010.07.033; Gill JM, 2013, J PSYCHOSOM RES, V74, P301, DOI 10.1016/j.jpsychores.2012.10.013; Gokce N, 2002, CIRCULATION, V105, P1567, DOI 10.1161/01.CIR.0000012543.55874.47; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacobs M., 2009, EUR J CLIN INVEST, V41, P167; Krueger C, 2011, J VIRAL HEPATITIS, V18, pE284, DOI 10.1111/j.1365-2893.2010.01408.x; Leger D, 2012, SLEEP MED, V13, P43, DOI 10.1016/j.sleep.2011.03.020; Lopresti AL, 2014, PROG NEURO-PSYCHOPH, V48, P102, DOI 10.1016/j.pnpbp.2013.09.017; Luxton DD, 2011, SLEEP, V34, P1189, DOI 10.5665/SLEEP.1236; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Macera CA, 2013, SLEEP, V36, P83, DOI 10.5665/sleep.2306; MacKenzie EJ, 2002, QUAL LIFE RES, V11, P797, DOI 10.1023/A:1020820017658; Maes M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-66; Maes M, 2012, PROG NEURO-PSYCHOPH, V36, P169, DOI 10.1016/j.pnpbp.2011.09.006; Miller NL, 2010, SLEEP, V33, P1623, DOI 10.1093/sleep/33.12.1623; Mysliwiec V, 2013, CHEST, V144, P549, DOI 10.1378/chest.13-0088; Paulus EJ, 2013, J TRAUMA STRESS, V26, P169, DOI 10.1002/jts.21785; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Phillips AC, 2009, PSYCHOSOM MED, V71, P395, DOI 10.1097/PSY.0b013e31819e6706; Pittman JOE, 2012, QUAL LIFE RES, V21, P99, DOI 10.1007/s11136-011-9918-3; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Scherrer JF, 2010, AM HEART J, V159, P772, DOI 10.1016/j.ahj.2010.02.033; Schnabel RB, 2013, ARTERIOSCL THROM VAS, V33, P1728, DOI 10.1161/ATVBAHA.112.301174; Singh-Manoux A, 2007, PSYCHOSOM MED, V69, P138, DOI 10.1097/PSY.0b013e318030483a; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trivedi MH, 2004, PSYCHOL MED, V34, P73, DOI 10.1017/S0033291703001107; van Zuiden M, 2013, BRAIN BEHAV IMMUN, V30, P12, DOI 10.1016/j.bbi.2012.08.015; van Zuiden M, 2012, PSYCHONEUROENDOCRINO, V37, P1822, DOI 10.1016/j.psyneuen.2012.03.018; Wagner JS, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-199; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Xu J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-330; Xue Y, 2012, AM J CARDIOL, V109, P1215, DOI 10.1016/j.amjcard.2011.11.063; Zen AL, 2012, HEALTH PSYCHOL, V31, P194, DOI 10.1037/a0025989	53	28	28	0	19	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	APR 30	2014	216	1					116	122		10.1016/j.psychres.2014.01.046			7	Psychiatry	Psychiatry	AE6XL	WOS:000334141200018	24559851				2021-06-18	
J	Canty, AL; Fleming, J; Patterson, F; Green, HJ; Man, D; Shum, DHK				Canty, Allana L.; Fleming, Jennifer; Patterson, Freyr; Green, Heather J.; Man, David; Shum, David H. K.			Evaluation of a virtual reality prospective memory task for use with individuals with severe traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Prospective memory; Virtual reality; Brain injury; Ecological validity; Assessment	MULTIPLE; EVENT; PERFORMANCE; VALIDITY; DEFICITS; ADULTS; TIME	The current study aimed to evaluate the sensitivity, convergent validity and ecological validity of a newly developed virtual reality prospective memory (PM) task (i.e., the Virtual Reality Shopping Task; VRST) for use with individuals with traumatic brain injury (TBI). Thirty individuals with severe TBI and 24 uninjured adults matched on age, gender and education level were administered the VRST, a lexical decision PM task (LDPMT), an index of task-friendliness and a cognitive assessment battery. Significant others rated disruptions in the TBI participants' occupational activities, interpersonal relationships and independent living skills. The performance of the TBI group was significantly poorer than that of controls on event-based PM as measured by the LDPMT, and on time-and event-based PM as measured by the VRST. Performance on the VRST significantly predicted significant others' ratings of patients' occupational activities and independent living skills. The VRST was rated as significantly more reflective of an everyday activity, interesting and was afforded a higher recommendation than the LDPMT. For the TBI group, event and total PM performance on the VRST significantly correlated with performance on measures of mental flexibility and verbal fluency, and total PM performance correlated with verbal memory. These results provide preliminary but promising evidence of the sensitivity, as well as the convergent and ecological validity of the VRST.	[Canty, Allana L.; Green, Heather J.; Shum, David H. K.] Griffith Univ, Griffith Hlth Inst, Behav Basis Hlth Res Program, Nathan, Qld 4111, Australia; [Canty, Allana L.; Green, Heather J.; Shum, David H. K.] Griffith Univ, Sch Appl Psychol, Nathan, Qld 4111, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Sch Hlth & Rehabil Sci, Woolloongabba, Qld 4102, Australia; [Fleming, Jennifer] Univ Queensland, St Lucia, Qld, Australia; [Patterson, Freyr] Princess Alexandra Hosp, Occupat Therapy Dept, Woolloongabba, Qld 4102, Australia; [Man, David] Hong Kong Polytech Univ, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China	Shum, DHK (corresponding author), Griffith Univ, Gold Coast Campus, Nathan, Qld 4222, Australia.	d.shum@griffith.edu.au	Shum, David/A-3914-2008; Fleming, Jennifer/AAH-5108-2020; Green, Heather/C-1169-2008	Shum, David/0000-0002-4810-9262; Green, Heather/0000-0003-4254-4076			Benton AL, 1978, MULTILINGUAL APHASIA; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COLTHEART M, 1981, MRC PSYCHOLINGUISTIC; Craik FIM, 2006, MEM COGNITION, V34, P1236, DOI 10.3758/BF03193268; Einstein GO, 2005, CURR DIR PSYCHOL SCI, V14, P286, DOI 10.1111/j.0963-7214.2005.00382.x; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Ellis JA., 1996, PROSPECTIVE MEMORY T, P1; Fleming J, 2008, J INT NEUROPSYCH SOC, V14, P823, DOI 10.1017/S1355617708080971; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS; HARRIS JE, 1982, HUM LEARN, V1, P123; Jansari A., 2004, S JOINT 27 C AUSTR S; Joyner KB, 2009, J PSYCHOEDUC ASSESS, V27, P452, DOI 10.1177/0734282909333945; Kinsella GJ, 2009, BRAIN IMPAIR, V10, P45, DOI 10.1375/brim.10.1.45; Klinger E, 2006, CYBERPSYCHOL BEHAV, V9, P342, DOI 10.1089/cpb.2006.9.342; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Knight RG, 2009, BRAIN IMPAIR, V10, P3, DOI 10.1375/brim.10.1.3; Lam YS, 2006, NEUROREHABILITATION, V21, P245; Levin H., 2002, HDB MEMORY DISORDERS, P381; Logie RH, 2011, MEM COGNITION, V39, P1561, DOI 10.3758/s13421-011-0120-1; Man DWK, 2011, NEUROPSYCHOL REHABIL, V21, P884, DOI 10.1080/09602011.2011.627270; Marsh RL, 1998, J EXP PSYCHOL LEARN, V24, P350, DOI 10.1037/0278-7393.24.2.350; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maujean A., 2003, BRAIN IMPAIR, V4, P135, DOI DOI 10.1375/BRIM.4.2.135.27024; McCauley SR, 2011, J CLIN EXP NEUROPSYC, V33, P639, DOI 10.1080/13803395.2010.547844; McDaniel M. A., 2007, PROSPECTIVE MEMORY O; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; National Health and Medical Research Council (NH&MRC), 2007, NATL STAT ETH COND H; Potvin MJ, 2011, BRAIN INJURY, V25, P192, DOI 10.3109/02699052.2010.541896; Rand D, 2009, AM J OCCUP THER, V63, P535, DOI 10.5014/ajot.63.5.535; Rastle K., 2002, 358 534 NONWORDS ARC; Reitan RM., 1985, HALSTEAD REITAN NEUR; Renison B, 2012, J INT NEUROPSYCH SOC, V18, P440, DOI 10.1017/S1355617711001883; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Schmitter-Edgecombe M, 2009, NEUROPSYCHOLOGY, V23, P168, DOI 10.1037/a0014186; Shallice, 1997, HAYLING BRIXTON TEST; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D, 2011, NEUROPSYCHOLOGIA, V49, P2156, DOI 10.1016/j.neuropsychologia.2011.02.006; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Sweeney S, 2010, NEUROPSYCHOL REHABIL, V20, P239, DOI 10.1080/09602010903080531; Tabachnick BG, 2007, USING MULTIVARIATE S; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wilson B., 2005, CAMBRIDGE PROSPECTIV; Woods SP, 2009, J INT NEUROPSYCH SOC, V15, P42, DOI 10.1017/S1355617708090012	49	28	30	1	24	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	APR	2014	24	2					238	265		10.1080/09602011.2014.881746			28	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	AI9BG	WOS:000337220800005	24559498	Green Accepted			2021-06-18	
J	Ellis, A; Wieseler, J; Favret, J; Johnson, KW; Rice, KC; Maier, SF; Falci, S; Watkins, LR				Ellis, Amanda; Wieseler, Julie; Favret, Jacob; Johnson, Kirk W.; Rice, Kenner C.; Maier, Steven F.; Falci, Scott; Watkins, Linda R.			Systemic Administration of Propentofylline, Ibudilast, and (+)-Naltrexone Each Reverses Mechanical Allodynia in a Novel Rat Model of Central Neuropathic Pain	JOURNAL OF PAIN			English	Article						Avulsion; toll-like receptor 4; D-naltrexone; glia; pain	SPINAL-CORD-INJURY; MIGRATION INHIBITORY FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; ROOT AVULSION; NEURONAL HYPEREXCITABILITY; RECEPTOR 4; PHOSPHODIESTERASE INHIBITOR; GLIAL ACTIVATION; ELEVATING AGENTS	Central neuropathic pain (CNP) is a debilitating consequence of central nervous system damage for which current treatments are ineffective. To explore mechanisms underlying CNP, we developed a rat model involving T13/L1 dorsal root avulsion. The resultant dorsal horn damage creates bilateral below-level (L4-L6) mechanical allodynia. This allodynia, termed spinal neuropathic avulsion pain, occurs in the absence of confounding paralysis. To characterize this model, we undertook a series of studies aimed at defining whether spinal neuropathic avulsion pain could be reversed by any of 3 putative glial activation inhibitors, each with distinct mechanisms of action. Indeed, the phosphodiesterase inhibitor propentofylline, the macrophage migration inhibitory factor inhibitor ibudilast, and the toll-like receptor 4 antagonist (+)-naltrexone each reversed below-level allodynia bilaterally. Strikingly, none of these impacted spinal neuropathic avulsion pain upon first administration but required 1 to 2 weeks of daily administration before pain reversal was obtained. Given reversal of CNP by each of these glial modulatory agents, these results suggest that glia contribute to the maintenance of such pain and enduring release of macrophage migration inhibitory factor and endogenous agonists of toll-like receptor 4 is important for sustaining CNP. The markedly delayed efficacy of all 3 glial modulatory drugs may prove instructive for interpretation of apparent drug failures after shorter dosing regimens. Perspective: CNP that develops after trauma is often described by patients as severe and intolerable. Unfortunately, current treatments are not effective. This work suggests that using pharmacologic treatments that target glial cells could be an effective clinical treatment for CNP. (C) 2014 by the American Pain Society. Published by Elsevier Inc. All rights reserved	[Ellis, Amanda; Wieseler, Julie; Favret, Jacob; Maier, Steven F.; Watkins, Linda R.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA; [Johnson, Kirk W.] Medicinova, San Diego, CA USA; [Rice, Kenner C.] NIDA, Chem Biol Res Branch, Rockville, MD USA; [Rice, Kenner C.] NIAAA, NIH, Rockville, MD 20852 USA; [Falci, Scott] Craig Hosp, Englewood, CO USA	Ellis, A (corresponding author), Univ Colorado, Dept Psychol & Neurosci, 345 UCB, Boulder, CO 80309 USA.	ellisal@colorado.edu		Falci, Scott/0000-0003-4209-0959	Craig Hospital;  [DA024044]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE021966] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K05DA024044, ZIADA000530] Funding Source: NIH RePORTER	Financial and material support was given by Craig Hospital and DA024044. All animal work was done on the University of Colorado Boulder campus.	Alexander JK, 2012, EXP NEUROL, V236, P351, DOI 10.1016/j.expneurol.2012.04.018; Alvarez Y, 2009, J IMMUNOL, V183, P1471, DOI 10.4049/jimmunol.0900312; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; BANATI RB, 1994, J CEREBR BLOOD F MET, V14, P145, DOI 10.1038/jcbfm.1994.19; Bao F, 2011, J NEUROTRAUM, V28, P1035, DOI 10.1089/neu.2010.1575; Berland D, 2012, AM FAM PHYSICIAN, V86, P252; Berman JS, 1998, PAIN, V75, P199, DOI 10.1016/S0304-3959(97)00220-0; Bland ST, 2009, BRAIN BEHAV IMMUN, V23, P492, DOI 10.1016/j.bbi.2009.01.014; Boivie J, 2006, HAND CLINIC, V81, P715, DOI 10.1016/S0072-9752(06)80052-7; Breuer B, 2007, CLIN THER, V29, P2022, DOI 10.1016/j.clinthera.2007.09.023; Buchanan MM, 2010, J NEUROCHEM, V114, P13, DOI 10.1111/j.1471-4159.2010.06736.x; Burstein R, 2004, ANN NEUROL, V55, P19, DOI 10.1002/ana.10786; Calvo M, 2012, EXP NEUROL, V234, P271, DOI 10.1016/j.expneurol.2011.08.018; Carlstedt T, 2008, RESTOR NEUROL NEUROS, V26, P225; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chew DJ, 2011, NEUROPATH APPL NEURO, V37, P613, DOI 10.1111/j.1365-2990.2011.01176.x; Chew DJ, 2013, J NEUROTRAUM, V30, P160, DOI 10.1089/neu.2012.2481; Cho Y, 2010, P NATL ACAD SCI USA, V107, P11313, DOI 10.1073/pnas.1002716107; Diogenes A, 2011, J DENT RES, V90, P759, DOI 10.1177/0022034511400225; EDGAR RE, 1993, J SPINAL DISORD, V6, P48; Eigler A, 1998, J LEUKOCYTE BIOL, V63, P101; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; Falci S, 2002, J NEUROSURG, V97, P193, DOI 10.3171/spi.2002.97.2.0193; Finnerup NB, 2008, CURR OPIN ANESTHESIO, V21, P586, DOI 10.1097/ACO.0b013e32830a4c11; Frampton MA, 2003, COCHRANE DB SYST REV; Fujimoto T, 1999, J NEUROIMMUNOL, V95, P35, DOI 10.1016/S0165-5728(98)00251-3; Graeber MB, 2012, EXP NEUROL, V234, P255, DOI 10.1016/j.expneurol.2012.01.007; Gwak YS, 2009, NEUROSCIENCE, V161, P895, DOI 10.1016/j.neuroscience.2009.03.055; Gwak YS, 2009, EXP NEUROL, V220, P154, DOI 10.1016/j.expneurol.2009.08.012; Gwak YS, 2008, PAIN, V138, P410, DOI 10.1016/j.pain.2008.01.021; Gwak YS, 2007, J NEUROSCI RES, V85, P2352, DOI 10.1002/jnr.21379; Hagman S, 2011, J NEUROIMMUNOL, V234, P141, DOI 10.1016/j.jneuroim.2011.02.009; Hama AT, 2012, J NEUROTRAUM, V29, P600, DOI 10.1089/neu.2011.1863; HARVEY LO, 1986, BEHAV RES METH INSTR, V18, P623, DOI 10.3758/BF03201438; Heblich Fay, 2008, Channels (Austin), V2, P4; Hook MA, 2007, BEHAV BRAIN RES, V179, P281, DOI 10.1016/j.bbr.2007.02.035; Hutchinson MR, 2012, J NEUROSCI, V32, P11187, DOI 10.1523/JNEUROSCI.0684-12.2012; Hutchinson MR, 2008, EUR J NEUROSCI, V28, P20, DOI 10.1111/j.1460-9568.2008.06321.x; Hutchinson MR, 2011, PHARMACOL REV, V63, P772, DOI 10.1124/pr.110.004135; Hutchinson MR, 2010, BRAIN BEHAV IMMUN, V24, P83, DOI 10.1016/j.bbi.2009.08.004; Jin S-L Catherine, 2012, Chang Gung Med J, V35, P197; Jones TL, 2004, J PHARMACOL EXP THER, V310, P223, DOI 10.1124/jpet.103.064741; Jung S, 1997, J AUTOIMMUN, V10, P519, DOI 10.1006/jaut.1997.0159; Kim Y, 2012, PAIN, V153, P1022, DOI 10.1016/j.pain.2012.02.003; Kukkar A, 2013, ARCH PHARM RES, V36, P237, DOI 10.1007/s12272-013-0057-y; Ledeboer A, 2006, NEURON GLIA BIOL, V2, P279, DOI 10.1017/S1740925X0700035X; Ledeboer A, 2007, EXPERT OPIN INV DRUG, V16, P935, DOI 10.1517/13543784.16.7.935; Lee JY, 2012, BRAIN RES, V1431, P97, DOI 10.1016/j.brainres.2011.11.007; Li HG, 2007, DIGEST DIS SCI, V52, P1973, DOI 10.1007/s10620-006-9211-4; Li LC, 2008, ARTHRIT RHEUM-ARTHR, V59, P1171, DOI 10.1002/art.23931; Madelian V, 1996, BIOCHEM PHARMACOL, V51, P1739, DOI 10.1016/0006-2952(96)00167-0; Methe H, 2005, CIRCULATION, V111, P2654, DOI 10.1161/CIRCULATIONAHA.104.498865; Milligan ED, 2001, J NEUROSCI, V21, P2808, DOI 10.1523/JNEUROSCI.21-08-02808.2001; Morales F, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4030; NAGATA K, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1034; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nishio Y, 2009, ACTA NEUROPATHOL, V117, P321, DOI 10.1007/s00401-008-0476-x; Obata H, 2010, BRAIN RES, V1363, P72, DOI 10.1016/j.brainres.2010.09.105; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Raghavendra V, 2003, J PHARMACOL EXP THER, V306, P624, DOI 10.1124/jpet.103.052407; Rahn KA, 2011, BRAIN RES, V1381, P243, DOI 10.1016/j.brainres.2011.01.036; Rile G, 2001, THROMB RES, V102, P239, DOI 10.1016/S0049-3848(01)00258-4; Rintala DH, 2007, ARCH PHYS MED REHAB, V88, P1547, DOI 10.1016/j.apmr.2007.07.038; Rolan P, 2009, EXPERT OPIN PHARMACO, V10, P2897, DOI 10.1517/14656560903426189; Schubert P, 2000, ANN NY ACAD SCI, V903, P24, DOI 10.1111/j.1749-6632.2000.tb06346.x; Sebastiani G, 2006, NEUROBIOL AGING, V27, P691, DOI 10.1016/j.neurobiolaging.2005.03.024; Shichita T, 2012, J NEUROCHEM, V123, P29, DOI 10.1111/j.1471-4159.2012.07941.x; Siddall PJ, 1999, PAIN, V81, P187, DOI 10.1016/S0304-3959(99)00023-8; Siegmund B, 1997, EUR J PHARMACOL, V321, P231, DOI 10.1016/S0014-2999(96)00947-8; Stein A, 2013, ARCH PHYS MED REHAB, V94, P1498, DOI 10.1016/j.apmr.2013.04.004; Sweitzer Sarah, 2011, Handb Exp Pharmacol, P235, DOI 10.1007/978-3-642-13443-2_8; Sweitzer SM, 2001, J PHARMACOL EXP THER, V297, P1210; Tawfik VL, 2008, NEUROSCIENCE, V152, P1086, DOI 10.1016/j.neuroscience.2008.01.065; Tawfik VL, 2007, BRAIN BEHAV IMMUN, V21, P238, DOI 10.1016/j.bbi.2006.07.001; Theberge FR, 2013, BIOL PSYCHIAT, V73, P729, DOI 10.1016/j.biopsych.2012.12.019; Thompson CD, 2013, J NEUROTRAUM, V30, P1311, DOI 10.1089/neu.2012.2651; Toh ML, 2006, J IMMUNOL, V177, P4818, DOI 10.4049/jimmunol.177.7.4818; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vakili A, 2011, DARU, V19, P306; Wang LJ, 2009, STROKE, V40, P973, DOI 10.1161/STROKEAHA.108.530535; Watkins LR, 2012, EXP NEUROL, V234, P351, DOI 10.1016/j.expneurol.2012.01.006; Whitehead KJ, 2010, BRAIN BEHAV IMMUN, V24, P569, DOI 10.1016/j.bbi.2009.12.007; Wieseler J, 2012, METHODS MOL BIOL, V851, P171, DOI 10.1007/978-1-61779-561-9_12; Wieseler J, 2010, J NEUROTRAUM, V27, P1697, DOI 10.1089/neu.2010.1311; Woller SA, 2012, J NEUROTRAUM, V29, P1650, DOI 10.1089/neu.2011.2100; Yoshikawa M, 1999, MULT SCLER J, V5, P126, DOI 10.1191/135245899678847194; Yoshioka A, 1998, J NEUROCHEM, V70, P2416; ZHANG Y, 1994, BIOCHEM PHARMACOL, V48, P2025, DOI 10.1016/0006-2952(94)90501-0; Zhou ZG, 2009, EXP NEUROL, V220, P183, DOI 10.1016/j.expneurol.2009.08.018	89	28	28	0	6	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	APR	2014	15	4					407	421		10.1016/j.jpain.2013.12.007			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AF3YM	WOS:000334648600007	24412802	Green Accepted			2021-06-18	
J	Mannelli, LD; Pacini, A; Matera, C; Zanardelli, M; Mello, T; De Amici, M; Dallanoce, C; Ghelardini, C				Mannelli, Lorenzo Di Cesare; Pacini, Alessandra; Matera, Carlo; Zanardelli, Matteo; Mello, Tommaso; De Amici, Marco; Dallanoce, Clelia; Ghelardini, Carla			Involvement of alpha 7 nAChR subtype in rat oxaliplatin-induced neuropathy: Effects of selective activation	NEUROPHARMACOLOGY			English	Article						Neuropathic pain; Microglia; Astrocyte; alpha 7 nAChR; alpha 4 nAChR; Receptor down-regulation; Receptor up-regulation; Neuroprotection	NICOTINIC ACETYLCHOLINE-RECEPTOR; POSITIVE ALLOSTERIC MODULATORS; INDUCED PERIPHERAL NEUROPATHY; TRAUMATIC BRAIN-INJURY; UP-REGULATION; CHRONIC PAIN; DIFFERENT SCHEDULES; CHOLINERGIC SYSTEM; 1ST-LINE TREATMENT; ADJUVANT TREATMENT	Oxaliplatin, unlike other platinum anticancer agents, has only mild toxic effects on the hematopoietic, urinary and gastrointestinal systems. Its dose-limiting side effect is neurotoxicity that may evolve to a neuropathic syndrome which is difficult to treat. In this study we treated rats with oxaliplatin (2.4 mg/kg/day intraperitoneally, for 3 weeks), and observed that expression levels of the alpha 7 nicotinic acetylcholine receptor (nAChR) subunit were dramatically decreased both in the peripheral and central nervous system. The repeated administration (30 mg/kg/day per os, for 3 weeks) of (R)-ICH3, the most active enantiomer of a novel alpha 7 nAChR agonist, and of PNU-282987 prevented the receptor down-regulation. On the other hand, both agonists per se up-regulated the alpha 7 nAChR subunit compared to control. (R)-ICH3 and PNU-282987 significantly reduced oxaliplatin-dependent alterations of the pain threshold when noxious or non-noxious stimuli were used. Further ex vivo analysis highlighted their neuroprotective effects in dorsal root ganglia and peripheral nerves. The two agonists did not prevent the increase in microglia cell number induced by oxaliplatin in the central nervous system. Astrocyte density was enhanced by the agonist treatment in the spinal cord, thalamus and somatosensory area 1 as opposed to the effects of oxaliplatin treatment. (R)-ICH3 and PNU-282987 per se increased glial cell number in a region-specific manner. In summary, alpha 7 nAChR is involved in oxaliplatin-dependent neuropathology and the agonists (R)-ICH3 and PNU-282987 reduce pain and protect nervous tissue with concomitant glial activation. Since glial cells play a role both in pain and in neuroprotection, an alpha 7 AChR-dependent modulation of glial functions is suggested to distinguish rescue signals from the pathological pain-mediating pathway. (C) 2013 Elsevier Ltd. All rights reserved.	[Mannelli, Lorenzo Di Cesare; Zanardelli, Matteo; Ghelardini, Carla] Univ Florence, Dipartimento Neurosci, Area Farmaco & Salute Bambino, Neurofarba,Sez Farmacol & Tossicol, I-50139 Florence, Italy; [Pacini, Alessandra] Univ Florence, DMSC, Sez Anat & Istol, I-50134 Florence, Italy; [Mello, Tommaso] Univ Florence, Dipartimento Sci Biomed Sperimentali & Clin SBSC, I-50134 Florence, Italy; [Matera, Carlo; De Amici, Marco; Dallanoce, Clelia] Univ Milan, Dipartimento Sci Farmaceut, Sez Chim Farmaceut Pietro Pratesi, I-20133 Milan, Italy	Mannelli, LD (corresponding author), Univ Florence, Dipartimento Neurosci, Area Farmaco & Salute Bambino, Neurofarba,Sez Farmacol & Tossicol, Viale Pieraccini 6, I-50139 Florence, Italy.	lorenzo.mannelli@unifi.it	Mello, Tommaso/I-4715-2012; Mello, Tommaso/AAO-7831-2021; Matera, Carlo/G-3808-2015; De Amici, Marco/F-9684-2015; Di Cesare Mannelli, Lorenzo/A-1641-2015	Mello, Tommaso/0000-0002-6192-6902; Mello, Tommaso/0000-0002-6192-6902; Matera, Carlo/0000-0001-6939-3859; GHELARDINI, CARLA/0000-0001-9856-8144; De Amici, Marco/0000-0002-0236-0662; Dallanoce, Clelia/0000-0002-7383-1484; Di Cesare Mannelli, Lorenzo/0000-0001-8374-4432	Italian Ministry of Instruction, University and Research (MIUR)Ministry of Education, Universities and Research (MIUR); University of Florence; Italian MIURMinistry of Education, Universities and Research (MIUR) [PRIN 2009RTWCZS]; "Dote ricerca": FSE, Regione LombardiaRegione Lombardia	This research was funded by the Italian Ministry of Instruction, University and Research (MIUR) and by the University of Florence. In particular, MDA wishes to thank the Italian MIUR, contract grant number: PRIN 2009RTWCZS. Carlo Matera wishes to thank "Dote ricerca": FSE, Regione Lombardia for co-financing his postdoctoral position. The authors have no conflicts of interest to declare.	Albers J.W., 2011, COCHRANE DB SYST REV, V2; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Argyriou AA, 2012, CRIT REV ONCOL HEMAT, V82, P51, DOI 10.1016/j.critrevonc.2011.04.012; Banerjee C, 2000, NEUROBIOL DIS, V7, P666, DOI 10.1006/nbdi.2000.0317; Bannon AW, 1998, SCIENCE, V279, P77, DOI 10.1126/science.279.5347.77; Bartolini Alessandro, 2011, Recent Pat CNS Drug Discov, V6, P119; Benfante R, 2011, J NEUROIMMUNOL, V230, P74, DOI 10.1016/j.jneuroim.2010.09.008; Bodnar AL, 2005, J MED CHEM, V48, P905, DOI 10.1021/jm049363q; Boivin A, 2007, J NEUROSCI, V27, P12565, DOI 10.1523/JNEUROSCI.3027-07.2007; Boylan K, 2009, J NEUROCHEM, V111, P1182, DOI 10.1111/j.1471-4159.2009.06386.x; Burghaus L, 2003, PARKINSONISM RELAT D, V9, P243, DOI 10.1016/S1353-8020(03)00028-2; Carnevale D., 2007, CNS & Neurological Disorders-Drug Targets, V6, P388; Cavaletti G, 2001, EUR J CANCER, V37, P2457, DOI 10.1016/S0959-8049(01)00300-8; Chernyavsky AI, 2010, AM J PHYSIOL-CELL PH, V299, pC903, DOI 10.1152/ajpcell.00216.2010; Christensen DZ, 2010, J NEUROCHEM, V114, P1205, DOI 10.1111/j.1471-4159.2010.06845.x; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; COGGESHALL RE, 1990, J NEUROSCI METH, V35, P187, DOI 10.1016/0165-0270(90)90123-W; Czura CJ, 2005, J INTERN MED, V257, P156, DOI 10.1111/j.1365-2796.2004.01442.x; Dallanoce C, 2011, CHEMMEDCHEM, V6, P889, DOI 10.1002/cmdc.201000514; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Di Cesare Mannelli L, 2013, J PAIN, DOI DOI 10.1016/JJPAIN.2013.08.002; Ferchmin PA, 2003, J PHARMACOL EXP THER, V305, P1071, DOI 10.1124/jpet.102.048173; Floto RA, 2003, LANCET, V361, P1069, DOI 10.1016/S0140-6736(03)12902-9; Galitovskiy V, 2011, J IMMUNOL, V187, P2677, DOI 10.4049/jimmunol.1002711; Ghelardini C, 2000, BRIT J PHARMACOL, V129, P1633, DOI 10.1038/sj.bjp.0703268; Govind AP, 2009, BIOCHEM PHARMACOL, V78, P756, DOI 10.1016/j.bcp.2009.06.011; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; Guo LH, 2007, CELL MOL LIFE SCI, V64, P1128, DOI 10.1007/s00018-007-6494-3; Hajos M, 2005, J PHARMACOL EXP THER, V312, P1213, DOI 10.1124/jpet.104.076968; Hellstrom-Lindahl E, 1999, MOL BRAIN RES, V66, P94, DOI 10.1016/S0169-328X(99)00030-3; Holmes J, 1998, TOXICOL SCI, V46, P342, DOI 10.1006/toxs.1998.2558; Iwamoto K, 2013, NEUROSCIENCE, V237, P184, DOI 10.1016/j.neuroscience.2013.02.003; Jones PG, 2007, NEUROPHARMACOLOGY, V53, P197, DOI 10.1016/j.neuropharm.2007.04.002; Jonnala RR, 2001, J NEUROSCI RES, V66, P565, DOI 10.1002/jnr.10022; Kaley TJ, 2009, BRIT J HAEMATOL, V145, P3, DOI 10.1111/j.1365-2141.2008.07558.x; Kannarkat G, 2007, CURR OPIN NEUROL, V20, P719; Kawashima K, 2003, LIFE SCI, V74, P675, DOI 10.1016/j.lfs.2003.09.037; Kelso ML, 2006, BRAIN RES, V1083, P204, DOI 10.1016/j.brainres.2006.01.127; Kim SJ, 2004, MOL CELLS, V17, P242; Laudenbach V, 2002, FASEB J, V16, P423, DOI 10.1096/fj.01-0532fje; LEIGHTON GE, 1988, BRIT J PHARMACOL, V93, P553, DOI 10.1111/j.1476-5381.1988.tb10310.x; Lester HA, 2009, AAPS J, V11, P167, DOI 10.1208/s12248-009-9090-7; Libert C, 2003, NATURE, V421, P328, DOI 10.1038/421328a; Loram LC, 2012, J PAIN, V13, P1162, DOI 10.1016/j.jpain.2012.08.009; Malaspina A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-500; Malysz J, 2009, ASSAY DRUG DEV TECHN, V7, DOI 10.1089/adt.2009.0194; Mannelli LD, 2013, FREE RADICAL BIO MED, V61, P143, DOI 10.1016/j.freeradbiomed.2013.03.019; Mannelli LDC, 2007, EUR J NEUROSCI, V26, P820, DOI 10.1111/j.1460-9568.2007.05722.x; Mannelli LD, 2012, J PAIN, V13, P276, DOI 10.1016/j.jpain.2011.11.009; Mannelli LDC, 2009, J NEUROSCI RES, V87, P200, DOI 10.1002/jnr.21815; Marchand F, 2005, NAT REV NEUROSCI, V6, P521, DOI 10.1038/nrn1700; Martin SE, 2004, BRAIN RES, V1022, P254, DOI 10.1016/j.brainres.2004.07.016; Melzack R, 1999, PAIN, pS121, DOI 10.1016/S0304-3959(99)00145-1; Millar NS, 2008, MOL MEMBR BIOL, V25, P279, DOI 10.1080/09687680802035675; Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533; Mudo G, 2007, J NEURAL TRANSM, V114, P135, DOI 10.1007/s00702-006-0561-z; MULLER LJ, 1990, CANCER RES, V50, P2437; Obata K, 2003, PAIN, V101, P65, DOI 10.1016/S0304-3959(02)00296-8; Ono K, 2008, NEUROSCIENCE, V154, P994, DOI 10.1016/j.neuroscience.2008.04.028; Pacini A, 2010, PAIN, V150, P542, DOI 10.1016/j.pain.2010.06.014; Parada E, 2013, ANTIOXID REDOX SIGN, V19, P1135, DOI 10.1089/ars.2012.4671; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Petrioli R, 2008, CANCER CHEMOTH PHARM, V61, P105, DOI 10.1007/s00280-007-0454-3; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Rowbotham MC, 2009, PAIN, V146, P245, DOI 10.1016/j.pain.2009.06.013; Sakurai M, 2009, PAIN, V147, P165, DOI 10.1016/j.pain.2009.09.003; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; Seifert F, 2011, CURR OPIN ANESTHESIO, V24, P515, DOI 10.1097/ACO.0b013e32834a1079; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shen H, 2010, BRIT J PHARMACOL, V161, P127, DOI 10.1111/j.1476-5381.2010.00894.x; Souglakos J, 2002, J CLIN ONCOL, V20, P2651, DOI 10.1200/JCO.2002.08.015; Sung CS, 2012, GLIA, V60, P2004, DOI 10.1002/glia.22415; Suzuki T, 2006, J NEUROSCI RES, V83, P1461, DOI 10.1002/jnr.20850; Thomsen MS, 2012, J NEUROCHEM, V123, P73, DOI 10.1111/j.1471-4159.2012.07876.x; Thomsen MS, 2012, J NEUROIMMUNOL, V251, P65, DOI 10.1016/j.jneuroim.2012.07.006; Thomsen MS, 2012, CURR DRUG TARGETS, V13, P707, DOI 10.2174/138945012800399035; TOMIWA K, 1986, ACTA NEUROPATHOL, V69, P295, DOI 10.1007/BF00688308; Tracey KJ, 2001, FASEB J, V15, P1575, DOI 10.1096/fj.01-0148hyp; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Ulloa L, 2005, NAT REV DRUG DISCOV, V4, P673, DOI 10.1038/nrd1797; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Vincler M, 2007, EXPERT OPIN THER TAR, V11, P891, DOI 10.1517/14728222.11.7.891; Wala EP, 2012, ANESTH ANALG, V115, P713, DOI 10.1213/ANE.0b013e31825a3c72; Walker DP, 2006, BIOORGAN MED CHEM, V14, P8219, DOI 10.1016/j.bmc.2006.09.019; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wilson RH, 2002, J CLIN ONCOL, V20, P1767, DOI 10.1200/JCO.2002.07.056; Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018; WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z	88	28	28	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2014	79						37	48		10.1016/j.neuropharm.2013.10.034			12	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AE1ZX	WOS:000333774200005	24225197				2021-06-18	
J	Nirula, R; Millar, D; Greene, T; McFadden, M; Shah, L; Scalea, TM; Stein, DM; Magnotti, LJ; Jurkovich, GJ; Vercruysse, G; Demetriades, D; Scherer, LA; Peitzman, A; Sperry, J; Beauchamp, K; Bell, S; Feiz-Erfan, I; O'Neill, P; Coimbra, R				Nirula, Ram; Millar, D.; Greene, Tom; McFadden, Molly; Shah, Lubdha; Scalea, Thomas M.; Stein, Deborah M.; Magnotti, Louis J.; Jurkovich, Gregory J.; Vercruysse, Gary; Demetriades, Demetrios; Scherer, Lynette A.; Peitzman, Andrew; Sperry, Jason; Beauchamp, Kathryn; Bell, Scott; Feiz-Erfan, Iman; O'Neill, Patrick; Coimbra, Raul			Decompressive craniectomy or medical management for refractory intracranial hypertension: An AAST-MIT propensity score analysis	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Decompressive craniectomy; mortality; propensity; brain injury	TRAUMATIC BRAIN-INJURY; CHILDREN; ICP	BACKGROUND Moderate/severe traumatic brain injury (TBI) management involves minimizing cerebral edema to maintain brain oxygen delivery. While medical therapy (MT) consisting of diuresis, hyperosmolar therapy, ventriculostomy, and barbiturate coma is the standard of care, decompressive craniectomy (DC) for refractory intracranial hypertension (ICH) has gained renewed interest. Since TBI treatment guidelines consider DC a second-tier intervention after MT failure, we sought to determine if early DC (< 48 hours) was associated with improved survival in patients with refractory ICH. METHODS Eleven Level 1 trauma centers provided clinical data and head computed tomographic scans for patients with a Glasgow Coma Scale (GCS) score of 13 or less and radiographic evidence of TBI excluding deaths within 48 hours. Computed tomographic scans were graded according to the Marshall classification. A propensity score to receive DC (regardless of whether DC was performed) was calculated for each patient based on patient characteristics, physiology, injury severity, GCS, severity of intracranial injury, and treatment center. Patients who actually received a DC were matched to patients with similar propensity scores who received MT for analysis. Outcomes were compared between early (< 48 hours of injury) primary or secondary DC and matched controls and then between early primary DC only and matched controls. RESULTS There were 2,602 patients who met the inclusion criteria ,of whom 264 (10.1%) received DC (either primary or secondary to another cranial procedure) and 109 (5%) had a DC that was primary. Variables associated with performing a DC included sex, race, intracranial pressure monitor placement, in-house trauma attending, traumatic subarachnoid hemorrhage, midline shift, and basal cistern compression. There was no survival benefit with early primary DC compared with the controls (relative risk, 1.07; 95% confidence interval, 0.67-1.73; p = 0.77), and resource use was higher. CONCLUSION Early DC does not seem to significantly improve mortality in patients with refractory ICH compared with MT. Neurosurgeons should pause before entertaining this resource-demanding form of therapy. LEVEL OF EVIDENCE Therapeutic care/management, level III.	[Nirula, Ram; Millar, D.; Greene, Tom; McFadden, Molly; Shah, Lubdha] Univ Utah, Salt Lake City, UT 84132 USA; [Scalea, Thomas M.; Stein, Deborah M.] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA; [Magnotti, Louis J.] Univ Tennessee, Memphis, TN USA; [Jurkovich, Gregory J.] Univ Washington, Seattle, WA 98195 USA; [Vercruysse, Gary] Emory Univ, Atlanta, GA 30322 USA; [Demetriades, Demetrios] Univ So Calif, Los Angles Cty Med Ctr, Los Angeles, CA USA; [Scherer, Lynette A.] Univ Calif Davis, Sacramento, CA 95817 USA; [Coimbra, Raul] Univ Calif San Diego, San Diego, CA 92103 USA; [Peitzman, Andrew; Sperry, Jason] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Beauchamp, Kathryn; Bell, Scott] Univ Colorado, Denver Hlth, Denver, CO 80202 USA; [Feiz-Erfan, Iman; O'Neill, Patrick] Maricopa Integrated Hlth Syst, Phoenix, AZ USA	Nirula, R (corresponding author), Univ Utah, Dept Surg, 50 North Med Dr, Salt Lake City, UT 84132 USA.	r.nirula@hsc.utah.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851; Greene, Tom/0000-0002-3706-7570	American Recovery and Reinvestment Act/NIH National Institute of Neurological Disorders and Stroke [1RC1NS069066-01, 5RC1NS069066-02]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC1NS069066] Funding Source: NIH RePORTER	This study was supported by a Challenge Grant supported by the American Recovery and Reinvestment Act/NIH National Institute of Neurological Disorders and Stroke (1RC1NS069066-01 and 5RC1NS069066-02).	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Ahmadi SA, 2010, BRAIN INJURY, V24, P1539, DOI 10.3109/02699052.2010.523049; Akyuz M, 2010, TURK NEUROSURG, V20, P382, DOI 10.5137/1019-5149.JTN.2785-09.1; Al-Jishi A, 2011, CAN J NEUROL SCI, V38, P612, DOI 10.1017/S0317167100012154; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bao YH, 2010, J NEUROTRAUM, V27, P341, DOI 10.1089/neu.2009.1040; Bergstralh EJ, 2003, LOCALLY WRITTEN SAS; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Cavusoglu H, 2010, ULUS TRAVMA ACIL CER, V16, P119; Centers for Disease Control and Prevention (CDC), 2008, TRAUMATIC BRAIN INJU; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Eberle BM, 2010, INJURY, V41, P894, DOI 10.1016/j.injury.2010.02.023; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Honeybul S, 2012, J NEUROTRAUM, V29, P1872, DOI 10.1089/neu.2012.2356; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Huang APH, 2008, J NEUROTRAUM, V25, P1347, DOI 10.1089/neu.2008.0625; Hutchinson P, 2011, CAN J NEUROL SCI, V38, P541, DOI 10.1017/S0317167100012051; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kunze E, 1998, ACT NEUR S, V71, P16; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Li G, 2008, CHIN J TRAUMATOL, V11, P253, DOI 10.1016/S1008-1275(08)60052-8; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Munch E, 2000, NEUROSURGERY, V47, P315; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Rekate Harold L., 2001, Child's Nervous System, V17, P632, DOI 10.1007/s003810100487; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Schneider GH, 2002, ACT NEUR S, V81, P77; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Wang HK, 2012, INJURY, V43, P594, DOI 10.1016/j.injury.2010.06.004; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Yatsushige H, 2010, ACTA NEUROCHIR SUPPL, V106, P265, DOI 10.1007/978-3-211-98811-4_50	40	28	28	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2014	76	4					944	952		10.1097/TA.0000000000000194			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AE7FF	WOS:000334161500012	24662856				2021-06-18	
J	Saw, MM; Chamberlain, J; Barr, M; Morgan, MPG; Burnett, JR; Ho, KM				Saw, Melanie M.; Chamberlain, Jenny; Barr, Michelle; Morgan, Matt P. G.; Burnett, John R.; Ho, Kwok M.			Differential Disruption of Blood-Brain Barrier in Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Blood-brain barrier dysfunction; Traumatic brain injury; Cerebrospinal fluid; External ventricular drain	CEREBROSPINAL-FLUID; INTRACRANIAL-PRESSURE; SODIUM-CHLORIDE; SALINE; SERUM; HYPERTENSION; VALIDATION; BREAKDOWN; PLASMA; RAT	Traumatic brain injury (TBI) is a significant cause of death and disability in young adults, but not much is known about the incidence and characteristics of blood-brain barrier (BBB) dysfunction in this group. In this proof of concept study, we sought to quantify the incidence of BBB dysfunction (defined as a cerebrospinal fluid (CSF)-plasma albumin quotient of a parts per thousand yen0.007) and examine the relationship between plasma and CSF levels of proteins and electrolytes, in patients with severe TBI. We recruited 30 patients, all of whom were receiving hypertonic 20 % saline infusion for intracranial hypertension and had external ventricular drains in situ. Simultaneous CSF and blood samples were obtained. Biochemical testing was performed for sodium, osmolality, potassium, glucose, albumin, immunoglobulin-G, and total protein. Eleven patients (37 %) showed evidence of impairment of passive BBB function, with a CSF-plasma albumin quotient of a parts per thousand yen0.007. There were strong positive correlations seen among CSF-plasma albumin quotient and CSF-plasma immunoglobulin-G quotient and CSF-plasma total protein quotient (r = 0.967, P < 0.001 and r = 0.995, P < 0.001, respectively). We also found a higher maximum intracranial pressure (24 vs. 21 mmHg, P = 0.029) and a trend toward increased mortality (27 vs. 11 %, P = 0.33) in patients with BBB disruption. In summary, passive BBB dysfunction is common in patients with severe TBI, and may have important implications for effectiveness of osmotherapy and long-term outcomes. Also, our results suggest that the CSF-plasma total protein quotient, a measurement which is readily available, can be used instead of the CSF-plasma albumin quotient for evaluating BBB dysfunction.	[Saw, Melanie M.] Fremantle Hosp, Intens Care Unit, Fremantle, WA 6959, Australia; [Chamberlain, Jenny; Barr, Michelle; Ho, Kwok M.] Royal Perth Hosp, Intens Care Unit, Perth, WA 6001, Australia; [Morgan, Matt P. G.] Cardiff Univ, Sch Med, Cardiff CF14 4XN, S Glam, Wales; [Burnett, John R.] Royal Perth Hosp, PathWest Lab Med, Dept Clin Biochem, Perth, WA 6001, Australia; [Burnett, John R.] Univ Western Australia M570, Sch Med & Pharmacol, Crawley, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia	Saw, MM (corresponding author), Fremantle Hosp, Intens Care Unit, POB 480, Fremantle, WA 6959, Australia.	melanie.saw@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004	Royal Perth Hospital Medical Research Foundation	JRB was supported by a Practitioner Fellowship from the Royal Perth Hospital Medical Research Foundation.	BALDYMOULINIER M, 1971, EUR NEUROL, V6, P107, DOI 10.1159/000114476; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Cooper DJ, 2013, J NEUROTRAUM, V30, P512, DOI 10.1089/neu.2012.2573; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Gagliardi R J, 1982, Arq Neuropsiquiatr, V40, P230; Harrington Michael G, 2010, Cerebrospinal Fluid Res, V7, P3, DOI 10.1186/1743-8454-7-3; Ho KM, 2012, ANAESTH INTENS CARE, V40, P595, DOI 10.1177/0310057X1204000403; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jeffcote T, 2010, ANAESTH INTENS CARE, V38, P274, DOI 10.1177/0310057X1003800208; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Kerwin AJ, 2009, J TRAUMA, V67, P277, DOI 10.1097/TA.0b013e3181acc726; Lazaridis C, 2013, CRIT CARE MED, V41, P1353, DOI 10.1097/CCM.0b013e31827ca4b3; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Polderman KH, 2003, CRIT CARE MED, V31, P584, DOI 10.1097/01.CCM.0000050287.68977.84; Privitera MD, 2010, CLIN CHEM THEORY ANA, p[907, 923]; Reiber H, 2001, J NEUROL SCI, V184, P101, DOI 10.1016/S0022-510X(00)00501-3; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; The National Health and Medical Research Council (Australia), 2007, NAT STAT ETH COND HU; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; von Holst H, 1990, Br J Neurosurg, V4, P123; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA	32	28	28	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2014	20	2					209	216		10.1007/s12028-013-9933-z			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	AD0XA	WOS:000332956400006	24233818				2021-06-18	
J	Johansson, B; Wentzel, AP; Andrell, P; Odenstedt, J; Mannheimer, C; Ronnback, L				Johansson, B.; Wentzel, A. -P.; Andrell, P.; Odenstedt, J.; Mannheimer, C.; Ronnback, L.			Evaluation of dosage, safety and effects of methylphenidate on post-traumatic brain injury symptoms with a focus on mental fatigue and pain	BRAIN INJURY			English	Article						TBI; mental fatigue; pain; methylphenidate; safety	DOUBLE-BLIND; HEAD-INJURY; ATTENTION DEFICITS; VITAL SIGNS; MILD; PLACEBO; DISORDER; MODERATE; ADULTS; REHABILITATION	Objective: The neurobehavioural symptoms and pain following traumatic brain injury (TBI) can be long-lasting. The condition impairs the persons' ability to function in their work, studies and gatherings with family and friends. The aim of this study was to investigate dosage, safety and effects of methylphenidate on mental fatigue and pain. Methods: Twenty-nine physically-well rehabilitated TBI victims, 28 with a mild TBI and one with TBI and also with pain in the neck, shoulders and head were included in the study. Methylphenidate was tested in each patient using three treatment strategies: no medication, low dose (5 mg x 3) and normal dose (20 mg x 3) for 4 weeks using a randomized cross-over design. Results: Twenty-four patients completed the three treatment periods. Five participants discontinued, four females due to adverse reactions and one male due to attenuated motivation. Only minor adverse events were reported. Methylphenidate significantly decreased mental fatigue, as evaluated by the Mental Fatigue Scale (p < 0.001), and the effects on mental fatigue were dose-dependent. No effect on pain was detected. Conclusions: Methylphenidate decreased mental fatigue for subjects suffering a traumatic brain injury, the treatment is considered to be safe and is recommended, starting with a low dose.	[Johansson, B.; Ronnback, L.] Univ Gothenburg, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, S-41345 Gothenburg, Sweden; [Wentzel, A. -P.; Andrell, P.; Mannheimer, C.] Univ Gothenburg, Sahlgrenska Univ Hosp, Ctr Multidisciplinary Pain, Dept Mol & Clin Med,Inst Med, S-41345 Gothenburg, Sweden; [Wentzel, A. -P.; Mannheimer, C.] Kungalv Hosp, Pain Ctr, Gothenburg, Sweden; [Odenstedt, J.] Sahlgrens Univ Hosp, Dept Cardiol, Gothenburg, Sweden	Johansson, B (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Per Dubbsgatan 14,1tr, S-41345 Gothenburg, Sweden.	birgitta.johansson@neuro.gu.se		, Birgitta/0000-0003-0240-1142	Health & Medical Care Committee of the Region, Vastra Gotaland	The authors report no conflicts of interest. The study is an academic research project and was funded by grants from The Health & Medical Care Committee of the Region, Vastra Gotaland.	Adler LA, 2009, J CLIN PSYCHOPHARM, V29, P239, DOI 10.1097/JCP.0b013e3181a390ce; Alban JP, 2004, AM J PHYS MED REHAB, V83, P131, DOI 10.1097/01.phm.0000112308.68586.1d; Altman D, 1991, PRACTICAL STAT MED R; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Belmont A, 2009, NEUROREHAB NEURAL RE, V23, P939, DOI 10.1177/1545968309340327; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Habel LA, 2011, JAMA-J AM MED ASSOC, V306, P2673, DOI 10.1001/jama.2011.1830; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Johansson B., 2012, BRAIN INJURY FUNCTIO, V1, P3, DOI [10.5772/27042, DOI 10.5772/27042]; Johansson B, 2010, BRAIN INJURY, V24, P2, DOI 10.3109/02699050903452961; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Leonard BE, 2004, HUM PSYCHOPHARM CLIN, V19, P151, DOI 10.1002/hup.579; LINDQVIST G, 1993, ACTA PSYCHIAT SCAND, V88, P5, DOI 10.1111/j.1600-0447.1993.tb05611.x; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Martinez-Raga J, 2013, CNS DRUGS, V27, P15, DOI 10.1007/s40263-012-0019-9; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Platon B, 2010, PAIN, V148, P114, DOI 10.1016/j.pain.2009.10.023; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Rodholm M, 2001, ACTA NEUROL SCAND, V103, P379, DOI 10.1034/j.1600-0404.2001.103006379.x; Ronnback L., 2012, LONG LASTING MENTAL; Senn S, 2002, CROSS OVER TRIALS CL; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Svanborg P, 2001, J AFFECT DISORDERS, V64, P203, DOI 10.1016/S0165-0327(00)00242-1; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Willmott C, 2009, J NEUROL NEUROSUR PS, V80, P552, DOI 10.1136/jnnp.2008.159632; Willmott C, 2009, J REHABIL MED, V41, P585, DOI 10.2340/16501977-0369; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	41	28	28	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2014	28	3					304	310		10.3109/02699052.2013.865267			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AC0RI	WOS:000332202100006	24377326				2021-06-18	
J	Donahue, DL; Beck, J; Fritz, B; Davis, P; Sandoval-Cooper, MJ; Thomas, SG; Yount, RA; Walsh, M; Ploplis, VA; Castellino, FJ				Donahue, Deborah L.; Beck, Julia; Fritz, Braxton; Davis, Patrick; Sandoval-Cooper, Mayra J.; Thomas, Scott G.; Yount, Robert A.; Walsh, Mark; Ploplis, Victoria A.; Castellino, Francis J.			Early Platelet Dysfunction in a Rodent Model of Blunt Traumatic Brain Injury Reflects the Acute Traumatic Coagulopathy Found in Humans	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; coagulopathy; platelets; thromboelastography; trauma	ACTIVATION	Acute coagulopathy is a serious complication of traumatic brain injury (TBI) and is of uncertain etiology because of the complex nature of TBI. However, recent work has shown a correlation between mortality and abnormal hemostasis resulting from early platelet dysfunction. The aim of the current study was to develop and characterize a rodent model of TBI that mimics the human coagulopathic condition so that mechanisms of the early acute coagulopathy in TBI can be more readily assessed. Studies utilizing a highly reproducible constrained blunt-force brain injury in rats demonstrate a strong correlation with important postinjury pathological changes that are observed in human TBI patients, namely, diminished platelet responses to agonists, especially adenosine diphosphate (ADP), and subarachnoid bleeding. Additionally, administration of a direct thrombin inhibitor, preinjury, recovers platelet functionality to ADP stimulation, indicating a direct role for excess thrombin production in TBI-induced early platelet dysfunction.	[Donahue, Deborah L.; Beck, Julia; Davis, Patrick; Sandoval-Cooper, Mayra J.; Ploplis, Victoria A.; Castellino, Francis J.] Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; [Beck, Julia; Ploplis, Victoria A.; Castellino, Francis J.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Fritz, Braxton; Thomas, Scott G.; Yount, Robert A.; Walsh, Mark] Mem Hosp South Bend, South Bend, IN USA	Castellino, FJ (corresponding author), Univ Notre Dame, WM Keck Ctr Transgene Res, 230 Raclin Carmichael Hall, Notre Dame, IN 46556 USA.	fcastell@nd.edu		Walsh, Mark/0000-0002-5795-1144	Haemonetics (Braintree, MA); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL019982]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL019982] Funding Source: NIH RePORTER	This study was funded, in part, by an equipment grant from Haemonetics (Braintree, MA) and the National Institutes of Health (HL019982; to F.J.C.).	Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Frith D, 2012, THROMB RES, V129, P551, DOI 10.1016/j.thromres.2011.11.053; Gryglewski RJ, 2008, PHARMACOL REP, V60, P3; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jennings LK, 2009, THROMB HAEMOSTASIS, V102, P248, DOI 10.1160/TH09-03-0192; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Kunio NR, 2012, AM J SURG, V203, P584, DOI 10.1016/j.amjsurg.2011.12.011; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; LAPETINA EG, 1979, P NATL ACAD SCI USA, V76, P121, DOI 10.1073/pnas.76.1.121; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Medzon R, 2010, J EMERG MED, V39, P399, DOI 10.1016/j.jemermed.2007.11.059; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; PARETI FI, 1980, AM J MED, V69, P235, DOI 10.1016/0002-9343(80)90383-6; Pathak A, 2005, Neurol India, V53, P178; Sahler CS, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/659652; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Utter GH, 2002, J TRAUMA, V52, P1071, DOI 10.1097/00005373-200206000-00008; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Woulfe D, 2001, J CLIN INVEST, V107, P1503, DOI 10.1172/JCI13361	26	28	30	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2014	31	4					404	410		10.1089/neu.2013.3089			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AA7PY	WOS:000331290600013	24040968	Green Published			2021-06-18	
J	Santo, KP; Berkowitz, ML				Santo, Kolattukudy P.; Berkowitz, Max L.			Shock wave interaction with a phospholipid membrane: Coarse-grained computer simulations	JOURNAL OF CHEMICAL PHYSICS			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; TRAUMATIC BRAIN-INJURY; CAVITATION BUBBLES; MODEL; ULTRASOUND; MIXTURES; WATER	We used MARTINI coarse-grained force field to study poration of a lipid bilayer by a shock wave induced nanobubble collapse. Different systems containing different sized nanobubbles that were exposed to shock waves propagating with different velocities were simulated. We observed creation of pores and damage to bilayers and also subsequent pore closing and the bilayer recovery after shock wave passed the bilayer. In all our systems where bilayers were damaged, they recovered; nevertheless we observed that a large amount of water crossed the pore that was temporarily created. We also observed that not every lipid molecule remained in the bilayer after recovery, some lipids moved out into water and created micelles. (C) 2014 AIP Publishing LLC.	[Santo, Kolattukudy P.; Berkowitz, Max L.] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	Santo, KP (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.		Poulose, Santo/AAC-7499-2021	Poulose, Santo/0000-0001-6817-737X; Berkowitz, Max/0000-0002-9116-0362	Office of Naval ResearchOffice of Naval Research [N000141310396]	The support by a grant (Grant No. N000141310396) from the Office of Naval Research is gratefully acknowledged.	Arun P, 2012, NEUROREPORT, V23, P342, DOI 10.1097/WNR.0b013e328351b58d; Arun P, 2011, NEUROREPORT, V22, P379, DOI 10.1097/WNR.0b013e328346b138; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Chiang YW, 2007, J PHYS CHEM B, V111, P11260, DOI 10.1021/jp0732110; Choubey A, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3518472; Feller SE, 1997, LANGMUIR, V13, P6555, DOI 10.1021/la970746j; Ganzenmuller GC, 2011, SOFT MATTER, V7, P4307, DOI 10.1039/c0sm01296c; Goetz R, 1999, PHYS REV LETT, V82, P221, DOI 10.1103/PhysRevLett.82.221; Henderson L. F., 2001, HDB SHOCK WAVES, V1, P143; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Holian BL, 1998, SCIENCE, V280, P2085, DOI 10.1126/science.280.5372.2085; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Koshiyama K, 2006, BIOPHYS J, V91, P2198, DOI 10.1529/biophysj.105.077677; Marrink SJ, 2007, J PHYS CHEM B, V111, P7812, DOI 10.1021/jp071097f; Marrink SJ, 2013, CHEM SOC REV, V42, P6801, DOI 10.1039/c3cs60093a; Marrink SJ, 2004, J PHYS CHEM B, V108, P750, DOI 10.1021/jp036508g; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Ng KY, 2002, MED RES REV, V22, P204, DOI 10.1002/med.10004; Ohl CD, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.214502; Ohl CD, 2006, BIOPHYS J, V91, P4285, DOI [10.1529/biophysj.105.075366, 10.1529/biophysj.106.075366]; Rosetti C, 2012, J PHYS CHEM B, V116, P3525, DOI 10.1021/jp212406u; RYBAKOV AP, 1995, EUR J MECH B-FLUID, V14, P323; Rzepiela AJ, 2010, FARADAY DISCUSS, V144, P431, DOI 10.1039/b901615e; Shekhar A, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.184503; Sundaram J, 2003, BIOPHYS J, V84, P3087, DOI 10.1016/S0006-3495(03)70034-4; Tomita Y, 2003, J APPL PHYS, V94, P2809, DOI 10.1063/1.1594277; Vedadi M, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.014503; ZHANG YH, 1995, J CHEM PHYS, V103, P10252, DOI 10.1063/1.469927	29	28	28	0	41	AMER INST PHYSICS	MELVILLE	1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA	0021-9606	1089-7690		J CHEM PHYS	J. Chem. Phys.	FEB 7	2014	140	5							054906	10.1063/1.4862987			9	Chemistry, Physical; Physics, Atomic, Molecular & Chemical	Chemistry; Physics	AA7PK	WOS:000331289200064	24511978				2021-06-18	
J	Naim-Feil, J; Fitzgerald, PB; Bradshaw, JL; Lubman, DI; Sheppard, D				Naim-Feil, Jodie; Fitzgerald, Paul B.; Bradshaw, John L.; Lubman, Dan I.; Sheppard, Dianne			Neurocognitive Deficits, Craving, and Abstinence among Alcohol-Dependent Individuals Following Detoxification	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Neurocognitive deficits; Alcohol dependence; Frontostriatal dysfunction; Attentional control; Craving; Cognitive recovery	RANDOM-NUMBER-GENERATION; DORSOLATERAL PREFRONTAL CORTEX; COMPULSIVE DRINKING SCALE; HIGH-FUNCTIONING AUTISM; TRAUMATIC BRAIN-INJURY; STOP SIGNAL INHIBITION; SUSTAINED-ATTENTION; EXECUTIVE FUNCTIONS; PARKINSONS-DISEASE; RESPONSE-TASK	Alcohol dependence, a chronic relapsing disorder, is characterized by an impaired ability to regulate compulsive urges to consume alcohol. Very few empirical studies have examined the presence of these executive deficits, how they relate to craving, and the enduring nature of these deficits during abstinence. As such, the current study aimed to characterize these cognitive deficits within a sample of 24 alcohol-dependent participants post-detoxification and 23 non-alcohol-dependent participants. Participants were administered the Sustained Attention to Response Task to measure response inhibition and sustained attention and the Random Number Generation Task to examine executive deficits. Correlations between cognitive performance and clinical measures of alcohol dependence were examined. As predicted, the alcohol-dependent group exhibited poorer performance across the domains of response inhibition, executive function, and attentional control. Cognitive performance was related to clinical measures of craving and years of alcohol consumption, whereas the duration of abstinence was not associated with improved cognitive performance. These findings highlight the need for therapeutic strategies to target these enduring neurocognitive deficits in improving the treatment of alcohol dependence.	[Naim-Feil, Jodie; Fitzgerald, Paul B.] Alfred & Monash Univ, Cent Clin Sch, Monash Alfred Psychiat Res Ctr, Prahran, Vic 3004, Australia; [Naim-Feil, Jodie; Bradshaw, John L.] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic, Australia; [Lubman, Dan I.] Eastern Hlth, Turning Point Alcohol & Drug Ctr, Box Hill, Vic, Australia; [Lubman, Dan I.] Monash Univ, Clayton, Vic 3800, Australia; [Sheppard, Dianne] Monash Univ, Monash Injury Res Inst, Clayton, Vic, Australia	Naim-Feil, J (corresponding author), Alfred & Monash Univ, Cent Clin Sch, Monash Alfred Psychiat Res Ctr, Prahran, Vic 3004, Australia.	jodie@naimfeil.org	Fitzgerald, Paul B/A-1225-2008	Fitzgerald, Paul B/0000-0003-4217-8096; Lubman, Dan/0000-0002-6747-1937; Sheppard, Dianne/0000-0002-9928-1740; Feil, Jodie/0000-0001-7895-4021	Graduate Women Victoria scholarship; NHMRC Practitioner FellowshipNational Health and Medical Research Council of Australia	J.N.-F. is a recipient of the Graduate Women Victoria scholarship, which supported the development of this study. P.B.F. has received equipment for research from Medtronic Ltd, MagVenture A/S, and Brainsway Ltd. He has undertaken research with funding and equipment from Cervel Neurotech. He is supported by a NHMRC Practitioner Fellowship.	Alfonso-Loeches S, 2011, CRIT REV CL LAB SCI, V48, P19, DOI 10.3109/10408363.2011.580567; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anton RF, 1996, ARCH GEN PSYCHIAT, V53, P225; Anton RF, 2000, ADDICTION, V95, pS211; BADDELEY AD, 1966, Q J EXP PSYCHOL, V18, P119, DOI 10.1080/14640746608400019; Baicy K, 2007, ADDICTION, V102, P5, DOI 10.1111/j.1360-0443.2006.01777.x; Bates ME, 2002, EXP CLIN PSYCHOPHARM, V10, P193, DOI 10.1037//1064-1297.10.3.193; Beck A., 1987, MANUAL BECK DEPRESSI; Bonnefond A, 2010, BEHAV BRAIN RES, V211, P185, DOI 10.1016/j.bbr.2010.03.030; Bottlender M, 2004, ALCOHOL ALCOHOLISM, V39, P357, DOI 10.1093/alcalc/agh073; Bowden-Jones H, 2005, J NEUROPSYCH CLIN N, V17, P417, DOI 10.1176/appi.neuropsych.17.3.417; Braet W, 2009, NEUROPSYCHOLOGIA, V47, P3143, DOI 10.1016/j.neuropsychologia.2009.07.018; BRANDT J, 1983, ARCH GEN PSYCHIAT, V40, P435; Braver TS, 2003, NEURON, V39, P713, DOI 10.1016/S0896-6273(03)00466-5; Brown RG, 1998, NEUROPSYCHOLOGIA, V36, P1355, DOI 10.1016/S0028-3932(98)00015-3; Brugger P, 1997, PERCEPT MOTOR SKILL, V84, P627, DOI 10.2466/pms.1997.84.2.627; Carriere JSA, 2010, PSYCHOL AGING, V25, P569, DOI 10.1037/a0019363; Chambers CD, 2006, J COGNITIVE NEUROSCI, V18, P444, DOI 10.1162/jocn.2006.18.3.444; Chan KKS, 2011, PERCEPT MOTOR SKILL, V112, P91, DOI 10.2466/02.15.19.22.PMS.112.1.91-103; Chan RCK, 2009, COGN BEHAV NEUROL, V22, P180, DOI 10.1097/WNN.0b013e3181b7ef84; Chan RCK, 2004, CLIN NEUROPSYCHOL, V18, P114, DOI 10.1080/13854040490507208; Chanraud S, 2007, NEUROPSYCHOPHARMACOL, V32, P429, DOI 10.1038/sj.npp.1301219; Cohen HL, 1997, ALCOHOL CLIN EXP RES, V21, P1398; Cox WM, 2002, DRUG ALCOHOL DEPEN, V68, P237, DOI 10.1016/S0376-8716(02)00219-3; Crews FT, 2005, ALCOHOL CLIN EXP RES, V29, P1504, DOI 10.1097/01.alc.0000175013.50644.61; Davies SJC, 2005, ALCOHOL ALCOHOLISM, V40, P498, DOI 10.1093/alcalc/agh203; De Wilde B, 2007, ALCOHOL CLIN EXP RES, V31, P1820, DOI 10.1111/j.1530-0277.2007.00484.x; Dirnberger G, 2005, NEUROIMAGE, V25, P588, DOI 10.1016/j.neuroimage.2004.11.023; Dirnberger G, 2010, EXP BRAIN RES, V201, P535, DOI 10.1007/s00221-009-2068-y; Dockree PM, 2005, NEUROIMAGE, V27, P587, DOI 10.1016/j.neuroimage.2005.05.044; Durazzo TC, 2008, ALCOHOL ALCOHOLISM, V43, P683, DOI 10.1093/alcalc/agn078; Evren C, 2012, DRUG ALCOHOL REV, V31, P81, DOI 10.1111/j.1465-3362.2011.00303.x; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Feil J, 2010, NEUROSCI BIOBEHAV R, V35, P248, DOI 10.1016/j.neubiorev.2010.03.001; Fein G, 2006, ALCOHOL CLIN EXP RES, V30, P1538, DOI 10.1111/j.1530-0277.2006.00185.x; Fernandez-Serrano MJ, 2011, NEUROSCI BIOBEHAV R, V35, P377, DOI 10.1016/j.neubiorev.2010.04.008; Ginsburg N, 1995, PERCEPT MOTOR SKILL, V81, P1183, DOI 10.2466/pms.1995.81.3f.1183; Gordon SM, 2006, AM J ADDICTION, V15, P242, DOI 10.1080/10550490600626556; Helton WS, 2009, CONSCIOUS COGN, V18, P600, DOI 10.1016/j.concog.2009.06.002; Hermens DF, 2013, CORTEX, V49, P3, DOI 10.1016/j.cortex.2012.05.021; Hester R, 2004, CEREB CORTEX, V14, P986, DOI 10.1093/cercor/bhh059; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; Ihara H, 2000, J NEUROL NEUROSUR PS, V68, P731, DOI 10.1136/jnnp.68.6.731; Jahanshahi M, 2000, NEUROIMAGE, V12, P713, DOI 10.1006/nimg.2000.0647; Jahanshahi M, 1998, BRAIN, V121, P1533, DOI 10.1093/brain/121.8.1533; Jahanshahi M, 1999, NEUROPSYCHOLOGIA, V37, P181; Jahanshahi M, 2006, NEUROPSYCHOLOGY, V20, P391, DOI 10.1037/0894-4105.20.4.391; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Joppich G, 2004, NEUROSCI RES, V49, P157, DOI 10.1016/j.neures.2004.02.003; Kamarajan C, 2005, BIOL PSYCHOL, V69, P353, DOI 10.1016/j.biopsycho.2004.08.004; Kamarajan C, 2004, INT J PSYCHOPHYSIOL, V51, P155, DOI 10.1016/j.ijpsycho.2003.09.004; Keppel G, 2004, DESIGN ANAL RES HDB; Knoch D, 2005, CEREB CORTEX, V15, P885, DOI 10.1093/cercor/bhh196; Kranzler HR, 1999, ALCOHOL CLIN EXP RES, V23, P108, DOI 10.1097/00000374-199901000-00015; Lawrence AJ, 2009, PSYCHOPHARMACOLOGY, V207, P163, DOI 10.1007/s00213-009-1645-x; Li CSR, 2008, NEUROPSYCHOPHARMACOL, V33, P1798, DOI 10.1038/sj.npp.1301568; Li CSR, 2006, DRUG ALCOHOL DEPEN, V85, P205, DOI 10.1016/j.drugalcdep.2006.04.008; Li CSR, 2009, ALCOHOL CLIN EXP RES, V33, P740, DOI 10.1111/j.1530-0277.2008.00891.x; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manning V, 2008, EUR ADDICT RES, V14, P226, DOI 10.1159/000156479; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; Middleton FA, 2000, BRAIN RES REV, V31, P236, DOI 10.1016/S0165-0173(99)00040-5; Molenberghs P, 2009, NEUROPSYCHOLOGIA, V47, P2866, DOI 10.1016/j.neuropsychologia.2009.06.012; Monterosso JR, 2005, DRUG ALCOHOL DEPEN, V79, P273, DOI 10.1016/j.drugalcdep.2005.02.002; Morrison F, 2011, INT J MENT HEALTH AD, V9, P151, DOI 10.1007/s11469-009-9261-x; Noel X, 2002, ALCOHOL ALCOHOLISM, V37, P347, DOI 10.1093/alcalc/37.4.347; Noel X, 2001, ARCH GEN PSYCHIAT, V58, P1152, DOI 10.1001/archpsyc.58.12.1152; Noel X, 2001, ALCOHOL ALCOHOLISM, V36, P556, DOI 10.1093/alcalc/36.6.556; Noel X, 2007, PSYCHOPHARMACOLOGY, V192, P291, DOI 10.1007/s00213-006-0695-6; Noel X, 2010, J PSYCHOPHYSIOL, V24, P240, DOI 10.1027/0269-8803/a000037; O'Connell RG, 2008, NEUROPSYCHOLOGIA, V46, P1379, DOI 10.1016/j.neuropsychologia.2007.12.018; O'Connell RG, 2006, NEUROPSYCHOL REHABIL, V16, P653, DOI 10.1080/09602010500200250; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; O'Connor C, 2004, BRAIN COGNITION, V54, P133, DOI 10.1016/S0278-2626(03)00268-9; Oscar-Berman M, 2007, NEUROPSYCHOL REV, V17, P239, DOI 10.1007/s11065-007-9038-6; Peters M, 2007, J INT NEUROPSYCH SOC, V13, P626, DOI 10.1017/S1355617707070786; Potvin S., 2012, ADDICTION BIOL; Ratti MT, 2002, ACTA NEUROL SCAND, V105, P276, DOI 10.1034/j.1600-0404.2002.0o315.x; Rinehart NJ, 2006, AUTISM, V10, P70, DOI 10.1177/1362361306062011; Roberts JS, 1999, ALCOHOL CLIN EXP RES, V23, P1484, DOI 10.1097/00000374-199909000-00010; Robertson C, 1996, NEUROPSYCHOLOGIA, V34, P1069, DOI 10.1016/0028-3932(96)00031-0; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rogers BP, 2012, ALCOHOL CLIN EXP RES, V36, P294, DOI 10.1111/j.1530-0277.2011.01614.x; Rubia K, 2003, NEUROIMAGE, V20, P351, DOI 10.1016/S1053-8119(03)00275-1; Rubio G, 2008, ALCOHOL CLIN EXP RES, V32, P1681, DOI 10.1111/j.1530-0277.2008.00746.x; Salame P, 2007, J INT NEUROPSYCH SOC, V13, P277, DOI 10.1017/S1355617707070300; Schmidt P, 2011, SUBST ABUSE TREAT PR, V6, DOI 10.1186/1747-597X-6-14; Sorg SF, 2012, BIOL PSYCHIAT, V71, P262, DOI 10.1016/j.biopsych.2011.09.022; STOCKWELL T, 1994, ADDICTION, V89, P167, DOI 10.1111/j.1360-0443.1994.tb00875.x; STOCKWELL T, 1979, BRIT J ADDICT, V74, P79; Sullivan EV, 2000, NEUROPSYCHOLOGY, V14, P178, DOI 10.1037//0894-4105.14.2.178; Tapert SF, 2007, PSYCHOPHARMACOLOGY, V194, P173, DOI 10.1007/s00213-007-0823-y; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; Towse JN, 1997, EUR J COGN PSYCHOL, V9, P381, DOI 10.1080/713752566; Verdejo-Garcia A, 2008, NEUROSCI BIOBEHAV R, V32, P777, DOI 10.1016/j.neubiorev.2007.11.003; Verdejo-Garcia A, 2012, PSYCHOPHARMACOLOGY, V219, P519, DOI 10.1007/s00213-011-2512-0; Verdejo-Garcia AJ, 2007, ADDICT BEHAV, V32, P950, DOI 10.1016/j.addbeh.2006.06.032; VIVIAN TN, 1973, PERCEPT MOTOR SKILL, V36, P136, DOI 10.2466/pms.1973.36.1.136; Wechsler D., 2001, WECHSLER TEST ADULT; Weinstein A, 2006, J PSYCHOPHARMACOL, V20, P850, DOI 10.1177/0269881106061116; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Williams MA, 2002, J AUTISM DEV DISORD, V32, P43, DOI 10.1023/A:1017904207328; Yucel M, 2007, MOL PSYCHIATR, V12, P691, DOI 10.1038/sj.mp.4001955; Zinn S, 2004, ALCOHOL CLIN EXP RES, V28, P1338, DOI 10.1097/01.ALC.0000139814.81811.62	106	28	34	0	21	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2014	29	1					26	37		10.1093/arclin/act090			12	Psychology, Clinical; Psychology	Psychology	AA1CA	WOS:000330832700004	24334264	Bronze			2021-06-18	
J	Mauritz, W; Brazinova, A; Majdan, M; Leitgeb, J				Mauritz, Walter; Brazinova, Alexandra; Majdan, Marek; Leitgeb, Johannes			Epidemiology of traumatic brain injury in Austria	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						Traumatic brain injury; Epidemiology; Outcome; Severity; Age; Sex; Geographical factors	HEAD-INJURY; UNITED-STATES; NEW-ZEALAND; POPULATION; TRENDS; IMPACT; SEVERITY; GERMANY	Traumatic brain injury (TBI) is an important cause of preventable deaths. The goal of this study was to provide data on epidemiology of TBI in Austria. Data on all hospital discharges, outpatients, and extra- as well as in-hospital deaths due to TBI were collected from various sources for the years 2009-2011. Population data (number of male/female people per age-group, population of Austrian cities, towns, and villages) for 2009-2011 were collected from the national statistical office. Incidence, case fatality rate(s) (CFR), and mortality rate(s) (MR) were calculated for the whole population and for age groups. Incidence (303/100,000/year), CFR (3.6 %), and MR (11/100,000/year) of TBI in Austria are comparable with those from other European countries. We found a high rate of geriatric TBI. The ratio between male and female cases was 1.4:1 for all cases, and was 2.2:1 for fatal cases. The most common mechanism was falls; traffic accidents accounted for only 7 % of the cases. Males died more frequently from traffic accidents and suicides, and females died more frequently from falls. CFRs and MRs increased with increasing age. CFRs were higher in patients from less populated areas, and MRs were lower in cases who lived closer to hospitals that admitted TBI. The high rate of geriatric TBI warrants better prevention of falls in this age group.	[Mauritz, Walter] Trauma Hosp Lorenz Boehler, A-1200 Vienna, Austria; [Brazinova, Alexandra; Majdan, Marek] Trnava Univ, Dept Publ Hlth, Fac Hlth & Social Serv, Vienna, Austria; [Leitgeb, Johannes] Med Univ Vienna, Dept Traumatol, Vienna, Austria	Mauritz, W (corresponding author), Trauma Hosp Lorenz Boehler, Donaueschingestr 13, A-1200 Vienna, Austria.	walter.mauritz@auva.at; abrazinova@igeh.org; mmajdan@igeh.org; johannes.leitgeb@meduniwien.ac.at	Brazinova, Alexandra/C-4265-2016; Majdan, Marek/K-5017-2012	Brazinova, Alexandra/0000-0003-0625-256X; Majdan, Marek/0000-0001-8037-742X; Mauritz, Walter/0000-0001-9043-3712	Austrian Worker's Compensation Board (AUVA) [FK 09/13]; Mrs. Ala Auersperg-Isham and Mr. Ralph Isham	This work was supported by a grant from the Austrian Worker's Compensation Board (AUVA; FK 09/13). The International Neurotrauma Research Organization (INRO) is supported by an annual grant from Mrs. Ala Auersperg-Isham and Mr. Ralph Isham, and by small donations from various sources.	Adekoya N, 2004, PUBLIC HEALTH REP, V119, P486, DOI 10.1016/j.phr.2004.07.006; Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P32, DOI 10.1159/000170090; Coburn K, 1992, AACN Clin Issues Crit Care Nurs, V3, P9; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Rosso A, 2007, WIEN KLIN WOCHENSCHR, V119, P29, DOI 10.1007/s00508-006-0761-4; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	22	28	29	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	JAN	2014	126	1-2					42	52		10.1007/s00508-013-0456-6			11	Medicine, General & Internal	General & Internal Medicine	304JR	WOS:000330743400008	24249325	Green Published, Bronze			2021-06-18	
J	Shaklai, S; Peretz, R; Spasser, R; Simantov, M; Groswasser, Z				Shaklai, Sharon; Peretz, Relly; Spasser, Raluca; Simantov, Maya; Groswasser, Zeev			Long-term functional outcome after moderate-to-severe paediatric traumatic brain injury	BRAIN INJURY			English	Article						Childhood; educational system; moderate traumatic brain injury (TBI); prognostic factors; severe TBI; work	CLOSED-HEAD-INJURY; CHILDREN; RECOVERY; REHABILITATION; RETURN; WORK; PREDICTORS; AGE	Background: Long-term follow-up studies after severe and moderate pediatric traumatic brain injury (TBI) are not common and inconclusive. Most studies focused on neurobehavioural sequelae, less data is reported about age appropriate function. Different prognostic factors were noted over past decades. Methods: A prospective historical study describing the functional long-term outcome after childhood moderate and severe TBI was conducted. Seventy-seven children who suffered either severe or moderate TBI were followed for an average of ten years and clinical functional outcome was recorded. Factors influencing prognosis were investigated. Results: All children but six were integrated into educational systems after discharge from rehabilitation settings (department and day-care); 61% of children who suffered severe-moderate TBI were able to function within their normative age peers. Positive outcome predictors were Glasgow Coma Scale (GCS) >5, length of unconsciousness (LOC) <11 days, Functional Independence Measure (FIM) and Intelligence Quotient (IQ) at discharge from rehabilitation, length of acute hospitalization and rehabilitation. Negative outcome predictors were vegetative state at admission to rehabilitation and associated anoxic brain injury. Conclusions: Guarded optimistic functional outcome can be expected after severe or moderate childhood TBI.	[Shaklai, Sharon; Peretz, Relly; Spasser, Raluca; Groswasser, Zeev] Loewenstein Hosp & Rehabil Ctr, Pediat Unit, IL-43100 Raanana, Israel; [Shaklai, Sharon; Simantov, Maya; Groswasser, Zeev] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Shaklai, S (corresponding author), Loewenstein Hosp & Rehabil Ctr, Pediat Unit, 278 Ahuza St,POB 3, IL-43100 Raanana, Israel.	sharons5@clalit.org.il					Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Avesani R, 2005, BRAIN INJURY, V19, P933, DOI 10.1080/02699050400002371; Bedell Gary M, 2002, Pediatr Rehabil, V5, P107, DOI 10.1080/1363849021000013540; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Brooks N, 1993, BRAIN INJURY, V1, P5; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chang W C, 1997, J Outcome Meas, V1, P192; Chang W C, 1997, J Outcome Meas, V1, P259; Cohen S, 1996, ACQUIRED BRAIN INJUR, P149; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; De Oliveira Thais MER, 2012, J NEUROPSYCHOL, V7, P1; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; FACCO E, 1986, CHILD NERV SYST, V2, P67; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Formisano R, 2004, BRAIN INJURY, V18, P103, DOI 10.1080/0269905031000149470; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; GENSEMER IB, 1989, J TRAUMA, V29, P1616, DOI 10.1097/00005373-198912000-00003; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; JENNETT B, 1975, LANCET, V1, P480; Jensen MP, 2005, ARCH PHYS MED REHAB, V86, P116, DOI 10.1016/j.apmr.2004.01.040; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kothari S., 2007, BRAIN INJURY MED PRI, P169; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; NAJENSON T, 1974, SCAND J REHABIL MED, V6, P5; ntroduction to the Disability Rating Scale, 2000, CTR OUTCOME MEASUREM, P2000; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Petrella RJ, 2002, AM J PHYS MED REHAB, V81, P639, DOI 10.1097/00002060-200209000-00001; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; Rice SA, 2004, AM J PHYS MED REHAB, V83, P27, DOI 10.1097/01.PHM.0000104667.81620.FA; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; Weschsler D, 1991, WESCHLER INTELLIGENC	57	28	29	0	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	7					915	921		10.3109/02699052.2013.862739			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH9XL	WOS:000336498600005	24826955				2021-06-18	
J	Simpson, JR				Simpson, Joseph R.			DSM-5 and Neurocognitive Disorders	JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW			English	Article							TRAUMATIC BRAIN-INJURY; OPERATION IRAQI FREEDOM	The newest edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) introduces several changes in the diagnostic criteria for dementia and other cognitive disorders. Some of these changes may prove helpful for clinical and forensic practitioners, particularly when evaluating less severe cognitive impairments. The most substantial change is that the cognitive disorder-not otherwise specified category found in prior editions has been eliminated. Those disorders that do not cause sufficient impairment to qualify for a diagnosis of dementia are now defined as neurocognitive disorders and placed on a spectrum with the more severe conditions. The concept of social cognition is also introduced as one of the core functional domains that can be affected by a neurocognitive disorder. This concept may be particularly significant in the evaluation of patients with non-Alzheimer's dementias, such as frontotemporal dementia. With the aging of the population and the increasing recognition of the possibility of long-lasting cognitive deficits after traumatic brain injury, the need for assessment of cognitive disorders in medicolegal contexts is certain to increase. Forensic psychiatrists who perform these evaluations should understand the conceptualization of Neurocognitive Disorders as presented in DSM-5 and how it differs from prior diagnostic systems.	[Simpson, Joseph R.] Los Angeles Cty Jail Mental Hlth Serv, Los Angeles, CA USA; [Simpson, Joseph R.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA	Simpson, JR (corresponding author), POB 818, Hermosa Beach, CA 90254 USA.	jrsimpsonmd@gmail.com					American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gordon C, 2013, EXPERT REV NEUROTHER, V13, P1247, DOI 10.1586/14737175.2013.856265; Korngold C, 2013, J AM ACAD PSYCHIATRY, V41, P430; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; McCrea M, 2008, MILD TRAUMATIC BRAIN; Mendez MF, 2010, J AM ACAD PSYCHIATRY, V38, P318; Wallace D, 2009, AUSTRALAS PSYCHIATRY, V17, P218, DOI 10.1080/10398560902878679	12	28	30	0	2	AMER ACAD PSYCHIATRY & LAW	BLOOMFIELD	ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA	1093-6793	1943-3662		J AM ACAD PSYCHIATRY	J. Am. Acad. Psychiatry Law		2014	42	2					159	164					6	Law; Psychiatry	Government & Law; Psychiatry	AL6GA	WOS:000339229400005	24986342				2021-06-18	
J	Ubukata, S; Tanemura, R; Yoshizumi, M; Sugihara, G; Murai, T; Ueda, K				Ubukata, Shiho; Tanemura, Rumi; Yoshizumi, Miho; Sugihara, Genichi; Murai, Toshiya; Ueda, Keita			Social cognition and its relationship to functional outcomes in patients with sustained acquired brain injury	NEUROPSYCHIATRIC DISEASE AND TREATMENT			English	Article						Eyes test; social emotion perception; social function; social participation; theory of mind	EMOTION RECOGNITION; PREFRONTAL LESIONS; FACIAL EXPRESSION; MIND; REHABILITATION; IMPAIRMENTS; DEFICITS; ASSOCIATION; ABILITIES; AWARENESS	Deficits in social cognition are common after traumatic brain injury (TBI). However, little is known about how such deficits affect functional outcomes. The purpose of this study was to investigate the relationship between social cognition and functional outcomes in patients with TBI. We studied this relationship in 20 patients with TBI over the course of 1 year post-injury. Patients completed neurocognitive assessments and social cognition tasks. The social cognition tasks included an emotion-perception task and three theory of mind tasks: the Faux Pas test, Reading the Mind in the Eyes (Eyes) test, and the Moving-Shapes paradigm. The Craig Handicap Assessment and Reporting Technique was used to assess functional outcomes. Compared with our database of normal subjects, patients showed impairments in all social cognition tasks. Multiple regression analysis revealed that theory of mind ability as measured by the Eyes test was the best predictor of the cognitive aspects of functional outcomes. The findings of this pilot study suggest that the degree to which a patient can predict what others are thinking is an important measure that can estimate functional outcomes over 1 year following TBI.	[Ubukata, Shiho; Yoshizumi, Miho; Sugihara, Genichi; Murai, Toshiya; Ueda, Keita] Kyoto Univ, Grad Sch Med, Dept Psychiat, Kyoto 6068507, Japan; [Ubukata, Shiho; Tanemura, Rumi] Kobe Univ, Grad Sch Hlth Sci, Dept Rehabil Sci, Kobe, Hyogo 657, Japan	Ubukata, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Psychiat, 54 Kawaharacho, Kyoto 6068507, Japan.	ubukata@kuhp.kyoto-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [23118004]; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [23791328, 26461766]; General Insurance Association of Japan; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26461766, 25510002] Funding Source: KAKEN	We thank Uta and Chris Frith and their staff members for kindly providing the Moving-Shapes paradigm and rating descriptions. We also sincerely thank Katja Koelkebeck and Akira Oshita for their contribution to the data analysis. This work was supported by a Grant-in-Aid for Scientific Research in Innovative Areas (23118004) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, a Grant-in-Aid for Young Scientists B (23791328) and C (26461766) from the Japan Society for the Promotion of Science, and a research grant from the General Insurance Association of Japan.	Abell F, 2000, COGNITIVE DEV, V15, P1, DOI 10.1016/S0885-2014(00)00014-9; Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056; Arlinghaus KA, 2005, TXB TRAUMATIC BRAIN; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; BARONCOHEN S, 1994, BRIT J PSYCHIAT, V165, P640, DOI 10.1192/bjp.165.5.640; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bivona U, 2014, J HEAD TRAUMA REHAB, V29, P157, DOI 10.1097/HTR.0b013e3182864f0b; Brothers L., 1990, CONCEPTS NEUROSCIENC, V1, P27, DOI DOI 10.7551/MITPRESS/3077.003.0029; Callahan BL, 2011, BRAIN COGNITION, V77, P412, DOI 10.1016/j.bandc.2011.08.017; Das P, 2012, SCHIZOPHR RES, V134, P158, DOI 10.1016/j.schres.2011.08.019; Frith CD, 2007, PHILOS T R SOC B, V362, P671, DOI 10.1098/rstb.2006.2003; Geraci A, 2010, BRAIN INJURY, V24, P978, DOI 10.3109/02699052.2010.487477; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hirao K, 2008, SCHIZOPHR RES, V105, P165, DOI 10.1016/j.schres.2008.07.021; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Koelkebeck K, 2013, SOC NEUROSCI-UK, V8, P631, DOI 10.1080/17470919.2013.837094; Kubota Y, 2003, SCHIZOPHR RES, V61, P265, DOI 10.1016/S0920-9964(02)00298-0; Kumamoto K, 2002, SOGO REHABIL, V30, P249; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Levine B, 2013, NEUROIMAGE-CLIN, V2, P534, DOI 10.1016/j.nicl.2013.03.015; Manly T, 2012, CURR OPIN NEUROL, V25, P656, DOI 10.1097/WCO.0b013e3283594872; Matsumoto D., 1988, JAPANESE CAUCASIAN F; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Newsome MR, 2012, INT J DEV NEUROSCI, V30, P255, DOI 10.1016/j.ijdevneu.2011.10.008; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Roca M, 2011, NEUROPSYCHOLOGIA, V49, P3525, DOI 10.1016/j.neuropsychologia.2011.09.003; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sato W, 2002, CORTEX, V38, P727, DOI 10.1016/S0010-9452(08)70040-6; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; WHITENECK G, 1987, REHABILITATION OUTCO; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Wilson B.A., 1997, BEHAV ASSESSMENT DYS; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553; World Health Organization, 1992, ICD 10 CLASS MENT BE	49	28	30	0	34	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND		1178-2021		NEUROPSYCH DIS TREAT	Neuropsychiatr. Dis. Treat.		2014	10						2061	2068		10.2147/NDT.S68156			8	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	AS1WJ	WOS:000344069600001	25395854	DOAJ Gold, Green Published			2021-06-18	
J	Wang, ZY; Liu, WG; Muharram, A; Wu, ZY; Lin, JH				Wang, Zhen-Yu; Liu, Wen-Ge; Muharram, Akram; Wu, Zhao-Yan; Lin, Jian-Hua			Neuroprotective Effects of Autophagy Induced by Rapamycin in Rat Acute Spinal Cord Injury Model	NEUROIMMUNOMODULATION			English	Article						Acute spinal cord injury; Cell autophagy; Cell apoptosis; Rapamycin	TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; NEUROTROPHIC FACTOR; MEDIATED APOPTOSIS; SIGNALING PATHWAY; NEURONS; METHYLPREDNISOLONE; NEURODEGENERATION; INFLAMMATION; IMPAIRMENT	Background/Aims: To explore the effects of rapamycin-induced autophagy on apoptosis in a rat model of acute spinal cord injury (SCI), and to explore the effect of rapamycin on apoptosis in primary spinal cord cell culture. Methods: SCI was induced at T10 in female adult Sprague-Dawley rats. After injury was induced, the rats were injected with rapamycin and/or methylprednisolone and were sacrificed at various days after injury. Apoptosis and autophagy were examined with TUNEL staining and electron microscopy. Hind limb function was assessed by the Gale scale. Results:The expression of the apoptosis-related protein caspase-3 did not significantly increase until 21 days following injury, while increases in LC3II and LC3I began 10 days after injury, but then declined. TUNEL staining and electron microscopy confirmed that following injury autophagy occurred before apoptosis, but by 14 days after the injury, the level of autophagy had decreased significantly while the level of apoptosis showed a continued increase. Following treatment with rapamycin, apoptosis was significantly higher than in the vehicle control group, but significantly lower than in the sham-operated group, showing a protective effect of rapamycin. Gale scale grades in rats treated with rapamycin were significantly higher compared with the vehicle control group, suggesting a functional effect of rapamycin-induced inhibition of apoptosis. Conclusions: The results indicate that rapamycin significantly improved the prognosis of acute SCI in rats by inhibiting cell apoptosis. Rapamycin might be useful as a therapeutic agent for acute SCI. (C) 2014 S. Karger AG, Basel	[Wang, Zhen-Yu; Liu, Wen-Ge] Fujian Med Univ, Affiliated Union Hosp, Dept Orthoped, Fuzhou 350005, Peoples R China; [Wu, Zhao-Yan; Lin, Jian-Hua] Fujian Med Univ, Affiliated Hosp 1, Dept Orthoped, Fuzhou 350005, Peoples R China; [Muharram, Akram] Xinjiang Med Univ, Affiliated Hosp 5, Dept Orthoped, Urumqi, Peoples R China	Lin, JH (corresponding author), Fujian Med Univ, Affiliated Hosp 1, Dept Orthoped, 20 Chazhong Rd, Fuzhou 350005, Peoples R China.	Dazhusngsurgeon@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [8137343]; Medical Innovation Research Fund Project of Fujian Provincial Health Bureau, China [2012-CXB-020]; Youth Research Fund of Fujian Provincial Health Bureau, China [2011-2-7]	This work was supported by grants from the National Natural Science Foundation of China (Grant No. 8137343), Medical Innovation Research Fund Project of Fujian Provincial Health Bureau, China (2012-CXB-020), and Youth Research Fund of Fujian Provincial Health Bureau, China (2011-2-7).	Cai Zhiyou, 2013, J Biochem Pharmacol Res, V1, P84; Chen HC, 2013, J SURG RES, V179, pE203, DOI 10.1016/j.jss.2012.02.023; Chen HC, 2012, SPINE, V37, P470, DOI 10.1097/BRS.0b013e318221e859; Cheng Bin, 2009, Journal of Chinese Integrative Medicine, V7, P842, DOI 10.3736/jcim20090909; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; Del Gaizo DJ, 2013, SPINE J, V13, P439, DOI 10.1016/j.spinee.2012.11.024; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Freire MAM, 2012, W INDIAN MED J, V61, P751; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Gingras M, 2007, J NEUROSCI METH, V163, P111, DOI 10.1016/j.jneumeth.2007.02.024; Grander D, 2010, FUTURE MED CHEM, V2, P285, DOI [10.4155/fmc.09.155, 10.4155/FMC.09.155]; Huang Y, 2005, CELL MOL IMMUNOL, V2, P113; Jiang XY, 2006, J NEUROSCI METH, V158, P13, DOI 10.1016/j.jneumeth.2006.05.014; Kahan B, 2011, EXPERT OPIN DRUG SAF, V10, P727, DOI 10.1517/14740338.2011.579898; Kanno H, 2012, CELL CYCLE, V11, P3175, DOI 10.4161/cc.21262; KAUFFMAN KS, 1994, PEDIATR RES, V35, P515, DOI 10.1203/00006450-199405000-00001; Kawabata H, 2010, SPINE, V35, P1109, DOI 10.1097/BRS.0b013e3181bd14b6; Kertmen H, 2013, EUR J PHARMACOL, V714, P148, DOI 10.1016/j.ejphar.2013.05.012; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kubeck JP, 2006, SPINE, V31, P257, DOI 10.1097/01.brs.0000197151.95849.7f; Leber Brian, 2010, F1000 Biol Rep, V2, P88, DOI 10.3410/B2-88; Cui LY, 2007, ACTA PHARMACOL SIN, V28, P1671, DOI 10.1111/j.1745-7254.2007.00642.x; Liu WG, 2011, NEUROL RES, V33, P686, DOI 10.1179/1743132810Y.0000000031; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mortensen M, 2011, J EXP MED, V208, P455, DOI 10.1084/jem.20101145; Nakajima H, 2010, SPINE, V35, P497, DOI 10.1097/BRS.0b013e3181b8e89b; Persson S, 2008, NEUROSCIENCE, V157, P656, DOI 10.1016/j.neuroscience.2008.09.017; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Reggiori F, 2005, CURR OPIN CELL BIOL, V17, P415, DOI 10.1016/j.ceb.2005.06.007; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Walker CL, 2012, PLOS ONE, V7, P315, DOI 10.1371/journal.pone.0030012; Wei YM, 2013, CELL PHYSIOL BIOCHEM, V31, P925, DOI 10.1159/000350111; Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004; Wilson JR, 2012, J NEUROSURG-SPINE, V17, P11, DOI 10.3171/2012.4.AOSPINE1245; Witko-Sarsat V, 2010, J INNATE IMMUN, V2, P201, DOI 10.1159/000296505; Yu WR, 2011, ACTA NEUROPATHOL, V122, P747, DOI 10.1007/s00401-011-0882-3; Zhao CQ, 2007, APOPTOSIS, V12, P2155, DOI 10.1007/s10495-007-0137-x	40	28	29	0	16	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7401	1423-0216		NEUROIMMUNOMODULAT	Neuroimmunomodulation		2014	21	5					257	267		10.1159/000357382			11	Endocrinology & Metabolism; Immunology; Neurosciences	Endocrinology & Metabolism; Immunology; Neurosciences & Neurology	AI5FI	WOS:000336890400006	24603048				2021-06-18	
J	Zhou, YF; Li, WT; Han, HC; Gao, DK; He, XS; Li, L; Song, JN; Fei, Z				Zhou, Yue-fei; Li, Wen-tao; Han, Hong-cheng; Gao, Da-kuan; He, Xiao-sheng; Li, Liang; Song, Jin-ning; Fei, Zhou			Allicin protects rat cortical neurons against mechanical trauma injury by regulating nitric oxide synthase pathways	BRAIN RESEARCH BULLETIN			English	Article						Traumatic brain injury; Nitric oxide synthase; ERIC; Akt	ISCHEMIA-REPERFUSION INJURY; BRAIN-INJURY; CEREBRAL-ISCHEMIA; NEUROPROTECTION; INHIBITION; KINASE; ERK; PHOSPHORYLATION; AMINOGUANIDINE; EXPRESSION	Allicin, a small molecule that is responsible for the typical smell and most of the functions of garlic, possesses a broad spectrum of pharmacological activities and is considered to have therapeutic potential in many pathologic conditions. In the present study, we investigated the potential protective effect of allicin in an in vitro model of traumatic brain injury (TBI) using primary cultured rat cortical neurons. We found that allicin treatment significantly reduced mechanical trauma-induced lactate dehydrogenase (LDH) release and inhibited apoptotic neuronal death in a dose-dependent manner. These protective effects were observed even if allicin treatment was delayed to 2 h after injury. Allicin significantly decreased the expression of inducible nitric oxide synthase (iNOS) and increased the phosphorylation of endothelial NOS (eNOS) but had no effect on neuronal NOS (nNOS) expression. Allicin-induced protection in cortical neurons was augmented by iNOS and nNOS antagonists and was partly reversed by blocking eNOS phosphorylation. In addition, allicin treatment inhibited the TBI-induced activation of ERIC and further enhanced the phosphorylation of Akt in TBI-injured neurons. The Akt inhibitor LY294002 attenuated the allicin-induced increase in eNOS expression and phosphorylation, whereas the ERIC inhibitor PD98059 had opposite effects on the expression of iNOS and eNOS. Pretreatment with LY294002 or PD98059 partly prevented or further enhanced allicin-induced neuroprotection, respectively. Collectively, these data demonstrate that allicin treatment may be an effective therapeutic strategy for traumatic neuronal injury and that the potential underlying mechanism involves Akt- and ERIC-mediated regulation of NOS pathways. (C) 2013 Elsevier Inc. All rights reserved.	[Zhou, Yue-fei; Gao, Da-kuan; He, Xiao-sheng; Li, Liang; Fei, Zhou] Fourth Mil Med Univ, Dept Neurosurg, Xijing Inst Clin Neurosci, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China; [Li, Wen-tao; Song, Jin-ning] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Neurosurg, Xian 710061, Shaanxi, Peoples R China; [Han, Hong-cheng] Xian Cent Hosp, Dept Cadre Ward, Xian 710000, Shaanxi, Peoples R China	Fei, Z (corresponding author), Fourth Mil Med Univ, Dept Neurosurg, Xijing Inst Clin Neurosci, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.	jinnings@126.com; fmmuzhoufei@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30930093]; National Science & Technology Pillar Program [2012BAI11B02]; Research Foundation of PLA [2010gxjs078, AWS11J008]	The work was supported by the National Natural Science Foundation of China (No. 30930093), the National Science & Technology Pillar Program (No. 2012BAI11B02) and the Research Foundation of PLA (No. 2010gxjs078 and No. AWS11J008).	Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Asahi M, 2005, J CEREBR BLOOD F MET, V25, P722, DOI 10.1038/sj.jcbfm.9600070; Baek JA, 2009, NITRIC OXIDE-BIOL CH, V20, P122, DOI 10.1016/j.niox.2008.10.003; Barbosa VA, 2013, INT J CARDIOL, V167, P2983, DOI 10.1016/j.ijcard.2012.08.050; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Fu WG, 2013, J SURG RES, V183, P876, DOI 10.1016/j.jss.2013.01.044; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Ginter E, 2010, BRATISL MED J, V111, P452; Horev-Azaria L, 2009, EUR J NUTR, V48, P67, DOI 10.1007/s00394-008-0762-3; Hou YC, 1999, CURR PHARM DESIGN, V5, P417; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hunter R, 2005, ANN NY ACAD SCI, V1056, P234, DOI 10.1196/annals.1352.011; Jones NC, 2004, J NEUROPATH EXP NEUR, V63, P708, DOI 10.1093/jnen/63.7.708; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lawson LD, 2005, J AGR FOOD CHEM, V53, P6254, DOI 10.1021/jf050536+; Liu HQ, 2012, BRAIN RES BULL, V89, P65, DOI 10.1016/j.brainresbull.2012.06.010; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Peng B, 2012, BRAIN RES, V1445, P92, DOI 10.1016/j.brainres.2012.01.033; Shioda N, 2009, INT REV NEUROBIOL, V85, P375, DOI 10.1016/S0074-7742(09)85026-5; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Subramaniam S, 2010, FEBS J, V277, P22, DOI 10.1111/j.1742-4658.2009.07367.x; Topolovec-Vranic J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1059; Villmann C, 2007, NEUROSCIENTIST, V13, P594, DOI 10.1177/1073858406296259; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wang RM, 2013, HIPPOCAMPUS, V23, P634, DOI 10.1002/hipo.22126; Zhao H, 2006, MOL NEUROBIOL, V34, P249, DOI 10.1385/MN:34:3:249; Zhao Xiao-gang, 2007, Chin J Traumatol, V10, P376; Zhou L, 2009, NITRIC OXIDE-BIOL CH, V20, P223, DOI 10.1016/j.niox.2009.03.001; Zhu JW, 2012, NEUROCHEM INT, V61, P640, DOI 10.1016/j.neuint.2012.06.021	38	28	30	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	JAN	2014	100						14	21		10.1016/j.brainresbull.2013.10.013			8	Neurosciences	Neurosciences & Neurology	AB0KG	WOS:000331480000003	24184006				2021-06-18	
J	McGannon, KR; Cunningham, SM; Schinke, RJ				McGannon, Kerry R.; Cunningham, Sarah M.; Schinke, Robert J.			Understanding concussion in socio-cultural context: A media analysis of a National Hockey League star's concussion	PSYCHOLOGY OF SPORT AND EXERCISE			English	Article						Concussion; Media analysis; Cultural sport psychology	HEGEMONIC MASCULINITY; SPORTS CONCUSSION; INJURY; PSYCHOLOGY; RISK; REPRESENTATIONS; PLAYERS; ISSUE; BODY	Objectives: Sport psychology researchers have yet to explore the socio-cultural context of concussion. The aim with this study was to explore the contribution of one socio-cultural context (i.e., sport media) toward understanding the construction of meaning(s) of a sport celebrity's concussion and the implications for sport psychology. Design: A qualitative approach was used to explore concussion as a socio-cultural issue shaped by cultural narratives (i.e., news media). The meanings and implications for how sport concussion is understood and "constructed" through a key media incident were of interest. Method: An ethnographic content analysis (see Altheide, 1996) of the mediation of the National Hockey League's (NHL) star player Sidney Crosby's concussion from January 1, am (when the concussion occurred) to June 30, 2011 (end of the NHL season) was undertaken on North American news data. Results: The ethnographic content analysis of 68 articles revealed that Crosby's concussion and its associated meanings were constructed within a central narrative: a culture of-risk and its impact on athletes. Multiple meanings of concussion within the risk narrative emerged depending on three sub-narratives: (a) Crosby's concussion as a cautionary tale, (b) Crosby's concussion as a political platform, and (c) concussion as ambiguous. Conclusions: The culture of risk narrative raises awareness of the physical risks, physiological effects and the politics of concussion. These cultural meanings do not acknowledge/include the psychological implications/effects of concussion. This study furthers understandings of sport concussion within a sociocultural context. (C) 2013 Elsevier Ltd. All rights reserved.	[McGannon, Kerry R.; Cunningham, Sarah M.; Schinke, Robert J.] Laurentian Univ, Sch Human Kinet, Sudbury, ON P3E 2C6, Canada	McGannon, KR (corresponding author), Laurentian Univ, Sch Human Kinet, Sudbury, ON P3E 2C6, Canada.	kmcgannon@laurentian.ca	McGannon, Kerry R./M-2213-2016; Schinke, Robert/AAS-2966-2020	McGannon, Kerry R./0000-0002-8614-697X; Schinke, Robert J./0000-0002-4432-0730			Allain KA, 2011, INT REV SOCIOL SPORT, V46, P3, DOI 10.1177/1012690210376294; Altheide DL, 1996, QUALITATIVE RES METH, V38; Amin K., 2012, MEDUCATOR, V1, P14; Anderson E, 2012, MEN MASC, V15, P152, DOI 10.1177/1097184X11430127; Andrews David L., 2001, SPORT STARS CULTURAL, P1; Arthur B., 2011, NATL POST       0314; Barth JT, 2012, J CLIN SPORT PSYCHOL, V6, P409, DOI 10.1123/jcsp.6.4.409; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Caron JG, 2013, J SPORT EXERCISE PSY, V35, P168, DOI 10.1123/jsep.35.2.168; Coakley Jay., 2009, SPORTS SOC ISSUES CO, V2nd ed; Connell RW, 2005, GENDER SOC, V19, P829, DOI 10.1177/0891243205278639; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Donnelly P., 2004, SPORTING BODIES DAMA, P29, DOI [10.1017/S1355617718000437, DOI 10.1016/S1476-2854(04)02001-1]; Fallis J, 2012, CAN MED ASSOC J, V184, pE113, DOI 10.1503/cmaj.109-4080; Goodman D, 2002, CLIN J SPORT MED, V12, P265, DOI 10.1097/00042752-200209000-00001; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Gutkin C, 2011, CAN FAM PHYSICIAN, V57, P968; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Kontos AP, 2004, J APPL SPORT PSYCHOL, V16, P220, DOI 10.1080/10413200490485568; Mainwaring L, 2012, J CLIN SPORT PSYCHOL, V6, P307, DOI 10.1123/jcsp.6.4.307; Mainwaring L, 2012, J CLIN SPORT PSYCHOL, V6, P203, DOI 10.1123/jcsp.6.3.203; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; McCrory P, 2009, J ATHL TRAINING, P36; McDonald, 2000, READING SPORT CRITIC; McGannon KR, 2012, PSYCHOL SPORT EXERC, V13, P820, DOI 10.1016/j.psychsport.2012.06.005; McGannon KR, 2012, PSYCHOL SPORT EXERC, V13, P26, DOI 10.1016/j.psychsport.2011.08.001; Messner M. A., 1990, International Review for the Sociology of Sport, V25, P203, DOI 10.1177/101269029002500303; Messner M. A., 2000, Journal of Sport & Social Issues, V24, P380, DOI 10.1177/0193723500244006; Messner MA., 2007, OUT PLAY CRITICAL ES; Nixon H.L., 1992, J SPORT SOCIAL ISSUE, V16, P127, DOI [DOI 10.1177/019372359201600208, 10.1177/019372359201600208]; NIXON HL, 1993, SOCIOL SPORT J, V10, P183, DOI 10.1123/ssj.10.2.183; Ryba T.V., 2010, CULTURAL TURN SPORT; Sabo D., 2004, SPORTING BODIES DAMA, P59; Safai P, 2003, SOCIOL SPORT J, V20, P127, DOI 10.1123/ssj.20.2.127; Schinke R, 2009, SPORTS ATHL PREP PER, P1; Smith B., 2010, INT REV SPORT EXER P, V3, P87, DOI [DOI 10.1080/17509840903390937, 10.1080/]; Smith B, 2013, HEALTH PSYCHOL, V32, P110, DOI 10.1037/a0029187; Smith M. D., 1978, SPORT PSYCHOL ANAL A, P187; Sparkes AC, 2008, DISABIL SOC, V23, P679, DOI 10.1080/09687590802469172; Sparkes AC, 2009, PSYCHOL SPORT EXERC, V10, P491, DOI 10.1016/j.psychsport.2009.02.006; TRUJILLO N, 1991, CRIT STUD MASS COMM, V8, P290, DOI 10.1080/15295039109366799; Visek A, 2005, SPORT PSYCHOL, V19, P178, DOI 10.1123/tsp.19.2.178; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Whannel G, 2002, MEDIA SPORT STARS MA; Wiese-Bjornstal DM, 2010, SCAND J MED SCI SPOR, V20, P103, DOI 10.1111/j.1600-0838.2010.01195.x; Wiese-Bjornstal DM, 1998, J APPL SPORT PSYCHOL, V10, P46, DOI 10.1080/10413209808406377; YOUNG K, 1994, SOCIOL SPORT J, V11, P175, DOI 10.1123/ssj.11.2.175; YOUNG K, 1993, SOCIOL SPORT J, V10, P373, DOI 10.1123/ssj.10.4.373; Young K, 2004, SPORTING BODIES DAMA, P1, DOI DOI 10.1016/S1476-2854(04)02023-0; Zirin Dave., 2005, WHATS MY NAME FOOL S	51	28	28	0	30	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1469-0292	1878-5476		PSYCHOL SPORT EXERC	Psychol. Sport Exerc.	NOV	2013	14	6					891	899		10.1016/j.psychsport.2013.08.003			9	Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences	Social Sciences - Other Topics; Psychology; Sport Sciences	251DI	WOS:000326907600015					2021-06-18	
J	Kapoor, S; Kim, SM; Farook, JM; Mir, S; Saha, R; Sen, N				Kapoor, Suraj; Kim, Seon-Myung; Farook, Justin M.; Mir, Sajad; Saha, Rahul; Sen, Nilkantha			Foxo3a Transcriptionally Upregulates AQP4 and Induces Cerebral Edema Following Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							AQUAPORIN-4; EXPRESSION; PROTEIN; STRESS; RATS; MICE; SUPPRESSION; ASTROCYTES; CYTOKINE	Increased cranial pressure due to development of edema contributes significantly to the pathology of traumatic brain injury (TBI). Induction of an astrocytic water channel protein, Aquaporin 4 (AQP4), is known to predominantly contribute to cytotoxic edema following TBI. However, the mechanism for the increase in AQP4 following 24 h of TBI is poorly understood. Here we show that transcriptional activation of a ubiquitously expressed mammalian forkhead transcription factor, Foxo3a, induces cerebral edema by increasing the AQP4 level in the controlled cortical impact model of TBI in mice. TBI stimulates nuclear translocation of Foxo3a in astrocytes and subsequently augments its binding to AQP4 promoter in pericontusional cortex. Nuclear accumulation of Foxo3a is augmented by a decrease in phosphorylation at its Ser256 residue due to inactivation of Akt after TBI. Depletion of Foxo3a in mice rescues cytotoxic edema by preventing induction of AQP4 as well as attenuates memory impairment after TBI in mice.	[Sen, Nilkantha] Georgia Regents Univ, Inst Mol Med & Genet, Augusta, GA 30912 USA; Georgia Regents Univ, Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA	Sen, N (corresponding author), Georgia Regents Univ, Inst Mol Med & Genet, 1120 15th St,CA 2018, Augusta, GA 30912 USA.	nsen@gru.edu	Sen, Nilkantha/AAW-9788-2020		Georgia Regents University	S.K., S.M., J.F., R.S., and N.S. were supported by a startup package provided by Georgia Regents University. We thank Dr. Lin Mei for his advice and technical support.	ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Arden KC, 2004, MOL CELL, V14, P416, DOI 10.1016/S1097-2765(04)00213-8; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Das S, 2011, J BIOL CHEM, V286, P29806, DOI 10.1074/jbc.M111.271460; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hedrick SM, 2012, NAT REV IMMUNOL, V12, P649, DOI 10.1038/nri3278; Hewett SJ, 2006, J PHARMACOL EXP THER, V319, P1219, DOI 10.1124/jpet.106.109876; Hu Hua, 2005, J Zhejiang Univ Sci B, V6, P33, DOI 10.1631/jzus.2005.B0033; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P393; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mojsilovic-Petrovic J, 2009, J NEUROSCI, V29, P8236, DOI 10.1523/JNEUROSCI.1805-09.2009; Sen N, 2009, NEURON, V63, P81, DOI 10.1016/j.neuron.2009.05.024; Tsai KL, 2007, NUCLEIC ACIDS RES, V35, P6984, DOI 10.1093/nar/gkm703; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vallee M, 1997, J NEUROSCI, V17, P2626; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570	32	28	29	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 30	2013	33	44					17398	17403		10.1523/JNEUROSCI.2756-13.2013			6	Neurosciences	Neurosciences & Neurology	246BB	WOS:000326509800017	24174672	Bronze, Green Published			2021-06-18	
J	Kouvonen, A; Kivimaki, M; Oksanen, T; Pentti, J; De Vogli, R; Virtanen, M; Vahtera, J				Kouvonen, Anne; Kivimaki, Mika; Oksanen, Tuula; Pentti, Jaana; De Vogli, Roberto; Virtanen, Marianna; Vahtera, Jussi			Obesity and Occupational Injury: A Prospective Cohort Study of 69,515 Public Sector Employees	PLOS ONE			English	Article							BODY-MASS INDEX; HEALTH; RISK; WEIGHT; WORK; MORTALITY; HEIGHT	Background: Obesity and overweight are suggested to increase the risk of occupational injury but longitudinal evidence to confirm this is rare. We sought to evaluate obesity and overweight as risk factors for occupational injuries. Methodology/Principal Findings: A total of 69,515 public sector employees (80% women) responded to a survey in 20002002, 2004 or 2008. Body mass index (kg/m(2)) was derived from self-reported height and weight and was linked to records of subsequent occupational injuries obtained from national registers. Different injury types, locations and events or exposures (the manner in which the injury was produced or inflicted) were analyzed by body mass index category adjusting for baseline socio-demographic characteristics, work characteristics, health-risk behaviors, physical and mental health, insomnia symptoms, and sleep duration. During the mean follow-up of 7.8 years (SD = 3.2), 18% of the employees (N = 12,204) recorded at least one occupational injury. Obesity was associated with a higher overall risk of occupational injury; multivariable adjusted hazard ratio (HR) 1.21 (95% CI 1.14-1.27). A relationship was observed for bone fractures (HR = 1.37; 95% CI: 1.10-1.70), dislocations, sprains and strains (HR = 1.36; 95% CI: 1.25-1.49), concussions and internal injuries (HR = 1.26; 95% CI: 1.11-1.44), injuries to lower extremities (HR = 1.62; 95%: 1.46-1.79) and injuries to whole body or multiple sites (HR = 1.37; 95%: 1.10-1.70). Furthermore, obesity was associated with a higher risk of injuries caused by slipping, tripping, stumbling and falling (HR = 1.55; 95% CI: 1.40-1.73), sudden body movement with or without physical stress (HR = 1.24; 95% CI: 1.10-1.41) and shock, fright, violence, aggression, threat or unexpected presence (HR = 1.33; 95% CI: 1.03-1.72). The magnitude of the associations between overweight and injuries was smaller, but the associations were generally in the same direction as those of obesity. Conclusions/Significance: Obese employees record more occupational injuries than those with recommended healthy weight.	[Kouvonen, Anne] Queens Univ Belfast, Sch Sociol Social Policy & Social Work, Belfast, Antrim, North Ireland; [Kouvonen, Anne] Queens Univ Belfast, UKCRC Ctr Excellence Publ Hlth Northern Ireland, Belfast, Antrim, North Ireland; [Kivimaki, Mika; Oksanen, Tuula; Pentti, Jaana; Virtanen, Marianna; Vahtera, Jussi] Finnish Inst Occupat Hlth, Turku, Finland; [Kivimaki, Mika; Oksanen, Tuula; Pentti, Jaana; Virtanen, Marianna; Vahtera, Jussi] Finnish Inst Occupat Hlth, Helsinki, Finland; [Kivimaki, Mika; De Vogli, Roberto] UCL, Dept Epidemiol & Publ Hlth, London, England; [Kivimaki, Mika] Univ Helsinki, Inst Behav Sci, Helsinki, Finland; [De Vogli, Roberto] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA; [Vahtera, Jussi] Univ Turku, Dept Publ Hlth, Turku, Finland; [Vahtera, Jussi] Turku Univ Hosp, FIN-20520 Turku, Finland	Kouvonen, A (corresponding author), Queens Univ Belfast, Sch Sociol Social Policy & Social Work, Belfast, Antrim, North Ireland.	a.kouvonen@qub.ac.uk	Kivimaki, Mika/B-3607-2012; Oksanen, Tuula/AAK-5599-2021	Kivimaki, Mika/0000-0002-4699-5627; Vahtera, Jussi/0000-0002-6036-061X; Kouvonen, Anne/0000-0001-6997-8312	Academy of FinlandAcademy of FinlandEuropean Commission [264944, 258598]; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [RES-590-28-001]; Academy of FinlandAcademy of FinlandEuropean Commission; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [K013351]; United States National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL036310, R01AG034454]; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC); Economic and Social Research Council (ESRC)UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [RES-070-27-0034]; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/J023299/1] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/K013351/1] Funding Source: researchfish; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL036310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034454] Funding Source: NIH RePORTER	The Finnish Public Sector Study is supported by the Academy of Finland (grant # 264944) and the participating organizations. A Kouvonen is supported by the Economic and Social Research Council funded United Kingdom Clinical Research Collaboration Centre of Excellence for Public Health (Northern Ireland) (RES-590-28-001). M Kivimaki is supported by the Academy of Finland, the Medical Research Council (K013351), the United States National Institutes of Health (R01HL036310; R01AG034454) and a professorial fellowship from the Economic and Social Research Council. R De Vogli is supported by a grant from the Economic and Social Research Council (ESRC) (RES-070-27-0034). M Virtanen is supported by the Academy of Finland (grant # 258598). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bes-Rastrollo M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-213; Cao JJ, 2011, J ORTHOP SURG RES, V6, DOI 10.1186/1749-799X-6-30; Chau N, 2009, OCCUP MED-OXFORD, V59, P114, DOI 10.1093/occmed/kqp002; Cohen A, 2013, J CLIN ENDOCR METAB, V98, P2562, DOI 10.1210/jc.2013-1047; Dimitri P, 2012, BONE, V50, P457, DOI 10.1016/j.bone.2011.05.011; Gauchard GC, 2006, OCCUP MED-OXFORD, V56, P187, DOI 10.1093/occmed/kqj016; Goldberg D, 1988, USERS GUIDE GEN HLTH; HEINEMAN EF, 1989, AM J IND MED, V15, P267; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; Janssen I, 2011, J OBES, V2011, DOI 10.1155/2011/531403; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; Kivimaki M, 2010, DIABETES CARE, V33, P2611, DOI 10.2337/dc10-1187; Koritzky G, 2012, APPETITE, V59, P289, DOI 10.1016/j.appet.2012.05.020; Kujala UM, 1998, JAMA-J AM MED ASSOC, V279, P440, DOI 10.1001/jama.279.6.440; Lombardi DA, 2012, CHRONOBIOL INT, V29, P556, DOI 10.3109/07420528.2012.675253; Morgan PJ, 2012, J OCCUP ENVIRON MED, V54, P122, DOI 10.1097/JOM.0b013e31824329ab; Myers AH, 1999, AM J PUBLIC HEALTH, V89, P1036, DOI 10.2105/AJPH.89.7.1036; Nyholm M, 2007, OBESITY, V15, P197, DOI 10.1038/oby.2007.536; OECD, 2012, OECD OB UPD 2012; Ostbye T, 2007, ARCH INTERN MED, V167, P766, DOI 10.1001/archinte.167.8.766; Pollack KM, 2007, INJURY PREV, V13, P297, DOI 10.1136/ip.2006.014787; Pollack KM, 2007, AM J EPIDEMIOL, V166, P204, DOI 10.1093/aje/kwm058; Rimm EB, 1999, BMJ-BRIT MED J, V319, P1523, DOI 10.1136/bmj.319.7224.1523; Salminen S, 2010, J SLEEP RES, V19, P207, DOI 10.1111/j.1365-2869.2009.00780.x; Statistics Finland, 1987, CLASS OCC, V14; Straker LM, 2009, ERGONOMICS, V52, P1215, DOI 10.1080/00140130903039101; Taylor AW, 2006, AUST NZ J PUBL HEAL, V30, P238, DOI 10.1111/j.1467-842X.2006.tb00864.x; U.S. Department of Labor Bureu of Labor Statistics, 2012, OCC INJ ILLN CLASS M; Virtanen M, 2011, OCCUPATIONAL ENV MED, V68, P1; Wang YC, 2011, LANCET, V378, P815, DOI 10.1016/S0140-6736(11)60814-3; WOHL AR, 1995, EPIDEMIOLOGY, V6, P110, DOI 10.1097/00001648-199503000-00004; World Heath Organization [WHO], 2006, GLOB DAT BOD MASS IN	32	28	28	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2013	8	10							e77178	10.1371/journal.pone.0077178			8	Multidisciplinary Sciences	Science & Technology - Other Topics	239JR	WOS:000326019400096	24146966	DOAJ Gold, Green Published			2021-06-18	
J	Lobel, DA; Elder, JB; Schirmer, CM; Bowyer, MW; Rezai, AR				Lobel, Darlene A.; Elder, J. Bradley; Schirmer, Clemens M.; Bowyer, Mark W.; Rezai, Ali R.			A Novel Craniotomy Simulator Provides a Validated Method to Enhance Education in the Management of Traumatic Brain Injury	NEUROSURGERY			English	Article						Craniotomy; Curriculum; Education; Neurotrauma; Residency; Simulation; Traumatic brain injury	VIRTUAL-REALITY; CONSTRUCT-VALIDATION; TECHNICAL SKILL; COUNCIL	BACKGROUND: in a variety of surgical simulation-based technologies play an important role in resident training. The Congress of Neurological Surgeons (CNS) established an initiative to enhance neurosurgical training by developing a simulation-based curriculum to complement standard and clinical learning. OBJECTIVE: To enhance resident education in management of traumatic brain injury by the use of simulation-based training. METHODS: A course-based neurosurgical simulation curriculum was developed and offered at the 2012 CNS annual meeting. Within this curriculum, a trauma module was developed to teach skills necessary in the management of traumatic brain injury, including the performance of craniotomy for trauma. Didactic and simulator-based instruction were incorporated into the course. Written and practical pre- and posttests, as well as questionnaires, were used to assess the improvement in skill level and to validate the simulator as a teaching tool. RESULTS: Fourteen trainees participated in the didactic section of the trauma module. Average performance improved significantly in written scores from pretest (75%) to posttest (87.5%, P < .05). Eight participants completed the trauma craniotomy simulator. Incision planning, burr hole placement (P < .02), and craniotomy size (P < .05) improved significantly. Junior residents (postgraduate years 1-3) demonstrated the most improvement during the course. CONCLUSION: The CNS simulation trauma module provides a complementary method for residents to acquire necessary skills in the management of traumatic brain injury. Preliminary data indicate improvement in didactic and hands-on knowledge after training. Additional data are needed to confirm the validity of the simulator.	[Lobel, Darlene A.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA; [Elder, J. Bradley; Rezai, Ali R.] Ohio State Univ, Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA; [Schirmer, Clemens M.] Baystate Med Ctr, Div Neurosurg, Springfield, MA USA; [Schirmer, Clemens M.] Tufts Univ, Sch Med, Dept Neurosurg, Boston, MA 02111 USA; [Bowyer, Mark W.] Uniformed Serv Univ Hlth Sci, Norman M Rich Dept Surg, Bethesda, MD 20814 USA	Lobel, DA (corresponding author), Mayo Clin, Dept Neurol Surg, 200 1st St SW, Rochester, MN 55905 USA.	Darlene.a.lobel@hotmail.com		Schirmer, Clemens/0000-0003-1743-8781			Abboudi H, 2013, BJU INT, V111, P194, DOI 10.1111/j.1464-410X.2012.11270.x; Accreditation Council for Graduate Medical Education (ACGME), 2011, COMM PROGR REQ; Acosta E, 2007, STUD HEALTH TECHNOL, V125, P1; Alaraj A, 2013, NEUROSURGERY, V72, pA115, DOI 10.1227/NEU.0b013e3182753093; Dayal R, 2004, J VASC SURG, V40, P1112, DOI 10.1016/j.jvs.2004.09.028; Delorme S, 2012, NEUROSURGERY, V71, P32, DOI 10.1227/NEU.0b013e318249c744; Dumont TM, 2012, J NEUROSURG, V116, P483, DOI 10.3171/2011.9.JNS116; Faulkner H, 1996, ACAD MED, V71, P1363, DOI 10.1097/00001888-199612000-00023; Gallagher AG, 2005, ANN SURG, V241, P364, DOI 10.1097/01.sla.0000151982.85062.80; Ganju A, 2012, WORLD NEUROSURG; Ghobrial GM, NEUROSURGERY S1, V73, pS111; Kelly DC, 2012, UROLOGY, V79, P1068, DOI 10.1016/j.urology.2012.01.028; Khan MS, 2013, BJU INT, V111, P518, DOI 10.1111/j.1464-410X.2012.11204.x; Leiter JR, 2012, KNEE SURG SPORTS TRA; Lemole GM, 2007, NEUROSURGERY, V61, P142, DOI 10.1227/01.neu.0000279734.22931.21; Liss MA, 2012, J ENDOUROL, V26, P1629, DOI 10.1089/end.2012.0328; Mazzola CA, 2010, NEUROSURGERY, V67, P225, DOI 10.1227/01.NEU.0000372206.41812.23; Palter VN, 2013, ANN SURG, V257, P224, DOI 10.1097/SLA.0b013e31827051cd; Pflesser Bernhard, 2002, Comput Aided Surg, V7, P74; Plooy AM, 2012, GASTROINTEST ENDOSC, V76, P144, DOI 10.1016/j.gie.2012.03.246; Scerbo MW, 2010, P HUM FACT ERG SOC 5, V54, P2361; Sim P., 2000, THESIS U LEEDS; Singapogu RB, 2013, SURG ENDOSC, V27, P1653, DOI 10.1007/s00464-012-2648-y; Tedesco MM, 2008, J VASC SURG, V47, P1008, DOI 10.1016/j.jvs.2008.01.007; Wong GKC, 2007, NEUROSURGERY, V61, P564, DOI 10.1227/01.NEU.0000290904.46061.0D	25	28	29	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2013	73			1			57	65		10.1227/NEU.0000000000000116			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	300SG	WOS:000330483300012	24051884				2021-06-18	
J	Raj, R; Siironen, J; Kivisaari, R; Kuisma, M; Brinck, T; Lappalainen, J; Skrifvars, MB				Raj, Rahul; Siironen, Jari; Kivisaari, Riku; Kuisma, Markku; Brinck, Tuomas; Lappalainen, Jaakko; Skrifvars, Markus B.			Factors correlating with delayed trauma center admission following traumatic brain injury	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Traumatic brain injury; Pre-hospital; Transport; Triage; Outcome; Emergency medical service	ACUTE SUBDURAL-HEMATOMA; DIRECT TRANSPORT; HEAD-INJURY; PREHOSPITAL MANAGEMENT; ALCOHOL CONCENTRATION; COMPUTED-TOMOGRAPHY; EPIDEMIOLOGY; MORTALITY; PREDICTION; PROGNOSIS	Background: Delayed admission to appropriate care has been shown increase mortality following traumatic brain injury (TBI). We investigated factors associated with delayed admission to a hospital with neurosurgical expertise in a cohort of TBI patients in the intensive care unit (ICU). Methods: A retrospective analysis of all TBI patients treated in the ICUs of Helsinki University Central Hospital was carried out from 1.1.2009 to 31.12.2010. Patients were categorized into two groups: direct admission and delayed admission. Patients in the delayed admission group were initially transported to a local hospital without neurosurgical expertise before inter-transfer to the designated hospital. Multivariate logistic regression was utilized to identify pre-hospital factors associated with delayed admission. Results: Of 431 included patients 65% of patients were in the direct admission groups and 35% in the delayed admission groups (median time to admission 1:07h, IQR 0:52-1:28 vs. 4:06h, IQR 2:53-5:43, p < 0.001). In multivariate analysis factors increasing the likelihood of delayed admission were (OR, 95% CI): male gender (3.82, 1.60-9.13), incident at public place compared to home (0.26, 0.11-0.61), high energy trauma (0.05, 0.01-0.28), pre-hospital physician consultation (0.15, 0.06-0.39) or presence (0.08, 0.03-0.22), hypotension (0.09, 0.01-0.93), major extra cranial injury (0.17, 0.05-0.55), abnormal pupillary light reflex (0.26, 0.09-0.73) and severe alcohol intoxication (12.44, 2.14-72.38). A significant larger proportion of patients in the delayed admission group required acute craniotomy for mass lesion when admitted to the neurosurgical hospital (57%, 21%, p < 0.001). No significant difference in 6-month mortality was noted between the groups (p=0.814). Conclusion: Delayed trauma center admission following TBI is common. Factors increasing likelihood of this were: male gender, incident at public place compared to home, low energy trauma, absence of pre-hospital physician involvement, stable blood pressure, no major extra cranial injuries, normal pupillary light reflex and severe alcohol intoxication. Focused educational efforts and access to physician consultation may help expedite access to appropriate care in TBI patients.	[Raj, Rahul; Siironen, Jari; Kivisaari, Riku; Lappalainen, Jaakko] Univ Helsinki, Cent Hosp, Dept Neurosurg, Helsinki, Finland; [Kuisma, Markku; Skrifvars, Markus B.] Univ Helsinki, Cent Hosp, Dept Anesthesiol Intens Care Emergency Care & Pai, Helsinki, Finland; [Brinck, Tuomas] Univ Helsinki, Cent Hosp, Dept Orthoped & Traumatol, Helsinki, Finland	Raj, R (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurosurg, Helsinki, Finland.	rahul.raj@helsinki.fi	Raj, Rahul/K-7693-2012	Raj, Rahul/0000-0003-4243-9591; Kuisma, Markku/0000-0002-3057-6524			Andelic Nada, 2010, J Trauma Manag Outcomes, V4, P6, DOI 10.1186/1752-2897-4-6; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Berry C, 2011, AM SURGEON, V77, P1416; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chen CM, 2012, J STUD ALCOHOL DRUGS, V73, P531, DOI 10.15288/jsad.2012.73.531; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Goldschlager T, 2007, J CLIN NEUROSCI, V14, P618, DOI 10.1016/j.jocn.2006.02.018; Hannan EL, 2005, J AM COLL SURGEONS, V200, P584, DOI 10.1016/j.jamcollsurg.2004.12.016; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kool B, 2009, INJURY PREV, V15, P341, DOI 10.1136/ip.2008.021303; Lindberg L, 2007, FORENSIC SCI INT, V168, P200, DOI 10.1016/j.forsciint.2006.07.018; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Moen KG, 2008, EUR J EMERG MED, V15, P249, DOI 10.1097/MEJ.0b013e3282f4d111; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Poyry T, 2013, J HEAD TRAUMA REHAB, V28, P89, DOI 10.1097/HTR.0b013e318250eadd; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; Sasser SM, 2011, MMWR-MORBID MORTAL W, V61, P1; Savola O, 2005, ALCOHOL ALCOHOLISM, V40, P269, DOI 10.1093/alcalc/agh159; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Shahin H, 2010, J TRAUMA, V69, P1176, DOI 10.1097/TA.0b013e3181edbd47; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stiver SI, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E5; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Wright KD, 1996, INJURY, V27, P719, DOI 10.1016/S0020-1383(96)00119-2	36	28	29	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	SEP 10	2013	21								67	10.1186/1757-7241-21-67			9	Emergency Medicine	Emergency Medicine	217UP	WOS:000324387700001	24020630	DOAJ Gold, Green Published			2021-06-18	
J	Forslund, MV; Roe, C; Arango-Lasprilla, JC; Sigurdardottir, S; Andelic, N				Forslund, Marit V.; Roe, Cecilie; Arango-Lasprilla, Juan C.; Sigurdardottir, Solrun; Andelic, Nada			IMPACT OF PERSONAL AND ENVIRONMENTAL FACTORS ON EMPLOYMENT OUTCOME TWO YEARS AFTER MODERATE-TO-SEVERE TRAUMATIC BRAIN INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; environmental factors; employment; prospective study	COMMUNITY INTEGRATION QUESTIONNAIRE; FOLLOW-UP; EARLY REHABILITATION; RACIAL-DIFFERENCES; PREDICTING RETURN; WORK; POPULATION; TBI; INDIVIDUALS; PERSPECTIVE	Objectives: To describe employment outcomes and assess the impact of personal and environmental factors on employment outcomes 2 years after moderate-to-severe traumatic brain injury. Design/subjects: A prospective cohort of 100 patients with moderate-to-severe traumatic brain injury, aged 16-55 years, hospitalized in a Trauma Referral Centre during the period 2005-2007 and followed up at 1 and 2 years post-injury. Methods: Variables of interest were divided into personal and environmental factors. Personal factors include sociodemographics (age, gender, education, work demands, marital status and child-care). Environmental factors included social (support by friends), institutional (number of rehabilitation services, need for well-coordinated healthcare services), and physical (access to own transportation) factors. A multivariate logistic regression analysis was conducted with employment (working part-/full-time or studying) at 2-year follow-up as the dependent variable, and including independent variables based on significance from a univariate analysis, adjusting for injury severity. Results: At the 2-year follow-up, 44% of patients were employed. Patients with less severe injuries (odds ratio (OR)=1.2, p=0.03), those supported by friends (OR=3.5, p=0.07), those not in need of well-coordinated health services (OR-=4.1, p=0.04), and patients driving a vehicle at the 1-year follow-up (OR=8.4, p<0.001) were more likely to be employed at the 2-year follow-up. Conclusion: Rehabilitation professionals should be aware of the role of environmental factors when planning vocational rehabilitation services after traumatic brain injury.	[Forslund, Marit V.; Roe, Cecilie; Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Forslund, Marit V.; Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway; [Sigurdardottir, Solrun; Andelic, Nada] Univ Oslo, Fac Med, CHARM Res Ctr Habilitat & Rehabil Models & Serv, Oslo, Norway; [Arango-Lasprilla, Juan C.] Univ Deusto, IKERBASQUE Basque Fdn Sci, Bilbao, Spain; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp Trust, Akershus, Norway	Forslund, MV (corresponding author), Olav M Troviks Vei 28 H505, NO-0864 Oslo, Norway.	mvforslund@gmail.com		Andelic, Nada/0000-0002-3719-4406	Norwegian Health South-East Authority; Research Council of NorwayResearch Council of Norway	The authors would like to thank all the patients for their participation. Special thanks to Nini Hammergren for assistance with patient registrations. This study was funded by grants from the Norwegian Health South-East Authority and The Research Council of Norway.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Borg J, 2011, AM J PHYS MED REHAB, V90, P65, DOI 10.1097/PHM.0b013e3181fc80e7; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Fleming J, 1999, BRAIN INJURY, V13, P417; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hoffmann B, 2002, ACT NEUR S, V79, P33; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johansson U, 2001, DISABIL REHABIL, V23, P474; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Schanke AK, 2008, J REHABIL MED, V40, P733, DOI 10.2340/16501977-0256; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Stergiou-Kita M, 2011, J OCCUP REHABIL, V21, P374, DOI 10.1007/s10926-010-9282-0; TEASDALE G, 1974, LANCET, V2, P81; Tingvoll WA, 2010, J NURS MANAGE, V18, P767, DOI 10.1111/j.1365-2834.2010.01112.x; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; World Health Organization, 2001, INT CLASS FUNCT DIS	41	28	29	0	16	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					801	807		10.2340/16501977-1168			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500016	24002317	DOAJ Gold			2021-06-18	
J	Kaushik, DK; Basu, A				Kaushik, Deepak Kumar; Basu, Anirban			A Friend in Need May Not be a Friend Indeed: Role of Microglia in Neurodegenerative Diseases	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Alzheimer's disease; central nervous system; cytokines; microglia; neuroinflammation; Parkinson's disease; toll-like receptors	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; AMYOTROPHIC-LATERAL-SCLEROSIS; TUMOR-NECROSIS-FACTOR; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; BACTERIAL-ENDOTOXIN EXPOSURE; AMYLOID-BETA-PEPTIDE; TOLL-LIKE RECEPTORS	Inflammation plays a critical role in the progression of neurodegenerative diseases. Microglia are the resident macrophages of the central nervous system (CNS) which actively take part in the neuronal development of CNS and are involved in clearance of pathogens as well as cellular debris from the system upon insult to this organization. Chronic activation of microglia in neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) as well as inflammatory conditions of CNS such as multiple sclerosis (MS) results in overall upregulation of pro-inflammatory cytokines and chemokines in the brain parenchyma. This compromises the neuronal health which further activates microglia by releasing death associated molecules such as neuromelanin, A peptides and cellular debris at the lesion site thereby forming a vicious cycle of disease advancement. Targeting microglial activation has proven to be a viable option in the treatment of inflammation related neurodegenerative diseases. This review will discuss the central position of inflammation and therapeutic strategies aiming to alleviate disease progression in some of the important inflammatory conditions of CNS.	[Kaushik, Deepak Kumar; Basu, Anirban] Natl Brain Res Ctr, Manesar 122051, Haryana, India	Kaushik, DK (corresponding author), Natl Brain Res Ctr, Manesar 122051, Haryana, India.	deepakkaushiik@gmail.com		Basu, Anirban/0000-0002-5200-2054	Life Science Research Board, Defence Research & Developmental Organization, Government of IndiaDefence Research & Development Organisation (DRDO) [DLS/81/48222/LSRB-213/EPB2010]; Indian Council of Medical Research (ICMR)Indian Council of Medical Research (ICMR); Department of Biotechnology (DBT)Department of Biotechnology (DBT) India	The work in the author's laboratory is funded by Life Science Research Board, Defence Research & Developmental Organization (DLS/81/48222/LSRB-213/EPB2010), Government of India. DKK is a recipient of Senior Research Fellowship from Indian Council of Medical Research (ICMR). AB is a recipient of the National Bioscience Award for Career Development-2010 from the Department of Biotechnology (DBT).	Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Almer G, 2002, NEUROLOGY, V58, P1277, DOI 10.1212/WNL.58.8.1277; Alvarez-Erviti L, 2011, NEUROSCI RES, V69, P337, DOI 10.1016/j.neures.2010.12.020; Badiola N, 2009, NEUROBIOL DIS, V35, P438, DOI 10.1016/j.nbd.2009.06.005; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Beraud D, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00080; Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459; BILLINGHAM RE, 1953, PROC R SOC SER B-BIO, V141, P392, DOI 10.1098/rspb.1953.0049; Bjorkqvist M, 2008, J EXP MED, V205, P1869, DOI 10.1084/jem.20080178; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; Brambilla R, 2011, BRAIN, V134, P2736, DOI 10.1093/brain/awr199; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Caballol N, 2007, MOVEMENT DISORD, V22, pS358, DOI 10.1002/mds.21677; Hernandez-Romero MC, 2012, NEUROTOXICOLOGY, V33, P347, DOI 10.1016/j.neuro.2012.01.018; Carrasco E, 2002, PARKINSONISM RELAT D, V8, P407, DOI 10.1016/S1353-8020(02)00022-6; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Casper D, 2000, NEUROSCI LETT, V289, P201, DOI 10.1016/S0304-3940(00)01294-5; Centonze D, 2009, J NEUROSCI, V29, P3442, DOI 10.1523/JNEUROSCI.5804-08.2009; Chakraborty S, 2010, J NEUROSCI RES, V88, P1615, DOI 10.1002/jnr.22343; Chechneva OV, 2011, NEUROBIOL DIS, V44, P63, DOI 10.1016/j.nbd.2011.06.004; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Chiu IM, 2008, P NATL ACAD SCI USA, V105, P17913, DOI 10.1073/pnas.0804610105; Diaz-Hernandez M, 2009, FASEB J, V23, P1893, DOI 10.1096/fj.08-122275; Dibaj P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017910; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Eng LF, 1996, NEUROCHEM RES, V21, P511, DOI 10.1007/BF02527717; Eugenin EA, 2003, METHODS, V29, P351, DOI 10.1016/S1046-2023(02)00359-6; Farez MF, 2009, NAT IMMUNOL, V10, P958, DOI 10.1038/ni.1775; Fassbender K, 2004, FASEB J, V18, P203, DOI 10.1096/fj.03-0364fje; Freeman TB, 2000, P NATL ACAD SCI USA, V97, P13877, DOI 10.1073/pnas.97.25.13877; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Gao Z., 2012, NEUROL RES INT, V2011; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Gelinas DS, 2004, P NATL ACAD SCI USA, V101, P14657, DOI 10.1073/pnas.0404866101; Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Gowing G, 2008, J NEUROSCI, V28, P10234, DOI 10.1523/JNEUROSCI.3494-08.2008; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Gris D, 2010, J IMMUNOL, V185, P974, DOI 10.4049/jimmunol.0904145; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Hebert SS, 2008, P NATL ACAD SCI USA, V105, P6415, DOI 10.1073/pnas.0710263105; Henderson APD, 2009, ANN NEUROL, V66, P739, DOI 10.1002/ana.21800; Henkel JS, 2009, J NEUROIMMUNE PHARM, V4, P389, DOI 10.1007/s11481-009-9171-5; Henkel JS, 2004, ANN NEUROL, V55, P221, DOI 10.1002/ana.10805; Hensley K, 2003, NEUROBIOL DIS, V14, P74, DOI 10.1016/S0969-9961(03)00087-1; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Herber DL, 2007, J NEUROIMMUNE PHARM, V2, P222, DOI 10.1007/s11481-007-9069-z; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Hoozemans JJM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-171; Huang Y, 2005, CELL MOL IMMUNOL, V2, P113; Huizinga R, 2012, GLIA, V60, P422, DOI 10.1002/glia.22276; Hunot S, 1996, NEUROSCIENCE, V72, P355, DOI 10.1016/0306-4522(95)00578-1; Iadecola C, 1996, AM J PHYSIOL-REG I, V271, pR990; Jack C, 2005, J NEUROSCI RES, V81, P363, DOI 10.1002/jnr.20482; Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Johnston LC, 2008, MOL THER, V16, P1392, DOI 10.1038/mt.2008.113; Kaisho T, 2000, CRIT REV IMMUNOL, V20, P393; Kanneganti TD, 2006, J BIOL CHEM, V281, P36560, DOI 10.1074/jbc.M607594200; Kanwar JR, 2005, CURR MED CHEM, V12, P2947, DOI 10.2174/092986705774462833; Kaur C, 2008, CURR MED CHEM, V15, P3068, DOI 10.2174/092986708786848640; Kaushik DK, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-68; Kaushik DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032270; Kaushik DK, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-57; Kaushik DK, 2011, FRONT BIOSCI-LANDMRK, V16, P2187, DOI 10.2741/3847; Kihara Y, 2009, P NATL ACAD SCI USA, V106, P21807, DOI 10.1073/pnas.0906891106; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kim YS, 2005, J NEUROSCI, V25, P3701, DOI 10.1523/JNEUROSCI.4346-04.2005; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Kraft AD, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.02.015; Kriz J, 2002, NEUROBIOL DIS, V10, P268, DOI 10.1006/nbdi.2002.0487; Kuhle J, 2009, EUR J NEUROL, V16, P771, DOI 10.1111/j.1468-1331.2009.02560.x; Kurkowska-Jastrzebska I, 2004, INT IMMUNOPHARMACOL, V4, P1307, DOI 10.1016/j.intimp.2004.05.006; Kurkowska-Jastrzebska I, 2002, INT IMMUNOPHARMACOL, V2, P1213, DOI 10.1016/S1567-5769(02)00078-4; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Lautner Ronald, 2011, Int J Alzheimers Dis, V2011, P939426, DOI 10.4061/2011/939426; Lee DC, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-56; Liang XB, 2008, ANN NEUROL, V64, P304, DOI 10.1002/ana.21437; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; Ling ZD, 2004, NEUROSCIENCE, V124, P619, DOI 10.1016/j.neuroscience.2003.12.017; Ling ZD, 2002, MOVEMENT DISORD, V17, P116, DOI 10.1002/mds.10078; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; Liu SR, 2012, J IMMUNOL, V188, P1098, DOI 10.4049/jimmunol.1101121; Liu Y, 2005, BRAIN, V128, P1778, DOI 10.1093/brain/awh531; Lobsiger CS, 2007, NAT NEUROSCI, V10, P1355, DOI 10.1038/nn1988; Long-Smith CM, 2009, PROG NEUROBIOL, V89, P277, DOI 10.1016/j.pneurobio.2009.08.001; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Ma L, 2003, GLIA, V43, P274, DOI 10.1002/glia.10261; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mannix Rebekah C, 2012, Int J Alzheimers Dis, V2012, P608732, DOI 10.1155/2012/608732; Martin R, 2012, BRIT J PHARMACOL, V166, P1708, DOI 10.1111/j.1476-5381.2012.01869.x; MATSUMOTO Y, 1986, J NEUROIMMUNOL, V12, P265; McGann JC, 2012, CURR OPIN NEUROBIOL; McGeer PL, 1998, ALZ DIS ASSOC DIS, V12, pS1; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MCGEER PL, 1987, CAN J NEUROL SCI, V14, P363, DOI 10.1017/S0317167100037756; McMahon EJ, 2005, NAT MED, V11, P335, DOI 10.1038/nm1202; Meda L, 1999, J NEUROIMMUNOL, V93, P45, DOI 10.1016/S0165-5728(98)00188-X; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Meissner F, 2010, P NATL ACAD SCI USA, V107, P13046, DOI 10.1073/pnas.1002396107; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; Rubio-Perez JM, 2012, SCI WORLD J, DOI 10.1100/2012/756357; Mills JH, 2012, J IMMUNOL, V188, P5713, DOI 10.4049/jimmunol.1200545; Minones-Moyano E, 2011, HUM MOL GENET, V20, P3067, DOI 10.1093/hmg/ddr210; Monk PN, 2006, NAT MED, V12, P885, DOI 10.1038/nm0806-885; Montgomery SL, 2011, AM J PATHOL, V179, P2053, DOI 10.1016/j.ajpath.2011.07.001; Moreau C, 2005, NEUROLOGY, V65, P1958, DOI 10.1212/01.wnl.0000188907.97339.76; Murphy AC, 2010, BRAIN BEHAV IMMUN, V24, P641, DOI 10.1016/j.bbi.2010.01.014; Murugaiyan G, 2011, J IMMUNOL, V187, P2213, DOI 10.4049/jimmunol.1003952; Nakajima K, 1998, GLIA, V24, P272, DOI 10.1002/(SICI)1098-1136(199811)24:3<272::AID-GLIA2>3.0.CO;2-4; Napoli I, 2010, EXP NEUROL, V225, P24, DOI 10.1016/j.expneurol.2009.04.024; Neniskyte U, 2011, J BIOL CHEM, V286, P39904, DOI 10.1074/jbc.M111.267583; Nunez-Iglesias J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008898; Ogata A, 1997, J NEUROVIROL, V3, P141, DOI 10.3109/13550289709015803; Olah M, 2012, GLIA, V60, P306, DOI 10.1002/glia.21266; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Pathak SK, 2004, J BIOL CHEM, V279, P55127, DOI 10.1074/jbc.M409885200; Pavese N, 2006, NEUROLOGY, V66, P1638, DOI 10.1212/01.wnl.0000222734.56412.17; Penfield W., 1932, CYTOLOGY CELLULAR PA, P483; Politis M, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00096; Politis M, 2011, HUM BRAIN MAPP, V32, P258, DOI 10.1002/hbm.21008; Pollari E, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-74; Poloni M, 2000, NEUROSCI LETT, V287, P211, DOI 10.1016/S0304-3940(00)01177-0; Pompl PN, 2003, FASEB J, V17, P725, DOI 10.1096/fj.02-0876fje; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Qian L, 2006, J NEURAL TRANSM-SUPP, P367; Quintana A, 2009, J IMMUNOL, V183, P2079, DOI 10.4049/jimmunol.0900242; Ramaglia V, 2012, P NATL ACAD SCI USA, V109, P965, DOI 10.1073/pnas.1111924109; Ratchford JN, 2012, J NEUROL, V259, P1199, DOI 10.1007/s00415-011-6337-x; Rentzos M, 2007, AMYOTROPH LATERAL SC, V8, P283, DOI 10.1080/17482960701419232; RICHARDSON A, 1993, GLIA, V7, P25, DOI 10.1002/glia.440070107; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rus H, 2006, J NEUROIMMUNOL, V180, P9, DOI 10.1016/j.jneuroim.2006.07.009; Ryu JK, 2004, EXP NEUROL, V187, P150, DOI 10.1016/j.expneurol.2004.01.006; Ryu JK, 2005, NEUROBIOL DIS, V20, P550, DOI 10.1016/j.nbd.2005.04.010; Samii A, 2004, LANCET, V363, P1783, DOI 10.1016/S0140-6736(04)16305-8; Sargsyan SA, 2005, GLIA, V51, P241, DOI 10.1002/glia.20210; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; Schutz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; Shi JQ, 2011, BRAIN RES, V1368, P239, DOI 10.1016/j.brainres.2010.10.053; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Simmons DA, 2007, GLIA, V55, P1074, DOI 10.1002/glia.20526; Singhrao SK, 1999, EXP NEUROL, V159, P362, DOI 10.1006/exnr.1999.7170; Song M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-92; SOTREL A, 1991, NEUROLOGY, V41, P1117, DOI 10.1212/WNL.41.7.1117; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sta M, 2011, NEUROBIOL DIS, V42, P211, DOI 10.1016/j.nbd.2011.01.002; Stefanova N, 2011, AM J PATHOL, V179, P954, DOI 10.1016/j.ajpath.2011.04.013; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; Tahara K, 2006, BRAIN, V129, P3006, DOI 10.1093/brain/awl249; Tai YF, 2007, BRAIN, V130, P1759, DOI 10.1093/brain/awm044; Tai YF, 2007, BRAIN RES BULL, V72, P148, DOI 10.1016/j.brainresbull.2006.10.029; Thomas M, 2004, CURR PHARM DESIGN, V10, P679, DOI 10.2174/1381612043453162; TOPPER R, 1993, EXP NEUROL, V123, P271, DOI 10.1006/exnr.1993.1159; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Van Den Bosch L, 2002, NEUROREPORT, V13, P1067, DOI 10.1097/00001756-200206120-00018; van Loo G, 2006, NAT IMMUNOL, V7, P954, DOI 10.1038/ni1372; Varnum MM, 2012, ARCH IMMUNOL THER EX, V60, P251, DOI 10.1007/s00005-012-0181-2; Varvel NH, 2009, J CLIN INVEST, V119, P3692, DOI 10.1172/JCI39716; Venero JL, 2011, CELL DEATH DIFFER, V18, P1679, DOI 10.1038/cdd.2011.107; von Bernhardi R, 2010, J NEUROCHEM, V112, P1099, DOI 10.1111/j.1471-4159.2009.06537.x; Westin K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030525; Williams AH, 2009, SCIENCE, V326, P1549, DOI 10.1126/science.1181046; WILLIAMS KC, 1994, CLIN NEUROSCI, V2, P229; Wilms H, 2003, J NEUROIMMUNOL, V144, P139, DOI 10.1016/j.jneuroim.2003.08.042; Wilms H, 2003, NEUROBIOL DIS, V14, P417, DOI 10.1016/j.nbd.2003.07.002; Wilms H, 2003, FASEB J, V17, P500, DOI 10.1096/fj.02-0314fje; Yan Q, 2003, J NEUROSCI, V23, P7504; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com; Zhang Y, 2011, GENE THER, V18, P1139, DOI 10.1038/gt.2011.170; Zhao J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-150	186	28	29	0	25	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	SEP	2013	12	6					726	740		10.2174/18715273113126660170			15	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	263HD	WOS:000327797200005	24070095				2021-06-18	
J	Ponsford, JL; Spitz, G; Cromarty, F; Gifford, D; Attwood, D				Ponsford, Jennie L.; Spitz, Gershon; Cromarty, Fiona; Gifford, David; Attwood, David			Costs of Care after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						costs; long-term care; hospital; medical; paramedical; TBI	CHARGES; OUTCOMES; LENGTH; STAY	Traumatic brain injuries (TBI) impose a significant burden on the health care system. The aim of the current study was to explore variation in costs in a group of rehabilitation patients in Victoria, Australia, following complicated mild-to-severe TBI treated under the accident compensation system administered by the Transport Accident Commission. Study participants included 1237 individuals with mild-to-severe TBI recruited consecutively from a TBI rehabilitation program. Long-term care, hospital, medical, and paramedical costs were obtained 10 years post-injury and their association with demographic and injury-related variables were examined. Significant variability in costs was evident. Long-term care costs were highest, followed by hospital, paramedical, and medical costs. Duration of post-traumatic amnesia (PTA) was a strong predictor of all costs, and stronger than Glasgow Coma Score (GCS). Longer acute hospital stay was related to higher costs. In addition to PTA duration and GCS, other factors associated with higher long-term costs were having an abnormal CT scan and epilepsy early after injury. Higher hospital and medical costs were associated with these factors, but also with other physical injuries, lower education, pre-injury unemployment, living outside the city, speaking English at home, and, in the case of medical costs, older age and having had pre-injury psychiatric treatment. Higher paramedical costs were associated with most of these variables, but also with being employed prior to injury and being female. In line with the multifaceted nature of TBI, the current findings suggest that both injury-related and demographic factors determine costs following injury.	[Ponsford, Jennie L.; Spitz, Gershon] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie L.; Spitz, Gershon] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Cromarty, Fiona; Gifford, David; Attwood, David] Transport Accid Commiss, Geelong, Vic, Australia	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia.	Jennie.Ponsford@monash.edu	Spitz, Gershon/H-7755-2014; Young, Richard A/F-6495-2012	Spitz, Gershon/0000-0002-7810-1480; Young, Richard A/0000-0001-8855-8647	Transport Accident Commission (TAC), through Institute for Safety, Compensation, and Recovery Research (ISCRR)	This project is funded by the Transport Accident Commission (TAC), through the Institute for Safety, Compensation, and Recovery Research (ISCRR).	AIHW, 2007, DIS AUSTR ACQ BRAIN; [Anonymous], 2009, EC COST SPINAL CORD, P1; Berg Jenny, 2004, Eur J Health Econ, V5 Suppl 1, pS84, DOI 10.1007/s10198-005-0293-2; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Helps Y., 2008, INJURY RES STAT SERI, V45; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; Homaifar BY, 2009, J REHABIL RES DEV, V46, P1003, DOI 10.1682/JRRD.2008.12.0166; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mayer NH, 2003, ARCH PHYS MED REHAB, V84, P242, DOI 10.1053/apmr.2003.50101; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Morris S, 2008, ANAESTHESIA, V63, P499, DOI 10.1111/j.1365-2044.2007.05432.x; Ponsford J, 2012, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prang KH, 2012, BRAIN INJURY, V26, P441	19	28	29	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2013	30	17					1498	1505		10.1089/neu.2012.2843			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202HX	WOS:000323205800005	23570260				2021-06-18	
J	Walker, WC; Marwitz, JH; Wilk, AR; Ketchum, JM; Hoffman, JM; Brown, AW; Lucas, S				Walker, William C.; Marwitz, Jennifer H.; Wilk, Amber R.; Ketchum, Jessica M.; Hoffman, Jeanne M.; Brown, Allen W.; Lucas, Sylvia			Prediction of headache severity (density and functional impact) after traumatic brain injury: A longitudinal multicenter study	CEPHALALGIA			English	Article						Headache; outcomes; post-traumatic headache; traumatic brain injury; head injury	POSTTRAUMATIC HEADACHE; CHRONIC PAIN; DISABILITY; MODERATE; DURATION	Background: Headache (HA) following traumatic brain injury (TBI) is common, but predictors and time course are not well established, particularly after moderate to severe TBI. Methods: A prospective, longitudinal cohort study of HA severity post-TBI was conducted on 450 participants at seven participating rehabilitation centers. Generalized linear mixed-effects models (GLMMs) were used to model repeated measures (months 3, 6, and 12 post-TBI) of two outcomes: HA density (a composite of frequency, duration, and intensity) and HA disruptions to activities of daily living (ADL). Results: Although HA density and ADL disruptions were nominally highest during the first three months post-TBI, neither showed significant changes over time. At all time points, history of pre-injury migraine was by far the strongest predictor of both HA density and ADL disruptions (odds ratio (OR)=8.0 and OR=7.2, averaged across time points, respectively). Furthermore, pre-injury non-migraine HA (at three and six months post-TBI), penetrating-type TBI (at six months post-TBI), and female sex (at six and 12 months post-TBI) were each associated with an increase in the odds of a more severe HA density. Severity of TBI (post-traumatic amnesia (PTA) duration) was not associated with either outcome. Conclusion: Individuals with HA at three months after moderate-severe TBI do not improve over the ensuing nine months with respect to HA density or ADL disruptions. Those with pre-injury HA, particularly of migraine type, are at greatest risk for HA post-TBI. Other independent risk factors are penetrating-type TBI and, to a lesser degree and post-acutely only, female sex. Individuals with these risk factors should be monitored and considered for aggressive early intervention.	[Walker, William C.; Marwitz, Jennifer H.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Wilk, Amber R.; Ketchum, Jessica M.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA; [Ketchum, Jessica M.] Virginia Commonwealth Univ, Ctr Rehabil Sci & Engn, Richmond, VA 23298 USA; [Hoffman, Jeanne M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; [Lucas, Sylvia] Univ Washington, Dept Neurol, Seattle, WA 98195 USA	Walker, WC (corresponding author), Virginia Commonwealth Univ, VCU Box 980661, Richmond, VA 23298 USA.	wwalker@mcvh-vcu.edu	Ketchum, Jessica/AAE-8200-2020; Walker, William C/N-3162-2014	Brown, Allen W./0000-0001-7228-3351; Ketchum, Jessica/0000-0002-5566-3691	National Institute on Disability and Rehabilitation Research (NIDRR), Office of Special Education and Rehabilitative Services (OSERS), Dept. of Education, Washington, D.C. [H133A070013, H133A070032, H133A070036]	This work was supported by the National Institute on Disability and Rehabilitation Research (NIDRR), Office of Special Education and Rehabilitative Services (OSERS), Dept. of Education, Washington, D.C. (grant numbers H133A070013, H133A070032, and H133A070036).	Annoni J M, 1992, Disabil Rehabil, V14, P23; BARNAT MR, 1986, HEADACHE, V26, P271, DOI 10.1111/j.1526-4610.1986.hed2606271.x; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; GOLDSTEIN J, 1991, MED CLIN N AM, V75, P641, DOI 10.1016/S0025-7125(16)30439-4; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Holroyd KA, 1999, PAIN, V83, P571, DOI 10.1016/S0304-3959(99)00165-7; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; JONES JH, 1992, ARCH PHYS MED REHAB, V73, P145; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lieba-Samal D, 2011, CEPHALALGIA, V31, P1618, DOI 10.1177/0333102411428954; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; STEWART WF, 1994, NEUROLOGY, V44, P24; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; 2004, CEPHALALGIA S1, V24, P9	27	28	28	0	14	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	SEP	2013	33	12					998	1008		10.1177/0333102413482197			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	193VZ	WOS:000322590900002	23575819				2021-06-18	
J	Andersson, D; Wilhelmsson, U; Nilsson, M; Kubista, M; Stahlberg, A; Pekna, M; Pekny, M				Andersson, Daniel; Wilhelmsson, Ulrika; Nilsson, Michael; Kubista, Mikael; Stahlberg, Anders; Pekna, Marcela; Pekny, Milos			Plasticity Response in the Contralesional Hemisphere after Subtle Neurotrauma: Gene Expression Profiling after Partial Deafferentation of the Hippocampus	PLOS ONE			English	Article							FIBRILLARY ACIDIC PROTEIN; SYNAPSE FORMATION; MICE DEFICIENT; THROMBOSPONDIN-4; RAT; TRANSCRIPTOME; ASTROCYTES; ABSENCE; STROKE; MODEL	Neurotrauma or focal brain ischemia are known to trigger molecular and structural responses in the uninjured hemisphere. These responses may have implications for tissue repair processes as well as for the recovery of function. To determine whether the plasticity response in the uninjured hemisphere occurs even after a subtle trauma, we subjected mice to a partial unilateral deafferentation of the hippocampus induced by stereotactically performed entorhinal cortex lesion (ECL). The expression of selected genes was assessed by quantitative real-time PCR in the hippocampal tissue at the injured side and the contralesional side at day 4 and 14 after injury. We observed that expression of genes coding for synaptotagmin 1, ezrin, thrombospondin 4, and C1q proteins, that have all been implicated in the synapse formation, re-arrangement and plasticity, were upregulated both in the injured and the contralesional hippocampus, implying a plasticity response in the uninjured hemisphere. Several of the genes, the expression of which was altered in response to ECL, are known to be expressed in astrocytes. To test whether astrocyte activation plays a role in the observed plasticity response to ECL, we took advantage of mice deficient in two intermediate filament (nanofilament) proteins glial fibrillary acidic protein (GFAP) and vimentin (GFAP(-/-) Vim(-/-)) and exhibiting attenuated astrocyte activation and reactive gliosis. The absence of GFAP and vimentin reduced the ECL-induced upregulation of thrombospondin 4, indicating that this response to ECL depends on astrocyte activation and reactive gliosis. We conclude that even a very limited focal neurotrauma triggers a distinct response at the contralesional side, which at least to some extent depends on astrocyte activation.	[Andersson, Daniel; Wilhelmsson, Ulrika; Nilsson, Michael; Stahlberg, Anders; Pekna, Marcela; Pekny, Milos] Univ Gothenburg, Ctr Brain Repair & Rehabil, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol,Sahlgrenska Acad, Gothenburg, Sweden; [Nilsson, Michael] Hunter Med Res Inst, Newcastle, NSW, Australia; [Kubista, Mikael] Acad Sci Czech Republ, Inst Biotechnol, Prague, Czech Republic; [Kubista, Mikael] TATAA Bioctr, Gothenburg, Sweden; [Stahlberg, Anders] Univ Gothenburg, Dept Pathol, Inst Biomed, Sahlgrenska Acad, Gothenburg, Sweden	Pekny, M (corresponding author), Univ Gothenburg, Ctr Brain Repair & Rehabil, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol,Sahlgrenska Acad, Gothenburg, Sweden.	milos.pekny@neuro.gu.se	NILSSON, MICHAEL/ABE-7821-2020; Pekna, Marcela/AAM-3261-2021; Kubista, Mikael/A-5689-2008; Pekna, Marcela/AAM-3249-2021	NILSSON, MICHAEL/0000-0002-8826-1621; Pekna, Marcela/0000-0003-2734-8237; Kubista, Mikael/0000-0002-2940-352X; Pekna, Marcela/0000-0003-2734-8237; Stahlberg, Anders/0000-0003-4243-0191; Andersson, Daniel/0000-0002-4564-6652	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission [11548]; AFA Insurance; ALF Goteborg [11392]; Sten A. Olsson Foundation for Research and Culture; VINNOVA Health ProgramVinnova; Swedish Stroke Foundation; Swedish Society of Medicine; Free Mason Foundation; Wilhelm and Martina Lundgren Foundations; NanoNet COST ActionEuropean Cooperation in Science and Technology (COST) [279017]	This work was supported by the Swedish Medical Research Council (project 11548), AFA Insurance, ALF Goteborg (project 11392), Sten A. Olsson Foundation for Research and Culture, VINNOVA Health Program, the Swedish Stroke Foundation, the Swedish Society of Medicine, the Free Mason Foundation, Wilhelm and Martina Lundgren Foundations, NanoNet COST Action (BM1002), the EU FP 7 Program EduGlia (237956) and the EU FP 7 Program TargetBraIn (279017). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; ARBER S, 1995, J CELL BIOL, V131, P1083, DOI 10.1083/jcb.131.4.1083; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Berg A, 2012, EXP NEUROL, V237, P8, DOI 10.1016/j.expneurol.2012.06.008; Buga AM, 2008, J CELL MOL MED, V12, P2731, DOI 10.1111/j.1582-4934.2008.00252.x; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Deller T, 2007, PROG BRAIN RES, V163, P501, DOI 10.1016/S0079-6123(07)63027-1; Dunkle ET, 2007, EXP EYE RES, V84, P707, DOI 10.1016/j.exer.2006.12.014; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Eroglu C, 2009, CELL, V139, P380, DOI 10.1016/j.cell.2009.09.025; Gardzinski P, 2007, J PHYSIOL-LONDON, V581, P75, DOI 10.1113/jphysiol.2006.127472; Hernandez MR, 2002, GLIA, V38, P45, DOI 10.1002/glia.10051; Hori M, 2012, DIS MODEL MECH, V5, P270, DOI 10.1242/dmm.008276; Kim DS, 2012, J NEUROSCI, V32, P8977, DOI 10.1523/JNEUROSCI.6494-11.2012; Kim MW, 2005, BRAIN RES, V1052, P16, DOI 10.1016/j.brainres.2005.05.070; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; Lavialle M, 2011, P NATL ACAD SCI USA, V108, P12915, DOI 10.1073/pnas.1100957108; Li SL, 2010, NAT NEUROSCI, V13, P1496, DOI 10.1038/nn.2674; Lu YB, 2011, FASEB J, V25, P624, DOI 10.1096/fj.10-163790; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; Nakazawa T, 2007, INVEST OPHTH VIS SCI, V48, P2760, DOI 10.1167/iovs.06-1398; Parpura V, 2012, J NEUROCHEM, V121, P4, DOI 10.1111/j.1471-4159.2012.07664.x; Pekna M, 2012, STROKE, V43, P2819, DOI 10.1161/STROKEAHA.112.654228; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Pekny M., 2013, CYTOSKELETON IMAGING, P299, DOI DOI 10.1007/978-1-62703-266-7_13; PFENNINGER KH, 1991, MOL NEUROBIOL, V5, P143, DOI 10.1007/BF02935543; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stahlberg A, 2005, EXPERT REV MOL DIAGN, V5, P221, DOI 10.1586/14737159.5.2.221; Stahlberg A, 2004, CLIN CHEM, V50, P1678, DOI 10.1373/clinchem.2004.035469; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999; Turner DA, 1998, PROG NEUROBIOL, V55, P537, DOI 10.1016/S0301-0082(98)00019-7; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012	37	28	28	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2013	8	7							e70699	10.1371/journal.pone.0070699			6	Multidisciplinary Sciences	Science & Technology - Other Topics	191SQ	WOS:000322433300112	23936241	DOAJ Gold, Green Published			2021-06-18	
J	Frattalone, AR; Ling, GSF				Frattalone, Anthony R.; Ling, Geoffrey S. F.			Moderate and Severe Traumatic Brain Injury: Pathophysiology and Management	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Clinical practice guidelines; Head injury; Concussion; Coma; ICP (intracranial pressure); OPP (cerebral perfusion pressure)	RAPID-SEQUENCE INTUBATION; SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; GLASGOW COMA SCALE; INTRACRANIAL-PRESSURE; INTENSIVE-CARE; BLOOD-PRESSURE; IMPACT; TISSUE; HYPOTENSION	Traumatic brain injury (TBI) is a serious disorder that is all too common. TBI ranges in severity from mild concussion to a severe life-threatening state. Across this spectrum, rational therapeutic approaches exist. Early identification that TBI has occurred in a patient is paramount to optimal outcome. Proper clinical management should be instituted as soon as possible by appropriately trained medical providers. More seriously injured patients must be triaged to advanced care centers. It is only through this rational approach to TBI that patients may expect to achieve optimal clinical and functional outcome.	[Frattalone, Anthony R.; Ling, Geoffrey S. F.] Johns Hopkins Med Inst, Div Neurocrit Care, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Frattalone, Anthony R.; Ling, Geoffrey S. F.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Ling, GSF (corresponding author), US Army, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	geoffrey.ling@usuhs.edu					Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bochicchio GV, 2006, JPEN-PARENTER ENTER, V30, P503, DOI 10.1177/0148607106030006503; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Bulger E., 2010, JAMA-J AM MED ASSOC, V304, P1445; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Butler J, 2002, EMERG MED J, V19, P554, DOI 10.1136/emj.19.6.554; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; DOCZI T, 1993, ACTA NEUROCHIR, V121, P1, DOI 10.1007/BF01405174; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Eken C, 2009, EUR J EMERG MED, V16, P29, DOI 10.1097/MEJ.0b013e32830346ab; Eriksson EA, 2012, CLIN NEUROPHYSIOL, V123, P1255, DOI 10.1016/j.clinph.2011.08.035; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Fernandez-Ortega JF, 2012, J NEUROTRAUM, V29, P1364, DOI 10.1089/neu.2011.2033; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gjerris F, 2000, PATHOPHYSIOLOGY CERE; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Johnston AJ, 2003, BRIT J ANAESTH, V91, P781, DOI 10.1093/bja/aeg256; Meirelles CMJ, 2011, NUTR HOSP, V26, P1120, DOI [10.3305/nh.2011.26.5.5133, 10.1590/S0212-16112011000500030]; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Kubal WS, 2012, RADIOL CLIN N AM, V50, P15, DOI 10.1016/j.rcl.2011.08.010; Ley EJ, 2011, J TRAUMA, V71, P1689, DOI 10.1097/TA.0b013e31823cc5df; LYONS MK, 1990, MAYO CLIN PROC, V65, P684, DOI 10.1016/S0025-6196(12)65131-3; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Manz H J, 1979, Pathobiol Annu, V9, P359; Marshall GT, 2010, J TRAUMA, V69, P275, DOI 10.1097/TA.0b013e3181de74c7; MCCOMB JG, 1983, J NEUROSURG, V59, P369, DOI 10.3171/jns.1983.59.3.0369; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MOULTON C, 1994, LANCET, V343, P1261, DOI 10.1016/S0140-6736(94)92155-5; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; RAPHAEL JH, 1994, ANAESTHESIA, V49, P437; Robinson N, 2001, EMERG MED J, V18, P453, DOI 10.1136/emj.18.6.453; Rossi S, 2001, J NEUROL NEUROSUR PS, V71, P448, DOI 10.1136/jnnp.71.4.448; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; Scalfani MT, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.10.008; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SHRIBMAN AJ, 1987, BRIT J ANAESTH, V59, P295, DOI 10.1093/bja/59.3.295; Stead LG, 2009, NEUROCRIT CARE, V10, P50, DOI 10.1007/s12028-008-9145-0; Stein NR, 2011, NEUROCRIT CARE, V32, P1639; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; STOELTING RK, 1977, ANESTHESIOLOGY, V47, P381, DOI 10.1097/00000542-197710000-00012; Stone MB, 2010, ACAD EMERG MED, V17, P100, DOI 10.1111/j.1553-2712.2009.00624.x; Suarez JI, 2004, CRIT CARE MED, V32, P2311, DOI 10.1097/01.CCM.0000146132.29042.4c; Sydenham E., 2009, COCHRANE DATABASE SY; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Thillai M, 2000, BRIT MED J, V320, P399, DOI 10.1136/bmj.320.7232.399; Varelas PN, 2004, CRIT CARE MED, V32, P2191, DOI 10.1097/01.CCM.0000146131.03578.21; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Wijdicks EF, 2010, PRACTICE EMERGENCY C; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Zhang XY, 2011, AM J EMERG MED, V29, P699, DOI 10.1016/j.ajem.2010.01.042	78	28	30	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	JUL	2013	24	3					309	+		10.1016/j.nec.2013.03.006			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	191NY	WOS:000322421100002	23809027				2021-06-18	
J	O'Connell, KM; Littleton-Kearney, MT				O'Connell, Karen M.; Littleton-Kearney, Marguerite T.			The Role of Free Radicals in Traumatic Brain Injury	BIOLOGICAL RESEARCH FOR NURSING			English	Article						free radicals; traumatic brain injury; secondary injury; superoxide; nitric oxide; peroxynitrite	NITRIC-OXIDE SYNTHASE; SEVERE HEAD-INJURY; CORTICAL IMPACT INJURY; CEREBRAL-BLOOD-FLOW; OXIDATIVE STRESS; COLD INJURY; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; GLUTAMATE TRANSPORTERS; ENERGY-METABOLISM	Traumatic brain injury (TBI) is a significant cause of death and disability in both the civilian and the military populations. The primary impact causes initial tissue damage, which initiates biochemical cascades, known as secondary injury, that expand the damage. Free radicals are implicated as major contributors to the secondary injury. Our review of recent rodent and human research reveals the prominent role of the free radicals superoxide anion, nitric oxide, and peroxynitrite in secondary brain injury. Much of our current knowledge is based on rodent studies, and the authors identified a gap in the translation of findings from rodent to human TBI. Rodent models are an effective method for elucidating specific mechanisms of free radical-induced injury at the cellular level in a well-controlled environment. However, human TBI does not occur in a vacuum, and variables controlled in the laboratory may affect the injury progression. Additionally, multiple experimental TBI models are accepted in rodent research, and no one model fully reproduces the heterogeneous injury seen in humans. Free radical levels are measured indirectly in human studies based on assumptions from the findings from rodent studies that use direct free radical measurements. Further study in humans should be directed toward large samples to validate the findings in rodent studies. Data obtained from these studies may lead to more targeted treatment to interrupt the secondary injury cascades.	[O'Connell, Karen M.; Littleton-Kearney, Marguerite T.] Uniformed Serv Univ Hlth Sci, Grad Sch Nursing, Bethesda, MD 20814 USA	O'Connell, KM (corresponding author), Uniformed Serv Univ Hlth Sci, Grad Sch Nursing, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	karen.oconnell17@gmail.com					Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Besson VC, 2003, FREE RADICAL RES, V37, P1201, DOI 10.1080/10715760310001612568; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brzezinska AK, 2000, AM J PHYSIOL-HEART C, V278, pH1883; Camacho A, 2006, ARCH MED RES, V37, P11, DOI 10.1016/j.arcmed.2005.05.014; Carpenter KLH, 2008, ACTA NEUROCHIR SUPPL, V102, P207, DOI 10.1007/978-3-211-85578-2_41; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Centers for Disease Control, 2010, MAN PEOPL HAV TBI; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Defense and Veterans Brain Injury Center, 2011, DOD WORLDW NUMB TRAU; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; DeWitt DS, 2001, J CEREBR BLOOD F MET, V21, P253, DOI 10.1097/00004647-200103000-00009; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Droge W, 2002, PHYSIOL REV, V82, P47; Erdincler P, 2002, ACTA NEUROCHIR, V144, P195, DOI 10.1007/s007010200024; Faraci FM, 2006, J APPL PHYSIOL, V100, P739, DOI 10.1152/japplphysiol.01044.2005; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Grzeschik SM, 2003, J NEUROTRAUM, V20, P571, DOI 10.1089/089771503767168492; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Hlatky R, 2003, J CEREBR BLOOD F MET, V23, P582, DOI 10.1097/01.WCB.0000059586.71206.F3; Hlatky R, 2002, ACT NEUR S, V81, P347; Hlatky R, 2002, ACT NEUR S, V81, P331; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huttemann M, 2008, NEUROSCIENCE, V151, P148, DOI 10.1016/j.neuroscience.2007.09.029; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Jones NC, 2004, J NEUROPATH EXP NEUR, V63, P708, DOI 10.1093/jnen/63.7.708; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; National Institute of Neurological Disorders and Stroke, 2002, TRAUM BRAIN INJ HOP; Nayak Chandrika D, 2007, Indian J Med Sci, V61, P381; Ono K, 2010, NEUROSCI LETT, V473, P146, DOI 10.1016/j.neulet.2010.02.041; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Panickar KS, 2002, NEUROCHEM RES, V27, P161, DOI 10.1023/A:1014875210852; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; Park CO, 2001, YONSEI MED J, V42, P518, DOI 10.3349/ymj.2001.42.5.518; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Safari M, 2009, Pak J Biol Sci, V12, P1156; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tuzgen S, 2003, NEUROL RES, V25, P31, DOI 10.1179/016164103101201085; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Uzan M, 2001, SURG NEUROL, V56, P350, DOI 10.1016/S0090-3019(01)00633-4; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Ziaja M, 2007, J NEUROTRAUM, V24, P1845, DOI 10.1089/neu.2007.0303	66	28	29	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1099-8004	1552-4175		BIOL RES NURS	Biol. Res. Nurs.	JUL	2013	15	3					253	263		10.1177/1099800411431823			11	Nursing	Nursing	158BP	WOS:000319943800001	22345426				2021-06-18	
J	Roebuck-Spencer, TM; Vincent, AS; Schlegel, RE; Gilliland, K				Roebuck-Spencer, Tresa M.; Vincent, Andrea S.; Schlegel, Robert E.; Gilliland, Kirby			Evidence for Added Value of Baseline Testing in Computer-Based Cognitive Assessment	JOURNAL OF ATHLETIC TRAINING			English	Article						Automated Neuropsychological Assessment Metrics; computerized neuropsychological testing; concussions; mild traumatic brain injuries; military athletes	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT METRICS; SPORT-RELATED CONCUSSION; DEPLOYMENT; PERFORMANCE; MANAGEMENT; IRAQ	Context: Large-scale baseline cognitive assessment for individuals at risk for concussion is a common part of the protocol for concussion-surveillance programs, particularly in sports. Baseline cognitive testing is also being conducted in US military service members before deployment. Recently, the incremental validity of large-scale baseline cognitive assessment has been questioned. Objective: To examine the added value of baseline cognitive testing in computer-based neuropsychological assessment by comparing 2 methods of classifying atypical performance in a presumed healthy sample. Design: Cross-sectional study. Setting: Military base. Patients or Other Participants: Military service members who took the Automated Neuropsychological Assessment Matrix (ANAM) before and after deployment (n = 8002). Main Outcome Measure(s): Rates of atypical performance in this healthy, active-duty sample were determined first by comparing postdeployment scores with a military normative database and then with each individual's personal baseline performance using a reliable change index. Results: Overall rates of atypical performance were comparable across these 2 methods. However, these methods were highly discordant in terms of which individuals were classified as atypical. When norm-referenced methods were used, 2.6% of individuals classified as normal actually demonstrated declines from baseline. Further, 65.7% of individuals classified as atypical using norm-referenced scores showed no change from baseline (ie, potential false-positive findings). Conclusions: Knowing an individual's baseline performance is important for minimizing potential false-positive errors and reducing the risks and stresses of misdiagnosis.	[Roebuck-Spencer, Tresa M.; Vincent, Andrea S.; Schlegel, Robert E.; Gilliland, Kirby] Univ Oklahoma, Norman, OK 73072 USA	Roebuck-Spencer, TM (corresponding author), Univ Oklahoma, Cognit Sci Res Ctr, 3200 Marshall Ave,Suite 260, Norman, OK 73072 USA.	tresa@ou.edu			US Army Medical Research & Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC); Telemedicine & Advanced Technology Research Center (TATRC), at Fort Detrick, MD [W81XWH-07-2-0097]	This project was conducted by the Cognitive Science Research Center (formerly the Center for the Study of Human Operator Performance: C-SHOP) at the University of Oklahoma and is made possible by a Department of Defense Grant that was awarded and administered by the US Army Medical Research & Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Research Center (TATRC), at Fort Detrick, MD, under contract number W81XWH-07-2-0097. We acknowledge the significant contributions of the many individuals, staff, and service members at the following organizations who made data collection for this analysis possible: Fort Campbell, KY; Neurocognitive Assessment Branch, Rehabilitation and Reintegration Division, US Army Office of the Surgeon General; and the Defense and Veterans Brain Injury Center.	Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Brooks BL, 2010, ARCH CLIN NEUROPSYCH, V25, P14, DOI 10.1093/arclin/acp100; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Heaton RK, 2004, REVISED COMPREHENSIV; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Maassen GH, 2006, BRIT J SPORT MED, V40, P829, DOI 10.1136/bjsm.2005.023713; McCaffrey RJ, 2007, ARCH CLIN NEUROPS S1, V22, P1; Randolph C, 2009, J INT NEUROPSYCH SOC, V15, P512, DOI 10.1017/S135561770909064X; Roebuck-Spencer T, 2010, NAT AC NEUR OCT 13 1; Roebuck-Spencer TM, 2012, CLIN NEUROPSYCHOL, V26, P473, DOI 10.1080/13854046.2011.650214; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Vincent AS, 2012, MIL MED, V177, P256, DOI 10.7205/MILMED-D-11-00289; Vincent AS, 2012, MIL MED, V177, P248, DOI 10.7205/MILMED-D-11-00156	25	28	28	0	10	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2013	48	4					499	505		10.4085/1062-6050-48.3.11			7	Sport Sciences	Sport Sciences	211GX	WOS:000323895400009	23724773	Green Published, Bronze			2021-06-18	
J	Cervelli, M; Bellavia, G; D'Amelio, M; Cavallucci, V; Moreno, S; Berger, J; Nardacci, R; Marcoli, M; Maura, G; Piacentini, M; Amendola, R; Cecconi, F; Mariottini, P				Cervelli, Manuela; Bellavia, Gabriella; D'Amelio, Marcello; Cavallucci, Virve; Moreno, Sandra; Berger, Joachim; Nardacci, Roberta; Marcoli, Manuela; Maura, Guido; Piacentini, Mauro; Amendola, Roberto; Cecconi, Francesco; Mariottini, Paolo			A New Transgenic Mouse Model for Studying the Neurotoxicity of Spermine Oxidase Dosage in the Response to Excitotoxic Injury	PLOS ONE			English	Article							D-ASPARTATE RECEPTOR; ORNITHINE-DECARBOXYLASE ACTIVITY; POLYAMINE RECOGNITION SITE; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; KAINIC ACID; RAT-BRAIN; SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; HUNTINGTONS-DISEASE; CELLULAR FUNCTIONS	Spermine oxidase is a FAD-containing enzyme involved in polyamines catabolism, selectively oxidizing spermine to produce H2O2, spermidine, and 3-aminopropanal. Spermine oxidase is highly expressed in the mouse brain and plays a key role in regulating the levels of spermine, which is involved in protein synthesis, cell division and cell growth. Spermine is normally released by neurons at synaptic sites where it exerts a neuromodulatory function, by specifically interacting with different types of ion channels, and with ionotropic glutamate receptors. In order to get an insight into the neurobiological roles of spermine oxidase and spermine, we have deregulated spermine oxidase gene expression producing and characterizing the transgenic mouse model JoSMOrec, conditionally overexpressing the enzyme in the neocortex. We have investigated the effects of spermine oxidase overexpression in the mouse neocortex by transcript accumulation, immunohistochemical analysis, enzymatic assays and polyamine content in young and aged animals. Transgenic JoSMOrec mice showed in the neocortex a higher H2O2 production in respect to Wild-Type controls, indicating an increase of oxidative stress due to SMO overexpression. Moreover, the response of transgenic mice to excitotoxic brain injury, induced by kainic acid injection, was evaluated by analysing the behavioural phenotype, the immunodistribution of neural cell populations, and the ultrastructural features of neocortical neurons. Spermine oxidase overexpression and the consequently altered polyamine levels in the neocortex affects the cytoarchitecture in the adult and aging brain, as well as after neurotoxic insult. It resulted that the transgenic JoSMOrec mouse line is more sensitive to KA than Wild-Type mice, indicating an important role of spermine oxidase during excitotoxicity. These results provide novel evidences of the complex and critical functions carried out by spermine oxidase and spermine in the mammalian brain.	[Cervelli, Manuela; Bellavia, Gabriella; Moreno, Sandra; Mariottini, Paolo] Univ Roma Tre, Dipartimento Biol, Rome, Italy; [D'Amelio, Marcello; Cavallucci, Virve; Cecconi, Francesco] Fdn Santa Lucia, IRCCS, Lab Mol Neuroembryol, Rome, Italy; [Berger, Joachim] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Nardacci, Roberta; Piacentini, Mauro] IRCCS L Spallanzani, Ist Nazl Malattie Infett, Rome, Italy; [Marcoli, Manuela; Maura, Guido] Univ Genoa, Ctr Eccellenza Ric Biomed CEBR, Sez Farmacol & Tossicol, Dipartimento Farm, Genoa, Italy; [Amendola, Roberto] Agenzia Nazl Nuove Tecnol Energia & Sviluppo Econ, Ctr Ric Casaccia 2, Sez Tossicol & Sci Biomed BAS BIOTECMED, Rome, Italy	Cervelli, M (corresponding author), Univ Roma Tre, Dipartimento Biol, Rome, Italy.	cervelli@uniroma3.it	Nardacci, Roberta/K-6555-2016; Piacentini, Mauro/I-2411-2016; OLIVERIO, MARCO/F-2229-2010; Cecconi, Francesco/K-3969-2016; Amendola, Roberto/AAM-2034-2020; Moreno, Sandra/D-4254-2014; Berger, Joachim/N-2979-2019; Cervelli, Manuela/ABC-6913-2020	Nardacci, Roberta/0000-0002-9209-1207; Piacentini, Mauro/0000-0003-2919-1296; OLIVERIO, MARCO/0000-0002-0316-4364; Cecconi, Francesco/0000-0002-5614-4359; Berger, Joachim/0000-0002-7859-545X; Cervelli, Manuela/0000-0001-8535-8279; Cavallucci, Virve/0000-0003-3082-6359; D'Amelio, Marcello/0000-0001-6526-1832; moreno, sandra/0000-0002-1079-3222; Bellavia, Gabriella/0000-0003-0431-0180	Universita Roma Tre	The financial support utilized for this work was mainly from the Universita Roma Tre, the year budget was below 10,000 Euro. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	ALHONEN L, 1995, INT J CANCER, V63, P402, DOI 10.1002/ijc.2910630317; Amendola R, 2009, CURR CANCER DRUG TAR, V9, P118, DOI 10.2174/156800909787580935; Benkovic SA, 2004, BRAIN RES, V1024, P59, DOI 10.1016/j.brainres.2004.07.021; Casero RA, 2009, BIOCHEM J, V421, P323, DOI 10.1042/BJ20090598; Cervelli M, 2004, EUR J BIOCHEM, V271, P760, DOI 10.1111/j.1432-1033.2004.03979.x; Cervelli M, 2012, AMINO ACIDS, V42, P441, DOI 10.1007/s00726-011-1014-z; Cervelli M, 2009, INT J BIOCHEM CELL B, V41, P934, DOI 10.1016/j.biocel.2008.09.009; COYLE JT, 1987, CIBA F SYMP, V126, P186; DEVERA N, 1991, J NEUROCHEM, V57, P1; Dingledine R, 1999, PHARMACOL REV, V51, P7; Doctrow S R, 1997, Adv Pharmacol, V38, P247; FAGE D, 1992, J NEUROCHEM, V58, P2170, DOI 10.1111/j.1471-4159.1992.tb10960.x; Fiori LM, 2011, INT J NEUROPSYCHOPH, V14, P595, DOI 10.1017/S1461145710001574; Fiori LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015146; Fleidervish IA, 2008, P NATL ACAD SCI USA, V105, P18994, DOI 10.1073/pnas.0803464105; HALONEN T, 1993, EUR J NEUROSCI, V5, P1233, DOI 10.1111/j.1460-9568.1993.tb00978.x; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; HOGAN B, 1983, NATURE, V306, P313, DOI 10.1038/306313a0; Iannicola C, 2000, J NEUROCHEM, V75, P830, DOI 10.1046/j.1471-4159.2000.0750830.x; Iarashi K, 2010, INT J BIOCHEM CELL B, V42, P39, DOI 10.1016/j.biocel.2009.07.009; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Janne J, 2005, J CELL MOL MED, V9, P865, DOI 10.1111/j.1582-4934.2005.tb00385.x; Janne J, 2004, EUR J BIOCHEM, V271, P877, DOI 10.1111/j.1432-1033.2004.04009.x; Kaasinen K, 2000, EUR J NEUROSCI, V12, P540, DOI 10.1046/j.1460-9568.2000.00940.x; Kaasinen SK, 2003, EXP NEUROL, V183, P645, DOI 10.1016/S0014-4886(03)00186-9; Kaasinen SK, 2004, PHARM BIOCH BEHAV, V78, P3545; Kauppinen RA, 1995, PROG NEUROBIOL, V47, P545, DOI 10.1016/0301-0082(95)00037-2; Liu W, 2001, J NEUROCHEM, V79, P976, DOI 10.1046/j.1471-4159.2001.00650.x; LUKKARAINEN J, 1995, EUR J NEUROSCI, V7, P1840, DOI 10.1111/j.1460-9568.1995.tb00704.x; Lukkarinen J, 1997, STROKE, V28, P639, DOI 10.1161/01.STR.28.3.639; Lukkarinen JA, 1999, BRAIN RES, V826, P325, DOI 10.1016/S0006-8993(99)01327-X; Lukkarinen JA, 1998, EUR J NEUROSCI, V10, P2046, DOI 10.1046/j.1460-9568.1998.00216.x; MARTINEZ E, 1991, LIFE SCI, V48, P77, DOI 10.1016/0024-3205(91)90427-D; Mastroberardino P, 2002, CELL DEATH DIFFER, V9, P873, DOI 10.1038/sj.cdd.4401093; Masuko T, 2003, J NEUROCHEM, V84, P610, DOI 10.1046/j.1471-4159.2003.01558.x; MATES JM, 1992, AGENTS ACTIONS, V36, P17, DOI 10.1007/BF01991222; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Mony L, 2011, EMBO J, V30, P3134, DOI 10.1038/emboj.2011.203; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NAJM I, 1992, DEV BRAIN RES, V69, P11, DOI 10.1016/0165-3806(92)90117-F; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PASCHEN W, 1991, BRAIN RES, V566, P354, DOI 10.1016/0006-8993(91)91726-H; PASCHEN W, 1992, MOL CHEM NEUROPATHOL, V16, P241, DOI 10.1007/BF03159973; PASCHEN W, 1990, J CEREBR BLOOD F MET, V10, P236, DOI 10.1038/jcbfm.1990.40; Pledgie A, 2005, J BIOL CHEM, V280, P39843, DOI 10.1074/jbc.M508177200; Rea G, 2004, IUBMB LIFE, V56, P167, DOI 10.1080/15216540410001673996; Schauwecker PE, 2003, MOL BRAIN RES, V112, P70, DOI 10.1016/S0169-328X(03)00048-2; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Traynelis SF, 2010, PHARMACOL REV, V62, P405, DOI 10.1124/pr.109.002451; van den Bout CJ, 2002, MECH DEVELOP, V110, P179, DOI 10.1016/S0925-4773(01)00597-4; Wang Q, 2005, MOL NEUROBIOL, V31, P3, DOI 10.1385/MN:31:1-3:003; Wang YL, 2005, BIOCHEM J, V386, P543, DOI 10.1042/BJ20041084; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; WILLIAMS K, 1989, MOL PHARMACOL, V36, P575; WILLIAMS K, 1990, NEURON, V5, P199, DOI 10.1016/0896-6273(90)90309-4; Yang DS, 2008, AM J PATHOL, V173, P665, DOI 10.2353/ajpath.2008.071176; Yoshida M, 2010, BIOCHEM BIOPH RES CO, V391, P1234, DOI 10.1016/j.bbrc.2009.12.049; Zahedi K, 2010, J NEUROTRAUM, V27, P515, DOI 10.1089/neu.2009.1097; Zhang XM, 2011, CURR NEUROPHARMACOL, V9, P388, DOI 10.2174/157015911795596540; Zhu XY, 2001, BRAIN RES, V922, P293, DOI 10.1016/S0006-8993(01)03159-6	60	28	28	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2013	8	6							e64810	10.1371/journal.pone.0064810			16	Multidisciplinary Sciences	Science & Technology - Other Topics	190ST	WOS:000322361200005	23840306	DOAJ Gold, Green Published			2021-06-18	
J	Farst, K; Ambadwar, PB; King, AJ; Bird, TM; Robbins, JM				Farst, Karen; Ambadwar, Pratibha B.; King, Andrew J.; Bird, T. M.; Robbins, James M.			Trends in Hospitalization Rates and Severity of Injuries From Abuse in Young Children, 1997-2009	PEDIATRICS			English	Article						injury; maltreatment; child abuse; health policy	TRAUMATIC BRAIN-INJURY; PHYSICAL ABUSE; UNITED-STATES; HEAD TRAUMA; DISCHARGE DATA; MALTREATMENT; SURVEILLANCE; FRACTURES; MULTICENTER; DISPARITIES	OBJECTIVES: To examine trends in incidence of hospitalizations for injury from abuse in young children from 1997 through 2009 and to examine injury severity trends. METHODS: Cases were identified in the National Inpatient Sample database of the Healthcare Cost and Utilization Project by using International Classification of Diseases, Ninth Revision, Clinical Modification codes for child maltreatment and external cause of injury for assault in children aged 0 through 3 years. Incidence was calculated by age, gender, and region. Trends in incidence of hospitalization and injury severity were calculated over time. RESULTS: Hospitalization rates for injury from abuse showed no significant change over the study period, ranging from a low of 2.10 per 10 000 children in 1998 to a high of 3.01 per 10 000 children in 2005 (P = .755). Children aged <1 had significantly higher hospitalization rates for injury from abuse (6.01 vs 1.12, P < .001) and higher mean injury severity scores compared with children aged 1 to 3 years (12.50, SD = 0.14 vs 8.56, SD = 0.21, P < .001). Injury severity scores increased significantly over the study period. CONCLUSIONS: No significant change in hospitalization rates for injury from abuse among young children was observed from 1997 to 2009. These results coincide with other reports of stable or modestly increasing rates of serious physical abuse or death in young children but not with reports from child welfare data showing declines in physical abuse during the same period. Diverse sources of data may provide important complementary methods to track child abuse.	[Farst, Karen] Univ Arkansas Med Sci, Sect Children Risk, Little Rock, AR 72202 USA; [Ambadwar, Pratibha B.; King, Andrew J.; Robbins, James M.] Univ Arkansas Med Sci, Ctr Appl Res & Evaluat, Dept Pediat, Little Rock, AR 72202 USA; [Bird, T. M.] Univ Arkansas Med Sci, Dept Obstet & Gynecol, Little Rock, AR 72202 USA	Farst, K (corresponding author), Univ Arkansas Med Sci, Dept Pediat, Sect Children Risk, 1 Childrens Way,Slot 512-24 A, Little Rock, AR 72202 USA.	kfarst@uams.edu		Robbins, James/0000-0003-2200-1947	Academic Pediatric Association	Partially supported by a Young Investigator Grant awarded by the Academic Pediatric Association in 2008 to Dr Karen Farst, who was the principal investigator for the grant.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Belfer RA, 2001, AM J EMERG MED, V19, P122, DOI 10.1053/ajem.2001.21345; Berger RP, 2011, PEDIATRICS, V128, P637, DOI 10.1542/peds.2010-2185; Center for Injury Research and Policy of The Johns Hopkins University School of Public Health, 1997, ICDMAP 90 SOFTW; Centers for Disease Control and Prevention, INJ PREV CONTR DAT S; Chang DC, 2004, J TRAUMA, V57, P1189, DOI 10.1097/01.TA.0000145076.05111.E1; Coben JH, 2006, INJURY PREV, V12, P199, DOI 10.1136/ip.2005.010512; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Finkelhor D, 2006, J SOC ISSUES, V62, P685, DOI 10.1111/j.1540-4560.2006.00483.x; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Jones L, 2007, UPDATED TRENDS CHILD; Lane WG, 2012, CHILD ABUSE NEGLECT, V36, P142, DOI 10.1016/j.chiabu.2011.09.010; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Laskey AL, 2004, J PEDIATR-US, V144, P719, DOI 10.1016/j.jpeds.2004.02.023; Lawrence BA, 2007, ACCIDENT ANAL PREV, V39, P319, DOI 10.1016/j.aap.2006.08.001; Leventhal JM, 2008, PEDIATRICS, V122, P599, DOI 10.1542/peds.2007-1959; Leventhal JM, 2012, PEDIATRICS, V130, P847, DOI 10.1542/peds.2012-0922; Leventhal JM, 2012, PEDIATRICS, V129, P458, DOI 10.1542/peds.2011-1277; Leventhal JM, 2010, PEDIATRICS, V126, pE104, DOI 10.1542/peds.2009-1076; McKenzie K, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-7; National Center for Injury Prevention and Control Center for Disease Control, 2008, REC FRAM E COD GROUP; Parks SE, 2012, INJURY PREV, V18, P193, DOI 10.1136/injuryprev-2011-040128; Rangel EL, 2010, J TRAUMA, V69, P20, DOI 10.1097/TA.0b013e3181bbd7c3; Schnitzer PG, 2011, CHILD ABUSE NEGLECT, V35, P3, DOI 10.1016/j.chiabu.2010.06.008; Schnitzer PG, 2004, AM J PREV MED, V27, P379, DOI 10.1016/j.amepre.2004.08.007; Sedlak A. J., 2010, 4 NATL INCIDENCE STU; Thompson AK, 2011, ACCIDENT ANAL PREV, V43, P143, DOI 10.1016/j.aap.2010.07.020; U.S. Census Bur, 2011, HLTH INS HIST TABL; US Department of Health and Human Services, NAT CHILD AB NEGL DA; Westfall JM, 2001, MED CARE, V39, P459, DOI 10.1097/00005650-200105000-00006; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031	31	28	28	1	15	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUN	2013	131	6					E1796	E1802		10.1542/peds.2012-1464			7	Pediatrics	Pediatrics	197HH	WOS:000322840200012	23690524				2021-06-18	
J	Jimenez, N; Ebel, BE; Wang, J; Koepsell, TD; Jaffe, KM; Dorsch, A; Durbin, D; Vavilala, MS; Temkin, N; Rivara, FP				Jimenez, Nathalia; Ebel, Beth E.; Wang, Jin; Koepsell, Thomas D.; Jaffe, Kenneth M.; Dorsch, Andrea; Durbin, Dennis; Vavilala, Monica S.; Temkin, Nancy; Rivara, Frederick P.			Disparities in Disability After Traumatic Brain Injury Among Hispanic Children and Adolescents	PEDIATRICS			English	Article						disability; disparities; Hispanic children; traumatic brain injury	QUALITY-OF-LIFE; ETHNIC DISPARITIES; RELIABILITY; OUTCOMES; VALIDITY; REHABILITATION; PEDSQL(TM)-4.0; INVENTORY; LANGUAGE	OBJECTIVE: To compare the extent of disability in multiple areas of functioning after mild, moderate, and severe traumatic brain injury (TBI) between Hispanic and non-Hispanic white (NHW) children. METHODS: This was a prospective cohort study of children aged <18 years treated for a TBI between March 1, 2007, and September 30, 2008. Hispanic (n = 74) and NHW (n = 457) children were included in the study. Outcome measures were disability in health-related quality of life, adaptive skills, and participation in activities 3, 12, 24, and 36 months after injury compared with preinjury functioning. We compared change in outcome scores between Hispanic and NHW children at each follow-up time. All analyses were adjusted for age, gender, severity and intent of injury, insurance, family function at baseline, parental education, and income. RESULTS: The health-related quality of life for all children was lower at all follow-up times compared with baseline. Although NHW children showed some improvement during the first 3 years after injury, Hispanic children remained significantly impaired. Significant differences were also observed in the domains of communication and self-care abilities after TBI. Differences between groups in scores for participation in activities were also present but were only significant 3 months after injury. CONCLUSIONS: Hispanic children with TBI report larger and long-term reductions in their quality of life, participation in activities, communication, and self-care abilities compared with NHW children. The reasons for these differences need to be better understood and interventions implemented to improve the outcomes of these children.	[Jimenez, Nathalia; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Jimenez, Nathalia] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Ebel, Beth E.; Koepsell, Thomas D.; Jaffe, Kenneth M.; Durbin, Dennis; Rivara, Frederick P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Ebel, Beth E.; Koepsell, Thomas D.; Rivara, Frederick P.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Ebel, Beth E.; Wang, Jin; Jaffe, Kenneth M.; Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Jaffe, Kenneth M.] Univ Washington, Ctr Clin & Epidemiol Res, Seattle, WA 98195 USA; [Jaffe, Kenneth M.; Temkin, Nancy] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Durbin, Dennis] Childrens Hosp Philadelphia, Dept Emergency Med, Philadelphia, PA 19104 USA; [Durbin, Dennis] Univ Penn, Philadelphia, PA 19104 USA	Jimenez, N (corresponding author), Dept Anesthesiol & Pain Med, Box 9824,4800 Sand Point Way NE, Seattle, WA 98105 USA.	jimenez@seattlechildrens.org		Jimenez, Nathalia/0000-0002-6785-8330; Ebel, Beth/0000-0001-9310-8325	Department of Health and Human Services [1T32GM086270-01]; National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK 082325]; National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD078453] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01DK082325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM086270] Funding Source: NIH RePORTER	This work was supported by the Department of Health and Human Services (1T32GM086270-01 to Dr Jimenez; Principal Investigator: Debra Schwinn), the National Institute of Diabetes and Digestive and Kidney Diseases (DK 082325 to Dr Jimenez; Principal Investigator: Dedra Buchwald), and National Center for Injury Prevention and Control, Centers for Disease Control and Prevention grant R49 CE 001021. Funded by the National Institutes of Health (NIH).	[Anonymous], 2009, STAT PORTR HISP US; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bedell G., CHILD ADOLESCENT PAR; Bedell G., 2006, BRAIN INJ PROF, V3, P14; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Flores G, 2006, PEDIATRICS, V118, pE730, DOI 10.1542/peds.2005-2599; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Harrison PL, TECHNICAL REPORT; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Marr AL., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2007, J TRAUMA, V63, pS122, DOI 10.1097/TA.0b013e31815accdf; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mosnaim GS, 2007, J ALLERGY CLIN IMMUN, V120, P1160, DOI 10.1016/j.jaci.2007.08.040; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Newman DA, 2010, EUR J PSYCHOL ASSESS, V26, P194, DOI 10.1027/1015-5759/a000026; Rivara FP, 2012, J NEUROTRAUM, V29, P2499, DOI 10.1089/neu.2012.2434; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Robertson Charlene M. T., 2001, Pediatr Crit Care Med, V2, P145, DOI 10.1097/00130478-200104000-00009; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Stevens GD, 2010, J IMMIGR MINOR HEALT, V12, P273, DOI 10.1007/s10903-008-9185-8; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-2; Varni JW, 2009, PEDIATR CLIN N AM, V56, P843, DOI 10.1016/j.pcl.2009.05.016; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Vitullo MW, 2002, J HEALTH CARE POOR U, V13, P504, DOI 10.1177/104920802237533; WASSERMAN RC, 1992, PEDIATRICS, V89, P834	34	28	28	0	13	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2013	131	6					E1850	E1856		10.1542/peds.2012-3354			7	Pediatrics	Pediatrics	197HH	WOS:000322840200019	23650302	Green Published			2021-06-18	
J	Larimer, EL; Fallon, SC; Westfall, J; Frost, M; Wesson, DE; Naik-Mathuria, BJ				Larimer, Emily L.; Fallon, Sara C.; Westfall, Jaimee; Frost, Mary; Wesson, David E.; Naik-Mathuria, Bindi J.			The importance of surgeon involvement in the evaluation of non-accidental trauma patients	JOURNAL OF PEDIATRIC SURGERY			English	Article						Pediatrics; Child Abuse; Non-accidental Trauma	CHILD-ABUSE; ABDOMINAL-TRAUMA; INJURIES	Introduction: Non-Accidental Trauma (NAT) is a significant cause of childhood morbidity and mortality, causing 50% of trauma-related deaths at our institution. Our purpose was to evaluate the necessity of primary surgical evaluation and admission to the trauma service for children presenting with NAT. Methods: We reviewed all NAT patients from 2007-2011. Injury types, demographic data, and hospitalization information were collected. Comparisons to accidental trauma (AT) patients were made using Wilcoxon rank sum and Student's t tests. Results: We identified 267 NAT patients presenting with 473 acute injuries. Injuries in NAT patients were more severe than in AT patients, and Injury Severity Scores, ICU admission rates, and mortality were all significantly (p < 0.001) higher. The majority suffered from polytrauma. Multiple areas of injury were seen in patients with closed head injuries (72%), extremity fractures (51%), rib fractures (82%), and abdominal/thoracic trauma (80%). Despite these complex injury patterns, only 56% received surgical consults, resulting in potential delays in diagnosis, as 24% of abdominal CT scans were obtained > 12 hours after hospitalization. Conclusion: Given the high incidence of polytrauma in NAT patients, prompt surgical evaluation is necessary to determine the scope of injury. Admission to the trauma service and a thorough tertiary survey should be considered for all patients. (c) 2013 Elsevier Inc. All rights reserved.	[Larimer, Emily L.; Fallon, Sara C.; Westfall, Jaimee; Frost, Mary; Wesson, David E.; Naik-Mathuria, Bindi J.] Baylor Coll Med, Div Pediat Surg, Texas Childrens Hosp Trauma Program, Michael E DeBakey Dept Surg, Houston, TX 77030 USA	Naik-Mathuria, BJ (corresponding author), Baylor Coll Med, Div Pediat Surg, Texas Childrens Hosp Trauma Program, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.	bnaik@texaschildrens.org					Barnes PM, 2005, LANCET, V366, P234, DOI 10.1016/S0140-6736(05)66913-9; Berdon WE, 2012, CHILD ABUSE NEGLECT, V36, P200, DOI 10.1016/j.chiabu.2011.07.010; Bowkett B, 1998, AUST NZ J SURG, V68, P380, DOI 10.1111/j.1445-2197.1998.tb04779.x; Champion MP, 2002, ARCH DIS CHILD, V87, P432, DOI 10.1136/adc.87.5.432; COOPER A, 1988, J TRAUMA, V28, P1483, DOI 10.1097/00005373-198810000-00015; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; Forjuoh SN, 2000, CHILD ABUSE NEGLECT, V24, P1019, DOI 10.1016/S0145-2134(00)00163-0; Gipson CL, 2006, SOUTH MED J, V99, P536, DOI 10.1097/01.smj.0000216471.54786.e5; Lane WG, 2012, CHILD ABUSE NEGLECT, V36, P142, DOI 10.1016/j.chiabu.2011.09.010; Lane WG, 2011, PEDIATRICS, V127; Leventhal JM, 2012, PEDIATRICS, V129, P458, DOI 10.1542/peds.2011-1277; Roaten JB, 2006, J PEDIATR SURG, V41, P2013, DOI 10.1016/j.jpedsurg.2006.08.028; Roaten JB, 2005, AM J SURG, V190, P827, DOI 10.1016/j.amjsurg.2005.05.049; Sagar M, 2012, PEDIATR EMERG CARE, V28, P61, DOI 10.1097/PEC.0b013e3182417a77; TRACY T, 1993, AM SURGEON, V59, P342; Trokel M, 2006, PEDIATR EMERG CARE, V22, P700, DOI 10.1097/01.pec.0000238734.76413.d0	16	28	28	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	JUN	2013	48	6					1357	1362		10.1016/j.jpedsurg.2013.03.035			6	Pediatrics; Surgery	Pediatrics; Surgery	187YW	WOS:000322158600038	23845630				2021-06-18	
J	Yonutas, HM; Sullivan, PG				Yonutas, Heather M.; Sullivan, Patrick G.			Targeting PPAR Isoforms Following CNS Injury	CURRENT DRUG TARGETS			English	Article						Mitochondria; mitoNEET; traumatic brain injury; spinal cord injury; excitotoxicity; neuroinflammation	TRAUMATIC BRAIN-INJURY; ACTIVATED-RECEPTOR-ALPHA; SPINAL-CORD-INJURY; GAMMA AGONIST ROSIGLITAZONE; MITOCHONDRIAL PERMEABILITY TRANSITION; OXIDATIVE DAMAGE; PROTEIN MITONEET; ADULT RATS; PROLIFERATOR; MECHANISMS	A major focus has developed for the discovery of proregenerative and neuroprotective therapeutic agents to help the millions of Americans who receive a CNS injury annually. Tribulations have been encountered along the way due to the complicated set of pathways that are initiated post-injury. To target this complicated multifaceted signaling cascade, the most promising therapeutics target multiple pathways involved in the secondary injury cascade, such as neuroinflammation, the generation of ROS and mitochondrial dysfunction. Compelling experimental data demonstrates that mitochondrial dysfunction is a pivotal link in the neuropathological sequelae of brain injury. A group of PPAR agonists, specifically rosiglitazone and pioglitazone, have shown an extreme amount of promise in the realm of drug discovery for CNS injury due to their ability to increase functional recovery and decrease lesion volumes following injury. The therapeutic effects of these PPAR agonists are thought to be a direct result of PPAR activity however new data is arising that shows some of the effects may be independent of PPAR activity, targeting a novel mitochondrial protein called mitoNEET. In this review, a thorough evaluation of the role of PPAR and mitoNEET in rosiglitazone and pioglitazone mediated neuroprotection will be completed in order to shed light on the mechanism of a new possible therapeutic intervention for CNS injury.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Sullivan, PG (corresponding author), Univ Kentucky, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Chandler Coll Med, 475 BBSRB,741 South Limestone St, Lexington, KY 40536 USA.	patsullivan@uky.edu					Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso E, 2013, BBA-MOL BASIS DIS, V1832, P1241, DOI 10.1016/j.bbadis.2013.03.006; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Benani A, 2004, NEUROSCI LETT, V369, P59, DOI 10.1016/j.neulet.2004.07.056; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Bhateja DK, 2012, EUR J PHARMACOL, V674, P33, DOI 10.1016/j.ejphar.2011.10.029; Bieganski RM, 2011, J MOL GRAPH MODEL, V29, P965, DOI 10.1016/j.jmgm.2011.04.001; Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341; Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Bright JJ, 2008, PPAR RES, V2008, DOI 10.1155/2008/658520; Brightt JJ, 2008, EXPERT OPIN THER TAR, V12, P1565, DOI [10.1517/14728220802515400, 10.1517/14728220802515400 ]; Cabrera JA, 2012, TRANSL RES, V159, P383, DOI 10.1016/j.trsl.2011.11.001; Cabrero A., 2002, Current Drug Targets - Inflammation and Allergy, V1, P243, DOI 10.2174/1568010023344616; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Chinetti G, 2001, NAT MED, V7, P53; Colca JR, 2004, AM J PHYSIOL-ENDOC M, V286, pE252, DOI 10.1152/ajpendo.00424.2003; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; Crisafulli C, 2009, J PHARMACOL EXP THER, V331, P796, DOI 10.1124/jpet.109.156646; Crisafulli C, 2009, SHOCK, V32, P62, DOI 10.1097/SHK.0b013e31818bbad6; Cuzzocrea S, 2008, MOL PHARMACOL, V73, P323, DOI 10.1124/mol.107.041475; Cuzzocrea S, 2006, J LEUKOCYTE BIOL, V79, P999, DOI 10.1189/jlb.0605341; Deplanque D, 2003, J NEUROSCI, V23, P6264; Desvergne B, 2004, MOL ENDOCRINOL, V18, P1321, DOI 10.1210/me.2004-0088; Divakaruni AS, 2013, P NATL ACAD SCI USA, V110, P5422, DOI 10.1073/pnas.1303360110; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Erickson MA, 2012, NEUROIMMUNOMODULAT, V19, P121, DOI 10.1159/000330247; Esposito E, 2012, SPINE, V37, pE73, DOI 10.1097/BRS.0b013e3182276d88; Esposito E, 2011, EXPERT OPIN THER TAR, V15, P943, DOI 10.1517/14728222.2011.581231; Frazier-Wood AC, 2012, PHARMACOGENOMICS J; Gao W, 2013, MOL MED REP, V7, P862, DOI 10.3892/mmr.2013.1282; Geldenhuys WJ, 2011, BIOORG MED CHEM LETT, V21, P5498, DOI 10.1016/j.bmcl.2011.06.111; Glaser J, 2004, J NEUROSCI RES, V77, P701, DOI 10.1002/jnr.20204; Glaser J, 2006, J NEUROSCI RES, V84, P724, DOI 10.1002/jnr.20982; Guan YF, 2002, DRUG NEWS PERSPECT, V15, P147, DOI 10.1358/dnp.2002.15.3.840011; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hall MG, 2008, PPAR RES, V2008, DOI 10.1155/2008/780452; Heun R, 2012, INT J MOL EPIDEMIOL, V3, P39; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Martin HL, 2012, EXP NEUROL, V235, P528, DOI 10.1016/j.expneurol.2012.02.017; Mattiasson G, 2006, ANTIOXID REDOX SIGN, V8, P1, DOI 10.1089/ars.2006.8.1; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Meng B, 2011, J INT MED RES, V39, P805, DOI 10.1177/147323001103900313; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Morales-Garcia JA, 2011, GLIA, V59, P293, DOI 10.1002/glia.21101; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Muia C, 2006, SHOCK, V25, P17, DOI 10.1097/01.shk.0000186930.95227.4f; Nadra K, 2006, MOL CELL BIOL, V26, P3266, DOI 10.1128/MCB.26.8.3266-3281.2006; Neher MD, 2012, PPAR RES, V2012, DOI 10.1155/2012/728461; Pajoohesh-Ganji A, 2011, NEUROTHERAPEUTICS, V8, P195, DOI 10.1007/s13311-011-0036-2; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Paterniti I, 2010, J PHARMACOL EXP THER, V333, P465, DOI 10.1124/jpet.110.165605; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Roth AD, 2003, J NEUROSCI RES, V72, P425, DOI 10.1002/jnr.10596; SAKAKI S, 1986, STROKE, V17, P196, DOI 10.1161/01.STR.17.2.196; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schnegg CI, 2013, FREE RADICAL BIO MED, V61, P1, DOI 10.1016/j.freeradbiomed.2013.03.002; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Sood HS, 2003, AM J PHYSIOL-LUNG C, V284, pL333, DOI 10.1152/ajplung.00183.2002; Stahel PF, 2008, PPAR RES, V2008, DOI 10.1155/2008/538141; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tan NS, 2007, MOL CELL BIOL, V27, P7161, DOI 10.1128/MCB.00436-07; Tate CC, 2007, EXP NEUROL, V207, P13, DOI 10.1016/j.expneurol.2007.05.008; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Tian XY, 2012, DIABETES, V61, P3285, DOI 10.2337/db12-0117; Tyagi S, 2011, J ADV PHARM TECHNOL, V2, P236, DOI 10.4103/2231-4040.90879; Varanyuwatana P, 2012, MITOCHONDRION, V12, P120, DOI 10.1016/j.mito.2011.04.006; White AT, 2010, J NEUROCHEM, V115, P845, DOI 10.1111/j.1471-4159.2010.06999.x; Wilson JL, 2012, PPAR RES, V2012, DOI 10.1155/2012/645969; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang Q, 2011, NEUROSCIENCES, V16, P46; Zhang Q, 2010, NEUROL RES, V32, P852, DOI 10.1179/016164110X12556180206112	90	28	29	0	22	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1389-4501			CURR DRUG TARGETS	Curr. Drug Targets	JUN	2013	14	7					733	742		10.2174/1389450111314070003			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	150IQ	WOS:000319384200003	23627890				2021-06-18	
J	Coelho, C; Le, Ke; Mozeiko, J; Hamilton, M; Tyler, E; Krueger, F; Grafman, J				Coelho, Carl; Le, Karen; Mozeiko, Jennifer; Hamilton, Mark; Tyler, Elizabeth; Krueger, Frank; Grafman, Jordan			Characterizing Discourse Deficits Following Penetrating Head Injury: A Preliminary Model	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						traumatic brain injury; language disorders; memory; executive functions; pragmatics	TRAUMATIC BRAIN-INJURY; NARRATIVE DISCOURSE; EXECUTIVE FUNCTIONS; MEASURING GOODNESS; STORY NARRATIVES; ELICITATION TASK; WORKING-MEMORY; LANGUAGE; ABILITIES; CHILDREN	Purpose: Discourse analyses have demonstrated utility for delineating subtle communication deficits following closed head injuries (CHIs). The present investigation examined the discourse performance of a large group of individuals with penetrating head injury (PHI). Performance was also compared across 6 subgroups of PHI based on lesion locale. A preliminary model of discourse production following PHI was proposed and tested. Method: Story narratives were elicited from 2 groups of participants, 167 with PHI and 46 non brain-injured (NBI). Micro- and macrostructural components of each story were analyzed. Measures of memory, executive functions, and intelligence were also administered. All measures were compared across groups and PHI subgroups. The proposed model of discourse production was tested with a structural equation modeling procedure. Results: No differences for the discourse measures were noted across the six PHI subgroups. Three measures distinguished the PHI and NBI groups: narrative length, story grammar, and completeness. The proposed model of discourse production had an adequate-to-good fit with the cognitive and discourse data. Conclusion: In spite of differing mechanisms of injury, the PHI group's discourse performance was consistent with what has been reported for individuals with CHI. The model tested represents a preliminary step toward understanding discourse production following traumatic brain injury.	[Coelho, Carl; Le, Karen; Mozeiko, Jennifer; Hamilton, Mark; Tyler, Elizabeth] Univ Connecticut, Storrs, CT 06269 USA; [Krueger, Frank] George Mason Univ, Fairfax, VA 22030 USA; [Grafman, Jordan] Rehabil Inst Chicago, Chicago, IL USA	Coelho, C (corresponding author), Univ Connecticut, Storrs, CT 06269 USA.	coelho@uconn.edu		Grafman, Jordan H./0000-0001-8645-4457	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [F31 DC012748] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [F31DC012748] Funding Source: NIH RePORTER		Barrett J., 1998, OLD MCDONALD HAD APA; Body R, 2004, BRAIN INJURY, V18, P707, DOI 10.1080/02699050310001596914; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Brookshire RH, 1993, DISCOURSE COMPREHENS; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; Clark LA, 1995, PSYCHOL ASSESSMENT, V7, P309, DOI 10.1037/1040-3590.7.3.309; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coelho C, 2012, NEUROPSYCHOLOGIA, V50, P3564, DOI 10.1016/j.neuropsychologia.2012.09.005; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dimitrov M, 1999, NEUROPSYCHOLOGY, V13, P135, DOI 10.1037/0894-4105.13.1.135; Duff MC, 2012, SEMIN SPEECH LANG, V33, P44, DOI 10.1055/s-0031-1301162; Ferstl EC, 2008, HUM BRAIN MAPP, V29, P581, DOI 10.1002/hbm.20422; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Gernsbacher Morton Ann, 1999, Discourse Stud, V1, P355, DOI 10.1177/1461445699001003004; GERNSBACHER Morton Ann, 1990, LANGUAGE COMPREHENSI; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Hooper D., 2008, ELECT J BUS RES METH, V6, P53, DOI [10.21427/D7CF7R, DOI 10.21427/D7CF7R]; HUNT KW, 1970, MONOGR SOC RES CHILD, V35, P1; Kaplan E., 1983, BOSTON NAMING TEST; Kenny D.A., 2012, STRUCTURAL EQUATION; Kline R.B., 2011, PRINCIPLES PRACTICE; Le K, 2012, AM J SPEECH-LANG PAT, V21, pS115, DOI 10.1044/1058-0360(2012/11-0114); Le K, 2011, APHASIOLOGY, V25, P748, DOI 10.1080/02687038.2010.539696; Le K, 2011, J SPEECH LANG HEAR R, V54, P118, DOI 10.1044/1092-4388(2010/09-0022); LILES BZ, 1995, J SPEECH HEAR RES, V38, P415, DOI 10.1044/jshr.3802.415; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; Liles BZ, 1998, ANAL DISCOURSE COMMU, P65; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Miyake A, 2012, CURR DIR PSYCHOL SCI, V21, P8, DOI 10.1177/0963721411429458; Miyake Akira, 2000, Seminars in Speech and Language, V21, P169, DOI 10.1055/s-2000-7563; MOHR JP, 1980, NEUROLOGY, V30, P1273, DOI 10.1212/WNL.30.12.1273; Mozeiko J, 2011, APHASIOLOGY, V25, P826, DOI 10.1080/02687038.2010.543983; PLAG JA, 1967, PERS PSYCHOL, V20, P323, DOI 10.1111/j.1744-6570.1967.tb01527.x; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; SCHWARTZCOWLEY R, 1989, TOP LANG DISORD, V9, P1, DOI 10.1097/00011363-198903000-00003; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Stein N., 1979, NEW DIRECTIONS DISCO; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; U. S. Department of Defense, 1984, TEST MAN ARM SERV VO; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Wechsler D., 1997, WECHSLER INTELLIGENC; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wertheimer JC, 2008, ARCH PHYS MED REHAB, V89, P1983, DOI 10.1016/j.apmr.2008.04.010; Ylioja S, 2010, CLIN NEUROPSYCHOL, V24, P1097, DOI 10.1080/13854046.2010.516021; Ylvisaker M., 2008, LANGUAGE INTERVENTIO, P879; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951; Zafonte RD, 1997, BRAIN INJURY, V11, P403	59	28	29	0	8	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	MAY 1	2013	22	2					S438	S448		10.1044/1058-0360(2013/12-0076)			11	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	156LD	WOS:000319822600017	23695915	Green Accepted			2021-06-18	
J	Gerretsen, P; Chakravarty, MM; Mamo, D; Menon, M; Pollock, BG; Rajji, TK; Graff-Guerrero, A				Gerretsen, Philip; Chakravarty, M. Mallar; Mamo, David; Menon, Mahesh; Pollock, Bruce G.; Rajji, Tarek K.; Graff-Guerrero, Ariel			Frontotemporoparietal asymmetry and lack of illness awareness in schizophrenia	HUMAN BRAIN MAPPING			English	Article						schizophrenia; insight; anosognosia; illness awareness; VBM; deformation-based analysis	VOXEL-BASED MORPHOMETRY; PREFRONTAL CORTEX; HUMAN-BRAIN; INSIGHT; PSYCHOSIS; MATTER; LATERALIZATION; SEGMENTATION; REGISTRATION; UNAWARENESS	Introduction: Lack of illness awareness or anosognosia occurs in both schizophrenia and right hemisphere lesions due to stroke, dementia, and traumatic brain injury. In the latter conditions, anosognosia is thought to arise from unilateral hemispheric dysfunction or interhemispheric disequilibrium, which provides an anatomical model for exploring illness unawareness in other neuropsychiatric disorders, such as schizophrenia. Methods: Both voxel-based morphometry using Diffeomorphic Anatomical Registration through Exponentiated Lie Algebra (DARTEL) and a deformation-based morphology analysis of hemispheric asymmetry were performed on 52 treated schizophrenia subjects, exploring the relationship between illness awareness and gray matter volume. Analyses included age, gender, and total intracranial volume as covariates. Results: Hemispheric asymmetry analyses revealed illness unawareness was significantly associated with right < left hemisphere volumes in the anteroinferior temporal lobe (t = 4.83, P = 0.051) using DARTEL, and the dorsolateral prefrontal cortex (t = 5.80, P = 0.003) and parietal lobe (t = 4.3, P = 0.050) using the deformation-based approach. Trend level associations were identified in the right medial prefrontal cortex (t = 4.49, P = 0.127) using DARTEL. Lack of illness awareness was also strongly associated with reduced total white matter volume (r = 0.401, P < 0.01) and illness severity (r = 0.559, P < 0.01). Conclusion: These results suggest a relationship between anosognosia and hemispheric asymmetry in schizophrenia, supporting previous volume-based MRI studies in schizophrenia that found a relationship between illness unawareness and reduced right hemisphere gray matter volume. Functional imaging studies are required to examine the neural mechanisms contributing to these structural observations. Hum Brain Mapp, 2013. (c) 2012 Wiley Periodicals, Inc.	[Gerretsen, Philip; Mamo, David; Menon, Mahesh; Graff-Guerrero, Ariel] Ctr Addict & Mental Hlth, Multimodal Imaging Grp, Toronto, ON, Canada; [Gerretsen, Philip; Mamo, David; Pollock, Bruce G.; Rajji, Tarek K.] Ctr Addict & Mental Hlth, Geriatr Mental Hlth Program, Toronto, ON, Canada; [Gerretsen, Philip; Mamo, David; Menon, Mahesh; Pollock, Bruce G.; Rajji, Tarek K.; Graff-Guerrero, Ariel] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Chakravarty, M. Mallar] Baycrest, Rotman Res Inst, Toronto, ON, Canada; [Chakravarty, M. Mallar] Hosp Sick Children, Mouse Imaging Ctr MICe, Toronto, ON M5G 1X8, Canada; [Menon, Mahesh; Graff-Guerrero, Ariel] Ctr Addict & Mental Hlth, Schizophrenia Program, Toronto, ON, Canada	Graff-Guerrero, A (corresponding author), PET Ctr, CAMH Multimodal Imaging Grp, 250 Coll St, Toronto, ON M5T 1R8, Canada.	ariel_graff@camh.net	Rajji, Tarek K/K-1543-2015	Gerretsen, Philip/0000-0003-4053-6814	Bristol-Myers SquibbBristol-Myers Squibb; Grants Health Research, Clinician Scientist Program; Department of Psychiatry, University of Toronto	Contract grant sponsors: Bristol-Myers Squibb (DM); Grants Health Research, Clinician Scientist Program; Department of Psychiatry, University of Toronto.	AMADOR XF, 1994, ARCH GEN PSYCHIAT, V51, P826; APM, 2000, DIAGN STAT MAN MENT; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Babinski J., 1914, REV NEUROL, V27, P845, DOI [10.1016/J.CORTEX.2014.04.019, DOI 10.1016/J.CORTEX.2014.04.019]; BASCH MF, 1988, UNDERSTANDING PSYCHO; Bassitt DP, 2007, EUR ARCH PSY CLIN N, V257, P58, DOI 10.1007/s00406-006-0685-z; Berge D, 2011, ACTA PSYCHIAT SCAND, V123, P431, DOI 10.1111/j.1600-0447.2010.01635.x; BIRCHWOOD M, 1994, ACTA PSYCHIAT SCAND, V89, P62, DOI 10.1111/j.1600-0447.1994.tb01487.x; Buckley PF, 2007, CNS DRUGS, V21, P129, DOI 10.2165/00023210-200721020-00004; Chakravarty MM, 2009, HUM BRAIN MAPP, V30, P3574, DOI 10.1002/hbm.20780; Chung MK, 2001, NEUROIMAGE, V14, P595, DOI 10.1006/nimg.2001.0862; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Collins DL, 1995, HUM BRAIN MAPP, V3, P190, DOI 10.1002/hbm.460030304; Cooke MA, 2008, SCHIZOPHR RES, V103, P40, DOI 10.1016/j.schres.2008.04.022; Cuesta MJ, 2000, BRIT J PSYCHIAT, V177, P233, DOI 10.1192/bjp.177.3.233; DAVID AS, 1990, BRIT J PSYCHIAT, V156, P798, DOI 10.1192/bjp.156.6.798; Drake RJ, 2007, J CLIN PSYCHIAT, V68, P81, DOI 10.4088/JCP.v68n0111; Flashman LA, 2001, J NEUROPSYCH CLIN N, V13, P255, DOI 10.1176/appi.neuropsych.13.2.255; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; GLICK SD, 1982, BRAIN RES, V234, P53, DOI 10.1016/0006-8993(82)90472-3; Grabner G, 2006, LECT NOTES COMPUT SC, V4191, P58; Henley SMD, 2010, AM J NEURORADIOL, V31, P711, DOI 10.3174/ajnr.A1939; Honea R, 2005, AM J PSYCHIAT, V162, P2233, DOI 10.1176/appi.ajp.162.12.2233; Hugdahl K, 2000, ACTA PSYCHOL, V105, P211, DOI 10.1016/S0001-6918(00)00062-7; Jablensky A, 1992, Psychol Med Monogr Suppl, V20, P1; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kemp R, 1996, BRIT J PSYCHIAT, V169, P444, DOI 10.1192/bjp.169.4.444; Klein A, 2009, NEUROIMAGE, V46, P786, DOI 10.1016/j.neuroimage.2008.12.037; MCEVOY JP, 1989, J NERV MENT DIS, V177, P43, DOI 10.1097/00005053-198901000-00007; Mohamed S, 2009, SCHIZOPHRENIA BULL, V35, P336, DOI 10.1093/schbul/sbn067; Morgan KD, 2010, BRIT J PSYCHIAT, V197, P141, DOI 10.1192/bjp.bp.109.070888; Oertel-Knochel V., 2011, NEUROSCIENTIST; OKE A, 1978, SCIENCE, V200, P1411, DOI 10.1126/science.663623; Olfson M, 2006, PSYCHIAT SERV, V57, P205, DOI 10.1176/appi.ps.57.2.205; Orfei MD, 2008, NEUROSCIENTIST, V14, P203, DOI 10.1177/1073858407309995; Pallanti S, 1999, PSYCHIAT RES, V86, P239, DOI 10.1016/S0165-1781(99)00033-5; Parellada M, 2011, SCHIZOPHRENIA BULL, V37, P38, DOI 10.1093/schbul/sbq109; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Ramachandran VS, 2007, MED HYPOTHESES, V69, P486, DOI 10.1016/j.mehy.2006.12.036; RAMACHANDRAN VS, 1995, CONSCIOUS COGN, V4, P22, DOI 10.1006/ccog.1995.1002; Robbins S, 2004, MED IMAGE ANAL, V8, P311, DOI 10.1016/j.media.2004.06.009; Sanz M, 1998, PSYCHOL MED, V28, P437, DOI 10.1017/S0033291797006296; Sapara A, 2007, SCHIZOPHR RES, V89, P22, DOI 10.1016/j.schres.2006.09.016; Shad MU, 2006, PSYCHIAT RES-NEUROIM, V146, P35, DOI 10.1016/j.pscychresns.2005.11.001; Shad MU, 2004, NEUROIMAGE, V22, P1315, DOI 10.1016/j.neuroimage.2004.03.016; Shad MU, 2007, INT REV PSYCHIATR, V19, P439, DOI 10.1080/09540260701486324; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Spalletta G, 2003, SCHIZOPHR RES, V64, P15, DOI 10.1016/S0920-9964(03)00010-0; Toga AW, 2003, NAT REV NEUROSCI, V4, P37, DOI 10.1038/nrn1009; Tsang O, 2008, IEEE ENG MED BIO, P3924, DOI 10.1109/IEMBS.2008.4650068; TUCKER DM, 1984, PSYCHOL REV, V91, P185, DOI 10.1037/0033-295X.91.2.185; Van Essen DC, 2005, NEUROIMAGE, V28, P635, DOI 10.1016/j.neuroimage.2005.06.058; WAGNER HN, 1983, SCIENCE, V221, P1264, DOI 10.1126/science.6604315; White T, 2001, NEUROIMAGE, V13, P577, DOI 10.1006/nimg.2000.0716; Wilke M, 2003, NEUROIMAGE, V20, P330, DOI 10.1016/S1053-8119(03)00296-9; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933	58	28	29	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAY	2013	34	5					1035	1043		10.1002/hbm.21490			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	122DT	WOS:000317297500004	22213454	Green Published			2021-06-18	
J	Marcano, DC; Bitner, BR; Berlin, JM; Jarjour, J; Lee, JM; Jacob, A; Fabian, RH; Kent, TA; Tour, JM				Marcano, Daniela C.; Bitner, Brittany R.; Berlin, Jacob M.; Jarjour, Jane; Lee, Juhye M.; Jacob, Aakash; Fabian, Roderic H.; Kent, Thomas A.; Tour, James M.			Design of Poly(ethylene Glycol)-Functionalized Hydrophilic Carbon Clusters for Targeted Therapy of Cerebrovascular Dysfunction in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						antioxidants; in vitro; mildTBI; P-selectin; targeted drug delivery; vascular dysfunction	ABSORBENCY CAPACITY ASSAY; HYDROGEN-PEROXIDE; DRUG-DELIVERY; HEAD-INJURY; ANTIOXIDANT CAPACITY; ENDOTHELIAL-CELLS; HYDROXYL RADICALS; OXIDATIVE STRESS; CATALYTIC METALS; IRON COMPLEXES	Traumatic brain injury (TBI) involves the elaboration of oxidative stress that causes cerebrovascular dysfunction, including impairment of autoregulation of cerebral blood flow. Currently, there is no clinically effective antioxidant treatment for these pathologies. Most currently available antioxidants act through mechanisms in which the antioxidant either transfers the radical or requires regeneration, both of which are impaired in the toxic post-TBI environment. We previously reported that single-walled carbon nanotubes (SWCNTs) and ultrashort SWCNTs possess antioxidant activity, and their characteristics suggest that radical annihilation is the major mechanism. We have now developed a biologically compatible class of carbon-based nanovectors, poly(ethylene glycol)-functionalized hydrophilic carbon clusters (PEG-HCCs) that can be further functionalized with antibodies, and hence show promise as targeted drug delivery platforms. Here we report that PEG-HCCs possess innate antioxidant activity and can be rapidly targeted via an antibody to the P-selectin antigen in a model of injured cultured brain endothelial cells. One immediate application of this therapy is to vascular dysfunction that accompanies TBI and worsens outcome in the face of systemic hypotension. These in vitro results support the need for further investigation in animal models.	[Marcano, Daniela C.; Berlin, Jacob M.; Jarjour, Jane; Lee, Juhye M.; Jacob, Aakash; Tour, James M.] Rice Univ, Dept Chem, Houston, TX 77005 USA; [Marcano, Daniela C.; Berlin, Jacob M.; Tour, James M.] Rice Univ, Smalley Inst Nanoscale Sci & Technol, Houston, TX 77005 USA; [Bitner, Brittany R.; Kent, Thomas A.] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Bitner, Brittany R.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Fabian, Roderic H.; Kent, Thomas A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Fabian, Roderic H.; Kent, Thomas A.] Michael E DeBakey VA Med Ctr, Houston, TX USA	Tour, JM (corresponding author), Rice Univ, Dept Chem, 6100 Main St MS222, Houston, TX 77005 USA.	tkent@bcm.edu; tour@rice.edu	Nanozymes, Nanozymes/D-8197-2019	Kent, Thomas/0000-0002-9877-7584; Lee, Juhye/0000-0002-8133-2562; Marcano, Daniela C./0000-0002-3446-8010; Tour, James/0000-0002-8479-9328	Alliance for NanoHealth through University of Texas Health Science Center, Houston (Department of Defense) [W8XWH-09-2-0139]; Traumatic Brain Injury Consortium; United States ArmyUnited States Department of Defense [W81XWH-08-2-0141, W81XWH-08-2-0143]; Nanoscale Science and Engineering Initiative of the National Science Foundation (NSF) through the NSF Center for Biological and Environmental NanotechnologyNational Science Foundation (NSF) [EEC-0647452]	Funding came from the Alliance for NanoHealth through a subcontract from the University of Texas Health Science Center, Houston (Department of Defense, W8XWH-09-2-0139); the Traumatic Brain Injury Consortium, funded by the United States Army (W81XWH-08-2-0141 and W81XWH-08-2-0143); and the Nanoscale Science and Engineering Initiative of the National Science Foundation (NSF) under NSF Award EEC-0647452 for funding through the NSF Center for Biological and Environmental Nanotechnology.	Alconcel SNS, 2011, POLYM CHEM-UK, V2, P1442, DOI 10.1039/c1py00034a; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; BAKER MS, 1984, ARCH BIOCHEM BIOPHYS, V234, P258, DOI 10.1016/0003-9861(84)90348-5; Barz M, 2011, POLYM CHEM-UK, V2, P1900, DOI 10.1039/c0py00406e; Berlin JM, 2011, ACS NANO, V5, P6643, DOI 10.1021/nn2021293; Berlin JM, 2010, ACS NANO, V4, P4621, DOI 10.1021/nn100975c; Bernhardt PV, 2003, J BIOL INORG CHEM, V8, P866, DOI 10.1007/s00775-003-0486-z; Buettner G.R., 1985, FREE RADICAL RES COM, V1, P349; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; Buettner GR, 1996, RADIAT RES, V145, P532, DOI 10.2307/3579271; CAO GH, 1993, FREE RADICAL BIO MED, V14, P303, DOI 10.1016/0891-5849(93)90027-R; Chen ZY, 2006, J AM CHEM SOC, V128, P10568, DOI 10.1021/ja063283p; DEAN RT, 1994, FREE RADICAL RES, V20, P83, DOI 10.3109/10715769409147506; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dickinson BC, 2011, NAT CHEM BIOL, V7, P504, DOI [10.1038/NCHEMBIO.607, 10.1038/nchembio.607]; Duncan R, 2011, CURR OPIN BIOTECH, V22, P492, DOI 10.1016/j.copbio.2011.05.507; FABIAN RH, 1995, J CEREBR BLOOD F MET, V15, P242, DOI 10.1038/jcbfm.1995.30; Freeman LR, 2012, BBA-MOL BASIS DIS, V1822, P822, DOI 10.1016/j.bbadis.2011.12.009; Gillespie KM, 2007, NAT PROTOC, V2, P867, DOI 10.1038/nprot.2007.100; GLAZER AN, 1990, METHOD ENZYMOL, V186, P161; Golding EA, 2003, J CEREBR BLOOD F MET, V23, P210, DOI 10.1097/01.WCB.0000044739.64940.B5; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Han YH, 2008, ONCOL REP, V20, P689, DOI 10.3892/or_00000061; Haseneder R, 2007, WATER SCI TECHNOL, V55, P83, DOI 10.2166/wst.2007.391; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Jokerst JV, 2011, NANOMEDICINE-UK, V6, P715, DOI [10.2217/nnm.11.19, 10.2217/NNM.11.19]; Kent T.A., 2011, 25 INT S CER BLOOD F; Kerem Z, 1998, P NATL ACAD SCI USA, V95, P10373, DOI 10.1073/pnas.95.18.10373; Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672; Kocha T, 1997, BBA-PROTEIN STRUCT M, V1337, P319, DOI 10.1016/S0167-4838(96)00180-X; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; Liu-Snyder P, 2007, J EXP BIOL, V210, P1455, DOI 10.1242/jeb.02756; Lucas-Abellan C, 2011, FOOD CHEM TOXICOL, V49, P1255, DOI 10.1016/j.fct.2011.03.004; Lucente-Schultz RM, 2009, J AM CHEM SOC, V131, P3934, DOI 10.1021/ja805721p; Malhotra R, 2011, AM J PHYSIOL-HEART C, V300, pH1733, DOI 10.1152/ajpheart.01054.2010; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Ou BX, 2001, J AGR FOOD CHEM, V49, P4619, DOI 10.1021/jf010586o; Potts Mathew B, 2006, NeuroRx, V3, P143; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Price BK, 2009, CHEM MATER, V21, P3917, DOI 10.1021/cm9021613; Prior RL, 2003, J AGR FOOD CHEM, V51, P3273, DOI 10.1021/jf0262256; Raz E, 2011, AM J NEURORADIOL, V32, P1851, DOI 10.3174/ajnr.A2637; Richardson DR, 2006, J MED CHEM, V49, P6510, DOI 10.1021/jm0606342; Rigg JL, 2005, J HEAD TRAUMA REHAB, V20, P389, DOI 10.1097/00001199-200507000-00010; Robertson CS, 2012, J NEUROTRAUM, V29, P1156, DOI 10.1089/neu.2011.1827; Schopfer P, 2001, PLANT PHYSIOL, V125, P1591, DOI 10.1104/pp.125.4.1591; Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Wei Y, 2007, ANGEW CHEM INT EDIT, V46, P4722, DOI 10.1002/anie.200604859; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; Zhao HT, 2005, P NATL ACAD SCI USA, V102, P5727, DOI 10.1073/pnas.0501719102; Zulueta A, 2009, FOOD CHEM, V114, P310, DOI 10.1016/j.foodchem.2008.09.033	57	28	28	0	28	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2013	30	9			SI		789	796		10.1089/neu.2011.2301			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	145BJ	WOS:000318987600010	22928502				2021-06-18	
J	Haas, BM; Price, L; Freeman, JA				Haas, B. M.; Price, L.; Freeman, J. A.			Qualitative evaluation of a Community Peer Support Service for people with spinal cord injury	SPINAL CORD			English	Article						peer support; peer mentoring; qualitative research; self-efficacy	TRAUMATIC BRAIN-INJURY; INDIVIDUALS; EXPERIENCES	Study design: Qualitative study involving individual semistructured in-depth interviews. Objectives: To evaluate peer support provided in general hospitals for people with spinal cord injuries (SCIs). Setting: The South West of the United Kingdom. Methods: Fourteen in-depth qualitative interviews were conducted with people with SCI and their close relatives, and with health-care professionals involved in their care. Transcribed interviews were coded inductively and analysed thematically. Themes were patterned around positive and less positive aspects of the experience of the peer support service. Results: The psychological and emotional support provided by the peer support officer was highly valued by the participants. The peer support officer's direct experience of living with a spinal injury gave credibility to the practical advice, information and signposting provided; as well as to the empathy demonstrated by them during their involvement with people with SCI and their families. Health-care professionals appreciated their unique perspective and considered them as a valuable member of the multidisciplinary team. Conclusion: Peer support is valued by the people affected by SCI. There is a need to further investigate the key aspects of the service, including the optimal timing for introducing this peer support as well as more formal training of mentors. Spinal Cord (2013) 51, 295-299; doi:10.1038/sc.2012.143; published online 27 November 2012	[Haas, B. M.; Freeman, J. A.] Univ Plymouth, Sch Hlth Profess, Plymouth PL6 8BH, Devon, England; [Price, L.] Univ Exeter, Peninsula Med Sch, Exeter, Devon, England	Haas, BM (corresponding author), Univ Plymouth, Peninsula Allied Hlth Ctr, Sch Hlth Profess, Derriford Rd, Plymouth PL6 8BH, Devon, England.	bhaas@plymouth.ac.uk	Freeman, Jennifer/AAN-1217-2021		Plymouth University Vice Chancellors Community Research Award	We would like to thank the Spinal Injuries Association (SIA) United Kingdom for their valuable input and support. In particular, we would like to acknowledge the input of Anne Curran, Peter Hutchings and Debbie Schofield. We would also like to thank all those who gave their time freely and generously during the interviews and chat-room discussions. This study was supported through a Plymouth University Vice Chancellors Community Research Award.	Alvarez K, 2011, EUR J SOC PSYCHOL, V41, P397, DOI 10.1002/ejsp.789; Badger K, 2010, SOC WORK HEALTH CARE, V49, P299, DOI 10.1080/00981380903493095; Boschen KA, 2003, INT J REHABIL RES, V26, P157, DOI 10.1097/00004356-200309000-00001; Colella Tracey J F, 2004, Eur J Cardiovasc Nurs, V3, P211; Consortium for Spinal Cord Medicine, 2008, J SPINAL CORD MED, V31, P408; Dennis CL, 2003, INT J NURS STUD, V40, P321, DOI 10.1016/S0020-7489(02)00092-5; Funck-Brentano I, 2005, AIDS, V19, P1501, DOI 10.1097/01.aids.0000183124.86335.0a; Giesbers J, 2010, PSYCHO-ONCOLOGY, V19, P887, DOI 10.1002/pon.1636; Hanks RA, 2012, ARCH PHYS MED REHAB, V93, P1297, DOI 10.1016/j.apmr.2012.04.027; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hoey LM, 2011, EUR J CANCER CARE, V20, P87, DOI 10.1111/j.1365-2354.2009.01151.x; Hughes J, 2009, HEALTH EXPECT, V12, P396, DOI 10.1111/j.1369-7625.2009.00568.x; Ieropoli SC, 2011, EUR J CANCER CARE, V20, P455, DOI 10.1111/j.1365-2354.2010.01218.x; Jalovcic D, 2009, TOP SPINAL CORD INJ, V15, P59; Ljungberg I, 2011, J CLIN NURS, V20, P351, DOI 10.1111/j.1365-2702.2010.03432.x; MacNeil C, 2005, AM J EVAL, V26, P231, DOI 10.1177/1098214005275633; Magasi S, 2009, ARCH PHYS MED REHAB, V90, pe37; Patterson RW, 2005, TOP SPINAL CORD INJ, V10, P30; Percy CA, 2009, J ADV NURS, V65, P2046, DOI 10.1111/j.1365-2648.2009.05061.x; Shem K, 2011, SPINAL CORD, V49, P544, DOI 10.1038/sc.2010.166; Standal OF, 2008, ADAPT PHYS ACT Q, V25, P208, DOI 10.1123/apaq.25.3.208; Thoits PA, 2000, HEALTH PSYCHOL, V19, P264, DOI 10.1037//0278-6133.19.3.264; Veith EM, 2006, REHABIL PSYCHOL, V51, P289, DOI 10.1037/0090-5550.51.4.289	23	28	28	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	APR	2013	51	4					295	299		10.1038/sc.2012.143			5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	119OO	WOS:000317107400008	23184023	Bronze			2021-06-18	
J	Sangiorgi, S; De Benedictis, A; Protasoni, M; Manelli, A; Reguzzoni, M; Cividini, A; Dell'Orbo, C; Tomei, G; Balbi, S				Sangiorgi, Simone; De Benedictis, Alessandro; Protasoni, Marina; Manelli, Alessandro; Reguzzoni, Marcella; Cividini, Andrea; Dell'Orbo, Carlo; Tomei, Giustino; Balbi, Sergio			Early-stage microvascular alterations of a new model of controlled cortical traumatic brain injury: 3D morphological analysis using scanning electron microscopy and corrosion casting Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						controlled cortical impact injury; cerebral edema; corrosion casting; scanning electron microscope; transmission electron microscope; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; SEVERE HEAD-INJURY; CEREBRAL-CORTEX; BLOOD-VESSELS; SUBARACHNOID HEMORRHAGE; EDEMA; MICROVESSELS; HYPOXIA; ARTERIOLES	Object. This study was performed to study the microvascular changes that occur during the first 12 hours after traumatic brain injury (TBI) using the corrosion casting technique. Methods. The authors performed a qualitative and quantitative morphological study of the changes in cerebral vessels at acute (3 hours) and subacute (12 hours) stages after experimental TBI. They used a model of controlled cortical impact (CCI) injury induced by a recently developed electromagnetic device (impactor), focusing their observations mainly on the microvascular alterations responsible for the formation and maintenance of tissue edema and consequent brain swelling during the first hours after TBI. They used corrosion casting, scanning electron microscopy (SEM), light microscopy, and transmission electron microscopy (TEM) to obtain a morphological qualitative map with both 2D and 3D details. Results. Scanning electron microscopy analysis of vascular casts documented in 3 dimensions the typical injuries occurring after a TBI: subdural, subarachnoid, and intraparenchymal hemorrhages, along with alterations of the morphological characteristics and architecture of both medium-sized and capillary vessels, including ectasia of pial vessels, sphincter constrictions at the origin of the perforating vessels, focal swelling of perforating vessels, widening of intercellular junctions, and some indirect evidence of structural impairment of endothelial cells. All of these vascular alterations were confirmed in 2D analyses using light microscopy and TEM. Conclusions. The corrosion casting SEM technique applied to a CCI experimental model proved to be a reliable method for studying the pathophysiology of the vascular alterations occurring at acute and subacute stages after CCI injury. It was also possible to obtain topographical localization of the vascular and cellular events that usually lead to hyperemia, edema, and brain swelling. Moreover, by applying informatic software to anatomical images it was possible to perform quantification and statistical analysis of the observed events. (http://thejns.org/doi/abs/10.3171/2012.11.JNS12627)	[Sangiorgi, Simone; Cividini, Andrea; Tomei, Giustino; Balbi, Sergio] Univ Insubria, Dept Biotechnol & Life Sci, Neurosurg Unit, I-21100 Varese, Italy; [Protasoni, Marina; Reguzzoni, Marcella; Dell'Orbo, Carlo] Univ Insubria, Dept Morphol Sci, Lab Human Anat L Cattaneo, I-21100 Varese, Italy; [De Benedictis, Alessandro] IRCCS, Bambino Gesu Childrens Hosp, Dept Neurosci, Div Neurosurg, Rome, Italy; [Manelli, Alessandro] ASL 1 Imperiese, Phys Rehabil Unit, Imperia, Italy	Sangiorgi, S (corresponding author), Univ Insubria, Dept Biotechnol & Life Sci, Neurosurg Unit, 57 Viale L Borri, I-21100 Varese, Italy.	simo.med@libero.it		Balbi, Sergio/0000-0002-8391-0434; PROTASONI, MARINA/0000-0002-8405-596X; Marcella, Reguzzoni/0000-0003-3738-6632			Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bullock M Ross, 2006, Neurosurgery, V58, pS47; Bullock M Ross, 2006, Neurosurgery, V58, pS7; CERVOSNAVARRO J, 1978, NEUROPATH APPL NEURO, V4, P369, DOI 10.1111/j.1365-2990.1978.tb01349.x; CRAIGIE EH, 1945, BIOL REV, V20, P133, DOI 10.1111/j.1469-185X.1945.tb00446.x; DAHL E, 1973, Z ZELLFORSCH MIK ANA, V145, P577, DOI 10.1007/BF00306725; Hodde K C, 1980, Scan Electron Microsc, P89; Hodde K. C., 1996, P111; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KRASZNAI L, 1994, NEUROL RES, V16, P40; LAMETSCHWANDTNER A, 1990, SCANNING MICROSCOPY, V4, P889; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LEVESQUE MJ, 1979, ATHEROSCLEROSIS, V34, P457, DOI 10.1016/0021-9150(79)90070-4; LEWIS OJ, 1957, J ANAT, V91, P40; LONG DM, 1982, CLIN NEUR, V29, P174; Marion DW, 2006, NEUROSURGERY, V58, P655; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MIODONSKI A, 1980, ARCH OTOLARYNGOL, V106, P321; MIRONOV V, 1994, BRAIN RES, V660, P73, DOI 10.1016/0006-8993(94)90840-0; MIYOSHI Y, 1995, BRAIN RES, V681, P131, DOI 10.1016/0006-8993(95)00304-9; MOTTI EDF, 1987, SCANNING MICROSCOPY, V1, P207; MURAI N, 1992, J ELECTRON MICROSC, V41, P123; MURAKAMI T, 1971, Archivum Histologicum Japonicum, V32, P445; NAKAI K, 1989, SCANNING MICROSCOPY, V3, P337; Nonaka H, 2003, NEUROPATHOLOGY, V23, P111, DOI 10.1046/j.1440-1789.2003.00486.x; NORTHOVER JMA, 1980, J ANAT, V130, P43; Ohkuma H, 1997, NEUROSURGERY, V41, P230, DOI 10.1097/00006123-199707000-00036; Portella G, 2002, ACT NEUR S, V81, P173; Raspanti M, 2005, MICROSC RES TECHNIQ, V67, P1, DOI 10.1002/jemt.20176; Reina-De La Torre F, 1998, ANAT RECORD, V251, P87, DOI 10.1002/(SICI)1097-0185(199805)251:1<87::AID-AR14>3.0.CO;2-7; Rodriguez-Baeza A, 1998, ANAT RECORD, V252, P176, DOI 10.1002/(SICI)1097-0185(199810)252:2<176::AID-AR3>3.0.CO;2-1; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; ROSENBLUM WI, 1994, HUMAN BRAIN CIRCULATION, P23; ROWBOTHAM GF, 1965, BRIT J SURG, V52, P8, DOI 10.1002/bjs.1800520104; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Secomb TW, 2000, MICROCIRCULATION, V7, P237, DOI 10.1038/sj.mn.7300114; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; WEISS HR, 1976, MICROVASC RES, V12, P305, DOI 10.1016/0026-2862(76)90028-5	41	28	30	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2013	118	4					763	774		10.3171/2012.11.JNS12627			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	114BT	WOS:000316715700013	23350772				2021-06-18	
J	Nordstrom, A; Edin, BB; Lindstrom, S; Nordstrom, P				Nordstrom, Anna; Edin, Benoni B.; Lindstroem, Sara; Nordstrom, Peter			Cognitive function and other risk factors for mild traumatic brain injury in young men: nationwide cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COLLABORATING-CENTER; TWINS DISCORDANT; TASK-FORCE; INTELLIGENCE; VALIDATION	Objective To investigate cognitive function and other risk factors for mild traumatic brain injury in young men. Design Nationwide prospective cohort study. Setting Sweden. Participants 305 885 men conscripted for military service from 1989 to 1994. Main outcome measure mild traumatic brain injuries in relation to cognitive function and other potential risk factors assessed at conscription and follow-up. Results Men with one mild traumatic brain injury within two years before (n=1988) or after cognitive testing (n=2214) had about 5.5% lower overall cognitive function scores than did men with no mild traumatic brain injury during follow up (P<0.001 for both). Moreover, men with at least two mild traumatic brain injuries after cognitive testing (n=795) had 15% lower overall cognitive function scores compared with those with no such injury (P<0.001). Independent strong risk factors (P<1x10(-10)) for at least one mild traumatic brain injury after cognitive testing (n=12 494 events) included low overall cognitive function, a previous mild traumatic brain injury, hospital admission for intoxications, and low education and socioeconomic status. In a sub-cohort of twin pairs in which one twin had a mild traumatic brain injury before cognitive testing (n=63), both twins had lower logical performance and technical performance compared with men in the total cohort with no mild traumatic brain injury (P<0.05 for all). Conclusion Low cognitive function, intoxications, and factors related to low socioeconomic status were strong independent risk factors for mild traumatic brain injuries in men. The low cognitive function in twin pairs discordant for mild traumatic brain injury suggests a genetic component to the low cognitive function associated with such injuries. The study included only men, so inferences to women should be made with caution.	[Nordstrom, Anna; Nordstrom, Peter] Umea Univ, Dept Community Med & Rehabil, SE-90187 Umea, Sweden; [Edin, Benoni B.] Umea Univ, Physiol Sect, Dept Integrat Med Biol, SE-90187 Umea, Sweden; [Lindstroem, Sara] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Nordstrom, A (corresponding author), Umea Univ, Dept Community Med & Rehabil, SE-90187 Umea, Sweden.	anna.nordstrom@idrott.umu.se	Nordstrom, Anna/O-2504-2018; Edin, Benoni B/AAI-3964-2020; Edin, Benoni/D-1057-2009; Nordstrom, Anna/F-2238-2010	Nordstrom, Anna/0000-0003-3534-456X; Edin, Benoni B/0000-0001-9010-5612; Edin, Benoni/0000-0001-9010-5612; Nordstrom, Anna/0000-0003-3534-456X; Nordstrom, Peter/0000-0003-2924-508X	Swedish Research CouncilSwedish Research CouncilEuropean Commission	The study was funded by the Swedish Research Council. The researchers conducted this study totally independently of the funding body.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Andersen L. B., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P318; ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; Ashman TA, 2006, MT SINAI J MED, V73, P999; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brinch CN, 2012, P NATL ACAD SCI USA, V109, P425, DOI 10.1073/pnas.1106077109; CARLSTEDT B, 1993, SCAND J PSYCHOL, V34, P353, DOI 10.1111/j.1467-9450.1993.tb01131.x; Carlstedt B, 2005, SCAND J PSYCHOL, V46, P31, DOI 10.1111/j.1467-9450.2005.00432.x; Carlstedt B., 2000, COGNITIVE ABILITIES; Davies G, 2011, MOL PSYCHIATR, V16, P996, DOI 10.1038/mp.2011.85; Deary IJ, 2007, INTELLIGENCE, V35, P13, DOI 10.1016/j.intell.2006.02.001; Gilbertson MW, 2006, J ABNORM PSYCHOL, V115, P484, DOI 10.1037/0021-843X.115.3.484; Heckman JJ, 2006, SCIENCE, V312, P1900, DOI 10.1126/science.1128898; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Murray CJL., 1996, GLOBAL HLTH STAT COM; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; National Institute of Neurological Disorders and Stroke, 2002, NIH PUBL; Nordstrom A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001151; Pitman RK, 2006, ANN NY ACAD SCI, V1071, P242, DOI 10.1196/annals.1364.019; Royall DR, 2002, J NEUROPSYCH CLIN N, V14, P377, DOI 10.1176/appi.neuropsych.14.4.377; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	28	28	28	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2013	346								f723	10.1136/bmj.f723			9	Medicine, General & Internal	General & Internal Medicine	108VQ	WOS:000316324700012	23482939	Other Gold			2021-06-18	
J	Balan, IS; Saladino, AJ; Aarabi, B; Castellani, RJ; Wade, C; Stein, DM; Eisenberg, HM; Chen, HGH; Fiskum, G				Balan, Irina S.; Saladino, Andrew J.; Aarabi, Bizhan; Castellani, Rudolf J.; Wade, Christine; Stein, Deborah M.; Eisenberg, Howard M.; Chen, Hegang H.; Fiskum, Gary			Cellular Alterations in Human Traumatic Brain Injury: Changes in Mitochondrial Morphology Reflect Regional Levels of Injury Severity	JOURNAL OF NEUROTRAUMA			English	Article						cristae; electron microscopy; matrix; penumbra	RAT LIVER MITOCHONDRIA; LINKED MECHANICAL ACTIVITY; CYCLOSPORINE-A; ULTRASTRUCTURAL-CHANGES; AXONAL INJURY; ISCHEMIA; DYNAMICS; DAMAGE; DEATH; TRANSITION	Mitochondrial dysfunction may be central to the pathophysiology of traumatic brain injury (TBI) and often can be recognized cytologically by changes in mitochondrial ultrastructure. This study is the first to broadly characterize and quantify mitochondrial morphologic alterations in surgically resected human TBI tissues from three contiguous cortical injury zones. These zones were designated as injury center (Near), periphery (Far), and Penumbra. Tissues from 22 patients with TBI with varying degrees of damage and time intervals from TBI to surgical tissue collection within the first week post-injury were rapidly fixed in the surgical suite and processed for electron microscopy. A large number of mitochondrial structural patterns were identified and divided into four survival categories: normal, normal reactive, reactive degenerating, and end-stage degenerating profiles. A tissue sample acquired at 38 hours post-injury was selected for detailed mitochondrial quantification, because it best exhibited the wide variation in cellular and mitochondrial changes consistently noted in all the other cases. The distribution of mitochondrial morphologic phenotypes varied significantly between the three injury zones and when compared with control cortical tissue obtained from an epilepsy lobectomy. This study is unique in its comparative quantification of the mitochondrial ultrastructural alterations at progressive distances from the center of injury in surviving TBI patients and in relation to control human cortex. These quantitative observations may be useful in guiding the translation of mitochondrial-based neuroprotective interventions to clinical implementation.	[Balan, Irina S.; Fiskum, Gary] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Balan, Irina S.; Wade, Christine; Stein, Deborah M.; Fiskum, Gary] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res, Baltimore, MD 21201 USA; [Saladino, Andrew J.; Castellani, Rudolf J.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Stein, Deborah M.] Univ Maryland, Sch Med, Dept Surg, Program Trauma, Baltimore, MD 21201 USA; [Aarabi, Bizhan; Eisenberg, Howard M.] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Chen, Hegang H.] Univ Maryland, Sch Med, Div Biostat & Bioinformat, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Saladino, Andrew J.] Vet Affairs Med Ctr, Pathol Serv, Baltimore, MD USA	Fiskum, G (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 685 W Baltimore St MSTF 5-34, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu		Balan, Irina/0000-0002-2299-6115; Stein, Deborah/0000-0003-3683-3963	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM075776, P01 HD16596]; Paragon Bioservices, Inc.; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM075776] Funding Source: NIH RePORTER	This work was supported by NIH grants T32 GM075776 and P01 HD16596 and a grant from Paragon Bioservices, Inc.	Ahn ES, 2008, J NEUROSURG, V108, P124, DOI 10.3171/JNS/2008/108/01/0124; Balan I.S., 2012, ANIMAL MODELS ACUTE, P29; Balan IS, 2010, BRAIN RES, V1316, P112, DOI 10.1016/j.brainres.2009.12.042; Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253; Benani A, 2009, J NEUROSCI METH, V178, P301, DOI 10.1016/j.jneumeth.2008.12.023; Bereiter-Hahn J, 2010, INT REV CEL MOL BIO, V284, P1, DOI 10.1016/S1937-6448(10)84001-8; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Castejon O.J., 2004, STRUCTURAL PATTERNS; Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Colbourne F, 1999, J NEUROSCI, V19, P4200; Cook AM, 2009, EXPERT OPIN DRUG SAF, V8, P411, DOI 10.1517/14740330903066742; CRAGG BG, 1976, J ANAT, V121, P331; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; GREENAWALT JW, 1964, J CELL BIOL, V23, P21, DOI 10.1083/jcb.23.1.21; Gunawardena S, 2004, J NEUROBIOL, V58, P258, DOI 10.1002/neu.10319; HACKENBROCK CR, 1968, J CELL BIOL, V37, P345, DOI 10.1083/jcb.37.2.345; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; HACKENBROCK CR, 1971, J CELL BIOL, V51, P123, DOI 10.1083/jcb.51.1.123; Harris Kristen M., 2008, P1, DOI 10.1007/978-0-387-77232-5_1; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; Immonen R, 2010, J CEREBR BLOOD F MET, V30, P1318, DOI 10.1038/jcbfm.2010.15; Jahani-Asl A, 2011, J BIOL CHEM, V286, P4772, DOI 10.1074/jbc.M110.167155; Johannessen J.V., 1978, ELECT MICROSCOPY HUM, P1; Kristian T, 1996, LIFE SCI, V59, P357, DOI 10.1016/0024-3205(96)00314-1; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lai Y, 2008, J NEUROCHEM, V104, P1700, DOI 10.1111/j.1471-4159.2007.05114.x; Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Liu CL, 2010, J NEUROCHEM, V115, P68, DOI 10.1111/j.1471-4159.2010.06905.x; Liu X, 2011, CELL DEATH DIFFER, V18, P1561, DOI 10.1038/cdd.2011.13; Lyamzaev KG, 2008, BBA-BIOENERGETICS, V1777, P817, DOI 10.1016/j.bbabio.2008.03.027; Mannella CA, 2006, BBA-MOL BASIS DIS, V1762, P140, DOI 10.1016/j.bbadis.2005.07.001; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Mishchenko Y, 2010, NEURON, V67, P1009, DOI 10.1016/j.neuron.2010.08.014; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; MYRON DR, 1971, J CELL BIOL, V48, P291, DOI 10.1083/jcb.48.2.291; Neuspiel M, 2008, CURR BIOL, V18, P102, DOI 10.1016/j.cub.2007.12.038; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; ONG WY, 1991, J ANAT, V175, P79; PACKER L, 1970, FED PROC, V29, P1533; Perez-Pinzon MA, 2012, J CEREBR BLOOD F MET, V32, P1362, DOI 10.1038/jcbfm.2012.32; Peters A, 1991, FINE STRUCTURE NERVO; Popov V, 2005, J COMP NEUROL, V492, P50, DOI 10.1002/cne.20682; Sanchez V, 2011, ANESTHESIOLOGY, V115, P992, DOI 10.1097/ALN.0b013e3182303a63; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Skulachev VP, 2004, MOL CELL BIOCHEM, V256, P341, DOI 10.1023/B:MCBI.0000009880.94044.49; SLOPER JJ, 1979, PHILOS T R SOC B, V285, P141, DOI 10.1098/rstb.1979.0003; Solenski NJ, 2002, STROKE, V33, P816, DOI 10.1161/hs0302.104541; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Taiushev K G, 1999, Morfologiia, V116, P7; Taiushev K G, 1990, Arkh Anat Gistol Embriol, V99, P26; Thomale UW, 2007, NEUROL RES, V29, P594, DOI 10.1179/016164107X166272; TRUMP BF, 1976, CIRCULATION, V53, P17; TRUMP BF, 1965, LAB INVEST, V14, P343; Ugriumov V M, 1977, Zh Vopr Neirokhir Im N N Burdenko, P3; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Yin W, 2008, STROKE, V39, P3057, DOI 10.1161/STROKEAHA.108.520114; Zick M, 2009, BBA-MOL CELL RES, V1793, P5, DOI 10.1016/j.bbamcr.2008.06.013	66	28	30	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2013	30	5					367	381		10.1089/neu.2012.2339			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	103CI	WOS:000315891600007	23131111	Green Published			2021-06-18	
J	Cuberos-Urbano, G; Caracuel, A; Vilar-Lopez, R; Valls-Serrano, C; Bateman, A; Verdejo-Garcia, A				Cuberos-Urbano, Gustavo; Caracuel, Alfonso; Vilar-Lopez, Raquel; Valls-Serrano, Carlos; Bateman, Andrew; Verdejo-Garcia, Antonio			Ecological validity of the Multiple Errands Test using predictive models of dysexecutive problems in everyday life	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Neuropsychology; Dysexecutive syndrome; Ecological validity	TRAUMATIC BRAIN-INJURY; SIMPLIFIED VERSION; SYMPTOMS; IMPAIRMENTS; BEHAVIOR; SAMPLE	Thedysexecutive syndrome is composed of a range of cognitive, emotional, and behavioral deficits that are difficult to evaluate using traditional neuropsychological tests. The Multiple Errands Test (MET) was originally developed to systematize the assessment of the more elusive manifestations of the dysexecutive syndrome. The aims of this study were to examining the reliability of the MET and to investigate the predictive ability of its indices to explain a range of dysexecutive-related symptoms in everyday life. Thirty patients with acquired brain injury participated in this study. The MET showed an adequate inter-rater reliability and ecological validity. The main performance indices from the MET were able to significantly predict severity of everyday life executive problems, with different indices predicting particular manifestations of different components of executive functions.	[Cuberos-Urbano, Gustavo; Vilar-Lopez, Raquel; Valls-Serrano, Carlos; Verdejo-Garcia, Antonio] Univ Granada, Dept Clin Psychol, E-18071 Granada, Spain; [Caracuel, Alfonso] Univ Granada, Dept Dev Psychol, E-18071 Granada, Spain; [Caracuel, Alfonso; Vilar-Lopez, Raquel; Verdejo-Garcia, Antonio] Univ Granada, Inst Neurosci F Oloriz, E-18071 Granada, Spain; [Bateman, Andrew] Princess Wales Hosp, Oliver Zangwill Ctr Neuropsychol Rehabil, Ely, Wales; [Bateman, Andrew] NIHR CLAHRC Cambridgeshire & Peterborough, Cambridge, England	Vilar-Lopez, R (corresponding author), Univ Granada, Dept Personalidad Evaluac & Tratamiento Psicol, Fac Psychol, Campus La Cartuja S-N, E-18071 Granada, Spain.	rvilar@ugr.es	Vilar-Lopez, Raquel/I-7847-2016; Caracuel, Alfonso/V-3695-2019	Vilar-Lopez, Raquel/0000-0001-9639-0143; Caracuel, Alfonso/0000-0002-9738-8456; Verdejo-Garcia, Antonio/0000-0001-8874-9339; Bateman, Andrew/0000-0002-2547-5921	Spanish Ministry of Health, Instituto de Salud Carlos III, Fondo de Investigacion SanitariaInstituto de Salud Carlos IIISpanish Government [PI09/91008]; National Institute for Health Research (NIHR) Collaborations for Leadership in Applied Health Research and Care (CLAHRC C-P)	This study was funded by Grant PI09/91008 from the Spanish Ministry of Health, Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria (PI: A. V. G). A. B. was funded by the National Institute for Health Research (NIHR) Collaborations for Leadership in Applied Health Research and Care (CLAHRC C-P).	Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Alexander M, 2006, J INT NEUROPSYCH SOC, V12, P192, DOI 10.1017/S1355617706060292; Amieva H, 2003, BRAIN COGNITION, V53, P129, DOI 10.1016/S0278-2626(03)00094-0; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Caracuel A, 2008, ARCH CLIN NEUROPSYCH, V23, P447, DOI 10.1016/j.acn.2008.03.004; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Chaytor N, 2007, BRAIN INJURY, V21, P615, DOI 10.1080/02699050701426949; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Dawson DR, 2009, ARCH PHYS MED REHAB, V90, pS41, DOI 10.1016/j.apmr.2009.07.012; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; Hair J. F., 2006, MULTIVARIATE DATA AN, V6; Hanna-Pladdy B, 2007, J Neurol Phys Ther, V31, P119; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; MALLOY P, 1993, ARCH CLIN NEUROPSYCH, V8, P185, DOI 10.1016/0887-6177(93)90035-Y; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Nigg JT, 2000, PSYCHOL BULL, V126, P220, DOI 10.1037/0033-2909.126.2.220; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Simpson A, 2002, BRAIN INJURY, V16, P1075, DOI 10.1080/02699050210155249; Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Wilson BA, 1996, BEHAV ASSESSMENT DYS	23	28	28	0	17	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAR 1	2013	35	3					329	336		10.1080/13803395.2013.776011			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	104IM	WOS:000315985900010	23458357				2021-06-18	
J	Di Pietro, V; Amorini, AM; Tavazzi, B; Hovda, DA; Signoretti, S; Giza, CC; Lazzarino, G; Vagnozzi, R; Lazzarino, G; Belli, A				Di Pietro, Valentina; Amorini, Angela M.; Tavazzi, Barbara; Hovda, David A.; Signoretti, Stefano; Giza, Christopher C.; Lazzarino, Giacomo; Vagnozzi, Roberto; Lazzarino, Giuseppe; Belli, Antonio			Potentially neuroprotective gene modulation in an in vitro model of mild traumatic brain injury	MOLECULAR AND CELLULAR BIOCHEMISTRY			English	Article						Mild traumatic brain injury; Gene expression; Mitochondrial dysfunction; Hypometabolism; Hibernation; Neuroprotection	LOW-FLOW ISCHEMIA; MITOCHONDRIAL DYSFUNCTION; TEMPORAL WINDOW; ENERGY-METABOLISM; OXIDATIVE STRESS; NO-FLOW; HIBERNATION; DAMAGE; VULNERABILITY; DEPRESSION	In this study, we investigated the hypothesis that mild traumatic brain injury (mTBI) triggers a controlled gene program as an adaptive response finalized to neuroprotection, similar to that found in hibernators and in ischemic preconditioning. A stretch injury device was used to produce an equi-biaxial strain field in rat organotypic hippocampal slice cultures at a specified Lagrangian strain of 10 % and a constant strain rate of 20 s(-1). After 24 h from injury, propidium iodide staining, HPLC analysis of metabolites and microarray analysis of cDNA were performed to evaluate cell viability, cell energy state and gene expression, respectively. Compared to control cultures, 10 % stretch injured cultures showed no change in viability, but demonstrated a hypometabolic state (decreased ATP, ATP/ADP, and nicotinic coenzymes) and a peculiar pattern of gene modulation. The latter was characterized by downregulation of genes encoding for proteins of complexes I, III, and IV of the mitochondrial electron transport chain and of ATP synthase; downregulation of transcriptional and translational genes; downregulation and upregulation of genes controlling the synthesis of glutamate and GABA receptors, upregulation of calmodulin and calmodulin-binding proteins; proper modulation of genes encoding for proapoptotic and antiapoptotic proteins. These results support the hypothesis that, following mTBI, a hibernation-type response is activated in non-hibernating species. Unlike in hibernators and ischemic preconditioning, this adaptive gene programme, aimed at achieving maximal neuroprotection, is not triggered by decrease in oxygen availability. It seems rather activated to avoid increase in oxidative/nitrosative stress and apoptosis during a transient period of mitochondrial malfunctioning.	[Di Pietro, Valentina; Belli, Antonio] Univ Birmingham, Neuropharmacol & Neurobiol Sect, Sch Clin & Expt Med, Coll Med & Dent Sci, Birmingham, W Midlands, England; [Di Pietro, Valentina] Univ Southampton, Sch Med, Div Clin Neurosci, Southampton, Hants, England; [Amorini, Angela M.; Tavazzi, Barbara; Lazzarino, Giacomo] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Dept Neurosurg,Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Signoretti, Stefano] San Camillo Hosp, Div Neurosurg, Dept Neurosci Head & Neck Surg, Rome, Italy; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr,Mattel Childrens Hosp, Div Pediat Neurol,Dept Neurosurg, Los Angeles, CA 90095 USA; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Div Neurotraumatol & Neuroradiol, Dept Biomed & Prevent, Rome, Italy; [Lazzarino, Giuseppe] Univ Catania, Div Biochem & Mol Biol, Dept Biol Geol & Environm Sci, Viale A Doria 6, I-95125 Catania, Italy	Lazzarino, G (corresponding author), Univ Catania, Div Biochem & Mol Biol, Dept Biol Geol & Environm Sci, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@unict.it	TAVAZZI, BARBARA/AAB-9830-2019; Belli, Antonio/I-3799-2015; Signoretti, stefano/AAL-5631-2020; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; Belli, Antonio/0000-0002-3211-9933; Signoretti, stefano/0000-0002-8086-1622; lazzarino, giuseppe/0000-0002-5917-7279; Di Pietro, Valentina/0000-0001-9430-4723; AMORINI, Angela Maria/0000-0003-3525-9955; Lazzarino, Giacomo/0000-0003-1639-0966	Wessex Medical Research Centre; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD004612] Funding Source: NIH RePORTER	We wish to thank the Wessex Medical Research Centre for funding this study and for their support to our research. We also wish to thank Ms. Kathryn Rasco for her technical assistance in the manuscript preparation.	Arun P, 2010, J NEUROTRAUM, V27, P293, DOI 10.1089/neu.2009.0994; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Belli A, 2006, J NEUROCHEM, V96, P861, DOI 10.1111/j.1471-4159.2005.03602.x; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Blackstone E, 2005, SCIENCE, V308, P518, DOI 10.1126/science.1108581; BOCHAROVA LS, 1992, COMP BIOCHEM PHYS B, V101, P189, DOI 10.1016/0305-0491(92)90177-S; Boczek T, 2012, MOL CELL BIOCHEM, V360, P89, DOI 10.1007/s11010-011-1047-3; Buck PW, 2011, HEALTH SOC WORK, V36, P299, DOI 10.1093/hsw/36.4.299; Budinger GRS, 1998, J BIOL CHEM, V273, P3320, DOI 10.1074/jbc.273.6.3320; Chen JP, 2008, COMP BIOCHEM PHYS B, V149, P388, DOI 10.1016/j.cbpb.2007.10.011; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; Depre C, 2007, HEART FAIL REV, V12, P307, DOI 10.1007/s10741-007-9040-3; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Dickinson BC, 2011, NAT CHEM BIOL, V7, P504, DOI [10.1038/NCHEMBIO.607, 10.1038/nchembio.607]; Domeniconi M, 2005, J NEUROL SCI, V233, P43, DOI 10.1016/j.jns.2005.03.023; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; Ferrari R, 1996, CIRCULATION, V94, P2587, DOI 10.1161/01.CIR.94.10.2587; Frerichs KU, 1998, P NATL ACAD SCI USA, V95, P14511, DOI 10.1073/pnas.95.24.14511; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hardeland R, 2009, MOLECULES, V14, P5054, DOI 10.3390/molecules14125054; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Jay G W, 1996, J Insur Med, V27, P262; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kim DY, 2001, MOL CELL NEUROSCI, V17, P1025, DOI 10.1006/mcne.2001.0988; Kim GS, 2012, J CEREBR BLOOD F MET, V32, P720, DOI 10.1038/jcbfm.2011.176; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; Levy RJ, 2007, SHOCK, V28, P24, DOI 10.1097/01.shk.0000235089.30550.2d; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; MacDonald JA, 1999, BIOCHEM BIOPH RES CO, V254, P424, DOI 10.1006/bbrc.1998.9960; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Nystul TG, 2004, P NATL ACAD SCI USA, V101, P9133, DOI 10.1073/pnas.0403312101; Ranaivo HR, 2011, J NEUROTRAUM, V28, P1757, DOI 10.1089/neu.2011.1799; Ross AP, 2006, J CEREBR BLOOD F MET, V26, P1148, DOI 10.1038/sj.jcbfm.9600271; SCHULZ R, 1995, CIRC RES, V76, P942, DOI 10.1161/01.RES.76.6.942; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Singh BK, 2011, MOL CELL BIOCHEM, V357, P373, DOI 10.1007/s11010-011-0908-0; Slemmer JE, 2005, NEUROBIOL DIS, V18, P421, DOI 10.1016/j.nbd.2004.09.022; Soustiel JF, 2010, NEUROTHERAPEUTICS, V7, P13, DOI 10.1016/j.nurt.2009.11.001; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; Storey KB, 2004, BIOL REV, V79, P207, DOI 10.1017/S1464793103006195; STOREY KB, 1990, SCI AM, V263, P92, DOI 10.1038/scientificamerican1290-92; Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; TEASDALE G, 1974, LANCET, V2, P81; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Van Damme K, 2003, BRAIN RES, V960, P1, DOI 10.1016/S0006-8993(02)03672-7; Vroom MB, 1996, J CARDIOTHOR VASC AN, V10, P789, DOI 10.1016/S1053-0770(96)80209-6; WANG LCH, 1988, CRYOBIOLOGY, V25, P355, DOI 10.1016/0011-2240(88)90043-0; Wang SQ, 2002, J EXP BIOL, V205, P2957; Williams DR, 2005, PHYSIOL GENOMICS, V24, P13, DOI 10.1152/physiolgenomics.00301.2004; Zhao HWW, 2006, J NEUROSCI RES, V84, P291, DOI 10.1002/jnr.20893; Zhou F, 2001, AM J PATHOL, V158, P2145, DOI 10.1016/S0002-9440(10)64686-X	63	28	28	1	28	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-8177	1573-4919		MOL CELL BIOCHEM	Mol. Cell. Biochem.	MAR	2013	375	1-2					185	198		10.1007/s11010-012-1541-2			14	Cell Biology	Cell Biology	077MR	WOS:000314032300020	23242602				2021-06-18	
J	Jacoby, M; Averbuch, S; Sacher, Y; Katz, N; Weiss, PL; Kizony, R				Jacoby, Michele; Averbuch, Sara; Sacher, Yaron; Katz, Noomi; Weiss, Patrice L.; Kizony, Rachel			Effectiveness of Executive Functions Training Within a Virtual Supermarket for Adults With Traumatic Brain Injury: A Pilot Study	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						Executive functions; randomized controlled trial; traumatic brain injury; virtual environment	MULTIPLE ERRANDS TEST; COGNITIVE REHABILITATION; ECOLOGICAL VALIDITY; SIMPLIFIED VERSION; REALITY; DYSFUNCTION; RELIABILITY; ENVIRONMENT; PEOPLE	Impairments of executive functions (EF) significantly affect the ability to lead an independent lifestyle. Virtual environments offer a way to rehabilitate EF due to their ecological validity. The purpose of this pilot study was to examine the effectiveness of a virtual reality (VR) supermarket (VMall) for treatment of EF in patients with Traumatic Brain Injury (TBI), compared to conventional occupational therapy (OT), in order to provide initial data regarding the effect sizes for calculation of sample size as well as to establish an intervention protocol for future Randomized Control Trials (RCTs). Twelve men and women, aged 19-55 years, who had TBI resulting in EF impairments participated in this study. Outcome measures were the Multiple Errands Test-Simplified Version (MET-SV) and the Executive Function Performance Test (EFPT). Cognitive treatment provided to both groups was based on the same principles; the participants in the experimental group received 10 45-min VR-based treatment sessions and the control group participants received 10 sessions of occupational therapy cognitive retraining without VR. Baseline performance prior to intervention showed no statistically significant differences between groups. Most participants improved their performance after therapy. Following a Bonferroni correction for multiple comparisons, no significant between or within group differences were found, Nevertheless, large effect sizes (0.51) for the percent (%) relative change of the MET-SV total score and EFPT total score after intervention were high in favor of the experimental group indicating a larger improvement in EF. Based on this pilot study, results show a trend towards an advantage to VR therapy compared to cognitive retraining OT without VR, as it leads to greater improvement in complex everyday activities.	[Jacoby, Michele; Averbuch, Sara; Sacher, Yaron] Loewenstein Hosp & Rehabil Ctr, Dept Occupat Therapy, IL-43100 Raanana, Israel; [Jacoby, Michele; Averbuch, Sara; Sacher, Yaron] Loewenstein Hosp & Rehabil Ctr, Dept Traumat Brain Injury, IL-43100 Raanana, Israel; [Katz, Noomi] Ono Acad Coll, Res Inst Hlth & Med Profess, IL-60375 Or Yehuda, Israel; [Weiss, Patrice L.; Kizony, Rachel] Univ Haifa, Dept Occupat Therapy, IL-31905 Haifa, Israel; [Kizony, Rachel] Chaim Sheba Med Ctr, Dept Occupat Therapy, IL-52621 Tel Hashomer, Israel	Jacoby, M (corresponding author), Loewenstein Hosp & Rehabil Ctr, Dept Occupat Therapy, IL-43100 Raanana, Israel.	ohadjacoby@gmail.com; sarahab@clalit.org.il; ysacher@clalit.org.il; noomi.katz@ono.ac.il; tamar@research.haifa.ac.il; rkizony@univ.haifa.ac.il			Loewenstein Legacy Heritage Fund	This work was supported by the Loewenstein Legacy Heritage Fund.	Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; American Occupational Therapy Association, 2008, AM J OCCUPATIONAL TH, V62, P625, DOI DOI 10.5014/AJOT.62.6.625; Averbach S., 2011, COGNITION OCCUPATION, P277; Baum C., 2007, EXECUTIVE FUNCTION P; Baum CM, 2008, AM J OCCUP THER, V62, P446, DOI 10.5014/ajot.62.4.446; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Corder GW, 2009, NONPARAMETRIC STAT N; Cromby J. J., 1996, P 1 EUR C DIS VIRT R, P103; Dawson DR, 2009, ARCH PHYS MED REHAB, V90, pS41, DOI 10.1016/j.apmr.2009.07.012; Fong KNK, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-19; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Gitlin LA, 2001, MEASURING OCCUPATION, P161; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Groswasser Z., 1990, REHABILITATION BRAIN, P143; Holm MB, 2000, AM J OCCUP THER, V54, P575, DOI 10.5014/ajot.54.6.575; Josman N, 2006, 2006 INTERNATIONAL WORKSHOP ON VIRTUAL REHABILITATION, P106, DOI 10.1109/IWVR.2006.1707536; Josman N, 2009, SCHIZOPHR RES, V115, P270, DOI 10.1016/j.schres.2009.09.015; Katz N., 2005, DISABIL REHABIL, V29, P177; Katz N., 2007, OCCUPATIONAL THERAPY, V27, P1; Katz N., 2011, COGNITION OCCUPATION, P13; Kizony R, 2003, J VISUAL COMP ANIMAT, V14, P261, DOI 10.1002/vis.323; Kizony R, 2008, ISRAELI J OCCUPAT TH, V17, pE47; Kizony R., 2011, COGNITION OCCUPATION, P143; Klinger E, 2004, CYBERPSYCHOL BEHAV, V7, P292; Klinger E, 2006, CYBERPSYCHOL BEHAV, V9, P342, DOI 10.1089/cpb.2006.9.342; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Lam YS, 2006, NEUROREHABILITATION, V21, P245; Levav M, 2005, VALIDITY MULTIPLE ER; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; MANTOVANI F, 2003, BEING THERE CONCEPTS; Mayer S. A, 2005, MERRITTS NEUROLOGY, P483; McComas J, 2002, CYBERPSYCHOL BEHAV, V5, P185, DOI 10.1089/109493102760147150; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; Rabinowicz S, 2010, ISRAELI J OCCUPAT TH, V19, pH209; Rand D, 2005, ANN REV CYBERTHERAPY, V3, P193; Rand D, 2007, DISABIL REHABIL, V29, P1710, DOI 10.1080/09638280601107450; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; Rand D, 2009, AM J OCCUP THER, V63, P535, DOI 10.5014/ajot.63.5.535; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Sweeney S, 2010, NEUROPSYCHOL REHABIL, V20, P239, DOI 10.1080/09602010903080531; Toglia J. P., 2011, COGNITION OCCUPATION, P161; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Weiss P, 2006, TXB NEURAL REPAIR RE, V51, P182; Weiss PL, 2009, PHYS THER REV, V14, P307, DOI 10.1179/108331909X12488667117339; Weiss PL, 2004, J REHABIL RES DEV, V41, pVII; Werner P, 2009, DEMENT GERIATR COGN, V27, P301, DOI 10.1159/000204915; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Yip BCB, 2009, BRAIN INJURY, V23, P1017, DOI 10.3109/02699050903379412	55	28	29	2	64	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	MAR	2013	21	2					182	190		10.1109/TNSRE.2012.2235184			9	Engineering, Biomedical; Rehabilitation	Engineering; Rehabilitation	108AW	WOS:000316264100004	23292820				2021-06-18	
J	Titus, DJ; Furones, C; Kang, Y; Atkins, CM				Titus, D. J.; Furones, C.; Kang, Y.; Atkins, C. M.			AGE-DEPENDENT ALTERATIONS IN CAMP SIGNALING CONTRIBUTE TO SYNAPTIC PLASTICITY DEFICITS FOLLOWING TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						cAMP; fluid-percussion; long-term potentiation; phosphodiesterase; rolipram; traumatic brain injury	LONG-TERM POTENTIATION; AMP-SELECTIVE PHOSPHODIESTERASE; PROTEIN-KINASE ACTIVITY; HIPPOCAMPAL AREA CA1; RAT-BRAIN; CREB PHOSPHORYLATION; FLUID-PERCUSSION; SPATIAL MEMORY; MIDDLE-AGE; ROLIPRAM	The elderly have comparatively worse cognitive impairments from traumatic brain injury (TBI) relative to younger adults, but the molecular mechanisms that underlie this exacerbation of cognitive deficits are unknown. Experimental models of TBI have demonstrated that the cyclic AMP-protein kinase A (cAMP-PKA) signaling pathway is downregulated after brain trauma. Since the cAMP-PKA signaling pathway is a key mediator of long-term memory formation, we investigated whether the TBI-induced decrease in cAMP levels is exacerbated in aged animals. Aged (19 months) and young adult (3 months) male Fischer 344 rats received sham surgery or mild (1.4-1.6 atmospheres, atm) or moderate (1.7-2.1 atm) parasagittal fluid-percussion brain injury. At various time points after surgery, the ipsilateral parietal cortex, hippocampus, and thalamus were assayed for cAMP levels. Mild TBI lowered cAMP levels in the hippocampus of aged, but not young adult animals. Moderate TBI lowered cAMP levels in the hippocampus and parietal cortex of both age groups. In the thalamus, cAMP levels were significantly lowered after moderate, but not mild TBI. To determine if the TBI-induced decreases in cAMP had physiological consequences in aged animals, hippocampal long-term potentiation (LTP) in the Schaffer collateral pathway of the CA1 region was assessed. LTP was significantly decreased in both young adult and aged animals after mild and moderate TBI as compared to sham surgery animals. Rolipram rescued the LTP deficits after mild TBI for young adult animals and caused a partial recovery for aged animals. However, rolipram did not rescue LTP deficits after moderate TBI in either young adult or aged animals. These results indicate that the exacerbation of cognitive impairments in aged animals with TBI may be due to decreased cAMP levels and deficits in hippocampal LTP. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Atkins, C. M.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Atkins, C. M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA	Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Post Box 016960,R-48, Miami, FL 33136 USA.	catkins@med.miami.edu		Titus, David/0000-0001-7819-734X; Atkins, Coleen/0000-0003-4718-7493	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG033266, NS069721, NS056072]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056072, R01NS069721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG033266] Funding Source: NIH RePORTER	The authors thank Dayaris Morffi for technical assistance and Drs. W. Dalton Dietrich, H.M. Bramlett, I. Hentall, and Kaming Lo for critical reading of the manuscript. We thank the University of Miami Biostatistics Collaboration and Consulting Core for statistical support. This work was supported by NIH Grants AG033266, NS069721, NS056072 and The Miami Project to Cure Paralysis.	Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI [10.1089/neu.2008.0765, 10.1089/neu.2008-0765]; Anderson WW, 2007, J NEUROSCI METH, V162, P346, DOI 10.1016/j.jneumeth.2006.12.018; ASANUMA M, 1993, ARCH GERONTOL GERIAT, V16, P191, DOI 10.1016/0167-4943(93)90009-7; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Bach ME, 1999, P NATL ACAD SCI USA, V96, P5280, DOI 10.1073/pnas.96.9.5280; Barad M, 1998, P NATL ACAD SCI USA, V95, P15020, DOI 10.1073/pnas.95.25.15020; Barnes CA, 1997, NEUROBIOL AGING, V18, P445, DOI 10.1016/S0197-4580(97)00044-4; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; BICKFORDWIMER PC, 1987, NEUROPHARMACOLOGY, V26, P597, DOI 10.1016/0028-3908(87)90153-5; Bodhinathan K, 2010, J NEUROSCI, V30, P1914, DOI 10.1523/JNEUROSCI.5485-09.2010; Boric K, 2008, J NEUROSCI, V28, P8034, DOI 10.1523/JNEUROSCI.2036-08.2008; Davare MA, 2003, P NATL ACAD SCI USA, V100, P16018, DOI 10.1073/pnas.2236970100; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Foster TC, 2001, J NEUROSCI, V21, P4066, DOI 10.1523/JNEUROSCI.21-11-04066.2001; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Godbout JP, 2006, NEUROL CLIN, V24, P521, DOI 10.1016/j.ncl.2006.03.010; Gong B, 2004, J CLIN INVEST, V114, P1624, DOI 10.1172/JCI200422831; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hattiangady B, 2005, EXP NEUROL, V195, P353, DOI 10.1016/j.expneurol.2005.05.014; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; Hsu KS, 2002, HIPPOCAMPUS, V12, P787, DOI 10.1002/hipo.10032; Itoh T, 2012, BRAIN STRUC IN PRESS; Karege F, 2001, BRAIN RES, V903, P86, DOI 10.1016/S0006-8993(01)02409-X; Karege F, 2001, NEUROSCI LETT, V315, P89, DOI 10.1016/S0304-3940(01)02358-8; Kato H, 1997, J NEURAL TRANSM, V104, P269, DOI 10.1007/BF01273187; Kato H, 1998, METHOD FIND EXP CLIN, V20, P403, DOI 10.1358/mf.1998.20.5.485701; Kudo K, 2005, BRAIN RES, V1054, P30, DOI 10.1016/j.brainres.2005.06.045; Lin SL, 2003, J NEUROCHEM, V87, P1076, DOI 10.1046/j.1471-4159.2003.02076.x; Martinez M, 2001, BRAIN RES, V922, P148, DOI 10.1016/S0006-8993(01)03009-8; Maughan PH, 2000, J NEUROTRAUM, V17, P1141, DOI 10.1089/neu.2000.17.1141; Mawhinney LJ, 2012, BRAIN RES, V1431, P23, DOI 10.1016/j.brainres.2011.11.004; Mons N, 2004, NEUROBIOL AGING, V25, P1095, DOI 10.1016/j.neurobiolaging.2003.10.014; Monti B, 2005, HIPPOCAMPUS, V15, P1041, DOI 10.1002/hipo.20099; Murray CA, 1998, J NEUROSCI, V18, P2974; Navakkode S, 2004, J NEUROSCI, V24, P7740, DOI 10.1523/JNEUROSCI.1796-04.2004; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PARFITT KD, 1990, NEUROBIOL AGING, V11, P591, DOI 10.1016/0197-4580(90)90022-R; Porte Y, 2008, NEUROBIOL AGING, V29, P1533, DOI 10.1016/j.neurobiolaging.2007.03.023; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; Reis GF, 2005, J NEUROPHYSIOL, V93, P3381, DOI 10.1152/jn.00827.2004; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Sanders MJ, 2001, BRAIN RES, V904, P141, DOI 10.1016/S0006-8993(01)02424-6; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Shah SA, 2006, EXP GERONTOL, V41, P1201, DOI 10.1016/j.exger.2006.07.006; Shankar S, 1998, J NEUROPHYSIOL, V79, P334; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tohda M, 1996, BIOL PHARM BULL, V19, P300; Vincent G. K., 2010, CURR POPULATION REP, P1125; Waltereit R, 2003, MOL NEUROBIOL, V27, P99, DOI 10.1385/MN:27:1:99; Watabe AM, 2003, NEUROBIOL AGING, V24, P267, DOI 10.1016/S0197-4580(02)00082-9; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Zhang GR, 2009, HIPPOCAMPUS, V19, P413, DOI 10.1002/hipo.20506	59	28	30	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	FEB 12	2013	231						182	194		10.1016/j.neuroscience.2012.12.002			13	Neurosciences	Neurosciences & Neurology	087EN	WOS:000314744200017	23238576	Green Accepted			2021-06-18	
J	Cote, N; Turgeon, AF; Lauzier, F; Moore, L; Scales, DC; Bernard, F; Zarychanski, R; Burns, KEA; Meade, MO; Zygun, D; Simard, JF; Boutin, A; Brochu, JG; Fergusson, DA				Cote, Nicolas; Turgeon, Alexis F.; Lauzier, Francois; Moore, Lynne; Scales, Damon C.; Bernard, Francis; Zarychanski, Ryan; Burns, Karen E. A.; Meade, Maureen O.; Zygun, David; Simard, Jean-Francois; Boutin, Amelie; Brochu, Jacques G.; Fergusson, Dean A.			Factors Associated with the Withdrawal of Life-Sustaining Therapies in Patients with Severe Traumatic Brain Injury: A Multicenter Cohort Study	NEUROCRITICAL CARE			English	Article						Withdrawal of life-sustaining therapy; Mortality; Traumatic brain injury; Risk factors; End-of-life	INTENSIVE-CARE-UNIT; INTRACEREBRAL HEMORRHAGE; MECHANICAL VENTILATION; NEW-ZEALAND; SUPPORT; MORTALITY; DOCUMENTATION; EPIDEMIOLOGY; MODELS; DEATH	To identify factors associated with decisions to withdraw life-sustaining therapies in patients with severe traumatic brain injury (TBI). We conducted a 2-year multicenter retrospective cohort study (2005-2006) in mechanically ventilated patients aged 16 years and older admitted to the intensive care units (ICUs) of six Canadian level I trauma centers following severe TBI. One hundred and twenty charts were randomly selected at each center (n = 720). Data on ICU management strategies, patients' clinical condition, surgical procedures, diagnostic imaging, and decision to withdraw life-sustaining therapies were collected. The association of factors pertaining to the injury, interventions, and management strategies with decisions to withdraw life-sustaining therapies was evaluated among non-survivors. Among the 228 non-survivors, 160 died following withdrawal of life-sustaining therapies. Patients were predominantly male (69.7 %) with a mean age of 50.7 (+/- 21.7) years old. Brain herniation was more often reported in patients who died following decisions to withdraw life-sustaining therapies (odds ratio [OR] 2.91, 95 % confidence interval [CI] 1.16-7.30, p = 0.02) compared to those who died due to other causes (e.g., cardiac arrest, shock, etc.). Epidural hematomas (OR 0.18, 95 % CI 0.06-0.56, p < 0.01), craniotomies (OR 0.12, 95 % CI 0.02-0.68, p = 0.02), and other non-neurosurgical procedures (OR 0.08, 95 % CI 0.02-0.43, p < 0.01) were less often associated with death following withdrawal of life-sustaining therapies than death from other causes. Death following decisions to withdraw life-sustaining therapies is associated with specific patient and clinical factors, and the intensity of care.	[Turgeon, Alexis F.; Lauzier, Francois; Moore, Lynne; Simard, Jean-Francois; Boutin, Amelie] Univ Laval, Ctr Rech FRQ S, Ctr Hosp, Univ Quebec,Hop Enfant Jesus,CHA Res Ctr,Care Med, Quebec City, PQ G1J 1Z4, Canada; [Cote, Nicolas; Turgeon, Alexis F.; Lauzier, Francois; Brochu, Jacques G.] Univ Laval, Dept Anesthesiol, Div Crit Care Med, Quebec City, PQ, Canada; [Lauzier, Francois] Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; [Moore, Lynne] Univ Laval, Dept Social & Prevent Med, Quebec City, PQ, Canada; [Scales, Damon C.] Univ Laval, Interdept Div Crit Care Med, Toronto, ON, Canada; [Bernard, Francis] Univ Montreal, Dept Internal Med, Montreal, PQ, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Sect Crit Care Med, Winnipeg, MB, Canada; [Burns, Karen E. A.] Univ Toronto, St Michaels Hosp, Dept Crit Care Med, Toronto, ON M5B 1W8, Canada; [Meade, Maureen O.] McMaster Univ, Dept Crit Care Med, Hamilton, ON, Canada; [Zygun, David] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Fergusson, Dean A.] Univ Ottawa, Ottawa Hosp, Res Inst, Clin Epidemiol Unit, Ottawa, ON, Canada	Turgeon, AF (corresponding author), Univ Laval, Ctr Rech FRQ S, Ctr Hosp, Univ Quebec,Hop Enfant Jesus,CHA Res Ctr,Care Med, 1401,18e Rue,Local H-012A, Quebec City, PQ G1J 1Z4, Canada.	Alexis.Turgeon@fmed.ulaval.ca	Lauzier, Francois/B-9237-2015	Lauzier, Francois/0000-0002-6530-5513; Fergusson, Dean/0000-0002-3389-2485; Zarychanski, Ryan/0000-0001-9455-6138; Boutin, Amelie/0000-0003-1907-2920	Fondation de l'Hopital de l'Enfant-Jesus (Enfant-Jesus Hospital Foundation); Fonds de Recherche Quebec-Sante (FRQ-S); Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); CIHR RCTCanadian Institutes of Health Research (CIHR); CIHRCanadian Institutes of Health Research (CIHR)	The authors would like to thank Tran Cong Dung MD, MSc; Mohana Ratnapalan HBSc, Stephanie Todd BSc, MBT, John Harlock MD, Frederic Morin RN and David Simonyan MD MSc, for their help in data acquisition; Valerie Murat MSc for her participation in the data cleaning process; Mrs. Valerie Boucher for her secretarial assistance. This work was presented in part at the Intensive Care and Emergency Medicine Symposium (Brussels, Belgium, March 2011). The work was supported in part by the Fondation de l'Hopital de l'Enfant-Jesus (Enfant-Jesus Hospital Foundation) who had no role in any part of conduct of the study or preparation of the manuscript. Drs. Turgeon and Lauzier are recipients of a Research Career Award from the Fonds de Recherche Quebec-Sante (FRQ-S). Drs. Moore, Scales, and Fergusson are recipients of New Investigator Awards from the Canadian Institutes for Health Research (CIHR). Dr. Zarychanski is a recipient of a CIHR RCT Mentorship Award. Dr. Burns holds a Clinician Scientist Phase 2 Award from the CIHR.	Azoulay E, 2009, INTENS CARE MED, V35, P623, DOI 10.1007/s00134-008-1310-6; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; *BRAIN TRAUM FDN, 2000, MAN PROGN SEV TRAUM; Brain Trauma Foundation, 2006, NEUROSURGERY, V58; Brain Trauma Foundation, 2007, GUID MAN SEV TRAUM B; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; Cooper Z, 2009, J TRAUMA, V66, P1327, DOI 10.1097/TA.0b013e31819ea047; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Diringer MN, 2001, CRIT CARE MED, V29, P1792, DOI 10.1097/00003246-200109000-00023; Esteban A, 2001, INTENS CARE MED, V27, P1744, DOI 10.1007/s00134-001-1111-7; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; Ho KM, 2004, ANAESTH INTENS CARE, V32, P781, DOI 10.1177/0310057X0403200609; Keenan SP, 1997, CRIT CARE MED, V25, P1324, DOI 10.1097/00003246-199708000-00019; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mayor SA, 1999, NEUROLOGY, V52, P1602, DOI 10.1212/WNL.52.8.1602; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; National Scientific Advisory Committee, 2004, LIST DIR INJ FIN REP; OCALLAHAN JG, 1995, CRIT CARE MED, V23, P1567, DOI 10.1097/00003246-199509000-00018; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Ratnapalan M, 2010, BMC MED ETHICS, V11, DOI 10.1186/1472-6939-11-1; Rocker G, 2004, CRIT CARE MED, V32, P1149, DOI 10.1097/01.CCM.0000126402.51524.52; Rocker GM, 2006, CAN J ANAESTH, V53, P814, DOI 10.1007/BF03022799; Spronk PE, 2009, ANESTH ANALG, V109, P841, DOI 10.1213/ane.0b013e3181acc64a; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Varelas PN, 2008, SEMIN NEUROL, V28, P726, DOI 10.1055/s-0028-1105969; Wilkinson D, 2009, THEOR MED BIOETH, V30, P401, DOI 10.1007/s11017-009-9120-6; Zahuranec DB, 2010, NEUROLOGY, V75, P626, DOI 10.1212/WNL.0b013e3181ed9cc9	32	28	28	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2013	18	1					154	160		10.1007/s12028-012-9787-9			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	086SY	WOS:000314708500024	23099846				2021-06-18	
J	Ohta, M; Higashi, Y; Yawata, T; Kitahara, M; Nobumoto, A; Ishida, E; Tsuda, M; Fujimoto, Y; Shimizu, K				Ohta, Manabu; Higashi, Youichirou; Yawata, Toshio; Kitahara, Masahiro; Nobumoto, Atsuya; Ishida, Eri; Tsuda, Masayuki; Fujimoto, Yasunori; Shimizu, Keiji			Attenuation of axonal injury and oxidative stress by edaravone protects against cognitive impairments after traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic axonal injury; Edaravone; Free radical; Memory deficits; Amyloid precursor protein	FREE-RADICAL SCAVENGER; MEDIATED CYTOSKELETAL DEGRADATION; OXIDE SYNTHASE ISOFORMS; NITRIC-OXIDE; HEAD-INJURY; SUPEROXIDE-DISMUTASE; RAT HIPPOCAMPUS; TRANSIENT; DAMAGE; DISABILITY	Traumatic axonal injury (TAI), a feature of traumatic brain injury (TBI), progressively evolves over hours through impaired axonal transport and is thought to be a major contributor to cognitive dysfunction. In spite of various studies suggesting that pharmacologic or physiologic interventions might reduce TAI, clinical neuroprotective treatments are still unavailable. Edaravone, a free radical scavenger, has been shown to exert neuroprotective effects in animal models of several brain disorders. In this study, to evaluate whether edaravone suppresses TAI following TBI, mice were subjected to weight drop injury and had either edaravone (3.0 mg/kg) or saline administered intravenously immediately after impact. Axonal injury and oxidative stress were assessed using immunohistochemistry with antibodies against amyloid precursor protein, a marker of impaired axonal transport, and with 8-hydroxy-2'-deoxyguanosine, a marker of oxidative DNA damage. Edaravone significantly suppressed axonal injury and oxidative stress in the cortex, corpus callosum, and hippocampus 24 h after injury. The neuroprotective effects of edaravone were observed in mice receiving 1.0, 3.0, or 10 mg/kg of edaravone immediately after impact, but not after 0.3 mg/kg of edaravone. With treatment 1 h after impact, axonal injury was also significantly suppressed and this therapeutic effect persisted up to 6 h after impact. Furthermore, behavioral tests performed 9 days after injury showed memory deficits in saline-treated traumatized mice, which were not evident in the edaravone-treated group. These results suggest that edaravone protects against memory deficits following TBI and that this protection is mediated by suppression of TAI and oxidative stress. (c) 2012 Elsevier B.V. All rights reserved.	[Ohta, Manabu; Higashi, Youichirou; Yawata, Toshio; Kitahara, Masahiro; Ishida, Eri; Fujimoto, Yasunori; Shimizu, Keiji] Kochi Med Sch, Dept Neurosurg, Nankoku, Kochi 7838505, Japan; [Nobumoto, Atsuya; Tsuda, Masayuki] Kochi Med Sch, Inst Lab Anim Res, Nankoku, Kochi 7838505, Japan	Shimizu, K (corresponding author), Kochi Med Sch, Dept Neurosurg, Okoh Cho, Nankoku, Kochi 7838505, Japan.	b08d6b05@s.kochi-u.ac.jp; higasi@kochi-u.ac.jp; yawatat@kochi-u.ac.jp; mstsuda@kochi-u.ac.jp; yfujimoto@kochi-u.ac.jp; kshimizu@kochi-u.ac.jp			Japanese Ministry of Education, Culture, Sports, Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [24592133, 22791349]; General Insurance Association of Japan; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24592133] Funding Source: KAKEN	This work was supported in part by Grants-in-Aid for Scientific Research ((C), No. 24592133) and for Young Scientists ((B), No. 22791349) from the Japanese Ministry of Education, Culture, Sports, Science and Technology, and the General Insurance Association of Japan. We thank Mitsubishi Tanabe Pharma for providing the edaravone used in this study.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Balaratnasingam C, 2009, BRAIN RES, V1263, P155, DOI 10.1016/j.brainres.2009.01.031; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Christensen DZ, 2008, ACTA NEUROPATHOL, V116, P647, DOI 10.1007/s00401-008-0451-6; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Gahm C, 2000, NEUROSURGERY, V46, P169; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Johnson VE, EXP NEUROL IN PRESS; Kamida T, 2009, SEIZURE-EUR J EPILEP, V18, P71, DOI 10.1016/j.seizure.2008.06.012; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Lapchak PA, 2010, EXPERT OPIN PHARMACO, V11, P1753, DOI 10.1517/14656566.2010.493558; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Li SH, 2006, J NEUROSCI RES, V83, P292, DOI 10.1002/jnr.20720; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Mintz Y, 2002, ISRAEL MED ASSOC J, V4, P554; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Naritomi Hiroaki, 2010, Drugs R D, V10, P155, DOI 10.2165/11586550-000000000-00000; Otani H, 2005, EUR J PHARMACOL, V512, P129, DOI 10.1016/j.ejphar.2005.01.050; PARKIN AJ, 1984, CORTEX, V20, P479, DOI 10.1016/S0010-9452(84)80053-2; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Sharma R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013463; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Tang YP, 1997, BRIT J PHARMACOL, V122, P257, DOI 10.1038/sj.bjp.0701385; Vaziri ND, 2001, J PHARMACOL EXP THER, V298, P679; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Wu ZF, 2010, J CLIN BIOCHEM NUTR, V46, P187, DOI 10.3164/jcbn.09-104-2; YERMILOV V, 1995, FEBS LETT, V376, P207, DOI 10.1016/0014-5793(95)01281-6; Yoshida H, 2006, CNS DRUG REV, V12, P9, DOI 10.1111/j.1527-3458.2006.00009.x; Zakaria N, 2012, BRAIN RES, V1467, P81, DOI 10.1016/j.brainres.2012.05.046	45	28	29	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 15	2013	1490						184	192		10.1016/j.brainres.2012.09.011			9	Neurosciences	Neurosciences & Neurology	079BC	WOS:000314144200019	22982593				2021-06-18	
J	Levine, B; Kovacevic, N; Nica, EI; Schwartz, ML; Gao, F; Black, SE				Levine, Brian; Kovacevic, Natasa; Nica, Elena Irina; Schwartz, Michael L.; Gao, Fuqiang; Black, Sandra E.			Quantified MRI and cognition in TBI with diffuse and focal damage	NEUROIMAGE-CLINICAL			English	Article						Structural MRI; Neuropsychological assessment; Executive Function; Attention; Memory; Traumatic Brain Injury	TRAUMATIC BRAIN-INJURY; AUTOMATED IMAGE REGISTRATION; WHITE-MATTER; AUTOBIOGRAPHICAL MEMORY; CORPUS-CALLOSUM; FRONTAL-LOBE; ATROPHY; TENSOR; NEUROPATHOLOGY; PERFORMANCE	In patients with chronic-phase traumatic brain injury (TBI), structural MRI is readily attainable and provides rich anatomical information, yet the relationship between whole-brain structural MRI measures and neurocognitive outcome is relatively unexplored and can be complicated by the presence of combined focal and diffuse injury. In this study, sixty-three patients spanning the full range of TBI severity received high-resolution structural MRI concurrent with neuropsychological testing. Multivariate statistical analysis assessed covariance patterns between volumes of grey matter, white matter, and sulcal/subdural and ventricular CSF across 38 brain regions and neuropsychological test performance. Patients with diffuse and diffuse + focal injury were analyzed both separately and together. Tests of speeded attention, working memory, and verbal learning and memory robustly covaried with a distributed pattern of volume loss over temporal, ventromedial prefrontal, right parietal regions, and cingulate regions. This pattern was modulated by the presence of large focal lesions, but held even when analyses were restricted to those with diffuse injury. Effects were most consistently observed within grey matter. Relative to regional brain volumetric data, clinically defined injury severity (depth of comaat time of injury) showed only weak relation to neuropsychological outcome. The results showed that neuropsychological test performance in patients with TBI is related to a distributed pattern of volume loss in regions mediating mnemonic and attentional processing. This relationship holds for patients with and without focal lesions, indicating that diffuse injury alone is sufficient to cause significant neuropsychological disability in relation to regional volume loss. Quantified structural brain imaging data provides a highly sensitive index of brain integrity that is related to cognitive functioning in chronic phase TBI. (C) 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.	[Levine, Brian; Kovacevic, Natasa; Black, Sandra E.] Rotman Res Inst, Toronto, ON, Canada; [Levine, Brian] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Levine, Brian; Black, Sandra E.] Univ Toronto, Dept Med Neurol, Toronto, ON M5S 1A1, Canada; [Nica, Elena Irina] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada; [Schwartz, Michael L.; Black, Sandra E.] Univ Toronto, Dept Surg Neurosurg, Toronto, ON M5S 1A1, Canada; [Black, Sandra E.] Sunnybrook Hlth Sci Ctr, Dept Med Neurol, Toronto, ON M4N 3M5, Canada; [Gao, Fuqiang; Black, Sandra E.] Sunnybrook Hlth Sci Ctr, LC Campbell Cognit Neurol Res Unit, Toronto, ON M4N 3M5, Canada; [Gao, Fuqiang; Black, Sandra E.] Sunnybrook Hlth Sci Ctr, Heart & Stroke Fdn, Ctr Stroke Recovery, Toronto, ON M4N 3M5, Canada	Levine, B (corresponding author), Rotman Res Inst Baycrest, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	blevine@research.baycrest.org	Levine, Brian/G-4328-2010; Levine, Brian/O-2725-2019	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Black, Sandra/0000-0001-7093-8289	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MT-14744, MOP-37535, MOP-108540]; NIH-NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD42385-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042385] Funding Source: NIH RePORTER	Ann Campbell, Catherine Hynes, Sabitha Kanagasabai, Colleen O'Toole, Marina Mandic, Karen Philp, Adriana Restagno, Joel Ramirez, Jovanka Skocic, and Gary Turner are thanked for technical assistance. We gratefully thank the TBI patients and non-injured volunteers for participating in this research. This research was supported by grants from the Canadian Institutes of Health Research (Grant #s MT-14744, MOP-37535, and MOP-108540), and the NIH-NICHD (Grant # HD42385-01) to B.L. B.L. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data and analysis.	Army Individual Test Battery, 1944, MAN DIR SCOR; ARNDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bookstein FL, 2001, NEUROIMAGE, V14, P1454, DOI 10.1006/nimg.2001.0770; Christodoulou C, 2003, NEUROLOGY, V60, P1793, DOI 10.1212/01.WNL.0000072264.75989.B8; Collins DL, 1997, INT J PATTERN RECOGN, V11, P1271, DOI 10.1142/S0218001497000597; Courville C. B., 1937, PATHOLOGY CENTRAL 4; Dade LA, 2004, NEUROIMAGE, V22, P1492, DOI 10.1016/j.neuroimage.2004.03.023; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; Edgington E. S., 1980, RANDOMIZATION TESTS; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gale S.D., 1994, NEUROPSY NEUROPSY BE, V7, P60; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Green P., 1996, THE WORD MEMORY TEST; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kovacevic N, 2002, NEUROIMAGE, V17, P1087, DOI 10.1006/nimg.2002.1221; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; McIntosh AR, 1996, NEUROIMAGE, V3, P143, DOI 10.1006/nimg.1996.0016; McIntosh AR, 2004, NEUROIMAGE, V23, pS250, DOI 10.1016/j.neuroimage.2004.07.020; McKinnon MC, 2008, J COGNITIVE NEUROSCI, V20, P1839, DOI 10.1162/jocn.2008.20126; Morris R, 1999, EUR J NEUROSCI, V11, P2506, DOI 10.1046/j.1460-9568.1999.00672.x; Parmenter BA, 2007, MULT SCLER J, V13, P52, DOI 10.1177/1352458506070750; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raja Beharelle A, 2012, NEUROIMAGE, V60, P1528, DOI 10.1016/j.neuroimage.2012.01.037; Rosenbaum RS, 2008, J COGNITIVE NEUROSCI, V20, P1490, DOI 10.1162/jocn.2008.20105; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith A., 1978, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Turken AU, 2008, NEUROIMAGE, V42, P1032, DOI 10.1016/j.neuroimage.2008.03.057; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; WASSERMAN S, 1989, PSYCHOPHYSIOLOGY, V26, P208, DOI 10.1111/j.1469-8986.1989.tb03159.x; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zachary R., 1986, SHIPLEY I LIVING SCA	60	28	28	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2013	2						534	541		10.1016/j.nicl.2013.03.015			8	Neuroimaging	Neurosciences & Neurology	V37LH	WOS:000209276800058	24049744	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Olah, G; Heredi, J; Menyhart, A; Czinege, Z; Nagy, D; Fuzik, J; Kocsis, K; Knapp, L; Krucso, E; Gellert, L; Kis, Z; Farkas, T; Fulop, F; Pardutz, A; Tajti, J; Vecsei, L; Toldi, J				Olah, Gaspar; Heredi, Judit; Menyhart, Akos; Czinege, Zsolt; Nagy, David; Fuzik, Janos; Kocsis, Kitti; Knapp, Levente; Krucso, Erika; Gellert, Levente; Kis, Zsolt; Farkas, Tamas; Fueloep, Ferenc; Pardutz, Arpad; Tajti, Janos; Vecsei, Laszlo; Toldi, Jozsef			Unexpected effects of peripherally administered kynurenic acid on cortical spreading depression and related blood-brain barrier permeability	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						blood-brain barrier; cortical spreading depression; glutamate receptors; kynurenic acid; kynurenines; NMDAR	STIMULATION-INDUCED INCREASE; ANOXIC DEPOLARIZATION; RAT NEOCORTEX; NITRIC-OXIDE; MIGRAINE; GLUTAMATE; EXPRESSION; RESPONSES; NUCLEUS; STROKE	Cortical spreading depression (CSD) involves a slowly-propagating depolarization wave in the cortex, which can appear in numerous pathophysiological conditions, such as migraine with aura, stroke, and traumatic brain injury. Neurons and glial cells are also depolarized transiently during the phenomena. CSD is followed by a massive increase in glutamate release and by changes in the brain microcirculation. The aim of this study was to investigate the effects of two N-methyl-D-aspartate receptor antagonists, endogenous kynurenic acid (KYNA) and dizocilpine, on CSD and the related blood-brain barrier (BBB) permeability in rats. In intact animals, KYNA hardly crosses the BBB but has some positive features as compared with its precursor L-Kynurenine, which is frequently used in animal studies (KYNA cannot be metabolized to excitotoxic agents such as 3-hydroxy-L-kynurenine and quinolinic acid). We therefore investigated the possible effects of peripherally administered KYNA. Repetitive CSD waves were elicited by the application of 1 M KCl solution to the cortex. Direct current-electrocorticograms were measured for 1 hour. Four parameters of the waves were compared. Evans blue dye and fluorescent microscopy were used to study the possible changes in the permeability of the BBB. The results demonstrated that N-methyl-D-aspartate receptor antagonists can reduce the number of CSD waves and decrease the permeability of the BBB during CSD. These results suggest that KYNA itself or its derivatives may offer a new approach in the therapy of migraines.	[Olah, Gaspar; Heredi, Judit; Menyhart, Akos; Nagy, David; Fuzik, Janos; Kocsis, Kitti; Knapp, Levente; Krucso, Erika; Gellert, Levente; Kis, Zsolt; Farkas, Tamas; Toldi, Jozsef] Univ Szeged, Dept Physiol Anat & Neurosci, H-6726 Szeged, Hungary; [Czinege, Zsolt] Univ Szeged, Dept Software Engn, H-6726 Szeged, Hungary; [Fueloep, Ferenc] Univ Szeged, Inst Pharmaceut Chem, H-6726 Szeged, Hungary; [Fueloep, Ferenc] Univ Szeged, MTA SZTE Res Grp Stereochem, H-6726 Szeged, Hungary; [Pardutz, Arpad; Tajti, Janos; Vecsei, Laszlo] Univ Szeged, Dept Neurol, H-6726 Szeged, Hungary; [Pardutz, Arpad; Tajti, Janos; Vecsei, Laszlo] Univ Szeged, MTA SZTE Neurosci Res Grp, H-6726 Szeged, Hungary	Toldi, J (corresponding author), Univ Szeged, Dept Physiol Anat & Neurosci, Kozep Fasor 52, H-6726 Szeged, Hungary.	toldi@bio.u-szeged.hu	Heredi, Judit/M-5044-2018; Vecsei, Laszlo/B-2066-2010; Toldi, Jozsef/M-4858-2018; Kis, Zsolt/A-4583-2009; Farkas, Tamas/B-7193-2008	Heredi, Judit/0000-0002-8248-3485; Vecsei, Laszlo/0000-0001-8037-3672; Toldi, Jozsef/0000-0001-7355-0503; Kis, Zsolt/0000-0002-6896-5883; Menyhart, Akos/0000-0002-1355-3208; Gellert, Levente/0000-0003-2254-2970	TAMOP [4.2.2-A-11/KONV-2012-0052, 4.2.4. A/2-11-1-2012-0001]; OTKAOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [K105077]	This work was supported by TAMOP 4.2.2-A-11/KONV-2012-0052, OTKA K105077 and TAMOP 4.2.4. A/2-11-1-2012-0001 "National Excellence Program - Elaborating and operating an inland student and researcher personal support system".	Andras IE, 2007, J CEREBR BLOOD F MET, V27, P1431, DOI 10.1038/sj.jcbfm.9600445; Andreou AP, 2009, EXPERT OPIN INV DRUG, V18, P789, DOI [10.1517/13543780902913792 , 10.1517/13543780902913792]; Brennan KC, 2007, J NEUROPHYSIOL, V97, P4143, DOI 10.1152/jn.00028.2007; Chauvel V, 2012, EXP NEUROL, V236, P207, DOI 10.1016/j.expneurol.2012.05.002; Chen Y, 2000, ACT NEUR S, V76, P131; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; FABRICIUS M, 1993, BRAIN RES, V612, P61, DOI 10.1016/0006-8993(93)91644-8; Fejes A, 2011, CURR NEUROPHARMACOL, V9, P376, DOI 10.2174/157015911795596621; FUKUI S, 1991, J NEUROCHEM, V56, P2007, DOI 10.1111/j.1471-4159.1991.tb03460.x; GARDNERMEDWIN AR, 1981, J EXP BIOL, V95, P111; Gniel HM, 2010, J NEUROPHYSIOL, V104, P3203, DOI 10.1152/jn.00922.2009; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; HEYES MP, 1990, J CHROMATOGR-BIOMED, V530, P108, DOI 10.1016/S0378-4347(00)82308-7; Hilmas C, 2001, J NEUROSCI, V21, P7463; Jander S, 2001, J CEREBR BLOOD F MET, V21, P218, DOI 10.1097/00004647-200103000-00005; Knyihar-Csillik E, 2007, J NEURAL TRANSM, V114, P417, DOI 10.1007/s00702-006-0545-z; Knyihar-Csillik E, 2007, NEUROSCI LETT, V418, P122, DOI 10.1016/j.neulet.2007.03.007; Konradsson-Geuken A, NEUROSCIENCE, V15, P1848; Koroleva VI, 2000, ZH VYSSH NERV DEYAT+, V50, P612; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Longoni M, 2006, NEUROL SCI, V27, pS107, DOI 10.1007/s10072-006-0582-2; Ramadan NM, 2003, CNS SPECTRUMS, V8, P446, DOI 10.1017/S1092852900018757; ROUSSEL S, 1990, BRAIN RES, V518, P353, DOI 10.1016/0006-8993(90)90997-P; Santos E, 2012, CEPHALALGIA, V32, P433, DOI 10.1177/0333102412441414; Scharfman HE, 1998, NEUROSCIENCE, V86, P751, DOI 10.1016/S0306-4522(98)00073-6; Schwarcz R, 2002, J PHARMACOL EXP THER, V303, P1, DOI 10.1124/jpet.102.034439; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Stone TW, 2007, METAB BRAIN DIS, V22, P337, DOI 10.1007/s11011-007-9064-3; Tajti J, 2012, J NEURAL TRANSM, V119, P557, DOI 10.1007/s00702-012-0788-9; Thiel VE, 2001, ANTIOXID REDOX SIGN, V3, P273, DOI 10.1089/152308601300185223; TURSKI WA, 1988, EXP BRAIN RES, V71, P563, DOI 10.1007/BF00248748; Vamos E, 2009, NEUROPHARMACOLOGY, V57, P425, DOI 10.1016/j.neuropharm.2009.06.033; Zhang XC, 2010, J NEUROSCI, V30, P8807, DOI 10.1523/JNEUROSCI.0511-10.2010	34	28	28	0	7	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2013	7						981	987		10.2147/DDDT.S44496			7	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	216LX	WOS:000324286100001	24068867	DOAJ Gold, Green Published			2021-06-18	
J	Sultan, S; Gebara, E; Toni, N				Sultan, Sebastien; Gebara, Elias; Toni, Nicolas			Doxycycline increases neurogenesis and reduces microglia in the adult hippocampus	FRONTIERS IN NEUROSCIENCE			English	Article						dentate gyrus; hippocampus; adult neurogenesis; doxycycline; tetracycline; gene expression regulation	NEURAL STEM-CELLS; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; GFP TRANSGENIC MICE; DENTATE GYRUS; HYPOXIA-ISCHEMIA; MATRIX METALLOPROTEINASES; SYNAPTIC PLASTICITY; PARKINSONS-DISEASE	Adult hippocampal neurogenesis results in the continuous formation of new neurons and is a process of brain plasticity involved in learning and memory. Although inducible-reversible transgenic mouse models are increasingly being used to investigate adult neurogenesis, transgene control requires the administration of an activator, doxycycline (Dox), with unknown effects on adult neurogenesis. Here, we tested the effect of Dox administration on adult neurogenesis in vivo. We found that 4 weeks of Dox treatment at doses commonly used for gene expression control, resulted in increased neurogenesis. Furthermore, the dendrites of new neurons displayed increased spine density. Concomitantly, lba1-expressing microglia was reduced by Dox treatment. These results indicate that Dox treatment may interfere with parameters of relevance for the use of inducible transgenic mice in studies of adult neurogenesis or brain inflammation.	[Sultan, Sebastien; Gebara, Elias; Toni, Nicolas] Univ Lausanne, Dept Fundamental Neurosci, CH-1005 Lausanne, Switzerland	Toni, N (corresponding author), Univ Lausanne, Dept Fundamental Neurosci, 9 Rue Bugnon, CH-1005 Lausanne, Switzerland.	nicolas.toni@unil.ch	Toni, Nicolas/M-2057-2014	Toni, Nicolas/0000-0001-5585-268X; Gebara, Elias/0000-0003-4389-6604	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission	The authors wish to thank Romain Gosselin (Department of Fundamental Neurosciences, University of Lausanne, Switzerland) for critical insight on in vitro experiments and Coralie Rummel and Florian Udry for technical assistance. Images acquisition was performed at the Cellular Imaging Facility of the university of Lausanne (Lausanne, Switzerland). This work was supported by the Swiss National Science Foundation.	ALTMAN J, 1969, J COMP NEUROL, V136, P269, DOI 10.1002/cne.901360303; Barkho BZ, 2008, STEM CELLS, V26, P3139, DOI 10.1634/stemcells.2008-0519; Beckervordersandforth R, 2010, CELL STEM CELL, V7, P744, DOI 10.1016/j.stem.2010.11.017; Bozdagi O, 2007, J NEUROPHYSIOL, V98, P334, DOI 10.1152/jn.00202.2007; Buller KM, 2009, J NEUROSCI RES, V87, P599, DOI 10.1002/jnr.21890; Burggraf D, 2007, NEUROBIOL DIS, V25, P506, DOI 10.1016/j.nbd.2006.10.013; Cho Y, 2009, NEUROTOX RES, V16, P361, DOI 10.1007/s12640-009-9078-1; Chow JDY, 2012, TRANSGENIC RES, V21, P415, DOI 10.1007/s11248-011-9525-7; Clark WM, 1997, J MOL NEUROSCI, V9, P103, DOI 10.1007/BF02736854; Dupret D, 2007, PLOS BIOL, V5, P1683, DOI 10.1371/journal.pbio.0050214; Ehninger D, 2008, CELL TISSUE RES, V331, P243, DOI 10.1007/s00441-007-0478-3; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Encinas JM, 2011, CELL STEM CELL, V8, P566, DOI 10.1016/j.stem.2011.03.010; Ethell IM, 2007, J NEUROSCI RES, V85, P2813, DOI 10.1002/jnr.21273; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Ge SY, 2008, J PHYSIOL-LONDON, V586, P3759, DOI 10.1113/jphysiol.2008.155655; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gu Y, 2012, NAT NEUROSCI, V15, P1700, DOI 10.1038/nn.3260; Hodge RD, 2008, J NEUROSCI, V28, P3707, DOI 10.1523/JNEUROSCI.4280-07.2008; Huntley GW, 2012, NAT REV NEUROSCI, V13, P743, DOI 10.1038/nrn3320; Huttmann K, 2003, EUR J NEUROSCI, V18, P2769, DOI 10.1111/j.1460-9568.2003.03002.x; Jantzie LL, 2010, J PSYCHIATR NEUROSCI, V35, P20, DOI 10.1503/jpn.090061; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kohman RA, 2013, BEHAV BRAIN RES, V242, P17, DOI 10.1016/j.bbr.2012.12.032; Kohman RA, 2012, BRAIN BEHAV IMMUN, V26, P803, DOI 10.1016/j.bbi.2011.10.006; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Krzisch M, 2013, ANESTHESIOLOGY, V118, P602, DOI 10.1097/ALN.0b013e3182815948; Laplagne DA, 2006, PLOS BIOL, V4, P2349, DOI 10.1371/journal.pbio.0040409; Lee H, 2009, NEUROBIOL DIS, V34, P189, DOI 10.1016/j.nbd.2008.12.012; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Lu L, 2010, CNS NEUROL DISORD-DR, V9, P232, DOI 10.2174/187152710791012035; Ma DK, 2009, CELL RES, V19, P672, DOI 10.1038/cr.2009.56; Mandyam CD, 2007, NEUROSCIENCE, V146, P108, DOI 10.1016/j.neuroscience.2006.12.064; Massa F, 2011, P NATL ACAD SCI USA, V108, P6644, DOI 10.1073/pnas.1016928108; McIver SR, 2012, EXP BIOL MED, V237, P1129, DOI 10.1258/ebm.2012.012029; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Nolte C, 2001, GLIA, V33, P72; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Peixoto RT, 2012, NEURON, V76, P396, DOI 10.1016/j.neuron.2012.07.006; Richter C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062621; Romero-Grimaldi C, 2011, STEM CELLS, V29, P1628, DOI 10.1002/stem.710; Samuels BA, 2011, EUR J NEUROSCI, V33, P1152, DOI 10.1111/j.1460-9568.2011.07614.x; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Saxe MD, 2007, P NATL ACAD SCI USA, V104, P4642, DOI 10.1073/pnas.0611718104; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Shors TJ, 2012, BEHAV BRAIN RES, V227, P450, DOI 10.1016/j.bbr.2011.04.023; Stegmeier F, 2005, P NATL ACAD SCI USA, V102, P13212, DOI 10.1073/pnas.0506306102; Svedin P, 2007, J NEUROSCI, V27, P1511, DOI 10.1523/JNEUROSCI.4391-06.2007; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Thomas M, 2003, CLIN NEUROPHARMACOL, V26, P18, DOI 10.1097/00002826-200301000-00005; Thuret S, 2009, HIPPOCAMPUS, V19, P658, DOI 10.1002/hipo.20550; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; Toni N, 2007, NAT NEUROSCI, V10, P727, DOI 10.1038/nn1908; Toni N, 2011, EUR J NEUROSCI, V33, P1062, DOI 10.1111/j.1460-9568.2011.07604.x; Tronel S, 2012, HIPPOCAMPUS, V22, P292, DOI 10.1002/hipo.20895; Trouche S, 2009, P NATL ACAD SCI USA, V106, P5919, DOI 10.1073/pnas.0811054106; van Praag H, 1999, NAT NEUROSCI, V2, P266; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vukovic J, 2012, J NEUROSCI, V32, P6435, DOI 10.1523/JNEUROSCI.5925-11.2012; Wang XB, 2008, P NATL ACAD SCI USA, V105, P19520, DOI 10.1073/pnas.0807248105; Wideroe M, 2012, EUR J NEUROSCI, V36, P2006, DOI 10.1111/j.1460-9568.2012.08114.x; Yamaguchi M, 2000, NEUROREPORT, V11, P1991, DOI 10.1097/00001756-200006260-00037; Yang CP, 2011, DEVELOPMENT, V138, P4351, DOI 10.1242/dev.065540; Yao J, 2012, PROTEIN CELL, V3, P251, DOI 10.1007/s13238-012-2033-6; Yoon SY, 2012, NEUROSCIENCE, V221, P214, DOI 10.1016/j.neuroscience.2012.06.024; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006; Zhou X, 2006, GENE THER, V13, P1382, DOI 10.1038/sj.gt.3302780	74	28	29	0	0	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.		2013	7								131	10.3389/fnins.2013.00131			10	Neurosciences	Neurosciences & Neurology	AW9HF	WOS:000346567300130	23898238	DOAJ Gold, Green Published			2021-06-18	
J	Schmidt, W; Schafer, F; Striggow, V; Frohlich, K; Striggow, F				Schmidt, W.; Schaefer, F.; Striggow, V.; Froehlich, K.; Striggow, F.			CANNABINOID RECEPTOR SUBTYPES 1 AND 2 MEDIATE LONG-LASTING NEUROPROTECTION AND IMPROVE MOTOR BEHAVIOR DEFICITS AFTER TRANSIENT FOCAL CEREBRAL ISCHEMIA	NEUROSCIENCE			English	Article						cerebral ischemia; endocannabinoid system; CB1 receptor; CB2 receptor; neuroprotection	ACID AMIDE HYDROLASE; TRAUMATIC BRAIN-INJURY; CB2 RECEPTOR; ENDOCANNABINOID SYSTEM; ALZHEIMERS-DISEASE; DIRECT SUPPRESSION; CEREBELLAR CORTEX; CELL ACTIVATION; BAY 38-7271; IN-VITRO	The endocannabinoid system is crucially involved in the regulation of brain activity and inflammation. We have investigated the localization of cannabinoid CB1 and CB2 receptors in adult rat brains before and after focal cerebral ischemia due to endothelin-induced transient occlusion of the middle cerebral artery (eMCAO). Using immunohistochernistry, both receptor subtypes were identified in cortical neurons. After eMCAO, neuronal cell death was accompanied by reduced neuronal CB1 and CB2 receptor-linked immunofluorescence. In parallel, CBI receptor was found in activated microglia/macrophages 3 days post eMCAO and in astroglia cells at days 3 and 7. CB2 receptor labeling was identified in activated microglia/macrophages or astroglia 3 and 7 days post ischemia, respectively. In addition, immune competent CD45-positive cells were characterized by pronounced CB2 receptor staining 3 and 7 days post eMCAO. KN38-72717, a potent and selective CBI and CB2 receptor agonist, revealed a significant, dose-dependent and long-lasting reduction of cortical lesion sizes due to eMCAO, when applied consecutively before, during and after eMCAO. In addition, severe motor deficits of animals suffering from eMCAO were significantly improved by KN38-7271. KN38-7271 remained effective, even if its application was delayed up to 6 h post eMCAO. Finally, we show that the endocannabinoid system assembles a comprehensive machinery to defend the brain against the devastating consequences of cerebral ischemia. In summary, this study underlines the therapeutic potential of CBI and/or CB2 receptor agonists against neurodegenerative diseases or injuries involving acute or chronic imbalances of cerebral blood flow and energy consumption. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Schmidt, W.; Striggow, F.] German Ctr Neurodegenerat Dis DZNE, AG Neurodegenerat & Intervent Strategies, D-39120 Magdeburg, Germany; [Schmidt, W.; Schaefer, F.; Striggow, V.; Froehlich, K.; Striggow, F.] KeyNeurotek Pharmaceut AG, D-39120 Magdeburg, Germany	Striggow, F (corresponding author), German Ctr Neurodegenerat Dis DZNE, AG Neurodegenerat & Intervent Strategies, Leipziger Str 44, D-39120 Magdeburg, Germany.	frank.striggow@dzne.de			Federal Ministry for Education and Research (BMBF)Federal Ministry of Education & Research (BMBF) [03IS2211I]	The authors would like to thank J. Hubner, C. Schinke and M. Hajri for their excellent technical assistance. This work was supported by the Federal Ministry for Education and Research (BMBF), Grant number 03IS2211I.	Albayram O, 2011, P NATL ACAD SCI USA, V108, P11256, DOI 10.1073/pnas.1016442108; Ashton JC, 2006, NEUROSCI LETT, V396, P113, DOI 10.1016/j.neulet.2005.11.038; Ashton JC, 2007, NEUROSCI LETT, V412, P114, DOI 10.1016/j.neulet.2006.10.053; Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x; Beltramo M, 2006, EUR J NEUROSCI, V23, P1530, DOI 10.1111/j.1460-9568.2006.04684.x; Benito C, 2005, J NEUROSCI, V25, P2530, DOI 10.1523/JNEUROSCI.3923-04.2005; Benito C, 2003, J NEUROSCI, V23, P11136; Brusco A, 2008, SYNAPSE, V62, P944, DOI 10.1002/syn.20569; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584; Campbell VA, 2007, BRIT J PHARMACOL, V152, P655, DOI 10.1038/sj.bjp.0707446; Carayon P, 1998, BLOOD, V92, P3605, DOI 10.1182/blood.V92.10.3605.422k05_3605_3615; Carlisle SJ, 2002, INT IMMUNOPHARMACOL, V2, P69, DOI 10.1016/S1567-5769(01)00147-3; Chavez AE, 2010, NAT NEUROSCI, V13, P1511, DOI 10.1038/nn.2684; Daniel H, 2001, J PHYSIOL-LONDON, V537, P793; DePetrocellis L, 1997, BIOCHEM BIOPH RES CO, V231, P82, DOI 10.1006/bbrc.1997.6000; DEROCQ JM, 1995, FEBS LETT, V369, P177, DOI 10.1016/0014-5793(95)00746-V; Deutsch DG, 1997, BIOCHEM PHARMACOL, V53, P255, DOI 10.1016/S0006-2952(96)00830-1; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Di Marzo V, 2008, NAT REV DRUG DISCOV, V7, P438, DOI 10.1038/nrd2553; Di Marzo V, 2011, NAT NEUROSCI, V14, P9, DOI 10.1038/nn.2720; Dittel BN, 2008, BRIT J PHARMACOL, V153, P271, DOI 10.1038/sj.bjp.0707493; Edlich F, 2006, J BIOL CHEM, V281, P14961, DOI 10.1074/jbc.M600452200; Eljaschewitsch E, 2006, NEURON, V49, P67, DOI 10.1016/j.neuron.2005.11.027; Fernandez-Ruiz J, 2008, MOL CELL ENDOCRINOL, V286, pS91, DOI 10.1016/j.mce.2008.01.001; Firsching R, 2012, J NEUROL SURG PART A, V73, P204, DOI 10.1055/s-0032-1304815; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Gong JP, 2006, BRAIN RES, V1071, P10, DOI 10.1016/j.brainres.2005.11.035; Harvey BS, 2012, NEUROTOXICOLOGY, V33, P138, DOI 10.1016/j.neuro.2011.12.015; Hillard CJ, 1999, J PHARMACOL EXP THER, V289, P1427; Hohmann AG, 2005, NATURE, V435, P1108, DOI 10.1038/nature03658; Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968-0896(99)00219-9; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Katona I, 2008, NAT MED, V14, P923, DOI 10.1038/nm.f.1869; Kawamura Y, 2006, J NEUROSCI, V26, P2991, DOI 10.1523/JNEUROSCI.4872-05.2006; Klegeris A, 2003, BRIT J PHARMACOL, V139, P775, DOI 10.1038/sj.bjp.0705304; Landucci E, 2011, NEUROPHARMACOLOGY, V60, P674, DOI 10.1016/j.neuropharm.2010.11.021; Maresz K, 2007, NAT MED, V13, P492, DOI 10.1038/nm1561; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Mauler F, 2003, CNS DRUG REV, V9, P343; Mauler F, 2003, BRAIN RES, V989, P99, DOI 10.1016/S0006-8993(03)03376-6; Mauler F, 2002, J PHARMACOL EXP THER, V302, P359, DOI 10.1124/jpet.302.1.359; McCoy KL, 1999, J PHARMACOL EXP THER, V289, P1620; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2012, ANN REV PSYCHOL; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Miller AM, 2008, BRIT J PHARMACOL, V153, P299, DOI 10.1038/sj.bjp.0707523; Mor M, 2004, J MED CHEM, V47, P4998, DOI 10.1021/jm031140x; Murikinati S, 2010, FASEB J, V24, P788, DOI 10.1096/fj.09-141275; Nagayama T, 1999, J NEUROSCI, V19, P2987; Onaivi ES, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001640; Onaivi ES, 2008, ANN NY ACAD SCI, V1139, P434, DOI 10.1196/annals.1432.036; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Paxinos G, 2005, RAT BRAIN STEREOTOXI; Pietr M, 2009, FEBS LETT, V583, P2071, DOI 10.1016/j.febslet.2009.05.028; Price DA, 2009, EUR J NEUROSCI, V29, P2177, DOI 10.1111/j.1460-9568.2009.06764.x; Puente N, 2011, NAT NEUROSCI, V14, P1542, DOI 10.1038/nn.2974; Sanchez AJ, 2012, CLIN IMMUNOL, V142, P57, DOI 10.1016/j.clim.2011.02.010; Schatz AR, 1997, TOXICOL APPL PHARM, V142, P278, DOI 10.1006/taap.1996.8034; Schlicker E, 2001, TRENDS PHARMACOL SCI, V22, P565, DOI 10.1016/S0165-6147(00)01805-8; SHARKEY J, 1995, J NEUROSCI METH, V60, P125, DOI 10.1016/0165-0270(95)00003-D; Shen MX, 1998, MOL PHARMACOL, V54, P459; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Stella N, 2004, GLIA, V48, P267, DOI 10.1002/glia.20084; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Striggow F, 2002, NEW DRUGS, V1, P30; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; Szabo B, 2006, J PHYSIOL-LONDON, V577, P263, DOI 10.1113/jphysiol.2006.119362; Tarzia G, 2003, J MED CHEM, V46, P2352, DOI 10.1021/jm021119g; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Walter L, 2003, J NEUROSCI, V23, P1398; Wolf SA, 2008, CURR PHARM DESIGN, V14, P2266, DOI 10.2174/138161208785740090; Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1387, DOI 10.1038/sj.jcbfm.9600447; Zurolo E, 2010, NEUROSCIENCE, V170, P28, DOI 10.1016/j.neuroscience.2010.07.004	80	28	29	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	DEC 27	2012	227						313	326		10.1016/j.neuroscience.2012.09.080			14	Neurosciences	Neurosciences & Neurology	051GB	WOS:000312113100030	23069763				2021-06-18	
J	Jackman, RP; Utter, GH; Muench, MO; Heitman, JW; Munz, MM; Jackman, RW; Biswas, HH; Rivers, RM; Tobler, LH; Busch, MP; Norris, PJ				Jackman, Rachael P.; Utter, Garth H.; Muench, Marcus O.; Heitman, John W.; Munz, Matthew M.; Jackman, Robert W.; Biswas, Hope H.; Rivers, Ryan M.; Tobler, Leslie H.; Busch, Michael P.; Norris, Philip J.			Distinct roles of trauma and transfusion in induction of immune modulation after injury	TRANSFUSION			English	Article							MULTIPLE ORGAN FAILURE; TUMOR-NECROSIS-FACTOR; SOLUBLE ICAM-1 CORRELATE; BLOOD-TRANSFUSION; HEMORRHAGIC-SHOCK; TISSUE TRAUMA; MAJOR INJURY; BLUNT TRAUMA; BRAIN-INJURY; T-HELPER-2-TYPE LYMPHOKINES	BACKGROUND: Trauma and transfusion can both alter immunity, and while transfusions are common among traumatically injured patients, few studies have examined their combined effects on immunity. STUDY DESIGN AND METHODS: We tracked the plasma levels of 41 immunomodulatory proteins in 56 trauma patients from time of injury up to 1 year later. In addition, a murine model was developed to distinguish between the effects of transfusion and underlying injury and blood loss. RESULTS: Thirty-one of the proteins had a significant change over time after traumatic injury, with a mixed early response that was predominantly anti-inflammatory followed by a later increase in proteins involved in wound healing and homeostasis. Results from the murine model revealed similar cytokine responses to humans. In mice, trauma and hemorrhage caused early perturbations in a number of the pro- and anti-inflammatory mediators measured, and transfusion blunted early elevations in interleukin (IL)-6, IL-10, matrix metalloproteinase-9, and interferon-?. Transfusion caused or exacerbated changes in monocyte chemotactic protein-1, IL-1a, IL-5, IL-15, and soluble E-selectin. Finally, trauma and hemorrhage alone increased CXCL1 and IL-13. CONCLUSIONS: This work provides a detailed characterization of the major shift in the immunologic environment in response to trauma and transfusion and clarifies which immune mediators are affected by trauma and hemorrhage and which by transfusion.	[Jackman, Rachael P.] Blood Syst Res Inst, San Francisco, CA 94118 USA; Univ Calif Davis, Dept Surg, Davis, CA 95616 USA; Univ Calif Davis, Dept Polit Sci, Davis, CA 95616 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA	Jackman, RP (corresponding author), Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.	rjackman@bloodsystems.org	Muench, Marcus O./C-5025-2009; Jackman, Rachael P/AAH-8398-2020	Muench, Marcus O./0000-0001-8946-6605; Jackman, Rachael P/0000-0001-8591-7819; Utter, Garth/0000-0001-7747-3429	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 HL-083388-01A1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL083388] Funding Source: NIH RePORTER	This work was supported by NIH RO1 HL-083388-01A1.	ABRAHAM E, 1989, J IMMUNOL, V142, P899; ABRAHAM E, 1986, CRIT CARE MED, V14, P81, DOI 10.1097/00003246-198602000-00001; Asadullah K, 1999, ARCH DERMATOL, V135, P187, DOI 10.1001/archderm.135.2.187; Baker CC, 1998, J TRAUMA, V44, P1045; Biffl WL, 1996, ANN SURG, V224, P647, DOI 10.1097/00000658-199611000-00009; BJORNSON AB, 1978, ANN SURG, V188, P102, DOI 10.1097/00000658-197807000-00017; BURROWS L, 1982, LANCET, V2, P662; Caron A, 2005, EXP CELL RES, V310, P105, DOI 10.1016/j.yexcr.2005.07.004; Choudhry MA, 2007, INJURY, V38, P1382, DOI 10.1016/j.injury.2007.09.027; Como JJ, 2004, TRANSFUSION, V44, P809, DOI 10.1111/j.1537-2995.2004.03409.x; CONE JB, 1994, J TRAUMA, V37, P109; De AK, 2000, CLIN IMMUNOL, V96, P52, DOI 10.1006/clim.2000.4879; de Vries DK, 2009, AM J TRANSPLANT, V9, P1574, DOI 10.1111/j.1600-6143.2009.02675.x; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; DIPIRO JT, 1995, ARCH SURG-CHICAGO, V130, P1159; DIPIRO JT, 1992, ANN SURG, V215, P460, DOI 10.1097/00000658-199205000-00008; DiPiro JT, 1995, ARCH SURG-CHICAGO, V130, P1162; ENDO S, 1994, CRIT CARE MED, V22, P949, DOI 10.1097/00003246-199406000-00012; FAIST E, 1993, J TRAUMA, V34, P846, DOI 10.1097/00005373-199306000-00016; FAIST E, 1986, ARCH SURG-CHICAGO, V121, P1000; Ferguson KL, 1997, ACAD EMERG MED, V4, P1035, DOI 10.1111/j.1553-2712.1997.tb03676.x; FOEX BA, 1993, INJURY, V24, P373, DOI 10.1016/0020-1383(93)90098-Q; GARDLUND B, 1995, J INFECT DIS, V172, P296, DOI 10.1093/infdis/172.1.296; Giannoudis PV, 2003, INJURY, V34, P397, DOI 10.1016/S0020-1383(02)00416-3; Giannoudis PV, 2000, INTENS CARE MED, V26, P1076, DOI 10.1007/s001340051320; GIANOTTI L, 1992, TRANSFUSION, V32, P312, DOI 10.1046/j.1537-2995.1992.32492263443.x; Golde WT, 2005, LAB ANIMAL, V34, P39, DOI 10.1038/laban1005-39; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Hess JR, 2005, CRIT CARE, V9, pS10, DOI 10.1186/cc3780; HOCH RC, 1993, CRIT CARE MED, V21, P839, DOI 10.1097/00003246-199306000-00010; Hsieh CH, 2008, J IMMUNOL, V181, P2806, DOI 10.4049/jimmunol.181.4.2806; Jackman RP, 2011, CLIN VACCINE IMMUNOL, V18, P318, DOI 10.1128/CVI.00465-10; Kang SC, 2004, CYTOKINE, V26, P223, DOI 10.1016/j.cyto.2004.03.005; Kavathia N, 2009, AGING-US, V1, P652, DOI 10.18632/aging.100069; Kawasaki T, 2006, J IMMUNOL, V177, P4514, DOI 10.4049/jimmunol.177.7.4514; KEANE RM, 1983, SURG GYNECOL OBSTET, V156, P163; Kelly JL, 1997, SURGERY, V122, P146, DOI 10.1016/S0039-6060(97)90003-9; Kobbe P, 2008, SHOCK, V30, P43, DOI [10.1097/SHK.0b013e31815d190b, 10.1097/SHK.0b013e318d190b]; KUKIELKA GL, 1994, ANN NY ACAD SCI, V723, P258, DOI 10.1111/j.1749-6632.1994.tb36732.x; Kuyvenhoven JP, 2004, THROMB HAEMOSTASIS, V91, P506, DOI 10.1160/TH03-05-0272; LAW MM, 1994, J TRAUMA, V37, P100, DOI 10.1097/00005373-199407000-00017; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Li LX, 2010, ANN NY ACAD SCI, V1203, P151, DOI 10.1111/j.1749-6632.2010.05555.x; LIVINGSTON DH, 1988, ARCH SURG-CHICAGO, V123, P1309; Lyons A, 1997, ANN SURG, V226, P450, DOI 10.1097/00000658-199710000-00006; MacConmara MP, 2006, ANN SURG, V244, P514, DOI 10.1097/01.sla.0000239031.06906.1f; Mack VE, 1996, ARCH SURG-CHICAGO, V131, P1303; Mannick JA, 2001, J AM COLL SURGEONS, V193, P237, DOI 10.1016/S1072-7515(01)01011-0; Martin C, 1997, CRIT CARE MED, V25, P1813, DOI 10.1097/00003246-199711000-00018; Miller SJ, 2007, AM J PHYSIOL-HEART C, V293, pH2634, DOI 10.1152/ajpheart.00397.2007; Mimasaka S, 2007, INJURY, V38, P1047, DOI 10.1016/j.injury.2007.02.045; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; Moore FA, 1996, J TRAUMA, V40, P510; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; Murphy TJ, 2005, J IMMUNOL, V174, P2957, DOI 10.4049/jimmunol.174.5.2957; Napolitano LA, 2005, JAIDS-J ACQ IMM DEF, V40, P581, DOI 10.1097/01.qai.0000187442.53708.b4; Ni Choileain N, 2006, J IMMUNOL, V176, P225; Nuki G, 2002, ARTHRITIS RHEUM, V46, P2838, DOI 10.1002/art.10578; Oberholzer A, 2000, J TRAUMA, V48, P932, DOI 10.1097/00005373-200005000-00019; OKUNO K, 1994, AM J SURG, V168, P340, DOI 10.1016/S0002-9610(05)80161-8; OMAHONY JB, 1984, J TRAUMA, V24, P869, DOI 10.1097/00005373-198410000-00001; OPELZ G, 1973, TRANSPLANT P, V5, P253; OSULLIVAN ST, 1995, ANN SURG, V222, P482; Partrick DA, 1996, AM J SURG, V172, P425, DOI 10.1016/S0002-9610(96)00252-8; Paunel-Gorgulu A, 2011, CRIT CARE, V15, DOI 10.1186/cc9965; Perl M, 2003, SHOCK, V19, P299, DOI 10.1097/00024382-200304000-00001; PINCEMAIL J, 1991, J IMMUNOL METHODS, V137, P181, DOI 10.1016/0022-1759(91)90023-9; Pirenne J, 2005, TRANSPLANTATION, V79, pS25, DOI 10.1097/01.TP.0000153295.51565.F1; Proczka RM, 2006, J PHYSIOL PHARMACOL, V57, P305; Crespo ART, 2007, BRAIN INJURY, V21, P441, DOI 10.1080/02699050701311125; Puyana JC, 1998, J TRAUMA, V44, P1037, DOI 10.1097/00005373-199806000-00017; RABINOVICI R, 1993, J TRAUMA, V35, P698, DOI 10.1097/00005373-199311000-00008; Richter V, 2003, GERONTOLOGY, V49, P293, DOI 10.1159/000071710; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; SALVATIERRA O, 1980, ANN SURG, V192, P543, DOI 10.1097/00000658-198010000-00012; Schroder J, 1998, ARCH SURG-CHICAGO, V133, P1200, DOI 10.1001/archsurg.133.11.1200; Seekamp A, 1998, J TRAUMA, V44, P874, DOI 10.1097/00005373-199805000-00022; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Sherry RM, 1996, J TRAUMA, V40, P613, DOI 10.1097/00005373-199604000-00016; Shurin GV, 2007, CYTOKINE, V39, P123, DOI 10.1016/j.cyto.2007.06.006; SINGAL DP, 1982, HUM IMMUNOL, V4, P93, DOI 10.1016/0198-8859(82)90010-6; STEPHAN RN, 1987, ARCH SURG-CHICAGO, V122, P62; STYLIANOS S, 1991, J TRAUMA, V31, P1063, DOI 10.1097/00005373-199131080-00003; Sullivan DJ, 1998, J SURG RES, V75, P54, DOI 10.1006/jsre.1997.5254; SZABO G, 1991, J CLIN IMMUNOL, V11, P326, DOI 10.1007/BF00918798; Trunkey DD, 2000, CLIN ORTHOP RELAT R, P36; Ulrich D, 2003, PLAST RECONSTR SURG, V111, P1423, DOI 10.1097/01.PRS.0000049450.95669.07; US Department of Health and Human Services and others, 2011, 2009 NAT BLOOD COLL; Utter GH, 2007, VOX SANG, V93, P188, DOI 10.1111/j.1423-0410.2007.00954.x; Wichmann MW, 1998, CRIT CARE MED, V26, P1372, DOI 10.1097/00003246-199808000-00024; Wichmann MW, 2000, INTENS CARE MED, V26, P167, DOI 10.1007/s001340050041; Wick M, 2000, ARCH SURG-CHICAGO, V135, P1309, DOI 10.1001/archsurg.135.11.1309; Winslow Glenn A., 1996, Journal of Burn Care and Rehabilitation, V17, P117, DOI 10.1097/00004630-199603000-00005; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354; Yokoyama Y, 2002, IMMUNOL RES, V26, P63, DOI 10.1385/IR:26:1-3:063; Zou Y, 2003, FASEB J, V17, P320, DOI 10.1096/fj.03-0849fje	97	28	30	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0041-1132	1537-2995		TRANSFUSION	Transfusion	DEC	2012	52	12					2533	2550		10.1111/j.1537-2995.2012.03618.x			18	Hematology	Hematology	056BI	WOS:000312461500007	22452342	Green Accepted			2021-06-18	
J	Pandya, NK; Edmonds, EW				Pandya, Nirav K.; Edmonds, Eric W.			Immediate Intramedullary Flexible Nailing of Open Pediatric Tibial Shaft Fractures	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						tibia fracture; open fracture; flexible nailing; immediate; infection; healing; trauma; pediatric	CHILDREN; INFECTION; NONUNION	Background: Flexible nailing has become the preferred implant for pediatric patients with tibial shaft fractures that require operative fixation. Immediate definitive fracture fixation with flexible nails in patients with high-energy, open fractures has not been examined. The purpose of our study was to determine if immediate flexible nailing of open pediatric tibial shaft fractures is safe and efficacious from a bone healing, wound, and infectious standpoint. Methods: A retrospective review of 26 tibial shaft fractures consecutively treated with flexible nailing at our institution from 2003 to 2010 was performed. Age, mechanism of injury, associated injuries, presence of compartment syndrome, antibiotic administration, systemic insults, time to union, as well as bone healing (nonunion, delayed union, malunion, leg length discrepancy, growth arrest), wound, and infectious complications were collected. Comparisons were made between patients with open fractures and those with closed fractures. Results: We identified 14 patients with open fractures and a control group of 12 patients with closed injuries who underwent flexible nailing. Patients with open fractures were more likely to have polytraumatic injuries (71.0% vs. 25.0%, P = 0.04). There was no difference (P = 1.0) in the rates of compartment syndrome (open = 14.0%, closed = 17.0%) between the 2 groups. Systemic complications (pulmonary compromise and increased intracranial pressure) were noted in 2 patients who underwent immediate nailing of their open fractures; both of whom had closed head injuries. There was no difference (P = 1.0) in the rates of wound/infectious complications between the open (7.0%) and closed (4.0%) fractures groups, with no cases of wound breakdown or osteomyelitis. There was an increased rate (P = 0.02) of bone healing complications in the open fracture group (21.0% vs. 4.0%); all in patients with Gustilo type 2 or 3 injuries. All patients achieved radiographic union at final follow-up. Conclusions: Immediate flexible nailing of open pediatric tibial shaft fractures can be safely performed with minimal risk of wound or infectious complications. Clinicians should understand that prolonged bone healing (particularly in Gustilo type 2 or 3 injuries) should be expected in patients who undergo immediate flexible nailing of their open fractures. Open tibial shaft fractures are high-energy injuries, and should be seen as surrogate markers of polytrauma in the pediatric population. The risk of compartment syndrome is high regardless of whether a patient has a closed or open tibia fracture, and caution should be used in performing flexible nailing in patients who may have closed head injury due to a risk of systemic complications. Level of Evidence: Level III, therapeutic study, retrospective cohort.	[Edmonds, Eric W.] Rady Childrens Hosp San Diego, Dept Pediat Orthopaed Surg, San Diego, CA 92123 USA; [Pandya, Nirav K.] Univ Calif San Francisco, Dept Pediat Orthopaed, Childrens Hosp & Res Ctr Oakland, Oakland, CA USA	Edmonds, EW (corresponding author), Rady Childrens Hosp San Diego, Dept Pediat Orthopaed Surg, 3030 Childrens Way,Suite 410, San Diego, CA 92123 USA.	ewedmonds@rchsd.org					Arslan H, 2002, ARCH ORTHOP TRAUM SU, V122, P494, DOI 10.1007/s00402-002-0439-y; Baldwin KD, 2009, J CHILD ORTHOP, V3, P199, DOI 10.1007/s11832-009-0169-6; Bartlett CS, 1997, J ORTHOP TRAUMA, V11, P357, DOI 10.1097/00005131-199707000-00010; BUCKLEY SL, 1990, J BONE JOINT SURG AM, V72A, P1462, DOI 10.2106/00004623-199072100-00006; Galano GJ, 2005, J PEDIATR ORTHOPED, V25, P39; Gopal S, 2000, J BONE JOINT SURG BR, V82B, P959, DOI 10.1302/0301-620X.82B7.10482; Gordon JE, 2007, J PEDIATR ORTHOPED, V27, P442, DOI 10.1097/01.bpb.0000271333.66019.5c; Grimard G, 1996, CLIN ORTHOP RELAT R, P62; GUSTILO RB, 1984, J TRAUMA, V24, P742, DOI 10.1097/00005373-198408000-00009; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HOPE PG, 1992, J BONE JOINT SURG BR, V74, P546; Kakar S, 2007, J ORTHOP TRAUMA, V21, P153, DOI 10.1097/BOT.0b013e3180336923; Kubiak EN, 2005, J BONE JOINT SURG AM, V87A, P1761, DOI 10.2106/JBJS.C.01616; Lascombes P, 2006, J PEDIATR ORTHOPED, V26, P827, DOI 10.1097/01.bpo.0000235397.64783.d6; LIGIER JN, 1988, J BONE JOINT SURG BR, V70, P74; Liow RYL, 2002, J PEDIATR ORTHOPED, V22, P754, DOI 10.1097/00004694-200211000-00012; Mashru RP, 2005, J AM ACAD ORTHOP SUR, V13, P345, DOI 10.5435/00124635-200509000-00008; Myers SH, 2007, J PEDIATR ORTHOPED, V27, P537, DOI 10.1097/01.bpb.0000279033.04892.25; O'Brien T, 2004, J PEDIATR ORTHOPED, V24, P601, DOI 10.1097/01241398-200411000-00001; Sankar WN, 2007, J CHILD ORTHOP, V1, P281, DOI 10.1007/s11832-007-0056-y; SHANNAK AO, 1988, J PEDIATR ORTHOPED, V8, P306, DOI 10.1097/01241398-198805000-00010; Skaggs DL, 2005, J BONE JOINT SURG AM, V87A, P8, DOI 10.2106/JBJS.C.01561; Srivastava AK, 2008, J PEDIATR ORTHOPED, V28, P152, DOI 10.1097/BPO.0b013e318165210d; Vallamshetla VRP, 2006, J BONE JOINT SURG BR, V88B, P536, DOI 10.1302/0301-620X.88B4.17363; van Oldenrijk J, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-93	25	28	29	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0271-6798	1539-2570		J PEDIATR ORTHOPED	J. Pediatr. Orthop.	DEC	2012	32	8					770	776		10.1097/BPO.0b013e318270468b			7	Orthopedics; Pediatrics	Orthopedics; Pediatrics	037MI	WOS:000311109000010	23147618				2021-06-18	
J	James, ML; Olson, DM; Graffagnino, C				James, M. L.; Olson, D. M.; Graffagnino, C.			A pilot study of cerebral and haemodynamic physiological changes during sedation with dexmedetomidine or propofol in patients with acute brain injury	ANAESTHESIA AND INTENSIVE CARE			English	Article						neurocritical care; sedation; dexmedetomidine; acute brain injury; microdialysis; human; clinical trial; propofol	INTENSIVE-CARE-UNIT; SUBARACHNOID HEMORRHAGE; CRITICALLY-ILL; MICRODIALYSIS; PHARMACOKINETICS; MIDAZOLAM	Sedation for the mechanically-ventilated, brain-injured patient remains challenging. The purpose of this pilot study was to compare the cerebral physiologic effects of sedation with propofol versus dexmedetomidine in mechanically-ventilated, brain-injured patients. Using a randomised, crossover, unblinded clinical trial, we enrolled patients with severe brain injury (Glasgow Coma Score <= 8) from traumatic injury, subarachnoid haemorrhage or intracerebral haemorrhage undergoing multimodal monitoring (intracranial pressure, brain temperature, oximetry and microdialysis). Patients received an infusion of either propofol or dexmedetomidine for six hours and then a crossover for the subsequent six hours after sufficient washout/in. Clinical and physiological measurements were recorded hourly. In eight patients, (four traumatic injury, three subarachnoid haemorrhage and one intracerebral haemorrhage), the mean dose of propofol used was 25.5 mu g/kg/minute while the mean dose of dexmedetomidine was 0.54 mu g/kg/hour. All subjects were effectively sedated to a goal of Richmond Agitation Sedation Scale -2 and Bispectral Index of 50-70 throughout the study period. We did not observe any statistically significant differences between the groups in systemic or cerebral physiologic metrics. Though differences were noted in cerebral metabolic substrates (lactate/pyruvate ratio), none were statistically significant. In our pilot cohort, dexmedetomidine and propofol appear equally effective in sedating severely brain-injured patients and neither is associated with adverse physiological effects as measured by multimodal monitoring. Larger long-term studies are required to determine whether clinically favourable benefits demonstrated in the medical critical care setting also apply to this patient population.	[James, M. L.; Olson, D. M.; Graffagnino, C.] Duke Univ Hosp, Neurosci Intens Care Unit, Durham, NC USA	James, ML (corresponding author), Duke Univ, Box 3094, Durham, NC 27710 USA.	michael.james@duke.edu	James, Michael L./AAJ-5592-2020; Olson, DaiWai/I-5932-2019	James, Michael L./0000-0002-8715-5210; Olson, DaiWai/0000-0002-9280-078X	Hospira Worldwide, Inc; American Heart Association Scientist Development GrantAmerican Heart Association	This study was made possible through grant-in-aid funding by Hospira Worldwide, Inc and the American Heart Association Scientist Development Grant. Dr M. L. James serves as a speaking consultant for Hospira Worldwide, Inc.	Arbour Richard, 2003, AACN Clin Issues, V14, P185, DOI 10.1097/00044067-200305000-00009; Blumenfeld H, 2002, NEUROANATOMY CLIN CA; Cortinez LI, 2010, BRIT J ANAESTH, V105, P448, DOI 10.1093/bja/aeq195; Cortinez LI, 2004, ANESTHESIOLOGY, V101, P1077, DOI 10.1097/00000542-200411000-00006; Greenberg MS, 2001, HDB NEUROSURGERY; Hemphill JC, 2011, NAT REV NEUROL, V7, P451, DOI 10.1038/nrneurol.2011.101; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hughes CG, 2011, ANESTH ANALG, V112, P1212, DOI 10.1213/ANE.0b013e318215366d; King Cecil A, 2012, AORN J, V95, P365, DOI 10.1016/j.aorn.2011.06.009; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; Miller A, 2000, ANESTHESIOLOGY; MIRSKI MA, 1995, CRIT CARE MED, V23, P2038, DOI 10.1097/00003246-199512000-00013; Mirski MA, 2010, INTENS CARE MED, V36, P1505, DOI 10.1007/s00134-010-1874-9; Murdoch S, 2000, INTENS CARE MED, V26, P922, DOI 10.1007/s001340051282; Nanas S, 2007, ANAESTH INTENS CARE, V35, P920, DOI 10.1177/0310057X0703500610; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Olson Daiwai M, 2005, Crit Care Nurs Clin North Am, V17, P257, DOI 10.1016/j.ccell.2005.04.008; Olson DM, 2009, NEUROCRIT CARE, V11, P20, DOI 10.1007/s12028-008-9184-6; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Padmanabhan U, 2009, ANESTH ANALG, V109, P1448, DOI 10.1213/ane.0b013e3181a6ad31; Peerdeman SM, 2003, J NEUROL, V250, P797, DOI 10.1007/s00415-003-1079-z; RONAN KP, 1995, CRIT CARE MED, V23, P286, DOI 10.1097/00003246-199502000-00014; Sarrafzadeh AS, 2004, STROKE, V35, P638, DOI 10.1161/01.STR.0000116101.66624.F1; Schuttler J, 2000, ANESTHESIOLOGY, V92, P727, DOI 10.1097/00000542-200003000-00017; Skoglund K, 2012, CRIT CARE MED, V40, P216, DOI 10.1097/CCM.0b013e31822d7dbd; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Venn RM, 2001, BRIT J ANAESTH, V87, P684, DOI 10.1093/bja/87.5.684; Young C, 2000, CRIT CARE MED, V28, P854, DOI 10.1097/00003246-200003000-00041	29	28	35	0	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	NOV	2012	40	6					949	957		10.1177/0310057X1204000605			9	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	043HL	WOS:000311533400005	23194203	Bronze			2021-06-18	
J	Leon-Carrion, J; Leon-Dominguez, U; Pollonini, L; Wu, MH; Frye, RE; Dominguez-Morales, MR; Zouridakis, G				Leon-Carrion, Jose; Leon-Dominguez, Umberto; Pollonini, Luca; Wu, Meng-Hung; Frye, Richard E.; Rosario Dominguez-Morales, Maria; Zouridakis, George			Synchronization between the anterior and posterior cortex determines consciousness level in patients with traumatic brain injury (TBI)	BRAIN RESEARCH			English	Article						Severe neurocognitive disorder; QEEG; Functional cortical connectivity; Minimal conscious state; Consciousness	INDEPENDENT COMPONENT ANALYSIS; PREFRONTAL CORTEX; OLDER-ADULTS; HEAD-INJURY; CONNECTIVITY; NETWORK; STATE; EEG; HYPOTHESIS; BEHAVIOR	Survivors of traumatic brain injury (TB!) often suffer disorders of consciousness as a result of a breakdown in cortical connectivity. However, little is known about the neural discharges and cortical areas working in synchrony to generate consciousness in these patients. In this study, we analyzed cortical connectivity in patients with severe neurocognitive disorder (SND) and in the minimally conscious state (MCS). We found two synchronized networks subserving consciousness; one retrolandic (cognitive network) and the other frontal (executive control network). The synchrony between these networks is severely disrupted in patients in the MCS as compared to those with better levels of consciousness and a preserved state of alertness (SND). The executive control network could facilitate the synchronization and coherence of large populations of distant cortical neurons using high frequency oscillations on a precise temporal scale. Consciousness is altered or disappears after losing synchrony and coherence. We suggest that the synchrony between anterior and retrolandic regions is essential to awareness, and that a functioning frontal lobe is a surrogate marker for preserved consciousness. This article is part of a Special Issue entitled: Brain Integration. (c) 2012 Elsevier B.V. All rights reserved.	[Leon-Carrion, Jose] Univ Seville, Human Neuropsychol Lab, Dept Expt Psychol, Seville 41018, Spain; [Leon-Carrion, Jose; Leon-Dominguez, Umberto; Rosario Dominguez-Morales, Maria] Ctr Brain Injury Rehabil CRECER, Seville, Spain; [Wu, Meng-Hung; Frye, Richard E.] Univ Texas Hlth Sci Ctr, Houston, TX USA; [Pollonini, Luca; Wu, Meng-Hung; Zouridakis, George] Univ Houston, Biomed Imaging Lab, Houston, TX 77004 USA	Leon-Carrion, J (corresponding author), Univ Seville, Human Neuropsychol Lab, Dept Expt Psychol, C Camilo Jose Cela S-N, Seville 41018, Spain.	leoncarrion@us.es	Pollonini, Luca/J-9274-2014; Zouridakis, George/R-8876-2019; Frye, Richard/AAB-5543-2020	Pollonini, Luca/0000-0003-2955-6355; Zouridakis, George/0000-0002-7770-9857; Leon-Dominguez, Umberto/0000-0001-5170-2553	Center for Brain Injury Rehabilitation [(CRECER)]; Spanish Ministry of Science and InnovationSpanish Government [PSI-2008-04218/PSIC]; Fundacion CajaSol de Sevilla, Spain; Fundacion Plenum, Sevilla, Spain	Funding for this study was made possible through grants from the Center for Brain Injury Rehabilitation [(CRECER) (www.neurocrecer.es)], the Spanish Ministry of Science and Innovation (PSI-2008-04218/PSIC), the Fundacion CajaSol de Sevilla, Spain, and the Fundacion Plenum, Sevilla, Spain.	Alkire MT, 2008, SCIENCE, V322, P876, DOI 10.1126/science.1149213; Baars B. J, 1989, COGNITIVE THEORY CON; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bendat J.S., 2010, RANDOM DATA ANAL MEA, V4th; Berger H, 1938, ARCH PSYCHIAT NERVEN, V108, P407, DOI 10.1007/BF01824101; Box G.E.P., 2008, TIME SERIES ANAL FOR; Brovelli A, 2004, P NATL ACAD SCI USA, V101, P9849, DOI 10.1073/pnas.0308538101; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cavanna AE, 2007, CNS SPECTRUMS, V12, P545, DOI 10.1017/S1092852900021295; Crick F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/nn0203-119; Cui J, 2008, NEURAL NETWORKS, V21, P1094, DOI 10.1016/j.neunet.2008.05.007; Dehaene S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/j.tics.2006.03.007; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Fallani FD, 2010, INT J BIFURCAT CHAOS, V20, P905, DOI 10.1142/S0218127410026198; Frye R.E., 2007, CHANGES CORTICAL CON; FRYE RE, 2007, P WSEAS INT C COMP C; Fuster JM, 2008, PREFRONTAL CORTEX, 4TH EDITION, P1; Gaillard R, 2009, PLOS BIOL, V7, P472, DOI 10.1371/journal.pbio.1000061; Giacino J.T., 2009, MINIMALLY CONSCIOUS; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GoldmanRakic PS, 1995, ANN NY ACAD SCI, V769, P71, DOI 10.1111/j.1749-6632.1995.tb38132.x; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Hagen C., 1972, LEVELS COGNITIVE FUN; HALL K, 1997, J REHABIL OUTCOMES M, V1, P63; Iriarte J, 2003, J CLIN NEUROPHYSIOL, V20, P249, DOI 10.1097/00004691-200307000-00004; John ER, 2005, PROG BRAIN RES, V150, P143, DOI 10.1016/S0079-6123(05)50011-6; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kopell N, 2000, P NATL ACAD SCI USA, V97, P1867, DOI 10.1073/pnas.97.4.1867; Lau HC, 2006, P NATL ACAD SCI USA, V103, P18763, DOI 10.1073/pnas.0607716103; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Leon-Carrion J, 2008, CLIN NEUROPHYSIOL, V119, P1506, DOI 10.1016/j.clinph.2008.03.030; Leon-Carrion J, 2002, NEUROREHABILITATION, V17, P115; Leon-Carrion J, 2006, BRAIN INJURY, V20, P857, DOI 10.1080/02699050600832304; LHERMITTE F, 1983, BRAIN, V106, P237, DOI 10.1093/brain/106.2.237; Lisman J, 2005, HIPPOCAMPUS, V15, P913, DOI 10.1002/hipo.20121; Luria A. R., 1966, HUMAN BRAIN PSYCHOL; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Marshall LF, J NEUROSURG, V75, pS14; Passingham RE, 1993, FRONTAL LOBES VOLUNT; Pollonini L, 2010, BRAIN TOPOGR, V23, P221, DOI 10.1007/s10548-010-0139-9; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Seth AK, 2005, NETWORK-COMP NEURAL, V16, P35, DOI 10.1080/09548980500238756; Seth AK, 2007, NEURAL COMPUT, V19, P910, DOI 10.1162/neco.2007.19.4.910; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Sporns O, 2002, BEHAV BRAIN RES, V135, P69, DOI 10.1016/S0166-4328(02)00157-2; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; Ward LM, 2011, CONSCIOUS COGN, V20, P464, DOI 10.1016/j.concog.2011.01.007; Weiskrantz, 1999, CONSCIOUSNESS LOST F; Wilson CRE, 2010, TRENDS NEUROSCI, V33, P533, DOI 10.1016/j.tins.2010.08.001	53	28	32	0	21	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 2	2012	1476				SI		22	30		10.1016/j.brainres.2012.03.055			9	Neurosciences	Neurosciences & Neurology	035JV	WOS:000310943600003	22534483				2021-06-18	
J	Bagnato, S; Boccagni, C; Sant'Angelo, A; Prestandrea, C; Rizzo, S; Galardi, G				Bagnato, Sergio; Boccagni, Cristina; Sant'Angelo, Antonino; Prestandrea, Caterina; Rizzo, Silvia; Galardi, Giuseppe			Patients in a vegetative state following traumatic brain injury display a reduced intracortical modulation	CLINICAL NEUROPHYSIOLOGY			English	Article						Consciousness disorders; Cortical excitability; Cortical functions; Intracortical inhibition (ICI); Minimally conscious state; Transcranial magnetic stimulation (TMS)	HUMAN MOTOR CORTEX; MINIMALLY CONSCIOUS STATES; HEAD-INJURY; EXCITABILITY; STIMULATION; INHIBITION; DEFINITION; DISORDERS; NEURONS; SINGLE	Objective: Patients in coma who fail to wake develop a condition known as a vegetative state (VS). While we know that some cortical activities exist in patients in VS, it remains unclear whether interneuronal modulation can be abnormal in the cerebral cortex of these patients. The aim of the study was to evaluate the inhibitory and excitatory interneuronal circuits in patients in VS following a traumatic brain injury. Methods: Cortical excitability was studied in 5 VS patients and in 10 healthy subjects using paired pulses transcranial magnetic stimulation (TMS). Resting motor threshold and intracortical inhibition and facilitation at short intervals (2 and 10 ms, respectively) were evaluated. Two patients were studied again after their level of consciousness transitioned into a minimally conscious state (MCS). Results: Both intracortical inhibition and facilitation were significantly reduced in patients compared to healthy subjects (p < 0.05). In addition, these results did not significantly change in the 2 patients who evolved into a MCS. Conclusions: This is the first report showing an abnormal cortical excitability in patients in VS. Significance: Our findings suggest a pathophysiological base for future work aiming to restore the lack of interneuronal transmission in patients in VS. (C) 2012 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Bagnato, Sergio; Boccagni, Cristina; Sant'Angelo, Antonino; Prestandrea, Caterina; Galardi, Giuseppe] Fdn Ist San Raffaele G Giglio, Rehabil Dept, Unit Neurophysiol, I-90015 Cefalu, PA, Italy; [Bagnato, Sergio; Boccagni, Cristina; Sant'Angelo, Antonino; Rizzo, Silvia; Galardi, Giuseppe] Fdn Ist San Raffaele G Giglio, Unit Severe Acquired Brain Injuries, Rehabil Dept, I-90015 Cefalu, PA, Italy	Bagnato, S (corresponding author), Fdn Ist San Raffaele G Giglio, Rehabil Dept, Unit Neurophysiol, Viale G Giardina, I-90015 Cefalu, PA, Italy.	sergiobagnato@gmail.com	Bagnato, Sergio/H-6842-2013	Bagnato, Sergio/0000-0002-6289-1887; Boccagni, Cristina/0000-0002-6317-015X			Abbruzzese G, 2002, J CLIN NEUROPHYSIOL, V19, P307, DOI 10.1097/00004691-200208000-00005; Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Ascoli GA, 2008, NAT REV NEUROSCI, V9, P557, DOI 10.1038/nrn2402; Avesani M, 2008, EXP BRAIN RES, V187, P17, DOI 10.1007/s00221-008-1274-3; Bagnato S, 2010, CLIN NEUROPHYSIOL, V121, P274, DOI 10.1016/j.clinph.2009.11.008; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Boccagni C, 2011, J CLIN NEUROPHYSIOL, V28, P489, DOI 10.1097/WNP.0b013e318231c8c8; Buritica E, 2009, J NEUROTRAUM, V26, P2145, DOI 10.1089/neu.2009.0894; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Clauss RP, 2010, MED HYPOTHESES, V75, P287, DOI 10.1016/j.mehy.2010.03.005; Deschenes M, 1996, NEUROSCIENCE, V72, P679, DOI 10.1016/0306-4522(96)00001-2; Fingelkurts AA, COGNIT PROC IN PRESS; Fingelkurts AA, 2012, CONSCIOUS COGN, V21, P149, DOI 10.1016/j.concog.2011.10.004; Fingelkurts AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025967; FONSECA M, 1993, NEUROSCIENCE, V55, P1107, DOI 10.1016/0306-4522(93)90324-9; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Ilic TV, 2002, J PHYSIOL-LONDON, V545, P153, DOI 10.1113/jphysiol.2002.030122; Jacob TC, 2008, NAT REV NEUROSCI, V9, P331, DOI 10.1038/nrn2370; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Molnar GF, 2006, NEUROLOGY, V66, P566, DOI 10.1212/01.wnl.0000198254.08581.6b; Molnar Z, 2006, NEUROSCI RES, V55, P105, DOI 10.1016/j.neures.2006.02.008; Monti MM, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3765; Muller-Dahlhaus JFM, 2008, J PHYSIOL-LONDON, V586, P495, DOI 10.1113/jphysiol.2007.142059; O'Connor RM, 2010, EUR J PHARMACOL, V639, P123, DOI 10.1016/j.ejphar.2010.02.059; Royal College of Physicians, 2003, PERM VEG STAT GUID D; Schabus M, 2011, FUNCT NEUROL, V26, P31; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Schwenkreis P, 1999, NEUROSCI LETT, V270, P137, DOI 10.1016/S0304-3940(99)00492-9; Soddu A, 2011, FUNCT NEUROL, V26, P37; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006	35	28	28	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	OCT	2012	123	10					1937	1941		10.1016/j.clinph.2012.03.014			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	005GU	WOS:000308739700010	22560638				2021-06-18	
J	AbdelFattah, KR; Eastman, AL; Aldy, KN; Wolf, SE; Minei, JP; Scott, WW; Madden, CJ; Rickert, KL; Phelan, HA				AbdelFattah, Kareem R.; Eastman, Alexander L.; Aldy, Kim N.; Wolf, Steven E.; Minei, Joseph P.; Scott, William W.; Madden, Christopher J.; Rickert, Kim L.; Phelan, Herb A.			A prospective evaluation of the use of routine repeat cranial CT scans in patients with intracranial hemorrhage and GCS score of 13 to 15	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Intracranial hemorrhage; repeat cranial CT scans; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; MINIMAL HEAD-INJURY; SERIAL COMPUTED-TOMOGRAPHY; CLINICAL-EFFICACY; UTILITY; MANAGEMENT	BACKGROUND: Scheduled repeat head computed tomography after mild traumatic brain injury has been shown to have limited use for predicting the need for an intervention. We hypothesized that repeat computed tomography in persons with intracranial hemorrhage and a Glasgow Coma Scale (GCS) score of 13 to 15, without clinical progression of neurologic symptoms, does not impact the need for neurosurgical intervention or discharge GCS scores. METHODS: This prospective cohort study followed all patients presenting to our urban Level I trauma center with intracranial hemorrhage and a GCS score of 13 to 15 from February 2010 to December 2010. Subjects were divided into two groups: those in whom repeat CT scans were performed routinely (ROUTINE) and those in whom they were performed selectively (SELECTIVE) based on changes in clinical examination. CT scanning decisions were made at the discretion of the neurosurgical service attending physician. RESULTS: One hundred forty-five patients met the inclusion criteria (ROUTINE, n = 92; SELECTIVE, n = 53). Group demographics, including age, sex, and presenting GCS score were not significantly different. Of SELECTIVE patients, six (11%) required a repeat head computed tomography for a neurologic change, with one having a radiographic progression of hemorrhage (16%) versus 26 (28%) of 92 in the ROUTINE group showing a radiographic progression. No patient in either group required medical or neurosurgical intervention based on repeat scan. The number of CT scans performed differed between the two groups (three scans in ROUTINE vs. one scan in SELECTIVE, p < 0.001), as did the intensive care unit (2 days vs. 1 day, p < 0.001) and hospital (5 days vs. 2 days, p < 0.001) lengths of stay. Discharge GCS score was similar for both groups (15 vs. 15, p = 0.37). One death occurred in the SELECTIVE group, unrelated to intracranial findings. The negative predictive value of a repeat CT scan leading to neurosurgical intervention with no change in clinical examination was 100% for both groups. CONCLUSION: A practice of selective repeat head CT scans in patients with traumatic brain injury admitted with a GCS score of 13 to 15 decreases use of the test and is associated with decreased hospital length of stay, without impacting discharge GCS scores. (J Trauma Acute Care Surg. 2012; 73: 685-688. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[AbdelFattah, Kareem R.; Eastman, Alexander L.; Aldy, Kim N.; Wolf, Steven E.; Minei, Joseph P.; Phelan, Herb A.] Univ Texas SW Med Ctr Dallas, Div Burns Trauma & Crit Care, Dept Surg, Dallas, TX 75390 USA; [Scott, William W.; Madden, Christopher J.; Rickert, Kim L.] Univ Texas SW Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75390 USA	AbdelFattah, KR (corresponding author), Univ Texas SW Med Ctr Dallas, Div Burns Trauma & Crit Care, Dept Surg, 5323 Harry Hines Blvd H8-220, Dallas, TX 75390 USA.	kareem.abdelfattah@phhs.org		Wolf, Steven/0000-0003-2972-3440	National Institutes of Health (NIH) from the National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1 KL2 RR024983-01]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH from the National Institute of General Medical Sciences [T32GM0859]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024983] Funding Source: NIH RePORTER	H.A.P. was supported by National Institutes of Health (NIH) Grant No. 1 KL2 RR024983-01 titled, "North and Central Texas Clinical and Translational Science Initiative" (Milton Packer, M. D., PI) from the National Center for Research Resources (NCRR), a component of the NIH and NIH Roadmap for Medical Research. The contents herein are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or the NIH. Information on NCRR is available at http://www.ncrr.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp. K. R. A. was supported by NIH T32 Fellowship Grant T32GM0859 titled, "Training in Trauma, Inflammation, Sepsis, and Critical Care (Fiemu Nwariaku, M. D., PI) from the National Institute of General Medical Sciences.	Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Park HK, 2009, BRIT J NEUROSURG, V23, P617, DOI 10.3109/02688690902999302; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Sifri ZC, 2011, J TRAUMA, V71, P1605, DOI 10.1097/TA.0b013e31822b3728; Sing RF, 2006, J TRAUMA, V60, P499; Sinson G, 2001, J TRAUMA, V51, P875; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; Stein SC, 2008, J TRAUMA, V65, P66, DOI 10.1097/TA.0b013e318068d75f; Thomas BW, 2010, J AM COLL SURGEONS, V210, P824, DOI 10.1016/j.jamcollsurg.2009.12.039; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d	15	28	28	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2012	73	3					685	688		10.1097/TA.0b013e318265ccd9			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	009TK	WOS:000309047900023	22929497				2021-06-18	
J	Albert-Weissenberger, C; Stetter, C; Meuth, SG; Gobel, K; Bader, M; Siren, AL; Kleinschnitz, C				Albert-Weissenberger, Christiane; Stetter, Christian; Meuth, Sven G.; Goebel, Kerstin; Bader, Michael; Siren, Anna-Leena; Kleinschnitz, Christoph			Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damage and astroglia activation	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						astrocytes; beta-APP; closed head injury; kinin receptors; R-715; TNF-alpha	TRAUMATIC BRAIN-INJURY; B-2 RECEPTORS; RAT-BRAIN; ANTAGONIST ANATIBANT; KININ RECEPTORS; EDEMA FORMATION; MURINE MODEL; EXPRESSION; INHIBITION; ASTROCYTES	The two bradykinin receptors B1R and B2R are central components of the kallikrein-kinin system with different expression kinetics and binding characteristics. Activation of these receptors by kinins triggers inflammatory responses in the target organ and in most situations enhances tissue damage. We could recently show that blocking of B1R, but not B2R, protects from cortical cryolesion by reducing inflammation and edema formation. In the present study, we investigated the role of B1R and B2R in a closed head model of focal traumatic brain injury (TBI; weight drop). Increased expression of B1R in the injured hemispheres of wild-type mice was restricted to the later stages after brain trauma, i.e. day 7 (P<0.05), whereas no significant induction could be observed for the B2R (P > 0.05). Mice lacking the B1R, but not the B2R, showed less functional deficits on day 3 (P<0.001) and day 7 (P<0.001) compared with controls. Pharmacological blocking of B1R in wildtype mice had similar effects. Reduced axonal injury and astroglia activation could be identified as underlying mechanisms, while inhibition of B1R had only little influence on the local inflammatory response in this model. Inhibition of B1R may become a novel strategy to counteract trauma-induced neurodegeneration. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 1747-1756; doi:10.1038/jcbfm.2012.62; published online 9 May 2012	[Albert-Weissenberger, Christiane; Kleinschnitz, Christoph] Univ Clin Wurzburg, Dept Neurol, Wurzburg, Germany; [Stetter, Christian; Siren, Anna-Leena] Univ Clin Wurzburg, Dept Neurosurg, Wurzburg, Germany; [Meuth, Sven G.; Goebel, Kerstin] Univ Munster, Inst Physiol Neuropathophysiol, Munster, Germany; [Meuth, Sven G.] Univ Munster, Dept Neurol Inflammatory Disorders Nervous Syst &, Munster, Germany; [Bader, Michael] Max Delbruck Ctr Mol Med, Berlin, Germany	Kleinschnitz, C (corresponding author), Univ Wurzburg, Dept Neurol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.	Siren.A@nch.uni-wuerzburg.de; christoph.kleinschnitz@uni-wuerzburg.de	Siren, Anna-Leena/AAE-1374-2019	Siren, Anna-Leena/0000-0002-2217-0081; Bader, Michael/0000-0003-4780-4164; Kleinschnitz, Christoph/0000-0002-1650-8875	Deutsche Forschungsgemeinschaft (DFG), Bonn, GermanyGerman Research Foundation (DFG) [SFB 688 (TP A13)]; Wilhelm-Sander-Stiftung, Munich, Germany	This work was supported by the Deutsche Forschungsgemeinschaft (DFG), SFB 688 (TP A13), Bonn, Germany and the Wilhelm-Sander-Stiftung, Munich, Germany.	Albert-WeiSSenberger Christiane, 2012, Exp Transl Stroke Med, V4, P1, DOI 10.1186/2040-7378-4-1; Austinat M, 2009, STROKE, V40, P285, DOI 10.1161/STROKEAHA.108.526673; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; CAMARGO ACM, 1973, BIOCHEMISTRY-US, V12, P1838, DOI 10.1021/bi00733a028; CHOLEWINSKI AJ, 1991, J NEUROCHEM, V57, P1456, DOI 10.1111/j.1471-4159.1991.tb08314.x; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Frugier T, 2012, J NEUROPATH EXP NEUR, V71, P242, DOI 10.1097/NEN.0b013e3182496149; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GIMPL G, 1992, NEUROSCI LETT, V144, P139, DOI 10.1016/0304-3940(92)90735-P; Gobeil F, 1996, HYPERTENSION, V28, P833, DOI 10.1161/01.HYP.28.5.833; Gobel K, 2011, J AUTOIMMUN, V36, P106, DOI 10.1016/j.jaut.2010.11.004; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Hsieh HL, 2004, CELL SIGNAL, V16, P1163, DOI 10.1016/j.cellsig.2004.03.021; KARIYA K, 1985, J NEUROCHEM, V44, P1892, DOI 10.1111/j.1471-4159.1985.tb07185.x; Ker K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006686.pub2; KIZUKI K, 1994, BRAZ J MED BIOL RES, V27, P1891; Kleinschnitz C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000479; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marceau F, 2004, NAT REV DRUG DISCOV, V3, P845, DOI 10.1038/nrd1522; Marmarou A, 2005, J NEUROTRAUM, V22, P1444, DOI 10.1089/neu.2005.22.1444; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pesquero JB, 2000, P NATL ACAD SCI USA, V97, P8140, DOI 10.1073/pnas.120035997; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Raidoo DM, 1997, J NEUROIMMUNOL, V77, P39, DOI 10.1016/S0165-5728(97)00048-9; Raslan F, 2010, J CEREBR BLOOD F MET, V30, P1477, DOI 10.1038/jcbfm.2010.28; Lemos MTR, 2010, NEUROPEPTIDES, V44, P163, DOI 10.1016/j.npep.2009.12.006; Rodi D, 2005, CURR PHARM DESIGN, V11, P1313, DOI 10.2174/1381612053507422; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Sargin D, 2009, GLIA, V57, P693, DOI 10.1002/glia.20797; Shakur H, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-109; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Thal SC, 2009, CRIT CARE MED, V37, P2228, DOI 10.1097/CCM.0b013e3181a068fc; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; Zhang L, 2000, NEUROREPORT, V11, P409, DOI 10.1097/00001756-200002070-00037; Zweckberger K, 2009, NEUROSCI LETT, V454, P115, DOI 10.1016/j.neulet.2009.02.014	41	28	29	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2012	32	9					1747	1756		10.1038/jcbfm.2012.62			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	000MR	WOS:000308390900009	22569191	Green Published, Other Gold			2021-06-18	
J	Tallus, J; Lioumis, P; Hamalainen, H; Kahkonen, S; Tenovuo, O				Tallus, J.; Lioumis, P.; Hamalainen, H.; Kahkonen, S.; Tenovuo, O.			Long-lasting TMS motor threshold elevation in mild traumatic brain injury	ACTA NEUROLOGICA SCANDINAVICA			English	Article						head injury; electromyography; neurophysiology; neurotraumatology; transcranial magnetic stimulation	TRANSCRANIAL MAGNETIC STIMULATION; CORTICOMOTOR THRESHOLD; CORTICAL EXCITABILITY; SLEEP-DEPRIVATION; SPORTS CONCUSSION; CORTEX DISTANCE; HEAD-INJURY; REPEATABILITY; IMPAIRMENT; RESPONSES	Tallus J, Lioumis P, Hamalainen H, Kahkonen S, Tenovuo O. Long-lasting TMS motor threshold elevation in mild traumatic brain injury. ?Acta Neurol Scand: 2012: 126: 178182.(C) 2011 John Wiley & Sons A/S. Objectives Mild traumatic brain injury (mTBI) is very common, and part of the patients experience persistent symptoms. These may be caused by diffuse neuronal damage and could therefore affect cortical excitability. The motor threshold (MT), measured by transcranial magnetic stimulation (TMS), is a measure of cortical excitability and cortico-spinal tract integrity. Materials and methods We used navigated TMS (nTMS) and electromyography to determine subjects left hemisphere MTs. Nineteen subjects with mTBI (11 with persistent symptoms and eight fully recovered) and nine healthy controls were tested. The injuries had occurred on average 5 years earlier. All participants had normal brain MRIs, that is, no signs of injury. None used centrally acting medication. Results The mean MT in controls was 43.0% (SD 2.5) of maximum stimulator output. The mTBI subjects mean MT was 53.4% (SD 9.7), being higher than the controls threshold. Subjective recovery did not correlate with MT. Conclusions The results show chronic MT elevation in a sample of subjects with symptomatic or recovered mTBI. This suggests that mTBI may be compensated, although not fully recovered, years after the injury. While the cause for MT elevation cannot be concluded from these preliminary observations, possible explanations include decreased cortical excitability and impaired subcortical conduction.	[Tallus, J.; Hamalainen, H.] Univ Turku, Ctr Cognit Neurosci, Dept Psychol, Turku 20014, Finland; [Lioumis, P.] Univ Helsinki, BioMag Lab, HUSLAB, Cent Hosp, Helsinki, Finland; [Kahkonen, S.] Univ Helsinki, Cent Hosp, BioMag Lab & Pain Clin, Helsinki, Finland; [Tenovuo, O.] Hosp Dist SW Finland, Turku, Finland	Tallus, J (corresponding author), Univ Turku, Ctr Cognit Neurosci, Dept Psychol, Assistentinkatu 7, Turku 20014, Finland.	jptall@utu.fi	Lioumis, Pantelis/A-3801-2019	Lioumis, Pantelis/0000-0003-2016-9199			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BARKER AT, 1985, LANCET, V1, P1106; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Civardi C, 2001, J NEUROL NEUROSUR PS, V71, P809, DOI 10.1136/jnnp.71.6.809; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Di Lazzaro V, 2003, J PHYSIOL-LONDON, V547, P485, DOI 10.1113/jphysiol.2002.030486; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Herbsman T, 2009, HUM BRAIN MAPP, V30, P2044, DOI 10.1002/hbm.20649; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; Kahkonen S, 2004, J PSYCHOPHARMACOL, V18, P257, DOI 10.1177/0269881104042631; Kimiskidis VK, 2004, NEUROPHYSIOL CLIN, V34, P259, DOI 10.1016/j.neucli.2004.10.002; Lioumis P, 2009, HUM BRAIN MAPP, V30, P1387, DOI 10.1002/hbm.20608; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Manganotti P, 2006, J NEUROL NEUROSUR PS, V77, P56, DOI 10.1136/jnnp.2004.041137; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mills KR, 1997, MUSCLE NERVE, V20, P570, DOI 10.1002/(SICI)1097-4598(199705)20:5<570::AID-MUS5>3.3.CO;2-F; Petersen NC, 2010, ACTA PHYSIOL, V198, P403, DOI 10.1111/j.1748-1716.2009.02066.x; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Ruohonen J., 2002, HDB TRANSCRANIAL MAG, P18; Saisanen L, 2008, J CLIN NEUROPHYSIOL, V25, P367, DOI 10.1097/WNP.0b013e31818e7944; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Stokes MG, 2005, J NEUROPHYSIOL, V94, P4520, DOI 10.1152/jn.00067.2005; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	30	28	28	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	SEP	2012	126	3					178	182		10.1111/j.1600-0404.2011.01623.x			5	Clinical Neurology	Neurosciences & Neurology	983DX	WOS:000307099800006	22103909				2021-06-18	
J	Wagner, AK; Brett, CA; McCullough, EH; Niyonkuru, C; Loucks, TL; Dixon, CE; Ricker, J; Arenth, P; Berga, SL				Wagner, Amy K.; Brett, Christopher A.; McCullough, Emily H.; Niyonkuru, Christian; Loucks, Tammy L.; Dixon, C. Edward; Ricker, Joseph; Arenth, Patricia; Berga, Sarah L.			Persistent hypogonadism influences estradiol synthesis, cognition and outcome in males after severe TBI	BRAIN INJURY			English	Article						Traumatic brain injury; testosterone; estradiol; cognitive outcome	TRAUMATIC BRAIN-INJURY; SYNAPTIC PLASTICITY; ANTIPITUITARY ANTIBODIES; GENDER-DIFFERENCES; BINDING GLOBULIN; CRITICALLY-ILL; ACUTE-PHASE; TESTOSTERONE; ESTROGEN; RECOVERY	Objective: Acute hypogonadotropic hypogonadism (AHH) occurs frequently after TBI, as does chronic hypogonadotropic hypogonadism. However, AHH and persistent hypogonadotropic hypogonadism (PHH) after TBI are not well studied. The objective of this study was to characterize longitudinal hormone profiles and the impact of AHH and PHH on outcome. Methods: In this prospective cohort study, men with severe TBI (n=38) had serum gonadal and gonadotropic hormones measured during weeks 1-52 post-injury. AHH, PHH and/or early resolving hypogonadotropic hypogonadism (ERHH) were based on temporal hormone assessments. PHH and hormone profiles were then compared to multiple outcome measures 6-12 months post-TBI. Results: AHH affected 100% of the population, while 37% subsequently developed PHH. Acute testosterone (TEST) and estradiol/testosterone (E2/TEST) ratios were associated with PHH and outcome. Over time, post-acute TEST and E2 levels for the ERHH group approached normal range, while levels for the PHH group remained low. Post-acute gonadotrophin levels were within the normal range for both groups. PHH, along with lower post-acute TEST and E2 profiles, was associated with worse functional and cognitive outcomes at 6 and 12 months post-injury. Conclusions: These results support screening for post-acute secondary hypogonadism and further research to assess the mechanisms underlying PHH and associated functional and cognitive deficits.	[Wagner, Amy K.; McCullough, Emily H.; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Wagner, Amy K.; Brett, Christopher A.; McCullough, Emily H.; Niyonkuru, Christian; Dixon, C. Edward; Ricker, Joseph; Arenth, Patricia] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Loucks, Tammy L.; Berga, Sarah L.] Emory Univ, Dept Obstet & Gynecol, Atlanta, GA 30322 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Loucks, Tammy/N-8223-2019	Loucks, Tammy/0000-0001-7651-7602; Ricker, Joseph/0000-0003-3415-991X	CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR323155]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01NS030318-16]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER	This work was supported by CDC grant # R49/CCR323155 (AKW, SB) and NIH 5P01NS030318-16 to (CED). The authors report no conflicts of interest.	Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; [Anonymous], 1998, REH PERS TRAUM BRAIN, P1; Bain J, 2010, MATURITAS, V66, P16, DOI 10.1016/j.maturitas.2010.01.009; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bassil N, 2005, J THERAPEUTICS CLIN, V5, P427; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Beauchet O, 2006, EUR J ENDOCRINOL, V155, P773, DOI 10.1530/eje.1.02306; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bezner JR, 2001, ARCH PHYS MED REHAB, V82, P787, DOI 10.1053/apmr.2001.23269; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Bullock R., 1996, EUR J EMERG MED, V3, P109, DOI 10.1097/00063110-199606000-00010; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Carlson NE, 2009, BRAIN INJURY, V23, P336, DOI 10.1080/02699050902788535; Cherrier MM, 2003, J ANDROL, V24, P568; Cherrier MM, 2009, FRONT HORM RES, V37, P150, DOI 10.1159/000176051; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Dawson JD, 2010, J AM GERIATR SOC, V58, P1090, DOI 10.1111/j.1532-5415.2010.02872.x; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Della Corte F, 1998, CRIT CARE MED, V26, P1419; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dossett LA, 2008, J TRAUMA, V64, P580, DOI 10.1097/TA.0b013e31816543dd; Dossett LA, 2008, SURG INFECT, V9, P41, DOI 10.1089/sur.2007.037; DUNN JF, 1981, J CLIN ENDOCR METAB, V53, P58, DOI 10.1210/jcem-53-1-58; Estes Susie M, 2005, Pituitary, V8, P267, DOI 10.1007/s11102-006-6053-1; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Foy MR, 2011, NEUROBIOL LEARN MEM, V95, P134, DOI 10.1016/j.nlm.2010.11.003; Foy MR, 2010, VITAM HORM, V82, P219, DOI 10.1016/S0083-6729(10)82012-6; Garringer J, 2010, AM J PHYS MED REH  S, V89, pS6; Gillies GE, 2010, PHARMACOL REV, V62, P155, DOI 10.1124/pr.109.002071; Green RE, 2008, ARCH PHYS ME S12 S60, V89; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Hohl A, 2009, ARQ BRAS ENDOCRINOL, V53, P908, DOI 10.1590/S0004-27302009000800003; JENNETT B, 1975, LANCET, V1, P480; Kalantaridou SN, 2004, J REPROD IMMUNOL, V62, P61, DOI 10.1016/j.jri.2003.09.004; Kasturi BS, 2009, J NEUROTRAUM, V26, P1315, DOI [10.1089/neu.2008.0751, 10.1089/neu.2008-0751]; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klein M. J., 2009, POSTHEAD INJURY ENDO; Kleindienst A, 2009, J NEUROTRAUM, V26, P1435, DOI 10.1089/neu.2008.0601; Klose M, 2008, PITUITARY, V11, P255, DOI 10.1007/s11102-008-0102-x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Kramar EA, 2012, NEUROBIOL AGING, V33, P708, DOI 10.1016/j.neurobiolaging.2010.06.008; Kronenberg HM, 2011, WILLIAMS TXB ENDOCRI; Lanfranco F, 2004, LANCET, V364, P273, DOI 10.1016/S0140-6736(04)16678-6; LARRABEE GJ, 1995, J CLIN EXP NEUROPSYC, V17, P536, DOI 10.1080/01688639508405144; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mastorakos G, 2005, HORM METAB RES, V37, P577, DOI 10.1055/s-2005-870426; Matousek RH, 2010, HORM BEHAV, V57, P352, DOI 10.1016/j.yhbeh.2010.01.004; May AK, 2008, CRIT CARE MED, V36, P62, DOI 10.1097/01.CCM.0000292015.16171.6D; Menon SK, 2009, SINGAP MED J, V50, P1080; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Moura PJ, 2010, REV NEUROSCIENCE, V21, P363; O'Kelly P, 2006, TBI FACTS STATS; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Pallais JC, 2007, GENEREVIEWS; Peck-Palmer O, 2010, ADULT PEDIAT REFEREN; Reitan RM, 1985, NEUROPSYCHOLOGICAL T; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Schulz K, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00187; Seidman SN, 1999, AM J GERIAT PSYCHIAT, V7, P18; Shang XL, 2010, NEUROSCI BULL, V26, P133, DOI 10.1007/s12264-010-0913-4; Sheridan LK, 2006, ARCH CLIN NEUROPSYCH, V21, P23, DOI 10.1016/j.acn.2005.07.003; Shores MM, 2009, J CLIN PSYCHIAT, V70, P1009, DOI 10.4088/JCP.08m04478; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith A, 1982, SYMBOL DIGITS MODALI; SOHRABJI F, 1995, P NATL ACAD SCI USA, V92, P11110, DOI 10.1073/pnas.92.24.11110; Spritzer MD, 2007, DEV NEUROBIOL, V67, P1321, DOI 10.1002/dneu.20457; Spritzer MD, 2011, HORM BEHAV, V59, P484, DOI 10.1016/j.yhbeh.2011.01.009; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Sutton-Tyrrell K, 2005, CIRCULATION, V111, P1242, DOI 10.1161/01.CIR.0000157697.54255.CE; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tanriverdi F, 2010, EUR J ENDOCRINOL, V162, P861, DOI 10.1530/EJE-09-1024; TEASDALE G, 1974, LANCET, V2, P81; ter Horst GJ, 2010, VITAM HORM, V82, P319, DOI 10.1016/S0083-6729(10)82017-5; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Van den Berghe G, 2001, J CLIN ENDOCR METAB, V86, P3217, DOI 10.1210/jc.86.7.3217; van Veelen NMJ, 2010, SCHIZOPHR RES, V120, P191, DOI 10.1016/j.schres.2010.04.011; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Wagner AK, 2000, ARCH PHYS MED REHAB, V81, P1267; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wagner J, 2010, J NEUROTRAUM, V27, P1007, DOI 10.1089/neu.2009.1092; Williams GP, 2010, EUR J CANCER PREV, V19, P256, DOI 10.1097/CEJ.0b013e328338f7d2; WINTERS SJ, 1994, ENDOCRIN METAB CLIN, V23, P709, DOI 10.1016/S0889-8529(18)30063-X; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zarrour FA, 2009, J PSYCHIATR PRACT, V15, P289, DOI 10.1097/01.pra.0000358315.88931.fc; Zhao Y, 1996, MOL ENDOCRINOL, V10, P1350, DOI 10.1210/me.10.11.1350	109	28	28	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2012	26	10					1226	1242		10.3109/02699052.2012.667594			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	984GR	WOS:000307178600008	22571223				2021-06-18	
J	Yang, Z; Yeo, RA; Pena, A; Ling, JM; Klimaj, S; Campbell, R; Doezema, D; Mayer, AR				Yang, Zhen; Yeo, Ronald A.; Pena, Amanda; Ling, Josef M.; Klimaj, Stefan; Campbell, Richard; Doezema, David; Mayer, Andrew R.			An fMRI Study of Auditory Orienting and Inhibition of Return in Pediatric Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						auditory orienting; bottom-up; functional magnetic resonance imaging; pediatric; traumatic brain injury	EVENT-RELATED FMRI; WORKING-MEMORY; HEAD-INJURY; ATTENTIONAL SKILLS; FUNCTIONAL MRI; EARLY-CHILDHOOD; POSTCONCUSSIVE SYMPTOMS; NEUROCOGNITIVE OUTCOMES; VISUOSPATIAL ATTENTION; VISUAL-ATTENTION	Studies in adult mild traumatic brain injury (mTBI) have shown that two key measures of attention, spatial reorienting and inhibition of return (IOR), are impaired during the first few weeks of injury. However, it is currently unknown whether similar deficits exist following pediatric mTBI. The current study used functional magnetic resonance imaging (fMRI) to investigate the effects of semi-acute mTBI (<3 weeks post-injury) on auditory orienting in 14 pediatric mTBI patients (age 13.50 +/- 1.83 years; education: 6.86 +/- 1.88 years), and 14 healthy controls (age 13.29 +/- 2.09 years; education: 7.21 +/- 2.08 years), matched for age and years of education. The results indicated that patients with mTBI showed subtle (i.e., moderate effect sizes) but non-significant deficits on formal neuropsychological testing and during IOR. In contrast, functional imaging results indicated that patients with mTBI demonstrated significantly decreased activation within the bilateral posterior cingulate gyrus, thalamus, basal ganglia, midbrain nuclei, and cerebellum. The spatial topography of hypoactivation was very similar to our previous study in adults, suggesting that subcortical structures may be particularly affected by the initial biomechanical forces in mTBI. Current results also suggest that fMRI may be a more sensitive tool for identifying semi-acute effects of mTBI than the procedures currently used in clinical practice, such as neuropsychological testing and structural scans. fMRI findings could potentially serve as a biomarker for measuring the subtle injury caused by mTBI, and documenting the course of recovery.	[Yang, Zhen; Yeo, Ronald A.; Pena, Amanda; Ling, Josef M.; Klimaj, Stefan; Mayer, Andrew R.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM 87106 USA; [Yang, Zhen; Yeo, Ronald A.; Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Campbell, Richard] Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA; [Doezema, David] Univ New Mexico, Sch Med, Dept Emergency Med, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA	Mayer, AR (corresponding author), Lovelace Biomed & Environm Res Inst, Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	He, Hongbo/H-1815-2013; Klimaj, Stefan/AAV-4060-2020; He, Robert/L-9441-2013		Graduate Dean's Dissertation Fellowship; University of New Mexico; Benjamin Franklin Haught Scholarship; Department of Psychology, University of New Mexico; Mind Research Network [DOE Grant] [DE-FG02-99ER62764]	The first author was supported by The Graduate Dean's Dissertation Fellowship sponsored by the University of New Mexico and The Benjamin Franklin Haught Scholarship sponsored by the Department of Psychology, University of New Mexico. This research was supported by grants from The Mind Research Network [DOE Grant No. DE-FG02-99ER62764] to A.R.M. Special thanks to Diana South, George Malloy, Cathy Smith, Terri Teshiba, Flannery Merideth, and Jim Youngblood for assistance with data collection and/or data entry, to Jesse Rael, M.D. for review of anatomical images, and to Vince Clark and John Phillips for serving on the dissertation committee.	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Allen DN, 2010, ARCH CLIN NEUROPSYCH, V25, P618, DOI 10.1093/arclin/acq051; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Arrington CM, 2000, J COGNITIVE NEUROSCI, V12, P106, DOI 10.1162/089892900563975; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2010, DEV NEUROSCI-BASEL, V32, P431, DOI 10.1159/000320667; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bayly PV, 2006, BRAIN RES, V1107, P70, DOI 10.1016/j.brainres.2006.05.102; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belin P, 2002, NEUROPSYCHOLOGIA, V40, P1956, DOI 10.1016/S0028-3932(02)00062-3; Brodeur DA, 1997, CAN J EXP PSYCHOL, V51, P20, DOI 10.1037/1196-1961.51.1.20; Burock MA, 1998, NEUROREPORT, V9, P3735, DOI 10.1097/00001756-199811160-00030; Catale C, 2009, J CLIN EXP NEUROPSYC, V31, P331, DOI 10.1080/13803390802134616; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Catroppa C, 2011, BRAIN INJURY, V25, P858, DOI 10.3109/02699052.2011.589794; Cazalis Fabienne, 2011, Front Neurol, V1, P158, DOI 10.3389/fneur.2010.00158; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Clements-Stephens AM, 2009, NEUROSCI LETT, V449, P155, DOI 10.1016/j.neulet.2008.10.094; Corbetta M, 2011, ANNU REV NEUROSCI, V34, P569, DOI 10.1146/annurev-neuro-061010-113731; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Dennis M, 2005, NEUROPSYCHOLOGIA, V43, P976, DOI 10.1016/j.neuropsychologia.2004.08.012; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Ginstfeldt T, 2010, BRAIN INJURY, V24, P1123, DOI 10.3109/02699052.2010.506853; Glover GH, 1999, NEUROIMAGE, V9, P416, DOI 10.1006/nimg.1998.0419; Goldberg MC, 2001, DEVELOPMENTAL SCI, V4, P209, DOI 10.1111/1467-7687.00166; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hamilton NA, 2010, SEMIN PEDIATR SURG, V19, P271, DOI 10.1053/j.sempedsurg.2010.06.005; Harris NS, 1999, COGNITIVE BRAIN RES, V8, P61, DOI 10.1016/S0926-6410(99)00006-3; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Karunanayaka PR, 2007, NEUROREHABILITATION, V22, P355; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Kramer ME, 2008, J INT NEUROPSYCH SOC, V14, P424, DOI 10.1017/S1355617708080545; Kramer ME, 2009, J PEDIATR REHAB MED, V2, P255, DOI 10.3233/PRM-2009-0091; Krivitzky LS, 2011, J INT NEUROPSYCH SOC, V17, P1143, DOI 10.1017/S1355617711001226; Lepsien J, 2002, J COGNITIVE NEUROSCI, V14, P127, DOI 10.1162/089892902317236795; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mayer AR, 2007, J COGNITIVE NEUROSCI, V19, P455, DOI 10.1162/jocn.2007.19.3.455; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; Mayer AR, 2004, NEUROIMAGE, V23, P534, DOI 10.1016/j.neuroimage.2004.06.027; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Posner M.I., 2007, ED HUMAN BRAIN, P62; Ravizza SM, 2001, J COGNITIVE NEUROSCI, V13, P285, DOI 10.1162/08989290151137340; Reynolds CR., 2004, BEHAV ASSESSMENT SYS, V2nd; Rueda MR, 2004, NEUROPSYCHOLOGIA, V42, P1029, DOI 10.1016/j.neuropsychologia.2003.12.012; Salmi J, 2007, BRAIN STRUCT FUNCT, V212, P181, DOI 10.1007/s00429-007-0152-2; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Scalea TM, 2005, NEUROTRAUMA EVIDENCE, P3; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Sowell ER, 2002, DEV MED CHILD NEUROL, V44, P4, DOI 10.1017/S0012162201001591; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Talairach J., 1988, COPLANAR STEREOTAXIC; Talavage T. M., 2010, J NEUROTRAUMA; Thiel CM, 2004, NEUROIMAGE, V21, P318, DOI 10.1016/j.neuroimage.2003.08.044; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P181, DOI 10.1017/S1355617710001414; Tomasi D, 2008, NEUROSCIENCE, V151, P1006, DOI 10.1016/j.neuroscience.2007.08.040; Waszak F, 2010, DEV PSYCHOL, V46, P337, DOI 10.1037/a0018541; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Zatorre RJ, 2002, NAT NEUROSCI, V5, P905, DOI 10.1038/nn904; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	94	28	28	0	16	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2012	29	12					2124	2136		10.1089/neu.2012.2395			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	993KZ	WOS:000307859900002	22533632	Green Published			2021-06-18	
J	Elias, PZ; Spector, M				Elias, Paul Z.; Spector, Myron			Implantation of a collagen scaffold seeded with adult rat hippocampal progenitors in a rat model of penetrating brain injury	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Penetrating brain injury; Traumatic brain injury; Collagen scaffold; Brain tissue engineering; Stem cells; Adult hippocampal neural progenitors	NEURAL STEM-CELLS; MAJOR HISTOCOMPATIBILITY COMPLEX; STEM/PROGENITOR CELLS; IN-VITRO; PERINEURONAL OLIGODENDROCYTES; NEURONAL DIFFERENTIATION; FUNCTIONAL RECOVERY; PARKINSONS-DISEASE; COGNITIVE FUNCTION; MHC EXPRESSION	Penetrating brain injury (PBI) is a complex central nervous system injury in which mechanical damage to brain parenchyma results in hemorrhage, ischemia, broad areas of necrosis, and eventually cavitation. The permanent loss of brain tissue affords the possibility of treatment using a biomaterial scaffold to fill the lesion site and potentially deliver pharmacological or cellular therapeutic agents. The administration of cellular therapy may be of benefit in both mitigating the secondary injury process and promoting regeneration through replacement of certain cell populations. This study investigated the survival and differentiation of adult rat hippocampal neural progenitor cells delivered by a collagen scaffold in a rat model of PBI. The cell-scaffold construct was implanted 1 week after injury and was observed to remain intact with open pores upon analysis 4 weeks later. Implanted neural progenitors were found to have survived within the scaffold, and also to have migrated into the surrounding brain. Differentiated phenotypes included astrocytes, oligodendrocytes, vascular endothelial cells, and possibly macrophages. The demonstrated multipotency of this cell population in vivo in the context of traumatic brain injury has implications for regenerative therapies, but additional stimulation appears necessary to promote neuronal differentiation outside normally neurogenic regions. (c) 2012 Elsevier B.V. All rights reserved.	[Elias, Paul Z.; Spector, Myron] VA Boston Healthcare Syst, Tissue Engn Labs, Boston, MA 02130 USA; [Elias, Paul Z.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Spector, Myron] Harvard Univ, Sch Med, Dept Orthoped Surg, Brigham & Womens Hosp, Boston, MA 02115 USA	Elias, PZ (corresponding author), VA Boston Healthcare Syst, Tissue Engn Labs, Mail Stop 151,150 S Huntington Ave, Boston, MA 02130 USA.	pzelias@alum.mit.edu; mspector@rics.bwh.harvard.edu		Spector, Myron/0000-0003-3328-4858	U.S. Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health Administration, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs	This research was supported by the U.S. Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service.	Aberg MAI, 2003, MOL CELL NEUROSCI, V24, P23, DOI 10.1016/S1044-7431(03)00082-4; Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; Andres RH, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E15; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Astradsson A, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E5; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Baschong W, 2001, J HISTOCHEM CYTOCHEM, V49, P1565, DOI 10.1177/002215540104901210; Ben-Hur T, 2008, ANN NY ACAD SCI, V1142, P218, DOI 10.1196/annals.1444.014; Ben-Shaanan TL, 2008, MOL PSYCHIATR, V13, P222, DOI 10.1038/sj.mp.4002084; Bifari Francesco, 2010, World J Stem Cells, V2, P50, DOI 10.4252/wjsc.v2.i3.50; Bolliet C, 2008, TISSUE ENG PART C-ME, V14, P207, DOI 10.1089/ten.tec.2008.0168; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Capetian P, 2011, SEMIN IMMUNOPATHOL, V33, P619, DOI 10.1007/s00281-011-0272-x; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Chen ZG, 2008, HUM MOL GENET, V17, pR84, DOI 10.1093/hmg/ddn104; Chen ZG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014787; Chen ZY, 2011, BRAIN RES, V1368, P71, DOI 10.1016/j.brainres.2010.10.028; Chiba S, 2004, J NEUROL SCI, V219, P107, DOI 10.1016/j.jns.2004.01.006; Chopp M, 2008, ACTA NEUROCHIR SUPPL, V105, P79; Clelland CD, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E8; Compton CC, 1998, J INVEST DERMATOL, V110, P908, DOI 10.1046/j.1523-1747.1998.00200.x; Coras R, 2010, BRAIN, V133, P3359, DOI 10.1093/brain/awq215; Cromey DW, 2010, SCI ENG ETHICS, V16, P639, DOI 10.1007/s11948-010-9201-y; Dayer AG, 2007, BRAIN, V130, P2962, DOI 10.1093/brain/awm200; Delcroix GJR, 2010, BIOMATERIALS, V31, P2105, DOI 10.1016/j.biomaterials.2009.11.084; Dziewczapolski G, 2003, EXP NEUROL, V183, P653, DOI 10.1016/S0014-4886(03)00212-7; Elias PZ, 2012, J MECH BEHAV BIOMED, V12, P63, DOI 10.1016/j.jmbbm.2012.03.014; Elias PZ, 2012, J NEUROTRAU IN PRESS; Faijerson J, 2006, J NEUROSCI RES, V84, P1415, DOI 10.1002/jnr.21044; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Goya RL, 2011, NEUROBIOL DIS, V41, P407, DOI 10.1016/j.nbd.2010.10.008; Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Harley BA, 2004, CELLS TISSUES ORGANS, V176, P153, DOI 10.1159/000075035; Harley BA, 2007, ACTA BIOMATER, V3, P463, DOI 10.1016/j.actbio.2006.12.009; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hermann A, 2006, J NEUROCHEM, V98, P629, DOI 10.1111/j.1471-4159.2006.03916.x; Hori J, 2003, STEM CELLS, V21, P405, DOI 10.1634/stemcells.21-4-405; Hsieh J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/jcb.200308101; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Hsu WC, 2000, INVEST OPHTH VIS SCI, V41, P2404; Jain KK, 2009, MOL BIOTECHNOL, V42, P367, DOI 10.1007/s12033-009-9166-8; Jessberger S, 2008, NAT NEUROSCI, V11, P888, DOI 10.1038/nn.2148; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Johansson S, 2008, STEM CELLS, V26, P2444, DOI 10.1634/stemcells.2008-0116; Klassen H, 2003, VISION RES, V43, P947, DOI 10.1016/S0042-6989(03)00094-4; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; LUDWIN SK, 1984, NEUROPATH APPL NEURO, V10, P143, DOI 10.1111/j.1365-2990.1984.tb00345.x; LUDWIN SK, 1979, ACTA NEUROPATHOL, V47, P49, DOI 10.1007/BF00698272; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Naegele JR, 2010, NEUROPHARMACOLOGY, V58, P855, DOI 10.1016/j.neuropharm.2010.01.019; Nakada A, 2009, CELLS TISSUES ORGANS, V190, P326, DOI 10.1159/000223233; Nehlin JO, 2009, BIOGERONTOLOGY, V10, P339, DOI 10.1007/s10522-009-9213-7; Odeberg J, 2005, J NEUROIMMUNOL, V161, P1, DOI 10.1016/j.jneuroim.2004.11.016; Oishi K, 2004, J PHARMACOL SCI, V96, P208, DOI 10.1254/jphs.FP0040373; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Pagani L, 2008, NEUROL RES, V30, P244, DOI 10.1179/016164107X230667; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Prajerova I, 2010, CELL MOL NEUROBIOL, V30, P199, DOI 10.1007/s10571-009-9443-x; Ricci-Vitiani L, 2006, NEUROL RES, V28, P488, DOI 10.1179/016164106X115134; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Roshal LM, 2009, B EXP BIOL MED+, V148, P140, DOI 10.1007/s10517-009-0642-8; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Sapsford W, 2003, J R Army Med Corps, V149, P5; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Spilker MH, 2001, RESTOR NEUROL NEUROS, V18, P23; Sun JQ, 2010, DEV DYNAM, V239, P2345, DOI 10.1002/dvdy.22377; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; Takasaki C, 2010, EUR J NEUROSCI, V32, P1326, DOI 10.1111/j.1460-9568.2010.07377.x; Taniike M, 2002, J NEUROSCI, V22, P4885, DOI 10.1523/JNEUROSCI.22-12-04885.2002; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Teng FYH, 2009, DIFFERENTIATION, V77, P121, DOI 10.1016/j.diff.2008.09.013; Ubiali F, 2007, INT IMMUNOL, V19, P1063, DOI 10.1093/intimm/dxm079; Walker PA, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/369578; Wang TW, 2009, ACTA BIOMATER, V5, P2371, DOI 10.1016/j.actbio.2009.03.033; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Wong DY, 2008, J NEUROSURG, V109, P715, DOI 10.3171/JNS/2008/109/10/0715; Wong DY, 2007, TISSUE ENG, V13, P2515, DOI 10.1089/ten.2006.0440; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; Yin L, 2008, STEM CELLS DEV, V17, P53, DOI 10.1089/scd.2007.0063	97	28	31	1	23	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUL 30	2012	209	1					199	211		10.1016/j.jneumeth.2012.06.003			13	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	983QB	WOS:000307132700024	22698665				2021-06-18	
J	Hoarau, X; Richer, E; Dehail, P; Cuny, E				Hoarau, Xavier; Richer, Edwige; Dehail, Patrick; Cuny, Emmanuel			A 10-year follow-up study of patients with severe traumatic brain injury and dysautonomia treated with intrathecal baclofen therapy	BRAIN INJURY			English	Article						Severe traumatic brain injury; dysautonomia; spasticity; hypertonia; consciousness; intrathecal baclofen therapy	ALLEVIATES AUTONOMIC DYSFUNCTION; SUPRASPINAL SPASTICITY; DIENCEPHALIC SEIZURES; VEGETATIVE STATE; INFUSION; RECOVERY; RELIABILITY; HYPERTONIA; PREDICTION; DYSTONIA	Primary objective: To describe the long-term disorders of consciousness in patients with dysautonomia and hypertonia treated with intrathecal baclofen therapy (IBT). Methods and procedures: Forty-three patients with severe traumatic brain injuries who were previously implanted with an intrathecal baclofen pump were included to be evaluated in the long-term with the Coma Recovery Scale-Revised. The Barthel Index, the Glasgow Outcome Scale, the Ashworth scale, the scores of hypertonic attacks, of sweating episodes and of voluntary motor responses were used to describe functional abilities and residual impairments. A retrospective analysis highlighted patients' characteristics at admission, before surgery and their complications. Main outcomes and results: After a mean follow-up of 10 years, nine of 43 (20.9%) patients had died, 13/43 (30.2%) patients were severely disabled or in an unresponsive wakefulness syndrome and 21/43 (48.8%) patients had good recovery of consciousness. The latter patients tended to receive IBT later, suggesting a later development of uncontrolled symptoms of dysautonomia and hypertonia. They needed lower doses of baclofen, suggesting that they had less severe symptoms. Their dysautonomia, limb hypertonia and voluntary motor responses improved significantly compared to patients with poor outcome. Conclusions: Recovery of good long-term consciousness is possible. A low level of consciousness recovery and the early development of severe and persistent symptoms of dysautonomia associated with hypertonia could be linked to poor long-term outcome.	[Cuny, Emmanuel] Univ Bordeaux Segalen, CHU Bordeaux, Hop Pellegrin, Serv Neurochirurg B, F-33076 Bordeaux, France; [Hoarau, Xavier; Cuny, Emmanuel] Hop Pellegrin, Serv Neurochirurg, F-33076 Bordeaux, France; [Richer, Edwige] LADAPT, Ctr Reeducat, Cenac, France; [Dehail, Patrick] Hop Pellegrin, Serv Med Phys & Readaptat, F-33076 Bordeaux, France	Cuny, E (corresponding author), Univ Bordeaux Segalen, CHU Bordeaux, Hop Pellegrin, Serv Neurochirurg B, Pl Amelie Raba Leon, F-33076 Bordeaux, France.	emmanuel.cuny@chu-bordeaux.fr	Dehail, Patrick/T-5081-2019				Ahmadi SA, 2010, BRAIN INJURY, V24, P1539, DOI 10.3109/02699052.2010.523049; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Atzema C, 2006, J TRAUMA, V60, P1010, DOI 10.1097/01.ta.0000218038.28064.9d; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Becker R, 1999, J NEUROL NEUROSUR PS, V66, P114, DOI 10.1136/jnnp.66.1.114; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; COHADON F, 1993, NEUROCHIRURGIE, V39, P281; Condouret JPM, 1988, HEMIPLEGIE VASCULAIR, P45; Corral L, 2009, BRAIN INJURY, V23, P403, DOI 10.1080/02699050902788477; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Dario A, 2002, ACTA NEUROL SCAND, V105, P83, DOI 10.1034/j.1600-0404.2002.1o042.x; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Francois B, 2001, J TRAUMA, V50, P158, DOI 10.1097/00005373-200101000-00035; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hendricks HT, 2010, EUR J NEUROL, V17, P1172, DOI 10.1111/j.1468-1331.2010.02989.x; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lippert-Gruener M, 2007, BRAIN INJURY, V21, P1001, DOI 10.1080/02699050701468933; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MAHONEY F I, 1965, Md State Med J, V14, P61; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P461, DOI 10.1016/S0003-9993(96)90034-9; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Rawicki B, 1999, J NEUROSURG, V91, P733, DOI 10.3171/jns.1999.91.5.0733; Richard I, 2007, ACTA NEUROCHIR SUPPL, V97, P213; Rifici C, 1994, Funct Neurol, V9, P29; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Taira T, 2009, PROG BRAIN RES, V177, P317, DOI 10.1016/S0079-6123(09)17721-X; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188	51	28	29	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2012	26	7-8					927	940		10.3109/02699052.2012.661913			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	957CB	WOS:000305135100004	22668125				2021-06-18	
J	Mioni, G; Stablum, F; McClintock, SM; Cantagallo, A				Mioni, Giovanna; Stablum, Franca; McClintock, Shawn M.; Cantagallo, Anna			Time-Based Prospective Memory in Severe Traumatic Brain Injury Patients: The Involvement of Executive Functions and Time Perception	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Time monitoring; Time reproduction; Inhibition; Updating; Patients study; Cognitive disorder	WORKING-MEMORY; PROCESSING SPEED; EVENT; ATTENTION; ADULTS; DAMAGE; TASKS	Prospective memory (PM) is the ability to remember to perform a future action at a specified later time, which is investigated through the use of event-based and time-based tasks. Prior investigations have found that PM is impaired following traumatic brain injury (TB!). However, there is limited information regarding the cognitive functions that mediate TB! and PM performance. Thus, this study investigated time-based PM in TBI patients, and the relationship among time-based PM, time perception, and executive functions. To accomplish this objective, 18 severe TBI patients and 18 healthy matched controls performed a time-based PM task, a time reproduction task, and two executive functions (Stroop and n-back) tasks. While both groups increased their monitoring frequency close to the target time, TB! patients monitored more and were less accurate than healthy controls at the target time confirming the time-based PM dysfunction in these patients. Importantly, executive functions, particularly inhibition and updating abilities, were strongly related to time-based PM performance; both time perception and executive functions are involved in time-based prospective memory in controls, whereas, only executive functions appear to be involved in TBI time-based prospective memory performance. (JINS, 2012, 18, 697-705)	[Mioni, Giovanna; Stablum, Franca] Univ Padua, Dipartimento Psicol Gen, I-35131 Padua, Italy; [McClintock, Shawn M.] UT SW Med Ctr, Dept Psychiat, Dallas, TX USA; [McClintock, Shawn M.] Columbia Univ, New York State Psychiat Inst, Dept Psychiat, New York, NY USA; [Cantagallo, Anna] Univ Ferrara, Riabilitaz Azienda Osped, Dipartimento Neurosci, UMR, I-44100 Ferrara, Italy	Mioni, G (corresponding author), Univ Padua, Dipartimento Psicol Gen, Via Venezia 8, I-35131 Padua, Italy.	giovanna.mioni@unipd.it	McClintock, Shawn/N-1526-2017	Stablum, Franca/0000-0003-0123-5090; mioni, Giovanna/0000-0002-1212-4591			Baudouin A, 2006, BRAIN COGNITION, V62, P17, DOI 10.1016/j.bandc.2006.03.003; Block, 1996, TIME INTERNAL CLOCKS, V115, P143, DOI DOI 10.1016/S0166-4115(96)80057-4; Block RA, 1998, PSYCHOL AGING, V13, P584, DOI 10.1037/0882-7974.13.4.584; Block RA, 2006, TIMING THE FUTURE: THE CASE FOR A TIME-BASED PROSPECTIVE MEMORY, P25, DOI 10.1142/9789812707123_0002; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Carlesimo G.A., 2004, BEHAV NEUROL, V22, P101; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Del Missier F, 2010, THINK REASONING, V16, P69, DOI 10.1080/13546781003630117; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; ELLIS J, 2000, APPL COGNITIVE PSYCH, V14, P1, DOI DOI 10.1002/ACP.767; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Glicksohn J, 2006, TIMING THE FUTURE: THE CASE FOR A TIME-BASED PROSPECTIVE MEMORY, P1; Gonneaud J, 2011, MEMORY, V19, P360, DOI 10.1080/09658211.2011.570765; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hagen C, 1979, REHABILITATION HEAD; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Henry J.D., 2007, J CLIN EXPT NEUROPSY, V1, P1; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Kliegel M, 2001, MEMORY, V9, P1, DOI 10.1080/09658210042000003; Kliegel M., 2008, PROSPECTIVE MEMORY C; Kopp UA, 2003, INT J PSYCHOL, V38, P229, DOI 10.1080/00207590344000150; Labelle MA, 2009, EUR J COGN PSYCHOL, V21, P501, DOI 10.1080/09541440802031000; Laiacona M, 2000, NEUROL SCI, V21, P279, DOI 10.1007/s100720070065; Mantyla T, 2006, TIMING THE FUTURE: THE CASE FOR A TIME-BASED PROSPECTIVE MEMORY, P191, DOI 10.1142/9789812707123_0008; Mantyla T, 2007, J EXP CHILD PSYCHOL, V96, P1, DOI 10.1016/j.jecp.2006.08.003; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maujean A., 2003, BRAIN IMPAIR, V4, P135, DOI DOI 10.1375/BRIM.4.2.135.27024; McDaniel M A, 1993, Memory, V1, P23, DOI 10.1080/09658219308258223; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; McFarland CP, 2009, NEUROPSYCHOLOGIA, V47, P1660, DOI 10.1016/j.neuropsychologia.2009.02.023; MEYERS CA, 1992, NEUROPSY NEUROPSY BE, V5, P28; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Nichelli P, 1995, ANN NY ACAD SCI, V769, P183, DOI 10.1111/j.1749-6632.1995.tb38139.x; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Schmitter-Edgecombe M, 2008, J CLIN EXP NEUROPSYC, V30, P212, DOI 10.1080/13803390701363803; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D, 2011, NEUROPSYCHOLOGIA, V49, P2156, DOI 10.1016/j.neuropsychologia.2011.02.006; TEASDALE G, 1974, LANCET, V2, P81; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Wilson BA, 1996, BEHAV ASSESSMENT DYS; ZAKAY D, 1993, PERCEPTION, V22, P91, DOI 10.1068/p220091; Zimmermann P., 2002, BATTERIA TEST ESAME	46	28	31	1	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2012	18	4					697	705		10.1017/S1355617712000306			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	978BN	WOS:000306714600008	22433779				2021-06-18	
J	Kim, JH; Nam, YP; Jeon, SM; Han, HS; Suk, K				Kim, Jong-Heon; Nam, Young-Pyo; Jeon, Sang-Min; Han, Hyung-Soo; Suk, Kyoungho			Amyloid neurotoxicity is attenuated by metallothionein: dual mechanisms at work	JOURNAL OF NEUROCHEMISTRY			English	Article						Alzheimer's disease; beta-amyloid; glia; metallothionein; neurodegenerative disease; neuroinflammation	CENTRAL-NERVOUS-SYSTEM; ENDOPLASMIC-RETICULUM STRESS; GROWTH-INHIBITORY FACTOR; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; GENE-EXPRESSION; MICROGLIAL ACTIVATION; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; METAL CHELATORS	J. Neurochem. (2012) 121, 751762. Abstract Alzheimers disease (AD) is a neurodegenerative disorder characterized by a progressive loss of memory and cognition. One of the hallmarks of AD is the accumulation of beta-amyloid (A beta). Although endoplasmic reticulum stress, mitochondrial dysfunction, and oxidative stress have been implicated in A beta toxicity, the molecular mechanism(s) of A beta-induced neurotoxicity are not fully understood. In this study, we present evidence that the glia-derived stress protein metallothionein (MT) attenuates A beta-induced neurotoxicity by unique mechanisms. MT expression was increased in brain astrocytes of a NSE-APPsw transgenic mouse model of AD. Astrocyte-derived MT protected N2a neuroblastoma cells and primary cortical neurons against A beta toxicity with concurrent reduction of reactive oxygen species levels. MT reversed A beta-induced down-regulation of Bcl-2 and survival signaling in neuroblastoma cells. Moreover, MT inhibited A beta-induced proinflammatory cytokine production from microglia. The neurotoxicity of A beta-stimulated microglia was significantly attenuated by MT-I. The results indicate that MT released from reactive astrocytes may antagonize A beta neurotoxicity by direct inhibition of A beta neurotoxicity and indirect suppression of neurotoxic microglial activation. These findings broaden the understanding of neurotoxic mechanisms of A beta and the crosstalk between A beta and MT in AD.	[Kim, Jong-Heon; Nam, Young-Pyo; Jeon, Sang-Min; Suk, Kyoungho] Kyungpook Natl Univ, Sch Med, Dept Pharmacol, CMRI, Taegu 700422, South Korea; [Han, Hyung-Soo] Kyungpook Natl Univ, Sch Med, Dept Physiol, CMRI, Taegu 700422, South Korea; [Kim, Jong-Heon; Nam, Young-Pyo; Jeon, Sang-Min; Han, Hyung-Soo; Suk, Kyoungho] Kyungpook Natl Univ, Sch Med, Brain Sci & Engn Inst, Taegu 700422, South Korea	Suk, K (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Pharmacol, CMRI, 101 Dong In, Taegu 700422, South Korea.	hshan@knu.ac.kr; ksuk@knu.ac.kr			Ministry of Health & Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A100870, A111345]; Ministry of Knowledge Economy (MKE, Korea)Ministry of Knowledge Economy, Republic of Korea [10035197]; National Research Foundation (NRF); Ministry of Education, Science and Technology (MEST) of Korean governmentMinistry of Education, Science and Technology, Republic of Korea [2011-0028240]	This work was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A100870, A111345), and by a grant of the Industrial Strategic Technology Development Program (10035197) funded by the Ministry of Knowledge Economy (MKE, Korea). This work was also supported by the National Research Foundation (NRF) grants funded by the Ministry of Education, Science and Technology (MEST) of Korean government (2011-0028240). The authors declare no conflict of interest.	Ambjorn M, 2008, J NEUROCHEM, V104, P21, DOI 10.1111/j.1471-4159.2007.05036.x; AOKI Y, 1991, J BIOCHEM BIOPH METH, V23, P207, DOI 10.1016/0165-022X(91)90013-M; AOKI Y, 1986, ANAL BIOCHEM, V157, P117, DOI 10.1016/0003-2697(86)90204-6; Asmussen JW, 2009, J NEUROSCI RES, V87, P2926, DOI 10.1002/jnr.22118; Blaauwgeers H. G. T., 1994, Biological Signals, V3, P181; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Cameron B, 2010, NEUROBIOL DIS, V37, P503, DOI 10.1016/j.nbd.2009.10.006; Carrasco J, 2006, NEUROSCIENCE, V143, P911, DOI 10.1016/j.neuroscience.2006.08.054; Cherian MG, 2000, CELL MOL BIOL, V46, P347; Chung RS, 2008, J NEUROCHEM, V104, P14, DOI 10.1111/j.1171-4159.2007.05026.x; Chung RS, 2007, CELL MOL LIFE SCI, V64, P2716, DOI 10.1007/s00018-007-7267-8; Chung RS, 2009, NEUROTOX RES, V15, P381, DOI 10.1007/s12640-009-9044-y; Chung RS, 2008, J BIOL CHEM, V283, P15349, DOI 10.1074/jbc.M708446200; Chung RS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012030; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; Davenport CM, 2010, J NEUROCHEM, V112, P552, DOI 10.1111/j.1471-4159.2009.06485.x; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; DUGUID JR, 1989, P NATL ACAD SCI USA, V86, P7260, DOI 10.1073/pnas.86.18.7260; Ebadi M, 1987, Experientia Suppl, V52, P289; El Ghazi I, 2010, INT J ALZHEIMERS DIS, V2011, DOI DOI 10.4061/2011/20863421234102; Fitzgerald M, 2007, EXP BRAIN RES, V183, P171, DOI 10.1007/s00221-007-1032-y; Floden AM, 2005, J NEUROSCI, V25, P2566, DOI 10.1523/JNEUROSCI.4998-04.2005; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Hao QA, 2007, J CELL PHYSIOL, V210, P428, DOI 10.1002/jcp.20874; Hayashi T, 2005, J CEREBR BLOOD F MET, V25, P41, DOI 10.1038/sj.jcbfm.9600005; Hidalgo J, 2002, METHOD ENZYMOL, V348, P238, DOI 10.1016/S0076-6879(02)48642-9; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Hidalgo J, 2006, EXP BIOL MED, V231, P1450, DOI 10.1177/153537020623100902; Hwang DY, 2004, EXP NEUROL, V186, P20, DOI 10.1016/j.expneurol.2003.09.021; Irie Y, 2003, BRAIN RES, V960, P228, DOI 10.1016/S0006-8993(02)03891-X; Irie Y, 2001, BIOCHEM BIOPH RES CO, V282, P416, DOI 10.1006/bbrc.2001.4594; Jana A, 2010, J NEUROSCI, V30, P12676, DOI 10.1523/JNEUROSCI.1243-10.2010; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kay CJ, 1997, FEBS LETT, V403, P230, DOI 10.1016/S0014-5793(97)00076-8; Kobayakawa Mutsutaka, 2010, Brain and Nerve (Tokyo), V62, P737; Kondo Y, 1997, MOL PHARMACOL, V52, P195; Leung YKJ, 2010, EXP NEUROL, V221, P98, DOI 10.1016/j.expneurol.2009.10.006; Manso Y, 2011, J BIOL INORG CHEM, V16, P1103, DOI 10.1007/s00775-011-0802-y; Marchesi VT, 2011, FASEB J, V25, P5, DOI 10.1096/fj.11-0102ufm; Maret W, 2003, J NUTR, V133, p1460S, DOI 10.1093/jn/133.5.1460S; Maret W, 2011, J BIOL INORG CHEM, V16, P1079, DOI 10.1007/s00775-011-0800-0; Martin BL, 2006, MOL CELL BIOCHEM, V283, P129, DOI 10.1007/s11010-006-2390-7; Martinho A, 2010, FEBS J, V277, P3427, DOI 10.1111/j.1742-4658.2010.07749.x; MASTERS BA, 1994, J NEUROSCI, V14, P5844; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Meloni G, 2008, NAT CHEM BIOL, V4, P366, DOI 10.1038/nchembio.89; Meplan C, 2000, ONCOGENE, V19, P5227, DOI 10.1038/sj.onc.1203907; Ock J, 2010, BRIT J PHARMACOL, V159, P1646, DOI 10.1111/j.1476-5381.2010.00659.x; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Penkowa M, 2006, J NEUROSCI RES, V83, P974, DOI 10.1002/jnr.20790; Penkowa M, 2005, J NEUROSCI RES, V79, P522, DOI 10.1002/jnr.20387; Penkowa M, 1999, EXP NEUROL, V156, P149, DOI 10.1006/exnr.1998.7009; Penkowa M, 2000, GLIA, V32, P247, DOI 10.1002/1098-1136(200012)32:3<247::AID-GLIA50>3.0.CO;2-T; Penkowa M, 2006, J NEUROSCI RES, V84, P1452, DOI 10.1002/jnr.21043; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; Sakono M, 2010, FEBS J, V277, P1348, DOI 10.1111/j.1742-4658.2010.07568.x; Sawada Jun-Ichi, 1994, Biological Signals, V3, P157; Tabner BJ, 2005, BIOCHEM SOC T, V33, P548, DOI 10.1042/BST0330548; Tabner BJ, 2005, J BIOL CHEM, V280, P35789, DOI 10.1074/jbc.C500238200; Tougu V, 2011, METALLOMICS, V3, P250, DOI 10.1039/c0mt00073f; Tougu V, 2009, J NEUROCHEM, V110, P1784, DOI 10.1111/j.1471-4159.2009.06269.x; Trayhurn P, 2000, HORM METAB RES, V32, P542, DOI 10.1055/s-2007-978683; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Uchida Y, 2002, J BIOL CHEM, V277, P32353, DOI 10.1074/jbc.M111263200; Vallee B L, 1987, Experientia Suppl, V52, P5; VARSHNEY U, 1986, MOL CELL BIOL, V6, P26, DOI 10.1128/MCB.6.1.26; Vasak M, 2005, J TRACE ELEM MED BIO, V19, P13, DOI 10.1016/j.jtemb.2005.03.003; Vasak M, 2011, J BIOL INORG CHEM, V16, P1067, DOI 10.1007/s00775-011-0799-2; West AK, 2004, REV NEUROSCIENCE, V15, P157; Ye B, 2001, P NATL ACAD SCI USA, V98, P2317, DOI 10.1073/pnas.041619198; Yin XY, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-21; Zambenedetti P, 1998, J CHEM NEUROANAT, V15, P21, DOI 10.1016/S0891-0618(98)00024-6	75	28	29	0	7	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-3042			J NEUROCHEM	J. Neurochem.	JUN	2012	121	5					751	762		10.1111/j.1471-4159.2012.07725.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	933UE	WOS:000303387800008	22404335	Bronze			2021-06-18	
J	Matthews, S; Spadoni, A; Knox, K; Strigo, I; Simmons, A				Matthews, Scott; Spadoni, Andrea; Knox, Kerry; Strigo, Irina; Simmons, Alan			Combat-Exposed War Veterans at Risk for Suicide Show Hyperactivation of Prefrontal Cortex and Anterior Cingulate During Error Processing	PSYCHOSOMATIC MEDICINE			English	Article						OEF-OIF veterans; functional magnetic resonance imaging; suicide; self-monitoring; error processing; anterior cingulate	TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; INHIBITION; DEPRESSION; PREVALENCE; MODEL; IRAQ	Objective: Suicide is a significant public health problem. Suicidal ideation (SI) increases the risk for completed suicide. However, the brain basis of SI is unknown. The objective of this study was to examine the neural correlates of self-monitoring in individuals at risk for suicide. We hypothesized that combat veterans with a history of SI relative to those without such a history would show altered activation in the anterior cingulate cortex and related circuitry during self-monitoring. Methods: Two groups of combat-exposed war veterans (13 men with and 13 men without history of SI) were studied. Both the SI and non-SI participants had two or more of the following: a) current major depressive disorder, b) current posttraumatic stress disorder, and c) history of mild traumatic brain injury, and each subject performed a validated stop task during functional magnetic resonance imaging Error-related activation was compared between the Si and non-SI groups. Results: The SI group demonstrated more error-related activation of the anterior cingulate (8256 mm(3), t = 2.51) and prefrontal cortex (i.e., clusters >2048 mm(3), voxelwise p < .05). The SI and non-SI participants showed similar behavioral task performance (i.e., mean error rate, F values < 0.63, p values > .43; and mean reaction times, F = 0.27, p = .61). Conclusions: These findings suggest neural correlates of altered self-monitoring in individuals with a history of SI and may further suggest that functional magnetic resonance imaging could be used to identify individuals at risk for suicide before they engage in suicidal behavior.	[Matthews, Scott; Spadoni, Andrea; Strigo, Irina; Simmons, Alan] VA San Diego Healthcare Syst, La Jolla, CA 92093 USA; [Matthews, Scott; Spadoni, Andrea; Strigo, Irina; Simmons, Alan] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Matthews, Scott; Strigo, Irina; Simmons, Alan] VASDHS Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Matthews, Scott] VASDHS Mental Illness Educ Res & Clin Ctr, San Diego, CA USA; [Knox, Kerry] VA VISN 2 Ctr Excellence Suicide Prevent, Albany, NY USA; [Knox, Kerry] Univ Rochester, Dept Psychiat, Rochester, NY USA	Matthews, S (corresponding author), VA San Diego Healthcare Syst, 3350 La Jolla Village Dr,Mail Code 116-A, La Jolla, CA 92093 USA.	scmatthews@ucsd.edu	Simmons, Alan N/A-9815-2008; strigo, irina A/L-9882-2016	Simmons, Alan N/0000-0003-3963-2112; strigo, irina A/0000-0002-8799-716X; Spadoni, Andrea/0000-0002-8367-6406	Veterans AdministrationUS Department of Veterans Affairs; Congressionally Directed Medical Research ProgramUnited States Department of Defense; VA Mental Illness Research, Education and Clinical Center; VA Center of Excellence for Stress and Mental Health; CDA-2 from VA Clinical Science Research and Development; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH018399, R00MH080003] Funding Source: NIH RePORTER	This work was funded by grants from the Veterans Administration and the Congressionally Directed Medical Research Program and was supported by the VA Mental Illness Research, Education and Clinical Center and the VA Center of Excellence for Stress and Mental Health. Dr. Matthews' VA salary is supported by a CDA-2 from VA Clinical Science Research and Development.	Amen DG, 2009, J NEUROPSYCH CLIN N, V21, P430, DOI 10.1176/appi.neuropsych.21.4.430; Beck AT, 2008, AM J PSYCHIAT, V165, P969, DOI 10.1176/appi.ajp.2008.08050721; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Courtet P, 2010, EUR PSYCHIAT, V25, P294, DOI 10.1016/j.eurpsy.2009.12.010; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; FAWCETT J, 1990, AM J PSYCHIAT, V147, P1189; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jollant F, 2008, AM J PSYCHIAT, V165, P740, DOI 10.1176/appi.ajp.2008.07081239; Jollant F, 2010, NEUROIMAGE, V51, P1275, DOI 10.1016/j.neuroimage.2010.03.027; Kang HK, 2009, ANN EPIDEMIOL, V19, P757, DOI 10.1016/j.annepidem.2009.05.004; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Matthews SC, 2005, NEUROREPORT, V16, P755, DOI 10.1097/00001756-200505120-00020; Matthews S, 2009, PSYCHIAT RES-NEUROIM, V172, P1, DOI 10.1016/j.pscychresns.2008.08.006; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Oquendo MA, 2003, ARCH GEN PSYCHIAT, V60, P14, DOI 10.1001/archpsyc.60.1.14; Pan LA, 2011, J AM ACAD CHILD PSY, V50, P602, DOI 10.1016/j.jaac.2011.03.018; Rudd MD, 2000, SUICIDE LIFE-THREAT, V30, P18; Schwab K, 2006, NEUROLOGY, V22, P377; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Talairach J., 1998, COPLANAR STEREOTAXIC; Weissman MM, 1999, PSYCHOL MED, V29, P9, DOI 10.1017/S0033291798007867	29	28	28	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0033-3174	1534-7796		PSYCHOSOM MED	Psychosom. Med.	JUN	2012	74	5					471	475		10.1097/PSY.0b013e31824f888f			5	Psychiatry; Psychology; Psychology, Multidisciplinary	Psychiatry; Psychology	959GB	WOS:000305299800006	22511726	Green Accepted			2021-06-18	
J	Min, KJ; Jeong, HK; Kim, B; Hwang, DH; Shin, HY; Nguyen, AT; Kim, JH; Jou, I; Kim, BG; Joe, EH				Min, Kyoung-Jin; Jeong, Hey-Kyeong; Kim, Beomsue; Hwang, Dong Hoon; Shin, Hae Young; An Tran Nguyen; Kim, Jong-hyeon; Jou, Ilo; Kim, Byung G.; Joe, Eun-hye			Spatial and temporal correlation in progressive degeneration of neurons and astrocytes in contusion-induced spinal cord injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Microglia; Monocytes; Astrocytes; Spinal cord injury; Secondary injury	GLUTAMATE TRANSPORTERS; MICROGLIAL CELLS; NITRIC-OXIDE; CULTURED ASTROCYTES; HUNTINGTONS-DISEASE; NEUROTROPHIC FACTOR; INFLAMMATORY CELLS; AMINO-ACIDS; MOUSE MODEL; RAT-BRAIN	Background: Traumatic spinal cord injury (SCI) causes acute neuronal death followed by delayed secondary neuronal damage. However, little is known about how microenvironment regulating cells such as microglia, astrocytes, and blood inflammatory cells behave in early SCI states and how they contribute to delayed neuronal death. Methods: We analyzed the behavior of neurons and microenvironment regulating cells using a contusion-induced SCI model, examining early (3-6 h) to late times (14 d) after the injury. Results: At the penumbra region close to the damaged core (P1) neurons and astrocytes underwent death in a similar spatial and temporal pattern: both neurons and astrocytes died in the medial and ventral regions of the gray matter between 12 to 24 h after SCI. Furthermore, mRNA and protein levels of transporters of glutamate (GLT-1) and potassium (Kir4.1), functional markers of astrocytes, decreased at about the times that delayed neuronal death occurred. However, at P1 region, ramified Iba-1(+) resident microglia died earlier (3 to 6 h) than neurons (12 to 24 h), and at the penumbra region farther from the damaged core (P2), neurons were healthy where microglia were morphologically activated. In addition, round Iba-1/CD45-double positive monocyte-like cells appeared after neurons had died, and expressed phagocytic markers, including mannose receptors, but rarely expressed proinflammatory mediators. Conclusion: Loss of astrocyte function may be more critical for delayed neuronal death than microglial activation and monocyte infiltration.	[Min, Kyoung-Jin; Jeong, Hey-Kyeong; Kim, Beomsue; An Tran Nguyen; Kim, Jong-hyeon; Jou, Ilo; Joe, Eun-hye] Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, Kyunggi Do, South Korea; [Jeong, Hey-Kyeong; Shin, Hae Young; Kim, Jong-hyeon; Jou, Ilo; Kim, Byung G.; Joe, Eun-hye] Ajou Univ, Sch Med, Neurosci Grad Program, Suwon 442721, Kyunggi Do, South Korea; [Hwang, Dong Hoon; Shin, Hae Young; Kim, Byung G.] Ajou Univ, Sch Med, Inst Med Sci, Suwon 442721, Kyunggi Do, South Korea; [Kim, Byung G.; Joe, Eun-hye] Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 442721, Kyunggi Do, South Korea; [Jou, Ilo; Kim, Byung G.; Joe, Eun-hye] Ajou Univ, Sch Med, Chron Inflammatory Dis Res Ctr, Suwon 442721, Kyunggi Do, South Korea	Joe, EH (corresponding author), Ajou Univ, Sch Med, Dept Pharmacol, San 5 Woncheon Dong, Suwon 442721, Kyunggi Do, South Korea.	ehjoe@ajou.ac.kr	Kim, Beomsue/X-3045-2019; Kim, Byung Gon/L-6884-2019	Kim, Beomsue/0000-0003-1207-7876; Kim, Byung Gon/0000-0003-2233-9569	KOSEF NRL Program grant; Korean government (MEST)Ministry of Education, Science and Technology, Republic of KoreaKorean Government [2-2008025-0]; Brain Research Center of the 21st Century Frontier Research ProgramMinistry of Education, Science and Technology, Republic of Korea [M103KV010011-06K2201-01110]; Ministry of Science and Technology, Republic of KoreaMinistry of Science and Technology (MOST) Korea; KOSEF grant through the Chronic Inflammatory Disease Research Center (CIDRC) at Ajou University [R13-2003-019]	This work was supported by a KOSEF NRL Program grant funded by the Korean government (MEST, 2-2008025-0), a grant (M103KV010011-06K2201-01110) from the Brain Research Center of the 21st Century Frontier Research Program funded by the Ministry of Science and Technology, Republic of Korea, and a KOSEF grant through the Chronic Inflammatory Disease Research Center (CIDRC) at Ajou University (R13-2003-019) to E Joe.	Adachi K, 2005, NEUROSCI RES, V51, P73, DOI 10.1016/j.neures.2004.10.007; Arzberger T, 1997, J NEUROPATH EXP NEUR, V56, P440, DOI 10.1097/00005072-199704000-00013; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Bao F, 2006, NEUROSCIENCE, V140, P1011, DOI 10.1016/j.neuroscience.2006.02.061; Bao F, 2009, EXP NEUROL, V215, P308, DOI 10.1016/j.expneurol.2008.10.022; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Benowitz LI, 2011, CURR OPIN NEUROL, V24, P577, DOI 10.1097/WCO.0b013e32834c208d; Bolanos JP, 1999, BBA-BIOENERGETICS, V1411, P415, DOI 10.1016/S0005-2728(99)00030-4; Campanella M, 2002, STROKE, V33, P586, DOI 10.1161/hs0202.103399; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Davies SJA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017328; Dhandapani KM, 2003, J BIOL CHEM, V278, P43329, DOI 10.1074/jbc.M305835200; Elkabes S, 1996, J NEUROSCI, V16, P2508; Ermakova IV, 2005, B EXP BIOL MED+, V140, P677, DOI 10.1007/s10517-006-0052-0; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Gegelashvili G, 1998, BRAIN RES BULL, V45, P233, DOI 10.1016/S0361-9230(97)00417-6; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; HERTZ L, 1978, BRAIN RES, V145, P202, DOI 10.1016/0006-8993(78)90812-0; HOLNESS CL, 1993, BLOOD, V81, P1607; Jeong HK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013756; Ji KA, 2007, GLIA, V55, P1577, DOI 10.1002/glia.20571; Kaiser M, 2006, J NEUROCHEM, V99, P900, DOI 10.1111/j.1471-4159.2006.04131.x; Kim GM, 2001, J NEUROSCI, V21, P6617; Kim HM, 2011, GLIA, V59, P1094, DOI 10.1002/glia.21182; Kim JH, 2010, J NEUROCHEM, V115, P1161, DOI 10.1111/j.1471-4159.2010.07004.x; Koennecke LA, 1999, J NEUROCHEM, V73, P770, DOI 10.1046/j.1471-4159.1999.0730770.x; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; Lee D, 2005, GLIA, V51, P98, DOI 10.1002/glia.20190; Lee SM, 2011, J NEUROTRAUM, V28, P1893, DOI 10.1089/neu.2011.1860; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; Lepore AC, 2011, GLIA, V59, P1996, DOI 10.1002/glia.21241; Lievens JC, 2001, NEUROBIOL DIS, V8, P807, DOI 10.1006/nbdi.2001.0430; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Matsumoto H, 2007, J NEUROSCI RES, V85, P994, DOI 10.1002/jnr.21198; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Min KJ, 2006, J NEUROSCI, V26, P1880, DOI 10.1523/JNEUROSCI.3696-05.2006; MULLER HW, 1982, J NEUROSCI RES, V8, P195, DOI 10.1002/jnr.490080209; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; NEWMAN SL, 1982, J EXP MED, V156, P430, DOI 10.1084/jem.156.2.430; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Olsen ML, 2006, GLIA, V53, P516, DOI 10.1002/glia.20312; Pineau I, 2010, BRAIN BEHAV IMMUN, V24, P540, DOI 10.1016/j.bbi.2009.11.007; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Polazzi E, 2010, PROG NEUROBIOL, V92, P293, DOI 10.1016/j.pneurobio.2010.06.009; RAPS SP, 1989, BRAIN RES, V493, P398, DOI 10.1016/0006-8993(89)91178-5; RONG H, 1993, BRAIN RES, V618, P346, DOI 10.1016/0006-8993(93)91289-5; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rozengurt N, 2003, HEARING RES, V177, P71, DOI 10.1016/S0378-5955(02)00799-2; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Speake T, 2001, MICROSC RES TECHNIQ, V52, P49, DOI 10.1002/1097-0029(20010101)52:1<49::AID-JEMT7>3.0.CO;2-C; Streit WJ, 2005, BRAIN RES REV, V48, P234, DOI 10.1016/j.brainresrev.2004.12.013; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Takahashi S, 1999, EUR J PHARMACOL, V372, P297, DOI 10.1016/S0014-2999(99)00208-3; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Yawata I, 2008, LIFE SCI, V82, P1111, DOI 10.1016/j.lfs.2008.03.010; Yong VW, 2010, NEUROSCIENTIST, V16, P408, DOI 10.1177/1073858410371379; YOUNG W, 1982, BRAIN RES, V253, P115, DOI 10.1016/0006-8993(82)90678-3	68	28	30	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 25	2012	9								100	10.1186/1742-2094-9-100			13	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	993JQ	WOS:000307855300001	22632146	DOAJ Gold, Green Published			2021-06-18	
J	Mossberg, KA; Fortini, E				Mossberg, Kurt A.; Fortini, Elizabeth			Responsiveness and Validity of the Six-Minute Walk Test in Individuals With Traumatic Brain Injury	PHYSICAL THERAPY			English	Article							MAXIMAL OXYGEN-CONSUMPTION; ADVANCED HEART-FAILURE; AEROBIC CAPACITY; CARDIORESPIRATORY FITNESS; ENERGY-EXPENDITURE; SUBACUTE STROKE; EXERCISE; RELIABILITY; CHILDREN; DISEASE	Background. A simple test of aerobic fitness for patients with traumatic brain injury (TBI) that is valid, reliable, and responsive to change is needed to provide clinicians a functional measure of cardiorespiratory capacity. Objective. The purpose of this study was to examine the validity and responsiveness to change of the Six-Minute Walk Test (6MWT) in individuals with TBI. Design. A cohort, pretest-posttest, comparison study was conducted. Methods. Twenty-one patients performed the 6MWT upon admission to and prior to discharge from a postacute rehabilitation facility. Heart rate and distance traveled were recorded. A physiologic cost index (PCI) (beats per meter) was calculated based on steady-state heart rate. At discharge, all participants were able to perform a graded treadmill exercise test to exhaustion during which peak oxygen consumption (Vo(2)) was measured. Results. Between admission and discharge, mean total distance increased from 342.6 m (SD=127.0) to 408.9 m (SD=124.2), and work increased from 27,185 kg.m (SD=10,528) to 34,114 kg.m (SD=12,057). The effect size indexes were 1.10 and 1.12 for distance and work, respectively. Correlations (r) between the discharge peak Vo(2) and the discharge 6MWT distance, PCI, and work were.58, -.61, and .47, respectively. Limitations. Stratification by gait speed may have improved responsiveness, especially for the slow ambulators. Conclusions. All measures correlated well with peak Vo(2), establishing an acceptable level of criterion-related (concurrent) validity. The addition of heart rate and calculating the PCI was only slightly better at predicting peak Vo(2), albeit nonsignificant, than a simple measure of total distance. The 6MWT provides a good estimate of peak aerobic capacity, and some measures are more responsive to change than others in patients recovering from TBI.	[Mossberg, Kurt A.] Univ Texas Med Branch, Dept Phys Therapy SHP, Galveston, TX 77555 USA; [Fortini, Elizabeth] Transit Learning Ctr, Dept Phys Therapy, Galveston, TX USA	Mossberg, KA (corresponding author), Univ Texas Med Branch, Dept Phys Therapy SHP, 301 Univ Blvd, Galveston, TX 77555 USA.	kmossber@utmb.edu			National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Moody Foundation	This work was supported by the National Institute of Child Health and Human Development and the Moody Foundation.	BALKE B, 1959, U S Armed Forces Med J, V10, P675; BERG K, 1971, AM J CLIN NUTR, V24, P1438; BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; CAHALIN L, 1995, CHEST, V108, P452, DOI 10.1378/chest.108.2.452; Cahalin LP, 1996, CHEST, V110, P325, DOI 10.1378/chest.110.2.325; Carter R, 2003, CHEST, V123, P1408, DOI 10.1378/chest.123.5.1408; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COOPER KH, 1968, J AMER MED ASSOC, V203, P201, DOI 10.1001/jama.203.3.201; Demers C, 2001, AM HEART J, V142, P698, DOI 10.1067/mhj.2001.118468; Duncan P, 1998, STROKE, V29, P2055, DOI 10.1161/01.STR.29.10.2055; Eaton T, 2005, AM J RESP CRIT CARE, V171, P1150, DOI 10.1164/rccm.200405-578OC; Eng JJ, 2004, ARCH PHYS MED REHAB, V85, P113, DOI 10.1016/S0003-9993(03)00436-2; Eng JJ, 2002, STROKE, V33, P756, DOI 10.1161/hs0302.104195; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HERMANSE.L, 1969, J APPL PHYSIOL, V26, P31; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; Injury Prevention and Control, INJ PREV CONTR TRAUM; Kelly JO, 2003, ARCH PHYS MED REHAB, V84, P1780, DOI 10.1016/S0003-9993(03)00376-9; Latham NK, 2008, ARCH PHYS MED REHAB, V89, P2146, DOI 10.1016/j.apmr.2008.04.016; LIANG MH, 1990, MED CARE, V28, P632, DOI 10.1097/00005650-199007000-00008; Lucas C, 1999, AM HEART J, V138, P618, DOI 10.1016/S0002-8703(99)70174-2; MacGregor J, 1981, Physiotherapy, V67, P30; MCGAVIN CR, 1976, BMJ-BRIT MED J, V1, P822, DOI 10.1136/bmj.1.6013.822; Montgomery PS, 1998, J AM GERIATR SOC, V46, P706, DOI 10.1111/j.1532-5415.1998.tb03804.x; MOSSBERG KA, 1990, ARCH PHYS MED REHAB, V71, P490; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; Mossberg KA, 2003, AM J PHYS MED REHAB, V82, P385, DOI 10.1097/01.PHM.0000052589.96202.BE; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; MOSSBERG KA, 2003, BRAIN INJURY, V17, P266; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; NENE AV, 1990, ARCH PHYS MED REHAB, V71, P116; Nixon PA, 1996, J PEDIATR-US, V129, P362, DOI 10.1016/S0022-3476(96)70067-7; O'Keeffe ST, 1998, HEART, V80, P377, DOI 10.1136/hrt.80.4.377; Oudiz RJ, 2006, AM J CARDIOL, V97, P123, DOI 10.1016/j.amjcard.2005.07.129; Price LG, 1988, ARTHRIT CARE RES, V1, P33; Solway S, 2001, CHEST, V119, P256, DOI 10.1378/chest.119.1.256; STALLARD J, 1978, J MED ENG TECHNOL, V2, P22, DOI 10.3109/03091907809161744; Tang A, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-23; Thompson WR., 2010, ACSMS GUIDELINES EXE; Vitale AE, 1997, BRAIN INJURY, V11, P67, DOI 10.1080/026990597123827; Zugck C, 2000, EUR HEART J, V21, P540, DOI 10.1053/euhj.1999.1861	41	28	29	0	17	AMER PHYSICAL THERAPY ASSOC	ALEXANDRIA	1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA	0031-9023			PHYS THER	Phys. Ther.	MAY	2012	92	5					726	733		10.2522/ptj.20110157			8	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	933PD	WOS:000303373400009	22282772	Green Published, Bronze			2021-06-18	
J	Wilson, AG; Crystal, JD				Wilson, A. George; Crystal, Jonathon D.			Prospective memory in the rat	ANIMAL COGNITION			English	Article						Prospective memory; Prospection; Comparative cognition; Animal model; Rat	MENTAL TIME-TRAVEL; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; WESTERN SCRUB-JAYS; ALZHEIMERS-DISEASE; TASK INTERFERENCE; RADIAL MAZE; FUTURE; ANIMALS; PERFORMANCE	The content of prospective memory is comprised of representations of an action to perform in the future. When people form prospective memories, they temporarily put the memory representation in an inactive state while engaging in other activities, and then activate the representation in the future. Ultimately, successful activation of the memory representation yields an action at an appropriate, but temporally distant, time. A hallmark of prospective memory is that activation of the memory representation has a deleterious effect on current ongoing activity. Recent evidence suggests that scrub jays and non-human primates, but not other species, are capable of future planning. We hypothesized that prospective memory produces a selective deficit in performance at the time when rats access a memory representation but not when the memory representation is inactive. Rats were trained in a temporal bisection task (90 min/day). Immediately after the bisection task, half of the rats received an 8-g meal (meal group) and the other rats received no additional food (no-meal group). Sensitivity to time in the bisection task was reduced as the 90-min interval elapsed for the meal group but not for the no-meal group. This time-based prospective-memory effect was not based on response competition, an attentional limit, anticipatory contrast, or fatigue. Our results suggest that rats form prospective memories, which produces a negative side effect on ongoing activity.	[Wilson, A. George; Crystal, Jonathon D.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA; [Wilson, A. George; Crystal, Jonathon D.] Univ Georgia, Dept Psychol, Athens, GA 30602 USA	Crystal, JD (corresponding author), Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA.	jcrystal@indiana.edu			National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080052]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080052] Funding Source: NIH RePORTER	This work was supported by National Institute of Mental Health grant R01MH080052 to JDC. We thank our colleague, the late Rich Marsh-scholar of prospective memory-for encouraging this work. We thank four anonymous reviewers for constructive criticism.	Aberle I, 2010, DEV PSYCHOL, V46, P1444, DOI 10.1037/a0020718; Atance CM, 2001, TRENDS COGN SCI, V5, P533, DOI 10.1016/S1364-6613(00)01804-0; Blanco-Campal A, 2009, J INT NEUROPSYCH SOC, V15, P154, DOI 10.1017/S1355617708090127; Church R.M., 1978, COGNITIVE PROCESS, P277; CHURCH RM, 1977, J EXP PSYCHOL ANIM B, V3, P216, DOI 10.1037/0097-7403.3.3.216; Clayton NS, 2003, NAT REV NEUROSCI, V4, P685, DOI 10.1038/nrn1180; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COOK RG, 1985, J EXP PSYCHOL ANIM B, V11, P453, DOI 10.1037/0097-7403.11.3.453; Correia SPC, 2007, CURR BIOL, V17, P856, DOI 10.1016/j.cub.2007.03.063; Craik F.I.M., 1986, HUMAN MEMORY COGNITI, P409; Crystal JD, 2003, BEHAV BRAIN RES, V144, P57, DOI 10.1016/S0166-4328(03)00062-7; Crystal JD, 2007, BEHAV PROCESS, V74, P152, DOI 10.1016/j.beproc.2006.10.008; Crystal JD, 2009, BEHAV PROCESS, V80, P269, DOI 10.1016/j.beproc.2008.09.009; d'Ydewalle G, 2001, AM J PSYCHOL, V114, P411, DOI 10.2307/1423688; Driscoll I, 2005, NEUROPSYCHOLOGY, V19, P28, DOI 10.1037/0894-4105.19.1.28; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Flaherty C. F., 1996, INCENTIVE RELATIVITY; FLAHERTY CF, 1982, ANIM LEARN BEHAV, V10, P177, DOI 10.3758/BF03212267; Foster ER, 2009, NEUROPSYCHOLOGY, V23, P347, DOI 10.1037/a0014692; Gallistel, 1990, ORG LEARNING; Gallistel CR, 2009, PSYCHOL REV, V116, P439, DOI 10.1037/a0015251; GIBBON J, 1984, ANN NY ACAD SCI, V423, P52, DOI 10.1111/j.1749-6632.1984.tb23417.x; Gipson CD, 2008, LEARN MOTIV, V39, P285, DOI 10.1016/j.lmot.2008.04.002; Harris J. E., 1984, EVERYDAY MEMORY ACTI, P71; Henry JD, 2004, PSYCHOL AGING, V19, P27, DOI 10.1037/0882-7974.19.1.27; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Hicks JL, 2005, J MEM LANG, V53, P430, DOI 10.1016/j.jml.2005.04.001; Jones S, 2006, NEUROPSYCHOLOGY, V20, P144, DOI 10.1037/0894-4105.20.2.144; Kliegel M, 2001, MEMORY, V9, P1, DOI 10.1080/09658210042000003; Marsh RL, 2006, MEM COGNITION, V34, P1037, DOI 10.3758/BF03193250; Marsh RL, 1998, MEM COGNITION, V26, P633, DOI 10.3758/BF03211383; McCauley SR, 2009, NEUROPSYCHOLOGY, V23, P201, DOI 10.1037/a0014192; McDaniel M. A., 2007, PROSPECTIVE MEMORY O; MECK WH, 1983, J EXP PSYCHOL ANIM B, V9, P171, DOI 10.1037/0097-7403.9.2.171; Mulcahy NJ, 2006, SCIENCE, V312, P1038, DOI 10.1126/science.1125456; Naqshbandi M, 2006, J COMP PSYCHOL, V120, P345, DOI 10.1037/0735-7036.120.4.345; Osvath M, 2008, ANIM COGN, V11, P661, DOI 10.1007/s10071-008-0157-0; Osvath M, 2009, CURR BIOL, V19, pR190, DOI 10.1016/j.cub.2009.01.010; Raby CR, 2007, NATURE, V445, P919, DOI 10.1038/nature05575; Raby CR, 2009, BEHAV PROCESS, V80, P314, DOI 10.1016/j.beproc.2008.12.005; Raskin SA, 2011, NEUROPSYCHOLOGY, V25, P201, DOI 10.1037/a0020999; Roberts WA, 2002, PSYCHOL BULL, V128, P473, DOI 10.1037//0033-2909.128.3.473; Roberts WA, 2009, TRENDS COGN SCI, V13, P271, DOI 10.1016/j.tics.2009.03.003; Russell J, 2010, COGNITION, V114, P56, DOI 10.1016/j.cognition.2009.08.013; Schmitter-Edgecombe M, 2009, NEUROPSYCHOLOGY, V23, P168, DOI 10.1037/a0014186; Sheskin D., 2004, HDB PARAMETRIC NONPA, V3rd; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Smith RE, 2007, J EXP PSYCHOL LEARN, V33, P734, DOI 10.1037/0278-7393.33.4.734; Suddendorf T, 2005, LEARN MOTIV, V36, P110, DOI 10.1016/j.lmot.2005.02.010; Suddendorf T, 2003, TRENDS COGN SCI, V7, P391, DOI 10.1016/S1364-6613(03)00187-6; Suddendorf T, 1997, GENET SOC GEN PSYCH, V123, P133; Suddendorf T, 2007, BEHAV BRAIN SCI, V30, P299, DOI 10.1017/S0140525X07001975; Troyer AK, 2007, J INT NEUROPSYCH SOC, V13, P365, DOI 10.1017/S1355617707070452; TULVING E, 2001, AGE FRONTAL LOBES, P311; Tulving E., 2005, MISSING LINK COGNITI, P3, DOI [DOI 10.1093/ACPROF:OSO/9780195161564.003.0001, 10.1093/acprof:oso/9780195161564.003.0001]; Zentall TR, 2006, BEHAV PROCESS, V72, P173, DOI 10.1016/j.beproc.2006.01.009; Zentall TR, 2005, LEARN MOTIV, V36, P208, DOI 10.1016/j.lmot.2005.03.001	57	28	28	0	24	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1435-9448	1435-9456		ANIM COGN	Anim. Cogn.	MAY	2012	15	3					349	358		10.1007/s10071-011-0459-5			10	Behavioral Sciences; Zoology	Behavioral Sciences; Zoology	926ED	WOS:000302813200006	21922257	Green Accepted			2021-06-18	
J	Guresir, E; Schuss, P; Seifert, V; Vatter, H				Gueresir, Erdem; Schuss, Patrick; Seifert, Volker; Vatter, Hartmut			Decompressive Craniectomy in Children: Single-Center Series and Systematic Review	NEUROSURGERY			English	Article						Brain swelling; Decompressive craniectomy; Subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; REFRACTORY INTRACRANIAL HYPERTENSION; OF-THE-LITERATURE; HEAD-INJURY; MALIGNANT INFARCTION; OXYGENATION CHANGES; CENTER EXPERIENCE; CLINICAL ARTICLE; HEMICRANIECTOMY	BACKGROUND: Decompressive craniectomy (DC) is performed as a life-saving procedure in patients with intractably increased intracranial pressure after traumatic brain injury, bleeding, cerebral infarction, or brain swelling of other causes. However, the application of DC is as controversial in the pediatric population as it is in adults. OBJECTIVE: To find factors influencing the outcome in pediatric patients who underwent DC because of sustained high intracranial pressure. METHODS: Between April 2000 and December 2009, 34 pediatric patients (age 0-18 years) underwent DC. Patients were stratified according to the indication for DC. Outcome was assessed according to the modified Rankin Scale score at 6 months. MEDLINE was searched for published studies or reports of DC in pediatric patients to gain a larger population. Two reviewers independently extracted data. RESULTS: Literature data, including the current series, revealed a total of 172 pediatric patients. Overall, a favorable outcome was achieved in 106 of 172 patients (62%). A favorable outcome was achieved in 25 of 36 patients without traumatic brain injury vs 81 of 136 patients with traumatic brain injury (69% vs 60%). Patients without signs of cerebral herniation had a better outcome than patients with unilateral or bilateral dilated pupils (73% vs 60% vs 45%, respectively). CONCLUSION: The current data indicate that DC in children with traumatic or non-traumatic brain swelling might be warranted, regardless of the underlying cause. Despite mydriasis, a favorable outcome might be achieved in a significant number of pediatric patients. Nevertheless, careful individual decision making is needed for each patient, especially when signs of cerebral herniation have persisted for a long time.	[Gueresir, Erdem; Schuss, Patrick; Seifert, Volker; Vatter, Hartmut] Goethe Univ Frankfurt, Dept Neurosurg, D-60528 Frankfurt, Germany	Guresir, E (corresponding author), Goethe Univ Frankfurt, Dept Neurosurg, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	Gueresir@em.uni-frankfurt.de	guresir, erdem/AAL-4484-2020; Schuss, Patrick/ABC-6469-2020	guresir, erdem/0000-0002-6624-6885; Schuss, Patrick/0000-0002-5806-2576; Guresir, Erdem/0000-0001-8319-0847			Adamo MA, 2009, J NEUROSURG-PEDIATR, V4, P414, DOI 10.3171/2009.6.PEDS0939; Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Aghakhani N, 2009, J NEUROS-PEDIATR, V3, P66, DOI 10.3171/2008.10.PEDS08116; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; Ausman J I, 1976, Surg Neurol, V6, P97; Berger S, 2002, J TRAUMA, V53, P558, DOI 10.1097/00005373-200209000-00027; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; COOK DJ, 1992, CHEST, V102, pS305; Coutinho JM, 2009, STROKE, V40, P2233, DOI 10.1161/STROKEAHA.108.543421; Csokay A, 2001, ACTA NEUROCHIR, V143, P173, DOI 10.1007/s007010170125; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Figaji AA, 2007, CHILD NERV SYST, V23, P1331, DOI 10.1007/s00381-007-0388-4; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; Fukai J, 2009, NEUROL MED-CHIR, V49, P22, DOI 10.2176/nmc.49.22; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Guresir E, 2011, J NEUROSURG, V114, P954, DOI 10.3171/2009.12.JNS091065; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Johnson DL, 1998, PEDIATR NEUROSURG, V28, P167, DOI 10.1159/000028643; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kim KT, 2009, ACTA NEUROCHIR, V151, P21, DOI 10.1007/s00701-008-0164-6; Lee MC, 2003, PEDIATR NEUROSURG, V38, P181, DOI 10.1159/000069096; Marion DW, 2006, NEUROSURGERY, V58, P655; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Rabelino GAG, 2008, PEDIATR NEUROL, V39, P201, DOI 10.1016/j.pediatrneurol.2008.06.006; Ramaswamy V, 2008, J CHILD NEUROL, V23, P889, DOI 10.1177/0883073808314960; Ranger A, 2009, PEDIATR NEUROSURG, V45, P390, DOI 10.1159/000260910; Reithmeier T, 2005, CHILD NERV SYST, V21, P249, DOI 10.1007/s00381-004-1044-x; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Ruggiero A, 2009, INT J HEMATOL, V90, P87, DOI 10.1007/s12185-009-0333-2; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Schwab S, 1997, NEUROLOGY, V48, P412, DOI 10.1212/WNL.48.2.412; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Taferner E, 2001, INTENS CARE MED, V27, P1426, DOI 10.1007/s001340101027; Tan MA, 2006, CHILD NERV SYST, V22, P523, DOI 10.1007/s00381-005-0001-7; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thomale UW, 2010, CHILD NERV SYST, V26, P1563, DOI 10.1007/s00381-010-1103-4; Ushewokunze S, 2009, CHILD NERV SYST, V25, P341, DOI 10.1007/s00381-008-0752-z; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Visocchi M, 2007, ACTA NEUROCHIR, V149, P347, DOI 10.1007/s00701-006-1102-0; Walz B, 2002, J NEUROL, V249, P1183, DOI 10.1007/s00415-002-0798-x; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	61	28	28	1	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2012	70	4					881	888		10.1227/NEU.0b013e318237a6a6			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	914FF	WOS:000301934000044	21946506				2021-06-18	
J	Ahmed, AI; Shtaya, AB; Zaben, MJ; Owens, EV; Kiecker, C; Gray, WP				Ahmed, Aminul I.; Shtaya, Anan B.; Zaben, Malik J.; Owens, Emma V.; Kiecker, Clemens; Gray, William P.			Endogenous GFAP-Positive Neural Stem/Progenitor Cells in the Postnatal Mouse Cortex Are Activated following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral cortex; organotypic slices; stem cells; TBI	HIPPOCAMPAL SLICE CULTURES; CENTRAL-NERVOUS-SYSTEM; SONIC-HEDGEHOG; STEM-CELLS; CEREBRAL-CORTEX; ADULT MICE; PROGENITOR CELLS; DENTATE GYRUS; NEURONAL PRECURSORS; COGNITIVE FUNCTION	Interest in promoting regeneration of the injured nervous system has recently turned toward the use of endogenous stem cells. Elucidating cues involved in driving these precursor cells out of quiescence following injury, and the signals that drive them toward neuronal and glial lineages, will help to harness these cells for repair. Using a biomechanically validated in vitro organotypic stretch injury model, cortico-hippocampal slices from postnatal mice were cultured and a stretch injury equivalent to a severe traumatic brain injury (TBI) applied. In uninjured cortex, proliferative potential under in vitro conditions is virtually absent in older slices (equivalent postnatal day 15 compared to 8). However, following a severe stretch injury, this potential is restored in injured outer cortex. Using slices from mice expressing a fluorescent reporter on the human glial fibrillary acidic protein (GFAP) promoter, we show that GFAP + cells account for the majority of proliferating neurospheres formed, and that these cells are likely to arise from the cortical parenchyma and not from the subventricular zone. Moreover, we provide evidence for a correlation between upregulation of sonic hedgehog signaling, a pathway known to regulate stem cell proliferation, and this restoration of regenerative potential following TBI. Our results indicate that a source of quiescent endogenous stem cells residing in the cortex and subcortical tissue proliferate in vitro following TBI. Moreover, these proliferating cells are multipotent and are derived mostly from GFAP-expressing cells. This raises the possibility of using this endogenous source of stem cells for repair following TBI.	[Gray, William P.] Univ Southampton, Fac Med, Dept Clin Neurosci, Southampton SO16 6YD, Hants, England; [Ahmed, Aminul I.; Shtaya, Anan B.; Zaben, Malik J.; Gray, William P.] Southampton Univ Hosp NHS Trust, Wessex Neurol Ctr, Southampton, Hants, England; [Kiecker, Clemens] Kings Coll London, MRC Ctr Dev Neurobiol, London WC2R 2LS, England	Gray, WP (corresponding author), Univ Southampton, Fac Med, Dept Clin Neurosci, LD70,Level D,S Acad Block,Tremona Rd, Southampton SO16 6YD, Hants, England.	W.P.Gray@soton.ac.uk	Kiecker, Clemens/C-7170-2009; Shtaya, Anan/AAX-2494-2020	Shtaya, Anan/0000-0001-7459-8437; Gray, William/0000-0001-7595-8887; Ahmed, Aminul/0000-0001-6670-0438; Zaben, Malik/0000-0002-7446-4532	Wessex Medical Research; Wessex Neurological Centre Trust; Royal College of Surgeons of England; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0300356]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0801418B] Funding Source: researchfish	This study was supported by the Wessex Medical Research (A. I. A), the Wessex Neurological Centre Trust (A. I. A), the Royal College of Surgeons of England (A. I. A), and the Medical Research Council (strategic grant G0300356 to W. P. G). We thank Professor Frank Kirchhoff (Gottingen) and Alexei Verkhratsky (Manchester) for supply of the GFAP-GFP transgenic mice, and David Johnston (Biomedical Imaging Unit, University of Southampton) for help with image analysis.	Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009; Arsenijevic Y, 2001, EXP NEUROL, V170, P48, DOI 10.1006/exnr.2001.7691; Bendel O, 2005, J CEREBR BLOOD F MET, V25, P1586, DOI 10.1038/sj.jcbfm.9600153; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; Burns KA, 2009, GLIA, V57, P1115, DOI 10.1002/glia.20835; CAVINESS VS, 1973, J COMP NEUROL, V148, P141, DOI 10.1002/cne.901480202; Chapman SC, 2002, DEV BIOL, V245, P187, DOI 10.1006/dbio.2002.0641; Chechneva O, 2005, NEUROSCIENCE, V136, P343, DOI 10.1016/j.neuroscience.2005.07.058; Chen JH, 2004, P NATL ACAD SCI USA, V101, P16357, DOI 10.1073/pnas.0406795101; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Coles-Takabe BLK, 2008, STEM CELLS, V26, P2938, DOI 10.1634/stemcells.2008-0558; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; Dimou L, 2008, J NEUROSCI, V28, P10434, DOI 10.1523/JNEUROSCI.2831-08.2008; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Garcia ADR, 2010, J NEUROSCI, V30, P13597, DOI 10.1523/JNEUROSCI.0830-10.2010; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Han YG, 2008, NAT NEUROSCI, V11, P277, DOI 10.1038/nn2059; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Jhaveri DJ, 2010, J NEUROSCI, V30, P2795, DOI 10.1523/JNEUROSCI.3780-09.2010; Jiao J, 2008, STEM CELLS, V26, P1221, DOI 10.1634/stemcells.2007-0513; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Koketsu D, 2003, J NEUROSCI, V23, P937; Kondziolka D, 2005, J NEUROSURG, V103, P38, DOI 10.3171/jns.2005.103.1.0038; Kornack DR, 2001, SCIENCE, V294, P2127, DOI 10.1126/science.1065467; Krystkowiak P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000166; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Magavi SS, 2000, NATURE, V405, P951; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nolte C, 2001, GLIA, V33, P72; Ohira K, 2010, NAT NEUROSCI, V13, P173, DOI 10.1038/nn.2473; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Palmer TD, 1999, J NEUROSCI, V19, P8487; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Raineteau O, 2004, MOL CELL NEUROSCI, V26, P241, DOI 10.1016/j.mcn.2004.01.003; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; Richardson RM, 2006, ACTA NEUROCHIR, V148, P773, DOI 10.1007/s00701-006-0778-5; Rivers LE, 2008, NAT NEUROSCI, V11, P1392, DOI 10.1038/nn.2220; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; RUIZ IAA, 2002, NAT REV NEUROSCI, V3, P24, DOI DOI 10.1038/NRN704; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Seidenfaden R, 2006, MOL CELL NEUROSCI, V32, P187, DOI 10.1016/j.mcn.2006.04.003; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Seri B, 2004, J COMP NEUROL, V478, P359, DOI 10.1002/cne.20288; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Soares HD, 1995, J NEUROSCI, V15, P8223; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2010, J NEUROSCI, V30, P14008, DOI 10.1523/JNEUROSCI.3605-10.2010; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Wang L, 2007, J BIOL CHEM, V282, P32462, DOI 10.1074/jbc.M706880200; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zaben M, 2009, STEM CELLS, V27, P2539, DOI 10.1002/stem.184	75	28	30	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					828	842		10.1089/neu.2011.1923			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900011	21895532	Green Published			2021-06-18	
J	Hudak, AM; Hynan, LS; Harper, CR; Diaz-Arrastia, R				Hudak, A. M.; Hynan, L. S.; Harper, C. R.; Diaz-Arrastia, R.			Association of Depressive Symptoms With Functional Outcome After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						BDI-II; depression; function; FSE; outcomes; Traumatic brain injury	COMORBIDITY SURVEY REPLICATION; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; SIGNIFICANT OTHERS; MASS VIOLENCE; INVENTORY-II; HEAD TRAUMA; BDI-II; MILD; MODERATE	Objective: To test whether improved functional status correlates with more depressive symptoms after traumatic brain injury (TBI). This is based on the concept that increasing awareness of deficits may exacerbate depression, even while survivors are making functional improvements. Participants: A total of 471 individuals with TBI (72% white; 71% men; median Glasgow Coma Scale (GCS) score = 11) enrolled during acute care or inpatient rehabilitation and followed up at a median of 6 months. Main Measure: Beck Depression Inventory-II (BDI-II), Glasgow Outcome Scale-Extended, and Functional Status Examination (FSE). Results: We found significant Spearman rank order correlations between BDI-II scores and the total FSE as well as all domains of the FSE. Lower functional levels correlated with more depressive symptoms. Modeling of predictive factors, including subject characteristics, injury-related characteristics, and outcome measures, resulted in 2 models, both containing age and GCS along with other factors. Conclusion: The relation between depressive symptoms and functional outcomes is complex and a fertile area for further research. The authors would encourage clinicians to monitor patients for depressive symptoms to help to prevent the detrimental impact on recovery.	[Hudak, A. M.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Hynan, L. S.] Univ Texas SW Med Ctr Dallas, Div Biostat, Dept Clin Sci, Dallas, TX 75390 USA; [Hynan, L. S.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Harper, C. R.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Diaz-Arrastia, R.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Rockville, MD USA	Hudak, AM (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 730 E Broad St,Box 843038, Richmond, VA 23298 USA.	Ahudak@vcu.edu	Hynan, Linda S/P-6473-2016	Diaz-Arrastia, Ramon/0000-0001-6051-3594; Hynan, Linda/0000-0002-4642-7769	 [NIH 5 KL2 RR024983-02];  [NIH R01 HD48179];  [NIH U01 HD42652];  [NIDRR H133AO252604]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024983] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003138] Funding Source: NIH RePORTER	This work was supported in part by grants NIH 5 KL2 RR024983-02, NIH R01 HD48179, NIH U01 HD42652, and NIDRR H133AO252604.	[Anonymous], 2000, DIAGNOSTIC STAT MANU; Beck A.T., 1996, MANUAL BECK DEPRESSI; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chaytor N, 2007, J INT NEUROPSYCH SOC, V13, P377, DOI 10.1017/S1355617707070592; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dozois DJA, 1998, PSYCHOL ASSESSMENT, V10, P83, DOI 10.1037/1040-3590.10.2.83; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Henry JD, 2005, J CLIN EXP NEUROPSYC, V27, P78, DOI 10.1080/138033990513654; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; HOSMER DW, 1989, APPL LOGISTIC REGRES, P86; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kirkness Catherine J, 2002, J Neurosci Nurs, V34, P134; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Mollica RF, 2002, BRIT J PSYCHIAT, V181, P339, DOI 10.1192/bjp.181.4.339; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; Prigatano GP, 1997, PERSP PSYCH, V6, P341; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; SAS, 2008, SAS WIND VERS 9 2; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SPSS, 2008, SPSS WIND VERS 17; Storch EA, 2004, DEPRESS ANXIETY, V19, P187, DOI 10.1002/da.20002; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; TEASDALE G, 1974, LANCET, V2, P81; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wallace CA, 2000, BRAIN INJURY, V14, P549; Weinstein CS, 2001, NEUROPSYCHOL REV, V11, P131, DOI 10.1023/A:1016650623996; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Whisman MA, 2000, J CLIN PSYCHOL, V56, P545, DOI 10.1002/(SICI)1097-4679(200004)56:4<545::AID-JCLP7>3.0.CO;2-U; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 1993, INT CLASS IMP DIS HA	66	28	28	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2012	27	2					87	98		10.1097/HTR.0b013e3182114efd			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	912LI	WOS:000301799100001	22411107	Green Accepted			2021-06-18	
J	Ji, J; Tyurina, YY; Tang, MK; Feng, WH; Stolz, DB; Clark, RSB; Meaney, DF; Kochanek, PM; Kagan, VE; Bayir, H				Ji, Jing; Tyurina, Yulia Y.; Tang, Minke; Feng, Weihong; Stolz, Donna B.; Clark, Robert S. B.; Meaney, David F.; Kochanek, Patrick M.; Kagan, Valerian E.; Bayir, Huelya			Mitochondrial Injury after Mechanical Stretch of Cortical Neurons in vitro: Biomarkers of Apoptosis and Selective Peroxidation of Anionic Phospholipids	JOURNAL OF NEUROTRAUMA			English	Article						cardiolipin; in vitro traumatic brain injury; mitochondria; oxidative lipidomics; oxidative stress	TRAUMATIC BRAIN-INJURY; DEPENDENT PROTEIN-KINASE; CYTOCHROME-C RELEASE; INDUCED CELL-DEATH; OXIDATIVE LIPIDOMICS; ER STRESS; CARDIOLIPIN; MODEL; ACTIVATION; DAMAGE	Mechanical injury of neurites accompanied by rupture of mitochondrial membranes may lead to immediate nonspecific release and spreading of pro-apoptotic factors and activation of proteases, that is, execution of apoptotic program. In the current work, we studied the time course of the major biomarkers of apoptosis as they are induced by exposure of rat cortical neurons to mechanical stretch. By using transmission electron microscopy, we found that mitochondria in the neurites were damaged early (1 h) after mechanical stretch injury whereas somal mitochondria were significantly more resistant and demonstrated structural damage and degenerative mitochondrial changes at a later time point after stretch (12 h). We also report that the stretch injury caused immediate activation of reactive oxygen species production followed by selective oxidation of a mitochondria-specific phospholipid, cardiolipin, whose individual peroxidized molecular species have been identified and quantified by electrospray ionization mass spectrometry analysis. Most abundant neuronal phospholipids - phosphatidylcholine, phophatidylethanolamine - did not undergo oxidative modification. Simultaneously, a small-scale release of cytochrome c was observed. Notably, caspase activation and phosphatidylserine externalization - two irreversible apoptotic events designating a point of no return - are substantially delayed and do not occur until 6-12 h after the initial impact. The early onset of reactive oxygen species production and cytochrome c release may be relevant to direct stretch-induced damage to mitochondria. The delayed emergence of apoptotic neuronal death after the immediate mechanical damage to mitochondria suggests a possible window of opportunity for targeted therapies.	[Ji, Jing; Tyurina, Yulia Y.; Feng, Weihong; Kagan, Valerian E.; Bayir, Huelya] Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA USA; [Ji, Jing; Tyurina, Yulia Y.; Feng, Weihong; Kagan, Valerian E.; Bayir, Huelya] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Tang, Minke; Clark, Robert S. B.; Kochanek, Patrick M.; Bayir, Huelya] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Tang, Minke; Clark, Robert S. B.; Kochanek, Patrick M.; Bayir, Huelya] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Stolz, Donna B.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Tyurina, YY (corresponding author), Bridgeside Point, 100 Technol Dr,Suite 350, Pittsburgh, PA 15219 USA.	yyt1@pitt.edu; bayihx@ccm.upmc.edu	Ji, J/O-2816-2013; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Kagan, Valerian E./0000-0002-7245-1885; Tyurina, Yulia/0000-0003-0287-2091; Meaney, David/0000-0002-0954-4122	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL70755, U19AI068021, NS061817]; Defense Advanced Research Projects Agency Preventing Violent Explosive Neurologic Trauma (DARPA PREVENT) [N66001-10-C-2124]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL070755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061817] Funding Source: NIH RePORTER	This work was ssupported by grants from the National Institute of Health (HL70755, U19AI068021, NS061817) and by the Defense Advanced Research Projects Agency Preventing Violent Explosive Neurologic Trauma (DARPA PREVENT) blast program N66001-10-C-2124. The views, opinions, and/or findings contained in this article should not be interpreted as representing the official views or policies, either expressed or implied, of DARPA or the Department of Defense.	Ainslie KM, 2008, ACS NANO, V2, P1076, DOI 10.1021/nn800071k; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bayir H, 2009, J BIOL CHEM, V284, P15951, DOI 10.1074/jbc.M900418200; Borisenko GG, 2008, BIOCHEMISTRY-US, V47, P13699, DOI 10.1021/bi801507s; BOTTCHER CSF, 1961, ANAL CHIM ACTA, V1061, P203; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Cao GD, 2007, J NEUROSCI, V27, P9278, DOI 10.1523/JNEUROSCI.2826-07.2007; Cardaci S, 2008, MOL PHARMACOL, V74, P1234, DOI 10.1124/mol.108.048975; Chauvier D, 2007, CELL DEATH DIFFER, V14, P387, DOI 10.1038/sj.cdd.4402044; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Dai DF, 2011, J AM COLL CARDIOL, V58, P73, DOI 10.1016/j.jacc.2010.12.044; Dietz GPH, 2007, BRAIN RES, V1164, P136, DOI 10.1016/j.brainres.2007.06.025; Fadeel B, 2003, CELL MOL LIFE SCI, V60, P2575, DOI 10.1007/s00018-003-3145-1; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gartlon J, 2006, TOXICOL IN VITRO, V20, P1569, DOI 10.1016/j.tiv.2006.07.009; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gil-Ad I, 2001, CELL MOL NEUROBIOL, V21, P705, DOI 10.1023/A:1015152021192; Iverson SL, 2004, ARCH BIOCHEM BIOPHYS, V423, P37, DOI 10.1016/j.abb.2003.12.002; Ji J., 2010, J NEUROTRAUM, V5, pA; Jiang JF, 2004, LIPIDS, V39, P1133, DOI 10.1007/s11745-004-1340-1; Jiang JF, 2008, INT J RADIAT ONCOL, V70, P816, DOI 10.1016/j.ijrobp.2007.10.047; Kagan VE, 2009, MOL NUTR FOOD RES, V53, P104, DOI 10.1002/mnfr.200700402; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kagan VE, 2003, AM J PHYSIOL-LUNG C, V285, pL1, DOI 10.1152/ajplung.00365.2002; Kapralov AA, 2007, BIOCHEMISTRY-US, V46, P14232, DOI 10.1021/bi701237b; Kiebish MA, 2008, J NEUROCHEM, V106, P299, DOI 10.1111/j.1471-4159.2008.05383.x; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuznetsov AV, 2009, INT J BIOCHEM CELL B, V41, P1928, DOI 10.1016/j.biocel.2009.03.007; Lahiry L, 2008, APOPTOSIS, V13, P771, DOI 10.1007/s10495-008-0213-x; LAI JCK, 1977, J NEUROCHEM, V28, P625, DOI 10.1111/j.1471-4159.1977.tb10434.x; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Macias CA, 2007, ANN SURG, V245, P305, DOI 10.1097/01.sla.0000236626.57752.8e; Mironov SL, 2009, INT J BIOCHEM CELL B, V41, P2005, DOI 10.1016/j.biocel.2009.04.009; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pedersen MO, 2009, PROG HISTOCHEM CYTO, V44, P1, DOI 10.1016/j.proghi.2008.10.002; Petrosillo G, 2006, FEBS LETT, V580, P6311, DOI 10.1016/j.febslet.2006.10.036; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Pop C, 2008, METHOD ENZYMOL, V446, P351, DOI 10.1016/S0076-6879(08)01621-2; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Samali A, 1999, CELL DEATH DIFFER, V6, P495, DOI 10.1038/sj.cdd.4400520; Schlame M, 2008, J LIPID RES, V49, P1607, DOI 10.1194/jlr.R700018-JLR200; Schwartz J.C., 2005, P 53 AM SOC MASS SPE; Shimazawa M, 2007, INVEST OPHTH VIS SCI, V48, P3729, DOI 10.1167/iovs.06-1122; Shimazawa M, 2006, NEUROSCI LETT, V409, P192, DOI 10.1016/j.neulet.2006.09.074; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Suzuki M, 2005, J NEUROSCI RES, V80, P549, DOI 10.1002/jnr.20461; Tyurin VA, 2008, J NEUROCHEM, V107, P1614, DOI 10.1111/j.1471-4159.2008.05728.x; Tyurina YY, 2006, MOL PHARMACOL, V70, P706, DOI 10.1124/mol.106.022731; Tyurina YY, 2004, BIOCHEM BIOPH RES CO, V324, P1059, DOI 10.1016/j.bbrc.2004.09.102; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yang LH, 2000, NEUROSCI LETT, V295, P97, DOI 10.1016/S0304-3940(00)01597-4; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zielonka J, 2010, FREE RADICAL BIO MED, V48, P983, DOI 10.1016/j.freeradbiomed.2010.01.028	75	28	30	1	18	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					776	788		10.1089/neu.2010.1602			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900008	21895519	Green Published			2021-06-18	
J	Kaloostian, P; Robertson, C; Gopinath, SP; Stippler, M; King, CC; Qualls, C; Yonas, H; Nemoto, EM				Kaloostian, Paul; Robertson, Claudia; Gopinath, Shankar P.; Stippler, Martina; King, C. Christopher; Qualls, Clifford; Yonas, Howard; Nemoto, Edwin M.			Outcome Prediction within Twelve Hours after Severe Traumatic Brain Injury by Quantitative Cerebral Blood Flow	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; Glasgow Outcome Scale; outcome prediction; quantitative stable xenon CT; traumatic brain injury	GLASGOW COMA SCALE; PROGNOSTIC ANALYSIS; CLINICAL-TRIALS; HEAD-INJURY; ISCHEMIA; NEUROPROTECTION; HYPEROXIA; IMPACT; TISSUE; EPIDEMIOLOGY	We measured quantitative cortical mantle cerebral blood flow (CBF) by stable xenon computed tomography (CT) within the first 12 h after severe traumatic brain injury (TBI) to determine whether neurologic outcome can be predicted by CBF stratification early after injury. Stable xenon CT was used for quantitative measurement of CBF (mL/100g/min) in 22 cortical mantle regions stratified as follows: low (0-8), intermediate (9-30), normal (31-70), and hyperemic (>70) in 120 patients suffering severe (Glasgow Coma Scale [GCS] score <= 8) TBI. For each of these CBF strata, percentages of total cortical mantle volume were calculated. Outcomes were assessed by Glasgow Outcome Scale (GOS) score at discharge (DC), and 1, 3, and 6 months after discharge. Quantitative cortical mantle CBF differentiated GOS 1 and GOS 2 (dead or vegetative state) from GOS 3-5 (severely disabled to good recovery; p < 0.001). Receiver operating characteristic (ROC) curve analysis for percent total normal plus hyperemic flow volume (TNHV) predicting GOS 3-5 outcome at 6 months for CBF measured < 6 and < 12 h after injury showed ROC area under the curve (AUC) cut-scores of 0.92 and 0.77, respectively. In multivariate analysis, percent TNHV is an independent predictor of GOS 3-5, with an odds ratio of 1.460 per 10 percentage point increase, as is initial GCS score (OR = 1.090). The binary version of the Marshall CT score was an independent predictor of 6-month outcome, whereas age was not. These results suggest that quantitative cerebral cortical CBF measured within the first 6 and 12 h after TBI predicts 6-month outcome, which may be useful in guiding patient care and identifying patients for randomized clinical trials. A larger multicenter randomized clinical trial is indicated.	[Kaloostian, Paul; Stippler, Martina; Yonas, Howard; Nemoto, Edwin M.] Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA; [Robertson, Claudia; Gopinath, Shankar P.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [King, C. Christopher] AMC Emergency Med Grp, Dept Emergency Med, Albany, NY USA	Nemoto, EM (corresponding author), Univ New Mexico, Dept Neurosurg, 1 Univ New Mexico, Albuquerque, NM 87131 USA.	enemoto@salud.unm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS061216, NS051639, P01-NS38660]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051639, P01NS038660, R03NS061216] Funding Source: NIH RePORTER	We wish to acknowledge the xenon CT technicians at Baylor College of Medicine as well as the nursing staff for their dedication to this project. This work was supported in part by National Institutes of Health grants no. NS061216, NS051639, and P01-NS38660.	ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; Bandera E, 2006, STROKE, V37, P1334, DOI 10.1161/01.STR.0000217418.29609.22; Baron JC, 2001, CEREBROVASC DIS, V11, P2, DOI 10.1159/000049119; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Dunham CM, 2004, J TRAUMA, V56, P482, DOI 10.1097/01.TA.0000114537.52540.95; Hattori N, 2003, J NUCL MED, V44, P1709; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; JENNETT B, 1976, LANCET, V1, P1031; Jovin TG, 2003, STROKE, V34, P2426, DOI 10.1161/01.STR.0000091232.81947.C9; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Marchal G, 1996, STROKE, V27, P599, DOI 10.1161/01.STR.27.4.599; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mazzeo AT, 2006, J NEUROSURG ANESTH, V18, P170, DOI 10.1097/01.ana.0000210999.18033.f6; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Menon DK, 2006, CURR OPIN CRIT CARE, V12, P85, DOI 10.1097/01.ccx.0000216572.19062.8f; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Symon L., 1997, J CLIN PATHOL S, V11, P149; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yeoman P, 2011, J TRAUMA, V71, P387, DOI 10.1097/TA.0b013e31820ceadd; YONAS H, 1991, J CEREBR BLOOD F MET, V11, P716, DOI 10.1038/jcbfm.1991.128; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	53	28	30	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					727	734		10.1089/neu.2011.2147			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900003	22111910	Green Published			2021-06-18	
J	Shah, S; Yallampalli, R; Merkley, TL; McCauley, SR; Bigler, ED; MacLeod, M; Chu, ZL; Li, XQ; Troyanskaya, M; Hunter, JV; Levin, HS; Wilde, EA				Shah, Sanjeev; Yallampalli, Ragini; Merkley, Tricia L.; McCauley, Stephen R.; Bigler, Erin D.; MacLeod, Marianne; Chu, Zili; Li, Xiaoqi; Troyanskaya, Maya; Hunter, Jill V.; Levin, Harvey S.; Wilde, Elisabeth A.			Diffusion tensor imaging and volumetric analysis of the ventral striatum in adults with traumatic brain injury	BRAIN INJURY			English	Article						Neuroimaging; MRI; DTI; TBI; executive functioning	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; NUCLEUS-ACCUMBENS; DECISION-MAKING; PREFRONTAL CORTEX; AXONAL INJURY; HEAD-INJURY; MODERATE; SCALE; IMPULSIVITY; MORPHOMETRY	Objectives: The aim was to determine if there are changes in the integrity and volume of the ventral striatum following severe traumatic brain injury (TBI) and if these changes relate to executive functioning. Methods: This study recruited 14 participants with severe TBI (mean age: 22 years) and 15 demographically-matched controls. All participants underwent magnetic resonance imaging with diffusion tensor imaging (DTI) and volumetric analysis at 6 months post-injury. Participants with TBI underwent neuropsychological testing and the relation between imaging data and cognitive performance was examined. Results: Differences in DTI parameters (fractional anisotropy (FA) and apparent diffusion coefficient (ADC)) were found between participants with TBI and controls. Correlations between right and left ventral striatum ADC and the executive functioning factor of the Neurobehavioural Rating Scale-Revised (NRS-R) were found. Correlations between right ventral striatum FA and the Controlled Oral Word Association Test, Trails Making Test Part B (TMT-B) time and NRS-R executive functioning factor were also found. Volumetric analysis showed a difference only in left nucleus accumbens between TBI and control groups. Conclusions: The integrity of the ventral striatum is affected following severe TBI. Decreases in executive functioning are related to damage to the ventral striatum and its associated structures.	[Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Shah, Sanjeev] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Shah, Sanjeev; Yallampalli, Ragini; Merkley, Tricia L.; McCauley, Stephen R.; MacLeod, Marianne; Li, Xiaoqi; Troyanskaya, Maya; Levin, Harvey S.; Wilde, Elisabeth A.] Univ Texas Houston Med Sch, Houston, TX USA; [Yallampalli, Ragini; McCauley, Stephen R.; Troyanskaya, Maya; Levin, Harvey S.; Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Merkley, Tricia L.; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [McCauley, Stephen R.; Levin, Harvey S.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Chu, Zili; Hunter, Jill V.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA	Wilde, EA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	ewilde@bcm.edu	Merkley, Tricia/AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	Dana Foundation	The authors report no conflicts of interest. Funding for this project was provided by a grant from the Dana Foundation (PI: Wilde).	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Basar K, 2010, PROG NEUROBIOL, V92, P533, DOI 10.1016/j.pneurobio.2010.08.007; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bolla KI, 2004, CEREB CORTEX, V14, P1226, DOI 10.1093/cercor/bhh083; Buchel C, 2011, NEUROIMAGE, V57, P1124, DOI 10.1016/j.neuroimage.2011.05.031; Cardinal RN, 2001, SCIENCE, V292, P2499, DOI 10.1126/science.1060818; Carmona S, 2009, BIOL PSYCHIAT, V66, P972, DOI 10.1016/j.biopsych.2009.05.013; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; Cohen J, 1988, POWER ANAL BEHAV SCI; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; George O, 2010, NEUROSCI BIOBEHAV R, V35, P232, DOI 10.1016/j.neubiorev.2010.05.002; Goldenberg G, 1999, J NEUROL NEUROSUR PS, V67, P163, DOI 10.1136/jnnp.67.2.163; Haber SN, 2003, J CHEM NEUROANAT, V26, P317, DOI 10.1016/j.jchemneu.2003.10.003; Haber SN, 1999, ANN NY ACAD SCI, V877, P33, DOI 10.1111/j.1749-6632.1999.tb09259.x; Heimer L, 2006, NEUROSCI BIOBEHAV R, V30, P126, DOI 10.1016/j.neubiorev.2005.06.006; Heimer L, 1975, GOLGI CENTENNIAL S P, P177; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Lehericy S, 2004, ANN NEUROL, V55, P522, DOI 10.1002/ana.20030; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; MACDONALD PA, 2011, PARKINSONS DIS-US, P72743, DOI DOI 10.4061/2011/572743; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Martinaud O, 2009, EUR J NEUROL, V16, P595, DOI 10.1111/j.1468-1331.2009.02546.x; Martinez D, 2005, BIOL PSYCHIAT, V58, P779, DOI 10.1016/j.biopsych.2005.04.044; Matthews SC, 2004, NEUROREPORT, V15, P2123, DOI 10.1097/00001756-200409150-00025; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Salat DH, 2009, NEUROIMAGE, V48, P21, DOI 10.1016/j.neuroimage.2009.06.074; Scheres A, 2007, BIOL PSYCHIAT, V61, P720, DOI 10.1016/j.biopsych.2006.04.042; Slawik H, 2009, J NEUROTRAUM, V26, P1891, DOI 10.1089/neu.2009.0942; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; TEASDALE G, 1974, LANCET, V2, P81; Tranel D, 2005, BRAIN, V128, P2872, DOI 10.1093/brain/awh643; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; Volkow ND, 2007, J NEUROSCI, V27, P12700, DOI 10.1523/JNEUROSCI.3371-07.2007; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333	42	28	28	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2012	26	3					201	210		10.3109/02699052.2012.654591			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	899XD	WOS:000300849100001	22372408				2021-06-18	
J	Zumsteg, JM; Ennis, SK; Jaffe, KM; Mangione-Smith, R; MacKenzie, EJ; Rivara, FP				Zumsteg, Jennifer M.; Ennis, Stephanie K.; Jaffe, Kenneth M.; Mangione-Smith, Rita; MacKenzie, Ellen J.; Rivara, Frederick P.		Natl Expert Panel Dev Pediat Rehab	Quality of Care Indicators for the Structure and Organization of Inpatient Rehabilitation Care of Children With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Outcome and process assessment (health care); Pediatrics; Quality of health care; Rehabilitation	POSTACUTE REHABILITATION; UNITED-STATES; OUTCOMES; MORTALITY; VOLUME; CENTERS; POLICY	Zumsteg JM, Ennis SK, Jaffe KM, MangioneSmith R, MacKenzie EJ, Rivara FP, and the National Expert Panel for the Development of Pediatric Rehabilitation Quality of Care Indicators. Quality of care indicators for the structure and organization of inpatient rehabilitation care of children with traumatic brain injury. Arch Phys Med Rehabil 2012;93:386-93. Objectives: To develop evidence-based and expert-driven quality indicators for measuring variations in the structure and organization of acute inpatient rehabilitation for children after traumatic brain injury (TBI) and to survey centers across the United States to determine the degree of variation in care. Design: Quality indicators were developed using the RAND/UCLA modified Delphi method. Adherence to these indicators was determined from a survey of rehabilitation facilities. Setting: Inpatient rehabilitation units in the United States. Participants: A sample of rehabilitation programs identified using data from the National Association of Children's Hospitals and Related Institutions, Uniform Data System for Medical Rehabilitation, and the Commission on Accreditation of Rehabilitation Facilities yielded 74 inpatient units treating children with TBI. Survey respondents comprised 31 pediatric and 28 all age units. Interventions: Not applicable. Main Outcome Measures: Variations in structure and organization of care among institutions providing acute inpatient rehabilitation for children with TBI. Results: Twelve indicators were developed. Pediatric inpatient rehabilitation units and units with higher volumes of children with TBI were more likely to have: a census of at least 1 child admitted with a TBI for at least 90% of the time; adequate specialized equipment; a classroom; a pediatric sub-specialty trained medical director; and more than 75% of therapists with pediatric training. Conclusions: There were clinically and statistically significant variations in the structure and organization of acute pediatric rehabilitation based on the pediatric focus of the unit and volume of children with TBI.	[Ennis, Stephanie K.; Jaffe, Kenneth M.; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Zumsteg, Jennifer M.; Ennis, Stephanie K.; Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; [Mangione-Smith, Rita; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98104 USA; [Mangione-Smith, Rita; Rivara, Frederick P.] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA	Rivara, FP (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Box 359960,325 9th Ave, Seattle, WA 98104 USA.	fpr@uw.edu		Krach, Linda/0000-0002-0993-8199; Zumsteg, Jennifer/0000-0002-0678-0103; Gaebler-Spira, Deborah/0000-0001-6827-4241	Eunice Kennedy Shriver National Institute of Child Health & Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21 HD059049-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD059049] Funding Source: NIH RePORTER	Supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development (grant no. R21 HD059049-01A1).	Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987; Aiken LH, 2010, HEALTH SERV RES, V45, P904, DOI 10.1111/j.1475-6773.2010.01114.x; [Anonymous], 2011, EM MED SERV TRAUM SY; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; BROOK RH, 1994, METHODOLOGICAL PERSP; Carney N, 1999, Evid Rep Technol Assess (Summ), P1; Clohan DB, 2007, ARCH PHYS MED REHAB, V88, P1535, DOI 10.1016/j.apmr.2007.07.022; Committee for the Accreditation of Rehabilitation Facilities (CARF), 2009, MED REH STAND MAN; Cortes CG, 2008, J PEDIATR REHAB MED, V1, P51; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Donabedian A., 1980, EXPLORATIONS QUALITY; Duncan PW, 2007, ARCH PHYS MED REHAB, V88, P1482, DOI 10.1016/j.apmr.2007.08.118; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fitch K, 2006, RAND UCLA APPROPRIAT; FRENCH K, 1981, INT J NURS STUD, V18, P7, DOI 10.1016/0020-7489(81)90004-3; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Hemingway H, 2001, NEW ENGL J MED, V344, P645, DOI 10.1056/NEJM200103013440906; Hoenig H, 2002, MED CARE, V40, P1036, DOI 10.1097/00005650-200211000-00005; Hoenig H, 2001, HEALTH SERV RES, V35, P1293; Jaffe KM, 2008, J TRAUMA, V64, P819, DOI 10.1097/TA.0b013e318165f177; Jha AK, 2008, NEW ENGL J MED, V359, P1921, DOI 10.1056/NEJMsa0804116; Kane RL, 2007, MED CARE, V45, P1195, DOI 10.1097/MLR.0b013e3181468ca3; Kravitz RL, 1997, HEALTH POLICY, V42, P135, DOI 10.1016/S0168-8510(97)00064-X; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 2008, J BONE JOINT SURG AM, V90A, P101, DOI 10.2106/JBJS.F.01225; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Odetola FO, 2010, ARCH PEDIAT ADOL MED, V164, P277, DOI 10.1001/archpediatrics.2009.285; Orr RA, 2009, PEDIATRICS, V124, P40, DOI 10.1542/peds.2008-0515; Petrosyan M, 2009, J TRAUMA, V67, pS114, DOI 10.1097/TA.0b013e3181ad3251; PHILIPS B, OXFORD CTR EVIDENCE; Potoka DA, 2001, J TRAUMA, V51, P824, DOI 10.1097/00005373-200111000-00002; Reuben DB, 2002, MED CARE, V40, P416, DOI 10.1097/00005650-200205000-00007; Shekelle PG, 1998, INT J TECHNOL ASSESS, V14, P707, DOI 10.1017/S0266462300012022; Sitzia J, 1998, INT J QUAL HEALTH C, V10, P311, DOI 10.1093/intqhc/10.4.311; The ERABI Research Group, EV BAS REV MOD SEV A; TURNERSTOKES L, 2003, REHABILITATION FOLLO; Wesson D, 2001, J TRAUMA, V51, P832; Whyte J, 2009, NEUROPSYCHOL REHABIL, V19, P807, DOI 10.1080/09602010903031146	41	28	28	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2012	93	3					386	393		10.1016/j.apmr.2011.08.018			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	902GW	WOS:000301027600002	22280893	Green Accepted			2021-06-18	
J	Rodger, J; Drummond, ES; Hellstrom, M; Robertson, D; Harvey, AR				Rodger, Jennifer; Drummond, Eleanor S.; Hellstroem, Mats; Robertson, Donald; Harvey, Alan R.			Long-Term Gene Therapy Causes Transgene-Specific Changes in the Morphology of Regenerating Retinal Ganglion Cells	PLOS ONE			English	Article							PERIPHERAL-NERVE GRAFTS; LEBERS CONGENITAL AMAUROSIS; NEUROTROPHIC FACTOR; NEURITE OUTGROWTH; DENDRITIC GROWTH; PROTEASE NEXIN-1; ADULT CATS; SYMPATHETIC NEURONS; HIPPOCAMPAL-NEURONS; AXONAL REGENERATION	Recombinant adeno-associated viral (rAAV) vectors can be used to introduce neurotrophic genes into injured CNS neurons, promoting survival and axonal regeneration. Gene therapy holds much promise for the treatment of neurotrauma and neurodegenerative diseases; however, neurotrophic factors are known to alter dendritic architecture, and thus we set out to determine whether such transgenes also change the morphology of transduced neurons. We compared changes in dendritic morphology of regenerating adult rat retinal ganglion cells (RGCs) after long-term transduction with rAAV2 encoding: (i) green fluorescent protein (GFP), or (ii) bi-cistronic vectors encoding GFP and ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor (BDNF) or growth-associated protein-43 (GAP43). To enhance regeneration, rats received an autologous peripheral nerve graft onto the cut optic nerve of each rAAV2 injected eye. After 5-8 months, RGCs with regenerated axons were retrogradely labeled with fluorogold (FG). Live retinal wholemounts were prepared and GFP positive (transduced) or GFP negative (non-transduced) RGCs injected iontophoretically with 2% lucifer yellow. Dendritic morphology was analyzed using Neurolucida software. Significant changes in dendritic architecture were found, in both transduced and non-transduced populations. Multivariate analysis revealed that transgenic BDNF increased dendritic field area whereas GAP43 increased dendritic complexity. CNTF decreased complexity but only in a subset of RGCs. Sholl analysis showed changes in dendritic branching in rAAV2-BDNF-GFP and rAAV2-CNTF-GFP groups and the proportion of FG positive RGCs with aberrant morphology tripled in these groups compared to controls. RGCs in all transgene groups displayed abnormal stratification. Thus in addition to promoting cell survival and axonal regeneration, vector-mediated expression of neurotrophic factors has measurable, gene-specific effects on the morphology of injured adult neurons. Such changes will likely alter the functional properties of neurons and may need to be considered when designing vector-based protocols for the treatment of neurotrauma and neurodegeneration.	[Rodger, Jennifer] Univ Western Australia, Sch Anim Biol, Perth, WA 6009, Australia; [Drummond, Eleanor S.; Hellstroem, Mats; Harvey, Alan R.] Univ Western Australia, Sch Anat & Human Biol, Perth, WA 6009, Australia; [Robertson, Donald] Univ Western Australia, Discipline Physiol, Sch Biomed & Biomol Sci, Perth, WA 6009, Australia	Rodger, J (corresponding author), Univ Western Australia, Sch Anim Biol, Perth, WA 6009, Australia.	alan.harvey@uwa.edu.au	Drummond, Eleanor/AAB-9731-2021; Harvey, Alan/A-4911-2008; Rodger, Jennifer/H-5735-2014	Rodger, Jennifer/0000-0003-3413-4229; , Alan/0000-0002-2590-831X; Drummond, Eleanor/0000-0002-5466-4609	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia; WA Neurotrauma Research Program; Raine Foundation of Western Australia; International Postgraduate Student Scholarship	The research was supported by the National Health and Medical Research Council (NHMRC) and the WA Neurotrauma Research Program. JR was funded by the Raine Foundation of Western Australia and a Senior Research Fellowship from NHMRC. MH was funded by an International Postgraduate Student Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268; Baumgartner BJ, 1997, J NEUROSCI, V17, P6504; BIFFO S, 1990, EUR J NEUROSCI, V2, P487, DOI 10.1111/j.1460-9568.1990.tb00440.x; Bjorklund T, 2010, MOVEMENT DISORD, V25, pS161, DOI 10.1002/mds.22785; BRAY GM, 1987, J EXP BIOL, V132, P5; Chacon PJ, 2010, MOL CELL NEUROSCI, V43, P384, DOI 10.1016/j.mcn.2010.01.005; Chiwitt C, 2011, RESTOR NEUROL NEUROS, V29, P127, DOI 10.3233/RNN-2011-0586; CHOI BH, 1995, NEUROBIOL AGING, V16, P557, DOI 10.1016/0197-4580(95)00060-R; Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086; Cohen-Cory S, 2004, INT J DEV BIOL, V48, P947, DOI 10.1387/ijdb.041883sc; Cui Q, 2000, NEUROREPORT, V11, P3999, DOI 10.1097/00001756-200012180-00019; D Kuipers S, 2006, CURR OPIN DRUG DISC, V9, P580; de Winter W, 2001, NATURE, V409, P710, DOI 10.1038/35055547; Deplano S, 2004, DEV NEUROSCI-BASEL, V26, P396, DOI 10.1159/000082282; Deplano S, 1999, J COMP NEUROL, V405, P262, DOI 10.1002/(SICI)1096-9861(19990308)405:2<262::AID-CNE9>3.0.CO;2-4; DIAZNIDO J, 1991, J CELL SCI, V98, P409; Dijkhuizen PA, 2005, PROG BRAIN RES, V147, P17, DOI 10.1016/S0079-6123(04)47002-2; DREHER B, 1985, BRAIN BEHAV EVOLUT, V26, P10, DOI 10.1159/000118764; Du JL, 2004, NATURE, V429, P878, DOI 10.1038/nature02618; Eberling JL, 2008, NEUROLOGY, V70, P1980, DOI 10.1212/01.wnl.0000312381.29287.ff; FAMIGLIETTI EV, 1976, SCIENCE, V194, P193, DOI 10.1126/science.959847; Frey D, 2000, J CELL BIOL, V149, P1443, DOI 10.1083/jcb.149.7.1443; FUKUDA Y, 1977, BRAIN RES, V119, P327, DOI 10.1016/0006-8993(77)90314-6; Fukuda Y, 1998, VISION RES, V38, P1545, DOI 10.1016/S0042-6989(98)00005-4; Gauthier-Campbell C, 2004, MOL BIOL CELL, V15, P2205, DOI 10.1091/mbc.E03-07-0493; Germain F, 2003, EUR J NEUROSCI, V18, P1103, DOI 10.1046/j.1460-9568.2003.02842.x; Guo X, 1999, J NEUROSCI, V19, P2113; GURWITZ D, 1990, J CELL PHYSIOL, V142, P155, DOI 10.1002/jcp.1041420119; Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002; Hellstrom M, 2011, MOL CELL NEUROSCI, V46, P507, DOI 10.1016/j.mcn.2010.12.003; Hellstrom M, 2011, J NEUROTRAUM, V28, P2475, DOI 10.1089/neu.2011.1928; Hellstrom M, 2011, CURR GENE THER, V11, P116, DOI 10.2174/156652311794940746; Horch HW, 2004, REV NEUROSCIENCE, V15, P117; Horch HW, 2002, NAT NEUROSCI, V5, P1177, DOI 10.1038/nn927; Huberman AD, 2008, NEURON, V59, P425, DOI 10.1016/j.neuron.2008.07.018; Huxlin KR, 1997, J COMP NEUROL, V385, P309; Kells AP, 2008, GENE THER, V15, P966, DOI 10.1038/gt.2008.23; Klein RL, 1999, BRAIN RES, V832, P136, DOI 10.1016/S0006-8993(99)01482-1; Klein RL, 1999, NEUROSCIENCE, V90, P815, DOI 10.1016/S0306-4522(98)00537-5; Kong JH, 2005, J COMP NEUROL, V489, P293, DOI 10.1002/cne.20631; Kwon M, 2011, J NEUROSCI, V31, P9735, DOI 10.1523/JNEUROSCI.6785-10.2011; Lagriffoul A, 1996, J BIOL CHEM, V271, P31508, DOI 10.1074/jbc.271.49.31508; LAU KC, 1991, RESTOR NEUROL NEUROS, V3, P235, DOI 10.3233/RNN-1991-3502; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252; Lin B, 2004, NEURON, V43, P475, DOI 10.1016/j.neuron.2004.08.002; Luikart BW, 2008, J NEUROSCI, V28, P7006, DOI 10.1523/JNEUROSCI.0195-08.2008; Mandel RJ, 2010, CURR OPIN MOL THER, V12, P240; Marks WJ, 2008, LANCET NEUROL, V7, P400, DOI 10.1016/S1474-4422(08)70065-6; MARTIN PR, 1986, EXP BRAIN RES, V62, P77; Meins M, 2001, J NEUROSCI, V21, P8830, DOI 10.1523/JNEUROSCI.21-22-08830.2001; Miller FD, 2003, CURR OPIN NEUROBIOL, V13, P391, DOI 10.1016/s0959-4388(03)00072-2; Milosevic NT, 2009, J THEOR BIOL, V259, P142, DOI 10.1016/j.jtbi.2009.03.011; Miyoshi T, 1999, EXP BRAIN RES, V124, P383, DOI 10.1007/s002210050635; Mizuguchi H, 2000, MOL THER, V1, P376, DOI 10.1006/mthe.2000.0050; Niclou SP, 1998, EUR J NEUROSCI, V10, P1590, DOI 10.1046/j.1460-9568.1998.00183.x; Park KK, 2009, MOL CELL NEUROSCI, V41, P313, DOI 10.1016/j.mcn.2009.04.002; Parrish JZ, 2007, ANNU REV NEUROSCI, V30, P399, DOI 10.1146/annurev.neuro.29.051605.112907; PERRY VH, 1979, PROC R SOC SER B-BIO, V204, P363, DOI 10.1098/rspb.1979.0033; Quan MZ, 1999, INVEST OPHTH VIS SCI, V40, P2360; Ramaswamy S, 2009, NEUROBIOL DIS, V34, P40, DOI 10.1016/j.nbd.2008.12.005; REINHARD E, 1994, J NEUROSCI RES, V37, P256, DOI 10.1002/jnr.490370211; Richardson RM, 2011, MOL THER, V19, P1048, DOI 10.1038/mt.2011.11; Robinson GA, 2004, VISION RES, V44, P2667, DOI 10.1016/j.visres.2004.06.010; Ruitenberg MJ, 2004, NEUROBIOL DIS, V15, P394, DOI 10.1016/j.nbd.2003.11.018; Sapieha PS, 2003, MOL CELL NEUROSCI, V24, P656, DOI 10.1016/S1044-7431(03)00228-8; Schmeer C, 2002, EUR J NEUROSCI, V15, P637, DOI 10.1046/j.1460-9568.2002.01893.x; SHOLL DA, 1953, J ANAT, V87, P387; Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277; Smith PD, 2009, NEURON, V64, P617, DOI 10.1016/j.neuron.2009.11.021; Sommerfeld MT, 2000, J BIOL CHEM, V275, P8982, DOI 10.1074/jbc.275.12.8982; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; Sun WZ, 2002, VISUAL NEUROSCI, V19, P483, DOI 10.1017/S0952523802194107; THANOS S, 1995, J NEUROSCI, V15, P1057, DOI 10.1523/jneurosci.15-02-01057.1995; THANOS S, 1988, CELL TISSUE RES, V254, P599; Tolwani RJ, 2002, NEUROSCIENCE, V114, P795, DOI 10.1016/S0306-4522(02)00301-9; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; WASSLE H, 1988, TRENDS NEUROSCI, V11, P87, DOI 10.1016/0166-2236(88)90147-6; WATANABE M, 1993, J NEUROSCI, V13, P2105; Weber AJ, 2008, INVEST OPHTH VIS SCI, V49, P2456, DOI 10.1167/iovs.07-1325; Wu K, 2003, HUM GENE THER, V14, P1463, DOI 10.1089/104303403769211673; Yacoubian TA, 2000, NAT NEUROSCI, V3, P342; Yang Y, 2009, J GENE MED, V11, P899, DOI 10.1002/jgm.1377; Yata T, 2007, NEUROSCIENCE, V148, P53, DOI 10.1016/j.neuroscience.2007.05.042; Zagrebelsky M, 2005, J NEUROSCI, V25, P9989, DOI 10.1523/JNEUROSCI.2492-05.2005; ZURN AD, 1988, DEV NEUROSCI-BASEL, V10, P17, DOI 10.1159/000111951	87	28	28	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2012	7	2							e31061	10.1371/journal.pone.0031061			14	Multidisciplinary Sciences	Science & Technology - Other Topics	924ZP	WOS:000302730100037	22347429	DOAJ Gold, Green Published			2021-06-18	
J	Joosse, P; Saltzherr, TP; van Lieshout, WAM; van Exter, P; Ponsen, KJ; Vandertop, WP; Goslings, JC				Joosse, Pieter; Saltzherr, Teun-Peter; van Lieshout, Willem A. M.; van Exter, Pieternel; Ponsen, Kees-Jan; Vandertop, W. Peter; Goslings, J. Carel		TraumaNet AMC Collaborating Hosp	Impact of secondary transfer on patients with severe traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Brain injury; Gclasgow Outcome Scale; Glasgow Coma Scale; In-hospital mortality; Patient transfer	EARLY DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; CHILDREN; SURGERY	BACKGROUND: Within a trauma network in the Netherlands, neurosurgical facilities are usually limited to Level I hospitals. Initial transport to a district hospital of patients who are later found to require neurosurgical intervention may cause delay. The purpose of this study was to assess the influence on outcome and time intervals of secondary transfer in trauma patients requiring emergency neurosurgical intervention. METHODS: In a 3-year period, all patients who sustained a severe traumatic brain injury and underwent a neurosurgical intervention within 6 hours after admission to a Level I trauma center were included. Patients were classified into two groups: direct presentation to the Level I trauma center (TC) group or requiring secondary transport after having been diagnosed for neurosurgical intervention in other hospitals (transfer group). RESULTS: Eighty patients were included for analyses. Twenty-four patients in the transfer group had a better Glasgow Coma Scale on-scene but a higher 30-day mortality compared with patients who were primarily presented to the Level I trauma center (33% vs. 27%; p = 0.553). In the transfer group, time to operation was 304 minutes compared with 151 minutes in the TC group (p < 0.001). Most delay occurred during the initial trauma evaluation and the interval between the first computed tomography and the transfer ambulance departure at the referring hospital. CONCLUSION: Patients requiring an emergency neurosurgical intervention appear to have a clinically relevant worse outcome after secondary transfer to a neurosurgical service. Therefore, patient care can probably be improved by better triage on-scene and standardized procedures in case of a secondary transfer. (J Trauma. 2012; 72: 487-490. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Joosse, Pieter; Saltzherr, Teun-Peter; van Lieshout, Willem A. M.; Goslings, J. Carel] Acad Med Ctr, Dept Surg, Trauma Unit, NL-1100 DD Amsterdam, Netherlands; [van Exter, Pieternel] Reg Ambulance Serv, Amsterdam, Netherlands; [Ponsen, Kees-Jan] Med Ctr Alkmaar, Dept Surg, Alkmaar, Netherlands; [Vandertop, W. Peter] Neurosurg Ctr, Amsterdam, Netherlands	Joosse, P (corresponding author), Acad Med Ctr, Dept Surg, Trauma Unit, Meibergdreef 9,POB 22660, NL-1100 DD Amsterdam, Netherlands.	p.joosse@amc.nl	Vandertop, William P./K-9288-2018				Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; American College of Surgeons Committee on Trauma, 2006, RES OPT CAR INJ PAT; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Eberle BM, 2010, INJURY, V41, P894, DOI 10.1016/j.injury.2010.02.023; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hedges JR, 2009, J EMERG MED, V37, P115, DOI 10.1016/j.jemermed.2008.07.001; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Joosse P, 2009, J CLIN NEUROSCI, V16, P925, DOI 10.1016/j.jocn.2008.06.014; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28; Splavski B, 1998, SURG NEUROL, V50, P194, DOI 10.1016/S0090-3019(98)00047-0; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P583; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J Neurotrauma, V17, P563, DOI 10.1089/neu.2000.17.563	22	28	29	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2012	72	2					487	490		10.1097/TA.0b013e318226ed59			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	898ZN	WOS:000300781000048	22327988				2021-06-18	
J	Cui, X; Chopp, M; Shehadah, A; Zacharek, A; Kuzmin-Nichols, N; Sanberg, CD; Dai, JH; Zhang, CL; Ueno, Y; Roberts, C; Chen, JL				Cui, Xu; Chopp, Michael; Shehadah, Amjad; Zacharek, Alex; Kuzmin-Nichols, Nicole; Sanberg, Cyndy Davis; Dai, Junhao; Zhang, Chunling; Ueno, Yuji; Roberts, Cynthia; Chen, Jieli			Therapeutic Benefit of Treatment of Stroke With Simvastatin and Human Umbilical Cord Blood Cells: Neurogenesis, Synaptic Plasticity, and Axon Growth	CELL TRANSPLANTATION			English	Article						Simvastatin; Human umbilical cord blood cells (HUCBCs); Neurogenesis; Synaptic plasticity; Stroke	TRAUMATIC BRAIN-INJURY; ISCHEMIA-INDUCED NEUROGENESIS; STEM-CELLS; VASCULAR STABILIZATION; BEHAVIORAL DEFICITS; NEUROTROPHIC FACTOR; CEREBRAL-ISCHEMIA; INFARCT VOLUME; UP-REGULATION; RAT MODEL	The therapeutic efficacy of cell-based therapy after stroke can be enhanced by making the host brain tissue more receptive to the administered cells, which thereby facilitates brain plasticity. We hypothesized that simvastatin increases human umbilical cord blood cell (HUCBC) migration into the ischemic brain and promotes brain plasticity and neurological functional outcome after stroke. Rats were subjected to 2-h middle cerebral artery occlusion (MCAo) and administered subtherapeutic doses of simvastatin (0.5 mg/kg, gavaged daily for 7 days), HUCBCs (1 x 10(6), one time injection via tail vein), or combination simvastatin with HUCBCs starting at 24 h after stroke. Combination treatment of stroke showed an interactive effect in improvement of neurological outcome compared with simvastatin or HUCBC monotherapy groups. In addition, combination treatment significantly increased brain-derived neurotrophic factor/TrkB expression and the number of engrafted HUCBCs in the ischemic brain compared with HUCBC monotherapy. The number of engrafted HUCBCs was significantly correlated with functional outcome (modified neurological severity score). Combination treatment significantly increased neurogenesis and synaptic plasticity in the ischemic brain, and promoted neuroblast migration in cultured subventricular zone explants. Using primary cultured neurons (PCNs), we found that combination treatment enhanced neurite outgrowth compared with nontreatment control, simvastatin or HUCBC supernatant monotherapy. Inhibition of TrkB significantly attenuated combination treatment-induced neurite outgrowth. Our data indicate that combination simvastatin and HUCBC treatment of stroke increases BDNF/TrkB expression, enhances HUCBC migration into the ischemic brain, amplifies endogenous neurogenesis, synaptic plasticity and axonal growth, and thereby improves functional outcome after stroke.	[Cui, Xu; Chopp, Michael; Shehadah, Amjad; Zacharek, Alex; Dai, Junhao; Zhang, Chunling; Ueno, Yuji; Roberts, Cynthia; Chen, Jieli] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Kuzmin-Nichols, Nicole; Sanberg, Cyndy Davis] Saneron CCEL Therapeut Inc, Tampa, FL USA	Chen, JL (corresponding author), Henry Ford Hosp, Dept Neurol, E&R Bldg,Room 3091,2799 W Grand Blvd, Detroit, MI 48202 USA.	jieli@neuro.hfh.edu	Ueno, Yuji/ABB-2492-2020	Shehadah, Amjad/0000-0001-8679-3774; Cui, Xu/0000-0002-6937-6191	National Institute of Neurological Disorder and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R41NS064708]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [RO1 AG031811]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [PO1 NS23393]; American Heart Association grantAmerican Heart Association [09GRNT2300151]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS023393, R41NS064708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031811] Funding Source: NIH RePORTER	The authors thank Qinge Lu and Supata Santra for technical assistance. This work was supported by National Institute of Neurological Disorder and Stroke (NINDS) 1R41NS064708 (J.C.), National Institute on Aging RO1 AG031811 (J.C.), NINDS PO1 NS23393 (M.C.), and American Heart Association grant 09GRNT2300151 (J.C.). J. Chen is a consultant for Saneron CCEL Therapeutics, Inc.	Arboix A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-47; Buga AM, 2009, ROM J MORPHOL EMBRYO, V50, P559; Chen JL, 2009, J CELL MOL MED, V13, P1348, DOI 10.1111/j.1582-4934.2008.00380.x; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Cui X, 2010, STROKE, V41, P2044, DOI 10.1161/STROKEAHA.110.589333; Cui X, 2009, NEUROBIOL DIS, V36, P35, DOI 10.1016/j.nbd.2009.06.012; Daadi MM, 2001, BRAIN RES BULL, V56, P147, DOI 10.1016/S0361-9230(01)00621-9; Gordon Tessa, 2009, Neurosurg Focus, V26, pE3, DOI 10.3171/FOC.2009.26.2.E3; Gorski JA, 2003, J NEUROSCI, V23, P6856; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gustafsson E, 2003, STROKE, V34, P2710, DOI 10.1161/01.STR.0000096025.35225.36; Halterman MW, 2009, J NEUROSCI METH, V177, P348, DOI 10.1016/j.jneumeth.2008.10.023; Huang GP, 2007, CELL TRANSPLANT, V16, P579, DOI 10.3727/000000007783465073; Iwai M, 2010, STROKE, V41, P1032, DOI 10.1161/STROKEAHA.109.570325; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; Kadam SD, 2008, BRAIN RES, V1208, P35, DOI 10.1016/j.brainres.2008.02.037; Karnezis T, 2004, NAT NEUROSCI, V7, P736, DOI 10.1038/nn1261; Knowles DW, 2006, P NATL ACAD SCI USA, V103, P4445, DOI 10.1073/PNAS.0509944102; Koestenbauer S, 2009, CELL TRANSPLANT, V18, P1059, DOI 10.3727/096368909X471288; Kozlowska H, 2007, STEM CELLS DEV, V16, P481, DOI 10.1089/scd.2007.9993; Liu YP, 2009, ACTA NEUROPATHOL, V117, P469, DOI 10.1007/s00401-009-0516-1; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Markus A, 2002, NEURON, V35, P65, DOI 10.1016/S0896-6273(02)00752-3; Mattson MP, 2008, ANN NY ACAD SCI, V1144, P97, DOI 10.1196/annals.1418.005; Meng QX, 2010, NEUROSCI LETT, V480, P25, DOI 10.1016/j.neulet.2010.05.067; Neuhoff S, 2007, EXP HEMATOL, V35, P1119, DOI 10.1016/j.exphem.2007.03.019; Park DH, 2009, CELL TRANSPLANT, V18, P985, DOI 10.3727/096368909X471279; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Reimann, 2009, DTSCH ARZTEBL INT, V106, P831, DOI 10.3238/arztebl.2009.0831; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tang YM, 2007, CELL TRANSPLANT, V16, P159; Ujike H, 2002, ANN NY ACAD SCI, V965, P55; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Wagner JE, 2010, SEMIN HEMATOL, V47, P3, DOI 10.1053/j.seminhematol.2009.10.011; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yamauchi A, 2005, CELL MOL NEUROBIOL, V25, P923, DOI 10.1007/s10571-005-4956-5; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zacharek A, 2009, STROKE, V40, P254, DOI 10.1161/STROKEAHA.108.524116; Zhang RL, 2011, J CEREBR BLOOD F MET, V31, P614, DOI 10.1038/jcbfm.2010.134; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	44	28	31	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2012	21	5					845	856		10.3727/096368911X627417			12	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	974SB	WOS:000306455600005	22405262	Green Accepted			2021-06-18	
J	Garcia-Altes, A; Perez, K; Novoa, A; Suelves, JM; Bernabeu, M; Vidal, J; Arrufat, V; Santamarina-Rubio, E; Ferrando, J; Cogollos, M; Cantera, CM; Luque, JCG				Garcia-Altes, Anna; Perez, Katherine; Novoa, Ana; Suelves, Josep M.; Bernabeu, Montserrat; Vidal, Joan; Arrufat, Vita; Santamarina-Rubio, Elena; Ferrando, Josep; Cogollos, Mar; Martin Cantera, Carlos; Gonzalez Luque, Juan Carlos		Working Grp Study Injuries Spanish	Spinal Cord Injury and Traumatic Brain Injury: A Cost-of-Illness Study	NEUROEPIDEMIOLOGY			English	Article						Brain injuries; Traffic accidents; Cost of illness	EPIDEMIOLOGY	Background: Among traumatic injuries, spinal cord injuries (SCI) and traumatic brain injuries (TBI) are of major importance because of their epidemiological and economic impact on society. The overall objective of this study was to estimate the economic cost associated with people with SCI and TBI in Spain in 2007. Methods: A cost-of-illness analysis was performed, considering the perspective of society, using a 1-year time horizon. Medical costs, adaptation costs, material costs, administrative costs, and costs of police, firefighters and roadside assistance, productivity losses due to institutionalization and sick leave, as well as an estimate of productivity losses of carers, and productivity losses due to death were included. Results:The economic cost associated with people with SCI is between EUR 92,087,080.97 and 212,496,196.41 (USD 131 million and 302 million) according to the injury mechanism, and between EUR 1,079,223,688.66Brain injuries Traffic accidents Cost of illness and 3,833,752,692.78 (USD 1,536 million and 5,458 million) for people with TBI. Conclusions:There is an urgent need to develop effective interventions known to prevent SCI and TBI, and to evaluate their effectiveness and efficiency. Copyright (c) 2012 S. Karger AG, Basel	[Garcia-Altes, Anna] Agencia Informacio Avaluacio & Qualitat Salut, ES-08005 Barcelona, Spain; [Perez, Katherine; Novoa, Ana; Santamarina-Rubio, Elena] Agencia Salut Publ Barcelona, CIBER Epidemiol & Salud Publ CIBERESP, Inst Invest Biomed IIB St Pau, Barcelona, Spain; [Suelves, Josep M.] Agencia Salut Publ Catalunya, Barcelona, Spain; [Ferrando, Josep] Univ Autonoma Barcelona, CIBER Epidemiol & Salud Publ CIBERESP, E-08193 Barcelona, Spain; [Martin Cantera, Carlos] Univ Autonoma Barcelona, Dept Med, Unitat Suport Recerca Barcelona, IDIAP Jordi Gol,CAP Passeig St Joan,ICS, E-08193 Barcelona, Spain; [Bernabeu, Montserrat; Vidal, Joan] Inst Guttmann Neurorehabil Hosp, Badalona, Spain; [Arrufat, Vita] Ctr Salut Publ Area 02, Negociat Programes Promocio Salut, Castellon de La Plana, Spain; [Cogollos, Mar] AESLEME, Pozuelo Alarcon, Madrid, Spain; [Gonzalez Luque, Juan Carlos] Observ Nacl Seguridad Vial, Direcc Gen Traf, Madrid, Spain	Garcia-Altes, A (corresponding author), Agencia Informacio Avaluacio & Qualitat Salut, Roc Boronat 81-95,2On Pis, ES-08005 Barcelona, Spain.	agarciaaltes@aatrm.catsalut.cat	Suelves, Josep M/F-9080-2011; Joan, Vidal/AAR-5232-2021; Martin Cantera, Carlos/D-2693-2011	Suelves, Josep M/0000-0002-7716-6944; Martin Cantera, Carlos/0000-0003-0656-8126; Perez, Katherine/0000-0001-5892-2807; Gonzalez-Luque, Juan Carlos/0000-0001-8081-0377	Direccion General de Salud Publica, Ministerio de Sanidad, Politica Social e Igualdad	This study was developed by the working group for the study of injuries of the Spanish Society of Epidemiology. Thanks also to Ma Antonia Astorga (MSPS), Marivi Librada (MSPS), Pilar Zori (DGT), Rogelio Cozar (MSPS), Ma Angeles Gogorcena (MSPS), and Araceli Diaz (SAS). This study was partially funded by the Direccion General de Salud Publica, Ministerio de Sanidad, Politica Social e Igualdad.	Abellan JM, 2011, VALOR MONETARIO VIDA; Asociacion ICEA, 2008, INV COOP ENT AS FOND; Azeldegui BF, 2002, MED INTENSIVA, V26, P491; Barcelo C., 2010, 2 C DAN CER ADQ COM; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bastida JL, 2004, J TRAUMA, V56, P883, DOI 10.1097/01.TA.0000069207.43004.A5; Berkowitz M., 1998, SPINAL CORD INJURY A; BLINCOE LJ, 2002, 809446 DOT HS NAT HI; Chiu WT, 2010, ASIA-PAC J PUBLIC HE, V22, P9, DOI 10.1177/1010539509355470; French DD, 2007, J SPINAL CORD MED, V30, P477, DOI 10.1080/10790268.2007.11754581; Hensher DA, 2006, TRANSPORT REV, V26, P521, DOI 10.1080/01441640600602369; INE, ENC AN COST LAB 2007; INE, 1961, NIV CAL COND VID IND; Institut Guttmann, 2011, SIN DISC ALG XIFR ES; Instituto de Estudios de Automocion, 2002, SECT TRANSP ESP EV H; Laboratorio de medidas potenciadoras de la autonomia, 2009, LAB MED POT AUT SAT; Llado A, 2007, COSTE ACCIDENTES TRA; MacLeod JBA, 2007, AM J SURG, V193, P195, DOI 10.1016/j.amjsurg.2006.09.010; National Spinal Cord Injury Statistical Center, 2006, SPIN CORD INJ FACTS; Observatori Social de Barcelona, 2006, OBS SOC BARC GREUG C; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; UNESPA, 2008, MEM SOC SEG ESP 2007; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328	24	28	30	0	15	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350	1423-0208		NEUROEPIDEMIOLOGY	Neuroepidemiology		2012	39	2					103	108		10.1159/000338297			6	Public, Environmental & Occupational Health; Clinical Neurology	Public, Environmental & Occupational Health; Neurosciences & Neurology	005DP	WOS:000308731000005	22846706				2021-06-18	
J	Kubal, WS				Kubal, Wayne S.			Updated Imaging of Traumatic Brain Injury	RADIOLOGIC CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Computed tomography; Magnetic resonance imaging; Diffusion tensor imaging; Magnetic resonance spectroscopy	DIFFUSE AXONAL INJURY; ACUTE SUBDURAL-HEMATOMA; CLOSED-HEAD-INJURY; GUNSHOT INJURIES; CORPUS-CALLOSUM; CT FINDINGS; PREVALENCE; RECOVERY; SPECTROSCOPY; TOMOGRAPHY	Computed tomography (CT) and magnetic resonance (MR) play important roles in the evaluation of traumatic brain injury. Modern CT scanners allow for rapid and accurate diagnosis of intracranial hemorrhage and mass effect and allow the efficient implementation of emergent CT angiography. Newer sequences, such as gradient recalled echo, susceptibility-weighted imaging, and diffusion-weighted imaging, can provide greater sensitivity for specific types of diffuse posttraumatic brain injury. MR spectroscopy can provide additional chemical information, and diffusion tensor imaging can provide information about white matter injury. Patient treatment can be optimized using the diagnostic and prognostic information derived from current imaging techniques.	Univ Arizona, Hlth Sci Ctr, Dept Radiol, Tucson, AZ 85724 USA	Kubal, WS (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Radiol, Room 1369,1501 N Campbell Ave,POB 245067, Tucson, AZ 85724 USA.	wkubal@email.arizona.edu					ALEXANDER E, 1982, SURG NEUROL, V17, P107, DOI 10.1016/S0090-3019(82)80031-1; Almandoz JED, 2010, RADIOLOGY, V255, P570, DOI 10.1148/radiol.10091565; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Arrangoiz R, 2010, AM SURGEON, V76, P1255; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Brocker B, 1991, NEUROIMAG CLIN N AM, V1, P387; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; GEAN AD, 1994, IMAGING HEAD TRAUMA, P75; GEAN AD, 1994, IMAGING HEAD TRAUMA, P207; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GOODWIN JR, 1994, J TRAUMA, V37, P119, DOI 10.1097/00005373-199407000-00021; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hofbauer M, 2010, J TRAUMA, V69, P770, DOI 10.1097/TA.0b013e3181c81d7d; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnson Michele H., 1995, V134, P98; Kim TW, 2007, J TRAUMA, V62, P1446, DOI 10.1097/01.ta.0000222909.31666.db; KUBAL WS, 2000, ARRS, P1; Lee Kyeong-Seok, 1997, Journal of Korean Medical Science, V12, P353; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MIRVIS SE, 1990, AM J ROENTGENOL, V154, P1293, DOI 10.2214/ajr.154.6.2110744; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakabayashi M, 2007, J NEUROSURG, V106, P370, DOI 10.3171/jns.2007.106.3.370; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; NOGUCHI K, 1995, RADIOLOGY, V196, P773, DOI 10.1148/radiology.196.3.7644642; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; POPP JA, 1985, NEUROSURGERY, P1536; Provenzale J, 2007, EMERG RADIOL, V14, P1, DOI 10.1007/s10140-007-0587-z; Provenzale JM, 2010, AM J ROENTGENOL, V194, P16, DOI 10.2214/AJR.09.3687; REED D, 1986, AM J NEURORADIOL, V7, P417; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; ROTHFUS WE, 1987, AM J NEURORADIOL, V8, P1073; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Tate DF, 2011, J INT NEUROPSYCH SOC, V17, P308, DOI 10.1017/S1355617710001670; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van den Brink WA, 1999, ACTA NEUROCHIR, V141, P509, DOI 10.1007/s007010050332; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; WERNICK S, 1989, J COMPUT ASSIST TOMO, V13, P323, DOI 10.1097/00004728-198903000-00027; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	62	28	29	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0033-8389			RADIOL CLIN N AM	Radiol. Clin. N. Am.	JAN	2012	50	1					15	+		10.1016/j.rcl.2011.08.010			28	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	865LE	WOS:000298311600003	22099485				2021-06-18	
J	Lundberg, J; Sodersten, E; Sundstrom, E; Le Blanc, K; Andersson, T; Hermanson, O; Holmin, S				Lundberg, Johan; Sodersten, Erik; Sundstrom, Erik; Le Blanc, Katarina; Andersson, Tommy; Hermanson, Ola; Holmin, Staffan			Targeted Intra-arterial Transplantation of Stem Cells to the Injured CNS Is More Effective Than Intravenous Administration: Engraftment Is Dependent on Cell Type and Adhesion Molecule Expression	CELL TRANSPLANTATION			English	Article						Endovascular; Transplantation; Human mesenchymal stem cells (hMSCs); Rat neural progenitor cells (rNPCs); Human neural progenitor cells (hNPCs); Vascular cell adhesion molecule-1 (VCAM-1)	TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM; IN-VITRO; STROKE; RAT; THERAPY; MODEL; NEUROPROTECTION; INJECTION; MIGRATION	Stem cell transplantation procedures using intraparenchymal injections cause tissue injury in addition to associated surgical risks. Intravenous cell administration give engraftment in parenchymal lesions although the method has low efficacy and specificity. In pathological conditions with inflammation, such as traumatic brain injury, there is a transient up-regulation of ICAM-I and VCAM-1 which might provide environmental cues for migration of stem cells from blood to parenchyma. The aim of this study was to i) analyze the effect of intra-arterial administration on cellular engraftment, ii) compare engraftment and side effects between three different stem cell systems, and iii) analyze gene expression in these three systems. We performed specific intra-arterial transplantations with human mesenchymal stem cells (hMSCs), human neural progenitor cells (hNPCs), and rat neural progenitor cells (rNPCs) in a rat model of traumatic brain injury. These results were compared to the intravenous route for each cell type, respectively. Analysis of engraftment and recipient characterization was performed by immunohistochemistry. We further characterized the different types of cells by microarray and RT-qPCR analysis. Specific intra-arterial transplantations produced significantly higher engraftment compared to intravenous transplantation with hMSCs and rNPCs. No engraftment was detected after intra-arterial or intravenous administration of hNPCs. Characterization of integrin expression indicated that CD49dVCAM-1 and possibly ICAM-1 interactions through CD18 and CD11a, respectively, are important for engraftment after intravascular cell administration. No side effects, such as thromboembolic complications, were detected. When translating stem cell therapies to clinical practice, the route of transplantation and the properties of the cell lines (homing, diapedesis, and migration) become important. This study supports the use of selective intra-arterial transplantation for improving engraftment after traumatic brain injury. In addition, we conclude that careful analysis of cells intended for local, intra-arterial transplantation with respect to integrin expression is important.	[Lundberg, Johan; Andersson, Tommy; Holmin, Staffan] Karolinska Univ Hosp, Dept Neuroradiol, S-17176 Stockholm, Sweden; [Lundberg, Johan; Andersson, Tommy; Holmin, Staffan] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Sodersten, Erik; Hermanson, Ola] Karolinska Inst, Dept Neurosci, DBRM, Stockholm, Sweden; [Sundstrom, Erik] Karolinska Inst, Div Neurodegenerat, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden; [Sundstrom, Erik] Stiftelsen Stockholms Sjukhem, Stockholm, Sweden; [Le Blanc, Katarina] Karolinska Inst, Dept Lab Med, Div Clin Immunol, Stockholm, Sweden; [Le Blanc, Katarina] Karolinska Univ Hosp, Hematol Ctr, S-17176 Stockholm, Sweden	Holmin, S (corresponding author), Karolinska Univ Hosp, Dept Neuroradiol, S-17176 Stockholm, Sweden.	staffan.holmin@karolinska.se	Le Blanc, Katarina/L-4631-2019; , Ola/AAF-5126-2021	Sodersten, Erik/0000-0002-2998-4889; Hermanson, Ola/0000-0001-9320-7921; Holmin, Staffan/0000-0002-1628-1615	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Karolinska InstitutetKarolinska Institutet; Swedish Society of Medicine and Strokefonden	The authors wish to thank BEA, Karolinska for excellent technical assistance with the microarray analysis. This study was supported by grants from the Swedish Research Council, Karolinska Institutet funds, the Swedish Society of Medicine and Strokefonden. The authors declare no conflict of interest.	Akesson E, 2007, PHYSIOL BEHAV, V92, P60, DOI 10.1016/j.physbeh.2007.05.056; Amar AP, 2003, NEUROSURGERY, V52, P402, DOI 10.1227/01.NEU.0000043698.86548.A0; Andersson T, 2009, J BIOL CHEM, V284, P3672, DOI 10.1074/jbc.M808119200; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Ben-Haim S, 2009, NEUROSURGERY, V64, P754, DOI 10.1227/01.NEU.0000339173.77240.34; Bliss TM, 2010, NEUROBIOL DIS, V37, P275, DOI 10.1016/j.nbd.2009.10.003; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Field P, 2001, J NEUROSURG, V94, P545, DOI 10.3171/jns.2001.94.4.0545; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gordon PH, 2004, ARCH NEUROL-CHICAGO, V61, P858, DOI 10.1001/archneur.61.6.858; Grinnemo KH, 2006, ANN MED, V38, P144, DOI 10.1080/07853890500422982; Guzman R, 2008, STROKE, V39, P1300, DOI 10.1161/STROKEAHA.107.500470; Heng BC, 2009, CELL TRANSPLANT, V18, P1111, DOI 10.3727/096368909X12483162197006; Jackson JS, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt17; Jin KL, 2005, NEUROBIOL DIS, V18, P366, DOI 10.1016/j.nbd.2004.10.010; Kamiya N, 2008, LIFE SCI, V83, P433, DOI 10.1016/j.lfs.2008.07.018; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; Lundberg J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010449; Lundberg J, 2009, NEURORADIOLOGY, V51, P661, DOI 10.1007/s00234-009-0551-6; Piao JH, 2006, J NEUROSCI RES, V84, P471, DOI 10.1002/jnr.20955; RYCHLIK W, 1990, NUCLEIC ACIDS RES, V18, P6409, DOI 10.1093/nar/18.21.6409; Savitz SI, 2005, CEREBROVASC DIS, V20, P101, DOI 10.1159/000086518; Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005; Stuve O, 2008, J NEUROL, V255, P58, DOI 10.1007/s00415-008-6011-0; Sykova E, 2006, CELL TRANSPLANT, V15, P675, DOI 10.3727/000000006783464381; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Yu SJ, 2009, CELL TRANSPLANT, V18, P111, DOI 10.3727/096368909788341243	31	28	33	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2012	21	1					333	343		10.3727/096368911X576036			11	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	932KS	WOS:000303290600024	21669035				2021-06-18	
J	Petrov, IY; Petrov, Y; Prough, DS; Deyo, DJ; Cicenaite, I; Esenaliev, RO				Petrov, I. Y.; Petrov, Y.; Prough, D. S.; Deyo, D. J.; Cicenaite, I.; Esenaliev, R. O.			Optoacoustic monitoring of cerebral venous blood oxygenation through extracerebral blood	BIOMEDICAL OPTICS EXPRESS			English	Article							HEMOGLOBIN CONCENTRATION; OPTICAL-PROPERTIES; IN-VIVO; REAL-TIME; BRAIN; SPECTROSCOPY; INCREASE; HYPOXIA	There is strong clinical evidence that controlling cerebral venous oxygenation (oxyhemoglobin saturation) is critically important for patients with severe traumatic brain injury as well as for patients undergoing cardiac surgery. However, the only available method for cerebral venous blood oxygenation monitoring is invasive and requires catheterization of the internal jugular vein. We designed and built a novel optoacoustic monitor of cerebral venous oxygenation as measured in the superior sagittal sinus (SSS), the large midline cerebral vein. To the best of our knowledge, optical monitoring of cerebral venous blood oxygenation through overlying extracerebral blood is reported for the first time in this paper. The system was capable of detecting SSS signals in vivo at 700, 800, and 1064 nm through the thick (5-6 mm) sheep skull containing the circulating blood. The high (submillimeter) in-depth resolution of the system provided identification of the SSS peaks in the optoacoustic signals. The SSS peak amplitude closely followed the actual SSS blood oxygenation measured invasively using catheterization, blood sampling, and "gold standard" CO-Oximetry. Our data indicate the system may provide accurate measurement of the SSS blood oxygenation in patients with extracerebral blood over the SSS. (C) 2011 Optical Society of America	[Petrov, I. Y.; Petrov, Y.; Cicenaite, I.; Esenaliev, R. O.] Univ Texas Galveston, Med Branch, Ctr Biomed Engn, Lab Opt Sensing & Monitoring, Galveston, TX 77555 USA; [Prough, D. S.; Deyo, D. J.; Esenaliev, R. O.] Univ Texas Galveston, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Esenaliev, R. O.] Univ Texas Galveston, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA	Petrov, IY (corresponding author), Univ Texas Galveston, Med Branch, Ctr Biomed Engn, Lab Opt Sensing & Monitoring, 301 Univ Blvd, Galveston, TX 77555 USA.	riesenal@utmb.edu	Esenaliev, Rinat/Y-4361-2019; Prough, Donald S/G-5793-2013	Esenaliev, Rinat/0000-0002-2848-5906; Prough, Donald S/0000-0001-7994-532X	National Institutes of Health from the National Institute of Biomedical Imaging and Bioengineering [R01 EB00763, U54EB007954]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS044345]; National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R41HL10309501]; Moody Center for Brain and Spinal Cord Injury Research/Mission Connect of UTMB; Texas Emerging Technology Fund; UTMB	This work is supported in part by the National Institutes of Health (Grants R01 EB00763 and U54EB007954 from the National Institute of Biomedical Imaging and Bioengineering, Grant R01 NS044345 from the National Institute of Neurological Disorders and Stroke, Grant R41HL10309501 from the National Heart, Lung and Blood Institute), the Moody Center for Brain and Spinal Cord Injury Research/Mission Connect of UTMB, Texas Emerging Technology Fund, and UTMB Seed Grant Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIBIB or NIH. Drs. Prough and Esenaliev are co-owners of Noninvasix, Inc., a UTMB-based startup that has licensed the rights to optoacoustic monitoring technology.	Andreev VG, 2009, PROC SPIE, V7177, DOI 10.1117/12.816043; Brecht HP, 2007, OPT EXPRESS, V15, P16261, DOI 10.1364/OE.15.016261; CHEONG WF, 1990, IEEE J QUANTUM ELECT, V26, P2166, DOI 10.1109/3.64354; Choi J, 2004, J BIOMED OPT, V9, P221, DOI 10.1117/1.1628242; Enderle J., 2000, INTRO BIOMEDICAL ENG; Esenaliev RO, 2000, OSA TRENDS OPT PHOTO, V38, P272; Esenaliev RO, 2002, APPL OPTICS, V41, P4722, DOI 10.1364/AO.41.004722; FRY FJ, 1978, J ACOUST SOC AM, V63, P1576, DOI 10.1121/1.381852; HALE GM, 1973, APPL OPTICS, V12, P555, DOI 10.1364/AO.12.000555; Horecker BL, 1943, J BIOL CHEM, V148, P173; Jacques SL, OPTICAL ABSORPTION M; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Jose J, 2011, OPT EXPRESS, V19, P2093, DOI 10.1364/OE.19.002093; Kuwahira I, 1999, J APPL PHYSIOL, V86, P181; Laser Institute of America, 2000, AM NAT STAND SAF US; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; Murkin John M, 2004, Semin Cardiothorac Vasc Anesth, V8, P13, DOI 10.1177/108925320400800104; Oka T, 2007, PEDIATR INT, V49, P898, DOI 10.1111/j.1442-200X.2007.02481.x; Passler K, 2011, BIOMED OPT EXPRESS, V2, P2655, DOI 10.1364/BOE.2.002655; Petrov YY, 2006, OPT LETT, V31, P1827, DOI 10.1364/OL.31.001827; Petrov YY, 2004, P ANN INT IEEE EMBS, V26, P2052; Petrov YY, 2005, ANESTHESIOLOGY, V102, P69, DOI 10.1097/00000542-200501000-00014; Petrova IY, 2009, OPT EXPRESS, V17, P7285, DOI 10.1364/OE.17.007285; Prahl S, OPTICAL ABSORPTION H; Richardson MX, 2009, EUR J APPL PHYSIOL, V105, P63, DOI 10.1007/s00421-008-0873-9; Simpson CR, 1998, PHYS MED BIOL, V43, P2465, DOI 10.1088/0031-9155/43/9/003; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Stevens Wendy J, 2004, J Neurosci Nurs, V36, P332; Taroni P, 2007, OPT EXPRESS, V15, P3301, DOI 10.1364/OE.15.003301; Taruttis A, 2010, OPT EXPRESS, V18, P19592, DOI 10.1364/OE.18.019592; Tuchin V, 2000, TISSUE OPTICS LIGHT; Wang XD, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2192804	32	28	28	0	2	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	2156-7085			BIOMED OPT EXPRESS	Biomed. Opt. Express	JAN 1	2012	3	1					125	136		10.1364/BOE.3.000125			12	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	886WM	WOS:000299884600011	22254173	DOAJ Gold, Green Published			2021-06-18	
J	Probst, C; Mirzayan, MJ; Mommsen, P; Zeckey, C; Tegeder, T; Geerken, L; Maegele, M; Samii, A; van Griensven, M				Probst, C.; Mirzayan, M. J.; Mommsen, P.; Zeckey, C.; Tegeder, T.; Geerken, L.; Maegele, M.; Samii, A.; van Griensven, M.			Systemic Inflammatory Effects of Traumatic Brain Injury, Femur Fracture, and Shock: An Experimental Murine Polytrauma Model	MEDIATORS OF INFLAMMATION			English	Article							TUMOR-NECROSIS-FACTOR; PENTOXIFYLLINE IMPROVES SURVIVAL; MULTIPLE ORGAN FAILURE; CLOSED-HEAD-INJURY; FACTOR-ALPHA; RAT-BRAIN; MORTALITY; EXPRESSION; MCP-1; DYSFUNCTION	Objective. Despite broad research in neurotrauma and shock, little is known on systemic inflammatory effects of the clinically most relevant combined polytrauma. Experimental investigation in an animal model may provide relevant insight for therapeutic strategies. We describe the effects of a combined injury with respect to lymphocyte population and cytokine activation. Methods. 45 male C57BL/6J mice (mean weight 27 g) were anesthetized with ketamine/xylazine. Animals were subjected to a weight drop closed traumatic brain injury (WD-TBI), a femoral fracture and hemorrhagic shock (FX-SH). Animals were subdivided into WD-TBI, FX-SH and combined trauma (CO-TX) groups. Subjects were sacrificed at 96 h. Blood was analysed for cytokines and by flow cytometry for lymphocyte populations. Results. Mortality was 8%, 13% and 47% for FX-SH, WD-TBI and CO-TX groups (P < 0.05). TNF alpha (11/13/139 for FX-SH/WD-TBI/CO-TX; P < 0.05), CCL2 (78/96/227; P < 0.05) and IL-6 (16/48/281; P = 0.05) showed significant increases in the CO-TX group. Lymphocyte populations results for FX-SH, WD-TBI and CO-TX were: CD-4 (31/21/22; P = n.s.), CD-8 (7/28/34, P < 0.05), CD-4-CD-8 (11/12/18; P = n.s.), CD-56 (36/7/8; P < 0.05). Conclusion. This study shows that a combination of closed TBI and femur-fracture/shock results in an increase of the humoral inflammation. More attention to combined injury models in inflammation research is indicated.	[Probst, C.; Maegele, M.] Univ Witten Herdecke, Dept Trauma & Orthopaed Surg, Cologne Merheim Med Ctr, Fac Hlth,Sch Med, D-51109 Cologne, Germany; [Mirzayan, M. J.] Hannover Med Sch, Dept Trauma, D-30623 Hannover, Germany; [Mommsen, P.; Zeckey, C.; Tegeder, T.] Hannover Med Sch, Dept Traumatol, D-30623 Hannover, Germany; [Geerken, L.] Nordstadt Hosp Hannover, Dept Anaesthesiol, D-30167 Hannover, Germany; [Samii, A.] Univ Technol Munich, Inst Expt Traumatol, D-81675 Munich, Germany; [van Griensven, M.] Int Neurosci Inst Hannover, Dept Neurosurg, D-30625 Hannover, Germany	Probst, C (corresponding author), Univ Witten Herdecke, Dept Trauma & Orthopaed Surg, Cologne Merheim Med Ctr, Fac Hlth,Sch Med, Ostmerheimer Str 200, D-51109 Cologne, Germany.	probstc@kliniken-koeln.de	Mommsen, Philipp/ABC-3510-2020; van Griensven, Martijn/F-5808-2012	van Griensven, Martijn/0000-0001-5104-9881			Aguilar MM, 1998, J TRAUMA, V45, P14, DOI 10.1097/00005373-199807000-00003; AYALA A, 1990, Cytokine, V2, P170, DOI 10.1016/1043-4666(90)90012-I; Bardenheuer M, 2000, UNFALLCHIRURG, V103, P355, DOI 10.1007/s001130050550; Berman JW, 1996, J IMMUNOL, V156, P3017; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; COCCIA MT, 1989, CRIT CARE MED, V17, P36, DOI 10.1097/00003246-198901000-00009; Durham RM, 2003, J TRAUMA, V55, P608, DOI 10.1097/01.TA.0000092378.10660.D1; Frink M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/797383; Frink M, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-49; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Giannoudis PV, 2002, AM J SURG, V183, P261, DOI 10.1016/S0002-9610(02)00783-3; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Harkness KA, 2003, J NEUROIMMUNOL, V142, P1, DOI 10.1016/S0165-5728(03)00251-0; Hildebrand F, 2005, INJURY, V36, P544, DOI 10.1016/j.injury.2004.10.017; Jiang J, 1997, Zhonghua Wai Ke Za Zhi, V35, P406; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; LUNDBLAD R, 1995, SHOCK, V3, P210, DOI 10.1097/00024382-199503000-00009; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Meixensberger J, 1998, LANGENBECK ARCH SURG, V383, P214, DOI 10.1007/s004230050121; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Nast-Kolb D, 2001, J TRAUMA, V51, P835, DOI 10.1097/00005373-200111000-00003; Pape HC, 2008, J ORTHOP RES, V26, P1478, DOI 10.1002/jor.20697; Probst C, 2009, J TRAUMA, V66, P1212, DOI 10.1097/TA.0b013e318197b97c; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SMAIL N, 1995, INTENS CARE MED, V21, P813, DOI 10.1007/BF01700964; Thibeault I, 2001, J COMP NEUROL, V434, P461, DOI 10.1002/cne.1187; Tsukamoto T, 2009, SHOCK, V31, P3, DOI 10.1097/SHK.0b013e31817fdabf; van Griensven M, 2002, EXP TOXICOL PATHOL, V54, P203, DOI 10.1078/0940-2993-00247; van Griensven M., 2003, EUR J TRAUMA, V29, P181, DOI [10.1007/s00068-001-1324-z, DOI 10.1007/S00068-001-1324-Z]	37	28	30	0	4	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2012	2012								136020	10.1155/2012/136020			7	Cell Biology; Immunology	Cell Biology; Immunology	923VB	WOS:000302647100001	22529516	DOAJ Gold, Green Published			2021-06-18	
J	Ruff, RL; Riechers, RG; Wang, XF; Piero, T; Ruff, SS				Ruff, Robert L.; Riechers, Ronald G., II; Wang, Xiao-Feng; Piero, Traci; Ruff, Suzanne S.			For veterans with mild traumatic brain injury, improved posttraumatic stress disorder severity and sleep correlated with symptomatic improvement	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						combat; concussion; headache; mild traumatic brain injury; OIF/OEF; olfaction; pain; prazosin; PTSD; sleep	OPERATIONS ENDURING FREEDOM; MONTREAL COGNITIVE ASSESSMENT; OLFACTORY DYSFUNCTION; PRAZOSIN TREATMENT; NIGHTMARES; IRAQ; DISTURBANCE; POLYTRAUMA; HEADACHES; HEALTH	This was an observational study of a cohort of 63 Operation Iraqi Freedom/Operation Enduring Freedom veterans with mild traumatic brain injury (mTBI) associated with an explosion. They had headaches, residual neurological deficits (NDs) on neurological examination, and posttraumatic stress disorder (PTSD) and were seen on average 2.5 years after their last mTBI. We treated them with sleep hygiene counseling and oral prazosin. We monitored headache severity, daytime sleepiness using the Epworth Sleepiness Scale, cognitive performance using the Montreal Cognitive Assessment test, and the presence of NDs. We quantitatively measured olfaction and assessed PTSD severity using the PTSD Checklist-Military Version. Nine weeks after starting sleep counseling and bedtime prazosin, the veterans' headache severity decreased, cognitive function as assayed with a brief screening tool improved, and daytime sleepiness diminished. Six months after completing treatment, the veterans demonstrated additional improvement in headache severity and daytime sleepiness and their improvements in cognitive function persisted. There were no changes in the prevalence of NDs or olfaction scores. Clinical improvements correlated with reduced PTSD severity and daytime sleepiness. The data suggested that reduced clinical manifestations following mTBI correlated with PTSD severity and improvement in sleep, but not the presence of NDs or olfaction impairment.	[Ruff, Robert L.; Riechers, Ronald G., II] Louis Stokes Cleveland Dept Vet Affairs Med Ctr C, Neurol Serv, Cleveland, OH USA; [Ruff, Robert L.; Riechers, Ronald G., II; Piero, Traci] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; [Ruff, Robert L.; Riechers, Ronald G., II; Ruff, Suzanne S.] CVAMC, Polytrauma Syst Care, Cleveland, OH USA; [Wang, Xiao-Feng] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Ruff, Suzanne S.] CVAMC, Psychol Serv, Cleveland, OH USA	Ruff, RL (corresponding author), Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Neurol Serv, 127 W,10701 East Blvd, Cleveland, OH 44106 USA.	robert.ruff1@va.gov			Department of Veterans AffairsUS Department of Veterans Affairs; Office of Research and Development; Rehabilitation Research and Development ServiceUS Department of Veterans Affairs; Functional Electrical Stimulation Center of Excellence. Award	This material is based on work supported by Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Service, 2010 Magnuson Award (R. L. Ruff) and Functional Electrical Stimulation Center of Excellence. Award (R. L Ruff, Co-Principal Investigator).	Agresti A., 1996, INTRO CATEGORICAL DA; Agresti A., 1992, STAT SCI, V7, P131, DOI [10.1214/ss/1177011454, DOI 10.1214/SS/1177011454]; Alhola Paula, 2007, Neuropsychiatr Dis Treat, V3, P553; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belle G. V., 2004, BIOSTATISTICS METHOD; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boehnlein James K, 2007, J Psychiatr Pract, V13, P72, DOI 10.1097/01.pra.0000265763.79753.c1; Boynton L, 2009, J PSYCHIATR PRACT, V15, P454, DOI 10.1097/01.pra.0000364287.63210.92; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Calohan J, 2010, J TRAUMA STRESS, V23, P645, DOI 10.1002/jts.20570; Carlson K, 2009, ASSESSMENT TREATMENT, P72; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; COGGON D, 2003, STAT CLIN PRACTICE; Costanzo RM, 2006, ADV OTO-RHINO-LARYNG, V63, P99, DOI 10.1159/000093753; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; Department of Veterans Affairs, 2010, NAT CTR PTSD US PTSD; Dierks MR, 2007, ANN PHARMACOTHER, V41, P1013, DOI 10.1345/aph.1H588; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 2001, ANNU REV PSYCHOL, V52, P423, DOI 10.1146/annurev.psych.52.1.423; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Gurvits TV, 2006, ARCH GEN PSYCHIAT, V63, P571, DOI 10.1001/archpsyc.63.5.571; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Pietrzak RH, 2010, J PSYCHOSOM RES, V69, P441, DOI 10.1016/j.jpsychores.2010.07.002; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P745, DOI 10.1002/da.20558; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Roberts RJ, 2008, SCI AM MIND, V19, P51, DOI DOI 10.1038/SCIENTIFICAMERICANMIND1208-50; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sailer U, 2008, NEUROPSYCHOLOGIA, V46, P2836, DOI 10.1016/j.neuropsychologia.2008.05.022; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taylor FB, 2008, BIOL PSYCHIAT, V63, P629, DOI 10.1016/j.biopsych.2007.07.001; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Verbeke G., 2000, LINEAR MIXED MODELS; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Whalley MG, 2009, BRAIN COGNITION, V69, P98, DOI 10.1016/j.bandc.2008.05.008; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; Zadikoff C, 2008, MOVEMENT DISORD, V23, P297, DOI 10.1002/mds.21837	57	28	28	0	20	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	9					1305	1320		10.1682/JRRD.2011.12.0251			16	Rehabilitation	Rehabilitation	149FB	WOS:000319303300003	23408213	Bronze			2021-06-18	
J	Tyerman, A				Tyerman, Andy			Vocational rehabilitation after traumatic brain injury: Models and services	NEUROREHABILITATION			English	Article						Brain injury; return to work; vocational rehabilitation models	QUALITY-OF-LIFE; FOLLOW-UP; COMMUNITY INTEGRATION; SUPPORTED EMPLOYMENT; PROGNOSTIC-FACTORS; SOCIAL-ADJUSTMENT; JOB PLACEMENT; HEAD-INJURY; WORK; RETURN	Background: A recent systematic review suggests that around 40% of people with traumatic brain injury (TBI) return to work (RTW). Yet in the UK currently only a small minority of people with TBI receive vocational rehabilitation (VR) to enable a RTW. Agencies with an interest in developing such services are likely to favour different models of VR. Objective: The primary objective of this paper was to review models of specialist VR after TBI and their outcomes to inform service development across relevant agencies. Method: A literature review on VR after TBI was undertaken in MEDLINE, EMBASE and PsychINFO (from 1967 to date). Papers reporting models of VR were selected for more detailed consideration. Results: Illustrative examples of VR models are outlined: brain injury rehabilitation programmes with added VR elements, VR models adapted for TBI, case coordination/resource facilitation models, and consumer-directed models. Models differ, both within and across these four broad categories, in provision of core TBI rehabilitation, work preparation, work trials and supported placements. Methodological variation limits direct comparison of outcomes across models with few comparative or controlled studies. Conclusions: There is evidence to support the benefits of a wide range of models of specialist VR after TBI. However, there remains a need for controlled studies to inform service development and more evidence on cost-effectiveness to inform funding decisions.	Camborne Ctr, Community Head Injury Serv, Aylesbury HP21 7ET, Bucks, England	Tyerman, A (corresponding author), Camborne Ctr, Community Head Injury Serv, Jansel Sq, Aylesbury HP21 7ET, Bucks, England.	andy.tyerman@buckspct.nhs.uk					Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Bjorkdahl A, 2010, BRAIN INJURY, V24, P1061, DOI 10.3109/02699052.2010.494588; BritishPsychological Society, 2005, CLIN NEUR REH SERV A; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; Coetzer B R, 2002, Aust J Rural Health, V10, P229, DOI 10.1046/j.1440-1584.2002.00425.x; Conder R L, 1989, Brain Inj, V3, P1, DOI 10.3109/02699058909008067; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; Department of Health, 2005, NAT SERV FRAM LONG T; DESHPANDE P, 2004, SURVEY VOCATIONAL RE, P35; DEVANEY CW, 1991, J HEAD TRAUMA REHAB, V6, P59; Fadyl JK, 2009, J HEAD TRAUMA REHAB, V24, P195, DOI 10.1097/HTR.0b013e3181a0d458; Gamboa AM, 2006, NEUROREHABILITATION, V21, P327; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; Haffey W.J., 1991, J HEAD TRAUMA REHAB, V6, P24; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P467, DOI 10.1097/00001199-200611000-00002; Hart T, 2010, J VOCAT REHABIL, V32, P135, DOI 10.3233/JVR-2010-0505; Hirsh A, 1996, J VOCAT REHABIL, V7, P217; Jacobs HE, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199710000-00003; Jacobs HE, 1996, J VOCATIONAL REHABIL, V7, P169, DOI DOI 10.1016/1052-2263(96)00219-X; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Johnson R, 1987, Int Disabil Stud, V9, P49; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Johnstone B, 2006, NEUROREHABILITATION, V21, P335; Kendall E, 2006, J VOCAT REHABIL, V25, P149; Kolakowsky-Hayner SA, 2001, NEUROREHABILITATION, V16, P41; Kregel J, 1994, NeuroRehabilitation, V4, P1, DOI 10.3233/NRE-1994-4103; Kreutzer J.S., 2000, COMMUNITY INTEGRATIO, pXIII; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; Malec JF, 2006, BRAIN INJURY, V20, P227, DOI 10.1080/02699050500488124; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; Meehan M., 2010, VOCATIONAL ASSESSMEN; Murphy L, 2006, BRAIN INJURY, V20, P1119, DOI 10.1080/02699050600664335; Niemeier JP, 2010, J VOCAT REHABIL, V33, P167, DOI 10.3233/JVR-2010-0525; Nightingale EJ, 2007, BRAIN IMPAIR, V8, P101, DOI [10.1375/brim.8.2.101, DOI 10.1375/BRIM.8.2.101]; O'Brien L, 2007, BRAIN INJURY, V21, P465, DOI 10.1080/02699050701315134; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; O'Neill JH, 2004, ARCH PHYS MED REHAB, V85, pS68, DOI 10.1016/j.apmr.2003.08.114; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; PARENTE R, 1996, J VOCATIONAL REHABIL, V7, P181; Phillips J, 2010, BRIT J OCCUP THER, V73, P422, DOI 10.4276/030802210X12839367526138; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Radford K., 2011, RETURN WORK TRAUMATI; ROESSLER RT, 1992, J REHABIL, V58, P17; ROSENBAUM M, 1978, SCAND J REHABIL MED, V10, P1; Sale P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, 10.1097/00001199-199109000-00004.]; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; TEASDALE TW, 1993, BRAIN INJURY, V7, P535, DOI 10.3109/02699059309008181; Trexler LE, 2010, J HEAD TRAUMA REHAB, V25, P440, DOI 10.1097/HTR.0b013e3181d41139; TURNERSTOKES L, 2003, REHABILITATION FOLLO; Tyerman A, 2008, PROCEEDINGS OF THE 16TH EUROPEAN CONGRESS OF PHYSICAL AND REHABILITATION MEDICINE, P269; Tyerman A., 1999, J APPL OCCUP PSYCHOL, V2, P31; Tyerman A., 2000, J APPL OCCUPATIONAL, V2, P13; Tyerman A, 2004, VOCATIONAL ASSESSMEN; Tyerman A., 2008, PSYCHOL APPROACHES R, P376; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; Wall JR, 1998, NEUROREHABILITATION, V10, P39, DOI 10.3233/NRE-1998-10105; Wall JR, 1998, BRAIN INJURY, V12, P215; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; WEHMAN P, 1988, REHABIL COUNS BULL, V31, P298; WEHMAN P, 1994, AM J PHYS MED REHAB, V73, P280, DOI 10.1097/00002060-199407000-00010; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Wilson B.A., 2000, INT HDB NEUROPSYCHOL, P231; WITOL AD, 1996, J VOCATIONAL REHABIL, V7, P159	79	28	28	0	25	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2012	31	1					51	62		10.3233/NRE-2012-0774			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	976SU	WOS:000306605900006	22523013				2021-06-18	
J	Sackellares, JC; Shiau, DS; Halford, JJ; LaRoche, SM; Kelly, KM				Sackellares, J. Chris; Shiau, Deng-Shan; Halford, Jonathon J.; LaRoche, Suzette M.; Kelly, Kevin M.			Quantitative EEG analysis for automated detection of nonconvulsive seizures in intensive care units	EPILEPSY & BEHAVIOR			English	Article						Intensive care unit; Nonconvulsive seizures; Continuous electroencephalographic monitoring; Seizure detection; Quantitative EEG trending	TRAUMATIC BRAIN-INJURY; STATUS EPILEPTICUS; ELECTROGRAPHIC SEIZURES; ICU	Because of increased awareness of the high prevalence of nonconvulsive seizures in critically ill patients, use of continuous EEG (cEEG) monitoring is rapidly increasing in ICUs. However, cEEG monitoring is labor intensive, and manual review and interpretation of the EEG are impractical in most ICUs. Effective methods to assist in rapid and accurate detection of nonconvulsive seizures would greatly reduce the cost of cEEG monitoring and enhance the quality of patient care. In this study, we report a preliminary investigation of a novel ICU EEG analysis and seizure detection algorithm. Twenty-four prolonged cEEG recordings were included in this study. Seizure detection sensitivity and specificity were assessed for the new algorithm and for the two commercial seizure detection software systems. The new algorithm performed with a mean sensitivity of 90.4% and a mean false detection rate of 0.066/hour. The two commercial detection products performed with low sensitivities (12.9 and 10.1%) and false detection rates of 1.036/hour and 0.013/hour, respectively. These findings suggest that the novel algorithm has potential to be the basis of clinically useful software that can assist ICU staff in timely identification of nonconvulsive seizures. This study also suggests that currently available seizure detection software does not perform sufficiently in detection of nonconvulsive seizures in critically ill patients. This article is part of a Supplemental Special Issue entitled The Future of Automated Seizure Detection and Prediction. (C) 2011 Elsevier Inc. All rights reserved.	[Sackellares, J. Chris; Shiau, Deng-Shan] Optima Neurosci Inc, Alachua, FL 32615 USA; [Halford, Jonathon J.] Med Univ S Carolina, Div Neurol, Dept Neurosci, Charleston, SC 29425 USA; [LaRoche, Suzette M.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Kelly, Kevin M.] Allegheny Gen Hosp, Allegheny Singer Res Inst, Ctr Neurosci Res, Pittsburgh, PA 15212 USA; [Kelly, Kevin M.] Drexel Univ, Coll Med, Dept Neurol, Philadelphia, PA 19104 USA; [Kelly, Kevin M.] Drexel Univ, Coll Med, Dept Neurobiol, Philadelphia, PA 19104 USA; [Kelly, Kevin M.] Drexel Univ, Coll Med, Dept Anat, Philadelphia, PA 19104 USA	Sackellares, JC (corresponding author), Optima Neurosci Inc, 13420 Progress Blvd,Suite 200, Alachua, FL 32615 USA.	csackellares@optimaneuro.com		Halford, Jonathan/0000-0003-1681-6744	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R43 NS064647, R44 NS064647, R43 NS076045] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS064647, R43NS076045, R43NS064647] Funding Source: NIH RePORTER		American Clinical Neurophysiology Society, 1994, J CLIN NEUROPHYSIOL, V11, P114; Bearden Scott, 2008, Am J Electroneurodiagnostic Technol, V48, P11; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Halford Jonathan J, 2010, Am J Electroneurodiagnostic Technol, V50, P133; Hirsch Lawrence J, 2004, Am J Electroneurodiagnostic Technol, V44, P137; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P305; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Hyllienmark L, 2007, EUR J PAEDIATR NEURO, V11, P70, DOI 10.1016/j.ejpn.2006.11.005; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Jirsch J, 2007, CLIN NEUROPHYSIOL, V118, P1660, DOI 10.1016/j.clinph.2006.11.312; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Kaplan PW, 2006, J CLIN NEUROPHYSIOL, V23, P221, DOI 10.1097/01.wnp.0000220837.99490.66; Kelly KM, 2010, CLIN NEUROPHYSIOL, V121, P1832, DOI 10.1016/j.clinph.2010.04.016; Kull LL, 2005, J CLIN NEUROPHYSIOL, V22, P107, DOI 10.1097/01.WNP.0000158361.24544.2D; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; Scheuer ML, 2004, J CLIN NEUROPHYSIOL, V21, P353; Shiau DS, 2010, CYBERN SYST ANAL+, V46, P922, DOI 10.1007/s10559-010-9273-3; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Waterhouse EJ, 1998, EPILEPSY RES, V29, P175, DOI 10.1016/S0920-1211(97)00071-5; Young GB, 1996, NEUROLOGY, V47, P83; Zhang J, 2009, EPILEPSIA, V51, P243	31	28	28	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	DEC	2011	22			1			S69	S73		10.1016/j.yebeh.2011.08.028			5	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	862CQ	WOS:000298067800011	22078521	Green Accepted			2021-06-18	
J	Dubourg, J; Messerer, M				Dubourg, Julie; Messerer, Mahmoud			Sports-related chronic repetitive head trauma as a cause of pituitary dysfunction	NEUROSURGICAL FOCUS			English	Article						concussion; hypopituitarism; sports-related concussion; traumatic brain injury	GROWTH-HORMONE DEFICIENCY; BRAIN-INJURY TBI; ANTIPITUITARY ANTIBODIES; APOLIPOPROTEIN-E; SUBARACHNOID HEMORRHAGE; DIABETES-INSIPIDUS; FOOTBALL-LEAGUE; GH DEFICIENCY; HIGH-RISK; HYPOPITUITARISM	Traumatic brain injury (TBI) is recognized as a cause of hypopituitarism even after mild TBI. Although over the past decade, a growing body of research has detailed neuroendocrine changes induced by TBI, the mechanisms and risk factors responsible for this pituitary dysfunction are still unclear. Around the world, sports-especially combative sports-are very popular. However, sports are not generally considered as a cause of TBI in most epidemiological studies, and the link between sports-related head trauma and hypopituitarism has not been investigated until recently. Thus, there is a paucity of data regarding this important concern. Because of the large number of young sports participants with near-normal life expectancy, the implications of undiagnosed or untreated postconcussion pituitary dysfunction can be dramatic. Understanding the pathophysiological mechanisms and risk factors of hypopituitarism caused by sports injuries is thus an important issue that concerns both medical staff and sponsors of sports. The aim of this paper was to summarize the best evidence for understanding the pathophysiological mechanisms and to discuss the current data and recommendations on sports-related head trauma as a cause of hypopituitarism. (DOI: 10.3171/2011.8.FOCUS11182)	[Messerer, Mahmoud] CHU Vaudois, Dept Neurosci Clin, Serv Neurochirurg, CH-1011 Lausanne, Switzerland; [Dubourg, Julie] Univ Lyon 1, Ctr Invest Clin 201, Grp Hosp Est, Hosp Civils Lyon, F-69622 Villeurbanne, France	Messerer, M (corresponding author), CHU Vaudois, Dept Neurosci Clin, Serv Neurochirurg, Rue Bugnon 21, CH-1011 Lausanne, Switzerland.	m.messerer@laposte.net	Messerer, Mahmoud/AAZ-3527-2020; Dubourg, Julie/AAK-4332-2020	Messerer, Mahmoud/0000-0002-0493-6151; Dubourg, Julie/0000-0002-5514-8075			Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Apuzzo MLJ, 2008, NEUROSURGERY, V62, P202, DOI 10.1227/01.NEU.0000311078.58272.3E; Bailes JE, 2009, J INT NEUROPSYCH SOC, V15, P509, DOI 10.1017/S1355617709090936; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BISTRITZER T, 1981, AM J DIS CHILD, V135, P966, DOI 10.1001/archpedi.1981.02130340070022; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Boughey JC, 2004, AM SURGEON, V70, P500; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; Caturegli P, 2005, ENDOCR REV, V26, P599, DOI 10.1210/er.2004-0011; CEBALLOS R, 2002, ALA J MED SCI, V3, P185; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; DANIEL P M, 1963, Sci Basis Med Annu Rev, P83; DANIEL PM, 1959, LANCET, V2, P927; De Bellis A, 2003, J CLIN ENDOCR METAB, V88, P650, DOI 10.1210/jc.2002-021054; De Bellis A, 2006, J CLIN ENDOCR METAB, V91, P2484, DOI 10.1210/jc.2006-0040; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; GOUDIE RB, 1962, J PATHOL BACTERIOL, V83, P584, DOI 10.1002/path.1700830241; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Ives JC, 2007, J ATHL TRAINING, V42, P431; Jordan B. D., 1991, P MILD BRAIN INJ SPO, P43; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kokshoorn NE, 2011, EUR J ENDOCRINOL, V165, P225, DOI 10.1530/EJE-11-0365; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Manetti L, 2007, J CLIN ENDOCR METAB, V92, P2176, DOI 10.1210/jc.2006-2748; MASSOL J, 1987, NEURORADIOLOGY, V29, P299, DOI 10.1007/BF00451773; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nishida Y, 2005, GENE, V344, P133, DOI 10.1016/j.gene.2004.09.007; Park KD, 2010, BRAIN INJURY, V24, P1330, DOI 10.3109/02699052.2010.506863; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rudehill S, 2006, ACTA NEUROCHIR, V148, P199, DOI 10.1007/s00701-005-0673-5; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Simmonds M, 1914, DEUT MED WOCHENSCHR, V40, P322, DOI 10.1055/s-0029-1190185; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stein TD, 2002, J NEUROPATH EXP NEUR, V61, P1100, DOI 10.1093/jnen/61.12.1100; Tanriverdi F, 2008, J NEUROTRAUM, V25, P1071, DOI 10.1089/neu.2007.0456; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tanriverdi F, 2010, EUR J ENDOCRINOL, V162, P861, DOI 10.1530/EJE-09-1024; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91; WelshBohmer KA, 1997, ANN NEUROL, V42, P319, DOI 10.1002/ana.410420308; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; 1996, CLIN NEUROSURG, V14, P424	70	28	28	1	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2011	31	5							E2	10.3171/2011.8.FOCUS11182			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	844QL	WOS:000296762300003	22044101				2021-06-18	
J	McColgan, P; Sharma, P; Bentley, P				McColgan, Peter; Sharma, Pankaj; Bentley, Paul			Stem Cell Tracking in Human Trials: A Meta-Regression	STEM CELL REVIEWS AND REPORTS			English	Article							MARROW MONONUCLEAR-CELLS; MAGNETIC-RESONANCE TRACKING; PROGENITOR CELLS; MYOCARDIAL-INFARCTION; CD34(+) CELLS; INTRACORONARY INJECTION; TISSUE DISTRIBUTION; STROKE; TRANSPLANTATION; MIGRATION	The potential effectiveness of cell therapies is dependent upon homing of transplanted cells to relevant target organs. In this study we firstly characterise the range of methods employed in all human therapeutic-cell studies published to date investigated with cell-tracking. Secondly, we determine factors that predict target-organ cell uptake efficiency by meta-regression. Following a comprehensive literature search, we identified 19 relevant trials, representing 145 patients over the following 7 diseases: myocardial infarction; Chagasic cardiomyopathy; ischemic stroke; traumatic injury of brain or spinal cord; diabetes and cirrhosis. Cell-labelling strategies employed were: 18-fluorodeoxyglucose-PET, 111-indium-SPECT; 99-technetium-SPECT, and iron oxide-MRI. The following methodological parameters were extracted: label type; label dose; labelling efficiency; stability; cell dose; percentage labelled cells; disease type and chronicity; cell purity; cell type; and cell uptake efficiency. Meta-regression techniques were used to identify predictors of cell-labelling efficiency; viability and cell uptake efficiency. These analyses found that labelling efficiency is proportionate to cell dose, while cell viability is lowest with indium and long label incubation times. Uptake efficiency of cells is predicted by stem cell purity (positive association) and cell infusion number (negative association), although these two variables are themselves strongly negatively correlated between studies. In summary the methodological factors associated with enhanced therapeutic-cell homing from both our own analysis, and within-trial comparisons, are: acute (versus chronic) disease, selective stem cells (versus unselected cells), and intra-arterial (versus intravenous) delivery. However, future trials need to keep cell doses and imaging times constant so as to enable meaningful comparisons in uptake efficiency.	[Bentley, Paul] Univ London Imperial Coll Sci Technol & Med, Imperial Coll Cerebrovasc Res Unit ICCRU, London W6 8RF, England; [McColgan, Peter; Sharma, Pankaj] Imperial Coll Hosp, Imperial Coll Cerebrovasc Res Unit ICCRU, London W6 8RF, England	Bentley, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Imperial Coll Cerebrovasc Res Unit ICCRU, Fulham Palace Rd, London W6 8RF, England.	p.bentley@imperial.ac.uk		Bentley, Paul/0000-0001-8036-7010	UK Department of Health Senior	PS and PB supported by UK Department of Health Senior Fellowships.	Alexandrescu DT, 2010, J IMMUNOTHER, V33, P570, DOI 10.1097/CJI.0b013e3181e032e8; Arminan A, 2010, J AM COLL CARDIOL, V55, P2244, DOI 10.1016/j.jacc.2009.08.092; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Ballios BG, 2010, CAN J OPHTHALMOL, V45, P342, DOI 10.3129/i10-070; da Fonseca LMB, 2010, EXP NEUROL, V221, P122, DOI 10.1016/j.expneurol.2009.10.010; da Fonseca LMB, 2009, CIRCULATION, V120, P539, DOI 10.1161/CIRCULATIONAHA.109.863084; Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001; Bersano A, 2010, CURR VASC PHARMACOL, V8, P29, DOI 10.2174/157016110790226570; Blocklet D, 2006, STEM CELLS, V24, P333, DOI 10.1634/stemcells.2005-0201; Bonavita AG, 2010, XENOTRANSPLANTATION, V17, P181, DOI 10.1111/j.1399-3089.2010.00588.x; Brenner W, 2004, J NUCL MED, V45, P512; Callera F, 2007, STEM CELLS DEV, V16, P461, DOI 10.1089/scd.2007.0083; Caveliers V, 2007, Q J NUCL MED MOL IM, V51, P61; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Correa PL, 2007, CLIN NUCL MED, V32, P839, DOI 10.1097/RLU.0b013e318156b980; DAFONSECA LMB, 2010, INT J CARDIOLOGY MAR; Dedobbeleer C, 2009, J CARDIOVASC PHARM, V53, P480, DOI 10.1097/FJC.0b013e3181a7b572; Gera A, 2010, REGEN MED, V5, P73, DOI 10.2217/RME.09.79; Goussetis E, 2006, STEM CELLS, V24, P2279, DOI 10.1634/stemcells.2005-0589; Grogaard HK, 2007, CARDIOVASC REVASCULA, V8, P21, DOI 10.1016/j.carrev.2006.09.001; Halban PA, 2010, J CLIN ENDOCR METAB, V95, P1034, DOI 10.1210/jc.2009-1819; Hofmann M, 2005, CIRCULATION, V111, P2198, DOI 10.1161/01.CIR.0000163546.27639.AA; ISHIWATA K, 1993, J NUCL MED, V34, P1936; Jacob José Luiz Balthazar, 2007, Arq. Bras. Cardiol., V89, pe10, DOI 10.1590/S0066-782X2007001400014; Jendelova P, 2005, CELL TRANSPLANT, V14, P173, DOI 10.3727/000000005783983124; Jin JY, 2009, EUR J HEART FAIL, V11, P147, DOI 10.1093/eurjhf/hfn017; Kang WJ, 2006, J NUCL MED, V47, P1295; Khan AA, 2010, CELL TRANSPLANT, V19, P409, DOI 10.3727/096368910X498241; Kurisaki A, 2010, HUM CELL, V23, P1, DOI 10.1111/j.1749-0774.2010.00080.x; Kurpisz M, 2007, INT J CARDIOL, V121, P194, DOI 10.1016/j.ijcard.2006.08.062; Li L, 2010, J CEREBR BLOOD F MET, V30, P653, DOI 10.1038/jcbfm.2009.238; Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e; Lindvall O, 2009, TRENDS PHARMACOL SCI, V30, P260, DOI 10.1016/j.tips.2009.03.001; Ly HQ, 2008, NAT CLIN PRACT CARD, V5, pS96, DOI 10.1038/ncpcardio1159; Ma J, 2005, BASIC RES CARDIOL, V100, P217, DOI 10.1007/s00395-005-0521-z; Mesquita CT, 2005, J NUCL CARDIOL, V12, P610, DOI 10.1016/j.nuclcard.2005.05.010; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Pajtasz-Piasecka E, 2010, IMMUNOTHERAPY-UK, V2, P257, DOI [10.2217/imt.10.7, 10.2217/IMT.10.7]; Palestro CJ, 2009, Q J NUCL MED MOL IM, V53, P105; Park DH, 2011, STEM CELL REV REP, V7, P181, DOI 10.1007/s12015-010-9163-0; Penicka M, 2007, HEART, V93, P837, DOI 10.1136/hrt.2006.091934; Politi LS, 2007, NEURORADIOLOGY, V49, P523, DOI 10.1007/s00234-007-0219-z; Schachinger V, 2008, CIRCULATION, V118, P1425, DOI 10.1161/CIRCULATIONAHA.108.777102; Singh S, 2009, CLIN CARDIOL, V32, P176, DOI 10.1002/clc.20470; SRIVASTAVA SC, 1984, SEMIN NUCL MED, V14, P68, DOI 10.1016/S0001-2998(84)80022-7; Steinman RM, 2001, INT J CANCER, V94, P459, DOI 10.1002/ijc.1503; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; TENBERGE RJM, 1983, J NUCL MED, V24, P615; Toso C, 2008, AM J TRANSPLANT, V8, P701, DOI 10.1111/j.1600-6143.2007.02120.x; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhu JH, 2006, NEW ENGL J MED, V355, P2376, DOI 10.1056/NEJMc055304	51	28	29	0	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1550-8943	1558-6804		STEM CELL REV REP	Stem Cell Rev. Rep.	NOV	2011	7	4					1031	1040		10.1007/s12015-011-9260-8			10	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	855WU	WOS:000297597800024	21475954				2021-06-18	
J	Park, BN; Shim, W; Lee, G; Bang, OY; An, YS; Yoon, JK; Ahn, YH				Park, Bok-Nam; Shim, Wooyoung; Lee, Gwang; Bang, Oh Young; An, Young-Sil; Yoon, Joon-Kee; Ahn, Young Hwan			Early distribution of intravenously injected mesenchymal stem cells in rats with acute brain trauma evaluated by Tc-99m-HMPAO labeling	NUCLEAR MEDICINE AND BIOLOGY			English	Article						Tc-99m-HMPAO; Bone marrow mesenchymal stem cells; Traumatic brain injury; Cell tracking; Gamma camera; Gamma counter	HEMATOPOIETIC PROGENITOR CELLS; IN-VIVO; MYOCARDIAL-INFARCTION; DIFFERENTIATION; TRANSPLANTATION; THERAPIES; MIGRATION; SPECT	Introduction: Stem cell tracking is essential for evaluation of its migration, transplantation and therapeutic response. The aim of this study was to evaluate early distribution of intravenously transplanted rat bone marrow mesenchymal stem cells (BMSCs) in rats with acute cerebral trauma by labeling with Tc-99m-hexamethylpropyleneamine oxime (Tc-99m-HMPAO). Methods: Tc-99m-HMPAO-labeled BMSCs were injected intravenously to trauma rats (n=14) and sham-operated controls (n=13). Gamma camera images were acquired at 4 h after injection, and then organs were removed for gamma counting. Confocal microscope was used to confirm the migration of Tc-99m-BMSCs by co-labeling with PKH26. Cytometric analysis was performed to evaluate apoptotic or necrotic change until the seventh day after labeling. Results: Tc-99m-BMSCs were distributed mostly to lungs, liver and spleen at 4 h, and uptake of these organs was not significantly different between traumatic rats and controls. Meanwhile, the cerebral uptake of Tc-99m-BMSCs was significantly higher in the traumatic rats than in controls (0.40% vs. 0.20%; P=.0002). Additionally, Tc-99m-BMSCs' uptake of traumatic hemisphere was significantly higher than that of contralateral ones (0.27% vs. 0.13%; P=.0001) in traumatic rats. Regardless of radiolabeling, BMSCs migrated to traumatic regions, but not to nontraumatic hemispheres. However, gamma camera failed to demonstrate Tc-99m-BMSCs in traumatic hemispheres. No significant apoptotic or necrotic change was observed until 7 days after radiolabeling. Conclusions: Early distribution of BMSCs in traumatic brain disease could be monitored by Tc-99m-labeling, which does not induce cellular death. However, our data showed that the amount of migrated Tc-99m-BMSCs was not enough to be demonstrated by clinical gamma camera. (C) 2011 Elsevier Inc. All rights reserved.	[Park, Bok-Nam; An, Young-Sil; Yoon, Joon-Kee] Ajou Univ, Sch Med, Dept Nucl Med & Mol Imaging, Suwon 442749, South Korea; [Shim, Wooyoung; Lee, Gwang; Ahn, Young Hwan] Ajou Univ, Sch Med, Inst Neuroregenerat & Stem Cell Res, Suwon 442749, South Korea; [Shim, Wooyoung; Lee, Gwang] Ajou Univ, Dept Mol Sci & Technol, Suwon 442749, South Korea; [Lee, Gwang] Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 442749, South Korea; [Bang, Oh Young] Yonsei Univ, Sch Med, Dept Neurol, Seoul 102752, South Korea; [Ahn, Young Hwan] Ajou Univ, Sch Med, Dept Neurosurg, Suwon 442749, South Korea	Yoon, JK (corresponding author), Ajou Univ, Sch Med, Dept Nucl Med & Mol Imaging, Suwon 442749, South Korea.	jkyoon3@gmail.com		An, Young-Sil/0000-0003-0777-6226	Korea Food and Drug Administration, Republic of Korea [KFDA2006-7710[1]]; Department of Medical Sciences, The Graduate School, Ajou University	This work was supported by the Korea Food and Drug Administration, Republic of Korea (KFDA2006-7710[1]), and the 2008 grant from the Department of Medical Sciences, The Graduate School, Ajou University (J.K. Yoon).	Ballas CB, 2002, J CELL BIOCHEM, P20, DOI 10.1002/jcb.10127; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; Beeres SLMA, 2007, J AM COLL CARDIOL, V49, P1137, DOI 10.1016/j.jacc.2006.10.072; Bengel FM, 2005, EUR J NUCL MED MOL I, V32, pS404, DOI 10.1007/s00259-005-1898-5; Bindslev L, 2006, EUR J NUCL MED MOL I, V33, P1171, DOI 10.1007/s00259-006-0093-7; Brenner W, 2004, J NUCL MED, V45, P512; Chen Z, 2006, TOXICOL LETT, V163, P109, DOI 10.1016/j.toxlet.2005.10.003; Cho YH, 2006, ACTA NEUROCHIR SUPPL, V99, P125, DOI 10.1007/978-3-211-35205-2_24; Detante O, 2009, CELL TRANSPLANT, V18, P1369, DOI 10.3727/096368909X474230; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Fierro FA, 2004, CLIN EXP METASTAS, V21, P313, DOI 10.1023/B:CLIN.0000046130.79363.33; Frankel MS, 2000, SCIENCE, V287, P1397, DOI 10.1126/science.287.5457.1397; FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83; Hellmann MA, 2006, NEUROSCI LETT, V395, P124, DOI 10.1016/j.neulet.2005.10.097; Hill JM, 2003, CIRCULATION, V108, P1009, DOI 10.1161/01.CIR.0000084537.66419.7A; Kang WJ, 2006, J NUCL MED, V47, P1295; Kraitchman DL, 2003, CIRCULATION, V107, P2290, DOI 10.1161/01.CIR.0000070931.62772.4E; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Stodilka RZ, 2006, NUCL MED COMMUN, V27, P807, DOI 10.1097/01.mnm.0000237987.31597.cf; Yoon JK, 2010, NUCL MED BIOL, V37, P381, DOI 10.1016/j.nucmedbio.2009.12.001; Zhu W, 2006, EXP MOL PATHOL, V80, P267, DOI 10.1016/j.yexmp.2005.07.004	24	28	32	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0969-8051			NUCL MED BIOL	Nucl. Med. Biol.	NOV	2011	38	8					1175	1182		10.1016/j.nucmedbio.2011.05.009			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	862DQ	WOS:000298070400013	21831649				2021-06-18	
J	Thompson, DO; Hurtado, TR; Liao, MM; Byyny, RL; Gravitz, C; Haukoos, JS				Thompson, David O.; Hurtado, Timothy R.; Liao, Michael M.; Byyny, Richard L.; Gravitz, Craig; Haukoos, Jason S.			Validation of the Simplified Motor Score in the Out-of-Hospital Setting for the Prediction of Outcomes After Traumatic Brain Injury	ANNALS OF EMERGENCY MEDICINE			English	Article							GLASGOW COMA SCALE; EMERGENCY-DEPARTMENT; INTERRATER RELIABILITY; ADVANCED STATISTICS; CLINICAL-RESEARCH; MISSING DATA	Study objective: The Glasgow Coma Scale (GCS) score is widely used to assess patients with head injury but has been criticized for its complexity and poor interrater reliability. A 3-point Simplified Motor Score (SMS) (defined as obeys commands=2, localizes pain=1, and withdraws to pain or worse=0) was created to address these limitations. Our goal is to validate the SMS in the out-of-hospital setting, with the hypothesis that it is equivalent to the GCS score for discriminating brain injury outcomes. Methods: This was a secondary analysis of an urban Level I trauma registry. Four outcomes and their composite were studied: emergency tracheal intubation, clinically meaningful brain injury, need for neurosurgical intervention, and mortality. The out-of-hospital GCS score and SMS were evaluated by comparing areas under the receiver operating characteristic curve with a paired nonparametric approach. Multiple imputation was used for missing data. A clinically significant difference in areas under the receiver operating characteristic curve was defined as greater than or equal to 0.05, according to previous literature. Results: We included 19,408 patients, of whom 18% were tracheally intubated, 18% had brain injuries, 8% required neurosurgical intervention, and 6% died. The difference between the area under the receiver operating characteristic curve for the out-of-hospital GCS score and SMS was 0.05 (95% confidence interval [CI] 0.01 to 0.11) for emergency tracheal intubation, 0.05 (95% CI 0 to 0.09) for brain injury, 0.04 (95% CI -0.01 to 0.09) for neurosurgical intervention, 0.08 (95% CI 0.02 to 0.15) for mortality, and 0.05 (95% CI 0 to 0.10) for the composite outcome. Conclusion: In this external validation, SMS was similar to the GCS score for predicting outcomes in traumatic brain injury in the out-of-hospital setting. [Ann Emerg Med. 2011;58:417-425.]	[Thompson, David O.; Hurtado, Timothy R.; Liao, Michael M.; Byyny, Richard L.; Haukoos, Jason S.] Denver Hlth Med Ctr, Dept Emergency Med, Denver, CO 80204 USA; [Gravitz, Craig] Denver Hlth Med Ctr, Dept Surg, Denver, CO USA; [Thompson, David O.; Liao, Michael M.; Byyny, Richard L.; Haukoos, Jason S.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA; [Hurtado, Timothy R.] Front Range Emergency Specialists PC, Colorado Springs, CO USA; [Haukoos, Jason S.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA	Thompson, DO (corresponding author), Denver Hlth Med Ctr, Dept Emergency Med, Denver, CO 80204 USA.	davidothompson@gmail.com		Byyny, Richard/0000-0002-9145-7457	Agency for Healthcare Research and Quality (AHRQ)United States Department of Health & Human ServicesAgency for Healthcare Research & Quality [F32 HS018123, K02 HS017526]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [F32HS018123, K02HS017526] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). Dr. Liao was supported by the Agency for Healthcare Research and Quality (AHRQ) (F32 HS018123), as was Dr. Haukoos (K02 HS017526).	Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2007, ANN EMERG MED, V49, P403, DOI 10.1016/j.annemergmed.2006.03.031; Gill M, 2006, ACAD EMERG MED, V13, P968, DOI 10.1197/j.aem.2006.05.019; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Haukoos JS, 2007, ACAD EMERG MED, V14, P662, DOI 10.1197/j.aem.2006.11.037; Haukoos JS, 2007, ANN EMERG MED, V50, P18, DOI 10.1016/j.annemergmed.2006.10.004; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Heard K, 2004, HUM EXP TOXICOL, V23, P197, DOI 10.1191/0960327104ht436oa; Holdgate Anna, 2006, Emerg Med Australas, V18, P379, DOI 10.1111/j.1742-6723.2006.00867.x; Kornbluth J, 2011, NEUROCRIT CARE, V14, P134, DOI 10.1007/s12028-010-9409-3; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; Newgard CD, 2006, ACAD EMERG MED, V13, P314, DOI 10.1197/j.aem.2005.09.011; Newgard CD, 2007, ACAD EMERG MED, V14, P669, DOI 10.1197/j.aem.2006.11.038; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Rubin DB., 1987, MULTIPLE IMPUTATION; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81	24	28	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	NOV	2011	58	5					417	425		10.1016/j.annemergmed.2011.05.033			9	Emergency Medicine	Emergency Medicine	846ZU	WOS:000296942500003	21803448				2021-06-18	
J	Pachalska, M; Lukowicz, M; Kropotov, JD; Herman-Sucharska, I; Talar, J				Pachalska, Maria; Lukowicz, Malgorzata; Kropotov, Juri D.; Herman-Sucharska, Izabela; Talar, Jan			Evaluation of differentiated neurotherapy programs for a patient after severe TBI and long term coma using event-related potentials	MEDICAL SCIENCE MONITOR			English	Article						TBI; executive dysfunctions; behavioral changes; neurotherapy; ERP's	TRAUMATIC BRAIN-INJURY; TRANSCRANIAL MAGNETIC STIMULATION; FRONTAL BEHAVIORAL INVENTORY; EPIDEMIOLOGY; REHABILITATION; BIOFEEDBACK	Background: This article examines the effectiveness of differentiated rehabilitation programs for a patient with frontal syndrome after severe TBI and long-term coma. We hypothesized that there would be a small response to relative beta training, and a good response to rTMS, applied to regulate the dynamics of brain function. Case Report: M. L-S, age 26, suffered from anosognosia, executive dysfunction, and behavioral changes, after a skiing accident and prolonged coma, rendering him unable to function independently in many situations of everyday life. Only slight progress was made after traditional rehabilitation. The patient took part in 20 sessions of relative beta training (program A) and later in 20 sessions of rTMS (program B); both programs were combined with behavioral training. We used standardized neuropsychological testing, as well as ERPs before the experiment, after the completion of program A, and again after the completion of program B. As hypothesized, patient M. L-S showed small improvements in executive dysfunction and behavioral disorders after the conclusion of program A, and major improvement after program B. Similarly, in physiological changes the patient showed small improvement after relative beta training and a significant improvement of the P300 NOGO component after the rTMS program. Conclusions: The rTMS program produced larger physiological and behavioral changes than did relative beta training. A combination of different neurotherapeutical approaches (such as neurofeedback, rTMS, tDCS) can be suggested for similar severe cases of TBI. ERPs can be used to assess functional brain changes induced by neurotherapeutical programs.	[Pachalska, Maria] Andrzej Frycz Modrzewski Cracow Univ, Chair Neuropsychol, PL-30705 Krakow, Poland; [Pachalska, Maria] Ctr Cognit & Commun, New York, NY USA; [Lukowicz, Malgorzata] Nicolaus Copernicus Univ, Coll Med, Laser Therapy & Physiotherapy Dept, Bydgoszcz, Poland; [Kropotov, Juri D.] Russian Acad Sci, Inst Human Brain, Lab Neurobiol Act Programming, St Petersburg 196140, Russia; [Kropotov, Juri D.] Norwegian Univ Sci & Technol, Inst Psychol, N-7034 Trondheim, Norway; [Herman-Sucharska, Izabela] Jagiellonian Univ, Coll Med, Dept Radiol, Magnet Resonance Lab, Krakow, Poland; [Talar, Jan] Elblag Univ Humanities & Econ, Dept Hlth Sci, Elblag, Poland	Pachalska, M (corresponding author), Andrzej Frycz Modrzewski Cracow Univ, Chair Neuropsychol, Herlinga Grudzinskiego 1 Str, PL-30705 Krakow, Poland.	neuropsychologia23@o2.pl		Malgorzata, Lukowicz/0000-0002-4574-8050			Barry RJ, 2009, INT J PSYCHOPHYSIOL, V71, P124, DOI 10.1016/j.ijpsycho.2008.09.009; Bashir S, 2010, PM&R, V2, pS253, DOI 10.1016/j.pmrj.2010.10.015; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Blair M, 2007, DEMENT GERIATR COGN, V23, P406, DOI 10.1159/000101908; Bolognini N, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-8; Choi JH, 2008, J TRAUMA, V65, P1028, DOI 10.1097/TA.0b013e31815eba9b; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Fregni F, 2006, STROKE, V37, P2115, DOI 10.1161/01.STR.0000231390.58967.6b; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Kertesz A, 1997, CAN J NEUROL SCI, V24, P29, DOI 10.1017/S0317167100021053; Kertesz A, 2000, J INT NEUROPSYCH SOC, V6, P460, DOI 10.1017/S1355617700644041; Kropotov JD, 2005, INT J PSYCHOPHYSIOL, V55, P23, DOI 10.1016/j.ijpsycho.2004.05.011; Kropotov JD, 2009, QUANTITATIVE EEG EVE, P542; Kropotov JD, 2009, ACTA NEUROPSYCHOL, V7, P169; Marvasti Jamshid A, 2011, Conn Med, V75, P133; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; Meinzer M, 2011, APHASIOLOGY, V25, P271, DOI 10.1080/02687038.2010.530672; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Nitsche MA, 2007, J NEUROPHYSIOL, V97, P3109, DOI 10.1152/jn.01312.2006; Pachalska M, 2002, ORTOPEDIA TRAUMATOLO, V4, P81; Pachalska M, 2008, REHABILITACJA NEUROP; Pachalska M, 2010, MED SCI MONITOR, V16, pCS157; Pape TLB, 2006, J HEAD TRAUMA REHAB, V21, P437, DOI 10.1097/00001199-200609000-00063; Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7; Pascual-Leone A., 2002, HDB TRANSCRANIAL MAG; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rossi S, 2004, TRENDS COGN SCI, V8, P273, DOI 10.1016/j.tics.2004.04.012; Schoenberger NE, 2001, J HEAD TRAUMA REHAB, V16, P260, DOI 10.1097/00001199-200106000-00005; Slawik H, 2009, J NEUROTRAUM, V26, P1891, DOI 10.1089/neu.2009.0942; Thatcher RW, 2000, CLIN ELECTROENCEPHAL, V31, P38, DOI 10.1177/155005940003100110; Thornton KE, 2009, APPL PSYCHOPHYS BIOF, V34, P59, DOI 10.1007/s10484-009-9075-4; Velikonja D, 2010, J CLIN EXP NEUROPSYC, V32, P610, DOI 10.1080/13803390903401302; Wagner T, 2007, ANNU REV BIOMED ENG, V9, P527, DOI 10.1146/annurev.bioeng.9.061206.133100	34	28	28	0	36	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	OCT	2011	17	10					CS120	CS128		10.12659/MSM.881970			9	Medicine, Research & Experimental	Research & Experimental Medicine	861QL	WOS:000298034200009	21959618	Green Published			2021-06-18	
J	Pitkanen, A; Lukasiuk, K				Pitkanen, Asla; Lukasiuk, Katarzyna			Molecular biomarkers of epileptogenesis	BIOMARKERS IN MEDICINE			English	Article						cerebrospinal fluid; microRNA; proteomics; serum; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; COMPUTED-TOMOGRAPHY FINDINGS; SPECTRIN BREAKDOWN PRODUCTS; FIBRILLARY ACIDIC PROTEIN; CEREBROSPINAL-FLUID; OUTCOME PREDICTION; HEAD TRAUMA; SERUM; S100B	The heterogeneity of epilepsy syndromes and pathologies creates a great challenge for the search for biomarkers. Not surprisingly, identification of a marker that is specific and sensitive for a given epileptogenic pathology remains an unmet need. There have, however, been several studies of major epileptogenic etiologies like traumatic brain injury that aimed to identify molecular markers in blood and cerebrospinal fluid that predict outcome, by using proteomics and metabolomics. Unfortunately, epileptogenesis has not been analyzed as an outcome measure. Another question to be explored is whether a palette of molecular markers is needed, rather than a single molecule, with each marker probing a different component of epileptogenic pathology. Further, perhaps multiple biomarker platforms (e.g., imaging, proteomics, electrophysiology) should be used in combination and/or in a defined temporal sequence.	[Pitkanen, Asla] Univ Eastern Finland, Virtanen Inst Mol Sci, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Lukasiuk, Katarzyna] Polish Acad Sci, Nencki Inst Expt Biol, Warsaw, Poland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland	Pitkanen, A (corresponding author), Univ Eastern Finland, Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitkanen@uef.fi	Lukasiuk, Katarzyna/F-4636-2010	Lukasiuk, Katarzyna/0000-0002-1582-0920	Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; CURE; Nencki Institute	The authors were supported by the Academy of Finland (A Pitkanen), The Sigrid Juselius Foundation (A Pitkanen), CURE (A Pitkanen), and statutory funds of the Nencki Institute (K Lukasiuk). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Bernard F, 2008, J TRAUMA, V64, P872, DOI 10.1097/TA.0b013e31803428cc; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cardali S, 2006, J Neurosurg Sci, V50, P25; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Darwish RS, 2010, NEUROCRIT CARE, V12, P337, DOI 10.1007/s12028-009-9328-3; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; McKeating EG, 1998, ACT NEUR S, V71, P200; McKeating EG, 1998, ACT NEUR S, V71, P117; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Schuff N, 2006, ADV EXP MED BIOL, V576, P241; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Tang Y, 2005, ARCH NEUROL-CHICAGO, V62, P210, DOI 10.1001/archneur.62.2.210; Tang Y, 2001, ANN NEUROL, V50, P699, DOI 10.1002/ana.10042; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Ucar T, 2004, J TRAUMA, V57, P95, DOI 10.1097/01.TA.0000071352.95491.75; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Wang L, 2010, CLIN CHIM ACTA, V411, P581, DOI 10.1016/j.cca.2010.01.022; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Xiao F, 2009, BRAIN RES, V1255, P180, DOI 10.1016/j.brainres.2008.12.008; Xiao Z, 2010, CLIN BIOCHEM, V43, P1129, DOI 10.1016/j.clinbiochem.2010.06.015; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	50	28	31	0	20	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1752-0363	1752-0371		BIOMARK MED	Biomark. Med.	OCT	2011	5	5					629	633		10.2217/BMM.11.67			5	Medicine, Research & Experimental	Research & Experimental Medicine	857TW	WOS:000297744900012	22003911	Green Published			2021-06-18	
J	Spencer, DD; Jacobi, J; Juenke, JM; Fleck, JD; Kays, MB				Spencer, Dustin D.; Jacobi, Judith; Juenke, JoEtta M.; Fleck, James D.; Kays, Michael B.			Steady-State Pharmacokinetics of Intravenous Levetiracetam in Neurocritical Care Patients	PHARMACOTHERAPY			English	Article						levetiracetam; pharmacokinetics; seizure prophylaxis; neurocritical care	CRITICALLY-ILL PATIENTS; PHARMACODYNAMIC TARGET ATTAINMENT; INTRACEREBRAL HEMORRHAGE; SEIZURE PROPHYLAXIS; INFUSION; TOLERABILITY; EPILEPSY; SAFETY; PHENYTOIN; CHILDREN	Study Objectives. To characterize the steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients requiring seizure prophylaxis after a neurologic injury and to determine which dosing regimens achieve serum concentrations within the recommended therapeutic range of 6-20 mu g/ml. Design. Prospective, open-label, steady-state pharmacokinetic study. Setting. Neurocritical care unit in a tertiary care medical center. Patients. Twelve adults (five men, seven women) admitted to the neurocritical care unit who required prophylactic anticonvulsant therapy after subarachnoid hemorrhage, subdural hematoma, or traumatic brain injury. Intervention. Patients received an intravenous infusion of levetiracetam 500 mg over 15 minutes every 12 hours. Measurements and Main Results. Serial blood samples were collected from all patients after a minimum of four doses of therapy. Serum levetiracetam concentrations were determined by ultraperformance liquid chromatography with tandem mass spectrometry detection, and pharmacokinetic data were analyzed by compartmental and noncompartmental methods. Monte Carlo simulations were performed for multiple levetiracetam dosing regimens to determine the probability of achieving a target trough concentration of 6 mu g/ml or greater, 20 mu g/ml or greater, and 6-20 mu g/ml. The mean +/- SD levetiracetam maximum serum concentration was 28.0 +/- 8.0 mu g/ml, minimum serum concentration 3.1 +/- 1.8 mu g/ml, half-life 5.2 +/- 1.2 hours, systemic clearance 5.6 +/- 1.8 L/hour, and volume of distribution at steady state 36.8 +/- 6.3 L. Increasing the doses of levetiracetam increased the probability of achieving a target trough concentration of 6 mu g/ml or greater but also increased the probability of achieving trough concentrations greater than 20 mu g/ml. Levetiracetam doses of 1000 mg every 8 hours and 1500-2000 mg every 12 hours provided the highest probability of achieving a target trough concentration between 6 and 20 mu g/ml. Conclusion. Compared with previously published results in healthy volunteers and adults in status epilepticus, levetiracetam systemic clearance was faster and the terminal elimination half-life was shorter in neurocritical care patients. Higher doses or more frequent dosing may be needed to achieve target trough concentrations of 6-20 mu g/ml.	[Spencer, Dustin D.; Jacobi, Judith] Indiana Univ Hlth, Methodist Hosp, Dept Pharm, Indianapolis, IN 46202 USA; [Juenke, JoEtta M.] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA; [Fleck, James D.] Indiana Univ Hlth Phys, Indianapolis, IN USA; [Kays, Michael B.] Purdue Univ, Coll Pharm, Dept Pharm Practice, Indianapolis, IN USA	Spencer, DD (corresponding author), Indiana Univ Hlth, Methodist Hosp, Dept Pharm, 1701 N Senate Blvd,AG401, Indianapolis, IN 46202 USA.	dspence2@iuhealth.org	Spencer, Dustin/AAI-2761-2021; Jacobi, Judith/ABE-2757-2020	Jacobi, Judith/0000-0003-2421-0734			Betts T, 2000, SEIZURE-EUR J EPILEP, V9, P80, DOI 10.1053/seiz.2000.0380; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; DeRyke CA, 2007, PHARMACOTHERAPY, V27, P333, DOI 10.1592/phco.27.3.333; Fountain NB, 2009, EPILEPSY CURR, V9, P71, DOI 10.1111/j.1535-7511.2009.01297.x; Gibaldi M., 1982, PHARMACOKINETICS; Glauser TA, 2007, EPILEPSIA, V48, P1117, DOI 10.1111/j.1528-1167.2007.01090.x; Hirsch LJ, 2007, EPILEPSIA, V48, P1351, DOI 10.1111/j.1528-1167.2007.01043.x; Johannessen SI, 2003, THER DRUG MONIT, V25, P347, DOI 10.1097/00007691-200306000-00016; Kim A, 2009, CLIN THER, V31, P2765, DOI 10.1016/j.clinthera.2009.11.026; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Naidech AM, 2009, STROKE, V40, P3810, DOI 10.1161/STROKEAHA.109.559948; Nau KM, 2009, NEUROCRIT CARE, V11, P34, DOI 10.1007/s12028-009-9185-0; Patsalos PN, 2004, CLIN PHARMACOKINET, V43, P707, DOI 10.2165/00003088-200443110-00002; Pellock JM, 2001, EPILEPSIA, V42, P1574, DOI 10.1046/j.1528-1157.2001.41300.x; Radtke RA, 2001, EPILEPSIA, V42, P24, DOI 10.1046/j.1528-1157.2001.0420s4024.x; Ramael S, 2006, CLIN THER, V28, P734, DOI 10.1016/j.clinthera.2006.05.004; Ramael S, 2006, EPILEPSIA, V47, P1128, DOI 10.1111/j.1528-1167.2006.00586.x; Ruegg S, 2008, EPILEPSY BEHAV, V12, P477, DOI 10.1016/j.yebeh.2008.01.004; Sahaya K, 2010, EPILEPSIA, V51, P2492, DOI 10.1111/j.1528-1167.2010.02788.x; Szaflarski JP, 2008, EPILEPSIA, V49, P974, DOI 10.1111/j.1528-1167.2007.01513.x; Szaflarski JP, 2007, NEUROCRIT CARE, V7, P140, DOI 10.1007/s12028-007-0042-8; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; *UCB INC, 2008, KEPPR LEV INJ INTR U; Uges JWF, 2009, EPILEPSIA, V50, P415, DOI 10.1111/j.1528-1167.2008.01889.x; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; WEISBERG LA, 1991, NEUROLOGY, V41, P1197, DOI 10.1212/WNL.41.8.1197	27	28	28	0	5	PHARMACOTHERAPY PUBLICATIONS INC	BOSTON	NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA	0277-0008			PHARMACOTHERAPY	Pharmacotherapy	OCT	2011	31	10					934	941		10.1592/phco.31.10.934			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	831WI	WOS:000295761400002	21950640				2021-06-18	
J	Choi, S; Cunningham, DT; Aguila, F; Corrigan, JD; Bogner, J; Mysiw, WJ; Knopp, MV; Schmalbrock, P				Choi, Seongjin; Cunningham, Dustin T.; Aguila, Francisco; Corrigan, John D.; Bogner, Jennifer; Mysiw, W. Jerry; Knopp, Michael V.; Schmalbrock, Petra			DTI at 7 and 3 T: systematic comparison of SNR and its influence on quantitative metrics	MAGNETIC RESONANCE IMAGING			English	Article						DTI; 7 T; SNR; Partial volume effects	TRAUMATIC BRAIN-INJURY; DIFFUSION-TENSOR MRI; WHITE-MATTER; MAGNETIC-RESONANCE; ANISOTROPY; QUANTIFICATION; TRACTOGRAPHY; SCHEMES; TRACTS; SENSE	Diffusion tensor imaging (DTI) and advanced related methods such as diffusion spectrum and kurtosis imaging are limited by low signal-to-noise ratio (SNR) at conventional field strengths. DTI at 7 T can provide increased SNR; however, B0 and B1 inhomogeneity and shorter T2* still pose formidable challenges. The purpose of this study was to quantify and compare SNR at 7 and 3 T for different parallel imaging reduction factors, R, and TE, and to evaluate SNRs influences on fractional anisotropy (FA) and apparent diffusion coefficient (ADC). We found that R>4 at 7 T and R >= 2 at 3 T were needed to reduce geometric distortions due to B0 inhomogeneity. For these R at 7 T, SNR was 70-90 for b=0 s/mm(2) and 22-28 for b=1000s/mm(2) in central brain regions. SNR was lower at 3 T (40 for b=0 s/mm(2) and 15 for b=1000 s/mm(2)) and in lateral brain regions at 7 T due to B1 inhomogeneity. FA and ADC did not change with MRI field strength, SENSE factor or TE in the tested range. However, the coefficient of variation for FA increased for SNR <15 and for SNR <10 in ADC, consistent with published theoretical studies. Our study demonstrates that 7 T is advantageous for DTI and lays the groundwork for further development. Foremost, future work should further address challenges with B0 and B1 inhomogencity to take full advantage for the increased SNR at 7 T. (C) 2011 Elsevier Inc. All rights reserved.	[Choi, Seongjin; Cunningham, Dustin T.; Aguila, Francisco; Knopp, Michael V.; Schmalbrock, Petra] Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA; [Corrigan, John D.; Bogner, Jennifer; Mysiw, W. Jerry] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Schmalbrock, P (corresponding author), Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA.	schmalbrock.1@osu.edu	Choi, Seongjin/E-2889-2011; Corrigan, John D./E-2921-2011; Bogner, Jennifer/E-2773-2011	Choi, Seongjin/0000-0002-7949-3359	Wright Center of Innovation in Biomedical Imaging at The Ohio State University, Ohio Department of Development [AGMT TECH 03-051]	This work was supported by The Wright Center of Innovation in Biomedical Imaging at The Ohio State University, Ohio Department of Development (AGMT TECH 03-051).	Alexander AL, 2001, MAGN RESON MED, V45, P770, DOI 10.1002/mrm.1105; Alexander AL, 2006, NEUROIMAGING CLIN N; Bernstein MA, 2004, HDB MRI PULSE SEQUEN, P620; Brunner DO, 2009, NATURE, V457, P994, DOI 10.1038/nature07752; Choi S, 2010, P 18 ANN M INT SOC M, P1602; Cruz L Celso Hygino Jr, 2006, Magn Reson Imaging Clin N Am, V14, P183, DOI 10.1016/j.mric.2006.06.003; Dhital B, 2010, P 18 ANN M INT SOC M, V13, P3994; Finsterbusch J, 2010, J MAGN RESON IMAGING, V31, P1530, DOI 10.1002/jmri.22196; Heidemann RM, 2010, MAGN RESON MED, V64, P9, DOI 10.1002/mrm.22480; Thierry AGM, 2006, EUR RADIOL, V16, P1651, DOI 10.1007/s00330-006-0175-8; Ibrahim TS, 2005, MAGN RESON MED, V54, P683, DOI 10.1002/mrm.20596; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jaermann T, 2006, MAGN RESON MED, V55, P335, DOI 10.1002/mrm.20769; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Jeong HK, 2010, P 18 ANN M INT SOC M, P1616; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kezele IB, 2008, MULT SCLER, V14, P779, DOI 10.1177/1352458507088106; Koay CG, 2006, J MAGN RESON, V179, P317, DOI 10.1016/j.jmr.2006.01.016; Koay CG, 2006, J MAGN RESON, V182, P115, DOI 10.1016/j.jmr.2006.06.020; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kristoffersen A, 2009, J MAGN RESON IMAGING, V29, P237, DOI 10.1002/jmri.21589; Kumazawa S, 2010, P 18 ANN M INT SOC M, P3126; Landman BA, 2008, MAGN RESON IMAGING, V26, P790, DOI 10.1016/j.mri.2008.01.034; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Metcalf M, 2007, P 15 ANN M INT SOC M, P2180; Mihai G, 2007, THESIS OHIO STATE U; Morgan PS, 2009, P 17 ANN M INT SOC M, P1807; Mukherjee P, 2005, NEUROIMAG CLIN N AM, V15, P655, DOI 10.1016/j.nic.2005.08.010; Mukherjee P, 2008, MAGN RESON IMAGING, V26, P171, DOI 10.1016/j.mri.2007.05.011; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Oouchi H, 2007, AM J NEURORADIOL, V28, P1102, DOI 10.3174/ajnr.A0488; Pfefferbaum A, 2003, MAGNET RESON MED, V49, P953, DOI 10.1002/mrm.10452; Piatkowski J, 2010, P 18 ANN M INT SOC M, P1574; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Pierpaoli C, 2010, P 18 ANN M INT SOC M, P1616; Polders D, 2009, P 17 ANN M INT SOC M, P1406; Polders DL, 2010, P 18 ANN M INT SOC M, P1641; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO;2-S; Qin W, 2009, MAGN RESON MED, V61, P755, DOI 10.1002/mrm.21920; Sammet S, 2007, P 15 ANN M INT SOC M; Sarlis JE, 2010, P 18 ANN M INT SOC M, P1612; Taoka T, 2006, AM J NEURORADIOL, V27, P1040; Tsao S, 2010, P 18 ANN M INT SOC M, P1647; Von Morze J, 2010, P 18 ANN M INT SOC M, P3993; Vos SB, 2010, P 18 ANN M INT SOC M, P113; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; Yarnykh VL, 2007, MAGN RESON MED, V57, P192, DOI 10.1002/mrm.21120	50	28	28	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0730-725X	1873-5894		MAGN RESON IMAGING	Magn. Reson. Imaging	JUL	2011	29	6					739	751		10.1016/j.mri.2011.02.009			13	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	787EG	WOS:000292358800001	21571473				2021-06-18	
J	Rambousek, L; Bubenikova-Valesova, V; Kacer, P; Syslova, K; Kenney, J; Holubova, K; Najmanova, V; Zach, P; Svoboda, J; Stuchlik, A; Chodounska, H; Kapras, V; Adamusova, E; Borovska, J; Vyklicky, L; Vales, K				Rambousek, Lukas; Bubenikova-Valesova, Vera; Kacer, Petr; Syslova, Kamila; Kenney, Jana; Holubova, Kristina; Najmanova, Vera; Zach, Petr; Svoboda, Jan; Stuchlik, Ales; Chodounska, Hana; Kapras, Vojtech; Adamusova, Eva; Borovska, Jirina; Vyklicky, Ladislav; Vales, Karel			Cellular and behavioural effects of a new steroidal inhibitor of the N-methyl-D-aspartate receptor 3 alpha 5 beta-pregnanolone glutamate	NEUROPHARMACOLOGY			English	Article						Neuroactive steroid; 3 alpha 5 beta-Pregnanolone glutamate; Glutamate excitotoxicity; Neuroprotectivity; Cognitive function	TRAUMATIC BRAIN-INJURY; NEUROACTIVE STEROIDS; NMDA RECEPTOR; PLACE AVOIDANCE; ANTAGONIST; RATS; NEUROTOXICITY; ISCHEMIA; NEUROSTEROIDS; HIPPOCAMPUS	Preclinical studies have demonstrated a considerable role for N-methyl-h-aspartate (NMDA) receptors in excitotoxicity and the concurrent neuroprotective effect of NMDA receptor antagonists. Because NMDA receptors are one of the most widespread receptors in the central nervous system, application of their antagonist often leads to serious side effects ranging from motor impairment to induction of schizophrenic-like psychosis. Therefore, we have initiated development and testing of a novel synthetic NMDA receptor antagonist derived from naturally occurring neurosteroids. 20-oxo-5 beta-pregnan-3 alpha-yl-L-glutamyl-1-ester (3 alpha 5 beta P-Glu) is a novel synthetic steroidal inhibitor of the NMDA receptor. Our results show that 3 alpha 5 beta P-Glu preferentially inhibits tonically activated NMDA receptors, is able to cross the blood brain barrier, does not induce psychotomimetic symptoms (such as hyperlocomotion and sensorimotor gating deficit) and reduced an excitotoxic damage of brain tissue and subsequent behavioural impairment in rats. In particular, 3 alpha 5 beta P-Glu significantly ameliorated neuronal damage in the dentate gyrus and subiculum, and improved behavioural performance in active allothetic place avoidance tasks (AAPA, also known as the carousel maze) after bilateral NMDA-induced lesions to the hippocampi. These findings provide a possible new therapeutic approach for the treatment of diseases induced by NMDA receptor overactivation. (C) 2011 Elsevier Ltd. All rights reserved.	[Bubenikova-Valesova, Vera] Prague Psychiat Ctr, Dept Biochem & Brain Pathophysiol, Ustavni 91, Prague 18103 8, Czech Republic; [Rambousek, Lukas; Bubenikova-Valesova, Vera; Kenney, Jana; Holubova, Kristina; Svoboda, Jan; Stuchlik, Ales; Adamusova, Eva; Borovska, Jirina; Vyklicky, Ladislav; Vales, Karel] Acad Sci Czech Republ, Inst Physiol, Prague 4, Czech Republic; [Chodounska, Hana; Kapras, Vojtech] Acad Sci Czech Republ, Inst Organ Chem & Biochem, Prague 6, Czech Republic; [Zach, Petr] Charles Univ Prague, Fac Med 3, Prague 10, Czech Republic; [Rambousek, Lukas; Kacer, Petr; Syslova, Kamila; Najmanova, Vera] Inst Chem Technol, CR-16628 Prague 6, Czech Republic	Bubenikova-Valesova, V (corresponding author), Prague Psychiat Ctr, Dept Biochem & Brain Pathophysiol, Ustavni 91, Prague 18103 8, Czech Republic.	bubenikova@pcp.lf3.cuni.cz	Zach, Petr/D-8955-2016; Stuchlik, Ales/V-8543-2019; Rambousek, Lukas/F-8571-2012; Vyklicky, Ladislav/C-1851-2012; Vales, Karel/C-2941-2012; Chodounska, Hana/A-9104-2010; Holubova, Kristina/Q-9408-2018; Svoboda, Jan/C-2811-2012	Zach, Petr/0000-0003-1941-2972; Stuchlik, Ales/0000-0002-5394-6305; Vyklicky, Ladislav/0000-0002-0015-0098; Vales, Karel/0000-0001-7892-4535; Chodounska, Hana/0000-0002-4851-9472; Holubova, Kristina/0000-0002-4936-2737; Svoboda, Jan/0000-0002-0343-5347	IGA Ministry of Health [NS10365, NR 9180-3]; GACRGrant Agency of the Czech Republic [309/07/0271, 203/08/1498, 309/09/0286]; AS CRCzech Academy of Sciences [AVOZ 50110509]; ECEuropean CommissionEuropean Commission Joint Research Centre [LSHM-CT-2007-037765]; Ministry of Education, Youth and Sports of the Czech RepublicMinistry of Education, Youth & Sports - Czech Republic [1M0157, LC554];  [Z4 055 0506]	This work was supported by the IGA Ministry of Health NS10365, NR 9180-3 and GACR (309/07/0271; 203/08/1498; 309/09/0286), Research Project of the AS CR AVOZ 50110509, EC FP6 PHOTOLYSIS (LSHM-CT-2007-037765) and The Ministry of Education, Youth and Sports of the Czech Republic (1M0157 and LC554). Hana Chodonska was supported by Research Project Z4 055 0506.	Bowen CA, 1999, J PHARMACOL EXP THER, V289, P405; Bubenikova-Valesova V, 2006, NEUROCHEM INT, V48, P515, DOI 10.1016/j.neuint.2006.01.019; Bubenikova-Valesova V, 2008, NEUROSCI BIOBEHAV R, V32, P1014, DOI 10.1016/j.neubiorev.2008.03.012; Bubenikova-Valesova V, 2007, NEUROPHARMACOLOGY, V52, P1071, DOI 10.1016/j.neuropharm.2006.11.004; Bures J, 1998, NEUROPHARMACOLOGY, V37, P689, DOI 10.1016/S0028-3908(98)00031-8; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1988, J NEUROSCI, V8, P185; Cimadevilla JM, 2001, P NATL ACAD SCI USA, V98, P3531, DOI 10.1073/pnas.051628398; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Gasior M, 1999, TRENDS PHARMACOL SCI, V20, P107, DOI 10.1016/S0165-6147(99)01318-8; Geyer M.A., 2001, CURRENT PROTOCOLS NE, P1; KNAPSTEIN P, 1968, STEROIDS, V11, P885, DOI 10.1016/S0039-128X(68)80102-3; Kubik S, 2006, PHYSIOL RES, V55, P445; Kussius CL, 2009, J NEUROSCI, V29, P6819, DOI 10.1523/JNEUROSCI.0281-09.2009; Lapchak PA, 2006, EXP NEUROL, V197, P531, DOI 10.1016/j.expneurol.2005.10.025; Lapchak PA, 2004, BRAIN RES, V997, P152, DOI 10.1016/j.brainres.2003.10.047; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; Li H, 2001, BRAIN RES, V888, P263, DOI 10.1016/S0006-8993(00)03077-8; MacNevin CJ, 2009, J MED CHEM, V52, P6012, DOI 10.1021/jm900712n; Manahan-Vaughan D, 2008, HIPPOCAMPUS, V18, P125, DOI 10.1002/hipo.20367; MCDONALD JW, 1990, NEUROSCIENCE, V36, P589, DOI 10.1016/0306-4522(90)90002-L; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Mellon SH, 2008, BRAIN RES REV, V57, P410, DOI 10.1016/j.brainresrev.2007.05.012; Morrow AL, 2007, PHARMACOL THERAPEUT, V116, P1, DOI 10.1016/j.pharmthera.2007.04.003; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; Park-Chung M., 1997, MOL PHARM, V46, P146; Paxinos G., 2004, RAT BRAIN STEREOTAXI; Petrovic M, 2005, J NEUROSCI, V25, P8439, DOI 10.1523/JNEUROSCI.1407-05.2005; Pringle AK, 2003, EUR J NEUROSCI, V18, P117, DOI 10.1046/j.1460-9568.2003.02734.x; Rao VLR, 2001, BRAIN RES, V911, P96; Reed MJ, 2005, ENDOCR REV, V26, P171, DOI 10.1210/er.2004-0003; Sadri-Vakili G, 2003, J NEUROCHEM, V86, P92, DOI 10.1046/j.1471-4159.2003.01814.x; Schauwecker PE, 2010, EXP NEUROL, V224, P207, DOI 10.1016/j.expneurol.2010.03.013; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sedlacek M, 2008, PHYSIOL RES, V57, pS49; Shiigi Y, 1999, PSYCHOPHARMACOLOGY, V146, P67, DOI 10.1007/s002130051089; Stastna E, 2009, STEROIDS, V74, P256, DOI 10.1016/j.steroids.2008.11.011; Stuchlik A, 2008, BEHAV BRAIN RES, V189, P139, DOI 10.1016/j.bbr.2007.12.025; van den Buuse M, 2010, SCHIZOPHRENIA BULL, V36, P246, DOI 10.1093/schbul/sbp132; VYKLICKY L, 1990, J PHYSIOL-LONDON, V428, P313, DOI 10.1113/jphysiol.1990.sp018214; Wang MD, 1997, J STEROID BIOCHEM, V62, P299, DOI 10.1016/S0960-0760(97)00041-1; Weaver CE, 1997, P NATL ACAD SCI USA, V94, P10450, DOI 10.1073/pnas.94.19.10450; Wesierska M, 2005, J NEUROSCI, V25, P2413, DOI 10.1523/JNEUROSCI.3962-04.2005	43	28	28	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	JUL-AUG	2011	61	1-2					61	68		10.1016/j.neuropharm.2011.02.018			8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	787WU	WOS:000292408200007	21354187				2021-06-18	
J	Sashindranath, M; Samson, AL; Downes, CE; Crack, PJ; Lawrence, AJ; Li, QX; Ng, AQP; Jones, NC; Farrugia, JJ; Abdella, E; Vassalli, JD; Madani, R; Medcalf, RL				Sashindranath, Maithili; Samson, Andre Laval; Downes, Catherine Eliza; Crack, Peter John; Lawrence, Andrew John; Li, Qiao-Xin; Ng, Ashley Quan Ping; Jones, Nigel Charles; Farrugia, Jessica Jade; Abdella, Eman; Vassalli, Jean-Dominique; Madani, Rime; Medcalf, Robert Lindsay			Compartment- and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation	LABORATORY INVESTIGATION			English	Article						alzheimer's disease; amidolytic assay; head trauma; morphine; seizure; spinocerebellar ataxia; stroke; tissue-type plasminogen activator	APPSWE/PS1DE9 MOUSE MODEL; FOCAL CEREBRAL-ISCHEMIA; LONG-TERM POTENTIATION; A-BETA DEGRADATION; AMYLOID DEPOSITION; ALZHEIMERS-DISEASE; EXPRESSION; SEIZURE; SYSTEM; MICE	Tissue-type plasminogen activator (tPA) is a major protease of the central nervous system. Most studies to date have used in situ-or gel-based zymographic assays to monitor in vivo changes in neural tPA activity. In this study, we demonstrate that the amidolytic assay can be adapted to accurately detect changes in net tPA activity in mouse brain tissues. Using the amidolytic assay, we examined differences in net tPA activity in the cerebral cortex, sub-cortical structures and cerebellum in wildtype (WT) and tPA(-/-) mice, and in transgenic mice selectively overexpressing tPA in neurons. In addition, we assessed changes in endogenous net tPA activity in WT mice following morphine administration, epileptic seizures, traumatic brain injury and ischaemic stroke-neurological settings in which tPA has a known functional role. Under these conditions, acute and compartment-specific regulation of tPA activity was observed. tPA also participates in various forms of chronic neurodegeneration. Accordingly, we assessed tPA activity levels in mouse models of Alzheimer's disease (AD) and spinocerebellar ataxia type-1 (SCA1). Decreased tPA activity was detected in the cortex and subcortex of AD mice, whereas increased tPA activity was found in the cerebellum of SCA1 mice. These findings extend the existing hypotheses that low tPA activity promotes AD, whereas increased tPA activity contributes to cerebellar degeneration. Collectively, our results exemplify the utility of the amidolytic assay and emphasise tPA as a complex mediator of brain function and dysfunction. On the basis of this evidence, we propose that alterations in tPA activity levels could be used as a biomarker for perturbations in brain homeostasis. Laboratory Investigation (2011) 91, 1079-1091; doi:10.1038/labinvest.2011.67; published online 25 April 2011	[Sashindranath, Maithili; Samson, Andre Laval; Farrugia, Jessica Jade; Abdella, Eman; Medcalf, Robert Lindsay] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia; [Downes, Catherine Eliza; Crack, Peter John] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3052, Australia; [Lawrence, Andrew John] Univ Melbourne, Florey Neurosci Inst, Parkville, Vic 3052, Australia; [Lawrence, Andrew John; Li, Qiao-Xin] Univ Melbourne, Ctr Neurosci, Parkville, Vic 3052, Australia; [Li, Qiao-Xin] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [Ng, Ashley Quan Ping; Jones, Nigel Charles] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Parkville, Vic 3052, Australia; [Vassalli, Jean-Dominique; Madani, Rime] Univ Geneva, Fac Med, Dept Genet Med & Dev, CH-1211 Geneva 4, Switzerland	Medcalf, RL (corresponding author), Monash Univ, Australian Ctr Blood Dis, Level 6,Burnet Bldg,89 Commercial Rd, Melbourne, Vic 3004, Australia.	robert.medcalf@monash.edu	Medcalf, Robert L/E-9632-2011; Jones, Nigel C/K-7773-2012; Crack, Peter/ABE-2065-2020; Samson, Andre L/I-3432-2012; Sashindranath, Maithili/AAI-7408-2021	Crack, Peter/0000-0002-5030-0330; Samson, Andre L/0000-0003-4825-1645; Sashindranath, Maithili/0000-0002-9712-4784; Samson, Andre/0000-0002-0637-2716; Jones, Nigel/0000-0002-1080-8439	National Health and Medical Research Council (NH&MRC) of AustraliaNational Health and Medical Research Council of Australia [606659]; NHMRCNational Health and Medical Research Council of Australia [491152, 606660, 628391, G 08M 3821]; Victorian Neurotrauma Initiative [D0-34]	We thank Prof Norman Saunders, Dr Mark Habgood, Dr Simone Beckham and Mr Adam Galle for constructing the electromagnetic CCI device. We also thank Ms Amanda Au for assisting in the preparation of mouse brain lysates following MCAo. Be'eri Niego for constructive comments regarding the amidolytic assay. Volga Tarlac and Elsdon Storey from the Van Cleef Roet Centre for Nervous Diseases for providing us with the SCA1 mutant and wild-type littermate mice, and Prof John Hamilton (Department of Medicine, Royal Melbourne Hospital) for providing the mice for the seizure studies. This study was supported by grant numbers 606659 awarded to RLM and ALS from the National Health and Medical Research Council (NH&MRC) of Australia and by grant numbers 491152 and 606660 awarded to RLM from the NH&MRC and D0-34 awarded to RLM from the Victorian Neurotrauma Initiative. This study was also supported by grant numbers 628391 and G 08M 3821 awarded to PJC from the NH&MRC and the National Heart Foundation of Australia, respectively, and by grant number 566544 awarded to NCJ from the NH&MRC. AJL and RLM are also supported with Senior Research Fellowships, and NCJ supported with a Career Development Award, from the NH&MRC.	Armstead WM, 2005, DEV BRAIN RES, V156, P139, DOI 10.1016/j.devbraines.2005.02.012; Cacquevel M, 2007, NEUROBIOL DIS, V27, P164, DOI 10.1016/j.nbd.2007.04.004; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Dietzmann K, 2000, PATHOL RES PRACT, V196, P15, DOI 10.1016/S0344-0338(00)80017-5; ERIKSSON E, 1987, THROMB RES, V46, P213, DOI 10.1016/0049-3848(87)90283-0; Fabbro S, 2009, J NEUROCHEM, V109, P303, DOI 10.1111/j.1471-4159.2009.05894.x; Garcia-Alloza M, 2006, NEUROBIOL DIS, V24, P516, DOI 10.1016/j.nbd.2006.08.017; GRANELLIPIPERNO A, 1978, J EXP MED, V148, P223, DOI 10.1084/jem.148.1.223; Hamann GF, 2004, STROKE, V35, P764, DOI 10.1161/01.STR.0000116866.60794.21; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Iyer AM, 2010, NEUROSCIENCE, V167, P929, DOI 10.1016/j.neuroscience.2010.02.047; Jacobsen JS, 2008, P NATL ACAD SCI USA, V105, P8754, DOI 10.1073/pnas.0710823105; Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3; KIM JW, 2010, NEUROCHEM INT; KINGSTON IB, 1995, NAT MED, V1, P138; Lahtinen L, 2006, EUR J NEUROSCI, V24, P1935, DOI 10.1111/j.1460-9568.2006.05062.x; Ledesma MD, 2000, EMBO REP, V1, P530; Li JX, 2006, P NATL ACAD SCI USA, V103, P7847, DOI 10.1073/pnas.0602440103; LIJNEN HR, 1984, EUR J BIOCHEM, V144, P541, DOI 10.1111/j.1432-1033.1984.tb08499.x; LIU RM, 2009, NEUROBIOL A IN PRESS; Lu WQ, 2002, DEVELOPMENT, V129, P2043; Lu WQ, 2002, J NEUROSCI, V22, P10781; Madani R, 1999, EMBO J, V18, P3007, DOI 10.1093/emboj/18.11.3007; Melchor JP, 2005, THROMB HAEMOSTASIS, V93, P655, DOI 10.1160/TH04-12-0838; Melchor JP, 2003, J NEUROSCI, V23, P8867; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Muller A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001641; Nagai N, 1999, CIRCULATION, V99, P2440, DOI 10.1161/01.CIR.99.18.2440; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Niego B, 2008, BLOOD COAGUL FIBRIN, V19, P322, DOI 10.1097/MBC.0b013e3282f54568; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rogove AD, 2002, CELL DEATH DIFFER, V9, P801, DOI 10.1038/sj.cdd.4401041; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Roussel BD, 2009, BRAIN, V132, P2219, DOI 10.1093/brain/awp162; Ruan LF, 2009, CURR ALZHEIMER RES, V6, P531, DOI 10.2174/156720509790147070; Salzberg M, 2007, EPILEPSIA, V48, P2079, DOI 10.1111/j.1528-1167.2007.01246.x; Samson AL, 2006, NEURON, V50, P673, DOI 10.1016/j.neuron.2006.04.013; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; Seeds NW, 2003, J NEUROSCI, V23, P7368; SHIMADA H, 1981, THROMB HAEMOSTASIS, V46, P507; STEPHENS R, 1987, J IMMUNOL METHODS, V105, P245, DOI 10.1016/0022-1759(87)90272-9; Thewke DP, 1999, BRAIN RES, V821, P356, DOI 10.1016/S0006-8993(99)01115-4; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; VERHEIJEN JH, 1982, THROMB HAEMOSTASIS, V48, P266; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Wong CHY, 2008, J NEUROCHEM, V107, P241, DOI 10.1111/j.1471-4159.2008.05605.x; Wu YP, 2000, J CELL BIOL, V148, P1295, DOI 10.1083/jcb.148.6.1295; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308; Yepes M, 2000, BLOOD, V96, P569; Yepes M, 2009, TRENDS NEUROSCI, V32, P48, DOI 10.1016/j.tins.2008.09.006; ZOGHBI HY, 1995, SEMIN CELL BIOL, V6, P29, DOI 10.1016/1043-4682(95)90012-8	54	28	29	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0023-6837	1530-0307		LAB INVEST	Lab. Invest.	JUL	2011	91	7					1079	1091		10.1038/labinvest.2011.67			13	Medicine, Research & Experimental; Pathology	Research & Experimental Medicine; Pathology	784WL	WOS:000292189100010	21519332	Bronze			2021-06-18	
J	Assaf, F; Fishbein, M; Gafni, M; Keren, O; Sarne, Y				Assaf, Fadi; Fishbein, Miriam; Gafni, Mikhal; Keren, Ora; Sarne, Yosef			Pre- and post-conditioning treatment with an ultra-low dose of Delta(9)-tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage	BEHAVIOURAL BRAIN RESEARCH			English	Article						Neuroprotection; Cannabinoid; Epileptic seizures; Preconditioning; Postconditioning; Cognitive deficit	TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; IN-VIVO; NEUROGENIC NEUROPROTECTION; ENDOCANNABINOID SYSTEM; STATUS EPILEPTICUS; NEURONAL INJURY; SPATIAL MEMORY; TIME-COURSE; EPILEPSY	Preconditioning, a phenomenon where a minor noxious stimulus protects from a subsequent more severe insult, and post-conditioning, where the protective intervention is applied following the insult, offer new insight into the neuronal mechanism(s) of neuroprotection and may provide new strategies for the prevention and treatment of brain damage. We have previously reported that a single administration of an extremely low dose of Delta(9)-tetrahydrocannabinol (THC; the psychoactive ingredient of marijuana) to mice induced minor long-lasting cognitive deficits. In the present study we examined the possibility that such a low dose of THC will protect the mice from more severe cognitive deficits induced by the epileptogenic drug pentylenetetrazole (PTZ). THC (0.002 mg/kg, a dose that is 3-4 orders of magnitude lower than the doses that induce the conventional effects of THC) was administered 1-7 days before, or 1-3 days after the injection of PTZ (60 mg/kg). The consequences of this treatment were studied 3-7 weeks later by various behavioral tests that evaluated different aspects of memory and learning. We found that a single administration of THC either before or after PTZ abolished the PTZ-induced long-lasting cognitive deficits. Biochemical studies indicated a concomitant reduction in phosphorylated-ERK (extracellular signal-regulated kinase) in the cerebella of mice 7 weeks following the injection of THC. Our results suggest that a pre- or post-conditioning treatment with extremely low doses of THC, several days before or after brain injury, may provide safe and effective long-term neuroprotection. (C) 2011 Elsevier B.V. All rights reserved.	[Sarne, Yosef] Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, Adelson Ctr Biol Addict Dis, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Mauerberger Chair Neuropharmacol, IL-69978 Tel Aviv, Israel	Sarne, Y (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, Adelson Ctr Biol Addict Dis, IL-69978 Tel Aviv, Israel.	sarney@post.tau.ac.il			Israel Anti Drug Authority	Tetrahydrocannabinol was kindly donated by Prof. R. Mechoulam of The Hebrew University of Jerusalem, Israel and by The National Institute on Drug Abuse (NIDA), USA. This study was supported by a grant of the Israel Anti Drug Authority.	Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Amal H, 2010, BEHAV BRAIN RES, V206, P245, DOI 10.1016/j.bbr.2009.09.021; Bladin CF, 2000, ARCH NEUROL-CHICAGO, V57, P1617, DOI 10.1001/archneur.57.11.1617; Braida D, 2000, NEUROSCI LETT, V296, P69, DOI 10.1016/S0304-3940(00)01634-7; CharriautMarlangue C, 1996, TRENDS NEUROSCI, V19, P109, DOI 10.1016/S0166-2236(96)80039-7; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Clark RE, 2005, HIPPOCAMPUS, V15, P260, DOI 10.1002/hipo.20056; Clement AB, 2003, J NEUROSCI, V23, P3916; De Reuck J, 2006, EUR J NEUROL, V13, P402; Dere E, 2007, NEUROSCI BIOBEHAV R, V31, P673, DOI 10.1016/j.neubiorev.2007.01.005; Derkinderen P, 2003, J NEUROSCI, V23, P2371; Di Marzo V, 2008, NAT REV DRUG DISCOV, V7, P438, DOI 10.1038/nrd2553; Dirnagl U, 2009, LANCET NEUROL, V8, P398, DOI 10.1016/S1474-4422(09)70054-7; Fowler CJ, 2010, EXP NEUROL, V224, P37, DOI 10.1016/j.expneurol.2010.03.021; Galve-Roperh I, 2008, CURR PHARM DESIGN, V14, P2279, DOI 10.2174/138161208785740117; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Golanov EV, 2003, CELL MOL NEUROBIOL, V23, P651, DOI 10.1023/A:1025088516742; Hausenloy DJ, 2006, CARDIOVASC RES, V70, P240, DOI 10.1016/j.cardiores.2006.01.017; Hausenloy DJ, 2009, ATHEROSCLEROSIS, V204, P334, DOI 10.1016/j.atherosclerosis.2008.10.029; Hayakawa K, 2007, LIFE SCI, V80, P1466, DOI 10.1016/j.lfs.2007.01.014; Huang LT, 2002, EPILEPSIA, V43, P567, DOI 10.1046/j.1528-1157.2002.29101.x; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; Lamberty Y, 2000, EPILEPSY BEHAV, V1, P256, DOI 10.1006/ebeh.2000.0085; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Mitchell AJ, 2010, ACTA NEUROPSYCHIATR, V22, P2, DOI 10.1111/j.1601-5215.2009.00439.x; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nagayama T, 1999, J NEUROSCI, V19, P2987; Obrenovitch TP, 2008, PHYSIOL REV, V88, P211, DOI 10.1152/physrev.00039.2006; Pacher P, 2008, BRIT J PHARMACOL, V153, P252, DOI 10.1038/sj.bjp.0707582; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pertwee RG, 2009, BRIT J PHARMACOL, V156, P397, DOI 10.1111/j.1476-5381.2008.00048.x; Pignataro G, 2008, J CEREBR BLOOD F MET, V28, P232, DOI 10.1038/sj.jcbfm.9600559; Pignataro G, 2009, FEBS J, V276, P46, DOI 10.1111/j.1742-4658.2008.06769.x; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Reis DJ, 1998, BRAIN RES, V780, P161, DOI 10.1016/S0006-8993(97)01017-2; Rubino T, 2004, MOL CELL NEUROSCI, V25, P355, DOI 10.1016/j.mcn.2003.11.003; Rutten A, 2002, EUR J NEUROSCI, V16, P501, DOI 10.1046/j.1460-9568.2002.02103.x; Sankar R, 1998, J NEUROSCI, V18, P8382; Senn R, 2008, PHARMACOL BIOCHEM BE, V88, P230, DOI 10.1016/j.pbb.2007.08.005; Shouman B, 2006, BRIT J PHARMACOL, V148, P442, DOI 10.1038/sj.bjp.0706755; Sommer C, 2009, ACTA NEUROPATHOL, V117, P511, DOI 10.1007/s00401-008-0473-0; Tanay E, 2006, BRAIN RES, V1112, P222, DOI 10.1016/j.brainres.2006.07.004; Troy CM, 2002, J BIOL CHEM, V277, P34295, DOI 10.1074/jbc.M205167200; Tselnicker I, 2007, NEUROSCI LETT, V411, P108, DOI 10.1016/j.neulet.2006.10.033; van der Stelt M, 2001, J NEUROSCI, V21, P6475; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Viscomi MT, 2010, EXP NEUROL, V224, P56, DOI 10.1016/j.expneurol.2010.03.023; Wang P, 2008, BRAIN RES, V1238, P108, DOI 10.1016/j.brainres.2008.07.103; Zaleska MM, 2009, NEUROPHARMACOLOGY, V56, P329, DOI 10.1016/j.neuropharm.2008.10.006; Zemke D, 2004, NEUROTOXICOLOGY, V25, P895, DOI 10.1016/j.neuro.2004.03.009; Zhao H, 2009, J CEREBR BLOOD F MET, V29, P873, DOI 10.1038/jcbfm.2009.13; Zhao ZQ, 2006, CARDIOVASC RES, V70, P200, DOI 10.1016/j.cardiores.2006.01.024	52	28	28	0	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 20	2011	220	1					194	201		10.1016/j.bbr.2011.02.005			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	752PC	WOS:000289703600024	21315768				2021-06-18	
J	O'Callaghan, AM; McAllister, L; Wilson, L				O'Callaghan, Anna M.; McAllister, Lindy; Wilson, Linda			Experiences of care: Perspectives of carers of adults with traumatic brain injury	INTERNATIONAL JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						Traumatic brain injury; family members; survey methodology; healthcare journey; experiences; carers; continuum of care	FAMILY CAREGIVERS; NEEDS; BURDEN; INDIVIDUALS; PREDICTORS; DISTRESS	This paper describes the results of a survey that explored the experiences of carers when accessing rehabilitative services alongside their family member with a moderate-severe TBI. The 184 carers who completed these surveys reflected retrospectively on the care they received. The results of this study indicated that 61% of the carer respondents recollected accessing inpatient rehabilitation following their acute care. However, following inpatient discharge only 33% of carers reported receiving ongoing services. One quarter of carers stated they received inadequate information while transitioning through their healthcare journey and fewer than 20% of carers recollected receiving any formal support service. The results of this study showed that as carers transitioned through the healthcare journey with their family member with TBI, health services progressively declined. As this occurred, carers' satisfaction with services reduced, while their responsibilities for caring increased. This trend is concerning given the needs of carers have been shown to change over time and increase if not addressed. This paper describes both carer experience following TBI in Australia and encourages clinicians to advocate for carers needs when planning and providing rehabilitation services.	[O'Callaghan, Anna M.; Wilson, Linda] Charles Sturt Univ, Albury, NSW, Australia; [McAllister, Lindy] Univ Queensland, Brisbane, Qld, Australia	O'Callaghan, AM (corresponding author), Charles Sturt Univ, POB 789, Albury, NSW, Australia.	aocallaghan@csu.edu.au	Copley, Anna/D-1067-2011; McAllister, Lindy/C-8027-2009; Wilson, Linda/P-8523-2015	Copley, Anna/0000-0003-1784-9070; Wilson, Linda/0000-0003-4175-7125			Albert SM, 2002, J HEAD TRAUMA REHAB, V17, P175, DOI 10.1097/00001199-200204000-00007; British Society of Rehabilitation Medicine Royal College of Physicians, 2003, REH FOLL ACQ BRAIN I; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; *DEP HUM SERV, 1995, PUBL HOSP PAT CHART; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fyffe C, 1996, Aust J Rural Health, V4, P232, DOI 10.1111/j.1440-1584.1996.tb00216.x; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Lefebvre H, 2005, BRAIN INJURY, V19, P585, DOI 10.1080/02699050400025026; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Miles M.B., 1994, QUALITATIVE DATA ANA; Murray HM, 2006, BRAIN INJURY, V20, P575, DOI 10.1080/02699050600664590; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; O'Callaghan AM, 2010, INT J SPEECH-LANG PA, V12, P107, DOI 10.3109/17549500903431774; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; Smith J E, 2000, Care Manag J, V2, P27; Stebbins P, 1998, J REHABIL, V64, P15; Turner B, 2007, BRAIN INJURY, V21, P1119, DOI 10.1080/02699050701651678; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062	25	28	28	0	6	INFORMA HEALTHCARE	NEW YORK	52 VANDERBILT AVE, NEW YORK, NY 10017 USA	1754-9507			INT J SPEECH-LANG PA	Int. J. Speech-Lang. Pathol.	JUN	2011	13	3					218	226		10.3109/17549507.2011.549240			9	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	763CU	WOS:000290532400005	21563896				2021-06-18	
J	Staal, JA; Vickers, JC				Staal, Jerome A.; Vickers, James C.			Selective Vulnerability of Non-Myelinated Axons to Stretch Injury in an In Vitro Co-Culture System	JOURNAL OF NEUROTRAUMA			English	Article						axon myelination; diffuse axonal injury; oligodendrocytes; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; SECONDARY AXOTOMY; CALCIUM INFLUX; NEUROFILAMENT COMPACTION; CYTOSKELETAL CHANGES; UNMYELINATED AXONS; CORPUS-CALLOSUM; SODIUM-CHANNELS; MYELINATION	Diffuse axonal injury (DAI) is an evolving axonopathy commonly characterized clinically as widespread damage to the white matter tracts. In recent electrophysiological studies, researchers have proposed that myelinated and unmyelinated axons differ in their vulnerability and functional recovery following DAI. In this study we present for the first time an in vitro stretch-injury approach that utilizes a novel myelinating co-culture system to determine the differential response between myelinated and non-myelinated axon bundles to injury. In implementing this technique we demonstrate that myelinated axon bundles are less vulnerable to stretch injury compared to caliber-matched non-myelinated bundles. Interestingly, moderate axonal strain did not induce demyelination, but instead caused an increase in the proportion of degenerated myelin basic protein over time. Additionally, there were no significant differences in the expression of axonal swellings, which is indicative of disrupted axonal transport. In summary, we present an ideal in vitro model that permits further mechanistic investigations into the role of myelin and oligodendrocyte-neuron interactions in response to DAI.	[Staal, Jerome A.; Vickers, James C.] Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Hobart, Tas 7001, Australia	Staal, JA (corresponding author), Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Bag 23, Hobart, Tas 7001, Australia.	Jastaal@utas.edu.au	Vickers, James C/J-7464-2014	Vickers, James C/0000-0001-5671-4879	Tasmanian Masonic Medical Research Foundation; University of Tasmania	A. S. is a Masonic Medical Research and Alzheimer's Australia Fellow. This work was supported by the Tasmanian Masonic Medical Research Foundation, and the University of Tasmania.	Armstrong RC, 1998, METHODS, V16, P282, DOI 10.1006/meth.1998.0685; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bauer NG, 2009, GLIA, V57, P1691, DOI 10.1002/glia.20885; Bauer Nina G., 2009, Journal of Biology (London), V8, P78, DOI 10.1186/jbiol169; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Chung RS, 2005, J NEUROTRAUM, V22, P1081, DOI 10.1089/neu.2005.22.1081; Colley BS, 2010, EXP NEUROL, V224, P241, DOI 10.1016/j.expneurol.2010.03.026; Dickson TC, 2000, J NEUROTRAUM, V17, P1095, DOI 10.1089/neu.2000.17.1095; Fields RD, 2008, NEUROSCIENTIST, V14, P540, DOI 10.1177/1073858408320294; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Nave KA, 2010, NATURE, V468, P244, DOI 10.1038/nature09614; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rodriguez M, 2003, BRAIN, V126, P751, DOI 10.1093/brain/awg070; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Staal JA, 2007, DEV NEUROBIOL, V67, P1831, DOI 10.1002/dneu.20552; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Staal JA, 2009, J NEUROTRAUM, V26, P781, DOI 10.1089/neu.2008.0669; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Watkins TA, 2008, NEURON, V60, P555, DOI 10.1016/j.neuron.2008.09.011; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	33	28	28	0	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					841	847		10.1089/neu.2010.1658			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100284	21235329				2021-06-18	
J	Young, JC; Kearns, LA; Roper, BL				Young, J. Christopher; Kearns, Lee A.; Roper, Brad L.			Validation of the MMPI-2 Response Bias Scale and Henry-Heilbronner Index in a U.S. Veteran Population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Minnesota Multiphasic Personality Inventory; Response bias; Military veterans; Neuropsychological assessment; Psychometrics	FAKE-BAD-SCALE; PERSONAL-INJURY LITIGANTS; TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; VALIDITY SCALES; COMPENSATION SEEKING; DISABILITY; RBS; NEUROPSYCHOLOGY; FBS	The Response Bias Scale (RBS) and the Henry-Heilbronner Index (HHI) are two recently developed Minnesota Multiphasic Personality Inventory-2 (MMPI-2) validity scales empirically derived for the purpose of detecting feigned symptom report. Utilizing a veteran sample, the present study examined the utility of these and other MMPI-2 validity scales in predicting Word Memory Test (WMT) failure and presence of recent, current, or upcoming compensation evaluation. Although a significant predictor of WMT performance, RBS did not show incremental validity over Infrequency scale of the MMPI-2 in prediction of WMT failure and was not significantly associated with membership in the "Compensation-Context" (CC) group. In contrast, HHI best predicted CC group membership, but only trended toward significance in predicting WMT failure. In predicting CC group membership, HHI showed incremental validity above the established MMPI-2 validity scales, but its specificity was low. In the context of current literature on RBS and HHI, results support continued use of RBS and HHI but suggest that these scales may perform differently in samples other than the compensation-seeking samples on which they were developed.	[Young, J. Christopher; Roper, Brad L.] Memphis Vet Affairs Med Ctr, Memphis, TN 38104 USA; [Kearns, Lee A.] Western Washington Med Grp, Everett, WA USA	Young, JC (corresponding author), Memphis Vet Affairs Med Ctr, 1030 Jefferson Ave, Memphis, TN 38104 USA.	john.young5@va.gov; brad.roper@va.gov					Allen L.M., 1997, CARB 97 MANUAL COMPU; American Psychological Association, 2002, AM PSYCHOL, V57, P1, DOI [10.1037/0003-066X.57.12.1060, DOI 10.1037/0003-066X.57.12.1060]; Arbisi P.A, 2004, PSYCHOL SERV, V1, P56, DOI DOI 10.1037/1541-1559.1.1.56; Arbisi P. A., 2006, PSYCHOL SERV, V3, P249, DOI DOI 10.1037/1541-1559.3.4.249; Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; ATKINSON RM, 1982, AM J PSYCHIAT, V139, P1118; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Ben-Porath YS, 2010, PSYCHOL INJ LAW, V3, P77, DOI 10.1007/s12207-009-9049-0; Ben-Porath YS, 2009, PSYCHOL INJ LAW, V2, P62, DOI 10.1007/s12207-009-9037-4; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher JN, 2008, PSYCHOL INJ LAW, V1, P191, DOI 10.1007/s12207-007-9002-z; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Frueh BC, 2007, AM J PUBLIC HEALTH, V97, P2143, DOI 10.2105/AJPH.2007.115436; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Frueh BC, 1996, J TRAUMA STRESS, V9, P427, DOI 10.1002/jts.2490090303; Frueh BC, 2003, PSYCHIATR SERV, V54, P84, DOI 10.1176/appi.ps.54.1.84; Gervais RO, 2005, ARCH CLIN NEUROPSYCH, V20, P891; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Green P, 2003, WORD MEMORY TEST WIN; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry GK, 2008, CLIN NEUROPSYCHOL, V22, P919, DOI 10.1080/13854040701625853; Henry GK, 2006, CLIN NEUROPSYCHOL, V20, P786, DOI 10.1080/13854040500287749; Iverson GL, 2003, HANDBOOK OF FORENSIC NEUROPSYCHOLOGY, P137; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Kaemmer B, 2001, MMPI-2: Manual for Administration and Scoring; Laffaye C, 2007, MIL MED, V172, P1039, DOI 10.7205/MILMED.172.10.1039; Larrabee G. J., 2008, J INT NEUROPSYCH SOC, V14, P122; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Morel K. R., 2010, DIFFERENTIAL DIAGNOS; Morel KR, 2008, CLIN NEUROPSYCHOL, V22, P350, DOI 10.1080/13854040701300531; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Nelson NW, 2007, J CLIN EXP NEUROPSYC, V29, P67, DOI 10.1080/13803390500488546; SHAW DJ, 1965, J CLIN PSYCHOL, V21, P405, DOI 10.1002/1097-4679(196510)21:4<405::AID-JCLP2270210416>3.0.CO;2-I; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spoont M. R., 2008, PSYCHOL SERV, V5, P49, DOI DOI 10.1037/1541-1559.5.1.49; Tellegen A., 2003, MMPI 2 RESTRUCTURED; Tombaugh TN, 1996, TEST MEMORY MALINGER; United States Department of Veterans Affairs, 2009, VET COMP BEN RAT TAB; United States Government Accountability Office, 2010, VET DIS BEN FURTH EV; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001; Williams CL, 2009, PSYCHOL INJ LAW, V2, P182, DOI 10.1007/s12207-009-9046-3; Wygant DB, 2010, PSYCHOL ASSESSMENT, V22, P745, DOI 10.1037/a0020042	51	28	28	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	APR	2011	26	3					194	204		10.1093/arclin/acr015			11	Psychology, Clinical; Psychology	Psychology	756WV	WOS:000290046400004	21459900	Bronze			2021-06-18	
J	Funk, JR; Cormier, JM; Bain, CE; Guzman, H; Bonugli, E; Manoogian, SJ				Funk, James R.; Cormier, Joseph M.; Bain, Charles E.; Guzman, Herb; Bonugli, Enrique; Manoogian, Sarah J.			Head and Neck Loading in Everyday and Vigorous Activities	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Biomechanics; Injury criteria; Head; Brain; Concussion; Neck; Whiplash	FOOTBALL; WHIPLASH; ACCELERATIONS; IMPACT	The purpose of this study was to document head and neck loading in a group of ordinary people engaged in non-injurious everyday and more vigorous physical activities. Twenty (20) volunteers that were representative of the general population were subjected to seven test scenarios: a soccer ball impact to the forehead, a self-imposed hand strike to the forehead, vigorous head shaking, plopping down in a chair, jumping off a step, a seated drop onto the buttocks, and a vertical drop while seated supine in a chair. Some scenarios involved prescribed and well-controlled stimuli, while others allowed the volunteers to perform common activities at a self-selected level of intensity. Head accelerations up to 31 g and 2888 rad/s(2) and neck loads up to 268 N in posterior shear, 526 N in compression, and 36 Nm in extension were recorded. Most head and neck injury criteria predicted a low risk of injury in all activities. However, rotational head accelerations and Neck Injury Criterion (NIC) values were much higher than some proposed tolerance limits in a large number of tests, all of which were non-injurious. The data from this study help us to establish an envelope of head and neck loading that is commonly encountered and presents a minimal risk of injury.	[Funk, James R.; Cormier, Joseph M.; Bain, Charles E.; Guzman, Herb; Bonugli, Enrique; Manoogian, Sarah J.] Biodynam Res Corp, San Antonio, TX 78249 USA	Funk, JR (corresponding author), Biodynam Res Corp, 5711 Univ Hts Blvd,Suite 100, San Antonio, TX 78249 USA.	jfunk@brconline.com	Cormier, Joseph/L-7470-2019	Manoogian, Sarah/0000-0001-9822-5619			ALLEN ME, 1994, SPINE, V19, P1285, DOI 10.1097/00007632-199405310-00017; Beier G, 1980, P 5 INT C BIOK IMP, P218; Bostrom O., 1996, P IRCOBI C, P123; BUSSONE WR, 2009, 2009010383 SAE; Carragee E, 2006, SPINE, V31, P2942, DOI 10.1097/01.brs.0000248429.10963.13; Carvalho A. V. D., 2009, ACP MED, P11; Castro WHM, 2001, INT J LEGAL MED, V114, P316, DOI 10.1007/s004140000193; Clauser C. E., 1969, WEIGHT VOLUME CTR MA, P1; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Funk JR, 2009, 2009010251 SAE; FUNK JR, 2007, P INT IRCOBI C, P233; FUNK JR, 2007, P ASS ADV AUTOMOT ME, V51, P343; KULLGREN A, 2003, P 18 ENH SAF VEH C; Manoogian SJ, 2010, 2010010146 SAE; MERTZ HJ, 2000, P 44 STAPP CAR CRASH; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Ng TP, 2006, BIOMED SCI INSTRUM, V42, P25; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; ONO K, 1997, P 41 STAPP CAR CRASH, P339; Pincemaille Y, 1989, P 33 STAPP CAR CRASH, P177; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; SCHMITT KU, 2001, P 17 ENH SAF VEH C; SCHNEIDER LW, 1983, UMTRI83531 NAT HIGHW; VANDENKROONENBE.A, 1998, P 42 STAPP CAR CRASH, P207; Vorst MV, 2007, J TRAUMA, V62, P199, DOI 10.1097/01.ta.0000238665.09611.4b; VIJAYAKUMAR V, 2006, 2006010247 SAE, P49	27	28	28	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	FEB	2011	39	2					766	776		10.1007/s10439-010-0183-3			11	Engineering, Biomedical	Engineering	719OD	WOS:000287213300014	20960061				2021-06-18	
J	Jenrow, KA; Liu, JG; Brown, SL; Kolozsvary, A; Lapanowski, K; Kim, JH				Jenrow, Kenneth A.; Liu, Jianguo; Brown, Stephen L.; Kolozsvary, Andrew; Lapanowski, Karen; Kim, Jae Ho			Combined atorvastatin and ramipril mitigate radiation-induced impairment of dentate gyrus neurogenesis	JOURNAL OF NEURO-ONCOLOGY			English	Article						Atorvastatin; Ramipril; Radiation; Dentate gyrus; Neurogenesis	ADULT HIPPOCAMPAL NEUROGENESIS; ANGIOTENSIN-CONVERTING ENZYME; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; IONIZING-RADIATION; IRRADIATION; STATINS; CELLS; ACTIVATION; RATS	Whole brain irradiation (WBI) is commonly administered therapeutically and is routinely associated with late delayed radiation injuries, manifesting as severe and irreversible cognitive impairment. Neural progenitors within the subgranular zone (SGZ) of the dentate gyrus are among the most radiosensitive cell types in the adult brain and are known to participate in hippocampal plasticity and normal cognitive function. These progenitors and the specialized SGZ microenvironment required for neuronal differentiation are the source of neurogenic potential in the adult dentate gyrus, and provide a continuous supply of immature neurons which may then migrate into the adjacent granule cell layer to become mature granule cell neurons. The extreme radiosensitivity of these progenitors and the SGZ microenvironment implicate them as potentially significant contributors to radiation-induced cognitive impairment. Previous reports suggest that statin drugs may be neuroprotective and may promote neurogenesis within the SGZ following both traumatic and ischemic brain injury. Here we investigate whether atorvastatin might similarly protect progenitors and/or preserve neurogenic potential within the SGZ when administered following radiation injury. We also investigate whether such mitigating effects might be enhanced by administering atorvastatin in combination with the angiotensin converting enzyme (ACE) inhibitor, ramipril, which has previously been shown to produce subtle mitigating effects in this context. Atorvastatin was administered to adult male Fisher 344 rats beginning 24 h post-WBI at doses of 10 and 15 Gy, and maintained daily until sacrifice at 12 weeks post-WBI. Combined atorvastatin and ramipril (atorvastatin + ramipril) were administered according to the same protocol following WBI doses of 10 Gy. Progenitor proliferation, neuronal differentiation, and microglial activation were assayed immunohistochemically. Our results indicate that chronic administration of atorvastatin is relatively ineffective as a mitigator of radiation injury in this context, whereas atorvastatin + ramipril appear to interact synergistically to potently and selectively mitigate radiation-induced disruption of neurogenic signaling within SGZ microenvironment.	[Jenrow, Kenneth A.; Liu, Jianguo; Brown, Stephen L.; Kolozsvary, Andrew; Lapanowski, Karen; Kim, Jae Ho] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Jenrow, Kenneth A.; Liu, Jianguo; Brown, Stephen L.; Kolozsvary, Andrew; Lapanowski, Karen; Kim, Jae Ho] Henry Ford Hlth Syst, Dept Radiat Oncol, Detroit, MI 48202 USA	Jenrow, KA (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA.	nskje@neuro.hfh.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U19AI067734-010005]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI067734] Funding Source: NIH RePORTER	This study was supported by NIH U19AI067734-010005 (JHK). The authors also wish to acknowledge the contributions of Christina Liccardello, Kelli McDonough, and Jegor Korzyukov for assistance with image acquisition and cell counting.	Abayomi OK, 2002, ACTA ONCOL, V41, P346, DOI 10.1080/028418602760169389; Andres-Mach M, 2008, CELL TISSUE RES, V331, P251, DOI 10.1007/s00441-007-0480-9; Bromet EJ, 2007, HEALTH PHYS, V93, P516, DOI 10.1097/01.HP.0000279635.14108.02; Bruel-Jungerman E, 2006, J NEUROSCI, V26, P5888, DOI 10.1523/JNEUROSCI.0782-06.2006; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Cho BP, 2006, GLIA, V53, P92, DOI 10.1002/glia.20265; Conover JC, 2008, CELL TISSUE RES, V331, P211, DOI 10.1007/s00441-007-0503-6; Diomede L, 2001, ARTERIOSCL THROM VAS, V21, P1327, DOI 10.1161/hq0801.094222; Gamache GL, 2005, ARCH CLIN NEUROPSYCH, V20, P81, DOI 10.1016/j.acn.2004.03.005; Haendeler J, 2004, CIRCULATION, V110, P856, DOI 10.1161/01.CIR.0000138743.09012.93; Hattiangady B, 2010, HIPPOCAMPUS, V20, P97, DOI 10.1002/hipo.20594; HAYDONT V, 2007, INT J RADIAT ONCOL, V68, P1417; Hwang SY, 2006, NEUROBIOL DIS, V21, P457, DOI 10.1016/j.nbd.2005.08.006; Jackson EK, 2001, GOODMAN GILMANS PHAR; Jeltsch H, 2001, NEUROBIOL LEARN MEM, V76, P81, DOI 10.1006/nlme.2000.3986; Jenrow KA, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-6; Keles MS, 2009, MOL CELL BIOCHEM, V328, P109, DOI 10.1007/s11010-009-0080-y; KING DS, 2001, PHARMACOTHERAPY, V21, P371; Koulouris S, 2005, AM J CARDIOL, V95, P1386, DOI 10.1016/j.amjcard.2005.01.092; LAROCHE S, 1989, NEUROSCIENCE, V28, P375, DOI 10.1016/0306-4522(89)90184-X; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Mizumatsu S, 2003, CANCER RES, V63, P4021; Monje ML, 2003, CURR OPIN NEUROL, V16, P129, DOI 10.1097/00019052-200304000-00002; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Pizzi C, 2004, CIRCULATION, V109, P53, DOI 10.1161/01.CIR.0000100722.34034.E4; Radaelli A, 2007, ARTERIOSCL THROM VAS, V27, P2750, DOI 10.1161/ATVBAHA.107.149039; Ramanan S, 2009, INT J RADIAT ONCOL, V75, P870, DOI 10.1016/j.ijrobp.2009.06.059; Robbins ME, 2009, INT J RADIAT ONCOL, V73, P499, DOI 10.1016/j.ijrobp.2008.09.058; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Rola R, 2007, FREE RADICAL BIO MED, V42, P1133, DOI 10.1016/j.freeradbiomed.2007.01.020; Rosi S, 2009, BRAIN, V132, P2464, DOI 10.1093/brain/awp148; Sandmann S, 2006, BLOOD PRESSURE, V15, P116, DOI 10.1080/08037050600586593; SAS Institute Inc, 2004, SAS STAT 9 1 US GUID; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Schelman WR, 1997, MOL BRAIN RES, V48, P197, DOI 10.1016/S0169-328X(97)00093-4; Schindler MK, 2008, INT J RADIAT ONCOL, V70, P826, DOI 10.1016/j.ijrobp.2007.10.054; Shishehbor MH, 2003, CIRCULATION, V108, P426, DOI 10.1161/01.CIR.0000080895.05158.8B; Sparks D L, 2002, J Nutr Health Aging, V6, P324; Sugama S, 2003, NEUROSCIENCE, V116, P925, DOI 10.1016/S0306-4522(02)00572-9; Uberti D, 2001, MOL BRAIN RES, V93, P81, DOI 10.1016/S0169-328X(01)00180-2; Wang J, 2007, INT J RADIAT ONCOL, V68, P1483, DOI 10.1016/j.ijrobp.2007.03.036; Williams JP, 2004, RADIAT RES, V161, P560, DOI 10.1667/RR3168; Yamashima T, 2004, HIPPOCAMPUS, V14, P861, DOI 10.1002/hipo.20001; Yang XP, 2001, CIRC RES, V88, P1072, DOI 10.1161/hh1001.090759	48	28	29	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0167-594X	1573-7373		J NEURO-ONCOL	J. Neuro-Oncol.	FEB	2011	101	3					449	456		10.1007/s11060-010-0282-x			8	Oncology; Clinical Neurology	Oncology; Neurosciences & Neurology	709VI	WOS:000286469100010	20617366				2021-06-18	
J	Le, K; Coelho, C; Mozeiko, J; Grafman, J				Le, Karen; Coelho, Carl; Mozeiko, Jennifer; Grafman, Jordan			Measuring Goodness of Story Narratives	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						discourse analysis; content analysis; story grammar; narrative discourse	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; DISCOURSE PRODUCTION; ADULTS; ADOLESCENTS; KNOWLEDGE; CHILDREN; ABILITY; SKILLS; MILD	Purpose: The purpose of this article was to evaluate a new measure of story narrative performance: story completeness. It was hypothesized that by combining organizational (story grammar) and completeness measures, story "goodness" could be quantified. Method: Discourse samples from 46 typically developing adults were compared with those from 24 adults with acquired brain injuries. Story retellings were elicited and analyzed for episode structure (story grammar). Each story was also evaluated for the presence of 5 key components, yielding the story completeness score. Story goodness was quantified by combining the story grammar and completeness measures using a 2-coordinate grid system. A multivariate analysis of variance was performed as well as correlational analyses between the story grammar and story completeness scores. Results: There were significant group differences on both story grammar and story completeness. Moderate correlations were noted between the 2 measures, suggesting that the indices were not entirely measuring the same abilities. Plotting the 2 sets of scores into quadrants discriminated the comparison group and the group with brain injury into 4 distinct categories of story "goodness." Conclusion: The combination of measures provided a more accurate depiction of discourse performance than either measure alone. Results suggest the measure is sensitive, is reliable, and has potential utility for investigating discourse deficits in clinical populations.	[Le, Karen; Coelho, Carl; Mozeiko, Jennifer] Univ Connecticut, Storrs, CT USA; [Grafman, Jordan] NIH, Bethesda, MD 20892 USA	Grafman, J (corresponding author), NINDS, Cognit Neurosci Sect, Bldg 10,7D43,MSC 1440, Bethesda, MD 20892 USA.	grafmanj@ninds.nih.gov		Grafman, Jordan H./0000-0001-8645-4457	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002792] Funding Source: NIH RePORTER		Barrett J., 1998, OLD MCDONALD HAD APA; Body R, 2004, BRAIN INJURY, V18, P707, DOI 10.1080/02699050310001596914; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO C A, 1991, Brain Injury, V5, P381, DOI 10.3109/02699059109008111; Coelho C. A., 1994, DISCOURSE ANAL APPL, P96; Coelho CA, 2003, APHASIOLOGY, V17, P499, DOI 10.1080/02687030344000111; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; FREDERIKSEN CH, 1975, COGNITIVE PSYCHOL, V7, P371, DOI 10.1016/0010-0285(75)90016-X; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; Grafman J., 2002, PRINCIPLES FRONTAL L, P292; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Hunt K., 1965, 3 NCTEH; Kaplan E., 1983, BOSTON NAMING TEST; Kaufer D. J, 2007, HUMAN FRONTAL LOBES, P44; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MERRITT DD, 1987, J SPEECH HEAR RES, V30, P539, DOI 10.1044/jshr.3004.539; PLAG JA, 1967, PERS PSYCHOL, V20, P323, DOI 10.1111/j.1744-6570.1967.tb01527.x; Rankin K. P., 2007, HUMAN FRONTAL LOBES, P345; Stein N. L., 1979, NEW DIRECTIONS DISCO, V2, P53; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; THORNDYKE PW, 1980, POETICS, V9, P23, DOI 10.1016/0304-422X(80)90011-X; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; U. S. Department of Defense, 1984, TEST MAN ARM SERV VO; Wood JN, 2005, CEREB CORTEX, V15, P1155, DOI 10.1093/cercor/bhh215	30	28	28	0	5	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1092-4388	1558-9102		J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	FEB 1	2011	54	1					118	126		10.1044/1092-4388(2010/09-0022)			9	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	714IY	WOS:000286804500015	20719868				2021-06-18	
J	Suhr, JA; Sullivan, BK; Rodriguez, JL				Suhr, Julie A.; Sullivan, Brian K.; Rodriguez, Jose Luis			The Relationship of Noncredible Performance to Continuous Performance Test Scores in Adults Referred for Attention-Deficit/Hyperactivity Disorder Evaluation	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Malingering; Attention deficit disorder with hyperactivity; Neuropsychological assessment; Continuous performance tests	DEFICIT HYPERACTIVITY DISORDER; WORD MEMORY TEST; TRAUMATIC BRAIN-INJURY; COLLEGE-STUDENTS; SELF-REPORT; PRESCRIPTION STIMULANTS; SYMPTOM EXAGGERATION; ILLICIT USE; ADHD; PREVALENCE	Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults is complicated by the fact that neither symptom report nor neuropsychological findings are specific to the diagnosis. Few studies have addressed the possibility that noncredible performance influences the effectiveness of neuropsychological test findings in ADHD assessment. The present study utilized archival data on Conner's Continuous Performance Test (CPT) scores from young adults referred for concerns about ADHD at two different universities, who were divided into three groups: (1) those who failed a measure of noncredible performance (the Word Memory Test; WMT), (2) those who met diagnostic criteria for ADHD, and (3) controls with psychological symptoms who did not meet the diagnostic criteria for ADHD. More individuals who failed the WMT were also clinically impaired on the CPT than individuals diagnosed with ADHD and individuals with psychological symptoms, who could not be distinguished from each other. Results demonstrate the importance of assessing for noncredible performance before interpreting neuropsychological test scores in ADHD assessment. Results also emphasize the importance of considering other disorders that can impact CPT performance prior to interpreting CPT impairment as indicative of ADHD.	[Suhr, Julie A.] Ohio Univ, Dept Psychol, Athens, OH 45701 USA; [Sullivan, Brian K.; Rodriguez, Jose Luis] Coll Charleston, Counseling Serv, Charleston, SC 29401 USA; [Sullivan, Brian K.; Rodriguez, Jose Luis] Coll Charleston, Substance Abuse Serv, Charleston, SC 29401 USA	Suhr, JA (corresponding author), Ohio Univ, Dept Psychol, Athens, OH 45701 USA.	suhr@ohio.edu					Advokat Claire, 2007, J Atten Disord, V10, P253, DOI 10.1177/1087054706292106; ALFANO K, 2007, ASSESSMENT FEIGNED C; Barkley RA, 2006, ATTENTION DEFICIT HY; Booksh RL, 2010, J ATTEN DISORD, V13, P325, DOI 10.1177/1087054708329927; Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Cohen Andrew L, 2007, J Atten Disord, V11, P49, DOI 10.1177/1087054706292162; Conners C., 2000, CONNERS CONTINUOUS P; Conners CK., 1998, CONNERS ADULT ATTENT; Conti RP, 2004, PSYCHOL REP, V94, P987; DuPaul GJ, 2001, J LEARN DISABIL-US, V34, P370, DOI 10.1177/002221940103400412; Egeland J, 2007, ARCH CLIN NEUROPSYCH, V22, P763, DOI 10.1016/j.acn.2007.06.004; Epstein JN, 1998, CLIN NEUROPSYCHOL, V12, P155, DOI 10.1076/clin.12.2.155.2000; Faraone Stephen V, 2005, J Atten Disord, V9, P384, DOI 10.1177/1087054705281478; Frazier TW, 2008, ARCH CLIN NEUROPSYCH, V23, P501, DOI 10.1016/j.acn.2008.04.001; Goodrich-Hunsaker NJ, 2009, NEUROPSYCHOLOGY, V23, P529, DOI 10.1037/a0015444; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2005, GREENS WORD MEMORY T; GROTE CL, 2007, ASSESSMENT MALINGERE; Hall KM, 2005, J AM COLL HEALTH, V53, P167, DOI 10.3200/JACH.53.4.167-174; Harrison A.G., 2004, ADHD REPORT, V12, P8, DOI [10.1521/adhd.12.6.8.55256, DOI 10.1521/ADHD.12.6.8.55256]; Harrison AG, 2007, ARCH CLIN NEUROPSYCH, V22, P577, DOI 10.1016/j.acn.2007.03.008; Harrison AG, 2010, APPL NEUROPSYCHOL, V17, P135, DOI 10.1080/09084281003715642; Heiligenstein E, 1998, J AM COLL HEALTH, V46, P185, DOI 10.1080/07448489809595609; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jachimowicz G, 2004, COGNITIVE SCI, V2, P6; Leark RA, 2002, ARCH CLIN NEUROPSYCH, V17, P335, DOI 10.1016/S0887-6177(01)00118-4; Lewandowski LJ, 2008, J ATTEN DISORD, V12, P156, DOI 10.1177/1087054707310882; Mannuzza S, 2002, AM J PSYCHIAT, V159, P1882, DOI 10.1176/appi.ajp.159.11.1882; McCabe SE, 2005, ADDICTION, V100, P96, DOI 10.1111/j.1360-0443.2005.00944.x; McCann BS, 2004, COMPR PSYCHIAT, V45, P175, DOI 10.1016/j.comppsych.2004.02.006; Murphy K., 1996, J ATTEN DISORD, DOI [10.1177/108705479600100303, DOI 10.1177/108705479600100303]; MURPHY K, 1994, ADHD REPORT, V2, P3; Murphy P, 2000, AM J PSYCHIAT, V157, P1156, DOI 10.1176/appi.ajp.157.7.1156; Nigg JT, 2005, BIOL PSYCHIAT, V57, P1424, DOI 10.1016/j.biopsych.2004.11.011; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Quinn CA, 2003, ARCH CLIN NEUROPSYCH, V18, P379, DOI 10.1016/S0887-6177(02)00150-6; Riccio C. A., 2001, CLIN APPL CONTINUOUS; ROYBYRNE R, 1997, COMPR PSYCHIAT, V38, P133, DOI DOI 10.1016/S0010-440X(97)90065-1; Solanto MV, 2004, CNS SPECTRUMS, V9, P649, DOI 10.1017/S1092852900001929; Stefanatos GA, 2007, NEUROPSYCHOL REV, V17, P5, DOI 10.1007/s11065-007-9020-3; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Sullivan BK, 2007, APPL NEUROPSYCHOL, V14, P189, DOI 10.1080/09084280701509083; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Teter CJ, 2005, J AM COLL HEALTH, V53, P253, DOI 10.3200/JACH.53.6.253-262; *US DEP ED, 1999, STUD DIS POSTS ED PR; WEYANDT LL, 1995, J PSYCHOPATHOL BEHAV, V17, P293, DOI 10.1007/BF02229304; White BP, 2006, J AM COLL HEALTH, V54, P261, DOI 10.3200/JACH.54.5.261-268	49	28	28	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2011	26	1					1	7		10.1093/arclin/acq094			7	Psychology, Clinical; Psychology	Psychology	709SU	WOS:000286462500001	21159792	Bronze			2021-06-18	
J	Walson, KH; Tang, MK; Glumac, A; Alexander, H; Manole, MD; Ma, L; Hsia, CJ; Clark, RS; Kochanek, PM; Kagan, VE; Bayir, H				Walson, Karen H.; Tang, Minke; Glumac, Ashley; Alexander, Henry; Manole, Mioara D.; Ma, Li; Hsia, Carelton J.; Clark, Robert S.; Kochanek, Patrick M.; Kagan, Valerian E.; Bayir, Huelya			Normoxic versus hyperoxic resuscitation in pediatric asphyxial cardiac arrest: Effects on oxidative stress	CRITICAL CARE MEDICINE			English	Article						oxidant injury; cardiac arrest; immature brain; cardiopulmonary resuscitation; brain hypoxia-ischemia; hyperoxia	TRANSIENT FOCAL ISCHEMIA; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; INTERNATIONAL LIAISON COMMITTEE; PROTEIN-TYROSINE NITRATION; ADVANCED LIFE-SUPPORT; REDUCES INFARCT SIZE; CEREBRAL-ISCHEMIA; POLYNITROXYL-ALBUMIN; SUPEROXIDE-DISMUTASE	Objective: To determine the effects of normoxic vs. hyperoxic resuscitation on oxidative stress in a model of pediatric asphyxial cardiac arrest. Design: Prospective, interventional study. Setting: University research laboratory. Subjects: Postnatal day 16-18 rats (n = 5 per group). Interventions: Rats underwent asphyxial cardiac arrest for 9 min. Rats were randomized to receive 100% oxygen, room air, or 100% oxygen with polynitroxyl albumin (10 mL.kg(-1) intravenously, 0 and 30 min after resuscitation) for 1 hr from the start of cardiopulmonary resuscitation. Shams recovered in 100% oxygen or room air after surgery. Measurements and Main Results: Physiological variables were recorded at baseline to 1 hr after resuscitation. At 6 hrs after asphyxial cardiac arrest, levels of reduced glutathione and protein-thiols (fluorescent assay), activities of total superoxide dismutase and mitochondrial manganese superoxide dismutase (cytochrome c reduction method), manganese superoxide dismutase expression (Western blot), and lipid peroxidation (4-hydroxynonenal Michael adducts) were evaluated in brain tissue homogenates. Hippocampal 3-nitrotyrosine levels were determined by immunohistochemistry 72 hrs after asphyxial cardiac arrest. Survival did not differ among groups. At 1 hr after resuscitation, PaO2, pH, and mean arterial pressure were decreased in room air vs. 100% oxygen rats (59 +/- 3 vs. 465 +/- 46 mm Hg, 7.36 +/- 0.05 vs. 7.42 +/- 0.03, 35 +/- 4 vs. 45 +/- 5 mm Hg; p<.05). Rats resuscitated with 100% oxygen had decreased hippocampal reduced glutathione levels vs. sham (15.3 +/- 0.4 vs. 20.9 +/- 4.1 nmol.mgprotein(-1); p<.01). Hippocampal manganese superoxide dismutase activity was significantly increased in 100% oxygen rats vs. sham (14 +/- 2.4 vs. 9.5 +/- 1.6 units.mg protein(-1), p<.01), with no difference in protein expression of manganese superoxide dismutase. Room air and 100% oxygen plus polynitroxyl albumin groups had hippocampal reduced glutathione and manganese superoxide dismutase activity levels comparable with sham. Protein thiol levels were unchanged across groups. Compared with all other groups, rats receiving 100% oxygen had increased immunopositivity for 3-nitrotyrosine in the hippocampus and increased lipid peroxidation in the cortex. Conclusions: Resuscitation with 100% oxygen leads to increased oxidative stress in a model that mimics pediatric cardiac arrest. This may be prevented by using room air or giving an antioxidant with 100% oxygen resuscitation. (Crit Care Med 2011; 39: 335-343)	[Walson, Karen H.; Clark, Robert S.; Kochanek, Patrick M.; Bayir, Huelya] Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Glumac, Ashley; Kagan, Valerian E.; Bayir, Huelya] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Tang, Minke; Alexander, Henry; Manole, Mioara D.; Clark, Robert S.; Kochanek, Patrick M.; Bayir, Huelya] Univ Pittsburgh, Grad Sch Publ Hlth, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Kagan, Valerian E.; Bayir, Huelya] Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA USA; [Ma, Li; Hsia, Carelton J.] SynZyme Technol, Irvine, CA USA	Walson, KH (corresponding author), Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA.	karen.walson@choa.org; bayihx@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Kagan, Valerian E./0000-0002-7245-1885	Department of Defense, Washington, DCUnited States Department of Defense [PR054755 W81XWH0610247]; National Institutes of Health, Bethesda, MDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS061817, HD057587, HD045968]; Laerdal Foundation, Stavanger, Norway; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD058798] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD057587, R01HD045968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061817] Funding Source: NIH RePORTER	Supported, in part, by grants from the Department of Defense, Washington, DC (PR054755 W81XWH0610247), National Institutes of Health, Bethesda, MD (NS061817, HD057587, and HD045968), and the Laerdal Foundation, Stavanger, Norway.	Alvarez-Diaz A, 2007, NEONATOLOGY, V92, P227, DOI 10.1159/000103741; Atkins DL, 2006, PEDIATRICS, V117, pE955, DOI 10.1542/peds.2006-0206; Atkins DL, 2006, PEDIATRICS, V117, pE1005, DOI 10.1542/peds.2006-0346; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; Balan IS, 2006, STROKE, V37, P3008, DOI 10.1161/01.STR.0000248455.73785.b1; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Beaulieu C, 1998, J CEREBR BLOOD F MET, V18, P1022; Behringer W, 2002, J CEREBR BLOOD F MET, V22, P105, DOI 10.1097/00004647-200201000-00013; Bostek C C, 1989, AANA J, V57, P231; Buonocore G, 2007, SEMIN FETAL NEONAT M, V12, P287, DOI 10.1016/j.siny.2007.01.020; Candelario-Jalil E, 2001, NEUROSCI RES, V41, P233, DOI 10.1016/S0168-0102(01)00282-6; CERCHIARI EL, 1993, RESUSCITATION, V25, P9, DOI 10.1016/0300-9572(93)90003-9; Chaudhari T, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006817.pub2; Chen Patrick, 2005, Air Med J, V24, P244, DOI 10.1016/j.amj.2005.08.003; CHEVION M, 1988, FREE RADICAL BIO MED, V5, P27, DOI 10.1016/0891-5849(88)90059-7; Deguchi K, 2008, BRAIN RES, V1188, P1, DOI 10.1016/j.brainres.2007.07.104; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dohi K, 2003, ACT NEUR S, V86, P87; Donoghue AJ, 2005, ANN EMERG MED, V46, P512, DOI 10.1016/j.annemergmed.2005.05.028; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Fink Ericka L, 2004, Pediatr Crit Care Med, V5, P139, DOI 10.1097/01.PCC.0000112376.29903.8F; GUTTERIDGE JMC, 1994, CHEM-BIOL INTERACT, V91, P133, DOI 10.1016/0009-2797(94)90033-7; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Hayashi T, 2004, NEUROBIOL DIS, V15, P229, DOI 10.1016/j.nbd.2003.10.005; Hou ST, 2002, INT REV CYTOL, V221, P93; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Ischiropoulos H, 2009, ARCH BIOCHEM BIOPHYS, V484, P117, DOI 10.1016/j.abb.2008.10.034; Ishibashi N, 2002, J IMMUNOL, V168, P1926, DOI 10.4049/jimmunol.168.4.1926; IZUMI Y, 1995, SYNAPSE, V20, P19, DOI 10.1002/syn.890200104; JACKSON PS, 1993, J NEUROPHYSIOL, V70, P1412; Kentner R, 2002, J TRAUMA, V53, P968, DOI 10.1097/00005373-200211000-00025; Kilgannon JH, 2008, RESUSCITATION, V79, P410, DOI 10.1016/j.resuscitation.2008.07.019; Kim GW, 2002, STROKE, V33, P809, DOI 10.1161/hs0302.103745; KIRSCH JR, 1992, J NEUROTRAUM, V9, pS157; Klaus S, 2003, RESUSCITATION, V56, P299, DOI 10.1016/S0300-9572(02)00342-8; Kliegman RM, 2007, NELSON TXB PEDIAT; Kondo T, 1997, J NEUROSCI, V17, P4180; Kuisma M, 2006, RESUSCITATION, V69, P199, DOI 10.1016/j.resuscitation.2005.08.010; Kuppusamy P, 1996, BIOCHEMISTRY-US, V35, P7051, DOI 10.1021/bi952857s; Kutzsche S, 2001, PEDIATR RES, V49, P834, DOI 10.1203/00006450-200106000-00020; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li HQ, 2002, FREE RADICAL BIO MED, V32, P712, DOI 10.1016/S0891-5849(02)00762-1; LIU TH, 1989, AM J PHYSIOL, V256, pH589; Liu YB, 1998, STROKE, V29, P1679, DOI 10.1161/01.STR.29.8.1679; Love S, 1999, BRAIN PATHOL, V9, P119; Lukic-Panin V, 2007, BRAIN RES, V1176, P143, DOI 10.1016/j.brainres.2007.07.038; Macdonald RL, 1998, NEUROL MED-CHIR, V38, P1, DOI 10.2176/nmc.38.1; MacLean DA, 1998, CIRCULATION, V98, P1990, DOI 10.1161/01.CIR.98.19.1990; Margaill I, 2005, FREE RADICAL BIO MED, V39, P429, DOI 10.1016/j.freeradbiomed.2005.05.003; Martin RJ, 2008, SEMIN PERINATOL, V32, P355, DOI 10.1053/j.semperi.2008.08.002; Matchett GA, 2009, NEUROL RES, V31, P128, DOI 10.1179/174313209X393546; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; McCracken E, 2001, BRAIN PATHOL, V11, P414, DOI 10.1111/j.1750-3639.2001.tb00409.x; Mullner M, 1996, STROKE, V27, P59, DOI 10.1161/01.STR.27.1.59; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; Nicole A, 1998, BIOMED PHARMACOTHER, V52, P349, DOI 10.1016/S0753-3322(99)80001-8; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Ramji S, 2003, Indian Pediatr, V40, P510; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Safar P, 2002, CRIT CARE MED, V30, pS140, DOI 10.1097/00003246-200204001-00004; Saito A, 2005, MOL NEUROBIOL, V31, P105, DOI 10.1385/MN:31:1-3:105; Saugstad OD, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e1; Saugstad OD, 2005, BIOL NEONATE, V87, P27, DOI 10.1159/000080950; Saugstad OD, 2003, PEDIATRICS, V112, P296, DOI 10.1542/peds.112.2.296; Sirbaugh PE, 1999, ANN EMERG MED, V33, P174, DOI 10.1016/S0196-0644(99)70391-4; Skinner MR, 1996, J PHYSIOL-LONDON, V495, P553, DOI 10.1113/jphysiol.1996.sp021615; Solas A B, 2001, Pediatr Crit Care Med, V2, P340; Solberg R, 2007, PEDIATR RES, V62, P559, DOI 10.1203/PDR.0b013e318156e8aa; Soule BP, 2007, FREE RADICAL BIO MED, V42, P1632, DOI 10.1016/j.freeradbiomed.2007.02.030; Sugawara T, 2003, ANTIOXID REDOX SIGN, V5, P597, DOI 10.1089/152308603770310266; Sugawara T, 2001, NEUROREPORT, V12, P3609, DOI 10.1097/00001756-200111160-00047; Sugawara Taku, 2004, NeuroRx, V1, P17, DOI 10.1602/neurorx.1.1.17; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Ullegaddi R, 2005, EUR J CLIN NUTR, V59, P1367, DOI 10.1038/sj.ejcn.1602248; VAAGENES P, 1984, CRIT CARE MED, V12, P846, DOI 10.1097/00003246-198410000-00002; Vento M, 2002, SEMIN PERINATOL, V26, P406, DOI 10.1053/sper.2002.37312; Vento M, 2003, J PEDIATR-US, V142, P240, DOI 10.1067/mpd.2003.91; Vento M, 2001, PEDIATRICS, V107, P642, DOI 10.1542/peds.107.4.642; Vereczki V, 2006, J CEREBR BLOOD F MET, V26, P821, DOI 10.1038/sj.jcbfm.9600234; Vos GD, 2003, EUR J EMERG MED, V10, P195, DOI 10.1097/00063110-200309000-00007; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Zhang N, 2005, STROKE, V36, P2220, DOI 10.1161/01.STR.0000182241.07096.06; Zhang S, 2000, FREE RADICAL BIO MED, V29, P42, DOI 10.1016/S0891-5849(00)00295-1; ZWEMER CF, 1994, RESUSCITATION, V27, P159, DOI 10.1016/0300-9572(94)90009-4	89	28	28	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2011	39	2					335	343		10.1097/CCM.0b013e3181ffda0e			9	Critical Care Medicine	General & Internal Medicine	709GN	WOS:000286426400014	21057313				2021-06-18	
J	Chen, ZY; Lu, XCM; Shear, DA; Dave, JR; Davis, AR; Evangelista, CA; Duffy, D; Tortella, FC				Chen, Zhiyong; Lu, X. -C. May; Shear, Deborah A.; Dave, Jitendra R.; Davis, Angela R.; Evangelista, Clifford A.; Duffy, Danelle; Tortella, Frank C.			Synergism of human amnion-derived multipotent progenitor (AMP) cells and a collagen scaffold in promoting brain wound recovery: Pre-clinical studies in an experimental model of penetrating ballistic-like brain injury	BRAIN RESEARCH			English	Article						Human amnion; Progenitor cells; Traumatic brain injury; Penetrating ballistic-like brain injury; Axon degeneration; Collagen scaffold	TRAUMATIC BRAIN; RAT MODEL; NEURAL DIFFERENTIATION; TRANSPLANTATION; IMPLANTATION; DOPAMINE; SURVIVE; DISEASE; GROWTH	One of the histopathological consequences of a penetrating ballistic brain injury is the formation of a permanent cavity. In a previous study using the penetrating ballistic-like brain injury (PBBI) model, engrafted human amnion-derived multipotent progenitor (AMP) cells failed to survive when injected directly in the injury tract, suggesting that the cell survival requires a supportive matrix. In this study, we seated AMP cells in a collagen-based scaffold, injected into the injury core, and investigated cell survival and neuroprotection following PBBI. AMP cells suspended in AMP cell conditioned medium (ACCS) or in a liquefied collagen matrix were injected immediately after a PBBI along the penetrating injury tract. Injured control rats received only liquefied collagen matrix. All animals were allowed to survive two weeks. Consistent with our previous results, AMP cells suspended in ACCS failed to survive; likewise, no collagen was identified at the injury site when injected alone. In contrast, both AMP cells and the collagen were preserved in the injury cavity when injected together. In addition, AMP cells/collagen treatment preserved some apparent brain tissue in the injury cavity, and there was measurable infiltration of endogenous neural progenitor cells and astrocytes into the preserved brain tissue. AMP cells were also found to, have migrated into the subventricular zone and the corpus callosum. Moreover, the AMP cell/collagen treatment significantly attenuated the PBBI-induced axonal degeneration in the corpus callosum and ipsilateral thalamus and improved motor impairment on rotarod performance. Overall, collagen-based scaffold provided a supportive matrix for AMP cell survival, migration, and neuroprotection. Published by Elsevier B.V.	[Chen, Zhiyong; Lu, X. -C. May; Shear, Deborah A.; Dave, Jitendra R.; Davis, Angela R.; Evangelista, Clifford A.; Tortella, Frank C.] Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD 20910 USA; [Duffy, Danelle] Stemnion Inc, Pittsburgh, PA USA	Chen, ZY (corresponding author), Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	Zhiyong.chen@amedd.army.mil	Dave, Jitendra R/A-8940-2011; Shear, Deborah/B-3607-2011		DODUnited States Department of Defense [W81XWH-08-2-0127]	Funding for this project was provided by DOD CDMRP Grant W81XWH-08-2-0127. The material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official, or as reflecting true views of the Department of the Army or Department of Defense. The authors have no conflict of interest.	Badylak SF, 2009, ACTA BIOMATER, V5, P1, DOI 10.1016/j.actbio.2008.09.013; Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Banas RA, 2008, HUM IMMUNOL, V69, P321, DOI 10.1016/j.humimm.2008.04.007; Bantubungi K, 2008, MOL CELL NEUROSCI, V37, P454, DOI 10.1016/j.mcn.2007.11.001; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Chen ZY, 2009, J NEUROTRAUM, V26, P1987, DOI 10.1089/neu.2008.0863; DeFina P, 2009, CLIN NEUROPSYCHOL, V23, P1391, DOI 10.1080/13854040903058978; DUNNETT SB, 1994, J NEUROL, V242, pS43, DOI 10.1007/BF00939242; Farndale RW, 2008, BIOCHEM SOC T, V36, P241, DOI 10.1042/BST0360241; Fulop ZL, 1997, INT J NEUROSCI, V90, P203, DOI 10.3109/00207459709000639; Hermanns S, 2001, RESTOR NEUROL NEUROS, V19, P139; HOOVLER DW, 1991, ACTA NEUROPATHOL, V81, P303, DOI 10.1007/BF00305872; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Kakishita K, 2000, EXP NEUROL, V165, P27, DOI 10.1006/exnr.2000.7449; Kakishita K, 2003, BRAIN RES, V980, P48, DOI 10.1016/S0006-8993(03)02875-0; Kong XY, 2008, BRAIN RES, V1205, P108, DOI 10.1016/j.brainres.2008.02.040; Lanza R, 2007, PRINCIPLES OF TISSUE ENGINEERING, 3RD EDITION, P1; Lin HJ, 2004, DEV BRAIN RES, V153, P163, DOI 10.1016/j.devbrainres.2004.08.010; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood U, 2004, RADIOLOGY, V233, P625, DOI 10.1148/radiol.2333041190; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Meng XT, 2007, CELL BIOL INT, V31, P691, DOI 10.1016/j.cellbi.2006.11.038; Niknejad H, 2010, EUR CELLS MATER, V19, P22, DOI 10.22203/eCM.v019a03; O'Connor SM, 2000, J NEUROSCI METH, V102, P187, DOI 10.1016/S0165-0270(00)00303-4; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Potter W, 2008, FRONT BIOSCI-LANDMRK, V13, P806, DOI 10.2741/2721; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shinya M, 2010, FETAL PEDIATR PATHOL, V29, P133, DOI 10.3109/15513811003777292; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Steed David L, 2008, Eplasty, V8, pe18; STEIN DG, 1988, BEHAV NEUROSCI, V102, P260, DOI 10.1037/0735-7044.102.2.260; VANDERWOLF CH, 1990, EXP BRAIN RES, V81, P426; Willerth SM, 2007, ADV DRUG DELIVER REV, V59, P325, DOI 10.1016/j.addr.2007.03.014; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17	36	28	28	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 12	2011	1368						71	81		10.1016/j.brainres.2010.10.028			11	Neurosciences	Neurosciences & Neurology	714ZJ	WOS:000286849900009	20951684				2021-06-18	
J	Gatson, JW; Simpkins, JW; Yi, KD; Idris, AH; Minei, JP; Wigginton, JG				Gatson, J. W.; Simpkins, J. W.; Yi, K. D.; Idris, A. H.; Minei, J. P.; Wigginton, J. G.			Aromatase Is Increased in Astrocytes in the Presence of Elevated Pressure	ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; IN-VITRO; NEUROBLASTOMA-CELLS; EXPERIMENTAL STROKE; ESTRADIOL TREATMENT; GENDER-DIFFERENCES; MESSENGER-RNA; ANIMAL-MODELS	After traumatic brain injury (TBI), a progressive injury and death of neurons and glia leads to decreased brain function. Endogenous and exogenous estrogens may protect these vulnerable cells. In this study, we hypothesized that increased pressure leads to an increase in aromatase expression and estrogen production in astrocytes. In this study, we subjected rat glioma (C6) cells and primary cortical astrocytes to increased pressure (25 mm Hg) for 1, 3, 6, 12, 24, 48, and 72 h. Total aromatase protein and RNA levels were measured using Western analysis and RT-PCR, respectively. In addition, we measured aromatase activity by assaying estrone levels after administration of its precursor, androstenedione. We found that increased pressure applied to the C6 cells and primary cortical astrocytes resulted in a significant increase in both aromatase RNA and protein. To extend these findings, we also analyzed aromatase activity in the primary astrocytes during increased pressure. We found that increased pressure resulted in a significant (P < 0.01) increase in the conversion of androstenedione to estrone. In conclusion, we propose that after TBI, astrocytes sense increased pressure, leading to an increase in aromatase production and activity in the brain. These results may suggest mechanisms of brain estrogen production after increases in pressure as seen in TBI patients. (Endocrinology 152: 207-213, 2011)	[Gatson, J. W.; Idris, A. H.; Minei, J. P.; Wigginton, J. G.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Simpkins, J. W.; Yi, K. D.] Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA; [Gatson, J. W.; Idris, A. H.; Wigginton, J. G.] Dallas Ft Worth Ctr Resuscitat Res, Dallas, TX 75390 USA	Gatson, JW (corresponding author), 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joshua.gatson@utsw.edu		Wigginton, Jane/0000-0002-8561-3492	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH 5 T32 GM08593-14, NIH 5 P50 GM21681-44]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P50GM021681, T32GM008593] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health (NIH) T32 Training Grant (NIH 5 T32 GM08593-14) and NIH P50 Burn Center Grant (NIH 5 P50 GM21681-44).	Ali MA, 2009, INT J ONCOL, V34, P1051, DOI 10.3892/ijo_00000231; Azcoitia I, 2003, ANN NY ACAD SCI, V1007, P298, DOI 10.1196/annals.1286.028; Behl C, 1997, MOL PHARMACOL, V51, P535; BISHOP J, 1994, MOL CELL NEUROSCI, V5, P303, DOI 10.1006/mcne.1994.1036; Brown CM, 2009, SEMIN REPROD MED, V27, P240, DOI 10.1055/s-0029-1216277; Carswell HVO, 2005, J STEROID BIOCHEM, V96, P89, DOI 10.1016/j.jsbmb.2005.02.016; Chen G, 2007, GLIA, V55, P1509, DOI 10.1002/glia.20563; COLD G, 1975, ACTA NEUROL SCAND, V52, P187, DOI 10.1111/j.1600-0404.1975.tb05773.x; Darwish RS, 2010, NEUROCRIT CARE, V12, P337, DOI 10.1007/s12028-009-9328-3; ENEVOLDSEN EM, 1977, CLIN NEUROL NEUROSUR, V80, P213; Freking F, 1998, J NEUROBIOL, V36, P30, DOI 10.1002/(SICI)1097-4695(199807)36:1<30::AID-NEU3>3.0.CO;2-B; FUJISHIMA M, 1975, STROKE, V6, P707, DOI 10.1161/01.STR.6.6.707; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Green PS, 1996, NEUROSCI LETT, V218, P165, DOI 10.1016/S0304-3940(96)13148-7; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Knoferl MW, 2000, ARCH SURG-CHICAGO, V135, P425, DOI 10.1001/archsurg.135.4.425; Kondo Y, 1997, NEUROSCI LETT, V238, P45, DOI 10.1016/S0304-3940(97)00847-1; Liu MY, 2007, J CEREBR BLOOD F MET, V27, P135, DOI 10.1038/sj.jcbfm.9600331; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; Merchenthaler I, 2003, ANN NY ACAD SCI, V1007, P89, DOI 10.1196/annals.1286.009; MICHAEL MD, 1995, J BIOL CHEM, V270, P13561, DOI 10.1074/jbc.270.22.13561; NAFTOLIN F, 1971, J ENDOCRINOL, V51, P795, DOI 10.1677/joe.0.0510795; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; O'Phelan KH, 2009, NEUROCRIT CARE, V10, P280, DOI 10.1007/s12028-008-9183-7; Pastor-Soler N, 2003, J BIOL CHEM, V278, P49523, DOI 10.1074/jbc.M309543200; Peterson RS, 2001, J NEUROENDOCRINOL, V13, P317, DOI 10.1046/j.1365-2826.2001.00647.x; Roberts EL, 2000, BRAIN RES, V875, P171, DOI 10.1016/S0006-8993(00)02587-7; ROBERTS I, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000033; Roof RL, 1999, PHYSIOL BEHAV, V68, P81, DOI 10.1016/S0031-9384(99)00162-6; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Saldanha CJ, 2000, J COMP NEUROL, V423, P619, DOI 10.1002/1096-9861(20000807)423:4<619::AID-CNE7>3.0.CO;2-U; Saldanha CJ, 2009, FRONT NEUROENDOCRIN, V30, P106, DOI 10.1016/j.yfrne.2009.04.016; Satoh K, 2008, BIOL PHARM BULL, V31, P357, DOI 10.1248/bpb.31.357; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Simpson ER, 2000, J MOL ENDOCRINOL, V25, P149, DOI 10.1677/jme.0.0250149; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Uzan M, 2006, ACTA NEUROCHIR, V148, P1157, DOI 10.1007/s00701-006-0887-1; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zwain IH, 1997, BBA-GEN SUBJECTS, V1334, P338, DOI 10.1016/S0304-4165(96)00115-8	50	28	29	0	4	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	JAN	2011	152	1					207	213		10.1210/en.2010-0724			7	Endocrinology & Metabolism	Endocrinology & Metabolism	698DT	WOS:000285573000021	21047944	Green Published, Bronze			2021-06-18	
J	Mogensen, J				Mogensen, Jesper			Reorganization of the injured brain: implications for studies of the neural substrate of cognition	FRONTIERS IN PSYCHOLOGY			English	Article						neural plasticity; reorganization; brain injury; localization of function; recovery; recovery of function; consciousness; neural organization	TRANSCRANIAL MAGNETIC STIMULATION; FORNIX AND/OR ABLATION; SPATIAL DELAYED ALTERNATION; GENE-EXPRESSION; SOMATOSENSORY CORTEX; PRISM ADAPTATION; NEURONAL REPLACEMENT; CORTICAL PLASTICITY; CEREBRAL PLASTICITY; FUNCTIONAL RECOVERY	In the search for a neural substrate of cognitive processes, a frequently utilized method is the scrutiny of post-traumatic symptoms exhibited by individuals suffering focal injury to the brain. For instance, the presence or absence of conscious awareness within a particular domain may, combined with knowledge of which regions of the brain have been injured, provide important data in the search for neural correlates of consciousness. Like all studies addressing the consequences of brain injury, however, such research has to face the fact that in most cases, post-traumatic impairments are accompanied by a "functional recovery" during which symptoms are reduced or eliminated. The apparent contradiction between localization and recovery, respectively, of functions constitutes a problem to almost all aspects of cognitive neuroscience. Several lines of investigation indicate that although the brain remains highly plastic throughout life, the post-traumatic plasticity does not recreate a copy of the neural mechanisms lost to injury. Instead, the uninjured parts of the brain are functionally reorganized in a manner which - in spite of not recreating the basic information processing lost to injury - is able to allow a more or less complete return of the surface phenomena (including manifestations of consciousness) originally impaired by the trauma. A novel model [the Reorganization of Elementary Functions-model] of these processes is presented - and some of its implications discussed relative to studies of the neural substrates of cognition and consciousness.	Univ Copenhagen, Dept Psychol, Unit Cognit Neurosci, DK-1353 Copenhagen K, Denmark	Mogensen, J (corresponding author), Univ Copenhagen, Dept Psychol, Unit Cognit Neurosci, Oester Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.	jesper.mogensen@psy.ku.dk		Mogensen, Jesper/0000-0003-1959-581X			Ansaldo AI, 2003, BRAIN LANG, V87, P177, DOI 10.1016/S0093-934X(03)00258-X; Ansaldo AN, 2002, BRAIN LANG, V82, P206, DOI 10.1016/S0093-934X(02)00017-2; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Banks C., 2010, J STROKE CEREBROVASC, P1; Barrett HC, 2006, PSYCHOL REV, V113, P628, DOI 10.1037/0033-295X.113.3.628; Bartolomeo P, 2007, CURR OPIN NEUROL, V20, P381, DOI 10.1097/WCO.0b013e32816aa3a3; Baumgaertner A, 2005, BRAIN LANG, V95, P211, DOI 10.1016/j.bandl.2005.07.110; Berardi N, 2004, NEURON, V44, P905, DOI 10.1016/S0896-6273(04)00796-2; Berry M, 1982, Bibl Anat, P1; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Buller D. J., 2000, BRAIN MIND, V1, P307, DOI [10.1023/A:1011573226794, DOI 10.1023/A:1011573226794]; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CHEN DF, 1995, P NATL ACAD SCI USA, V92, P7287, DOI 10.1073/pnas.92.16.7287; Chen JH, 2004, P NATL ACAD SCI USA, V101, P16357, DOI 10.1073/pnas.0406795101; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Choi JY, 2007, J NUCL MED, V48, P194; Coltheart M., 2001, HDB COGNITIVE NEUROP, P3; Danckert J, 2000, CURR BIOL, V10, pR64, DOI 10.1016/S0960-9822(00)00284-0; Del Rio JA, 2007, CURR PHARM DESIGN, V13, P2485; DELFS JM, 1995, J NEUROSCI, V15, P6562; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; FAWCETT JW, 1989, DEV BIOL, V135, P449, DOI 10.1016/0012-1606(89)90193-0; Fodor J. A., 1983, MODULARITY MIND; Fodor Jerry, 2000, MIND DOESNT WORK WAY; Frassinetti F, 2002, BRAIN, V125, P608, DOI 10.1093/brain/awf056; Friston KJ, 2003, TRENDS COGN SCI, V7, P151, DOI 10.1016/S1364-6613(03)00054-8; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Funk J, 2010, NEUROPSYCHOLOGIA, V48, P298, DOI 10.1016/j.neuropsychologia.2009.09.018; Goldberg JL, 2002, SCIENCE, V296, P1860, DOI 10.1126/science.1068428; Hagemann G, 1998, ANN NEUROL, V44, P255, DOI 10.1002/ana.410440217; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hermann DM, 1999, RESTOR NEUROL NEUROS, V14, P103; Hiramoto M, 2000, NATURE, V406, P886, DOI 10.1038/35022571; Irvine DRF, 2007, HEARING RES, V229, P158, DOI 10.1016/j.heares.2007.01.006; Karl A, 2001, J NEUROSCI, V21, P3609, DOI 10.1523/JNEUROSCI.21-10-03609.2001; Kentridge RW, 1999, P ROY SOC B-BIOL SCI, V266, P1805, DOI 10.1098/rspb.1999.0850; Keynes R J, 1992, Curr Opin Neurobiol, V2, P55, DOI 10.1016/0959-4388(92)90162-E; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Koeberle PD, 2004, J NEUROBIOL, V59, P162, DOI 10.1002/neu.10345; Krechevsky I, 1933, J COMP PSYCHOL, V16, P99, DOI 10.1037/h0072223; Krechevsky I, 1932, PSYCHOL REV, V39, P516, DOI 10.1037/h0073500; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; Lane RD, 1997, BIOL PSYCHIAT, V42, P834, DOI 10.1016/S0006-3223(97)00050-4; Leavitt BR, 1999, EXP NEUROL, V157, P43, DOI 10.1006/exnr.1999.6982; Leon-Carrion J., 2001, REV ESPANOLA NEUROPS, V3, P58; Lepore F., 1985, CAN J PSYCHOL, V37, P527; Magavi SS, 2000, NATURE, V405, P951; Marcel AJ, 1998, BRAIN, V121, P1565, DOI 10.1093/brain/121.8.1565; McGee AW, 2005, SCIENCE, V309, P2222, DOI 10.1126/science.1114362; Meinzer M, 2008, NEUROIMAGE, V39, P2038, DOI 10.1016/j.neuroimage.2007.10.008; Merzenich M M, 1993, J Hand Ther, V6, P89; Mogensen J, 2005, BRAIN RES BULL, V65, P41, DOI 10.1016/j.brainresbull.2004.11.010; Mogensen J, 2004, BRAIN RES BULL, V63, P217, DOI 10.1016/j.brainresbull.2004.02.008; Mogensen J, 2003, PHARMACOL BIOCHEM BE, V75, P381, DOI 10.1016/S0091-3057(03)00107-2; MOGENSEN J, 1987, ACTA NEUROBIOL EXP, V47, P45; Mogensen J, 2002, NEUROBIOL LEARN MEM, V78, P139, DOI 10.1006/nlme.2001.4055; Mogensen J., 2011, FRONT CONSC IN PRESS; Mogensen J., 2011, HDB LAB ANI IN PRESS, VII; Mogensen J., 2003, HDB LAB ANIMAL SCI, VII, P95; Mogensen J, 2008, BRAIN RES BULL, V77, P1, DOI 10.1016/j.brainresbull.2008.05.005; Mogensen J, 2007, BRAIN RES BULL, V73, P86, DOI 10.1016/j.brainresbull.2007.02.006; Mogensen J, 2009, SCAND J PSYCHOL, V50, P561, DOI 10.1111/j.1467-9450.2009.00781.x; Monakow C., 1914, LOKALISATION GROSSHI; Munte TF, 2002, NAT REV NEUROSCI, V3, P473, DOI 10.1038/nrn843; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Natsoulas T, 1997, AM J PSYCHOL, V110, P1, DOI 10.2307/1423698; NORMAN DA, 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Nudo RJ, 2003, J REHABIL MED, V35, P7, DOI 10.1080/16501960310010070; Olton D. S., 1978, CIBA F S, V58, P327; Panksepp J., 2000, EVOLUTION COGNITION, V6, P108, DOI DOI 10.1146/ANNUREV.AN.18.100189.0; Pascual-Leone A, 1999, PHILOS T R SOC B, V354, P1229, DOI 10.1098/rstb.1999.0476; Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7; Perani D, 2003, BRAIN LANG, V85, P357, DOI 10.1016/S0093-934X(02)00561-8; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Polleux F, 2000, NATURE, V404, P567; Price CJ, 2002, TRENDS COGN SCI, V6, P416, DOI 10.1016/S1364-6613(02)01976-9; Ptito M, 2005, BRAIN, V128, P606, DOI 10.1093/brain/awh380; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; RAKIC P, 1985, MOL BASES NEURAL DEV, P139; Ramachandran VS, 1998, PHANTOMS BRAIN PROBI; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; RECANZONE GH, 1993, J NEUROSCI, V13, P87; ROBERTSON D, 1989, J COMP NEUROL, V282, P456, DOI 10.1002/cne.902820311; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rossetti Y, 1998, NATURE, V395, P166, DOI 10.1038/25988; Rumelhart D. E., 1986, PARALLEL DISTRIBUTED; Sarri M, 2008, NEUROPSYCHOLOGIA, V46, P1069, DOI 10.1016/j.neuropsychologia.2007.11.005; Schafer R, 2008, NEUROSCI LETT, V439, P61, DOI 10.1016/j.neulet.2008.04.098; Scharff C, 2000, NEURON, V25, P481, DOI 10.1016/S0896-6273(00)80910-1; Scheich H, 1991, Curr Opin Neurobiol, V1, P236, DOI 10.1016/0959-4388(91)90084-K; Schindler I, 2006, NEUROPSYCHOLOGIA, V44, P1444, DOI 10.1016/j.neuropsychologia.2005.12.003; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Selnes OA., 2001, HDB COGNITIVE NEUROP, P23; Serino A, 2007, NEUROPSYCHOL REHABIL, V17, P657, DOI 10.1080/09602010601052006; Serino A, 2006, NEUROPSYCHOLOGIA, V44, P1068, DOI 10.1016/j.neuropsychologia.2005.10.024; Silvanto J, 2008, CURR BIOL, V18, pR950, DOI 10.1016/j.cub.2008.08.016; Specht K, 2009, NEUROIMAGE, V47, P2057, DOI 10.1016/j.neuroimage.2009.06.011; Thai-Van H, 2007, HEARING RES, V233, P14, DOI 10.1016/j.heares.2007.06.003; Thomas C, 1997, ELECTROEN CLIN NEURO, V102, P86, DOI 10.1016/S0921-884X(96)95653-2; Thulborn KR, 1999, STROKE, V30, P749, DOI 10.1161/01.STR.30.4.749; Walsh V, 2000, NAT REV NEUROSCI, V1, P73, DOI 10.1038/35036239; Weiss T, 2000, EXP BRAIN RES, V134, P199, DOI 10.1007/s002210000456; Werbos P.J., 1994, ROOTS BACKPROPAGATIO, VVolume 1; Wilms I, 2010, NEUROPSYCHOL REHABIL, V20, P830, DOI 10.1080/09602011.2010.492711; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Xerri C, 1996, J PHYSIOLOGY-PARIS, V90, P277, DOI 10.1016/S0928-4257(97)81438-6; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	108	28	28	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-1078			FRONT PSYCHOL	Front. Psychol.		2011	2								7	10.3389/fpsyg.2011.00007			10	Psychology, Multidisciplinary	Psychology	V31DG	WOS:000208863700019	21713186	DOAJ Gold, Green Published			2021-06-18	
J	Panczykowski, DM; Okonkwo, DO				Panczykowski, David M.; Okonkwo, David O.			Premorbid oral antithrombotic therapy and risk for reaccumulation, reoperation, and mortality in acute subdural hematomas Clinical article	JOURNAL OF NEUROSURGERY			English	Article						acute subdural hematoma; oral antithrombotic therapy; traumatic brain injury; neurological outcome	TRAUMATIC INTRACRANIAL HEMORRHAGE; ANTICOAGULANT-THERAPY; HEAD-INJURY; WARFARIN; OUTCOMES; COAGULOPATHY; ANTIPLATELET; PREDICTION; MANAGEMENT	Object. Acute subdural hematomas (SDHs) impart serious morbidity and mortality on the elderly population, with only 5% of those older than 65 years of age attaining functional independence. Despite its widespread use, oral antithrombotic therapy (OAT) in the context of acute SDH has not been extensively studied. The authors sought to evaluate the impact of premorbid OAT on recurrence of SDH, radiographic outcome, and mortality in patients undergoing surgical evacuation of an acute SDH. Methods. The authors conducted a retrospective comparative cohort study reviewing all surgically treated cases of acute SDH at their institution between September 2005 and December 2008. They assessed baseline demographics, coagulation parameters, surgical management, and clinical course. Study end points included additional craniotomy for SDH reaccumulation, follow-up Rotterdam score, recurrent SDH volumetric analysis, Glasgow Outcome Score, and death. Results. A total of 300 patients with acute SDH treated by craniotomy were assessed. Of these patients, 49% (148 patients) were receiving OAT. Of those who were on a regimen of OAT, 49% were taking warfarin (mean international normalized ratio 3.1 +/- 1.8), 31% were receiving antiplatelet therapy, and 20% were on a regimen of a combination of agents. On presentation, 72% of those using OAT received reversal agents. Recurrence of SDH necessitating additional evacuation was not significantly different with respect to premorbid OAT status (13% vs 14%). Patients with a history of OAT did not demonstrate a significant difference in Rotterdam score (2 vs 2), recurrent SDH volume (24.1 vs 19.6 cm(3)), GOS score (4 vs 3), or mortality (21% vs 24%). These findings remained stable after controlling for age, injury mechanism, and injury severity. Conclusions. Premorbid OAT was not a significant risk factor for recurrence of SDH necessitating additional evacuation following acute SDH. Additionally, postoperative Rotterdam score, volume of SDH reaccumulation, and overall mortality were not predicted by antithrombotic history. While prernorbid use may predispose the patient to an SDH, OAT does not increase the risk of morbidity or mortality following surgical intervention. (DOI: 10.3171/2010.7.JNS10446)	[Panczykowski, David M.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15213 USA	Okonkwo, DO (corresponding author), Univ Pittsburgh, Dept Neurol Surg, Med Ctr, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.	okonkwodo@upmc.edu					Aiyagari V, 2009, CURR OPIN CRIT CARE, V15, P87, DOI 10.1097/MCC.0b013e3283269e4d; Bershad EM, 2008, J NEUROSURG, V109, P664, DOI 10.3171/JNS/2008/109/10/0664; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Larson BJG, 2005, CHEST, V127, P922, DOI 10.1378/chest.127.3.922; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marion DW, 2006, NEUROSURGERY, V58, P655; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Oake N, 2008, CAN MED ASSOC J, V179, P235, DOI 10.1503/cmaj.080171; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Senft C, 2009, NEUROL RES, V31, P1012, DOI 10.1179/174313209X409034; Torn M, 2009, ARCH INTERN MED, V169, P1203, DOI 10.1001/archinternmed.2009.176; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	17	28	28	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2011	114	1					47	52		10.3171/2010.7.JNS10446			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	699NG	WOS:000285669500013	20722610				2021-06-18	
J	Pervin, F; Chen, WNW				Pervin, Farhana; Chen, Weinong W.			Effect of inter-species, gender, and breeding on the mechanical behavior of brain tissue	NEUROIMAGE			English	Article						Brain tissues; Species; Strain rates; Stress-strain; Kolsky Bar	HOPKINSON PRESSURE BAR	Mechanical response of brain tissue deforming at high rates are needed to build high-fidelity computer models for traumatic brain injury (TBI) studies. Different types of mammalian brains have been used to obtain the constitutive behavior of tissue. It is necessary to examine how these different brains compare to each other in order to determine which animal might be the best surrogate for human brain tissue. In this experimental study, fresh brain tissue from three different mammals, two types of porcine breeds, and genders were loaded under uniaxial compression over a wide range of strain rates. The experiments at higher rates were conducted with a Kolsky bar modified for soft tissue characterization, whereas lower rate experiments were performed on a conventional hydraulic material test frame. Experimental results did not show any significant difference in high-rate compressive response of the brain tissue of different animals, different breeds, and different genders. However, there was significant rate dependence for all tissues tested, especially in the Kolsky bar range. Further investigation is necessary to identify the source of the rate effects. (C) 2010 Elsevier Inc. All rights reserved.	[Chen, Weinong W.] Purdue Univ, Sch Aeronaut Astronaut, W Lafayette, IN 47907 USA; Purdue Univ, Sch Mat Engn, W Lafayette, IN 47907 USA	Chen, WNW (corresponding author), Purdue Univ, Sch Aeronaut Astronaut, 3323 Neil Armstrong Hall Engn,701 W Stadium Ave, W Lafayette, IN 47907 USA.	wchen@purdue.edu			US Army Research Office (ARO); Joint Improvised Explosive Device Defeat Organization (JIEDDO) through Massachusetts Institute of Technology (MIT)	This research was financially supported by US Army Research Office (ARO) and Joint Improvised Explosive Device Defeat Organization (JIEDDO) through Massachusetts Institute of Technology (MIT).	Atay SM, 2008, J BIOMECH ENG, V130, P1; BRANDS D. W. A., 2000, P STAPP CAR CRASH C, V44, P249; Brands D.W.A., 2002, THESIS U EINDHOVEN E; Casem D, 2005, EXP MECH, V45, P368, DOI 10.1177/0014485105056090; Chen W, 1999, EXP MECH, V39, P81, DOI 10.1007/BF02331109; Chen W, 2000, EXP MECH, V40, P1, DOI 10.1007/BF02327540; Darvish K., 2003, STAPP CAR CRASH J, V47, P79; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; ESTES M, 1970, P 4 ASME BIOM C, P1; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Frew DJ, 2001, EXP MECH, V41, P40, DOI 10.1007/BF02323102; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gray III G.T., 2000, ASM HDB, V8, P488, DOI [10.31399/asm.hb.v08, DOI 10.31399/ASM.HB.V08]; McElhaney JH, 1973, PERSPECTIVES BIOMEDI, P215, DOI DOI 10.1007/978-1-349-01604-4_34; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prange M T, 2000, Stapp Car Crash J, V44, P205; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]	23	28	28	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	JAN	2011	54			1			S98	S102		10.1016/j.neuroimage.2010.03.077			5	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	813ZF	WOS:000294408600014	20362684				2021-06-18	
J	Prabhu, SP				Prabhu, Sanjay P.			The Role of Neuroimaging in Sport-Related Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Concussion; Neuroimaging; Sport-related	TRAUMATIC BRAIN-INJURY; PROTON MR SPECTROSCOPY; WHITE-MATTER; OUTCOME PREDICTION; MILD; ABNORMALITIES; IMPAIRMENT; PERFUSION; ISCHEMIA; ATLAS	This article describes some of the newer techniques that are being used in the clinical assessment of patients following mild to moderate TBI, addresses their use in the acute setting, and explores their potential role in long-term follow-up. Also addressed are the challenges faced before some of these newer techniques can be incorporated into routine clinical management. Large studies are needed with a special emphasis on the effects of repeated head trauma in the young athlete. This is especially relevant where conventional imaging does not demonstrate a macroscopic abnormality. The emphasis has to shift from identifying structural abnormalities on imaging studies to understanding the functional changes in the brain that may explain the long-term neuropsychological effects of concussion and mTBI.	[Prabhu, Sanjay P.] Childrens Hosp Boston, Dept Radiol, Div Neuroradiol, Boston, MA 02115 USA; [Prabhu, Sanjay P.] Harvard Univ, Sch Med, Boston, MA 02115 USA	Prabhu, SP (corresponding author), Childrens Hosp, Dept Radiol, 300 Longwood Ave, Boston, MA 02115 USA.	sanjay.prabhu@childrens.harvard.edu	PRABHU, SANJAY/A-9947-2013	PRABHU, SANJAY/0000-0003-0871-115X			Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Barnes SRS, 2009, MAGN RESON IMAGING C, V17, P47, DOI 10.1016/j.mric.2008.12.002; Bigler ED, 2001, INVEST RADIOL, V36, P539, DOI 10.1097/00004424-200109000-00006; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Easdon C, 2004, BRAIN COGNITION, V54, P136; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Greer DM, 2009, CRIT CARE MED, V37, P1523, DOI 10.1097/CCM.0b013e31819d2df2; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hofmann M, 2008, J NUCL MED, V49, P1875, DOI 10.2967/jnumed.107.049353; Jellison BJ, 2004, AM J NEURORADIOL, V25, P356; Kawai N, 2008, ACTA NEUROCHIR SUPPL, V102, P241, DOI 10.1007/978-3-211-85578-2_46; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mader I, 2008, EUR J RADIOL, V67, P250, DOI 10.1016/j.ejrad.2008.02.033; Martuzzi R, 2010, NEUROIMAGE, V49, P823, DOI 10.1016/j.neuroimage.2009.07.028; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Silver JM, 2005, TXB TRAUMATIC BRAIN; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Ziegler A, 2002, MAGN RESON MATER PHY, V14, P45, DOI 10.1016/S1352-8661(01)00156-9	42	28	28	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					103	+		10.1016/j.csm.2010.09.003			13	Sport Sciences	Sport Sciences	691XR	WOS:000285114800010	21074085				2021-06-18	
J	Serrano-Perez, MC; Martin, ED; Vaquero, CF; Azcoitia, I; Calvo, S; Cano, E; Tranque, P				Serrano-Perez, Maria C.; Martin, Eduardo D.; Vaquero, Cecilia F.; Azcoitia, Inigo; Calvo, Soledad; Cano, Eva; Tranque, Pedro			Response of Transcription Factor NFATc3 to Excitotoxic and Traumatic Brain Insults: Identification of a Subpopulation of Reactive Astrocytes	GLIA			English	Article						astrogliosis; glia; brain lesion; glial scar; neuroinflammation	NUCLEAR ACCUMULATION; GENE-EXPRESSION; GLIAL-CELLS; KAINIC ACID; CALCINEURIN; ACTIVATION; CYCLOOXYGENASE-2; INDUCTION; PROTEINS; CALCIUM	Astrocytes react to brain injury triggering neuroinflammatory processes that determine the degree of neuronal damage. However, the signaling events associated to astrocyte activation remain largely undefined. The nuclear factor of activated T-cells (NFAT) is a transcription factor family implicated in activation of immune cells. We previously characterized the expression of NFAT isoforms in cultured astrocytes, and NFAT activation in response to mechanical lesion. Here we analyze NFATc3 in two mouse models of inflammatory brain damage: hippocampal excitotoxicity induced by intracerebral kainic acid (KA) injection and cortical mechanical lesion. Immunofluorescence results demonstrated that NFATc3 is specifically induced in a subset of reactive astrocytes, and not in microglia or neurons. In KA-treated brains, NFATc3 expression is transient and NFATc3-positive astrocytes concentrate around damaged neurons in areas CA3 and CA1. Complementary Western blot and RT-PCR analysis revealed an NFAT-dependent induction of RCAN1-4 and COX-2 in hippocampus as soon as 6 h after KA exposure, indicating that NFAT activation precedes NFATc3 over-expression. Moreover, activation of NFAT by ATP increased NFATc3 mRNA levels in astrocyte cultures, suggesting that NFATc3 expression is controlled through an auto-regulatory loop. Meanwhile, stab wound enhanced NFATc3 expression specifically in a subclass of reactive astrocytes confined within the proximal layer of the glial scar, and GFAP immunoreactivity was attenuated in NFATc3-expressing astrocytes. In conclusion, our work establishes NFATc3 as a marker of activation for a specific population of astrocytes in response to brain damage, which may have consequences for neuronal survival. (C) 2010 Wiley-Liss, Inc.	[Tranque, Pedro] Univ Castilla La Mancha, Inst Invest Discapacidades Neurol IDINE, Fac Med, Albacete 02006, Spain; [Vaquero, Cecilia F.] Univ Castilla La Mancha, CRIB, Albacete 02006, Spain; [Azcoitia, Inigo] Univ Complutense, Fac Biol, Dept Biol Celular, Madrid, Spain; [Cano, Eva] Inst Salud Carlos III, Area Biol Celular & Desarrollo, Ctr Nacl Microbiol, Unidad Neuroinflamac, Madrid, Spain	Tranque, P (corresponding author), Univ Castilla La Mancha, Inst Invest Discapacidades Neurol IDINE, Fac Med, Av Almansa 14, Albacete 02006, Spain.	pedro.tranque@uclm.es	Romo, Jose A./J-3024-2012; Azcoitia, Inigo/A-6208-2011; Cano, Eva/A-2049-2010; Martin, Eduardo D./V-3344-2017	Romo, Jose A./0000-0003-2907-580X; Azcoitia, Inigo/0000-0002-5791-9144; Cano, Eva/0000-0003-2750-6135; Martin, Eduardo D./0000-0003-1768-3488; Fernandez Vaquero, Cecilia/0000-0002-7415-9060; Tranque Gomez, Pedro Antonio/0000-0003-1072-7337	MICINNSpanish GovernmentEuropean Commission [SAF2009-12869]; CEC-JCCM [PII1I09-0092-30]; FISInstituto de Salud Carlos III [PI09/218]	Grant sponsor: MICINN; Grant number: SAF2009-12869; Grant sponsor: CEC-JCCM; Grant number: PII1I09-0092-30; Grant sponsor: FIS; Grant number: PI09/218.	Abbracchio Maria P, 2006, Purinergic Signal, V2, P595, DOI 10.1007/s11302-006-9016-0; Abdul Hafiz Mohmmad, 2010, Mol Cell Pharmacol, V2, P7; Abdul HM, 2009, J NEUROSCI, V29, P12957, DOI 10.1523/JNEUROSCI.1064-09.2009; Aramburu J, 2004, EMBO REP, V5, P343, DOI 10.1038/sj.embor.7400133; Blanco A, 2008, J IMMUNOL, V180, P530, DOI 10.4049/jimmunol.180.1.530; Blom MAA, 1997, BRAIN RES, V777, P210, DOI 10.1016/S0006-8993(97)01204-3; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Canellada A, 2008, GLIA, V56, P709, DOI 10.1002/glia.20647; Cano E, 2005, J BIOL CHEM, V280, P29435, DOI 10.1074/jbc.M506205200; Che YZ, 2001, MOL BRAIN RES, V94, P157, DOI 10.1016/S0169-328X(01)00233-9; Chen ZG, 2002, BRAIN RES, V931, P135, DOI 10.1016/S0006-8993(02)02268-0; Cho IH, 2003, J NEUROSCI RES, V74, P736, DOI 10.1002/jnr.10794; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Davies KJA, 2007, FASEB J, V21, P3023, DOI 10.1096/fj.06-7246com; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026; Dienz O, 2007, P NATL ACAD SCI USA, V104, P7175, DOI 10.1073/pnas.0610442104; Fernandez AM, 2007, J NEUROSCI, V27, P8745, DOI 10.1523/JNEUROSCI.1002-07.2007; Filosa JA, 2007, AM J PHYSIOL-CELL PH, V293, pC1797, DOI 10.1152/ajpcell.00554.2006; FRANKLIN G, 2001, MOUSE BRAIN STEREOTA, P264; Friedman LK, 2006, MOL INTERV, V6, P315, DOI 10.1124/mi.6.6.5; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Graef IA, 2006, TRANSCRIPTION FACTOR, P353; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hua LWL, 2002, J NEUROIMMUNOL, V126, P180, DOI 10.1016/S0165-5728(02)00055-3; Jones EA, 2003, J NEUROSCI RES, V72, P191, DOI 10.1002/jnr.10584; Kao SC, 2009, SCIENCE, V323, P651, DOI 10.1126/science.1166562; Kuwahara K, 2006, J CLIN INVEST, V116, P3114, DOI 10.1172/JCI27702; Kyrkanides S, 2002, MOL BRAIN RES, V104, P159, DOI 10.1016/S0169-328X(02)00353-4; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lerma J, 2001, PHYSIOL REV, V81, P971; Liu QH, 2009, NAT CELL BIOL, V11, P154, DOI 10.1038/ncb1823; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lobsiger CS, 2007, NAT NEUROSCI, V10, P1355, DOI 10.1038/nn1988; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Matyash V, 2010, BRAIN RES REV, V63, P2, DOI 10.1016/j.brainresrev.2009.12.001; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nilsson LM, 2007, AM J PHYSIOL-CELL PH, V292, pC1167, DOI 10.1152/ajpcell.00590.2005; Norris CM, 2005, J NEUROSCI, V25, P4649, DOI 10.1523/JNEUROSCI.0365-05.2005; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Park HJ, 2008, EPILEPSIA, V49, P163, DOI 10.1111/j.1528-1167.2007.01308.x; Perez-Ortiz JM, 2004, J BIOL CHEM, V279, P8976, DOI 10.1074/jbc.M308518200; Perez-Ortiz JM, 2008, EUR J NEUROSCI, V27, P2453, DOI 10.1111/j.1460-9568.2008.06197.x; Renault-Mihara F, 2008, INT J BIOCHEM CELL B, V40, P1649, DOI 10.1016/j.biocel.2008.03.009; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Sama MA, 2008, J BIOL CHEM, V283, P21953, DOI 10.1074/jbc.M800148200; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schwarcz R, 2008, EPILEPSIA, V49, P1, DOI 10.1111/j.1528-1167.2008.01487.x; Serfling E, 2006, TRENDS IMMUNOL, V27, P461, DOI 10.1016/j.it.2006.08.005; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Weigmann B, 2008, J EXP MED, V205, P2099, DOI 10.1084/jem.20072484; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Zhou B, 2002, J BIOL CHEM, V277, P10704, DOI 10.1074/jbc.M107068200	63	28	28	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JAN	2011	59	1					94	107		10.1002/glia.21079			14	Neurosciences	Neurosciences & Neurology	693FL	WOS:000285209900009	20967884				2021-06-18	
J	Riggio, S				Riggio, Silvana			Traumatic Brain Injury and Its Neurobehavioral Sequelae	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Postconcussive syndrome; Neuropsychiatric disorders; Frontal lobe seizures	POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; CHRONIC PAIN; PSYCHIATRIC-DISORDERS; SYMPTOMS; FATIGUE; ASSOCIATION; PREVALENCE; CONCUSSION; DISABILITY	The neurobehavioral sequelae (NBS) of traumatic brain injury (TBI) consist of a spectrum of somatic neurological and psychiatric symptoms The challenge for clinicians lies in understanding the interface of the various symptoms and how they interrelate with other entities Specifically, the challenge is differentiating post-TBI-related symptoms from pre-existing or de novo psychiatric neurological and/or systemic disorders A comprehensive evaluation and a multidisciplinary approach to evaluating patients are essential to be able to develop the differential diagnosis needed to design a management plan that maximizes recovery	[Riggio, Silvana] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; [Riggio, Silvana] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Riggio, Silvana] James J Peters VAMC, Dept Psychiat, Bronx, NY USA	Riggio, S (corresponding author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.						Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Greve KW, 2001, BRAIN INJURY, V15, P255; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCracken LM, 2001, J PAIN SYMPTOM MANAG, V21, P392, DOI 10.1016/S0885-3924(01)00267-6; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Quesney LF, 1986, RECENT ADV EPILEPSY, V3, P81; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; RIGGIO S, 1995, ADV NEUROL, V66, P153; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Ruff RM, 1996, BRAIN INJURY, V8, P61; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316	46	28	28	1	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	DEC	2010	33	4					807	+		10.1016/j.psc.2010.08.004			14	Psychiatry	Psychiatry	694TA	WOS:000285320700006	21093680				2021-06-18	
J	Weiss, H; Agimi, Y; Steiner, C				Weiss, Harold; Agimi, Yll; Steiner, Claudia			Youth Motorcycle-Related Brain Injury by State Helmet Law Type: United States, 2005-2007	PEDIATRICS			English	Article						hospitalizations; hospital discharges; motorcycle; motorcycle helmets; helmet laws; scooters; traffic accidents; non-traffic accidents; adolescents; injury; traumatic brain injury; injury severity	HEAD-INJURIES; HOSPITALIZATIONS; LEGISLATION	BACKGROUND AND OBJECTIVES: Twenty-seven states have youth-specific helmet laws even though such laws have been shown to decrease helmet use and increase youth mortality compared with all-age (universal) laws. Our goal was to quantify the impact of age-specific helmet laws on youth under age 20 hospitalized with traumatic brain injury (TBI). METHODS: Our cross-sectional ecological group analysis compared TBI proportions among US states with different helmet laws. We examined the following null hypothesis: If age-specific helmet laws are as effective as universal laws, there will be no difference in the proportion of hospitalized young motorcycle riders with TBI in the respective states. The data are derived from the 2005 to 2007 State Inpatient Databases of the Healthcare Cost and Utilization Project. We examined data for 17 states with universal laws, 6 states with laws for ages <21, and 12 states with laws for children younger than 18 (9287 motorcycle injury discharges). RESULTS: In states with a <21 law, serious TBI among youth was 38% higher than in universal-law states. Motorcycle riders aged 12 to 17 in 18 helmet-law states had a higher proportion of serious/severe TBI and higher average Abbreviated Injury Scores for head-region injuries than riders from universal-law states. CONCLUSIONS: States with youth-specific laws had an increased risk of TBI that required hospitalization, serious and severe TBI, TBI-related disability, and in-hospital death among the youth they are supposed to protect. The only method known to keep motorcycle-helmet use high among youth is to adopt or maintain universal helmet laws. Pediatrics 2010;126:1149-1155	[Weiss, Harold] Univ Pittsburgh, Ctr Injury Res & Control, Pittsburgh, PA USA; [Agimi, Yll] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA; [Agimi, Yll] Assoc Sch Publ Hlth, Washington, DC USA; [Steiner, Claudia] Ctr Delivery Org & Markets Agcy Healthcare Res &, Rockville, MD USA	Weiss, H (corresponding author), POB 56, Dunedin 9054, New Zealand.	hw@injurycontrol.com	AGIMI, YLL/AAL-9337-2021				Agency for Healthcare Research and Quality, OV STAT INP DAT SID; Agency for Healthcare Research and Quality, APP A CLIN CLASS SOF; *AM MOT ASS, STAT MOT LAWS; Beck LF, 2007, AM J EPIDEMIOL, V166, P212, DOI 10.1093/aje/kwm064; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Butler J, 2001, CENTRAL NERVOUS SYST; Centers for Disease Control and Prevention, WISQARS INJ MORT REP; CLARK DE, 2008, 9 WORLD C INJ PREV S; Coben JH, 2007, ACCIDENT ANAL PREV, V39, P190, DOI 10.1016/j.aap.2006.06.018; Hagel B, 2006, BMJ-BRIT MED J, V332, P725, DOI 10.1136/bmj.332.7543.725; HEILMAN DR, 1982, ANN EMERG MED, V11, P659, DOI 10.1016/S0196-0644(82)80258-8; Hingson R, 2001, INJURY CONTROL, P157; Houston DJ, 2007, J SAFETY RES, V38, P329, DOI 10.1016/j.jsr.2007.05.002; *INS I HIGHW SAF, Q AS MOT HELM US LAW; Kyrychenko Sergey Y, 2006, Traffic Inj Prev, V7, P55, DOI 10.1080/15389580500377833; Liu BC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004333.pub3; Macpherson AK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e60; Mertz KJ, 2008, AM J PUBLIC HEALTH, V98, P1464, DOI 10.2105/AJPH.2007.123299; Mullin B, 2000, Inj Prev, V6, P32, DOI 10.1136/ip.6.1.32; *NAT C STAT LEG, STAT TRAFF SAF LEG T; *NAT CTR HLTH STAT, BAR INJ DIAGN MATR F; *NAT TRANSP SAF BO, 2007, SAF REC; National Highway Traffic Safety Administration, TRAFF SAF FACTS 2007; Robinson DL, 2006, BMJ-BRIT MED J, V332, P722, DOI 10.1136/bmj.332.7543.722-a; Ross H. L., 1982, DETERRING DRINKING D; Scuffham P, 2000, ACCIDENT ANAL PREV, V32, P565, DOI 10.1016/S0001-4575(99)00081-0; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Ulmer R, 2005, 809849 DOT HS NAT HI; US General Accounting Office, 1991, HIGHW SAF MOT HELM L; Weiss H, 2010, PEDIATRICS, V126, P1141, DOI 10.1542/peds.2010-0271; Zambon F, 2006, ACCIDENT ANAL PREV, V38, P1183, DOI 10.1016/j.aap.2006.05.005	31	28	30	0	8	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	DEC	2010	126	6					1149	1155		10.1542/peds.2010-0902			7	Pediatrics	Pediatrics	688EF	WOS:000284831900041	21078726	Bronze			2021-06-18	
J	Khadr, SN; Crofton, PM; Jones, PA; Wardhaugh, B; Roach, J; Drake, AJ; Minns, RA; Kelnar, CJH				Khadr, Sophie N.; Crofton, Patricia M.; Jones, Patricia A.; Wardhaugh, Barbara; Roach, Jennifer; Drake, Amanda J.; Minns, Robert A.; Kelnar, Christopher J. H.			Evaluation of pituitary function after traumatic brain injury in childhood	CLINICAL ENDOCRINOLOGY			English	Article							GROWTH-HORMONE; CONSENSUS GUIDELINES; CORTISOL RESPONSE; PROVOCATIVE TESTS; REFERENCE CURVES; DYSFUNCTION; DIAGNOSIS; UK; HYPOGLYCEMIA; DEFICIENCY	Objectives Post-traumatic hypopituitarism is well described amongst adult traumatic brain injury (TBI) survivors. We aimed to determine the prevalence and clinical significance of pituitary dysfunction after head injury in childhood. Design Retrospective exploratory study. Patients: 33 survivors of accidental head injury (27 boys). Mean (range) age at study was 13.4 years (5.4-21.7 years) and median (range) interval since injury 4.3 years (1.4-7.8 years). Functional outcome at study: 15 good recovery, 16 moderate disability, two severe disability. Measurements Early morning urine osmolality and basal hormone evaluation were followed by the gonadotrophin releasing hormone (GnRH) and insulin tolerance (n = 25) or glucagon tests (if previous seizures, n = 8). Subjects were not primed. Head injury details were extracted from patient records. Results No subject had short stature (mean height SD score +0.50, range -1.57 to +3.00). Suboptimal GH responses (<5 mu g/l) occurred in six peri-pubertal boys (one with slow growth on follow-up) and one postpubertal adolescent (peak GH 3.2 mu g/l). Median peak cortisol responses to insulin tolerance or glucagon tests were 538 and 562 nm. Nine of twenty-five and two of eight subjects had suboptimal responses, respectively, two with high basal cortisol levels. None required routine glucocorticoid replacement. In three, steroid cover was recommended for moderate/severe illness or injury. One boy was prolactin deficient. Other basal endocrine results and GnRH-stimulated LH and FSH were appropriate for age, sex and pubertal stage. Abnormal endocrine findings were unrelated to the severity or other characteristics of TBI or functional outcome. Conclusions No clinically significant endocrinopathy was identified amongst survivors of accidental childhood TBI, although minor pituitary hormone abnormalities were observed.	[Khadr, Sophie N.; Jones, Patricia A.; Drake, Amanda J.; Minns, Robert A.; Kelnar, Christopher J. H.] Univ Edinburgh, Sect Child Life & Hlth, Edinburgh, Midlothian, Scotland; [Crofton, Patricia M.; Wardhaugh, Barbara; Roach, Jennifer] Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland; Univ Edinburgh, Dept Child Life & Hlth, Edinburgh, Midlothian, Scotland	Khadr, SN (corresponding author), UCL Inst Child Hlth, Gen & Adolescent Paediat Unit, 30 Guilford St, London WC1N 3EH, England.	s.khadr@ich.ucl.ac.uk			Novo NordiskNovo Nordisk	The research was supported by a grant from Novo Nordisk.	Acerini CL, 2008, J PEDIATR ENDOCR MET, V21, P611; Agha A, 2004, CLIN ENDOCRINOL, V60, P688, DOI 10.1111/j.1365-2265.2004.02035.x; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Aimaretti G, 2000, EUR J ENDOCRINOL, V142, P347, DOI 10.1530/eje.0.1420347; Amed S, 2008, HORM RES, V69, P290, DOI 10.1159/000114860; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; Clayton PE, 2005, EUR J ENDOCRINOL, V152, P165, DOI 10.1530/eje.1.01829; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Crofton PM, 2004, HORM RES, V61, P92, DOI 10.1159/000075339; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Ghigo E, 1996, J CLIN ENDOCR METAB, V81, P3323, DOI 10.1210/jc.81.9.3323; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Lazar L, 2010, HORM RES PAEDIAT, V73, P299, DOI 10.1159/000284396; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martinez AS, 2000, J CLIN ENDOCR METAB, V85, P4168, DOI 10.1210/jc.85.11.4168; *NAT I HLTH CLIN E, 2003, 64 NAT I HLTH CLIN E; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Paisley AN, 2009, J CLIN ENDOCR METAB, V94, P1757, DOI 10.1210/jc.2008-2392; Pfeifer M, 2001, CLIN ENDOCRINOL, V54, P17, DOI 10.1046/j.1365-2265.2001.01179.x; Poomthavorn P, 2008, ARCH DIS CHILD, V93, P133, DOI 10.1136/adc.2007.121137; Reynolds RM, 2006, CLIN ENDOCRINOL, V64, P82, DOI 10.1111/j.1365-2265.2005.02421.x; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Sizonenko PC, 2001, GROWTH HORM IGF RES, V11, P137, DOI 10.1054/ghir.2001.0203; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; TEASDALE G, 1974, LANCET, V2, P81; Yeste D, 2007, HORM RES, V67, P42, DOI 10.1159/000096055; Zevenhuijzena H, 2004, HORM RES, V62, P168, DOI 10.1159/000080324	35	28	28	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	NOV	2010	73	5					637	644		10.1111/j.1365-2265.2010.03857.x			8	Endocrinology & Metabolism	Endocrinology & Metabolism	660IY	WOS:000282635000012	20681995				2021-06-18	
J	Pietrzak, RH; Morgan, CA; Southwick, SM				Pietrzak, Robert H.; Morgan, Charles A., III; Southwick, Steven M.			Sleep quality in treatment-seeking veterans of Operations Enduring Freedom and Iraqi Freedom: The role of cognitive coping strategies and unit cohesion	JOURNAL OF PSYCHOSOMATIC RESEARCH			English	Article						Veterans; Combat; Posttraumatic stress disorder; Sleep; Social support; Coping	POSTTRAUMATIC-STRESS-DISORDER; THOUGHT CONTROL QUESTIONNAIRE; TRAUMATIC BRAIN-INJURY; RANDOMIZED CLINICAL-TRIAL; SOCIAL SUPPORT; BEHAVIORAL THERAPY; UNWANTED THOUGHTS; PRIMARY INSOMNIA; MENTAL-HEALTH; DISTURBANCE	Objective: Sleep difficulties are common in individuals exposed to stress or trauma, and maladaptive cognitive coping strategies, such as worry and fear of losing vigilance, as well as low social support, may further impair sleep quality. This study examined the severity and correlates of sleep difficulties in a sample of treatment-seeking veterans of Operations Enduring Freedom and Iraqi Freedom (OEF-OIF). Method: A total of 167 OEF-OIF veterans seeking behavioral or primary care services completed a questionnaire containing measures of sleep quality, combat exposure, psychopathology, fear of loss of vigilance, cognitive coping strategies, and unit and postdeployment social support within I year of returning from deployment. Results: Mean Pittsburgh Sleep Quality Inventory scores in the full sample were indicative of severely impaired sleep. Posttraumatic stress disorder (PTSD) was associated with increased sleep difficulties, most notably sleep disturbances, daytime dysfunction, and sleep quality. Hierarchical regression analysis in the full sample revealed that PTSD symptoms and scores on measures of worry and fear of loss of vigilance were positively associated with sleep difficulties and that scores on a measure of unit member support were negatively associated with sleep difficulties. Among veterans with PTSD, fear of loss of vigilance was positively associated with sleep difficulties and cognitive distraction and unit member support were negatively associated with sleep difficulties. Conclusions: Treatment-seeking OEF-OIF veterans report severe sleep difficulties, with more pronounced impairment in veterans with PTSD. The results of this study suggest that interventions to mitigate worry and fear of loss of vigilance and to enhance perceived unit member support may be helpful in reducing sleep difficulties following return from deployment in this population. (C) 2010 Elsevier Inc. All rights reserved.	[Pietrzak, Robert H.; Morgan, Charles A., III; Southwick, Steven M.] VA Connecticut Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, Resilience Lab, West Haven, CT 06516 USA; [Pietrzak, Robert H.; Morgan, Charles A., III; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA	Pietrzak, RH (corresponding author), VA Connecticut Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, Resilience Lab, 950 Campbell Ave 151E, West Haven, CT 06516 USA.	robert.pietrzak@yale.edu			Clinical Neurosciences Division of the National Center for Posttraumatic Stress Disorder	This work was supported by the Clinical Neurosciences Division of the National Center for Posttraumatic Stress Disorder and a private donation. These funding sources had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. We thank the veterans who volunteered to participate in this survey. We appreciate the assistance of Amanda Russo, BA, Alison Rivers, BA, and Alicia Christensen, BA, in collecting and managing the data.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barahmand U, 2009, PSYCHIAT RES, V169, P240, DOI 10.1016/j.psychres.2008.06.029; Bazargan M, 1996, INT J AGING HUM DEV, V42, P143, DOI 10.2190/GM89-NRTY-DERQ-LC7D; Bennett SA, 2009, BEHAV RES THER, V47, P1018, DOI 10.1016/j.brat.2009.07.015; Brummett BH, 2006, HEALTH PSYCHOL, V25, P220, DOI 10.1037/0278-6133.25.2.220; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Davis JL, 2007, J TRAUMA STRESS, V20, P123, DOI 10.1002/jts.20199; Edinger JD, 2009, SLEEP, V32, P499, DOI 10.1093/sleep/32.4.499; Edinger JD, 2001, JAMA-J AM MED ASSOC, V285, P1856, DOI 10.1001/jama.285.14.1856; Ellis Jason, 2002, Sleep Med, V3, P393, DOI 10.1016/S1389-9457(02)00039-4; EWING JA, 1984, CAGE QUESTIONNAIRE J, V252, P1905; Fabsitz RR, 1997, J SLEEP RES, V6, P50, DOI 10.1046/j.1365-2869.1997.00026.x; Gadinger MC, 2009, J SLEEP RES, V18, P229, DOI 10.1111/j.1365-2869.2008.00715.x; Germain A, 2005, J ANXIETY DISORD, V19, P233, DOI 10.1016/j.janxdis.2004.02.001; Gold MA, 2000, MIL MED, V165, P147; Guthrie R, 2000, BEHAV RES THER, V38, P899, DOI 10.1016/S0005-7967(99)00120-5; Harvey AG, 2003, CLIN PSYCHOL REV, V23, P377, DOI 10.1016/S0272-7358(03)00032-1; Harvey AG, 2002, BEHAV RES THER, V40, P869, DOI 10.1016/S0005-7967(01)00061-4; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Inman D. J., 1990, J TRAUMA STRESS, V3, P429, DOI [10.1002/jts.2490030311, DOI 10.1007/BF00974782]; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Lamarche LJ, 2007, J CLIN PSYCHIAT, V68, P1257, DOI 10.4088/JCP.v68n0813; Lewis V, 2009, MIL MED, V174, P948, DOI 10.7205/MILMED-D-04-0208; Lu M, 2009, J TRAUMA STRESS, V22, P236, DOI 10.1002/jts.20407; Maher MJ, 2006, CNS DRUGS, V20, P567, DOI 10.2165/00023210-200620070-00003; Mayou RA, 2002, BEHAV RES THER, V40, P665, DOI 10.1016/S0005-7967(01)00069-9; MELLMAN TA, 1995, BIOL PSYCHIAT, V38, P174, DOI 10.1016/0006-3223(94)00238-X; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P110; Morin CM, 2007, SLEEP, V30, P1547, DOI 10.1093/sleep/30.11.1547; Murray J, 2002, BRIT J PSYCHIAT, V180, P363, DOI 10.1192/bjp.180.4.363; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Nomura K, 2009, SLEEP MED, V10, P626, DOI 10.1016/j.sleep.2008.06.010; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Pietrzak RH, 2010, J AFFECT DISORDERS, V120, P188, DOI 10.1016/j.jad.2009.04.015; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P745, DOI 10.1002/da.20558; Pillar G, 2000, SLEEP MED REV, V4, P183, DOI 10.1053/smrv.1999.0095; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Ree MJ, 2005, BEHAV RES THER, V43, P985, DOI 10.1016/j.brat.2004.07.003; Reynolds M, 1999, PSYCHOL MED, V29, P1089, DOI 10.1017/S003329179900104X; Ritterband LM, 2009, ARCH GEN PSYCHIAT, V66, P692, DOI 10.1001/archgenpsychiatry.2009.66; Rona RJ, 2009, J TRAUMA STRESS, V22, P11, DOI 10.1002/jts.20383; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Scarpa A, 2009, BEHAV RES THER, V47, P809, DOI 10.1016/j.brat.2009.06.002; Singareddy Ravi Kumar, 2002, Ann Clin Psychiatry, V14, P183, DOI 10.3109/10401230209147455; Spoormaker VI, 2008, SLEEP MED REV, V12, P169, DOI 10.1016/j.smrv.2007.08.008; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thompson CE, 2008, J TRAUMA STRESS, V21, P417, DOI 10.1002/jts.20351; Tsao JCI, 2003, DEPRESS ANXIETY, V18, P177, DOI 10.1002/da.10074; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Warda G, 1998, BEHAV RES THER, V36, P1171, DOI 10.1016/S0005-7967(98)00082-5; WATTS FN, 1994, BRIT J CLIN PSYCHOL, V33, P211, DOI 10.1111/j.2044-8260.1994.tb01115.x; Weathers F., 1991, PTSD CHECKLIST MILIT; WELLS A, 1994, BEHAV RES THER, V32, P871, DOI 10.1016/0005-7967(94)90168-6; Zeitlhofer J, 2000, ACTA NEUROL SCAND, V102, P249, DOI 10.1034/j.1600-0404.2000.102004249.x	57	28	28	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3999			J PSYCHOSOM RES	J. Psychosomat. Res.	NOV	2010	69	5					441	448		10.1016/j.jpsychores.2010.07.002			8	Psychiatry	Psychiatry	675LD	WOS:000283831300002	20955863				2021-06-18	
J	Schober, ME; Block, B; Beachy, JC; Statler, KD; Giza, CC; Lane, RH				Schober, Michelle E.; Block, Benjamin; Beachy, Joanna C.; Statler, Kimberly D.; Giza, Christopher C.; Lane, Robert H.			Early and Sustained Increase in the Expression of Hippocampal IGF-1, But Not EPO, in a Developmental Rodent Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; controlled cortical impact; erythropoietin receptor; insulin-like growth factor-1 receptor; neurocognitive impairment	GROWTH-FACTOR-I; CONTROLLED CORTICAL IMPACT; RAT-BRAIN; GENE-EXPRESSION; IMMATURE RATS; APOPTOTIC NEURODEGENERATION; PROTEIN EXPRESSION; NERVOUS-SYSTEM; MESSENGER-RNA; CELL-DEATH	Pediatric traumatic brain injury (pTBI) is the leading cause of traumatic death and disability in children in the United States. Impaired learning and memory in these young survivors imposes a heavy toll on society. In adult TBI (aTBI) models, cognitive outcome improved after administration of erythropoietin (EPO) or insulin-like growth factor-1 (IGF-1). Little is known about the production of these agents in the hippocampus, a brain region critical for learning and memory, after pTBI. Our objective was to describe hippocampal expression of EPO and IGF-1, together with their receptors (EPOR and IGF-1R, respectively), over time after pTBI in 17-day-old rats. We used the controlled cortical impact (CCI) model and measured hippocampal mRNA levels of EPO, IGF-1, EPOR, IGF-1R, and markers of caspase-dependent apoptosis (bcl2, bax, and p53) at post-injury days (PID) 1, 2, 3, 7, and 14. CCI rats performed poorly on Morris water maze testing of spatial working memory, a hippocampally-based cognitive function. Apoptotic markers were present early and persisted for the duration of the study. EPO in our pTBI model increased much later (PID7) than in aTBI models (12 h), while EPOR and IGF-1 increased at PID1 and PID2, respectively, similar to data from aTBI models. Our data indicate that EPO expression showed a delayed upregulation post-pTBI, while EPOR increased early. We speculate that administration of EPO in the first 1-2 days after pTBI would increase hippocampal neuronal survival and function.	[Schober, Michelle E.; Statler, Kimberly D.] Univ Utah, Sch Med, Div Crit Care, Dept Pediat, Salt Lake City, UT 84158 USA; [Block, Benjamin; Beachy, Joanna C.; Lane, Robert H.] Univ Utah, Sch Med, Div Neonatol, Salt Lake City, UT 84158 USA; [Statler, Kimberly D.] Univ Utah, Inst Brain, Salt Lake City, UT 84158 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Brain Injury Res Ctr, Div Pediat Neurol, Los Angeles, CA USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA	Schober, ME (corresponding author), Univ Utah, Sch Med, Div Crit Care, Dept Pediat, POB 581289, Salt Lake City, UT 84158 USA.	michelle.schober@hsc.utah.edu			Primary Children's Medical Center Foundation; Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Utah, Salt Lake City, Utah; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001410] Funding Source: NIH RePORTER	Funding for this study was provided by the Primary Children's Medical Center Foundation and the Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Utah, Salt Lake City, Utah.	Adelson PD, 1998, ACT NEUR S, V71, P104; Agarwal MK, 2004, CELL CYCLE, V3, P205; Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI [10.1089/neu.2008.0765, 10.1089/neu.2008-0765]; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Bayly PV, 2006, BRAIN RES, V1107, P70, DOI 10.1016/j.brainres.2006.05.102; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; BREESE CR, 1994, NEUROSCIENCE, V63, P579, DOI 10.1016/0306-4522(94)90551-7; Cook JL, 1998, BRAIN RES PROTOC, V3, P1, DOI 10.1016/S1385-299X(98)00012-9; Dame C, 2001, BIOL NEONATE, V79, P228; Digicaylioglu M, 2004, P NATL ACAD SCI USA, V101, P9855, DOI 10.1073/pnas.0403172101; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; Hickey RW, 2007, PEDIATR RES, V62, P271, DOI 10.1203/PDR.0b013e3180db2902; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li XS, 1998, MOL BRAIN RES, V57, P92, DOI 10.1016/S0169-328X(98)00075-8; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; Ochalski PG, 2010, J NEUROTRAUM, V27, P647, DOI 10.1089/neu.2009.1142; OLCHOVSKY D, 1991, ENDOCRINOLOGY, V128, P923, DOI 10.1210/endo-128-2-923; Papaconstantinou J, 2005, MECH AGEING DEV, V126, P692, DOI 10.1016/j.mad.2005.01.002; Picha ME, 2006, GEN COMP ENDOCR, V147, P196, DOI 10.1016/j.ygcen.2005.12.020; Rao VLR, 2001, BRAIN RES, V911, P96; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; RINK A, 1995, AM J PATHOL, V147, P1575; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Russo VC, 2005, ENDOCR REV, V26, P916, DOI 10.1210/er.2004-0024; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sanchez PE, 2009, J COMP NEUROL, V514, P403, DOI 10.1002/cne.22020; Shah SA, 2006, EXP GERONTOL, V41, P1201, DOI 10.1016/j.exger.2006.07.006; Sola A, 2005, PEDIATR RES, V57, p110R, DOI 10.1203/01.PDR.0000159571.50758.39; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Stansberg C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-94; Tsuru-Aoyagi K, 2009, ANN NEUROL, V65, P540, DOI 10.1002/ana.21600; Walter HJ, 1997, ENDOCRINOLOGY, V138, P3024, DOI 10.1210/en.138.7.3024; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Zhang J, 2007, J NEUROSCI RES, V85, P1618, DOI 10.1002/jnr.21289; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	48	28	28	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					2011	2020		10.1089/neu.2009.1226			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500008	20822461	Green Published			2021-06-18	
J	Ledwith, MB; Bloom, S; Maloney-Wilensky, E; Coyle, B; Polomano, RC; Le Roux, PD				Ledwith, Mary B.; Bloom, Stephanie; Maloney-Wilensky, Eileen; Coyle, Bernadette; Polomano, Rosemary C.; Le Roux, Peter D.			Effect of Body Position on Cerebral Oxygenation and Physiologic Parameters in Patients With Acute Neurological Conditions	JOURNAL OF NEUROSCIENCE NURSING			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; HEALTH-CARE PROFESSIONALS; SPECIAL WRITING GROUP; PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; STROKE-COUNCIL; BRAIN-INJURY; MANAGEMENT; GUIDELINES; STATEMENT	How body position influences brain tissue oxygen (PbtO(2)) and intracranial pressure (ICP) in critically ill neurosurgical patients remains poorly defined. In a prospective observational repeated measures study, we examined the effects of 12 different body positions on neurodynamic and hemodynamic outcomes. Thirty-three consecutive patients (mean +/- SD, age = 48.3 +/- 16.6 years; 22 men), admitted after traumatic brain injury, subarachnoid hemorrhage, or craniotomy for tumor, were evaluated in a neurocritical care unit at a level 1 academic trauma center. Patients were eligible if the admission score in the Glasgow Coma Scale was <= 8 and they had a Licox CMP Monitoring System (Integra Neurosciences, Plainsboro, NJ). Patients were exposed to all 12 positions in random order. Changes from baseline to the 15-minute postposition assessment mean change scores showed a downward trend for PbtO(2) for all positions with statistically significant decreases observed for supine head of bed (HOB) elevated 30 degrees and 45 degrees (p < .01) and right and left lateral positioning HOB 30 degrees (p < .05). ICP decreased with supine HOB 45 degrees (p < .01) and knee elevation, HOB 30 degrees and 45 degrees(p < .05), and increased (p < .05) with right and left lateral HOB 15 degrees. Hemodynamic parameters were similar in the various positions. Positioning practices can positively or negatively affect PbtO(2) and ICP and fluctuate with considerable variability among patients. Nurses must consider potential effects of turning, evaluate changes with positioning on the basis of monitoring feedback from multimodality devices, and make independent clinical judgments about optimal positions to maintain or improve cerebral oxygenation.	[Ledwith, Mary B.] Hosp Univ Penn, Neuro Intens Care Unit, Philadelphia, PA 19104 USA; [Maloney-Wilensky, Eileen] Univ Penn, Dept Neurosurg, Midlevel Provider Program, Philadelphia, PA 19104 USA; [Coyle, Bernadette] Hosp Univ Penn, Dept Nursing, Philadelphia, PA 19104 USA; [Polomano, Rosemary C.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA	Ledwith, MB (corresponding author), Hosp Univ Penn, Neuro Intens Care Unit, 3400 Spruce St, Philadelphia, PA 19104 USA.	ledwithm@uphs.upenn.edu			Mary Elisabeth Groff Surgical and Medical Research Trust; Integra Foundation; Integra Neuroscience; University of Pennsylvania	This work was supported, in part, by research grants from the Mary Elisabeth Groff Surgical and Medical Research Trust (PDLR), the Integra Foundation (PDLR), and the Integra Neuroscience (PDLR). The authors thank the Neuro ICU nurses at the University of Pennsylvania for their support; without their help, the study would not have been possible.	Albano C, 2005, CRIT CARE NURS Q, V28, P135, DOI 10.1097/00002727-200504000-00006; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Blissitt PA, 2006, AACN ADV CRIT CARE, V17, P327, DOI 10.1097/01256961-200607000-00012; *BRAIN TRAUM FDN, 2007, FACTS TBI US; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Christie Robert James, 2008, Br J Nurs, V17, P638; Fan Jun-Yu, 2004, J Neurosci Nurs, V36, P278; Griffiths H, 2005, Nurs Stand, V19, P56; HICKEY V, 2003, CLIN PRACTICE NEUROL, P288; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; Iacono L A, 2000, J Neurosci Nurs, V32, P54; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Littlejohns L, 2005, AACN ADV CRIT CARE, V16, P501, DOI 10.1097/00044067-200510000-00007; March K, 1990, J Neurosci Nurs, V22, P375; Marklew Anna, 2006, Nurs Crit Care, V11, P16; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; Meixensberger J, 1997, NEUROL RES, V19, P249, DOI 10.1080/01616412.1997.11740808; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Nekludov M, 2006, ACTA ANAESTH SCAND, V50, P932, DOI 10.1111/j.1399-6576.2006.01099.x; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; PHILLIPS DL, 2003, AUSTRALASIAN J NEURO, V16, P8; PHILLIPS DL, 2003, AUSTRALASIAN J NEURO, V16, P5; PHILLIPS DL, 2003, AUSTRALASIAN J NEURO, V16, P10; Price Ann M, 2003, Nurs Crit Care, V8, P126, DOI 10.1046/j.1478-5153.2003.00019.x; RAO GSU, 2007, INTERNET J ANESTHESI, V12, P11; Reinprecht A, 2003, CRIT CARE MED, V31, P1831, DOI 10.1097/01.CCM.0000063453.93855.0A; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Stocchetti N, 1998, ACT NEUR S, V71, P162; Sullivan J, 2000, J Neurosci Nurs, V32, P204; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Winkelman C, 2000, Am J Crit Care, V9, P373; Winn HR., 2004, MANAGEMENT CEREBRAL, P303; Wojner Anne W, 2002, Crit Care Nurs Q, V24, P57; Wong F W, 2000, Crit Care Nurse, V20, P18; Yanko J R, 2001, Crit Care Nurs Q, V23, P1	39	28	29	2	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0888-0395	1945-2810		J NEUROSCI NURS	J. Neurosci. Nurs.	OCT	2010	42	5					280	287		10.1097/JNN.0b013e3181ecafd4			8	Clinical Neurology; Nursing	Neurosciences & Neurology; Nursing	652PC	WOS:000282019200007	20968224				2021-06-18	
J	Booth-Kewley, S; Larson, GE; Highfill-McRoy, RM; Garland, CF; Gaskin, TA				Booth-Kewley, Stephanie; Larson, Gerald E.; Highfill-McRoy, Robyn M.; Garland, Cedric F.; Gaskin, Thomas A.			Factors Associated With Antisocial Behavior in Combat Veterans	AGGRESSIVE BEHAVIOR			English	Article						antisocial behavior; post-traumatic stress disorder; combat deployment; mental health	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; WAR ZONE STRESSORS; VIETNAM VETERANS; MENTAL-HEALTH; INTERNALIZING SUBTYPES; SYMPTOMS; IRAQ; DEPLOYMENT; EXPOSURE	The objective of this study was to identify factors associated with antisocial behavior in 1,543 Marines who deployed to combat zones in support of conflicts in Iraq and Afghanistan during 2002-2007. Five factors were associated with antisocial behavior in multivariate analyses: post-traumatic stress disorder (PTSD) symptoms, deployment-related stressors, combat exposure, younger age, and being divorced. PTSD symptoms had a stronger association with antisocial behavior than any other variable. A unique and important finding of this study was the association between deployment-related stressors and a higher incidence of antisocial behavior. Because deployment-related stressors are potentially modifiable, the military may be able to address them in concrete ways such as by shortening deployments and improving communication with home. Aggr. Behav. 36:330-337, 2010. Published 2010 by Wiley-Liss, Inc.(dagger)	[Booth-Kewley, Stephanie] USN, Hlth Res Ctr, Behav Sci & Epidemiol Dept, San Diego, CA 92106 USA; [Garland, Cedric F.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; [Garland, Cedric F.] Moores UCSD Canc Ctr, La Jolla, CA USA; [Gaskin, Thomas A.] US Marine Corps, Combat Operat Stress Control, Headquarters, Quantico, VA USA	Booth-Kewley, S (corresponding author), USN, Hlth Res Ctr, Behav Sci & Epidemiol Dept, 140 Sylvester Rd, San Diego, CA 92106 USA.	stephanie.kewley@med.navy.mil			Headquarters, Marine Corps (Combat Operational Stress Control)	Grant sponsor: Headquarters, Marine Corps (Combat Operational Stress Control).; This study was funded by Headquarters, Marine Corps (Combat Operational Stress Control), under Work Unit 60518 at Naval Health Research Center.	Barrett DH, 1996, J ABNORM PSYCHOL, V105, P575, DOI 10.1037/0021-843X.105.4.575; Bartone PT, 1998, MIL MED, V163, P587; Beckham JC, 1997, J CLIN PSYCHOL, V53, P859, DOI 10.1002/(SICI)1097-4679(199712)53:8<859::AID-JCLP11>3.0.CO;2-J; Booth-Kewley S, 2010, J TRAUMA STRESS, V23, P69, DOI 10.1002/jts.20485; BRAY RM, 2006, RTI7841106FR; Engelhard IM, 2007, CAN J PSYCHIAT, V52, P505, DOI 10.1177/070674370705200808; Fontana A, 2005, J NERV MENT DIS, V193, P203, DOI 10.1097/01.nmd.0000154835.92962.e5; Fontana A, 1999, J TRAUMA STRESS, V12, P111, DOI 10.1023/A:1024750417154; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; KING DW, 1995, J ABNORM PSYCHOL, V104, P184, DOI 10.1037/0021-843X.104.1.184; KURDEK LA, 1993, J PERS SOC PSYCHOL, V64, P221, DOI 10.1037/0022-3514.64.2.221; Litz BT, 1997, J CONSULT CLIN PSYCH, V65, P1001, DOI 10.1037/0022-006X.65.6.1001; Litz BT, 1997, AM J PSYCHIAT, V154, P178; MHAT (Mental Health Advisory Team), 2008, MENT HLTH ADV TEAM M; Miller MW, 2004, J ABNORM PSYCHOL, V113, P636, DOI 10.1037/0021-843X.113.4.636; Miller MW, 2003, PSYCHOL ASSESSMENT, V15, P205, DOI 10.1037/1040-3590.15.2.205; RESNICK HS, 1989, J CLIN PSYCHOL, V45, P860, DOI 10.1002/1097-4679(198911)45:6<860::AID-JCLP2270450605>3.0.CO;2-5; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shiner RL, 2002, J PERS SOC PSYCHOL, V83, P1165, DOI 10.1037//0022-3514.83.5.1165; Simon RW, 2002, AM J SOCIOL, V107, P1065, DOI 10.1086/339225; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Taft CT, 2007, J TRAUMA STRESS, V20, P135, DOI 10.1002/jts.20197; Vaughan D, 2006, TODAYS OFFICER FALL, P20; Vogt DS, 2005, J TRAUMA STRESS, V18, P115, DOI 10.1002/jts.20018; Weathers F. W., 1993, ANN M INT SOC TRAUM; WRIGHT KM, 1995, OPERATION DESERT CHI; YAGER T, 1984, ARCH GEN PSYCHIAT, V41, P327	30	28	28	0	11	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0096-140X			AGGRESSIVE BEHAV	Aggressive Behav.	SEP-OCT	2010	36	5					330	337		10.1002/ab.20355			8	Behavioral Sciences; Psychology, Multidisciplinary	Behavioral Sciences; Psychology	641MS	WOS:000281131500006	20626042				2021-06-18	
J	Douglas, JM				Douglas, Jacinta M.			Using the La Trobe Communication Questionnaire to Measure Perceived Social Communication Ability in Adolescents With Traumatic Brain Injury	BRAIN IMPAIRMENT			English	Article						social communication; adolescents; brain injury; assessment		Introduction: The La Trobe Communication Questionnaire (LCQ) was developed to measure perceived social communication ability from various sources including the self-perceptions of individuals as well as those of others with whom they converse regularly (e. g., family members, friends and clinicians). It has been psychometrically evaluated with healthy young adults and adults with traumatic brain injury (TBI) and found to have acceptable reliability and validity. The present study was conducted to gauge the ability of the LCQ to distinguish between a group of adolescents who had sustained TBI and a control group of neurologically normal adolescents matched on the variables of socio-economic status (SES), age, gender and level of education completed. Method: Participants were 19 TBI dyads (TBI adolescents and close relatives) and 19 control dyads. All TBI adolescents had sustained severe injury (mean posttraumatic amnesia duration 33.76 days, SD 18.13) due to moving vehicle-related trauma. Mean age at the time of injury was 16.33 years (SD 1.67) and at the time of assessment 17.11 years (SD 1.90). The LCQ was administered to all participants at home. Results: Perceptions of TBI adolescents and their relatives were significantly different from those of control dyads and consistent with a higher frequency of social communication difficulties in the TBI group. Difficulties reflected reduced conversational fluency and problems with managing the multiple demands of social discourse. Conclusions: The LCQ is a clinical tool that has sound potential to contribute to the multifaceted assessment of social communication in adolescents with TBI.	La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia	Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.	J.Douglas@latrobe.edu.au		Douglas, Jacinta/0000-0003-0940-6624			ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; [Anonymous], 2009, MOSBYS MED DICT; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BODY R, 1999, BRAIN DAM B, P81; Bracy C. A., 2005, BRAIN IMPAIR, V6, P1, DOI [10.1375/brim.6.1.1.65476., DOI 10.1375/BRIM.6.1.1.65476, DOI 10.1375/brim.6.1.1.65476]; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Chelune GJ, 1986, ADV CLIN NEUROPSYCHO, P95, DOI DOI 10.1007/978-1-4613-2211-5_; Ciccia AH, 2009, TOP LANG DISORD, V29, P249, DOI 10.1097/TLD.0b013e3181b53211; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Dahl RE, 2004, ANN NY ACAD SCI, V1021, P1, DOI 10.1196/annals.1308.001; Damico J.S., 1991, ASSESSMENT THERAPY M, P125; Damico JS, 1985, COMMUNICATION SKILLS, P165; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; Eisenberg N, 2004, HDB ADOLESCENT PSYCH, P155, DOI DOI 10.1002/9780471726746.CH6; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Fyrberg A, 2007, INT J REHABIL RES, V30, P153; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Godfrey H.P.D., 1993, J CLIN EXP PSYCHOL, V15, P530; Grice P, 1975, SYNTAX SEMANTICS, VIII, P41; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; KEATING DP, 2004, HDB ADOLESCENT PSYCH, P45; Kim J, 2005, J INT NEUROPSYCH SOC, V11, P434, DOI 10.1017/S1355617705050563; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Larson RW, 2002, J RES ADOLESCENCE, V12, P159, DOI 10.1111/1532-7795.00029; Larson RW, 2002, J RES ADOLESCENCE, V12, P31, DOI 10.1111/1532-7795.00024; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Paus T, 2005, TRENDS COGN SCI, V9, P60, DOI 10.1016/j.tics.2004.12.008; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Snow PC, 2000, BRAIN INJURY, V14, P397; Steinberg L, 2005, TRENDS COGN SCI, V9, P69, DOI 10.1016/j.tics.2004.12.005; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Trewin D., 2006, AUSTR NZ STANDARD CL; Turkstra L, 2003, LANG SPEECH HEAR SER, V34, P117, DOI 10.1044/0161-1461(2003/010); Turkstra L., 1995, BRAIN INJURY, V10, P319; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	75	28	28	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646			BRAIN IMPAIR	Brain Impair.	SEP	2010	11	2			SI		171	182		10.1375/brim.11.2.171			12	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	V24IS	WOS:000208404700008					2021-06-18	
J	Mitchell, EJ; Canter, J; Norris, P; Jenkins, J; Morris, J				Mitchell, Erika J.; Canter, Jeffrey; Norris, Patrick; Jenkins, Judith; Morris, John			The Genetics of Heterotopic Ossification: Insight Into the Bone Remodeling Pathway	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						Heterotopic Ossification; fracture healing; genetics; bone remodeling	TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM; MORTALITY; RISK	Objectives: Heterotopic Ossification (HO) is a significant complication after trauma occurring in 12% to 25% of fractures Although clinical predictors have been studied to determine the likelihood of developing HO, the results have been inconsistent This study examines genetic predictors of the HO phenotype to identify the "at-risk" patient and increase the understanding of the genetic contribution to the formation of HO Methods: We examined the frequency of 61 single nucleotide polymorphisms (SNPs) in 1095 consecutive trauma patients with fractures Radiographic studies of these patients were examined for HO in follow-up Ten percent of the patients in the study demonstrated radiographic evidence of HO Multivariate logistic regression was used to analyze each SNP independently while adjusting for severity of injury (as measured by the Trauma and Injury Severity Score) Results: Three SNPs (beta(2)-adrenergic receptor, toll-like receptor 4. complement factor H) were identified that were associated with an increased or decreased frequency of HO The less common polymorphism of the beta(2)-adrenergic receptor gene was associated with increased risk of HO For toll-like receptor 4 and complement factor H, the less common polymorphism was associated with a decreased risk of HO Conclusions: The SNPs identified as predictors of HO formation are representative of the adrenergic system, immune system. and the alternative complement system This represents the interplay of multiple pathways that affect bone remodeling, aberrations of which may be found in the genome	[Mitchell, Erika J.] Vanderbilt Univ, Med Ctr, Dept Orthopaed, Div Orthopaed Trauma,Med Ctr E, Nashville, TN 37232 USA; [Canter, Jeffrey] Vanderbilt Univ, Med Ctr, Ctr Human Genet, Nashville, TN 37232 USA; [Norris, Patrick; Jenkins, Judith; Morris, John] Vanderbilt Univ, Med Ctr, Div Trauma, Nashville, TN 37232 USA	Mitchell, EJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Orthopaed, Div Orthopaed Trauma,Med Ctr E, South Tower,Suite 4200, Nashville, TN 37232 USA.				US Army Medical ResearchUnited States Department of DefenseUS Army Research Laboratory (ARL);  [W81XWH-08-1-0384]	This work was supported by the US Army Medical Research and Material Command. Orthopaedic Extremity Trauma Research Program. under Award No W81XWH-08-1-0384	Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; CANTER JA, 2009, J AM COLL SURGEONS, V66, P1270; CANTER JA, 2009, J AM COLL SURGEONS, V66, P1265; DOVICHI N, 2010, J PROTEOME RES  0303; Elefteriou F, 2005, CELL MOL LIFE SCI, V62, P2339, DOI 10.1007/s00018-005-5175-3; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Johnson GB, 2004, FASEB J, V18, P1282, DOI 10.1096/fj.04-1572fje; Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007-0038; Morley J, 2005, INJURY, V36, P363, DOI 10.1016/j.injury.2004.08.028; Morris JA, 2009, J AM COLL SURGEONS, V208, P663, DOI 10.1016/j.jamcollsurg.2008.12.017; Morris JA, 2009, J TRAUMA, V66, P1265, DOI 10.1097/TA.0b013e31819ea61a; NORRIS PR, 2009, ANN SURG        0827; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; Rigaux P, 2005, JOINT BONE SPINE, V72, P146, DOI 10.1016/j.jbspin.2004.05.012; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; 2007, NATURE, V447, P661	16	28	30	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	SEP	2010	24	9					530	533		10.1097/BOT.0b013e3181ed147b			4	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	647FL	WOS:000281603100004	20736788				2021-06-18	
J	Harford-Wright, E; Thornton, E; Vink, R				Harford-Wright, Elizabeth; Thornton, Emma; Vink, Robert			Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Captopril; Angiotensin-converting enzyme; Neurogenic inflammation; Substance P; Neurotrauma	SUBSTANCE-P; FUNCTIONAL DEFICITS; HEAD-INJURY; RATS; INFLAMMATION; EDEMA; MODEL	Angiotensin-converting enzyme (ACE) inhibitors are widely used as blood pressure medications in hypertensive individuals. However, ACE inhibitors also play an integral role in the breakdown of neuronal substance P. which has been recently implicated in the development of functional deficits following traumatic brain injury (TBI) The present study therefore examined the effects of ACE inhibitors on histological and motor outcome following TBI. Male Sprague-Dawley rats were treated with Captopril. Enalapril or equal volume saline for 7 days prior to the induction of diffuse TBI using the impact acceleration model. At 5 h post-injury, animals administered Captopril demonstrated significantly increased substance P immunoreactivity compared to vehicle controls (p < 0.01), and Increased dark cell change that persisted to 7 days post-trauma. Captopril also resulted in exacerbated motor deficits compared to vehicle treated animals (p < 0 05) as assessed by the rotarod test over a 7-day post-traumatic period. Administration of the alternative ACE inhibitor, Enalapril, likewise exacerbated motor deficits, confirming a class effect of ACE inhibitors rather than a compound effect specific to Captopril We conclude that ACE inhibitors are deleterious to outcome following TBI, presumably by impairing the degradation of substance P and increasing substance P mediated neuronal injury (C) 2010 Elsevier Ireland Ltd. All rights reserved	[Harford-Wright, Elizabeth; Thornton, Emma; Vink, Robert] Univ Adelaide, Sch Med Sci, Discipline Anat & Pathol, Adelaide, SA 5005, Australia	Vink, R (corresponding author), Univ Adelaide, Sch Med Sci, Discipline Anat & Pathol, Adelaide, SA 5005, Australia.		AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	Supported, in part, by a grant from the National Health and Medical Research Council of Australia. We thank Dr Stephen Helps for the substance P semi-quantitation by colour deconvolution.	Blumbergs P.C., 2008, GREENFIELDS NEUROPAT, P733; Campos MM, 2000, NEUROPEPTIDES, V34, P314, DOI 10.1054/npep.2000.0823; Castro-Obregon S, 2002, CELL DEATH DIFFER, V9, P807, DOI 10.1038/sj.cdd.4401035; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Emanueli C, 1998, HYPERTENSION, V31, P1299, DOI 10.1161/01.HYP.31.6.1299; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; GAUMANN DM, 1990, NEUROSCIENCE, V39, P761, DOI 10.1016/0306-4522(90)90259-7; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HAFSTROM I, 1989, J RHEUMATOL, V16, P1033; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; LANDINI G, 2009, COLOUR DECONVOLUTION; Leong PKK, 2006, AM J PHYSIOL-RENAL, V290, pF854, DOI 10.1152/ajprenal.00353.2005; Lin RCS, 1995, NEUROREPORT, V7, P310, DOI 10.1097/00001756-199512290-00074; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; PERSSON MG, 1991, EUR J PHARMACOL, V205, P295, DOI 10.1016/0014-2999(91)90913-B; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Scholzen TE, 2003, J IMMUNOL, V170, P3866, DOI 10.4049/jimmunol.170.7.3866; VALDEMARSSON S, 1991, J INTERN MED, V230, P325, DOI 10.1111/j.1365-2796.1991.tb00452.x; Vink R, 2010, NEUROTHERAPEUTICS, V7, P74, DOI 10.1016/j.nurt.2009.10.018; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; WERNER C, 1991, STROKE, V22, P910, DOI 10.1161/01.STR.22.7.910; WILLIAMS TA, 1991, J NEUROCHEM, V57, P193, DOI 10.1111/j.1471-4159.1991.tb02115.x	28	28	28	0	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 30	2010	481	1					26	29		10.1016/j.neulet.2010.06.044			4	Neurosciences	Neurosciences & Neurology	639VW	WOS:000281005100006	20600611				2021-06-18	
J	Kamali, A; Kramer, LA; Hasan, KM				Kamali, Arash; Kramer, Larry A.; Hasan, Khader M.			Feasibility of prefronto-caudate pathway tractography using high resolution diffusion tensor tractography data at 3 T	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Diffusion tensor imaging; High spatial resolution; Frontostriatal; Caudate; Tractography	TRAUMATIC BRAIN-INJURY; WHITE-MATTER; INTERNAL CAPSULE; FIBER TRACKING; CONNECTIONS; ANISOTROPY; METRICS; GRAY	Mapping the human brain frontostriatal pathways using noninvasive diffusion tensor imaging (DTI) has been hampered by the inadequate imaging sensitivity, poor spatial resolution, lower tensor anisotropy within gray matter, increased partial volume averaging effects and poor signal-to-noise ratio. We investigated for the first time the utility of high spatial resolution DTI-based fiber-tractography using the fiber assignment by continuous tracking (FACT) to reconstruct and quantify bilaterally the prefronto-caudothalamic connections within the human brain at 3 T. Five healthy right-handed men (age range 24-37 years) were studied. We traced the anterior thalamic radiation and prefronto-caudo-thalamic pathways bilaterally and measured the volume of each tract and the corresponding diffusion tensor metrics in all subjects. The anterior thalamic radiation tract volume and corresponding fractional anisotropy (FA) were significantly larger bilaterally than prefronto-caudate pathway, whereas the mean diffusivity (D,) values were similar (p> 0.7). For both anterior thalamic radiation and prefronto-caudate pathway the tract volume and corresponding DTI metrics (FA, D) were not significantly different between the two hemispheres (p > 0.2). Our DTI acquisition protocol and analysis permitted the reconstruction of the connectivity of the caudate with the thalamus as well as with the prefrontal cortex and allowed tracking of the whole trajectory of the prefronto-caudo-thalamic pathway. (C) 2010 Elsevier B.V. All rights reserved.	[Kamali, Arash; Kramer, Larry A.; Hasan, Khader M.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA	Hasan, KM (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, 6431 Fannin St,MSB 2-100, Houston, TX 77030 USA.	HKhader.M.Hasan@uth.tmc.edu	kamali, Arash/AAG-5803-2020; Hasan, Khader M./ABB-5767-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS052505, R01 NS052505-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052505] Funding Source: NIH RePORTER		AFIFI AK, 1998, TEXT ATLAS; Alexander AL, 2001, MAGN RESON MED, V45, P770, DOI 10.1002/mrm.1105; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Casey BJ, 2007, AM J PSYCHIAT, V164, P1729, DOI 10.1176/appi.ajp.2007.06101754; Casey BJ, 2002, DEV PSYCHOBIOL, V40, P237, DOI 10.1002/dev.10030; Cowan FM, 2005, SEMIN FETAL NEONAT M, V10, P461, DOI 10.1016/j.siny.2005.05.007; Hagler DJ, 2009, HUM BRAIN MAPP, V30, P1535, DOI 10.1002/hbm.20619; Hasan KM, 2008, MAGN RESON MED, V59, P7, DOI 10.1002/mrm.21434; Hasan KM, 2007, MAGN RESON IMAGING, V25, P1196, DOI 10.1016/j.mri.2007.02.011; Hasan KM, 2011, HUM BRAIN MAPP, V32, P107, DOI 10.1002/hbm.21004; Hasan KM, 2009, MAGN RESON IMAGING, V27, P631, DOI 10.1016/j.mri.2008.10.007; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Haznedar MM, 2005, BIOL PSYCHIAT, V57, P733, DOI 10.1016/j.biopsych.2005.01.002; Henry RG, 2009, J NEUROL SCI, V282, P61, DOI 10.1016/j.jns.2009.02.379; Jaermann T, 2008, AM J NEURORADIOL, V29, P146, DOI 10.3174/ajnr.A0742; Jones DK, 2005, MAGNET RESON MED, V53, P1143, DOI 10.1002/mrm.20466; KAMALI A, 2009, EUR RADIAL, V19, P1408; Kim M, 2006, NEUROIMAGE, V32, P1243, DOI 10.1016/j.neuroimage.2006.06.006; Kloppel S, 2008, BRAIN, V131, P196, DOI 10.1093/brain/awm275; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Landman BA, 2010, P SOC PHOTO OPT INST, V7623; Lawes INC, 2008, NEUROIMAGE, V39, P62, DOI 10.1016/j.neuroimage.2007.06.041; Leh SE, 2007, NEUROSCI LETT, V419, P113, DOI 10.1016/j.neulet.2007.04.049; Lehericy S, 2004, ANN NEUROL, V55, P522, DOI 10.1002/ana.20030; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Oouchi H, 2007, AM J NEURORADIOL, V28, P1102, DOI 10.3174/ajnr.A0488; Papadakis NG, 2002, MAGNET RESON MED, V48, P394, DOI 10.1002/mrm.10204; Poonawalla AH, 2004, J MAGN RESON IMAGING, V19, P489, DOI 10.1002/jmri.20020; Rose SE, 2006, NEUROIMAGE, V32, P16, DOI 10.1016/j.neuroimage.2006.03.003; Santiago O, 2007, ARCH CLIN NEUROPSYCH, V22, P623, DOI 10.1016/j.acn.2007.04.003; Suzuki M, 2004, PSYCHIAT RES-NEUROIM, V130, P213, DOI 10.1016/j.pscychresns.2004.01.001; TAYLOR AE, 1990, BRAIN COGNITION, V13, P211, DOI 10.1016/0278-2626(90)90051-O; Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268; Valente AA, 2005, BIOL PSYCHIAT, V58, P479, DOI 10.1016/j.biopsych.2005.04.021; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Yamada K, 2009, P NATL ACAD SCI USA, V106, pE14, DOI 10.1073/pnas.0812352106; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	40	28	28	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	AUG 30	2010	191	2					249	254		10.1016/j.jneumeth.2010.06.026			6	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	651KR	WOS:000281927100015	20600311	Green Accepted			2021-06-18	
J	Ralph, DM; Robinson, SR; Campbell, MS; Bishop, GM				Ralph, David M.; Robinson, Stephen R.; Campbell, Melissa S.; Bishop, Glenda M.			Histidine, cystine, glutamine, and threonine collectively protect astrocytes from the toxicity of zinc	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Astrocyte; Cystine; Free radicals; Glutamine; Glutathione; Glutathione reductase; Histidine; Threonine; Total antioxidant capacity; Zinc	TOTAL ANTIOXIDANT CAPACITY; CORTICAL NEURONAL DEATH; ZN2+-INDUCED CELL-DEATH; AMINO-ACIDS; GLUTATHIONE-REDUCTASE; ASTROGLIAL CULTURES; IN-VITRO; PLASMA; ZN2+; INJURY	In epilepsy, traumatic brain injury, and ischemic stroke, toxic levels of zinc released from neurons contribute to the brain damage associated with these disorders. Zinc causes oxidative stress by increasing the generation of reactive oxygen species and by inhibiting glutathione reductase (GR). This study investigated whether naturally occurring amino acids can protect cultured mouse astrocytes from zinc. Astrocytes incubated for 24 h with 33 mu M zinc acetate in a minimal medium displayed a loss of GR activity, a depletion of total glutathione, and a loss of total antioxidant capacity. These changes were accompanied by extensive cell death. Four amino acids (200 mu M L-histidine, 201 mu M L-cystine, 4 mM L-glutamine, 798 FM mu L-threonine), which are a subset of the 15 present in Dulbecco's modified Eagle medium, were found to collectively prevent zinc toxicity. Histidine was the most protective, followed by cystine, glutamine, and threonine. It is proposed that each of these amino acids protects against different aspects of zinc toxicity by chelating zinc, by serving as precursors for glutathione, or by converting to tricarboxylic acid cycle intermediates. It is possible that these 4 amino acids contribute in vivo to the protection of brain cells from the toxic effects of zinc. (C) 2010 Elsevier Inc. All rights reserved.	[Ralph, David M.; Robinson, Stephen R.; Campbell, Melissa S.; Bishop, Glenda M.] Monash Univ, Sch Psychol & Psychiat, Blood Brain Interact Grp, Clayton, Vic 3800, Australia	Bishop, GM (corresponding author), Monash Univ, Sch Psychol & Psychiat, Blood Brain Interact Grp, Clayton, Vic 3800, Australia.	glenda.bishop@monash.edu	Bishop, Glenda M/G-6031-2010; Robinson, Stephen R/B-7155-2013	Robinson, Stephen/0000-0002-0987-0075; Bishop, Glenda/0000-0002-2736-0415	National Health & Medical Research CouncilNational Health and Medical Research Council of Australia [284393]; School of Psychology & Psychiatry, Monash UniversityMonash University	G.M.B. was supported by a National Health & Medical Research Council Peter Doherty Fellowship (ID: 284393). Additional financial support was provided by the School of Psychology & Psychiatry, Monash University. We thank Hania Czerwinska for valuable technical support throughout the project and Jeff Liddell for adapting the TAC assays for use with cultured cells.	Abe S, 2006, J PHARMACOL SCI, V102, P103, DOI 10.1254/jphs.FP0060342; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Aki T, 2008, J PHARMACOL SCI, V107, P238, DOI 10.1254/jphs.08053FP; Apak R, 2004, J AGR FOOD CHEM, V52, P7970, DOI 10.1021/jf048741x; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bishop GM, 2007, FREE RADICAL BIO MED, V42, P1222, DOI 10.1016/j.freeradbiomed.2007.01.022; Canzoniero LMT, 2003, NEUROPHARMACOLOGY, V45, P420, DOI 10.1016/S0028-3908(03)00171-0; Capasso M, 2005, J ALZHEIMERS DIS, V8, P93; Chen CJ, 2003, J NEUROCHEM, V85, P443, DOI 10.1046/j.1471-4159.2003.01691.x; Chen CJ, 2003, NEUROCHEM INT, V42, P471, DOI 10.1016/S0197-0186(02)00154-7; Chen L, 2006, NEUROSCI LETT, V409, P163, DOI 10.1016/j.neulet.2006.09.033; Cho IH, 2003, J NEUROSCI RES, V74, P736, DOI 10.1002/jnr.10794; CLOUES R, 1993, PFLUG ARCH EUR J PHY, V424, P152, DOI 10.1007/BF00374606; Deniel N, 2007, MOL CELL PROTEOMICS, V6, P1671, DOI 10.1074/mcp.M600428-MCP200; Dineley KE, 2000, NEUROBIOL DIS, V7, P310, DOI 10.1006/nbdi.2000.0303; Dolinska B, 2001, FARMACO, V56, P737, DOI 10.1016/S0014-827X(01)01129-6; Dringen R, 1998, DEV NEUROSCI-BASEL, V20, P401, DOI 10.1159/000017337; Dringen R, 2005, J NEUROSCI RES, V79, P157, DOI 10.1002/jnr.20280; Dringen R, 1996, J NEUROCHEM, V67, P1375, DOI 10.1046/j.1471-4159.1996.67041375.x; Dringen R, 1998, BRAIN RES PROTOC, V2, P223, DOI 10.1016/S1385-299X(97)00047-0; Erel O, 2004, CLIN BIOCHEM, V37, P277, DOI 10.1016/j.clinbiochem.2003.11.015; Franek F, 2002, ARCH BIOCHEM BIOPHYS, V398, P141, DOI 10.1006/abbi.2001.2698; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; GOCKEL P, 1993, HELV CHIM ACTA, V76, P511, DOI 10.1002/hlca.19930760133; HALLMAN PS, 1971, BIOCHEM J, V121, P549, DOI 10.1042/bj1210549; HAMBERGER A, 1990, NEUROCHEM RES, V15, P307, DOI 10.1007/BF00968677; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P341; Herraiz T, 2004, FREE RADICAL RES, V38, P323, DOI 10.1080/10611860310001648167; Hertz L, 1999, J NEUROSCI RES, V57, P417, DOI 10.1002/(SICI)1097-4547(19990815)57:4<417::AID-JNR1>3.3.CO;2-E; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; IKEDA T, 1980, J NUTR SCI VITAMINOL, V26, P357, DOI 10.3177/jnsv.26.357; Kawahara M, 2002, CELL MOL NEUROBIOL, V22, P87, DOI 10.1023/A:1015345813075; Kawahara Masahiro, 2007, Recent Pat CNS Drug Discov, V2, P145, DOI 10.2174/157488907780832698; Kim D, 2003, NEUROREPORT, V14, P187, DOI 10.1097/00001756-200302100-00005; Kim EY, 1999, EUR J NEUROSCI, V11, P327, DOI 10.1046/j.1460-9568.1999.00437.x; Kim YH, 1999, NEUROSCIENCE, V89, P175, DOI 10.1016/S0306-4522(98)00313-3; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kranich O, 1998, GLIA, V22, P11, DOI 10.1002/(SICI)1098-1136(199801)22:1<11::AID-GLIA2>3.3.CO;2-Z; KROTKIEWSKA B, 1992, INT J BIOCHEM, V24, P1501, DOI 10.1016/0020-711X(92)90078-F; Lewinska A, 2007, CLIN EXP PHARMACOL P, V34, P781, DOI 10.1111/j.1440-1681.2007.04637.x; Lorca RA, 2005, J NEUROCHEM, V95, P499, DOI 10.1111/j.1471-4159.2005.03387.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; MCGALE EHF, 1977, J NEUROCHEM, V29, P291, DOI 10.1111/j.1471-4159.1977.tb09621.x; MIZE CE, 1962, J BIOL CHEM, V237, P1596; Nelson D.L., 2008, LEHNINGER PRINCIPLES; Noh KM, 2000, J NEUROSCI, V20; PERRY TL, 1975, J NEUROCHEM, V24, P587, DOI 10.1111/j.1471-4159.1975.tb07680.x; Ryu JR, 2002, EXP BRAIN RES, V143, P257, DOI 10.1007/s00221-001-0991-7; Sheline CT, 2004, GLIA, V46, P18, DOI 10.1002/glia.10313; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; SLOVITER RS, 1985, BRAIN RES, V330, P150, DOI 10.1016/0006-8993(85)90017-4; Smart TG, 2004, NEUROSCIENTIST, V10, P432, DOI 10.1177/1073858404263463; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Trzaskowski B, 2008, J BIOL INORG CHEM, V13, P133, DOI 10.1007/s00775-007-0306-y; van Overveld FWPC, 2000, CHEM-BIOL INTERACT, V127, P151, DOI 10.1016/S0009-2797(00)00179-4; Walther UI, 1999, BIOL TRACE ELEM RES, V67, P97, DOI 10.1007/BF02784066; WAPNIR RA, 1983, J NUTR, V113, P1346; Yoo MH, 2004, INVEST OPHTH VIS SCI, V45, P1523, DOI 10.1167/iovs.03-1315	61	28	29	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	AUG 15	2010	49	4					649	657		10.1016/j.freeradbiomed.2010.05.023			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	630TA	WOS:000280295800017	20570723				2021-06-18	
J	Li, XY; Li, J; Feng, DF; Gu, L				Li, X. Y.; Li, J.; Feng, D. F.; Gu, L.			DIFFUSE AXONAL INJURY INDUCED BY SIMULTANEOUS MODERATE LINEAR AND ANGULAR HEAD ACCELERATIONS IN RATS	NEUROSCIENCE			English	Article						traumatic brain injury; animal model; amyloid protein precursor; neurological severity score	TRAUMATIC BRAIN-INJURY; COGNITIVE DEFICITS; EXPERIMENTAL-MODEL; AMYLOID-BETA; IMPACT; DAMAGE; ACCUMULATION; DIAGNOSIS; PATHOPHYSIOLOGY; MOTOR	Diffuse axonal injury (DAI) is one of the most common and important pathologic features of human traumatic brain injury (TBI), accounting for high mortality and development of persistent post-traumatic neurologic sequelae. Although a relatively high number of therapies have been shown to be effective in experimental models, there are currently few treatments that are effective for improving the prognosis of clinical DAI. A major reason is the failure of current models to validly reproduce the pathophysiological characteristics observed after clinical DAI. In the present study, we employed a specially designed, highly controllable model to induce a sudden rotation in the coronal plane (75 degrees rotation at 1.6 x 10(4) degrees/s) combined with lateral translation (1.57 cm displacement at 3.4 x 10(2) cm/s) to the rat's head. We were interested in discovering whether the combined accelerations could reproduce the pathophysiological changes analogous to those seen in human DAI. The axonal injury as assessed with amyloid protein precursor (APP) as a marker was consistently present in all injured rats. The commonly injured brain regions included the subcortical regions, deep white matter, corpus callosum and brain stem. The evolution of APP accumulations in brain sections depicted the detailed progression of axonal pathology. Ultrastructural studies gave further insights into the presence and progression of axonal injury. All injured rats exhibited transient physiological dysfunction, as well as immediate and dramatic neurological impairment that still persisted at 14 days after injury. These results suggest that this model reproduced the major pathophysiological changes analogous to those observed after severe clinical TBI and provides an attractive vehicle for experimental brain injury research. (C) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.	[Feng, D. F.] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Dept Neurosurg,Peoples Hosp 3, Shanghai 201900, Peoples R China; [Feng, D. F.] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai 201900, Peoples R China	Feng, DF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Dept Neurosurg,Peoples Hosp 3, 280 Mo He Rd, Shanghai 201900, Peoples R China.	feng_df@yahoo.com			Shanghai committee of Science and TechnologyShanghai Science & Technology Committee [064119639]; Shanghai Jiao Tong University School of Medicine [09XJ21072]; Shanghai Jiao Tong University [YG08PETMS19]	This study was supported by grants from the Shanghai committee of Science and Technology (NO. 064119639), Shanghai Jiao Tong University School of Medicine (NO. 09XJ21072) and the Medical Engineering Project of Shanghai Jiao Tong University (NO. YG08PETMS19). Transmission electron microscopy was carried out at the Department of EM, Shanghai School of Medicine, Fudan University.	ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Fijalkowski RJ, 2006, BIOMED SCI INSTRUM, V42, P108; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goldsmith W, 2001, CRIT REV BIOMED ENG, V29, P441, DOI 10.1615/CritRevBiomedEng.v29.i56.10; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; He XS, 2000, J NEUROSURG, V93, P626, DOI 10.3171/jns.2000.93.4.0626; KAO CC, 1983, SPINAL CORD RECONSTR, P41; King A.I., 2003, IRCOBI C LISB PORT, P1; Lammie GA, 1999, J NEUROTRAUM, V16, P603, DOI 10.1089/neu.1999.16.603; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Mahoney EJ, 2003, J TRAUMA, V55, P1065, DOI 10.1097/01.TA.0000100381.89107.93; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maruichi K, 2009, NEUROPATHOLOGY, V29, P132, DOI 10.1111/j.1440-1789.2008.00956.x; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; PAXIOS G, 2001, MOUSE BRAIN STEREOTA; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Sahuquillo J, 2002, ADV TECH STAND NEUR, V27, P23; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; Schroeter ML, 2007, NEUROPSYCHOLOGIA, V45, P3149, DOI 10.1016/j.neuropsychologia.2007.07.004; Schroeter ML, 2010, NEUROPSYCHOLOGIA, V48, P185, DOI 10.1016/j.neuropsychologia.2009.09.004; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SKANDSEN T, 2009, J NEUROSURG, V23, P1; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; STALHAMMAR D, 1990, HDB CLIN NEUROLOGY, V13, P17; STALHAMMAR DA, 1991, ADV NEUROTRAUMATOLOG, V3, P1; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; Yuan XQ, 1991, J NEUROTRAUM, V8, P219, DOI 10.1089/neu.1991.8.219; Zhao M, 2003, NEUROBIOL DIS, V14, P391, DOI 10.1016/j.nbd.2003.07.006; Zwahlen RA, 2007, J CRANIO MAXILL SURG, V35, P142, DOI 10.1016/j.jcms.2007.01.006	54	28	34	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	AUG 11	2010	169	1					357	369		10.1016/j.neuroscience.2010.04.075			13	Neurosciences	Neurosciences & Neurology	621LB	WOS:000279579200035	20451584				2021-06-18	
J	Williams, G; Morris, ME; Schache, A; McCrory, PR				Williams, Gavin; Morris, Meg E.; Schache, Anthony; McCrory, Paul R.			People Preferentially Increase Hip Joint Power Generation to Walk Faster Following Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						brain injury; gait; assessment; rehabilitation; postural balance	MOBILITY ASSESSMENT-TOOL; GAIT; LEVEL; SPEED; PLANTARFLEXORS; HEMIPARESIS; MANAGEMENT; EXTENSORS; CAPACITY; VALIDITY	Background. Reduced gait speed is common following traumatic brain injury (TBI). Several studies have found that people with TBI display increased lateral movement in their center of mass while walking. It has been hypothesized that reduced gait speed following TBI is a consequence of increased caution and postural instability, but reduced ankle power generation at push-off may also play a contributing role. Objective. To determine whether postural instability or reduced muscle power were associated with reduced gait speed following TBI. Methods . A convenience sample of 55 people with TBI receiving physiotherapy for gait disorders were assessed using 3D gait analysis at self-selected and fast walking speeds. A comparison group of 10 healthy controls performed walking trials at a speed matched to the mean TBI self-selected speed and at a fast walking speed. Results. When matched for speed, people with TBI walked with similar cadence and step length but with reduced ankle power generation at push-off and increased hip power generation both in early stance and in preswing compared with healthy controls. Width of base of support and postural instability were also significantly increased for people with TBI. The differences between the 2 groups at the matched speed remained for the fast speed condition. Postural stability did not deteriorate with increasing gait speed in either group. Conclusion. Reduced gait speed following TBI appears to be attributable to biomechanical deficiencies such as reduced ankle power generation rather than reduced postural stability and increased caution.	[Williams, Gavin] Epworth Med Fdn, Melbourne, Vic, Australia; [Williams, Gavin; Morris, Meg E.; Schache, Anthony; McCrory, Paul R.] Univ Melbourne, Melbourne, Vic, Australia	Williams, G (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 89 Bridge Rd, Richmond, Vic 3121, Australia.	gavin.williams@epworth.org.au	Schache, Anthony G/F-4482-2016; McCrory, Paul/Q-8688-2019	Schache, Anthony G/0000-0002-1041-5213; Williams, Gavin/0000-0003-2758-7473; Morris, Meg/0000-0002-0114-4175; McCrory, Paul/0000-0003-4850-0568	Victorian Neurotrauma Initiative	This project was funded by the Victorian Neurotrauma Initiative as part of a postdoctoral fellowship.	Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; DeVita P, 2000, J APPL PHYSIOL, V88, P1804; Esquenazi A, 2004, J HEAD TRAUMA REHAB, V19, P109, DOI 10.1097/00001199-200403000-00004; Goldberg SR, 2004, J BIOMECH, V37, P1189, DOI 10.1016/j.jbiomech.2003.12.005; Harrington ME, 2007, J BIOMECH, V40, P595, DOI 10.1016/j.jbiomech.2006.02.003; Hosalkar H, 2008, CLIN ORTHOP RELAT R, V466, P2500, DOI 10.1007/s11999-008-0395-0; Jonkers I, 2009, GAIT POSTURE, V29, P129, DOI 10.1016/j.gaitpost.2008.07.010; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Keenan M A, 1988, Orthop Rev, V17, P1185; LAWRENCE SJ, 1994, FOOT ANKLE INT, V15, P340, DOI 10.1177/107110079401500610; Liu MQ, 2008, J BIOMECH, V41, P3243, DOI 10.1016/j.jbiomech.2008.07.031; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Milot MH, 2008, CLIN BIOMECH, V23, P415, DOI 10.1016/j.clinbiomech.2007.11.003; Milot MH, 2007, J ELECTROMYOGR KINES, V17, P184, DOI 10.1016/j.jelekin.2006.01.001; Nadeau S, 1999, CLIN BIOMECH, V14, P125, DOI 10.1016/S0268-0033(98)00062-X; Neptune RR, 2008, GAIT POSTURE, V28, P135, DOI 10.1016/j.gaitpost.2007.11.004; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Perry J, 1999, J HEAD TRAUMA REHAB, V14, P116, DOI 10.1097/00001199-199904000-00003; Requiao LF, 2005, J ELECTROMYOGR KINES, V15, P393, DOI 10.1016/j.jelekin.2004.12.004; Schache AG, 2007, GAIT POSTURE, V25, P440, DOI 10.1016/j.gaitpost.2006.05.018; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Williams G, 2006, ARCH PHYS MED REHAB, V87, P437, DOI 10.1016/j.apmr.2005.10.028; Williams G, J HEAD TRAU IN PRESS; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711	26	28	28	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUL	2010	24	6					550	558		10.1177/1545968309357925			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	616RB	WOS:000279225400006	20086196				2021-06-18	
J	Cho, Y; Shi, RY; Ivanisevic, A; Ben Borgens, R				Cho, Youngnam; Shi, Riyi; Ivanisevic, Albena; Ben Borgens, Richard			Functional Silica Nanoparticle-Mediated Neuronal Membrane Sealing Following Traumatic Spinal Cord Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						nanoparticles; nanotechnology; spinal cord injury; membrane sealing; PEG	DRUG-DELIVERY SYSTEM; OXIDATIVE STRESS; LIPID-PEROXIDATION; MOLECULAR REPAIR; NERVE MEMBRANES; PC12 CELLS; ACROLEIN; RECOVERY; THERAPY; NANOTECHNOLOGY	The mechanical damage to neurons and their processes induced by spinal cord injury (SCI) causes a progressive cascade of pathophysiological events beginning with the derangement of ionic equilibrium and collapse of membrane permeability. This leads to a cumulative deterioration of neurons, axons, and the tissue architecture of the cord. We have previously shown that the application of the hydrophilic polymer polyethylene glycol (PEG) following spinal cord or brain injury can rapidly restore membrane integrity, reduce oxidative stress, restore impaired axonal conductivity, and mediate functional recovery in rats, guinea pigs, and dogs. However there are limits to both the concentration and the molecular weight of the application that do not permit the broadest recovery across an injured animal population. In this study, PEG-decorated silica nanoparticles (PSiNPs) sealed cells, as shown by the significantly reduced leakage of lactate dehydrogenase from damaged cells compared with uncoated particles or PEG alone. Further in vivo tests showed that PSiNPs also significantly reduced the formation of reactive oxygen species and the process of lipid peroxidation of the membrane. Fabrication of PSiNPs containing embedded dyes also revealed targeting of the particles to damaged, but not undamaged, spinal cord tissues. In an in vivo crush/contusion model of guinea pig SCI, every animal but one injected with PSiNPs recovered conduction through the cord lesion, whereas none of the control animals did. These findings suggest that the use of multifunctional nanoparticles may offer a novel treatment approach for spinal cord injury, traumatic brain injury, and possibly neuro-degenerative disorders. (C) 2009 Wiley-Liss, Inc.	[Ben Borgens, Richard] Purdue Univ, Sch Vet Med, Weldon Sch Biomed Engn, Ctr Paralysis Res, W Lafayette, IN 47907 USA; [Ivanisevic, Albena] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Ben Borgens, R (corresponding author), Purdue Univ, Sch Vet Med, Weldon Sch Biomed Engn, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	cpr@purdue.edu			CPR (State of Indiana) [HB 1440]	Contract grant sponsor: General Funds from the CPR (State of Indiana HB 1440); Contract grant sponsor: Mrs. Mari Hulman George.	Barbe C, 2004, ADV MATER, V16, P1959, DOI 10.1002/adma.200400771; Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; Borgens RB, 2001, J NEUROSCI RES, V66, P1179; BORGENS RB, 2003, RESTORING FUNCTION I; Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014; Brent J, 2001, DRUGS, V61, P979, DOI 10.2165/00003495-200161070-00006; Caravati EM, 2005, CLIN TOXICOL, V43, P327, DOI 10.1080/07313820500184971; CHO Y, 2008, SMALL IN PRESS; Cho Y, 2008, NANOMEDICINE-UK, V3, P507, DOI 10.2217/17435889.3.4.507; Coleman WP, 2000, J SPINAL DISORD, V13, P185, DOI 10.1097/00002517-200006000-00001; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; Donaldson J, 2002, NEUROSURGERY, V50, P147, DOI 10.1097/00006123-200201000-00023; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Emerich DF, 2006, BIOMOL ENG, V23, P171, DOI 10.1016/j.bioeng.2006.05.026; Facchinetti F, 1998, CELL MOL NEUROBIOL, V18, P667, DOI 10.1023/A:1020221919154; Farokhzad OC, 2006, ADV DRUG DELIVER REV, V58, P1456, DOI 10.1016/j.addr.2006.09.011; Gelperina S, 2005, AM J RESP CRIT CARE, V172, P1487, DOI 10.1164/rccm.200504-613PP; GUTTERIDGE JMC, 1994, ANN NY ACAD SCI, V738, P201; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Kaminskas LM, 2004, ORG BIOMOL CHEM, V2, P2578, DOI 10.1039/b408796h; Koo YEL, 2006, ADV DRUG DELIVER REV, V58, P1556, DOI 10.1016/j.addr.2006.09.012; Koob Andrew O, 2008, J Biol Eng, V2, P9, DOI 10.1186/1754-1611-2-9; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; Laverty PH, 2004, J NEUROTRAUM, V21, P1767, DOI 10.1089/neu.2004.21.1767; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; LEE RC, 1994, ANN NY ACAD SCI, V720, P239, DOI 10.1111/j.1749-6632.1994.tb30453.x; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Liu YY, 2007, COLLOID SURFACE B, V58, P180, DOI 10.1016/j.colsurfb.2007.03.005; Liu-Snyder P, 2007, J EXP BIOL, V210, P1455, DOI 10.1242/jeb.02756; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P209, DOI 10.1002/jnr.20863; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P219, DOI 10.1002/jnr.20862; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Luo J, 2005, NEUROCHEM INT, V47, P449, DOI 10.1016/j.neuint.2005.07.002; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Mohanraj V. J., 2006, Tropical Journal of Pharmaceutical Research, V5, P561; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; Pathak S, 2006, J NEUROSCI, V26, P1893, DOI 10.1523/JNEUROSCI.3847-05.2006; Santra S, 2001, ANAL CHEM, V73, P4988, DOI 10.1021/ac010406+; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; SHI R, 2000, SOC NEUR ABSTR, V26, P1834; SHI R, 1999, J NEUROTRAUM, V16, P1014; Silva GA, 2006, NAT REV NEUROSCI, V7, P65, DOI 10.1038/nrn1827; Silva GA, 2007, SURG NEUROL, V67, P113, DOI 10.1016/j.surneu.2006.08.033; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Wang L, 2006, ANAL CHEM, V78, P646, DOI 10.1021/ac0693619; Working PK, 1997, ACS SYM SER, V680, P45; Xu YH, 2007, J MAGN MAGN MATER, V311, P131, DOI 10.1016/j.jmmm.2006.11.174; Yan JL, 2007, NANO TODAY, V2, P44, DOI 10.1016/S1748-0132(07)70086-5; Zhao XJ, 2004, ADV MATER, V16, P173, DOI 10.1002/adma.200305622	58	28	29	2	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 15	2010	88	7					1433	1444		10.1002/jnr.22309			12	Neurosciences	Neurosciences & Neurology	585VP	WOS:000276858600005	19998478				2021-06-18	
J	Fortune, PM; Shann, F				Fortune, Peter-Marc; Shann, Frank			The motor response to stimulation predicts outcome as well as the full Glasgow Coma Scale in children with severe head injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						brain injuries; Glasgow Coma Scale; Glasgow Outcome Scale; motor activity	EMERGENCY-DEPARTMENT; BRAIN-INJURY; PRACTICAL SCALE; ISCHEMIC COMA; SCORE; TRAUMA; CONSCIOUSNESS; RELIABILITY; TRIAGE; DAMAGE	Objectives: To evaluate how well the full Glasgow Coma Scale and the motor response, which is a subscore of the Glasgow Coma Scale, predict the outcome in children who have sustained a traumatic brain injury. The best scores in the first 24 hrs were used. Design: A retrospective observational study. Setting: A pediatric intensive care unit. Patients: Children admitted between January 1997 and December 1999. Interventions: None. Measurements and Main Results: Recovery with independent function (good outcome), or death, persistent coma, or dependent (bad outcome) at 6 months after the injury. Complete information was available for 130 patients. Both the full Glasgow Coma Scale and the motor response predicted outcome well: the area under the receiver operating characteristic plot was 0.88 (95% confidence interval, 0.82-0.95) for the full score and 0.89 (0.82-0.95) for the motor response. Conclusions: Both the full Glasgow Coma Scale score and the motor response provide a useful indication of long-term outcome, although neither score is sufficiently accurate to be used to limit treatment. The full Glasgow Coma Scale does not have a linear relationship with mortality, and there is poor interobserver agreement. The motor response should be used in children in preference to the full Glasgow Coma Scale; the predictive power is equivalent to the full Glasgow Coma Scale, there is a linear relationship to mortality, and it is easier to collect accurately. (Pediatr Crit Care Med 2010; 11:339-342)	[Fortune, Peter-Marc] Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England; [Shann, Frank] Royal Childrens Hosp, Melbourne, Vic, Australia	Fortune, PM (corresponding author), Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England.	peter-marc.fortune@manchester.ac.uk					Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; *AM ASS SURG TRAUM, 2003, PEDIAT CRIT CARE M S, V4, pS1; Bassi S, 1999, BRIT J NEUROSURG, V13, P526; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bullock M Ross, 2002, Neurosurg Focus, V13, pECP1; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Haukoos JS, 2007, ANN EMERG MED, V50, P18, DOI 10.1016/j.annemergmed.2006.10.004; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Holdgate Anna, 2006, Emerg Med Australas, V18, P379, DOI 10.1111/j.1742-6723.2006.00867.x; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1975, LANCET, V1, P480; Kerby JD, 2007, J TRAUMA, V63, P1026, DOI 10.1097/TA.0b013e318157d9e8; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; SACCO RL, 1990, ARCH NEUROL-CHICAGO, V47, P1181, DOI 10.1001/archneur.1990.00530110035013; Servadei F, 2006, LANCET, V367, P548, DOI 10.1016/S0140-6736(06)68197-X; TEASDALE G, 1974, LANCET, V2, P81; Van de Voorde P, 2008, RESUSCITATION, V76, P175, DOI 10.1016/j.resuscitation.2007.07.007; YAGER JY, 1990, AM J DIS CHILD, V144, P1088, DOI 10.1001/archpedi.1990.02150340032019; Zandbergen EGJ, 2001, INTENS CARE MED, V27, P1661, DOI 10.1007/s001340101076	26	28	28	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAY	2010	11	3					339	342		10.1097/PCC.0b013e3181c014ab			4	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	593WO	WOS:000277493200003	19838138				2021-06-18	
J	Doering, P; Stoltenberg, M; Penkowa, M; Rungby, J; Larsen, A; Danscher, G				Doering, Peter; Stoltenberg, Meredin; Penkowa, Milena; Rungby, Jorgen; Larsen, Agnete; Danscher, Gorm			Chemical Blocking of Zinc Ions in CNS Increases Neuronal Damage Following Traumatic Brain Injury (TBI) in Mice	PLOS ONE			English	Article							ENRICHED ZEN TERMINALS; HIPPOCAMPAL-NEURONS; CONTAINING PATHWAYS; MOUSE-BRAIN; CELL-DEATH; IN-VIVO; LOCALIZATION; BOUTONS; TRANSLOCATION; ACCUMULATION	Background: Traumatic brain injury (TBI) is one of the leading causes of disability and death among young people. Although much is already known about secondary brain damage the full range of brain tissue responses to TBI remains to be elucidated. A population of neurons located in cerebral areas associated with higher cognitive functions harbours a vesicular zinc pool co-localized with glutamate. This zinc enriched pool of synaptic vesicles has been hypothesized to take part in the injurious signalling cascade that follows pathological conditions such as seizures, ischemia and traumatic brain injury. Pathological release of excess zinc ions from pre-synaptic vesicles has been suggested to mediate cell damage/death to postsynaptic neurons. Methodology/Principal Findings: In order to substantiate the influence of vesicular zinc ions on TBI, we designed a study in which damage and zinc movements were analysed in several different ways. Twenty-four hours after TBI ZnT3-KO mice (mice without vesicular zinc) were compared to littermate Wild Type (WT) mice (mice with vesicular zinc) with regard to histopathology. Furthermore, in order to evaluate a possible neuro-protective dimension of chemical blocking of vesicular zinc, we treated lesioned mice with either DEDTC or selenite. Our study revealed that chemical blocking of vesicular zinc ions, either by chelation with DEDTC or accumulation in zinc-selenium nanocrystals, worsened the effects on the aftermath of TBI in the WT mice by increasing the number of necrotic and apoptotic cells within the first 24 hours after TBI, when compared to those of chemically untreated WT mice. Conclusion/Significance: ZnT3-KO mice revealed more damage after TBI compared to WT controls. Following treatment with DEDTC or selenium an increase in the number of both dead and apoptotic cells were seen in the controls within the first 24 hours after TBI while the degree of damage in the ZnT3-KO mice remained largely unchanged. Further analyses revealed that the damage development in the two mouse strains was almost identical after either zinc chelation or zinc complexion therapy.	[Doering, Peter; Stoltenberg, Meredin; Larsen, Agnete; Danscher, Gorm] Univ Aarhus, Inst Anat, Aarhus, Denmark; [Penkowa, Milena] Univ Copenhagen, Panum Inst, Fac Hlth Sci, Sect Neuroprotect,Dept Neurosci & Pharmacol, DK-2200 Copenhagen, Denmark; [Rungby, Jorgen] Univ Aarhus, Dept Pharmacol, Aarhus, Denmark	Doering, P (corresponding author), Univ Aarhus, Inst Anat, Aarhus, Denmark.	pdj@neuro.au.dk	Rungby, Jorgen/AAQ-4332-2021	Larsen, Agnete/0000-0001-8765-8443	Augustinus Foundation; Aase and Ejnar Danielsen Foundation; Aarhus University Research Foundation; Beckett Foundation; Danish Medical Association; Lundbeck FoundationLundbeckfonden; Direktor Jacob Madsen og Hustrus Fond	This study was supported by The Augustinus Foundation, The Aase and Ejnar Danielsen Foundation, The Aarhus University Research Foundation, The Beckett Foundation, The Danish Medical Association Research Fund, The Lundbeck Foundation and Direktor Jacob Madsen og Hustrus Fond. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Bitanihirwe BKY, 2009, SYNAPSE, V63, P1029, DOI 10.1002/syn.20683; Brown CE, 2004, J COMP NEUROL, V479, P156, DOI 10.1002/cne.20308; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Cole TB, 2000, EPILEPSY RES, V39, P153, DOI 10.1016/S0920-1211(99)00121-7; Cote A, 2005, J PHYSIOL-LONDON, V566, P821, DOI 10.1113/jphysiol.2005.089458; DANSCHER G, 1982, HISTOCHEMISTRY, V76, P281, DOI 10.1007/BF00543951; Danscher G, 2005, J HISTOCHEM CYTOCHEM, V53, P141, DOI 10.1369/jhc.4R6460.2005; Danscher G, 2001, NEUROSCIENCE, V105, P941, DOI 10.1016/S0306-4522(01)00243-3; DANSCHER G, 1975, BRAIN RES, V85, P522, DOI 10.1016/0006-8993(75)90825-2; DANSCHER G, 1973, EXP BRAIN RES, V16, P521, DOI 10.1007/BF00234478; DANSCHER G, 1976, THESIS AARHUS U; DANSCHER G, 1984, NEUROBIOLOGY ZINC B, P177; Danscher G, 2006, PROG HISTOCHEM CYTO, V41, P57, DOI 10.1016/j.proghi.2006.06.001; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; Doering P, 2007, NEUROSCIENCE, V150, P93, DOI 10.1016/j.neuroscience.2007.09.066; Dominguez MI, 2006, EPILEPSIA, V47, P887, DOI 10.1111/j.1528-1167.2006.00501.x; Frederickson CJ, 2005, J ALZHEIMERS DIS, V8, P155; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; Frederickson CJ, 2004, J NEUROSCI METH, V139, P79, DOI 10.1016/j.jneumeth.2004.04.033; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Hellmich HL, 2008, NEUROSCI LETT, V440, P155, DOI 10.1016/j.neulet.2008.05.068; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Ismail T, 2008, NEUROSCIENCE, V157, P697, DOI 10.1016/j.neuroscience.2008.09.011; Kitamura Y, 2006, J PHARMACOL SCI, V100, P142, DOI 10.1254/jphs.FP0050805; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Larsen A, 2008, HISTOCHEM CELL BIOL, V130, P681, DOI 10.1007/s00418-008-0448-1; Lee JM, 2002, NEUROSCIENCE, V115, P871, DOI 10.1016/S0306-4522(02)00513-4; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Lee JY, 2000, J NEUROSCI, V20; Linkous DH, 2008, J HISTOCHEM CYTOCHEM, V56, P3, DOI 10.1369/jhc.6A7035.2007; Maret W, 2009, BIOMETALS, V22, P149, DOI 10.1007/s10534-008-9186-z; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; Paoletti P, 2009, NEUROSCIENCE, V158, P126, DOI 10.1016/j.neuroscience.2008.01.061; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PerezClausell J, 1996, J CHEM NEUROANAT, V11, P99, DOI 10.1016/0891-0618(96)00131-7; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SLOMIANKA L, 1990, NEUROSCIENCE, V38, P843, DOI 10.1016/0306-4522(90)90076-G; SLOMIANKA L, 1992, NEUROSCIENCE, V48, P325, DOI 10.1016/0306-4522(92)90494-M; Sorensen JC, 1998, BRAIN RES, V812, P265, DOI 10.1016/S0006-8993(98)00943-3; Stoltenberg M, 2007, NEUROSCIENCE, V150, P357, DOI 10.1016/j.neuroscience.2007.09.025; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2001, BRAIN RES, V895, P25, DOI 10.1016/S0006-8993(01)01996-5; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Takeda A, 2000, BRAIN RES REV, V34, P137, DOI 10.1016/S0165-0173(00)00044-8; Takeda A, 2001, BIOMETALS, V14, P343, DOI 10.1023/A:1012982123386; Valente T, 2002, MOL CELL NEUROSCI, V21, P189, DOI 10.1006/mcne.2002.1159; Wang ZY, 2002, NEUROSCI LETT, V321, P37, DOI 10.1016/S0304-3940(01)02560-5; Wang ZY, 2001, BRAIN RES, V921, P165, DOI 10.1016/S0006-8993(01)03114-6; Wei G, 2004, NEUROSCIENCE, V125, P867, DOI 10.1016/j.neuroscience.2004.03.011; Weiss JH, 2000, TRENDS NEUROSCI, V23, P365, DOI 10.1016/S0166-2236(00)01610-6; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676; Yeiser EC, 2002, NUTR NEUROSCI, V5, P345, DOI 10.1080/1028415021000033811; Yeiser EC, 1999, NEUROSCI LETT, V277, P75, DOI 10.1016/S0304-3940(99)00825-3	55	28	30	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2010	5	4							e10131	10.1371/journal.pone.0010131			9	Multidisciplinary Sciences	Science & Technology - Other Topics	580WU	WOS:000276482100027	20396380	DOAJ Gold, Green Published			2021-06-18	
J	Pruthi, N; Chandramouli, BA; Kuttappa, TB; Rao, SL; Subbakrishna, DK; Abraham, MP; Mahadevan, A; Shankar, SK				Pruthi, Nupur; Chandramouli, B. A.; Kuttappa, Thelma B.; Rao, Shobini L.; Subbakrishna, D. K.; Abraham, Mariamma Philips; Mahadevan, Anita; Shankar, S. K.			Apolipoprotein E polymorphism and outcome after mild to moderate traumatic brain injury: A study of patient population in India	NEUROLOGY INDIA			English	Article						Apolipoprotein E; Glasgow outcome scale; neurotrauma; neuropsychological test	HEAD-INJURY; APOE GENOTYPE; ASSOCIATION; RECOVERY; ALLELE; EXPRESSION; EPSILON-4	Background: The nature and extent of recovery after traumatic brain injury (TBI) is heterogeneous. Apolipoprotein E (APOE) plays a major role in repair of cell membrane and growth of neurites following injury to cells. Studies done on the western population have shown that the APOE e4 genotype is associated with poor survival following neurotrauma. Aim: To explore the association of APOE polymorphism and outcome following TBI in a patient population from a tertiary care hospital exclusive for neurological diseases in south India. Patients and Methods: Ninety eight patients who sustained mild to moderate TBI (computed tomography (CT) scan brain showing traumatic parenchymal contusions) were the subjects of the study and the study period was from November 2003 to December 2008. APOE polymorphism status was determined by PCR technique using venous blood. Patients were assessed on follow-up with a battery of four neuropsychological tests as well as Glasgow outcome scale. Results: Of the 98 patients, 20 (20%) patients had at least one APOE e4 allele. A follow-up of minimum six months was available for 73 patients. None of the 12 patients who had at least one APOE e4 allele had a poor outcome at six-month follow-up whereas 11(18%) patients without an APOE e4 allele had a poor outcome (Fisher's Exact test, P = 0.192). On the neuropsychological tests, performance of patients with APOE e4 allele did not differ significantly from those without these alleles. Conclusion: This study does not support the current contention that the presence of APOE e4 allele should have a significant negative effect on the outcome after TBI.	[Mahadevan, Anita; Shankar, S. K.] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Human Brain Bank, Bangalore 560029, Karnataka, India; [Pruthi, Nupur; Chandramouli, B. A.] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India; [Rao, Shobini L.] Natl Inst Mental Hlth & Neurosci, Dept Mental Hlth & Social Psychol, Bangalore 560029, Karnataka, India; [Subbakrishna, D. K.; Abraham, Mariamma Philips] Natl Inst Mental Hlth & Neurosci, Dept Biostat, Bangalore 560029, Karnataka, India; [Kuttappa, Thelma B.] Univ Delhi, Dept Human Genet, New Delhi, India	Shankar, SK (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Human Brain Bank, Bangalore 560029, Karnataka, India.	shankar@nimhans.kar.nic.in					BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Brichtova E, 2008, CHILD NERV SYST, V24, P349, DOI 10.1007/s00381-007-0459-6; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; FISCHER RP, 1981, J TRAUMA, V21, P920, DOI 10.1097/00005373-198111000-00002; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; HALLMAN DM, 1991, AM J HUM GENET, V49, P338; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Hiekkanen H, 2009, BRAIN INJURY, V23, P396, DOI 10.1080/02699050902926259; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Mastana SS, 1998, ANN HUM BIOL, V25, P137, DOI 10.1080/03014469800005512; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Rao SL, 2004, NIMHANS NEUROPSYCHOL, P6; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Singh PP, 2006, ANN HUM BIOL, V33, P279, DOI 10.1080/03014460600594513; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thelma BK, 2001, HUM BIOL, V73, P135, DOI 10.1353/hub.2001.0012	24	28	29	0	7	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	MAR-APR	2010	58	2					264	269		10.4103/0028-3886.63810			6	Neurosciences	Neurosciences & Neurology	611YY	WOS:000278862600018	20508347				2021-06-18	
J	Agudo-Lopez, A; Miguel, BG; Fernandez, I; Martinez, AM				Agudo-Lopez, Alba; Miguel, Begona G.; Fernandez, Inmaculada; Martinez, Ana M.			Involvement of mitochondria on neuroprotective effect of sphingosine-1-phosphate in cell death in an in vitro model of brain ischemia	NEUROSCIENCE LETTERS			English	Article						Sphingosine-1-phosphate; Ischemia; Mitochondria; Neuroprotection	PROTEIN-KINASE-C; PERMEABILITY TRANSITION; PKC-EPSILON; REPERFUSION INJURY; PORE; CARDIOPROTECTION; PROTECTION; CALCIUM; ANOXIA; RAT	Sphingosine-1-phosphate (S1P) has been demonstrated to be an important regulator of cell death and survival. Although it has been suggested that the sphingolipid may act as a neuroprotector in the cell apoptosis induced by traumatic brain injury, the mechanisms involved in this action are unknown. In this study, the relationship between SIP and neuroprotective effect was studied in an in vitro model of ischemia, maintaining SH-SY5Y human neuroblastoma cells under oxygen-glucose deprivation (OGD). When cells were treated with 1 mu M S1P simultaneously with OGD and recovery, cell viability increases in a dose-response manner. SI P treatment reduces significantly both necrosis and apoptosis cell death. On the other hand, the treatment with specific PKC epsilon (V1-2), prevents S1P protective effect of OGD/recovery-induced necrosis. Moreover, SIP treatment provokes the translocation of PKC epsilon to the mitochondria. From these results, it is reasonable to assume that SIP protection from necrosis is mediated by PKC epsilon. We also studied the action of SIP on mitochondrial inner membrane potential and mitochondrial Ca2+ levels during ischemia. In this regard, we must point out that S1P treatment reduces the OGD-induced membrane depolarization and also reduces the increase of Ca2+ in mitochondria during OGD. Results also indicate that mitochondria from OGD treated cells have significantly less ability to resist swelling on Ca2+ loading than those obtained in presence of oxygen and glucose. Nevertheless, when SI P was added, this resistance increases considerably. These findings suggest that SIP may have a potential role as a neuroprotective agent in brain injury. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Agudo-Lopez, Alba; Miguel, Begona G.; Fernandez, Inmaculada; Martinez, Ana M.] Univ Complutense Madrid, Fac Quim, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain	Martinez, AM (corresponding author), Univ Complutense Madrid, Fac Quim, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain.	anamart@bbm1.ucm.es			Ministerio de Educacion (Spain)	We are extremely grateful to Dr. R.E. Catalan for helpful discussions and for reading of the manuscript. A. Agudo-Lopez was supported by a fellowship from Ministerio de Educacion (Spain).	ALLEY MC, 1988, CANCER RES, V48, P589; Barnett ME, 2007, CELL SIGNAL, V19, P1820, DOI 10.1016/j.cellsig.2007.05.014; Budas GR, 2007, BIOCHEM SOC T, V35, P1052, DOI 10.1042/BST0351052; Budas GR, 2007, PHARMACOL RES, V55, P523, DOI 10.1016/j.phrs.2007.04.005; Calcerrada MC, 2002, FEBS LETT, V514, P361, DOI 10.1016/S0014-5793(02)02401-8; Costa ADT, 2008, AM J PHYSIOL-HEART C, V295, pH874, DOI 10.1152/ajpheart.01189.2007; Costa ADT, 2006, J BIOL CHEM, V281, P20801, DOI 10.1074/jbc.M600959200; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Edmondson RD, 2002, MOL CELL PROTEOMICS, V1, P421, DOI 10.1074/mcp.M100036-MCP200; Fordel E, 2007, GENE, V398, P114, DOI 10.1016/j.gene.2007.03.022; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hausenloy D, 2004, CIRCULATION, V109, P1714, DOI 10.1161/01.CIR.0000126294.81407.7D; Iijima T, 2006, NEUROSCI RES, V55, P234, DOI 10.1016/j.neures.2006.04.005; Jaburek M, 2006, CIRC RES, V99, P878, DOI 10.1161/01.RES.0000245106.80628.d3; Javadov S, 2007, CELL PHYSIOL BIOCHEM, V20, P1, DOI 10.1159/000103747; Kametsu Y, 2003, J CEREBR BLOOD F MET, V23, P416, DOI 10.1097/01.WCB.0000052281.23292.7C; Khaliulin I, 2004, FREE RADICAL BIO MED, V37, P1, DOI 10.1016/j.freeradbiomed.2004.04.017; Kim MY, 2006, BRIT J PHARMACOL, V149, P1059, DOI 10.1038/sj.bjp.0706922; Miglio G, 2004, EUR J PHARMACOL, V489, P157, DOI 10.1016/j.ejphar.2004.03.006; MIYATA H, 1992, CIRC RES, V71, P605, DOI 10.1161/01.RES.71.3.605; Payne SG, 2002, FEBS LETT, V531, P54, DOI 10.1016/S0014-5793(02)03480-4; Ruiz-Meana M, 2006, CARDIOVASC RES, V71, P715, DOI 10.1016/j.cardiores.2006.06.019; Singh IN, 2008, J NEUROSCI RES, V86, P1419, DOI 10.1002/jnr.21586; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103	26	28	34	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 12	2010	470	2					130	133		10.1016/j.neulet.2009.12.070			4	Neurosciences	Neurosciences & Neurology	561AJ	WOS:000274946900009	20045720				2021-06-18	
J	Herrera, JJ; Haywood-Watson, RJL; Grill, RJ				Herrera, Juan J.; Haywood-Watson, Ricky J. L., II; Grill, Raymond J.			Acute and Chronic Deficits in the Urinary Bladder after Spinal Contusion Injury in the Adult Rat	JOURNAL OF NEUROTRAUMA			English	Article						bladder permeability; hematuria; inflammation; recovery; spinal cord injury	TIGHT JUNCTION PROTEIN; BLOOD-BRAIN-BARRIER; CORD-INJURY; EPITHELIAL INJURY; DYSFUNCTION; UROTHELIUM; BIOPSIES; OCCLUDIN; MICE	Traumatic spinal cord injury (SCI) permanently alters bladder function in humans. Hematuria and cystitis occur in both human SCI as well as in rodent models of SCI. Others have reported early SCI-dependent disruption to bladder uroepithelial integrity that results in increased permeability to urine and urine-borne substances. This can result in cystitis, or inflammation of the bladder, an ongoing pathological condition present throughout the chronic phase of SCI in humans. The goals of our study were twofold: (1) to begin to examine the inflammatory and molecular changes that occur within the bladder uroepithelium using a clinically-relevant spinal contusion model of injury, and (2) to assess whether these alterations continue into the chronic phase of SCI. Rats received either moderate SCI or sham surgery. Urine was collected from SCI and sham subjects over 7 days or at 7 months to assess levels of excreted proteins. Inflammation in the bladder wall was assessed via biochemical and immunohistochemical methods. Bladder tight junction proteins, mediators of uroepithelial integrity, were also measured in both the acute and chronic phases of SCI. Urine protein and hemoglobin levels rapidly increase following SCI. An SCI-dependent elevation in numbers of neutrophils within the bladder wall peaked at 48 h. Bladder tight junction proteins demonstrate a rapid but transient decrease as early as 2 h post-SCI. Surprisingly, elevated levels of urine proteins and significant deficits in bladder tight junction proteins could be detected in chronic SCI, suggesting that early pathological changes to the bladder may continue throughout the chronic phase of injury.	[Herrera, Juan J.; Haywood-Watson, Ricky J. L., II; Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX 77030 USA	Grill, RJ (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, 6431 Fannin St,Suite 4-110, Houston, TX 77030 USA.	raymond.j.grill@uth.tmc.edu			National Institute of Allergy and Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [NINDS NS45462, NINDS RO1 NS049409]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049409, F32NS045462] Funding Source: NIH RePORTER	The authors would like to acknowledge Bindu Nair for her technical help and assistance in this study. Funding was provided by the National Institutes of Health Postdoctoral Fellowship of the National Institute of Allergy and Infectious Diseases grants NINDS NS45462 and NINDS RO1 NS049409).	Acharya P, 2004, AM J PHYSIOL-RENAL, V287, pF305, DOI 10.1152/ajprenal.00341.2003; Apodaca G, 2003, AM J PHYSIOL-RENAL, V284, pF966, DOI 10.1152/ajprenal.00359.2002; Birder LA, 2006, PROG BRAIN RES, V152, P135, DOI 10.1016/S0079-6123(05)52009-0; Birder LA, 2004, SCAND J UROL NEPHROL, V38, P48, DOI 10.1080/03008880410015165; Birder LA, 2007, NAT CLIN PRACT UROL, V4, P46, DOI 10.1038/ncpuro0672; Brooks TA, 2005, AM J PHYSIOL-HEART C, V289, pH738, DOI 10.1152/ajpheart.01288.2004; Chin AC, 2007, ANNU REV PATHOL-MECH, V2, P111, DOI 10.1146/annurev.pathol.2.010506.091944; Craggs MD, 2006, AUTON NEUROSCI-BASIC, V126, P355, DOI 10.1016/j.autneu.2006.03.010; CROSBY WH, 1956, BLOOD, V11, P380, DOI 10.1182/blood.V11.4.380.380; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1; Ginzberg HH, 2001, AM J PHYSIOL-GASTR L, V281, pG705; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Hung EW, 2007, SPINAL CORD, V45, P616, DOI 10.1038/sj.sc.3102004; Janzen J, 1998, NEUROUROL URODYNAM, V17, P525; Janzen J, 2001, SPINAL CORD, V39, P568, DOI 10.1038/sj.sc.3101218; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; Pannek J, 2002, UROLOGY, V59, P240, DOI 10.1016/S0090-4295(01)01495-9; Patrick David M, 2006, BMC Physiol, V6, P2, DOI 10.1186/1472-6793-6-2; Samson Gregory, 2007, Phys Med Rehabil Clin N Am, V18, P255; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schulzke JD, 2005, BBA-BIOMEMBRANES, V1669, P34, DOI 10.1016/j.bbamem.2005.01.008; Tai CF, 2006, RESTOR NEUROL NEUROS, V24, P69; Toosi KK, 2008, ANN BIOMED ENG, V36, P1470, DOI 10.1007/s10439-008-9525-9; Vaidyanathan Subramanian, 2002, BMC Urol, V2, P5, DOI 10.1186/1471-2490-2-5; Vizzard MA, 1999, SOMATOSENS MOT RES, V16, P369, DOI 10.1080/08990229970429; Xu HP, 2005, INVEST OPHTH VIS SCI, V46, P2487, DOI 10.1167/iovs.04-1333; Yu X, 2003, UROLOGY, V62, P755, DOI 10.1016/S0090-4295(03)00486-2	28	28	29	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					423	431		10.1089/neu.2009.0997			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800015	19891526	Green Published			2021-06-18	
J	Griesdale, DEG; McEwen, J; Kurth, T; Chittock, DR				Griesdale, Donald E. G.; McEwen, Jonathan; Kurth, Tobias; Chittock, Dean R.			External Ventricular Drains and Mortality in Patients with Severe Traumatic Brain Injury	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							PULMONARY-ARTERY CATHETER; INTRACRANIAL-PRESSURE; LOGISTIC-REGRESSION; INTENSIVE-CARE; HYPERTENSION; EXPERIENCE; MANAGEMENT; PROTOCOL; EVENTS; NUMBER	Purpose: To determine our institutional adherence to the Brain Trauma Foundation guidelines with respect to intracranial pressure (ICP) monitoring, and examine the relationship between external ventricular drain (EVD) use and mortality. Materials & Methods: Retrospective cohort study of 171 patients with severe traumatic brain injury (TBI). Propensity score adjusted logistic regression was used to model the association between EVD use and mortality. Results: EVDs were inserted in 98 of 171 patients. Of the 73 patients without an EVD, 63 (86%) would have qualified for ICP monitoring under the current guidelines. EVDs were in situ for a median of 8 days (SD 6). In adjusted analyses, EVD use was associated with hospital mortality (OR 2.8, 95% CI: 1.1 - 7.1, p=0.04) and 28-day mortality (OR 2.1, 95% CI: 0.80 - 5.6, p=0.13). We observed significant modification of the association between EVD and 28-day mortality by GCS within 12 hours (p-interaction = 0.04), indicating strong association only among those patients with GCS score of at least 6 (OR 5.0, 95% CI: 1.5 - 16.7, p<0.01). Conclusions: The association of EVD with 28-day mortality was only apparent among patients with GCS score of >= 6. Further research is warranted to further refine which patients may benefit from ICP monitoring.	[Griesdale, Donald E. G.] Vancouver Gen Hosp, Program Crit Care Med, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.; McEwen, Jonathan] Univ British Columbia, Dept Anesthesiol, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.; McEwen, Jonathan] Univ British Columbia, Dept Anesthesia, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.; Chittock, Dean R.] Univ British Columbia, Dept Med, Div Crit Care Med, Vancouver, BC, Canada; [Kurth, Tobias] Univ Paris 06, INSERM, Neuroepidemiol U708, Paris, France; [Kurth, Tobias] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Kurth, Tobias] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, Boston, MA 02115 USA	Griesdale, DEG (corresponding author), Vancouver Gen Hosp, Program Crit Care Med, Room 2438,Jim Pattison Pavil,2nd Floor,855 W 12th, Vancouver, BC V5Z 1M9, Canada.		Kurth, Tobias/A-9243-2012	Kurth, Tobias/0000-0001-7169-2620; Griesdale, Donald/0000-0001-5985-8624			*AM ASS NEUR SURG, 2007, J NEUROTRAUMA S1, V24, pS37; Cepeda MS, 2003, AM J EPIDEMIOL, V158, P280, DOI 10.1093/aje/kwg115; Chittock DR, 2006, CRIT CARE MED, V34, P1820, DOI 10.1097/01.CCM.0000221151.44489.E3; Chittock DR, 2004, CRIT CARE MED, V32, P911, DOI 10.1097/01.CCM.0000119423.38610.65; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213	22	28	28	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	JAN	2010	37	1					43	48		10.1017/S031716710000963X			6	Clinical Neurology	Neurosciences & Neurology	549HT	WOS:000274039200008	20169772	Bronze			2021-06-18	
J	Jaffe, DH; Peleg, K				Jaffe, Dena H.; Peleg, Kobi		Israel Trauma Grp	Terror Explosive Injuries A Comparison of Children, Adolescents, and Adults	ANNALS OF SURGERY			English	Article							PEDIATRIC TRAUMA; HEPATIC-TRAUMA; MANAGEMENT; SEVERITY; OUTCOMES; CARE; PATTERNS; BOMBINGS; GENDER; LIVER	Objective: We sought to characterize injuries and outcomes from terror explosions with specific attention to children (0-10 years) and adolescents (11-15 years) compared to adults (16-45 years). Summary Background Data: Terror explosions target vulnerable populations and result in multidimensional injuries that may vary according to age group. The relative dearth of information regarding terror-related injuries among children inhibits proper preparedness and optimum management during such an event. Methods: A retrospective study was performed using data from the national Israel Trauma Registry (October 2000 to December 2005.). Included were civilians and nonactive military personnel hospitalized as a result of a terror explosion. Results: During the 5.3-year study period, 49 children (0-10 years), 65 adolescents (11-15 years), and 723 adults (16-45 years) were hospitalized from terror explosions. Children were more likely than adults to sustain severe injuries (27% vs. 12%) and traumatic brain injury (35% vs. 20%) and less likely to sustain injuries to their extremities (35% vs. 57%) or open wounds (39% vs. 59%) (P <= 0.05). The adolescent injury profile was similar to that of adults, however, adolescents presented with less internal injuries, more contusions, and superficial wounds to extremities and were more likely to require surgery for mild to moderate wounds. Differences in hospital utilization and outcomes by age groups were observed when data were stratified by injury severity. Conclusions: Compared to adults, children, and adolescents exposed to terror explosions present with different injuries and hospital utilization and outcomes. These results further confirm that preparedness of a pediatric healthcare system is essential for effective management in the event of a future mass casualty incident.	[Jaffe, Dena H.; Peleg, Kobi] Gertner Inst Epidemiol & Hlth Policy Res, Natl Ctr Trauma & Emergency Med Res, IL-52621 Tel Hashomer, Israel; [Peleg, Kobi] Tel Aviv Univ, Sch Publ Hlth, Dept Disaster Med, Tel Aviv, Israel	Jaffe, DH (corresponding author), Gertner Inst Epidemiol & Hlth Policy Res, Natl Ctr Trauma & Emergency Med Res, IL-52621 Tel Hashomer, Israel.	denaj@gertner.health.gov.il			Gertner Institute for Epidemiology and Health Policy Research	Supported by the Gertner Institute for Epidemiology and Health Policy Research.	Aharonson-Daniel L, 2003, PEDIATRICS, V112, pE280, DOI 10.1542/peds.112.4.e280; Almogy G, 2004, ANN SURG, V239, P295, DOI 10.1097/01.sla.0000114014.63423.55; Amir LD, 2005, ANN SURG, V241, P666, DOI 10.1097/01.sla.0000157233.18787.cd; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bauza G, 2008, J TRAUMA, V64, P304, DOI 10.1097/TA.0b013e3181634893; Bilston LE, 2007, SPINE, V32, P2339, DOI 10.1097/BRS.0b013e3181558886; Brandenburg M, 2006, J HOMEL SECUR EMERG, V3; Demetriades D, 2004, J AM COLL SURGEONS, V199, P382, DOI 10.1016/j.jamcollsurg.2004.03.027; Duane TM, 2004, J TRAUMA, V57, P494, DOI 10.1097/01.TA.0000141026.20937.81; Einav S, 2006, ANN SURG, V243, P533, DOI 10.1097/01.sla.0000206417.58432.48; Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001; Gee AC, 2008, SHOCK, V29, P334, DOI 10.1097/shk.0b013e3181506ee5; Ivarsson B Johan, 2006, Traffic Inj Prev, V7, P290, DOI 10.1080/15389580600652283; Kim H, 2008, J TRAUMA, V65, P1287, DOI 10.1097/TA.0b013e31817196f5; Kluger Y, 2004, J AM COLL SURGEONS, V199, P875, DOI 10.1016/j.jamcollsurg.2004.09.003; Kluger Y, 2003, ISRAEL MED ASSOC J, V5, P235; Markenson D, 2006, PEDIATRICS, V117, pE340, DOI 10.1542/peds.2005-2752; Maxson RT, 2002, CLIN PEDIAT EMERG ME, V3, P256; Mayo Ami, 2006, World J Emerg Surg, V1, P33, DOI 10.1186/1749-7922-1-33; McGuigan R, 2007, J PEDIATR SURG, V42, P207, DOI 10.1016/j.jpedsurg.2006.09.020; Miller K, 1998, J PEDIATR SURG, V33, P1459, DOI 10.1016/S0022-3468(98)90474-2; Mitra B, 2006, ANZ J SURG, V76, P343, DOI 10.1111/j.1445-2197.2006.03723.x; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Mostafa G, 2002, J TRAUMA, V53, P430, DOI 10.1097/00005373-200209000-00006; Newgard CD, 2005, PEDIATRICS, V115, P1579, DOI 10.1542/peds.2004-0555; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Peleg K, 2004, ANN SURG, V239, P311, DOI 10.1097/01.sla.0000114012.84732.be; Phelan HA, 2007, J TRAUMA, V63, P1127, DOI 10.1097/TA.0b013e318154c1b8; Spinella PC, 2008, CRIT CARE MED, V36, pS293, DOI 10.1097/CCM.0b013e31817da99f; Velmahos GC, 2003, ARCH SURG-CHICAGO, V138, P475, DOI 10.1001/archsurg.138.5.475; *WHO, 1986, OPT CAR DIS PEOPL; Willis RB, 2008, PEDIATRICS, V121, P849, DOI 10.1542/peds.2008-0094	33	28	28	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-4932			ANN SURG	Ann. Surg.	JAN	2010	251	1					138	143		10.1097/SLA.0b013e3181b5d7ab			6	Surgery	Surgery	538SF	WOS:000273203600021	19838104				2021-06-18	
J	McAuley, G; Schrag, M; Sipos, P; Sun, SW; Obenaus, A; Neelavalli, J; Haacke, EM; Holshouser, B; Madacsi, R; Kirsch, W				McAuley, Grant; Schrag, Matthew; Sipos, Pal; Sun, Shu-Wei; Obenaus, Andre; Neelavalli, Jaladhar; Haacke, E. Mark; Holshouser, Barbara; Madacsi, Ramona; Kirsch, Wolff			Quantification of Punctate Iron Sources Using Magnetic Resonance Phase	MAGNETIC RESONANCE IN MEDICINE			English	Article						iron quantification; phase images; susceptibility weighted imaging; brain microbleeds; blooming effect	DIFFUSE AXONAL INJURY; TRANSVERSE RELAXATION RATES; BRAIN IRON; ALZHEIMERS-DISEASE; LABELED CELLS; MR-IMAGES; SUSCEPTIBILITY; MICROBLEEDS; ARTIFACTS; FERRITIN	Iron-mediated tissue damage is present in cerebrovascular and neurodegenerative diseases and neurotrauma. Brain microbleeds are often present in these maladies and are assuming increasing clinical importance. Because brain microbleeds present a source of pathologic iron to the brain, the noninvasive quantification of this iron pool is potentially valuable. Past efforts to quantify brain iron have focused on content estimation within distributed brain regions. In addition, conventional approaches using "magnitude" images have met significant limitations. In this study, a technique is presented to quantify the iron content of punctate samples using phase images. Samples are modeled as magnetic dipoles and phase shifts due to local dipole field perturbations are mathematically related to sample iron content and radius using easily recognized geometric features in phase images. Phantoms containing samples of a chitosan-ferric oxyhydroxide composite (which serves as a mimic for hemosiderin) were scanned with a susceptibility-weighted imaging sequence at 11.7 T. Plots relating sample iron content and radius to phase image features were compared to theoretical predictions. The primary result is the validation of the technique by the excellent agreement between theory and the iron content plot. This research is a potential first step toward quantification of punctate brain iron sources such as brain microbleeds. Magn Reson Med 63:106-115, 2010. (C) 2009 Wiley-Liss, Inc.	[McAuley, Grant; Schrag, Matthew; Kirsch, Wolff] Loma Linda Univ, Neurosurg Ctr Res Training & Educ, Loma Linda, CA 92354 USA; [Sipos, Pal; Madacsi, Ramona] Univ Szeged, Dept Inorgan & Analyt Chem, Szeged, Hungary; [Sun, Shu-Wei; Obenaus, Andre] Loma Linda Univ, Sch Sci & Technol, Loma Linda, CA 92354 USA; [Obenaus, Andre] Loma Linda Univ, Noninvas Imaging Lab, Radiobiol Program, Loma Linda, CA 92354 USA; [Obenaus, Andre; Haacke, E. Mark; Holshouser, Barbara] Loma Linda Univ, Med Ctr, Loma Linda, CA 92354 USA; [Neelavalli, Jaladhar; Haacke, E. Mark] Magnet Resonance Inst Biomed Res, Detroit, MI USA; [Neelavalli, Jaladhar] Univ Oxford, ONNRU, Nuffield Dept Surg, Oxford OX1 2JD, England; [Haacke, E. Mark] Wayne State Univ, Dept Radiol, Detroit, MI USA	Kirsch, W (corresponding author), Loma Linda Univ, Neurosurg Ctr Res Training & Educ, 11175 Campus St,CPA11113, Loma Linda, CA 92354 USA.	wkirsch@llu.edu	McAuley, Grant/I-2497-2013; Sipos, Pal/B-8505-2018; NEELAVALLI, JALADHAR/C-6904-2014	McAuley, Grant/0000-0002-4083-5825; Sipos, Pal/0000-0003-1407-0950; NEELAVALLI, JALADHAR/0000-0002-9513-337X			Akter M, 2007, ACAD RADIOL, V14, P1011, DOI 10.1016/j.acra.2007.05.013; Andersen JK, 2004, J ALZHEIMERS DIS, V6, pS47; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; BARTZOKIS G, 1993, MAGN RESON MED, V29, P459, DOI 10.1002/mrm.1910290406; BIZZI A, 1990, RADIOLOGY, V177, P59, DOI 10.1148/radiology.177.1.2399339; Bos C, 2003, MAGNET RESON MED, V50, P400, DOI 10.1002/mrm.10505; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Cheng YCN, 2007, MAGN RESON IMAGING, V25, P1171, DOI 10.1016/j.mri.2007.01.008; Cordonnier C, 2007, BRAIN, V130, P1988, DOI 10.1093/brain/awl387; Dixon WT, 2009, MAGN RESON MED, V61, P1132, DOI 10.1002/mrm.21930; Duyn JH, 2007, P NATL ACAD SCI USA, V104, P11796, DOI 10.1073/pnas.0610821104; Gaasch JA, 2007, NEUROCHEM RES, V32, P1196, DOI 10.1007/s11064-007-9290-4; Gelman N, 1999, RADIOLOGY, V210, P759, DOI 10.1148/radiology.210.3.r99fe41759; Gilissen EP, 1999, J NEUROL SCI, V168, P21, DOI 10.1016/S0022-510X(99)00162-8; Gossuin Y, 2007, NMR BIOMED, V20, P749, DOI 10.1002/nbm.1140; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Haacke E.M., 1999, MAGNETIC RESONANCE I; Haacke EM, 2007, J MAGN RESON IMAGING, V26, P256, DOI 10.1002/jmri.22987; Haacke EM, 2005, MAGN RESON IMAGING, V23, P1, DOI 10.1016/j.mri.2004.10.001; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Helmer OM, 1934, J BIOL CHEM, V104, P157; House MJ, 2007, MAGN RESON MED, V57, P172, DOI 10.1002/mrm.21118; Jara Hernan, 2006, Top Magn Reson Imaging, V17, P19, DOI 10.1097/01.rmr.0000245460.82782.69; Jensen JH, 2009, MAGN RESON MED, V61, P481, DOI 10.1002/mrm.21823; KIM JK, 1993, RADIOLOGY, V187, P735, DOI 10.1148/radiology.187.3.8497623; MacKay A, 2006, MAGN RESON IMAGING, V24, P515, DOI 10.1016/j.mri.2005.12.037; Mills PH, 2008, MAGN RESON IMAGING, V26, P618, DOI 10.1016/j.mri.2008.01.007; Neelavalli J, 2009, J MAGN RESON IMAGING, V29, P937, DOI 10.1002/jmri.21693; Neema M, 2009, J NEUROIMAGING, V19, P3, DOI 10.1111/j.1552-6569.2008.00296.x; Nighoghossian N, 2002, STROKE, V33, P735, DOI 10.1161/hs0302.104615; Ogg RJ, 1999, MAGN RESON IMAGING, V17, P1141, DOI 10.1016/S0730-725X(99)00017-X; ORDIDGE RJ, 1994, MAGNET RESON MED, V32, P335, DOI 10.1002/mrm.1910320309; Pintaske J, 2006, PHYS MED BIOL, V51, P4707, DOI 10.1088/0031-9155/51/18/016; Pintaske J, 2006, MAGN RESON MATER PHY, V19, P46, DOI 10.1007/s10334-006-0026-2; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Robson P, 2005, AICHE J, V51, P1633, DOI 10.1002/aic.10408; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schenck JF, 2004, NMR BIOMED, V17, P433, DOI 10.1002/nbm.922; Sipos P, 2003, J INORG BIOCHEM, V95, P55, DOI 10.1016/S0162-0134(03)00068-0; Smirnov P, 2006, CONTRAST MEDIA MOL I, V1, P165, DOI 10.1002/cmmi.104; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Viswanathan A, 2006, STROKE, V37, P550, DOI 10.1161/01.STR.0000199847.96188.12; Vymazal J, 2007, J NEUROL SCI, V263, P20, DOI 10.1016/j.jns.2007.05.018; Wang Y, 2000, J MAGN RESON IMAGING, V12, P661, DOI 10.1002/1522-2586(200011)12:5<661::AID-JMRI2>3.0.CO;2-L; Wang ZYJ, 2005, RADIOLOGY, V234, P749, DOI 10.1148/radiol.2343031084; Yakushiji Y, 2008, STROKE, V39, P3323, DOI 10.1161/STROKEAHA.108.516112; Yamada N, 1996, RADIOLOGY, V198, P171, DOI 10.1148/radiology.198.1.8539373	48	28	29	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0740-3194	1522-2594		MAGN RESON MED	Magn. Reson. Med.	JAN	2010	63	1					106	115		10.1002/mrm.22185			10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	543LI	WOS:000273578600012	19953510	Bronze			2021-06-18	
J	Minnich, JE; Mann, SL; Stock, M; Stolzenbach, KA; Mortell, BM; Soderstrom, KE; Bohn, MC; Kozlowski, DA				Minnich, Jennie E.; Mann, Sarah L.; Stock, Megan; Stolzenbach, Kathryn A.; Mortell, Bridget M.; Soderstrom, Katherine E.; Bohn, Martha C.; Kozlowski, Dorothy A.			Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects cortical neurons from dying following a traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Traumatic brain injury; growth factors; behavioral assessments; forelimb sensorimotor cortex; controlled cortical impact	NERVE GROWTH-FACTOR; ADENOVIRUS-MEDIATED EXPRESSION; CEREBRAL-ARTERY OCCLUSION; RETINAL GANGLION-CELLS; SUBSTANTIA-NIGRA; SPINAL-CORD; TARGETED TRANSDUCTION; DOPAMINERGIC-NEURONS; PARKINSONS-DISEASE; ANIMAL-MODELS	Purpose: The therapeutic potential of glial cell line-derived neurotrophic factor (GDNF) gene delivery was examined in a rodent model of traumatic brain injury (TBI), the controlled cortical impact (CCI). Methods: An adenoviral vector harboring human GDNF (AdGDNF) or green fluorescent protein (AdGFP) was injected unilaterally into the forelimb sensorimotor cortex (FL-SMC) of the rat one week prior to a unilateral CCI. Tests of forelimb function and asymmetry were administered for 2 weeks post-injury. At 2 weeks post-injury, animals were sacrificed and contusion size, neuronal survival, neurodegeneration, and virally-mediated GDNF and GFP protein expression were measured. Results: Rats injected with AdGDNF had significantly smaller contusions, more surviving neurons, and less neurodegeneration than AdGFP injected and uninjected injured animals. GDNF gene delivery also resulted in significantly faster recovery of forelimb coordination and a smaller initial preference for the uninjured forelimb during exploration of the walls of a platform. However, overall recovery of symmetrical forelimb use was not achieved. Conclusions: The discrepancy between neural protection and behavioral recovery suggests that while GDNF gene delivery provided a high degree of protection of damaged cortical neurons in this model of TBI, it may not have fully protected their terminals and synaptic functioning, resulting in only mild protection against behavioral deficits.	[Minnich, Jennie E.; Mann, Sarah L.; Stock, Megan; Stolzenbach, Kathryn A.; Mortell, Bridget M.; Soderstrom, Katherine E.; Kozlowski, Dorothy A.] Depaul Univ, Dept Biol Sci, Chicago, IL 60614 USA; [Bohn, Martha C.] Northwestern Univ, Dept Pediat, Childrens Mem Res Ctr, Feinberg Sch Med, Chicago, IL 60611 USA	Kozlowski, DA (corresponding author), Depaul Univ, Dept Biol Sci, 2325 N Clifton, Chicago, IL 60614 USA.	dkozlows@depaul.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R-15 NS42583-01]; Roy J. Carver Foundation for viral vector preparations; DePaul University Liberal Arts Sciences; University Research Council; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS042583] Funding Source: NIH RePORTER	The authors would like to thank the University of Iowa Gene Transfer Vector Core, supported in part by the NIH and the Roy J. Carver Foundation for viral vector preparations. This study was supported by: NIH R-15 NS42583-01 (D. A. K.), DePaul University Liberal Arts & Sciences Research Grant and University Research Council Grants (D. A. K.) We thank Anne Shea and Kevin McDonough for assistance in data collection and analysis.	Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Baumgartner BJ, 1997, J NEUROSCI, V17, P6504; Baumgartner BJ, 1998, EXP NEUROL, V153, P102, DOI 10.1006/exnr.1998.6878; Bemelmans AP, 1999, HUM GENE THER, V10, P2987, DOI 10.1089/10430349950016393; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; Betz AL, 1998, EXP NEUROL, V150, P136, DOI 10.1006/exnr.1997.6755; BilangBleuel A, 1997, P NATL ACAD SCI USA, V94, P8818, DOI 10.1073/pnas.94.16.8818; Bohn MC, 2000, NOVART FDN SYMP, V231, P70, DOI 10.1002/0470870834.ch5; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; CastelBarthe MN, 1996, NEUROBIOL DIS, V3, P76, DOI 10.1006/nbdi.1996.0008; Chen Q, 2005, CURR GENE THER, V5, P71; Chen YH, 2008, FASEB J, V22, P261, DOI 10.1096/fj.07-8797com; Choi-Lundberg DL, 1998, EXP NEUROL, V154, P261, DOI 10.1006/exnr.1998.6887; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; Clarkson ED, 1997, CELL TISSUE RES, V289, P207, DOI 10.1007/s004410050867; Connor B, 1999, GENE THER, V6, P1936, DOI 10.1038/sj.gt.3301033; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Gerlai R, 2001, EUR J NEUROSCI, V14, P1153, DOI 10.1046/j.0953-816x.2001.01724.x; Giehl KM, 1997, EUR J NEUROSCI, V9, P2479, DOI 10.1111/j.1460-9568.1997.tb01665.x; Grondin R, 2003, PROG DRUG RES, V61, P101; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hendriks WTJ, 2004, PROG BRAIN RES, V146, P451; Hermann DM, 2001, NEUROBIOL DIS, V8, P964, DOI 10.1006/nbdi.2001.0448; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; HOVDA DA, 1996, NEUROTRAUMA, P1459; Iwai M, 2001, Hum Cell, V14, P27; Iwamoto Y, 1996, NEUROREPORT, V7, P609, DOI 10.1097/00001756-199601310-00056; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kirik D, 2004, NAT NEUROSCI, V7, P105, DOI 10.1038/nn1175; Kitagawa H, 1999, J CEREBR BLOOD F MET, V19, P1336, DOI 10.1097/00004647-199912000-00007; Kochanek PM, 2001, J NEUROTRAUM, V18, P73, DOI 10.1089/089771501750055785; Kozlowski DA, 2000, EXP NEUROL, V166, P1, DOI 10.1006/exnr.2000.7463; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; KOZLOWSKI DA, 1994, RESTOR NEUROL NEUROS, V7, P119, DOI 10.3233/RNN-1994-7207; Kozlowski DA, 1997, BRAIN RES, V763, P159, DOI 10.1016/S0006-8993(97)00377-6; Kozlowski DA, 2001, MOL THER, V3, P256, DOI 10.1006/mthe.2000.0256; Lapchak PA, 1997, BRAIN RES, V777, P153, DOI 10.1016/S0006-8993(97)01100-1; LI LX, 1995, P NATL ACAD SCI USA, V92, P9771, DOI 10.1073/pnas.92.21.9771; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Meijs MFL, 2004, J NEUROTRAUM, V21, P1415, DOI 10.1089/neu.2004.21.1415; Miller JD, 1996, NEUROTRAUMA, P61; Mohajeri MH, 1999, HUM GENE THER, V10, P1853, DOI 10.1089/10430349950017536; Pertusa A, 2008, NEUROBIOL AGING, V29, P1366, DOI 10.1016/j.neurobiolaging.2007.02.026; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Phillips RG, 2001, GENE THER, V8, P579, DOI 10.1038/sj.gt.3301397; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ribotta MGY, 1997, J NEUROSCI RES, V48, P281; Romero MI, 2001, J NEUROSCI, V21, P8408; Rosenblad C, 2000, EXP NEUROL, V161, P503, DOI 10.1006/exnr.1999.7296; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schmeer C, 2002, EUR J NEUROSCI, V15, P637, DOI 10.1046/j.1460-9568.2002.01893.x; Shin HK, 2004, CLIN EXP PHARMACOL P, V31, P1, DOI 10.1111/j.1440-1681.2004.03943.x; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Szentirmai O, 2008, NEUROSURGERY, V62, P1465, DOI [10.1227/01.NEU.0000129681.85731.00, 10.1227/01.neu.0000333811.56907.13]; Tang XQ, 2004, NEUROREPORT, V15, P425, DOI 10.1097/00001756-200403010-00009; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Tsai TT, 2000, EXP NEUROL, V166, P266, DOI 10.1006/exnr.2000.7505; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Tuszynski MH, 2004, PROG BRAIN RES, V146, P441; Wang Y, 2002, ANN NY ACAD SCI, V962, P423, DOI 10.1111/j.1749-6632.2002.tb04086.x; Watabe K, 2001, Hum Cell, V14, P7; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Weise J, 2000, NEUROBIOL DIS, V7, P212, DOI 10.1006/nbdi.2000.0285; Yagi T, 2000, BRAIN RES, V885, P273, DOI 10.1016/S0006-8993(00)02956-5; Zhang WR, 2002, BRAIN RES, V947, P140, DOI 10.1016/S0006-8993(02)02923-2	74	28	28	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2010	28	3					293	309		10.3233/RNN-2010-0528			17	Neurosciences	Neurosciences & Neurology	606QP	WOS:000278442500001	20479525				2021-06-18	
J	Moore, DW; Ashman, TA; Cantor, JB; Krinick, RJ; Spielman, LA				Moore, Dana W.; Ashman, Teresa A.; Cantor, Joshua B.; Krinick, Ren Jolie; Spielman, Lisa A.			Does gender influence cognitive outcome after traumatic brain injury?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Gender; Cognitive; Memory; Executive functioning	SEX-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; CONCUSSION SYMPTOMS; FUNCTIONAL RECOVERY; MENSTRUAL-CYCLE; NEURONAL LOSS; PROGESTERONE; MEMORY; TESTOSTERONE; PERFORMANCE	The aim of this study was to determine whether males and females differ in post-acute cognitive outcome following traumatic brain injury (TBI). Performances of 83 men and 75 women with mild to severe TBI were compared on measures of cognitive functions typically impacted by TBI (i.e., processing speed, executive functioning, and memory). Participants completed selected subtests of the Cambridge Neuropsychological Test Automated Battery (CANTAB). Among the participants with mild TBI, women scored significantly higher than men on a test of visual memory. There were no other significant gender differences in cognitive outcomes. These findings overall suggest that cognitive outcome after TBI does not differ according to gender, with the possible exception of memory functioning. Further research is needed to replicate this finding and determine which moderating variables may impact on the relationship between gender and cognitive outcome after TBI.	[Moore, Dana W.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Ashman, Teresa A.; Cantor, Joshua B.; Krinick, Ren Jolie; Spielman, Lisa A.] Mt Sinai Sch Med, New York, NY USA	Moore, DW (corresponding author), Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Neurol & Neurosci, 428 E 72nd St,Suite 500, New York, NY 10021 USA.	dwm2003@med.cornell.edu	Ashman, Teresa/B-1621-2013	Ashman, Teresa/0000-0003-2401-7192	National Institute on Disability and Rehabilitation Research (NIDRR) [H133A020501, H133P050004]	This study was funded by grant numbers H133A020501 and H133P050004 from the National Institute on Disability and Rehabilitation Research (NIDRR).	ALDERMAN N, 1996, BEHAV ASSESSMENT DYS; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Axelrod BN, 1996, J CLIN EXP NEUROPSYC, V18, P338, DOI 10.1080/01688639608408991; Barnfield AMC, 1999, PERCEPT MOTOR SKILL, V89, P339, DOI 10.2466/pms.1999.89.1.339; Basso MR, 2000, CLIN NEUROPSYCHOL, V14, P231, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT231; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Crawford JR, 2001, PSYCHOL MED, V31, P451, DOI 10.1017/S0033291701003634; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; DELUCA CR, 2008, J CLIN EXPT NEUROPSY, V25, P242; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Donders J, 2003, J HEAD TRAUMA REHAB, V18, P106, DOI 10.1097/00001199-200303000-00002; Elliott R, 1997, PSYCHOPHARMACOLOGY, V131, P196, DOI 10.1007/s002130050284; FEINGOLD A, 1988, AM PSYCHOL, V43, P95, DOI 10.1037/0003-066X.43.2.95; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; GORDON WA, 1998, LIVING LIFE TBI; Greendale GA, 2009, NEUROLOGY, V72, P1850, DOI 10.1212/WNL.0b013e3181a71193; Halari R, 2005, BEHAV NEUROSCI, V119, P104, DOI 10.1037/0735-7044.119.1.104; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Janowsky JS, 1998, DEV NEUROPSYCHOL, V14, P421, DOI 10.1080/87565649809540719; Jeppesen LL, 1996, ARTERIOSCL THROM VAS, V16, P749, DOI 10.1161/01.ATV.16.6.749; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Lewin C, 2001, NEUROPSYCHOLOGY, V15, P165, DOI 10.1037//0894-4105.15.2.165; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Maki PM, 2002, NEUROPSYCHOLOGIA, V40, P518, DOI 10.1016/S0028-3932(01)00126-9; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Mehta MA, 2000, J NEUROSCI, V20; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mordecai KL, 2008, HORM BEHAV, V54, P286, DOI 10.1016/j.yhbeh.2008.03.006; MORRIS RG, 1986, COGNITIVE NEUROCHEMI, P21; Nelson HE, 1982, NATL ADULT READING T; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Pan Y, 2005, BRAIN RES, V1043, P195, DOI 10.1016/j.brainres.2005.02.078; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P497, DOI 10.1016/0306-4530(92)90008-U; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; *RES TRAIN CTR COM, 1997, BRAIN INJ SCREEN QUE; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; SMITH D, 1998, COGNITIVE NEUROPSYCH, V3, P71, DOI DOI 10.1080/135468098396251; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; Wechsler D., 1997, WECHSLER ADULT MEMOR; Wechsler D., 1987, MANUAL WECHSLER MEMO; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Yang SH, 2002, J APPL PHYSIOL, V92, P195	50	28	28	0	14	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	3					340	354	PII 916210592	10.1080/09602010903250928			15	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	598RZ	WOS:000277857200002	19859853				2021-06-18	
J	Murillo-Cabezas, F; Munoz-Sanchez, MA; Rincon-Ferrari, MD; Martin-Rodriguez, JF; Amaya-Villar, R; Garcia-Gomez, S; Leon-Carrion, J				Murillo-Cabezas, Francisco; Angeles Munoz-Sanchez, Maria; Dolores Rincon-Ferrari, Maria; Francisco Martin-Rodriguez, Juan; Amaya-Villar, Rosario; Garcia-Gomez, Susana; Leon-Carrion, Jose			The prognostic value of the temporal course of S100 beta protein in post-acute severe brain injury: A prospective and observational study	BRAIN INJURY			English	Article						Acute brain injury; traumatic brain injury; serum S100 beta; brain injury biomarker; brain injury outcome	SERUM S-100B PROTEIN; SEVERE HEAD-INJURY; TRAUMATIC BRAIN; S100B; DAMAGE; MULTICENTER; TOMOGRAPHY; BIOMARKERS; PRESSURE; ADULTS	Methods and procedures: Eighty-seven patients with severe TBI were studied. Clinical and CT scan were taken at admission. S100 beta concentration was quantified at admission and 24, 48 and 72 hours post-TBI (days 0, 1, 2 and 3). Outcome was assessed 12 months after discharge using Glasgow Outcome Score (GOS). Results: Significant negative correlations were found between 1-year GOS and S100 beta concentrations on days 1-3, but not on day 0. Deceased patients showed higher S100 beta concentration than survivors on days 1-3. Good (GOS = 4-5) vs poor outcome (GOS = 1-3) differed significantly on day 3. Death outcome was independently predicted by day 2 (> 2.37 mu g l<SU-1</SU), day 3 (> 1.41 mu g l<SU-1</SU) samples and absence of pupillary reaction. Poor outcome was predicted independently only by pupillary reaction and the 72-hour sample (> 1.1 mu g l<SU-1</SU), but this predictive model was less satisfactory than the predictive model for death. Conclusions: A temporal profile of S100 beta release from admission to 72 hours post-TBI is strongly recommended for use in identifying patients at risk of developing a worse outcome. The S100 beta protein might be an early biomarker for predicting long-term outcome in patients with acute severe TBI.	[Murillo-Cabezas, Francisco; Angeles Munoz-Sanchez, Maria; Dolores Rincon-Ferrari, Maria; Amaya-Villar, Rosario; Garcia-Gomez, Susana] Univ Hosp Virgen del Rocio, Intens Care Unit, Seville, Spain; [Francisco Martin-Rodriguez, Juan; Leon-Carrion, Jose] Univ Seville, Human Neuropsychol Lab, Ctr Brain Injury Rehabil CRECER, Seville, Spain	Murillo-Cabezas, F (corresponding author), HHUU Virgen del Rocio, Dept Emergency & Crit Care, Avda Manuel Siurot S-N, Seville 41013, Spain.	murillomunoz@telefonica.net	Murillo-Cabezas, Francisco/AAO-3348-2021; IBIS, NEUROCRITICOS/C-1805-2016	Martin Rodriguez, Juan Francisco/0000-0003-1392-8775			Alber B, 2005, CLIN CHEM LAB MED, V43, P557, DOI 10.1515/CCLM.2005.097; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bishop Y.M., 2007, DISCRETE MULTIVARIAT; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; JENNETT B, 1975, LANCET, V1, P480; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Korfias S, 2006, CURR MED CHEM, V13, P3719, DOI 10.2174/092986706779026129; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McKeating EG, 1998, ACT NEUR S, V71, P117; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	31	28	30	0	10	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2010	24	4					609	619		10.3109/02699051003652823			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	570ML	WOS:000275682300005	20235763				2021-06-18	
J	O'Neill, B; Moran, K; Gillespie, A				O'Neill, Brian; Moran, Kate; Gillespie, Alex			Scaffolding rehabilitation behaviour using a voice-mediated assistive technology for cognition	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Assistive technology for cognition; Executive function; Guide; Complex behaviour; Limb-donning; Activities of daily living	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; MEMORY AIDS; PEOPLE; PREDICTORS; INDIVIDUALS; STRATEGIES; DISORDERS; SYSTEM	A variety of cognitive deficits can lead to difficulties performing complex behavioural sequences and thus, disability in the performance of routine and rehabilitation behaviours. Interventions to date involve increasing support or providing behavioural training. Assistive technologies for cognition have the potential to augment cognitive capacity thus enabling the performance of behavioural sequences. Guide is an assistive technology for cognition that scaffolds task performance by providing verbal prompts and responding to verbal feedback. Guide was used to provide verbal support and guidance for eight amputees (mean age 64), with cognitive impairment of vascular origin, putting on their prosthetic limbs. Participants were referred to the research due to problems learning the correct behavioural sequence. The research used repeated trials with random assignment to intervention and baseline conditions. The voice-mediated assistive technology for cognition resulted in a significant reduction of safety critical errors and omitted steps. Discussion focuses upon the relation between voice-mediated cognitive support for memory and executive function, and suggestions are made for future research.	[O'Neill, Brian; Gillespie, Alex] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; [O'Neill, Brian] Brain Injury Rehabil Trust, Glasgow, Lanark, Scotland; [Moran, Kate] Ayrshire Cent Hosp, Irvine, Ayr, Scotland	O'Neill, B (corresponding author), Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland.	brian.oneill@thedtgroup.org			Chief Scientist Office [CZG/2/319]; West of Scotland Mobility and Rehabilitation Centre	The authors would like to acknowledge the financial support of a Chief Scientist Office Research Grant (CZG/2/319). The support of Helen Scott and the therapy staff at the West of Scotland Mobility and Rehabilitation Centre was invaluable.	BACKMAN L, 1992, PSYCHOL BULL, V112, P259, DOI 10.1037/0033-2909.112.2.259; Bakeman R., 1997, OBSERVING INTERACTIO, V2nd; BALTES PB, 1987, DEV PSYCHOL, V23, P611, DOI 10.1037/0012-1649.23.5.611; Bergman MM, 2002, J HEAD TRAUMA REHAB, V17, P431, DOI 10.1097/00001199-200210000-00005; Berk L., 1995, SCAFFOLDING CHILDREN; BURGESS PW, 2000, PSYCHOL RES, V63, P379; Caplan D, 1997, J SPEECH LANG HEAR R, V40, P542, DOI 10.1044/jslhr.4003.542; CARMIEN S, 2005, P CHI 05 C HUM FACT, P1252, DOI DOI 10.1145/1056808.1056889; CAVALIER AR, 1993, P REH ENG SCO N AM R, P216; Cole E, 1999, NEUROREHABILITATION, V12, P39; Cornish F, 2009, J HEALTH PSYCHOL, V14, P800, DOI 10.1177/1359105309338974; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; CURRAN C, 2004, DISS ABSTR INT B, V64, P4074; DONAGHEY CL, CLIN REHABI IN PRESS; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Evans JJ, 2003, STUD NEUROPSYCHOL DE, P53; Feyereisen P, 1999, NEUROPSYCHOL REHABIL, V9, P169, DOI 10.1080/713755598; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; GILLESPIE A, J THEORY SO IN PRESS; Gitlin LN, 2002, GERONTOLOGIST, V42, P61, DOI 10.1093/geront/42.1.61; Gregor P, 2004, NEUROPSYCHOL REHABIL, V14, P1, DOI 10.1080/09602010343000093; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Inglis E. A., 2003, Universal Access in the Information Society, V2, P226, DOI 10.1007/s10209-003-0057-7; Iverson GL, 1998, INT J GERIATR PSYCH, V13, P661, DOI 10.1002/(SICI)1099-1166(1998100)13:10<661::AID-GPS838>3.0.CO;2-0; Kapur N, 2004, NEUROPSYCHOL REHABIL, V14, P41, DOI 10.1080/09602010343000138; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; Kirsch NL, 2004, J HEAD TRAUMA REHAB, V19, P366, DOI 10.1097/00001199-200409000-00002; Krabbendam L, 1999, CLIN NEUROPSYCHOL, V13, P370, DOI 10.1076/clin.13.3.370.1739; Lancioni GE, 1999, J INTELL DISABIL RES, V43, P61, DOI 10.1046/j.1365-2788.1999.43120165.x; LANGA KM, 2004, J GEN INTERNAL MED, V16, P770; Langan-Fox J, 2007, AUST PSYCHOL, V42, P39, DOI 10.1080/00050060600827607; LaPlante MP, 2002, HEALTH SERV RES, V37, P397, DOI 10.1111/1475-6773.029; Larner S, 2003, CLIN REHABIL, V17, P493, DOI 10.1191/0269215503cr641oa; Levinson R, 1997, J HEAD TRAUMA REHAB, V12, P85, DOI 10.1097/00001199-199704000-00010; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; Luria A. R., 1961, ROLE SPEECH REGULATI; Mathuranath PS, 2000, NEUROLOGY, V55, P1613, DOI 10.1212/01.wnl.0000434309.85312.19; Maxwell JP, 2001, Q J EXP PSYCHOL-A, V54, P1049, DOI 10.1080/02724980143000073; Mihailidis A, 2004, NEUROPSYCHOL REHABIL, V14, P135, DOI 10.1080/09602010343000156; O'Neill B, 2008, PSYCHOPROSTHETICS ST; O'Neill B, 2008, J ASSIST TECHNOL, V2, P22, DOI 10.1108/17549450200800015; O'Neill BF, 2009, DISABIL REHABIL, V31, P1083, DOI 10.1080/09638280802509579; Pea RD, 2004, J LEARN SCI, V13, P423, DOI 10.1207/s15327809jls1303_6; Pijnenborg GHM, 2007, REHABIL PSYCHOL, V52, P236, DOI 10.1037/0090-5550.52.2.236; Proot I M, 2000, Clin Nurs Res, V9, P460, DOI 10.1177/10547730022158690; Randolph C, 1998, REPEATABLE BATTERY A; Scherer M., 2001, ASSISTIVE TECHNOLOGY; Schoppen T, 2003, ARCH PHYS MED REHAB, V84, P803, DOI 10.1016/S0003-9993(02)04952-3; Semkovska M, 2004, SCHIZOPHR RES, V69, P289, DOI 10.1016/j.schres.2003.07.005; Shepherd A, 2001, HIERARCHICAL TASK AN; Stone CA, 1998, J LEARN DISABIL-US, V31, P344, DOI 10.1177/002221949803100404; Tierney MC, 2007, AM J GERIAT PSYCHIAT, V15, P140, DOI 10.1097/01.JGP.0000230661.32735.c0; Todman J. B., 2001, SINGLE CASE SMALL N; Vygotsky L. S., 1994, VYGOTSKY READER; Wherton JP, 2008, INT J HUM-COMPUT ST, V66, P571, DOI 10.1016/j.ijhcs.2008.03.001; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Winsler A, 2003, CHILD DEV, V74, P659, DOI 10.1111/1467-8624.00561; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239; Ylvisaker M., 2003, BRAIN IMPAIR, V4, P1, DOI [10.1375/brim.4.1.1.27031, DOI 10.1375/brim.4.1.1.27031]; Zittoun T, 2007, HUM DEV, V50, P208, DOI 10.1159/000103361	61	28	28	0	11	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	4					509	527	PII 919471431	10.1080/09602010903519652			19	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	622BT	WOS:000279634300002	20182951	Green Accepted			2021-06-18	
J	Panayiotou, A; Jackson, M; Crowe, SF				Panayiotou, Anita; Jackson, Martin; Crowe, Simon F.			A meta-analytic review of the emotional symptoms associated with mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Postconcussion syndrome; Mild traumatic brain injury; Meta-analysis; Depression; Anxiety	POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSION-LIKE SYMPTOMS; POST-CONCUSSION SYNDROME; HEAD-INJURY; CHRONIC PAIN; BASE RATES; EXPECTATION; DEPRESSION; QUESTIONNAIRE; LITIGATION	Given the prevalence of mild traumatic brain injury (mTBI) and enduring subjective complaints known as postconcussion symptoms (PCS), it is important to investigate the nature and extent of these difficulties. This study used meta-analytic techniques to integrate the available information on the emotional symptoms associated with mTBI. Small effect sizes were found across all domains (depression, anxiety, coping, and psychosocial disability); however, significance depended upon the weighting method employed. The results indicate that mTBI had a small to negligible effect on emotional symptom reporting. This has implications for the etiology of PCS, the delivery of therapeutic interventions, and medico-legal disputations.	[Panayiotou, Anita; Jackson, Martin; Crowe, Simon F.] La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3086, Australia	Crowe, SF (corresponding author), La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3086, Australia.	s.crowe@latrobe.edu.au		Crowe, Simon/0000-0002-4407-8542			Alfano DP, 2000, BRAIN COGNITION, V44, P90; Axelrod BN, 1998, ARCH CLIN NEUROPSYCH, V13, P543, DOI 10.1016/S0887-6177(97)00044-9; BECK A, 1997, BECK ANXIETY INVENTO; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bell BD, 1999, ARCH CLIN NEUROPSYCH, V14, P389, DOI 10.1016/S0887-6177(98)00020-1; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Derogatis L.R., 1994, SCL 90 R ADM SCORING, V3rd; DEROGATIS LR, 1983, SYMPTOM CHECKLIST 90, V2; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Glass GV., 1981, METAANALYSIS SOCIAL; Goldberg D.P, 1972, DETECTION PSYCHIAT I; Goodyear B., 1998, FORENSIC EXAMINER, V7, P32; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Hedges L.V., 1985, STAT METHODS META AN; Helps Y., 2008, HOSP SEPARATIONS DUE; Hillier SL, 1997, BRAIN INJURY, V11, P649; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Littell J. H., 2008, SYSTEMATIC REV META; Malec JF, 1997, ARCH PHYS MED REHAB, V78, P334, DOI 10.1016/S0003-9993(97)90045-9; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McCaffrey RJ, 2006, PRACTITIONERS GUIDE; McNair D.M., 1981, MANUAL PROFILE MOOD; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Miller WG, 1986, NEUROPSYCHOLOGY HDB, P347; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; NELSON L, 1994, NEUROBEHAVIORAL BEHA; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Raskin SA, 1997, BRAIN INJURY, V11, P587, DOI 10.1080/026990597123287; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; ROSENTHAL R, 1991, PSYCHOSOM MED, V53, P247, DOI 10.1097/00006842-199105000-00001; Rosenthal R., 1991, META ANAL PROCEDURES, V1st; Rosenthal R., 1984, ESSENTIALS BEHAV RES; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; SCHREURS PJG, 1987, UTRECHTSE COPING LIJ; Slavin R. E., 1986, EDUC RES, V15, P5, DOI [10.3102/0013189X015009005, DOI 10.3102/0013189X015009005]; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WARE JE, 1992, SF 36 HLTH SURVEY MA; Westcott MC, 2005, BRAIN INJURY, V19, P1261, DOI 10.1080/02699050500150104; Wolf F. M., 1986, METAANALYSIS QUANTIT; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	94	28	28	0	20	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	5					463	473	PII 915531020	10.1080/13803390903164371			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	602FS	WOS:000278124500003	20524220				2021-06-18	
J	Park, DH; Eve, DJ; Chung, YG; Sanberg, PR				Park, Dong-Hyuk; Eve, David J.; Chung, Yong-Gu; Sanberg, Paul R.			Regenerative Medicine for Neurological Disorders	THESCIENTIFICWORLDJOURNAL			English	Article						alternative medicine; ASNTR; neuroscience; regenerative medicine; stem cell; transplantation	UMBILICAL-CORD BLOOD; NEURAL STEM-CELLS; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; G93A SOD1 MICE; SPINAL-CORD; ALZHEIMERS-DISEASE; MOUSE MODEL; STEM/PROGENITOR CELLS; PRECURSOR CELLS	The annual meeting of the American Society for Neural Therapy and Repair (ASNTR) has always introduced us to top-notch and up-to-date approaches for regenerative medicine related to neuroscience, ranging from stem cell-based therapy to novel drugs. The 16th ASNTR meeting focused on a variety of different topics, including the unknown pathogenesis or mechanisms of specific neurodegenerative diseases, stem cell biology, and development of novel alternative medicines or devices. Newly developed stem cells, such as amniotic epithelial stem cells and induced pluripotent stem cells, as well as well-known traditional stem cells, such as neural, embryonic, bone marrow mesenchymal, and human umbilical cord blood-derived stem cells, were reported. A number of commercialized stem cells were also covered at this meeting. Fetal neural tissues, such as ventral mesencephalon, striatum, and Schwann cells, were investigated for neurodegenerative diseases or spinal cord injury. A number of studies focused on novel methods for drug monitoring or graft tracking, and combination therapy with stem cells and medicine, such as cytokines or trophic factors. Finally, the National Institutes of Health guidelines for human stem cell research, clinical trials of commercialized stem cells without larger animal testing, and prohibition of medical tourism were big controversial issues that led to heated discussion.	[Park, Dong-Hyuk; Eve, David J.; Sanberg, Paul R.] Univ S Florida, Coll Med, Dept Neurosurg, Ctr Excellence Aging & Brain Repair, Tampa, FL 33620 USA; [Park, Dong-Hyuk; Chung, Yong-Gu] Korea Univ, Coll Med, Dept Neurosurg, Med Ctr, Seoul 136705, South Korea	Eve, DJ (corresponding author), Univ S Florida, Coll Med, Dept Neurosurg, Ctr Excellence Aging & Brain Repair, Tampa, FL 33620 USA.	doctorns@korea.com; deve@health.usf.edu; yongku9@chol.com; psanberg@health.usf.edu					Acosta SA, 2009, CELL TRANSPLANT, V18, P207; Airavaara M, 2009, CELL TRANSPLANT, V18, P207; Andres RH, 2009, CELL TRANSPLANT, V18, P208; Bachstetter AD, 2009, CELL TRANSPLANT, V18, P208; Bacigaluppi M, 2008, THESCIENTIFICWORLDJO, V8, P698, DOI 10.1100/tsw.2008.94; Baek SH, 2009, CELL TRANSPLANT, V18, P209; Behrouz B, 2009, CELL TRANSPLANT, V18, P209; Bergamaschini L, 2009, THESCIENTIFICWORLDJO, V9, P891, DOI 10.1100/tsw.2009.100; Berk MA, 2009, CELL TRANSPLANT, V18, P209; Bernal GM, 2009, CELL TRANSPLANT, V18, P210; BJUGSTAD KB, 2009, TISSUE CELL, V18, P210; Bobek V, 2009, CELL TRANSPLANT, V18, P211; Boger HA, 2009, CELL TRANSPLANT, V18, P211; Brown DR, 2009, THESCIENTIFICWORLDJO, V9, P1061, DOI 10.1100/tsw.2009.111; Chermenina M, 2009, CELL TRANSPLANT, V18, P211; Cicchetti F, 2009, CELL TRANSPLANT, V18, P211; Collado LM, 2009, CELL TRANSPLANT, V18, P212; Daadi MM, 2009, CELL TRANSPLANT, V18, P212; Deb KD, 2009, THESCIENTIFICWORLDJO, V9, P236, DOI 10.1100/tsw.2009.25; Dentelli P, 2008, THESCIENTIFICWORLDJO, V8, P1111, DOI 10.1100/tsw.2008.142; Devi SA, 2009, THESCIENTIFICWORLDJO, V9, P366, DOI 10.1100/tsw.2009.46; Dodiya HB, 2009, CELL TRANSPLANT, V18, P212; Emborg EM, 2009, CELL TRANSPLANT, V18, P213; Eve DJ, 2009, CELL TRANSPLANT, V18, P213; Federici T, 2009, CELL TRANSPLANT, V18, P213; Fortress AM, 2009, CELL TRANSPLANT, V18, P214; Freeman L, 2009, CELL TRANSPLANT, V18, P214; Garbuzova-Davis S, 2009, CELL TRANSPLANT, V18, P214; GARCIARODRIGUEZ JC, 2009, SCI WORLD J, V9, P970, DOI DOI 10.1100/TSW.2009.103; Ghosh M, 2009, CELL TRANSPLANT, V18, P215; Golshani R, 2009, CELL TRANSPLANT, V18, P215; Gombash SE, 2009, CELL TRANSPLANT, V18, P216; Gorenkova N, 2009, CELL TRANSPLANT, V18, P216; Granholm AC, 2009, CELL TRANSPLANT, V18, P216; Guglielmotto M, 2009, THESCIENTIFICWORLDJO, V9, P781, DOI 10.1100/tsw.2009.93; Hallett PJ, 2009, CELL TRANSPLANT, V18, P217; Harvey BK, 2009, CELL TRANSPLANT, V18, P217; Hayashi T, 2009, CELL TRANSPLANT, V18, P217; Hermann DM, 2009, THESCIENTIFICWORLDJO, V9, P967, DOI 10.1100/tsw.2009.104; Hess DC, 2009, CELL TRANSPLANT, V18, P218; Jain A, 2009, CELL TRANSPLANT, V18, P218; JENSEN P, 2009, CELL TRANSPLANT, V18, P218; Jergova S, 2009, CELL TRANSPLANT, V18, P219; Jinwal UK, 2009, CELL TRANSPLANT, V18, P219; Johansson S, 2009, CELL TRANSPLANT, V18, P219; Kelly L, 2009, CELL TRANSPLANT, V18, P220; KHAING ZZ, 2009, CELL TRANSPLANT, V18, P220; Kulkarni SK, 2009, THESCIENTIFICWORLDJO, V9, P1233, DOI 10.1100/tsw.2009.137; Kuruba R, 2009, CELL TRANSPLANT, V18, P221; Lanari A, 2009, THESCIENTIFICWORLDJO, V9, P961, DOI 10.1100/tsw.2009.106; Lee CT, 2009, CELL TRANSPLANT, V18, P221; Lee DC, 2009, CELL TRANSPLANT, V18, P222; Li Q, 2009, CELL TRANSPLANT, V18, P222; Lieu CA, 2009, CELL TRANSPLANT, V18, P222; Luo Y, 2009, CELL TRANSPLANT, V18, P223; Ma BF, 2009, CELL TRANSPLANT, V18, P223; Macklis JD, 2009, CELL TRANSPLANT, V18, P223; Madhavan L, 2009, CELL TRANSPLANT, V18, P224; Maiese K, 2009, THESCIENTIFICWORLDJO, V9, P1072, DOI 10.1100/tsw.2009.121; Maksoud YA, 2009, CELL TRANSPLANT, V18, P224; Manfredsson FP, 2009, CELL TRANSPLANT, V18, P225; Manfredsson FP, 2009, CELL TRANSPLANT, V18, P224; Marschinke F, 2009, CELL TRANSPLANT, V18, P225; Marupudi NI, 2009, CELL TRANSPLANT, V18, P225; Mervis RF, 2009, CELL TRANSPLANT, V18, P226; Miller C, 2009, CELL TRANSPLANT, V18, P226; Mitra S, 2008, THESCIENTIFICWORLDJO, V8, P421, DOI 10.1100/tsw.2008.60; Monahan AJ, 2009, CELL TRANSPLANT, V18, P226; Moradian S, 2009, CELL TRANSPLANT, V18, P227; Musso J, 2009, CELL TRANSPLANT, V18, P227; Nagata T, 2008, THESCIENTIFICWORLDJO, V8, P683, DOI 10.1100/tsw.2008.93; Neckel ND, 2009, CELL TRANSPLANT, V18, P227; Nevalainen N, 2009, CELL TRANSPLANT, V18, P228; Newman MB, 2009, CELL TRANSPLANT, V18, P228; Nguyen T, 2009, CELL TRANSPLANT, V18, P228; Nikas JB, 2009, CELL TRANSPLANT, V18, P229; Pabon MM, 2009, CELL TRANSPLANT, V18, P229; Panza F, 2009, THESCIENTIFICWORLDJO, V9, P373, DOI 10.1100/tsw.2009.48; Parihar VK, 2009, CELL TRANSPLANT, V18, P229; Park DH, 2009, CELL TRANSPLANT, V18, P230; Park JS, 2009, OZONE-SCI ENG, V31, P15, DOI 10.1080/01919510802587143; Pendharkar AV, 2009, CELL TRANSPLANT, V18, P230; Petrovic V, 2009, THESCIENTIFICWORLDJO, V9, P1167, DOI 10.1100/tsw.2009.125; Piao CS, 2009, CELL TRANSPLANT, V18, P231; Priest C, 2009, CELL TRANSPLANT, V18, P231; Quiroz C, 2009, THESCIENTIFICWORLDJO, V9, P1321, DOI 10.1100/tsw.2009.143; Rachubinski A, 2009, CELL TRANSPLANT, V18, P231; Rehnmark A, 2009, CELL TRANSPLANT, V18, P232; Reiss AB, 2009, THESCIENTIFICWORLDJO, V9, P1242, DOI 10.1100/tsw.2009.141; Ross JM, 2009, CELL TRANSPLANT, V18, P232; Rossignol J, 2009, CELL TRANSPLANT, V18, P233; Sanchez-Ramos J, 2009, CELL TRANSPLANT, V18, P233; Scheckhuber CQ, 2009, THESCIENTIFICWORLDJO, V9, P250, DOI 10.1100/tsw.2009.33; Schmitz T, 2008, THESCIENTIFICWORLDJO, V8, P1119, DOI 10.1100/tsw.2008.140; Selenica MLB, 2009, CELL TRANSPLANT, V18, P233; Shahaduzzaman SD, 2009, CELL TRANSPLANT, V18, P234; Sinden J, 2009, CELL TRANSPLANT, V18, P234; Singec I, 2009, CELL TRANSPLANT, V18, P234; Sladek JR, 2009, CELL TRANSPLANT, V18, P234; Smith AJ, 2009, CELL TRANSPLANT, V18, P235; Snyder EY, 2009, CELL TRANSPLANT, V18, P207, DOI 10.3727/096368909788341315; Solfrizzi V, 2009, THESCIENTIFICWORLDJO, V9, P792, DOI 10.1100/tsw.2009.82; Solomon B, 2009, THESCIENTIFICWORLDJO, V9, P909, DOI 10.1100/tsw.2009.99; Soo ETL, 2008, THESCIENTIFICWORLDJO, V8, P270, DOI 10.1100/tsw.2008.48; Spieles-Engemann AL, 2009, CELL TRANSPLANT, V18, P235; Stahl K, 2009, THESCIENTIFICWORLDJO, V9, P811, DOI 10.1100/tsw.2009.68; Steece-Collier K, 2009, CELL TRANSPLANT, V18, P236; Steuer I, 2009, THESCIENTIFICWORLDJO, V9, P490, DOI 10.1100/tsw.2009.63; Stoner S, 2009, CELL TRANSPLANT, V18, P236; Stromberg I, 2009, CELL TRANSPLANT, V18, P237; Teng YD, 2009, CELL TRANSPLANT, V18, P237; Thal DR, 2009, THESCIENTIFICWORLDJO, V9, P557, DOI 10.1100/tsw.2009.72; Thompson VB, 2009, CELL TRANSPLANT, V18, P237; Timmer M, 2009, CELL TRANSPLANT, V18, P238; Vazin T, 2009, CELL TRANSPLANT, V18, P238; Vorobyeva TM, 2009, CELL TRANSPLANT, V18, P239; Wakeman DR, 2009, CELL TRANSPLANT, V18, P239; Walczak P, 2009, CELL TRANSPLANT, V18, P239; Wang L, 2009, CELL TRANSPLANT, V18, P240; Womble TA, 2009, CELL TRANSPLANT, V18, P240; Woods RL, 2009, CELL TRANSPLANT, V18, P241; Worden LT, 2009, CELL TRANSPLANT, V18, P241; Yu S, 2009, CELL TRANSPLANT, V18, P241; Zhu Y, 2009, CELL TRANSPLANT, V18, P242	124	28	28	0	32	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1537-744X			THESCIENTIFICWORLDJO	TheScientificWorldJOURNAL		2010	10						470	489		10.1100/tsw.2010.39			20	Environmental Sciences; Multidisciplinary Sciences	Environmental Sciences & Ecology; Science & Technology - Other Topics	573BB	WOS:000275882300006	20305989	DOAJ Gold, Green Published			2021-06-18	
J	Williams, C; Wood, RL				Williams, Claire; Wood, Rodger Ll.			Impairment in the recognition of emotion across different media following traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Emotion recognition; Affective valence; Cognitive tests; Media presentation	CLOSED-HEAD INJURY; DIFFUSE AXONAL INJURY; SOCIAL-PERCEPTION; FACIAL EXPRESSIONS; AMYGDALA DAMAGE; FACES; LESIONS; COMMUNICATION; ALEXITHYMIA; VALIDITY	The current study examined emotion recognition following traumatic brain injury (TBI) and examined whether performance differed according to the affective valence and type of media presentation of the stimuli. A total of 64 patients with TBI and matched controls completed the Emotion Evaluation Test (EET) and Ekman 60 Faces Test (E-60-FT). Patients with TBI also completed measures of information processing and verbal ability. Results revealed that the TBI group were significantly impaired compared to controls when recognizing emotion on the EET and E-60-FT. A significant main effect of valence was found in both groups, with poor recognition of negative emotions. However, the difference between the recognition of positive and negative emotions was larger in the TBI group. The TBI group were also more accurate recognizing emotion displayed in audiovisual media (EET) than that displayed in still media (E-60-FT). No significant relationship was obtained between emotion recognition tasks and information-processing speed. A significant positive relationship was found between the E-60-FT and one measure of verbal ability. These findings support models of emotion that specify separate neurological pathways for certain emotions and different media and confirm that patients with TBI are vulnerable to experiencing emotion recognition difficulties.	[Williams, Claire; Wood, Rodger Ll.] Swansea Univ, Dept Psychol, Sch Human Sci, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales	Williams, C (corresponding author), Swansea Univ, Dept Psychol, Sch Human Sci, Brain Injury Res Grp, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	200528@swansea.ac.uk		Williams, Claire/0000-0002-0791-744X	Brain Injury Rehabilitation Trust, UK	Funding for this research was obtained, in part, from the Brain Injury Rehabilitation Trust, UK.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams RB, 2003, SCIENCE, V300, P1536, DOI 10.1126/science.1082244; Adolphs R, 2002, J COGNITIVE NEUROSCI, V14, P1264, DOI 10.1162/089892902760807258; Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2003, BRAIN COGNITION, V52, P61, DOI 10.1016/S0278-2626(03)00009-5; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; BASSILI JN, 1978, J EXP PSYCHOL HUMAN, V4, P373, DOI 10.1037/0096-1523.4.3.373; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; BOWERS D, 1985, BRAIN COGNITION, V4, P258, DOI 10.1016/0278-2626(85)90020-X; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Ekman P., 1976, PICTURES FACIAL AFFE; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; HUMPHREYS GW, 1993, NEUROPSYCHOLOGIA, V31, P173, DOI 10.1016/0028-3932(93)90045-2; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; Lane RD, 1996, PSYCHOSOM MED, V58, P203, DOI 10.1097/00006842-199605000-00002; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S., 2002, AWARENESS SOCIAL INF; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; PARRY FM, 1991, J CLIN EXP NEUROPSYC, V13, P545, DOI 10.1080/01688639108401070; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SCHERER KR, 1991, MOTIV EMOTION, V15, P123, DOI 10.1007/BF00995674; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Spreen O., 1998, COMPENDIUM NEUROPSYC; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; Taylor G. J., 1997, DISORDERS AFFECT REG; TEASDALE G, 1974, LANCET, V2, P81; Tulsky D., 1997, WAIS 3 WMS 3 TECHNIC; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518; Young A., 2002, FACIAL EXPRESSIONS E	51	28	28	0	18	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	2					113	122		10.1080/13803390902806543			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	550YX	WOS:000274172300001	19484648				2021-06-18	
J	Bernabeu, M; Demirtas-Tatlidede, A; Opisso, E; Lopez, R; Tormos, JM; Pascual-Leone, A				Bernabeu, Montse; Demirtas-Tatlidede, Asli; Opisso, Eloy; Lopez, Raquel; Ma Tormos, Jose; Pascual-Leone, Alvaro			Abnormal Corticospinal Excitability in Traumatic Diffuse Axonal Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						corticospinal excitability; diffuse axonal injury; transcranial magnetic stimulation; traumatic brain injury	TRANSCRANIAL MAGNETIC STIMULATION; SILENT PERIOD; MOTOR CORTEX; HEAD-INJURY; INHIBITION; RECOVERY; POTENTIALS; MODERATE	This study aimed to investigate the cortical motor excitability characteristics in diffuse axonal injury (DAI) due to severe traumatic brain injury (TBI). A variety of excitatory and inhibitory transcranial magnetic stimulation (TMS) paradigms were applied to primary motor cortices of 17 patients and 11 healthy controls. The parameters of testing included resting motor threshold (MT), motor evoked potential (MEP) area under the curve, input-output curves, MEP variability, and silent period (SP) duration. The patient group overall revealed a higher MT, smaller MEP areas, and narrower recruitment curves compared to normal controls (p<0.05). The alterations in excitability were more pronounced with an increase in DAI severity (p<0.005) and the presence of motor impairment (p<0.05), while co-existence of focal lesions did not affect the degree of MEP changes. MEP variability was significantly lower in the group with motor impairment only (p<0.05). The intracortical inhibition, as revealed by SP duration, did not exhibit any significant differences in any of the patient groups. In conclusion, our findings expand the concept that impairment of the excitatory and inhibitory phenomena in the motor cortex does not proceed in parallel and demonstrate distinct patterns of aberrations in TBI. Furthermore, these data suggest that alterations in the corticospinal excitatory mechanisms are determined predominantly by the severity of DAI, and show a significant relationship with clinical motor dysfunction following severe trauma diffusely affecting the motor cortical connections. In severe TBI, motor and functional recovery might be linked to restitution of normal corticospinal mechanisms, indexed by normalization of the cortical excitability parameters.	[Demirtas-Tatlidede, Asli; Pascual-Leone, Alvaro] Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA; [Bernabeu, Montse; Opisso, Eloy; Lopez, Raquel; Ma Tormos, Jose] Guttmann Univ, Inst Neurorehabil UAB, Badalona, Spain	Pascual-Leone, A (corresponding author), Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, 330 Brookline Ave KS 158, Boston, MA 02215 USA.	apleone@bidmc.harvard.edu	Pascual-Leone, Alvaro/G-6566-2011; Pascual-Leone, Alvaro/AAC-5101-2019	Pascual-Leone, Alvaro/0000-0001-8975-0382; Demirtas-Tatlidede, MD, PhD, Asli/0000-0003-2050-5674; Tormos Munoz, Jose Maria/0000-0002-8764-2289	BBVA Translational Research Chair in BiomedicineBBVA Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K 24 RR018875]; Instituto de Salud Carlos III ResearchInstituto de Salud Carlos III; Non-Invasive Brain Stimulation; Robot-Assisted Rehabilitation to Improve TBI [PI082004]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K24RR018875] Funding Source: NIH RePORTER	Supported in part by a BBVA Translational Research Chair in Biomedicine, and a mentoring grant form the National Institutes of Health (K 24 RR018875), and the Instituto de Salud Carlos III Research Grant, Non-Invasive Brain Stimulation and Robot-Assisted Rehabilitation to Improve TBI recovery (PI082004). Special thanks go to Dr. Felip Orient, who assisted in collecting part of the data. We would also like to take this opportunity to thank the anonymous peer reviewers, whose reviews greatly helped to improve the manuscript.	Abbruzzese G, 2002, J CLIN NEUROPHYSIOL, V19, P307, DOI 10.1097/00004691-200208000-00005; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Catano A, 1997, ELECTROMYOGR MOTOR C, V105, P290, DOI 10.1016/S0924-980X(97)00021-0; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; Damron LA, 2008, J NEUROSCI METH, V173, P121, DOI 10.1016/j.jneumeth.2008.06.001; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Fujiki M, 2006, NEUROSCI LETT, V405, P226, DOI 10.1016/j.neulet.2006.07.005; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; HALLETT M, 1995, ADV NEUROL, V67, P107; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; KIERS L, 1993, ELECTROEN CLIN NEURO, V89, P415, DOI 10.1016/0168-5597(93)90115-6; KIERS L, 1995, ELECTROMYOGR MOTOR C, V97, P131, DOI 10.1016/0924-980X(94)00325-2; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lopantsev V, 1999, J NEUROPHYSIOL, V82, P1218; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; Moosavi SH, 1999, J NEUROL SCI, V164, P179, DOI 10.1016/S0022-510X(99)00065-9; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Pena-Casanova J, 1997, Neurologia, V12, P99; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; REID AE, 2002, HDB TRANSCRANIAL MAG, P97; ROICK H, 1993, EXP BRAIN RES, V94, P489, DOI 10.1007/BF00230207; Rossini P M, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P171; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.3.CO;2-O; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; STERIADE M, 1990, ELECTROEN CLIN NEURO, V76, P481, DOI 10.1016/0013-4694(90)90001-Z; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Weber HK, 1997, J MOL CATAL B-ENZYM, V3, P131, DOI 10.1016/S1381-1177(96)00045-8; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073	43	28	28	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2185	2193		10.1089/neu.2008.0859			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200006	19604100	Green Published			2021-06-18	
J	Matschke, J; Voss, J; Obi, N; Gorndt, J; Sperhake, JP; Puschel, K; Glatzel, M				Matschke, Jakob; Voss, Janina; Obi, Nadia; Goerndt, Jennifer; Sperhake, Jan-Peter; Pueschel, Klaus; Glatzel, Markus			Nonaccidental Head Injury Is the Most Common Cause of Subdural Bleeding in Infants < 1 Year of Age	PEDIATRICS			English	Article						abusive head trauma; subdural bleeding; nonaccidental head injury; infant; forensic neuropathology	SHAKEN BABY SYNDROME; DURAL HEMORRHAGE; HEMATOMA; DEATHS; DIAGNOSIS; CHILDREN; EXPLAIN	OBJECTIVE: Subdural bleeding (SDB) in infants is considered an essential symptom of nonaccidental head injury (NAHI). Recently, this view has been challenged by the "unified hypothesis," which claims that SDB in infants is related to hypoxia and brain swelling rather than to traumatic shearing of bridging veins. We analyzed a large series of infants' autopsies for the presence and causes of SDB, which should be a common event according to the unified hypothesis. METHODS: Autopsy, clinical, and legal information for infants <1 year of age from a single institution over 50 years were analyzed regarding cause of death, presence, morphology, and cause of SDB, and brain weight. RESULTS: From a total of 16 661 autopsies during the study period, 715 (4.3%) involved infants <1 year of age. Fifty (7.0%) of those had SDB. NAHI was identified in 17 patients. The most common cause of SDB was trauma (15 cases [30.0%]), with NAHI accounting for 14 cases. SDB was present in 82.4% of patients with NAHI but only 5.2% of infants with other causes of death. Four patients (8.0%) had unexplained SDB with no discernible cause of bleeding. Statistical analysis did not reveal any correlation between the presence of SDB and brain weight. CONCLUSIONS: In the study population, unexplained SDB in infants was an extreme rarity. Moreover, a correlation between brain swelling and the presence of SDB could not be drawn. Our data argue strongly against the unified hypothesis and strengthen the association between SDB and NAHI in infancy. Pediatrics 2009;124:1587-1594	[Matschke, Jakob; Voss, Janina; Glatzel, Markus] Univ Med Ctr Hamburg Eppendorf, Inst Neuropathol, D-20246 Hamburg, Germany; [Voss, Janina; Goerndt, Jennifer; Sperhake, Jan-Peter; Pueschel, Klaus] Univ Med Ctr Hamburg Eppendorf, Inst Legal Med, D-20246 Hamburg, Germany; [Obi, Nadia] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, D-20246 Hamburg, Germany	Matschke, J (corresponding author), Univ Med Ctr Hamburg Eppendorf, Inst Neuropathol, Martinistr 52, D-20246 Hamburg, Germany.	matschke@uke.de	Glatzel, Markus/G-3356-2011; Matschke, Jakob/F-6641-2013; Glatzel, Markus/V-8844-2019	Glatzel, Markus/0000-0002-7720-8817; Matschke, Jakob/0000-0001-6080-0198; Glatzel, Markus/0000-0002-7720-8817			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Block RW, 2004, PEDIATRICS, V113, P432, DOI 10.1542/peds.113.2.432; Byard RW, 2007, PEDIATR DEVEL PATHOL, V10, P348, DOI 10.2350/06-08-0154.1; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; Dawson TP, 2003, NEUROPATHOLOGY TECHN; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; Geddes JF, 2004, BMJ-BRIT MED J, V328, P719, DOI 10.1136/bmj.328.7442.719; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Harding B, 2004, BMJ-BRIT MED J, V328, P720, DOI 10.1136/bmj.328.7442.720; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Hoskote A, 2002, CHILD NERV SYST, V18, P311, DOI 10.1007/s00381-002-0616-x; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; Kemp AM, 2002, ARCH DIS CHILD, V86, P98, DOI 10.1136/adc.86.2.98; King WJ, 2003, CAN MED ASSOC J, V168, P155; Krous HF, 2004, PEDIATRICS, V114, P234, DOI 10.1542/peds.114.1.234; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; Matschke J, 2007, PEDIATR NEUROSURG, V43, P330, DOI 10.1159/000103317; Matschke J, 2009, INT J LEGAL MED, V123, P189, DOI 10.1007/s00414-008-0293-8; Miller M, 2004, PEDIATRICS, V114, P326, DOI 10.1542/peds.114.1.326; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Punt J, 2006, ARCH DIS CHILD, V91, P714; Punt J, 2004, Pediatr Rehabil, V7, P173, DOI 10.1080/13638490410001711515; Richards PG, 2006, ARCH DIS CHILD, V91, P205, DOI 10.1136/adc.2005.090761; SKULLERUD K, 1985, ACTA NEUROL SCAND, V71, P5; Smith C, 2003, NEUROPATH APPL NEURO, V29, P411, DOI 10.1046/j.1365-2990.2003.00500.x; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3; Uscinski R, 2002, BRIT J NEUROSURG, V16, P217, DOI 10.1080/02688690220148978; Uscinski RH, 2006, NEUROL MED-CHIR, V46, P57, DOI 10.2176/nmc.46.57; Uscinski RH, 2004, J NEUROSURG, V100, P574; Wilkins B, 1997, ARCH DIS CHILD, V76, P393, DOI 10.1136/adc.76.5.393	38	28	30	0	8	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2009	124	6					1587	1594		10.1542/peds.2008-3734			8	Pediatrics	Pediatrics	524SE	WOS:000272162400011	19948629				2021-06-18	
J	Castillo, LG; Caver, KA				Castillo, Linda G.; Caver, Kelly A.			Expanding the Concept of Acculturation in Mexican American Rehabilitation Psychology Research and Practice	REHABILITATION PSYCHOLOGY			English	Article						Mexican American; acculturation; enculturation; rehabilitation	TRAUMATIC BRAIN-INJURY; FAMILY SUPPORT; HEALTH; PREDICTORS; HISPANICS; IDENTITY; MACHISMO; BELIEFS; CANCER; ISSUES	The acculturation process is increasingly being viewed as an important variable that provides a context for understanding Mexican American health disparities. Although rehabilitation psychologists have noted the importance of utilizing acculturation in research and practice, scholars continue to use out-dated conceptualizations and models of acculturation. Objectives: The authors provide a brief overview of current trends in acculturation theory and research. Limitations of current rehabilitation research and how acculturation theory can help explain Mexican American health outcomes are discussed. Finally, recommendations for rehabilitation research and practice are provided. Conclusions: The authors recommend that rehabilitation scholars develop and test theoretical models that incorporates multiple dimensions of acculturation in order to understand how it influences Mexican American health outcomes. Rehabilitation professionals should incorporate acculturation theory and culturally informed interventions into rehabilitation practice with Mexican Americans.	[Castillo, Linda G.; Caver, Kelly A.] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA	Castillo, LG (corresponding author), Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA.	lcastillo@tamu.edu	Castillo, Linda/A-5208-2010	Castillo, Linda/0000-0001-7634-7973			Abraido-Lanza AF, 2007, ETHNIC DIS, V17, P153; Abraido-Lanza AF, 2006, AM J PUBLIC HEALTH, V96, P1342, DOI 10.2105/AJPH.2005.064980; AGUIRREMOLINA M, 2001, HLTH ISSUES LATINO C; *AM PSYCH ASS, 2002, AM PSYCHOL, V57, P1060, DOI DOI 10.1037/0003-066X.57.12.1060; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Arciniega GM, 2008, J COUNS PSYCHOL, V55, P19, DOI 10.1037/0022-0167.55.1.19; Arends-Toth J, 2006, MON PARENT, P33; Berry J.W., 1980, ACCULTURATION THEORY, P9, DOI DOI 10.1525/AE.1981.8.4.02A00200; Berry J. W., 2003, ACCULTURATION ADV TH, P17, DOI [10.1037/10472-004, DOI 10.1037/10472-004]; Berry J.W., 1986, FIELD METHODS CROSS, P291; BERRY JW, 1989, APPL PSYCHOL-INT REV, V38, P185, DOI 10.1111/j.1464-0597.1989.tb01208.x; Boone KB, 2007, ARCH CLIN NEUROPSYCH, V22, P355, DOI 10.1016/j.acn.2007.01.010; Bourhis RY, 1997, INT J PSYCHOL, V32, P369, DOI 10.1080/002075997400629; BUNDEK NI, 1993, HEALTH PSYCHOL, V12, P193, DOI 10.1037/0278-6133.12.3.193; Caballero AE, 2006, ETHNIC DIS, V16, P559; CANUL GD, 1994, J CLIN PSYCHOL, V50, P736, DOI 10.1002/1097-4679(199409)50:5<736::AID-JCLP2270500511>3.0.CO;2-Z; Carter-Pokras O., 2001, HLTH ISSUES LATINO C, P23; Castillo LG, 2004, J COUNS PSYCHOL, V51, P151, DOI 10.1037/0022-0167.51.2.151; Castillo LG, 2008, INT J STRESS MANAGE, V15, P43, DOI DOI 10.1037/1072-5245.15.1.43; CASTILLO LG, 2007, CROSS CULTURAL PSYCH, P85; CASTILLO LG, 2009, CONSTRUCTION V UNPUB; Castillo Linda G, 2007, Cultur Divers Ethnic Minor Psychol, V13, P232, DOI 10.1037/1099-9809.13.3.232; CAVALLO MM, 1995, J HEAD TRAUMA REHAB, V10, P66, DOI 10.1097/00001199-199504000-00008; Cianelli R, 2008, CULT HEALTH SEX, V10, P297, DOI 10.1080/13691050701861439; CUELLAR I, 1995, HISPANIC J BEHAV SCI, V17, P275, DOI 10.1177/07399863950173001; Cuellar I., 2004, HDB CHICANA PSYCHOL, P23; Dunn DS, 2008, REHABIL PSYCHOL, V53, P254, DOI 10.1037/a0012962; Edwards LM, 2006, J COUNS PSYCHOL, V53, P279, DOI 10.1037/0022-0167.53.3.279; ELLIOTT TR, 2007, PSYCHOL MANAGEMENT P, P16; FALICOV CJ, 2003, SPIRITUAL RESOURCES, P104; Getrich C, 2007, SOC SCI MED, V65, P319, DOI 10.1016/j.socscimed.2007.03.004; Gordon Milton, 1964, ASSIMILATION AM LIFE; GRAVES TD, 1967, SOUTHWEST J ANTHROP, V23, P337, DOI 10.1086/soutjanth.23.4.3629450; Hanson SL, 2007, REHABIL PSYCHOL, V52, P409, DOI 10.1037/0090-5550.52.4.409; Helms JE, 2005, AM PSYCHOL, V60, P27, DOI 10.1037/0003-066X.60.1.27; HOGG MA, 2005, SOCIAL OUTCAST OSTRA, P243; Hovell M, 2003, SOC SCI MED, V56, P1789, DOI 10.1016/S0277-9536(02)00176-4; Hubbell FA, 1996, ARCH INTERN MED, V156, P2353, DOI 10.1001/archinte.156.20.2353; Jetten J, 2004, J PERS SOC PSYCHOL, V86, P862, DOI 10.1037/0022-3514.86.6.862; Kim B. S. K., 2007, HDB ASIAN AM PSYCHOL, P141; Kim B.S.K., 2001, HDB MULTICULTURAL CO, V2nd, P394; Kochhar Rakesh., 2005, OCCUPATIONAL STATUS; KOHATSU EL, 2005, HDB RACIAL CULTURAL, V1, P207; Kumpfer KL., 1999, RESILIENCE DEV POSIT, P179, DOI DOI 10.1007/B108350; LAFROMBOISE T, 1993, PSYCHOL BULL, V114, P395, DOI 10.1037/0033-2909.114.3.395; Livingston G., 2008, HISPANICS HLTH CARE; Losada A, 2006, AGING MENT HEALTH, V10, P69, DOI 10.1080/13607860500307647; MARIN G, 2003, ACCULTURATION ADV TH, P17; Moreno CL, 2007, QUAL HEALTH RES, V17, P340, DOI 10.1177/1049732306297387; *NAT ALL HISP HLTH, 2001, PRIM CULT PROF QUAL; NEFF JA, 1993, J COMMUNITY PSYCHOL, V21, P3, DOI 10.1002/1520-6629(199301)21:1<3::AID-JCOP2290210102>3.0.CO;2-9; Neville HA, 2000, REHABIL PSYCHOL, V45, P89, DOI 10.1037/0090-5550.45.1.89; Niemeier J, 2007, J HEAD TRAUMA REHAB, V22, P75, DOI 10.1097/01.HTR.0000265095.06565.7b; Niemeier JP, 2003, ARCH PHYS MED REHAB, V84, P1240, DOI 10.1016/S0003-9993(03)00295-8; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Oquendo MA, 2005, J NERV MENT DIS, V193, P438, DOI 10.1097/01.nmd.0000168262.06163.31; PANIAGUA FA, 2005, ASSESSING TREATING C; Parra EO, 2001, AIDS PATIENT CARE ST, V15, P83, DOI 10.1089/108729101300003681; Passel J. S., 2008, US POPULATION PROJEC; PEREZSTABLE EJ, 1992, JAMA-J AM MED ASSOC, V268, P3219, DOI 10.1001/jama.268.22.3219; Phinney JS, 2007, J COUNS PSYCHOL, V54, P271, DOI 10.1037/0022-0167.54.3.271; Phinney JS, 1997, J YOUTH ADOLESCENCE, V26, P165, DOI 10.1023/A:1024500514834; Quintana S.M., 2001, HDB MULTICULTURAL CO, P604; Quintana SM, 1999, COUNS PSYCHOL, V27, P485, DOI 10.1177/0011000099274002; Razani J, 2007, ARCH CLIN NEUROPSYCH, V22, P333, DOI 10.1016/j.acn.2007.01.008; Redfield R, 1936, AM ANTHROPOL, V38, P149, DOI [DOI 10.1525/AA.1936.38.1.02A00330, 10.1525/aa.1936.38.1.02a00330]; ROGLER LH, 1991, AM PSYCHOL, V46, P585, DOI 10.1037/0003-066X.46.6.585; Ryder AG, 2000, J PERS SOC PSYCHOL, V79, P49, DOI 10.1037//0022-3514.79.1.49; Shah M, 2006, CANCER DETECT PREV, V30, P306, DOI 10.1016/j.cdp.2006.04.003; Sharma P, 2002, REHABIL PSYCHOL, V47, P230, DOI 10.1037//0090-5550.47.2.230; Singelis T.M., 1995, CROSS CULTUR RES, V29, P240, DOI [DOI 10.1177/106939719502900302, 10.1177/106939719502900302]; SLAVIN LA, 1991, J COUNS DEV, V70, P156, DOI 10.1002/j.1556-6676.1991.tb01578.x; SMART JF, 1992, J REHABIL, V58, P29; SMEDLEY BD, 2003, UNEQUAL TREATMENT CO; Sobralske M, 2006, J AM ACAD NURSE PRAC, V18, P348, DOI 10.1111/j.1745-7599.2006.00144.x; Sobralske MC, 2006, J TRANSCULT NURS, V17, P129, DOI 10.1177/1043659606286767; SUNDQUIST J, 2000, INT J EPIDEMIOL, V29, P723; Szapocznik J., 1980, INT J INTERCULT RELA, V4, P353, DOI [DOI 10.1016/0147-1767(80)90010-3, 10.1016/0147-1767(80)90010-3]; Tajfel Henri, 1986, PSYCHOL INTERGROUP R, P7, DOI DOI 10.4324/9780203505984-16; Triandis H.C., 2001, BLACKWELL HDB SOCIAL, V4, P367; Unger J.B., 2009, HISP HLTH CARE INT, V7, P145, DOI [10.1891/1540-4153.7.3.145, DOI 10.1891/1540-4153.7.3.145]; Urizar GG, 2006, J BEHAV MED, V29, P255, DOI 10.1007/s10865-006-9050-y; Uswatte G, 1997, REHABIL PSYCHOL, V42, P61, DOI 10.1037/0090-5550.42.1.61; Vaeth PAC, 2005, ANN EPIDEMIOL, V15, P373, DOI 10.1016/j.annepidem.2004.11.003; Vega WA, 1999, AM J PSYCHIAT, V156, P928, DOI 10.1176/ajp.156.6.928; VILLAGRAN M, 2008, EMERGING PERSPECTIVE, P203; Weston R, 2008, REHABIL PSYCHOL, V53, P340, DOI 10.1037/a0013039; Weston R, 2006, COUNS PSYCHOL, V34, P719, DOI 10.1177/0011000006286345; Zane N., 2003, ACCULTURATION ADV TH, P39, DOI DOI 10.1037/10472-005	89	28	28	0	5	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2009	54	4					351	362		10.1037/a0017801			12	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	526YF	WOS:000272331600001	19929116				2021-06-18	
J	Larson, MJ; Kaufman, DAS; Perlstein, WM				Larson, Michael J.; Kaufman, David A. S.; Perlstein, William M.			Conflict adaptation and cognitive control adjustments following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Event-related potentials (ERPs); Conflict; Adaptation; Sequential trial; N450; Conflict SP; Cognitive control; Anterior cingulate cortex (ACC); Gratton; Traumatic brain injury; TBI; Stroop	ANTERIOR CINGULATE CORTEX; WORKING-MEMORY LOAD; CLOSED-HEAD INJURY; SEVERE TBI; NEURAL ACTIVITY; STROOP; TASK; INTERFERENCE; ACTIVATION; ATTENTION	Survivors of severe traumatic brain injury (TBI) often demonstrate impairments in the cognitive control functions of detecting response conflict and signaling for recruitment of cognitive resources to appropriately adjust performance. These cognitive control functions can be measured using conflict adaptation effects, wherein manifestations of conflict detection and processing are reduced following high-relative to low-conflict trials. Event-related potentials (ERPs) were collected while 18 survivors of severe traumatic brain injury (TBI) and 21 demographically matched control participants performed it modified Stroop task. The incongruent-minus-congruent trial Stroop effect for trials preceded by incongruent (high conflict) and congruent (low conflict) trials were compared for behavioral (response time [RT] and error rate) and ERP reflections of cognitive control. Behavioral data showed a reduction in the Stroop effect for both control and TBI participant Us when preceded by incongruent trials. The magnitude of these effects did not differentiate control and TBI participants. ERP data revealed a centro-parietal conflict slow potential (conflict SP) that differentiated incongruent from congruent trials. Planned comparisons showed it decreased amplitude conflict SP when ERPs were preceded by incongruent trials in control, but not TBI participants. Results indicate subtle TBI-related impairments in conflict resolution mechanisms in the context of intact RT-related conflict adaptation. (JINS, 2009, 15, 927-937.)	[Larson, Michael J.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Larson, Michael J.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Kaufman, David A. S.; Perlstein, William M.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Perlstein, William M.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Perlstein, William M.] Univ Florida, McKnight Brain Inst, Gainesville, FL 32611 USA	Larson, MJ (corresponding author), Brigham Young Univ, Dept Psychol, 244 TLRB, Provo, UT 84602 USA.	michael_larson@byu.edu	Larson, Michael J/C-8543-2012	Larson, Michael J/0000-0002-8199-8065	National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F31 NS053335, K01 MH01857, R21 MH073076]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01MH001857, R21MH073076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS053335] Funding Source: NIH RePORTER	This original research has not been published elsewhere and was supported by a pre-doctoral National Institute of Health (NIH) Fellowship to MJL(F31 NS053335) and grants K01 MH01857 and R21 MH073076 from the NIH to WMP. We thank Cortney Mauer, Megan Mclntyre, Drew Nagle, Allen Sirizi, and Raechel Steckley for their assistance in data collection. The authors report no conflicts of interest.	Benton A., 1976, MULTILINGUAL APHASIA; BERG P, 1994, ELECTROEN CLIN NEURO, V90, P229, DOI 10.1016/0013-4694(94)90094-9; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Brandt J., 2001, HOPKINS VERBAL LEARN; Carroll JFX., 2001, MENTAL HLTH SCREENIN; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; di Pellegrino G, 2007, J COGNITIVE NEUROSCI, V19, P275, DOI 10.1162/jocn.2007.19.2.275; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Egner T, 2005, NEUROIMAGE, V24, P539, DOI 10.1016/j.neuroimage.2004.09.007; Egner T, 2007, COGN AFFECT BEHAV NE, V7, P380, DOI 10.3758/CABN.7.4.380; GRATTON G, 1992, J EXP PSYCHOL GEN, V121, P480, DOI 10.1037/0096-3445.121.4.480; Hanslmayr S, 2008, J COGNITIVE NEUROSCI, V20, P215, DOI 10.1162/jocn.2008.20020; Hommel B, 2004, PSYCHOL RES-PSYCH FO, V68, P1, DOI 10.1007/s00426-003-0132-y; Hommel B, 1998, VIS COGN, V5, P183, DOI 10.1080/713756773; Ille N, 2002, J CLIN NEUROPHYSIOL, V19, P113, DOI 10.1097/00004691-200203000-00002; ILLE N, 1997, BIOMED TECH S, V42, P80; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kerns JG, 2006, NEUROIMAGE, V33, P399, DOI 10.1016/j.neuroimage.2006.06.012; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P615, DOI 10.1017/S1355617707070762; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Larson MJ, 2009, NEUROPSYCHOLOGIA, V47, P663, DOI 10.1016/j.neuropsychologia.2008.11.013; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Liotti M, 2000, NEUROPSYCHOLOGIA, V38, P701, DOI 10.1016/S0028-3932(99)00106-2; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Mayr U, 2003, NAT NEUROSCI, V6, P450, DOI 10.1038/nn1051; MAYR U, PSYCHOL RES IN PRESS; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Neter J., 1985, APPL LINEAR STAT MOD; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Notebaert W, 2001, PSYCHOL RES-PSYCH FO, V65, P170, DOI 10.1007/s004260000054; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Rasmussen IA, 2008, J NEUROTRAUM, V25, P1057, DOI 10.1089/neu.2008.0520; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Ridderinkhof KR, 2002, ATTENTION PERFORM, V19, P494; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Scherg M., 1990, AUDITORY EVOKED MAGN, V6, P65; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Ullsperger M, 2005, COGN AFFECT BEHAV NE, V5, P467, DOI 10.3758/CABN.5.4.467; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wendt M, 2006, J EXP PSYCHOL HUMAN, V32, P644, DOI 10.1037/0096-1523.32.3.644; West R, 1999, COGNITIVE BRAIN RES, V8, P157, DOI 10.1016/S0926-6410(99)00017-8; West R, 2000, BRAIN RES, V873, P102, DOI 10.1016/S0006-8993(00)02530-0; West R, 2005, CORTEX, V41, P570, DOI 10.1016/S0010-9452(08)70197-7; West R, 2004, J COGNITIVE NEUROSCI, V16, P103, DOI 10.1162/089892904322755593; West R, 2003, NEUROPSYCHOLOGIA, V41, P1122, DOI 10.1016/S0028-3932(02)00297-X	64	28	31	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2009	15	6					927	937		10.1017/S1355617709990701			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	523ZV	WOS:000272114500015	19765356				2021-06-18	
J	Yamaguchi, S; Tanabe, K; Takai, S; Matsushima-Nishiwaki, R; Adachi, S; Iida, H; Kozawa, O; Dohi, S				Yamaguchi, Shinobu; Tanabe, Kumiko; Takai, Shinji; Matsushima-Nishiwaki, Rie; Adachi, Seiji; Iida, Hiroki; Kozawa, Osamu; Dohi, Shuji			Involvement of Rho-kinase in tumor necrosis factor-alpha-induced interleukin-6 release from C6 glioma cells	NEUROCHEMISTRY INTERNATIONAL			English	Article						Rho-kinase inhibitor; Intrleukin-6; TNF-alpha; MAP kinase; CNS	ACTIVATED PROTEIN-KINASE; SUBARACHNOID HEMORRHAGE; INTRATHECAL APPLICATION; CYTOKINE EXPRESSION; NEUROPATHIC PAIN; IN-VITRO; INHIBITOR; FASUDIL; BRAIN; PHOSPHORYLATION	Tumor necrosis factor (TNF)-alpha stimulated interleukin (IL)-6 release and induced the phosphorylation of myosin phosphatase targeting subunit (MYPT)-1, a Rho-kinase substrate. The IL-6 release was significantly suppressed by Y-27632 and fasudil, Rho-kinase inhibitors. Although I kappa B inhibitor suppressed the TNF-alpha-induced IL-6 release, the Rho-kinase inhibitors did not affect the TNF-alpha-induced I kappa B phosphorylation. TNF-alpha induced the phosphorylation of p38 mitogen-activated protein (MAP) kinase, stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK), and p44/p42 MAP kinase. The TNF-alpha-induced IL-6 release was suppressed by SB203580, a p38 MAPK inhibitor, or SP600125, a SAPK/JNK inhibitor, but not by PD98059, a MAP kinase/extracellular signal-regulated kinase kinase inhibitor. The Rho-kinase inhibitors attenuated the TNF-alpha-induced phosphorylation of both p38 MAP kinase and SAPK/JNK. Rho-kinase, which has been used for the clinical treatment of cerebral vasospasms, may be involved in other central nervous system (CNS) disorders such as traumatic injury, stroke, neurodegenerative disease and neuropathic pain. TNF-alpha, a proinflammatory cytokine that affects the CNS through cytokines, such as IL-6, release from neurons, astrocytes and microglia. Therefore, we investigated the involvement of Rho-kinase in the TNF-alpha-induced IL-6 release from rat C6 glioma cells. These results strongly suggest that Rho-kinase regulates the TNF-alpha-induced IL-6 release at a point upstream from p38 MAPK and SAPK/JNK in C6 glioma cells. Therefore, Rho-kinase inhibitor may be considered to be a new clinical candidate for the treatment of CNS disorders in addition to cerebral vasospasms. (C) 2009 Elsevier Ltd. All rights reserved.	[Yamaguchi, Shinobu; Tanabe, Kumiko; Iida, Hiroki; Dohi, Shuji] Gifu Univ, Grad Sch Med, Dept Anesthesiol & Pain Med, Gifu 5011194, Japan; [Takai, Shinji; Matsushima-Nishiwaki, Rie; Adachi, Seiji; Kozawa, Osamu] Gifu Univ, Grad Sch Med, Dept Pharmacol, Gifu 5011194, Japan	Tanabe, K (corresponding author), Gifu Univ, Grad Sch Med, Dept Anesthesiol & Pain Med, Gifu 5011194, Japan.	kumiko-t@m2.gyao.ne.jp			Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [19209050, 20591798]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [20591798, 19209050] Funding Source: KAKEN	We are very grateful to Yoko Kawamura (Secretary, Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu, Japan) for her skillful technical assistance.; This work was supported in part by a Grant-in-Aid for Scientific Research (Nos. 19209050 and 20591798) from the Ministry of Education, Science, Sports and Culture of Japan.	AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Buyukafsar K, 2006, EUR J PHARMACOL, V541, P49, DOI 10.1016/j.ejphar.2006.04.042; Chang JY, 2007, NEUROSCI LETT, V416, P217, DOI 10.1016/j.neulet.2007.01.076; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Clark WM, 2001, EXPERT OPIN BIOL TH, V1, P227, DOI 10.1517/14712598.1.2.227; Covey WC, 2002, REGION ANESTH PAIN M, V27, P357, DOI 10.1053/rapm.2002.31930; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Fan YY, 2005, J SURG RES, V129, P196, DOI 10.1016/j.jss.2005.07.041; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Gahring LC, 1996, NEUROIMMUNOMODULAT, V3, P289, DOI 10.1159/000097283; Gosselin D, 2007, BRAIN BEHAV IMMUN, V21, P281, DOI 10.1016/j.bbi.2006.12.004; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heymann D, 2000, CYTOKINE, V12, P1455, DOI 10.1006/cyto.2000.0747; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Ishida T, 2006, BIOL PHARM BULL, V29, P397, DOI 10.1248/bpb.29.397; Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kishi T, 2005, CIRCULATION, V111, P2741, DOI 10.1161/CIRCULATIONAHA.104.510248; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Madura T, 2007, PLAST RECONSTR SURG, V119, P526, DOI 10.1097/01.prs.0000246380.40596.29; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Mueller BK, 2005, NAT REV DRUG DISCOV, V4, P387, DOI 10.1038/nrd1719; Naugler WE, 2008, TRENDS MOL MED, V14, P109, DOI 10.1016/j.molmed.2007.12.007; Ohtori S, 2004, SPINE, V29, P1082, DOI 10.1097/00007632-200405150-00006; Ramer LM, 2004, J NEUROSCI, V24, P10796, DOI 10.1523/JNEUROSCI.3337-04.2004; Roach JD, 2008, NEUROIMMUNOMODULAT, V15, P117, DOI 10.1159/000148194; Samland H, 2003, J NEUROSCI RES, V73, P176, DOI 10.1002/jnr.10635; Satoh S, 2001, LIFE SCI, V69, P1441, DOI 10.1016/S0024-3205(01)01229-2; SHIBUYA M, 1992, J NEUROSURG, V76, P571, DOI 10.3171/jns.1992.76.4.0571; Shimokawa H, 2007, TRENDS PHARMACOL SCI, V28, P296, DOI 10.1016/j.tips.2007.04.006; Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007; Spangelo BL, 2004, NEUROIMMUNOMODULAT, V11, P332, DOI 10.1159/000079414; Spangelo BL, 2000, ANN NY ACAD SCI, V917, P597; Suzuki Y, 2008, NEUROL MED-CHIR, V48, P241, DOI 10.2176/nmc.48.241; Takanashi Y, 2001, NEUROL MED-CHIR, V41, P107, DOI 10.2176/nmc.41.107; Tatsumi S, 2005, NEUROSCIENCE, V131, P491, DOI 10.1016/j.neuroscience.2004.10.022; Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004; Watabe-Uchida M, 2006, J NEUROSCI, V26, P10633, DOI 10.1523/JNEUROSCI.4084-06.2006; Widmann C, 1999, PHYSIOL REV, V79, P143; WILLINGHAM MC, 1976, INT REV CYTOL, V44, P319, DOI 10.1016/S0074-7696(08)61652-6; Zhang Z, 2006, CELL MOL BIOL LETT, V11, P12, DOI 10.2478/s11658-006-0002-x; Zumwalt JW, 1999, ENDOCRINOLOGY, V140, P888, DOI 10.1210/en.140.2.888	49	28	32	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	NOV	2009	55	6					438	445		10.1016/j.neuint.2009.04.016			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	502WT	WOS:000270491800012	19427347				2021-06-18	
J	Marklund, N; Morales, D; Clausen, F; Hanell, A; Kiwanuka, O; Pitkanen, A; Gimbel, DA; Philipson, O; Lannfelt, L; Hillered, L; Strittmatter, SM; McIntosh, TK				Marklund, N.; Morales, D.; Clausen, F.; Hanell, A.; Kiwanuka, O.; Pitkanen, A.; Gimbel, D. A.; Philipson, O.; Lannfelt, L.; Hillered, L.; Strittmatter, S. M.; McIntosh, T. K.			FUNCTIONAL OUTCOME IS IMPAIRED FOLLOWING TRAUMATIC BRAIN INJURY IN AGING Nogo-A/B-DEFICIENT MICE	NEUROSCIENCE			English	Article						traumatic brain injury; Nogo-A; Nogo-B; Morris water maze; neurological motor deficits	CONTROLLED CORTICAL IMPACT; NEURITE OUTGROWTH INHIBITOR; AMYLOID-BETA; SPINAL-CORD; AXON REGENERATION; COGNITIVE DEFICITS; TRANSGENIC MICE; RECEPTOR; RECOVERY; ADULT	Increasing age is associated with a poor prognosis following traumatic brain injury (TBI). CNS axons may recover poorly following TBI due to expression of myelin-derived inhibitors to axonal outgrowth such as Nogo-A. To study the role of Nogo-A/B in the pathophysiological response of the elderly to TBI, 1-year-old mice deficient in Nogo-A/B (Nogo-A/B homozygous(-/-) mice), Nogo-A/B heterozygous(-/+) mice, and age-matched wild-type (WT) littermate controls were subjected to a controlled cortical impact (CCI) TBI. Sham-injured WT mice (7 months old) and 12 month old naive Nogo-A/B-/- and Nogo-A/B-/+ served as controls. Neurological motor function was evaluated up to 3 weeks, and cognitive function, hemispheric tissue loss, myelin staining and hippocampal beta-amyloid (A beta) immunohistochemistry were evaluated at 4 weeks post-injury. In WT littermates, TBI significantly impaired learning ability at 4 weeks and neurological motor function up to 2 weeks post-injury and caused a significant loss of hemispheric tissue. Following TBI, Nogo-A/B-/- mice showed significantly less recovery from neurological motor and cognitive deficits compared to brain-injured WT mice. Naive Nogo-A/B-/- and Nogo-A/B-/+ mice quickly learned the MWM task in contrast to brain-injured Nogo-A/B-/- mice who failed to learn the MWM task at 4 weeks post-injury. Hemispheric tissue loss and cortical lesion volume were similar among the brain-injured genotypes. Neither TBI nor the absence of NogoA/B caused an increased A beta expression. Myelin staining showed a reduced area and density in the corpus callosum in brain-injured Nogo-A/B-/- animals compared to their littermate controls. These novel and unexpected behavioral results demonstrate that the absence of Nogo-A/B may negatively influence outcome, possibly related to hypomyelination, following TBI in mice and suggest a complex role for this myelin-associated axonal growth inhibitor following TBI. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.	[Marklund, N.; Clausen, F.; Hanell, A.; Kiwanuka, O.; Hillered, L.] Univ Uppsala Hosp, Dept Neurosurg, SE-75185 Uppsala, Sweden; [Marklund, N.; Morales, D.; McIntosh, T. K.] Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; [Gimbel, D. A.; Strittmatter, S. M.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA; [Marklund, N.; McIntosh, T. K.] Vet Adm Med Ctr, Philadelphia, PA 19104 USA; [Pitkanen, A.] Univ Kuopio, Epilepsy Res Lab, Al Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland; [Pitkanen, A.] Univ Kuopio, Dept Neurol, FIN-70211 Kuopio, Finland; [Philipson, O.; Lannfelt, L.] Univ Uppsala Hosp, Dept Publ Hlth & Caring Sci, SE-75185 Uppsala, Sweden	Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, SE-75185 Uppsala, Sweden.	niklas.marklund@neurokir.uu.se	Hanell, Anders/E-4776-2011; Strittmatter, Stephen/F-5739-2011	Hanell, Anders/0000-0001-9369-3886; Clausen, Fredrik/0000-0003-3592-4417; Hillered, Lars/0000-0002-2808-9292; Kiwanuka, Olivia/0000-0003-3562-5513; Marklund, Niklas/0000-0002-9797-5626; Strittmatter, Stephen/0000-0001-8188-3092; Morales, Diego/0000-0001-6672-9046	NIH NSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS RO1-40978, NS P50-08803, NS RO1-56485, NS RO1-39962]; Swedish MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Uppsala University Hospital; Swedish Brain Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS033020, R01NS039962, R01NS056485, R01NS042304, P50NS008803, R01NS040978] Funding Source: NIH RePORTER	Supported by NIH NS RO1-40978, a Merit Review Grant from the Veterans Administration, NIH NS P50-08803, Swedish MRC, Uppsala University Hospital and the Swedish Brain Foundation. NIH NS RO1-56485 and NS RO1-39962 to S.M.S. We thank Rishi Puri, David LeBold, Carl T. Fulp, Lena Rundstrom and Hilaire J. Thompson for excellent technical support.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Acevedo L, 2004, NAT MED, V10, P382, DOI 10.1038/nm1020; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Buchli AD, 2005, ANN MED, V37, P556, DOI 10.1080/07853890500407520; Cafferty WBJ, 2007, NEURON, V54, P195, DOI 10.1016/j.neuron.2007.04.005; Cafferty WBJ, 2006, J NEUROSCI, V26, P12242, DOI 10.1523/JNEUROSCI.3827-06.2006; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Dimou L, 2006, J NEUROSCI, V26, P5591, DOI 10.1523/JNEUROSCI.1103-06.2006; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fournier AE, 2002, PROG BRAIN RES, V137, P361; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Huber AB, 2002, J NEUROSCI, V22, P3553; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hunt D, 2003, MOL CELL NEUROSCI, V24, P1083, DOI 10.1016/j.mcn.2003.09.002; Hunt D, 2002, J NEUROCYTOL, V31, P93, DOI 10.1023/A:1023941421781; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Li Q, 2001, ONCOGENE, V20, P3929, DOI 10.1038/sj.onc.1204536; Li SX, 2003, J NEUROSCI, V23, P4219; Liebscher T, 2005, ANN NEUROL, V58, P706, DOI 10.1002/ana.20627; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Lord A, 2006, NEUROBIOL AGING, V27, P67, DOI 10.1016/j.neurobiolaging.2004.12.007; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; Markus TM, 2005, ANN NEUROL, V58, P950, DOI 10.1002/ana.20676; Marriott MP, 2008, GLIA, V56, P686, DOI 10.1002/glia.20646; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Meier S, 2003, FASEB J, V17, P1153, DOI 10.1096/fj.02-0453fje; Modo M, 2000, J NEUROSCI METH, V104, P99, DOI 10.1016/S0165-0270(00)00329-0; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Oertle T, 2003, J NEUROSCI, V23, P5393; Park JH, 2006, J NEUROSCI, V26, P1386, DOI 10.1523/JNEUROSCI.3291-05.2006; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pernet V, 2008, J NEUROSCI, V28, P7435, DOI 10.1523/JNEUROSCI.0727-08.2008; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Seymour AB, 2005, J CEREBR BLOOD F MET, V25, P1366, DOI 10.1038/sj.jcbfm.9600134; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Tang BL, 2007, J NEUROCHEM, V100, P314, DOI 10.1111/j.1471-4159.2006.04215.x; Teng FYH, 2005, J NEUROCHEM, V94, P865, DOI 10.1111/j.1471-4159.2005.03238.x; Teng FYH, 2005, J NEUROSCI RES, V79, P273, DOI 10.1002/jnr.20361; The Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, AGE J NEUROTRAUMA, V17, P573; Wang XX, 2006, ANN NEUROL, V60, P540, DOI 10.1002/ana.20953; Wang XX, 2002, J NEUROSCI, V22, P5505; Willi R, 2009, GENES BRAIN BEHAV, V8, P181, DOI 10.1111/j.1601-183X.2008.00460.x; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	65	28	30	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 6	2009	163	2					540	551		10.1016/j.neuroscience.2009.06.042			12	Neurosciences	Neurosciences & Neurology	496JR	WOS:000269967800005	19555742	Green Accepted			2021-06-18	
J	Figaji, AA; Zwane, E; Thompson, C; Fieggen, AG; Argent, AC; Le Roux, PD; Peter, JC				Figaji, Anthony A.; Zwane, Eugene; Thompson, Crispin; Fieggen, A. Graham; Argent, Andrew C.; Le Roux, Peter D.; Peter, Jonathan C.			Brain tissue oxygen tension monitoring in pediatric severe traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						Brain oxygen; Children; Traumatic brain injury; Intracranial pressure; Cerebral perfusion pressure; Monitoring	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; TARGETED THERAPY; CHILDREN; DELIVERY; METABOLISM; HYPEROXIA; SATURATION; REDUCTION	Introduction Brain tissue oxygen tension (PbtO(2)) monitoring is used increasingly in adult severe traumatic brain injury (TBI) management. Several factors are known to influence PbtO(2) in adults, but the variables that affect PbtO(2) in pediatric TBI are not well described. This study examines the relationships between PbtO(2) and (1) physiological markers of potential secondary insults commonly used in pediatric TBI, in particular intracranial pressure (ICP), cerebral perfusion pressure (CPP), and systemic hypoxia, and (2) other clinical factors and treatment received that may influence PbtO(2). Materials and methods In this prospective observational study, 52 children (mean age, 6.5 +/- 3.4 years; range, 9 months to 14 years old) with severe TBI and a median post-resuscitation Glasgow Coma Score (GCS) of 5 were managed with continuous PbtO(2) monitoring. The relationships between PbtO(2) parameters (PbtO(2low), PbtO(2) < 5, PbtO(2) < 10, and mPbtO(224)) and clinical, physiological, and treatment factors were explored using time-linked data and Spearman's correlation coefficients. Results No clinical, physiological, or treatment variable was significantly associated with all PbtO(2) parameters, but individual associations were found with initial GCS (PbtO(2) < 5, p = 0.0113), admission Pediatric Trauma Score (PbtO(2) < 10, 0.0175), mICP > 20 (mPbtO(224), p = 0.0377), CPPlow (PbtO(2low), p = 0.0065), CPP < 40 (PbtO(2low), p = 0.0269; PbtO(2) < 5, p = 0.0212), PaO2 < 60 (mPbtO(224), p = 0.0037), SaO2 < 90 (PbtO(2low), p = 0.0438), and use of inotropes during ICU care (PbtO(2low), p = 0.0276; PbtO(2) < 10, p = 0.0277; p = mPbtO(224)). Conclusion Delivery of oxygen to the brain is important to limit secondary neuronal injury after severe TBI. Our data show that PbtO(2) is poorly predicted by clinical and physiological factors commonly measured in the pediatric ICU. Multimodality monitoring may be needed to detect all secondary cerebral insults in pediatric TBI.	[Figaji, Anthony A.] Red Cross War Mem Childrens Hosp, Inst Child Hlth, ZA-7700 Rondebosch, Cape Town, South Africa; [Figaji, Anthony A.; Thompson, Crispin; Fieggen, A. Graham; Peter, Jonathan C.] Univ Cape Town, Div Neurosurg, Sch Child & Adolescent Hlth, Red Cross Childrens Hosp, ZA-7925 Cape Town, South Africa; [Zwane, Eugene] Univ Cape Town, Infect Dis Epidemiol Unit Biostat, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa; [Le Roux, Peter D.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19107 USA	Figaji, AA (corresponding author), Red Cross War Mem Childrens Hosp, Inst Child Hlth, Room 617,Klipfontein Rd, ZA-7700 Rondebosch, Cape Town, South Africa.	Anthony.Figaji@uct.ac.za	Argent, Andrew/J-1605-2019	Argent, Andrew/0000-0001-9333-2036; Figaji, Anthony/0000-0002-3357-6490; Fieggen, Graham/0000-0001-6541-8377	Integra Foundation	Dr Figaji has received a grant from the South African- Swedish Links Programme (SIDA, National Research Foundation). Drs Figaji and Le Roux have also received a grant from the Integra Foundation for the study of cerebral perfusion pressure thresholds in children.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Akopian G, 2007, AM SURGEON, V73, P447; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cremer OL, 2008, EUR J ANAESTH, V25, P87, DOI 10.1017/S0265021507003237; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Flynn EP, 2002, ANN NEUROL, V52, P566, DOI 10.1002/ana.10322; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Mileski WJ, 2004, J TRAUMA, V56, P472; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rossi S, 2000, ACTA NEUROCHIR SUPPL, V76, P199; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 1998, J NEUROTRAUM, V15, P813, DOI 10.1089/neu.1998.15.813; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Wiegand C, 2007, DEV MED CHILD NEUROL, V49, P935, DOI 10.1111/j.1469-8749.2007.00935.x; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	52	28	29	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	OCT	2009	25	10					1335	1343		10.1007/s00381-009-0821-y			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	494TE	WOS:000269838900022	19214533				2021-06-18	
J	Nott, MT; Chapparo, C; Heard, R				Nott, Melissa T.; Chapparo, Christine; Heard, Robert			Reliability of the Perceive, Recall, Plan and Perform System of Task Analysis: A criterion-referenced assessment	AUSTRALIAN OCCUPATIONAL THERAPY JOURNAL			English	Article						agitation; assessment; brain injuries; occupational performance; reliability	BRAIN-INJURY; REHABILITATION	Objective: To conduct preliminary examination of the rater and test-reliability of the Perceive, Recall, Plan and Perform (PRPP) System of Task Analysis, an ecological measure designed to assess task-embedded information processing capacity during occupational therapy assessment of confused and agitated adults following traumatic brain injury. Methods: Occupational therapists observed and scored client performance using the PRPP System of Task Analysis. Correlational analysis and measures of agreement were performed to determine interrater and intrarater reliability. Test procedures were examined for reliability and internal consistency. Results: Interrater and test reliability considered three factors: therapists, clients and tasks. A moderate level of interrater reliability was achieved between trained therapists (intraclass correlation coefficient (ICC) = 0.60). Test procedures were highly reliable (ICC = 0.88). Across two measurement occasions, therapists showed a tendency towards harder rating on the second test occasion ((d) over bar -4.5%; 95% confidence interval for (d) over bar: -10.67% -> 3.17%). Conclusion: The findings of this study support the use of criterion-referenced tests in the area of occupational performance measurement. Occupational therapists achieved moderate interrater reliability when measuring the performance of adults with brain injury on various activities of daily living. Test procedures were found to be highly reliable in measuring the occupational performance of adults demonstrating confusion and agitation typical to the stage of post-traumatic amnesia following head injury.	[Nott, Melissa T.; Chapparo, Christine; Heard, Robert] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia	Nott, MT (corresponding author), J Block,Rm J126,POB 170, Lidcombe, NSW 1825, Australia.	mnot2529@mail.usyd.edu.au	Nott, Melissa T/M-6778-2018	Nott, Melissa T/0000-0001-7088-5826			Anastasi A., 1988, PSYCHOL TESTING; ARNADOTTIR G, 1990, BRAIN BEHAV ASSESSIN; BAUM C, 1993, AM J OCCUP THER, V47, P431, DOI 10.5014/ajot.47.5.431; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Boman IL, 2004, BRAIN INJURY, V18, P985, DOI 10.1080/02699050410001672396; CARLSON T, 2000, HIGHER ED RES DEV, V19, P103, DOI DOI 10.1080/07294360050020507; Chapparo C., 1997, OCCUPATIONAL PERFORM, V1, P189; CHAPPARO C, 1997, OCCUPATIONAL PERFORM, V1; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; Dunn L, 2004, STUDENT ASSESSMENT H; EISNER EW, 1993, J CURRICULUM STUD, V25, P219, DOI 10.1080/0022027930250302; Fry K, 2002, AUSTR OCCUPATIONAL T, V49, P182, DOI 10.1046/j.1440-1630.2002.00337.x; GLASER R, 1981, AM PSYCHOL, V36, P923, DOI 10.1037/0003-066X.36.9.923; Griffin P., 1995, AUSTR NZ J VOCATIONA, V3, P34; HAGEN C, 2001, RELEARNING TIMES, V8, P1; LANDIS JR, 1977, BIOMETRICS, V33, P174; LOHRI J, 2005, INFORM SENSORY PROCE; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; MUNKHETVIT P, 2005, THESIS U SYDNEY SYDN; NOTT MT, 2007, AUSTR OCCUPATIONAL T, V55, P188; Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9010.88.5.879; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; Rockwood K, 1997, J CLIN EPIDEMIOL, V50, P581, DOI 10.1016/S0895-4356(97)00014-0; Romiszowski A, 1984, DESIGNING INSTRUCTIO; Schraagen J. M., 2000, COGNITIVE TASK ANAL; Slifer KJ, 1997, BRAIN INJURY, V11, P877; Sudsawad P, 2005, AM J OCCUP THER, V59, P351, DOI 10.5014/ajot.59.3.351; Weir N, 2006, BRAIN INJURY, V20, P927, DOI 10.1080/02699050600832684; Whiting SE, 1985, RIVERMEAD PERCEPTUAL; WILSON BA, 2003, RIVERMEAD BEHAVIOURA, V2; Wong SP, 1999, EDUC PSYCHOL MEAS, V59, P270, DOI 10.1177/00131649921969848; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	32	28	28	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0045-0766	1440-1630		AUST OCCUP THER J	Aust. Occup. Ther. J.	OCT	2009	56	5					307	314		10.1111/j.1440-1630.2008.00763.x			8	Rehabilitation	Rehabilitation	504JB	WOS:000270611100003	20854536				2021-06-18	
J	Beacher, FDCC; Gray, MA; Mathias, CJ; Critchley, HD				Beacher, Felix D. C. C.; Gray, Marcus A.; Mathias, Christopher J.; Critchley, Hugo D.			Vulnerability to simple faints is predicted by regional differences in brain anatomy	NEUROIMAGE			English	Article						Neurocardiogenic syncope; Vasovagal syncope; Blood pressure; Brain anatomy; Magnetic Resonance Imaging; Voxel-based morphometry	OBSESSIVE-COMPULSIVE DISORDER; VOXEL-BASED MORPHOMETRY; HEART-RATE-VARIABILITY; NEURALLY-MEDIATED SYNCOPE; CEREBRAL-BLOOD-FLOW; VENTROLATERAL PERIAQUEDUCTAL GRAY; MULTIPLE SYSTEM ATROPHY; CAUDAL MIDLINE MEDULLA; UP TILT TEST; VASOVAGAL SYNCOPE	Neurocardiogenic syncope (NCS, simple fainting) is a common and typically benign familial condition, which rarely may result in traumatic injury or hypoxic convulsions. NCS is associated with emotional triggers, anxiety states and stress. However, the etiology of NCS, as a psychophysiological process, is poorly understood. We therefore investigated the relationship between NCS and brain anatomy. We studied a non-clinical sample of eighteen individuals with histories characteristic of NCS, and nineteen matched controls who had never fainted. We recorded fainting frequency, testing heart rate variability measures and anxiety levels. Structural T1-weighted magnetic resonance images (MRI) were acquired at 1.5 T. Associations between brain morphometry (regional gray and white matter Volumes) and NCS, testing physiology and anxiety were tested using voxel-based morphometry (VBM). Compared to controls, NCS participants had lower regional brain volume within medulla and midbrain (a priori regions of interest). Moreover, across NCS individuals, lower gray matter Volume in contiguous regions of left caudate nucleus predicted enhanced parasympathetic cardiac tone, fainting frequency and anxiety levels. Our findings provide preliminary evidence for a hierarchical anatomical basis to NCS. First, differences in the volume of brainstem centers supporting cardiovascular homeostasis may relate to constitutional predisposition to NCS. Second, differences in the Structural organization of the caudate nucleus in NCS individuals may relate to fainting frequency via interactions between emotional state and Parasympathetic control of the heart. These observations highlight the application of VBM to the identification of neurovisceral mechanisms relevant to psychosomatic medicine and the neuroscience of emotion. Crown Copyright (C) 2009 Published by Elsevier Inc. All rights reserved.	[Beacher, Felix D. C. C.; Gray, Marcus A.; Critchley, Hugo D.] Brighton & Sussex Med Sch, Clin Imaging Sci Ctr, Brighton BN1 9RY, E Sussex, England; [Mathias, Christopher J.] Univ London Imperial Coll Sci Technol & Med, Div Neurosci & Mental Hlth, London SW7 2AZ, England		f.beacher@bsms.ac.uk	critchley, hugo d/G-9267-2011; Gray, Marcus/F-6521-2013	critchley, hugo d/0000-0002-2445-9284; Gray, Marcus/0000-0001-8671-6939; beacher, felix/0000-0002-4130-4073	Wellcome TrustWellcome TrustEuropean Commission	This study was supported by a Wellcome Trust Programme Grant to HDC. Neuroimaging was undertaken at the Clinical Imaging Sciences Centre, Brighton and Sussex Medical School.	Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Bergouignan L, 2009, NEUROIMAGE, V45, P29, DOI 10.1016/j.neuroimage.2008.11.006; Brignole M, 2004, EUR HEART J, V25, P2054, DOI 10.1016/j.ehj.2004.09.004; Brodal P., 2004, CENTRAL NERVOUS SYST; Cavun S, 2001, AM J PHYSIOL-REG I, V281, pR747; Cohen TJ, 2000, PACE, V23, P837, DOI 10.1111/j.1540-8159.2000.tb00852.x; Della Nave R, 2008, J NEUROL NEUROSUR PS, V79, P82, DOI 10.1136/jnnp.2007.124297; Donadio V, 2007, BRAIN, V130, P1653, DOI 10.1093/brain/awm037; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Ellenbogen KA, 1997, PACE, V20, P788, DOI 10.1111/j.1540-8159.1997.tb03905.x; FRIEDMAN BH, 1993, BIOL PSYCHIAT, V34, P298, DOI 10.1016/0006-3223(93)90087-T; Furlan R, 1998, CIRCULATION, V98, P1756, DOI 10.1161/01.CIR.98.17.1756; Ginestroni A, 2008, J NEUROL, V255, P1153, DOI 10.1007/s00415-008-0860-4; Golanov EV, 2001, BRAIN RES, V892, P1, DOI 10.1016/S0006-8993(00)02949-8; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Gracie J, 2006, EUROPACE, V8, P636, DOI 10.1093/europace/eul073; Gray MA, 2009, J NEUROSCI, V29, P1817, DOI 10.1523/JNEUROSCI.3363-08.2009; Grubb BP, 2005, NEW ENGL J MED, V352, P1004, DOI 10.1056/NEJMcp042601; GRUBB BP, 1991, CIRCULATION, V84, P1157, DOI 10.1161/01.CIR.84.3.1157; Hainsworth R, 2004, CLIN AUTON RES, V14, P18, DOI 10.1007/s10286-004-1004-2; Hauser TK, 2006, MOVEMENT DISORD, V21, P1674, DOI 10.1002/mds.21032; Henderson LA, 2000, NEUROSCIENCE, V98, P779, DOI 10.1016/S0306-4522(00)00117-2; Heslop DJ, 2002, NEUROSCIENCE, V113, P555, DOI 10.1016/S0306-4522(02)00161-6; Jardine DL, 1998, AM J PHYSIOL-HEART C, V274, pH2110; Kapoor WN, 2000, NEW ENGL J MED, V343, P1856, DOI 10.1056/NEJM200012213432507; Kochiadakis GE, 1998, INT J CARDIOL, V64, P185, DOI 10.1016/S0167-5273(98)00039-4; Kochiadakis GE, 1997, PACE, V20, P1332, DOI 10.1111/j.1540-8159.1997.tb06788.x; Kouakam C, 1999, HEART, V82, P312, DOI 10.1136/hrt.82.3.312; Kouakam C, 2002, AM J CARDIOL, V89, P530, DOI 10.1016/S0002-9149(01)02292-5; Lee TM, 1996, CLIN CARDIOL, V19, P137, DOI 10.1002/clc.4960190212; LIPSITZ LA, 1990, CIRCULATION, V81, P1803, DOI 10.1161/01.CIR.81.6.1803; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; MARK AL, 1983, J AM COLL CARDIOL, V1, P90, DOI 10.1016/S0735-1097(83)80014-X; Mathias CJ, 2001, LANCET, V357, P348, DOI 10.1016/S0140-6736(00)03642-4; Mathias CJ, 1998, LANCET, V352, P33, DOI 10.1016/S0140-6736(05)79513-1; Minnerop M, 2007, NEUROIMAGE, V36, P1086, DOI 10.1016/j.neuroimage.2007.04.028; Morillo CA, 1997, CIRCULATION, V96, P2509, DOI 10.1161/01.CIR.96.8.2509; MORILLO CA, 1994, AM J CARDIOL, V74, P1258, DOI 10.1016/0002-9149(94)90559-2; MORINO M, 1994, J AUTONOM NERV SYST, V49, P159, DOI 10.1016/0165-1838(94)90135-X; MosquedaGarcia R, 1997, J CLIN INVEST, V99, P2736, DOI 10.1172/JCI119463; OBERG B, 1972, ACTA PHYSIOL SCAND, V85, P164, DOI 10.1111/j.1748-1716.1972.tb05247.x; OST LG, 1984, BEHAV RES THER, V22, P109, DOI 10.1016/0005-7967(84)90099-8; Piccirillo G, 2004, CLIN SCI, V107, P55, DOI 10.1042/CS20030327; Porges SW., 1993, BODY PERCEPTION QUES; Robertson RM, 1999, AM J MED SCI, V317, P102, DOI 10.1097/00000441-199902000-00004; ROBINSON D, 1995, ARCH GEN PSYCHIAT, V52, P393; RUBIN RT, 1992, ARCH GEN PSYCHIAT, V49, P695; Sarasin FP, 2001, AM J MED, V111, P177, DOI 10.1016/S0002-9343(01)00797-5; Saxena S, 2001, BIOL PSYCHIAT, V50, P159, DOI 10.1016/S0006-3223(01)01123-4; SCHADT JC, 1991, AM J PHYSIOL, V260, pH305; Serletis A, 2006, EUR HEART J, V27, P1965, DOI 10.1093/eurheartj/ehl147; SHALEV Y, 1991, J AM COLL CARDIOL, V18, P746, DOI 10.1016/0735-1097(91)90798-E; SHARPEYSCHAFER EP, 1956, BRIT MED J, V1, P506, DOI 10.1136/bmj.1.4965.506; SILVERSTEIN MD, 1982, JAMA-J AM MED ASSOC, V248, P1185, DOI 10.1001/jama.248.10.1185; SPRENGELMEYER R, 1995, MOVEMENT DISORD, V10, P51, DOI 10.1002/mds.870100110; STEPTOE A, 1988, PSYCHOSOM MED, V50, P402, DOI 10.1097/00006842-198807000-00008; Sutton R, 1992, EUR J CARD PACING EL, V2, P180; SWEDO SE, 1992, ARCH GEN PSYCHIAT, V49, P690; Troy BP, 2003, AUTON NEUROSCI-BASIC, V108, P1, DOI 10.1016/S1566-0702(03)00152-8; Uchida RR, 2008, PSYCHIAT RES-NEUROIM, V163, P21, DOI 10.1016/j.pscychresns.2007.04.015; Vagg DJ, 2008, NEUROSCIENCE, V152, P1099, DOI 10.1016/j.neuroscience.2007.10.070; Verner TA, 2008, BRAIN RES, V1208, P128, DOI 10.1016/j.brainres.2008.02.028; Woermann FG, 1999, NEUROIMAGE, V10, P373, DOI 10.1006/nimg.1999.0481; Yassa MA, 2009, NEUROIMAGE, V44, P319, DOI 10.1016/j.neuroimage.2008.09.016	65	28	28	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	SEP	2009	47	3					937	945		10.1016/j.neuroimage.2009.05.038			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	482YI	WOS:000268926200019	19464376	Green Published, Other Gold			2021-06-18	
J	Vincenzi, R; Cepeda, LA; Pirani, WM; Sannomyia, P; Rocha-e-Silva, M; Cruz, RJ				Vincenzi, Rodrigo; Cepeda, Lourdes A.; Pirani, William M.; Sannomyia, Paulina; Rocha-e-Silva, Mauricio; Cruz, Ruy J., Jr.			Small volume resuscitation with 3% hypertonic saline solution decrease inflammatory response and attenuates end organ damage after controlled hemorrhagic shock	AMERICAN JOURNAL OF SURGERY			English	Article						Hemorrhagic shock; Hypertonic solution; Inflammation; Cytokines; Trauma; Acute lung injury	LACTATED RINGERS; INTRACRANIAL-PRESSURE; CEREBRAL EDEMA; LUNG INJURY; MODEL; PENTOXIFYLLINE; NACL; INFUSION; TRAUMA; BRAIN	BACKGROUND: Recently, studies have been conducted examining the efficacy of 3% hypertonic saline solution (HS) for the treatment of traumatic brain injury; however, few studies have analyzed the effects of 3% hemorrhagic shock during hemorrhagic shock. The aim of this study was to test the potential immunomodulatory benefits of 3% hemorrhagic shock resuscitation over standard fluid resuscitation. METHODS: Wistar rats were bled to a mean arterial pressure of 35 mm Hg and then randomized into 3 groups: those treated with lactated Ringer's solution (LR; 33 mL/kg, n = 7), 3% HS (10 mL/kg, n = 7), and 7.5% HS (4 mL/kg, n = 7). Half of the extracted blood was reinfused after fluid resuscitation. Animals that did not undergo shock served as controls (n = 5). Four hours after hemorrhagic shock, blood was collected for the evaluation of tumor necrosis factor-a and interleukin-6 by enzyme immunoassay. Lung and intestinal samples were obtained for histopathologic analysis. RESULTS: Animals in the HS groups had significantly higher mean arterial pressure than those in the LR group 1 hour after treatment. Osmolarity and sodium levels were markedly elevated in the HS groups. Tumor necrosis factor-alpha and interleukin-6 levels were similar between the control and HS groups but significantly higher in the LR group (P < .05). The lung injury score was significantly higher in the LR group compared with the 7.5% HS and 3% HS groups (5.7 +/- 0.7, 2.1 +/- 0.4, and 2.7 +/- 0.5, respectively). Intestinal injury was attenuated in the 7.5% HS and 3% HS groups compared with the LR group (2.0 +/- 0.6, 2.3 +/- 0.4, and 5.9 +/- 0.6, respectively). CONCLUSIONS: A small-volume resuscitation strategy modulates the inflammatory response and decreases end-organ damage after HS. Three percent HS provides immunomodulatory and metabolic effects similar to those observed with conventional concentrations of HS. (C) 2009 Elsevier Inc. All rights reserved.	[Cruz, Ruy J., Jr.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA; [Vincenzi, Rodrigo; Sannomyia, Paulina; Rocha-e-Silva, Mauricio] Univ Sao Paulo, Sch Med, InCor, Div Res, Sao Paulo, Brazil; [Cepeda, Lourdes A.; Pirani, William M.] Univ Santo Amaro, Sch Med, Dept Pathol, Sao Paulo, Brazil	Cruz, RJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA.	cruzrj@upmc.edu					Angle N, 1998, J TRAUMA, V45, P7, DOI 10.1097/00005373-199807000-00002; Brasel KJ, 2008, J AM COLL SURGEONS, V206, P220, DOI 10.1016/j.jamcollsurg.2007.07.020; Chang JX, 2005, WORLD J GASTROENTERO, V11, P5485, DOI 10.3748/wjg.v11.i35.5485; Choileain NN, 2006, ARCH SURG-CHICAGO, V141, P1132; Ciesla DJ, 2000, SHOCK, V14, P265, DOI 10.1097/00024382-200014030-00004; Coimbra R, 1996, J SURG RES, V64, P203, DOI 10.1006/jsre.1996.0329; Cruz RJ, 2006, ANESTH ANALG, V102, P1518, DOI 10.1213/01.ane.0000204255.35494.f2; de Figueiredo LFP, 2005, J INVEST SURG, V18, P257, DOI 10.1080/08941930500248904; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; Kiraly LN, 2006, J TRAUMA, V61, P57, DOI 10.1097/01.ta.0000220373.29743.69; Lee CC, 2005, SHOCK, V24, P177, DOI 10.1097/01.shk.0000171870.42900.15; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629; Murao Y, 2003, SHOCK, V20, P23, DOI 10.1097/01.shk.0000078832.57685.6c; Pascual JL, 2003, J TRAUMA, V54, P121, DOI 10.1097/00005373-200301000-00015; Pinto FCG, 2006, J TRAUMA, V60, P758, DOI 10.1097/01.ta.0000214581.89316.73; Powers KA, 2003, SURGERY, V134, P312, DOI 10.1067/msy.2003.246; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Rizoli SB, 1998, J IMMUNOL, V161, P6288; Rocha-e-Silva Mauricio, 2005, Clinics, V60, P159, DOI 10.1590/S1807-59322005000200013; Shi HP, 2002, SHOCK, V17, P496, DOI 10.1097/00024382-200206000-00010; Todd SR, 2007, J TRAUMA, V62, P636, DOI 10.1097/TA.0b013e31802ee521; Vaid SU, 2006, CRIT CARE MED, V34, P1185, DOI 10.1097/01.CCM.0000207341.78696.3A; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; Watters JM, 2006, J TRAUMA, V61, P75, DOI 10.1097/01.ta.0000222723.54559.47; Yada-Langui MM, 2004, EXP BIOL MED, V229, P684; Yada-Langui MM, 2000, SHOCK, V14, P594, DOI 10.1097/00024382-200014060-00004; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048	30	28	38	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	SEP	2009	198	3					407	414		10.1016/j.amjsurg.2009.01.017			8	Surgery	Surgery	502FK	WOS:000270440800017	19520355				2021-06-18	
J	Gaetz, MB; Iverson, GL				Gaetz, M. B.; Iverson, G. L.			Sex differences in self-reported symptoms after aerobic exercise in non-injured athletes: implications for concussion management programmes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							BINDING-SITE POLYMORPHISM; ANTERIOR CRUCIATE LIGAMENT; ACHILLES-TENDON INJURIES; OSTEOPOROTIC FRACTURE; SP1 POLYMORPHISM; COL5A1 GENE; RISK; PARTICIPANTS; DENSITY; WOMEN	Background: After a concussion, when symptoms have decreased substantially at rest, it is recommended that athletes begin light aerobic exercise before progressing to sport specific exercise. The British Columbia Concussion Rehabilitation Programme (BC-CRP) uses a standardized cognitive and exercise test protocol designed to indicate when an athlete should progress to sport-specific exercise after a concussion. Objective: To document the effects of exercise on symptom reporting in healthy, uninjured, male and female amateur athletes. Design: Quasi-experimental, pretest-post-test, nonequivalent groups design. Methods: Before the exercise protocol, 45 female and 30 male young amateur athletes completed computerized cognitive testing, symptom ratings and balance testing. The 15-minute cycle ergometry protocol, conducted at 90 revolutions/minute, was as follows: 0-2 minutes at 0 W tension, 2-5 minutes at 50 W, 5-8 minutes at 100 W, 8-11 minutes at 150 W and 11-14 minutes at 200 W tension followed by a 1-minute cooling-down period. After exercise, participants completed symptom ratings, balance testing and perceived exertion ratings. Self-reported symptoms were assessed using an abbreviated version of the Post-Concussion Scale. Results: Significant increases in self-reported balance problems, numbness and tingling were seen for both genders after aerobic exercise. For women, emotional symptoms such as irritability, sadness, nervousness and feeling more emotional decreased significantly after aerobic exercise. Headache also decreased in the women, but no significant change was seen in the men. Conclusions: Sex differences exist for symptom reporting after aerobic exercise. Both genders report increases in somatic symptoms, but only women report decreases in emotional symptoms. The concept of being "asymptomatic'' after exercise should be reconsidered to include expected mild increases and decreases in certain symptoms.	[Gaetz, M. B.] Univ Fraser Valley, Dept Kinesiol & Phys Educ, Abbotsford, BC V2S 7M8, Canada; [Iverson, G. L.] Univ British Columbia, Fac Med, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada	Gaetz, MB (corresponding author), Univ Fraser Valley, Dept Kinesiol & Phys Educ, 33844 King Rd, Abbotsford, BC V2S 7M8, Canada.	michael.gaetz@ufv.ca		Iverson, Grant/0000-0001-7348-9570			Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Collins M, 2010, BRIT J SPORT MED, V44, P1063, DOI 10.1136/bjsm.2008.056184; de Loes M, 2000, SCAND J MED SCI SPOR, V10, P90, DOI 10.1034/j.1600-0838.2000.010002090.x; Flynn RK, 2005, AM J SPORT MED, V33, P23, DOI 10.1177/0363546504265678; Frank C. B., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P199; Griffin LY, 2006, AM J SPORT MED, V34, P1512, DOI 10.1177/0363546506286866; Hoffmann A, 2007, INT ORTHOP, V31, P791, DOI 10.1007/s00264-007-0395-9; Khoschnau S, 2008, AM J SPORT MED, V36, P2432, DOI 10.1177/0363546508320805; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; Lian K, 2005, ARTHRITIS RHEUM-US, V52, P1431, DOI 10.1002/art.21011; Lo IKY, 2003, CLIN ORTHOP RELAT R, P249, DOI 10.1097/01.blo.0000037442.23683.35; Mann V, 2001, J CLIN INVEST, V107, P899, DOI 10.1172/JCI10347; Mann V, 2003, BONE, V32, P711, DOI 10.1016/S8756-3282(03)00087-5; Marshall S., 2007, UNDERSTANDING PREVEN, P5; Meeuwisse W.H., 1994, CLIN J SPORT MED, V4, P166, DOI [DOI 10.1097/00042752-199407000-00004, 10.1097/00042752-199407000-00004]; Mokone GG, 2006, SCAND J MED SCI SPOR, V16, P19, DOI 10.1111/j.1600-0838.2005.00439.x; Mokone GG, 2005, AM J SPORT MED, V33, P1016, DOI 10.1177/0363546504271986; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Parkkari J, 2008, BRIT J SPORT MED, V42, P422, DOI 10.1136/bjsm.2008.046185; Posthumus M, 2009, J SCI MED SPORT, V12, P184, DOI 10.1016/j.jsams.2007.12.006; Raleigh SM, 2009, BRIT J SPORT MED, V43, P514, DOI 10.1136/bjsm.2008.053892; September AV, 2009, BRIT J SPORT MED, V43, P357, DOI 10.1136/bjsm.2008.048793; Skorupski P, 2006, AM J OBSTET GYNECOL, V194, P346, DOI 10.1016/j.ajog.2005.07.034; Speer G, 2006, ACTA CARDIOL, V61, P321, DOI 10.2143/AC.61.3.2014835; Tilkeridis C, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.033225	25	28	28	0	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	JUL	2009	43	7					508	513		10.1136/bjsm.2008.051748			6	Sport Sciences	Sport Sciences	467FS	WOS:000267724100008	19139034				2021-06-18	
J	Avramescu, S; Nita, DA; Timofeev, I				Avramescu, Sinziana; Nita, Dragos A.; Timofeev, Igor			Neocortical Post-Traumatic Epileptogenesis Is Associated with Loss of GABAergic Neurons	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cortical deafferentation; epilepsy; GABA; GAD	TEMPORAL-LOBE EPILEPSY; GABA-IMMUNOREACTIVE NEURONS; PARTIAL CORTICAL DEAFFERENTATION; PILOCARPINE-INDUCED SEIZURES; V PYRAMIDAL NEURONS; STATUS EPILEPTICUS; VISUAL-CORTEX; DENTATE GYRUS; IN-VITRO; DEVELOPMENTAL NEUROPATHOLOGY	The subtle mechanisms of post-traumatic epileptogenesis remain unknown, although the incidence of chronic epilepsy after penetrating cortical wounds is high. Here, we investigated whether the increased frequency of seizures occurring within 6 weeks following partial deafferentation of the suprasylvian gyrus in cats is accompanied with a change in the ratio between the number of excitatory and inhibitory neurons. Immunohistochemical labeling of all neurons with neuronal-specific nuclear protein (NeuN) antibody, and of the GABAergic inhibitory neurons with either gamma-aminobutyric acid (GABA) or glutamic acid decarboxylase (GAD 65&67) antibodies, was performed on sections obtained from control and epileptic animals with chronically deafferented suprasylvian gyrus. Quantification of the labeled neurons was performed in control animals and at 2, 4, and 6 weeks following cortical deafferentation, in the suprasylvian and marginal gyri, both ipsi- and contra-lateral to the cortical trauma. In all epileptic animals, the neuronal loss was circumscribed to the deafferented suprasylvian gyrus. Inhibitory GABAergic neurons were particularly more sensitive to cortical deafferentation than excitatory ones, leading to a progressively increasing ratio between excitation and inhibition towards excitation, potentially explaining the increased propensity to seizures in chronic undercut cortex.	[Avramescu, Sinziana; Nita, Dragos A.; Timofeev, Igor] Univ Laval Robert Giffard, Ctr Rech, Univ Laval, Sch Med, Quebec City, PQ G1J 2G3, Canada	Timofeev, I (corresponding author), Univ Laval Robert Giffard, Ctr Rech, Univ Laval, Sch Med, 2601 Canardiere, Quebec City, PQ G1J 2G3, Canada.	igor.timofeev@phs.ulaval.ca	Timofeev, Igor/AAP-7529-2021; Timofeev, Igor/E-8828-2012; Nita, Dragos A/C-6445-2008	Timofeev, Igor/0000-0002-1389-5857	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-67175, MOP-93611]; Natural Science and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC) [298475]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS060870-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060870] Funding Source: NIH RePORTER	This research was supported by grants (MOP-67175 and MOP-93611) from the Canadian Institutes of Health Research, Natural Science and Engineering Research Council of Canada ( grant 298475), and National Institute of Neurological Disorders and Stroke (1R01NS060870-01). I. T. is a scholar of Fonds de la Recherche en Sante du Quebec, and S. A. is a Savoy Foundation fellow.	AVRAMESCU S, 2007, NEUR M PLANN SOC NEU; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Baillarger J. G. F., 1840, MEM ACAD ROY MED, V8, P149; Bernard C, 2000, EPILEPSIA, V41, pS90, DOI 10.1111/j.1528-1157.2000.tb01564.x; Bianchi MT, 2002, J NEUROSCI, V22, P5321; BLOOM FE, 1971, NATURE, V229, P628, DOI 10.1038/229628a0; Boucetta S, 2008, EPILEPSIA, V49, P1925, DOI 10.1111/j.1528-1167.2008.01707.x; Bouilleret V, 2000, NEUROSCIENCE, V97, P47, DOI 10.1016/S0306-4522(00)00017-8; BROMAN J, 1988, J COMP NEUROL, V274, P467, DOI 10.1002/cne.902740402; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; Bush PC, 1999, J NEUROPHYSIOL, V82, P1748; Cendes F, 2005, CURR OPIN NEUROL, V18, P173, DOI 10.1097/01.wco.0000162860.49842.90; Chen R, 1998, J NEUROSCI, V18, P3443; Chen R, 2002, NEUROSCIENCE, V111, P761, DOI 10.1016/S0306-4522(02)00025-8; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Dinocourt C, 2003, J COMP NEUROL, V459, P407, DOI 10.1002/cne.10622; Ebert U, 2002, EPILEPSIA, V43, P86, DOI 10.1046/j.1528-1157.43.s.5.39.x; ESPLIN MS, 1994, EPILEPSIA, V35, P911, DOI 10.1111/j.1528-1157.1994.tb02533.x; FRANCK JE, 1985, BRAIN RES, V329, P309, DOI 10.1016/0006-8993(85)90540-2; FRANCK JE, 1988, J NEUROSCI, V8, P1991; Fueta Y, 2005, NEUROSCIENCE, V132, P335, DOI 10.1016/j.neuroscience.2004.12.044; GABBOTT PLA, 1986, EXP BRAIN RES, V61, P323; Gorter JA, 2003, EPILEPSIA, V44, P647, DOI 10.1046/j.1528-1157.2003.53902.x; HENDRY SHC, 1990, J NEUROSCI, V10, P2438; HENDRY SHC, 1986, NATURE, V320, P750, DOI 10.1038/320750a0; HENDRY SHC, 1988, NEURON, V1, P701, DOI 10.1016/0896-6273(88)90169-9; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; Jacobs KM, 1999, J NEUROPHYSIOL, V81, P159; Jacobs KM, 1999, CEREB CORTEX, V9, P733, DOI 10.1093/cercor/9.7.733; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; KARLSSON G, 1992, NEUROSCIENCE, V47, P63, DOI 10.1016/0306-4522(92)90120-Q; Lin JJ, 2007, CEREB CORTEX, V17, P2007, DOI 10.1093/cercor/bhl109; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marcikic M, 1998, INJURY, V29, P613, DOI 10.1016/S0020-1383(98)00146-6; Marin-Padilla M, 1999, J NEUROPATH EXP NEUR, V58, P407, DOI 10.1097/00005072-199905000-00001; Marin-Padilla M, 2002, ACTA NEUROPATHOL, V103, P321, DOI 10.1007/s00401-001-0470-z; MATHERN GW, 1995, BRAIN, V118, P105, DOI 10.1093/brain/118.1.105; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MICHEVA KD, 1995, J COMP NEUROL, V361, P574, DOI 10.1002/cne.903610403; Mountcastle VB, 1997, BRAIN, V120, P701, DOI 10.1093/brain/120.4.701; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408; NIEDERMEYER E, 1969, DTSCH Z NERVENHEILKD, V195, P263; NISHIMURA Y, 1986, NATURE, V320, P753, DOI 10.1038/320753a0; Nita DA, 2006, J NEUROPHYSIOL, V95, P902, DOI 10.1152/jn.00742.2005; Nita DA, 2007, CEREB CORTEX, V17, P272, DOI 10.1093/cercor/bhj145; OBENAUS A, 1993, J NEUROSCI, V13, P4470; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; RIBAK CE, 1982, J NEUROSCI, V2, P1725; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; ROBBINS RJ, 1991, ANN NEUROL, V29, P325, DOI 10.1002/ana.410290316; ROMIJN HJ, 1988, EXP NEUROL, V100, P332, DOI 10.1016/0014-4886(88)90112-4; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Sanabria ERG, 2006, NEUROSCIENCE, V142, P871, DOI 10.1016/j.neuroscience.2006.06.057; Schwenkreis P, 2000, NEUROSCI LETT, V293, P143, DOI 10.1016/S0304-3940(00)01517-2; SLOPER JJ, 1980, BRAIN RES, V198, P204, DOI 10.1016/0006-8993(80)90356-X; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; Spreafico R, 1998, EPILEPSY RES, V32, P34, DOI 10.1016/S0920-1211(98)00038-2; Spreafico R, 1998, NEUROLOGY, V50, P27, DOI 10.1212/WNL.50.1.27; Steriade M, 1998, J NEUROPHYSIOL, V80, P1456; STERIADE M, 1995, J NEUROSCI, V15, P623; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Takase K, 2008, EPILEPSIA, V49, P997, DOI 10.1111/j.1528-1167.2008.01558.x; TECOMA ES, 1989, NEUROLOGY, V39, P676, DOI 10.1212/WNL.39.5.676; Topolnik L, 2003, CEREB CORTEX, V13, P883, DOI 10.1093/cercor/13.8.883; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/88259; WEISS JH, 1990, NEUROLOGY, V40, P1288, DOI 10.1212/WNL.40.8.1288; WELKER E, 1989, EXP BRAIN RES, V78, P659, DOI 10.1007/BF00230256; White HS, 1999, EPILEPSIA, V40, pS2, DOI 10.1111/j.1528-1157.1999.tb00913.x; WHITTINGTON MA, 1994, J PHYSIOL-LONDON, V481, P593, DOI 10.1113/jphysiol.1994.sp020466; Yamauchi T, 2006, PSYCHIAT CLIN NEUROS, V60, P507, DOI 10.1111/j.1440-1819.2006.01553.x; Ziemann U, 1998, J NEUROSCI, V18, P7000	76	28	29	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					799	812		10.1089/neu.2008.0739			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500014	19422294	Green Published, Green Accepted			2021-06-18	
J	Nance, ML; Polk-Williams, A; Collins, MW; Wiebe, DJ				Nance, Michael L.; Polk-Williams, Alison; Collins, Michael W.; Wiebe, Douglas J.			Neurocognitive Evaluation of Mild Traumatic Brain Injury in the Hospitalized Pediatric Population	ANNALS OF SURGERY			English	Article							CONCUSSION; IMPACT; SPORTS; EPIDEMIOLOGY; SENSITIVITY; SYMPTOMS	Objective: To test the feasibility of inpatient neurocognitive testing and measure the degree of disability in children hospitalized with mild traumatic brain injury (MTBI). Summary Background Data: MTBI is common in the pediatric Population. A standardized approach to identify neurocognitive impairment and determine optimal time to return to exertional activities (eg, school, sports) is lacking. Methods: For a 2-year period, children (age: 11-17 years) hospitalized at a level 1 urban Pediatric Trauma Center with MTBI were prospectively enrolled. Neurocognitive performance was assessed utilizing previously validated computer-based tests (Immediate Postconcussion Assessment and Cognitive Testing) as inpatient and in Follow-up clinic after discharge. The feasibility of inpatient testing and the degree neurocognitive impairment and symptomatology were assessed. This study was approved by the IRB and registered with clinicaltrials.gov (NCT00715949). Results: For the 2 years of study, 116 Subjects were prospectively enrolled and tested. The population had a mean age of 14 years and 69.8% were male. On initial in-hospital testing, the overall population demonstrated considerable neurocognitive deficits (mean values for all 4 subtests below 25th percentile, norm 50%) with at least one subtest score below 25% in 95.7% and an abnormal symptom score in 83.4% of patients. In comparing initial testing to follow-Lip testing (N = 63), significant improvements were noted for all subtests (verbal memory: 28.0% vs. 37.5%, respectively, norm 50%, P = 0.02; visual memory: 24.9% vs. 38.1%, respectively, norm 50%, P < 0.01; visual motor: 21.8% vs. 31.1%, respectively, norm 50%, P = 0.01% reaction time: 21.8% vs. 30.3%, respectively, norm 50%, P = 0.05), with a decline in the symptom score (26.9 vs. 9.2, respectively, norm 0-8, P < 0.01) as well. Patients not seen in follow-up (N = 53) did not differ demographically from those seen in clinic. Conclusions: Inpatient neurocognitive testing was feasible in pediatric MTBI patients. Neurocognitive abnormalities were nearly universally present on initial evaluation with significant improvements demonstrated at the time of outpatient follow-up. Return to activity recommendations are thus best deferred for most hospitalized MTBI children until formal assessment can be performed after discharge.	[Nance, Michael L.; Polk-Williams, Alison] Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Sports Concuss Program, Pittsburgh, PA USA; [Wiebe, Douglas J.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	Nance, ML (corresponding author), Childrens Hosp Philadelphia, Dept Surg, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	nance@email.chop.edu	Wiebe, Douglas J/Q-1168-2017				Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bergman DA, 1999, PEDIATRICS, V104, P1407; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Field M, 2003, J PEDIAT, V13, P222; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2005, J CLIN EXP NEUROPSYC, V27, P1; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Sosin DM, 1996, BRAIN INJURY, V10, P47; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	22	28	28	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	MAY	2009	249	5					859	863		10.1097/SLA.0b013e3181a41ae5			5	Surgery	Surgery	441HR	WOS:000265760400029	19387313				2021-06-18	
J	Manders, JE; Stoneman, Z				Manders, Jeanette E.; Stoneman, Zolinda			Children with disabilities in the child protective services system: An analog study of investigation and case management	CHILD ABUSE & NEGLECT			English	Article						Disability; Child abuse; Investigation; Services	DEVELOPMENTAL-DISABILITIES; MALTREATMENT; ABUSE	Objective: The study used a series of vignettes to investigate how the presence of three disabilities (cerebral palsy, intellectual disabilities, emotional/behavioral disabilities) affects the processes and Outcomes of child abuse investigations at two levels of child injury severity (moderate, severe). Method: Seventy-five CPS case workers completed study surveys and answered questions in response to a series of eight vignettes. Results: This study revealed differences in the responses of CPS case workers when the alleged victim of physical abuse had a disability. Children with disabilities were more likely than children without disabilities to be seen as having characteristics that contributed to their abuse. Most CPS workers felt at least some empathy with abusive parents; empathy was highest when the children had emotional/behavioral disabilities. Services recommended for families of children with disabilities were more likely to be child-focused. Parent-focused services, such as individual counseling and adult anger management, were more likely to be recommended for families of children without disabilities. In general, differences among disability groups and between cases involving children with and without disabilities were more pronounced when the children's injuries were less severe. Even with more severe injuries, such as a concussion or broken bones, the CPS workers still responded differently depending on the disability status of the child victims. Conclusions: Recommendations are made concerning the utilization of investigation teams that include disability specialists and the need for further disability-related training for CPS case workers. Practice implications: There is a strong need for training related to disability, with an emphasis on attitudes as well as knowledge and skills. The training should include examples of healthy family functioning and positive aspects of parenting a child with a disability to counteract the prevailing perception of disability as a cause of chronic stress and dysfunction; identification of broader ecological contexts in which these families live, including social response to disability and the disability-related service system and; strategies for disentangling the signs of abuse from characteristics of the disability. Interdisciplinary teams should include members from disability-related fields to share expertise and increase communication between systems. (c) 2009 Published by Elsevier Ltd.	[Manders, Jeanette E.; Stoneman, Zolinda] Univ Georgia, Inst Human Dev & Disabil, Athens, GA 30602 USA	Manders, JE (corresponding author), Univ Georgia, Inst Human Dev & Disabil, Rivers Crossing Bldg,850 Coll Stn Rd, Athens, GA 30602 USA.						ALTER CF, 1985, CHILD WELFARE, V64, P99; AMMERMAN RT, 1989, CHILD ABUSE NEGLECT, V13, P335, DOI 10.1016/0145-2134(89)90073-2; AMMERMAN RT, 1988, J FAMILY VIOLENCE, V3, P53; ANDRE CE, 1985, DISS ABSTR INT A, V46, P792; Baron RA, 1991, SOCIAL PSYCHOL UNDER; BENEDICT MI, 1990, CHILD ABUSE NEGLECT, V14, P207, DOI 10.1016/0145-2134(90)90031-N; BENEDICT MI, 1992, CHILD ABUSE NEGLECT, V16, P155, DOI 10.1016/0145-2134(92)90024-L; Bonner B., 1997, CHILD MALTREATMENT, V2, P52; BUCHELEASH A, 1995, MENTAL PHYSICAL DISA, V19, P115; CICCHINELLI LF, 1991, S RISK ASS CHILD PRO; CRAFT JL, 1980, J SOCIAL SERVICE RES, V4, P31; Crosse SB, 1993, REPORT MALTREATMENT; ELMER E, 1967, PEDIATRICS, V40, P596; FRIEDRICH WN, 1978, HOSP COMMUNITY PSYCH, V29, P248; GARBARINO J, 1987, SPECIAL CHILDREN SPE; *GEORG DEP FAM CHI, 1994, GEORG CHILD AB CENTR; Goldson E, 1998, CHILD ABUSE NEGLECT, V22, P663; HERRENKOHL EC, 1981, NAT C FAM VIOL RES; JACKSON D, 1994, REV UTILITY RI UNPUB; Kvam MH, 2000, CHILD ABUSE NEGLECT, V24, P1073, DOI 10.1016/S0145-2134(00)00159-9; LUJAN C, 1989, CHILD ABUSE NEGLECT, V13, P449, DOI 10.1016/0145-2134(89)90049-5; MANDERS J, 1995, CPS NEEDS ASSESSMENT; Mitchell L. M., 2000, J DISABIL POLICY STU, V10, P225, DOI DOI 10.1177/104420730001000206; MULLINS JB, 1986, J SCHOOL HEALTH, V56, P134, DOI 10.1111/j.1746-1561.1986.tb05720.x; OATES K, 1984, Australia and New Zealand Journal of Developmental Disabilities, V10, P27; Orelove FP, 2000, CHILD ABUSE NEGLECT, V24, P185, DOI 10.1016/S0145-2134(99)00134-9; RICHARDSON M, 1989, CHILD WELFARE, V68, P605; RINDFLEISCH N, 1984, CHILD ABUSE NEGLECT, V8, P33, DOI 10.1016/0145-2134(84)90047-4; ROSEN H, 1981, SOC WORK RES ABSTR, V17, P27; SHAPIRA M, 1993, SOC WORK RES ABSTR, V29, P14, DOI 10.1093/swra/29.2.14; Sobsey D, 1997, CHILD ABUSE NEGLECT, V21, P707, DOI 10.1016/S0145-2134(97)00033-1; Sobsey D., 2002, EXCEPTIONALITY, V10, P29, DOI DOI 10.1207/S15327035EX1001_3; Sobsey D.D., 1994, VIOLENCE ABUSE LIVES; Standen P. J., 2002, CHILD ABUSE REV, V11, P1, DOI DOI 10.1002/CAR.710; Sullivan P. M., 1998, DEV DISABILITIES B, V26, P59; Sullivan PM, 2000, CHILD ABUSE NEGLECT, V24, P1257, DOI 10.1016/S0145-2134(00)00190-3; Sullivan PM, 1998, CHILD ABUSE NEGLECT, V22, P271, DOI 10.1016/S0145-2134(97)00175-0; VERDUGO MA, 1995, CHILD ABUSE NEGLECT, V19, P205, DOI 10.1016/0145-2134(94)00117-D; Vig S, 2002, J DEV PHYS DISABIL, V14, P371, DOI 10.1023/A:1020334903216; von Hentig H., 1948, CRIMINAL HIS VICTIM; Von Hentig H., 1940, J CRIM LAW CRIM, V31, P303; WEST MA, 1992, MENT RETARD, V30, P221	42	28	28	1	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134	1873-7757		CHILD ABUSE NEGLECT	Child Abuse Negl.	APR	2009	33	4					229	237		10.1016/j.chiabu.2008.10.001			9	Family Studies; Psychology, Social; Social Work	Family Studies; Psychology; Social Work	435CO	WOS:000265321200005	19348941				2021-06-18	
J	Mora, AG; Ritenour, AE; Wade, CE; Holcomb, JB; Blackbourne, LH; Gaylord, KM				Mora, Alejandra G.; Ritenour, Amber E.; Wade, Charles E.; Holcomb, John B.; Blackbourne, Lorne H.; Gaylord, Kathryn M.			Posttraumatic Stress Disorder in Combat Casualties With Burns Sustaining Primary Blast and Concussive Injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Posttraumatic stress disorder; Primary blast injury; Mild traumatic brain injury; Burn injury; Explosion	TRAUMATIC BRAIN-INJURY; OPERATION-ENDURING-FREEDOM; TYMPANIC-MEMBRANE PERFORATION; MENTAL-HEALTH PROBLEMS; IRAQI-FREEDOM; SERVICE MEMBERS; WAR; SYMPTOMS; VETERANS; CARE	Background. There is a heightened focus on postexplosion functional outcomes in combat casualties. Previously, we reported a high prevalence of posttraumatic stress disorder (PTSD) (32%) and mild traumatic brain injury (mTBI) (41%) in patients with explosion-related burns. We hypothesized that the prevalence of PTSD in patients with burn was associated with primary blast injuries (PBIs) and mTBI. Methods. We reviewed the records of 333 patients admitted consecutively to the United States Army Institute of Surgical Research burn center for explosion-related injuries between March 2003 and March 2006. By using the Posttraumatic Checklist, Military Version (PCL-M), patients were evaluated for PTSD symptoms (PCL-M score >= 44). Loss of consciousness defined mTBI. Patient data were analyzed in groups based on PTSD (yes or no), mechanism of injury (improvised explosive device [IED] vs. other explosive), PBI (yes or no), and mTBI (yes or no). Results. Of 333 patients, 119 had PTSD assessments. Overall, PTSD was 22% (26 of 119). The prevalence of PTSD differed between mechanism of injury groups (p = 0.03). In the IED group (n = 105), 25% had PTSD symptoms and 18% had mTBI; patients injured by other explosive devices (n = 14) had no PTSD symptoms and one had mTBI (p = 0.04; p = 0.69, respectively). Also in the IED group, in patients with PBI, PTSD was 45% (9 of 20) compared with 20% (17 of 85) without PBI (odds ratio=3.27; 95% confidence interval, 1.17-9.16). More patients with PBI and mTBI (4 of 6; 67%) had PTSD symptoms compared with other patients (22 of 99; 22%) (odds ratio, 7.00; 95% confidence interval, 1.20-40.78). No other associations were found between PBI and mTBI. Conclusion: IED-wounded burn patients with PBI and mTBI have a greater prevalence of PTSD. Patients who did not have IED-related injuries did not have PTSD and only one had mTBI.	[Mora, Alejandra G.; Ritenour, Amber E.; Wade, Charles E.; Holcomb, John B.; Blackbourne, Lorne H.; Gaylord, Kathryn M.] USA, Inst Surg Res, Ft Sam Houston, TX 78234 USA	Gaylord, KM (corresponding author), USA, Inst Surg Res, 3400 Rawley E Chambers Rd, Ft Sam Houston, TX 78234 USA.	Kathryn.Gaylord@amedd.army.mil		holcomb, john/0000-0001-8312-9157			Aboutanos MB, 1997, J TRAUMA, V43, P719, DOI 10.1097/00005373-199710000-00031; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Born CT, 2005, SCAND J SURG, V94, P279, DOI 10.1177/145749690509400406; Bowen Anne Phelan, 2003, J Emerg Nurs, V29, P287, DOI 10.1067/men.2003.90; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cordts PR, 2008, J TRAUMA, V64, pS14, DOI 10.1097/TA.0b013e31816093bd; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dyster-Aas J, 2008, J TRAUMA, V64, P1349, DOI 10.1097/TA.0b013e318047e005; Feinstein Anthony, 2004, Evid Based Ment Health, V7, P88; Frueh BC, 2007, AM J PUBLIC HEALTH, V97, P2143, DOI 10.2105/AJPH.2007.115436; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Hayda R, 2004, CLIN ORTHOP RELAT R, P97, DOI 10.1097/01.blo.0000128295.28666.ee; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; JENSEN JH, 1993, ACTA OTO-LARYNGOL, V113, P62, DOI 10.3109/00016489309135768; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Lu MK, 2007, BURNS, V33, P649, DOI 10.1016/j.burns.2006.09.004; McGhee LL, 2008, J TRAUMA, V64, pS195, DOI 10.1097/TA.0b013e318160ba1d; McKibben JBA, 2008, J BURN CARE RES, V29, P22, DOI 10.1097/BCR.0b013e31815f59c4; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Pols H, 2007, AM J PUBLIC HEALTH, V97, P2132, DOI 10.2105/AJPH.2006.090910; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Stein M, 2005, SCAND J SURG, V94, P286, DOI 10.1177/145749690509400407; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Trunkey DD, 2008, ARCH SURG-CHICAGO, V143, P112, DOI 10.1001/archsurg.2007.38; Wade CE, 2008, EXPLOSION BLAST RELA, P41; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Xydakis MS, 2006, NEUROSURGERY, V59, P467, DOI 10.1227/00006123-200608000-00078; Yu BH, 1999, J BURN CARE REHABIL, V20, P426, DOI 10.1097/00004630-199909000-00017; 2008, ONE 5 IRAQ AFGHANIST; 2008, BLAST INJURY FAQS	44	28	28	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2009	66	4		S			S178	S184		10.1097/TA.0b013e31819ce2d6			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	431OW	WOS:000265073100028	19359963				2021-06-18	
J	Caeyenberghs, K; Wenderoth, N; Smits-Engelsman, BCM; Sunaert, S; Swinnen, SP				Caeyenberghs, K.; Wenderoth, N.; Smits-Engelsman, B. C. M.; Sunaert, S.; Swinnen, S. P.			Neural correlates of motor dysfunction in children with traumatic brain injury: exploration of compensatory recruitment patterns	BRAIN			English	Article						Traumatic brain injury; fMRI; motor control; interlimb coordination; children	PURKINJE-CELL VULNERABILITY; INTERLIMB COORDINATION; RHYTHMIC COORDINATION; FUNCTIONAL-ANATOMY; PHASE-TRANSITIONS; PARIETAL CORTEX; HAND MOVEMENTS; FOOT MOVEMENTS; CEREBELLAR; FMRI	Traumatic brain injury (TBI) is a common form of disability in children. Persistent deficits in motor control have been documented following TBI but there has been less emphasis on changes in functional cerebral activity. In the present study, children with moderate to severe TBI (n 9) and controls (n 17) were scanned while performing cyclical movements with their dominant and non-dominant hand and foot according to the easy isodirectional (same direction) and more difficult non-isodirectional (opposite direction) mode. Even though the children with TBI were shown to be less successful on various items of a clinical motor test battery than the control group, performance on the coordination task during scanning was similar between groups, allowing a meaningful interpretation of their brain activation differences. fMRI analysis revealed that the TBI children showed enhanced activity in medial and anterior parietal areas as well as posterior cerebellum as compared with the control group. Brain activation generally increased during the non-isodirectional as compared with the isodirectional mode and additional regions were involved, consistent with their differential degree of difficulty. However, this effect did not interact with group. Overall, the findings indicate that motor impairment in TBI children is associated with changes in functional cerebral activity, i.e. they exhibit compensatory activation reflecting increased recruitment of neural resources for attentional deployment and somatosensory processing.	[Caeyenberghs, K.; Wenderoth, N.; Smits-Engelsman, B. C. M.; Swinnen, S. P.] Katholieke Univ Leuven, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, Dept Biomed Kinesiol,Motor Control Lab, B-3001 Heverlee, Belgium; [Smits-Engelsman, B. C. M.] Univ Profess, Dept Healthcare, Breda, Netherlands; [Sunaert, S.] Katholieke Univ Leuven, Dept Radiol, Univ Hosp, Louvain, Belgium	Swinnen, SP (corresponding author), Katholieke Univ Leuven, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, Dept Biomed Kinesiol,Motor Control Lab, Tervuursevest 101, B-3001 Heverlee, Belgium.	stephan.swinnen@faber.kuleuven.be	Sunaert, Stefan/E-8031-2011; Wenderoth, Nicole/D-7262-2015	Sunaert, Stefan/0000-0002-1177-4680; Wenderoth, Nicole/0000-0002-3246-9386; Caeyenberghs, Karen/0000-0001-7009-6843	Research Programme of the Research Foundation-Flanders (FWO)FWO [7.0004.05]; Research Foundation-FlandersFWO; Research Fund K. U. LeuvenKU Leuven [OT/07/073]; Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [Grant P6/29]	Research Programme of the Research Foundation-Flanders (FWO) (Levenslijn # 7.0004.05); Research Foundation-Flanders (PhD fellowship to C. K.). Research Fund K. U. Leuven (OT/07/073); Grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government.	Bartenstein P, 1997, BRAIN, V120, P1553, DOI 10.1093/brain/120.9.1553; Behrmann M, 2004, CURR OPIN NEUROBIOL, V14, P212, DOI 10.1016/j.conb.2004.03.012; Blinkenberg M, 1996, J CEREBR BLOOD F MET, V16, P794, DOI 10.1097/00004647-199609000-00004; Burgund ED, 2002, NEUROIMAGE, V17, P184, DOI 10.1006/nimg.2002.1174; CARSON RG, 1995, J MOTOR BEHAV, V27, P211, DOI 10.1080/00222895.1995.9941711; Cavallari P, 2001, EXP BRAIN RES, V141, P398, DOI 10.1007/s00221-001-0898-3; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Ciesielski KT, 2006, NEUROIMAGE, V33, P980, DOI 10.1016/j.neuroimage.2006.07.028; Dassonville P, 1998, NEUROSCI RES, V32, P65, DOI 10.1016/S0168-0102(98)00064-9; Debaere F, 2004, NEUROIMAGE, V21, P1416, DOI 10.1016/j.neuroimage.2003.12.011; Debaere F, 2001, NEUROIMAGE, V14, P947, DOI 10.1006/nimg.2001.0892; Ehrsson HH, 2000, EUR J NEUROSCI, V12, P3385, DOI 10.1046/j.1460-9568.2000.00209.x; Ehrsson HH, 2002, J NEUROSCI, V22, P5074, DOI 10.1523/JNEUROSCI.22-12-05074.2002; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Gut M, 2007, ACTA NEUROBIOL EXP, V67, P43; Henderson S. E., 1992, MOVEMENT ASSESSMENT; Heuninckx S, 2005, J NEUROSCI, V25, P6787, DOI 10.1523/JNEUROSCI.1263-05.2005; Heuninckx S, 2008, J NEUROSCI, V28, P91, DOI 10.1523/JNEUROSCI.3300-07.2008; Hikosaka O, 1999, TRENDS NEUROSCI, V22, P464, DOI 10.1016/S0166-2236(99)01439-3; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Ivry R., 1989, J COGNITIVE NEUROSCI, V1, P134; Johnson-Frey SH, 2005, CEREB CORTEX, V15, P681, DOI 10.1093/cercor/bhh169; Kaelin-Lang A, 2008, NEUROREHABILITATION, V23, P89; Kang HC, 2003, NEUROIMAGE, V19, P16, DOI 10.1016/S1053-8119(03)00038-7; KELSO JAS, 1984, AM J PHYSIOL, V246, P1000; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; LEE TD, 1995, J MOTOR BEHAV, V27, P263, DOI 10.1080/00222895.1995.9941716; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lotze M, 2006, NEUROREHAB NEURAL RE, V20, P14, DOI 10.1177/1545968305282919; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; NORRSELL U, 1980, PHYSIOL REV, V60, P327; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Prigatano GP, 2004, BRAIN INJURY, V18, P661, DOI 10.1080/02699050310001646170; Rao SM, 1996, J CEREBR BLOOD F MET, V16, P1250, DOI 10.1097/00004647-199611000-00020; Rascol O, 1997, BRAIN, V120, P103, DOI 10.1093/brain/120.1.103; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Rizzolatti G, 1998, ELECTROEN CLIN NEURO, V106, P283, DOI 10.1016/S0013-4694(98)00022-4; Rizzolatti G, 1997, CURR OPIN NEUROBIOL, V7, P562, DOI 10.1016/S0959-4388(97)80037-2; Rocca MA, 2007, HUM BRAIN MAPP, V28, P218, DOI 10.1002/hbm.20271; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rossi C, 1996, ARCH PHYS MED REHAB, V77, P1062, DOI 10.1016/S0003-9993(96)90069-6; Sakai K, 2000, J NEUROSCI, V20, P2691; Samuel M, 1997, BRAIN, V120, P963, DOI 10.1093/brain/120.6.963; Serrien DJ, 2007, PROG NEUROBIOL, V82, P95, DOI 10.1016/j.pneurobio.2007.02.003; Serrien DJ, 2003, HUM BRAIN MAPP, V18, P296, DOI 10.1002/hbm.10086; Simon O, 2002, NEURON, V33, P475, DOI 10.1016/S0896-6273(02)00575-5; Smits-Engelsman BC, 1998, MOVEMENT ASSESSMENT; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; SWINNEN SP, 1995, EXP BRAIN RES, V105, P439; Swinnen SP, 1997, J COGNITIVE NEUROSCI, V9, P348, DOI 10.1162/jocn.1997.9.3.348; Swinnen SP, 2002, NAT REV NEUROSCI, V3, P350, DOI 10.1038/nrn807; Swinnen SP, 2004, TRENDS COGN SCI, V8, P18, DOI 10.1016/j.tics.2003.10.017; Thomas KM, 2004, J COGNITIVE NEUROSCI, V16, P1339, DOI 10.1162/0898929042304688; Verstynen T, 2005, J NEUROPHYSIOL, V93, P1209, DOI 10.1152/jn.00720.2004; Volman MJM, 2006, CHILD CARE HLTH DEV, V32, P693, DOI 10.1111/j.1365-2214.2006.00679.x; Ward NS, 2006, AGEING RES REV, V5, P239, DOI 10.1016/j.arr.2006.04.003; Ward NS, 2006, ARCH PHYS MED REHAB, V87, pS30, DOI 10.1016/j.apmr.2006.08.334; Ward NS, 2003, BRAIN, V126, P873, DOI 10.1093/brain/awg071; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; Wenderoth N, 2004, NEURO-BEHAVIORAL DETERMINANTS OF INTERLIMB COORDINATION, P187; Wenderoth N, 2005, EUR J NEUROSCI, V22, P235, DOI 10.1111/j.1460-9568.2005.04176.x; Wu T, 2005, BRAIN, V128, P2250, DOI 10.1093/brain/awh569; Wu T, 2005, J PHYSIOL-LONDON, V562, P605, DOI 10.1113/jphysiol.2004.076042; Wu X, 2008, NEUROREPORT, V19, P483, DOI 10.1097/WNR.0b013e3282f6030b; Zemke AC, 2003, STROKE, V34, pE23, DOI 10.1161/01.STR.0000065827.35634.5E	78	28	28	0	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR	2009	132		3				684	694		10.1093/brain/awn344			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	428YW	WOS:000264889000013	19153150	Bronze			2021-06-18	
J	Thornton, KE; Carmody, DP				Thornton, Kirtley E.; Carmody, Dennis P.			Traumatic Brain Injury Rehabilitation: QEEG Biofeedback Treatment Protocols	APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK			English	Article						EEG biofeedback; Traumatic brain injury; Cognitive rehabilitation; Activation QEEG; Memory rehabilitation; Cognitive challenge	CLOSED-HEAD-INJURY; DIFFUSION-TENSOR; QUANTITATIVE EEG; COHERENCE; NEUROTHERAPY; MEMORY; DELAY; INDEX; MRI	Interventions for improvement of cognitive problems in patients with traumatic brain injury (TBI) include electroencephalography biofeedback, also known as neurofeedback. Quantitative electroencephalography (QEEG) patterns are assessed in TBI patients and then compared to a database obtained from a normative population. Deviations in QEEG patterns from the normative group are the basis for an intervention plan. While QEEG patterns, obtained under an eyes closed, resting condition, provide information about deviations at rest, QEEG patterns obtained while the patient engages in cognitive tasks reflect specific deficiencies in brain functioning. This paper reviews and assesses QEEG patterns collected under both resting conditions as well as cognitive tasks. The article provides a theoretical and empirical base for QEEG interventions with TBI.	[Thornton, Kirtley E.] Brain Fdn, Edison, NJ 08817 USA; [Carmody, Dennis P.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Inst Study Child Dev, New Brunswick, NJ 08903 USA	Thornton, KE (corresponding author), Brain Fdn, 2 Ethel Rd,Ste 203C, Edison, NJ 08817 USA.	ket@chp-neurotherapy.com	Carmody, Dennis P./AAS-7734-2020	thornton, kirtley/0000-0002-3303-4747; Carmody, Dennis/0000-0002-1288-104X			Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Braver ER, 1997, JAMA-J AM MED ASSOC, V278, P1437, DOI 10.1001/jama.278.17.1437; BYERS AP, 1995, J NEUROTHERAPY, V1, P22, DOI DOI 10.1300/J184V01N01_; CARTER GC, 1987, P IEEE, V75, P236, DOI 10.1109/PROC.1987.13723; *CDC, 1999, FACTS CONC BRAIN INJ; Collura TF., 2008, J NEUROTHERAPY, V12, P99, DOI [10.1080/10874200802433274, DOI 10.1080/10874200802433274]; DEFILIPPIS NA, 1979, CATEGORY TEST; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; HARMONY T, 1990, INT J NEUROSCI, V54, P147, DOI 10.3109/00207459008986630; Heaton R. K, 1981, WISCONSIN CARD SORTI; HOOSHMAND H, 1989, CLIN ELECTROENCEPHAL, V20, P235, DOI 10.1177/155005948902000411; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; JOFFE D, 1992, LEXICOR NRS 24 BIOLE; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; Keller I., 2001, J NEUROTHER, V5, P19, DOI DOI 10.1300/J184V05N01_03; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Leon-Carrion J, 2008, BRAIN INJURY, V22, P61, DOI 10.1080/02699050701824143; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; RANDOLPH C, 1988, NEUROPSYCHOBIOLOGY, V20, P43, DOI 10.1159/000118471; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Schoenberger NE, 2001, J HEAD TRAUMA REHAB, V16, P260, DOI 10.1097/00001199-200106000-00005; *SKIL, 2008, AN SOFTW; STEPHENS J, 2006, EFFECTIVENESS EEG BI; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Thatcher RW, 2005, CLIN NEUROPHYSIOL, V116, P2129, DOI 10.1016/j.clinph.2005.04.026; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Thornton K, 2003, ARCH CLIN NEUROPSYCH, V18, P363, DOI 10.1016/S0887-6177(02)00139-7; Thornton K., 2000, J NEUROTHERAPY, V3, P1, DOI DOI 10.1300/J184V03N03_01; Thornton K. E., 2002, J NEUROTHER, V6, P37, DOI [10.1300/j184v06n03_04, DOI 10.1300/J184V06N03_04]; Thornton KE, 2005, CHILD ADOL PSYCH CL, V14, P137, DOI 10.1016/j.chc.2004.07.001; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; THORNTON KE, 2007, INT SOC NEUR REG SAN; THORNTON KE, 2001, Patent No. 6309361; THORNTON KE, 2009, J NEUROTHER IN PRESS; Thornton KE, 2008, APPL PSYCHOPHYS BIOF, V33, P101, DOI 10.1007/s10484-008-9056-z; Tinius T. P., 2000, J NEUROTHERAPY, V4, P27, DOI [10.1300/J184v04n02_05, DOI 10.1300/J184V04N02_05]; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Walker J.E., 2002, J NEUROTHER, V6, P31, DOI [10.1300/J184v06n02_05, DOI 10.1300/J184v06n02_05, DOI 10.1300/J184V06N02_]	45	28	30	0	18	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1090-0586	1573-3270		APPL PSYCHOPHYS BIOF	Appl. Psychophysiol. Biofeedback	MAR	2009	34	1					59	68		10.1007/s10484-009-9075-4			10	Psychology, Clinical	Psychology	409RJ	WOS:000263523200007	19199027				2021-06-18	
J	Jia, F; Mao, Q; Liang, YM; Jiang, JY				Jia, Feng; Mao, Qing; Liang, Yu-Min; Jiang, Ji-Yao			Effect of Post-Traumatic Mild Hypothermia on Hippocampal Cell Death after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						cell death; hippocampus; mild hypothermia; traumatic brain injury	CORTICAL IMPACT INJURY; MODERATE HYPOTHERMIA; NEURONAL DEATH; THERAPEUTIC HYPOTHERMIA; BEHAVIORAL DEFICITS; CEREBRAL-ISCHEMIA; HEAD-INJURY; APOPTOSIS; PROTECTION; NECROSIS	In this investigation, we evaluated the effect of post-traumatic mild hypothermia on cell death in the hippocampus after fluid percussion traumatic brain injury (TBI) in rats. Adult male Sprague-Dawley rats were randomly divided into three groups (n = 40/group): TBI with hypothermia treatment (32 degrees C), TBI with normothermia (37 degrees C), and sham injury. The TBI model was induced by a fluid percussion TBI device. Mild hypothermia (32 degrees C) was achieved by partial immersion in a water bath (0 degrees C) under general anesthesia for 4 h. All rats were killed at 24 or 72 h after TBI. The ipsilateral hippocampal CA1 in all rats were analyzed by hematoxylin and eosin staining, terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphatebiotin nick end labeling (TUNEL), and 4',6-diamidino-2-phenylindole (DAPI) staining for determining cell death. Caspase-3 expression was examined by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. At 24 h, based on TUNEL and DAPI results, the cell death index was 28.80 +/- 2.60% and 32.10 +/- 1.40% in the normothermia TBI group, while reaching only 14.30 +/- 2.70% and 18.40 +/- 2.10% in the hypothermic TBI group (p < 0.01). Based on RT-PCR and Western blotting results, the expression of caspase-3 was 210.20 +/- 5.30% and 170.30 +/- 4.80% in the normothermic TBI group, while reaching only 165.10 +/- 3.70% and 130.60 +/- 4.10% in the hypothermic TBI group (p < 0.05). At 72 h, based on TUNEL and DAPI results, the cell death index was 20.80 +/- 2.50% and 25.50 +/- 1.80% in the normothermic TBI group, while reaching only 10.20 +/- 2.60% and 15.50 +/- 2.10% in the hypothermic TBI group (p < 0.01). Based on RT-PCR and Western blotting results, the expression of caspase-3 was 186.20 +/- 6.20% and 142.30 +/- 5.10% in the normothermic TBI group, versus only 152.10 +/- 3.60% and 120.60 +/- 3.90% in the hypothermic TBI group (p < 0.05). Based on our findings, we conclude that post-traumatic hypothermia significantly attenuates cell death within the hippocampus following fluid percussion injury. Taken together with other studies, these observations support the premise that post-traumatic mild hypothermia can provide cerebral protection for patients with TBI.	[Jia, Feng; Mao, Qing; Liang, Yu-Min; Jiang, Ji-Yao] Shanghai Jiao Tong Univ, Shanghai Renji Hosp, Dept Neurosurg, Sch Med, Shanghai 200127, Peoples R China	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, RenJi Hosp, Dept Neurosurg, Sch Med, Shanghai 200127, Peoples R China.	jiangjyb@online.sh.cn			National Key Basic Research ProjectNational Basic Research Program of China [2005CB522604]; National Science and Nature [30571908]; Science and Technology Committee of ShanghaiShanghai Science & Technology Committee [07JC14038]; Program for Shanghai Outstanding Medical Academic Leader	This work was supported by the National Key Basic Research Project (grant 2005CB522604), National Science and Nature Grants (grant 30571908), Science and Technology Committee of Shanghai (grant 07JC14038), and Program for Shanghai Outstanding Medical Academic Leader.	Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Celik SE, 2006, J NEUROTRAUM, V23, P1355, DOI 10.1089/neu.2006.23.1355; Clark RSB, 1999, FASEB J, V13, P813; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FARBER E, 1994, MODERN PATHOL, V7, P605; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Greve KW, 2007, CLIN NEUROPSYCHOL, V21, P318, DOI 10.1080/13854040500488552; HAGERDAL M, 1979, ACTA ANAESTH SCAND, V23, P89; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; JESSIE T, 2005, BRAIN RES MOL BRAIN, V138, P124; Jiang JY, 2007, CURR OPIN CRIT CARE, V13, P153, DOI 10.1097/MCC.0b013e32807f2a80; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lin X, 2001, Chin J Traumatol, V4, P14; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; MAJNO G, 1995, AM J PATHOL, V146, P3; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; ORD JS, 2007, CLIN NEUROPSYCHOL, V13, P1; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Phanithi PB, 2000, NEUROPATHOLOGY, V20, P273, DOI 10.1046/j.1440-1789.2000.00346.x; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; RINK A, 1995, AM J PATHOL, V147, P1575; SEARLE J, 1982, PATHOL ANNU, V17, P229; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wu XH, 2007, J NEUROTRAUM, V24, P1502, DOI 10.1089/neu.2006.0228; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yang Xiao-feng, 2006, Chin J Traumatol, V9, P276; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	53	28	34	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2009	26	2					243	252		10.1089/neu.2008.0670			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	410NS	WOS:000263585100007	19236165				2021-06-18	
J	Herrera-Soto, JA; Price, CT				Herrera-Soto, Jose A.; Price, Charles T.			Traumatic Hip Dislocations in Children and Adolescents: Pitfalls and Complications	JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS			English	Article							FEMORAL-HEAD; CORE DECOMPRESSION; OPEN-REDUCTION; OSTEONECROSIS; CHILDHOOD; ARTHROGRAPHY; SEPARATION; EPIPHYSIS; FRACTURE; OSTEORADIOLOGY	Traumatic hip dislocation is an uncommon injury in children. Lack of familiarity with management of the treating physician may lead to complications. Hip dislocation in young children can occur with minor trauma; in adolescents, greater force is required to produce a traumatic complete hip dislocation. Transient hip dislocation with spontaneous but incomplete reduction is a diagnostic pitfall that can occur in adolescents. Any asymmetric widening of the hip joint warrants additional investigation. Most dislocations in children can be reduced with gentle manipulation. Urgent reduction of the hip within 6 hours of injury reduces the risk of osteonecrosis. However, closed reduction in adolescents should be performed with caution because of the risk of displacement of the femoral head during manipulation. Open reduction is indicated when closed reduction fails or when there is interposition of bone or soft tissue following attempted closed reduction. Late complications include osteonecrosis, coxa magna, and osteoarthritis.	[Herrera-Soto, Jose A.] Orlando Reg Med Ctr Inc, Pediat Orthopaed Fellowship Program, Orlando, FL 32806 USA	Herrera-Soto, JA (corresponding author), Orlando Reg Med Ctr Inc, Pediat Orthopaed Fellowship Program, 83 W Columbia St, Orlando, FL 32806 USA.						Adili A, 2003, CLIN ORTHOP RELAT R, P93, DOI 10.1097/01.blo.0000096815.78689.3e; AHMADI B, 1983, CLIN ORTHOP RELAT R, P209; Ashman CJ, 2000, AM J ROENTGENOL, V175, P541, DOI 10.2214/ajr.175.2.1750541; Banskota AK, 2007, J PEDIATR ORTHOPED, V27, P187, DOI 10.1097/BPO.0b013e31802c547e; BARQUET A, 1984, ARCH ORTHOP TRAUM SU, V103, P219, DOI 10.1007/BF00435558; BARQUET A, 1980, J TRAUMA, V20, P1003, DOI 10.1097/00005373-198011000-00022; BARQUET A, 1982, ACTA ORTHOP SCAND, V53, P815, DOI 10.3109/17453678208992299; BARQUET A, 1982, ACTA ORTHOP SCAND, V53, P809, DOI 10.3109/17453678208992298; Berbaum KS, 2001, AM J ROENTGENOL, V177, P252, DOI 10.2214/ajr.177.1.1770252c; CANALE ST, 1977, J BONE JOINT SURG AM, V59, P431, DOI 10.2106/00004623-197759040-00001; Cornwall R, 2000, CLIN ORTHOP RELAT R, P84; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, P116; EPSTEIN HC, 1985, CLIN ORTHOP RELAT R, P9; Gent E, 2004, J PEDIATR ORTHOPED, V24, P235, DOI 10.1097/01241398-200403000-00019; GIANOM D, 1994, HELV CHIR ACTA, V60, P623; GLYNN TP, 1989, SKELETAL RADIOL, V18, P29, DOI 10.1007/BF00366768; Grecula MJ, 2005, ORTHOP CLIN N AM, V36, P231, DOI 10.1016/j.ocl.2005.02.005; GUINGAND O, 1985, REV CHIR ORTHOP, V71, P575; Herrera-Soto JA, 2006, J PEDIATR ORTHOPED, V26, P371, DOI 10.1097/01.bpo.0000214925.41056.b9; HOUGAARD K, 1989, ORTHOPEDICS, V12, P375; KLEIN A, 1982, AM J ROENTGENOL, V138, P963, DOI 10.2214/ajr.138.5.963; Kumar S, 2005, CLIN ORTHOP RELAT R, P9, DOI 10.1097/01.blo.0000152366.58660.ea; Kutty S, 2001, PEDIATR EMERG CARE, V17, P32, DOI 10.1097/00006565-200102000-00009; Lieberman JR, 2004, CLIN ORTHOP RELAT R, P139, DOI 10.1097/01.blo.0000150312.53937.6f; MASS DP, 1980, CLIN ORTHOP RELAT R, P184; Mehlman CT, 2000, CLIN ORTHOP RELAT R, P68; Mont MA, 1998, J BONE JOINT SURG BR, V80B, P56, DOI 10.1302/0301-620X.80B1.7989; Mont MA, 2004, CLIN ORTHOP RELAT R, P131, DOI 10.1097/01.blo.0000150128.57777.8e; Mont Michael A, 2006, Instr Course Lect, V55, P167; MOWERY CA, 1986, J PEDIATR ORTHOPED, V6, P7, DOI 10.1097/01241398-198601000-00002; Muratli Hasan Hilmi, 2004, Acta Orthop Traumatol Turc, V38, P149; NOTZLI HP, 1995, J PEDIATR ORTHOPED, V15, P16, DOI 10.1097/01241398-199501000-00004; Odent T, 2003, ACTA ORTHOP SCAND, V74, P49, DOI 10.1080/00016470310013653; OFFIERSKI CM, 1981, J BONE JOINT SURG BR, V63, P194; OLSSON O, 1994, ACTA ORTHOP SCAND, V65, P476, DOI 10.3109/17453679408995496; Price CT, 2002, J ORTHOP TRAUMA, V16, P730, DOI 10.1097/00005131-200211000-00008; Ratliff A H, 1968, J Bone Joint Surg Br, V50, P757; Roberts C S, 1990, J Arthroplasty, V5, P89, DOI 10.1016/S0883-5403(06)80015-X; Rubinstein Richard A. Jr., 1993, Contemporary Orthopaedics, V27, P527; Salisbury RD, 2000, CLIN ORTHOP RELAT R, P106; SCHLONSKY J, 1973, J BONE JOINT SURG AM, VA 55, P1057, DOI 10.2106/00004623-197355050-00015; Schoenecker P L, 1997, Am J Orthop (Belle Mead NJ), V26, P257; *SCI RES COMM PENN, 1968, J BONE JOINT SURG AM, V50, P79; SCUDERI G, 1987, CLIN ORTHOP RELAT R, P179; SLAVIK M, 1986, ARCH ORTHOP TRAUM SU, V104, P385, DOI 10.1007/BF00454438; Steinberg ME, 2001, CLIN ORTHOP RELAT R, P71; Tavares JO, 1998, J PEDIATR ORTHOPED, V18, P651, DOI 10.1097/00004694-199809000-00019; Trousdale R T, 1997, Am J Orthop (Belle Mead NJ), V26, P76; TROUSDALE RT, 1997, AM J ORTHOPSYCHIAT, V26, P76; Urbaniak J R, 1998, J Am Acad Orthop Surg, V6, P44; Vialle R, 2005, J PEDIATR ORTHOPED, V25, P138, DOI 10.1097/01.bpo.0000151059.85227.ea; Vialle R, 2004, PEDIATR RADIOL, V34, P970, DOI 10.1007/s00247-004-1299-0; VONTOBEL BJ, 1994, ARCH ORTHOP TRAUM SU, V113, P83, DOI 10.1007/BF00572911; WEDGE JH, 1987, CLIN ORTHOP RELAT R, P93; WILCHINSKY ME, 1985, J PEDIATR ORTHOPED, V5, P534, DOI 10.1097/01241398-198509000-00005; YANG RS, 1991, CLIN ORTHOP RELAT R, P218	56	28	33	0	2	AMER ACAD ORTHOPAEDIC SURGEONS	ROSEMENT	6300 N RIVER ROAD, ROSEMENT, IL 60018-4262 USA	1067-151X			J AM ACAD ORTHOP SUR	J. Am. Acad. Orthop. Surg.	JAN	2009	17	1					15	21		10.5435/00124635-200901000-00003			7	Orthopedics; Surgery	Orthopedics; Surgery	390UL	WOS:000262189100004	19136423				2021-06-18	
J	McAllister, TW				McAllister, Thomas W.			Polymorphisms in Genes Modulating the Dopamine System: Do They Influence Outcome and Response to Medication After Traumatic Brain Injury?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							RECEPTOR-BINDING; WORKING-MEMORY; SCHIZOPHRENIA; TRANSPORTER; DRD2; PERFORMANCE; MECHANISMS; TOLCAPONE; GENOTYPE; ALLELE		[McAllister, Thomas W.] Dartmouth Med Sch, Sect Neuropsychiat, Hanover, NH USA	McAllister, TW (corresponding author), Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu			NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176]; NIDRR [H133G70031, H133000136]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS40472-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER	This work was supported in part by NICHD grant R01 HD048176, NIDRR grant; H133G70031 and H133000136, and NIH grant RO1 NS40472-01.	Bilder RM, 2002, BIOL PSYCHIAT, V52, P701, DOI 10.1016/S0006-3223(02)01416-6; Comings DE, 1998, ALCOHOL, V16, P61, DOI 10.1016/S0741-8329(97)00178-X; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Dulawa SC, 1999, J NEUROSCI, V19, P9550; Ebstein RP, 1998, MOL PSYCHIATR, V3, P238, DOI 10.1038/sj.mp.4000363; Ebstein RP, 2000, EUR J PHARMACOL, V410, P205, DOI 10.1016/S0014-2999(00)00852-9; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Gainetdinov RR, 1998, BRAIN RES REV, V26, P148, DOI 10.1016/S0165-0173(97)00063-5; Gasparini M, 1997, J NEURAL TRANSM, V104, P887, DOI 10.1007/BF01285556; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; Goldberg TE, 2003, ARCH GEN PSYCHIAT, V60, P889, DOI 10.1001/archpsyc.60.9.889; Guillin O, 2004, INT REV NEUROBIOL, V59, P425; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Jovanovic V, 1999, PHARMACOGENETICS, V9, P561, DOI 10.1097/00008571-199910000-00003; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Liljequist R, 1997, BEHAV BRAIN RES, V82, P195, DOI 10.1016/S0166-4328(97)80989-8; LIPSKY RH, 2005, J NEUROPSYCHIATRY CL, V17; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; Martinsson L, 2004, DRUG AGING, V21, P67, DOI 10.2165/00002512-200421020-00001; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Miller GM, 2002, MOL PSYCHIATR, V7, P44, DOI 10.1038/sj/mp/4000921; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; Ritchie T, 2003, NEUROCHEM RES, V28, P73, DOI 10.1023/A:1021648128758; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; Watts VJ, 1999, PSYCHOPHARMACOLOGY, V141, P83, DOI 10.1007/s002130050810; Weinberger DR, 2001, BIOL PSYCHIAT, V50, P825, DOI 10.1016/S0006-3223(01)01252-5; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Wong AHC, 2000, EUR J PHARMACOL, V410, P183	31	28	29	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2009	24	1					65	68		10.1097/HTR.0b013e3181996e6b			4	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	427GT	WOS:000264768500010	19158598	Green Accepted			2021-06-18	
J	Mowery, NT; Gunter, OL; Guillamondegui, O; Dossett, LA; Dortch, MJ; Morris, JA; May, AK				Mowery, Nathan T.; Gunter, Oliver L.; Guillamondegui, Oscor; Dossett, Lesly A.; Dortch, Marcus J.; Morris, John A., Jr.; May, Addison K.			Stress Insulin Resistance is a Marker for Mortality in Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Stress hyperglycemia; Insulin resistance; Intensive insulin therapy; Trauma; Intensive care; Traumatic brain injury	ADMISSION HYPERGLYCEMIA; ACUTE STROKE; GLUCOSE-METABOLISM; THERAPY; SURGERY; SYSTEM; MICRODIALYSIS; INFARCTION; TOLERANCE; PROTOCOL	Background: Both hyper- and hypo-glycemia have been associated with poor outcome in traumatic brain injury (TBI). Neither the risks nor benefit of tight glucose control (goal range, 80-110 mg/dL) have been documented in the TBI population. Objective: To analyze whether densely collected blood glucose data, using a computerized algorithm, to maintain tight glycemic control will reveal significant differences in blood glucose control between survivors and nonsurvivors in patients with TBI. Methods: From October 2005 to April 2006, all ventilated, critically ill surgical patients with TBI Abbreviated Injury Scale score of >= 3 were placed on an automated, euglycemia protocol with every 2-hour blood glucose sampling. Mortalities within 24 hours were excluded. The protocol calculates the insulin rate using a linear equation (rate = blood glucose - 60[M]). M is an adapting multiplier and used here as a marker for insulin resistance (111). Results: Of 1,636 trauma intensive care unit admissions 160 patients, (median Injury Severity Score 34, mortality 13.1%) had 10,071 samples collected. Median glucose 115.6 mg/dL, with 41% of values between 80 and 110 mg/dL, 81% between 80 and 150 mg/dL, and 0.3% <40 mg/dL. The median blood glucose was statistically different but not clinically different among the patients who lived and died (114; interquartile range, 109-132 vs. 118; 111-136, p = 0.01). The median insulin dose was a unit per hour higher among the patient who died (4.2; 2.7-5.9 vs. 3.2; 2.4-5.0, p = 0.006). A logistic regression model demonstrated insulin rate (odds ratio 0.736, 95% confidence interval, 0.549-0.985, p = 0.039) to be the only independent predictor of mortality among the measures of blood glucose control. Conclusion: Nonsurvivors with TBI have significantly higher markers of IR (insulin rate and multiplier). Markers of glucose control (median glucose, hypoglycemic episodes, and the percentage of values in range) did not differ clinically among groups. Despite this stress IR, tight glycemic control appears possible and safe with low levels of hypoglycemic episodes in the TBI population.	[Mowery, Nathan T.] Wake Forest Univ, Dept Surg, Winston Salem, NC 27109 USA; [Gunter, Oliver L.; Guillamondegui, Oscor; Dossett, Lesly A.; Dortch, Marcus J.; Morris, John A., Jr.; May, Addison K.] Vanderbilt Univ, Dept Surg, Nashville, TN 37240 USA	Mowery, NT (corresponding author), Med Ctr Blvd, Winston Salem, NC 27157 USA.	nmowery@wfubmc.edu	Dossett, Lesly/I-8881-2019	Dossett, Lesly/0000-0001-8060-1073			AARIMAA M, 1974, ANN SURG, V179, P926, DOI 10.1097/00000658-197406000-00019; Auer RN, 2004, METAB BRAIN DIS, V19, P169, DOI 10.1023/B:MEBR.0000043967.78763.5b; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Boord JB, 2007, J AM MED INFORM ASSN, V14, P278, DOI 10.1197/jamia.M2292; CANDELISE L, 1985, ARCH NEUROL-CHICAGO, V42, P661, DOI 10.1001/archneur.1985.04060070051014; Carlson GL, 2003, BRIT J SURG, V90, P259, DOI 10.1002/bjs.4081; CLARKE RSJ, 1970, BRIT J ANAESTH, V42, P295, DOI 10.1093/bja/42.4.295; Davidson PC, 2005, DIABETES CARE, V28, P2418, DOI 10.2337/diacare.28.10.2418; Dhindsa S, 2005, J CLIN ENDOCR METAB, V90, P5058, DOI 10.1210/jc.2005-0223; Dortch MJ, 2008, JPEN-PARENTER ENTER, V32, P18, DOI 10.1177/014860710803200118; FIETSAM R, 1991, AM SURGEON, V57, P551; Ghanim H, 2007, DIABETOLOGIA, V50, P278, DOI 10.1007/s00125-006-0508-9; HILL MR, 1986, J IMMUNOL, V137, P858; KEHLET H, 1979, BRIT J SURG, V66, P543, DOI 10.1002/bjs.1800660807; Kwoun MO, 1997, JPEN-PARENTER ENTER, V21, P91, DOI 10.1177/014860719702100291; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; Lattermann R, 2001, ANESTH ANALG, V93, P121; Ljungqvist O, 2000, SURGERY, V128, P757, DOI 10.1067/msy.2000.107166; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; Mowery NT, 2006, CRIT CARE MED, V34, pA11, DOI 10.1097/00003246-200612002-00044; Nygren J, 1998, CLIN NUTR, V17, P65, DOI 10.1016/S0261-5614(98)80307-5; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; ONEILL PA, 1991, STROKE, V22, P842, DOI 10.1161/01.STR.22.7.842; Pickup JC, 2000, LIFE SCI, V67, P291, DOI 10.1016/S0024-3205(00)00622-6; ROSS H, 1966, LANCET, V2, P563; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; Souba WW, 1997, NEW ENGL J MED, V336, P41, DOI 10.1056/NEJM199701023360107; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VANKOOTEN F, 1993, STROKE, V24, P1129, DOI 10.1161/01.STR.24.8.1129; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303; WERB MR, 1989, J CLIN ENDOCR METAB, V69, P1010, DOI 10.1210/jcem-69-5-1010; WHITE NH, 1982, ANN INTERN MED, V97, P210, DOI 10.7326/0003-4819-97-2-210; WOLFE RR, 1979, METABOLISM, V28, P1031, DOI 10.1016/0026-0495(79)90007-6; WOLFE RR, 1987, NEW ENGL J MED, V317, P403, DOI 10.1056/NEJM198708133170702; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Zhu CZ, 2004, J NEUROSURG, V101, P664, DOI 10.3171/jns.2004.101.4.0664	44	28	32	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					145	153		10.1097/TA.0b013e3181938c5e			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	395SJ	WOS:000262543500019	19131817				2021-06-18	
J	Parsons, TD; Notebaert, AJ; Shields, EW; Guskiewicz, KM				Parsons, Thomas D.; Notebaert, Andrew J.; Shields, Edgar W.; Guskiewicz, Kevin M.			Application of Reliable Change Indices to Computerized Neuropsychological Measures of Concussion	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						neurocognitive; reliable change; sports-related concussion; statistical assessment	COLLEGIATE FOOTBALL PLAYERS; COGNITIVE CHANGE; POSTURAL STABILITY; SPORTS; IMPAIRMENT; FREQUENCY; STATEMENT; RECOVERY; DEFICITS	Serial assessments of neurocognitive functioning in athletes with concussion are commonly used for return to play decisions. This study provides reliable change indices (RCIs) for computerized tests from 40 NCAA Division I collegiate athletes that suffered a sports-related concussion. The normative data that resulted from the RCIs and subsequent analyses of differences between improved and not improved athletes may aid both clinicians and researchers to assess whether observed change on neuropsychological measures is reliable change or change due simply to practice effects. Hence, the RCIs presented herein provide information that may be used judiciously by a clinician for assessing meaningful change.	[Parsons, Thomas D.] Univ So Calif, VRPSYCH Lab, Inst Creat Technol, Marina Del Rey, CA 90292 USA; [Parsons, Thomas D.] Univ So Calif, Sch Gerontol, Marina Del Rey, CA 90292 USA; [Notebaert, Andrew J.] Univ Iowa, Iowa City, IA 52242 USA; [Shields, Edgar W.; Guskiewicz, Kevin M.] Univ N Carolina, Chapel Hill, NC 27515 USA	Parsons, TD (corresponding author), Univ So Calif, VRPSYCH Lab, Inst Creat Technol, 13274 Fiji Way, Marina Del Rey, CA 90292 USA.	tparsons@usc.edu		Parsons, Thomas/0000-0003-0331-5019; Guskiewicz, Kevin/0000-0002-8682-2130			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; CHELUNE GJ, 1991, NEUROLOGY, V41, P399, DOI 10.1212/WNL.41.3.399; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Frerichs RJ, 2005, ARCH CLIN NEUROPSYCH, V20, P321, DOI 10.1016/j.acn.2004.08.002; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kane R. L., 1997, NEUROPSYCHOLOGY HDB, V1, P423; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; MEAD AD, 1993, PSYCHOL BULL, V114, P449, DOI 10.1037/0033-2909.114.3.449; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Wilson BA, 2000, J INT NEUROPSYCH SOC, V6, P469, DOI 10.1017/S1355617700644053; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P83, DOI 10.1016/j.acn.2005.07.008; Zillmer EA, 2003, APPL NEUROPSYCHOL, V10, P1, DOI 10.1207/S15324826AN1001_1	39	28	29	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0020-7454	1563-5279		INT J NEUROSCI	Int. J. Neurosci.		2009	119	4					492	507	PII 908857710	10.1080/00207450802330876			16	Neurosciences	Neurosciences & Neurology	410CO	WOS:000263553900005	19229718				2021-06-18	
J	Sancisi, E; Battistini, A; Di Stefano, C; Simoncini, L; Simoncini, L; Montagna, P; Piperno, R				Sancisi, Elisa; Battistini, Alberto; Di Stefano, Cristina; Simoncini, Laura; Simoncini, Loredana; Montagna, Pasquale; Piperno, Roberto			Late recovery from post-traumatic vegetative state	BRAIN INJURY			English	Article						Late recovery; vegetative state; minimally conscious state; outcome; follow-up; traumatic brain injury	MINIMALLY CONSCIOUS STATE; REHABILITATION; IMPROVEMENT	Aim: Late recovery of consciousness after 12 months in vegetative state is very rare and is almost invariably associated with severe disability. The aim of this study was to report that late recovery with moderate disability is possible, even after several months in vegetative state. Case report: This study describes the case of a 22-year-old male student who recovered consciousness from vegetative state 19 months after a traumatic brain injury which had occurred in December 2000. A further slow recovery of motor and cognitive functions up to a moderate disability was observed over 7 years after the brain injury. The patient now lives in the community, speaks, walks and undertakes daily living as well as outdoor leisure activities independently, has resumed his previous university studies and has a part-time non-competitive job. Conclusions: This case demonstrates that attaining a condition of independent living is possible even after more than 1 year of post-traumatic vegetative state, with an improvement of motor and cognitive functions that can continue for years. Cranioplasty and long-term rehabilitation programmes may be among the variables potentially influencing this unexpected recovery.	[Sancisi, Elisa; Montagna, Pasquale] Univ Bologna, Dept Neurol Sci, I-40123 Bologna, Italy; [Battistini, Alberto; Di Stefano, Cristina; Simoncini, Laura; Simoncini, Loredana; Piperno, Roberto] Maggiore Hosp, Rehabil Unit, Bologna, Italy	Sancisi, E (corresponding author), Univ Bologna, Dept Neurol Sci, Via Ugo Foscolo 7, I-40123 Bologna, Italy.	elisa.sancisi@unibo.it	Piperno, Roberto/AAC-3000-2021	Piperno, Roberto/0000-0002-2251-9191			Agner C, 2002, ACTA NEUROCHIR, V144, P1033, DOI 10.1007/s00701-002-0996-4; ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Avesani R, 2006, BRAIN INJURY, V20, P333, DOI 10.1080/02699050500487605; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; Faran S, 2006, J NEUROL NEUROSUR PS, V77, P998, DOI 10.1136/jnnp.2005.076554; Fins JJ, 2007, NEUROLOGY, V68, P304, DOI 10.1212/01.wnl.0000252376.43779.96; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Gruner ML, 2000, BRAIN INJURY, V14, P585; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; McMillan TM, 2004, BRAIN INJURY, V18, P935, DOI 10.1080/02699050410001675915; Sara M, 2007, BRAIN INJURY, V21, P101, DOI 10.1080/02699050601151761; Singh R, 2008, BRAIN INJURY, V22, P103, DOI 10.1080/02699050701829704; Sorbo A, 2005, BRAIN INJURY, V19, P493, DOI 10.1080/02699050400013709; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Zeman A, 1997, LANCET, V350, P795, DOI 10.1016/S0140-6736(97)06447-7	22	28	28	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	2					163	166	PII 908448418	10.1080/02699050802660446			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	403LD	WOS:000263083200010	19191095				2021-06-18	
J	Wang, YT; Kent, RD; Duffy, JR; Thomas, JE				Wang, Yu-Tsai; Kent, Ray D.; Duffy, Joseph R.; Thomas, Jack E.			Analysis of Diadochokinesis in Ataxic Dysarthria Using the Motor Speech Profile Program (TM)	FOLIA PHONIATRICA ET LOGOPAEDICA			English	Article						Diadochokinesis; Reliability; Validity	VOICE ONSET TIME; AMYOTROPHIC-LATERAL-SCLEROSIS; ALTERNATING MOTION RATE; TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; SPEAKING RATE; ORAL DIADOCHOKINESIS; MULTIPLE-SCLEROSIS; ACOUSTIC ANALYSIS; INDIVIDUALS	Aims: The Diadochokinetic Rate Analysis (DRA) in the Kay-PENTAX Motor Speech Profile is a computer program for the analysis of diadochokinesis (DDK). The objective of this study is to evaluate the suitability, reliability, and concurrent validity of the results from the DRA protocol and hand measurement for individuals with ataxic dysarthria, which is characteristically associated with dysdiadochokinesis. Methods: Twenty-one participants with ataxic dysarthria were recorded as they repeated various syllables as quickly and steadily as possible. The DDK samples were executed by the DRA protocol at different thresholds and were also hand-measured. Analyses were based on the percentage of nonexecutable DDK samples, defined as samples in which the lowest peak intensity during CV syllables is lower than the highest peak intensity during intersyllable pauses, and the comparisons of the results between repeated analyses at different thresholds and between automatic and manual measuring methods. Results: (1) More than one third of the DDK samples were nonexecutable; (2) the reliability at different thresholds and concurrent validity between different measuring methods were both satisfactory, and (3) temporal variation parameters were more inconsistent between different measuring methods than intensity variation parameters. Conclusion: DRA has notable limitations in its clinical application but there is a considerable potential for improving its performance. Copyright (C) 2008 S. Karger AG, Basel	[Wang, Yu-Tsai] Natl Yang Ming Univ, Sch Dent, Taipei 11211, Taiwan; [Kent, Ray D.] Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; [Duffy, Joseph R.; Thomas, Jack E.] Mayo Clin, Rochester, MN USA	Wang, YT (corresponding author), Natl Yang Ming Univ, Sch Dent, Rm 411,155,Sec 2,Li Nong St, Taipei 11211, Taiwan.	yutsaiwang@ym.edu.tw	Kent, Raymond D/AAI-1928-2020		National Institute on Deafness and Other Communication Disorders (NIDCD-NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [5 R01 DC00319]; National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC 95-2314-B010-095]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000319] Funding Source: NIH RePORTER	This work was supported in part by Research Grant No. 5 R01 DC00319 from the National Institute on Deafness and Other Communication Disorders (NIDCD-NIH) and NSC 95-2314-B010-095 from the National Science Council, Taiwan.	ACKERMANN H, 1995, FOLIA PHONIATR LOGO, V47, P15, DOI 10.1159/000266338; Auzou P, 2000, CLIN LINGUIST PHONET, V14, P131; BROWN JR, 1970, INT J NEUROL, V7, P302; Cohen W, 1998, Int J Lang Commun Disord, V33 Suppl, P428; Darley F., 1975, MOTOR SPEECH DISORDE; DAVIS K, 1995, J CHILD LANG, V22, P275, DOI 10.1017/S030500090000979X; Duffy JR, 2019, MOTOR SPEECH DISORDE; Fimbel EJ, 2005, J NEUROSCI METH, V146, P183, DOI 10.1016/j.jneumeth.2005.02.007; Fruchter B., 1973, FUNDAMENTAL STAT PSY; GENTIL M, 1990, BRAIN LANG, V38, P438, DOI 10.1016/0093-934X(90)90126-2; HALE ST, 1992, J SPEECH HEAR RES, V35, P1203, DOI 10.1044/jshr.3506.1203; Hartelius L, 2003, FOLIA PHONIATR LOGO, V55, P1, DOI 10.1159/000068057; HENRY CE, 1990, CLIN LINGUIST PHONET, V4, P121, DOI 10.3109/02699209008985476; KENT RD, 1987, J SPEECH HEAR DISORD, V52, P367, DOI 10.1044/jshd.5204.367; Kent RD, 1999, J MED SPEECH-LANG PA, V7, P83; Kent RD, 2000, J SPEECH LANG HEAR R, V43, P1275, DOI 10.1044/jslhr.4305.1275; KENT RD, 1991, J SPEECH HEAR RES, V34, P1269, DOI 10.1044/jshr.3406.1269; Kent RD, 1997, FOLIA PHONIATR LOGO, V49, P63, DOI 10.1159/000266440; Lundy DS, 2004, J VOICE, V18, P146, DOI 10.1016/j.jvoice.2003.12.001; Meurer EM, 2004, J VOICE, V18, P369, DOI 10.1016/j.jvoice.2003.02.001; MILENKOVIC P, 2001, TIME FREQUENCY ANAL; Nishio M, 2000, CLIN LINGUIST PHONET, V14, P485; Nishio M, 2006, FOLIA PHONIATR LOGO, V58, P114, DOI 10.1159/000089612; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Ozawa Y, 2001, FOLIA PHONIATR LOGO, V53, P67, DOI 10.1159/000052656; Ozsancak C, 2001, FOLIA PHONIATR LOGO, V53, P48, DOI 10.1159/000052653; Potter N. L., 2005, THESIS U WISCONSIN M; RENOUT KA, 1995, AM J SPEECH-LANG PAT, V4, P73; Rosen KM, 2005, FOLIA PHONIATR LOGO, V57, P28, DOI 10.1159/000081959; Samlan R. A., 1995, AM J SPEECH-LANG PAT, V4, P9; Schalling E, 2004, FOLIA PHONIATR LOGO, V56, P367, DOI 10.1159/000081084; Tavares ALT, 2005, MOVEMENT DISORD, V20, P1286, DOI 10.1002/mds.20556; Thoonen G, 1996, CLIN LINGUIST PHONET, V10, P311, DOI 10.3109/02699209608985178; Tjaden K, 2003, FOLIA PHONIATR LOGO, V55, P241, DOI 10.1159/000072155; Wang YT, 2005, J COMMUN DISORD, V38, P231, DOI 10.1016/j.jcomdis.2004.12.001; Wang YT, 2004, CLIN LINGUIST PHONET, V18, P57, DOI 10.1080/02699200310001596160; Wang YT, 2006, J MED SPEECH-LANG PA, V14, P109; WEISMER G, 1997, HDB PHONETIC SCI, P191; Williams P, 2000, CLIN LINGUIST PHONET, V14, P267; Yaruss JS, 2002, J FLUENCY DISORD, V27, P65; Ziegler W, 1996, NEUROLOGY, V47, P208, DOI 10.1212/WNL.47.1.208; Ziegler W, 2002, BRAIN LANG, V80, P556, DOI 10.1006/brln.2001.2614	42	28	30	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7762			FOLIA PHONIATR LOGO	Folia Phoniatr. Logop.		2009	61	1					1	11		10.1159/000184539			11	Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation	Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation	446CN	WOS:000266098100001	19088478	Green Published, Bronze			2021-06-18	
J	Rapoport, M; Wolf, U; Herrmann, N; Kiss, A; Shammi, P; Reis, M; Phillips, A; Feinstein, A				Rapoport, Mark; Wolf, Uri; Herrmann, Nathan; Kiss, Alex; Shammi, Prathiba; Reis, Marciano; Phillips, Andrea; Feinstein, Anthony			Traumatic brain injury, apolipoprotein E-epsilon 4, and cognition in older adults: A two-year longitudinal study	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article; Proceedings Paper	159th Annual Meeting of the American-Psychiatric-Association	MAY 20-25, 2006	Toronto, CANADA	Amer Psychiat Assoc			CLOSED-HEAD INJURY; NEUROBEHAVIORAL CONSEQUENCES; APOE GENOTYPE; FOLLOW-UP; MILD; RECOVERY; PERSPECTIVE; EPSILON-4	Patients with mild-to-moderate traumatic brain injury (TBI) (N= 69) were compared with age-, gender-, and education-matched healthy control group subjects (N=79) on performance of neuropsychological tests at one and 2 years following injury, and informant-rated functional abilities. All subjects were assessed for the presence of the Apolipoprotein E-epsilon 4 (APOE-epsilon 4) allele and rated for "mild cognitive impairment" (MCI) or dementia. Traumatic brain injury patients were no different from the comparison group on measures of cognition or functional impairment. Traumatic brain injury was not associated with higher rates of amnestic mild cognitive impairment or dementia, and APOE-epsilon 4 was not associated with cognition.	[Rapoport, Mark; Wolf, Uri; Herrmann, Nathan; Kiss, Alex; Shammi, Prathiba; Reis, Marciano; Phillips, Andrea; Feinstein, Anthony] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	Rapoport, M (corresponding author), FG37-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	mark.rapoport@sunnybrook.ca	Rapoport, Mark/AAD-8581-2020				AharonPeretz J, 1997, BRAIN INJURY, V11, P871; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI 10.1080/13854049308401883; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DELIS DC, 1987, CALIFORNIA VERBALL L; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; First M.B., 1996, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Heaton R., 1993, WISCONSIN CARD SORTI; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Mattis S, 1976, GERIATRIC PSYCHIAT, P77; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; *PSYCH CORP, 1997, WECHSL AD INT SCAL T; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; Ritchie K, 1999, INT J GERIATR PSYCH, V14, P695, DOI 10.1002/(SICI)1099-1166(199909)14:9<695::AID-GPS19>3.0.CO;2-R; Rubin DB., 1987, MULTIPLE IMPUTATION; Spreen O., 1998, COMPENDIUM NEUROPSYC; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009	35	28	29	0	11	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2008	20	1					68	73		10.1176/appi.neuropsych.20.1.68			6	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	264SP	WOS:000253311000007	18305286				2021-06-18	
J	Burr, RL; Kirkness, CJ; Mitchell, PH				Burr, Robert L.; Kirkness, Catherine J.; Mitchell, Pamela H.			Detrended Fluctuation Analysis of Intracranial Pressure Predicts Outcome Following Traumatic Brain Injury	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						Detrended fluctuation analysis (DFA); intracranial pressure (ICP); monitoring; outcome; traumatic brain injury (TBI)	HEART-RATE-VARIABILITY; APPROXIMATE ENTROPY; SYSTEMS-ANALYSIS; WAVE-FORM; HYPERTENSION; INFORMATION; DYNAMICS; SIGNALS; SCALE; COMA	Detrended fluctuation analysis (DFA) is a recently developed technique suitable for describing scaling behavior of variability in physiological signals. The purpose of this study is to explore applicability of DFA methods to intracranial pressure (ICP) signals recorded in patients with traumatic brain injury (TBI). In addition to establishing the degree of fit of the power-law scaling model of detrended fluctuations of ICP in TBI patients, we also examined the relationship of DFA coefficients (scaling exponent and intercept) to: 1) measures of initial neurological functioning; 2) measures of functional outcome at six month follow-up; and 3) measures of outcome, controlling for patient characteristics, and initial neurological status. In a sample of 147 moderate-to-severely injured TBI patients, we found that a higher DFA scaling exponent is significantly associated with poorer initial neurological functioning, and that lower DFA intercept and higher DFA scaling exponent jointly predict poorer functional outcome at six month follow-up, even after statistical control for covariates reflecting initial neurological condition. DFA describes properties of ICP signal in TBI patients that are associated with both initial neurological condition and outcome at six months postinjury.	[Burr, Robert L.; Kirkness, Catherine J.; Mitchell, Pamela H.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA	Burr, RL (corresponding author), Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA.	bobburr@u.washington.edu; kirkness@u.washington.edu; pmitch@u.washington.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIB R01 NR04501]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR004901, R01NR004501] Funding Source: NIH RePORTER	This work was supported in part by the National Institutes of Health under Grant NIB R01 NR04501.	Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Beaumont A, 2002, ACT NEUR S, V81, P193; Chen Z, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041107; CHOPP M, 1980, J NEUROSURG, V53, P516, DOI 10.3171/jns.1980.53.4.0516; Czosnyka M, 1998, ACT NEUR S, V71, P74; Echeverria JC, 2004, PHYSIOL MEAS, V25, P763, DOI 10.1088/0967-3334/25/3/015; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Havlin S, 1999, PHYSICA A, V274, P99, DOI 10.1016/S0378-4371(99)00333-7; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Ho KKL, 1997, CIRCULATION, V96, P842; Holm S, 2008, MED ENG PHYS, V30, P164, DOI 10.1016/j.medengphy.2007.03.003; Hornero R, 2005, IEEE T BIO-MED ENG, V52, P1671, DOI 10.1109/TBME.2005.855722; Hu K, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.011114; Iyengar N, 1996, AM J PHYSIOL-REG I, V271, pR1078, DOI 10.1152/ajpregu.1996.271.4.R1078; Jospin M, 2007, IEEE T BIO-MED ENG, V54, P840, DOI 10.1109/TBME.2007.893453; Kirkness CJ, 2006, AM J CRIT CARE, V15, P600; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LIN ES, 1991, BRIT J ANAESTH, V66, P476, DOI 10.1093/bja/66.4.476; Moody GB, 2001, IEEE ENG MED BIOL, V20, P70, DOI 10.1109/51.932728; PENG CK, 1994, PHYS REV E, V49, P1685, DOI 10.1103/PhysRevE.49.1685; Peng CK, 2002, ANN BIOMED ENG, V30, P683, DOI 10.1114/1.1481053; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; PENG CK, 1995, PHYSICA A, V221, P180, DOI 10.1016/0378-4371(95)00247-5; Penzel T, 2003, IEEE T BIO-MED ENG, V50, P1143, DOI 10.1109/TBME.2003.817636; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Seely AJE, 2004, CRIT CARE, V8, pR367, DOI 10.1186/cc2948; Tapanainen JM, 2002, AM J CARDIOL, V90, P347, DOI 10.1016/S0002-9149(02)02488-8; TEASDALE G, 1974, LANCET, V2, P81; TEICH MC, 2001, IEEE PRESS SERIES BI, V2, P171; Varela M, 2003, EUR J APPL PHYSIOL, V89, P230, DOI 10.1007/s00421-002-0790-2; Westhout FD, 2008, SURG NEUROL, V70, P70, DOI 10.1016/j.surneu.2007.04.020; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WILSON PS, 2003, PHYS REV E, V68, P31	33	28	29	0	4	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9294	1558-2531		IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	NOV	2008	55	11					2509	2518		10.1109/TBME.2008.2001286			10	Engineering, Biomedical	Engineering	371XI	WOS:000260865600003	18990620	Green Accepted			2021-06-18	
J	Dreer, LE; DeVivo, MJ; Novack, TA; Krzywanski, S; Marson, DC				Dreer, Laura E.; DeVivo, Michael J.; Novack, Thonias A.; Krzywanski, Sara; Marson, Daniel C.			Cognitive Predictors of Medical Decision-Making Capacity in Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						medical decision-making capacity; competency; traumatic brain injury; neurocognitive functioning	CLOSED-HEAD-INJURY; WORKING-MEMORY; ALZHEIMERS-DISEASE; COMPETENCE; CONSENT; IMPAIRMENT; RECOVERY; MODERATE; MODELS; STATE	Objective: To identify cognitive predictors of medical decision-making capacity (MDC) in participants with moderate to severe traumatic brain injury (TBI). Participants: At baseline, participants were 34 adults with TBI and 20 healthy adults. At 6-month follow-up, participants were 24 adults with TBI and 20 healthy adults. Main Outcome Measures: Participants were administered the Capacity to Consent to Treatment Instrument (CCTI) and neuropsychological test measures. Multivariate cognitive predictor models were developed for CCTI consent abilities/standards (S) of understanding (S5); reasoning (S4); and appreciation (S3). Results: At baseline, short-term verbal memory and semantic fluency predicted TBI group performance on understanding (S5): short-term verbal memory and attention predicted performance on reasoning (S4); and working memory predicted performance on appreciation (S3). At 6 month follow-up, executive function, verbal processing speed, and working memory predicted TBI performance on understanding (S5); working memory and short-term memory predicted reasoning (S4); and basic executive functioning predicted appreciation (S3). Conclusions: Multiple cognitive functions are associated with acute impairment and partial recovery of MDC in patients with TBI. Short-term verbal memory predicted consent capacity of TBI participants at the time of acute inpatient hospitalization, while executive functioning and working memory predicted improved capacity at six-month follow-up.	[Krzywanski, Sara; Marson, Daniel C.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35233 USA; [Dreer, Laura E.] Univ Alabama, Dept Ophthalmol, Tuscaloosa, AL 35487 USA; [DeVivo, Michael J.; Novack, Thonias A.] Univ Alabama, Dept Phys Med & Rehabil, Tuscaloosa, AL 35487 USA; [Krzywanski, Sara; Marson, Daniel C.] Univ Alabama, Alzheimers Dis Res Ctr, Tuscaloosa, AL 35487 USA	Marson, DC (corresponding author), Univ Alabama Birmingham, Dept Neurol, Room JT1216, Birmingham, AL 35233 USA.	dmarson@uab.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD053074, T32HD007420] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [K23EY017327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG010483, R01AG021927, P50AG016582] Funding Source: NIH RePORTER; NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [K23 EY017327] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG021927-04, U01 AG010483, P50 AG016582-07, P50 AG016582, R01 AG021927] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD053074-01A1, R01 HD053074, T32 HD007420] Funding Source: Medline		Benton A, 1989, MULTILINGUAL APHASIA; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bontke CF, 1994, J HEAD TRAUMA REHAB, V9, P62; *CDCP, 1997, MMWR-MORBID MORTAL W, V48, P8; Childs NL, 1997, J HEAD TRAUMA REHAB, V12, P70, DOI 10.1097/00001199-199708000-00007; Cope D. N., 1989, J HEAD TRAUMA REHAB, V4, P13; Dymek MP, 2001, NEUROLOGY, V56, P17, DOI 10.1212/WNL.56.1.17; Dymek MP, 1999, J FORENSIC NEUROPSYC, V1, P27, DOI DOI 10.1300/J151V01N01_; Earnst KS, 2000, J AM GERIATR SOC, V48, P919, DOI 10.1111/j.1532-5415.2000.tb06888.x; FITTEN LJ, 1990, ARCH INTERN MED, V150, P1717, DOI 10.1001/archinte.150.8.1717; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Griffith HR, 2005, NEUROLOGY, V65, P483, DOI 10.1212/01.wnl.0000171346.02965.80; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P149, DOI 10.1007/BF01499323; Grisso T., 1986, EVALUATING COMPETENC; HANNAY D, 2004, NEUROPSYCHOLOGICAL A, P158; Heaton R.K., 1991, COMPREHENSIVE NORMS; Hillier SL, 1997, BRAIN INJURY, V11, P661; Jacobs ML, 2008, ARCH CLIN NEUROPSYCH, V23, P113, DOI 10.1016/j.acn.2007.09.003; Jennett B, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199708000-00003; KAPP M, 1992, GERIATRICS LAW PATIE; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Leon-Carrion J, 1998, INT J NEUROSCI, V94, P75, DOI 10.3109/00207459808986440; Levin H, 1979, J NERV MENT DIS, V20, P694; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Marsh D., 2001, AERU Discussion Paper, P1; MARSH OC, 1896, AM J SCI, V2, P59; MARSON D, 2001, 21 ANN C NAT AC NEUR; Marson DC, 2001, AGING NEUROPSYCHOL C, V8, P164, DOI 10.1076/anec.8.3.164.827; Marson DC, 2005, ARCH PHYS MED REHAB, V86, P889, DOI 10.1016/j.apmr.2004.09.020; MARSON DC, 1994, ALZ DIS ASSOC DIS, V8, P5, DOI 10.1097/00002093-199424003-00002; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P949, DOI 10.1001/archneur.1995.00540340029010; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P955, DOI 10.1001/archneur.1995.00540340035011; Marson DC, 1996, NEUROLOGY, V46, P666, DOI 10.1212/WNL.46.3.666; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Mcwilliams J, 2008, BRAIN INJURY, V22, P243, DOI 10.1080/02699050801935252; Moye J, 2006, J GEN INTERN MED, V21, P78, DOI 10.1111/j.1525-1497.2005.00288.x; Mukherjee D, 2006, TOP STROKE REHABIL, V13, P75, DOI 10.1310/2M1U-71FQ-QV33-56PX; Okonkwo OC, 2008, J INT NEUROPSYCH SOC, V14, P297, DOI 10.1017/S1355617708080338; Phipps EJ, 1998, J HEAD TRAUMA REHAB, V13, P95, DOI 10.1097/00001199-199810000-00012; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Proctor A, 2000, BRAIN INJURY, V14, P633; Rao S., 1990, MANUAL BRIEF REPEATA; Reid-Proctor GM, 2001, BRAIN INJURY, V15, P377, DOI 10.1080/02699050010005977; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; ROTH LH, 1977, AM J PSYCHIAT, V134, P279; ROYALL DR, 1992, J AM GERIATR SOC, V40, P1221, DOI 10.1111/j.1532-5415.1992.tb03646.x; Simon Robert I., 1994, P569; SMITH A, 1982, SYMBOL DIGIT METALIT; Taylor E.M., 1959, PSYCHOL APPRAISAL CH; TEASDALE G, 1974, LANCET, V2, P81; TEPPER AM, 1984, LAW HUMAN BEHAV, V8, P205, DOI 10.1007/BF01044693; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; WECHLSER D, 1997, MANUAL WECHSLER ADUL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, MANUAL WECHSLER MEMO; Wolfson D., 1993, HALSTEAD REITAN NEUR; Wong JG, 1999, PSYCHOL MED, V29, P437, DOI 10.1017/S0033291798008113; WONG TM, 1998, AVOIDING ETHICAL MIS, P187; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	65	28	28	0	7	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2008	53	4					486	497		10.1037/a0013798			12	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	381ER	WOS:000261518900008	20686627	Green Accepted, Green Published			2021-06-18	
J	Rafaat, KT; Spear, RM; Kuelbs, C; Parsapour, K; Peterson, B				Rafaat, Karim T.; Spear, Robert M.; Kuelbs, Cynthia; Parsapour, Kourosh; Peterson, Bradley			Cranial computed tomographic findings in a large group of children with drowning: Diagnostic, prognostic, and forensic implications	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						near drowning; tomography; x-ray computed; Glasgow Outcome Scale; Glasgow Coma Scale; child abuse; hypoxiaischemia; brain	NONACCIDENTAL HEAD-INJURIES; TRAUMATIC BRAIN-INJURY; HYPOXIC ENCEPHALOPATHY; INFANTS; PATTERNS; DAMAGE; ABUSE; CT	Objectives: The primary aim of this study is to better define both the type and incidence of cranial computed tomography (CT) abnormalities in children following submersion injury. Design: This is a retrospective chart review; patients were selected from a drowning registry that extends from January 1989 to April 2006. Setting. Children's Hospital, San Diego. Patients: Patients were included if they were admitted to the hospital with a diagnosis of drowning and had a cranial CT within 24 hrs of submersion. Of 961 patients in the registry, 156 were included. Interventions: None. Measurements and Main Results: Eighteen percent (28 of 156) of children had an abnormal initial head CT, 82% (128 of 156) had a normal CT. Fifteen percent (24 of 156) of patients initially had a normal head CT and later had an abnormal CT. Abnormal CT findings were remarkable for diffuse loss of gray-white differentiation (75% on presentation) and bilateral basal ganglia edema/infarct (50% on presentation). There was no evidence of intra- or extra-axial blood nor were there any unilateral findings in any of the abnormal CTs. Presenting Glasgow Coma Scale was significantly lower in those who presented with an abnormal versus a normal head CT (p < 0.001). All patients with an abnormal initial CT presented with a Glasgow Coma Scale of 3, and all eventually died. Outcome was also very poor in those with a normal first CT and an abnormal second CT; 54% died and 42% remained in a persistent vegetative state. Conclusions: These data from the largest study of CT findings in pediatric drowning clearly illustrate that following submersion injury, intra- or extra-axial bleeding is not seen on cranial CT. Furthermore, an abnormal CT scan at any time was associated with a poor outcome (death or persistent vegetative state). The CT findings and the presenting Glasgow Coma Scale of patients with drowning differ from those of patients who have suffered abusive head trauma. (Pediatr Crit Care Med 2008; 9:567-572)	[Rafaat, Karim T.; Spear, Robert M.; Peterson, Bradley] Rady Childrens Hosp, Dept Pediat Crit Care, San Diego, CA USA; [Kuelbs, Cynthia] Rady Childrens Hosp, Dept Pediat, San Diego, CA USA; [Parsapour, Kourosh] Univ Calif Davis, Davis Childrens Hosp, Div Pediat Crit Care, Sacramento, CA 95817 USA	Rafaat, KT (corresponding author), Rady Childrens Hosp, Dept Pediat Crit Care, San Diego, CA USA.	krafaat@hotmail.com			Children's Hospital Department of Critical Care Research Fund	Supported, in part, by Children's Hospital Department of Critical Care Research Fund.	Corr P, 1999, S AFR MED J, V89, P1154; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; DEAN JM, 1981, NEUROSURGERY, V9, P627; DEREUCK J, 1971, EUR NEUROL, V5, P321; Dubowitz DJ, 1998, AM J NEURORADIOL, V19, P1617; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; FELDMAN KW, 1995, CHILD ABUSE NEGLECT, V19, P307, DOI 10.1016/S0145-2134(94)00130-8; FITCH SJ, 1985, RADIOLOGY, V156, P647, DOI 10.1148/radiology.156.3.4023223; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Ghahreman A, 2005, J NEUROSURG, V103, P213, DOI 10.3171/ped.2005.103.3.0213; Gilchrist J., 2004, Morbidity and Mortality Weekly Report, V53, P447; GONZALEZROTHI RJ, 1987, HEART LUNG, V16, P474; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; JENNETT B, 1975, LANCET, V1, P480; MARCOUX FW, 1982, STROKE, V13, P339, DOI 10.1161/01.STR.13.3.339; MERTEN DF, 1984, PEDIATR RADIOL, V14, P272, DOI 10.1007/BF01601874; MODELL JH, 1981, CRIT CARE MED, V9, P351; *NAT CTR INJ PREV, 2002, WISQUARS LEAD CAUS D, P1999; ORLOWSKI JP, 1987, PEDIATR CLIN N AM, V34, P75; ROMANO C, 1993, PEDIATR RADIOL, V23, P261, DOI 10.1007/BF02010911; SCHUIER FJ, 1980, STROKE, V11, P593, DOI 10.1161/01.STR.11.6.593; SHUMAN SH, 1976, CRIT CARE MED, V4, P127; TAYLOR SB, 1985, RADIOLOGY, V156, P641, DOI 10.1148/radiology.156.3.4023222; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; *WHO, 2002, WHO REP RED RISKS PR; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	29	28	28	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	NOV	2008	9	6					567	572		10.1097/PCC.0b013e31818c8955			6	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	372UX	WOS:000260928600003	18838936				2021-06-18	
J	Falcone, RA; Martin, C; Brown, RL; Garcia, VF				Falcone, Richard A., Jr.; Martin, Colin; Brown, Rebeccah L.; Garcia, Victor F.			Despite overall low pediatric head injury mortality, disparities exist between races	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	59th Annual Meeting of the American-Academy-of-Pediatrics	OCT 27-30, 2007	San Francisco, CA	Amer Acad Pediat		Racial disparities; Pediatric traumatic brain injury; Mortality	TRAUMATIC BRAIN-INJURY; HEALTH DISPARITIES; RACIAL DISPARITIES; UNITED-STATES; CHILDREN; CARE; OUTCOMES; SEVERITY; QUALITY; ABUSE	Background: To continually improve quality of care, it is important for centers caring for children with head injury to evaluate their overall outcome and that among diverse patient groups. Methods: Data on children with head injuries were extracted from the National Trauma Data Bank of the American College of Surgeons and our local trauma registry. Unadjusted mortality, as well as stratified analysis and logistic regression modeling, was used to evaluate overall and race-specific mortality. Results: There were 13,363 children in the National Trauma Data Base and 3111 in our database included. Our overall mortality rate compared favorably with the national data (3.2% vs 6.8%, P < .05). Our local data, however, showed a significant difference in mortality between white and African American (AA) children (2.2% vs 5.3%, P < .05), which was not identified in the national data. After stratification, the disparities by race persisted. Finally, multivariate regression modeling revealed that AA race was an independent predictor of mortality among our patient population, with an odds ratio of 3.1 (95% confidence interval, 1.2-7.8). Conclusion: Despite excellent outcomes for children with head injuries, we have uncovered unsettling inequities between AA and white children. These findings support the need to evaluate outcomes among specific groups to identify disparities that require further careful investigation. (C) 2008 Elsevier Inc. All rights reserved.	[Falcone, Richard A., Jr.; Martin, Colin; Brown, Rebeccah L.; Garcia, Victor F.] Univ Cincinnati, Coll Med, Div Pediat & Thorac Surg, Dept Surg,Cincinnati Childrens Hosp,Med Ctr, Cincinnati, OH 45229 USA	Falcone, RA (corresponding author), Univ Cincinnati, Coll Med, Div Pediat & Thorac Surg, Dept Surg,Cincinnati Childrens Hosp,Med Ctr, Cincinnati, OH 45229 USA.	richard.falcone@cchmc.org					Al West T, 2000, J TRAUMA, V49, P530, DOI 10.1097/00005373-200009000-00022; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Benz B, 1999, RESTOR NEUROL NEUROS, V14, P135; Burd R, 2006, J PEDIATR SURG, V41, P97; Burd RS, 2006, J TRAUMA, V60, P792, DOI 10.1097/01.ta.0000214589.02515.dd; Cuff S, 2007, J TRAUMA, V63, P172, DOI 10.1097/TA.0b013e31805c14b1; Densmore JC, 2006, J PEDIATR SURG, V41, P92, DOI 10.1016/j.jpedsurg.2005.10.013; Epstein AM, 2003, MED CARE, V41, P1240, DOI 10.1097/01.MLR.0000093423.38746.8C; Falcone Jr RA, 2007, J PEDIATR SURG, V42, P6; FALCONE JRRA, 2007, J PEDIATR SURG, V42, P6; Falcone RA, 2007, J PEDIATR SURG, V42, P1031, DOI 10.1016/j.jpedsurg.2007.01.038; Falcone RA, 2007, J PEDIATR SURG, V42, P172, DOI 10.1016/j.jpedsurg.2006.09.015; Gonzalez PC, 2003, PEDIATR CARDIOL, V24, P103, DOI 10.1007/s00246-002-0244-y; GREEN AR, 2007, J GEN INTERN MED; Hagendorf BA, 2007, ANN SURG, V245, P118, DOI 10.1097/01.sla.0000242715.66878.f8; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Hannan EL, 2000, J PEDIATR SURG, V35, P155, DOI 10.1016/S0022-3468(00)90001-0; HOWARD I, 2005, ETHN DIS S5, V15; Joseph L, 2004, J CLIN EPIDEMIOL, V57, P147, DOI 10.1016/j.jclinepi.2003.08.002; Kawachi I, 2005, HEALTH AFFAIR, V24, P343, DOI 10.1377/hlthaff.24.2.343; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kilbourne AM, 2006, AM J PUBLIC HEALTH, V96, P2113, DOI 10.2105/AJPH.2005.077628; Kokoska ER, 2007, J SURG RES, V137, P83, DOI 10.1016/j.jss.2006.06.020; Krieger N, 2003, AM J PUBLIC HEALTH, V93, P194, DOI 10.2105/AJPH.93.2.194; Krieger N, 1997, ANNU REV PUBL HEALTH, V18, P341, DOI 10.1146/annurev.publhealth.18.1.341; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Lucas FL, 2006, ANN SURG, V243, P281, DOI 10.1097/01.sla.0000197560.92456.32; Malat J, 2006, HEALTH-LONDON, V10, P303, DOI 10.1177/1363459306064486; Mangione-Smith R, 1998, HEALTH SERV RES, V33, P1059; Marcin JP, 2002, CRIT CARE MED, V30, pS457, DOI 10.1097/00003246-200211001-00011; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; Milazzo AS, 2002, J NATL MED ASSOC, V94, P875; Omoloja A, 2006, J NATL MED ASSOC, V98, P154; Ponsky TA, 2004, JAMA-J AM MED ASSOC, V292, P1977, DOI 10.1001/jama.292.16.1977; Randall TC, 2003, J CLIN ONCOL, V21, P4200, DOI 10.1200/JCO.2003.01.218; Rowell KS, 2007, J AM COLL SURGEONS, V204, P1293, DOI 10.1016/j.jamcollsurg.2007.03.024; Runy Lee Ann, 2006, Hosp Health Netw, V80, P48; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; *SERV USDOHAH, 2000, HLTH PEOPL 2010 UND; Skinner J, 2003, NEW ENGL J MED, V349, P1350, DOI 10.1056/NEJMsa021569; SMEDLEY BD, 2003, UNEQUAL TREATMENT CO; Stallion A, 2007, J TRAUMA, V62, P1262; Stylianos S, 2006, J AM COLL SURGEONS, V202, P247, DOI 10.1016/j.jamcollsurg.2005.10.012; Subramanian SV, 2004, EPIDEMIOL REV, V26, P78, DOI 10.1093/epirev/mxh003; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; *TRAUM ACOS CO, 2005, NAT TRAUM DAT BANK R; van Ryn M, 2002, MED CARE, V40, P140; WEST TA, 2000, J TRAUMA, V49, P40	48	28	28	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	OCT	2008	43	10					1858	1864		10.1016/j.jpedsurg.2008.01.058			7	Pediatrics; Surgery	Pediatrics; Surgery	364TX	WOS:000260359300017	18926221				2021-06-18	
J	Batten, SV; Pollack, SJ				Batten, Sonja V.; Pollack, Stacey J.			Integrative outpatient treatment for returning service members	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article						veterans; postdeployment; posttraumatic stress disorder; integrative treatment; depression; traumatic brain injury; psychotherapy	POSTTRAUMATIC-STRESS-DISORDER; MEDICAL-CARE; VETERANS; THERAPY	Veterans returning from Operations Enduring and Iraqi Freedom (OEF/OIF) frequently present with multiple psychological and physical symptoms. The authors propose an innovative approach in which primary care providers, polytrauma specialists, vocational rehabilitation specialists, and mental health clinicians work together to provide care that is not simply concurrent, but truly integrated. All members of this interdisciplinary team must provide a consistent message that supports treatment engagement and progress. The authors illustrate this approach with a case report of a soldier deployed to both OEF and OIF, requiring subsequent treatment for joint pain, headaches, mild traumatic brain injury, posttraumatic stress disorder, depression, and substance abuse. Despite the emphasis on early intervention, treatment engagement and retention remain challenges in this population. (c) 2008 Wiley Periodicals, Inc.	[Batten, Sonja V.] Univ Maryland, Sch Med, VA Maryland Hlth Care Syst 116MH, Trauma Recovery Programs, Baltimore, MD 21201 USA; [Pollack, Stacey J.] VA Med Ctr, Washington, DC USA	Batten, SV (corresponding author), Univ Maryland, Sch Med, VA Maryland Hlth Care Syst 116MH, Trauma Recovery Programs, 10 N Greene St, Baltimore, MD 21201 USA.	sonja.batten@va.gov					BATTEN SV, ACCEPTANCE IN PRESS; Blake D., 1990, CLIN ADM PTSD SCALE; Calhoun PS, 2002, AM J PSYCHIAT, V159, P2081, DOI 10.1176/appi.ajp.159.12.2081; Cummings NA, 2001, INTEGRATED BEHAV HEA; Druss BG, 2001, ARCH GEN PSYCHIAT, V58, P861, DOI 10.1001/archpsyc.58.9.861; Erbes CR, 2008, J CLIN PSYCHOL, V64, P972, DOI 10.1002/jclp.20521; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; MARLATT AG, 2002, HARM REDUCTION PRAGM; Martell C. R., 2001, DEPRESSION CONTEXT S; Monson CM, 2008, J CLIN PSYCHOL, V64, P958, DOI 10.1002/jclp.20511; Pearlman L.A., 1995, TRAUMA THERAPIST COU; Resick P. A., 1993, COGNITIVE PROCESSING; VHA Office of Public Health and Environmental Hazards, 2008, AN VA HLTH CAR UT US; Weathers F. W., 1993, 9 ANN M INT SOC TRAU; Weisner C, 2001, JAMA-J AM MED ASSOC, V286, P1715, DOI 10.1001/jama.286.14.1715	18	28	28	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9762	1097-4679		J CLIN PSYCHOL	J. Clin. Psychol.	AUG	2008	64	8					928	939		10.1002/jclp.20513			12	Psychology, Clinical	Psychology	330ES	WOS:000257922900002	18561182				2021-06-18	
J	Sammons, MT; Batten, SV				Sammons, Morgan T.; Batten, Sonja V.			Psychological services for returning veterans and their families: Evolving	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article						combat; veterans; posttraumatic stress disorder; couples; families; psychotherapy	WAR	The provision of effective and timely behavioral health care for veterans returning from the conflicts in, Iraq and Afghanistan has become the focus of national attention. In this special issue, attempts to provide psychological care for service members and their families are examined in light of three key constructs. First, it is contended that at no other time in history has more attention been paid to the psychological consequences of engaging in combat. Second, for the first time in recorded warfare, psychological morbidity is likely to far outstrip physical injury associated with combat. Finally, although posttraunnatic stress disorder and traumatic brain injury are serious concerns, most service members return without significant physical or psychological injury and will be able to return to functioning without notable problems. Accurate diagnosis, a focus on resilience, and the expectation of readjustment are essential precepts that should guide clinical efforts and resource allocation. (c) 2008 Wiley Periodicals, Inc.	[Sammons, Morgan T.] Calif Sch Profess Psychol, San Francisco, CA 94133 USA; [Batten, Sonja V.] Univ Maryland, Sch Med, VA Maryland Hlth Care Syst, Baltimore, MD 21201 USA	Sammons, MT (corresponding author), Calif Sch Profess Psychol, 1 Beach St,Suite 200, San Francisco, CA 94133 USA.	msammons@alliant.edu					Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Bliese PD, 2007, PSYCHOL SERV, V4, P141, DOI DOI 10.1037/1541-1559.4.3.141; Chemtob CM, 2000, EFFECTIVE TREATMENTS; CHRISTIAN JR, HARMS WAY P IN PRESS; Collins RC, 2008, J CLIN PSYCHOL, V64, P993, DOI 10.1002/jclp.20515; Department of Defence Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Eastridge BJ, 2006, J TRAUMA, V61, P1366, DOI 10.1097/01.ta.0000245894.78941.90; Erbes CR, 2008, J CLIN PSYCHOL, V64, P972, DOI 10.1002/jclp.20521; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Lincoln A, 2008, J CLIN PSYCHOL, V64, P984, DOI 10.1002/jclp.20520; Mental Health Advisory Team V, 2008, OP IR FREED 06 08; Monson CM, 2008, J CLIN PSYCHOL, V64, P958, DOI 10.1002/jclp.20511; Reger GM, 2008, J CLIN PSYCHOL, V64, P940, DOI 10.1002/jclp.20512; Silver SM, 2008, J CLIN PSYCHOL, V64, P947, DOI 10.1002/jclp.20510; Tanielian T, 2008, INVISIBLE WOUNDS WAR; VHA Office of Public Health and Environmental Hazards, 2008, AN VA HLTH CAR UT US; Wessely S, 2005, BRIT J PSYCHIAT, V186, P459, DOI 10.1192/bjp.186.6.459	18	28	28	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9762	1097-4679		J CLIN PSYCHOL	J. Clin. Psychol.	AUG	2008	64	8					921	927		10.1002/jclp.20519			7	Psychology, Clinical	Psychology	330ES	WOS:000257922900001	18615709				2021-06-18	
J	Vavilala, MS; Tontisirin, N; Udomphorn, Y; Armstead, W; Zimmerman, JJ; Chesnut, R; Lam, AM				Vavilala, Monica S.; Tontisirin, Nuj; Udomphorn, Yuthana; Armstead, William; Zimmerman, Jerry J.; Chesnut, Randall; Lam, Arthur M.			Hemispheric differences in cerebral autoregulation in children with moderate and severe traumatic brain injury	NEUROCRITICAL CARE			English	Article						pediatric traumatic brain injury; cerebral autoregulation	BLOOD-FLOW; ASYMMETRY; HEMODYNAMICS	Introduction To examine hemispheric differences in cerebral autoregulation in children with traumatic brain injury (TBI). After IRB approval and consent, subjects underwent static cerebral autoregulation testing during the first 9 days after PICU admission. Cerebral autoregulation was quantified using the autoregulatory index (ARI). Results Forty-two (27 M:15 F) children (10 +/- 5 years) with TBI and admission Glasgow coma scale score (5 +/- 2) were enrolled. Seven (54%) of the 13 children with focal TBI and 8 (28%) of 29 children with diffuse TBI had impairment or absence of cerebral autoregulation of atleast one hemisphere. In patients with isolated focal TBI, ARI was lower (0.40 +/- 0.40 vs. 0.67 +/- 0.40; P = 0.03) in the side of TBI than in the unaffected hemisphere, but cerebral autoregulation was often impaired on the side without TBI or shift (5/13) on head CT. There was no difference in ARI between hemispheres in children with diffuse TBI, with or without superimposed focal lesions (P = 0.17). Patients with bilateral intact cerebral autoregulation tended to have higher 6 month Glasgow Outcome Score (GOS) than patients with either unilateral or bilateral cerebral autoregulation impairment (GOS 4.0 +/- 0.60 vs. 3.6 +/- 0.80; P = 0.08). Conclusions Hemispheric differences in cerebral autoregulation were common in children with isolated focal TBI. Absence of TBI on CT was not always associated with intact cerebral autoregulation. Patients with bilaterally intact cerebral autoregulation tended to have better outcomes.	[Vavilala, Monica S.; Tontisirin, Nuj; Udomphorn, Yuthana] Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; [Vavilala, Monica S.; Zimmerman, Jerry J.] Univ Washington, Harborview Med Ctr, Dept Pediat, Seattle, WA 98104 USA; [Vavilala, Monica S.; Chesnut, Randall; Lam, Arthur M.] Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Seattle, WA 98104 USA; [Armstead, William] Univ Penn, Dept Anesthesiol, Philadelphia, PA 19104 USA	Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, 325 9th Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu		Chesnut, Randall/0000-0001-6377-3666	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632-04]	Thanks to Ms. Domonique Calhoun. This research was supported by National Institute of Child Health and Human Development Award K23HD044632-04.	ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Bakker SLM, 2004, NEUROEPIDEMIOLOGY, V23, P178, DOI 10.1159/000078503; Blaha M, 2003, J CLIN NEUROSCI, V10, P195, DOI 10.1016/S0967-5868(02)00126-1; Bode H., 1988, PEDIAT APPL TRANSCRA; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Cremer OL, 2004, ANESTHESIOLOGY, V100, P1101, DOI 10.1097/00000542-200405000-00011; HANBRICH C, 2004, STROKE, V35, P848; Hilz MJ, 2002, J NEUROL NEUROSUR PS, V72, P657, DOI 10.1136/jnnp.72.5.657; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Kumar A, 2005, J NEUROL NEUROSUR PS, V76, P1570, DOI 10.1136/jnnp.2004.059493; LAM AM, 1995, ANESTHESIOLOGY, V82, P1536, DOI 10.1097/00000542-199506000-00035; Lang EW, 2003, J CLIN NEUROSCI, V10, P670, DOI 10.1016/S0967-5868(03)00197-8; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; Novak V, 2003, NEUROLOGY, V60, P1657, DOI 10.1212/01.WNL.0000068023.14587.06; Park CW, 2003, STROKE, V34, P34, DOI 10.1161/01.STR.0000047122.42591.B3; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Rosengarten B, 2002, CEREBROVASC DIS, V13, P21, DOI 10.1159/000047741; Schmidt EA, 2002, ACT NEUR S, V81, P133; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; TOMURA N, 1993, COMPUT MED IMAG GRAP, V17, P443, DOI 10.1016/0895-6111(93)90060-Z; Tontisirin N, 2007, PEDIATRICS, V119, pE610, DOI 10.1542/peds.2006-2110; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F; VAVILALA MS, 2004, PEDIATR CRIT CARE ME, V5, P298; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X	27	28	28	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2008	9	1					45	54		10.1007/s12028-007-9036-9			10	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	340PM	WOS:000258657500009	18084727				2021-06-18	
J	Fujiki, M; Kubo, T; Kamida, T; Sugita, K; Hikawa, T; Abe, T; Ishii, K; Kobayashi, H				Fujiki, Minoru; Kubo, Takeshi; Kamida, Tohru; Sugita, Kenji; Hikawa, Takamitsu; Abe, Tatsuya; Ishii, Keisuke; Kobayashi, Hidenori			Neuroprotective and antiamnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						donepezil; mild traumatic brain injury; concussion; neuronal death; memory impairment; neuroprotection	HYDROCHLORIDE E2020; GENE-TRANSCRIPTION; NEUROTOXICITY; EXPRESSION; INHIBITORS	In this study we evaluated the effect of donepezil on the neurodegeneration and behavioral impairments induced by mild traumatic brain injury (MTBI). Donepezil is an acetylcholinesterase inhibitor that is used to treat Alzheimer's disease. Donepezil was given orally to rats subjected to MTBI. Treatment with a single oral dose of donepezil (12 mg/kg) immediately after injury significantly attenuated MTBI-induced neuronal death and cognitive impairment as measured by preservation of neurons in the CA1 region of the hippocampus and a water maze test respectively. However, these neuroprotective effects were prevented by concomitant injection of mecamylamine, a nicotinic acetylcholine-receptor (nAChR) antagonist, indicating that protection is mediated by nAChR activation. (C) 2007 Elsevier Ltd. All rights reserved.	[Fujiki, Minoru; Kubo, Takeshi; Kamida, Tohru; Sugita, Kenji; Hikawa, Takamitsu; Abe, Tatsuya; Ishii, Keisuke; Kobayashi, Hidenori] Oita Univ, Sch Med, Dept Neurosurg, Oita 87011, Japan	Fujiki, M (corresponding author), Oita Univ, Sch Med, Dept Neurosurg, 1-1 Idaigaoka, Hasama, Oita 8795593, Japan.	fujiki@med.oita-u.ac.jp					Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; Fujiki M, 2005, BRAIN RES, V1043, P236, DOI 10.1016/j.brainres.2005.02.063; Fujiki M, 2003, BRAIN RES, V991, P254, DOI 10.1016/S0006-8993(03)03540-6; Fujiki M, 2006, NEUROSCI LETT, V405, P226, DOI 10.1016/j.neulet.2006.07.005; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Kosasa T, 1999, EUR J PHARMACOL, V380, P101, DOI 10.1016/S0014-2999(99)00545-2; Kosasa T, 2000, EUR J PHARMACOL, V389, P173, DOI 10.1016/S0014-2999(99)00876-6; Meunier J, 2006, J PHARMACOL EXP THER, V317, P1307, DOI 10.1124/jpet.106.101527; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; Ogura H, 2000, METHOD FIND EXP CLIN, V22, P609, DOI 10.1358/mf.2000.22.8.701373; STEWARD O, 1991, P NATL ACAD SCI USA, V88, P6819, DOI 10.1073/pnas.88.15.6819; Takada Y, 2003, J PHARMACOL EXP THER, V306, P772, DOI 10.1124/jpet.103.050104	16	28	29	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	JUL	2008	15	7					791	796		10.1016/j.jocn.2007.07.002			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	315DD	WOS:000256857200011	18407501				2021-06-18	
J	Chan, F; Lanctot, KL; Feinstein, A; Herrmann, N; Strauss, J; Sicard, T; Kennedy, JL; McCullagh, S; Rapoport, MJ				Chan, Florance; Lanctot, Krista L.; Feinstein, Anthony; Herrmann, Nathan; Strauss, John; Sicard, Tricia; Kennedy, James L.; McCullagh, Scott; Rapoport, Mark J.			The serotonin transporter polymorphisms and major depression following traumatic brain injury	BRAIN INJURY			English	Article						depression; traumatic brain injury; genetic polymorphism	STRESSFUL LIFE EVENTS; CLOSED-HEAD INJURY; AFFECTIVE-DISORDERS; GENE POLYMORPHISMS; FUNCTIONAL POLYMORPHISM; PARKINSONS-DISEASE; ALLELIC VARIATION; RATING-SCALE; 5-HTTLPR POLYMORPHISM; PSYCHIATRIC-ILLNESS	Objective: The purpose of this study was to examine the role of the serotonin transporter gene polymorphisms on the risk of major depression following traumatic brain injury (TBI). Methods: Seventy-five patients who had sustained a TBI and who met the Diagnostic and Statistical Manual of Mental Disorders (4th ed) (DSM-IV) criteria for mood disorder due to TBI were compared to 99 controls with TBI but no mood disorder. The severity of depression was rated using the Hamilton Depression Rating Scale (HAMD) for the depressed patients. All patients were genotyped for the serotonin transporter gene-linked polymorphic region (5-HTTLPR) with the assay for the rs25531 allelic variant. Results: The distribution of genotype frequencies was not different between the depressed and control groups (chi(2) = 1.43, df = 2, p = 0.488) and for the depressed patients there was no association between HAMD scores and the polymorphisms (t-test = 1.71, df= 68, p = 0.092). Conclusion: There was no evidence of association between the serotonin transporter gene polymorphisms and depression post-TBI. Future research is indicated into the possible role of other candidate genes as risk factors for depression in this population.	[Chan, Florance; Lanctot, Krista L.; Feinstein, Anthony; Herrmann, Nathan; Strauss, John; Sicard, Tricia; Kennedy, James L.; McCullagh, Scott; Rapoport, Mark J.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	Rapoport, MJ (corresponding author), Sunnybrook Hlth Sci Ctr Psychiat, 2075 Bayview Ave,Suite FG37, Toronto, ON M4N 3M5, Canada.	Mark.Rapoport@Sunnybrook.ca	Rapoport, Mark/AAD-8581-2020; Kennedy, James Lowery/AAZ-6947-2020; Lanctot, Krista L./AAY-4820-2020	Kennedy, James Lowery/0000-0002-8733-3806; Lanctot, Krista L./0000-0001-7024-6637			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Anguelova M, 2003, MOL PSYCHIATR, V8, P574, DOI 10.1038/sj.mp.4001328; Assal F, 2004, ARCH NEUROL-CHICAGO, V61, P1249, DOI 10.1001/archneur.61.8.1249; Bellivier F, 1998, NEUROSCI LETT, V255, P143, DOI 10.1016/S0304-3940(98)00677-6; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Burn DJ, 2006, PARKINSONISM RELAT D, V12, P139, DOI 10.1016/j.parkreldis.2005.11.005; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Collier DA, 1996, MOL PSYCHIATR, V1, P453; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Deb S, 1999, AM J PSYCHIAT, V156, P374; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Eley TC, 2004, MOL PSYCHIATR, V9, P908, DOI 10.1038/sj.mp.4001546; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First M.B., 1996, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Furlong RA, 1998, AM J MED GENET, V81, P58, DOI 10.1002/(SICI)1096-8628(19980207)81:1<58::AID-AJMG11>3.0.CO;2-V; Gillespie NA, 2005, PSYCHOL MED, V35, P101, DOI 10.1017/S0033291704002727; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Heils A, 1996, J NEUROCHEM, V66, P2621; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hu XZ, 2006, AM J HUM GENET, V78, P815, DOI 10.1086/503850; Jacobs N, 2006, ARCH GEN PSYCHIAT, V63, P989, DOI 10.1001/archpsyc.63.9.989; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kendler KS, 2006, ARCH GEN PSYCHIAT, V63, P1113, DOI 10.1001/archpsyc.63.10.1113; Kendler KS, 2005, ARCH GEN PSYCHIAT, V62, P529, DOI 10.1001/archpsyc.62.5.529; Kim DK, 2000, NEUROREPORT, V11, P215, DOI 10.1097/00001756-200001170-00042; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kunugi H, 1997, MOL PSYCHIATR, V2, P457, DOI 10.1038/sj.mp.4000334; Lasky-Su JA, 2005, AM J MED GENET B, V133B, P110, DOI 10.1016/j.ajmg.b.30104; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532-5415.1968.tb02103.x; Liu WQ, 1999, PHARMACOGENETICS, V9, P491; Lotrich FE, 2004, PSYCHIAT GENET, V14, P121, DOI 10.1097/00041444-200409000-00001; MARION DW, 1996, MED REHABILITATION T, P35; Menza MA, 1999, J GERIATR PSYCH NEUR, V12, P49, DOI 10.1177/089198879901200202; Micheli D, 2006, J ALZHEIMERS DIS, V10, P371; Mossner R, 2001, MOL PSYCHIATR, V6, P350, DOI 10.1038/sj.mp.4000849; Nakamura M, 2000, MOL PSYCHIATR, V5, P32, DOI 10.1038/sj.mp.4000698; NAYAK AK, 1980, J NEUROL SCI, V47, P211, DOI 10.1016/0022-510X(80)90005-2; Ohara K, 1998, BIOL PSYCHIAT, V44, P550, DOI 10.1016/S0006-3223(98)00112-7; PAZOS A, 1987, NEUROSCIENCE, V21, P123, DOI 10.1016/0306-4522(87)90327-7; Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149; Ramasubbu R, 2006, J NEUROPSYCH CLIN N, V18, P96, DOI 10.1176/appi.neuropsych.18.1.96; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Raymer KA, 2005, MED HYPOTHESES, V65, P158, DOI 10.1016/j.mehy.2004.11.042; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; Surtees PG, 2006, BIOL PSYCHIAT, V59, P224, DOI 10.1016/j.biopsych.2005.07.014; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; Vannemreddy P, 2006, ACTA NEUROCHIR SUPPL, V96, P151; Wilhelm K, 2006, BRIT J PSYCHIAT, V188, P210, DOI 10.1192/bjp.bp.105.009522; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Willis-Owen SAG, 2005, BIOL PSYCHIAT, V58, P451, DOI 10.1016/j.biopsych.2005.04.050; Zalsman G, 2006, AM J PSYCHIAT, V163, P1588, DOI 10.1176/appi.ajp.163.9.1588	60	28	31	0	11	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2008	22	6					471	479		10.1080/02699050802084886			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	316TW	WOS:000256973600004	18465388				2021-06-18	
J	Naim, MY; Hoehn, KS; Hasz, RD; White, LS; Helfaer, MA; Nelson, RM				Naim, Maryam Y.; Hoehn, K. Sarah; Hasz, Richard D.; White, Lori S.; Helfaer, Mark A.; Nelson, Robert M.			The Children's Hospital of Philadelphia's experience with donation after cardiac death	CRITICAL CARE MEDICINE			English	Article						pediatric donation after cardiac death; pediatric non-heart-beating donation; organ transplantation; end-of-life care	ORGAN DONATION; LIFE CARE; DONORS; AUTORESUSCITATION	Objective: To describe our experience with pediatric donation after cardiac death. Design: Retrospective chart review of all cases of donation after cardiac death from 1995 to 2005. Setting: The Children's Hospital of Philadelphia pediatric intensive care unit. Patients: Twelve patients who were pediatric organ donors after cardiac death. Interventions: None. Measurements and Main Results: Charts for 12 patents were located, and donation after cardiac death was confirmed. There were two females and ten males. Patent age ranged from 1 to 17 yrs (mean 8 yrs). Four patients had severe traumatic brain injury, and eight patents had hypoxic ischemic encephalopathy. The organs procured were 24 kidneys, eight livers, four lungs, and one pancreas. The organs transplanted were 23 kidneys, four livers, and one pancreas. Ten of 12 cases of withdrawal of life-sustaining support occurred in the operating room area; the other two occurred in the holding area and the postanesthesia care unit Children received a wide range of medications at the time of extubation. No neummuscular blockers were used. The time of extubation to time of death ranged from 4 mins to 30 mins, with a mean of 14.5 mins. Death was declared based on cardiac asystole confirmed by auscultation and transthoracic impedance, with organ procurement initiated 5 mins later. Regarding who initiated conversation about donation after cardiac death, nine cases were family initiated, one case was physician initiated, and in two there was a collaborative approach with the physician and representative from the organ procurement organization. Of the organs transplanted, all organs other than one kidney and one split liver graft were functioning at 1 yr post-transplant Conclusions: Pediatric donation after cardiac death can be performed successfully; its impact on end-of-life care and bereavement needs further investigation.	[Hoehn, K. Sarah] Univ Chicago, Chicago, IL 60637 USA; [Nelson, Robert M.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [White, Lori S.] Gift Life Donor Program, Philadelphia, PA USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Helfaer, Mark A.] Endowed Chair, Div Crit Care Med, Philadelphia, PA USA	Hoehn, KS (corresponding author), Univ Chicago, Chicago, IL 60637 USA.	sarah1220@comcast.net					Burns JP, 2000, CRIT CARE MED, V28, P3060, DOI 10.1097/00003246-200008000-00064; Cecka JM, 2002, NEW ENGL J MED, V347, P281, DOI 10.1056/NEJMe020069; Daar AS, 2004, TRANSPL P, V36, P1885, DOI 10.1016/j.transproceed.2004.08.130; DeVita MA, 2001, CRIT CARE MED, V29, P1826; Devita Michael A., 1993, Kennedy Institute of Ethics Journal, V3, P113; Devita Michael A., 1993, Kennedy Institute of Ethics Journal, V3, P131; DeVita Michael A, 1995, Kennedy Inst Ethics J, V5, P43; DURALL AL, 2007, J PEDIATR, V119, pE201; Edwards J, 2006, CRIT CARE NURSE, V26, P101; Ferguson M, 2003, J PEDIATR GASTR NUTR, V37, P219, DOI 10.1097/00005176-200309000-00001; Howard RJ, 2005, TRANSPLANTATION, V80, P564, DOI 10.1097/01.tp.0000168156.79847.46; *I HLTH CAR IMPR, 2007, IMPR REP ORG DON BRE; *I MED, 1997, EX SUMM NON HEART BE; *I MED, 2000, NONHEARTBEATING ORG; Koogler T, 1998, PEDIATRICS, V101, P1049, DOI 10.1542/peds.101.6.1049; Lewis Jonathan, 2003, Prog Transplant, V13, P265; Luce JM, 2001, CRIT CARE MED, V29, pN40, DOI 10.1097/00003246-200102001-00008; Olson L, 2005, TRANSPL P, V37, P1188, DOI 10.1016/j.transproceed.2004.12.021; Saiki C, 2001, CAN J PHYSIOL PHARM, V79, P1036, DOI 10.1139/cjpp-79-12-1036; SANOCKA UM, 1992, J APPL PHYSIOL, V73, P749; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Truog RD, 2003, ANESTHESIOLOGY, V98, P599, DOI 10.1097/00000542-200303000-00003; Weber M, 2002, NEW ENGL J MED, V347, P248, DOI 10.1056/NEJMoa020274	23	28	31	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2008	36	6					1729	1733		10.1097/CCM.0b013e318174dd3d			5	Critical Care Medicine	General & Internal Medicine	310EZ	WOS:000256513000005	18520638				2021-06-18	
J	Zhang, Z; Fauser, U; Schluesener, HJ				Zhang, Z.; Fauser, U.; Schluesener, H. J.			Early attenuation of lesional interleukin-16 up-regulation by dexamethasone and FTY720 in experimental traumatic brain injury	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						dexamethasone; FTY720; interleukin-16; microglia; macrophages; traumatic brain injury	SPINAL-CORD-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HEAD-INJURY; ACTIVATED MICROGLIA/MACROPHAGES; INFLAMMATORY CYTOKINES; TIRILAZAD MESYLATE; CEREBRAL-ISCHEMIA; MICROGLIAL CELLS; HUMAN MONOCYTES; NERVOUS-SYSTEM	Aims: Interleukin-16 (IL16) is an immunomodulatory cytokine, which induces lymphocyte migration, expression of proinflammatory IL1 beta, IL6 and tumour necrosis factor-alpha, and modulates apoptosis. IL16 expression has been observed in several central nervous system diseases and may play a role in promoting inflammatory responses. Inflammation contributes considerably to secondary injury following traumatic brain injury (TBI). The aim of this study was to investigate early IL16 expression following experimental TBI and the effects of dexamethasone and FTY720 on early expression of IL16 in TBI rats. Methods: Rat TBI was induced using an open-skull weight-drop model. IL16 expression was studied by immunohistochemistry. TBI rats received an intraperitoneal injection of dexamethasone (1 mg/kg in 1 ml saline), FTY720 (1 mg/kg in 1 ml saline) or saline (1 ml) on Day 0 and Day 2 immediately after surgery. Results: Significant up-regulation of IL16 was seen as early as 24 h post TBI. Double-staining experiments, together with morphological classification, revealed a multicellular origin of IL16, including activated microglia/macrophages (about 85%), astrocytes (about 8%), neurones (about 5%) and granulocytes. Following peripheral administration of dexamethasone and FTY720, attenuated numbers of IL16(+) cells were observed on Days 1 and 2 but not on Day 4 post TBI for dexamethasone and on Day 4 but not earlier for FTY720 respectively. Conclusions: Our observations reveal that dexamethasone and FTY720 have different but complementary effects on reduction of early IL16 expression following TBI.	[Zhang, Z.; Fauser, U.; Schluesener, H. J.] Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany	Zhang, Z (corresponding author), Univ Tubingen, Inst Brain Res, Calwer St 3, D-72076 Tubingen, Germany.	zhangzhiren@yahoo.com	zhang, zhiren/I-1046-2014; Zhang, Zhiren/O-1012-2019	zhang, zhiren/0000-0002-5238-2835; Zhang, Zhiren/0000-0002-5238-2835			ADACHI K, 1995, BIOORG MED CHEM LETT, V5, P853, DOI 10.1016/0960-894X(95)00127-F; Arima M, 1999, AM J RESP CELL MOL, V21, P684, DOI 10.1165/ajrcmb.21.6.3671; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Chiba K, 2006, CELL MOL IMMUNOL, V3, P11; Cruikshank WW, 2000, J LEUKOCYTE BIOL, V67, P757; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; Deng JM, 2006, CHINESE MED J-PEKING, V119, P1017, DOI 10.1097/00029330-200606020-00009; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Gahm C, 2005, ACTA NEUROCHIR, V147, P1071, DOI 10.1007/s00701-005-0590-7; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Guo LH, 2004, J NEUROIMMUNOL, V146, P39, DOI 10.1016/j.jneuroim.2003.09.017; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; Holmin, 1996, ACTA NEUROCHIR, V138, P418, DOI 10.1007/BF01420304; Kaneider NC, 2004, FASEB J, V18, P1309, DOI 10.1096/fj.03-1050fje; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; Klimiuk PA, 1999, J IMMUNOL, V162, P4293; Laberge S, 1997, J ALLERGY CLIN IMMUN, V100, P569, DOI 10.1016/S0091-6749(97)70152-0; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Liebrich M, 2007, ARCH IMMUNOL THER EX, V55, P41, DOI 10.1007/s00005-007-0003-0; Lipton P, 1999, PHYSIOL REV, V79, P1431; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mathy NL, 2000, IMMUNOLOGY, V100, P63, DOI 10.1046/j.1365-2567.2000.00997.x; MEINIG G, 1990, ACT NEUR S, V51, P100; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mueller CA, 2006, J NEUROSURG-SPINE, V4, P233, DOI 10.3171/spi.2006.4.3.233; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Raivich G, 1999, ACTA NEUROCHIR SUPPL, V73, P21; Rausch M, 2004, J MAGN RESON IMAGING, V20, P16, DOI 10.1002/jmri.20057; Sauerland S, 2004, LANCET, V364, P1291, DOI 10.1016/S0140-6736(04)17202-4; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Schwab JM, 2001, J NEUROIMMUNOL, V114, P232, DOI 10.1016/S0165-5728(00)00433-1; Schwab JM, 2005, J NEUROIMMUNOL, V163, P185, DOI 10.1016/j.jneuroim.2005.02.016; Skundric DS, 2005, J NEUROSCI RES, V79, P680, DOI 10.1002/jnr.20377; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Webb M, 2004, J NEUROIMMUNOL, V153, P108, DOI 10.1016/j.jneuroim.2004.04.015; Yopp AC, 2006, CLIN TRANSPLANT, V20, P788, DOI 10.1111/j.1399-0012.2006.00570.x; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; ZHANG Z, J CELL MOL MED, V11, P307; Zhang ZY, 2007, ACTA NEUROPATHOL, V113, P675, DOI 10.1007/s00401-007-0195-8	46	28	29	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	JUN	2008	34	3					330	339		10.1111/j.1365-2990.2007.00893.x			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	292SU	WOS:000255287200007	17983426				2021-06-18	
J	Bernard, F; Al-Tamimi, YZ; Chafield, D; Lynch, AG; Matta, BF; Menon, DK				Bernard, Francis; Al-Tamimi, Yahia Z.; Chafield, Doris; Lynch, Andrew G.; Matta, Basil F.; Menon, David K.			Serum albumin level as a predictor of outcome in traumatic brain injury: Potential for treatment	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; albumin; oedema; neurological outcome; therapy	FOCAL CEREBRAL-ISCHEMIA; MARKED NEUROPROTECTIVE EFFICACY; COLLOID ONCOTIC THERAPY; PLASMA-PROTEINS; RATS; EDEMA; MORTALITY; ANTIOXIDANT; INFARCTION; OCCLUSION	Background: Serum albumin level is correlated with outcome in various clinical situations. Albumin has multiple physiologic properties that could be beneficial in brain injury. The Lund therapy for elevated intracranial pressure uses albumin as part of its protocol and demonstrates favorable outcome. We sought to find out if albumin is associated with outcome after traumatic brain injury to justify conducting a randomized trial. Methods: A retrospective study of traumatic brain injury patients was conducted. Characteristics known to influence outcome were included in a multiple logistic regression model to analyze predictors of poor outcome at 6 months. Results: Data were available for 138 patients. The majority of patients (65%) had a severe injury (Glasgow Coma Scale score <9). Seventy percent of patients had a favorable outcome. Albumin levels decrease considerably from normal values in the first few days after injury irrespective of outcome. Albumin remained <25 g/L for a longer period of time in patient with an unfavorable outcome (6 days vs. 3 days, p = 0.012). Multiple logistic regression analysis identified albumin levels, age, Glasgow Coma Scale score at admission, and Injury Severity Score as predictors of poor outcome. Conclusion: Serum albumin level seems to be an independent predictor of poor outcome. The model also identified classic predictors of poor outcome that tends to strengthen its adequacy. Because albumin level is the only modifiable factor influencing outcome, it seems justified to carry out a randomized trial of the use of albumin in the treatment of brain injury.	[Bernard, Francis] Hop Sacre Coeur, Intens Care Dept, Dept Crit Care Med, Montreal, PQ H4J 1C5, Canada; [Al-Tamimi, Yahia Z.; Chafield, Doris; Matta, Basil F.; Menon, David K.] Addenbrookes Hosp, Univ Dept Anaesthesia, Cambridge, England; [Lynch, Andrew G.] Univ Cambridge, Dept Publ Hlth & Primary Care, Ctr Appl Med Stat, Cambridge, England	Bernard, F (corresponding author), Hop Sacre Coeur, Intens Care Dept, Dept Crit Care Med, 5400 Boul Gouin Ouest, Montreal, PQ H4J 1C5, Canada.	bernard.francis@mail.com		Lynch, Andy/0000-0002-7876-7338	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001237, G9439390] Funding Source: Medline		Belayev L, 1998, STROKE, V29, P2587, DOI 10.1161/01.STR.29.12.2587; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Belayev L, 1999, BRAIN RES, V845, P107, DOI 10.1016/S0006-8993(99)01952-6; Belayev L, 2002, STROKE, V33, P1077, DOI 10.1161/hs0402.105555; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Belayev L, 1997, J NEUROSURG, V87, P595, DOI 10.3171/jns.1997.87.4.0595; CLASEN RA, 1982, J NEUROPATH EXP NEUR, V41, P113, DOI 10.1097/00005072-198203000-00003; Dubois MJ, 2006, CRIT CARE MED, V34, P2536, DOI 10.1097/01.CCM.0000239119.57544.0C; Dubois Marc-Jacques, 2002, Curr Opin Crit Care, V8, P299, DOI 10.1097/00075198-200208000-00005; Dziedzic T, 2004, STROKE, V35, pE156, DOI 10.1161/01.STR.0000126609.18735.be; EMERSON TE, 1989, CRIT CARE MED, V17, P690, DOI 10.1097/00003246-198907000-00020; Ginsberg MD, 2001, J NEUROSURG, V94, P499, DOI 10.3171/jns.2001.94.3.0499; Goldwasser P, 1997, J CLIN EPIDEMIOL, V50, P693, DOI 10.1016/S0895-4356(97)00015-2; Goslinga H, 1992, Ned Tijdschr Geneeskd, V136, P2422; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; HAKAMATA Y, 1995, STROKE, V26, P2149, DOI 10.1161/01.STR.26.11.2149; HALLIWELL B, 1988, BIOCHEM PHARMACOL, V37, P569, DOI 10.1016/0006-2952(88)90126-8; Huh PW, 1998, BRAIN RES, V804, P105, DOI 10.1016/S0006-8993(98)00674-X; JORGENSEN KA, 1980, THROMB RES, V17, P13, DOI 10.1016/0049-3848(80)90289-3; KEANEY JF, 1993, J CLIN INVEST, V91, P1582, DOI 10.1172/JCI116364; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Martin GS, 2005, CRIT CARE MED, V33, P1681, DOI 10.1097/01.CCM.0000171539.47006.02; MATSUI T, 1993, NEUROSURGERY, V33, P293, DOI 10.1227/00006123-199308000-00017; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; MIYASAKA Y, 1983, SHINKEI GEKA, V11, P947; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Naredi S, 2003, CRIT CARE MED, V31, P2713, DOI 10.1097/01.CCm.0000095462.89651.9C; Nicholson JP, 2000, BRIT J ANAESTH, V85, P599, DOI 10.1093/bja/85.4.599; Sung J, 2004, AM SURGEON, V70, P1099; Tabernero A, 1999, GLIA, V25, P1; TOMITA H, 1994, ACTA NEUROCHIR, P547; Vincent JL, 2005, CRIT CARE, V9, pR745, DOI 10.1186/cc3895; Vincent JL, 2003, ANN SURG, V237, P319, DOI 10.1097/00000658-200303000-00005; Ward RT, 2004, J CRIT CARE, V19, P54, DOI 10.1016/j.jcrc.2004.02.011; WAYNER DDM, 1985, FEBS LETT, V187, P33, DOI 10.1016/0014-5793(85)81208-4; Zoellner H, 1996, J CELL SCI, V109, P2571	37	28	29	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2008	64	4					872	875		10.1097/TA.0b013e31803428cc			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	287UN	WOS:000254942100005	18404050				2021-06-18	
J	Tran, MD; Wanner, IB; Neary, JT				Tran, Minh D.; Wanner, Ina B.; Neary, Joseph T.			Purinergic receptor signaling regulates N-cadherin expression in primary astrocyte cultures	JOURNAL OF NEUROCHEMISTRY			English	Article						Akt; mitogen-activated protein kinase; N-cadherin; purinergic receptors; traumatic brain injury	STRETCH-INDUCED INJURY; RAT CORTICAL ASTROCYTES; CELL-CELL-ADHESION; TRANSFORMED MOUSE FIBROBLASTS; ACTIVATED PROTEIN-KINASE; HAMSTER OVARY CELLS; EXTRACELLULAR ATP; SCHWANN-CELL; IN-VITRO; ADENOSINE-TRIPHOSPHATE	Extracellular ATP exerts both short-term and long-term effects in the CNS by stimulating cell-surface purinergic receptors. Here we have examined the effect of purinergic receptor activation on N-cadherin expression, a calcium-dependent cell adhesion molecule involved in many processes, including glia-glia and axon-glia interactions. When primary cultures of rat cortical astrocytes were treated with ATP, N-cadherin protein expression increased in a time- and concentration-dependent manner. In addition, ATP treatment caused an increase in N-cadherin immunoreactivity in both the cytoplasm and on the cell surface membrane. Interestingly, experiments with cycloheximide revealed that relocalization of N-cadherin to the cell surface membrane were independent of protein synthesis. The ATP-induced increase in N-cadherin protein expression was blocked by reactive blue 2 and 8-(p-sulfophenyl)-theophylline, suggesting involvement of both P2 and P1 purinergic receptors, respectively. In addition, N-cadherin expression was partially blocked when signaling from purinergic receptors to extracellular signal regulated protein kinase or Akt was inhibited by 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene or wortmannin, respectively. By using an in vitro model of traumatic CNS injury, we found that N-cadherin expression was increased when astrocytes were subjected to rapid and reversible mechanical strain. The findings presented here demonstrate a role for extracellular ATP, purinergic receptors and protein kinase signaling in regulating N-cadherin expression and suggest a role for this mechanism in cell-cell interactions.	[Tran, Minh D.; Neary, Joseph T.] Univ Miami, Miller Sch Med, Neurosci Program, Dept Pathol,Miami VA Med Ctr,Res Serv, Miami, FL USA; [Wanner, Ina B.] Univ Calif Los Angeles, David Geffen Sch Med, Mental Retardat Res Ctr, Los Angeles, CA 90095 USA; [Wanner, Ina B.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA	Neary, JT (corresponding author), VA Med Ctr, Res Serv 151, 1201 NW 16th St, Miami, FL 33125 USA.	jneary@med.miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS46651, NS045470] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046651, F31NS045470] Funding Source: NIH RePORTER		ABBRACCHIO MP, 1994, NEUROSCIENCE, V59, P67, DOI 10.1016/0306-4522(94)90099-X; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; BLASCHUK OW, 1989, DEV BIOL, V136, P564, DOI 10.1016/0012-1606(89)90283-2; Brambilla R, 2002, J NEUROCHEM, V83, P1285, DOI 10.1046/j.1471-4159.2002.01239.x; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018-007-6497-0; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chorna NE, 2004, J NEUROCHEM, V91, P119, DOI 10.1111/j.1471-4159.2004.02699.x; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Derycke LDM, 2004, INT J DEV BIOL, V48, P463, DOI 10.1387/ijdb.041793ld; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; ERB L, 1990, J BIOL CHEM, V265, P7424; Fairless R, 2005, MOL CELL NEUROSCI, V28, P253, DOI 10.1016/j.mcn.2004.09.009; Farookhi R, 1997, ANN NY ACAD SCI, V816, P165, DOI 10.1111/j.1749-6632.1997.tb52140.x; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fields RD, 2000, TRENDS NEUROSCI, V23, P625, DOI 10.1016/S0166-2236(00)01674-X; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Franke H, 1999, GLIA, V28, P190, DOI 10.1002/(SICI)1098-1136(199912)28:3<190::AID-GLIA3>3.3.CO;2-S; Franke H, 2006, PHARMACOL THERAPEUT, V109, P297, DOI 10.1016/j.pharmthera.2005.06.002; Franke H, 2001, BRIT J PHARMACOL, V134, P1180, DOI 10.1038/sj.bjp.0704353; Fumagalli M, 2003, GLIA, V43, P218, DOI 10.1002/glia.10248; Gendron Fernand-Pierre, 2003, Biomedical Research (Aligarh), V14, P47; Glass R, 2002, CELL MOL LIFE SCI, V59, P870, DOI 10.1007/s00018-002-8474-y; GONZALEZ FA, 1989, J CELL PHYSIOL, V139, P109, DOI 10.1002/jcp.1041390116; Hatoko M, 2004, SCAND J PLAST RECONS, V38, P198, DOI 10.1080/02844310410026735; Hatoko M, 2004, J RECONSTR MICROSURG, V20, P267; Jacques-Silva MC, 2004, BRIT J PHARMACOL, V141, P1106, DOI 10.1038/sj.bjp.0705685; Kanemaru K, 2007, J NEUROSCI, V27, P8957, DOI 10.1523/JNEUROSCI.2276-07.2007; King BF, 2005, BRIT J PHARMACOL, V145, P313, DOI 10.1038/sj.bjp.0706187; King BF, 1996, NEUROSCIENCE, V74, P1187, DOI 10.1016/S0306-4522(96)00209-6; Kiryushko D, 2004, ANN NY ACAD SCI, V1014, P140, DOI 10.1196/annals.1294.015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI KM, 1991, J NEUROCHEM, V57, P1510, DOI 10.1111/j.1471-4159.1991.tb06345.x; Lakatos A, 2000, GLIA, V32, P214, DOI 10.1002/1098-1136(200012)32:3<214::AID-GLIA20>3.0.CO;2-7; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Lenz G, 2000, BRIT J PHARMACOL, V129, P927, DOI 10.1038/sj.bjp.0703138; Lenz G, 2001, J NEUROCHEM, V77, P1001, DOI 10.1046/j.1471-4159.2001.00299.x; Liu JSH, 2000, J NEUROSCI, V20, P5292, DOI 10.1523/JNEUROSCI.20-14-05292.2000; MacCalman CD, 1997, ENDOCRINOLOGY, V138, P41, DOI 10.1210/en.138.1.41; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Monks DA, 2001, P NATL ACAD SCI USA, V98, P1312, DOI 10.1073/pnas.031562798; Monks DA, 2001, BRAIN RES, V895, P73, DOI 10.1016/S0006-8993(01)02031-5; Neary JT, 1999, PROG BRAIN RES, V120, P323; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; NEARY JT, 1994, NEUROREPORT, V5, P1617, DOI 10.1097/00001756-199408150-00019; NEARY JT, 1994, J NEUROCHEM, V63, P490; Neary JT, 1999, J NEUROSCI, V19, P4211, DOI 10.1523/jneurosci.19-11-04211.1999; Neary JT, 1998, NEUROSCI LETT, V242, P159, DOI 10.1016/S0304-3940(98)00067-6; NEARY JT, 1994, ACTA NEUROPATHOL, V87, P8; Neary JT, 1996, TRENDS NEUROSCI, V19, P13, DOI 10.1016/0166-2236(96)81861-3; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; NEUGEBAUER KM, 1988, J CELL BIOL, V107, P1177, DOI 10.1083/jcb.107.3.1177; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Oda H, 1998, DEV BIOL, V203, P435, DOI 10.1006/dbio.1998.9047; Okamura K, 2004, J CELL BIOL, V167, P961, DOI 10.1083/jcb.200406030; Otani N, 2006, J CLIN NEUROSCI, V13, P934, DOI 10.1016/j.jocn.2005.10.018; Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200; Panenka W, 2001, J NEUROSCI, V21, P7135, DOI 10.1523/JNEUROSCI.21-18-07135.2001; Pannu R, 2005, J BIOL CHEM, V280, P13742, DOI 10.1074/jbc.M411959200; Perryman KJ, 1996, ENDOCRINOLOGY, V137, P3877, DOI 10.1210/en.137.9.3877; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Pon YL, 2005, J BIOL CHEM, V280, P15438, DOI 10.1074/jbc.M410766200; Potter E, 1999, ENDOCR REV, V20, P207, DOI 10.1210/er.20.2.207; RATHBONE MP, 1992, NEUROSCI RES, V13, P1, DOI 10.1016/0168-0102(92)90030-G; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Schnadelbach O, 2000, MOL CELL NEUROSCI, V15, P288, DOI 10.1006/mcne.1999.0819; Schulte G, 2000, MOL PHARMACOL, V58, P477; Schulte G, 2002, MOL PHARMACOL, V62, P1137, DOI 10.1124/mol.62.5.1137; SEGER R, 1995, FASEB J, V9, P726; Seye CI, 2004, J BIOL CHEM, V279, P35679, DOI 10.1074/jbc.M401799200; Shan WS, 2002, J NEUROSCI RES, V69, P292, DOI 10.1002/jnr.10305; SHREIBER D, 1995, P 1995 INT RES C BIO, P233; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Thornton MR, 2005, J ANAT, V206, P69, DOI 10.1111/j.0021-8782.2005.00369.x; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; Tran MD, 2006, P NATL ACAD SCI USA, V103, P9321, DOI 10.1073/pnas.0603146103; Wang M, 2005, J NEUROCHEM, V95, P630, DOI 10.1111/j.1471-4159.2005.03408.x; Wanner IB, 2002, J NEUROSCI, V22, P4066, DOI 10.1523/JNEUROSCI.22-10-04066.2002; Wanner IB, 2006, GLIA, V54, P439, DOI 10.1002/glia.20390; Wanner IB, 2006, GLIA, V54, P424, DOI 10.1002/glia.20389; WIERASZKO A, 1989, BRAIN RES, V485, P244, DOI 10.1016/0006-8993(89)90567-2; Wilby MJ, 1999, MOL CELL NEUROSCI, V14, P66, DOI 10.1006/mcne.1999.0766; WU PH, 1978, NEUROCHEM RES, V3, P563, DOI 10.1007/BF00963759; Zimmermann H, 1999, PROG BRAIN RES, V120, P371; Zimmermann H, 2006, PFLUG ARCH EUR J PHY, V452, P573, DOI 10.1007/s00424-006-0067-4	89	28	28	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2008	105	1					272	286		10.1111/j.1471-4159.2008.05214.x			15	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	279VR	WOS:000254383800023	18182057	Bronze			2021-06-18	
J	Cloute, K; Mitchell, A; Yates, P				Cloute, Karen; Mitchell, Annie; Yates, Phil			Traumatic brain injury and the construction of identity: A discursive approach	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							HEAD-INJURY; QUALITATIVE RESEARCH; SELF; ADJUSTMENT; PSYCHOLOGY; DISTURBANCES; DISABILITY; NARRATIVES; COMMUNITY; PEOPLE	Using discourse analysis, this paper explores the co-construction of identity for individuals who have sustained a severe traumatic brain injury (TBI). An analysis of discourse, obtained through interviewing six adults with a TBI, each with one or two significant others, suggested four main interpretative repertoires which informed participants' co-construction of identity: Medical model referencing, dependence as intrinsic to TBI, TBI as deficit and progression and productivity as key life-defining features. Medical model referencing is discussed in relation to the common, passive positioning of individuals with TBI, which often occurred in relation to memory loss. The construction of abandonment was also common, due to participants' dependence on the provision of specialist, expert services in the community. Clinical implications are discussed in terms of facilitating individuals in the co-constructing and re-authorship of more empowering and inclusive narratives and providing community services that promote meaningful social identities, separate from medical discourse.	[Cloute, Karen] Somerset Partnership NHS & Social Care Trust, Yeovil, England; [Mitchell, Annie] Univ Plymouth, Plymouth PL4 8AA, Devon, England; [Yates, Phil] Univ Exeter, Mardon Neurorehabil Ctr, Exeter EX4 4QJ, Devon, England	Cloute, K (corresponding author), Balidon Ctr, Summerlands Site,Preston Rd, Yeovil BA20 2BX, England.	Karen.Cloute@sompar.nhs.uk					BEVAN S, 1999, CRITICAL TEXTWORK IN; BLAXTER L, 2001, SMALL VOICES BIG NOI; Breakwell G., 1986, COPING THREATENED ID; Burr Vivienne, 1995, INTRO SOCIAL CONSTRU; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; Chamberlain K, 1997, PSYCHOL HEALTH, V12, P691, DOI 10.1080/08870449708407415; Corker M., 2003, DISABILITY CULTURE I; Dawodu S.T., 2003, TRAUMATIC BRAIN INJU; Department of Health, 2005, NAT SERV FRAM LONG T; Dowell J, 2002, BRIT J GEN PRACT, V52, P24; Elliott R, 1999, BRIT J CLIN PSYCHOL, V38, P215, DOI 10.1348/014466599162782; FENTON M, 1989, PASSIVITY EMPOWERMEN; FIFE BL, 1994, SOC SCI MED, V38, P309, DOI 10.1016/0277-9536(94)90400-6; GERGEN KJ, 1985, AM PSYCHOL, V40, P266, DOI 10.1037/0003-066X.40.3.266; JUDD T, 1999, NEUROPSYCHOTHERAPY C; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KREFTING L, 1990, SOC SCI MED, V30, P859, DOI 10.1016/0277-9536(90)90213-C; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; McCluskey AE, 2000, BRAIN INJURY, V14, P943, DOI 10.1080/02699050050191896; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Oliver M., 1990, POLITICS DISABLEMENT; Olney MF, 2001, DISABIL SOC, V16, P563, DOI 10.1080/09687590120059540; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Potter J., 1987, DISCOURSE SOCIAL PSY; Potter J., 1995, RETHINKING METHODS P; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Psathas G., 1995, CONVERSATION ANAL ST; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Scior K, 2003, DISABIL SOC, V18, P779, DOI 10.1080/0968759032000119514; *SOC SERV INS, 1996, HIDD DIS REP SSI TRA; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; STEEL R, 2004, INVOLVING PUBLIC NHS; STILES WB, 1993, CLIN PSYCHOL REV, V13, P593, DOI 10.1016/0272-7358(93)90048-Q; Tajfel H., 1979, SOCIAL PSYCHOL INTER; TATE R, 2002, HDB MEMORY DISORDERS; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; Turner J., 1987, REDISCOVERING SOCIAL; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VANBESELAERE N, 1991, BASIC APPL SOC PSYCH, V12, P291; White M., 1990, NARRATIVE MEANS THER; Widdicombe S., 1995, LANGUAGE YOUTH SUBCU; WILLER B, 1994, BRAIN INJURY, V8, P647, DOI 10.3109/02699059409151017; Williams WH, 1999, NEUROPSYCHOL REHABIL, V9, P421, DOI 10.1080/096020199389482; WILLIAMS WH, 2003, NEUROPSYCHOLOGICAL R; Willig C., 2003, QUALITATIVE PSYCHOL; Yardley L, 1998, J Health Psychol, V3, P313, DOI 10.1177/135910539800300303; YATES PJ, 2003, BIOPSYCHOSOCIAL APPR; Ylvisaker M, 2000, BRAIN IMPAIR, V1, P12, DOI DOI 10.1375/BRIM.1.1.12	53	28	28	0	19	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	5-6					651	670		10.1080/09602010701306989			20	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	360PQ	WOS:000260070200012	17852757				2021-06-18	
J	Cullen, NK; Park, YG; Bayley, MT				Cullen, Nora K.; Park, Yoon-Ghil; Bayley, Mark T.			Functional recovery following traumatic vs non-traumatic brain injury: A case-controlled study	BRAIN INJURY			English	Article						Outcome assessment; rehabilitation; traumatic brain injury; non-traumatic brain injury	DISABILITY RATING-SCALE; EARLY INTENSIVE NEUROREHABILITATION; PROSPECTIVE MULTICENTER TRIAL; PROLONGED UNCONSCIOUS STATE; SEVERE HEAD-INJURY; INPATIENT REHABILITATION; YOUNG-ADULTS; CHILDREN; OUTCOMES; COMA	Primary objective: To explore differences in rate of recovery and functional outcome in case-matched patients with traumatic (TBI) vs non-traumatic brain injury (non-TBI) during inpatient rehabilitation and 1 year post-insult. Research design: Retrospective comparison study and case-controlled design. Methods and procedures: Demographic data, severity of injury, functional outcome measures and outcomes at 1 year follow-up were collected on 573 patients (404 TBI; 169 non-TBI) admitted to a multidisciplinary neurorehabilitation programme. After general cohort comparisons, 86 TBI and 86 non-TBI patients were matched on age, severity of injury and functional outcome scores. Main outcomes and results: In the general cohort analyses, TBI patients demonstrated better outcomes at discharge as indicated by lower Disability Rating Scale (DRS) scores and higher gain and efficiency scores on both motor and cognitive sub-scales of the Functional Independence Measure (FIM). After matching patients, TBI patients showed greater functional improvement throughout their rehabilitation stay. Outcomes at 1 year follow-up were mixed; TBI patients showed better outcomes compared to non-TBI patients on DRS scores; however, FIM scores were not significantly different. Conclusions: Results from the present study support the hypothesis that TBI patients achieve greater functional improvements compared to non-TBI patients when matched according to injury and demographic characteristics.	[Cullen, Nora K.; Bayley, Mark T.] Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Cullen, Nora K.; Bayley, Mark T.] Univ Toronto, Toronto, ON, Canada; [Park, Yoon-Ghil] Yonsei Univ, Coll Med, Seoul, South Korea; [Park, Yoon-Ghil] Yongdong Severance Hosp, Seoul, South Korea	Cullen, NK (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	cullen.nora@torontorehab.on.ca		Park, Yoon Ghil/0000-0001-9054-5300; Cullen, Nora/0000-0001-6359-9418; Bayley, Mark/0000-0001-7860-9463	Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; Province of Ontario	We would like to thank the Physicians' Services Foundation Inc. for their generous support of this project and the staff of the Toronto Rehabilitation Institute, ABI service, for their assistance in data collection. The research assistance of Charmagne Crescini is also gratefully acknowledged. Equipment and space have been funded with grants from the Canada Foundation for Innovation and the Province of Ontario. The views expressed here do not necessarily reflect those of the Ontario Ministry of Health and Long-Term Care.	Boake C, 2000, PHYS MED REHABILITAT, P1073; Chua KSG, 1999, INT J REHABIL RES, V22, P189, DOI 10.1097/00004356-199909000-00005; CUMMINS RA, 1992, AUST PSYCHOL, V27, P71, DOI 10.1080/00050069208257582; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS1, DOI 10.1016/j.apmr.2005.09.003; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Eilander HJ, 2007, BRAIN INJURY, V21, P53, DOI 10.1080/02699050601151795; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Fragala MA, 2002, BRAIN INJURY, V16, P149, DOI 10.1080/02699050110103328; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Haley SM, 2001, PHYS THER, V81, P1425, DOI 10.1093/ptj/81.8.1425; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; LANGFITT TW, 1982, CLIN NEUR, V29, P353; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; LIPPERTGRUNER M, 2002, BRAIN INJURY, V21, P1001; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schmidt JG, 1997, J NEUROL REHABIL, V11, P189; Shah MK, 2004, BRAIN INJURY, V18, P111, DOI 10.1080/0269905031000149551; Shah MK, 2007, J NEUROL SCI, V260, P95, DOI 10.1016/j.jns.2007.04.012; TEASDALE G, 1974, LANCET, V2, P81; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7	36	28	28	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	13-14					1013	1020	PII 907306637	10.1080/02699050802530581			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	389ZM	WOS:000262134100005	19117180				2021-06-18	
J	Jakobsson, L; Isaksson-Hellman, I; Lindman, M				Jakobsson, Lotta; Isaksson-Hellman, Irene; Lindman, Magdalena			WHIPS (Volvo Cars' Whiplash Protection System)-The Development and Real-World Performance	TRAFFIC INJURY PREVENTION			English	Article						Rear-End Impact; Whiplash; Protection; Prevention; City Safety	INJURY	Objectives: Present the performance of WHIPS and identify possible next steps of soft tissue neck injury reduction potentials, based on rear-end real-world crash data. Methods: Front-seat occupants (above 14 years of age) have been analyzed regarding influencing factors on reported incidences of soft tissue neck injuries. The outcome of 1858 occupants in cars equipped with WHIPS and 663 occupants in Volvo cars of model year 1999 without WHIPS are studied with respect to WHIPS injury-reducing effect for different impact severities and injury durations. The occupants in WHIPS are further studied with respect to seating position and sitting posture, such as turned head and head-to-head restraint distance. Results: Soft tissue neck injury risk reductions are seen for occupants in WHIPS as compared to prior Volvo cars; mean values ranging from 21 to 47% depending on impact severity and symptom duration. Sitting posture (turned head and increased backset) increases soft tissue neck injury risks. Based on the self-reported injury data, a significantly lower risk was found for occupants facing straight forward with the head in close proximity to the head restraint as compared to the risk for occupants with rotated head and a larger backset. Even though the highest risk of soft tissue neck injuries is found in higher impact severity, the large amount of soft tissue neck injuries sustained at low impact severity emphasizes the need of focusing measures for crash avoidance. Conclusions: This study presents the development and real-world performance of WHIPS as well as identifies situations for further focus and challenges for the next generation of soft tissue neck injury protection and prevention, including areas such as occupant posture and crash avoidance.	[Jakobsson, Lotta] Volvo Cars Safety Ctr, Dept 91410, S-40531 Gothenburg, Sweden	Jakobsson, L (corresponding author), Volvo Cars Safety Ctr, Dept 91410, PV21, S-40531 Gothenburg, Sweden.	ljakobss@volvocars.com					ASBERG A, 1973, P 4 INT TECH C EXP S, P359; CARLSSON G, 1985, P 1985 INT IRCOBI C, P277; COELINGH E, 2007, P 20 ESV C LY FRANC; Davidsson J., 1998, P IRCOBI C BIOM IMP, P377; Farmer Charles M, 2003, Traffic Inj Prev, V4, P83, DOI 10.1080/15389580309867; HAGG A, 1999, FOLKSAM CAR MODEL SA; Jakobsson L, 2000, ACCIDENT ANAL PREV, V32, P307, DOI 10.1016/S0001-4575(99)00107-4; Jakobsson L, 2004, P IRCOBI C BIOM IMP, P297; Jakobsson L., 1994, P 1994 INT IRCOBI C, P109; JAKOBSSON L, 2004, J WHIPLASH RELAT DIS, V3, P37; Jonsson Bertil, 2007, Traffic Inj Prev, V8, P87, DOI 10.1080/15389580600911010; KULLGREN A, 2007, P 20 ESV C LY FRANC; LUNDELL B, 1998, P 16 ESV C WINDS CAN, P1586; LUNDELL B, 1998, SAE WORLD C DETR MI; Olsson I, 1990, P INT IRCOBI C BIOM, P269; ONEILL B, 1972, AM J PUBLIC HEALTH N, V62, P399, DOI 10.2105/AJPH.62.3.399; SILVERBAGECARLS.G, 2003, P 47 AAAM C, P598; STURZENEGGER M, 1995, J NEUROL, V242, P443, DOI 10.1007/BF00873547; STURZENEGGER M, 1994, J NEUROL, V544, P688; TEMMING J, 2000, FRONTIERS WHIPLASH T, P118; Viano DC, 2001, J TRAUMA, V51, P959, DOI 10.1097/00005373-200111000-00022	21	28	28	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.		2008	9	6					600	605		10.1080/15389580802435636			6	Public, Environmental & Occupational Health; Transportation	Public, Environmental & Occupational Health; Transportation	387DN	WOS:000261932000014	19058108				2021-06-18	
J	Osiurak, F; Aubin, G; Allain, P; Jarry, C; Etcharry-Bouyx, F; Richard, I; Le Gall, D				Osiurak, Francois; Aubin, Ghislaine; Allain, Philippe; Jarry, Christophe; Etcharry-Bouyx, Frederique; Richard, Isabelle; Le Gall, Didier			Different constraints on grip selection in brain-damaged patients: Object use versus object transport	NEUROPSYCHOLOGIA			English	Article						tool use; apraxia; action; motor control; grasping; pantomime	IDEOMOTOR APRAXIA; POSTURE; HAND	The present study discusses the presence of different constraints on action selection during object use versus object transport. Sixteen left brain-damaged (LBD) patients, 10 right brain-damaged (RBD) and 35 healthy controls were examined on a grip preference test consisting of a grasping-to-transport and a grasping-to-use condition. Assessment included a general praxis testing (pantomime production, object utilization gesture recognition and object use). We also reported the case of a close-head injury patient (DR) with an atypical behavioural pattern. Our results supported the different constraint hypothesis. While several LBD and RBD patients performed inappropriate grips in the grasping-to-transport condition, only two patients (L2 and DR) used inappropriate grips in the grasping-to-use condition. No correlation was found between the two conditions of the grip preference test and measures of the general praxis testing. The discussion focuses on the nature of constraints on grip selection during object use and object transport. (C) 2008 Elsevier Ltd. All rights reserved.	[Osiurak, Francois; Aubin, Ghislaine; Allain, Philippe; Jarry, Christophe; Etcharry-Bouyx, Frederique; Le Gall, Didier] Univ Angers, UPRES EA 2646, Psychol Lab, Angers, France; [Osiurak, Francois; Aubin, Ghislaine; Allain, Philippe; Jarry, Christophe; Etcharry-Bouyx, Frederique; Le Gall, Didier] Univ Hosp Angers, Dept Neurol, Neuropsychol Unit, Angers, France; [Aubin, Ghislaine; Richard, Isabelle] Reg Ctr Funct Rehabil Angers, Angers, France	Le Gall, D (corresponding author), CHU Angers, Dept Neurol, Unite Neuropsychol, 4 Rue Larrey, F-49033 Angers 1, France.	DiLeGall@chu-angers.fr	Osiurak, Francois/F-1400-2011	Osiurak, Francois/0000-0003-3449-6377; ALLAIN, Philiooe/0000-0003-0668-0986			BERGEGO C, 1992, REV NEUROPSYCHOL, V2, P193; Buxbaum LJ, 2005, NEUROPSYCHOLOGIA, V43, P917, DOI 10.1016/j.neuropsychologia.2004.09.006; Buxbaum LJ, 2001, NEUROCASE, V7, P445, DOI 10.1076/neur.7.6.445.16223; Goldenberg G, 1998, NEUROPSYCHOLOGIA, V36, P581, DOI 10.1016/S0028-3932(97)00165-6; Goldenberg G, 1999, NEUROPSYCHOLOGIA, V37, P559, DOI 10.1016/S0028-3932(98)00111-0; Hermsdorfer J, 1999, EXP BRAIN RES, V128, P41, DOI 10.1007/s002210050815; JOHNSONFREY SH, 2003, PROGR BRAIN RES, P127; ROSENBAUM D, 1990, ATTENTION PERFORM, V13, P321; ROSENBAUM DA, 1992, J EXP PSYCHOL LEARN, V18, P1058, DOI 10.1037/0278-7393.18.5.1058; Rosenbaum DA, 2001, PSYCHOL REV, V108, P709, DOI 10.1037//0033-295X.108.4.709; ROTHI LJG, 1991, COGN NEUROPSYCHOL, V8, P443, DOI 10.1080/02643299108253382; Steenbergen B, 2004, COGNITIVE BRAIN RES, V19, P145, DOI 10.1016/j.cogbrainres.2003.11.008; Sunderland A, 2000, NEUROPSYCHOLOGIA, V38, P923, DOI 10.1016/S0028-3932(00)00021-X	13	28	28	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2008	46	9					2431	2434		10.1016/j.neuropsychologia.2008.03.018			4	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	326EP	WOS:000257641400017	18462765				2021-06-18	
J	Rabin, LA; Borgos, MJ; Saykin, AJ				Rabin, Laura A.; Borgos, Marlana J.; Saykin, Andrew J.			A Survey of Neuropsychologists' Practices and Perspectives Regarding the Assessment of Judgment Ability	APPLIED NEUROPSYCHOLOGY			English	Article; Proceedings Paper	34th Annual Meeting of the International-Neuropsychological-Society	FEB 01-04, 2006	Boston, MA	Int Neuropsychol Soc		judgment; judgment tests; neuropsychological assessment; survey	TRAUMATIC BRAIN-INJURY; PROBLEM-SOLVING SKILLS; DECISION-MAKING CAPACITY; TEST USAGE; EXECUTIVE DYSFUNCTION; ALZHEIMERS-DISEASE; OLDER-ADULTS; SCHIZOPHRENIA; AGE; INDIVIDUALS	Judgment is an important aspect of cognitive and real-world functioning that is commonly assessed during neuropsychological evaluations. This study utilized a brief, online survey to examine neuropsychologists' practices and perspectives regarding available judgment instruments. Participants (n=290, 17% response rate) were randomly selected members of the International Neuropsychological Society and the National Academy of Neuropsychology. Respondents rank-ordered the following issues that should be incorporated into assessments of judgment (from most to least important): safety, ability to perform activities of daily living, and problem solving/decision making about medical, financial, social/ethical, and legal matters. A majority of respondents reported that they often or always assessed judgment when evaluating patients with traumatic brain injury (89%), dementia (87%), and psychiatric disorders (70%). Surprisingly, the top-ranked instruments were not tests of judgment per se, and included the WAIS-III Comprehension, Wisconsin Card Sorting Test, and WAIS-III Similarities. Further, 61% of respondents were slightly confident, and only 23% were very confident, in their ability to assess a patient's judgment skills with their current tests. The overwhelming majority (87%) of respondents perceived a need for improved measures. Overall results indicate use of varied techniques by neuropsychologists to evaluate judgment and suggest the need for additional tests of this cognitive domain.	[Rabin, Laura A.] CUNY Brooklyn Coll, Dept Psychol, Brooklyn, NY 11210 USA; [Rabin, Laura A.] CUNY, Grad Ctr, Dept Psychol, Brooklyn, NY 11210 USA; [Rabin, Laura A.; Borgos, Marlana J.; Saykin, Andrew J.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Neuropsychol Program,Dept Psychiat, Hanover, NH 03756 USA; [Saykin, Andrew J.] Indiana Univ, Sch Med, Dept Radiol, Ctr Neuroimaging, Indianapolis, IN 46202 USA	Rabin, LA (corresponding author), CUNY Brooklyn Coll, Dept Psychol, 2900 Bedford Ave, Brooklyn, NY 11210 USA.	lrabin@brooklyn.cuny.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019771] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG019771, R01 AG19771, R01 AG019771-06] Funding Source: Medline		Allaire JC, 1999, PSYCHOL AGING, V14, P627, DOI 10.1037/0882-7974.14.4.627; Archer RP, 2006, J PERS ASSESS, V87, P84, DOI 10.1207/s15327752jpa8701_07; Artistico D, 2003, PSYCHOL AGING, V18, P68, DOI 10.1037/0882-7974.18.1.68; Bamdad MJ, 2003, BRAIN INJURY, V17, P1011, DOI 10.1080/0269905031000110553; Bearden CE, 2001, BIPOLAR DISORD, V3, P106, DOI 10.1034/j.1399-5618.2001.030302.x; Bertrand RM, 1999, AGING MENT HEALTH, V3, P281, DOI 10.1080/13607869956055; BORGOS MJ, 2006, P 34 ANN M INT NEUR, P24; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; BUTLER M, 1991, PROF PSYCHOL-RES PR, V22, P510, DOI 10.1037/0735-7028.22.6.510; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Channon S, 1999, NEUROPSYCHOLOGIA, V37, P757, DOI 10.1016/S0028-3932(98)00138-9; Cook C, 2000, EDUC PSYCHOL MEAS, V60, P821, DOI 10.1177/00131640021970934; CORNELIUS SW, 1987, PSYCHOL AGING, V2, P144, DOI 10.1037/0882-7974.2.2.144; DENNEY NW, 1989, PSYCHOL AGING, V4, P438, DOI 10.1037/0882-7974.4.4.438; Duke LM, 2000, NEUROPSYCHOL REV, V10, P75, DOI 10.1023/A:1009096603879; FITTEN LJ, 1990, J AM GERIATR SOC, V38, P1097, DOI 10.1111/j.1532-5415.1990.tb01372.x; Flashman Laura A, 2002, Curr Psychiatry Rep, V4, P346, DOI 10.1007/s11920-002-0082-x; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Grisso T, 1998, MACARTHUR COMPETENCE; Heaton R., 1993, WISCONSIN CARD SORTI; Kajanne A, 2003, J ADULT DEV, V10, P173, DOI 10.1023/A:1023414313800; Karlawish J, 2008, NEUROSIGNALS, V16, P91, DOI 10.1159/000109763; Karlawish JHT, 2005, NEUROLOGY, V64, P1514, DOI 10.1212/01.WNL.0000160000.01742.9D; Kim SYH, 2002, AM J GERIAT PSYCHIAT, V10, P151, DOI 10.1176/appi.ajgp.10.2.151; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; LAFLECHE G, 1995, NEUROPSYCHOLOGY, V9, P313, DOI 10.1037/0894-4105.9.3.313; Lai JM, 2007, AM J GERIAT PSYCHIAT, V15, P101, DOI 10.1097/01.JGP.0000239246.10056.2e; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Loeb P. A., 1996, INDEPENDENT LIVING S; LOWENSTEIN DA, 1989, J GERONTOL B-PSYCHOL, V44, P114; Marsiske M., 2006, HDB PSYCHOL AGING, P315, DOI [10.1016/B978-012101264-9/50017-3, DOI 10.1016/B978-012101264-9/50017-3]; Marson D, 1999, Semin Clin Neuropsychiatry, V4, P41; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Medalia A, 2002, SCHIZOPHR RES, V57, P165, DOI 10.1016/S0920-9964(01)00293-6; Medalia A, 2001, SCHIZOPHRENIA BULL, V27, P259, DOI 10.1093/oxfordjournals.schbul.a006872; *NC NEUR GROUP INC, 1988, MAN NEUR COGN STAT E; Rabin LA, 2007, J CLIN EXP NEUROPSYC, V29, P752, DOI 10.1080/13825580601025908; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rempfer MV, 2003, PSYCHIAT RES, V117, P103, DOI 10.1016/S0165-1781(02)00318-9; Revheim N, 2006, SCHIZOPHR RES, V83, P237, DOI 10.1016/j.schres.2005.12.849; Semkovska M, 2004, SCHIZOPHR RES, V69, P289, DOI 10.1016/j.schres.2003.07.005; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; STERN RA, 2003, NEUROPSYCHOLOGICAL A; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P325, DOI 10.1080/13854040600760488; Temple RO, 2006, ARCH CLIN NEUROPSYCH, V21, P371, DOI 10.1016/j.acn.2006.05.002; Thornton WL, 2007, PSYCHOL AGING, V22, P470, DOI 10.1037/0882-7974.22.3.470; Vellinga A, 2004, INT J GERIATR PSYCH, V19, P645, DOI 10.1002/gps.1139; WECHSLER D, 2003, WISC 4 ADM INTERPRET; Wechsler D, 1997, WAIS 3 ADM SCORING M; Willis S. L., 1993, TEST MANUAL EVERYDAY; Willis SL, 1998, GERONTOLOGIST, V38, P569, DOI 10.1093/geront/38.5.569; WILLIS SL, 1993, PENNSYLVANIA STATE U; Woods D.C., 2000, CLIN GERONTOLOGIST, V21, P49, DOI [https://doi.org/10.1300/J018v21n04_05, DOI 10.1300/J018V21N04_05]	55	28	29	0	9	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282			APPL NEUROPSYCHOL	Appl. Neuropsychol.		2008	15	4					264	273	PII 905792272	10.1080/09084280802325090			10	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	375DQ	WOS:000261094300004	19023743	Green Accepted			2021-06-18	
J	Wagstaff, GF; Wheatcroft, J; Cole, JC; Brunas-Wagstaff, J; Blackmore, V; Pilkington, A				Wagstaff, Graham F.; Wheatcroft, Jacqueline; Cole, Jon C.; Brunas-Wagstaff, Joana; Blackmore, Victoria; Pilkington, Andrew			Some cognitive and neuropsychological aspects of social inhibition and facilitation	EUROPEAN JOURNAL OF COGNITIVE PSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; VERBAL FLUENCY; MERE PRESENCE; EYEWITNESS CONFIDENCE; EXECUTIVE FUNCTIONS; DOMINANT RESPONSES; TASK-PERFORMANCE; WORKING-MEMORY; WORD RETRIEVAL; FRONTAL LOBES	Tasks that, in the working memory and neuropsychological literature, have been related to executive and frontal processing, and nonexecutive and more posterior brain processing, bear distinct similarities with the kinds of tasks that, in the social psychological literature, have been associated with social inhibition and facilitation, respectively. Accordingly, a cognitive-neuropsychological model of social inhibition and facilitation is proposed whereby the presence of others engages the executive and frontal systems, and facilitates the function of systems active in more automatic, nonexecutive processing. In two experiments, the tasks most associated with executive and frontal processing (phonemic switches and answers to complex questions) showed evidence of social inhibition, whereas those more associated with nonexecutive and more posterior temporal processing (phonemic clusters and confidence-accuracy correlations), showed some evidence of social facilitation. Implications are discussed.	[Wagstaff, Graham F.; Cole, Jon C.; Brunas-Wagstaff, Joana; Blackmore, Victoria] Univ Liverpool, Sch Psychol, Liverpool L69 7ZA, Merseyside, England; [Wheatcroft, Jacqueline; Pilkington, Andrew] Manchester Metropolitan Univ, Manchester M15 6BH, Lancs, England	Wagstaff, GF (corresponding author), Univ Liverpool, Sch Psychol, Eleanor Rathbone Bldg,Bedford St S, Liverpool L69 7ZA, Merseyside, England.	gwf@Liverpool.ac.uk		Pilkington, Andrew/0000-0001-7819-3728			Altemeier L, 2006, DEV NEUROPSYCHOL, V29, P161, DOI 10.1207/s15326942dn2901_8; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Baddeley A, 1998, Q J EXP PSYCHOL-A, V51, P819, DOI 10.1080/027249898391413; Baddeley Alan, 1996, Quarterly Journal of Experimental Psychology Section A Human Experimental Psychology, V49, P5, DOI 10.1080/027249896392784; Barber T. X., 1969, HYPNOSIS SCI APPROAC; Baron R.S., 1986, ADV EXPT SOCIAL PSYC, V19, P1, DOI [10.1016/S0065-2601(08)60211-7, DOI 10.1016/S0065-2601(08)60211-7]; BERGER SM, 1981, J PERS SOC PSYCHOL, V40, P479; Blascovich J, 1999, J PERS SOC PSYCHOL, V77, P68, DOI 10.1037/0022-3514.77.1.68; BLISS CB, 1892, STUDIES YALE PSYCHOL, V1, P1; Bond CF, 1996, BASIC APPL SOC PSYCH, V18, P31, DOI 10.1207/s15324834basp1801_4; BOND CF, 1982, J PERS SOC PSYCHOL, V42, P1042, DOI 10.1037/0022-3514.42.6.1042; BOND CF, 1983, PSYCHOL BULL, V94, P265, DOI 10.1037/0033-2909.94.2.265; Chamberlain SR, 2006, PSYCHOPHARMACOLOGY, V188, P397, DOI 10.1007/s00213-006-0391-6; Chua EF, 2004, J COGNITIVE NEUROSCI, V16, P1131, DOI 10.1162/0898929041920568; Coan JA, 2006, PSYCHOL SCI, V17, P1032, DOI 10.1111/j.1467-9280.2006.01832.x; COTTRELL NB, 1968, J PERS SOC PSYCHOL, V9, P245, DOI 10.1037/h0025902; CRISSON JE, 1995, BASIC APPL SOC PSYCH, V17, P357, DOI 10.1207/s15324834basp1703_5; Deffenbacher K. A., 1983, EVALUATING WITNESS E, P235; Deffenbacher KA, 2004, LAW HUMAN BEHAV, V28, P687, DOI 10.1007/s10979-004-0565-x; EDMONSTON WE, 1991, THEORIES HYPNOSIS CU, P197; EDMONSTON WE, 1977, AM J CLIN HYPN, V30, P69; Elfgren CI, 1998, NEUROPSYCHOLOGIA, V36, P505, DOI 10.1016/S0028-3932(97)00146-2; FREDRIKSON M, 1992, BIOL PSYCHOL, V33, P51, DOI 10.1016/0301-0511(92)90005-F; Frith C, 1996, COGNITIVE BRAIN RES, V5, P175, DOI 10.1016/S0926-6410(96)00054-7; GRUZELIER J, 1993, PSYCHOL MED, V23, P93, DOI 10.1017/S0033291700038885; Hardy L, 2007, BRIT J PSYCHOL, V98, P15, DOI 10.1348/000712606X103428; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hirshorn EA, 2006, NEUROPSYCHOLOGIA, V44, P2547, DOI 10.1016/j.neuropsychologia.2006.03.035; Hogg Michael A., 2002, SOCIAL PSYCHOL; Jahanshahi M, 1998, COGN NEUROPSYCHOL, V15, P483, DOI 10.1080/026432998381005; Jamieson GA, 2005, BRAIN RES BULL, V67, P298, DOI 10.1016/j.brainresbull.2005.06.033; Kallio S, 2001, INT J CLIN EXP HYP, V49, P95, DOI 10.1080/00207140108410061; Kebbell M., 1999, INTERVIEWING DECEPTI, P23; Kebbell MR, 1996, BRIT J PSYCHOL, V87, P653, DOI 10.1111/j.2044-8295.1996.tb02614.x; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Lewis BP, 1997, PERS SOC PSYCHOL B, V23, P937, DOI 10.1177/0146167297239003; MANSTEAD ASR, 1980, BRIT J SOC CLIN PSYC, V19, P119, DOI 10.1111/j.2044-8260.1980.tb00937.x; MARKUS H, 1978, J EXP SOC PSYCHOL, V14, P389, DOI 10.1016/0022-1031(78)90034-3; MARTIN A, 1994, NEUROPSYCHOLOGIA, V32, P1487, DOI 10.1016/0028-3932(94)90120-1; MASTERS RSW, 1993, PERS INDIV DIFFER, V14, P655, DOI 10.1016/0191-8869(93)90113-H; McCaffrey RJ, 1996, CLIN NEUROPSYCHOL, V10, P435, DOI 10.1080/13854049608406704; Monsell S., 1996, UNSOLVED MYSTERIES M, P93; Nolan J, 1998, APPL COGNITIVE PSYCH, V12, P43, DOI 10.1002/(SICI)1099-0720(199802)12:1<43::AID-ACP487>3.0.CO;2-1; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Olley AL, 2005, BIPOLAR DISORD, V7, P43, DOI 10.1111/j.1399-5618.2005.00254.x; Platania J, 2001, J SOC PSYCHOL, V141, P190, DOI 10.1080/00224540109600546; Rainville P, 1999, J COGNITIVE NEUROSCI, V11, P110, DOI 10.1162/089892999563175; Reverberi C, 2006, NEUROPSYCHOLOGIA, V44, P469, DOI 10.1016/j.neuropsychologia.2005.05.011; Risse GL, 2006, EPILEPSIA, V47, P87, DOI 10.1111/j.1528-1167.2006.00699.x; Robinson MD, 1998, LAW HUMAN BEHAV, V22, P409, DOI 10.1023/A:1025770926338; SANDERS GS, 1981, J EXP SOC PSYCHOL, V17, P227, DOI 10.1016/0022-1031(81)90024-X; SANNA LJ, 1990, J EXP SOC PSYCHOL, V26, P82, DOI 10.1016/0022-1031(90)90063-R; Schmidt R. A. R., 2000, MOTOR LEARNING PERFO; SCHMITT BH, 1986, J EXP SOC PSYCHOL, V22, P242, DOI 10.1016/0022-1031(86)90027-2; Shallice T, 1993, ATTENTION SELECTION, P171; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Sheehan P. W., 1976, METHODOLOGIES HYPNOS; SMITH VL, 1989, J APPL PSYCHOL, V74, P356, DOI 10.1037/0021-9010.74.2.356; STANG DJ, 1976, J SOC PSYCHOL, V98, P175, DOI 10.1080/00224545.1976.9923388; Sylvester CYC, 2003, NEUROPSYCHOLOGIA, V41, P357, DOI 10.1016/S0028-3932(02)00167-7; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370; Vandierendonck A, 1998, Q J EXP PSYCHOL-A, V51, P197, DOI 10.1080/713755748; VANGEMMERT WA, 1997, HUMAN PERCEPTION PER, V23, P1299; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2004, NEUROIMAGE, V22, P1679, DOI 10.1016/j.neuroimage.2004.03.052; Wagstaff G., 1981, HYPNOSIS COMPLIANCE; Wagstaff G.F., 2007, INT J PSYCHOL PSYCHO, V7, P27; Wallace B., 1996, HYPNOSIS IMAGINATION, P253; Warkentin S, 1997, DEMENT GERIATR COGN, V8, P105, DOI 10.1159/000106614; Wheatcroft JM, 2004, LEGAL CRIMINOL PSYCH, V9, P83, DOI 10.1348/135532504322776870; Yerkes RM, 1908, J COMP NEUROL PSYCHO, V18, P459, DOI 10.1002/cne.920180503; ZAJONC RB, 1966, J EXP SOC PSYCHOL, V2, P160, DOI 10.1016/0022-1031(66)90077-1	75	28	28	2	35	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0954-1446	1464-0635		EUR J COGN PSYCHOL	Eur. J. Cogn. Psychol.		2008	20	4					828	846		10.1080/09541440701469749			19	Psychology, Experimental	Psychology	318CD	WOS:000257068300009					2021-06-18	
J	Staal, JA; Dickson, TC; Chung, RS; Vickers, JC				Staal, J. A.; Dickson, T. C.; Chung, R. S.; Vickers, J. C.			Cyclosporin-A treatment attenuates delayed cytoskeletal alterations and secondary axotomy following mild axonal stretch injury	DEVELOPMENTAL NEUROBIOLOGY			English	Article						cytoskeleton; cytochrome-c; cyclosporin-A; axolemma permeability; neurofilament; axonal injury	TRAUMATIC BRAIN-INJURY; CYTOCHROME-C RELEASE; INTRAAXONAL NEUROFILAMENT COMPACTION; PIG OPTIC-NERVE; MITOCHONDRIAL DYSFUNCTION; PERMEABILITY TRANSITION; AXOLEMMAL PERMEABILITY; IN-VITRO; NEURONAL CYTOSKELETON; SPECTRIN PROTEOLYSIS	Following central nervous system trauma, diffuse axonal injury and secondary axotomy result from a cascade of cellular alterations including cytoskeletal and mitochondrial disruption. We have examined the link between intracellular changes following mild/ moderate axonal stretch injury and secondary axotomy in rat cortical neurons cultured to relative maturity (21 days in vitro). Axon bundles were transiently stretched to a strain level between 103% and 106% using controlled pressurized fluid. Double-immunohistochemical analysis of neurofilaments, neuronal spectrin, a-internexin, cytochrome-c, and ubiquitin was conducted at 24-, 48-, 72-, and 96-h postinjury. Stretch injury resulted in delayed cytoskeletal damage, maximal at 48-h postinjury. Accumulation of cytochrome-c and ubiquitin was also evident at 48 h following injury and colocalized to axonal regions of cytoskeletal disruption. Pretreatment of cultures with cyclosporin-A, an inhibitor of calcineurin and the mitochondrial membrane transitional pore, reduced the degree of cytoskeletal damage in stretch-injured axonal bundles. At 48-h postinjury, 20% of untreated cultures demonstrated secondary axotomy, whereas cyclosporin A-treated axon bundles remained intact. By 72-h postinjury, 50% of control preparations and 7% of cyclosporin A-treated axonal bundles had progressed to secondary axotomy, respectively. Statistical analyses demonstrated a significant (p < 0.05) reduction in secondary axotomy between treated and untreated cultures. In summary, these results suggest that cyclosporin-A reduces progressive cytoskeletal damage and secondary axotomy following transient axonal stretch injury in vitro. (c) 2007 Wiley Pedodicals, Inc.	Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Hobart, Tas, Australia	Vickers, JC (corresponding author), Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Hobart, Tas, Australia.	james.vickers@utas.edu.au	Vickers, James C/J-7464-2014; Chung, Roger/ABF-8395-2020	Vickers, James C/0000-0001-5671-4879; Chung, Roger/0000-0002-9286-947X; Dickson, Tracey/0000-0002-9196-1661			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Chung RS, 2005, J NEUROTRAUM, V22, P1081, DOI 10.1089/neu.2005.22.1081; Chung RS, 2004, NEUROSCIENCE, V123, P595, DOI 10.1016/j.neuroscience.2003.10.019; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; Dickson TC, 2000, J NEUROTRAUM, V17, P1095, DOI 10.1089/neu.2000.17.1095; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; FRAPPIER T, 1992, EUR J BIOCHEM, V205, P85, DOI 10.1111/j.1432-1033.1992.tb16754.x; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Gallyas F, 2002, ACTA NEUROPATHOL, V103, P36, DOI 10.1007/s004010100424; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Haas MA, 2007, CELL MOTIL CYTOSKEL, V64, P274, DOI 10.1002/cm.20182; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; King AE, 2006, J COMP NEUROL, V498, P277, DOI 10.1002/cne.21053; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lifshitz J, 2006, EXP NEUROL, V197, P318, DOI 10.1016/j.expneurol.2005.10.002; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J NEUROTRAUM, V20, P139, DOI 10.1089/08977150360547062; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luetjens CM, 2000, J NEUROSCI, V20, P5715; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mironov SL, 2005, J BIOL CHEM, V280, P715, DOI 10.1074/jbc.M409819200; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; Van den Heuvel C, 2004, J NEUROTRAUM, V21, P1562, DOI 10.1089/0897715042441783; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	65	28	29	0	2	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	1932-8451			DEV NEUROBIOL	Dev. Neurobiol.	DEC	2007	67	14					1831	1842		10.1002/dneu.20552			12	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	239TG	WOS:000251540000001	17702000				2021-06-18	
J	Terrte, R; Mearin, F				Terrte, Rosa; Mearin, Fermin			Prospective evaluation of oro-pharyngeal dysphagia after severe traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; dysphagia; aspiration; silent aspiration; outcome; videofluoroscopy	SWALLOWING DISORDERS; HEAD TRAUMA; ASPIRATION; THERAPY; PROGRESSION; STROKE; ADULTS	Primary objective: To evaluate clinical, videofluoroscopic findings and clinical evolution of neurogenic dysphagia and to establish the prognostic factors. Research design: Prospective cohort study. Methods and procedures: Forty-eight patients with severe traumatic brain injury (TBI) and clinically-suspected oropharyngeal dysphagia were studied. Clinical evaluation of oro-pharyngeal dysphagia and videofluoroscopic examination were performed. Clinical evolution was based on feeding mode at discharge, the presence of respiratory complications and body mass index (BMI) at admission and at discharge. Main outcomes and results: Sixty-five per cent of patients had impaired gag reflex and 44% cough during oral feeding. Videofluoroscopy revealed some type of disorder in 90% of cases: 65% in the oral phase and 73% in the pharyngeal phase (aspiration in 62.5%, being silent in 41%). At discharge, 45% were on normal diet, 27% on a modified oral diet 14% combined oral intake and gastrostomy feeding and 14% were fed exclusively by gastrostomy. Feeding mode at discharge substantially correlated with RLCF score at admission (p = 0.04) and with RLCF (p = 0.009) and DRS (p = 0.02) scores at discharge. Conclusions: Aspiration is very frequent in patients with severe TBI, being silent in almost half. Cognitive function evaluated with the RLCF is the best prognostic factor. At discharge, 72% of the patients were on oral food intake despite having severe TBI.	[Terrte, Rosa; Mearin, Fermin] Univ Autonoma Barcelona, Inst Guttmann, Unit Funct Digest Rehabil, Barcelona 08916, Spain	Terrte, R (corresponding author), Univ Autonoma Barcelona, Inst Guttmann, Unit Funct Digest Rehabil, Cami Can Ruti S-N, Barcelona 08916, Spain.	rterre@guttmann.com					Cherney LR, 1996, SEMIN NEUROL, V16, P349, DOI 10.1055/s-2008-1040993; Daniels S. K., 1997, AM J SPEECH-LANG PAT, V6, P17, DOI [DOI 10.1044/1058-0360.0604.17, 10.1044/ 1058- 0360.0604.17]; DAVIES AE, 1995, LANCET, V345, P487, DOI 10.1016/S0140-6736(95)90584-7; DEPIPPO KL, 1994, NEUROLOGY, V44, P1655, DOI 10.1212/WNL.44.9.1655; Field L H, 1989, Brain Inj, V3, P19, DOI 10.3109/02699058909008069; Hagen C, 1999, REHABILITATION HEAD; Kaye GM, 1997, ANN OTO RHINOL LARYN, V106, P705, DOI 10.1177/000348949710600817; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; Lazarus CL, 1989, J HEAD TRAUMA REHAB, V4, P34; Linden P., 1993, Dysphagia, V8, P170, DOI 10.1007/BF01354535; Logemann JA, 1994, J HEAD TRAUMA REHAB, V9, P43; Logemann JA, 1998, EVALUATION TREATMENT, P307; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Morgan A, 2004, J HEAD TRAUMA REHAB, V19, P226, DOI 10.1097/00001199-200405000-00004; Morgan A, 2004, BRAIN INJURY, V18, P359, DOI 10.1080/02699050310001617424; Morgan A, 2002, J HEAD TRAUMA REHAB, V17, P220, DOI 10.1097/00001199-200206000-00004; NEUMANN S, 1995, DYSPHAGIA, V10, P1, DOI 10.1007/BF00261272; POUDEROUX P, 1995, GASTROENTEROLOGY, V108, P1418, DOI 10.1016/0016-5085(95)90690-8; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schurr MJ, 1999, J TRAUMA, V46, P817, DOI 10.1097/00005373-199905000-00009; Spechler SJ, 1999, GASTROENTEROLOGY, V117, P233, DOI 10.1016/S0016-5085(99)70573-1; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; STANNDERS JA, 1993, CLIN PREDICTORS ASPI, P2; Terre R, 2006, NEUROGASTROENT MOTIL, V18, P200, DOI 10.1111/j.1365-2982.2005.00729.x; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992	27	28	32	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2007	21	13-14					1411	1417		10.1080/02699050701785096			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	253AA	WOS:000252488200009	18066943				2021-06-18	
J	Marshall, P; Happe, M				Marshall, Paul; Happe, Maggie			The performance of individuals with mental retardation on cognitive tests assessing effort and motivation	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; VERBAL-LEARNING TEST; CARD SORTING TEST; WORD MEMORY TEST; SUSPECT EFFORT; RECOGNITION TRIAL; CLINICAL-SAMPLES; PATIENT SAMPLES; HEAD-INJURY	The purpose of this study was to determine which tests of effort and motivation would be appropriate for use with patients with mental retardation when feigning of cognitive deficits is suspected. The seven measures evaluated included the WMS-III Rarely Missed Index Test, forced-choice recognition portion of the California Verbal Learning Test-II, Reliable Digit Span test, Rey 15-Item Test, Rey Dot Counting Test, the Rey 15-Item Test with Recognition Trial, and the Vocabulary (V)-Digit Span (DS) difference score. Results indicated that the forced-choice portion of the CVIT-II, the V-DS difference score, and the Rarely Missed Index Test from the WMS-III might be appropriate for use with this population with passing rates of 89%, 98%, and 91% respectivety.	Hennepin Cty Med Ctr, Dept Psychiat, Minneapolis, MN 55415 USA	Marshall, P (corresponding author), Hennepin Cty Med Ctr, Dept Psychiat, Minneapolis, MN 55415 USA.	paul.marshall@co.hennepin.mn.us					Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BOLLER F, 1966, BRAIN, V89, P815, DOI 10.1093/brain/89.4.815; BOLTER J, 1985, ITEM ERROR FREQUECIE; Boone K., 2002, DOT COUNTING TEST; Boone K. B., 2002, B TEST; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2000, ARCH CLIN NEUROPSYCH, V15, P227, DOI 10.1016/S0887-6177(99)00014-1; Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Dickens S. E., 1992, STRUCTURED INTERVIEW; Dunn L., 1981, PEABODY PICTURE VOCA; Frederick R.I., 1997, VALIDITY INDICATOR P; GOLDBERG JO, 1986, J CLIN PSYCHOL; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; GREEN P, 2003, GREEN WORD MEMORY TE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve KW, 2002, J CLIN EXP NEUROPSYC, V24, P48, DOI 10.1076/jcen.24.1.48.968; Griffin GAE, 1996, PSYCHOL ASSESSMENT, V8, P383; Hayes J S, 1998, Appl Neuropsychol, V5, P33, DOI 10.1207/s15324826an0501_4; Hurley KE, 2006, MENT RETARD, V44, P112, DOI 10.1352/0047-6765(2006)44[112:AIMMUW]2.0.CO;2; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; KENNEDY C, 2005, TEST MEMORY MALINGER; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; Larrabee GJ, 2005, FORENSIC NEUROPSYCHO, P3; Lewis RF., 1979, MANUAL REPEATABLE CO; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; MAJ M, 1993, ARCH CLIN NEUROPSYCH, V8, P123, DOI 10.1016/0887-6177(93)90030-5; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers JE, 1998, APPL NEUROPSYCHOL, V5, P120, DOI 10.1207/s15324826an0503_2; Millis S. R., 2002, J FORENSIC NEUROPSYC, V2, P147; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MILLIS SR, 1995, CLIN NEUROPSYCHOL, V9, P241, DOI 10.1080/13854049508400486; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; MORGAN S, 1997, QUALITATIVE ERROR FR; Paul D. S., 1992, INT J CLIN NEUROPSYC, V14, P1; Pulsifer M B, 1996, J Int Neuropsychol Soc, V2, P159; REY A, 1958, PSYCHOL EXAMINATION; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spreen O., 1991, COMPENDIUM NEUROPSYC; STEARNS RA, 2003, NEUROPSYCHOLOGICAL A; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; VICTOR TL, 2005, USE EFFORT TESTS MEN; WARRINGTON EK, 1984, RECOGNITION MEMORY; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M	55	28	28	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	SEP	2007	21	5					826	840		10.1080/13854040600801001			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	210KO	WOS:000249455300008	17676547				2021-06-18	
J	Azzopardi, D; Edwards, AD				Azzopardi, D.; Edwards, A. D.			Hypothermia	SEMINARS IN FETAL & NEONATAL MEDICINE			English	Article						asphyxia; disabilities; hypothermia; hypoxia-ischaemia; meta analyses; neuroprotection	HYPOXIC-ISCHEMIC ENCEPHALOPATHY; MILD SYSTEMIC HYPOTHERMIA; TRAUMATIC BRAIN-INJURY; WHOLE-BODY HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; MODERATE HYPOTHERMIA; PERINATAL ASPHYXIA; NEWBORN-INFANTS; POSTISCHEMIC HYPOTHERMIA	Experimental studies show that, following hypoxic ischaemic injury, mild induced hypothermia-a reduction of body temperature by about 3 IC-preserves cerebral energy metabolism, reduces cerebral tissue injury and improves neurological function. Randomized trials in full-term and near-full-term newborns suggest that treatment with mild hypothermia is safe and improves survival without disabilities up to 18 months of age. Although the optimal time of initiation, the depth and duration, and the method of cooling are uncertain, in the absence of specific treatments many clinicians will wish to consider treating asphyxiated infants with hypothermia. Guidance now needs to be provided to promote uniform practice, to avoid inappropriate treatment and to foster continuing collaboration in future studies of neuroprotection following asphyxia. If the promising results of the current trials are confirmed by the findings from other on-going studies, with longer follow-up, the impact of such a treatment on the babies, their families and health resources in the shorter and longer terms will be considerable. (C) 2007 Elsevier Ltd. All rights reserved.	Univ London Imperial Coll Sci Technol & Med, Div Clin Sci, Dept Med, London W12 0NN, England	Azzopardi, D (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Clin Sci, Dept Med, Hammersmith Campus,DuCane Rd, London W12 0NN, England.	d.azzopardi@imperial.ac.uk		Edwards, Anthony David/0000-0003-4801-7066	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0200270, G0100126] Funding Source: Medline		Akisu M, 2003, PROSTAG LEUKOTR ESS, V69, P45, DOI 10.1016/S0952-3278(03)00055-3; Ambalavanan N, 2006, PEDIATRICS, V118, P2084, DOI 10.1542/peds.2006-1591; Amess PN, 1999, DEV MED CHILD NEUROL, V41, P436, DOI 10.1017/S0012162299000973; Amess PN, 1997, PEDIATR RES, V41, P803, DOI 10.1203/00006450-199706000-00002; AZZOPARDI D, 1989, PEDIATR RES, V25, P445, DOI 10.1203/00006450-198905000-00004; Azzopardi D, 2000, PEDIATRICS, V106, P684, DOI 10.1542/peds.106.4.684; BARKS J, NEONATAL HYPOTHEMIA; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Blumberg RM, 1997, EXP BRAIN RES, V113, P130, DOI 10.1007/BF02454148; Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; Edwards AD, 2006, ARCH DIS CHILD-FETAL, V91, pF127, DOI 10.1136/adc.2005.071787; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Edwards AD, 2000, PEDIATR RES, V47, P431, DOI 10.1203/00006450-200004000-00003; Eicher DJ, 2005, PEDIATR NEUROL, V32, P18, DOI 10.1016/j.pediatrneurol.2004.06.015; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Evans K, 2001, J Obstet Gynaecol, V21, P114, DOI 10.1080/01443610020025967; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 2005, LANCET, V365, P1619, DOI 10.1016/S0140-6736(05)66505-1; Gunn AJ, 2005, J PERINAT MED, V33, P340, DOI 10.1515/JPM.2005.061; Gunn AJ, 1999, PEDIATR RES, V46, P274, DOI 10.1203/00006450-199909000-00005; Gunn AJ, 1998, PEDIATRICS, V102, P1098, DOI 10.1542/peds.102.5.1098; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Gunn TR, 1999, PEDIATRICS, V103, P1079, DOI 10.1542/peds.103.5.1079; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Higgins RD, 2006, J PEDIATR-US, V148, P170, DOI 10.1016/j.jpeds.2005.12.009; Higgins RD, 2005, OBSTET GYNECOL, V106, P1385, DOI 10.1097/01.AOG.0000190206.70375.b4; Holzer M, 2002, NEW ENGL J MED, V346, P549; HORAN M, 2006, EARLY HUM DEV   0710; Inder TE, 2004, J PEDIATR-US, V145, P835, DOI 10.1016/j.jpeds.2004.07.034; Lawn J, 2005, B WORLD HEALTH ORGAN, V83, P409; Lin ZL, 2006, J PERINATOL, V26, P180, DOI 10.1038/sj.jp.7211412; LOREK A, 1994, PEDIATR RES, V36, P699, DOI 10.1203/00006450-199412000-00003; MacLellan CL, 2004, J CEREBR BLOOD F MET, V24, P432, DOI 10.1097/00004647-200404000-00008; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Nolan JP, 2003, RESUSCITATION, V57, P231, DOI 10.1016/S0300-9572(03)00184-9; Northington FJ, 2001, NEUROBIOL DIS, V8, P207, DOI 10.1006/nbdi.2000.0371; Qing M, 2003, CRIT CARE MED, V31, P2769, DOI 10.1097/01.CCM.0000098858.64868.9C; Robertson NJ, 1999, PEDIATR RES, V46, P287, DOI 10.1203/00006450-199909000-00007; ROTH SC, 1992, DEV MED CHILD NEUROL, V34, P285; Rutherford MA, 2005, PEDIATRICS, V116, P1001, DOI 10.1542/peds.2005-0328; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SHANKARAN S, 2008, PEDIATR RES, V57, pA1548; SIESJO BK, 1995, J NEUROSURG ANESTH, V7, P47, DOI 10.1097/00008506-199501000-00009; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; SIESJO BK, 1984, ACTA PSYCHIAT SCAND, V69, P57; Siesjo BK, 1999, ACTA NEUROCHIR SUPPL, V73, P7; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Speer M, 2006, CLIN PERINATOL, V33, P169, DOI 10.1016/j.clp.2005.11.012; Taylor DL, 2002, PEDIATR RES, V51, P13, DOI 10.1203/00006450-200201000-00005; Taylor DL, 1999, BRAIN PATHOL, V9, P93; Thoresen M, 2005, CURR OPIN NEUROL, V18, P111, DOI 10.1097/01.wco.0000162850.44897.c6; Thoresen M, 2001, PEDIATR RES, V50, P405, DOI 10.1203/00006450-200109000-00017; Thoresen M, 2001, PEDIATR RES, V49, P594, DOI 10.1203/00006450-200104000-00024; Thoresen M, 2000, PEDIATRICS, V106, P92, DOI 10.1542/peds.106.1.92; Tomimatsu T, 2003, PEDIATR RES, V53, P57, DOI 10.1203/01.PDR.0000042444.90269.2A; Tooley JR, 2003, ANN NEUROL, V53, P65, DOI 10.1002/ana.10402; Van Leeuwen GMJ, 2000, PEDIATR RES, V48, P351, DOI 10.1203/00006450-200009000-00015; Wyatt JS, 2005, EARLY HUM DEV, V81, P5, DOI 10.1016/j.earlhumdev.2004.10.014; WYATT JS, IN PRESS PEDIATRICS; Xu LJ, 2002, J CEREBR BLOOD F MET, V22, P21, DOI 10.1097/00004647-200201000-00003; Zhang ZJ, 2001, MOL BRAIN RES, V95, P75, DOI 10.1016/S0169-328X(01)00247-9; Zhou WH, 2002, ACTA PHARMACOL SIN, V23, P64; Zhu CL, 2004, BRAIN RES, V996, P67, DOI 10.1016/j.brainres.2003.10.013	69	28	29	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1744-165X	1878-0946		SEMIN FETAL NEONAT M	Semin. Fetal Neonatal Med.	AUG	2007	12	4					303	310		10.1016/j.siny.2007.01.022			8	Pediatrics	Pediatrics	189ZT	WOS:000248028200009	17392043				2021-06-18	
J	Pagulayan, KF; Temkin, NR; Machamer, JE; Dikmen, SS				Farrell Pagulayan, Kathleen; Temkin, Nancy R.; Machamer, Joan E.; Dikmen, Sureyya S.			The measurement and magnitude of awareness difficulties after traumatic brain injury: A longitudinal study	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						impaired self-awareness; sickness impact profile; psychosocial symptoms; measurement; head injury; concordance	QUALITY-OF-LIFE; SELF-AWARENESS; IMPAIRED AWARENESS; HEAD-INJURY; RANDOMIZED-TRIAL; DEFICITS; REHABILITATION; LIMITATIONS; RATINGS; SCALE	Previous research suggests that reduced self-awareness is common following traumatic brain injury (TBI). However. few studies have examined the magnitude of this problem in a sample representative of hospitalized individuals. In this longitudinal study, individuals with complicated mild to severe TBIs and their significant others (SO) were evaluated at 1 and 12 months postinjury on the Sickness Impact Profile. Awareness was measured by comparing the level of injury-related problems reported by a person with TBI and their SO. Overall, individuals with TBI did not report fewer difficulties than their SO. In contrast, they frequently reported more injury-related difficulties than their SO. AS there is no commonly or universally accepted definition for differential awareness, the magnitude of underreporting and overreporting problems is presented using four different cutoff scores. A minimum discrepancy is proposed for defining awareness difficulties that is based on the standard error of measurement of the test-retest difference of the measure. Reduced self-awareness was inconsistent across both time and functional domains. These results suggest that reduced self-awareness is not the norm at 1 or 12 months postinjury and highlight the need for a more standardized approach to the measurement and classification of self-awareness.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Pagulayan, KF (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Box 356490,1959 NE Pacific St, Seattle, WA 98195 USA.	farkat@u.washington.edu	Pagulayan, Kati/AAR-9225-2020		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD048030] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS019643, R01 NS19643] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD048030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER		ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; AMADOR XF, 1994, ARCH GEN PSYCHIAT, V51, P826; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Clare L, 2004, BRIT J CLIN PSYCHOL, V43, P177, DOI 10.1348/014466504323088042; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; McCrae RR, 1998, J PERS, V66, P285, DOI 10.1111/1467-6494.00013; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sneeuw KCA, 1997, STROKE, V28, P1541, DOI 10.1161/01.STR.28.8.1541; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Wallace CA, 2000, BRAIN INJURY, V14, P549; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON BA, 1996, BEHAV ASS DYSEXECUTI; Wyrwich KW, 2005, QUAL LIFE RES, V14, P285, DOI 10.1007/s11136-004-0705-2	47	28	28	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2007	13	4					561	570		10.1017/S1355617707070713			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	186GJ	WOS:000247766800002	17521477				2021-06-18	
J	Selvanathan, S; Goldschlager, T; McMillen, J; Campbell, S				Selvanathan, S.; Goldschlager, T.; McMillen, J.; Campbell, S.			Penetrating craniocerebral injuries from nail-gun use	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						foreign bodies; penetrating head injuries; nails; nail-gun; false aneurysms; penetrating eye injuries	OF-THE-LITERATURE; ARTERY ANEURYSM; INTRACRANIAL NAIL; CAROTID-ARTERY; SECONDARY; SINUS; HEAD	Three patients with penetrating craniocerebral nail-gun injuries are described. In the first patient the nail was impinging on the internal carotid artery (ICA) in the carotid canal. On removal of the nail, the patient developed a false aneurysm at the site. To our knowledge, this is the first reported case of nail-gun injury affecting the ICA and also the first case of penetrating head injury affecting the ICA in the carotid canal. The second patient had seven intracranial nails in the frontal area. Three nails penetrated the left orbit, one of which perforated the globe. One nail damaged the optic nerve resulting in optic neuropathy. In the third patient the nail extended through the squamous temporal bone into the temporal lobe. All three were managed successfully via closed gentle traction without craniotomy and/ or endovascular intervention. The literature is reviewed and management options for penetrating head injuries are discussed. (c) 2006 Elsevier Ltd. All rights reserved.	Royal Brisbane Hosp, Kenneth G Jamieson Dept Neurosurg, Herston, Qld 4029, Australia	Goldschlager, T (corresponding author), Royal Brisbane Hosp, Kenneth G Jamieson Dept Neurosurg, Level 7,Ned Hanlon Bldg, Herston, Qld 4029, Australia.	tonygoldschlager@hotmail.com					Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; [Anonymous], 2001, J TRAUMA S, V51, pS34; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; BRAUN J, 1987, J COMPUT ASSIST TOMO, V11, P525, DOI 10.1097/00004728-198705000-00030; Cunningham EJ, 2004, NEUROSURGERY, V55, P1225, DOI 10.1227/01.NEU.0000140991.82075.01; Depauw P, 2003, MINIM INVAS NEUROSUR, V46, P250; Falcioni M, 1999, Acta Otorhinolaryngol Ital, V19, P36; Guyot LL, 2001, NEUROL RES, V23, P291, DOI 10.1179/016164101101198442; Jithoo R, 2001, S AFR MED J, V91, P316; Larson PS, 2000, NEUROSURG FOCUS, V8; Liu James K, 2004, Neurosurg Focus, V17, pE13; Moonis G, 2005, AM J NEURORADIOL, V26, P1324; Musa BS, 1997, BRIT J NEUROSURG, V11, P564; Ravelli V, 1987, J Neurosurg Sci, V31, P153; REZAI AR, 1994, SURG NEUROL, V42, P312, DOI 10.1016/0090-3019(94)90399-9; Sani S, 2005, J NEUROSURG, V103, P567, DOI 10.3171/jns.2005.103.3.0567; Shenoy SN, 2003, NEUROL INDIA, V51, P411; Spennato P, 2005, SURG NEUROL, V64, P368, DOI 10.1016/j.surneu.2004.12.003; Tancioni F, 1994, J Neurosurg Sci, V38, P239; THOMAS MD, 1987, MED J AUSTRALIA, V147, P602, DOI 10.5694/j.1326-5377.1987.tb133698.x	20	28	29	0	2	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	JUL	2007	14	7					678	683		10.1016/j.jocn.2006.02.017			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	184QL	WOS:000247656700015	17452105				2021-06-18	
J	Valadka, AB; Robertson, CS				Valadka, Alex B.; Robertson, Claudia S.			Surgery of cerebral trauma and associated critical care	NEUROSURGERY			English	Article						computed tomography; guidelines; neurocritical care; neurotrauma; Prehospital; traumatic; brain injury	SEVERE HEAD-INJURY; INTENSIVE INSULIN THERAPY; RECOMBINANT FACTOR VIIA; ACUTE SUBDURAL-HEMATOMA; BRAIN VOLUME REGULATION; DECOMPRESSIVE CRANIECTOMY; PERFUSION-PRESSURE; PROLONGED HYPERVENTILATION; INTRACRANIAL HYPERTENSION; MANAGEMENT	The last 30 years have been both exciting and frustrating for those in the field of traumatic brain injury (TBI). Much has been learned, but no new treatment has been shown to improve patient outcomes despite the execution of many clinical trials. The overall incidence of TBI has decreased, probably because of intensive efforts toward prevention and education. Rigorous assessment of available research has produced several evidence-based guidelines for the management of neurotrauma patients. The creation of organized emergency medical services systems in many regions has improved prehospital care. Computed tomographic scans have become the gold standard for obtaining immediate images of patients with TBI, and ongoing advances in visualizing cerebral metabolism continue to be remarkable. The major current question regarding surgical treatment for TBI involves the role of clecompressive craniectomy, an operation that first fell out of favor and has since (in the last three decades) enjoyed a resurgence of interest. Growing interest in the intensive care management of TBI patients helped to establish the new field of neurocritical care. Prophylactic hyperventilation is no longer recommended, and earlier recommendations for aggressive elevation of blood pressure have been softened to endorsement of a cerebral perfusion pressure of 60 mmHg. Recombinant factor Vlla is increasingly used for minimizing complications related to coagulopathy. Intracranial pressure monitoring is now recommended for the majority of TBI patients. At present, available technologies allow measurement of other aspects, of cerebral metabolism including cerebral blood flow, brain oxygen tension, biochemistry, and electrical activity. Therapeutic interventions that are growing in popularity or are presently under investigation include administration of hypertonic saline, hyperoxygenation, decompressive craniectomy, and hypothermia. Rehabilitation has become accepted as an important part of the TBI recovery process, and additional work is needed to identify optimal interventions in this area. Socioeconomic factors will play a growing role in our treatment of TBI patients. Although much progress has been made in the last 30 years, the challenge now is to find ways to translate that progress into improved care and outcomes for TB I patients.	Univ Texas, Sch Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Valadka, AB (corresponding author), Univ Texas, Sch Med, Dept Neurosurg, 6410 Fannin St,Suite 1020, Houston, TX 77030 USA.	alex.valadka@uthtmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS-38660] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Alves OL, 2003, ACTA NEUROCHIR, V145, P583, DOI 10.1007/s00701-003-0055-9; [Anonymous], 2006, HOSP BAS EM CAR BREA; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Brody DL, 2005, NEUROCRIT CARE, V2, P263, DOI 10.1385/NCC:2:3:263; Bullock M., 2006, NEUROSURGERY, V58; Bullock M Ross, 2006, Neurosurgery, V58, pS56; Bullock M Ross, 2006, Neurosurgery, V58, pS47; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Dutton RP, 2003, J CLIN ANESTH, V15, P184, DOI 10.1016/S0952-8180(03)00034-5; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Esposito TJ, 2006, J AM COLL SURGEONS, V202, P655, DOI 10.1016/j.jamcollsurg.2005.12.008; Fakhry SM, 2006, J TRAUMA, V60, P997, DOI 10.1097/01.ta.0000217285.94057.5e; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Gopinath SP, 1996, ANESTH ANALG, V83, P1014, DOI 10.1097/00000539-199611000-00020; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Lu J, 2005, ACT NEUR S, V95, P281; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Marion DW, 2006, NEUROSURGERY, V58, P655; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; Munch E, 2000, NEUROSURGERY, V47, P315; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; RICHARDSON JD, 1992, J TRAUMA, V32, P229, DOI 10.1097/00005373-199202000-00020; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TEASDALE G, 1974, LANCET, V2, P81; Turner-Stokes L, 2004, CLIN MED, V4, P10, DOI 10.7861/clinmedicine.4-1-10; VALADKA AB, 2000, TXB NEUROLOGICAL SUR; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wehner DE, 2005, J EMERG NURS, V31, P383, DOI 10.1016/j.jen.2005.06.001; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; 2001, J TRAUMA S2, V51, pS3	68	28	35	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2007	61	1		S			203	220		10.1227/01.NEU.0000255497.26440.01			18	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	187XW	WOS:000247883600016	18813168				2021-06-18	
J	Clough, RW; Neese, SL; Sherill, LK; Tan, AA; Duke, A; Roosevelt, RW; Browning, RA; Smith, DC				Clough, R. W.; Neese, S. L.; Sherill, L. K.; Tan, A. A.; Duke, A.; Roosevelt, R. W.; Browning, R. A.; Smith, D. C.			Cortical edema in moderate fluid percussion brain injury is attenuated by vagus nerve stimulation	NEUROSCIENCE			English	Article						traumatic brain injury; TBI; FPI; VNS; brain swelling; rats	REGIONAL CEREBRAL EDEMA; LOCUS-COERULEUS LESIONS; NOREPINEPHRINE TURNOVER; MOTOR DEFICITS; RECOVERY; CORTEX; RAT; DAMAGE; AMPHETAMINE; WIDESPREAD	Development of cerebral edema (intracellular and/or extracellular water accumulation) following traumatic brain injury contributes to mortality and morbidity that accompanies brain injury. Chronic intermittent vagus nerve stimulation (VNS) initiated at either 2 h or 24 h (VNS: 30 s train of 0.5 mA, 20 Hz, biphasic pulses every 30 min) following traumatic brain injury enhances recovery of motor and cognitive function in rats in the weeks following brain injury; however, the mechanisms of facilitated recovery are unknown. The present study examines the effects of VNS on development of acute cerebral edema following unilateral fluid percussion brain injury (FPI) in rats, concomitant with assessment of their behavioral recovery. Two hours following FPI, VNS was initiated. Behavioral testing, using both beam walk and locomotor placing tasks, was conducted at 1 and 2 days following FPI. Edema was measured 48 h post-FPI by the customary method of region-specific brain weights before and after complete dehydration. Results of this study replicated that VNS initiated at 2 h after FPI: 1) effectively facilitated the recovery of vestibulomotor function at 2 days after FPI assessed by beam walk performance (P<0.01); and 2) tended to improve locomotor placing performance at the same time point (P=0.18). Most interestingly, results of this study showed that development of edema within the cerebral cortex ipsilateral to FPI was significantly attenuated at 48 h in FPI rats receiving VNS compared with non-VNS FPI rats (P<0.04). Finally, a correlation analysis between beam walk performance and cerebral edema following FPI revealed a significant inverse correlation between behavior performance and cerebral edema. Together, these results suggest that VNS facilitation of motor recovery following experimental brain injury in rats is associated with VNS-mediated attenuation of cerebral edema. (c) 2007 IBRO. Published by Elsevier Ltd. All rights reserved.	So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA; So Illinois Univ, Brain & Cognit Sci Program, Dept Psychol, Carbondale, IL 62901 USA; So Illinois Univ, Dept Physiol, Sch Med, Carbondale, IL 62901 USA; So Illinois Univ, Ctr Integrat Res Cognit & Neural ci, Carbondale, IL 62901 USA	Clough, RW (corresponding author), So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA.	rclough@siumed.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041551] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41551] Funding Source: Medline		BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Baslow MH, 2002, NEUROCHEM INT, V40, P295, DOI 10.1016/S0197-0186(01)00095-X; Belli A, 2006, J NEUROCHEM, V96, P861, DOI 10.1111/j.1471-4159.2005.03602.x; Borges N, 1999, J AUTON PHARMACOL, V19, P209, DOI 10.1046/j.1365-2680.1999.00137.x; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1993, RESTOR NEUROL NEUROS, V5, P283, DOI 10.3233/RNN-1993-5404; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Cheney JA, 2001, J CEREBR BLOOD F MET, V21, P396, DOI 10.1097/00004647-200104000-00008; CLOUGH RW, 2006, J NEUROTRAUM, V22, P1258; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Feeney DM, 1998, RESTORATIVE NEUROLOGY, P35; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; Furukawa T, 2003, J NEUROTRAUM, V20, P269, DOI 10.1089/089771503321532851; Giorgi FS, 2004, NEUROSCI BIOBEHAV R, V28, P507, DOI 10.1016/j.neubiorev.2004.06.008; Goldstein LB, 1997, RESTOR NEUROL NEUROS, V11, P55, DOI 10.3233/RNN-1997-111206; GRIFFIN MP, 1994, J APPL PHYSIOL, V76, P2760; Groves DA, 2005, NEUROSCI BIOBEHAV R, V29, P493, DOI 10.1016/j.neubiorev.2005.01.004; Groves DA, 2005, NEUROSCI LETT, V379, P174, DOI 10.1016/j.neulet.2004.12.055; HARIK SI, 1984, ANN NEUROL, V15, P568, DOI 10.1002/ana.410150609; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Krahl SE, 1998, EPILEPSIA, V39, P709, DOI 10.1111/j.1528-1157.1998.tb01155.x; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; LIGHTHALL JW, 1988, J NEUROTRAUM, V5, P617; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MOUFARRIJ NA, 1986, NEUROL RES, V11, P97; NARITOKU DK, 1995, EPILEPSY RES, V22, P53, DOI 10.1016/0920-1211(95)00035-9; NATHAN BR, 1999, TXB CLIN NEUROLOGY, P475; Neese SL, 2007, BRAIN RES, V1128, P157, DOI 10.1016/j.brainres.2006.09.073; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; PAXINOS G, 1998, BRAIN RES; Rabinstein AA, 2006, NEUROLOGIST, V12, P59, DOI 10.1097/01.nrl.0000186810.62736.f0; RAICHLE ME, 1975, P NATL ACAD SCI USA, V72, P3726, DOI 10.1073/pnas.72.9.3726; ROBERT B, 1992, AGENTS ACTIONS, V37, P268, DOI 10.1007/BF02028119; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Schachter SC, 2002, NEUROLOGY, V59, pS1, DOI 10.1212/WNL.59.6_suppl_4.S1; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DC, 2006, J NEUROTRAUM, V23, P1549, DOI 10.1089/neu.2006.23.1549; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stover JF, 2002, INTENS CARE MED, V28, P1491, DOI 10.1007/s00134-002-1431-2; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Landeghem FKH, 2003, J NEUROTRAUM, V20, P1327, DOI 10.1089/089771503322686120; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wakai A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub2; WOODBURY DM, 1990, EPILEPSIA, V31, pS7, DOI 10.1111/j.1528-1157.1990.tb05852.x	64	28	33	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUN 29	2007	147	2					286	293		10.1016/j.neuroscience.2007.04.043			8	Neurosciences	Neurosciences & Neurology	187NA	WOS:000247853400004	17543463				2021-06-18	
J	Beaudin, M; Saint-Vil, D; Ouimet, A; Mercier, C; Crevier, L				Beaudin, Marianne; Saint-Vil, Dickens; Ouimet, Alain; Mercier, Claude; Crevier, Louis			Clinical algorithm and resource use in the management of children with minor head trauma	JOURNAL OF PEDIATRIC SURGERY			English	Article						minor head trauma; skull x-ray; head computed tomography; infant	INTRACRANIAL INJURY; REQUIRE HOSPITALIZATION; SKULL FRACTURE; ADMISSION; RULE; INFANTS	Purpose: There are no clear guidelines for the management of minor head injury, including the use of skull x-rays and computed tomography (CT) scans of the head. This is reflected in clinical practice by a wide variability in imaging study use and by the fact that some patients are discharged home from the emergency room (ER), whereas others are admitted to the hospital with or without a period of observation before admission. To address this issue, we proposed and applied a new protocol for minor head injury at our institution. Methods: Between January 2004 and December 2005, 417 patients presented to the emergency department at our institution with minor head injury. All of them had fallen from less than I in. Every chart was retrospectively evaluated, and pertinent data were extracted. Results: The mean age of the patients was 9.8 months (2 weeks to 32 months). One hundred fifty-three had a skull x-ray, and 13 had a CT scan of the head. Of the 153 patients who had a skull x-ray, only 15 had a skull fracture. Of these 15 patients, 3 also had a CT scan of the head that confirmed the diagnosis of skull fracture. Of the 13 CT scans that were done, only these 3 were positive. Eleven patients were kept in the ER for 6 hours for close observation, and 5 of these were eventually admitted. Overall, 8 patients were admitted to the hospital for observation. Of these 8 patients, 7 had a skull x-ray, from which 5 were positive. Only 2 of the admitted patients had a CT scan, and they Were both positive for a skull fracture. One of the CT also demonstrated a subdural hematoma along with subarachnoid hemorrhage. These 2 patients also had a positive skull x-ray. None of the patients that were admitted had headaches or neurologic impairments. The mean age of the patients admitted was 3.8 months (2 weeks to 12 months). The mean hospital stay was 1.2 days (1-3 days). Conclusion: Only 10% of the skull x-rays and CT scans were positive for a skull fracture, which led to an admission in half of these patients. The other half was mainly discharged from ER after being observed. Several patients underwent a skull x-ray that we feel was not necessary in the management of their minor head injury. For those who had a head CT scan, only one revealed additional information and none of them had an impact on the final management. Observation in the ER could have been reasonable for most cases. (C) 2007 Elsevier Inc. All rights reserved.	CHU St Justine, Div Pediat Gen Surg, Montreal, PQ H3T 1C5, Canada; CHU St Justine, Div Neurosurg, Montreal, PQ H3T 1C5, Canada	Saint-Vil, D (corresponding author), CHU St Justine, Div Pediat Gen Surg, Montreal, PQ H3T 1C5, Canada.	dickens_saint_vil@ssss.gouv.qc.ca					Adams J, 2001, J PEDIATR SURG, V36, P119, DOI 10.1053/jpsu.2001.20026; Dunning J, 2004, J NEUROTRAUM, V21, P877, DOI 10.1089/0897715041526122; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P453; KADISH HA, 1995, ANN EMERG MED, V26, P37, DOI 10.1016/S0196-0644(95)70235-0; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Ponsky TA, 2005, J TRAUMA, V59, P1292, DOI 10.1097/01.ta.0000197439.19171.25; QUAYLE KS, 1997, PEDIATRICS, V99, P11; Reed MJ, 2005, ARCH DIS CHILD, V90, P859, DOI 10.1136/adc.2004.053603; Roddy SP, 1998, PEDIATRICS, V101, P575, DOI 10.1542/peds.101.4.575; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Spencer MT, 2003, AM J EMERG MED, V21, P111, DOI 10.1053/ajem.2003.50031; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X	17	28	28	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	MAY	2007	42	5					849	852		10.1016/j.jpedsurg.2006.12.038			4	Pediatrics; Surgery	Pediatrics; Surgery	175JS	WOS:000247010500021	17502197				2021-06-18	
